data_2m9p_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2m9p _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.238 0 CA-C-O 120.857 0.361 . . . . 0.0 111.626 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -170.95 11.37 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 123.736 0.814 . . . . 0.0 109.669 -170.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -158.25 82.33 0.84 Allowed 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 -169.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . 0.407 ' HA ' ' HA ' ' A' ' 88' ' ' GLN . 7.4 mp -117.01 109.65 17.27 Favored 'General case' 0 C--O 1.202 -1.432 0 O-C-N 121.474 -0.766 . . . . 0.0 110.284 -175.221 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.598 ' HB2' ' HD3' ' A' ' 89' ' ' LYS . 37.3 tp10 -83.68 145.46 28.76 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.551 -0.718 . . . . 0.0 110.627 -176.304 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . 0.448 ' HB2' ' CD2' ' A' ' 121' ' ' HIS . 81.6 mt -89.32 114.66 26.08 Favored 'General case' 0 CA--C 1.547 0.856 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.508 171.177 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -112.28 107.88 16.89 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 125.108 1.363 . . . . 0.0 108.274 178.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 15.9 ttp180 -67.75 125.05 25.02 Favored 'General case' 0 N--CA 1.481 1.102 0 CA-C-N 118.441 0.564 . . . . 0.0 111.616 -172.088 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . 0.522 ' HB1' ' HG3' ' A' ' 85' ' ' ARG . . . -89.06 -40.54 12.89 Favored 'General case' 0 C--N 1.347 0.473 0 C-N-CA 124.02 0.928 . . . . 0.0 109.986 177.188 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -166.09 -176.25 3.67 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 115.08 -0.964 . . . . 0.0 110.776 -173.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 65.2 m-20 -110.22 146.78 35.01 Favored 'General case' 0 C--O 1.242 0.696 0 C-N-CA 124.085 0.954 . . . . 0.0 108.838 171.401 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.435 HG12 HG12 ' A' ' 208' ' ' VAL . 94.6 t -78.86 101.01 3.97 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 CA-C-O 121.503 0.668 . . . . 0.0 109.469 -177.171 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 33.8 ttpt -167.96 109.74 0.59 Allowed 'General case' 0 C--O 1.247 0.966 0 N-CA-C 105.247 -2.131 . . . . 0.0 105.247 175.767 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . 0.418 ' NE1' ' HB1' ' A' ' 169' ' ' ALA . 68.2 t90 -80.3 90.57 5.56 Favored 'General case' 0 CA--C 1.539 0.553 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 -177.153 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -157.88 60.46 0.47 Allowed 'General case' 0 CA--C 1.543 0.677 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 158.046 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.553 ' HB3' ' HB3' ' A' ' 169' ' ' ALA . 12.6 t70 -90.6 -58.93 2.32 Favored 'General case' 0 CA--C 1.554 1.134 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.775 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . 0.647 ' H ' ' HB2' ' A' ' 169' ' ' ALA . 17.7 mt-30 -150.28 4.27 0.52 Allowed 'General case' 0 N--CA 1.5 2.027 0 N-CA-C 113.953 1.094 . . . . 0.0 113.953 -172.485 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . 11.84 70.91 0.01 OUTLIER 'General case' 0 N--CA 1.506 2.365 0 C-N-CA 126.549 1.94 . . . . 0.0 115.484 -169.053 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -88.22 123.59 33.0 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 123.603 0.761 . . . . 0.0 109.9 -176.253 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 30.8 mm -75.58 134.87 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 C-N-CA 123.045 0.538 . . . . 0.0 110.187 -176.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 78.5 p -174.84 -162.46 0.12 Allowed 'General case' 0 CA--C 1.55 0.949 0 O-C-N 124.581 1.176 . . . . 0.0 109.954 172.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.599 ' HA3' ' H ' ' A' ' 173' ' ' LYS . . . 102.77 178.49 26.86 Favored Glycine 0 C--N 1.349 1.259 0 CA-C-O 119.522 -0.599 . . . . 0.0 111.805 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 44.0 t 64.02 98.17 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 124.212 1.005 . . . . 0.0 111.176 176.287 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 28.8 t -140.63 148.83 54.73 Favored Pre-proline 0 N--CA 1.479 0.993 0 CA-C-O 118.406 -0.807 . . . . 0.0 109.345 -176.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_exo -42.63 138.12 3.7 Favored 'Trans proline' 0 C--N 1.391 2.81 0 C-N-CA 123.87 3.046 . . . . 0.0 113.785 177.243 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.652 HD12 ' HB2' ' A' ' 176' ' ' LEU . 31.0 mm -63.52 111.13 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 -175.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.638 ' HB3' HG22 ' A' ' 217' ' ' THR . 13.6 mt -94.11 142.33 27.52 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 115.373 -0.83 . . . . 0.0 111.732 -167.69 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 60.4 p -85.52 140.8 30.36 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 123.358 0.663 . . . . 0.0 110.316 177.474 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.727 HG23 ' HD2' ' A' ' 177' ' ' PHE . 14.6 tt -148.39 138.6 16.7 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.794 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 -172.372 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 39.4 p -102.27 117.05 33.93 Favored 'General case' 0 CA--C 1.547 0.855 0 O-C-N 121.881 -0.512 . . . . 0.0 110.997 -170.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.607 ' HA ' ' HG3' ' A' ' 39' ' ' MET . 10.6 tp -61.25 145.11 13.09 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.077 0 C-N-CA 124.902 1.281 . . . . 0.0 112.208 -177.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 47.5 m -152.25 130.91 12.31 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 124.103 0.961 . . . . 0.0 110.068 -176.041 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 60.71 19.24 9.32 Favored 'General case' 0 CA--C 1.566 1.586 0 C-N-CA 123.479 0.712 . . . . 0.0 111.437 174.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 24.3 t70 76.05 -55.55 0.6 Allowed 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 125.617 1.567 . . . . 0.0 112.318 -178.359 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -89.0 -20.27 47.23 Favored Glycine 0 N--CA 1.475 1.268 0 N-CA-C 115.002 0.761 . . . . 0.0 115.002 -175.359 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 66.5 m -106.0 165.49 11.17 Favored 'General case' 0 N--CA 1.478 0.941 0 CA-C-N 117.646 0.723 . . . . 0.0 110.252 -177.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' MET . . . . . 0.607 ' HG3' ' HA ' ' A' ' 33' ' ' ILE . 3.7 mpp? -138.99 168.31 20.11 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 123.808 0.843 . . . . 0.0 108.861 168.901 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.791 ' HA ' HG12 ' A' ' 215' ' ' VAL . 64.5 m -150.39 -179.47 7.24 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 124.788 1.235 . . . . 0.0 108.282 167.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 41.7 mm -99.0 96.51 5.08 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 N-CA-C 108.261 -1.015 . . . . 0.0 108.261 167.417 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER 53.16 -79.63 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.154 0 C-N-CA 125.999 1.72 . . . . 0.0 112.164 -176.579 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 4.4 p30 -136.27 87.08 2.27 Favored 'General case' 0 CA--C 1.551 0.985 0 C-N-CA 124.486 1.115 . . . . 0.0 108.94 178.073 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -100.67 148.09 25.26 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.81 -172.215 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 . . . . . 0 N--CA 1.475 0.793 0 C-N-CA 124.17 0.988 . . . . 0.0 110.97 176.947 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 12.4 p-10 . . . . . 0 CA--C 1.54 0.587 0 CA-C-O 120.92 0.39 . . . . 0.0 111.298 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 169.0 -154.32 23.83 Favored Glycine 0 C--O 1.258 1.61 0 CA-C-N 115.34 -0.846 . . . . 0.0 111.85 -175.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -81.75 108.74 15.54 Favored 'General case' 0 C--O 1.237 0.445 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 176.364 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' TYR . . . . . 0.418 ' CD1' ' HB3' ' A' ' 8' ' ' LEU . 47.0 m-85 -102.91 156.56 17.58 Favored 'General case' 0 N--CA 1.469 0.479 0 C-N-CA 123.643 0.777 . . . . 0.0 110.704 -179.3 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' ARG . . . . . 0.522 ' HG3' ' HB1' ' A' ' 11' ' ' ALA . 60.0 mtt180 -103.06 132.57 49.23 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 106.09 -1.818 . . . . 0.0 106.09 166.36 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.516 ' H ' ' HA ' ' A' ' 99' ' ' ALA . 12.9 mt -91.84 107.83 19.31 Favored 'Isoleucine or valine' 0 C--O 1.256 1.434 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 171.388 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . 0.844 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 19.3 ptmt -99.27 139.2 35.27 Favored 'General case' 0 N--CA 1.441 -0.907 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 169.827 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . 0.407 ' HA ' ' HA ' ' A' ' 6' ' ' LEU . 0.5 OUTLIER -82.85 105.99 14.31 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 105.192 -2.151 . . . . 0.0 105.192 168.271 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . 0.598 ' HD3' ' HB2' ' A' ' 7' ' ' GLU . 60.0 tttt -113.67 98.5 7.08 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-N 114.562 -1.199 . . . . 0.0 108.082 -177.541 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -66.33 154.78 51.68 Favored Glycine 0 C--O 1.246 0.903 0 N-CA-C 108.279 -1.929 . . . . 0.0 108.279 160.557 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.508 HD12 ' HE2' ' A' ' 120' ' ' MET . 22.8 mm -68.19 -6.24 5.27 Favored 'Isoleucine or valine' 0 CA--C 1.572 1.796 0 CA-C-N 117.728 0.764 . . . . 0.0 110.483 -176.518 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 1.1 pp -134.52 25.44 3.76 Favored 'General case' 0 CA--C 1.564 1.507 0 C-N-CA 124.585 1.154 . . . . 0.0 111.901 172.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -164.98 133.07 2.85 Favored Glycine 0 N--CA 1.486 1.968 0 CA-C-N 117.869 0.304 . . . . 0.0 113.357 -178.416 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 71.6 m-85 -122.69 120.19 32.92 Favored 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 124.082 0.953 . . . . 0.0 110.015 -174.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 37.3 p -152.75 109.24 3.42 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 122.965 0.506 . . . . 0.0 110.75 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . 0.844 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 39.9 tt0 -74.1 140.53 45.34 Favored 'General case' 0 N--CA 1.485 1.3 0 CA-C-N 118.227 0.467 . . . . 0.0 110.705 179.046 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 1.6 pp -134.59 -16.25 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 N-CA-C 112.993 0.738 . . . . 0.0 112.993 -174.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -165.31 -157.75 10.05 Favored Glycine 0 C--N 1.342 0.867 0 C-N-CA 121.498 -0.382 . . . . 0.0 112.529 179.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.516 ' HA ' ' H ' ' A' ' 86' ' ' ILE . . . -146.01 170.81 15.89 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 123.489 0.716 . . . . 0.0 110.367 176.813 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -161.9 156.18 27.65 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 -179.294 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 24.1 t -118.15 114.0 43.82 Favored 'Isoleucine or valine' 0 C--O 1.241 0.608 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -175.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.462 ' CD2' ' HB2' ' A' ' 107' ' ' PHE . 0.4 OUTLIER -105.2 121.78 44.56 Favored 'General case' 0 N--CA 1.478 0.943 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 174.049 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.636 ' HB2' HD12 ' A' ' 146' ' ' LEU . 4.6 mmmp? -146.6 150.46 35.53 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 174.451 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 66.13 -84.28 0.03 OUTLIER 'General case' 0 CA--C 1.548 0.866 0 O-C-N 124.929 1.393 . . . . 0.0 110.49 173.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -154.59 21.27 0.62 Allowed Glycine 0 C--N 1.337 0.61 0 N-CA-C 111.816 -0.514 . . . . 0.0 111.816 178.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 97.1 m -142.65 135.1 27.75 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 123.583 0.753 . . . . 0.0 110.499 -175.753 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' PHE . . . . . 0.672 ' HB3' ' HB3' ' A' ' 140' ' ' TYR . 36.2 t80 -109.31 104.98 14.19 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 124.554 1.142 . . . . 0.0 109.363 175.635 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 42.1 p-80 -100.46 126.69 46.9 Favored 'General case' 0 C--O 1.239 0.521 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 173.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 13.8 t -137.77 -162.0 1.24 Allowed 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.319 176.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' MET . . . . . 0.519 ' SD ' ' O ' ' A' ' 212' ' ' GLY . 1.9 ttm -115.84 150.2 37.37 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.949 1.3 . . . . 0.0 109.817 -173.896 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 21.3 t90 -78.88 -42.76 26.51 Favored 'General case' 0 CA--C 1.553 1.077 0 C-N-CA 122.72 0.408 . . . . 0.0 110.777 -175.766 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 1.8 p-80 -71.47 3.47 3.82 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 113.807 1.04 . . . . 0.0 113.807 -175.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.7 m -53.95 -40.26 44.21 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.096 0 CA-C-N 118.273 0.488 . . . . 0.0 110.591 175.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 11.2 m -148.29 -83.61 0.11 Allowed 'General case' 0 CA--C 1.553 1.088 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 167.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 41.9 ttm180 -135.73 28.22 3.28 Favored 'General case' 0 N--CA 1.489 1.482 0 CA-C-O 121.696 0.76 . . . . 0.0 109.284 179.487 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.585 ' HA2' HD11 ' A' ' 138' ' ' ILE . . . 58.83 36.71 88.41 Favored Glycine 0 C--N 1.348 1.231 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 -166.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -79.02 175.31 10.7 Favored 'General case' 0 C--O 1.246 0.873 0 C-N-CA 124.161 0.985 . . . . 0.0 111.761 -169.428 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.6 m -72.83 142.36 15.21 Favored 'Isoleucine or valine' 0 C--O 1.244 0.782 0 CA-C-O 121.37 0.605 . . . . 0.0 109.784 -176.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -88.12 177.24 6.96 Favored 'General case' 0 CA--C 1.548 0.869 0 CA-C-N 114.676 -1.147 . . . . 0.0 110.099 171.357 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' MET . . . . . 0.508 ' HE2' HD12 ' A' ' 91' ' ' ILE . 9.1 ptp -159.04 155.76 28.03 Favored 'General case' 0 C--O 1.253 1.274 0 C-N-CA 123.874 0.87 . . . . 0.0 110.399 178.544 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.448 ' CD2' ' HB2' ' A' ' 8' ' ' LEU . 0.1 OUTLIER -153.19 104.13 2.77 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 114.727 -1.124 . . . . 0.0 108.134 -179.238 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt 61.74 30.08 18.27 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 123.844 0.715 . . . . 0.0 110.024 -175.246 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 83.94 -5.06 81.02 Favored Glycine 0 C--N 1.347 1.142 0 CA-C-O 119.012 -0.882 . . . . 0.0 114.185 -177.45 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . 0.467 ' O ' ' HA ' ' A' ' 120' ' ' MET . 21.6 ttmm -69.21 114.21 7.27 Favored 'General case' 0 C--N 1.357 0.924 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 170.65 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 36.2 ttm-85 -80.21 95.36 6.26 Favored 'General case' 0 CA--C 1.538 0.499 0 O-C-N 123.895 0.747 . . . . 0.0 109.36 -171.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 74.6 mt -80.14 93.74 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 C-N-CA 123.918 0.887 . . . . 0.0 108.701 -177.093 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -94.02 128.95 39.2 Favored Pre-proline 0 CA--C 1.542 0.636 0 CA-C-O 118.768 -0.634 . . . . 0.0 109.556 -177.117 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_exo -51.09 142.78 33.93 Favored 'Trans proline' 0 C--N 1.384 2.42 0 C-N-CA 123.419 2.746 . . . . 0.0 114.516 -176.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 54.7 p -97.8 -10.69 24.36 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 123.558 0.743 . . . . 0.0 110.429 172.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.671 ' HB3' ' HB2' ' A' ' 139' ' ' SER . 35.9 t-105 -155.38 147.18 23.26 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.647 1.179 . . . . 0.0 107.869 176.007 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -154.79 119.97 4.98 Favored 'General case' 0 C--O 1.237 0.436 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 170.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -109.7 112.24 24.19 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 123.859 0.864 . . . . 0.0 108.684 176.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 18.2 t -77.43 -27.4 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 C-N-CA 122.512 0.325 . . . . 0.0 110.739 -176.368 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 52.5 tttp -67.31 -49.39 64.38 Favored 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.022 0.529 . . . . 0.0 111.996 -172.442 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -80.19 -23.0 41.29 Favored 'General case' 0 N--CA 1.485 1.284 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 169.028 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 18.8 t70 74.46 55.37 0.09 Allowed 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 125.367 1.467 . . . . 0.0 110.202 176.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . 0.513 HD22 ' CZ3' ' A' ' 144' ' ' TRP . 4.6 mp -133.8 174.89 9.97 Favored 'General case' 0 CA--C 1.541 0.604 0 CA-C-N 115.074 -0.966 . . . . 0.0 111.368 172.616 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.585 HD11 ' HA2' ' A' ' 116' ' ' GLY . 78.9 mt -139.9 150.94 21.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 125.318 1.447 . . . . 0.0 108.327 -176.549 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' SER . . . . . 0.671 ' HB2' ' HB3' ' A' ' 130' ' ' TRP . 19.6 m -134.44 141.64 46.86 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 123.585 0.754 . . . . 0.0 109.563 171.507 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.672 ' HB3' ' HB3' ' A' ' 107' ' ' PHE . 83.4 t80 -128.79 142.16 51.07 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 177.241 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 90.48 -5.86 82.43 Favored Glycine 0 CA--C 1.531 1.044 0 N-CA-C 112.28 -0.328 . . . . 0.0 112.28 -173.701 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 146.87 -139.37 7.92 Favored Glycine 0 C--N 1.342 0.904 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -178.5 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -90.15 165.25 31.47 Favored Glycine 0 C--N 1.344 1.006 0 N-CA-C 110.157 -1.177 . . . . 0.0 110.157 167.16 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' TRP . . . . . 0.543 ' HZ2' ' HA2' ' A' ' 209' ' ' GLY . 7.0 t90 -61.11 105.58 0.5 Allowed 'General case' 0 CA--C 1.548 0.893 0 CA-C-O 121.281 0.562 . . . . 0.0 110.601 174.772 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . 0.552 ' HB2' ' HZ2' ' A' ' 145' ' ' LYS . 0.0 OUTLIER -137.88 156.28 48.07 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 115.352 -0.84 . . . . 0.0 109.386 176.022 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' LEU . . . . . 0.636 HD12 ' HB2' ' A' ' 103' ' ' LYS . 5.7 mt 169.24 -25.46 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.535 0 O-C-N 125.625 1.828 . . . . 0.0 109.015 -174.43 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 67.49 83.78 0.16 Allowed 'General case' 0 C--N 1.362 1.111 0 C-N-CA 125.185 1.394 . . . . 0.0 109.035 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -164.34 86.25 0.1 Allowed Glycine 0 C--N 1.337 0.599 0 CA-C-N 115.045 -0.979 . . . . 0.0 110.849 -170.292 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 28.1 tt0 -103.45 122.61 45.25 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 124.739 1.216 . . . . 0.0 109.327 177.317 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' TRP . . . . . . . . . . . . . 42.3 t90 -68.71 129.28 39.47 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 172.038 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 22.9 pttm -86.38 110.18 19.52 Favored 'General case' 0 CA--C 1.553 1.088 0 CA-C-O 121.408 0.623 . . . . 0.0 109.872 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -66.92 112.37 4.28 Favored 'General case' 0 N--CA 1.483 1.203 0 CA-C-O 121.609 0.718 . . . . 0.0 111.068 -178.036 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 153.81 -41.83 0.64 Allowed Glycine 0 N--CA 1.465 0.628 0 N-CA-C 110.191 -1.163 . . . . 0.0 110.191 -176.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 3.8 mp0 -88.55 -179.29 6.02 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 124.617 1.167 . . . . 0.0 109.907 175.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -73.23 142.34 47.28 Favored 'General case' 0 C--O 1.242 0.669 0 C-N-CA 122.976 0.51 . . . . 0.0 110.05 172.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . 0.463 HG13 ' HG1' ' A' ' 172' ' ' THR . 5.0 p -91.68 139.2 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 170.771 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 10.9 mm-40 -112.17 131.75 55.29 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 -176.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 53.7 t -126.21 124.08 65.05 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.642 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -177.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.461 ' HB2' ' HD2' ' A' ' 199' ' ' PRO . 51.1 mt -73.54 78.35 1.46 Allowed 'General case' 0 C--N 1.351 0.642 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 164.225 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -63.53 99.1 0.2 Allowed 'General case' 0 C--N 1.349 0.557 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -179.552 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 68.6 mt -72.16 95.95 1.73 Allowed 'General case' 0 C--O 1.24 0.563 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 179.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -62.47 139.09 96.63 Favored Pre-proline 0 CA--C 1.556 1.204 0 CA-C-N 115.249 -0.887 . . . . 0.0 109.775 178.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_exo -54.48 111.55 0.75 Allowed 'Trans proline' 0 C--N 1.38 2.219 0 C-N-CA 123.16 2.573 . . . . 0.0 113.862 -173.485 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 63.49 19.17 62.09 Favored Glycine 0 C--N 1.355 1.622 0 O-C-N 123.572 0.545 . . . . 0.0 113.784 179.067 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 56.7 mtpt -129.31 178.55 6.36 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 124.473 1.109 . . . . 0.0 110.348 -173.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -52.81 155.68 3.9 Favored Pre-proline 0 CA--C 1.559 1.291 0 CA-C-N 114.759 -1.109 . . . . 0.0 112.31 169.531 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -69.52 168.74 20.37 Favored 'Trans proline' 0 C--N 1.371 1.711 0 C-N-CA 122.235 1.957 . . . . 0.0 110.932 168.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 16.2 ttm180 -137.09 109.88 7.59 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 172.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . 0.647 ' HB2' ' H ' ' A' ' 19' ' ' GLN . . . -69.4 105.88 2.75 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 172.076 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 24.8 t -113.75 128.23 70.74 Favored 'Isoleucine or valine' 0 C--O 1.24 0.586 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 -178.185 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 14.6 mt-30 -83.73 103.84 13.35 Favored 'General case' 0 C--O 1.237 0.42 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 168.488 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 172' ' ' THR . . . . . 0.463 ' HG1' HG13 ' A' ' 156' ' ' VAL . 11.9 p -106.4 124.25 49.3 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 178.397 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . 0.599 ' H ' ' HA3' ' A' ' 24' ' ' GLY . 50.1 mttm -78.78 132.86 63.32 Favored Pre-proline 0 CA--C 1.548 0.884 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 171.244 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -59.37 171.92 2.2 Favored 'Trans proline' 0 C--N 1.377 2.061 0 C-N-CA 123.38 2.72 . . . . 0.0 114.242 -172.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -164.67 -177.12 37.03 Favored Glycine 0 C--N 1.335 0.512 0 CA-C-N 114.786 -1.097 . . . . 0.0 111.011 -179.644 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.652 ' HB2' HD12 ' A' ' 28' ' ' ILE . 69.6 mt -131.82 159.52 38.28 Favored 'General case' 0 N--CA 1.485 1.319 0 CA-C-N 117.414 0.607 . . . . 0.0 110.07 -174.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 177' ' ' PHE . . . . . 0.727 ' HD2' HG23 ' A' ' 31' ' ' ILE . 0.2 OUTLIER -141.18 125.3 17.32 Favored 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 123.101 0.56 . . . . 0.0 110.839 176.047 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 178' ' ' LYS . . . . . 0.499 ' HA ' ' HA ' ' A' ' 183' ' ' THR . 10.3 ptpp? -95.02 123.08 38.3 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 123.375 0.67 . . . . 0.0 111.028 -173.189 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 52.3 p -95.4 -173.44 2.91 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.771 0.828 . . . . 0.0 109.391 169.739 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 30.3 p-10 -68.9 -22.75 64.15 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 123.003 0.521 . . . . 0.0 110.764 171.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -77.87 -51.28 10.7 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 123.99 0.916 . . . . 0.0 110.322 176.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 164.46 -177.63 40.03 Favored Glycine 0 C--N 1.342 0.897 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.587 -179.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 183' ' ' THR . . . . . 0.499 ' HA ' ' HA ' ' A' ' 178' ' ' LYS . 13.2 t -80.23 136.71 36.52 Favored 'General case' 0 CA--C 1.544 0.749 0 CA-C-O 121.317 0.58 . . . . 0.0 110.735 -177.798 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . 0.421 ' HB ' ' CE1' ' A' ' 177' ' ' PHE . 14.9 mt -119.01 161.27 18.21 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.866 0 C-N-CA 124.9 1.28 . . . . 0.0 107.546 -177.087 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -100.74 138.78 14.05 Favored Glycine 0 C--N 1.349 1.281 0 N-CA-C 112.319 -0.312 . . . . 0.0 112.319 -176.257 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . 0.478 ' HB3' ' CE1' ' A' ' 177' ' ' PHE . . . -162.63 -169.95 2.25 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-O 122.029 0.919 . . . . 0.0 112.543 -169.616 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 187' ' ' VAL . . . . . . . . . . . . . 2.0 p -105.41 100.98 11.69 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.999 0 CA-C-N 113.76 -1.564 . . . . 0.0 107.317 156.513 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 65.8 p -98.38 111.44 23.78 Favored 'General case' 0 C--O 1.24 0.56 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 172.195 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 46.0 tp -146.22 138.41 25.15 Favored 'General case' 0 N--CA 1.485 1.306 0 CA-C-O 120.881 0.372 . . . . 0.0 111.811 -177.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 190' ' ' ASP . . . . . 0.472 ' HA ' ' HA ' ' A' ' 221' ' ' ALA . 32.7 t70 -81.92 103.23 11.42 Favored 'General case' 0 C--N 1.351 0.658 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 170.504 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 191' ' ' PHE . . . . . 0.536 ' HB3' ' HE1' ' A' ' 222' ' ' TYR . 68.2 t80 -177.23 166.71 2.36 Favored 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 124.71 1.204 . . . . 0.0 108.659 -173.655 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 33.7 p -64.94 117.04 35.05 Favored Pre-proline 0 CA--C 1.557 1.22 0 C-N-CA 123.639 0.776 . . . . 0.0 111.234 177.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -62.45 140.7 83.54 Favored 'Trans proline' 0 C--N 1.378 2.109 0 C-N-CA 123.078 2.519 . . . . 0.0 112.855 176.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -84.09 -176.24 51.09 Favored Glycine 0 C--N 1.344 0.977 0 N-CA-C 111.051 -0.819 . . . . 0.0 111.051 168.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 62.5 p -77.39 131.7 38.17 Favored 'General case' 0 CA--C 1.551 0.991 0 CA-C-N 117.149 0.474 . . . . 0.0 110.725 178.072 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -63.57 100.14 0.25 Allowed 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.561 0.744 . . . . 0.0 109.776 -176.833 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 140.05 -1.22 2.19 Favored Glycine 0 C--N 1.341 0.86 0 CA-C-N 114.519 -1.219 . . . . 0.0 112.148 -174.282 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 198' ' ' SER . . . . . 0.467 ' HB2' ' HD2' ' A' ' 211' ' ' TYR . 48.9 m -57.43 138.6 81.18 Favored Pre-proline 0 CA--C 1.558 1.277 0 C-N-CA 123.495 0.718 . . . . 0.0 111.512 173.889 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 199' ' ' PRO . . . . . 0.461 ' HD2' ' HB2' ' A' ' 159' ' ' LEU . 17.3 Cg_exo -67.05 132.81 29.04 Favored 'Trans proline' 0 C--N 1.38 2.203 0 C-N-CA 123.268 2.645 . . . . 0.0 113.492 -177.37 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 200' ' ' ILE . . . . . 0.441 HG21 HG21 ' A' ' 226' ' ' ILE . 16.6 mt -98.81 110.12 25.51 Favored 'Isoleucine or valine' 0 C--O 1.241 0.618 0 CA-C-O 121.982 0.896 . . . . 0.0 109.666 172.421 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 201' ' ' ILE . . . . . . . . . . . . . 47.0 mt -108.91 148.75 12.56 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.894 0 CA-C-N 114.644 -1.162 . . . . 0.0 108.082 177.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 202' ' ' ASP . . . . . 0.539 ' H ' ' HB ' ' A' ' 207' ' ' VAL . 18.1 t70 -89.51 160.21 16.85 Favored 'General case' 0 N--CA 1.48 1.075 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 172.215 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 83.1 tttt -63.37 -15.48 57.61 Favored 'General case' 0 CA--C 1.555 1.141 0 N-CA-C 113.479 0.918 . . . . 0.0 113.479 -170.487 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . 0.483 ' HZ2' ' HB3' ' A' ' 204' ' ' LYS . 7.9 mtpm? -76.42 -1.02 24.94 Favored 'General case' 0 N--CA 1.485 1.318 0 N-CA-C 112.502 0.556 . . . . 0.0 112.502 176.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 82.7 7.01 87.97 Favored Glycine 0 C--N 1.349 1.283 0 CA-C-O 120.913 0.174 . . . . 0.0 112.695 -178.734 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -117.2 164.09 15.31 Favored 'General case' 0 N--CA 1.475 0.793 0 C-N-CA 124.733 1.213 . . . . 0.0 108.714 174.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 207' ' ' VAL . . . . . 0.539 ' HB ' ' H ' ' A' ' 202' ' ' ASP . 57.4 t 90.77 160.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.254 0 C-N-CA 125.905 1.682 . . . . 0.0 108.562 -171.662 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 208' ' ' VAL . . . . . 0.589 HG23 ' HB3' ' A' ' 146' ' ' LEU . 1.8 m -174.34 13.8 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 C-N-CA 124.444 1.098 . . . . 0.0 109.666 -144.391 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.543 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . -64.87 -154.78 0.15 Allowed Glycine 0 C--N 1.354 1.549 0 C-N-CA 124.105 0.86 . . . . 0.0 115.013 -177.098 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 210' ' ' LEU . . . . . 0.431 HD13 HD21 ' A' ' 137' ' ' LEU . 6.0 tt -142.12 133.4 26.34 Favored 'General case' 0 C--O 1.242 0.691 0 O-C-N 122.048 -0.678 . . . . 0.0 110.588 -172.399 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 211' ' ' TYR . . . . . 0.467 ' HD2' ' HB2' ' A' ' 198' ' ' SER . 0.4 OUTLIER -102.49 108.56 19.91 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 124.844 1.258 . . . . 0.0 108.935 175.208 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 212' ' ' GLY . . . . . 0.519 ' O ' ' SD ' ' A' ' 110' ' ' MET . . . 171.22 70.05 0.04 OUTLIER Glycine 0 C--N 1.345 1.081 0 C-N-CA 120.65 -0.786 . . . . 0.0 114.719 156.061 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 213' ' ' ASN . . . . . 0.59 ' HB2' ' HB3' ' A' ' 225' ' ' ALA . 18.5 m120 -131.76 81.85 2.0 Allowed 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 172.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 160.57 -152.38 23.08 Favored Glycine 0 C--O 1.242 0.619 0 CA-C-N 113.965 -1.471 . . . . 0.0 111.341 -178.231 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 215' ' ' VAL . . . . . 0.791 HG12 ' HA ' ' A' ' 40' ' ' SER . 15.8 m -152.57 -173.94 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.213 0 C-N-CA 123.45 0.7 . . . . 0.0 111.235 -167.345 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 216' ' ' VAL . . . . . 0.525 ' HB ' ' HA2' ' A' ' 220' ' ' GLY . 17.0 m -85.15 113.0 22.9 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.771 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 164.706 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 217' ' ' THR . . . . . 0.638 HG22 ' HB3' ' A' ' 29' ' ' LEU . 23.5 m -102.81 158.99 15.88 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 123.944 0.898 . . . . 0.0 109.644 -174.806 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 2.5 tpm_? 69.89 -74.63 0.08 Allowed 'General case' 0 CA--C 1.552 1.023 0 C-N-CA 124.957 1.303 . . . . 0.0 110.095 -176.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 21.8 t -164.42 26.21 0.07 Allowed 'General case' 0 CA--C 1.551 1.007 0 C-N-CA 123.856 0.862 . . . . 0.0 110.148 175.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 220' ' ' GLY . . . . . 0.525 ' HA2' ' HB ' ' A' ' 216' ' ' VAL . . . 141.98 -6.88 2.35 Favored Glycine 0 N--CA 1.477 1.418 0 CA-C-O 119.884 -0.398 . . . . 0.0 113.72 -179.086 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 221' ' ' ALA . . . . . 0.472 ' HA ' ' HA ' ' A' ' 190' ' ' ASP . . . -70.76 97.83 1.44 Allowed 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.943 0.897 . . . . 0.0 110.044 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 222' ' ' TYR . . . . . 0.536 ' HE1' ' HB3' ' A' ' 191' ' ' PHE . 15.8 p90 -66.1 124.72 23.37 Favored 'General case' 0 CA--C 1.544 0.715 0 CA-C-O 121.534 0.683 . . . . 0.0 110.88 -171.08 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . 0.626 HG13 ' HB3' ' A' ' 177' ' ' PHE . 62.1 t -123.92 115.66 45.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 173.721 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 67.9 m -142.71 141.85 31.88 Favored 'General case' 0 N--CA 1.48 1.06 0 O-C-N 123.855 0.722 . . . . 0.0 110.312 176.062 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . 0.59 ' HB3' ' HB2' ' A' ' 213' ' ' ASN . . . -75.31 153.29 37.96 Favored 'General case' 0 C--O 1.244 0.782 0 C-N-CA 123.087 0.555 . . . . 0.0 112.238 -174.656 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 226' ' ' ILE . . . . . 0.441 HG21 HG21 ' A' ' 200' ' ' ILE . 88.9 mt -91.4 103.06 14.12 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.623 0 CA-C-N 114.758 -1.11 . . . . 0.0 109.748 -176.594 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -96.07 152.65 18.34 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 122.895 0.478 . . . . 0.0 109.952 178.36 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -148.19 168.55 22.17 Favored 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 124.515 1.126 . . . . 0.0 109.736 -172.118 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 59.0 p -66.88 110.61 3.38 Favored 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 123.006 0.522 . . . . 0.0 110.527 -176.232 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -116.97 -24.37 7.63 Favored 'General case' 0 N--CA 1.482 1.169 0 C-N-CA 123.418 0.687 . . . . 0.0 111.406 -172.34 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 23.3 mmtp -91.88 -141.02 0.19 Allowed 'General case' 0 CA--C 1.566 1.561 0 C-N-CA 122.974 0.51 . . . . 0.0 109.682 -172.409 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 70.0 p . . . . . 0 N--CA 1.479 0.998 0 C-N-CA 124.221 1.009 . . . . 0.0 108.873 -167.555 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.889 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -131.99 2.09 3.97 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 124.05 0.94 . . . . 0.0 109.742 -175.14 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -127.34 80.65 1.97 Allowed 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 114.526 -1.216 . . . . 0.0 108.14 -168.708 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 5.0 mp -127.05 101.97 6.77 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 -178.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.7 mm-40 -78.65 146.59 33.97 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 123.244 0.618 . . . . 0.0 110.979 -172.403 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . 0.482 HD23 HD13 ' A' ' 119' ' ' LEU . 30.4 mt -90.58 114.39 26.62 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-N 115.042 -0.981 . . . . 0.0 109.14 171.849 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -103.52 120.28 40.54 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 124.503 1.121 . . . . 0.0 108.328 -176.455 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 26.3 ptt180 -59.76 132.69 54.74 Favored 'General case' 0 N--CA 1.475 0.817 0 C-N-CA 122.859 0.464 . . . . 0.0 110.893 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . 0.433 ' HB3' ' HG3' ' A' ' 85' ' ' ARG . . . -121.27 -43.18 2.43 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 122.379 0.272 . . . . 0.0 111.362 -177.046 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . 178.37 -158.45 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 124.184 0.994 . . . . 0.0 110.041 -173.703 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -128.01 164.67 21.86 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 123.777 0.831 . . . . 0.0 108.85 168.503 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 53.9 t -75.45 102.36 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 N-CA-C 109.414 -0.588 . . . . 0.0 109.414 177.444 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 4.5 ptpp? -167.89 146.23 4.56 Favored 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 124.633 1.173 . . . . 0.0 108.557 174.294 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 28.8 t90 -78.99 110.7 14.48 Favored 'General case' 0 CA--C 1.547 0.844 0 O-C-N 123.533 0.52 . . . . 0.0 111.402 -172.505 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -73.68 145.43 45.26 Favored 'General case' 0 CA--C 1.544 0.737 0 CA-C-O 121.66 0.743 . . . . 0.0 111.506 172.427 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -68.01 -1.62 6.14 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 125.47 1.508 . . . . 0.0 112.967 -177.072 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 22.8 mm-40 -80.2 50.4 1.24 Allowed 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 123.766 0.826 . . . . 0.0 111.112 -178.306 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.43 ' HA ' ' O ' ' A' ' 169' ' ' ALA . . . -73.32 84.02 1.42 Allowed 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 124.615 1.166 . . . . 0.0 111.464 -174.67 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 38.8 mt-10 -103.57 123.12 46.35 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 124.031 0.932 . . . . 0.0 110.425 -175.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 9.6 tp -76.91 132.68 32.41 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.134 0 C-N-CA 122.47 0.308 . . . . 0.0 110.763 -177.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 95.7 p -148.68 -35.71 0.19 Allowed 'General case' 0 N--CA 1.484 1.275 0 N-CA-C 112.14 0.422 . . . . 0.0 112.14 175.567 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -53.39 98.1 0.03 OUTLIER Glycine 0 C--N 1.353 1.476 0 N-CA-C 113.917 0.327 . . . . 0.0 113.917 178.45 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 40.7 p -103.9 -68.72 0.83 Allowed 'General case' 0 CA--C 1.547 0.865 0 C-N-CA 124.014 0.926 . . . . 0.0 111.468 -172.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 20.0 m -72.98 126.08 90.7 Favored Pre-proline 0 N--CA 1.477 0.88 0 C-N-CA 123.598 0.759 . . . . 0.0 111.381 -171.12 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -70.85 -74.27 0.01 OUTLIER 'Trans proline' 0 C--N 1.366 1.467 0 C-N-CA 122.13 1.887 . . . . 0.0 111.59 167.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 51.0 mm -90.55 121.12 40.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.913 0 C-N-CA 123.26 0.624 . . . . 0.0 111.448 -167.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.404 ' O ' ' HA ' ' A' ' 177' ' ' PHE . 17.2 mt -143.37 133.48 24.34 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 123.737 0.815 . . . . 0.0 110.333 174.068 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 35.0 p -97.07 140.02 32.21 Favored 'General case' 0 N--CA 1.477 0.892 0 C-N-CA 123.851 0.86 . . . . 0.0 110.538 179.189 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 39.5 mt -131.53 160.58 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 124.265 1.026 . . . . 0.0 108.594 -178.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 66.7 p -96.03 114.33 26.03 Favored 'General case' 0 C--N 1.367 1.327 0 CA-C-N 118.889 0.768 . . . . 0.0 109.001 176.102 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 8.8 mm -55.93 125.89 12.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 C-N-CA 123.987 0.915 . . . . 0.0 109.934 175.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 5.8 m -117.42 135.53 53.82 Favored 'General case' 0 C--O 1.252 1.224 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 30.4 tt0 60.3 28.82 18.46 Favored 'General case' 0 CA--C 1.558 1.263 0 C-N-CA 124.725 1.21 . . . . 0.0 110.791 178.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 3.8 p30 46.5 30.05 1.02 Allowed 'General case' 0 N--CA 1.493 1.708 0 C-N-CA 125.631 1.572 . . . . 0.0 113.109 -174.584 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -145.13 -63.7 0.02 OUTLIER Glycine 0 C--N 1.353 1.515 0 CA-C-N 116.562 -0.29 . . . . 0.0 112.487 -177.67 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 38.8 t -105.85 125.97 51.62 Favored 'General case' 0 N--CA 1.486 1.361 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 -172.242 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' MET . . . . . 0.44 ' HE3' ' HB2' ' A' ' 39' ' ' MET . 1.8 mpp? -88.8 136.95 32.74 Favored 'General case' 0 CA--C 1.546 0.823 0 O-C-N 121.875 -0.515 . . . . 0.0 111.472 -173.745 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.5 m -125.15 164.12 20.95 Favored 'General case' 0 N--CA 1.482 1.125 0 C-N-CA 124.622 1.169 . . . . 0.0 109.915 176.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.454 ' H ' HG23 ' A' ' 215' ' ' VAL . 7.5 tp -93.07 92.51 3.74 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.845 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 -177.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 42.5 mmtm 57.88 -74.78 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.336 0 C-N-CA 123.382 0.673 . . . . 0.0 109.831 -161.238 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 5.2 p30 -147.32 118.16 7.62 Favored 'General case' 0 CA--C 1.552 1.045 0 C-N-CA 124.608 1.163 . . . . 0.0 110.034 175.181 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -174.13 130.78 0.39 Allowed 'General case' 0 N--CA 1.492 1.629 0 C-N-CA 123.685 0.794 . . . . 0.0 109.176 171.275 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 CA--C 1.554 1.108 0 C-N-CA 123.42 0.688 . . . . 0.0 110.104 -178.275 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . 0.666 ' HB2' ' HD2' ' A' ' 103' ' ' LYS . 8.2 p-10 . . . . . 0 CA--C 1.54 0.57 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 168.32 178.92 40.4 Favored Glycine 0 C--N 1.339 0.699 0 CA-C-N 115.973 -0.558 . . . . 0.0 112.42 177.268 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . 0.53 ' HB1' HD11 ' A' ' 161' ' ' LEU . . . -88.32 125.07 34.5 Favored 'General case' 0 CA--C 1.549 0.911 0 C-N-CA 123.947 0.899 . . . . 0.0 109.79 176.717 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 -122.12 148.46 44.87 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 123.596 0.758 . . . . 0.0 109.963 -177.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' ARG . . . . . 0.762 ' HG2' HG23 ' A' ' 195' ' ' THR . 37.3 mtm-85 -95.99 124.43 39.99 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 166.05 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.465 ' H ' ' HA ' ' A' ' 99' ' ' ALA . 27.8 mt -90.65 131.05 38.83 Favored 'Isoleucine or valine' 0 C--O 1.26 1.656 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . 0.426 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 0.2 OUTLIER -124.67 140.83 52.58 Favored 'General case' 0 N--CA 1.45 -0.459 0 CA-C-N 114.504 -1.226 . . . . 0.0 108.684 -174.224 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -84.76 104.09 14.42 Favored 'General case' 0 C--N 1.344 0.331 0 N-CA-C 104.581 -2.377 . . . . 0.0 104.581 175.549 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 14.4 tmtt? -120.64 98.27 5.95 Favored 'General case' 0 CA--C 1.518 -0.288 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 -170.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -79.91 152.47 35.01 Favored Glycine 0 C--O 1.242 0.644 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 170.359 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 2.3 mp -78.46 70.26 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.13 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 174.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 58.7 tp 167.29 -41.4 0.0 OUTLIER 'General case' 0 CA--C 1.554 1.123 0 C-N-CA 126.388 1.875 . . . . 0.0 109.029 -167.04 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -148.22 161.02 28.53 Favored Glycine 0 C--N 1.365 2.174 0 N-CA-C 114.8 0.68 . . . . 0.0 114.8 -169.56 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 77.4 m-85 -132.12 129.33 39.73 Favored 'General case' 0 N--CA 1.481 1.095 0 C-N-CA 124.049 0.94 . . . . 0.0 110.427 -172.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 24.5 m -145.42 153.75 41.53 Favored 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 124.652 1.181 . . . . 0.0 108.254 175.173 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . 0.426 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 1.5 pp0? -96.15 146.72 24.43 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-N 118.738 0.699 . . . . 0.0 109.242 168.509 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.43 HD13 HG21 ' A' ' 86' ' ' ILE . 1.6 pp -136.71 -10.03 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 177.443 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . 0.535 ' HA3' HG11 ' A' ' 113' ' ' VAL . . . 168.26 -147.06 11.01 Favored Glycine 0 C--N 1.348 1.241 0 C-N-CA 121.003 -0.618 . . . . 0.0 113.19 174.049 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.465 ' HA ' ' H ' ' A' ' 86' ' ' ILE . . . -154.33 153.76 32.2 Favored 'General case' 0 C--O 1.24 0.603 0 C-N-CA 123.663 0.785 . . . . 0.0 111.196 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -155.75 157.18 27.58 Favored Glycine 0 C--N 1.338 0.665 0 CA-C-N 114.937 -1.029 . . . . 0.0 111.209 178.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 53.1 t -120.82 120.69 63.16 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.778 0 C-N-CA 123.528 0.731 . . . . 0.0 111.517 -169.376 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.524 ' HB3' ' HA ' ' A' ' 81' ' ' ASP . 10.6 m-85 -74.36 135.81 42.47 Favored 'General case' 0 N--CA 1.482 1.163 0 N-CA-C 107.861 -1.163 . . . . 0.0 107.861 165.037 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.666 ' HD2' ' HB2' ' A' ' 81' ' ' ASP . 29.3 tptt -172.4 149.71 2.23 Favored 'General case' 0 N--CA 1.483 1.177 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 171.322 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 60.21 20.14 9.52 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 124.494 1.118 . . . . 0.0 112.048 -178.771 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 80.09 17.06 75.32 Favored Glycine 0 C--N 1.346 1.115 0 CA-C-N 116.036 -0.529 . . . . 0.0 114.377 -178.011 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 18.8 p -140.07 137.18 34.36 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.604 0.762 . . . . 0.0 109.716 -176.316 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' PHE . . . . . 0.595 ' HB3' ' HB2' ' A' ' 140' ' ' TYR . 42.2 t80 -89.87 103.43 16.09 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 120.937 0.399 . . . . 0.0 111.131 -175.084 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . 0.601 ' HB3' ' HE3' ' A' ' 144' ' ' TRP . 18.6 m170 -100.4 114.25 27.65 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 124.488 1.115 . . . . 0.0 110.563 -176.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' THR . . . . . 0.536 HG21 HG21 ' A' ' 138' ' ' ILE . 3.9 t -135.71 175.44 9.59 Favored 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 118.758 0.708 . . . . 0.0 112.158 -177.86 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' MET . . . . . 0.683 ' HE1' ' HA2' ' A' ' 212' ' ' GLY . 79.2 mmm -87.95 154.47 20.48 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 123.886 0.874 . . . . 0.0 109.014 172.807 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' TRP . . . . . 0.411 ' CE2' HG21 ' A' ' 133' ' ' VAL . 50.2 t90 -71.52 -45.74 61.58 Favored 'General case' 0 N--CA 1.486 1.338 0 CA-C-N 118.159 0.436 . . . . 0.0 111.504 -170.611 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . 0.481 ' HD1' ' HB3' ' A' ' 213' ' ' ASN . 4.3 p-80 -51.52 -21.09 2.21 Favored 'General case' 0 N--CA 1.488 1.465 0 C-N-CA 124.769 1.228 . . . . 0.0 114.247 -173.146 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.535 HG11 ' HA3' ' A' ' 98' ' ' GLY . 16.6 m -59.85 -44.14 93.53 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 CA-C-O 121.43 0.633 . . . . 0.0 110.265 -178.603 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 9.0 t -113.76 168.51 9.72 Favored 'General case' 0 C--O 1.238 0.488 0 C-N-CA 123.905 0.882 . . . . 0.0 109.212 -179.45 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 92.9 mtt180 -95.95 33.43 1.7 Allowed 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 124.194 0.997 . . . . 0.0 109.132 178.146 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 68.81 38.85 85.82 Favored Glycine 0 C--N 1.362 1.983 0 CA-C-N 115.158 -0.928 . . . . 0.0 111.528 -174.193 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -127.83 -179.96 5.23 Favored 'General case' 0 C--O 1.244 0.763 0 C-N-CA 123.647 0.779 . . . . 0.0 110.955 -171.106 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.2 p -75.4 139.65 18.71 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.211 0 CA-C-N 114.716 -1.129 . . . . 0.0 111.963 -176.329 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.482 HD13 HD23 ' A' ' 8' ' ' LEU . 58.3 mt -97.9 -177.78 3.87 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 124.084 0.953 . . . . 0.0 110.77 177.812 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 23.2 mmt -133.49 147.9 51.67 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 125.308 1.443 . . . . 0.0 109.762 -176.557 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.739 ' HB2' HD13 ' A' ' 126' ' ' ILE . 34.9 t-80 -151.03 96.63 2.35 Favored 'General case' 0 CA--C 1.54 0.595 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 25.5 ttpp 57.69 29.77 17.83 Favored 'General case' 0 N--CA 1.496 1.826 0 C-N-CA 124.186 0.995 . . . . 0.0 111.117 -175.693 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 94.95 -3.53 67.3 Favored Glycine 0 C--N 1.345 1.043 0 CA-C-N 115.768 -0.651 . . . . 0.0 113.47 -179.628 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -94.92 122.45 37.57 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 122.92 0.488 . . . . 0.0 109.92 177.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 91.0 mtm-85 -69.39 146.01 52.41 Favored 'General case' 0 C--O 1.243 0.734 0 C-N-CA 123.774 0.83 . . . . 0.0 111.976 178.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.739 HD13 ' HB2' ' A' ' 121' ' ' HIS . 5.0 mt -127.19 112.41 28.51 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.801 0 C-N-CA 123.791 0.836 . . . . 0.0 109.225 -179.0 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -83.01 139.36 42.68 Favored Pre-proline 0 CA--C 1.554 1.104 0 C-N-CA 123.838 0.855 . . . . 0.0 110.025 179.007 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -75.61 148.7 33.34 Favored 'Trans proline' 0 C--N 1.379 2.181 0 C-N-CA 122.808 2.339 . . . . 0.0 112.482 179.462 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 32.5 p -109.23 -32.35 7.23 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 124.031 0.932 . . . . 0.0 110.707 177.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 4.5 t-105 -132.87 144.03 49.91 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 107.624 -1.251 . . . . 0.0 107.624 -176.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -160.53 123.53 3.37 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.205 0.602 . . . . 0.0 110.222 178.488 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 41.4 m-20 -123.32 105.23 9.67 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 124.345 1.058 . . . . 0.0 108.552 167.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.411 HG21 ' CE2' ' A' ' 111' ' ' TRP . 16.7 t -68.24 -33.39 60.36 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.884 0 C-N-CA 123.53 0.732 . . . . 0.0 109.313 175.164 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -72.01 -33.13 67.82 Favored 'General case' 0 CA--C 1.547 0.863 0 CA-C-N 114.347 -1.297 . . . . 0.0 111.926 -179.177 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -97.07 -7.47 32.7 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 122.946 0.498 . . . . 0.0 111.792 179.586 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 27.5 t70 60.85 47.52 7.69 Favored 'General case' 0 CA--C 1.548 0.873 0 CA-C-O 122.449 1.118 . . . . 0.0 110.604 -178.027 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 49.7 mt -135.1 147.9 49.66 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 123.833 0.853 . . . . 0.0 109.557 176.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.536 HG21 HG21 ' A' ' 109' ' ' THR . 18.4 tt -153.54 143.66 14.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 N-CA-C 107.313 -1.365 . . . . 0.0 107.313 173.441 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' SER . . . . . 0.478 ' HB3' ' HA2' ' A' ' 143' ' ' GLY . 44.1 t -150.68 152.89 34.63 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-O 121.876 0.846 . . . . 0.0 110.97 -175.378 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.595 ' HB2' ' HB3' ' A' ' 107' ' ' PHE . 8.7 m-85 -125.26 108.71 12.0 Favored 'General case' 0 CA--C 1.543 0.708 0 CA-C-N 113.524 -1.671 . . . . 0.0 107.499 -164.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 97.48 -4.33 61.9 Favored Glycine 0 C--N 1.348 1.243 0 CA-C-N 116.149 -0.478 . . . . 0.0 112.821 -173.339 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 171.14 -152.64 18.77 Favored Glycine 0 C--N 1.347 1.163 0 CA-C-O 118.744 -1.031 . . . . 0.0 111.295 -179.625 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.478 ' HA2' ' HB3' ' A' ' 139' ' ' SER . . . -119.6 170.2 13.99 Favored Glycine 0 C--N 1.357 1.743 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 173.338 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' TRP . . . . . 0.601 ' HE3' ' HB3' ' A' ' 108' ' ' HIS . 41.6 t-105 -60.23 108.88 0.86 Allowed 'General case' 0 N--CA 1.483 1.188 0 CA-C-O 121.671 0.748 . . . . 0.0 110.728 176.291 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . 0.632 ' HA ' HG21 ' A' ' 229' ' ' THR . 0.0 OUTLIER -145.54 135.1 23.26 Favored 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 114.903 -1.044 . . . . 0.0 108.824 171.007 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' LEU . . . . . 0.603 HD22 ' HB3' ' A' ' 103' ' ' LYS . 13.6 mt -144.69 10.29 1.38 Allowed 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 123.67 0.788 . . . . 0.0 110.586 168.607 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 14.3 tt0 75.37 -18.5 0.44 Allowed 'General case' 0 N--CA 1.498 1.942 0 C-N-CA 124.67 1.188 . . . . 0.0 111.431 177.071 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . 0.411 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -77.65 138.47 21.66 Favored Glycine 0 C--N 1.346 1.119 0 C-N-CA 123.4 0.524 . . . . 0.0 113.135 -169.478 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -130.1 142.03 50.64 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 124.306 1.042 . . . . 0.0 108.399 -178.565 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' TRP . . . . . . . . . . . . . 43.2 t90 -73.19 137.34 44.99 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 122.719 0.407 . . . . 0.0 110.759 172.357 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 54.3 tttm -92.85 133.57 35.94 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 123.776 0.83 . . . . 0.0 109.225 174.368 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -66.85 146.42 54.44 Favored 'General case' 0 N--CA 1.479 1.012 0 CA-C-O 121.118 0.485 . . . . 0.0 111.826 178.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 92.56 -12.89 68.72 Favored Glycine 0 C--N 1.348 1.237 0 CA-C-N 115.027 -0.988 . . . . 0.0 112.921 -177.571 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 29.7 mm-40 -94.07 131.83 39.18 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 123.045 0.538 . . . . 0.0 111.696 -173.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -76.06 123.78 26.34 Favored 'General case' 0 C--O 1.245 0.863 0 N-CA-C 107.008 -1.478 . . . . 0.0 107.008 162.489 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -91.13 158.76 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 -168.544 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . 0.408 ' OE1' ' HG2' ' A' ' 171' ' ' GLN . 13.9 mm100 -100.58 133.61 44.77 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 123.32 0.648 . . . . 0.0 109.297 179.561 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 46.2 t -107.84 102.35 13.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 107.164 -1.421 . . . . 0.0 107.164 177.516 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.539 HD22 ' HB3' ' A' ' 169' ' ' ALA . 1.8 tm? -74.93 78.42 2.16 Favored 'General case' 0 CA--C 1.546 0.796 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 -175.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -72.05 110.18 6.36 Favored 'General case' 0 C--O 1.242 0.699 0 CA-C-N 114.129 -1.396 . . . . 0.0 111.004 -168.359 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . 0.53 HD11 ' HB1' ' A' ' 83' ' ' ALA . 29.9 mt -81.55 83.89 6.89 Favored 'General case' 0 C--O 1.24 0.599 0 CA-C-N 115.099 -0.955 . . . . 0.0 109.182 177.371 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 29.7 mm-40 -68.74 126.92 93.2 Favored Pre-proline 0 CA--C 1.552 1.031 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 174.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -61.77 115.76 3.01 Favored 'Trans proline' 0 C--N 1.384 2.4 0 C-N-CA 123.231 2.621 . . . . 0.0 112.503 -174.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 81.61 10.99 83.62 Favored Glycine 0 C--N 1.351 1.388 0 CA-C-N 115.485 -0.78 . . . . 0.0 113.467 -179.36 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 49.5 mttp -128.54 172.45 11.16 Favored 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 123.395 0.678 . . . . 0.0 110.9 -178.41 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -74.03 156.59 87.74 Favored Pre-proline 0 CA--C 1.555 1.159 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.989 173.826 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 15.8 Cg_exo -68.79 137.38 38.25 Favored 'Trans proline' 0 C--N 1.375 1.937 0 C-N-CA 122.581 2.187 . . . . 0.0 112.568 178.179 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 69.5 mtp180 -117.06 105.75 12.63 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 176.396 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . 0.539 ' HB3' HD22 ' A' ' 159' ' ' LEU . . . -86.04 103.3 14.6 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-O 121.034 0.445 . . . . 0.0 110.559 -176.797 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 42.8 t -94.63 129.71 44.46 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.718 0 C-N-CA 124.288 1.035 . . . . 0.0 111.269 -164.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 171' ' ' GLN . . . . . 0.408 ' HG2' ' OE1' ' A' ' 157' ' ' GLN . 20.6 mt-30 -79.3 121.37 25.01 Favored 'General case' 0 C--N 1.354 0.767 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 178.627 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 41.9 p -140.34 124.76 17.84 Favored 'General case' 0 C--O 1.237 0.436 0 C-N-CA 122.92 0.488 . . . . 0.0 109.753 -173.064 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 62.2 tttp -70.17 127.58 92.16 Favored Pre-proline 0 CA--C 1.547 0.862 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 171.487 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_exo -57.91 126.4 21.57 Favored 'Trans proline' 0 C--N 1.379 2.175 0 C-N-CA 122.686 2.257 . . . . 0.0 112.767 -179.574 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -98.34 178.44 31.6 Favored Glycine 0 C--N 1.337 0.638 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.391 176.488 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 5.3 mp -141.3 146.3 36.58 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 123.501 0.72 . . . . 0.0 109.267 176.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 177' ' ' PHE . . . . . 0.674 ' HE1' HG12 ' A' ' 223' ' ' VAL . 22.3 m-85 -93.47 121.63 35.07 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 176.551 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 57.1 tptt -86.29 95.87 9.77 Favored 'General case' 0 CA--C 1.541 0.596 0 O-C-N 123.783 0.677 . . . . 0.0 109.201 177.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 179' ' ' THR . . . . . 0.467 HG21 ' H ' ' A' ' 181' ' ' ALA . 23.0 m -110.47 150.6 28.63 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 176.383 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 24.7 p30 -61.75 -24.35 66.76 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 123.578 0.751 . . . . 0.0 111.914 175.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . 0.467 ' H ' HG21 ' A' ' 179' ' ' THR . . . -74.18 -39.91 62.87 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.274 1.03 . . . . 0.0 111.388 174.579 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 169.25 -174.16 43.67 Favored Glycine 0 C--N 1.341 0.841 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.569 -177.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 13.2 t -97.78 134.55 40.78 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 175.2 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . 0.557 ' HB ' ' HB2' ' A' ' 177' ' ' PHE . 23.6 mt -104.65 160.02 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 177.905 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -99.09 124.23 8.16 Favored Glycine 0 C--N 1.349 1.279 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 179.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . 0.43 ' HA ' ' HA ' ' A' ' 225' ' ' ALA . . . -147.98 -165.56 2.3 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-O 121.22 0.533 . . . . 0.0 112.395 -161.753 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 187' ' ' VAL . . . . . . . . . . . . . 4.7 p -158.39 131.12 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.728 0 C-N-CA 124.615 1.166 . . . . 0.0 108.9 175.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 7.1 m -111.42 103.5 11.87 Favored 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 123.118 0.567 . . . . 0.0 110.168 176.557 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 4.3 pp -125.67 141.63 51.92 Favored 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 123.37 0.668 . . . . 0.0 109.224 179.586 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -113.53 104.49 12.31 Favored 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 168.102 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 191' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -163.07 -178.3 5.96 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 124.143 0.977 . . . . 0.0 108.725 -170.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 31.4 m -52.11 122.34 23.21 Favored Pre-proline 0 CA--C 1.549 0.939 0 CA-C-O 118.542 -0.742 . . . . 0.0 109.86 170.406 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -61.57 91.31 0.11 Allowed 'Trans proline' 0 C--N 1.378 2.129 0 C-N-CA 122.695 2.263 . . . . 0.0 112.155 -173.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -60.02 123.28 32.62 Favored Glycine 0 C--N 1.348 1.219 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 172.43 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 195' ' ' THR . . . . . 0.762 HG23 ' HG2' ' A' ' 85' ' ' ARG . 8.8 t -54.22 144.37 20.24 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-O 121.663 0.744 . . . . 0.0 112.035 -173.207 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 196' ' ' SER . . . . . 0.47 ' HA ' ' HD2' ' A' ' 211' ' ' TYR . 13.4 m -72.28 95.56 1.72 Allowed 'General case' 0 C--O 1.242 0.688 0 CA-C-N 115.077 -0.965 . . . . 0.0 111.406 -169.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 197' ' ' GLY . . . . . 0.415 ' H ' ' HB3' ' A' ' 211' ' ' TYR . . . 133.63 4.94 2.99 Favored Glycine 0 C--N 1.34 0.753 0 CA-C-N 115.279 -0.873 . . . . 0.0 111.663 -176.684 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 72.0 m -56.32 131.81 75.86 Favored Pre-proline 0 C--N 1.361 1.101 0 C-N-CA 123.143 0.577 . . . . 0.0 110.229 171.089 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -64.23 111.67 1.67 Allowed 'Trans proline' 0 C--N 1.372 1.777 0 C-N-CA 122.209 1.939 . . . . 0.0 111.635 -176.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 200' ' ' ILE . . . . . 0.423 HD13 ' HA ' ' A' ' 211' ' ' TYR . 55.3 mt -77.93 111.69 15.04 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.414 0 N-CA-C 107.964 -1.125 . . . . 0.0 107.964 174.32 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 201' ' ' ILE . . . . . 0.429 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 63.5 mt -112.28 148.51 15.33 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.61 0 C-N-CA 124.741 1.216 . . . . 0.0 108.739 -174.545 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -71.55 160.49 32.61 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 123.802 0.841 . . . . 0.0 108.871 171.823 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 203' ' ' LYS . . . . . 0.587 ' HZ3' ' HB2' ' A' ' 203' ' ' LYS . 3.7 ttmp? -70.17 -13.18 62.07 Favored 'General case' 0 N--CA 1.483 1.195 0 C-N-CA 123.343 0.657 . . . . 0.0 111.358 -178.841 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 27.1 mtpp -89.23 15.11 9.46 Favored 'General case' 0 CA--C 1.552 1.052 0 C-N-CA 123.9 0.88 . . . . 0.0 111.788 175.499 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 70.53 22.9 77.94 Favored Glycine 0 C--N 1.356 1.642 0 O-C-N 123.102 0.251 . . . . 0.0 113.316 176.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 22.1 ttpt -112.62 112.84 24.65 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 124.715 1.206 . . . . 0.0 108.261 -176.585 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 207' ' ' VAL . . . . . 0.429 ' HA ' ' HA ' ' A' ' 201' ' ' ILE . 7.4 p -56.61 141.64 13.19 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 CA-C-N 118.953 0.797 . . . . 0.0 110.714 179.057 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 6.0 m -119.02 -33.9 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 C-N-CA 122.606 0.363 . . . . 0.0 110.363 178.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . . . . . . . . . . . -175.82 -167.13 34.33 Favored Glycine 0 C--N 1.349 1.304 0 O-C-N 123.197 0.311 . . . . 0.0 113.819 -174.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 210' ' ' LEU . . . . . 0.491 ' HB2' ' SD ' ' A' ' 110' ' ' MET . 87.3 mt -117.29 156.2 28.2 Favored 'General case' 0 C--O 1.255 1.356 0 C-N-CA 124.196 0.998 . . . . 0.0 109.916 175.107 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 211' ' ' TYR . . . . . 0.47 ' HD2' ' HA ' ' A' ' 196' ' ' SER . 37.8 t80 -73.33 116.09 13.47 Favored 'General case' 0 C--N 1.35 0.63 0 CA-C-N 114.644 -1.162 . . . . 0.0 109.251 178.561 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 212' ' ' GLY . . . . . 0.683 ' HA2' ' HE1' ' A' ' 110' ' ' MET . . . -73.99 -142.74 0.7 Allowed Glycine 0 C--N 1.339 0.731 0 O-C-N 124.051 0.844 . . . . 0.0 114.272 -174.291 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 213' ' ' ASN . . . . . 0.481 ' HB3' ' HD1' ' A' ' 112' ' ' HIS . 3.9 p30 -127.96 159.23 35.62 Favored 'General case' 0 C--O 1.239 0.503 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 -177.27 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 173.62 -136.03 3.47 Favored Glycine 0 N--CA 1.438 -1.227 0 N-CA-C 109.646 -1.381 . . . . 0.0 109.646 178.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 215' ' ' VAL . . . . . 0.454 HG23 ' H ' ' A' ' 41' ' ' ILE . 11.3 p -170.0 170.75 0.16 Allowed 'Isoleucine or valine' 0 C--O 1.242 0.683 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 -172.163 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 216' ' ' VAL . . . . . 0.464 ' HA ' ' O ' ' A' ' 221' ' ' ALA . 35.7 m -70.28 112.6 5.25 Favored 'Isoleucine or valine' 0 CA--C 1.557 1.221 0 CA-C-O 121.882 0.848 . . . . 0.0 108.908 168.548 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 217' ' ' THR . . . . . . . . . . . . . 8.3 m -119.69 171.84 8.1 Favored 'General case' 0 C--O 1.254 1.323 0 C-N-CA 124.661 1.184 . . . . 0.0 108.393 -174.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 22.2 ttt180 73.46 -74.68 0.08 Allowed 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 124.636 1.174 . . . . 0.0 110.327 -179.205 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 35.8 p -148.06 -0.47 0.6 Allowed 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 123.651 0.78 . . . . 0.0 111.297 -178.298 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 220' ' ' GLY . . . . . 0.425 ' HA2' ' HB ' ' A' ' 216' ' ' VAL . . . 134.27 12.55 1.42 Allowed Glycine 0 C--N 1.351 1.386 0 CA-C-O 120.0 -0.334 . . . . 0.0 113.048 -174.586 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 221' ' ' ALA . . . . . 0.473 ' O ' HG22 ' A' ' 223' ' ' VAL . . . -78.61 139.99 38.5 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 123.023 0.529 . . . . 0.0 109.597 178.449 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 222' ' ' TYR . . . . . . . . . . . . . 37.8 m-85 -78.81 99.21 6.61 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 123.614 0.766 . . . . 0.0 109.532 -176.093 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . 0.674 HG12 ' HE1' ' A' ' 177' ' ' PHE . 39.1 t -118.91 111.31 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 123.142 0.577 . . . . 0.0 110.148 -169.167 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 16.5 m -137.54 159.57 41.58 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.242 1.017 . . . . 0.0 110.554 -171.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . 0.43 ' HA ' ' HA ' ' A' ' 186' ' ' ALA . . . -70.93 171.92 9.89 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 123.921 0.888 . . . . 0.0 112.309 -179.009 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 226' ' ' ILE . . . . . . . . . . . . . 39.3 mt -127.22 124.47 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.183 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 173.298 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -114.18 109.67 18.77 Favored 'General case' 0 N--CA 1.487 1.402 0 CA-C-N 118.019 0.372 . . . . 0.0 110.525 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 -92.89 168.97 10.81 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 123.673 0.789 . . . . 0.0 111.37 -176.477 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.632 HG21 ' HA ' ' A' ' 145' ' ' LYS . 97.4 m -64.41 108.37 1.61 Allowed 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.602 0.761 . . . . 0.0 111.089 -174.736 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 16.2 mm-40 -156.34 12.98 0.29 Allowed 'General case' 0 N--CA 1.484 1.245 0 C-N-CA 123.645 0.778 . . . . 0.0 112.173 -176.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 231' ' ' LYS . . . . . 0.524 ' HA ' ' HE2' ' A' ' 231' ' ' LYS . 11.1 mmpt? -96.52 -92.33 0.22 Allowed 'General case' 0 N--CA 1.486 1.334 0 CA-C-N 119.103 0.865 . . . . 0.0 111.955 -174.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 66.8 p . . . . . 0 C--N 1.353 0.754 0 CA-C-N 118.735 0.698 . . . . 0.0 112.255 -169.362 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.173 0 CA-C-O 120.997 0.427 . . . . 0.0 111.054 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -163.48 20.74 0.08 Allowed 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 123.901 0.88 . . . . 0.0 109.406 -171.778 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 21.1 p-10 -142.84 58.83 1.43 Allowed 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 114.426 -1.261 . . . . 0.0 108.938 -162.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . 0.476 ' HG ' ' HG2' ' A' ' 88' ' ' GLN . 2.9 mp -134.32 117.73 16.72 Favored 'General case' 0 C--O 1.207 -1.149 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 173.143 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.476 ' HB3' ' HE3' ' A' ' 87' ' ' LYS . 37.4 tt0 -114.48 156.26 24.89 Favored 'General case' 0 N--CA 1.495 1.789 0 CA-C-N 119.745 1.157 . . . . 0.0 112.202 -175.645 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 81.6 mt -95.77 143.07 27.32 Favored 'General case' 0 N--CA 1.481 1.121 0 C-N-CA 124.161 0.984 . . . . 0.0 113.011 178.446 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 -131.34 116.3 17.39 Favored 'General case' 0 N--CA 1.483 1.18 0 C-N-CA 124.283 1.033 . . . . 0.0 108.637 172.349 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.512 ' HA ' ' HA ' ' A' ' 84' ' ' TYR . 36.7 ptt85 -62.33 110.66 1.71 Allowed 'General case' 0 N--CA 1.487 1.407 0 CA-C-N 119.503 1.047 . . . . 0.0 110.17 173.671 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . 0.491 ' HB2' HD13 ' A' ' 161' ' ' LEU . . . -91.5 -28.3 17.69 Favored 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 123.552 0.741 . . . . 0.0 110.457 -177.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -160.22 175.05 13.34 Favored 'General case' 0 C--O 1.239 0.504 0 C-N-CA 123.808 0.843 . . . . 0.0 110.613 -179.366 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -102.66 170.1 8.23 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 124.044 0.938 . . . . 0.0 109.947 175.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.631 HG23 ' HA2' ' A' ' 82' ' ' GLY . 82.0 t -72.22 101.54 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.626 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 167.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 31.0 ttmt -169.08 140.79 2.49 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -169.589 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 28.6 t90 -102.45 122.3 44.05 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 122.745 0.418 . . . . 0.0 110.064 179.313 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -81.33 146.18 30.5 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 124.08 0.952 . . . . 0.0 110.889 171.713 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -73.95 0.89 12.09 Favored 'General case' 0 N--CA 1.483 1.182 0 C-N-CA 124.325 1.05 . . . . 0.0 112.607 176.758 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 23.9 mt-30 -75.96 14.95 0.6 Allowed 'General case' 0 CA--C 1.555 1.143 0 C-N-CA 124.325 1.05 . . . . 0.0 112.966 -176.169 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.454 ' HB1' ' HB2' ' A' ' 171' ' ' GLN . . . -52.99 90.64 0.01 OUTLIER 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 124.367 1.067 . . . . 0.0 113.255 -168.594 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -62.56 131.94 50.75 Favored 'General case' 0 C--N 1.353 0.745 0 C-N-CA 124.46 1.104 . . . . 0.0 110.64 -178.876 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 3.0 mp -75.37 111.0 11.11 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 -173.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 19.1 m -142.13 179.35 6.95 Favored 'General case' 0 C--O 1.246 0.885 0 C-N-CA 124.663 1.185 . . . . 0.0 109.208 -175.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.433 ' HA2' ' O ' ' A' ' 188' ' ' SER . . . 88.27 84.75 1.23 Allowed Glycine 0 C--N 1.341 0.823 0 N-CA-C 111.306 -0.717 . . . . 0.0 111.306 -176.821 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 50.4 m -150.3 -28.13 0.23 Allowed 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.14 0.576 . . . . 0.0 111.555 -177.471 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 9.3 p -66.14 126.55 92.15 Favored Pre-proline 0 CA--C 1.553 1.086 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 177.612 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -75.82 -165.3 0.29 Allowed 'Trans proline' 0 C--N 1.377 2.061 0 C-N-CA 123.214 2.609 . . . . 0.0 113.452 -172.587 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.404 HD12 ' HG ' ' A' ' 176' ' ' LEU . 36.3 mm -63.17 111.82 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.953 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 177.833 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.603 HD22 ' HB2' ' A' ' 218' ' ' ARG . 0.3 OUTLIER -109.59 160.33 16.35 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.218 -172.249 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.424 ' H ' HD23 ' A' ' 29' ' ' LEU . 65.6 m -94.54 149.12 21.56 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 123.119 0.568 . . . . 0.0 110.05 171.608 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 17.6 tt -139.31 160.55 28.58 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.593 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 27.7 m -93.9 105.91 17.91 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 108.693 -0.855 . . . . 0.0 108.693 178.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 10.8 tp -73.71 148.55 8.49 Favored 'Isoleucine or valine' 0 C--O 1.246 0.903 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 169.803 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' SER . . . . . 0.505 ' HB2' ' HB2' ' A' ' 38' ' ' SER . 50.4 m -138.48 138.7 38.34 Favored 'General case' 0 C--O 1.242 0.695 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 178.302 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -60.41 156.47 15.92 Favored 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 123.499 0.72 . . . . 0.0 111.105 -174.61 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.8 t70 77.85 21.35 0.94 Allowed 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 125.317 1.447 . . . . 0.0 110.727 -179.01 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 78.7 38.49 23.87 Favored Glycine 0 C--N 1.35 1.317 0 CA-C-N 115.556 -0.747 . . . . 0.0 113.755 174.021 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' SER . . . . . 0.505 ' HB2' ' HB2' ' A' ' 34' ' ' SER . 28.4 m -107.33 150.36 26.78 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 122.937 0.495 . . . . 0.0 109.793 175.589 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 5.4 ptm -160.65 123.8 3.37 Favored 'General case' 0 N--CA 1.481 1.107 0 CA-C-O 120.901 0.382 . . . . 0.0 111.723 -175.041 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.457 ' HA ' HG13 ' A' ' 215' ' ' VAL . 15.7 p -177.42 -176.17 0.6 Allowed 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 124.549 1.139 . . . . 0.0 109.434 -178.525 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 1.4 mp -92.13 131.09 40.16 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 N-CA-C 105.796 -1.928 . . . . 0.0 105.796 156.283 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 49.3 pttt -52.98 89.76 0.01 OUTLIER 'General case' 0 CA--C 1.551 0.986 0 C-N-CA 124.531 1.132 . . . . 0.0 112.048 -177.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 64.0 m-20 -158.13 149.82 21.53 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.462 1.505 . . . . 0.0 108.329 -177.251 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -68.69 108.62 3.46 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 123.328 0.651 . . . . 0.0 110.234 -179.605 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 . . . . . 0 CA--C 1.537 0.457 0 C-N-CA 122.978 0.511 . . . . 0.0 109.954 176.566 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . 0.412 ' HB2' ' O ' ' A' ' 102' ' ' TYR . 0.5 OUTLIER . . . . . 0 N--CA 1.47 0.562 0 CA-C-O 121.265 0.555 . . . . 0.0 112.478 . . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.631 ' HA2' HG23 ' A' ' 14' ' ' VAL . . . 128.84 -157.9 21.7 Favored Glycine 0 C--O 1.248 1.031 0 CA-C-N 115.364 -0.834 . . . . 0.0 111.384 -177.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . 0.623 ' HB2' HD12 ' A' ' 161' ' ' LEU . . . -90.35 107.06 18.91 Favored 'General case' 0 CA--C 1.54 0.57 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -179.228 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' TYR . . . . . 0.512 ' HA ' ' HA ' ' A' ' 10' ' ' ARG . 7.4 m-85 -92.51 176.23 6.54 Favored 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 123.18 0.592 . . . . 0.0 109.405 177.455 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' ARG . . . . . 0.631 ' HA ' ' HA ' ' A' ' 99' ' ' ALA . 53.8 ttp180 -138.36 121.82 17.22 Favored 'General case' 0 C--O 1.239 0.54 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 -174.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.402 HG22 HD12 ' A' ' 119' ' ' LEU . 41.7 mt -90.67 116.04 31.16 Favored 'Isoleucine or valine' 0 C--O 1.25 1.116 0 CA-C-O 121.607 0.718 . . . . 0.0 110.134 -172.257 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . 0.603 ' HE3' ' HD2' ' A' ' 89' ' ' LYS . 48.3 pttt -105.35 142.13 35.65 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 168.564 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . 0.629 ' HB2' HD13 ' A' ' 97' ' ' ILE . 18.0 tm0? -84.44 106.48 16.06 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 104.534 -2.395 . . . . 0.0 104.534 165.784 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . 0.603 ' HD2' ' HE3' ' A' ' 87' ' ' LYS . 78.6 tttt -119.41 104.09 10.04 Favored 'General case' 0 C--O 1.241 0.613 0 C-N-CA 123.666 0.786 . . . . 0.0 110.36 -167.203 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -72.32 155.31 51.36 Favored Glycine 0 C--O 1.243 0.701 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 167.474 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 22.2 mm -79.41 62.15 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.563 1.442 0 CA-C-N 118.174 0.987 . . . . 0.0 109.067 -176.102 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 1.6 tm? 170.16 -40.1 0.0 OUTLIER 'General case' 0 CA--C 1.556 1.204 0 C-N-CA 126.347 1.859 . . . . 0.0 107.556 -168.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -137.96 151.66 21.45 Favored Glycine 0 C--N 1.369 2.379 0 N-CA-C 114.926 0.731 . . . . 0.0 114.926 -166.576 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -111.89 142.81 43.81 Favored 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 125.037 1.335 . . . . 0.0 110.738 -179.167 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 49.5 m -150.52 96.67 2.41 Favored 'General case' 0 N--CA 1.477 0.915 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 168.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . 0.52 HE22 ' HB3' ' A' ' 163' ' ' PRO . 35.8 tt0 -62.48 140.25 58.6 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 123.237 0.615 . . . . 0.0 111.243 -178.605 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.629 HD13 ' HB2' ' A' ' 88' ' ' GLN . 8.5 pt -132.76 -24.68 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 N-CA-C 112.604 0.594 . . . . 0.0 112.604 -173.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 178.85 -149.4 8.86 Favored Glycine 0 C--N 1.345 1.074 0 C-N-CA 120.847 -0.692 . . . . 0.0 113.031 179.484 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.631 ' HA ' ' HA ' ' A' ' 85' ' ' ARG . . . -143.59 178.11 8.01 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 124.44 1.096 . . . . 0.0 109.805 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -176.89 140.84 5.13 Favored Glycine 0 C--N 1.34 0.796 0 CA-C-O 119.826 -0.43 . . . . 0.0 112.123 174.042 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.589 ' HB ' ' HG3' ' A' ' 199' ' ' PRO . 3.3 p -89.36 127.14 42.22 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.942 0 CA-C-N 117.422 0.611 . . . . 0.0 111.001 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . 0.45 ' HD2' ' HB2' ' A' ' 107' ' ' PHE . 29.4 t80 -98.05 136.77 37.83 Favored 'General case' 0 N--CA 1.477 0.881 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 169.562 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.437 ' HD2' HG22 ' A' ' 14' ' ' VAL . 35.2 tttp -169.02 154.23 6.01 Favored 'General case' 0 N--CA 1.47 0.57 0 O-C-N 123.69 0.618 . . . . 0.0 110.071 171.927 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 11.8 tp10 72.86 17.28 4.35 Favored 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 124.684 1.194 . . . . 0.0 110.752 171.301 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 80.51 18.01 72.02 Favored Glycine 0 C--N 1.345 1.033 0 CA-C-N 115.925 -0.58 . . . . 0.0 113.303 -176.159 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' THR . . . . . 0.471 HG22 ' HD2' ' A' ' 108' ' ' HIS . 2.7 t -139.54 134.8 32.69 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 123.013 0.525 . . . . 0.0 110.584 176.662 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' PHE . . . . . 0.551 ' HB3' ' HB2' ' A' ' 140' ' ' TYR . 38.3 t80 -88.55 118.81 28.47 Favored 'General case' 0 C--N 1.349 0.579 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 174.716 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . 0.471 ' HD2' HG22 ' A' ' 106' ' ' THR . 4.1 p80 -133.45 114.1 13.27 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 123.051 0.54 . . . . 0.0 109.969 -175.267 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 11.5 t -136.17 -172.89 3.24 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 124.187 0.995 . . . . 0.0 110.359 -176.081 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' MET . . . . . 0.414 ' SD ' ' HE1' ' A' ' 112' ' ' HIS . 1.0 OUTLIER -67.14 152.57 45.51 Favored 'General case' 0 N--CA 1.479 1.02 0 C-N-CA 124.189 0.996 . . . . 0.0 110.702 171.542 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 84.1 t90 -74.0 -47.65 35.71 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 122.848 0.459 . . . . 0.0 110.654 -178.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . 0.414 ' HE1' ' SD ' ' A' ' 110' ' ' MET . 22.1 p-80 -59.78 -15.46 20.57 Favored 'General case' 0 N--CA 1.489 1.506 0 C-N-CA 124.38 1.072 . . . . 0.0 113.755 -170.035 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.471 ' O ' HD11 ' A' ' 97' ' ' ILE . 23.2 m -57.62 -27.53 29.84 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 C-N-CA 123.185 0.594 . . . . 0.0 111.032 178.695 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 10.8 t -135.5 165.22 26.03 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.163 0.985 . . . . 0.0 109.263 177.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 14.7 tpp180 -92.74 16.03 13.21 Favored 'General case' 0 N--CA 1.484 1.252 0 CA-C-O 121.642 0.734 . . . . 0.0 109.887 176.048 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 98.72 42.23 2.94 Favored Glycine 0 C--N 1.347 1.153 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 -177.169 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -106.79 167.56 9.79 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 123.608 0.763 . . . . 0.0 110.621 -179.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.409 HG22 ' HA ' ' A' ' 127' ' ' GLU . 7.3 p -84.93 137.73 20.33 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.006 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.408 178.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.402 HD12 HG22 ' A' ' 86' ' ' ILE . 1.8 mm? -84.37 -177.97 6.78 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 124.429 1.092 . . . . 0.0 111.1 -178.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 47.9 mtm -145.23 164.87 30.02 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 124.165 0.986 . . . . 0.0 111.119 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.401 ' HA ' ' HG3' ' A' ' 7' ' ' GLU . 12.0 t-160 -164.92 111.28 0.97 Allowed 'General case' 0 C--O 1.239 0.536 0 N-CA-C 106.497 -1.668 . . . . 0.0 106.497 171.454 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 73.1 tttt 70.55 20.34 5.88 Favored 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 124.131 0.972 . . . . 0.0 110.802 -179.739 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 93.13 -19.95 49.06 Favored Glycine 0 C--N 1.344 0.985 0 CA-C-N 114.811 -1.086 . . . . 0.0 113.334 -172.134 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 38.8 ttmt -77.37 119.6 21.21 Favored 'General case' 0 C--N 1.36 1.027 0 CA-C-N 117.509 0.654 . . . . 0.0 109.76 -179.135 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 3.6 mpt_? -59.68 143.8 49.7 Favored 'General case' 0 CA--C 1.551 1.014 0 C-N-CA 124.383 1.073 . . . . 0.0 111.75 177.306 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 57.9 mt -119.1 109.05 25.45 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 176.367 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . 0.409 ' HA ' HG22 ' A' ' 118' ' ' VAL . 10.8 pt-20 -80.01 134.42 56.39 Favored Pre-proline 0 CA--C 1.557 1.241 0 C-N-CA 124.42 1.088 . . . . 0.0 112.997 -167.793 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -76.3 110.38 3.05 Favored 'Trans proline' 0 C--N 1.383 2.357 0 C-N-CA 123.023 2.482 . . . . 0.0 111.365 176.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 34.1 p -85.6 -27.46 25.46 Favored 'General case' 0 N--CA 1.479 1.0 0 C-N-CA 123.315 0.646 . . . . 0.0 111.416 -179.362 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.509 ' HB3' ' HG ' ' A' ' 139' ' ' SER . 69.9 t-105 -147.86 153.9 39.72 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 123.706 0.802 . . . . 0.0 109.127 -178.538 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -155.99 118.28 4.08 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 123.196 0.599 . . . . 0.0 110.089 175.443 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 12.8 t0 -117.14 106.95 13.89 Favored 'General case' 0 N--CA 1.475 0.793 0 C-N-CA 124.312 1.045 . . . . 0.0 108.555 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 21.5 t -76.88 -16.42 14.7 Favored 'Isoleucine or valine' 0 CA--C 1.565 1.543 0 C-N-CA 123.263 0.625 . . . . 0.0 111.643 -174.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -79.16 -43.04 24.75 Favored 'General case' 0 N--CA 1.492 1.66 0 C-N-CA 123.203 0.601 . . . . 0.0 111.06 -175.859 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 11.8 mptt -78.19 -15.55 58.72 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 170.189 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 11.1 t0 58.69 61.86 2.09 Favored 'General case' 0 C--N 1.356 0.888 0 O-C-N 124.834 1.334 . . . . 0.0 108.512 -170.37 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . 0.482 HD13 ' HB1' ' A' ' 227' ' ' ALA . 87.0 mt -139.66 131.97 28.35 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 123.973 0.909 . . . . 0.0 109.607 176.808 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.419 HG22 ' HE1' ' A' ' 140' ' ' TYR . 20.2 tt -119.7 138.08 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.18 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 171.451 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' SER . . . . . 0.509 ' HG ' ' HB3' ' A' ' 130' ' ' TRP . 21.0 p -133.3 147.77 51.9 Favored 'General case' 0 CA--C 1.544 0.733 0 CA-C-O 121.827 0.822 . . . . 0.0 112.113 -171.501 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.551 ' HB2' ' HB3' ' A' ' 107' ' ' PHE . 17.5 m-85 -132.25 112.02 11.89 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.333 1.453 . . . . 0.0 108.476 -162.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.62 20.49 63.77 Favored Glycine 0 N--CA 1.474 1.229 0 O-C-N 123.084 0.24 . . . . 0.0 112.625 -176.029 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 157.04 -160.71 30.62 Favored Glycine 0 C--N 1.34 0.8 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 177.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.684 ' HA3' ' HB2' ' A' ' 232' ' ' SER . . . -98.75 -175.81 32.31 Favored Glycine 0 C--N 1.346 1.119 0 CA-C-N 117.348 0.574 . . . . 0.0 111.732 171.575 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' TRP . . . . . 0.574 ' CD1' ' HA ' ' A' ' 229' ' ' THR . 47.6 t-105 -61.78 107.64 0.87 Allowed 'General case' 0 C--N 1.352 0.707 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 167.828 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 38.6 ttpt -150.52 112.16 4.48 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-O 121.197 0.523 . . . . 0.0 110.791 -172.201 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' LEU . . . . . . . . . . . . . 1.6 pp -146.19 -2.37 0.7 Allowed 'General case' 0 N--CA 1.48 1.036 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.728 169.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 79.44 -22.86 0.26 Allowed 'General case' 0 N--CA 1.484 1.232 0 C-N-CA 126.108 1.763 . . . . 0.0 113.338 166.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -70.11 157.51 53.51 Favored Glycine 0 C--N 1.355 1.59 0 CA-C-N 118.055 0.389 . . . . 0.0 112.842 -175.149 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -141.12 154.05 45.7 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.097 0.559 . . . . 0.0 110.093 -173.026 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' TRP . . . . . 0.509 ' HB2' HG11 ' A' ' 208' ' ' VAL . 25.7 t90 -68.81 133.78 48.8 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 122.712 0.405 . . . . 0.0 110.107 169.709 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 60.2 tttm -86.33 97.5 10.45 Favored 'General case' 0 CA--C 1.549 0.921 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 171.246 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -59.06 109.91 0.94 Allowed 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 124.548 1.139 . . . . 0.0 112.144 -170.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 123.39 -9.24 8.83 Favored Glycine 0 N--CA 1.475 1.253 0 CA-C-N 115.764 -0.653 . . . . 0.0 112.056 -175.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . 0.48 ' HB3' ' HE3' ' A' ' 203' ' ' LYS . 62.3 mm-40 -101.17 163.25 12.37 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 123.424 0.689 . . . . 0.0 110.256 174.36 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 13.2 mp0 -82.57 146.2 29.3 Favored 'General case' 0 N--CA 1.477 0.919 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 172.071 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 29.6 m -89.8 140.55 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.558 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 25.5 mm-40 -99.66 128.26 45.76 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 178.293 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.494 ' HB ' ' HB ' ' A' ' 170' ' ' VAL . 58.0 t -98.97 103.18 14.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 -176.709 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -80.8 72.57 7.78 Favored 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 106.946 -1.501 . . . . 0.0 106.946 178.084 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -77.13 130.01 36.77 Favored 'General case' 0 C--N 1.343 0.321 0 CA-C-N 113.496 -1.684 . . . . 0.0 110.647 -173.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . 0.623 HD12 ' HB2' ' A' ' 83' ' ' ALA . 45.6 mt -95.93 108.91 21.33 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 177.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . 0.401 ' HA ' ' HD3' ' A' ' 163' ' ' PRO . 57.9 mt-10 -90.26 115.29 63.7 Favored Pre-proline 0 CA--C 1.544 0.728 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 167.499 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . 0.52 ' HB3' HE22 ' A' ' 96' ' ' GLN . 35.5 Cg_exo -61.55 116.05 3.17 Favored 'Trans proline' 0 C--N 1.372 1.811 0 C-N-CA 123.41 2.74 . . . . 0.0 112.259 -176.71 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 109.53 -23.72 21.69 Favored Glycine 0 C--N 1.341 0.851 0 CA-C-N 115.518 -0.765 . . . . 0.0 112.203 -176.035 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 11.8 mmpt? -105.76 173.94 6.1 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 123.902 0.881 . . . . 0.0 111.532 -172.11 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -67.77 161.84 63.13 Favored Pre-proline 0 CA--C 1.558 1.287 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.021 168.573 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_exo -56.83 138.85 87.36 Favored 'Trans proline' 0 C--N 1.378 2.114 0 C-N-CA 122.968 2.445 . . . . 0.0 111.979 172.05 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 17.1 mmt85 -121.28 97.7 5.64 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 123.681 0.792 . . . . 0.0 109.692 -171.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -79.24 132.72 36.59 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 175.489 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . 0.494 ' HB ' ' HB ' ' A' ' 158' ' ' VAL . 95.5 t -129.8 122.06 53.84 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.163 0 C-N-CA 123.196 0.599 . . . . 0.0 110.266 -178.478 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 171' ' ' GLN . . . . . 0.454 ' HB2' ' HB1' ' A' ' 20' ' ' ALA . 11.5 tt0 -80.82 110.58 16.47 Favored 'General case' 0 N--CA 1.48 1.03 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 -179.867 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 6.9 m -126.73 137.22 53.22 Favored 'General case' 0 C--O 1.238 0.499 0 CA-C-O 121.023 0.44 . . . . 0.0 109.954 -179.563 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . 0.406 ' H ' ' HA3' ' A' ' 24' ' ' GLY . 47.3 mttp -83.17 153.62 66.36 Favored Pre-proline 0 C--O 1.246 0.883 0 C-N-CA 124.115 0.966 . . . . 0.0 108.981 177.555 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 174' ' ' PRO . . . . . 0.46 ' HA ' ' O ' ' A' ' 186' ' ' ALA . 87.3 Cg_exo -49.73 125.99 15.47 Favored 'Trans proline' 0 C--N 1.381 2.252 0 C-N-CA 122.914 2.41 . . . . 0.0 113.36 179.627 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . 0.486 ' H ' ' C ' ' A' ' 186' ' ' ALA . . . -141.11 131.76 5.04 Favored Glycine 0 CA--C 1.541 1.662 0 CA-C-O 122.292 0.94 . . . . 0.0 114.616 178.444 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.56 HD11 ' HB ' ' A' ' 183' ' ' THR . 0.6 OUTLIER -139.31 155.09 47.95 Favored 'General case' 0 C--O 1.242 0.705 0 O-C-N 121.714 -0.874 . . . . 0.0 111.493 -170.292 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 177' ' ' PHE . . . . . 0.43 ' HZ ' ' HB3' ' A' ' 225' ' ' ALA . 3.1 p90 -124.13 139.32 54.04 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 113.696 -1.593 . . . . 0.0 109.781 -175.546 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 178' ' ' LYS . . . . . 0.441 ' HZ2' ' HB3' ' A' ' 178' ' ' LYS . 3.5 ttpm? -85.01 121.36 27.69 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 124.407 1.083 . . . . 0.0 110.167 -173.376 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 77.8 p -117.78 170.61 8.65 Favored 'General case' 0 C--O 1.243 0.731 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 164.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 10.5 t30 -66.21 -26.66 67.49 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 123.072 0.549 . . . . 0.0 109.91 173.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -68.76 -33.66 74.27 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 123.971 0.908 . . . . 0.0 111.055 173.178 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 150.66 172.43 19.81 Favored Glycine 0 C--N 1.35 1.323 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.341 175.325 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 183' ' ' THR . . . . . 0.56 ' HB ' HD11 ' A' ' 176' ' ' LEU . 44.5 p -75.83 95.8 3.56 Favored 'General case' 0 CA--C 1.545 0.782 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 174.723 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 20.3 pt -107.76 141.11 23.83 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 124.292 1.037 . . . . 0.0 110.378 -170.628 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 185' ' ' GLY . . . . . 0.565 ' HA2' ' HA ' ' A' ' 225' ' ' ALA . . . 115.92 173.61 17.35 Favored Glycine 0 N--CA 1.476 1.351 0 CA-C-O 119.432 -0.649 . . . . 0.0 112.612 -178.593 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . 0.486 ' C ' ' H ' ' A' ' 175' ' ' GLY . . . -175.55 40.58 0.01 OUTLIER 'General case' 0 C--O 1.206 -1.225 0 C-N-CA 123.328 0.651 . . . . 0.0 109.882 178.836 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 187' ' ' VAL . . . . . 0.569 HG13 ' HB3' ' A' ' 224' ' ' SER . 2.4 p -164.39 100.42 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.552 1.036 0 O-C-N 120.412 -1.43 . . . . 0.0 108.893 172.857 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 188' ' ' SER . . . . . 0.433 ' O ' ' HA2' ' A' ' 24' ' ' GLY . 80.3 p -118.13 125.67 50.71 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 123.17 0.588 . . . . 0.0 110.266 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 3.6 pp -150.73 -177.81 6.2 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-O 121.095 0.474 . . . . 0.0 110.958 176.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -138.8 103.42 4.82 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 166.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 191' ' ' PHE . . . . . . . . . . . . . 29.9 t80 -168.15 -179.61 4.15 Favored 'General case' 0 N--CA 1.486 1.326 0 C-N-CA 122.787 0.435 . . . . 0.0 109.934 -172.256 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 36.6 m -49.05 117.93 7.0 Favored Pre-proline 0 CA--C 1.554 1.125 0 C-N-CA 124.656 1.183 . . . . 0.0 111.585 175.259 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -69.2 99.79 0.71 Allowed 'Trans proline' 0 C--N 1.378 2.09 0 C-N-CA 122.421 2.081 . . . . 0.0 112.111 -179.347 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -60.93 130.94 48.4 Favored Glycine 0 C--N 1.348 1.22 0 N-CA-C 110.589 -1.005 . . . . 0.0 110.589 170.104 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 195' ' ' THR . . . . . 0.437 HG22 ' O ' ' A' ' 161' ' ' LEU . 12.6 t -59.45 140.37 56.25 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 123.202 0.601 . . . . 0.0 112.004 -169.811 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -69.47 104.08 2.21 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 123.961 0.904 . . . . 0.0 110.826 -165.026 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 197' ' ' GLY . . . . . 0.462 ' HA2' HD12 ' A' ' 210' ' ' LEU . . . 135.66 -7.2 4.22 Favored Glycine 0 C--O 1.24 0.525 0 CA-C-N 115.097 -0.956 . . . . 0.0 111.384 -172.526 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 69.6 m -60.99 124.93 82.28 Favored Pre-proline 0 CA--C 1.548 0.897 0 C-N-CA 123.802 0.841 . . . . 0.0 109.554 169.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 199' ' ' PRO . . . . . 0.589 ' HG3' ' HB ' ' A' ' 101' ' ' VAL . 2.9 Cg_exo -73.13 153.52 51.78 Favored 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 122.409 2.073 . . . . 0.0 111.553 -177.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 200' ' ' ILE . . . . . 0.49 HG23 ' HA ' ' A' ' 158' ' ' VAL . 9.7 pt -108.54 129.4 63.05 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 169.084 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 201' ' ' ILE . . . . . 0.428 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 66.4 mt -115.29 152.89 16.88 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.912 0 C-N-CA 125.165 1.386 . . . . 0.0 108.187 -178.252 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -84.9 162.03 19.62 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 175.139 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 203' ' ' LYS . . . . . 0.48 ' HE3' ' HB3' ' A' ' 154' ' ' GLU . 18.5 ptpt -61.98 -24.07 66.79 Favored 'General case' 0 N--CA 1.482 1.154 0 C-N-CA 123.316 0.646 . . . . 0.0 111.765 179.283 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 50.5 tttp -69.48 -21.62 63.69 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 124.012 0.925 . . . . 0.0 111.33 179.567 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 109.14 -12.61 34.06 Favored Glycine 0 C--N 1.349 1.269 0 CA-C-N 116.188 -0.46 . . . . 0.0 113.082 179.351 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 44.7 mmtm -88.51 138.98 30.94 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 177.505 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 207' ' ' VAL . . . . . 0.428 ' HA ' ' HA ' ' A' ' 201' ' ' ILE . 21.4 t -63.36 151.08 8.86 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.936 0 C-N-CA 123.566 0.746 . . . . 0.0 110.867 -176.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 208' ' ' VAL . . . . . 0.509 HG11 ' HB2' ' A' ' 150' ' ' TRP . 54.8 t -100.35 -52.48 8.65 Favored 'Isoleucine or valine' 0 C--O 1.241 0.656 0 C-N-CA 124.415 1.086 . . . . 0.0 109.02 173.083 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . . . . . . . . . . . 171.35 -121.79 0.92 Allowed Glycine 0 C--N 1.345 1.053 0 CA-C-N 114.582 -1.19 . . . . 0.0 111.495 -176.248 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 210' ' ' LEU . . . . . 0.527 ' HB2' ' CH2' ' A' ' 144' ' ' TRP . 9.0 tt -142.03 139.6 32.38 Favored 'General case' 0 CA--C 1.549 0.926 0 CA-C-N 117.481 0.641 . . . . 0.0 110.426 -175.842 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 79.5 t80 -71.64 109.31 5.48 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 123.922 0.889 . . . . 0.0 108.807 174.126 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -76.79 -138.74 0.92 Allowed Glycine 0 C--N 1.34 0.776 0 O-C-N 123.632 0.583 . . . . 0.0 114.455 -170.115 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 213' ' ' ASN . . . . . . . . . . . . . 81.0 m-20 -74.74 85.47 2.16 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 123.294 0.638 . . . . 0.0 109.93 -176.028 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . -72.32 73.22 0.92 Allowed Glycine 0 C--N 1.355 1.593 0 C-N-CA 123.69 0.662 . . . . 0.0 111.571 175.213 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 215' ' ' VAL . . . . . 0.457 HG13 ' HA ' ' A' ' 40' ' ' SER . 54.7 t -84.37 147.24 5.8 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 C-N-CA 123.282 0.633 . . . . 0.0 111.1 -170.128 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 216' ' ' VAL . . . . . 0.511 ' HB ' ' HA2' ' A' ' 220' ' ' GLY . 14.7 m -68.34 111.95 3.0 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.109 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 165.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 217' ' ' THR . . . . . 0.567 HG23 HD13 ' A' ' 29' ' ' LEU . 13.5 t -125.09 159.89 30.36 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 122.686 0.394 . . . . 0.0 110.977 -179.043 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 218' ' ' ARG . . . . . 0.603 ' HB2' HD22 ' A' ' 29' ' ' LEU . 65.0 ttt180 66.45 -74.25 0.06 Allowed 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 124.924 1.289 . . . . 0.0 109.799 -170.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 16.6 p -131.3 -36.89 1.27 Allowed 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 124.02 0.928 . . . . 0.0 109.903 175.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 220' ' ' GLY . . . . . 0.511 ' HA2' ' HB ' ' A' ' 216' ' ' VAL . . . -176.78 11.83 0.03 OUTLIER Glycine 0 C--N 1.358 1.781 0 CA-C-O 119.341 -0.699 . . . . 0.0 114.64 -178.103 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 221' ' ' ALA . . . . . 0.447 ' O ' HG21 ' A' ' 217' ' ' THR . . . -70.95 119.23 14.76 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 117.664 0.732 . . . . 0.0 109.939 -175.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 222' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -76.92 95.69 4.17 Favored 'General case' 0 N--CA 1.473 0.71 0 CA-C-O 121.64 0.733 . . . . 0.0 109.975 -177.636 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 96.5 t -116.67 135.88 55.56 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.092 -179.26 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 224' ' ' SER . . . . . 0.569 ' HB3' HG13 ' A' ' 187' ' ' VAL . 35.2 t -131.18 155.74 46.53 Favored 'General case' 0 C--O 1.243 0.752 0 C-N-CA 124.324 1.05 . . . . 0.0 111.102 -164.73 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . 0.565 ' HA ' ' HA2' ' A' ' 185' ' ' GLY . . . -97.49 121.27 39.2 Favored 'General case' 0 N--CA 1.467 0.388 0 C-N-CA 123.76 0.824 . . . . 0.0 109.319 174.818 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 226' ' ' ILE . . . . . 0.432 HG21 HD12 ' A' ' 200' ' ' ILE . 7.1 mt -64.77 114.18 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 CA-C-O 120.857 0.36 . . . . 0.0 110.501 174.451 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 227' ' ' ALA . . . . . 0.482 ' HB1' HD13 ' A' ' 137' ' ' LEU . . . -76.79 113.13 14.12 Favored 'General case' 0 C--O 1.239 0.501 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 168.444 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . 0.422 ' HG3' ' HG3' ' A' ' 230' ' ' GLU . 29.7 pt20 -93.39 156.24 16.9 Favored 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 123.782 0.833 . . . . 0.0 109.474 -174.36 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.574 ' HA ' ' CD1' ' A' ' 144' ' ' TRP . 40.7 m -80.11 107.43 12.89 Favored 'General case' 0 C--N 1.347 0.487 0 CA-C-O 121.605 0.717 . . . . 0.0 111.536 179.389 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 230' ' ' GLU . . . . . 0.422 ' HG3' ' HG3' ' A' ' 228' ' ' GLN . 40.5 mt-10 -125.22 88.42 2.88 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 107.049 -1.463 . . . . 0.0 107.049 171.433 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 231' ' ' LYS . . . . . 0.47 ' HA ' ' O ' ' A' ' 144' ' ' TRP . 54.6 pttt -57.73 107.92 0.51 Allowed 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.329 -178.64 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 232' ' ' SER . . . . . 0.684 ' HB2' ' HA3' ' A' ' 143' ' ' GLY . 13.9 m . . . . . 0 C--O 1.239 0.527 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 -175.401 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.143 0 CA-C-O 120.898 0.38 . . . . 0.0 110.169 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -155.9 47.42 0.49 Allowed 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 124.246 1.018 . . . . 0.0 108.356 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 22.3 m-20 -144.33 -18.38 0.55 Allowed 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 113.229 0.826 . . . . 0.0 113.229 -158.478 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . 0.656 ' HB2' ' HG ' ' A' ' 119' ' ' LEU . 1.9 mt -75.88 92.12 3.06 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 118.143 0.429 . . . . 0.0 111.124 -158.436 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -77.2 141.06 40.25 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.969 0.89 . . . . 0.0 111.575 -174.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . 0.467 ' HB3' ' CE2' ' A' ' 84' ' ' TYR . 11.3 mp -83.69 115.38 22.15 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 113.587 -1.642 . . . . 0.0 107.586 175.416 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -111.6 126.37 54.93 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 108.374 -0.972 . . . . 0.0 108.374 179.37 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.603 HH22 ' HB3' ' A' ' 13' ' ' ASP . 60.8 ttt85 -75.03 129.19 37.2 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 120.527 0.203 . . . . 0.0 110.539 -177.469 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . 0.474 ' HB1' ' HG3' ' A' ' 85' ' ' ARG . . . -104.23 -35.07 8.13 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 123.177 0.591 . . . . 0.0 109.96 175.149 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -177.72 -160.95 0.05 Allowed 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 124.421 1.088 . . . . 0.0 110.59 -175.218 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . 0.603 ' HB3' HH22 ' A' ' 10' ' ' ARG . 6.8 p-10 -126.56 170.03 12.46 Favored 'General case' 0 N--CA 1.476 0.87 0 C-N-CA 124.149 0.98 . . . . 0.0 109.847 171.568 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 60.2 t -73.66 104.4 2.5 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.861 -177.414 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 59.2 pttt -164.81 146.29 7.94 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 124.278 1.031 . . . . 0.0 108.804 -178.464 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 24.7 t90 -84.11 113.92 21.4 Favored 'General case' 0 CA--C 1.544 0.713 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 177.395 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 38.2 mm-40 -67.89 147.11 52.94 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 123.557 0.743 . . . . 0.0 111.54 174.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -70.44 -2.46 13.9 Favored 'General case' 0 CA--C 1.556 1.18 0 C-N-CA 125.153 1.381 . . . . 0.0 111.807 175.593 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . 0.52 ' HB2' ' H ' ' A' ' 169' ' ' ALA . 12.9 mm100 -80.14 14.11 2.02 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 124.532 1.133 . . . . 0.0 112.585 -174.355 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -53.89 100.32 0.03 OUTLIER 'General case' 0 C--N 1.364 1.196 0 C-N-CA 124.605 1.162 . . . . 0.0 112.92 -168.743 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.6 mm-40 -82.74 121.88 27.45 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.165 179.294 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 3.6 mp -78.62 103.5 5.66 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.807 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 63.5 m -142.64 -171.59 3.46 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 125.403 1.481 . . . . 0.0 107.2 174.163 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.419 ' HA3' ' H ' ' A' ' 173' ' ' LYS . . . 133.67 148.66 5.9 Favored Glycine 0 N--CA 1.468 0.828 0 N-CA-C 114.887 0.715 . . . . 0.0 114.887 169.37 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.471 ' HB2' ' HB2' ' A' ' 173' ' ' LYS . 15.4 t 65.57 97.98 0.05 OUTLIER 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 125.07 1.348 . . . . 0.0 111.733 173.317 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 15.6 m -111.29 160.96 27.27 Favored Pre-proline 0 CA--C 1.553 1.069 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 169.291 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -57.28 158.59 18.05 Favored 'Trans proline' 0 C--N 1.384 2.418 0 C-N-CA 122.715 2.277 . . . . 0.0 113.074 -176.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 35.5 mm -57.74 120.87 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 123.63 0.772 . . . . 0.0 110.334 -177.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.506 HD21 ' HE1' ' A' ' 177' ' ' PHE . 38.1 tp -98.85 143.12 29.53 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 115.096 -0.957 . . . . 0.0 110.145 -170.343 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.475 ' HG ' ' HB3' ' A' ' 178' ' ' LYS . 50.4 m -123.06 116.46 23.54 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 122.872 0.469 . . . . 0.0 109.766 -175.789 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 14.4 pt -138.29 173.48 12.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 C-N-CA 124.149 0.98 . . . . 0.0 110.155 178.475 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 36.4 p -93.85 125.26 38.37 Favored 'General case' 0 C--N 1.353 0.736 0 C-N-CA 122.787 0.435 . . . . 0.0 109.92 -173.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 10.6 tp -65.15 128.55 28.07 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.001 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 170.058 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 24.8 t -108.47 103.61 12.78 Favored 'General case' 0 C--O 1.267 2.005 0 CA-C-O 121.437 0.637 . . . . 0.0 109.567 -176.251 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 68.26 -79.57 0.04 OUTLIER 'General case' 0 C--N 1.357 0.914 0 CA-C-N 113.179 -1.828 . . . . 0.0 111.282 176.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -144.37 -72.84 0.27 Allowed 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.873 0.869 . . . . 0.0 109.26 -177.799 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -97.95 4.95 61.32 Favored Glycine 0 C--N 1.347 1.171 0 CA-C-O 118.812 -0.993 . . . . 0.0 114.227 -174.325 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 35.8 t -107.04 164.33 12.24 Favored 'General case' 0 C--N 1.359 1.021 0 CA-C-N 119.026 1.413 . . . . 0.0 107.967 172.405 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 39.7 ttp -164.24 126.47 2.36 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 178.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.457 ' HA ' HG11 ' A' ' 215' ' ' VAL . 68.3 m -150.95 -178.91 6.87 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 123.53 0.732 . . . . 0.0 110.968 -173.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.766 HD11 HG22 ' A' ' 217' ' ' THR . 2.3 mp -83.95 97.88 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 N-CA-C 105.729 -1.952 . . . . 0.0 105.729 163.255 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 13.2 mptt 57.64 -86.24 0.02 OUTLIER 'General case' 0 CA--C 1.55 0.952 0 C-N-CA 124.139 0.976 . . . . 0.0 108.731 -165.226 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 8.7 t30 -140.54 140.05 35.15 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 123.553 0.741 . . . . 0.0 109.318 172.001 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -154.86 121.64 5.45 Favored 'General case' 0 CA--C 1.537 0.458 0 N-CA-C 106.406 -1.702 . . . . 0.0 106.406 179.204 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.3 tp10 . . . . . 0 N--CA 1.476 0.863 0 C-N-CA 122.836 0.454 . . . . 0.0 110.33 -177.067 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . 0.509 ' HB2' ' HA ' ' A' ' 103' ' ' LYS . 8.2 p-10 . . . . . 0 C--O 1.245 0.861 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 159.52 -163.73 33.66 Favored Glycine 0 C--N 1.343 0.917 0 CA-C-N 116.031 -0.531 . . . . 0.0 113.396 178.536 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -89.84 123.99 34.29 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 124.137 0.975 . . . . 0.0 109.232 -177.451 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' TYR . . . . . 0.467 ' CE2' ' HB3' ' A' ' 8' ' ' LEU . 4.0 m-85 -126.09 151.38 47.29 Favored 'General case' 0 N--CA 1.48 1.034 0 C-N-CA 123.723 0.809 . . . . 0.0 112.09 -166.566 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' ARG . . . . . 0.504 ' HA ' ' HA ' ' A' ' 99' ' ' ALA . 25.3 mtm180 -113.71 131.02 56.33 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 124.817 1.247 . . . . 0.0 107.897 167.371 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 25.7 mt -94.33 124.55 46.85 Favored 'Isoleucine or valine' 0 C--O 1.249 1.048 0 CA-C-O 121.684 0.754 . . . . 0.0 110.513 -179.401 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . 0.498 ' HD3' ' HB3' ' A' ' 94' ' ' TYR . 1.7 ttmp? -105.72 136.68 44.88 Favored 'General case' 0 C--O 1.213 -0.816 0 C-N-CA 126.114 1.766 . . . . 0.0 108.305 177.599 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 22.9 tm0? -83.07 106.98 15.33 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 104.435 -2.431 . . . . 0.0 104.435 166.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 1.9 tmtp? -118.49 95.21 4.77 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-N 114.975 -1.011 . . . . 0.0 108.298 -166.577 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -82.48 150.52 28.53 Favored Glycine 0 C--O 1.248 1.012 0 N-CA-C 108.911 -1.675 . . . . 0.0 108.911 166.562 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 16.1 mm -80.2 59.63 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.265 0 CA-C-O 121.614 0.721 . . . . 0.0 109.07 -177.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 4.6 pp 168.55 -20.59 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 126.331 1.853 . . . . 0.0 110.433 -173.662 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -157.36 145.51 12.08 Favored Glycine 0 C--N 1.37 2.462 0 CA-C-O 119.841 -0.422 . . . . 0.0 113.239 -174.703 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . 0.498 ' HB3' ' HD3' ' A' ' 87' ' ' LYS . 28.3 m-85 -130.56 147.67 52.27 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-N 117.434 0.617 . . . . 0.0 111.192 -171.177 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 25.1 t -151.18 149.83 29.92 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 123.806 0.843 . . . . 0.0 109.447 175.2 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . . . . . . . . . 22.2 tp60 -94.83 111.22 23.01 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 108.858 -0.794 . . . . 0.0 108.858 177.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.428 HD12 ' HB3' ' A' ' 6' ' ' LEU . 28.6 pt -106.33 -16.86 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 N-CA-C 113.375 0.88 . . . . 0.0 113.375 -173.222 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 170.35 -146.32 9.76 Favored Glycine 0 N--CA 1.472 1.044 0 C-N-CA 120.453 -0.879 . . . . 0.0 113.193 173.604 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.504 ' HA ' ' HA ' ' A' ' 85' ' ' ARG . . . -149.32 176.36 10.62 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 123.684 0.794 . . . . 0.0 110.787 177.904 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -166.81 -170.52 31.81 Favored Glycine 0 C--N 1.344 1.02 0 N-CA-C 111.368 -0.693 . . . . 0.0 111.368 178.12 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 6.2 p -142.83 117.4 4.34 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.728 0 C-N-CA 124.034 0.934 . . . . 0.0 109.278 178.432 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 3.0 t80 -88.5 136.71 32.86 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 171.313 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.509 ' HA ' ' HB2' ' A' ' 81' ' ' ASP . 17.2 tptp -160.12 153.47 22.14 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 110.41 -0.219 . . . . 0.0 110.41 177.244 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 71.52 -85.47 0.03 OUTLIER 'General case' 0 CA--C 1.55 0.981 0 C-N-CA 124.868 1.267 . . . . 0.0 110.576 169.651 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -155.88 24.81 0.56 Allowed Glycine 0 N--CA 1.469 0.889 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 174.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' THR . . . . . 0.727 HG23 ' HA3' ' A' ' 141' ' ' GLY . 7.0 p -147.03 151.75 37.45 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.377 1.071 . . . . 0.0 110.011 -167.865 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' PHE . . . . . 0.508 ' HB3' ' HB3' ' A' ' 140' ' ' TYR . 31.4 t80 -104.63 139.16 39.88 Favored 'General case' 0 N--CA 1.484 1.235 0 N-CA-C 108.031 -1.099 . . . . 0.0 108.031 174.02 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . 0.419 ' HB3' ' CZ3' ' A' ' 144' ' ' TRP . 78.0 m-70 -132.35 113.58 13.36 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 123.549 0.74 . . . . 0.0 110.173 -175.555 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 9.0 t -136.47 -177.8 4.88 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 122.761 0.424 . . . . 0.0 110.673 177.495 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' MET . . . . . 0.496 ' SD ' ' HE1' ' A' ' 112' ' ' HIS . 3.3 mtp -89.52 152.42 21.44 Favored 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 123.677 0.791 . . . . 0.0 110.195 178.656 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 53.9 t90 -73.45 -39.13 65.2 Favored 'General case' 0 CA--C 1.542 0.642 0 O-C-N 123.634 0.584 . . . . 0.0 110.365 -175.848 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . 0.496 ' HE1' ' SD ' ' A' ' 110' ' ' MET . 18.6 p-80 -65.87 -8.39 21.76 Favored 'General case' 0 N--CA 1.49 1.555 0 C-N-CA 124.474 1.11 . . . . 0.0 113.087 -172.665 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 95.1 t -58.08 -37.97 64.82 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.977 0 C-N-CA 123.366 0.666 . . . . 0.0 110.1 178.231 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 17.5 p -147.78 -163.08 1.69 Allowed 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 124.448 1.099 . . . . 0.0 109.989 169.435 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.8 tpp180 -90.83 5.23 49.26 Favored 'General case' 0 CA--C 1.559 1.296 0 C-N-CA 123.562 0.745 . . . . 0.0 111.152 176.248 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 107.1 63.49 0.59 Allowed Glycine 0 C--N 1.35 1.329 0 N-CA-C 111.799 -0.52 . . . . 0.0 111.799 -178.364 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . 0.582 ' HB2' HD13 ' A' ' 6' ' ' LEU . . . -95.33 168.39 10.75 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 123.811 0.844 . . . . 0.0 111.823 -179.363 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.418 HG22 ' HA ' ' A' ' 127' ' ' GLU . 14.9 p -86.5 141.41 14.44 Favored 'Isoleucine or valine' 0 C--O 1.245 0.845 0 N-CA-C 108.369 -0.975 . . . . 0.0 108.369 165.565 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.656 ' HG ' ' HB2' ' A' ' 6' ' ' LEU . 6.4 mp -102.03 174.62 5.85 Favored 'General case' 0 C--O 1.222 -0.35 0 C-N-CA 124.072 0.949 . . . . 0.0 111.291 -173.667 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 25.4 mmt -121.78 165.71 15.43 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 125.36 1.464 . . . . 0.0 108.752 177.194 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 12.1 t-80 -170.03 97.44 0.28 Allowed 'General case' 0 C--O 1.246 0.879 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 166.435 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 49.1 tttm 56.87 37.63 28.92 Favored 'General case' 0 N--CA 1.489 1.483 0 CA-C-O 121.91 0.862 . . . . 0.0 110.889 173.358 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 101.38 -12.09 58.37 Favored Glycine 0 C--N 1.348 1.22 0 CA-C-O 119.135 -0.814 . . . . 0.0 114.349 177.007 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 53.4 mtpt -102.56 135.18 44.65 Favored 'General case' 0 N--CA 1.49 1.569 0 CA-C-N 118.155 0.977 . . . . 0.0 110.712 178.506 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . 0.435 ' HA ' ' O ' ' A' ' 119' ' ' LEU . 0.1 OUTLIER -85.21 122.79 29.9 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 123.196 0.599 . . . . 0.0 110.82 177.667 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.515 HG23 ' HB2' ' A' ' 140' ' ' TYR . 1.8 mp -87.13 100.07 9.38 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.917 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 172.606 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . 0.418 ' HA ' HG22 ' A' ' 118' ' ' VAL . 36.5 tt0 -92.42 104.63 11.61 Favored Pre-proline 0 CA--C 1.545 0.787 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.371 -177.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 12.9 Cg_exo -68.69 98.2 0.58 Allowed 'Trans proline' 0 C--N 1.374 1.905 0 C-N-CA 122.534 2.156 . . . . 0.0 112.195 -175.697 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 6.4 p -69.08 -24.66 64.17 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 123.797 0.839 . . . . 0.0 111.231 176.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.549 ' HB2' ' HA2' ' A' ' 142' ' ' GLY . 59.7 t-105 -107.32 138.43 43.52 Favored 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 108.712 -0.848 . . . . 0.0 108.712 171.334 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -155.35 120.89 4.99 Favored 'General case' 0 C--O 1.238 0.494 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 176.393 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -143.07 114.08 7.7 Favored 'General case' 0 CA--C 1.544 0.728 0 CA-C-O 120.879 0.371 . . . . 0.0 110.98 -178.099 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 14.2 p -77.45 -17.43 14.29 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.309 0 C-N-CA 124.219 1.008 . . . . 0.0 112.423 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 65.4 mttm -71.73 -45.52 61.5 Favored 'General case' 0 N--CA 1.485 1.306 0 C-N-CA 123.177 0.591 . . . . 0.0 110.735 -173.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . 0.601 ' HG2' ' HG2' ' A' ' 230' ' ' GLU . 4.6 mptp? -88.64 -10.06 49.92 Favored 'General case' 0 N--CA 1.477 0.898 0 C-N-CA 124.653 1.181 . . . . 0.0 109.897 174.876 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 56.1 t0 63.02 46.11 4.92 Favored 'General case' 0 C--N 1.36 1.037 0 O-C-N 124.549 1.156 . . . . 0.0 109.426 -177.124 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 96.2 mt -136.71 127.67 27.61 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.696 0.798 . . . . 0.0 110.392 -179.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 17.8 tt -124.14 136.81 59.18 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 175.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 80.5 p -148.58 146.0 28.07 Favored 'General case' 0 N--CA 1.475 0.796 0 CA-C-O 121.843 0.83 . . . . 0.0 113.146 -171.162 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.515 ' HB2' HG23 ' A' ' 126' ' ' ILE . 81.3 t80 -84.6 122.17 28.66 Favored 'General case' 0 N--CA 1.473 0.695 0 CA-C-N 114.446 -1.252 . . . . 0.0 108.396 172.601 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . 0.727 ' HA3' HG23 ' A' ' 106' ' ' THR . . . 123.69 -82.47 0.35 Allowed Glycine 0 C--N 1.34 0.801 0 O-C-N 124.281 0.988 . . . . 0.0 111.637 177.676 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . 0.549 ' HA2' ' HB2' ' A' ' 130' ' ' TRP . . . 147.57 84.09 0.05 OUTLIER Glycine 0 C--O 1.24 0.495 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 172.683 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 146.94 176.34 20.62 Favored Glycine 0 C--O 1.241 0.565 0 N-CA-C 111.233 -0.747 . . . . 0.0 111.233 177.312 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' TRP . . . . . 0.549 ' HH2' HD11 ' A' ' 210' ' ' LEU . 69.2 t-105 -110.16 109.21 19.64 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 166.491 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 28.7 mmmt -108.98 107.43 17.79 Favored 'General case' 0 N--CA 1.471 0.621 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -175.412 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' LEU . . . . . . . . . . . . . 60.2 mt -162.63 -45.74 0.04 OUTLIER 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 126.909 2.084 . . . . 0.0 106.784 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 63.89 22.88 13.17 Favored 'General case' 0 N--CA 1.482 1.128 0 C-N-CA 125.256 1.422 . . . . 0.0 112.758 176.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . 0.422 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -76.98 165.96 53.76 Favored Glycine 0 C--N 1.352 1.455 0 CA-C-N 116.262 -0.427 . . . . 0.0 113.017 179.543 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 22.2 tt0 -123.69 96.62 5.03 Favored 'General case' 0 C--O 1.239 0.506 0 C-N-CA 123.485 0.714 . . . . 0.0 109.26 -174.401 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' TRP . . . . . 0.54 ' HA ' ' HB ' ' A' ' 208' ' ' VAL . 29.1 t90 -55.63 116.05 2.68 Favored 'General case' 0 N--CA 1.481 1.098 0 O-C-N 123.308 0.38 . . . . 0.0 111.185 171.33 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 65.9 mttm -94.5 100.3 12.31 Favored 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 123.848 0.859 . . . . 0.0 109.419 -178.366 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -68.21 141.02 56.08 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 124.658 1.183 . . . . 0.0 111.918 -175.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 83.8 -23.56 6.63 Favored Glycine 0 C--N 1.351 1.389 0 CA-C-N 116.47 -0.332 . . . . 0.0 113.518 177.314 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -97.02 151.53 19.63 Favored 'General case' 0 C--O 1.24 0.57 0 C-N-CA 124.546 1.138 . . . . 0.0 108.53 -179.578 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . 0.426 ' HA ' ' HA ' ' A' ' 173' ' ' LYS . 1.2 pm0 -63.6 121.96 15.16 Favored 'General case' 0 C--N 1.345 0.406 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 176.051 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 33.9 m -89.93 179.51 0.5 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.537 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 174.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.47 133.4 51.21 Favored 'General case' 0 C--O 1.217 -0.641 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -175.87 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.437 ' O ' ' HA ' ' A' ' 169' ' ' ALA . 86.3 t -107.77 119.35 57.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 -176.795 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -93.1 77.43 4.63 Favored 'General case' 0 CA--C 1.54 0.584 0 N-CA-C 106.665 -1.605 . . . . 0.0 106.665 172.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -77.9 111.87 14.2 Favored 'General case' 0 CA--C 1.539 0.534 0 CA-C-N 114.69 -1.141 . . . . 0.0 111.006 -169.347 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 89.0 mt -79.1 102.61 8.52 Favored 'General case' 0 C--O 1.244 0.805 0 C-N-CA 123.993 0.917 . . . . 0.0 110.195 179.541 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . 0.518 ' HB2' ' HB2' ' A' ' 193' ' ' PRO . 39.1 tt0 -74.82 126.66 88.16 Favored Pre-proline 0 CA--C 1.541 0.614 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 173.124 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -64.13 116.03 3.48 Favored 'Trans proline' 0 C--N 1.376 1.988 0 C-N-CA 121.911 1.741 . . . . 0.0 110.375 173.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 113.1 -28.01 9.11 Favored Glycine 0 C--N 1.344 1.006 0 CA-C-O 119.583 -0.565 . . . . 0.0 113.816 177.369 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -136.47 -173.48 3.43 Favored 'General case' 0 N--CA 1.49 1.552 0 CA-C-N 117.986 0.893 . . . . 0.0 112.154 -175.08 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -60.0 161.27 12.88 Favored Pre-proline 0 CA--C 1.554 1.116 0 C-N-CA 124.983 1.313 . . . . 0.0 112.319 175.861 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -77.2 157.4 33.65 Favored 'Trans proline' 0 C--N 1.373 1.823 0 C-N-CA 122.016 1.811 . . . . 0.0 111.759 173.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . 0.506 HH11 ' HG3' ' A' ' 193' ' ' PRO . 58.7 mtp180 -124.58 131.97 53.46 Favored 'General case' 0 C--O 1.238 0.489 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.257 173.773 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . 0.52 ' H ' ' HB2' ' A' ' 19' ' ' GLN . . . -80.02 133.83 36.18 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.053 176.633 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 63.0 t -134.21 117.8 26.05 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.131 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 174.436 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 55.1 mt-30 -81.75 126.28 31.63 Favored 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 108.245 -1.021 . . . . 0.0 108.245 174.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 4.9 t -152.72 132.44 13.16 Favored 'General case' 0 CA--C 1.54 0.561 0 O-C-N 123.571 0.544 . . . . 0.0 111.738 -174.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . 0.471 ' HB2' ' HB2' ' A' ' 25' ' ' SER . 64.0 mttp -75.6 138.13 70.57 Favored Pre-proline 0 N--CA 1.475 0.782 0 C-N-CA 123.146 0.578 . . . . 0.0 110.069 171.69 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_endo -61.78 163.27 19.27 Favored 'Trans proline' 0 C--N 1.379 2.134 0 C-N-CA 123.091 2.527 . . . . 0.0 113.728 178.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -144.45 169.89 26.3 Favored Glycine 0 N--CA 1.468 0.785 0 N-CA-C 110.399 -1.08 . . . . 0.0 110.399 178.217 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 6.5 mp -124.34 152.13 43.5 Favored 'General case' 0 N--CA 1.488 1.463 0 CA-C-N 118.681 1.24 . . . . 0.0 111.887 -176.511 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 177' ' ' PHE . . . . . 0.506 ' HE1' HD21 ' A' ' 29' ' ' LEU . 68.4 m-85 -96.53 122.42 39.41 Favored 'General case' 0 C--N 1.344 0.356 0 CA-C-N 114.756 -1.111 . . . . 0.0 109.593 173.831 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 178' ' ' LYS . . . . . 0.475 ' HB3' ' HG ' ' A' ' 30' ' ' SER . 61.0 tttp -85.47 90.07 7.86 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 167.032 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 23.0 m -104.14 158.79 16.2 Favored 'General case' 0 C--O 1.242 0.689 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 -179.352 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -61.6 -34.88 76.4 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 122.356 0.262 . . . . 0.0 110.471 177.506 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -63.79 -33.85 76.59 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 123.572 0.749 . . . . 0.0 111.155 175.442 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 151.25 -169.13 30.88 Favored Glycine 0 C--N 1.342 0.888 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.97 177.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 183' ' ' THR . . . . . 0.45 ' HA ' ' O ' ' A' ' 177' ' ' PHE . 16.9 p -87.25 119.19 27.23 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 122.986 0.514 . . . . 0.0 109.776 176.522 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . 0.47 ' HB ' ' HB2' ' A' ' 177' ' ' PHE . 65.5 mt -103.01 144.51 13.69 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 124.223 1.009 . . . . 0.0 108.504 -176.833 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -99.23 120.24 6.79 Favored Glycine 0 C--N 1.345 1.038 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 -175.223 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . 0.414 ' HA ' ' HA ' ' A' ' 225' ' ' ALA . . . -146.93 -160.65 1.19 Allowed 'General case' 0 N--CA 1.465 0.294 0 C-N-CA 123.413 0.685 . . . . 0.0 111.102 -163.689 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 187' ' ' VAL . . . . . 0.415 ' HB ' HD12 ' A' ' 226' ' ' ILE . 3.7 p -132.22 103.86 7.13 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.989 0 C-N-CA 124.029 0.932 . . . . 0.0 108.498 169.552 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 188' ' ' SER . . . . . 0.515 ' HA ' HG13 ' A' ' 223' ' ' VAL . 15.6 t -76.96 100.65 5.68 Favored 'General case' 0 C--O 1.243 0.753 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.501 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -152.44 155.66 37.96 Favored 'General case' 0 C--N 1.358 0.939 0 CA-C-O 121.365 0.603 . . . . 0.0 110.689 -168.531 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 190' ' ' ASP . . . . . 0.627 ' HA ' ' HB2' ' A' ' 221' ' ' ALA . 16.6 t70 -69.08 162.76 26.26 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 124.869 1.267 . . . . 0.0 109.859 176.048 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 191' ' ' PHE . . . . . 0.519 ' HB3' ' H ' ' A' ' 222' ' ' TYR . 9.6 p90 -74.23 123.92 25.43 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-O 121.958 0.885 . . . . 0.0 110.522 -168.409 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 50.8 m -104.62 158.96 30.88 Favored Pre-proline 0 CA--C 1.547 0.854 0 CA-C-N 114.23 -1.35 . . . . 0.0 110.445 -174.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . 0.518 ' HB2' ' HB2' ' A' ' 162' ' ' GLU . 73.7 Cg_endo -72.78 69.69 3.62 Favored 'Trans proline' 0 C--N 1.372 1.8 0 C-N-CA 122.786 2.324 . . . . 0.0 112.2 173.44 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -154.01 146.63 15.02 Favored Glycine 0 C--N 1.347 1.145 0 CA-C-N 116.178 -0.465 . . . . 0.0 112.46 -177.42 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 25.3 p -110.39 156.37 20.87 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 123.684 0.793 . . . . 0.0 109.469 176.32 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.63 107.2 0.77 Allowed 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 123.858 0.863 . . . . 0.0 110.069 -175.557 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 132.6 -9.55 5.26 Favored Glycine 0 C--N 1.342 0.89 0 CA-C-N 114.749 -1.114 . . . . 0.0 112.338 -172.19 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 54.2 m -63.91 120.12 60.92 Favored Pre-proline 0 CA--C 1.55 0.953 0 C-N-CA 123.351 0.66 . . . . 0.0 109.553 173.48 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -60.39 125.29 17.04 Favored 'Trans proline' 0 C--N 1.375 1.949 0 C-N-CA 122.836 2.357 . . . . 0.0 112.292 -173.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 55.5 mt -88.22 107.56 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 173.665 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 201' ' ' ILE . . . . . 0.809 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 25.9 mt -97.06 176.55 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.044 0 C-N-CA 124.524 1.13 . . . . 0.0 108.942 -175.839 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 202' ' ' ASP . . . . . 0.413 ' N ' HG23 ' A' ' 201' ' ' ILE . 9.2 t70 -102.93 174.22 5.97 Favored 'General case' 0 C--O 1.24 0.604 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 169.886 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 2.4 mppt? -70.46 -28.74 65.25 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 123.84 0.856 . . . . 0.0 109.051 174.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp -81.96 1.6 34.65 Favored 'General case' 0 N--CA 1.477 0.878 0 C-N-CA 123.958 0.903 . . . . 0.0 111.927 178.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 90.96 -4.82 81.84 Favored Glycine 0 C--N 1.351 1.403 0 CA-C-O 119.965 -0.353 . . . . 0.0 113.562 177.249 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 31.3 mmtp -78.25 108.89 11.9 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 122.931 0.492 . . . . 0.0 110.064 179.651 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 207' ' ' VAL . . . . . 0.809 ' HA ' ' HA ' ' A' ' 201' ' ' ILE . 4.8 p -63.66 103.06 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.053 0 CA-C-O 121.437 0.636 . . . . 0.0 110.218 177.076 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 208' ' ' VAL . . . . . 0.54 ' HB ' ' HA ' ' A' ' 150' ' ' TRP . 27.2 m -81.68 -18.37 11.43 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.987 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.287 -169.782 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . . . . . . . . . . . 170.89 -138.84 5.15 Favored Glycine 0 C--N 1.344 0.99 0 CA-C-N 115.446 -0.797 . . . . 0.0 112.351 179.506 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 210' ' ' LEU . . . . . 0.549 HD11 ' HH2' ' A' ' 144' ' ' TRP . 4.9 tt -153.41 154.13 33.85 Favored 'General case' 0 CA--C 1.549 0.904 0 C-N-CA 123.864 0.866 . . . . 0.0 109.825 -168.219 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -67.97 114.42 6.5 Favored 'General case' 0 N--CA 1.481 1.12 0 C-N-CA 123.885 0.874 . . . . 0.0 109.868 -178.78 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -74.65 -136.67 0.44 Allowed Glycine 0 CA--C 1.528 0.895 0 O-C-N 124.349 1.031 . . . . 0.0 114.754 -169.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 213' ' ' ASN . . . . . . . . . . . . . 49.0 t-20 -123.99 135.15 53.44 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 -175.164 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 214' ' ' GLY . . . . . 0.513 ' HA3' ' HA ' ' A' ' 224' ' ' SER . . . -164.37 -152.42 6.96 Favored Glycine 0 CA--C 1.506 -0.528 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.918 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 215' ' ' VAL . . . . . 0.457 HG11 ' HA ' ' A' ' 40' ' ' SER . 7.4 p -162.76 157.09 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 123.02 0.528 . . . . 0.0 110.445 -171.412 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 216' ' ' VAL . . . . . 0.46 ' HA ' ' HA ' ' A' ' 222' ' ' TYR . 93.0 t -70.93 116.38 12.36 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 C-N-CA 123.891 0.877 . . . . 0.0 109.064 174.553 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 217' ' ' THR . . . . . 0.766 HG22 HD11 ' A' ' 41' ' ' ILE . 72.9 p -130.68 163.48 27.12 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 125.256 1.423 . . . . 0.0 109.525 -173.572 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 10.1 ttp180 54.31 76.57 0.23 Allowed 'General case' 0 CA--C 1.561 1.367 0 C-N-CA 123.133 0.573 . . . . 0.0 111.957 161.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 45.1 m 71.91 -5.69 1.64 Allowed 'General case' 0 N--CA 1.492 1.663 0 C-N-CA 124.901 1.28 . . . . 0.0 114.393 176.21 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . 118.27 43.82 0.54 Allowed Glycine 0 C--N 1.357 1.71 0 CA-C-N 118.583 0.629 . . . . 0.0 112.909 176.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 221' ' ' ALA . . . . . 0.627 ' HB2' ' HA ' ' A' ' 190' ' ' ASP . . . -130.39 120.91 24.99 Favored 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 124.712 1.205 . . . . 0.0 109.578 -178.611 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 222' ' ' TYR . . . . . 0.519 ' H ' ' HB3' ' A' ' 191' ' ' PHE . 11.0 p90 -86.3 127.45 34.78 Favored 'General case' 0 C--N 1.351 0.665 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 -169.643 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . 0.515 HG13 ' HA ' ' A' ' 188' ' ' SER . 96.4 t -113.49 132.95 60.95 Favored 'Isoleucine or valine' 0 C--O 1.241 0.633 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 176.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 224' ' ' SER . . . . . 0.513 ' HA ' ' HA3' ' A' ' 214' ' ' GLY . 35.8 t -136.3 158.74 43.71 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 124.199 0.999 . . . . 0.0 109.959 -168.898 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . 0.414 ' HA ' ' HA ' ' A' ' 186' ' ' ALA . . . -68.73 166.51 17.28 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 123.708 0.803 . . . . 0.0 111.234 175.232 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 226' ' ' ILE . . . . . 0.415 HD12 ' HB ' ' A' ' 187' ' ' VAL . 70.9 mt -108.71 111.56 36.55 Favored 'Isoleucine or valine' 0 C--O 1.243 0.731 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 168.634 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -74.62 131.83 41.25 Favored 'General case' 0 C--N 1.345 0.381 0 N-CA-C 107.516 -1.291 . . . . 0.0 107.516 169.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -111.39 171.12 7.67 Favored 'General case' 0 C--O 1.248 1.01 0 C-N-CA 123.626 0.77 . . . . 0.0 109.371 -177.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.466 ' HA ' ' CD1' ' A' ' 144' ' ' TRP . 87.1 m -66.94 115.31 6.53 Favored 'General case' 0 CA--C 1.544 0.738 0 O-C-N 123.59 0.556 . . . . 0.0 110.618 178.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 230' ' ' GLU . . . . . 0.601 ' HG2' ' HG2' ' A' ' 135' ' ' LYS . 10.0 tp10 -117.0 62.75 0.73 Allowed 'General case' 0 C--O 1.242 0.68 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 175.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 24.3 pttm -66.97 157.45 33.33 Favored 'General case' 0 N--CA 1.472 0.662 0 CA-C-N 114.985 -1.007 . . . . 0.0 112.911 -165.733 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 19.8 p . . . . . 0 CA--C 1.549 0.926 0 CA-C-N 113.935 -1.484 . . . . 0.0 112.132 -178.074 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.25 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -165.2 23.62 0.05 Allowed 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 123.142 0.577 . . . . 0.0 110.365 -175.489 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . 0.568 ' HA ' ' HE2' ' A' ' 120' ' ' MET . 8.9 p30 -175.55 64.73 0.02 OUTLIER 'General case' 0 C--N 1.344 0.367 0 C-N-CA 124.734 1.214 . . . . 0.0 108.069 -173.099 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . 0.663 ' HB2' HD12 ' A' ' 119' ' ' LEU . 15.6 mt -79.58 177.52 8.81 Favored 'General case' 0 C--O 1.213 -0.868 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 168.078 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 17.3 tt0 -152.39 142.35 22.15 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-N 119.104 0.866 . . . . 0.0 111.56 171.15 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . 0.443 ' HB3' ' CD2' ' A' ' 84' ' ' TYR . 89.3 mt -87.9 114.37 24.45 Favored 'General case' 0 C--O 1.24 0.56 0 CA-C-N 114.012 -1.449 . . . . 0.0 110.007 175.029 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -106.79 117.75 34.87 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 173.583 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 21.2 ptt180 -58.98 121.77 12.04 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 122.83 0.452 . . . . 0.0 110.08 177.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -113.8 -33.83 5.67 Favored 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 122.609 0.364 . . . . 0.0 110.676 -176.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -169.17 -172.16 1.46 Allowed 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 123.938 0.895 . . . . 0.0 109.9 -179.096 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -102.04 160.29 14.63 Favored 'General case' 0 C--O 1.245 0.83 0 N-CA-C 107.818 -1.178 . . . . 0.0 107.818 169.208 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 99.7 t -72.38 100.09 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 170.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 63.7 tttt -155.54 127.74 7.68 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 115.126 -0.943 . . . . 0.0 108.725 -166.111 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . 0.47 ' HE1' ' HG2' ' A' ' 157' ' ' GLN . 40.6 t90 -69.74 121.64 17.62 Favored 'General case' 0 C--O 1.236 0.375 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 167.802 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.479 ' HB3' ' H ' ' A' ' 169' ' ' ALA . 9.4 tp10 -92.74 134.35 35.13 Favored 'General case' 0 C--O 1.238 0.486 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 173.11 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -72.25 0.24 10.38 Favored 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 124.171 0.988 . . . . 0.0 113.093 -173.276 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . 0.472 ' HG2' ' HG3' ' A' ' 17' ' ' GLU . 11.6 mm-40 -74.77 47.73 0.34 Allowed 'General case' 0 CA--C 1.557 1.212 0 C-N-CA 124.326 1.05 . . . . 0.0 111.185 175.206 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.446 ' HA ' ' O ' ' A' ' 169' ' ' ALA . . . -73.87 89.29 1.85 Allowed 'General case' 0 C--N 1.352 0.697 0 C-N-CA 123.915 0.886 . . . . 0.0 110.098 -176.644 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -88.19 141.26 28.7 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 114.762 -1.108 . . . . 0.0 109.196 179.638 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 44.4 mm -76.11 102.58 3.11 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.424 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 173.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 47.5 m -121.7 -71.85 0.71 Allowed 'General case' 0 CA--C 1.538 0.497 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.502 -167.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.479 ' HA3' HG21 ' A' ' 172' ' ' THR . . . -85.01 133.05 11.49 Favored Glycine 0 C--N 1.353 1.482 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 174.332 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.546 ' HA ' ' HB2' ' A' ' 173' ' ' LYS . 62.2 p -163.62 10.46 0.05 Allowed 'General case' 0 N--CA 1.481 1.085 0 CA-C-N 117.477 0.638 . . . . 0.0 112.106 -178.112 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 20.7 p -94.12 145.51 29.91 Favored Pre-proline 0 CA--C 1.55 0.962 0 C-N-CA 123.0 0.52 . . . . 0.0 110.245 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -89.45 -82.87 0.0 OUTLIER 'Trans proline' 0 C--N 1.379 2.144 0 C-N-CA 123.005 2.47 . . . . 0.0 114.29 -175.461 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.415 ' HA ' ' O ' ' A' ' 176' ' ' LEU . 33.0 mm -101.93 130.68 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 C-N-CA 122.788 0.435 . . . . 0.0 111.173 -169.84 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.691 HD21 HG22 ' A' ' 217' ' ' THR . 0.0 OUTLIER -139.19 161.37 37.58 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 123.613 0.765 . . . . 0.0 110.586 170.96 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 34.2 p -88.59 144.46 26.3 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 123.171 0.588 . . . . 0.0 111.45 -178.318 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 10.4 tt -155.37 152.63 8.72 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.175 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -178.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 3.9 m -97.99 109.42 22.18 Favored 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 123.153 0.581 . . . . 0.0 110.794 -173.076 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 18.1 tt -90.6 141.83 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 O-C-N 121.771 -0.581 . . . . 0.0 110.123 178.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 25.1 m -143.79 151.5 40.03 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 123.217 0.607 . . . . 0.0 111.05 -177.061 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 54.61 25.9 6.83 Favored 'General case' 0 N--CA 1.487 1.418 0 C-N-CA 124.338 1.055 . . . . 0.0 112.307 175.114 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.8 t70 73.35 -60.82 0.52 Allowed 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 125.759 1.624 . . . . 0.0 111.378 -173.648 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -89.21 -34.31 8.85 Favored Glycine 0 C--N 1.348 1.234 0 N-CA-C 114.713 0.645 . . . . 0.0 114.713 -173.523 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 24.4 t -87.34 105.11 17.02 Favored 'General case' 0 N--CA 1.484 1.261 0 CA-C-N 117.428 0.614 . . . . 0.0 109.398 -167.629 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' MET . . . . . 0.497 ' HE1' ' HE1' ' A' ' 177' ' ' PHE . 43.5 ttp -125.41 131.18 52.97 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 122.656 0.382 . . . . 0.0 110.278 -171.412 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 72.4 m -155.76 -178.36 7.24 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 125.179 1.392 . . . . 0.0 109.177 -175.318 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.52 HG12 HG11 ' A' ' 215' ' ' VAL . 44.8 mm -80.62 150.02 4.9 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.821 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 159.512 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 45.4 pttt -67.61 76.24 0.18 Allowed 'General case' 0 CA--C 1.556 1.189 0 CA-C-O 122.172 0.987 . . . . 0.0 109.839 167.128 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 -148.12 -168.03 2.97 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 124.906 1.282 . . . . 0.0 108.813 -178.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -134.93 160.26 38.84 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 123.381 0.672 . . . . 0.0 109.439 -179.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.471 0.624 0 C-N-CA 123.788 0.835 . . . . 0.0 109.761 177.288 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 20.9 t70 . . . . . 0 CA--C 1.549 0.907 0 CA-C-O 119.932 -0.08 . . . . 0.0 110.857 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -177.41 -169.01 37.97 Favored Glycine 0 C--N 1.355 1.615 0 N-CA-C 115.198 0.839 . . . . 0.0 115.198 -175.502 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -97.85 122.65 41.21 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 124.479 1.112 . . . . 0.0 110.803 -176.051 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' TYR . . . . . 0.443 ' CD2' ' HB3' ' A' ' 8' ' ' LEU . 3.4 m-85 -117.42 154.8 30.73 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 123.498 0.719 . . . . 0.0 110.613 -175.383 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' ARG . . . . . 0.514 ' HG2' HG21 ' A' ' 195' ' ' THR . 22.1 mtm180 -99.17 127.91 45.22 Favored 'General case' 0 C--O 1.243 0.76 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 166.196 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.432 HG12 HD23 ' A' ' 8' ' ' LEU . 22.4 mt -92.12 129.7 42.35 Favored 'Isoleucine or valine' 0 C--O 1.25 1.13 0 CA-C-O 121.658 0.742 . . . . 0.0 109.346 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -117.37 154.17 31.78 Favored 'General case' 0 C--O 1.216 -0.675 0 CA-C-N 114.302 -1.317 . . . . 0.0 109.666 177.351 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 6.3 tp-100 -85.58 107.17 17.37 Favored 'General case' 0 C--O 1.243 0.719 0 N-CA-C 104.807 -2.294 . . . . 0.0 104.807 163.58 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.4 tttp -88.55 98.17 11.5 Favored 'General case' 0 C--O 1.242 0.679 0 CA-C-N 114.706 -1.134 . . . . 0.0 108.522 -173.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -71.54 131.94 19.83 Favored Glycine 0 N--CA 1.439 -1.141 0 N-CA-C 108.021 -2.032 . . . . 0.0 108.021 161.267 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 33.1 mm -62.57 -12.87 10.03 Favored 'Isoleucine or valine' 0 CA--C 1.566 1.584 0 C-N-CA 123.171 0.588 . . . . 0.0 110.569 -178.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 2.3 pp -111.93 -18.27 12.7 Favored 'General case' 0 CA--C 1.562 1.414 0 C-N-CA 123.974 0.91 . . . . 0.0 112.889 168.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -160.81 127.18 1.72 Allowed Glycine 0 N--CA 1.488 2.132 0 N-CA-C 114.763 0.665 . . . . 0.0 114.763 -172.25 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 9.2 m-85 -84.16 160.37 20.87 Favored 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 123.409 0.684 . . . . 0.0 111.635 -178.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 37.9 t -148.42 139.21 22.95 Favored 'General case' 0 C--O 1.207 -1.169 0 C-N-CA 124.616 1.167 . . . . 0.0 108.325 169.696 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . . . . . . . . . 9.5 tt0 -90.68 125.61 35.72 Favored 'General case' 0 N--CA 1.493 1.71 0 CA-C-N 119.461 1.028 . . . . 0.0 109.64 -178.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 27.6 pt -124.02 -8.62 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 N-CA-C 112.559 0.578 . . . . 0.0 112.559 -172.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 160.92 -139.39 6.02 Favored Glycine 0 C--N 1.343 0.926 0 C-N-CA 120.903 -0.665 . . . . 0.0 113.05 170.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.492 ' HB2' HG23 ' A' ' 195' ' ' THR . . . -153.19 168.72 25.0 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 123.515 0.726 . . . . 0.0 111.786 -178.159 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -174.51 154.17 18.2 Favored Glycine 0 C--N 1.345 1.071 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.903 177.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 28.1 m -97.85 126.86 50.7 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 CA-C-N 117.607 0.703 . . . . 0.0 110.678 -179.346 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 24.3 t80 -100.76 106.4 17.81 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.482 ' HB3' ' O ' ' A' ' 106' ' ' THR . 14.2 tmtt? -100.87 149.85 23.45 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 -172.144 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -62.31 96.15 0.07 Allowed 'General case' 0 CA--C 1.56 1.348 0 CA-C-O 121.982 0.896 . . . . 0.0 111.713 -178.06 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 104.58 -9.01 48.11 Favored Glycine 0 C--N 1.342 0.882 0 CA-C-N 115.29 -0.868 . . . . 0.0 112.867 177.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' THR . . . . . 0.482 ' O ' ' HB3' ' A' ' 103' ' ' LYS . 54.6 m -151.21 124.25 8.7 Favored 'General case' 0 CA--C 1.547 0.854 0 CA-C-N 117.363 0.581 . . . . 0.0 110.314 -175.402 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' PHE . . . . . 0.632 ' HB3' ' HB3' ' A' ' 140' ' ' TYR . 27.4 t80 -96.35 133.66 40.45 Favored 'General case' 0 CA--C 1.545 0.786 0 O-C-N 121.461 -0.774 . . . . 0.0 110.075 176.244 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . 0.465 ' HB3' ' HE3' ' A' ' 144' ' ' TRP . 32.1 m170 -133.34 115.89 15.44 Favored 'General case' 0 N--CA 1.48 1.04 0 C-N-CA 124.113 0.965 . . . . 0.0 110.707 -178.48 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' THR . . . . . 0.606 HG21 ' HB ' ' A' ' 138' ' ' ILE . 10.1 t -136.87 -176.39 4.35 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 122.749 0.42 . . . . 0.0 110.736 174.466 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' MET . . . . . 0.625 ' HA ' ' HA ' ' A' ' 137' ' ' LEU . 34.6 mtp -93.78 163.15 13.64 Favored 'General case' 0 C--O 1.24 0.558 0 C-N-CA 123.785 0.834 . . . . 0.0 111.098 169.626 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' TRP . . . . . 0.629 ' HA ' HG13 ' A' ' 138' ' ' ILE . 83.9 t90 -80.23 -38.36 31.19 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 123.523 0.729 . . . . 0.0 111.62 -175.908 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . 0.434 ' CE1' ' SD ' ' A' ' 110' ' ' MET . 1.1 p-80 -64.07 -9.42 16.17 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 125.03 1.332 . . . . 0.0 113.933 -169.162 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 33.9 m -57.36 -36.4 52.62 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.911 0 O-C-N 123.471 0.482 . . . . 0.0 110.278 176.424 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.404 HG22 ' H ' ' A' ' 115' ' ' ARG . 0.7 OUTLIER -152.74 -151.6 0.39 Allowed 'General case' 0 CA--C 1.56 1.334 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 175.022 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.404 ' H ' HG22 ' A' ' 114' ' ' THR . 55.8 ttt85 -99.4 32.73 2.67 Favored 'General case' 0 CA--C 1.557 1.227 0 C-N-CA 123.64 0.776 . . . . 0.0 110.112 176.251 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.483 ' HA2' HD13 ' A' ' 138' ' ' ILE . . . 85.0 53.29 3.2 Favored Glycine 0 C--N 1.346 1.131 0 N-CA-C 111.848 -0.501 . . . . 0.0 111.848 -176.338 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -94.83 169.43 10.15 Favored 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 123.513 0.725 . . . . 0.0 112.251 -174.034 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.534 HG22 ' HA ' ' A' ' 127' ' ' GLU . 7.1 p -91.69 142.83 12.46 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.073 0 CA-C-N 114.962 -1.017 . . . . 0.0 111.281 -176.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.663 HD12 ' HB2' ' A' ' 6' ' ' LEU . 2.9 mm? -93.48 152.87 18.79 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 124.236 1.015 . . . . 0.0 110.779 -174.517 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' MET . . . . . 0.568 ' HE2' ' HA ' ' A' ' 5' ' ' ASP . 32.5 mmt -110.32 158.2 18.68 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 169.581 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 80.3 t60 -161.95 96.54 1.01 Allowed 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 175.204 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 77.7 tttt 59.23 31.17 20.99 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 123.774 0.83 . . . . 0.0 111.085 176.088 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 101.63 -11.23 57.87 Favored Glycine 0 C--N 1.355 1.587 0 CA-C-N 115.945 -0.571 . . . . 0.0 113.553 -179.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 49.9 tttm -90.2 127.23 36.07 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 123.122 0.569 . . . . 0.0 109.612 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . 0.557 ' HG3' ' HE1' ' A' ' 120' ' ' MET . 28.2 ttm-85 -89.66 101.25 13.94 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 123.444 0.698 . . . . 0.0 109.518 179.0 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 68.7 mt -85.2 99.92 7.81 Favored 'Isoleucine or valine' 0 C--O 1.239 0.542 0 C-N-CA 123.837 0.855 . . . . 0.0 109.949 178.646 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . 0.534 ' HA ' HG22 ' A' ' 118' ' ' VAL . 0.3 OUTLIER -74.1 149.91 87.54 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.177 174.979 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_endo -79.59 152.95 23.18 Favored 'Trans proline' 0 C--N 1.366 1.499 0 C-N-CA 122.115 1.877 . . . . 0.0 111.8 167.587 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 95.3 p -89.36 -26.8 20.87 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 122.874 0.47 . . . . 0.0 110.131 171.744 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 74.7 t-105 -165.88 156.12 12.78 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 123.497 0.719 . . . . 0.0 109.665 179.344 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . 0.415 ' HB1' ' HD1' ' A' ' 111' ' ' TRP . . . -133.95 118.62 18.08 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.574 0.75 . . . . 0.0 109.024 172.664 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 22.5 t0 -90.09 104.41 16.98 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 124.288 1.035 . . . . 0.0 108.269 175.318 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 45.7 t -75.79 -26.79 18.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 122.929 0.492 . . . . 0.0 111.08 -176.428 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 26.6 mtpp -73.14 -51.47 17.79 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.351 0.661 . . . . 0.0 111.358 -175.158 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 42.8 mtpt -85.73 -4.14 59.08 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 115.45 -0.795 . . . . 0.0 111.554 -179.255 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 37.0 t0 65.22 56.77 0.98 Allowed 'General case' 0 CA--C 1.552 1.025 0 O-C-N 124.554 1.159 . . . . 0.0 109.621 175.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . 0.625 ' HA ' ' HA ' ' A' ' 110' ' ' MET . 62.6 mt -143.49 137.58 28.62 Favored 'General case' 0 N--CA 1.478 0.958 0 O-C-N 121.482 -0.762 . . . . 0.0 110.329 -177.701 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.629 HG13 ' HA ' ' A' ' 111' ' ' TRP . 84.8 mt -111.99 149.44 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.376 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 169.305 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' SER . . . . . 0.409 ' HB2' ' O ' ' A' ' 142' ' ' GLY . 33.5 p -145.44 148.44 33.3 Favored 'General case' 0 C--O 1.241 0.65 0 C-N-CA 123.374 0.67 . . . . 0.0 110.519 -172.545 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.632 ' HB3' ' HB3' ' A' ' 107' ' ' PHE . 37.5 t80 -144.27 120.01 10.51 Favored 'General case' 0 N--CA 1.466 0.333 0 C-N-CA 124.662 1.185 . . . . 0.0 108.705 178.004 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 86.25 3.69 84.51 Favored Glycine 0 C--N 1.345 1.054 0 O-C-N 123.572 0.545 . . . . 0.0 112.725 -178.003 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . 0.409 ' O ' ' HB2' ' A' ' 139' ' ' SER . . . 147.28 148.82 4.83 Favored Glycine 0 C--N 1.344 0.995 0 N-CA-C 110.386 -1.085 . . . . 0.0 110.386 -177.884 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -67.83 169.71 37.88 Favored Glycine 0 C--N 1.348 1.234 0 C-N-CA 123.126 0.393 . . . . 0.0 112.608 -179.562 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' TRP . . . . . 0.636 ' HZ2' ' HA2' ' A' ' 209' ' ' GLY . 57.1 t-105 -58.43 105.54 0.3 Allowed 'General case' 0 CA--C 1.555 1.135 0 CA-C-O 121.209 0.528 . . . . 0.0 110.977 -177.517 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . 0.625 ' HA ' ' HB ' ' A' ' 229' ' ' THR . 50.1 tttm -163.82 126.97 2.59 Favored 'General case' 0 CA--C 1.54 0.562 0 CA-C-N 115.04 -0.982 . . . . 0.0 109.433 176.513 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' LEU . . . . . 0.466 ' H ' ' HB ' ' A' ' 229' ' ' THR . 79.5 mt -141.8 -2.74 1.17 Allowed 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 125.744 1.618 . . . . 0.0 110.219 179.727 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 29.2 tt0 86.69 18.53 0.09 Allowed 'General case' 0 N--CA 1.5 2.043 0 C-N-CA 125.355 1.462 . . . . 0.0 110.848 171.197 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . 0.554 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -85.15 117.72 4.59 Favored Glycine 0 N--CA 1.434 -1.489 0 CA-C-N 115.376 -0.829 . . . . 0.0 113.466 173.578 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -116.04 95.12 4.95 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 124.06 0.944 . . . . 0.0 110.175 -175.311 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' TRP . . . . . 0.603 ' HZ2' ' HG3' ' A' ' 174' ' ' PRO . 35.8 t90 -82.86 146.97 28.6 Favored 'General case' 0 CA--C 1.553 1.095 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.27 168.313 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . 0.401 ' HB3' ' HG2' ' A' ' 154' ' ' GLU . 22.5 tptp -112.67 128.79 56.49 Favored 'General case' 0 N--CA 1.476 0.841 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 177.095 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -63.13 99.69 0.19 Allowed 'General case' 0 N--CA 1.483 1.221 0 C-N-CA 123.494 0.718 . . . . 0.0 111.059 -179.214 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 143.54 -23.25 2.18 Favored Glycine 0 C--N 1.341 0.851 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.345 -177.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . 0.401 ' HG2' ' HB3' ' A' ' 151' ' ' LYS . 32.7 mm-40 -75.91 133.58 40.48 Favored 'General case' 0 C--O 1.24 0.581 0 C-N-CA 123.324 0.65 . . . . 0.0 111.604 -179.452 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . 0.531 ' HG2' ' HG2' ' A' ' 173' ' ' LYS . 35.8 mt-10 -74.84 101.62 4.44 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 174.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 9.7 p -114.72 145.83 19.99 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 123.257 0.623 . . . . 0.0 109.577 -168.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . 0.47 ' HG2' ' HE1' ' A' ' 16' ' ' TRP . 1.8 mp0 -93.34 141.19 28.72 Favored 'General case' 0 C--O 1.217 -0.641 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 -172.541 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.576 HG11 ' HH ' ' A' ' 211' ' ' TYR . 46.9 t -101.2 116.11 44.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 177.019 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -72.08 86.37 1.04 Allowed 'General case' 0 CA--C 1.548 0.869 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 176.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -88.44 139.13 30.8 Favored 'General case' 0 C--O 1.249 1.044 0 CA-C-N 114.181 -1.372 . . . . 0.0 110.738 -174.453 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 35.2 mt -112.7 84.29 1.96 Allowed 'General case' 0 C--O 1.245 0.854 0 C-N-CA 124.718 1.207 . . . . 0.0 108.936 -178.891 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . 0.668 ' HB2' ' HB2' ' A' ' 165' ' ' LYS . 44.2 mt-10 -75.98 143.48 74.21 Favored Pre-proline 0 CA--C 1.547 0.855 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 176.183 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -70.35 114.12 3.69 Favored 'Trans proline' 0 C--N 1.374 1.897 0 C-N-CA 122.209 1.939 . . . . 0.0 110.591 -177.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 90.85 -11.24 72.54 Favored Glycine 0 C--N 1.34 0.76 0 CA-C-N 115.954 -0.566 . . . . 0.0 113.42 179.022 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . 0.668 ' HB2' ' HB2' ' A' ' 162' ' ' GLU . 47.5 mmtm -104.53 147.83 27.17 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 176.096 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -58.85 149.5 64.42 Favored Pre-proline 0 CA--C 1.554 1.111 0 O-C-N 123.553 0.533 . . . . 0.0 111.832 179.399 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo -56.56 118.09 4.87 Favored 'Trans proline' 0 C--N 1.376 1.994 0 C-N-CA 122.497 2.131 . . . . 0.0 110.348 171.442 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 16.0 ptt180 -135.25 134.09 39.64 Favored 'General case' 0 N--CA 1.47 0.556 0 CA-C-O 120.825 0.345 . . . . 0.0 110.202 -176.606 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . 0.479 ' H ' ' HB3' ' A' ' 17' ' ' GLU . . . -97.75 105.24 17.35 Favored 'General case' 0 C--O 1.225 -0.219 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.557 -177.691 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 27.7 m -97.64 133.63 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.234 0 C-N-CA 123.663 0.785 . . . . 0.0 110.125 -174.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 171' ' ' GLN . . . . . 0.408 ' HA ' ' HA ' ' A' ' 157' ' ' GLN . 37.3 tt0 -77.75 128.41 33.99 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-O 121.656 0.741 . . . . 0.0 110.328 -171.593 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 172' ' ' THR . . . . . 0.552 HG23 HG11 ' A' ' 187' ' ' VAL . 68.7 m -128.08 123.3 34.21 Favored 'General case' 0 C--O 1.246 0.908 0 CA-C-N 113.842 -1.526 . . . . 0.0 109.448 -175.205 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . 0.546 ' HB2' ' HA ' ' A' ' 25' ' ' SER . 27.5 mtpp -76.15 141.61 70.95 Favored Pre-proline 0 CA--C 1.544 0.743 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 168.808 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 174' ' ' PRO . . . . . 0.603 ' HG3' ' HZ2' ' A' ' 150' ' ' TRP . 39.4 Cg_exo -55.37 122.95 12.64 Favored 'Trans proline' 0 C--N 1.371 1.74 0 C-N-CA 122.511 2.14 . . . . 0.0 113.66 -171.481 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . 0.435 ' H ' ' C ' ' A' ' 186' ' ' ALA . . . -117.26 127.33 7.34 Favored Glycine 0 N--CA 1.482 1.723 0 CA-C-O 121.606 0.559 . . . . 0.0 113.594 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.453 ' N ' HD22 ' A' ' 176' ' ' LEU . 0.4 OUTLIER -132.01 127.97 37.35 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 121.914 0.864 . . . . 0.0 109.52 -169.031 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 177' ' ' PHE . . . . . 0.497 ' HE1' ' HE1' ' A' ' 39' ' ' MET . 0.1 OUTLIER -102.58 138.94 38.83 Favored 'General case' 0 C--O 1.245 0.86 0 CA-C-N 114.069 -1.423 . . . . 0.0 110.494 -169.505 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 58.5 tptt -86.0 124.89 32.95 Favored 'General case' 0 C--O 1.243 0.716 0 C-N-CA 124.585 1.154 . . . . 0.0 109.953 -178.552 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 68.9 p -120.53 175.86 5.78 Favored 'General case' 0 C--O 1.242 0.697 0 C-N-CA 123.31 0.644 . . . . 0.0 109.612 169.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 -68.07 -21.37 64.98 Favored 'General case' 0 CA--C 1.546 0.806 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.206 172.694 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -78.65 -53.04 7.58 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 123.724 0.81 . . . . 0.0 110.301 176.011 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 177.48 176.97 45.98 Favored Glycine 0 C--N 1.344 0.999 0 CA-C-N 115.623 -0.717 . . . . 0.0 112.331 -178.742 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 15.5 m -93.91 104.32 16.38 Favored 'General case' 0 CA--C 1.542 0.663 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 176.421 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -123.63 161.09 26.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 C-N-CA 123.455 0.702 . . . . 0.0 109.732 -174.122 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . 113.48 178.41 19.37 Favored Glycine 0 N--CA 1.47 0.912 0 CA-C-O 119.802 -0.443 . . . . 0.0 113.074 176.401 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . 0.435 ' C ' ' H ' ' A' ' 175' ' ' GLY . . . -173.22 38.12 0.01 OUTLIER 'General case' 0 C--N 1.364 1.222 0 C-N-CA 123.75 0.82 . . . . 0.0 110.967 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 187' ' ' VAL . . . . . 0.552 HG11 HG23 ' A' ' 172' ' ' THR . 58.5 t -155.1 117.51 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 C-N-CA 125.146 1.378 . . . . 0.0 107.48 171.539 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 188' ' ' SER . . . . . 0.52 ' HA ' HG11 ' A' ' 223' ' ' VAL . 68.4 m -129.83 86.2 2.38 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-O 121.877 0.846 . . . . 0.0 108.747 170.531 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 32.4 tp -106.38 103.77 13.31 Favored 'General case' 0 CA--C 1.543 0.687 0 CA-C-N 113.907 -1.497 . . . . 0.0 110.231 -173.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 190' ' ' ASP . . . . . 0.7 ' HA ' ' HA ' ' A' ' 221' ' ' ALA . 11.0 p-10 -90.52 102.04 14.78 Favored 'General case' 0 N--CA 1.478 0.934 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 175.348 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 191' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 179.41 -174.88 0.23 Allowed 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 125.981 1.713 . . . . 0.0 108.254 -174.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 9.5 m -51.19 119.89 13.25 Favored Pre-proline 0 CA--C 1.551 0.994 0 O-C-N 123.872 0.733 . . . . 0.0 109.801 172.627 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_exo -48.01 132.61 22.73 Favored 'Trans proline' 0 C--N 1.379 2.138 0 C-N-CA 123.471 2.781 . . . . 0.0 114.226 -171.024 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -67.0 167.18 39.37 Favored Glycine 0 C--N 1.348 1.232 0 CA-C-N 115.633 -0.712 . . . . 0.0 112.085 175.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 195' ' ' THR . . . . . 0.514 HG21 ' HG2' ' A' ' 85' ' ' ARG . 1.4 m -89.99 103.77 16.41 Favored 'General case' 0 CA--C 1.54 0.559 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -173.617 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 43.6 t -51.72 85.08 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.09 0 C-N-CA 125.285 1.434 . . . . 0.0 113.389 -170.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 126.03 16.01 2.74 Favored Glycine 0 C--N 1.355 1.586 0 CA-C-N 115.253 -0.885 . . . . 0.0 113.083 179.123 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 84.2 p -82.81 155.86 67.87 Favored Pre-proline 0 N--CA 1.483 1.21 0 CA-C-N 117.477 0.638 . . . . 0.0 110.156 178.082 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -74.15 142.64 31.02 Favored 'Trans proline' 0 C--N 1.386 2.535 0 C-N-CA 122.308 2.006 . . . . 0.0 113.157 -178.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 62.6 mt -108.59 113.57 44.37 Favored 'Isoleucine or valine' 0 C--O 1.255 1.36 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 175.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 201' ' ' ILE . . . . . 0.581 HG12 ' HA ' ' A' ' 208' ' ' VAL . 14.3 mt -117.24 134.95 59.19 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.085 0 CA-C-N 114.822 -1.081 . . . . 0.0 110.799 -167.445 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -68.37 162.82 24.5 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 125.06 1.344 . . . . 0.0 110.704 174.454 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 63.2 tttm -67.45 -15.54 63.73 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 124.6 1.16 . . . . 0.0 112.061 -173.049 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 21.6 ptmt -94.15 4.01 54.48 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 123.232 0.613 . . . . 0.0 112.147 177.387 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 80.41 38.87 16.39 Favored Glycine 0 C--N 1.351 1.393 0 C-N-CA 122.9 0.286 . . . . 0.0 112.856 -178.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 58.0 tttp -128.78 167.1 17.78 Favored 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 124.272 1.029 . . . . 0.0 109.758 -174.341 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 207' ' ' VAL . . . . . 0.554 ' O ' ' HA3' ' A' ' 148' ' ' GLY . 89.5 t 95.64 -74.91 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.146 0 C-N-CA 125.719 1.608 . . . . 0.0 110.157 171.079 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 208' ' ' VAL . . . . . 0.581 ' HA ' HG12 ' A' ' 201' ' ' ILE . 3.2 m 63.1 22.37 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 CA-C-O 122.484 1.135 . . . . 0.0 109.787 166.414 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.636 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . -83.08 128.85 8.72 Favored Glycine 0 C--N 1.347 1.18 0 CA-C-N 113.376 -1.738 . . . . 0.0 109.353 -172.456 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 87.4 mt -65.65 173.28 2.87 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-N 117.908 0.854 . . . . 0.0 111.287 -165.47 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 211' ' ' TYR . . . . . 0.576 ' HH ' HG11 ' A' ' 158' ' ' VAL . 6.3 m-85 -56.56 157.78 4.97 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.824 163.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 212' ' ' GLY . . . . . 0.594 ' HA3' ' HB2' ' A' ' 225' ' ' ALA . . . -105.87 -141.18 10.38 Favored Glycine 0 C--O 1.24 0.492 0 N-CA-C 111.264 -0.735 . . . . 0.0 111.264 173.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 213' ' ' ASN . . . . . . . . . . . . . 23.5 p-10 -100.13 130.47 46.27 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 -176.327 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . -176.45 -135.96 2.27 Favored Glycine 0 C--N 1.337 0.617 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.962 176.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 215' ' ' VAL . . . . . 0.52 HG11 HG12 ' A' ' 41' ' ' ILE . 7.4 p 176.06 162.85 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 C-N-CA 125.415 1.486 . . . . 0.0 107.936 -171.485 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 216' ' ' VAL . . . . . 0.685 ' HA ' ' HA ' ' A' ' 222' ' ' TYR . 7.8 p -75.07 110.27 9.5 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.498 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 161.167 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 217' ' ' THR . . . . . 0.691 HG22 HD21 ' A' ' 29' ' ' LEU . 53.2 m -87.69 141.82 28.31 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.992 0.917 . . . . 0.0 110.19 -178.448 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 218' ' ' ARG . . . . . 0.445 ' HG3' HG21 ' A' ' 217' ' ' THR . 57.3 mtp180 62.71 8.6 3.09 Favored 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 124.093 0.957 . . . . 0.0 111.574 -175.047 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 68.0 m 62.75 26.31 15.55 Favored 'General case' 0 C--N 1.359 1.006 0 C-N-CA 124.734 1.214 . . . . 0.0 112.077 -176.224 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . -153.88 -19.4 0.05 OUTLIER Glycine 0 C--N 1.349 1.277 0 CA-C-N 116.637 -0.256 . . . . 0.0 113.653 179.29 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 221' ' ' ALA . . . . . 0.7 ' HA ' ' HA ' ' A' ' 190' ' ' ASP . . . -113.87 89.65 3.14 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 123.333 0.653 . . . . 0.0 109.757 -175.576 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 222' ' ' TYR . . . . . 0.685 ' HA ' ' HA ' ' A' ' 216' ' ' VAL . 50.2 t80 -69.15 118.2 11.75 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 123.149 0.58 . . . . 0.0 110.453 -177.45 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . 0.52 HG11 ' HA ' ' A' ' 188' ' ' SER . 21.5 m -123.05 145.43 29.95 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.731 0 C-N-CA 123.507 0.723 . . . . 0.0 110.687 -179.039 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 70.2 m -158.7 159.78 35.67 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 124.915 1.286 . . . . 0.0 108.757 178.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . 0.594 ' HB2' ' HA3' ' A' ' 212' ' ' GLY . . . -76.64 -169.06 1.14 Allowed 'General case' 0 N--CA 1.482 1.147 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 167.239 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 226' ' ' ILE . . . . . . . . . . . . . 54.9 mt -127.83 106.34 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.12 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 174.5 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -85.14 92.03 8.28 Favored 'General case' 0 C--O 1.239 0.551 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 177.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 20.1 pt20 -92.31 158.88 15.87 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-N 115.248 -0.887 . . . . 0.0 108.813 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.625 ' HB ' ' HA ' ' A' ' 145' ' ' LYS . 30.5 p -69.12 107.44 3.19 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-O 121.589 0.709 . . . . 0.0 110.738 -161.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -168.75 79.59 0.14 Allowed 'General case' 0 N--CA 1.451 -0.401 0 N-CA-C 106.366 -1.716 . . . . 0.0 106.366 -171.801 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 231' ' ' LYS . . . . . 0.405 ' HD3' ' H ' ' A' ' 144' ' ' TRP . 59.1 tttp -145.85 -78.82 0.18 Allowed 'General case' 0 N--CA 1.48 1.07 0 CA-C-N 115.912 -0.585 . . . . 0.0 112.297 167.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 68.0 p . . . . . 0 N--CA 1.485 1.312 0 CA-C-N 118.884 0.765 . . . . 0.0 112.036 -174.098 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.426 ' HB1' ' NE2' ' A' ' 88' ' ' GLN . . . . . . . . 0 N--CA 1.473 0.724 0 CA-C-O 120.98 0.419 . . . . 0.0 110.674 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.58 41.11 1.06 Allowed 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 124.186 0.994 . . . . 0.0 109.798 -171.415 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . 0.49 ' HA ' ' HG2' ' A' ' 120' ' ' MET . 7.1 m-20 -153.86 52.53 0.7 Allowed 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 -163.168 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . 0.633 ' HB2' ' HG ' ' A' ' 119' ' ' LEU . 7.9 mt -95.18 89.36 5.49 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 177.113 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.691 ' HB3' ' HD2' ' A' ' 89' ' ' LYS . 11.8 pt-20 -78.7 147.26 33.55 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-O 121.446 0.641 . . . . 0.0 111.771 -173.63 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 41.9 mt -98.02 113.71 25.65 Favored 'General case' 0 C--O 1.238 0.489 0 CA-C-N 114.281 -1.327 . . . . 0.0 108.9 179.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -109.47 144.56 37.56 Favored 'General case' 0 N--CA 1.482 1.132 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 171.383 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 18.0 ttm-85 -69.24 129.09 38.85 Favored 'General case' 0 C--O 1.24 0.604 0 CA-C-O 121.169 0.509 . . . . 0.0 111.476 -173.09 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . 0.571 ' HB3' ' HB2' ' A' ' 85' ' ' ARG . . . -103.21 -37.62 7.62 Favored 'General case' 0 C--O 1.239 0.531 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.13 178.983 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . 0.433 ' HB3' ' HB2' ' A' ' 83' ' ' ALA . . . -165.87 170.3 13.96 Favored 'General case' 0 N--CA 1.474 0.733 0 CA-C-O 121.595 0.712 . . . . 0.0 111.456 -176.523 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -111.55 145.94 38.21 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 171.074 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 59.7 t -74.26 97.75 1.09 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.919 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 -179.29 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 24.1 ttmm -175.13 111.66 0.13 Allowed 'General case' 0 C--O 1.239 0.507 0 C-N-CA 125.615 1.566 . . . . 0.0 107.271 178.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . 0.518 ' HE1' ' HB2' ' A' ' 169' ' ' ALA . 34.7 t90 -93.5 95.01 8.99 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 122.086 0.155 . . . . 0.0 111.07 -178.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -159.68 64.36 0.37 Allowed 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 148.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -89.61 -62.06 1.56 Allowed 'General case' 0 N--CA 1.481 1.111 0 CA-C-O 121.242 0.544 . . . . 0.0 112.192 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . 0.43 ' H ' ' HB3' ' A' ' 169' ' ' ALA . 23.0 mt-30 -150.88 47.74 0.86 Allowed 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 124.203 1.001 . . . . 0.0 109.606 -168.575 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -48.77 95.42 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 113.556 0.947 . . . . 0.0 113.556 -172.368 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -136.48 164.5 28.01 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 125.631 1.572 . . . . 0.0 108.864 -177.532 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.594 HG23 ' HB2' ' A' ' 171' ' ' GLN . 0.2 OUTLIER -122.57 140.3 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.242 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 177.464 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 63.1 m -139.84 -57.82 0.56 Allowed 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -68.93 118.67 9.04 Favored Glycine 0 C--N 1.349 1.28 0 N-CA-C 114.469 0.547 . . . . 0.0 114.469 -168.628 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 68.0 m -164.31 24.32 0.07 Allowed 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 124.864 1.266 . . . . 0.0 109.572 -173.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.616 ' HB2' ' HB2' ' A' ' 188' ' ' SER . 18.4 m -73.88 161.53 78.19 Favored Pre-proline 0 CA--C 1.555 1.163 0 C-N-CA 123.323 0.649 . . . . 0.0 110.701 -177.549 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_exo -71.77 -173.68 1.09 Allowed 'Trans proline' 0 C--N 1.378 2.1 0 C-N-CA 122.471 2.114 . . . . 0.0 112.874 174.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.5 HD12 ' HB2' ' A' ' 176' ' ' LEU . 27.3 mm -76.14 140.91 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.461 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 14.0 mt -131.07 132.24 44.76 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 122.796 0.438 . . . . 0.0 111.605 -168.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.401 ' HA ' ' HB3' ' A' ' 178' ' ' LYS . 49.3 m -69.97 135.15 49.1 Favored 'General case' 0 C--N 1.35 0.62 0 O-C-N 124.098 0.874 . . . . 0.0 111.096 179.493 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 19.6 tt -142.62 141.26 27.79 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.744 0 C-N-CA 123.829 0.852 . . . . 0.0 109.205 -177.655 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 56.0 p -99.42 109.6 22.16 Favored 'General case' 0 CA--C 1.555 1.154 0 C-N-CA 123.24 0.616 . . . . 0.0 110.168 -176.546 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 1.5 mp -80.75 120.31 32.1 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 C-N-CA 123.687 0.795 . . . . 0.0 109.038 176.33 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 26.0 m -97.71 122.78 41.19 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 124.254 1.022 . . . . 0.0 110.094 -178.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 67.57 12.4 8.86 Favored 'General case' 0 N--CA 1.493 1.677 0 C-N-CA 124.358 1.063 . . . . 0.0 112.383 171.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 61.73 24.86 14.88 Favored 'General case' 0 N--CA 1.491 1.618 0 C-N-CA 124.436 1.094 . . . . 0.0 112.113 -177.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -143.03 -42.97 0.05 OUTLIER Glycine 0 C--N 1.338 0.683 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 -178.712 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 39.4 t -93.66 162.93 13.75 Favored 'General case' 0 C--O 1.241 0.609 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 175.092 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 20.9 ptm -161.73 134.77 6.18 Favored 'General case' 0 C--O 1.241 0.609 0 C-N-CA 122.829 0.452 . . . . 0.0 110.065 -175.694 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 28.5 p -173.26 -179.07 1.86 Allowed 'General case' 0 C--O 1.221 -0.43 0 C-N-CA 123.786 0.835 . . . . 0.0 109.422 179.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.743 HD11 HG21 ' A' ' 217' ' ' THR . 28.3 mm -72.12 151.03 8.46 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.971 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 165.593 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 15.3 ptmt -42.62 140.0 1.41 Allowed 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 124.968 1.307 . . . . 0.0 112.104 171.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 65.07 85.57 0.14 Allowed 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 124.999 1.319 . . . . 0.0 108.952 -160.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -86.18 26.91 0.97 Allowed 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 123.86 0.864 . . . . 0.0 113.125 -169.156 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 . . . . . 0 N--CA 1.48 1.07 0 C-N-CA 123.671 0.788 . . . . 0.0 110.772 172.461 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . 0.463 ' H ' ' HA ' ' A' ' 103' ' ' LYS . 4.5 m-20 . . . . . 0 N--CA 1.476 0.873 0 CA-C-O 121.548 0.689 . . . . 0.0 110.923 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -129.23 137.97 9.94 Favored Glycine 0 C--N 1.338 0.66 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 174.835 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . 0.433 ' HB2' ' HB3' ' A' ' 12' ' ' ALA . . . -89.21 120.64 30.76 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 178.544 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 47.6 m-85 -112.55 171.47 7.5 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-O 121.603 0.716 . . . . 0.0 111.127 -176.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' ARG . . . . . 0.571 ' HB2' ' HB3' ' A' ' 11' ' ' ALA . 44.4 ttm105 -131.77 122.83 26.48 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 -177.104 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.456 ' H ' ' HA ' ' A' ' 99' ' ' ALA . 24.5 mt -83.29 133.18 29.67 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 -175.856 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . 0.599 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 76.8 tttt -137.88 131.18 30.61 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 114.743 -1.117 . . . . 0.0 108.405 -170.205 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . 0.426 ' NE2' ' HB1' ' A' ' 3' ' ' ALA . 0.0 OUTLIER -82.55 130.11 35.05 Favored 'General case' 0 C--O 1.245 0.822 0 N-CA-C 106.753 -1.573 . . . . 0.0 106.753 176.315 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . 0.691 ' HD2' ' HB3' ' A' ' 7' ' ' GLU . 48.3 tttp -123.11 135.72 54.49 Favored 'General case' 0 CA--C 1.549 0.914 0 CA-C-N 114.573 -1.194 . . . . 0.0 112.264 -162.024 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . 0.525 ' O ' ' HG2' ' A' ' 89' ' ' LYS . . . -91.83 162.11 27.43 Favored Glycine 0 C--O 1.207 -1.569 0 N-CA-C 106.464 -2.654 . . . . 0.0 106.464 149.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 31.1 mm -54.99 -18.74 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.195 0 CA-C-N 121.333 2.566 . . . . 0.0 114.47 -167.444 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 66.5 mt -86.1 -38.21 18.02 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.385 -0.822 . . . . 0.0 110.464 167.524 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.443 ' HA2' ' HG3' ' A' ' 89' ' ' LYS . . . 145.29 -167.63 27.36 Favored Glycine 0 N--CA 1.477 1.399 0 CA-C-O 118.348 -1.251 . . . . 0.0 110.381 176.608 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . 0.527 ' H ' ' HE2' ' A' ' 87' ' ' LYS 0.285 3.0 p90 178.68 -79.51 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.728 0 C-N-CA 123.838 0.855 . . . . 0.0 112.276 146.488 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 93.6 p -117.45 135.07 54.16 Favored 'General case' 0 N--CA 1.504 2.246 0 CA-C-N 120.384 1.447 . . . . 0.0 112.444 -161.328 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . 0.599 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 5.1 pp0? -81.58 148.48 29.09 Favored 'General case' 0 N--CA 1.485 1.317 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 177.109 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 26.0 pt -133.18 -28.6 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 C-N-CA 123.354 0.662 . . . . 0.0 112.037 -171.758 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -167.41 -155.38 9.15 Favored Glycine 0 C--N 1.344 1.012 0 CA-C-O 119.803 -0.443 . . . . 0.0 112.237 -176.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.566 ' HA ' ' HA ' ' A' ' 85' ' ' ARG . . . -154.96 171.97 18.85 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 123.544 0.738 . . . . 0.0 110.507 -178.24 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -178.92 151.42 10.3 Favored Glycine 0 C--N 1.347 1.151 0 O-C-N 123.135 0.272 . . . . 0.0 112.594 179.487 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 14.9 p -89.15 138.17 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 122.93 0.492 . . . . 0.0 109.908 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -118.28 138.63 52.24 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 170.43 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.463 ' HA ' ' H ' ' A' ' 81' ' ' ASP . 64.4 tttp -135.14 105.9 6.53 Favored 'General case' 0 C--O 1.238 0.472 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 176.395 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 29.3 mt-10 63.39 -87.14 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.167 0 C-N-CA 125.031 1.332 . . . . 0.0 112.251 171.516 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -126.11 11.05 7.33 Favored Glycine 0 C--N 1.349 1.27 0 CA-C-O 120.163 -0.243 . . . . 0.0 113.025 -176.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 15.2 t -132.89 131.36 40.85 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 122.96 0.504 . . . . 0.0 110.094 -177.317 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 30.9 t80 -115.49 131.56 56.89 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 123.258 0.623 . . . . 0.0 109.805 -175.322 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 80.7 m-70 -135.15 123.5 23.22 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 123.058 0.543 . . . . 0.0 110.56 -177.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' THR . . . . . 0.599 HG23 HG22 ' A' ' 138' ' ' ILE . 1.9 t -139.35 175.24 9.73 Favored 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 123.245 0.618 . . . . 0.0 111.911 -179.324 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' MET . . . . . . . . . . . . . 8.0 mmt -75.07 150.1 38.97 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 124.36 1.064 . . . . 0.0 109.561 172.212 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 76.0 t90 -78.89 -43.98 23.75 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 123.071 0.549 . . . . 0.0 111.854 -169.282 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -65.76 -6.58 12.17 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 114.312 1.227 . . . . 0.0 114.312 -172.273 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 19.7 m -60.35 -40.4 83.85 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 176.455 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 90.0 m -164.5 140.0 5.82 Favored 'General case' 0 CA--C 1.551 1.017 0 C-N-CA 126.287 1.835 . . . . 0.0 107.396 171.299 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 32.8 mtt180 -80.85 33.08 0.32 Allowed 'General case' 0 N--CA 1.485 1.305 0 N-CA-C 114.152 1.167 . . . . 0.0 114.152 -166.45 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 107.27 62.15 0.57 Allowed Glycine 0 C--N 1.346 1.091 0 O-C-N 122.085 -0.384 . . . . 0.0 112.656 178.225 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -122.78 168.23 12.5 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 123.441 0.696 . . . . 0.0 110.064 174.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 87.9 t -75.44 144.43 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.802 0 C-N-CA 123.99 0.916 . . . . 0.0 110.96 -177.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.729 ' HB2' ' HB ' ' A' ' 126' ' ' ILE . 5.2 mp -111.16 161.17 16.23 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 123.077 0.551 . . . . 0.0 111.831 178.853 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' MET . . . . . 0.49 ' HG2' ' HA ' ' A' ' 5' ' ' ASP . 19.6 mmt -110.7 106.99 16.4 Favored 'General case' 0 C--O 1.241 0.619 0 CA-C-O 121.935 0.874 . . . . 0.0 110.1 179.191 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.541 ' HB2' HD12 ' A' ' 126' ' ' ILE . 13.9 t60 -104.13 95.07 5.73 Favored 'General case' 0 CA--C 1.542 0.663 0 N-CA-C 107.929 -1.137 . . . . 0.0 107.929 169.17 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 65.5 tttp 44.43 65.31 1.08 Allowed 'General case' 0 CA--C 1.554 1.115 0 C-N-CA 124.893 1.277 . . . . 0.0 112.76 176.109 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 80.73 -27.29 2.98 Favored Glycine 0 CA--C 1.531 1.076 0 CA-C-N 115.047 -0.979 . . . . 0.0 113.881 -179.576 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 94.7 mttt -85.36 154.34 21.94 Favored 'General case' 0 C--N 1.35 0.598 0 CA-C-N 117.395 0.598 . . . . 0.0 109.476 179.124 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 33.8 ptt85 -92.22 160.34 15.21 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-O 121.008 0.432 . . . . 0.0 110.367 178.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.729 ' HB ' ' HB2' ' A' ' 119' ' ' LEU . 80.8 mt -128.52 111.46 23.75 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 171.709 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -93.81 108.66 36.32 Favored Pre-proline 0 CA--C 1.546 0.818 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 178.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -56.7 103.65 0.13 Allowed 'Trans proline' 0 C--N 1.377 2.072 0 C-N-CA 122.884 2.389 . . . . 0.0 112.193 -178.42 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 86.5 p -74.9 -17.23 60.61 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 123.173 0.589 . . . . 0.0 111.277 -177.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 30.4 t-105 -143.26 149.92 38.55 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 -178.663 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -166.59 120.41 1.07 Allowed 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 122.98 0.512 . . . . 0.0 110.72 176.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -120.99 120.83 36.56 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.077 0.951 . . . . 0.0 109.265 171.643 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.476 HG11 ' HG3' ' A' ' 134' ' ' LYS . 4.6 p -69.05 -38.97 79.02 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 CA-C-N 114.657 -1.156 . . . . 0.0 111.844 -178.473 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.476 ' HG3' HG11 ' A' ' 133' ' ' VAL . 97.1 mttt -82.52 -27.95 31.39 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 123.307 0.643 . . . . 0.0 112.218 -173.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . 0.487 ' HB3' HD12 ' A' ' 137' ' ' LEU . 33.5 mmtp -71.83 -27.74 63.1 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 167.661 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . 0.405 ' HB3' HD21 ' A' ' 213' ' ' ASN . 8.9 t70 56.64 58.61 4.03 Favored 'General case' 0 CA--C 1.538 0.494 0 O-C-N 125.27 1.606 . . . . 0.0 109.37 -167.878 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . 0.487 HD12 ' HB3' ' A' ' 135' ' ' LYS . 6.6 mt -144.1 121.98 12.0 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 113.6 -1.637 . . . . 0.0 109.223 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.599 HG22 HG23 ' A' ' 109' ' ' THR . 9.2 tt -121.85 133.32 68.6 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 174.16 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 73.4 m -146.6 165.51 29.29 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-O 122.138 0.97 . . . . 0.0 112.575 -169.798 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 46.4 t80 -133.44 128.69 36.02 Favored 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 125.778 1.631 . . . . 0.0 107.764 175.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 102.29 -4.01 51.3 Favored Glycine 0 C--N 1.345 1.029 0 O-C-N 123.671 0.607 . . . . 0.0 112.324 -175.363 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 147.17 -165.58 28.58 Favored Glycine 0 C--N 1.349 1.272 0 N-CA-C 111.392 -0.683 . . . . 0.0 111.392 179.324 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -77.95 -173.64 41.34 Favored Glycine 0 C--N 1.353 1.501 0 CA-C-O 118.98 -0.9 . . . . 0.0 111.059 172.42 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' TRP . . . . . 0.522 ' HZ2' ' HA2' ' A' ' 209' ' ' GLY . 5.1 t-105 -55.0 108.01 0.36 Allowed 'General case' 0 N--CA 1.477 0.909 0 CA-C-N 118.267 1.033 . . . . 0.0 109.986 176.856 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 30.7 tptt -144.5 133.35 22.49 Favored 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 113.725 -1.579 . . . . 0.0 107.617 -174.463 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' LEU . . . . . . . . . . . . . 32.9 tp -153.37 -86.75 0.06 Allowed 'General case' 0 CA--C 1.534 0.345 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 174.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 161.31 38.23 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.078 0 C-N-CA 125.362 1.465 . . . . 0.0 109.384 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -126.29 119.78 3.52 Favored Glycine 0 C--N 1.336 0.583 0 CA-C-N 115.879 -0.6 . . . . 0.0 113.279 -172.234 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 5.0 mp0 -113.78 100.34 8.38 Favored 'General case' 0 N--CA 1.474 0.751 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 179.457 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' TRP . . . . . 0.5 ' HZ2' ' HG3' ' A' ' 174' ' ' PRO . 28.8 t90 -71.28 130.23 40.88 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 174.752 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 18.2 ttmm -87.29 106.87 18.22 Favored 'General case' 0 C--O 1.242 0.673 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 176.184 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -62.19 104.14 0.45 Allowed 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.122 0.969 . . . . 0.0 111.688 -173.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 141.68 -38.15 1.53 Allowed Glycine 0 C--N 1.347 1.176 0 CA-C-N 116.58 -0.282 . . . . 0.0 112.989 178.026 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 -72.51 152.9 41.62 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 123.054 0.542 . . . . 0.0 111.805 -178.338 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -69.73 120.06 14.92 Favored 'General case' 0 C--O 1.244 0.786 0 N-CA-C 108.258 -1.015 . . . . 0.0 108.258 169.042 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . 0.502 HG23 HG23 ' A' ' 208' ' ' VAL . 8.9 p -119.17 151.31 21.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.474 0 N-CA-C 108.974 -0.751 . . . . 0.0 108.974 -173.292 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . 0.45 ' HA ' ' HA ' ' A' ' 171' ' ' GLN . 0.0 OUTLIER -99.77 141.05 33.09 Favored 'General case' 0 N--CA 1.478 0.954 0 CA-C-O 121.081 0.467 . . . . 0.0 110.704 -168.779 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 89.7 t -117.6 131.35 70.59 Favored 'Isoleucine or valine' 0 C--O 1.245 0.825 0 C-N-CA 124.075 0.95 . . . . 0.0 108.444 170.258 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 44.6 mt -73.8 86.99 1.73 Allowed 'General case' 0 CA--C 1.544 0.717 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 171.356 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . 0.581 ' HB1' ' HB2' ' A' ' 168' ' ' ARG . . . -64.13 98.61 0.23 Allowed 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 123.357 0.663 . . . . 0.0 110.82 -176.882 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . 0.617 ' H ' ' HA2' ' A' ' 194' ' ' GLY . 71.6 mt -70.78 88.22 0.72 Allowed 'General case' 0 C--O 1.241 0.631 0 C-N-CA 124.549 1.139 . . . . 0.0 111.229 -173.9 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -85.34 119.08 71.96 Favored Pre-proline 0 CA--C 1.553 1.09 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.316 174.326 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_exo -59.0 115.78 2.8 Favored 'Trans proline' 0 C--N 1.379 2.167 0 C-N-CA 123.115 2.543 . . . . 0.0 113.322 -176.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 113.79 -15.26 21.7 Favored Glycine 0 N--CA 1.471 0.969 0 CA-C-O 119.348 -0.695 . . . . 0.0 113.663 174.073 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -123.21 -169.62 1.97 Allowed 'General case' 0 C--N 1.355 0.814 0 CA-C-N 117.63 0.715 . . . . 0.0 109.787 -177.249 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 -70.46 162.24 71.62 Favored Pre-proline 0 CA--C 1.563 1.445 0 CA-C-N 114.695 -1.139 . . . . 0.0 109.359 161.482 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_exo -71.17 135.54 27.34 Favored 'Trans proline' 0 C--N 1.365 1.414 0 C-N-CA 121.95 1.767 . . . . 0.0 111.934 172.284 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . 0.581 ' HB2' ' HB1' ' A' ' 160' ' ' ALA . 85.7 mtt180 -70.88 109.26 4.93 Favored 'General case' 0 CA--C 1.546 0.801 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 171.745 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . 0.518 ' HB2' ' HE1' ' A' ' 16' ' ' TRP . . . -75.78 102.11 5.33 Favored 'General case' 0 N--CA 1.474 0.725 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -179.483 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . 0.427 HG21 ' CE2' ' A' ' 191' ' ' PHE . 40.6 t -120.99 116.3 49.41 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 C-N-CA 122.52 0.328 . . . . 0.0 111.158 -170.02 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 171' ' ' GLN . . . . . 0.594 ' HB2' HG23 ' A' ' 22' ' ' ILE . 26.6 mt-30 -83.91 142.41 30.58 Favored 'General case' 0 C--O 1.243 0.751 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 173.565 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 5.6 t -152.38 136.28 16.34 Favored 'General case' 0 C--O 1.242 0.694 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.652 -168.736 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . 0.519 ' HD3' ' HD2' ' A' ' 174' ' ' PRO . 4.5 tppp? -72.33 126.04 91.17 Favored Pre-proline 0 CA--C 1.543 0.696 0 C-N-CA 123.557 0.743 . . . . 0.0 109.554 175.471 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 174' ' ' PRO . . . . . 0.519 ' HD2' ' HD3' ' A' ' 173' ' ' LYS . 9.2 Cg_endo -48.05 139.14 21.04 Favored 'Trans proline' 0 C--N 1.374 1.912 0 C-N-CA 123.739 2.96 . . . . 0.0 113.475 172.689 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . 0.624 ' H ' ' HA ' ' A' ' 187' ' ' VAL . . . -118.09 -172.77 15.84 Favored Glycine 0 C--O 1.237 0.293 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 175.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.5 ' HB2' HD12 ' A' ' 28' ' ' ILE . 5.5 mp -138.47 152.36 48.24 Favored 'General case' 0 N--CA 1.479 0.983 0 CA-C-N 117.8 0.8 . . . . 0.0 110.11 178.588 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 177' ' ' PHE . . . . . 0.649 ' HB2' ' HB ' ' A' ' 184' ' ' ILE . 35.7 m-85 -92.18 123.58 35.63 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.531 0.732 . . . . 0.0 109.85 176.571 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 178' ' ' LYS . . . . . 0.401 ' HB3' ' HA ' ' A' ' 30' ' ' SER . 23.8 ttmm -86.57 94.87 9.56 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 172.383 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 63.0 m -103.1 153.68 20.05 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 123.469 0.708 . . . . 0.0 110.621 -173.536 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 7.0 t30 -80.14 64.93 5.12 Favored 'General case' 0 N--CA 1.48 1.044 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 173.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -175.47 -38.83 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.569 1.548 . . . . 0.0 108.706 -176.495 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 170.49 -144.17 8.23 Favored Glycine 0 C--N 1.341 0.86 0 CA-C-N 114.862 -1.063 . . . . 0.0 111.143 -178.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 10.2 m -127.13 131.87 50.7 Favored 'General case' 0 CA--C 1.548 0.866 0 C-N-CA 123.319 0.648 . . . . 0.0 109.546 179.075 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . 0.649 ' HB ' ' HB2' ' A' ' 177' ' ' PHE . 31.4 mt -107.16 163.28 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 C-N-CA 124.152 0.981 . . . . 0.0 108.561 -179.537 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -99.89 132.34 10.9 Favored Glycine 0 N--CA 1.478 1.488 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . 0.68 ' HA ' ' HA ' ' A' ' 225' ' ' ALA . . . -154.51 -159.02 0.91 Allowed 'General case' 0 N--CA 1.474 0.751 0 CA-C-O 121.083 0.468 . . . . 0.0 112.105 -164.122 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 187' ' ' VAL . . . . . 0.624 ' HA ' ' H ' ' A' ' 175' ' ' GLY . 10.4 p -149.25 135.46 12.18 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 C-N-CA 123.98 0.912 . . . . 0.0 108.731 167.446 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 188' ' ' SER . . . . . 0.616 ' HB2' ' HB2' ' A' ' 26' ' ' SER . 11.9 p -106.38 101.87 11.31 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 123.679 0.792 . . . . 0.0 110.009 -173.322 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 65.5 tp -127.15 109.95 12.39 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 123.969 0.908 . . . . 0.0 110.786 -168.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 190' ' ' ASP . . . . . 0.469 ' HA ' ' HA ' ' A' ' 221' ' ' ALA . 13.5 p-10 -96.25 102.74 14.57 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 167.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 191' ' ' PHE . . . . . 0.427 ' CE2' HG21 ' A' ' 170' ' ' VAL . 50.5 t80 179.68 174.96 0.79 Allowed 'General case' 0 CA--C 1.551 0.985 0 CA-C-N 114.985 -1.007 . . . . 0.0 108.541 -168.117 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 33.6 m -86.87 96.17 0.51 Allowed Pre-proline 0 CA--C 1.554 1.114 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 169.548 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . 0.453 ' HG3' ' HB2' ' A' ' 222' ' ' TYR . 10.0 Cg_endo -93.1 -164.76 0.12 Allowed 'Trans proline' 0 C--N 1.373 1.828 0 C-N-CA 123.266 2.644 . . . . 0.0 114.055 -165.587 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 194' ' ' GLY . . . . . 0.617 ' HA2' ' H ' ' A' ' 161' ' ' LEU . . . -82.11 153.73 32.71 Favored Glycine 0 C--N 1.35 1.32 0 CA-C-N 115.053 -0.976 . . . . 0.0 112.793 176.395 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 2.8 m -70.87 155.08 41.24 Favored 'General case' 0 CA--C 1.554 1.128 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 174.201 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 4.1 m -63.67 87.41 0.04 OUTLIER 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 123.493 0.717 . . . . 0.0 112.428 -168.405 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 134.35 17.81 0.96 Allowed Glycine 0 N--CA 1.469 0.883 0 CA-C-N 114.797 -1.092 . . . . 0.0 111.823 -175.43 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 42.6 t -62.09 138.31 95.86 Favored Pre-proline 0 CA--C 1.545 0.762 0 C-N-CA 124.777 1.231 . . . . 0.0 111.388 177.246 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -71.9 129.79 15.86 Favored 'Trans proline' 0 C--N 1.37 1.71 0 C-N-CA 122.039 1.826 . . . . 0.0 112.259 179.371 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 22.9 mt -100.71 120.5 50.28 Favored 'Isoleucine or valine' 0 C--O 1.238 0.473 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 173.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 201' ' ' ILE . . . . . 0.465 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 56.5 mt -113.55 160.57 12.98 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.942 0 N-CA-C 107.826 -1.176 . . . . 0.0 107.826 178.221 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -99.6 169.27 9.4 Favored 'General case' 0 N--CA 1.478 0.942 0 O-C-N 121.739 -0.601 . . . . 0.0 110.539 176.188 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 7.3 ptpp? -58.66 -26.57 63.93 Favored 'General case' 0 CA--C 1.55 0.957 0 C-N-CA 124.207 1.003 . . . . 0.0 111.497 174.221 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 51.2 tptt -67.0 -20.62 65.91 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 124.064 0.946 . . . . 0.0 111.401 179.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 98.82 -14.1 61.88 Favored Glycine 0 C--N 1.345 1.078 0 N-CA-C 111.791 -0.524 . . . . 0.0 111.791 -175.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -85.79 136.89 33.14 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 123.96 0.904 . . . . 0.0 109.705 179.042 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 207' ' ' VAL . . . . . 0.465 ' HA ' ' HA ' ' A' ' 201' ' ' ILE . 13.7 p -67.88 151.95 9.95 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 123.627 0.771 . . . . 0.0 110.101 -179.629 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 208' ' ' VAL . . . . . 0.502 HG23 HG23 ' A' ' 156' ' ' VAL . 28.8 m -127.49 -26.62 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 CA-C-O 118.683 -0.675 . . . . 0.0 112.568 -179.211 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.522 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . 171.72 -147.03 9.82 Favored Glycine 0 C--N 1.36 1.871 0 C-N-CA 119.202 -1.475 . . . . 0.0 116.618 176.128 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 50.6 mt -129.65 143.33 50.77 Favored 'General case' 0 N--CA 1.491 1.623 0 C-N-CA 124.45 1.1 . . . . 0.0 111.804 -175.06 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 47.7 t80 -117.5 105.74 12.41 Favored 'General case' 0 C--O 1.236 0.386 0 C-N-CA 124.951 1.3 . . . . 0.0 108.505 -177.025 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . 172.86 71.49 0.05 OUTLIER Glycine 0 N--CA 1.442 -0.906 0 N-CA-C 111.348 -0.701 . . . . 0.0 111.348 160.286 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 213' ' ' ASN . . . . . 0.609 ' HB2' ' HB1' ' A' ' 225' ' ' ALA . 2.8 m120 -140.17 79.62 1.72 Allowed 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 175.308 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 169.17 -152.63 20.41 Favored Glycine 0 C--O 1.247 0.927 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.756 -176.265 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 215' ' ' VAL . . . . . . . . . . . . . 9.9 p -163.24 171.02 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.832 0 CA-C-N 116.905 0.353 . . . . 0.0 111.831 -166.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 216' ' ' VAL . . . . . . . . . . . . . 14.4 p -69.0 128.42 32.44 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.048 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 167.021 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 217' ' ' THR . . . . . 0.743 HG21 HD11 ' A' ' 41' ' ' ILE . 47.7 m -138.12 169.27 18.09 Favored 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 124.98 1.312 . . . . 0.0 108.848 -170.817 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 59.9 ttt180 69.22 -83.99 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 123.69 0.796 . . . . 0.0 111.526 168.099 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 23.2 p -163.27 42.36 0.11 Allowed 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 124.216 1.006 . . . . 0.0 109.011 -174.191 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . 101.39 37.89 3.42 Favored Glycine 0 C--N 1.345 1.069 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.149 -178.562 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 221' ' ' ALA . . . . . 0.469 ' HA ' ' HA ' ' A' ' 190' ' ' ASP . . . -118.96 100.61 7.48 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 123.802 0.841 . . . . 0.0 109.234 -172.479 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 222' ' ' TYR . . . . . 0.453 ' HB2' ' HG3' ' A' ' 193' ' ' PRO . 69.7 m-85 -77.4 97.81 5.05 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-O 121.601 0.715 . . . . 0.0 109.212 -177.003 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 45.7 t -97.52 113.71 32.72 Favored 'Isoleucine or valine' 0 C--O 1.235 0.29 0 CA-C-N 114.398 -1.273 . . . . 0.0 107.957 -178.708 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 8.8 t -130.91 154.58 47.95 Favored 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 124.737 1.215 . . . . 0.0 109.367 -173.025 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . 0.68 ' HA ' ' HA ' ' A' ' 186' ' ' ALA . . . -84.03 152.43 24.41 Favored 'General case' 0 C--O 1.247 0.947 0 CA-C-O 120.949 0.404 . . . . 0.0 110.545 178.545 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 226' ' ' ILE . . . . . . . . . . . . . 8.5 pt -114.53 93.14 2.37 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.806 0 CA-C-O 121.914 0.864 . . . . 0.0 109.855 -176.394 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 227' ' ' ALA . . . . . 0.43 ' O ' ' HA3' ' A' ' 209' ' ' GLY . . . -80.69 119.38 23.23 Favored 'General case' 0 N--CA 1.48 1.027 0 CA-C-N 114.939 -1.028 . . . . 0.0 111.108 -172.006 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . 0.423 HE21 ' HB3' ' A' ' 150' ' ' TRP . 4.0 pt20 -93.81 152.9 18.59 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 123.902 0.881 . . . . 0.0 109.188 177.621 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.416 ' HA ' ' NE1' ' A' ' 144' ' ' TRP . 87.4 m -65.06 122.36 16.85 Favored 'General case' 0 N--CA 1.477 0.907 0 CA-C-O 121.005 0.431 . . . . 0.0 111.872 -170.131 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 30.2 mt-10 -84.69 -41.73 15.99 Favored 'General case' 0 CA--C 1.543 0.694 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.313 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 231' ' ' LYS . . . . . 0.647 ' HB3' ' HZ3' ' A' ' 231' ' ' LYS . 0.0 OUTLIER 61.99 95.11 0.04 OUTLIER 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 124.9 1.28 . . . . 0.0 110.742 -177.284 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 85.2 p . . . . . 0 N--CA 1.476 0.858 0 CA-C-O 119.124 -0.465 . . . . 0.0 110.97 178.446 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.394 0 N-CA-C 114.214 1.191 . . . . 0.0 114.214 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -128.84 20.39 5.99 Favored 'General case' 0 N--CA 1.476 0.869 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 -177.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -123.94 10.41 8.86 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 126.109 1.764 . . . . 0.0 107.242 -177.18 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . 0.496 ' HB2' HD11 ' A' ' 119' ' ' LEU . 16.9 mt -67.73 166.51 15.12 Favored 'General case' 0 C--O 1.201 -1.461 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 -174.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -154.6 146.7 23.68 Favored 'General case' 0 C--O 1.247 0.968 0 CA-C-N 118.7 0.682 . . . . 0.0 110.144 176.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . 0.568 ' HB2' ' CD2' ' A' ' 121' ' ' HIS . 83.7 mt -87.54 125.45 34.34 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 115.032 -0.985 . . . . 0.0 109.933 172.536 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 22.7 tt0 -104.18 125.27 50.34 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 124.893 1.277 . . . . 0.0 108.275 178.391 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 15.5 ttt180 -60.24 109.35 0.96 Allowed 'General case' 0 N--CA 1.477 0.917 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 -179.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . 0.406 ' HB3' ' HG3' ' A' ' 85' ' ' ARG . . . -106.56 -43.88 4.62 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 122.487 0.315 . . . . 0.0 111.267 -170.113 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -174.25 172.91 3.16 Favored 'General case' 0 N--CA 1.477 0.913 0 O-C-N 124.095 0.872 . . . . 0.0 110.409 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -87.12 144.62 26.78 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 162.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 61.9 t -72.06 100.6 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.003 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 176.778 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 26.8 ttpp -172.05 103.49 0.17 Allowed 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 124.483 1.113 . . . . 0.0 108.884 -175.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . 0.526 ' NE1' ' HB1' ' A' ' 169' ' ' ALA . 92.4 t90 -80.59 94.78 6.36 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 123.224 0.61 . . . . 0.0 110.351 -179.244 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -157.81 57.62 0.48 Allowed 'General case' 0 CA--C 1.557 1.217 0 C-N-CA 123.195 0.598 . . . . 0.0 111.587 157.232 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -92.3 -63.42 1.24 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.445 -0.784 . . . . 0.0 112.689 177.675 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . 0.715 ' H ' ' HB2' ' A' ' 169' ' ' ALA . 48.8 mt-30 -153.09 43.8 0.63 Allowed 'General case' 0 N--CA 1.489 1.477 0 CA-C-N 114.693 -1.14 . . . . 0.0 111.248 -158.199 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -35.05 99.78 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.014 0 C-N-CA 125.537 1.535 . . . . 0.0 114.486 -175.135 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -126.52 118.48 24.99 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 123.748 0.819 . . . . 0.0 110.163 -176.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.529 ' HA ' ' HB2' ' A' ' 171' ' ' GLN . 0.2 OUTLIER -76.16 143.87 12.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 CA-C-O 121.052 0.453 . . . . 0.0 111.872 -174.478 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 77.2 p -154.35 156.71 37.39 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 124.558 1.143 . . . . 0.0 109.654 -178.502 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 160.25 103.82 0.19 Allowed Glycine 0 C--N 1.339 0.747 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -174.293 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.408 ' H ' ' HB3' ' A' ' 189' ' ' LEU . 29.4 t -109.72 -70.27 0.82 Allowed 'General case' 0 N--CA 1.478 0.961 0 CA-C-N 117.566 0.683 . . . . 0.0 111.342 -168.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 26.5 m -123.49 85.68 52.52 Favored Pre-proline 0 CA--C 1.551 1.014 0 C-N-CA 123.3 0.64 . . . . 0.0 109.526 -172.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 82.3 Cg_exo -45.41 -49.76 10.01 Favored 'Trans proline' 0 C--N 1.39 2.761 0 C-N-CA 124.293 3.329 . . . . 0.0 114.162 -173.149 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 49.1 mm -104.01 117.04 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 175.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.554 HD13 ' HB2' ' A' ' 218' ' ' ARG . 0.5 OUTLIER -138.26 128.52 25.95 Favored 'General case' 0 N--CA 1.478 0.942 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 -177.232 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 60.1 p -79.24 159.24 27.39 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 122.949 0.5 . . . . 0.0 111.195 179.088 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 16.0 tt -150.68 159.62 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 -177.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 35.3 m -94.88 110.81 22.65 Favored 'General case' 0 C--O 1.241 0.622 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 176.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 45.5 mm -72.12 115.75 12.98 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 173.673 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' SER . . . . . 0.481 ' HB2' ' HB3' ' A' ' 38' ' ' SER . 15.5 m -79.65 117.63 20.74 Favored 'General case' 0 C--O 1.241 0.627 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 170.641 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -60.37 -8.49 2.69 Favored 'General case' 0 N--CA 1.491 1.608 0 C-N-CA 124.473 1.109 . . . . 0.0 113.491 -169.206 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -65.79 -13.75 60.05 Favored 'General case' 0 CA--C 1.551 1.0 0 C-N-CA 124.756 1.222 . . . . 0.0 112.24 172.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.04 14.39 26.66 Favored Glycine 0 C--N 1.347 1.141 0 N-CA-C 111.693 -0.563 . . . . 0.0 111.693 -171.249 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' SER . . . . . 0.481 ' HB3' ' HB2' ' A' ' 34' ' ' SER . 23.1 t -109.03 164.97 11.95 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.496 0.719 . . . . 0.0 110.481 -179.303 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 68.3 mtp -133.29 134.71 44.23 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 123.518 0.727 . . . . 0.0 109.808 -179.015 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 13.3 p -169.44 174.4 6.0 Favored 'General case' 0 C--N 1.353 0.749 0 CA-C-O 121.436 0.636 . . . . 0.0 112.611 -175.185 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.622 HD12 HG21 ' A' ' 217' ' ' THR . 50.7 mm -89.44 152.33 3.35 Favored 'Isoleucine or valine' 0 C--O 1.241 0.635 0 N-CA-C 107.0 -1.482 . . . . 0.0 107.0 160.062 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 47.6 mtmt -72.65 75.74 1.1 Allowed 'General case' 0 CA--C 1.55 0.977 0 CA-C-O 121.665 0.745 . . . . 0.0 110.51 177.195 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 36.0 t30 -173.05 143.42 1.15 Allowed 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 126.079 1.752 . . . . 0.0 107.667 -176.504 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -148.5 150.53 33.56 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 122.537 0.335 . . . . 0.0 111.155 177.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 . . . . . 0 N--CA 1.473 0.682 0 C-N-CA 124.425 1.09 . . . . 0.0 109.866 179.419 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . 0.517 ' HB2' ' HA ' ' A' ' 103' ' ' LYS . 38.5 p-10 . . . . . 0 CA--C 1.537 0.449 0 N-CA-C 112.271 0.471 . . . . 0.0 112.271 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 142.27 -162.82 27.2 Favored Glycine 0 C--N 1.345 1.06 0 CA-C-N 115.296 -0.866 . . . . 0.0 112.256 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . 0.482 ' HB2' HD13 ' A' ' 161' ' ' LEU . . . -85.76 123.26 30.93 Favored 'General case' 0 N--CA 1.477 0.88 0 C-N-CA 123.67 0.788 . . . . 0.0 109.865 177.587 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 15.0 m-85 -129.79 140.43 51.04 Favored 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 123.356 0.663 . . . . 0.0 110.686 -176.145 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' ARG . . . . . 0.512 ' HD3' HE22 ' A' ' 96' ' ' GLN . 80.7 mtt85 -88.09 128.8 35.42 Favored 'General case' 0 N--CA 1.479 0.997 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 173.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 53.3 mt -91.02 122.03 42.0 Favored 'Isoleucine or valine' 0 C--O 1.247 0.957 0 CA-C-O 121.432 0.634 . . . . 0.0 110.209 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . 0.545 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 34.4 mtmm -114.84 146.96 40.5 Favored 'General case' 0 C--O 1.216 -0.675 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.316 174.657 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 19.7 tm0? -87.05 107.15 18.3 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 105.872 -1.899 . . . . 0.0 105.872 165.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 50.0 mtpt -114.38 94.04 4.62 Favored 'General case' 0 C--O 1.241 0.641 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 -176.078 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -70.28 137.9 28.5 Favored Glycine 0 C--O 1.242 0.619 0 N-CA-C 108.221 -1.951 . . . . 0.0 108.221 165.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 2.9 mp -75.13 68.9 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.566 1.584 0 N-CA-C 107.103 -1.443 . . . . 0.0 107.103 176.854 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 3.9 pp 170.5 -38.16 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.468 0 C-N-CA 126.435 1.894 . . . . 0.0 109.834 -165.549 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -161.66 134.33 3.48 Favored Glycine 0 C--N 1.353 1.492 0 CA-C-N 115.994 -0.548 . . . . 0.0 112.201 -174.417 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 8.2 m-85 -123.25 131.65 53.75 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.75 0.82 . . . . 0.0 109.756 -167.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 53.6 m -148.65 146.32 28.13 Favored 'General case' 0 N--CA 1.483 1.21 0 C-N-CA 123.956 0.902 . . . . 0.0 109.383 176.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . 0.545 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 61.9 tt0 -92.52 144.08 25.7 Favored 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 123.127 0.571 . . . . 0.0 110.904 178.312 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 25.5 pt -128.34 -26.4 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 C-N-CA 123.138 0.575 . . . . 0.0 112.158 -173.255 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . 0.426 ' HA2' ' HB ' ' A' ' 195' ' ' THR . . . -177.52 -149.54 7.93 Favored Glycine 0 C--N 1.349 1.271 0 C-N-CA 121.144 -0.55 . . . . 0.0 113.263 -177.643 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -157.23 175.47 13.98 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 124.119 0.967 . . . . 0.0 110.969 -176.447 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -178.21 -171.18 41.28 Favored Glycine 0 C--N 1.346 1.117 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.646 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 34.7 t -135.64 127.0 44.92 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.065 0 CA-C-O 121.552 0.691 . . . . 0.0 111.023 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -91.03 145.0 25.07 Favored 'General case' 0 CA--C 1.548 0.874 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 170.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.517 ' HA ' ' HB2' ' A' ' 81' ' ' ASP . 20.1 tptp -152.65 118.14 5.3 Favored 'General case' 0 N--CA 1.483 1.196 0 CA-C-N 119.168 0.895 . . . . 0.0 111.667 177.303 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 52.3 43.2 30.99 Favored 'General case' 0 N--CA 1.486 1.344 0 C-N-CA 124.629 1.171 . . . . 0.0 113.262 166.286 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 96.31 -33.76 5.42 Favored Glycine 0 C--N 1.348 1.244 0 CA-C-N 115.935 -0.575 . . . . 0.0 112.947 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 60.5 p -88.88 118.93 28.94 Favored 'General case' 0 CA--C 1.542 0.639 0 CA-C-N 117.023 0.412 . . . . 0.0 110.433 -178.213 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' PHE . . . . . 0.415 ' CE2' ' HG ' ' A' ' 119' ' ' LEU . 23.1 t80 -95.23 115.25 27.18 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 176.638 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . 0.603 ' HB2' ' HE3' ' A' ' 144' ' ' TRP . 1.0 OUTLIER -136.2 121.2 18.81 Favored 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 122.698 0.399 . . . . 0.0 110.808 -176.703 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 14.7 t -135.88 -179.71 5.82 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 122.999 0.52 . . . . 0.0 112.035 -169.09 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' MET . . . . . 0.567 ' HE1' ' HA2' ' A' ' 212' ' ' GLY . 0.0 OUTLIER -72.72 141.52 48.17 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 124.839 1.256 . . . . 0.0 110.023 171.247 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 80.7 t90 -76.03 -53.01 9.0 Favored 'General case' 0 N--CA 1.483 1.202 0 CA-C-O 119.328 -0.367 . . . . 0.0 111.616 -174.482 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . 0.617 ' HE1' ' HA ' ' A' ' 213' ' ' ASN . 3.4 p-80 -65.35 -2.88 3.48 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 114.119 1.155 . . . . 0.0 114.119 -170.437 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 78.1 t -58.07 -39.58 73.22 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.934 0 CA-C-O 121.524 0.678 . . . . 0.0 109.705 167.639 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.531 HG23 ' H ' ' A' ' 116' ' ' GLY . 9.4 t -138.6 -168.48 2.41 Favored 'General case' 0 CA--C 1.555 1.161 0 CA-C-N 114.607 -1.179 . . . . 0.0 109.765 -178.492 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 31.5 ttt180 -93.03 14.94 16.26 Favored 'General case' 0 CA--C 1.561 1.401 0 C-N-CA 124.063 0.945 . . . . 0.0 110.951 177.316 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.531 ' H ' HG23 ' A' ' 114' ' ' THR . . . 80.17 40.7 13.2 Favored Glycine 0 C--N 1.346 1.084 0 N-CA-C 111.816 -0.513 . . . . 0.0 111.816 -175.167 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -120.23 -169.89 1.88 Allowed 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 123.336 0.654 . . . . 0.0 111.543 -173.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 48.9 t -75.36 136.93 23.94 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 N-CA-C 114.184 1.179 . . . . 0.0 114.184 -159.854 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.496 HD11 ' HB2' ' A' ' 6' ' ' LEU . 3.7 mm? -103.13 151.63 22.36 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 124.89 1.276 . . . . 0.0 110.616 174.505 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 38.1 mmt -104.1 151.45 23.26 Favored 'General case' 0 C--O 1.262 1.744 0 C-N-CA 124.57 1.148 . . . . 0.0 108.197 173.284 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.568 ' CD2' ' HB2' ' A' ' 8' ' ' LEU . 0.1 OUTLIER -143.52 92.45 2.36 Favored 'General case' 0 CA--C 1.538 0.495 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 165.072 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.516 ' HB2' ' HZ2' ' A' ' 122' ' ' LYS . 10.1 mtmp? 56.72 28.45 14.24 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 124.591 1.157 . . . . 0.0 112.619 -174.614 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 100.66 -8.91 58.45 Favored Glycine 0 C--N 1.347 1.176 0 CA-C-O 119.683 -0.509 . . . . 0.0 113.229 -176.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 61.2 tttm -72.94 114.55 11.22 Favored 'General case' 0 C--N 1.357 0.901 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 171.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 47.1 ttp180 -82.86 86.13 6.98 Favored 'General case' 0 C--O 1.241 0.605 0 C-N-CA 124.258 1.023 . . . . 0.0 109.271 -174.368 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.443 HG13 ' HB2' ' A' ' 119' ' ' LEU . 23.8 pt -91.71 100.49 11.3 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 CA-C-O 122.334 1.064 . . . . 0.0 109.346 -177.71 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -94.22 126.79 47.14 Favored Pre-proline 0 CA--C 1.546 0.789 0 CA-C-N 113.972 -1.467 . . . . 0.0 110.063 -175.382 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . 0.405 ' HB3' HG23 ' A' ' 138' ' ' ILE . 88.0 Cg_exo -49.53 119.5 4.72 Favored 'Trans proline' 0 C--N 1.373 1.865 0 C-N-CA 123.266 2.644 . . . . 0.0 113.834 175.666 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 59.1 p -82.13 -10.41 59.19 Favored 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 123.799 0.84 . . . . 0.0 110.51 174.425 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.688 ' HB3' ' HB2' ' A' ' 139' ' ' SER . 64.8 t-105 -155.79 152.77 28.86 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 124.912 1.285 . . . . 0.0 109.096 178.176 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -161.86 120.48 2.33 Favored 'General case' 0 C--O 1.241 0.622 0 C-N-CA 124.152 0.981 . . . . 0.0 108.546 169.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -108.84 112.5 24.79 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 123.324 0.65 . . . . 0.0 109.627 176.652 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 11.5 t -75.47 -17.47 15.8 Favored 'Isoleucine or valine' 0 CA--C 1.557 1.228 0 C-N-CA 123.139 0.576 . . . . 0.0 110.159 179.316 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 23.4 ttmm -59.62 -51.5 69.55 Favored 'General case' 0 C--N 1.358 0.974 0 C-N-CA 124.486 1.114 . . . . 0.0 112.359 -174.584 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 79.6 tttt -109.79 4.9 22.2 Favored 'General case' 0 N--CA 1.485 1.291 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 172.606 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . 0.437 ' O ' ' HE3' ' A' ' 110' ' ' MET . 15.6 t70 67.96 71.15 0.33 Allowed 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 124.341 1.056 . . . . 0.0 111.368 170.175 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 47.8 mt -147.43 160.29 42.73 Favored 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 124.317 1.047 . . . . 0.0 110.278 178.043 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.405 HG23 ' HB3' ' A' ' 128' ' ' PRO . 38.0 mt -132.24 150.72 33.83 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 C-N-CA 125.739 1.615 . . . . 0.0 108.214 -176.675 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' SER . . . . . 0.688 ' HB2' ' HB3' ' A' ' 130' ' ' TRP . 20.4 m -145.36 143.98 30.44 Favored 'General case' 0 CA--C 1.554 1.123 0 C-N-CA 123.81 0.844 . . . . 0.0 110.887 -179.393 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 19.8 t80 -139.35 128.98 24.52 Favored 'General case' 0 N--CA 1.48 1.029 0 C-N-CA 125.544 1.538 . . . . 0.0 107.942 178.207 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.03 2.51 88.83 Favored Glycine 0 C--N 1.35 1.347 0 O-C-N 123.848 0.717 . . . . 0.0 113.178 179.336 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 165.09 -153.49 23.69 Favored Glycine 0 C--N 1.339 0.725 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -173.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -105.62 173.47 20.24 Favored Glycine 0 C--N 1.343 0.968 0 CA-C-N 117.122 0.461 . . . . 0.0 112.034 174.66 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' TRP . . . . . 0.603 ' HE3' ' HB2' ' A' ' 108' ' ' HIS . 36.2 t-105 -66.6 110.51 3.22 Favored 'General case' 0 C--O 1.245 0.853 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 170.064 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . 0.532 ' HA ' ' HB ' ' A' ' 229' ' ' THR . 0.1 OUTLIER -150.49 146.34 26.55 Favored 'General case' 0 CA--C 1.538 0.499 0 CA-C-O 121.6 0.714 . . . . 0.0 110.475 171.345 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' LEU . . . . . 0.514 HD13 ' HA2' ' A' ' 209' ' ' GLY . 72.7 mt -144.06 2.21 1.15 Allowed 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 125.997 1.719 . . . . 0.0 108.099 170.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 36.6 mt-10 71.07 36.2 1.47 Allowed 'General case' 0 C--N 1.372 1.564 0 C-N-CA 124.157 0.983 . . . . 0.0 111.421 171.045 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . 0.517 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -149.94 156.51 26.78 Favored Glycine 0 C--N 1.347 1.174 0 CA-C-O 121.436 0.465 . . . . 0.0 113.932 -177.613 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -151.12 131.29 13.53 Favored 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 124.022 0.929 . . . . 0.0 109.224 -176.071 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' TRP . . . . . 0.505 ' HE1' ' HB3' ' A' ' 174' ' ' PRO . 50.8 t-105 -91.7 143.78 26.19 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 122.985 0.514 . . . . 0.0 110.027 170.599 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 26.5 tptp -131.14 139.44 49.8 Favored 'General case' 0 CA--C 1.536 0.412 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 169.101 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -44.27 147.11 0.58 Allowed 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 126.165 1.786 . . . . 0.0 113.73 -178.162 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 152.12 -84.7 0.15 Allowed Glycine 0 C--N 1.342 0.867 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.804 179.389 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -88.73 -174.88 4.71 Favored 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 124.446 1.099 . . . . 0.0 110.538 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 11.6 mp0 -63.97 130.95 46.1 Favored 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 169.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 13.0 p -90.53 148.0 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 166.444 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 7.9 mm100 -103.72 140.5 37.52 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -170.24 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.574 HG23 HG12 ' A' ' 200' ' ' ILE . 19.1 t -127.63 120.02 53.35 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 176.139 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.599 ' HB3' ' HG2' ' A' ' 199' ' ' PRO . 0.2 OUTLIER -81.39 86.18 6.33 Favored 'General case' 0 CA--C 1.558 1.269 0 N-CA-C 107.481 -1.304 . . . . 0.0 107.481 174.249 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . 0.425 ' HB1' ' HB2' ' A' ' 168' ' ' ARG . . . -68.97 104.99 2.24 Favored 'General case' 0 N--CA 1.481 1.121 0 C-N-CA 123.263 0.625 . . . . 0.0 112.089 -172.43 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . 0.482 HD13 ' HB2' ' A' ' 83' ' ' ALA . 74.9 mt -75.42 83.8 2.52 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 174.359 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 15.0 tp10 -70.25 119.75 74.02 Favored Pre-proline 0 CA--C 1.551 1.017 0 CA-C-N 114.886 -1.052 . . . . 0.0 110.176 -176.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . 0.447 ' HG3' HG21 ' A' ' 195' ' ' THR . 63.5 Cg_exo -55.43 114.1 1.72 Allowed 'Trans proline' 0 C--N 1.377 2.045 0 C-N-CA 123.132 2.554 . . . . 0.0 113.378 -178.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 75.99 22.08 74.9 Favored Glycine 0 C--N 1.344 1.019 0 O-C-N 123.724 0.64 . . . . 0.0 113.418 175.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 54.1 tptt -151.69 156.88 41.25 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -174.434 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -58.28 148.21 64.08 Favored Pre-proline 0 CA--C 1.558 1.259 0 C-N-CA 123.034 0.534 . . . . 0.0 112.312 177.594 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -59.62 146.89 94.04 Favored 'Trans proline' 0 C--N 1.379 2.134 0 C-N-CA 123.213 2.609 . . . . 0.0 113.233 179.048 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . 0.425 ' HB2' ' HB1' ' A' ' 160' ' ' ALA . 80.9 mtp180 -123.91 110.54 14.96 Favored 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 123.804 0.842 . . . . 0.0 108.828 -172.465 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . 0.715 ' HB2' ' H ' ' A' ' 19' ' ' GLN . . . -78.84 106.37 10.81 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-O 120.808 0.337 . . . . 0.0 110.701 -178.662 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 21.9 t -105.64 139.19 27.57 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.894 0 C-N-CA 123.176 0.591 . . . . 0.0 109.778 -178.023 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 171' ' ' GLN . . . . . 0.529 ' HB2' ' HA ' ' A' ' 22' ' ' ILE . 11.2 mt-30 -97.09 102.87 14.73 Favored 'General case' 0 C--N 1.348 0.53 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 170.335 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 172' ' ' THR . . . . . 0.477 ' HB ' HD13 ' A' ' 189' ' ' LEU . 71.4 p -101.71 124.06 46.73 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -178.816 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 28.1 mtpp -71.03 133.17 86.06 Favored Pre-proline 0 CA--C 1.546 0.806 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 174.049 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 174' ' ' PRO . . . . . 0.505 ' HB3' ' HE1' ' A' ' 150' ' ' TRP . 37.7 Cg_endo -64.1 123.53 12.03 Favored 'Trans proline' 0 C--N 1.377 2.053 0 C-N-CA 122.288 1.992 . . . . 0.0 111.776 -169.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -100.0 -173.94 30.37 Favored Glycine 0 N--CA 1.45 -0.428 0 CA-C-N 114.956 -1.02 . . . . 0.0 112.229 177.064 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 5.6 mp -148.73 145.84 27.82 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.096 0.958 . . . . 0.0 109.172 178.476 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 177' ' ' PHE . . . . . 0.73 ' HB2' ' HB ' ' A' ' 184' ' ' ILE . 59.1 m-85 -92.71 122.67 35.35 Favored 'General case' 0 C--O 1.245 0.866 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 167.705 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 77.8 tttt -95.21 104.8 16.7 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 114.809 -1.087 . . . . 0.0 109.187 177.063 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 36.4 p -132.81 156.98 46.14 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 169.481 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 10.3 t30 -56.61 -38.74 72.47 Favored 'General case' 0 N--CA 1.484 1.232 0 C-N-CA 123.874 0.87 . . . . 0.0 112.892 -169.078 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -94.93 -35.68 11.91 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 123.067 0.547 . . . . 0.0 110.8 178.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -112.94 118.19 4.5 Favored Glycine 0 C--N 1.347 1.153 0 CA-C-N 116.279 -0.419 . . . . 0.0 113.859 -169.319 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 30.2 m -98.57 100.88 12.16 Favored 'General case' 0 CA--C 1.538 0.507 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 163.167 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . 0.73 ' HB ' ' HB2' ' A' ' 177' ' ' PHE . 46.9 mt -104.17 149.73 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 C-N-CA 123.512 0.725 . . . . 0.0 109.07 -169.546 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -99.17 124.6 8.29 Favored Glycine 0 C--N 1.349 1.305 0 N-CA-C 109.808 -1.317 . . . . 0.0 109.808 -179.577 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . 0.668 ' HA ' ' HA ' ' A' ' 225' ' ' ALA . . . -140.27 -174.66 4.0 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 114.125 1.157 . . . . 0.0 114.125 -159.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 187' ' ' VAL . . . . . 0.417 HG12 ' HB ' ' A' ' 172' ' ' THR . 98.4 t -126.27 99.86 6.14 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.641 0 N-CA-C 105.683 -1.969 . . . . 0.0 105.683 171.183 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 188' ' ' SER . . . . . 0.554 ' HA ' HG12 ' A' ' 223' ' ' VAL . 60.6 p -113.64 79.64 1.27 Allowed 'General case' 0 C--O 1.243 0.731 0 CA-C-O 122.243 1.021 . . . . 0.0 111.044 -171.343 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 189' ' ' LEU . . . . . 0.477 HD13 ' HB ' ' A' ' 172' ' ' THR . 0.0 OUTLIER -151.49 178.9 8.83 Favored 'General case' 0 N--CA 1.477 0.923 0 CA-C-N 114.596 -1.184 . . . . 0.0 111.528 175.723 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -80.03 102.33 9.21 Favored 'General case' 0 CA--C 1.542 0.635 0 N-CA-C 107.307 -1.368 . . . . 0.0 107.307 171.622 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 191' ' ' PHE . . . . . 0.701 ' HB3' ' HB2' ' A' ' 222' ' ' TYR . 69.5 t80 -106.58 164.22 12.24 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 124.32 1.048 . . . . 0.0 109.53 -174.269 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 16.8 m -58.79 155.15 32.7 Favored Pre-proline 0 CA--C 1.561 1.394 0 C-N-CA 124.748 1.219 . . . . 0.0 112.134 178.297 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_exo -64.84 10.91 0.12 Allowed 'Trans proline' 0 C--N 1.381 2.263 0 C-N-CA 123.123 2.548 . . . . 0.0 115.342 171.555 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 194' ' ' GLY . . . . . 0.442 ' HA2' ' HD3' ' A' ' 163' ' ' PRO . . . -50.05 134.13 27.72 Favored Glycine 0 CA--C 1.54 1.643 0 C-N-CA 123.621 0.629 . . . . 0.0 112.995 168.712 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 195' ' ' THR . . . . . 0.447 HG21 ' HG3' ' A' ' 163' ' ' PRO . 6.6 p -75.34 151.39 38.25 Favored 'General case' 0 CA--C 1.552 1.03 0 C-N-CA 124.285 1.034 . . . . 0.0 113.381 -169.919 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -62.98 128.91 38.03 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 124.333 1.053 . . . . 0.0 111.213 -172.643 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 197' ' ' GLY . . . . . 0.4 ' O ' HD23 ' A' ' 210' ' ' LEU . . . 96.68 8.19 57.35 Favored Glycine 0 C--N 1.34 0.755 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 -167.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 198' ' ' SER . . . . . 0.403 ' OG ' ' HA ' ' A' ' 160' ' ' ALA . 34.0 t -57.15 119.06 28.31 Favored Pre-proline 0 CA--C 1.557 1.243 0 C-N-CA 123.684 0.793 . . . . 0.0 109.839 164.278 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 199' ' ' PRO . . . . . 0.599 ' HG2' ' HB3' ' A' ' 159' ' ' LEU . 19.6 Cg_endo -58.04 131.63 44.61 Favored 'Trans proline' 0 C--N 1.377 2.033 0 C-N-CA 123.171 2.581 . . . . 0.0 113.832 -170.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 200' ' ' ILE . . . . . 0.574 HG12 HG23 ' A' ' 158' ' ' VAL . 18.9 mt -97.98 130.87 46.1 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.754 0 C-N-CA 123.988 0.915 . . . . 0.0 109.062 171.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 201' ' ' ILE . . . . . . . . . . . . . 50.3 mt -123.03 169.55 14.26 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.369 0 C-N-CA 124.706 1.202 . . . . 0.0 108.525 179.045 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -108.55 155.82 20.21 Favored 'General case' 0 N--CA 1.483 1.177 0 C-N-CA 124.346 1.058 . . . . 0.0 108.867 173.258 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 18.7 ptmt -66.4 -19.5 65.82 Favored 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 -170.578 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 45.3 mttp -73.99 -17.4 61.0 Favored 'General case' 0 N--CA 1.488 1.443 0 CA-C-N 117.911 0.323 . . . . 0.0 110.739 176.011 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 115.4 -16.45 17.16 Favored Glycine 0 C--N 1.351 1.362 0 N-CA-C 111.898 -0.481 . . . . 0.0 111.898 -176.066 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 1.2 tpmt? -73.21 119.2 17.12 Favored 'General case' 0 C--O 1.219 -0.502 0 C-N-CA 123.985 0.914 . . . . 0.0 109.239 -177.676 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 207' ' ' VAL . . . . . 0.517 ' O ' ' HA3' ' A' ' 148' ' ' GLY . 12.7 p -64.02 150.23 10.13 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.926 0 C-N-CA 122.798 0.439 . . . . 0.0 110.239 176.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 208' ' ' VAL . . . . . 0.475 ' HB ' HG22 ' A' ' 200' ' ' ILE . 93.4 t -106.26 -49.84 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 177.542 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.514 ' HA2' HD13 ' A' ' 146' ' ' LEU . . . 161.33 -117.49 0.77 Allowed Glycine 0 N--CA 1.441 -1.014 0 CA-C-N 114.876 -1.056 . . . . 0.0 112.986 178.709 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 210' ' ' LEU . . . . . 0.569 ' HG ' ' CH2' ' A' ' 144' ' ' TRP . 69.2 mt -124.37 166.43 15.96 Favored 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 123.406 0.683 . . . . 0.0 111.841 -177.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -69.9 112.65 6.46 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-N 114.213 -1.358 . . . . 0.0 107.602 167.608 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 212' ' ' GLY . . . . . 0.567 ' HA2' ' HE1' ' A' ' 110' ' ' MET . . . -74.5 -145.66 1.07 Allowed Glycine 0 C--N 1.341 0.814 0 N-CA-C 115.984 1.154 . . . . 0.0 115.984 -163.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 213' ' ' ASN . . . . . 0.617 ' HA ' ' HE1' ' A' ' 112' ' ' HIS . 14.2 p30 -100.66 123.56 45.04 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 121.295 0.569 . . . . 0.0 110.716 -166.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 177.49 -134.31 2.44 Favored Glycine 0 N--CA 1.442 -0.906 0 CA-C-N 114.736 -1.12 . . . . 0.0 111.293 178.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 215' ' ' VAL . . . . . . . . . . . . . 10.0 p -176.55 178.09 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 -165.133 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 216' ' ' VAL . . . . . . . . . . . . . 6.7 m -75.35 110.36 10.08 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.024 0 O-C-N 121.159 -0.963 . . . . 0.0 108.922 160.213 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 217' ' ' THR . . . . . 0.622 HG21 HD12 ' A' ' 41' ' ' ILE . 13.4 m -104.14 177.02 4.96 Favored 'General case' 0 CA--C 1.548 0.886 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 175.86 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 218' ' ' ARG . . . . . 0.554 ' HB2' HD13 ' A' ' 29' ' ' LEU . 71.0 ttt-85 63.38 30.98 15.42 Favored 'General case' 0 N--CA 1.491 1.604 0 CA-C-O 121.98 0.895 . . . . 0.0 110.119 176.096 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 19.6 m 68.33 17.32 9.24 Favored 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 125.47 1.508 . . . . 0.0 113.203 177.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . 153.14 -6.87 0.44 Allowed Glycine 0 C--N 1.355 1.618 0 N-CA-C 115.05 0.78 . . . . 0.0 115.05 174.779 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 221' ' ' ALA . . . . . 0.453 ' HB1' ' HB3' ' A' ' 218' ' ' ARG . . . -78.58 125.97 30.1 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 123.205 0.602 . . . . 0.0 110.167 -179.816 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 222' ' ' TYR . . . . . 0.701 ' HB2' ' HB3' ' A' ' 191' ' ' PHE . 11.6 m-85 -65.97 102.03 0.74 Allowed 'General case' 0 N--CA 1.481 1.087 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 178.216 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . 0.554 HG12 ' HA ' ' A' ' 188' ' ' SER . 92.4 t -124.64 108.54 20.46 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.922 0 C-N-CA 124.296 1.038 . . . . 0.0 109.469 -176.726 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 50.6 m -142.1 159.0 43.11 Favored 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 123.871 0.868 . . . . 0.0 109.451 -178.571 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . 0.668 ' HA ' ' HA ' ' A' ' 186' ' ' ALA . . . -65.12 -171.36 0.07 Allowed 'General case' 0 N--CA 1.482 1.155 0 N-CA-C 113.349 0.87 . . . . 0.0 113.349 -174.809 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 226' ' ' ILE . . . . . . . . . . . . . 46.5 mt -118.29 105.84 18.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 172.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -80.34 99.72 8.05 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 122.965 0.506 . . . . 0.0 109.857 -178.713 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 18.2 pt20 -94.25 162.14 13.97 Favored 'General case' 0 N--CA 1.484 1.235 0 C-N-CA 123.929 0.892 . . . . 0.0 110.184 -178.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.532 ' HB ' ' HA ' ' A' ' 145' ' ' LYS . 24.6 p -90.06 121.83 32.49 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 122.669 0.388 . . . . 0.0 111.284 -170.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -139.65 -21.0 0.91 Allowed 'General case' 0 N--CA 1.483 1.221 0 C-N-CA 123.464 0.706 . . . . 0.0 112.284 -166.695 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 2.4 mptp? -82.33 -80.42 0.16 Allowed 'General case' 0 N--CA 1.488 1.463 0 CA-C-N 117.921 0.328 . . . . 0.0 110.453 -164.165 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 232' ' ' SER . . . . . 0.408 ' HB2' ' HD2' ' A' ' 145' ' ' LYS . 73.0 m . . . . . 0 C--N 1.36 1.03 0 CA-C-N 118.304 0.502 . . . . 0.0 109.788 171.566 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.95 0 CA-C-O 119.541 -0.266 . . . . 0.0 110.463 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.538 ' O ' HG22 ' A' ' 118' ' ' VAL . . . -162.7 8.06 0.06 Allowed 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 112.175 0.435 . . . . 0.0 112.175 -175.774 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -123.37 83.92 2.2 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 177.223 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . 0.713 ' HA ' ' HA ' ' A' ' 88' ' ' GLN . 4.8 mp -125.07 98.79 5.83 Favored 'General case' 0 N--CA 1.481 1.122 0 CA-C-O 119.333 -0.365 . . . . 0.0 111.559 -173.663 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 30.3 tt0 -81.58 144.84 30.98 Favored 'General case' 0 C--O 1.252 1.207 0 CA-C-O 121.979 0.895 . . . . 0.0 111.197 -175.125 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . 0.553 HD23 HD12 ' A' ' 119' ' ' LEU . 53.9 mt -85.31 115.3 22.98 Favored 'General case' 0 C--O 1.242 0.706 0 CA-C-N 113.556 -1.656 . . . . 0.0 109.752 176.04 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -104.03 125.96 50.78 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 171.319 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 47.0 ptt85 -67.17 129.39 39.76 Favored 'General case' 0 N--CA 1.478 0.958 0 CA-C-N 118.36 0.527 . . . . 0.0 109.76 178.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . 0.423 ' HB3' HD12 ' A' ' 161' ' ' LEU . . . -121.69 -21.35 6.18 Favored 'General case' 0 N--CA 1.479 0.983 0 C-N-CA 122.746 0.418 . . . . 0.0 111.239 -176.366 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . 0.662 ' HB2' ' HB3' ' A' ' 83' ' ' ALA . . . -164.01 161.4 22.63 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 121.639 0.733 . . . . 0.0 111.058 178.592 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -93.71 155.84 17.02 Favored 'General case' 0 C--O 1.245 0.826 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 161.31 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.591 HG22 ' HA2' ' A' ' 82' ' ' GLY . 85.9 t -67.21 103.35 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 175.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 58.8 tttp -168.55 133.32 1.64 Allowed 'General case' 0 C--O 1.239 0.528 0 CA-C-N 115.123 -0.944 . . . . 0.0 108.617 -170.308 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 23.3 t90 -74.61 114.01 12.54 Favored 'General case' 0 CA--C 1.542 0.655 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 167.504 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.567 ' HB3' ' HB3' ' A' ' 169' ' ' ALA . 39.6 tt0 -72.25 145.42 47.94 Favored 'General case' 0 CA--C 1.548 0.888 0 C-N-CA 123.344 0.658 . . . . 0.0 109.825 176.825 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -78.32 -2.73 39.48 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 123.878 0.871 . . . . 0.0 112.716 -172.579 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 31.6 mm-40 -87.08 43.44 1.1 Allowed 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 122.99 0.516 . . . . 0.0 110.152 -175.616 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -60.4 101.27 0.12 Allowed 'General case' 0 C--N 1.354 0.788 0 C-N-CA 124.775 1.23 . . . . 0.0 110.803 -174.603 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -105.37 117.44 34.02 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 124.236 1.014 . . . . 0.0 109.496 -173.662 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.488 HD12 ' HB2' ' A' ' 171' ' ' GLN . 43.4 mm -76.55 127.43 37.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 C-N-CA 123.025 0.53 . . . . 0.0 110.063 -172.82 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 29.2 m -148.25 -171.55 3.86 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 124.149 0.98 . . . . 0.0 110.796 -172.604 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 133.4 66.28 0.08 OUTLIER Glycine 0 C--N 1.347 1.185 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.456 ' H ' ' HA ' ' A' ' 189' ' ' LEU . 13.1 m -66.62 -52.6 43.36 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-N 114.648 -0.776 . . . . 0.0 111.845 -167.308 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.429 ' HB2' ' OG ' ' A' ' 188' ' ' SER . 14.8 m -95.26 144.12 27.26 Favored Pre-proline 0 CA--C 1.552 1.048 0 C-N-CA 123.119 0.568 . . . . 0.0 110.525 -172.747 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -84.97 -161.06 0.12 Allowed 'Trans proline' 0 C--N 1.378 2.113 0 C-N-CA 123.0 2.467 . . . . 0.0 112.623 174.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 45.3 mm -63.05 133.72 28.68 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 168.405 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.488 HD12 HG23 ' A' ' 217' ' ' THR . 0.2 OUTLIER -143.75 163.72 32.53 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 123.719 0.808 . . . . 0.0 109.639 -163.428 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.3 t -108.65 145.84 34.34 Favored 'General case' 0 N--CA 1.479 1.013 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 172.699 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.427 HD11 ' CE2' ' A' ' 177' ' ' PHE . 14.9 tt -135.27 154.38 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 C-N-CA 123.4 0.68 . . . . 0.0 109.336 -174.143 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 34.7 p -95.35 103.77 15.65 Favored 'General case' 0 C--O 1.243 0.713 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 171.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.427 ' HA ' ' HA ' ' A' ' 39' ' ' MET . 15.7 tt -91.05 117.53 34.47 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.764 179.432 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' SER . . . . . 0.606 ' HB3' ' HB3' ' A' ' 38' ' ' SER . 35.5 t -82.97 118.52 23.55 Favored 'General case' 0 C--O 1.242 0.662 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.003 -178.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -52.84 -28.15 21.55 Favored 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 125.3 1.44 . . . . 0.0 112.474 -177.682 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -48.22 -41.26 26.94 Favored 'General case' 0 CA--C 1.55 0.957 0 C-N-CA 125.265 1.426 . . . . 0.0 111.884 174.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 145.68 9.89 0.28 Allowed Glycine 0 C--N 1.34 0.791 0 CA-C-N 114.929 -1.032 . . . . 0.0 111.942 178.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' SER . . . . . 0.606 ' HB3' ' HB3' ' A' ' 34' ' ' SER . 32.7 t -109.82 164.2 12.79 Favored 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 123.537 0.735 . . . . 0.0 110.334 -173.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' MET . . . . . 0.427 ' HA ' ' HA ' ' A' ' 33' ' ' ILE . 22.3 ptm -153.67 127.64 8.95 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 123.439 0.696 . . . . 0.0 109.133 173.604 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 17.7 p -169.46 169.82 8.68 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 123.091 0.556 . . . . 0.0 110.862 -175.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.0 mp -78.69 124.32 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 N-CA-C 104.815 -2.291 . . . . 0.0 104.815 157.699 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . 0.64 ' HB2' ' HZ3' ' A' ' 42' ' ' LYS . 0.0 OUTLIER -61.43 79.02 0.01 OUTLIER 'General case' 0 CA--C 1.558 1.278 0 C-N-CA 124.238 1.015 . . . . 0.0 112.824 -170.957 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 92.5 m-20 -130.5 173.65 10.65 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 125.017 1.327 . . . . 0.0 109.088 -177.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -72.23 143.08 48.94 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 123.54 0.736 . . . . 0.0 110.755 177.063 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 . . . . . 0 N--CA 1.473 0.678 0 C-N-CA 123.207 0.603 . . . . 0.0 110.594 177.593 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 . . . . . 0 C--O 1.239 0.524 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.591 ' HA2' HG22 ' A' ' 14' ' ' VAL . . . 163.28 -175.05 39.6 Favored Glycine 0 C--N 1.34 0.79 0 O-C-N 123.167 0.292 . . . . 0.0 112.574 -173.106 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . 0.662 ' HB3' ' HB2' ' A' ' 12' ' ' ALA . . . -93.18 110.17 21.68 Favored 'General case' 0 C--O 1.244 0.789 0 CA-C-O 121.102 0.477 . . . . 0.0 110.503 -177.761 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 18.1 m-85 -107.41 136.92 46.39 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 176.731 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.68 131.79 36.82 Favored 'General case' 0 C--O 1.245 0.837 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 175.183 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.507 HD11 ' HE2' ' A' ' 107' ' ' PHE . 38.0 mt -90.58 111.46 23.54 Favored 'Isoleucine or valine' 0 C--O 1.273 2.3 0 CA-C-O 122.559 1.171 . . . . 0.0 110.482 -176.426 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . 0.621 ' HZ1' ' HB3' ' A' ' 94' ' ' TYR . 7.1 tmtm? -116.73 130.89 57.0 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-N 112.857 -1.974 . . . . 0.0 107.061 179.075 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . 0.713 ' HA ' ' HA ' ' A' ' 6' ' ' LEU . 21.0 tm0? -79.86 111.08 15.84 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 106.838 -1.541 . . . . 0.0 106.838 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . 0.417 ' HE3' ' HB2' ' A' ' 89' ' ' LYS . 35.0 ttmt -117.1 93.61 4.25 Favored 'General case' 0 C--O 1.238 0.458 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 -178.277 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -104.51 144.61 15.86 Favored Glycine 0 CA--C 1.496 -1.152 0 CA-C-N 114.158 -1.383 . . . . 0.0 110.953 -176.263 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 2.9 mp -65.3 -15.34 18.27 Favored 'Isoleucine or valine' 0 CA--C 1.566 1.589 0 C-N-CA 125.087 1.355 . . . . 0.0 109.675 179.735 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 1.1 pp -118.43 0.31 11.6 Favored 'General case' 0 CA--C 1.557 1.229 0 N-CA-C 113.467 0.914 . . . . 0.0 113.467 175.658 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 175.67 154.45 11.43 Favored Glycine 0 N--CA 1.488 2.128 0 CA-C-N 119.289 0.95 . . . . 0.0 114.185 -175.048 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . 0.621 ' HB3' ' HZ1' ' A' ' 87' ' ' LYS . 75.4 m-85 -130.71 125.39 33.79 Favored 'General case' 0 N--CA 1.487 1.405 0 C-N-CA 123.421 0.688 . . . . 0.0 112.086 -171.89 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 39.8 m -135.66 157.36 47.06 Favored 'General case' 0 N--CA 1.492 1.675 0 C-N-CA 124.794 1.237 . . . . 0.0 110.734 171.506 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . . . . . . . . . 11.7 pt20 -100.19 148.89 24.12 Favored 'General case' 0 N--CA 1.496 1.875 0 N-CA-C 107.977 -1.12 . . . . 0.0 107.977 158.366 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.629 HD13 ' HB2' ' A' ' 88' ' ' GLN . 0.0 OUTLIER -132.17 -39.01 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 CA-C-N 119.629 1.104 . . . . 0.0 111.305 179.167 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -175.59 -145.99 5.68 Favored Glycine 0 C--N 1.347 1.143 0 C-N-CA 119.652 -1.261 . . . . 0.0 114.199 -171.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -158.64 175.28 13.85 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 123.488 0.715 . . . . 0.0 111.449 -177.048 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -172.25 176.47 45.25 Favored Glycine 0 C--N 1.344 0.993 0 CA-C-N 115.401 -0.818 . . . . 0.0 111.539 -178.608 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 47.2 t -123.12 125.93 72.81 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.012 0 C-N-CA 122.866 0.466 . . . . 0.0 111.028 -175.325 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 39.4 t80 -85.34 144.63 27.94 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 167.092 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.611 ' HG3' ' HG3' ' A' ' 104' ' ' GLU . 22.9 tptm -157.0 133.83 10.19 Favored 'General case' 0 C--O 1.239 0.518 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 173.665 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.611 ' HG3' ' HG3' ' A' ' 103' ' ' LYS . 29.5 mt-10 62.6 -91.83 0.03 OUTLIER 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 124.983 1.313 . . . . 0.0 111.569 176.062 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -143.89 31.26 1.88 Allowed Glycine 0 C--N 1.341 0.831 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.4 t -146.28 129.4 16.55 Favored 'General case' 0 C--O 1.241 0.653 0 C-N-CA 123.694 0.798 . . . . 0.0 110.614 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' PHE . . . . . 0.507 ' HE2' HD11 ' A' ' 86' ' ' ILE . 67.2 t80 -94.92 104.01 15.89 Favored 'General case' 0 C--N 1.345 0.386 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 171.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . 0.532 ' CE1' ' HB3' ' A' ' 103' ' ' LYS . 1.5 p-80 -107.8 121.08 44.01 Favored 'General case' 0 C--N 1.325 -0.481 0 C-N-CA 123.247 0.619 . . . . 0.0 109.492 -178.862 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 8.6 t -136.62 179.77 6.17 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 123.839 0.856 . . . . 0.0 111.241 -172.52 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' MET . . . . . 0.449 ' SD ' ' O ' ' A' ' 212' ' ' GLY . 27.7 ttm -74.92 150.42 39.12 Favored 'General case' 0 CA--C 1.547 0.86 0 C-N-CA 125.463 1.505 . . . . 0.0 109.94 173.204 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 86.8 t90 -73.61 -56.32 5.16 Favored 'General case' 0 N--CA 1.494 1.747 0 CA-C-N 118.32 0.509 . . . . 0.0 111.967 -168.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 1.2 p-80 -68.69 2.96 2.12 Favored 'General case' 0 N--CA 1.485 1.314 0 N-CA-C 114.332 1.234 . . . . 0.0 114.332 -171.358 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 23.0 m -60.32 -38.64 78.27 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 167.273 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 12.0 t -122.48 174.24 7.17 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 124.663 1.185 . . . . 0.0 108.498 178.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 50.7 ttt-85 -93.14 31.26 1.48 Allowed 'General case' 0 N--CA 1.485 1.275 0 CA-C-O 121.326 0.584 . . . . 0.0 109.588 -179.005 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 73.74 35.43 54.91 Favored Glycine 0 C--N 1.348 1.234 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 -167.22 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -122.36 -163.31 1.07 Allowed 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 123.663 0.785 . . . . 0.0 111.782 -168.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.667 HG23 ' HG3' ' A' ' 125' ' ' ARG . 2.0 m -89.21 156.56 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.127 0 C-N-CA 123.359 0.664 . . . . 0.0 110.822 -172.413 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.553 HD12 HD23 ' A' ' 8' ' ' LEU . 54.8 mt -110.46 174.78 5.7 Favored 'General case' 0 CA--C 1.551 1.018 0 C-N-CA 124.357 1.063 . . . . 0.0 109.586 170.758 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 23.5 mmt -124.63 137.6 54.36 Favored 'General case' 0 C--O 1.25 1.093 0 C-N-CA 123.534 0.734 . . . . 0.0 110.165 -176.026 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.415 ' HB2' HD11 ' A' ' 126' ' ' ILE . 77.6 t60 -130.88 95.85 3.93 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 168.002 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 62.93 20.44 12.25 Favored 'General case' 0 N--CA 1.495 1.811 0 C-N-CA 124.513 1.125 . . . . 0.0 111.523 -168.461 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 88.52 14.65 61.31 Favored Glycine 0 C--N 1.345 1.054 0 CA-C-O 119.7 -0.5 . . . . 0.0 112.682 -172.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -82.18 129.5 34.85 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 169.072 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . 0.667 ' HG3' HG23 ' A' ' 118' ' ' VAL . 35.8 ttm180 -78.59 98.71 6.25 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 124.794 1.237 . . . . 0.0 111.217 -173.619 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.415 HD11 ' HB2' ' A' ' 121' ' ' HIS . 18.4 mt -89.08 95.48 5.44 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.693 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 175.751 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -91.68 141.57 25.84 Favored Pre-proline 0 N--CA 1.487 1.422 0 C-N-CA 122.732 0.413 . . . . 0.0 110.256 -179.212 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -73.42 153.8 50.36 Favored 'Trans proline' 0 C--N 1.382 2.307 0 C-N-CA 122.924 2.416 . . . . 0.0 114.791 -170.786 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 66.4 p -101.88 -32.45 10.22 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 123.97 0.908 . . . . 0.0 110.209 172.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 72.4 t-105 -130.38 149.71 51.94 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 124.059 0.944 . . . . 0.0 109.355 -177.76 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -156.77 125.69 5.93 Favored 'General case' 0 C--O 1.241 0.654 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 175.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -141.75 110.16 6.0 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 123.108 0.563 . . . . 0.0 109.896 179.717 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 3.5 t -77.09 -17.02 14.56 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.286 0 C-N-CA 123.654 0.782 . . . . 0.0 111.307 -176.552 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 58.3 mttp -65.21 -53.79 39.36 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 123.697 0.799 . . . . 0.0 110.903 -176.53 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 47.6 mmtm -82.93 -17.38 43.81 Favored 'General case' 0 N--CA 1.478 0.934 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.181 172.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 11.5 t70 60.49 66.74 0.9 Allowed 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 125.865 1.666 . . . . 0.0 109.44 -173.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . 0.413 HD21 ' HA ' ' A' ' 110' ' ' MET . 51.8 mt -143.63 123.94 13.83 Favored 'General case' 0 CA--C 1.547 0.844 0 CA-C-N 113.673 -1.603 . . . . 0.0 108.7 -179.17 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 16.8 tt -118.7 138.79 48.26 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 176.076 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 35.0 t -134.37 151.76 51.4 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 121.785 0.802 . . . . 0.0 111.797 -175.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 18.8 m-85 -124.25 102.77 7.87 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 113.784 -1.553 . . . . 0.0 107.423 -169.754 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 97.09 -1.98 61.22 Favored Glycine 0 C--N 1.346 1.092 0 O-C-N 123.776 0.672 . . . . 0.0 113.366 -177.09 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . -175.69 -150.54 8.06 Favored Glycine 0 C--N 1.347 1.155 0 CA-C-O 119.503 -0.61 . . . . 0.0 111.986 -177.52 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -116.83 -179.43 17.79 Favored Glycine 0 C--N 1.352 1.419 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 171.185 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' TRP . . . . . 0.525 ' HA ' ' HB2' ' A' ' 108' ' ' HIS . 54.1 t-105 -70.61 105.15 3.03 Favored 'General case' 0 N--CA 1.476 0.867 0 CA-C-N 118.655 1.227 . . . . 0.0 108.782 175.964 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 19.2 ptmt -138.41 121.55 16.86 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 122.944 0.498 . . . . 0.0 110.944 -171.058 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' LEU . . . . . . . . . . . . . 46.1 mt -153.17 -33.13 0.12 Allowed 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 125.586 1.554 . . . . 0.0 107.928 172.609 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 71.65 101.55 0.07 Allowed 'General case' 0 C--N 1.362 1.12 0 C-N-CA 126.166 1.786 . . . . 0.0 110.545 -179.048 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . 0.451 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -167.75 148.03 12.37 Favored Glycine 0 C--O 1.242 0.655 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 178.218 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -151.66 108.57 3.53 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -177.193 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' TRP . . . . . 0.546 ' HB2' HG21 ' A' ' 208' ' ' VAL . 81.5 t90 -65.9 123.95 21.2 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-O 120.762 0.315 . . . . 0.0 110.692 172.775 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -151.52 90.49 1.57 Allowed 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 160.567 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . 0.44 ' HG3' ' H ' ' A' ' 154' ' ' GLU . 12.0 tp10 -131.81 142.91 49.86 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 115.133 -0.94 . . . . 0.0 109.285 178.793 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -64.19 -30.42 77.75 Favored Glycine 0 C--N 1.349 1.287 0 N-CA-C 111.404 -0.678 . . . . 0.0 111.404 173.158 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . 0.44 ' H ' ' HG3' ' A' ' 152' ' ' GLU . 29.9 mt-10 -81.22 173.34 12.61 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 124.786 1.234 . . . . 0.0 110.003 172.566 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . 0.505 ' HB2' ' HB3' ' A' ' 171' ' ' GLN . 4.4 mp0 -67.31 166.76 13.71 Favored 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 123.738 0.815 . . . . 0.0 112.41 -173.394 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 15.0 p -92.67 141.47 14.58 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.167 172.117 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 20.4 mp0 -99.22 131.51 45.2 Favored 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -173.392 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 41.4 t -133.95 102.06 4.2 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 -178.432 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.419 ' HA ' ' HA ' ' A' ' 169' ' ' ALA . 2.3 pt? -76.3 85.5 3.08 Favored 'General case' 0 CA--C 1.545 0.768 0 CA-C-O 122.386 1.089 . . . . 0.0 108.893 176.004 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -64.65 114.53 4.48 Favored 'General case' 0 C--O 1.239 0.549 0 CA-C-N 114.221 -1.354 . . . . 0.0 108.64 178.441 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . 0.423 HD12 ' HB3' ' A' ' 11' ' ' ALA . 84.6 mt -69.0 94.49 0.64 Allowed 'General case' 0 C--O 1.239 0.503 0 O-C-N 123.655 0.597 . . . . 0.0 109.913 -172.312 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -65.28 112.6 8.74 Favored Pre-proline 0 CA--C 1.548 0.889 0 CA-C-N 114.267 -1.333 . . . . 0.0 109.436 -177.479 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -61.31 115.91 3.05 Favored 'Trans proline' 0 C--N 1.375 1.933 0 C-N-CA 122.503 2.135 . . . . 0.0 112.522 -171.405 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 93.12 -6.42 75.96 Favored Glycine 0 C--N 1.348 1.196 0 CA-C-N 114.966 -1.016 . . . . 0.0 113.883 177.542 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 61.3 mttm -128.07 -179.3 4.91 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 123.626 0.77 . . . . 0.0 109.207 -176.691 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -61.38 160.7 22.54 Favored Pre-proline 0 CA--C 1.558 1.26 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 164.302 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . 0.447 ' HG3' ' HB3' ' A' ' 12' ' ' ALA . 30.9 Cg_exo -61.93 -172.53 0.11 Allowed 'Trans proline' 0 C--N 1.375 1.951 0 C-N-CA 122.361 2.041 . . . . 0.0 114.491 -178.309 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 20.0 ttm-85 -138.13 99.46 3.88 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 171.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . 0.567 ' HB3' ' HB3' ' A' ' 17' ' ' GLU . . . -73.39 107.2 5.56 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.341 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 77.2 t -112.11 123.94 68.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 C-N-CA 123.493 0.717 . . . . 0.0 110.069 -176.584 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 171' ' ' GLN . . . . . 0.505 ' HB3' ' HB2' ' A' ' 155' ' ' GLU . 20.9 mt-30 -93.03 118.29 31.02 Favored 'General case' 0 C--N 1.341 0.217 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 175.362 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 172' ' ' THR . . . . . 0.669 HG21 HG21 ' A' ' 187' ' ' VAL . 5.9 t -126.29 142.8 51.39 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 123.206 0.603 . . . . 0.0 109.471 176.511 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -75.89 156.89 84.21 Favored Pre-proline 0 CA--C 1.561 1.368 0 CA-C-N 115.993 -0.548 . . . . 0.0 109.612 178.058 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -69.43 124.55 11.33 Favored 'Trans proline' 0 C--N 1.375 1.939 0 C-N-CA 122.178 1.919 . . . . 0.0 112.708 -177.492 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -158.78 139.38 6.22 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 108.74 -1.744 . . . . 0.0 108.74 175.238 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.722 ' HG ' ' HB2' ' A' ' 186' ' ' ALA 0.264 0.0 OUTLIER -175.8 -169.97 0.37 Allowed 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 123.949 0.899 . . . . 0.0 110.754 178.95 . . . . . . . . 4 4 . 1 . 008 nuclear orig core ' A' A ' 177' ' ' PHE . . . . . 0.46 ' HA ' ' O ' ' A' ' 29' ' ' LEU . 79.3 m-85 -91.8 158.3 16.41 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 114.863 -1.062 . . . . 0.0 111.118 -152.28 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -133.36 109.48 9.38 Favored 'General case' 0 C--O 1.239 0.523 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 170.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 1.2 m -140.55 170.18 16.26 Favored 'General case' 0 N--CA 1.479 1.018 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 175.118 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 36.1 t30 -59.85 102.43 0.16 Allowed 'General case' 0 CA--C 1.548 0.892 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 168.324 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . 79.22 1.24 2.34 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 125.415 1.486 . . . . 0.0 111.492 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -123.86 54.2 0.73 Allowed Glycine 0 C--N 1.348 1.225 0 N-CA-C 111.409 -0.676 . . . . 0.0 111.409 178.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 84.6 m -110.21 98.16 7.48 Favored 'General case' 0 CA--C 1.536 0.441 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 175.452 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . 0.513 ' O ' ' HB3' ' A' ' 176' ' ' LEU . 3.6 mp -125.13 152.82 31.93 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 178.569 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -127.62 116.98 2.52 Favored Glycine 0 C--N 1.377 2.851 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 172.066 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . 0.722 ' HB2' ' HG ' ' A' ' 176' ' ' LEU . . . -161.87 -149.34 0.16 Allowed 'General case' 0 C--N 1.373 1.598 0 CA-C-N 119.056 1.428 . . . . 0.0 111.9 -159.225 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 187' ' ' VAL . . . . . 0.669 HG21 HG21 ' A' ' 172' ' ' THR . 0.4 OUTLIER -91.57 117.77 35.54 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.971 0 C-N-CA 124.288 1.035 . . . . 0.0 110.028 -176.228 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 188' ' ' SER . . . . . 0.429 ' OG ' ' HB2' ' A' ' 26' ' ' SER . 10.6 t -130.44 90.78 2.98 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 123.406 0.682 . . . . 0.0 109.861 -174.123 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 189' ' ' LEU . . . . . 0.456 ' HA ' ' H ' ' A' ' 25' ' ' SER . 1.7 pp -136.91 -175.0 3.89 Favored 'General case' 0 N--CA 1.489 1.524 0 C-N-CA 123.423 0.689 . . . . 0.0 112.081 -174.292 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -135.19 119.29 17.57 Favored 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 124.238 1.015 . . . . 0.0 108.982 171.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 191' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -149.15 -178.89 6.64 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 123.223 0.609 . . . . 0.0 111.916 -178.711 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 42.3 m -60.71 157.09 40.72 Favored Pre-proline 0 CA--C 1.555 1.161 0 C-N-CA 124.787 1.235 . . . . 0.0 111.28 176.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 3.8 Cg_exo -34.58 91.23 0.01 OUTLIER 'Trans proline' 0 C--N 1.393 2.881 0 C-N-CA 125.236 3.957 . . . . 0.0 115.225 -178.018 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -74.08 134.48 18.5 Favored Glycine 0 C--N 1.35 1.325 0 CA-C-N 114.582 -1.19 . . . . 0.0 112.394 -179.669 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 40.7 p -82.72 122.75 28.57 Favored 'General case' 0 C--O 1.244 0.796 0 C-N-CA 123.752 0.821 . . . . 0.0 110.097 178.013 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 18.1 m -62.45 88.08 0.03 OUTLIER 'General case' 0 C--N 1.363 1.17 0 C-N-CA 123.591 0.756 . . . . 0.0 110.847 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 197' ' ' GLY . . . . . 0.457 ' O ' HD21 ' A' ' 210' ' ' LEU . . . 129.12 21.14 1.37 Allowed Glycine 0 CA--C 1.523 0.553 0 CA-C-N 114.897 -1.047 . . . . 0.0 112.574 -179.276 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 198' ' ' SER . . . . . 0.457 ' HG ' ' HB3' ' A' ' 211' ' ' TYR . 32.2 p -70.18 123.64 89.23 Favored Pre-proline 0 N--CA 1.478 0.951 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 172.758 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 199' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 198' ' ' SER . 32.1 Cg_exo -58.71 141.88 98.13 Favored 'Trans proline' 0 C--N 1.374 1.918 0 C-N-CA 122.9 2.4 . . . . 0.0 114.368 -168.538 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 200' ' ' ILE . . . . . 0.497 HD11 HG12 ' A' ' 226' ' ' ILE . 47.8 mt -110.8 118.96 58.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.325 0 C-N-CA 124.851 1.26 . . . . 0.0 108.754 175.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 201' ' ' ILE . . . . . 0.587 HG12 HG23 ' A' ' 207' ' ' VAL . 24.0 mt -113.02 143.47 22.64 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.377 0 C-N-CA 124.563 1.145 . . . . 0.0 110.029 -176.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 202' ' ' ASP . . . . . 0.401 ' O ' HG21 ' A' ' 201' ' ' ILE . 43.5 t0 -84.83 153.6 22.84 Favored 'General case' 0 N--CA 1.486 1.357 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 170.21 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 84.0 tttt -48.33 -27.29 2.45 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 124.689 1.196 . . . . 0.0 113.96 -172.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . 0.506 ' H ' ' HD2' ' A' ' 204' ' ' LYS . 9.7 mptt -64.1 -20.09 65.71 Favored 'General case' 0 N--CA 1.484 1.227 0 C-N-CA 124.27 1.028 . . . . 0.0 111.78 -177.448 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 101.6 5.85 50.9 Favored Glycine 0 C--N 1.345 1.033 0 CA-C-N 116.361 -0.382 . . . . 0.0 112.676 -177.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 39.8 tttm -106.61 140.74 39.01 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 123.162 0.585 . . . . 0.0 109.618 -179.762 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 207' ' ' VAL . . . . . 0.587 HG23 HG12 ' A' ' 201' ' ' ILE . 61.9 t -82.63 123.98 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 123.208 0.603 . . . . 0.0 111.41 -168.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 208' ' ' VAL . . . . . 0.546 HG21 ' HB2' ' A' ' 150' ' ' TRP . 45.6 t -69.46 -52.56 31.39 Favored 'Isoleucine or valine' 0 C--O 1.239 0.548 0 O-C-N 124.574 1.171 . . . . 0.0 110.48 173.714 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.518 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . 177.71 -134.24 2.4 Favored Glycine 0 C--N 1.348 1.2 0 CA-C-N 115.157 -0.928 . . . . 0.0 113.694 -175.892 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 210' ' ' LEU . . . . . 0.457 HD21 ' O ' ' A' ' 197' ' ' GLY . 86.1 mt -131.44 152.64 50.5 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 123.836 0.854 . . . . 0.0 110.926 -176.793 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 211' ' ' TYR . . . . . 0.457 ' HB3' ' HG ' ' A' ' 198' ' ' SER . 51.1 t80 -102.15 104.54 15.15 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 123.861 0.864 . . . . 0.0 108.986 175.696 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 212' ' ' GLY . . . . . 0.449 ' O ' ' SD ' ' A' ' 110' ' ' MET . . . 169.72 74.27 0.04 OUTLIER Glycine 0 C--N 1.337 0.632 0 C-N-CA 120.892 -0.67 . . . . 0.0 113.424 161.514 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 213' ' ' ASN . . . . . 0.68 ' H ' ' HB3' ' A' ' 224' ' ' SER . 71.7 m-20 -146.09 81.96 1.6 Allowed 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 170.368 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 178.03 -121.58 0.78 Allowed Glycine 0 N--CA 1.445 -0.714 0 CA-C-N 114.71 -1.132 . . . . 0.0 111.839 178.303 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 215' ' ' VAL . . . . . . . . . . . . . 10.2 p -172.81 165.61 0.24 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.843 0 C-N-CA 122.883 0.473 . . . . 0.0 109.955 -164.015 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 216' ' ' VAL . . . . . . . . . . . . . 27.7 m -77.45 107.7 9.46 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.137 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 158.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 217' ' ' THR . . . . . 0.488 HG23 HD12 ' A' ' 29' ' ' LEU . 74.6 m -82.41 144.03 30.79 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 123.998 0.919 . . . . 0.0 109.351 -179.751 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 13.6 mmm180 63.81 17.54 10.56 Favored 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 124.03 0.932 . . . . 0.0 110.077 -169.633 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 35.5 m 61.33 31.95 19.23 Favored 'General case' 0 C--N 1.364 1.239 0 C-N-CA 125.536 1.534 . . . . 0.0 112.175 -175.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . -157.93 -52.85 0.01 OUTLIER Glycine 0 C--N 1.352 1.464 0 CA-C-O 120.019 -0.323 . . . . 0.0 113.358 -179.122 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -69.71 114.22 7.71 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 123.185 0.594 . . . . 0.0 111.562 -172.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 222' ' ' TYR . . . . . . . . . . . . . 7.5 m-85 -68.11 98.06 0.75 Allowed 'General case' 0 CA--C 1.551 1.0 0 C-N-CA 123.0 0.52 . . . . 0.0 110.272 179.063 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 94.9 t -127.5 127.17 68.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 C-N-CA 123.798 0.839 . . . . 0.0 110.089 -171.445 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 224' ' ' SER . . . . . 0.68 ' HB3' ' H ' ' A' ' 213' ' ' ASN . 58.5 m -153.75 159.06 41.82 Favored 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 123.237 0.615 . . . . 0.0 111.384 -171.026 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . . . . . . . . . . . -80.03 145.15 32.65 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.352 1.061 . . . . 0.0 110.986 177.451 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 226' ' ' ILE . . . . . 0.663 HG13 ' HB1' ' A' ' 186' ' ' ALA . 85.3 mt -78.85 102.89 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 174.065 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 227' ' ' ALA . . . . . 0.428 ' O ' ' HA3' ' A' ' 209' ' ' GLY . . . -77.76 101.75 6.83 Favored 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 177.757 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 49.0 mt-30 -89.87 169.37 11.3 Favored 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 123.088 0.555 . . . . 0.0 110.098 -171.316 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.432 ' HA ' ' CD1' ' A' ' 144' ' ' TRP . 71.4 p -80.05 123.41 27.82 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 123.079 0.552 . . . . 0.0 111.506 -177.566 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -99.6 -24.18 14.82 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 123.244 0.618 . . . . 0.0 109.504 167.886 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 13.4 ptpt 68.72 157.06 0.14 Allowed 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 127.392 2.277 . . . . 0.0 113.098 174.132 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 22.4 m . . . . . 0 CA--C 1.543 0.678 0 CA-C-N 115.536 -0.756 . . . . 0.0 110.64 166.58 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.426 ' O ' ' HB3' ' A' ' 117' ' ' ALA . . . . . . . . 0 N--CA 1.482 1.165 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -102.81 18.03 22.47 Favored 'General case' 0 N--CA 1.478 0.937 0 O-C-N 121.851 -0.531 . . . . 0.0 109.652 -175.027 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . 0.49 ' HB2' ' NE2' ' A' ' 88' ' ' GLN . 6.2 m-20 -126.02 26.88 6.45 Favored 'General case' 0 C--O 1.237 0.444 0 C-N-CA 124.525 1.13 . . . . 0.0 108.976 -169.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 83.7 mt -75.8 93.56 3.17 Favored 'General case' 0 C--O 1.215 -0.739 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.085 -173.172 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.446 ' HA ' ' O ' ' A' ' 120' ' ' MET . 23.2 tt0 -83.54 135.19 34.73 Favored 'General case' 0 N--CA 1.475 0.796 0 O-C-N 122.139 -0.351 . . . . 0.0 111.326 -179.651 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -102.1 138.89 38.46 Favored 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.337 177.096 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 19.1 pt-20 -143.33 144.51 32.12 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.802 0.841 . . . . 0.0 109.096 176.182 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . 0.506 ' NH2' ' HB3' ' A' ' 13' ' ' ASP . 50.7 ttt180 -63.41 120.73 12.21 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 112.286 0.476 . . . . 0.0 112.286 -165.603 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . 0.643 ' HB2' ' HG3' ' A' ' 85' ' ' ARG . . . -84.64 -45.89 12.05 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 124.108 0.963 . . . . 0.0 109.896 173.081 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -170.95 -178.21 2.44 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-N 115.178 -0.919 . . . . 0.0 112.006 -173.733 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . 0.506 ' HB3' ' NH2' ' A' ' 10' ' ' ARG . 10.4 p-10 -103.63 164.77 11.46 Favored 'General case' 0 CA--C 1.54 0.571 0 CA-C-N 114.121 -1.4 . . . . 0.0 108.571 165.373 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 53.0 t -88.11 101.44 11.61 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.856 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 179.03 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 62.7 tttp -172.73 113.74 0.27 Allowed 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 124.42 1.088 . . . . 0.0 108.187 -177.738 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 79.8 t90 -100.95 91.71 4.7 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 122.503 0.321 . . . . 0.0 110.465 -176.714 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -158.27 58.05 0.46 Allowed 'General case' 0 CA--C 1.549 0.931 0 C-N-CA 123.593 0.757 . . . . 0.0 109.746 162.114 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -86.93 -56.04 3.57 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 122.833 0.453 . . . . 0.0 111.17 179.052 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . 0.591 ' H ' ' HB2' ' A' ' 169' ' ' ALA . 0.0 OUTLIER -148.38 4.35 0.69 Allowed 'General case' 0 N--CA 1.484 1.267 0 C-N-CA 123.186 0.595 . . . . 0.0 111.396 -173.615 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . 13.71 81.55 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 126.521 1.928 . . . . 0.0 114.228 -168.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.464 ' O ' ' HG2' ' A' ' 171' ' ' GLN . 34.2 tt0 -101.97 147.44 26.55 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 114.306 -1.316 . . . . 0.0 109.221 -176.503 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 9.4 tp -93.03 149.05 4.34 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.798 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 174.348 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' SER . . . . . 0.516 ' HB3' HD21 ' A' ' 189' ' ' LEU . 69.1 m -91.73 -174.67 3.92 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 123.642 0.777 . . . . 0.0 111.455 178.341 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -87.23 -41.88 6.43 Favored Glycine 0 C--N 1.347 1.194 0 CA-C-N 115.436 -0.802 . . . . 0.0 111.28 178.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 35.5 m 63.0 87.47 0.1 Allowed 'General case' 0 C--N 1.358 0.968 0 C-N-CA 124.299 1.039 . . . . 0.0 110.219 177.836 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.539 ' HB2' ' HB3' ' A' ' 188' ' ' SER . 17.2 m -85.49 156.31 59.26 Favored Pre-proline 0 CA--C 1.555 1.147 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.988 -174.672 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -65.63 -168.56 0.13 Allowed 'Trans proline' 0 C--N 1.376 2.018 0 C-N-CA 123.244 2.63 . . . . 0.0 112.448 167.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 35.0 mm -66.14 138.37 23.14 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.267 0 CA-C-O 120.811 0.339 . . . . 0.0 110.662 -174.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.557 HD22 HG21 ' A' ' 217' ' ' THR . 4.3 mt -114.85 161.46 18.21 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 123.282 0.633 . . . . 0.0 110.564 175.167 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 30.4 t -112.24 114.65 27.56 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 178.579 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 12.9 tt -113.62 160.56 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 C-N-CA 124.649 1.18 . . . . 0.0 108.306 -174.793 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 82.2 p -93.89 104.96 17.0 Favored 'General case' 0 C--N 1.363 1.164 0 CA-C-N 119.845 1.202 . . . . 0.0 108.184 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.786 HG23 ' HA ' ' A' ' 179' ' ' THR . 3.5 tp -107.86 154.65 8.91 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 C-N-CA 125.887 1.675 . . . . 0.0 107.549 -176.62 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 9.1 p -157.27 161.91 39.18 Favored 'General case' 0 C--O 1.249 1.061 0 C-N-CA 123.264 0.626 . . . . 0.0 110.547 -171.743 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -58.29 158.02 7.76 Favored 'General case' 0 N--CA 1.481 1.103 0 C-N-CA 124.594 1.158 . . . . 0.0 111.505 -175.548 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 30.7 t70 78.39 14.55 1.38 Allowed 'General case' 0 N--CA 1.491 1.616 0 C-N-CA 124.911 1.284 . . . . 0.0 110.396 178.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 73.98 34.23 56.05 Favored Glycine 0 C--N 1.356 1.644 0 CA-C-N 115.343 -0.844 . . . . 0.0 112.265 -178.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 47.5 t -99.54 143.87 29.29 Favored 'General case' 0 N--CA 1.469 0.522 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -175.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' MET . . . . . 0.424 ' HB3' HD13 ' A' ' 33' ' ' ILE . 19.3 ptm -163.03 154.24 17.23 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 122.571 0.348 . . . . 0.0 111.053 -177.087 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 35.5 p -176.29 -179.09 1.03 Allowed 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 125.035 1.334 . . . . 0.0 108.96 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.419 HG21 ' O ' ' A' ' 216' ' ' VAL . 10.4 tp -107.17 96.72 4.86 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 172.309 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 7.5 mtpm? 50.77 31.0 5.47 Favored 'General case' 0 CA--C 1.559 1.318 0 C-N-CA 124.247 1.019 . . . . 0.0 113.082 170.729 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 41.8 t-20 79.15 -30.02 0.14 Allowed 'General case' 0 N--CA 1.502 2.132 0 C-N-CA 125.885 1.674 . . . . 0.0 111.959 -174.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -58.54 107.36 0.49 Allowed 'General case' 0 CA--C 1.55 0.949 0 C-N-CA 125.533 1.533 . . . . 0.0 112.86 -171.005 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 . . . . . 0 N--CA 1.474 0.759 0 C-N-CA 123.419 0.687 . . . . 0.0 110.684 172.471 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 18.9 t70 . . . . . 0 N--CA 1.487 1.413 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.43 ' HA3' ' HA ' ' A' ' 13' ' ' ASP . . . 93.49 -147.54 18.63 Favored Glycine 0 C--N 1.344 0.984 0 C-N-CA 123.076 0.369 . . . . 0.0 113.34 177.199 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -84.44 138.22 32.94 Favored 'General case' 0 N--CA 1.48 1.062 0 C-N-CA 123.493 0.717 . . . . 0.0 110.155 -177.397 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 12.0 m-85 -125.74 140.02 53.04 Favored 'General case' 0 N--CA 1.494 1.761 0 C-N-CA 123.334 0.654 . . . . 0.0 111.324 -179.061 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' ARG . . . . . 0.643 ' HG3' ' HB2' ' A' ' 11' ' ' ALA . 58.2 mtt-85 -85.41 122.21 29.23 Favored 'General case' 0 C--O 1.239 0.521 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 169.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.467 HD11 HD11 ' A' ' 119' ' ' LEU . 62.6 mt -98.3 119.82 46.82 Favored 'Isoleucine or valine' 0 C--O 1.253 1.237 0 CA-C-O 121.589 0.709 . . . . 0.0 109.394 175.299 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . 0.423 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 58.4 pttt -111.12 146.9 36.0 Favored 'General case' 0 C--O 1.239 0.548 0 CA-C-N 114.26 -1.336 . . . . 0.0 108.477 174.001 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . 0.49 ' NE2' ' HB2' ' A' ' 5' ' ' ASP . 0.1 OUTLIER -83.09 107.81 15.92 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 104.294 -2.484 . . . . 0.0 104.294 166.31 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . 0.489 ' O ' ' HB3' ' A' ' 5' ' ' ASP . 28.8 ttpt -117.34 96.92 5.64 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -175.506 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -67.11 154.2 52.86 Favored Glycine 0 C--N 1.339 0.725 0 N-CA-C 107.436 -2.266 . . . . 0.0 107.436 166.097 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 20.1 mm -78.86 63.93 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.39 0 CA-C-N 118.637 1.219 . . . . 0.0 108.926 -173.265 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 22.3 tp 167.81 -32.62 0.0 OUTLIER 'General case' 0 CA--C 1.562 1.431 0 C-N-CA 125.535 1.534 . . . . 0.0 109.854 -166.336 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -145.36 149.14 21.25 Favored Glycine 0 C--N 1.369 2.39 0 N-CA-C 114.265 0.466 . . . . 0.0 114.265 -171.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -124.98 133.36 53.04 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 124.614 1.166 . . . . 0.0 110.33 -169.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 44.7 m -151.45 103.19 2.96 Favored 'General case' 0 N--CA 1.493 1.705 0 CA-C-N 118.602 0.637 . . . . 0.0 112.085 176.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . 0.423 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 43.7 mt-30 -53.76 120.39 6.19 Favored 'General case' 0 N--CA 1.495 1.818 0 C-N-CA 123.489 0.716 . . . . 0.0 111.215 173.446 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.5 pp -122.54 -13.07 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 C-N-CA 123.806 0.842 . . . . 0.0 112.061 -176.645 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 174.87 -152.51 13.96 Favored Glycine 0 C--N 1.342 0.903 0 CA-C-O 119.637 -0.535 . . . . 0.0 112.313 174.619 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -156.36 164.3 38.46 Favored 'General case' 0 C--O 1.241 0.652 0 C-N-CA 123.384 0.674 . . . . 0.0 110.973 -176.594 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -158.31 149.94 20.46 Favored Glycine 0 C--N 1.339 0.731 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 177.209 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 37.2 t -96.14 118.91 43.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 C-N-CA 123.328 0.651 . . . . 0.0 110.192 -176.576 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 85.5 t80 -94.93 126.9 40.58 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 171.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.415 ' HA ' ' HD2' ' A' ' 103' ' ' LYS . 42.7 tptt -133.55 114.5 13.64 Favored 'General case' 0 C--O 1.239 0.548 0 C-N-CA 123.28 0.632 . . . . 0.0 109.565 175.054 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 68.52 -78.14 0.05 OUTLIER 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 125.282 1.433 . . . . 0.0 112.415 169.185 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -147.46 32.43 1.36 Allowed Glycine 0 N--CA 1.465 0.569 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 176.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 44.6 m -136.84 124.86 22.82 Favored 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 124.21 1.004 . . . . 0.0 109.563 178.331 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' PHE . . . . . 0.457 ' HZ ' HD13 ' A' ' 86' ' ' ILE . 57.0 t80 -110.13 118.05 35.35 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 172.634 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . 0.592 ' HE2' HD12 ' A' ' 137' ' ' LEU . 60.5 t60 -123.69 114.82 20.47 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 122.809 0.443 . . . . 0.0 109.97 -178.654 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 9.0 t -114.14 -165.71 1.03 Allowed 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 124.338 1.055 . . . . 0.0 109.525 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' MET . . . . . 0.591 ' HA ' ' HA ' ' A' ' 137' ' ' LEU . 13.6 mtp -107.43 160.56 15.55 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 124.13 0.972 . . . . 0.0 110.033 177.075 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 11.6 t90 -80.79 -31.47 35.74 Favored 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 122.645 0.378 . . . . 0.0 111.512 -175.561 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . 0.44 ' HE2' ' HB3' ' A' ' 196' ' ' SER . 46.1 p-80 -75.02 -18.02 60.41 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.639 -0.663 . . . . 0.0 111.051 174.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 68.7 t -81.98 -44.02 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.523 0.729 . . . . 0.0 109.519 173.675 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 90.1 m -135.16 108.3 7.7 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 107.752 -1.203 . . . . 0.0 107.752 -178.767 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 19.3 ptp180 -85.69 33.33 0.58 Allowed 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 123.298 0.639 . . . . 0.0 112.211 -172.533 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 91.74 27.76 16.06 Favored Glycine 0 N--CA 1.47 0.912 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -170.083 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . 0.426 ' HB3' ' O ' ' A' ' 3' ' ' ALA . . . -94.41 -178.92 4.74 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.065 0.946 . . . . 0.0 110.971 -177.189 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 70.2 t -100.3 133.25 43.99 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 123.404 0.681 . . . . 0.0 110.47 -176.341 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.514 ' HB2' ' HB ' ' A' ' 126' ' ' ILE . 2.4 mm? -92.01 162.31 14.43 Favored 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 124.155 0.982 . . . . 0.0 110.049 172.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' MET . . . . . 0.446 ' O ' ' HA ' ' A' ' 7' ' ' GLU . 23.5 mmt -139.25 136.79 35.33 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 124.066 0.947 . . . . 0.0 110.458 -171.609 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 56.8 t60 -169.38 137.0 1.8 Allowed 'General case' 0 N--CA 1.476 0.825 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 153.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 85.5 mttt 70.45 9.69 7.0 Favored 'General case' 0 N--CA 1.503 2.208 0 C-N-CA 124.238 1.015 . . . . 0.0 111.753 -178.45 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 83.46 -4.95 79.96 Favored Glycine 0 C--N 1.349 1.266 0 CA-C-O 119.953 -0.359 . . . . 0.0 112.519 -167.289 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 31.0 mmmt -72.64 117.61 14.54 Favored 'General case' 0 C--O 1.248 0.998 0 C-N-CA 123.512 0.725 . . . . 0.0 109.123 175.593 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 85.3 mtm180 -87.4 96.05 10.23 Favored 'General case' 0 C--O 1.237 0.418 0 O-C-N 124.665 1.228 . . . . 0.0 108.869 -179.122 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.514 ' HB ' ' HB2' ' A' ' 119' ' ' LEU . 97.2 mt -75.19 114.78 15.65 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.664 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.271 -179.069 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -92.91 146.9 32.92 Favored Pre-proline 0 CA--C 1.548 0.875 0 C-N-CA 124.126 0.97 . . . . 0.0 110.63 -174.554 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_exo -67.9 101.01 0.65 Allowed 'Trans proline' 0 C--N 1.367 1.528 0 C-N-CA 122.088 1.859 . . . . 0.0 110.866 169.336 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 22.7 t -64.33 -31.25 72.38 Favored 'General case' 0 N--CA 1.483 1.216 0 CA-C-O 121.271 0.558 . . . . 0.0 109.877 177.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 75.0 t-105 -150.7 156.33 41.11 Favored 'General case' 0 CA--C 1.543 0.695 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 165.306 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -136.76 120.09 16.86 Favored 'General case' 0 N--CA 1.467 0.419 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 176.278 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 27.3 m-20 -95.13 106.78 18.81 Favored 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 124.394 1.078 . . . . 0.0 109.247 175.518 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 60.3 t -75.59 -41.87 41.58 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.659 0 C-N-CA 123.141 0.577 . . . . 0.0 110.351 178.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 55.7 tttm -73.76 -34.98 64.95 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.954 -175.242 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 13.6 tppt? -80.88 -18.78 46.12 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 123.096 0.558 . . . . 0.0 110.797 176.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 26.3 t70 62.5 48.32 4.58 Favored 'General case' 0 N--CA 1.481 1.083 0 CA-C-O 122.72 1.248 . . . . 0.0 110.379 -175.4 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . 0.592 HD12 ' HE2' ' A' ' 108' ' ' HIS . 74.8 mt -149.98 138.6 20.76 Favored 'General case' 0 N--CA 1.476 0.838 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.155 -176.899 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 5.8 mt -112.22 145.02 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 C-N-CA 123.384 0.674 . . . . 0.0 110.416 175.206 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' SER . . . . . 0.403 ' HB3' ' O ' ' A' ' 142' ' ' GLY . 34.6 m -118.64 141.61 48.43 Favored 'General case' 0 CA--C 1.557 1.217 0 C-N-CA 125.015 1.326 . . . . 0.0 110.945 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 19.6 t80 -135.38 142.13 45.64 Favored 'General case' 0 N--CA 1.488 1.472 0 C-N-CA 124.835 1.254 . . . . 0.0 108.515 173.203 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.26 -60.5 4.7 Favored Glycine 0 C--N 1.352 1.42 0 N-CA-C 111.254 -0.738 . . . . 0.0 111.254 -176.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . 0.403 ' O ' ' HB3' ' A' ' 139' ' ' SER . . . -148.28 -171.82 17.57 Favored Glycine 0 C--O 1.242 0.635 0 N-CA-C 109.871 -1.292 . . . . 0.0 109.871 172.394 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -77.46 -177.17 46.06 Favored Glycine 0 C--N 1.337 0.627 0 N-CA-C 112.13 -0.388 . . . . 0.0 112.13 175.333 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' TRP . . . . . 0.487 ' HB2' ' CE1' ' A' ' 108' ' ' HIS . 13.4 t-105 -69.78 111.6 5.65 Favored 'General case' 0 C--O 1.243 0.756 0 O-C-N 122.585 -0.362 . . . . 0.0 110.44 177.19 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 23.0 pttm -135.64 152.34 51.12 Favored 'General case' 0 N--CA 1.466 0.334 0 O-C-N 124.092 0.87 . . . . 0.0 110.308 173.015 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' LEU . . . . . 0.407 HD11 ' CH2' ' A' ' 144' ' ' TRP . 4.1 mt 174.63 -8.89 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.945 0 C-N-CA 127.158 2.183 . . . . 0.0 108.207 178.521 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.452 ' N ' HG23 ' A' ' 229' ' ' THR . 7.6 mm-40 60.0 70.93 0.6 Allowed 'General case' 0 C--N 1.365 1.269 0 C-N-CA 125.387 1.475 . . . . 0.0 110.66 173.377 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -104.15 159.23 16.48 Favored Glycine 0 N--CA 1.444 -0.789 0 CA-C-N 114.069 -1.423 . . . . 0.0 113.998 -177.204 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -129.35 93.01 3.46 Favored 'General case' 0 C--O 1.243 0.742 0 C-N-CA 123.856 0.862 . . . . 0.0 109.142 178.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' TRP . . . . . . . . . . . . . 25.2 t90 -74.24 120.63 20.07 Favored 'General case' 0 C--O 1.238 0.498 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 173.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 20.4 mttm -85.15 94.68 8.93 Favored 'General case' 0 C--O 1.243 0.722 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 176.695 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -66.39 97.15 0.4 Allowed 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 123.671 0.788 . . . . 0.0 109.053 -176.961 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 143.27 -49.33 0.72 Allowed Glycine 0 C--N 1.341 0.842 0 CA-C-N 115.371 -0.832 . . . . 0.0 111.365 -178.357 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -85.33 157.94 20.41 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 122.889 0.476 . . . . 0.0 112.042 -175.659 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . 0.469 ' HA ' ' HA ' ' A' ' 173' ' ' LYS . 0.8 OUTLIER -62.5 131.1 48.0 Favored 'General case' 0 C--N 1.351 0.654 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.926 177.918 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . 0.461 HG13 HD13 ' A' ' 226' ' ' ILE . 34.0 m -93.25 159.11 2.83 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.562 179.421 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 25.2 mp0 -113.02 130.36 56.17 Favored 'General case' 0 C--O 1.215 -0.727 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -172.079 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 44.6 t -133.99 137.07 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -174.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -92.57 96.53 10.26 Favored 'General case' 0 CA--C 1.545 0.777 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 169.269 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -64.91 104.02 0.8 Allowed 'General case' 0 C--O 1.24 0.603 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.243 -178.565 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . 0.615 HD22 ' HB3' ' A' ' 167' ' ' PRO . 78.0 mt -69.01 84.74 0.33 Allowed 'General case' 0 C--O 1.241 0.641 0 C-N-CA 123.704 0.802 . . . . 0.0 108.873 177.109 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 28.3 tt0 -74.9 134.11 75.34 Favored Pre-proline 0 CA--C 1.545 0.767 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.297 -177.085 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_exo -46.25 112.59 0.48 Allowed 'Trans proline' 0 C--N 1.382 2.342 0 C-N-CA 123.53 2.82 . . . . 0.0 113.881 178.198 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 63.79 27.87 71.78 Favored Glycine 0 C--N 1.35 1.356 0 O-C-N 123.903 0.752 . . . . 0.0 113.819 173.703 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 53.0 tptt -146.49 173.21 12.51 Favored 'General case' 0 C--O 1.245 0.837 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 -176.03 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -56.87 151.09 34.6 Favored Pre-proline 0 CA--C 1.558 1.28 0 C-N-CA 123.701 0.8 . . . . 0.0 112.595 177.317 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . 0.615 ' HB3' HD22 ' A' ' 161' ' ' LEU . 6.9 Cg_exo -74.86 92.42 0.97 Allowed 'Trans proline' 0 C--N 1.372 1.789 0 C-N-CA 123.249 2.632 . . . . 0.0 110.188 171.393 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 31.7 ttp-105 -75.68 122.08 23.45 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.065 -170.211 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . 0.591 ' HB2' ' H ' ' A' ' 19' ' ' GLN . . . -68.77 105.36 2.29 Favored 'General case' 0 CA--C 1.538 0.505 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.934 179.606 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 18.8 t -129.24 135.01 62.85 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.095 0 C-N-CA 124.866 1.266 . . . . 0.0 108.257 176.353 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 171' ' ' GLN . . . . . 0.464 ' HG2' ' O ' ' A' ' 21' ' ' GLU . 27.3 pt20 -117.07 126.73 53.3 Favored 'General case' 0 N--CA 1.478 0.933 0 C-N-CA 123.651 0.781 . . . . 0.0 110.318 -176.122 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 172' ' ' THR . . . . . 0.48 HG22 HG13 ' A' ' 187' ' ' VAL . 5.4 t -118.0 143.13 46.65 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 124.207 1.003 . . . . 0.0 110.911 -173.006 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 155' ' ' GLU . 37.2 ttmt -85.46 142.07 37.26 Favored Pre-proline 0 N--CA 1.479 0.983 0 CA-C-O 118.549 -0.738 . . . . 0.0 109.334 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 174' ' ' PRO . . . . . 0.552 ' HA ' ' O ' ' A' ' 186' ' ' ALA . 89.6 Cg_exo -47.32 122.69 6.85 Favored 'Trans proline' 0 C--N 1.396 3.04 0 C-N-CA 123.116 2.544 . . . . 0.0 114.562 -175.244 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . 0.469 ' H ' ' C ' ' A' ' 186' ' ' ALA . . . -135.47 139.59 10.91 Favored Glycine 0 CA--C 1.541 1.679 0 CA-C-N 115.159 -0.928 . . . . 0.0 114.543 179.342 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.419 ' N ' HD22 ' A' ' 176' ' ' LEU . 0.3 OUTLIER -132.22 162.5 30.77 Favored 'General case' 0 C--O 1.241 0.619 0 O-C-N 121.551 -0.97 . . . . 0.0 110.18 -171.412 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 177' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -138.51 139.53 38.79 Favored 'General case' 0 C--O 1.242 0.668 0 CA-C-N 114.141 -1.391 . . . . 0.0 109.727 -167.334 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 178' ' ' LYS . . . . . 0.415 ' HE3' ' HB3' ' A' ' 178' ' ' LYS . 1.3 tmmt? -69.07 120.77 15.45 Favored 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 124.481 1.112 . . . . 0.0 111.648 -165.488 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 179' ' ' THR . . . . . 0.786 ' HA ' HG23 ' A' ' 33' ' ' ILE . 7.4 m -90.09 165.4 14.02 Favored 'General case' 0 CA--C 1.551 1.01 0 C-N-CA 125.89 1.676 . . . . 0.0 109.787 177.619 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 180' ' ' ASN . . . . . 0.555 ' ND2' HG21 ' A' ' 33' ' ' ILE . 63.4 m-80 -64.53 -35.14 79.99 Favored 'General case' 0 N--CA 1.487 1.384 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 170.82 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -75.62 -48.22 23.14 Favored 'General case' 0 CA--C 1.54 0.566 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.977 175.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . 0.572 ' H ' ' HB ' ' A' ' 179' ' ' THR . . . -165.73 -94.43 0.1 OUTLIER Glycine 0 C--N 1.345 1.045 0 CA-C-O 119.756 -0.469 . . . . 0.0 112.638 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 7.5 t -163.46 135.83 5.21 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 124.719 1.208 . . . . 0.0 109.354 178.092 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -132.98 155.73 41.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 122.898 0.479 . . . . 0.0 109.814 177.052 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . 129.83 177.58 14.96 Favored Glycine 0 C--N 1.343 0.935 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 173.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . 0.552 ' O ' ' HA ' ' A' ' 174' ' ' PRO . . . -171.66 38.85 0.02 OUTLIER 'General case' 0 C--O 1.193 -1.901 0 C-N-CA 123.486 0.715 . . . . 0.0 110.329 177.867 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 187' ' ' VAL . . . . . 0.48 HG13 HG22 ' A' ' 172' ' ' THR . 95.1 t -153.15 125.22 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 120.012 -1.68 . . . . 0.0 107.648 167.399 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 188' ' ' SER . . . . . 0.605 ' HA ' HG13 ' A' ' 223' ' ' VAL . 73.6 m -132.54 91.13 2.88 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 168.115 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 189' ' ' LEU . . . . . 0.516 HD21 ' HB3' ' A' ' 23' ' ' SER . 0.5 OUTLIER -126.97 104.36 7.96 Favored 'General case' 0 N--CA 1.48 1.039 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 -176.285 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 190' ' ' ASP . . . . . 0.666 ' HA ' ' HA ' ' A' ' 221' ' ' ALA . 8.0 p-10 -85.72 103.16 14.25 Favored 'General case' 0 C--N 1.356 0.865 0 CA-C-O 121.875 0.845 . . . . 0.0 109.992 -179.243 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 191' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -174.19 172.92 3.19 Favored 'General case' 0 N--CA 1.475 0.776 0 CA-C-N 115.059 -0.973 . . . . 0.0 108.541 -167.393 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 44.5 p -58.3 121.91 55.51 Favored Pre-proline 0 CA--C 1.548 0.883 0 C-N-CA 123.127 0.571 . . . . 0.0 110.614 175.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_endo -61.16 127.66 22.81 Favored 'Trans proline' 0 C--N 1.376 2.021 0 C-N-CA 122.246 1.964 . . . . 0.0 112.661 -178.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -72.41 173.44 46.43 Favored Glycine 0 C--N 1.35 1.326 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 162.099 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 7.4 m -80.66 135.78 36.09 Favored 'General case' 0 CA--C 1.562 1.416 0 CA-C-N 118.626 1.213 . . . . 0.0 111.334 -172.532 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 196' ' ' SER . . . . . 0.44 ' HB3' ' HE2' ' A' ' 112' ' ' HIS . 0.8 OUTLIER -65.19 88.44 0.08 Allowed 'General case' 0 C--N 1.367 1.339 0 C-N-CA 124.13 0.972 . . . . 0.0 111.304 -171.641 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 197' ' ' GLY . . . . . 0.624 ' HA2' HD21 ' A' ' 210' ' ' LEU . . . 144.59 9.58 0.36 Allowed Glycine 0 C--N 1.335 0.499 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.984 -175.908 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 198' ' ' SER . . . . . 0.406 ' O ' ' HB2' ' A' ' 211' ' ' TYR . 39.3 m -57.36 132.09 81.31 Favored Pre-proline 0 CA--C 1.556 1.208 0 C-N-CA 122.942 0.497 . . . . 0.0 109.838 166.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -69.91 137.44 35.02 Favored 'Trans proline' 0 C--N 1.369 1.621 0 C-N-CA 121.965 1.777 . . . . 0.0 111.108 174.072 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 39.9 mt -91.92 119.6 39.61 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 N-CA-C 107.923 -1.139 . . . . 0.0 107.923 170.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 201' ' ' ILE . . . . . 0.641 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 46.7 mt -103.61 168.87 2.19 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.483 0 C-N-CA 125.632 1.573 . . . . 0.0 109.786 179.768 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -104.6 167.19 9.89 Favored 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 124.752 1.221 . . . . 0.0 109.402 178.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 18.5 ptpt -55.11 -29.24 57.24 Favored 'General case' 0 N--CA 1.481 1.106 0 C-N-CA 124.626 1.17 . . . . 0.0 112.444 177.762 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 52.9 mtmt -82.33 10.57 6.75 Favored 'General case' 0 N--CA 1.481 1.11 0 C-N-CA 123.324 0.65 . . . . 0.0 112.277 -179.072 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 70.0 19.73 75.68 Favored Glycine 0 C--N 1.356 1.669 0 N-CA-C 112.115 -0.394 . . . . 0.0 112.115 -177.235 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 62.4 tttp -110.73 121.14 44.59 Favored 'General case' 0 C--O 1.212 -0.892 0 C-N-CA 124.381 1.072 . . . . 0.0 108.662 -176.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 207' ' ' VAL . . . . . 0.641 ' HA ' ' HA ' ' A' ' 201' ' ' ILE . 7.1 p -53.9 139.67 11.87 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.092 0 C-N-CA 123.191 0.596 . . . . 0.0 111.687 178.092 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 3.6 m -98.34 -35.43 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.854 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 170.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.581 ' HA3' ' HA ' ' A' ' 228' ' ' GLN . . . 166.86 -138.18 5.05 Favored Glycine 0 C--N 1.348 1.226 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.268 -178.229 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 210' ' ' LEU . . . . . 0.624 HD21 ' HA2' ' A' ' 197' ' ' GLY . 5.1 tt -122.58 154.01 38.52 Favored 'General case' 0 CA--C 1.545 0.779 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 -172.122 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 211' ' ' TYR . . . . . 0.442 ' N ' HD22 ' A' ' 210' ' ' LEU . 10.2 t80 -62.45 142.19 58.01 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 123.592 0.757 . . . . 0.0 109.956 178.467 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -77.45 -157.83 9.26 Favored Glycine 0 N--CA 1.475 1.298 0 CA-C-N 118.103 0.41 . . . . 0.0 112.622 178.392 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 213' ' ' ASN . . . . . . . . . . . . . 14.7 t-20 -81.92 85.59 6.66 Favored 'General case' 0 N--CA 1.477 0.904 0 N-CA-C 108.442 -0.948 . . . . 0.0 108.442 -176.658 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . -71.66 123.3 9.87 Favored Glycine 0 C--N 1.347 1.174 0 CA-C-N 114.789 -1.096 . . . . 0.0 112.008 177.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 215' ' ' VAL . . . . . . . . . . . . . 21.7 t -134.59 143.56 37.44 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.672 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 173.63 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 216' ' ' VAL . . . . . 0.568 ' HB ' ' HA2' ' A' ' 220' ' ' GLY . 15.4 m -87.98 111.3 22.01 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.891 0 CA-C-O 121.781 0.8 . . . . 0.0 109.536 -178.718 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 217' ' ' THR . . . . . 0.557 HG21 HD22 ' A' ' 29' ' ' LEU . 38.8 m -107.74 162.53 13.9 Favored 'General case' 0 N--CA 1.475 0.825 0 C-N-CA 124.329 1.052 . . . . 0.0 109.659 -170.692 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 20.3 ttm180 71.45 -73.77 0.09 Allowed 'General case' 0 N--CA 1.492 1.646 0 C-N-CA 124.217 1.007 . . . . 0.0 109.592 -177.065 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 41.1 m -140.96 -43.86 0.39 Allowed 'General case' 0 CA--C 1.547 0.838 0 C-N-CA 124.519 1.127 . . . . 0.0 109.19 178.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 220' ' ' GLY . . . . . 0.568 ' HA2' ' HB ' ' A' ' 216' ' ' VAL . . . -169.04 27.65 0.13 Allowed Glycine 0 C--N 1.348 1.218 0 CA-C-N 115.49 -0.777 . . . . 0.0 112.181 -175.744 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 221' ' ' ALA . . . . . 0.666 ' HA ' ' HA ' ' A' ' 190' ' ' ASP . . . -80.32 96.11 6.55 Favored 'General case' 0 N--CA 1.465 0.317 0 C-N-CA 123.684 0.794 . . . . 0.0 110.607 179.717 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 222' ' ' TYR . . . . . . . . . . . . . 12.3 t80 -66.61 95.9 0.36 Allowed 'General case' 0 CA--C 1.554 1.123 0 CA-C-N 114.804 -1.089 . . . . 0.0 109.543 -176.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . 0.605 HG13 ' HA ' ' A' ' 188' ' ' SER . 35.3 m -114.59 140.14 37.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 C-N-CA 123.81 0.844 . . . . 0.0 109.774 -177.157 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 33.1 t -152.16 160.68 43.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.623 -169.598 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . . . . . . . . . . . -81.64 -175.02 5.32 Favored 'General case' 0 CA--C 1.546 0.792 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.643 164.43 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 226' ' ' ILE . . . . . 0.461 HD13 HG13 ' A' ' 156' ' ' VAL . 78.2 mt -133.57 116.44 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 176.005 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -95.78 137.2 35.18 Favored 'General case' 0 C--O 1.233 0.196 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 176.015 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . 0.581 ' HA ' ' HA3' ' A' ' 209' ' ' GLY . 29.0 pt20 -120.26 174.3 6.59 Favored 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 175.318 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.474 ' HA ' ' CD1' ' A' ' 144' ' ' TRP . 39.4 p -66.14 107.71 2.02 Favored 'General case' 0 CA--C 1.546 0.825 0 CA-C-O 121.208 0.528 . . . . 0.0 110.802 -176.502 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 230' ' ' GLU . . . . . 0.473 ' HG2' ' O ' ' A' ' 228' ' ' GLN . 26.7 mm-40 -108.06 -30.16 8.58 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 124.425 1.09 . . . . 0.0 112.437 -168.384 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 29.8 mmtp -107.06 -99.78 0.35 Allowed 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 113.477 0.917 . . . . 0.0 113.477 -160.38 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 64.3 p . . . . . 0 C--N 1.361 1.093 0 CA-C-O 121.958 0.885 . . . . 0.0 110.672 -165.207 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.5 ' HB3' ' HB ' ' A' ' 114' ' ' THR . . . . . . . . 0 N--CA 1.494 1.753 0 N-CA-C 111.317 0.117 . . . . 0.0 111.317 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -150.76 -62.01 0.19 Allowed 'General case' 0 N--CA 1.477 0.875 0 C-N-CA 123.287 0.635 . . . . 0.0 110.054 -173.131 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . 0.723 ' HA ' ' HG3' ' A' ' 120' ' ' MET . 32.6 t70 -144.5 76.92 1.52 Allowed 'General case' 0 CA--C 1.528 0.113 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 -172.386 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . 0.508 HD22 HG21 ' A' ' 114' ' ' THR . 5.8 mp -117.56 124.4 48.57 Favored 'General case' 0 N--CA 1.488 1.471 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.051 -179.283 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.79 ' HB2' ' HD3' ' A' ' 89' ' ' LYS . 14.5 tp10 -80.9 134.54 35.76 Favored 'General case' 0 C--O 1.252 1.229 0 CA-C-N 118.06 0.391 . . . . 0.0 110.449 178.023 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . 0.459 ' HB2' HD12 ' A' ' 119' ' ' LEU . 18.1 tp -87.16 113.34 22.81 Favored 'General case' 0 CA--C 1.542 0.649 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 171.027 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -104.87 143.64 32.87 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 125.826 1.65 . . . . 0.0 108.176 -173.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.8 ptt-85 -76.29 147.16 38.42 Favored 'General case' 0 N--CA 1.481 1.104 0 CA-C-N 118.336 0.516 . . . . 0.0 110.505 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . 0.641 ' HB2' ' HG3' ' A' ' 85' ' ' ARG . . . -125.89 -51.12 1.57 Allowed 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 169.2 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -166.65 175.34 8.0 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.012 0.925 . . . . 0.0 110.279 -177.038 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -98.59 159.44 14.95 Favored 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 108.401 -0.962 . . . . 0.0 108.401 164.11 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 83.4 t -88.39 103.18 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 CA-C-O 121.545 0.688 . . . . 0.0 111.281 -176.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 2.4 ptpp? -155.98 158.67 38.28 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 124.891 1.277 . . . . 0.0 107.97 168.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 10.6 t90 -67.83 105.43 1.96 Allowed 'General case' 0 CA--C 1.549 0.923 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.26 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.563 ' HB3' ' HB2' ' A' ' 169' ' ' ALA . 2.6 tm-20 -70.35 145.03 51.45 Favored 'General case' 0 CA--C 1.554 1.127 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 170.496 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -75.65 -19.45 59.16 Favored 'General case' 0 N--CA 1.481 1.117 0 N-CA-C 113.885 1.069 . . . . 0.0 113.885 -165.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 6.6 tp60 -94.1 53.37 1.74 Allowed 'General case' 0 N--CA 1.476 0.828 0 CA-C-O 121.46 0.648 . . . . 0.0 110.592 -168.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.592 ' HB3' ' HB2' ' A' ' 171' ' ' GLN . . . -56.04 91.24 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 124.558 1.143 . . . . 0.0 111.843 178.34 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -62.74 126.51 27.59 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 124.851 1.261 . . . . 0.0 110.746 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 50.4 mm -77.08 109.16 11.3 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.613 0 C-N-CA 123.073 0.549 . . . . 0.0 109.609 -178.256 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.1 m -135.38 -174.78 3.72 Favored 'General case' 0 CA--C 1.551 1.015 0 C-N-CA 124.038 0.935 . . . . 0.0 110.026 -179.436 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.11 73.1 1.1 Allowed Glycine 0 C--N 1.349 1.259 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 -172.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.8 m -124.57 1.93 8.27 Favored 'General case' 0 N--CA 1.478 0.963 0 C-N-CA 122.971 0.508 . . . . 0.0 112.291 -164.636 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 13.7 m -120.45 137.88 26.7 Favored Pre-proline 0 CA--C 1.55 0.957 0 C-N-CA 123.291 0.636 . . . . 0.0 109.675 -176.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -82.43 -155.82 0.06 OUTLIER 'Trans proline' 0 C--N 1.379 2.151 0 C-N-CA 123.204 2.603 . . . . 0.0 112.253 179.506 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 48.6 mm -66.32 121.05 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 123.16 0.584 . . . . 0.0 110.632 -178.749 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.2 mt -105.53 164.87 11.55 Favored 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 124.658 1.183 . . . . 0.0 111.752 -175.139 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 39.4 m -122.46 116.18 23.52 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 123.5 0.72 . . . . 0.0 109.542 176.122 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.487 HD13 HG13 ' A' ' 223' ' ' VAL . 62.5 mt -116.24 145.09 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 C-N-CA 124.292 1.037 . . . . 0.0 108.561 178.391 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 35.9 p -93.56 105.13 17.21 Favored 'General case' 0 CA--C 1.543 0.703 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.125 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 9.2 tp -69.91 141.14 17.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 C-N-CA 124.159 0.983 . . . . 0.0 110.403 175.019 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 34.3 t -135.47 140.17 44.64 Favored 'General case' 0 C--O 1.242 0.701 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 176.788 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 65.14 15.98 10.3 Favored 'General case' 0 CA--C 1.563 1.476 0 C-N-CA 123.893 0.877 . . . . 0.0 111.133 174.756 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 58.12 32.65 22.27 Favored 'General case' 0 N--CA 1.49 1.545 0 C-N-CA 124.744 1.218 . . . . 0.0 111.67 -179.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -169.55 -44.41 0.03 OUTLIER Glycine 0 C--N 1.348 1.236 0 CA-C-N 116.32 -0.4 . . . . 0.0 112.669 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 25.6 m -89.15 106.2 18.29 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -176.373 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 27.3 mtm -88.05 162.59 16.71 Favored 'General case' 0 N--CA 1.476 0.873 0 O-C-N 121.909 -0.494 . . . . 0.0 110.856 -176.21 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 39.1 m -147.51 148.56 31.34 Favored 'General case' 0 C--O 1.238 0.492 0 C-N-CA 123.707 0.803 . . . . 0.0 109.379 -178.553 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 9.1 tp -96.12 151.7 3.97 Favored 'Isoleucine or valine' 0 C--O 1.239 0.55 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 169.326 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 50.2 mtmt -81.93 40.92 0.63 Allowed 'General case' 0 CA--C 1.558 1.261 0 C-N-CA 123.532 0.733 . . . . 0.0 111.222 175.31 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 7.8 t30 -167.49 75.34 0.14 Allowed 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 125.047 1.339 . . . . 0.0 107.661 176.518 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -75.29 117.66 17.34 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 177.398 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 . . . . . 0 C--O 1.245 0.827 0 C-N-CA 123.912 0.885 . . . . 0.0 109.398 177.939 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 CA--C 1.549 0.939 0 CA-C-O 121.458 0.647 . . . . 0.0 109.731 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -166.16 166.33 38.7 Favored Glycine 0 C--N 1.34 0.802 0 CA-C-N 115.805 -0.634 . . . . 0.0 113.455 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . 0.64 ' HB3' HD13 ' A' ' 161' ' ' LEU . . . -86.3 118.14 25.55 Favored 'General case' 0 C--O 1.243 0.719 0 CA-C-N 114.117 -1.041 . . . . 0.0 108.701 175.096 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 79.9 m-85 -118.46 142.4 47.6 Favored 'General case' 0 C--O 1.216 -0.676 0 C-N-CA 123.09 0.556 . . . . 0.0 109.622 -179.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' ARG . . . . . 0.641 ' HG3' ' HB2' ' A' ' 11' ' ' ALA . 54.9 mtt-85 -92.29 137.0 32.73 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 174.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 51.6 mt -102.37 121.3 53.26 Favored 'Isoleucine or valine' 0 C--O 1.26 1.629 0 CA-C-O 121.673 0.749 . . . . 0.0 110.151 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . 0.467 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 22.7 pttm -122.82 144.79 48.96 Favored 'General case' 0 C--N 1.349 0.554 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.823 177.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.18 119.65 24.33 Favored 'General case' 0 C--O 1.249 1.027 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 173.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . 0.79 ' HD3' ' HB2' ' A' ' 7' ' ' GLU . 53.2 pttt -115.31 152.74 32.23 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.686 -172.318 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -100.93 103.2 2.55 Favored Glycine 0 C--N 1.347 1.157 0 N-CA-C 106.135 -2.786 . . . . 0.0 106.135 160.414 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 4.8 tp 19.36 29.66 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.58 2.118 0 C-N-CA 129.298 3.039 . . . . 0.0 116.882 -167.542 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.438 ' N ' ' HD2' ' A' ' 89' ' ' LYS . 0.7 OUTLIER -177.41 -57.27 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.873 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 -169.77 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 177.05 161.89 26.52 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 114.732 0.653 . . . . 0.0 114.732 -177.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 53.2 p90 -165.8 -48.0 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 124.308 1.043 . . . . 0.0 112.05 156.17 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 12.6 t -152.72 149.83 28.8 Favored 'General case' 0 N--CA 1.495 1.783 0 CA-C-N 119.63 1.105 . . . . 0.0 112.067 -175.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' GLN . . . . . 0.467 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 0.8 OUTLIER -95.38 142.31 27.91 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 124.417 1.087 . . . . 0.0 110.445 -179.782 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.436 HD11 HD23 ' A' ' 6' ' ' LEU . 1.3 pp -133.49 -7.66 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 N-CA-C 113.575 0.954 . . . . 0.0 113.575 -175.052 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 175.92 -148.92 9.58 Favored Glycine 0 N--CA 1.475 1.242 0 CA-C-N 118.359 0.527 . . . . 0.0 113.017 173.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -156.41 176.06 13.19 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 123.585 0.754 . . . . 0.0 110.985 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -172.87 135.3 3.27 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -177.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.467 HG23 ' HB3' ' A' ' 199' ' ' PRO . 71.3 t -95.65 110.67 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 C-N-CA 123.285 0.634 . . . . 0.0 109.328 -177.447 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 17.7 t80 -77.66 134.51 38.14 Favored 'General case' 0 CA--C 1.536 0.439 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -179.468 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' LYS . . . . . 0.728 ' HZ2' HG23 ' A' ' 207' ' ' VAL . 35.5 mmtm -118.64 157.65 27.0 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 124.96 1.304 . . . . 0.0 109.045 -179.583 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -53.76 100.18 0.03 OUTLIER 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 123.86 0.864 . . . . 0.0 112.176 -173.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 83.55 -9.97 60.57 Favored Glycine 0 C--N 1.351 1.386 0 CA-C-N 115.48 -0.782 . . . . 0.0 113.766 178.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 20.3 p -123.81 120.45 32.65 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 124.038 0.935 . . . . 0.0 111.02 -175.121 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' PHE . . . . . 0.683 ' HB3' ' HB3' ' A' ' 140' ' ' TYR . 37.2 t80 -84.42 122.6 29.19 Favored 'General case' 0 N--CA 1.48 1.027 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 176.483 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 5.3 t-80 -132.97 102.3 5.57 Favored 'General case' 0 CA--C 1.554 1.129 0 C-N-CA 123.776 0.83 . . . . 0.0 110.434 -167.111 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' THR . . . . . 0.46 HG23 ' HB ' ' A' ' 138' ' ' ILE . 10.2 t -136.74 177.19 8.05 Favored 'General case' 0 N--CA 1.488 1.457 0 C-N-CA 123.889 0.876 . . . . 0.0 111.135 -178.601 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' MET . . . . . 0.474 ' HA ' ' HA ' ' A' ' 137' ' ' LEU . 44.2 mtp -93.55 157.14 16.34 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 124.296 1.038 . . . . 0.0 109.148 173.536 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 79.7 t90 -80.46 -61.88 1.84 Allowed 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 112.28 0.474 . . . . 0.0 112.28 -166.149 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 2.3 p-80 -73.97 3.93 6.12 Favored 'General case' 0 N--CA 1.5 2.048 0 N-CA-C 114.009 1.114 . . . . 0.0 114.009 -167.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 40.7 t -42.99 -41.6 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.279 0 C-N-CA 123.734 0.814 . . . . 0.0 110.29 161.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.508 HG21 HD22 ' A' ' 6' ' ' LEU . 0.2 OUTLIER -153.29 -163.03 1.59 Allowed 'General case' 0 CA--C 1.558 1.286 0 C-N-CA 125.267 1.427 . . . . 0.0 109.207 170.395 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 77.5 mtp180 -66.01 -26.65 67.63 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 113.362 0.875 . . . . 0.0 113.362 -172.747 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 93.78 62.84 1.07 Allowed Glycine 0 CA--C 1.53 0.983 0 O-C-N 123.205 0.316 . . . . 0.0 113.715 178.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -141.98 -85.66 0.17 Allowed 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 112.461 0.541 . . . . 0.0 112.461 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 26.6 t -110.98 109.0 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 123.359 0.663 . . . . 0.0 112.331 -169.028 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.506 HD11 HD12 ' A' ' 126' ' ' ILE . 1.3 tm? -91.33 152.06 20.61 Favored 'General case' 0 C--O 1.212 -0.908 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 169.108 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' MET . . . . . 0.723 ' HG3' ' HA ' ' A' ' 5' ' ' ASP . 45.7 mmm -135.01 138.85 44.36 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 124.06 0.944 . . . . 0.0 108.717 -172.755 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' HIS . . . . . 0.515 ' O ' ' HG2' ' A' ' 122' ' ' LYS . 18.5 t-160 -167.53 141.84 3.68 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -177.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.515 ' HG2' ' O ' ' A' ' 121' ' ' HIS . 32.8 pttt 68.92 3.12 3.84 Favored 'General case' 0 N--CA 1.501 2.086 0 C-N-CA 125.649 1.579 . . . . 0.0 112.766 176.194 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 99.96 -0.76 56.35 Favored Glycine 0 C--N 1.351 1.362 0 C-N-CA 123.144 0.402 . . . . 0.0 113.084 -174.282 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -118.45 152.93 34.97 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 123.813 0.845 . . . . 0.0 110.744 179.482 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' ARG . . . . . 0.439 ' HB3' ' SD ' ' A' ' 120' ' ' MET . 20.8 ptp180 -93.07 164.67 13.18 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.11 -179.276 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.506 HD12 HD11 ' A' ' 119' ' ' LEU . 27.5 mt -142.8 122.97 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 C-N-CA 125.628 1.571 . . . . 0.0 107.086 -172.396 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 44.8 mt-10 -125.73 132.69 24.39 Favored Pre-proline 0 N--CA 1.474 0.758 0 N-CA-C 108.604 -0.888 . . . . 0.0 108.604 175.427 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . 0.524 ' HA ' ' HB2' ' A' ' 140' ' ' TYR . 96.9 Cg_endo -73.78 157.65 47.62 Favored 'Trans proline' 0 C--N 1.373 1.86 0 C-N-CA 122.934 2.423 . . . . 0.0 113.943 -168.806 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' SER . . . . . 0.499 ' H ' ' HA ' ' A' ' 140' ' ' TYR . 28.8 p -76.77 -27.62 55.37 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-N 114.884 -1.053 . . . . 0.0 109.623 172.385 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 67.6 t-105 -152.5 144.94 24.07 Favored 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 123.314 0.645 . . . . 0.0 110.21 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -136.72 121.19 18.22 Favored 'General case' 0 C--O 1.241 0.613 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 171.566 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -114.13 109.09 17.88 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 123.437 0.695 . . . . 0.0 109.467 -173.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 17.1 t -77.44 -19.38 14.15 Favored 'Isoleucine or valine' 0 CA--C 1.562 1.407 0 C-N-CA 123.9 0.88 . . . . 0.0 111.304 -175.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 2.8 mptp? -69.46 -51.31 37.27 Favored 'General case' 0 N--CA 1.487 1.419 0 C-N-CA 123.461 0.704 . . . . 0.0 109.557 -177.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 31.9 mmtp -84.13 -20.08 33.1 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-N 115.088 -0.96 . . . . 0.0 110.346 178.681 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 14.2 t70 65.5 63.57 0.62 Allowed 'General case' 0 C--O 1.24 0.595 0 C-N-CA 125.56 1.544 . . . . 0.0 110.607 -175.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' LEU . . . . . 0.474 ' HA ' ' HA ' ' A' ' 110' ' ' MET . 1.5 mp -143.77 172.64 12.56 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.802 174.461 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.46 ' HB ' HG23 ' A' ' 109' ' ' THR . 21.6 mt -141.46 131.33 25.15 Favored 'Isoleucine or valine' 0 C--O 1.245 0.868 0 C-N-CA 125.952 1.701 . . . . 0.0 108.08 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 29.9 p -136.48 123.09 20.98 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 124.13 0.972 . . . . 0.0 110.282 -177.566 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.683 ' HB3' ' HB3' ' A' ' 107' ' ' PHE . 47.8 t80 -109.68 123.97 50.41 Favored 'General case' 0 N--CA 1.464 0.24 0 C-N-CA 124.626 1.17 . . . . 0.0 108.06 172.79 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 113.91 0.4 24.23 Favored Glycine 0 N--CA 1.474 1.19 0 O-C-N 123.885 0.741 . . . . 0.0 111.98 -173.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 147.46 -141.74 9.58 Favored Glycine 0 C--N 1.346 1.125 0 N-CA-C 109.944 -1.262 . . . . 0.0 109.944 177.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.781 ' HA3' ' HB2' ' A' ' 232' ' ' SER . . . -97.45 -175.06 34.19 Favored Glycine 0 C--N 1.345 1.058 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 164.285 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' TRP . . . . . 0.602 ' HZ2' ' HA2' ' A' ' 209' ' ' GLY . 7.4 t90 -69.76 104.02 2.32 Favored 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 177.279 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . 0.59 ' HB3' ' HA ' ' A' ' 231' ' ' LYS . 11.7 pttt -164.87 113.85 1.08 Allowed 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 123.7 0.8 . . . . 0.0 109.692 -177.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' LEU . . . . . 0.679 HD21 ' HD2' ' A' ' 103' ' ' LYS . 0.0 OUTLIER 167.62 -33.12 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 C-N-CA 125.178 1.391 . . . . 0.0 110.602 161.409 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.572 ' HG2' ' HE2' ' A' ' 103' ' ' LYS . 31.6 mt-10 -62.3 -81.91 0.02 OUTLIER 'General case' 0 C--N 1.367 1.353 0 O-C-N 123.714 0.634 . . . . 0.0 111.057 -166.139 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . 0.444 ' O ' ' HB ' ' A' ' 229' ' ' THR . . . 177.66 -174.26 46.75 Favored Glycine 0 C--N 1.341 0.813 0 O-C-N 123.464 0.477 . . . . 0.0 111.963 -178.097 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -124.85 107.37 10.83 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 -172.765 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' TRP . . . . . . . . . . . . . 27.5 t90 -54.89 135.57 48.0 Favored 'General case' 0 N--CA 1.477 0.923 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.625 172.161 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . 0.43 ' HZ3' ' HE3' ' A' ' 206' ' ' LYS . 53.6 mmtt -84.48 101.8 12.33 Favored 'General case' 0 C--O 1.239 0.508 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 179.042 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -62.65 107.72 1.01 Allowed 'General case' 0 CA--C 1.546 0.803 0 O-C-N 124.022 0.826 . . . . 0.0 109.765 -172.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 134.16 -31.62 2.77 Favored Glycine 0 C--N 1.34 0.803 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.688 -176.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -82.81 156.34 23.71 Favored 'General case' 0 C--O 1.242 0.708 0 C-N-CA 123.349 0.66 . . . . 0.0 109.48 178.559 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 10.0 pm0 -64.02 142.93 58.23 Favored 'General case' 0 C--O 1.243 0.731 0 O-C-N 124.207 0.942 . . . . 0.0 109.956 174.442 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . 0.406 ' HB ' HG21 ' A' ' 200' ' ' ILE . 15.8 m -92.48 142.34 13.26 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 CA-C-O 121.184 0.516 . . . . 0.0 109.822 174.552 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 157' ' ' GLN . . . . . 0.469 HE22 ' HB2' ' A' ' 171' ' ' GLN . 9.9 tp-100 -101.32 144.96 29.52 Favored 'General case' 0 N--CA 1.454 -0.235 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 173.008 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.597 ' HB ' ' HB ' ' A' ' 170' ' ' VAL . 49.1 t -128.03 146.02 34.28 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 123.445 0.698 . . . . 0.0 110.014 -174.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 159' ' ' LEU . . . . . 0.415 ' HB2' ' HG2' ' A' ' 199' ' ' PRO . 33.7 mt -97.04 85.55 3.76 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 160.82 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -64.16 100.5 0.34 Allowed 'General case' 0 C--O 1.237 0.403 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 -179.233 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 161' ' ' LEU . . . . . 0.64 HD13 ' HB3' ' A' ' 83' ' ' ALA . 70.6 mt -78.03 80.28 4.47 Favored 'General case' 0 C--O 1.242 0.691 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.628 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 10.1 mm-40 -61.59 125.3 84.26 Favored Pre-proline 0 CA--C 1.555 1.151 0 CA-C-N 113.412 -1.722 . . . . 0.0 110.074 -176.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -58.1 112.8 1.28 Allowed 'Trans proline' 0 C--N 1.382 2.293 0 C-N-CA 122.875 2.383 . . . . 0.0 112.626 -174.006 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 67.06 26.87 73.31 Favored Glycine 0 C--N 1.349 1.305 0 O-C-N 124.139 0.9 . . . . 0.0 113.291 176.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 49.8 mtpt -131.54 -172.49 2.87 Favored 'General case' 0 C--O 1.242 0.703 0 C-N-CA 124.282 1.033 . . . . 0.0 109.306 -176.533 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -72.48 141.7 83.23 Favored Pre-proline 0 CA--C 1.555 1.139 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.053 170.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_exo -67.48 122.33 9.54 Favored 'Trans proline' 0 C--N 1.368 1.577 0 C-N-CA 122.522 2.148 . . . . 0.0 111.006 170.384 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 56.6 mtp180 -105.51 167.6 9.65 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 123.912 0.885 . . . . 0.0 110.549 -178.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 169' ' ' ALA . . . . . 0.563 ' HB2' ' HB3' ' A' ' 17' ' ' GLU . . . -102.24 151.21 22.49 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 109.408 -0.589 . . . . 0.0 109.408 170.493 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . 0.597 ' HB ' ' HB ' ' A' ' 158' ' ' VAL . 95.5 t -136.17 117.08 18.51 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.239 0 C-N-CA 123.276 0.63 . . . . 0.0 110.286 175.159 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 171' ' ' GLN . . . . . 0.592 ' HB2' ' HB3' ' A' ' 20' ' ' ALA . 65.0 tt0 -94.81 111.24 23.03 Favored 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 172.441 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 4.5 t -140.52 140.53 35.27 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-O 121.001 0.429 . . . . 0.0 110.742 -174.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 21.5 ptmt -75.61 152.43 85.27 Favored Pre-proline 0 CA--C 1.55 0.953 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.961 177.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -70.3 143.54 48.52 Favored 'Trans proline' 0 C--N 1.374 1.909 0 C-N-CA 122.314 2.009 . . . . 0.0 112.692 171.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -132.84 155.55 21.67 Favored Glycine 0 N--CA 1.467 0.729 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 170.406 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.487 ' HG ' ' HA2' ' A' ' 185' ' ' GLY . 6.5 mp -116.81 157.17 26.02 Favored 'General case' 0 N--CA 1.482 1.143 0 CA-C-N 119.019 1.409 . . . . 0.0 109.231 -174.562 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 177' ' ' PHE . . . . . . . . . . . . . 50.2 p90 -137.02 149.55 47.53 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.802 175.301 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 60.1 tttp -97.78 128.01 44.13 Favored 'General case' 0 C--O 1.239 0.547 0 CA-C-N 115.577 -0.738 . . . . 0.0 109.977 -177.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 75.5 p -123.48 171.82 9.19 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.017 0.927 . . . . 0.0 109.355 168.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -65.94 -27.07 67.9 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 123.564 0.746 . . . . 0.0 110.607 174.334 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -68.65 -40.71 80.08 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 123.757 0.823 . . . . 0.0 110.602 175.455 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 158.22 -175.9 35.31 Favored Glycine 0 C--N 1.35 1.346 0 CA-C-N 115.831 -0.622 . . . . 0.0 112.423 177.634 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 8.5 t -77.98 115.42 17.71 Favored 'General case' 0 CA--C 1.543 0.695 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 172.55 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 52.8 mt -104.5 138.95 26.98 Favored 'Isoleucine or valine' 0 C--O 1.246 0.909 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -177.504 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 185' ' ' GLY . . . . . 0.487 ' HA2' ' HG ' ' A' ' 176' ' ' LEU . . . -100.45 119.43 6.51 Favored Glycine 0 C--N 1.349 1.291 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -175.121 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 186' ' ' ALA . . . . . 0.494 ' HA ' ' H ' ' A' ' 226' ' ' ILE . . . -144.94 -156.85 0.74 Allowed 'General case' 0 C--O 1.235 0.323 0 C-N-CA 123.837 0.855 . . . . 0.0 109.928 -165.694 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 187' ' ' VAL . . . . . 0.547 HG12 ' HB3' ' A' ' 224' ' ' SER . 2.4 p -135.77 123.06 34.98 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 C-N-CA 123.648 0.779 . . . . 0.0 109.285 175.085 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 41.6 m -117.75 115.29 24.72 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 123.779 0.832 . . . . 0.0 109.262 -176.796 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 189' ' ' LEU . . . . . 0.417 HD11 ' HB3' ' A' ' 191' ' ' PHE . 0.5 OUTLIER -149.44 164.0 36.22 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 124.065 0.946 . . . . 0.0 110.962 -175.44 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -101.52 104.1 14.99 Favored 'General case' 0 CA--C 1.541 0.634 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 170.246 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 191' ' ' PHE . . . . . 0.417 ' HB3' HD11 ' A' ' 189' ' ' LEU . 67.9 t80 -154.11 166.58 32.62 Favored 'General case' 0 N--CA 1.484 1.238 0 C-N-CA 123.217 0.607 . . . . 0.0 110.486 -171.79 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 48.8 m -69.53 156.25 92.01 Favored Pre-proline 0 CA--C 1.559 1.295 0 C-N-CA 124.952 1.301 . . . . 0.0 112.631 -178.713 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 193' ' ' PRO . . . . . 0.515 ' HA ' ' CE1' ' A' ' 222' ' ' TYR . 39.7 Cg_endo -64.24 99.18 0.28 Allowed 'Trans proline' 0 C--N 1.387 2.554 0 C-N-CA 123.009 2.473 . . . . 0.0 113.02 176.392 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -70.47 -136.39 0.12 Allowed Glycine 0 C--N 1.361 1.918 0 C-N-CA 123.745 0.688 . . . . 0.0 112.596 177.749 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 25.4 p -124.79 143.94 50.54 Favored 'General case' 0 N--CA 1.489 1.501 0 CA-C-N 118.979 1.39 . . . . 0.0 112.245 169.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 14.1 m -73.88 83.19 1.68 Allowed 'General case' 0 C--N 1.354 0.765 0 C-N-CA 123.645 0.778 . . . . 0.0 110.305 170.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 127.98 19.86 1.73 Allowed Glycine 0 C--N 1.339 0.747 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.536 -170.275 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 33.4 t -65.49 140.23 97.53 Favored Pre-proline 0 CA--C 1.554 1.108 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 164.118 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 199' ' ' PRO . . . . . 0.467 ' HB3' HG23 ' A' ' 101' ' ' VAL . 65.7 Cg_endo -81.04 131.85 8.1 Favored 'Trans proline' 0 C--N 1.374 1.881 0 C-N-CA 121.647 1.565 . . . . 0.0 113.374 179.016 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 200' ' ' ILE . . . . . 0.406 HG21 ' HB ' ' A' ' 156' ' ' VAL . 43.9 mt -87.43 117.91 32.33 Favored 'Isoleucine or valine' 0 C--O 1.248 1.002 0 CA-C-O 121.962 0.887 . . . . 0.0 108.739 163.091 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 201' ' ' ILE . . . . . . . . . . . . . 80.4 mt -102.87 136.49 35.12 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.812 0 CA-C-N 113.248 -1.796 . . . . 0.0 107.54 172.421 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 202' ' ' ASP . . . . . 0.518 ' HB3' ' HB2' ' A' ' 206' ' ' LYS . 19.1 t70 -73.31 148.56 43.41 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 167.415 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 60.6 pttt -60.38 -18.96 53.85 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 -172.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 86.1 tttt -67.52 -21.34 65.49 Favored 'General case' 0 CA--C 1.557 1.247 0 C-N-CA 123.546 0.738 . . . . 0.0 111.766 177.497 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 108.27 3.32 33.37 Favored Glycine 0 N--CA 1.471 0.967 0 C-N-CA 123.3 0.476 . . . . 0.0 111.949 -171.691 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 206' ' ' LYS . . . . . 0.518 ' HB2' ' HB3' ' A' ' 202' ' ' ASP . 46.4 mttm -74.45 136.22 42.3 Favored 'General case' 0 C--O 1.205 -1.244 0 C-N-CA 123.985 0.914 . . . . 0.0 109.428 173.436 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 207' ' ' VAL . . . . . 0.728 HG23 ' HZ2' ' A' ' 103' ' ' LYS . 7.5 p -86.68 135.91 24.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 N-CA-C 106.403 -1.702 . . . . 0.0 106.403 163.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 30.9 m -135.8 -21.08 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 N-CA-C 113.153 0.797 . . . . 0.0 113.153 -168.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 209' ' ' GLY . . . . . 0.602 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . 178.4 -151.37 10.47 Favored Glycine 0 C--N 1.35 1.329 0 C-N-CA 119.751 -1.214 . . . . 0.0 115.815 -176.116 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 210' ' ' LEU . . . . . 0.449 HD11 HD21 ' A' ' 137' ' ' LEU . 33.6 mt -130.82 133.74 46.22 Favored 'General case' 0 C--N 1.365 1.241 0 CA-C-O 121.88 0.848 . . . . 0.0 112.366 -175.751 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 64.0 t80 -94.09 133.96 37.03 Favored 'General case' 0 C--O 1.241 0.655 0 C-N-CA 126.409 1.884 . . . . 0.0 108.223 168.061 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -137.38 -138.05 3.69 Favored Glycine 0 C--O 1.229 -0.189 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 177.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 213' ' ' ASN . . . . . 0.449 ' HA ' ' HA ' ' A' ' 224' ' ' SER . 9.2 t30 -156.79 101.09 1.95 Allowed 'General case' 0 C--O 1.237 0.396 0 C-N-CA 125.694 1.598 . . . . 0.0 107.05 170.666 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . -56.22 -56.39 24.5 Favored Glycine 0 C--N 1.342 0.894 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 172.782 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 215' ' ' VAL . . . . . . . . . . . . . 3.4 m -162.2 -172.74 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 C-N-CA 125.241 1.416 . . . . 0.0 108.952 176.057 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 216' ' ' VAL . . . . . 0.487 HG12 ' HA ' ' A' ' 222' ' ' TYR . 3.4 m -117.83 129.89 73.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 168.135 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 217' ' ' THR . . . . . 0.416 HG23 ' H ' ' A' ' 218' ' ' ARG . 4.9 m -126.69 -178.9 4.54 Favored 'General case' 0 CA--C 1.552 1.031 0 N-CA-C 107.829 -1.175 . . . . 0.0 107.829 -178.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 218' ' ' ARG . . . . . 0.416 ' H ' HG23 ' A' ' 217' ' ' THR . 10.9 ttt85 64.19 25.57 13.66 Favored 'General case' 0 N--CA 1.496 1.863 0 CA-C-O 122.393 1.092 . . . . 0.0 110.879 171.367 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 10.2 t 69.9 2.07 3.72 Favored 'General case' 0 N--CA 1.489 1.507 0 C-N-CA 125.412 1.485 . . . . 0.0 112.975 176.501 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . 159.64 45.81 0.02 OUTLIER Glycine 0 C--N 1.349 1.263 0 CA-C-N 117.706 0.23 . . . . 0.0 112.572 -177.447 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -122.69 121.45 36.41 Favored 'General case' 0 C--O 1.238 0.478 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 176.048 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 222' ' ' TYR . . . . . 0.515 ' CE1' ' HA ' ' A' ' 193' ' ' PRO . 56.6 t80 -69.8 101.29 1.68 Allowed 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 125.136 1.374 . . . . 0.0 109.059 179.282 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 223' ' ' VAL . . . . . 0.487 HG13 HD13 ' A' ' 31' ' ' ILE . 8.2 t -96.89 98.56 7.68 Favored 'Isoleucine or valine' 0 C--O 1.249 1.039 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 -176.467 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 224' ' ' SER . . . . . 0.547 ' HB3' HG12 ' A' ' 187' ' ' VAL . 38.0 t -97.3 155.19 16.98 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 125.144 1.378 . . . . 0.0 109.744 179.059 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 225' ' ' ALA . . . . . . . . . . . . . . . -104.83 131.38 52.38 Favored 'General case' 0 C--O 1.241 0.626 0 C-N-CA 123.449 0.7 . . . . 0.0 109.675 176.428 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 226' ' ' ILE . . . . . 0.494 ' H ' ' HA ' ' A' ' 186' ' ' ALA . 78.8 mt -77.98 95.04 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.352 0.68 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 173.196 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 227' ' ' ALA . . . . . 0.412 ' O ' ' HA3' ' A' ' 209' ' ' GLY . . . -85.18 147.18 26.73 Favored 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 172.632 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 3.7 pt20 -147.54 153.56 39.63 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 123.918 0.887 . . . . 0.0 109.446 -169.246 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.444 ' HB ' ' O ' ' A' ' 148' ' ' GLY . 89.4 m -69.0 109.28 3.88 Favored 'General case' 0 CA--C 1.545 0.764 0 CA-C-O 121.161 0.505 . . . . 0.0 109.817 179.242 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 230' ' ' GLU . . . . . 0.412 ' O ' ' HG2' ' A' ' 231' ' ' LYS . 38.3 mt-10 -98.01 -11.83 22.58 Favored 'General case' 0 N--CA 1.481 1.081 0 CA-C-N 114.916 -1.038 . . . . 0.0 111.302 -175.193 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 231' ' ' LYS . . . . . 0.59 ' HA ' ' HB3' ' A' ' 145' ' ' LYS . 11.7 pttm 66.78 128.48 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 127.06 2.144 . . . . 0.0 112.189 -177.51 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 232' ' ' SER . . . . . 0.781 ' HB2' ' HA3' ' A' ' 143' ' ' GLY . 30.1 m . . . . . 0 C--N 1.351 0.659 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 172.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.652 0 CA-C-O 119.869 -0.406 . . . . 0.0 112.614 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.8 m -60.24 -42.05 94.42 Favored 'General case' 0 N--CA 1.48 1.04 0 C-N-CA 123.405 0.682 . . . . 0.0 111.605 -178.462 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 56.93 39.06 29.7 Favored 'General case' 0 N--CA 1.484 1.238 0 O-C-N 124.34 1.025 . . . . 0.0 111.626 175.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -170.95 11.37 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 123.736 0.814 . . . . 0.0 109.669 -170.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -158.25 82.33 0.84 Allowed 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 -169.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.407 ' HA ' ' HA ' ' A' ' 88' ' ' GLN . 7.4 mp -117.01 109.65 17.27 Favored 'General case' 0 C--O 1.202 -1.432 0 O-C-N 121.474 -0.766 . . . . 0.0 110.284 -175.221 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.598 ' HB2' ' HD3' ' A' ' 89' ' ' LYS . 37.3 tp10 -83.68 145.46 28.76 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.551 -0.718 . . . . 0.0 110.627 -176.304 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . 0.448 ' HB2' ' CD2' ' A' ' 121' ' ' HIS . 81.6 mt -89.32 114.66 26.08 Favored 'General case' 0 CA--C 1.547 0.856 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.508 171.177 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -112.28 107.88 16.89 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 125.108 1.363 . . . . 0.0 108.274 178.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 15.9 ttp180 -67.75 125.05 25.02 Favored 'General case' 0 N--CA 1.481 1.102 0 CA-C-N 118.441 0.564 . . . . 0.0 111.616 -172.088 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . 0.522 ' HB1' ' HG3' ' A' ' 85' ' ' ARG . . . -89.06 -40.54 12.89 Favored 'General case' 0 C--N 1.347 0.473 0 C-N-CA 124.02 0.928 . . . . 0.0 109.986 177.188 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -166.09 -176.25 3.67 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 115.08 -0.964 . . . . 0.0 110.776 -173.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 65.2 m-20 -110.22 146.78 35.01 Favored 'General case' 0 C--O 1.242 0.696 0 C-N-CA 124.085 0.954 . . . . 0.0 108.838 171.401 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.435 HG12 HG12 ' A' ' 208' ' ' VAL . 94.6 t -78.86 101.01 3.97 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 CA-C-O 121.503 0.668 . . . . 0.0 109.469 -177.171 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 33.8 ttpt -167.96 109.74 0.59 Allowed 'General case' 0 C--O 1.247 0.966 0 N-CA-C 105.247 -2.131 . . . . 0.0 105.247 175.767 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . 0.418 ' NE1' ' HB1' ' A' ' 169' ' ' ALA . 68.2 t90 -80.3 90.57 5.56 Favored 'General case' 0 CA--C 1.539 0.553 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 -177.153 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -157.88 60.46 0.47 Allowed 'General case' 0 CA--C 1.543 0.677 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 158.046 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.553 ' HB3' ' HB3' ' A' ' 169' ' ' ALA . 12.6 t70 -90.6 -58.93 2.32 Favored 'General case' 0 CA--C 1.554 1.134 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.775 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . 0.647 ' H ' ' HB2' ' A' ' 169' ' ' ALA . 17.7 mt-30 -150.28 4.27 0.52 Allowed 'General case' 0 N--CA 1.5 2.027 0 N-CA-C 113.953 1.094 . . . . 0.0 113.953 -172.485 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . 11.84 70.91 0.01 OUTLIER 'General case' 0 N--CA 1.506 2.365 0 C-N-CA 126.549 1.94 . . . . 0.0 115.484 -169.053 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -88.22 123.59 33.0 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 123.603 0.761 . . . . 0.0 109.9 -176.253 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 30.8 mm -75.58 134.87 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 C-N-CA 123.045 0.538 . . . . 0.0 110.187 -176.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 78.5 p -174.84 -162.46 0.12 Allowed 'General case' 0 CA--C 1.55 0.949 0 O-C-N 124.581 1.176 . . . . 0.0 109.954 172.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.599 ' HA3' ' H ' ' A' ' 173' ' ' LYS . . . 102.77 178.49 26.86 Favored Glycine 0 C--N 1.349 1.259 0 CA-C-O 119.522 -0.599 . . . . 0.0 111.805 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 44.0 t 64.02 98.17 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 124.212 1.005 . . . . 0.0 111.176 176.287 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 28.8 t -140.63 148.83 54.73 Favored Pre-proline 0 N--CA 1.479 0.993 0 CA-C-O 118.406 -0.807 . . . . 0.0 109.345 -176.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_exo -42.63 138.12 3.7 Favored 'Trans proline' 0 C--N 1.391 2.81 0 C-N-CA 123.87 3.046 . . . . 0.0 113.785 177.243 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.652 HD12 ' HB2' ' A' ' 176' ' ' LEU . 31.0 mm -63.52 111.13 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 -175.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.638 ' HB3' HG22 ' A' ' 217' ' ' THR . 13.6 mt -94.11 142.33 27.52 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 115.373 -0.83 . . . . 0.0 111.732 -167.69 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 60.4 p -85.52 140.8 30.36 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 123.358 0.663 . . . . 0.0 110.316 177.474 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.727 HG23 ' HD2' ' A' ' 177' ' ' PHE . 14.6 tt -148.39 138.6 16.7 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.794 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 -172.372 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 39.4 p -102.27 117.05 33.93 Favored 'General case' 0 CA--C 1.547 0.855 0 O-C-N 121.881 -0.512 . . . . 0.0 110.997 -170.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.607 ' HA ' ' HG3' ' A' ' 39' ' ' MET . 10.6 tp -61.25 145.11 13.09 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.077 0 C-N-CA 124.902 1.281 . . . . 0.0 112.208 -177.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 47.5 m -152.25 130.91 12.31 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 124.103 0.961 . . . . 0.0 110.068 -176.041 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 60.71 19.24 9.32 Favored 'General case' 0 CA--C 1.566 1.586 0 C-N-CA 123.479 0.712 . . . . 0.0 111.437 174.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 24.3 t70 76.05 -55.55 0.6 Allowed 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 125.617 1.567 . . . . 0.0 112.318 -178.359 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -89.0 -20.27 47.23 Favored Glycine 0 N--CA 1.475 1.268 0 N-CA-C 115.002 0.761 . . . . 0.0 115.002 -175.359 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 66.5 m -106.0 165.49 11.17 Favored 'General case' 0 N--CA 1.478 0.941 0 CA-C-N 117.646 0.723 . . . . 0.0 110.252 -177.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' MET . . . . . 0.607 ' HG3' ' HA ' ' A' ' 33' ' ' ILE . 3.7 mpp? -138.99 168.31 20.11 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 123.808 0.843 . . . . 0.0 108.861 168.901 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.791 ' HA ' HG12 ' A' ' 215' ' ' VAL . 64.5 m -150.39 -179.47 7.24 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 124.788 1.235 . . . . 0.0 108.282 167.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 41.7 mm -99.0 96.51 5.08 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 N-CA-C 108.261 -1.015 . . . . 0.0 108.261 167.417 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER 53.16 -79.63 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.154 0 C-N-CA 125.999 1.72 . . . . 0.0 112.164 -176.579 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 4.4 p30 -136.27 87.08 2.27 Favored 'General case' 0 CA--C 1.551 0.985 0 C-N-CA 124.486 1.115 . . . . 0.0 108.94 178.073 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -100.67 148.09 25.26 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.81 -172.215 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -85.27 178.08 7.61 Favored 'General case' 0 N--CA 1.475 0.793 0 C-N-CA 124.17 0.988 . . . . 0.0 110.97 176.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -152.44 146.01 24.96 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 123.347 0.659 . . . . 0.0 110.422 -176.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 -138.91 148.43 43.59 Favored 'General case' 0 C--O 1.244 0.791 0 C-N-CA 123.714 0.806 . . . . 0.0 110.134 -179.336 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 29.5 pt20 -71.21 146.76 48.86 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 123.572 0.749 . . . . 0.0 110.057 171.084 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.491 HG21 ' HB3' ' A' ' 163' ' ' PRO . 56.5 m -77.21 -39.19 49.58 Favored 'General case' 0 CA--C 1.554 1.109 0 C-N-CA 123.372 0.669 . . . . 0.0 110.997 178.409 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.404 ' HA ' ' H ' ' A' ' 96' ' ' GLN . 44.8 tp 68.54 132.61 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 125.814 1.645 . . . . 0.0 112.187 -175.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -143.85 157.37 27.04 Favored Glycine 0 C--N 1.353 1.514 0 N-CA-C 111.419 -0.672 . . . . 0.0 111.419 -178.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -112.84 -33.81 1.97 Allowed Glycine 0 C--N 1.348 1.218 0 CA-C-O 119.823 -0.432 . . . . 0.0 114.051 -168.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -62.95 153.82 44.53 Favored Glycine 0 N--CA 1.477 1.401 0 C-N-CA 123.241 0.448 . . . . 0.0 113.523 -176.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.493 ' HA2' ' HZ2' ' A' ' 66' ' ' TRP . . . 92.75 81.6 1.48 Allowed Glycine 0 C--N 1.339 0.729 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 -171.489 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 77.7 p -69.59 154.12 42.47 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 123.325 0.65 . . . . 0.0 112.001 -177.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -80.2 -9.27 86.79 Favored Glycine 0 C--N 1.347 1.187 0 CA-C-N 115.611 -0.722 . . . . 0.0 113.563 178.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -67.22 84.56 0.13 Allowed Glycine 0 C--N 1.349 1.264 0 N-CA-C 112.028 -0.429 . . . . 0.0 112.028 177.001 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 73.5 35.83 55.31 Favored Glycine 0 C--N 1.35 1.34 0 N-CA-C 112.064 -0.414 . . . . 0.0 112.064 -173.09 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -62.04 -26.83 67.9 Favored Glycine 0 C--N 1.356 1.659 0 O-C-N 123.828 0.369 . . . . 0.0 113.538 -175.728 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . 0.567 ' HG3' ' H ' ' A' ' 61' ' ' PHE . 9.6 pt-20 -90.48 -69.53 0.72 Allowed 'General case' 0 CA--C 1.549 0.912 0 CA-C-O 118.908 -0.568 . . . . 0.0 110.695 172.13 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.567 ' H ' ' HG3' ' A' ' 60' ' ' GLU . 74.2 t80 48.3 -86.23 0.01 OUTLIER 'General case' 0 CA--C 1.557 1.25 0 C-N-CA 124.966 1.306 . . . . 0.0 111.716 -176.639 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -177.31 -52.36 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 125.307 1.443 . . . . 0.0 108.273 -178.008 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 174.71 93.73 0.09 OUTLIER Glycine 0 C--N 1.342 0.861 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 178.232 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.577 ' HB ' ' HD2' ' A' ' 122' ' ' LYS . 1.8 t -90.94 -11.15 9.82 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.277 0 C-N-CA 123.59 0.756 . . . . 0.0 110.04 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.457 ' N ' ' HG3' ' A' ' 122' ' ' LYS . 3.9 mm? 69.29 129.96 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 125.813 1.645 . . . . 0.0 114.302 176.135 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . 0.545 ' CD1' ' HG2' ' A' ' 122' ' ' LYS . 68.3 m95 -92.79 79.19 4.74 Favored 'General case' 0 N--CA 1.482 1.164 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 166.732 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 30.5 t70 179.64 69.58 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 106.497 -1.668 . . . . 0.0 106.497 161.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 6.4 m -126.2 100.91 29.14 Favored Pre-proline 0 CA--C 1.553 1.093 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.99 -171.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -70.98 -47.08 0.6 Allowed 'Trans proline' 0 C--N 1.374 1.888 0 C-N-CA 122.333 2.022 . . . . 0.0 111.314 165.192 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 44.0 m -109.38 171.83 4.12 Favored Pre-proline 0 CA--C 1.561 1.376 0 C-N-CA 124.985 1.314 . . . . 0.0 108.789 171.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -52.65 146.27 35.24 Favored 'Trans proline' 0 C--N 1.386 2.511 0 C-N-CA 122.56 2.174 . . . . 0.0 111.788 171.448 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_exo -42.78 104.14 0.05 OUTLIER 'Trans proline' 0 C--N 1.39 2.717 0 C-N-CA 124.164 3.243 . . . . 0.0 114.321 -172.59 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -82.05 39.03 0.79 Allowed 'Trans proline' 0 C--N 1.376 1.982 0 C-N-CA 124.184 3.256 . . . . 0.0 113.444 -173.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 42.9 t 68.24 8.61 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.567 1.599 0 C-N-CA 124.27 1.028 . . . . 0.0 110.974 174.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -64.81 -45.75 91.71 Favored Glycine 0 C--N 1.362 1.976 0 CA-C-N 116.345 -0.388 . . . . 0.0 112.777 -175.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 38.3 ttmt 71.99 0.96 3.73 Favored 'General case' 0 CA--C 1.562 1.431 0 C-N-CA 125.135 1.374 . . . . 0.0 113.085 168.485 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -142.08 11.58 1.98 Allowed 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.803 -0.56 . . . . 0.0 112.444 -173.459 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -75.41 123.3 25.16 Favored 'General case' 0 CA--C 1.55 0.977 0 CA-C-O 121.313 0.578 . . . . 0.0 109.6 -179.419 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 1.2 pp -128.83 119.09 23.86 Favored 'General case' 0 N--CA 1.473 0.678 0 C-N-CA 124.254 1.022 . . . . 0.0 109.738 -173.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -84.12 61.77 6.69 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 124.325 1.05 . . . . 0.0 108.617 176.671 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 12.4 p-10 -66.8 142.95 57.18 Favored 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 114.03 -1.441 . . . . 0.0 111.298 -169.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 169.0 -154.32 23.83 Favored Glycine 0 C--O 1.258 1.61 0 CA-C-N 115.34 -0.846 . . . . 0.0 111.85 -175.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -81.75 108.74 15.54 Favored 'General case' 0 C--O 1.237 0.445 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 176.364 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . 0.418 ' CD1' ' HB3' ' A' ' 8' ' ' LEU . 47.0 m-85 -102.91 156.56 17.58 Favored 'General case' 0 N--CA 1.469 0.479 0 C-N-CA 123.643 0.777 . . . . 0.0 110.704 -179.3 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . 0.522 ' HG3' ' HB1' ' A' ' 11' ' ' ALA . 60.0 mtt180 -103.06 132.57 49.23 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 106.09 -1.818 . . . . 0.0 106.09 166.36 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.516 ' H ' ' HA ' ' A' ' 99' ' ' ALA . 12.9 mt -91.84 107.83 19.31 Favored 'Isoleucine or valine' 0 C--O 1.256 1.434 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 171.388 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.844 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 19.3 ptmt -99.27 139.2 35.27 Favored 'General case' 0 N--CA 1.441 -0.907 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 169.827 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . 0.407 ' HA ' ' HA ' ' A' ' 6' ' ' LEU . 0.5 OUTLIER -82.85 105.99 14.31 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 105.192 -2.151 . . . . 0.0 105.192 168.271 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . 0.598 ' HD3' ' HB2' ' A' ' 7' ' ' GLU . 60.0 tttt -113.67 98.5 7.08 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-N 114.562 -1.199 . . . . 0.0 108.082 -177.541 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -66.33 154.78 51.68 Favored Glycine 0 C--O 1.246 0.903 0 N-CA-C 108.279 -1.929 . . . . 0.0 108.279 160.557 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.508 HD12 ' HE2' ' A' ' 120' ' ' MET . 22.8 mm -68.19 -6.24 5.27 Favored 'Isoleucine or valine' 0 CA--C 1.572 1.796 0 CA-C-N 117.728 0.764 . . . . 0.0 110.483 -176.518 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 1.1 pp -134.52 25.44 3.76 Favored 'General case' 0 CA--C 1.564 1.507 0 C-N-CA 124.585 1.154 . . . . 0.0 111.901 172.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -164.98 133.07 2.85 Favored Glycine 0 N--CA 1.486 1.968 0 CA-C-N 117.869 0.304 . . . . 0.0 113.357 -178.416 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 71.6 m-85 -122.69 120.19 32.92 Favored 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 124.082 0.953 . . . . 0.0 110.015 -174.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 37.3 p -152.75 109.24 3.42 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 122.965 0.506 . . . . 0.0 110.75 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.844 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 39.9 tt0 -74.1 140.53 45.34 Favored 'General case' 0 N--CA 1.485 1.3 0 CA-C-N 118.227 0.467 . . . . 0.0 110.705 179.046 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 1.6 pp -134.59 -16.25 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 N-CA-C 112.993 0.738 . . . . 0.0 112.993 -174.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -165.31 -157.75 10.05 Favored Glycine 0 C--N 1.342 0.867 0 C-N-CA 121.498 -0.382 . . . . 0.0 112.529 179.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.516 ' HA ' ' H ' ' A' ' 86' ' ' ILE . . . -146.01 170.81 15.89 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 123.489 0.716 . . . . 0.0 110.367 176.813 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -161.9 156.18 27.65 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 -179.294 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 24.1 t -118.15 114.0 43.82 Favored 'Isoleucine or valine' 0 C--O 1.241 0.608 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -175.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.462 ' CD2' ' HB2' ' A' ' 107' ' ' PHE . 0.4 OUTLIER -105.2 121.78 44.56 Favored 'General case' 0 N--CA 1.478 0.943 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 174.049 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.636 ' HB2' HD12 ' A' ' 146' ' ' LEU . 4.6 mmmp? -146.6 150.46 35.53 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 174.451 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 66.13 -84.28 0.03 OUTLIER 'General case' 0 CA--C 1.548 0.866 0 O-C-N 124.929 1.393 . . . . 0.0 110.49 173.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -154.59 21.27 0.62 Allowed Glycine 0 C--N 1.337 0.61 0 N-CA-C 111.816 -0.514 . . . . 0.0 111.816 178.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 97.1 m -142.65 135.1 27.75 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 123.583 0.753 . . . . 0.0 110.499 -175.753 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' PHE . . . . . 0.672 ' HB3' ' HB3' ' A' ' 140' ' ' TYR . 36.2 t80 -109.31 104.98 14.19 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 124.554 1.142 . . . . 0.0 109.363 175.635 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 42.1 p-80 -100.46 126.69 46.9 Favored 'General case' 0 C--O 1.239 0.521 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 173.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 13.8 t -137.77 -162.0 1.24 Allowed 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.319 176.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' MET . . . . . 0.519 ' SD ' ' O ' ' A' ' 212' ' ' GLY . 1.9 ttm -115.84 150.2 37.37 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.949 1.3 . . . . 0.0 109.817 -173.896 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 21.3 t90 -78.88 -42.76 26.51 Favored 'General case' 0 CA--C 1.553 1.077 0 C-N-CA 122.72 0.408 . . . . 0.0 110.777 -175.766 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . 0.458 ' NE2' ' HB ' ' B' ' 255' ' ' M9P . 1.8 p-80 -71.47 3.47 3.82 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 113.807 1.04 . . . . 0.0 113.807 -175.393 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.7 m -53.95 -40.26 44.21 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.096 0 CA-C-N 118.273 0.488 . . . . 0.0 110.591 175.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 11.2 m -148.29 -83.61 0.11 Allowed 'General case' 0 CA--C 1.553 1.088 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 167.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 41.9 ttm180 -135.73 28.22 3.28 Favored 'General case' 0 N--CA 1.489 1.482 0 CA-C-O 121.696 0.76 . . . . 0.0 109.284 179.487 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.585 ' HA2' HD11 ' A' ' 138' ' ' ILE . . . 58.83 36.71 88.41 Favored Glycine 0 C--N 1.348 1.231 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 -166.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -79.02 175.31 10.7 Favored 'General case' 0 C--O 1.246 0.873 0 C-N-CA 124.161 0.985 . . . . 0.0 111.761 -169.428 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.6 m -72.83 142.36 15.21 Favored 'Isoleucine or valine' 0 C--O 1.244 0.782 0 CA-C-O 121.37 0.605 . . . . 0.0 109.784 -176.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -88.12 177.24 6.96 Favored 'General case' 0 CA--C 1.548 0.869 0 CA-C-N 114.676 -1.147 . . . . 0.0 110.099 171.357 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' MET . . . . . 0.508 ' HE2' HD12 ' A' ' 91' ' ' ILE . 9.1 ptp -159.04 155.76 28.03 Favored 'General case' 0 C--O 1.253 1.274 0 C-N-CA 123.874 0.87 . . . . 0.0 110.399 178.544 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.448 ' CD2' ' HB2' ' A' ' 8' ' ' LEU . 0.1 OUTLIER -153.19 104.13 2.77 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 114.727 -1.124 . . . . 0.0 108.134 -179.238 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.577 ' HD2' ' HB ' ' A' ' 64' ' ' VAL . 70.5 mmtt 61.74 30.08 18.27 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 123.844 0.715 . . . . 0.0 110.024 -175.246 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.431 ' HA3' ' O ' ' A' ' 60' ' ' GLU . . . 83.94 -5.06 81.02 Favored Glycine 0 C--N 1.347 1.142 0 CA-C-O 119.012 -0.882 . . . . 0.0 114.185 -177.45 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . 0.467 ' O ' ' HA ' ' A' ' 120' ' ' MET . 21.6 ttmm -69.21 114.21 7.27 Favored 'General case' 0 C--N 1.357 0.924 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 170.65 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 36.2 ttm-85 -80.21 95.36 6.26 Favored 'General case' 0 CA--C 1.538 0.499 0 O-C-N 123.895 0.747 . . . . 0.0 109.36 -171.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 74.6 mt -80.14 93.74 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 C-N-CA 123.918 0.887 . . . . 0.0 108.701 -177.093 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -94.02 128.95 39.2 Favored Pre-proline 0 CA--C 1.542 0.636 0 CA-C-O 118.768 -0.634 . . . . 0.0 109.556 -177.117 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_exo -51.09 142.78 33.93 Favored 'Trans proline' 0 C--N 1.384 2.42 0 C-N-CA 123.419 2.746 . . . . 0.0 114.516 -176.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 54.7 p -97.8 -10.69 24.36 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 123.558 0.743 . . . . 0.0 110.429 172.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.671 ' HB3' ' HB2' ' A' ' 139' ' ' SER . 35.9 t-105 -155.38 147.18 23.26 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.647 1.179 . . . . 0.0 107.869 176.007 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -154.79 119.97 4.98 Favored 'General case' 0 C--O 1.237 0.436 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 170.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -109.7 112.24 24.19 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 123.859 0.864 . . . . 0.0 108.684 176.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 18.2 t -77.43 -27.4 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 C-N-CA 122.512 0.325 . . . . 0.0 110.739 -176.368 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 52.5 tttp -67.31 -49.39 64.38 Favored 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.022 0.529 . . . . 0.0 111.996 -172.442 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -80.19 -23.0 41.29 Favored 'General case' 0 N--CA 1.485 1.284 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 169.028 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 18.8 t70 74.46 55.37 0.09 Allowed 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 125.367 1.467 . . . . 0.0 110.202 176.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . 0.513 HD22 ' CZ3' ' A' ' 144' ' ' TRP . 4.6 mp -133.8 174.89 9.97 Favored 'General case' 0 CA--C 1.541 0.604 0 CA-C-N 115.074 -0.966 . . . . 0.0 111.368 172.616 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.585 HD11 ' HA2' ' A' ' 116' ' ' GLY . 78.9 mt -139.9 150.94 21.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 125.318 1.447 . . . . 0.0 108.327 -176.549 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' SER . . . . . 0.671 ' HB2' ' HB3' ' A' ' 130' ' ' TRP . 19.6 m -134.44 141.64 46.86 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 123.585 0.754 . . . . 0.0 109.563 171.507 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.672 ' HB3' ' HB3' ' A' ' 107' ' ' PHE . 83.4 t80 -128.79 142.16 51.07 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 177.241 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 90.48 -5.86 82.43 Favored Glycine 0 CA--C 1.531 1.044 0 N-CA-C 112.28 -0.328 . . . . 0.0 112.28 -173.701 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . 0.477 ' HA3' ' O ' ' A' ' 233' ' ' ILE . . . 146.87 -139.37 7.92 Favored Glycine 0 C--N 1.342 0.904 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -178.5 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -90.15 165.25 31.47 Favored Glycine 0 C--N 1.344 1.006 0 N-CA-C 110.157 -1.177 . . . . 0.0 110.157 167.16 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' TRP . . . . . 0.543 ' HZ2' ' HA2' ' A' ' 209' ' ' GLY . 7.0 t90 -61.11 105.58 0.5 Allowed 'General case' 0 CA--C 1.548 0.893 0 CA-C-O 121.281 0.562 . . . . 0.0 110.601 174.772 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . 0.602 ' HG2' ' HA ' ' A' ' 233' ' ' ILE . 0.0 OUTLIER -137.88 156.28 48.07 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 115.352 -0.84 . . . . 0.0 109.386 176.022 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' LEU . . . . . 0.636 HD12 ' HB2' ' A' ' 103' ' ' LYS . 5.7 mt 169.24 -25.46 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.535 0 O-C-N 125.625 1.828 . . . . 0.0 109.015 -174.43 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 67.49 83.78 0.16 Allowed 'General case' 0 C--N 1.362 1.111 0 C-N-CA 125.185 1.394 . . . . 0.0 109.035 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -164.34 86.25 0.1 Allowed Glycine 0 C--N 1.337 0.599 0 CA-C-N 115.045 -0.979 . . . . 0.0 110.849 -170.292 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 28.1 tt0 -103.45 122.61 45.25 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 124.739 1.216 . . . . 0.0 109.327 177.317 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' TRP . . . . . . . . . . . . . 42.3 t90 -68.71 129.28 39.47 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 172.038 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 22.9 pttm -86.38 110.18 19.52 Favored 'General case' 0 CA--C 1.553 1.088 0 CA-C-O 121.408 0.623 . . . . 0.0 109.872 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -66.92 112.37 4.28 Favored 'General case' 0 N--CA 1.483 1.203 0 CA-C-O 121.609 0.718 . . . . 0.0 111.068 -178.036 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 153.81 -41.83 0.64 Allowed Glycine 0 N--CA 1.465 0.628 0 N-CA-C 110.191 -1.163 . . . . 0.0 110.191 -176.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 3.8 mp0 -88.55 -179.29 6.02 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 124.617 1.167 . . . . 0.0 109.907 175.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -73.23 142.34 47.28 Favored 'General case' 0 C--O 1.242 0.669 0 C-N-CA 122.976 0.51 . . . . 0.0 110.05 172.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . 0.463 HG13 ' HG1' ' A' ' 172' ' ' THR . 5.0 p -91.68 139.2 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 170.771 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 10.9 mm-40 -112.17 131.75 55.29 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 -176.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 53.7 t -126.21 124.08 65.05 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.642 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -177.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.461 ' HB2' ' HD2' ' A' ' 199' ' ' PRO . 51.1 mt -73.54 78.35 1.46 Allowed 'General case' 0 C--N 1.351 0.642 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 164.225 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -63.53 99.1 0.2 Allowed 'General case' 0 C--N 1.349 0.557 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -179.552 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 68.6 mt -72.16 95.95 1.73 Allowed 'General case' 0 C--O 1.24 0.563 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 179.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -62.47 139.09 96.63 Favored Pre-proline 0 CA--C 1.556 1.204 0 CA-C-N 115.249 -0.887 . . . . 0.0 109.775 178.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . 0.491 ' HB3' HG21 ' A' ' 49' ' ' THR . 63.1 Cg_exo -54.48 111.55 0.75 Allowed 'Trans proline' 0 C--N 1.38 2.219 0 C-N-CA 123.16 2.573 . . . . 0.0 113.862 -173.485 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 63.49 19.17 62.09 Favored Glycine 0 C--N 1.355 1.622 0 O-C-N 123.572 0.545 . . . . 0.0 113.784 179.067 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 56.7 mtpt -129.31 178.55 6.36 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 124.473 1.109 . . . . 0.0 110.348 -173.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -52.81 155.68 3.9 Favored Pre-proline 0 CA--C 1.559 1.291 0 CA-C-N 114.759 -1.109 . . . . 0.0 112.31 169.531 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -69.52 168.74 20.37 Favored 'Trans proline' 0 C--N 1.371 1.711 0 C-N-CA 122.235 1.957 . . . . 0.0 110.932 168.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 16.2 ttm180 -137.09 109.88 7.59 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 172.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . 0.647 ' HB2' ' H ' ' A' ' 19' ' ' GLN . . . -69.4 105.88 2.75 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 172.076 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 24.8 t -113.75 128.23 70.74 Favored 'Isoleucine or valine' 0 C--O 1.24 0.586 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 -178.185 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 14.6 mt-30 -83.73 103.84 13.35 Favored 'General case' 0 C--O 1.237 0.42 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 168.488 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 172' ' ' THR . . . . . 0.463 ' HG1' HG13 ' A' ' 156' ' ' VAL . 11.9 p -106.4 124.25 49.3 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 178.397 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . 0.599 ' H ' ' HA3' ' A' ' 24' ' ' GLY . 50.1 mttm -78.78 132.86 63.32 Favored Pre-proline 0 CA--C 1.548 0.884 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 171.244 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -59.37 171.92 2.2 Favored 'Trans proline' 0 C--N 1.377 2.061 0 C-N-CA 123.38 2.72 . . . . 0.0 114.242 -172.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -164.67 -177.12 37.03 Favored Glycine 0 C--N 1.335 0.512 0 CA-C-N 114.786 -1.097 . . . . 0.0 111.011 -179.644 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.652 ' HB2' HD12 ' A' ' 28' ' ' ILE . 69.6 mt -131.82 159.52 38.28 Favored 'General case' 0 N--CA 1.485 1.319 0 CA-C-N 117.414 0.607 . . . . 0.0 110.07 -174.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 177' ' ' PHE . . . . . 0.727 ' HD2' HG23 ' A' ' 31' ' ' ILE . 0.2 OUTLIER -141.18 125.3 17.32 Favored 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 123.101 0.56 . . . . 0.0 110.839 176.047 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 178' ' ' LYS . . . . . 0.499 ' HA ' ' HA ' ' A' ' 183' ' ' THR . 10.3 ptpp? -95.02 123.08 38.3 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 123.375 0.67 . . . . 0.0 111.028 -173.189 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 52.3 p -95.4 -173.44 2.91 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.771 0.828 . . . . 0.0 109.391 169.739 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 30.3 p-10 -68.9 -22.75 64.15 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 123.003 0.521 . . . . 0.0 110.764 171.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -77.87 -51.28 10.7 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 123.99 0.916 . . . . 0.0 110.322 176.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 164.46 -177.63 40.03 Favored Glycine 0 C--N 1.342 0.897 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.587 -179.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 183' ' ' THR . . . . . 0.499 ' HA ' ' HA ' ' A' ' 178' ' ' LYS . 13.2 t -80.23 136.71 36.52 Favored 'General case' 0 CA--C 1.544 0.749 0 CA-C-O 121.317 0.58 . . . . 0.0 110.735 -177.798 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . 0.421 ' HB ' ' CE1' ' A' ' 177' ' ' PHE . 14.9 mt -119.01 161.27 18.21 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.866 0 C-N-CA 124.9 1.28 . . . . 0.0 107.546 -177.087 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -100.74 138.78 14.05 Favored Glycine 0 C--N 1.349 1.281 0 N-CA-C 112.319 -0.312 . . . . 0.0 112.319 -176.257 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . 0.478 ' HB3' ' CE1' ' A' ' 177' ' ' PHE . . . -162.63 -169.95 2.25 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-O 122.029 0.919 . . . . 0.0 112.543 -169.616 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 187' ' ' VAL . . . . . . . . . . . . . 2.0 p -105.41 100.98 11.69 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.999 0 CA-C-N 113.76 -1.564 . . . . 0.0 107.317 156.513 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 65.8 p -98.38 111.44 23.78 Favored 'General case' 0 C--O 1.24 0.56 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 172.195 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 46.0 tp -146.22 138.41 25.15 Favored 'General case' 0 N--CA 1.485 1.306 0 CA-C-O 120.881 0.372 . . . . 0.0 111.811 -177.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 190' ' ' ASP . . . . . 0.472 ' HA ' ' HA ' ' A' ' 221' ' ' ALA . 32.7 t70 -81.92 103.23 11.42 Favored 'General case' 0 C--N 1.351 0.658 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 170.504 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 191' ' ' PHE . . . . . 0.536 ' HB3' ' HE1' ' A' ' 222' ' ' TYR . 68.2 t80 -177.23 166.71 2.36 Favored 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 124.71 1.204 . . . . 0.0 108.659 -173.655 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 33.7 p -64.94 117.04 35.05 Favored Pre-proline 0 CA--C 1.557 1.22 0 C-N-CA 123.639 0.776 . . . . 0.0 111.234 177.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . 0.571 ' HG2' ' HG3' ' B' ' 254' ' ' ARG . 30.0 Cg_endo -62.45 140.7 83.54 Favored 'Trans proline' 0 C--N 1.378 2.109 0 C-N-CA 123.078 2.519 . . . . 0.0 112.855 176.638 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -84.09 -176.24 51.09 Favored Glycine 0 C--N 1.344 0.977 0 N-CA-C 111.051 -0.819 . . . . 0.0 111.051 168.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 62.5 p -77.39 131.7 38.17 Favored 'General case' 0 CA--C 1.551 0.991 0 CA-C-N 117.149 0.474 . . . . 0.0 110.725 178.072 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -63.57 100.14 0.25 Allowed 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.561 0.744 . . . . 0.0 109.776 -176.833 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 140.05 -1.22 2.19 Favored Glycine 0 C--N 1.341 0.86 0 CA-C-N 114.519 -1.219 . . . . 0.0 112.148 -174.282 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 198' ' ' SER . . . . . 0.467 ' HB2' ' HD2' ' A' ' 211' ' ' TYR . 48.9 m -57.43 138.6 81.18 Favored Pre-proline 0 CA--C 1.558 1.277 0 C-N-CA 123.495 0.718 . . . . 0.0 111.512 173.889 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . 0.461 ' HD2' ' HB2' ' A' ' 159' ' ' LEU . 17.3 Cg_exo -67.05 132.81 29.04 Favored 'Trans proline' 0 C--N 1.38 2.203 0 C-N-CA 123.268 2.645 . . . . 0.0 113.492 -177.37 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 200' ' ' ILE . . . . . 0.441 HG21 HG21 ' A' ' 226' ' ' ILE . 16.6 mt -98.81 110.12 25.51 Favored 'Isoleucine or valine' 0 C--O 1.241 0.618 0 CA-C-O 121.982 0.896 . . . . 0.0 109.666 172.421 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 201' ' ' ILE . . . . . . . . . . . . . 47.0 mt -108.91 148.75 12.56 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.894 0 CA-C-N 114.644 -1.162 . . . . 0.0 108.082 177.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 202' ' ' ASP . . . . . 0.539 ' H ' ' HB ' ' A' ' 207' ' ' VAL . 18.1 t70 -89.51 160.21 16.85 Favored 'General case' 0 N--CA 1.48 1.075 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 172.215 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 83.1 tttt -63.37 -15.48 57.61 Favored 'General case' 0 CA--C 1.555 1.141 0 N-CA-C 113.479 0.918 . . . . 0.0 113.479 -170.487 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . 0.483 ' HZ2' ' HB3' ' A' ' 204' ' ' LYS . 7.9 mtpm? -76.42 -1.02 24.94 Favored 'General case' 0 N--CA 1.485 1.318 0 N-CA-C 112.502 0.556 . . . . 0.0 112.502 176.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 82.7 7.01 87.97 Favored Glycine 0 C--N 1.349 1.283 0 CA-C-O 120.913 0.174 . . . . 0.0 112.695 -178.734 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -117.2 164.09 15.31 Favored 'General case' 0 N--CA 1.475 0.793 0 C-N-CA 124.733 1.213 . . . . 0.0 108.714 174.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . 0.539 ' HB ' ' H ' ' A' ' 202' ' ' ASP . 57.4 t 90.77 160.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.254 0 C-N-CA 125.905 1.682 . . . . 0.0 108.562 -171.662 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 208' ' ' VAL . . . . . 0.589 HG23 ' HB3' ' A' ' 146' ' ' LEU . 1.8 m -174.34 13.8 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 C-N-CA 124.444 1.098 . . . . 0.0 109.666 -144.391 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.543 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . -64.87 -154.78 0.15 Allowed Glycine 0 C--N 1.354 1.549 0 C-N-CA 124.105 0.86 . . . . 0.0 115.013 -177.098 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . 0.431 HD13 HD21 ' A' ' 137' ' ' LEU . 6.0 tt -142.12 133.4 26.34 Favored 'General case' 0 C--O 1.242 0.691 0 O-C-N 122.048 -0.678 . . . . 0.0 110.588 -172.399 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 211' ' ' TYR . . . . . 0.467 ' HD2' ' HB2' ' A' ' 198' ' ' SER . 0.4 OUTLIER -102.49 108.56 19.91 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 124.844 1.258 . . . . 0.0 108.935 175.208 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 212' ' ' GLY . . . . . 0.519 ' O ' ' SD ' ' A' ' 110' ' ' MET . . . 171.22 70.05 0.04 OUTLIER Glycine 0 C--N 1.345 1.081 0 C-N-CA 120.65 -0.786 . . . . 0.0 114.719 156.061 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 213' ' ' ASN . . . . . 0.59 ' HB2' ' HB3' ' A' ' 225' ' ' ALA . 18.5 m120 -131.76 81.85 2.0 Allowed 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 172.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 160.57 -152.38 23.08 Favored Glycine 0 C--O 1.242 0.619 0 CA-C-N 113.965 -1.471 . . . . 0.0 111.341 -178.231 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 215' ' ' VAL . . . . . 0.791 HG12 ' HA ' ' A' ' 40' ' ' SER . 15.8 m -152.57 -173.94 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.213 0 C-N-CA 123.45 0.7 . . . . 0.0 111.235 -167.345 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 216' ' ' VAL . . . . . 0.525 ' HB ' ' HA2' ' A' ' 220' ' ' GLY . 17.0 m -85.15 113.0 22.9 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.771 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 164.706 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 217' ' ' THR . . . . . 0.638 HG22 ' HB3' ' A' ' 29' ' ' LEU . 23.5 m -102.81 158.99 15.88 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 123.944 0.898 . . . . 0.0 109.644 -174.806 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 2.5 tpm_? 69.89 -74.63 0.08 Allowed 'General case' 0 CA--C 1.552 1.023 0 C-N-CA 124.957 1.303 . . . . 0.0 110.095 -176.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 21.8 t -164.42 26.21 0.07 Allowed 'General case' 0 CA--C 1.551 1.007 0 C-N-CA 123.856 0.862 . . . . 0.0 110.148 175.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 220' ' ' GLY . . . . . 0.525 ' HA2' ' HB ' ' A' ' 216' ' ' VAL . . . 141.98 -6.88 2.35 Favored Glycine 0 N--CA 1.477 1.418 0 CA-C-O 119.884 -0.398 . . . . 0.0 113.72 -179.086 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . 0.472 ' HA ' ' HA ' ' A' ' 190' ' ' ASP . . . -70.76 97.83 1.44 Allowed 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.943 0.897 . . . . 0.0 110.044 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 222' ' ' TYR . . . . . 0.536 ' HE1' ' HB3' ' A' ' 191' ' ' PHE . 15.8 p90 -66.1 124.72 23.37 Favored 'General case' 0 CA--C 1.544 0.715 0 CA-C-O 121.534 0.683 . . . . 0.0 110.88 -171.08 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . 0.626 HG13 ' HB3' ' A' ' 177' ' ' PHE . 62.1 t -123.92 115.66 45.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 173.721 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 67.9 m -142.71 141.85 31.88 Favored 'General case' 0 N--CA 1.48 1.06 0 O-C-N 123.855 0.722 . . . . 0.0 110.312 176.062 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . 0.59 ' HB3' ' HB2' ' A' ' 213' ' ' ASN . . . -75.31 153.29 37.96 Favored 'General case' 0 C--O 1.244 0.782 0 C-N-CA 123.087 0.555 . . . . 0.0 112.238 -174.656 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 226' ' ' ILE . . . . . 0.441 HG21 HG21 ' A' ' 200' ' ' ILE . 88.9 mt -91.4 103.06 14.12 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.623 0 CA-C-N 114.758 -1.11 . . . . 0.0 109.748 -176.594 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -96.07 152.65 18.34 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 122.895 0.478 . . . . 0.0 109.952 178.36 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -148.19 168.55 22.17 Favored 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 124.515 1.126 . . . . 0.0 109.736 -172.118 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 59.0 p -66.88 110.61 3.38 Favored 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 123.006 0.522 . . . . 0.0 110.527 -176.232 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -116.97 -24.37 7.63 Favored 'General case' 0 N--CA 1.482 1.169 0 C-N-CA 123.418 0.687 . . . . 0.0 111.406 -172.34 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 23.3 mmtp -91.88 -141.02 0.19 Allowed 'General case' 0 CA--C 1.566 1.561 0 C-N-CA 122.974 0.51 . . . . 0.0 109.682 -172.409 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 70.0 p -158.13 178.39 10.25 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 124.221 1.009 . . . . 0.0 108.873 -167.555 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 233' ' ' ILE . . . . . 0.602 ' HA ' ' HG2' ' A' ' 145' ' ' LYS . 82.1 mt -53.79 -42.7 53.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 CA-C-N 118.391 0.541 . . . . 0.0 110.467 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 234' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 174.07 -72.52 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 125.363 1.465 . . . . 0.0 107.237 174.187 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -104.38 -38.89 6.65 Favored 'General case' 0 C--O 1.238 0.467 0 C-N-CA 124.852 1.261 . . . . 0.0 108.282 174.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 236' ' ' ASN . . . . . 0.411 ' HB2' ' HB ' ' A' ' 233' ' ' ILE . 17.0 m120 -67.73 152.79 96.01 Favored Pre-proline 0 CA--C 1.548 0.902 0 CA-C-N 114.882 -1.054 . . . . 0.0 109.776 172.625 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -60.38 -177.48 0.16 Allowed 'Trans proline' 0 C--N 1.381 2.263 0 C-N-CA 123.549 2.833 . . . . 0.0 113.5 177.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 238' ' ' GLU . . . . . 0.472 ' HG3' ' H ' ' A' ' 239' ' ' ILE . 4.9 pt-20 -51.31 -49.04 62.1 Favored 'General case' 0 CA--C 1.555 1.151 0 C-N-CA 123.498 0.719 . . . . 0.0 110.703 172.274 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 239' ' ' ILE . . . . . 0.472 ' H ' ' HG3' ' A' ' 238' ' ' GLU . 6.5 tp -153.07 -45.08 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 C-N-CA 124.521 1.128 . . . . 0.0 108.123 176.123 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 . . . . . 0 C--O 1.248 1.019 0 C-N-CA 124.088 0.955 . . . . 0.0 108.616 -179.507 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 251' ' ' BEZ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 253' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 68.51 -76.08 0.06 Allowed 'General case' 0 C--N 1.359 0.994 0 C-N-CA 124.818 1.247 . . . . 0.0 109.872 -169.377 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 254' ' ' ARG . . . . . 0.571 ' HG3' ' HG2' ' A' ' 193' ' ' PRO . 5.4 mmp_? 73.5 -30.27 0.21 Allowed 'General case' 0 N--CA 1.496 1.831 0 C-N-CA 125.749 1.619 . . . . 0.0 112.085 -172.678 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 255' ' ' M9P . . . . . 0.458 ' HB ' ' NE2' ' A' ' 112' ' ' HIS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.888 0 N-CA-C 112.794 -0.123 . . . . 0.0 112.794 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 39.0 t -144.0 152.57 41.22 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 123.707 0.803 . . . . 0.0 109.42 179.419 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.43 151.74 37.91 Favored 'General case' 0 N--CA 1.477 0.889 0 C-N-CA 123.538 0.735 . . . . 0.0 109.431 -179.343 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -131.99 2.09 3.97 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 124.05 0.94 . . . . 0.0 109.742 -175.14 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -127.34 80.65 1.97 Allowed 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 114.526 -1.216 . . . . 0.0 108.14 -168.708 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 5.0 mp -127.05 101.97 6.77 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 -178.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.7 mm-40 -78.65 146.59 33.97 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 123.244 0.618 . . . . 0.0 110.979 -172.403 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . 0.482 HD23 HD13 ' A' ' 119' ' ' LEU . 30.4 mt -90.58 114.39 26.62 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-N 115.042 -0.981 . . . . 0.0 109.14 171.849 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -103.52 120.28 40.54 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 124.503 1.121 . . . . 0.0 108.328 -176.455 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 26.3 ptt180 -59.76 132.69 54.74 Favored 'General case' 0 N--CA 1.475 0.817 0 C-N-CA 122.859 0.464 . . . . 0.0 110.893 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . 0.433 ' HB3' ' HG3' ' A' ' 85' ' ' ARG . . . -121.27 -43.18 2.43 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 122.379 0.272 . . . . 0.0 111.362 -177.046 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . 178.37 -158.45 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 124.184 0.994 . . . . 0.0 110.041 -173.703 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -128.01 164.67 21.86 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 123.777 0.831 . . . . 0.0 108.85 168.503 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 53.9 t -75.45 102.36 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 N-CA-C 109.414 -0.588 . . . . 0.0 109.414 177.444 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 4.5 ptpp? -167.89 146.23 4.56 Favored 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 124.633 1.173 . . . . 0.0 108.557 174.294 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 28.8 t90 -78.99 110.7 14.48 Favored 'General case' 0 CA--C 1.547 0.844 0 O-C-N 123.533 0.52 . . . . 0.0 111.402 -172.505 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -73.68 145.43 45.26 Favored 'General case' 0 CA--C 1.544 0.737 0 CA-C-O 121.66 0.743 . . . . 0.0 111.506 172.427 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -68.01 -1.62 6.14 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 125.47 1.508 . . . . 0.0 112.967 -177.072 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 22.8 mm-40 -80.2 50.4 1.24 Allowed 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 123.766 0.826 . . . . 0.0 111.112 -178.306 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.43 ' HA ' ' O ' ' A' ' 169' ' ' ALA . . . -73.32 84.02 1.42 Allowed 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 124.615 1.166 . . . . 0.0 111.464 -174.67 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 38.8 mt-10 -103.57 123.12 46.35 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 124.031 0.932 . . . . 0.0 110.425 -175.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 9.6 tp -76.91 132.68 32.41 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.134 0 C-N-CA 122.47 0.308 . . . . 0.0 110.763 -177.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 95.7 p -148.68 -35.71 0.19 Allowed 'General case' 0 N--CA 1.484 1.275 0 N-CA-C 112.14 0.422 . . . . 0.0 112.14 175.567 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -53.39 98.1 0.03 OUTLIER Glycine 0 C--N 1.353 1.476 0 N-CA-C 113.917 0.327 . . . . 0.0 113.917 178.45 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 40.7 p -103.9 -68.72 0.83 Allowed 'General case' 0 CA--C 1.547 0.865 0 C-N-CA 124.014 0.926 . . . . 0.0 111.468 -172.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 20.0 m -72.98 126.08 90.7 Favored Pre-proline 0 N--CA 1.477 0.88 0 C-N-CA 123.598 0.759 . . . . 0.0 111.381 -171.12 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -70.85 -74.27 0.01 OUTLIER 'Trans proline' 0 C--N 1.366 1.467 0 C-N-CA 122.13 1.887 . . . . 0.0 111.59 167.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 51.0 mm -90.55 121.12 40.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.913 0 C-N-CA 123.26 0.624 . . . . 0.0 111.448 -167.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.404 ' O ' ' HA ' ' A' ' 177' ' ' PHE . 17.2 mt -143.37 133.48 24.34 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 123.737 0.815 . . . . 0.0 110.333 174.068 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 35.0 p -97.07 140.02 32.21 Favored 'General case' 0 N--CA 1.477 0.892 0 C-N-CA 123.851 0.86 . . . . 0.0 110.538 179.189 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 39.5 mt -131.53 160.58 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 124.265 1.026 . . . . 0.0 108.594 -178.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 66.7 p -96.03 114.33 26.03 Favored 'General case' 0 C--N 1.367 1.327 0 CA-C-N 118.889 0.768 . . . . 0.0 109.001 176.102 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 8.8 mm -55.93 125.89 12.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 C-N-CA 123.987 0.915 . . . . 0.0 109.934 175.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 5.8 m -117.42 135.53 53.82 Favored 'General case' 0 C--O 1.252 1.224 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 30.4 tt0 60.3 28.82 18.46 Favored 'General case' 0 CA--C 1.558 1.263 0 C-N-CA 124.725 1.21 . . . . 0.0 110.791 178.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 3.8 p30 46.5 30.05 1.02 Allowed 'General case' 0 N--CA 1.493 1.708 0 C-N-CA 125.631 1.572 . . . . 0.0 113.109 -174.584 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -145.13 -63.7 0.02 OUTLIER Glycine 0 C--N 1.353 1.515 0 CA-C-N 116.562 -0.29 . . . . 0.0 112.487 -177.67 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 38.8 t -105.85 125.97 51.62 Favored 'General case' 0 N--CA 1.486 1.361 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 -172.242 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' MET . . . . . 0.44 ' HE3' ' HB2' ' A' ' 39' ' ' MET . 1.8 mpp? -88.8 136.95 32.74 Favored 'General case' 0 CA--C 1.546 0.823 0 O-C-N 121.875 -0.515 . . . . 0.0 111.472 -173.745 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.5 m -125.15 164.12 20.95 Favored 'General case' 0 N--CA 1.482 1.125 0 C-N-CA 124.622 1.169 . . . . 0.0 109.915 176.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.454 ' H ' HG23 ' A' ' 215' ' ' VAL . 7.5 tp -93.07 92.51 3.74 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.845 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 -177.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 42.5 mmtm 57.88 -74.78 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.336 0 C-N-CA 123.382 0.673 . . . . 0.0 109.831 -161.238 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 5.2 p30 -147.32 118.16 7.62 Favored 'General case' 0 CA--C 1.552 1.045 0 C-N-CA 124.608 1.163 . . . . 0.0 110.034 175.181 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -174.13 130.78 0.39 Allowed 'General case' 0 N--CA 1.492 1.629 0 C-N-CA 123.685 0.794 . . . . 0.0 109.176 171.275 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.412 ' HA ' ' NZ ' ' B' ' 253' ' ' LYS . 0.5 OUTLIER -166.52 27.51 0.04 OUTLIER 'General case' 0 CA--C 1.554 1.108 0 C-N-CA 123.42 0.688 . . . . 0.0 110.104 -178.275 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -105.65 125.21 50.72 Favored 'General case' 0 N--CA 1.483 1.18 0 C-N-CA 122.989 0.515 . . . . 0.0 111.246 -176.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -173.59 139.72 0.75 Allowed 'General case' 0 N--CA 1.478 0.952 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 171.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 27.7 tt0 -158.06 79.91 0.84 Allowed 'General case' 0 C--O 1.24 0.555 0 CA-C-O 121.14 0.495 . . . . 0.0 109.673 178.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 93.4 m -81.69 135.09 35.52 Favored 'General case' 0 CA--C 1.537 0.473 0 N-CA-C 108.577 -0.898 . . . . 0.0 108.577 165.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 8.1 mp -72.77 90.92 1.44 Allowed 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 123.159 0.583 . . . . 0.0 109.652 -178.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -63.17 150.78 48.81 Favored Glycine 0 C--N 1.35 1.327 0 CA-C-N 114.854 -1.066 . . . . 0.0 112.488 177.075 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 99.11 -31.08 8.66 Favored Glycine 0 C--N 1.34 0.796 0 N-CA-C 111.501 -0.64 . . . . 0.0 111.501 -172.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 128.72 -50.42 0.89 Allowed Glycine 0 C--N 1.349 1.256 0 N-CA-C 110.67 -0.972 . . . . 0.0 110.67 -176.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 145.82 -34.27 1.47 Allowed Glycine 0 C--N 1.349 1.305 0 O-C-N 123.666 0.274 . . . . 0.0 112.459 177.355 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 75.0 p -77.37 -22.74 51.27 Favored 'General case' 0 CA--C 1.555 1.136 0 C-N-CA 123.584 0.754 . . . . 0.0 111.787 -178.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 93.0 -50.79 2.51 Favored Glycine 0 C--N 1.35 1.316 0 C-N-CA 122.864 0.269 . . . . 0.0 112.894 177.506 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.414 ' HA3' ' HB2' ' A' ' 60' ' ' GLU . . . 137.35 146.53 5.12 Favored Glycine 0 C--N 1.347 1.174 0 N-CA-C 111.52 -0.632 . . . . 0.0 111.52 -178.891 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -74.84 -84.74 0.32 Allowed Glycine 0 C--N 1.35 1.315 0 CA-C-N 117.13 0.465 . . . . 0.0 112.011 -178.681 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -71.09 -15.37 74.35 Favored Glycine 0 C--N 1.347 1.165 0 O-C-N 123.567 0.216 . . . . 0.0 112.682 174.558 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . 0.414 ' HB2' ' HA3' ' A' ' 57' ' ' GLY . 36.6 mt-10 -71.14 -10.3 59.52 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 124.283 1.033 . . . . 0.0 112.349 179.212 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 81.8 t80 -65.98 117.14 7.91 Favored 'General case' 0 N--CA 1.478 0.937 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 173.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . 70.12 -65.43 0.32 Allowed 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 124.971 1.308 . . . . 0.0 110.476 -174.42 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -76.28 75.9 1.53 Allowed Glycine 0 C--N 1.344 1.013 0 N-CA-C 112.042 -0.423 . . . . 0.0 112.042 175.304 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.404 ' C ' ' HD3' ' A' ' 122' ' ' LYS . 5.0 t -85.18 60.7 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.116 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 178.777 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -45.36 132.32 7.82 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 124.686 1.194 . . . . 0.0 112.573 -169.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . 0.568 ' HE1' ' HB2' ' A' ' 122' ' ' LYS . 62.8 m95 -111.65 179.82 3.91 Favored 'General case' 0 C--O 1.243 0.713 0 C-N-CA 123.611 0.764 . . . . 0.0 111.242 -177.223 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -77.41 85.76 3.81 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 114.984 -1.007 . . . . 0.0 108.773 173.23 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 46.3 t -122.69 96.81 45.06 Favored Pre-proline 0 CA--C 1.551 0.995 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 175.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 11.9 Cg_exo -74.05 -27.6 11.8 Favored 'Trans proline' 0 C--N 1.379 2.17 0 C-N-CA 123.483 2.789 . . . . 0.0 111.853 172.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 52.1 p -69.07 162.21 66.95 Favored Pre-proline 0 CA--C 1.551 0.991 0 C-N-CA 123.733 0.813 . . . . 0.0 110.292 175.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 81.3 Cg_exo -47.2 149.07 4.05 Favored 'Trans proline' 0 C--N 1.377 2.027 0 C-N-CA 122.785 2.323 . . . . 0.0 113.492 171.463 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 80.3 Cg_exo -51.02 160.13 2.14 Favored 'Trans proline' 0 C--N 1.384 2.424 0 C-N-CA 123.563 2.842 . . . . 0.0 113.395 176.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_exo -45.7 84.05 0.01 OUTLIER 'Trans proline' 0 C--N 1.389 2.706 0 C-N-CA 124.332 3.354 . . . . 0.0 114.697 -179.121 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 26.8 m -137.64 -36.32 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 C-N-CA 124.441 1.096 . . . . 0.0 109.951 178.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -102.57 -37.97 3.12 Favored Glycine 0 C--N 1.348 1.241 0 CA-C-N 116.034 -0.53 . . . . 0.0 112.524 -178.815 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 55.7 tptt -157.34 -42.49 0.07 Allowed 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 122.891 0.476 . . . . 0.0 111.824 -179.171 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . 74.25 110.83 0.07 Allowed 'General case' 0 N--CA 1.491 1.606 0 C-N-CA 124.827 1.251 . . . . 0.0 109.625 -166.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -83.96 150.97 25.31 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 123.044 0.537 . . . . 0.0 111.024 -176.245 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 2.6 pp -100.29 -177.99 3.68 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 123.88 0.872 . . . . 0.0 110.074 174.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.453 ' HB2' ' HH ' ' A' ' 84' ' ' TYR . 3.1 mp0 -112.77 -170.97 1.77 Allowed 'General case' 0 N--CA 1.483 1.208 0 C-N-CA 123.34 0.656 . . . . 0.0 109.586 -176.868 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . 0.666 ' HB2' ' HD2' ' A' ' 103' ' ' LYS . 8.2 p-10 -135.84 129.28 32.16 Favored 'General case' 0 CA--C 1.54 0.57 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 163.771 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 168.32 178.92 40.4 Favored Glycine 0 C--N 1.339 0.699 0 CA-C-N 115.973 -0.558 . . . . 0.0 112.42 177.268 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . 0.53 ' HB1' HD11 ' A' ' 161' ' ' LEU . . . -88.32 125.07 34.5 Favored 'General case' 0 CA--C 1.549 0.911 0 C-N-CA 123.947 0.899 . . . . 0.0 109.79 176.717 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . 0.453 ' HH ' ' HB2' ' A' ' 80' ' ' GLU . 16.1 m-85 -122.12 148.46 44.87 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 123.596 0.758 . . . . 0.0 109.963 -177.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . 0.762 ' HG2' HG23 ' A' ' 195' ' ' THR . 37.3 mtm-85 -95.99 124.43 39.99 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 166.05 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.465 ' H ' ' HA ' ' A' ' 99' ' ' ALA . 27.8 mt -90.65 131.05 38.83 Favored 'Isoleucine or valine' 0 C--O 1.26 1.656 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.426 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 0.2 OUTLIER -124.67 140.83 52.58 Favored 'General case' 0 N--CA 1.45 -0.459 0 CA-C-N 114.504 -1.226 . . . . 0.0 108.684 -174.224 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -84.76 104.09 14.42 Favored 'General case' 0 C--N 1.344 0.331 0 N-CA-C 104.581 -2.377 . . . . 0.0 104.581 175.549 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 14.4 tmtt? -120.64 98.27 5.95 Favored 'General case' 0 CA--C 1.518 -0.288 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 -170.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -79.91 152.47 35.01 Favored Glycine 0 C--O 1.242 0.644 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 170.359 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 2.3 mp -78.46 70.26 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.13 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 174.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 58.7 tp 167.29 -41.4 0.0 OUTLIER 'General case' 0 CA--C 1.554 1.123 0 C-N-CA 126.388 1.875 . . . . 0.0 109.029 -167.04 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -148.22 161.02 28.53 Favored Glycine 0 C--N 1.365 2.174 0 N-CA-C 114.8 0.68 . . . . 0.0 114.8 -169.56 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 77.4 m-85 -132.12 129.33 39.73 Favored 'General case' 0 N--CA 1.481 1.095 0 C-N-CA 124.049 0.94 . . . . 0.0 110.427 -172.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 24.5 m -145.42 153.75 41.53 Favored 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 124.652 1.181 . . . . 0.0 108.254 175.173 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.426 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 1.5 pp0? -96.15 146.72 24.43 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-N 118.738 0.699 . . . . 0.0 109.242 168.509 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.43 HD13 HG21 ' A' ' 86' ' ' ILE . 1.6 pp -136.71 -10.03 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 177.443 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . 0.535 ' HA3' HG11 ' A' ' 113' ' ' VAL . . . 168.26 -147.06 11.01 Favored Glycine 0 C--N 1.348 1.241 0 C-N-CA 121.003 -0.618 . . . . 0.0 113.19 174.049 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.465 ' HA ' ' H ' ' A' ' 86' ' ' ILE . . . -154.33 153.76 32.2 Favored 'General case' 0 C--O 1.24 0.603 0 C-N-CA 123.663 0.785 . . . . 0.0 111.196 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -155.75 157.18 27.58 Favored Glycine 0 C--N 1.338 0.665 0 CA-C-N 114.937 -1.029 . . . . 0.0 111.209 178.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 53.1 t -120.82 120.69 63.16 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.778 0 C-N-CA 123.528 0.731 . . . . 0.0 111.517 -169.376 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.524 ' HB3' ' HA ' ' A' ' 81' ' ' ASP . 10.6 m-85 -74.36 135.81 42.47 Favored 'General case' 0 N--CA 1.482 1.163 0 N-CA-C 107.861 -1.163 . . . . 0.0 107.861 165.037 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.666 ' HD2' ' HB2' ' A' ' 81' ' ' ASP . 29.3 tptt -172.4 149.71 2.23 Favored 'General case' 0 N--CA 1.483 1.177 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 171.322 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 60.21 20.14 9.52 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 124.494 1.118 . . . . 0.0 112.048 -178.771 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 80.09 17.06 75.32 Favored Glycine 0 C--N 1.346 1.115 0 CA-C-N 116.036 -0.529 . . . . 0.0 114.377 -178.011 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 18.8 p -140.07 137.18 34.36 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.604 0.762 . . . . 0.0 109.716 -176.316 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' PHE . . . . . 0.595 ' HB3' ' HB2' ' A' ' 140' ' ' TYR . 42.2 t80 -89.87 103.43 16.09 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 120.937 0.399 . . . . 0.0 111.131 -175.084 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . 0.601 ' HB3' ' HE3' ' A' ' 144' ' ' TRP . 18.6 m170 -100.4 114.25 27.65 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 124.488 1.115 . . . . 0.0 110.563 -176.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' THR . . . . . 0.536 HG21 HG21 ' A' ' 138' ' ' ILE . 3.9 t -135.71 175.44 9.59 Favored 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 118.758 0.708 . . . . 0.0 112.158 -177.86 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' MET . . . . . 0.683 ' HE1' ' HA2' ' A' ' 212' ' ' GLY . 79.2 mmm -87.95 154.47 20.48 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 123.886 0.874 . . . . 0.0 109.014 172.807 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' TRP . . . . . 0.411 ' CE2' HG21 ' A' ' 133' ' ' VAL . 50.2 t90 -71.52 -45.74 61.58 Favored 'General case' 0 N--CA 1.486 1.338 0 CA-C-N 118.159 0.436 . . . . 0.0 111.504 -170.611 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . 0.481 ' HD1' ' HB3' ' A' ' 213' ' ' ASN . 4.3 p-80 -51.52 -21.09 2.21 Favored 'General case' 0 N--CA 1.488 1.465 0 C-N-CA 124.769 1.228 . . . . 0.0 114.247 -173.146 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.535 HG11 ' HA3' ' A' ' 98' ' ' GLY . 16.6 m -59.85 -44.14 93.53 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 CA-C-O 121.43 0.633 . . . . 0.0 110.265 -178.603 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 9.0 t -113.76 168.51 9.72 Favored 'General case' 0 C--O 1.238 0.488 0 C-N-CA 123.905 0.882 . . . . 0.0 109.212 -179.45 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 92.9 mtt180 -95.95 33.43 1.7 Allowed 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 124.194 0.997 . . . . 0.0 109.132 178.146 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 68.81 38.85 85.82 Favored Glycine 0 C--N 1.362 1.983 0 CA-C-N 115.158 -0.928 . . . . 0.0 111.528 -174.193 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -127.83 -179.96 5.23 Favored 'General case' 0 C--O 1.244 0.763 0 C-N-CA 123.647 0.779 . . . . 0.0 110.955 -171.106 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.2 p -75.4 139.65 18.71 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.211 0 CA-C-N 114.716 -1.129 . . . . 0.0 111.963 -176.329 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.482 HD13 HD23 ' A' ' 8' ' ' LEU . 58.3 mt -97.9 -177.78 3.87 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 124.084 0.953 . . . . 0.0 110.77 177.812 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 23.2 mmt -133.49 147.9 51.67 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 125.308 1.443 . . . . 0.0 109.762 -176.557 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.739 ' HB2' HD13 ' A' ' 126' ' ' ILE . 34.9 t-80 -151.03 96.63 2.35 Favored 'General case' 0 CA--C 1.54 0.595 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.568 ' HB2' ' HE1' ' A' ' 66' ' ' TRP . 25.5 ttpp 57.69 29.77 17.83 Favored 'General case' 0 N--CA 1.496 1.826 0 C-N-CA 124.186 0.995 . . . . 0.0 111.117 -175.693 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 94.95 -3.53 67.3 Favored Glycine 0 C--N 1.345 1.043 0 CA-C-N 115.768 -0.651 . . . . 0.0 113.47 -179.628 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -94.92 122.45 37.57 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 122.92 0.488 . . . . 0.0 109.92 177.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 91.0 mtm-85 -69.39 146.01 52.41 Favored 'General case' 0 C--O 1.243 0.734 0 C-N-CA 123.774 0.83 . . . . 0.0 111.976 178.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.739 HD13 ' HB2' ' A' ' 121' ' ' HIS . 5.0 mt -127.19 112.41 28.51 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.801 0 C-N-CA 123.791 0.836 . . . . 0.0 109.225 -179.0 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -83.01 139.36 42.68 Favored Pre-proline 0 CA--C 1.554 1.104 0 C-N-CA 123.838 0.855 . . . . 0.0 110.025 179.007 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -75.61 148.7 33.34 Favored 'Trans proline' 0 C--N 1.379 2.181 0 C-N-CA 122.808 2.339 . . . . 0.0 112.482 179.462 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 32.5 p -109.23 -32.35 7.23 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 124.031 0.932 . . . . 0.0 110.707 177.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 4.5 t-105 -132.87 144.03 49.91 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 107.624 -1.251 . . . . 0.0 107.624 -176.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -160.53 123.53 3.37 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.205 0.602 . . . . 0.0 110.222 178.488 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 41.4 m-20 -123.32 105.23 9.67 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 124.345 1.058 . . . . 0.0 108.552 167.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.411 HG21 ' CE2' ' A' ' 111' ' ' TRP . 16.7 t -68.24 -33.39 60.36 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.884 0 C-N-CA 123.53 0.732 . . . . 0.0 109.313 175.164 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -72.01 -33.13 67.82 Favored 'General case' 0 CA--C 1.547 0.863 0 CA-C-N 114.347 -1.297 . . . . 0.0 111.926 -179.177 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -97.07 -7.47 32.7 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 122.946 0.498 . . . . 0.0 111.792 179.586 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 27.5 t70 60.85 47.52 7.69 Favored 'General case' 0 CA--C 1.548 0.873 0 CA-C-O 122.449 1.118 . . . . 0.0 110.604 -178.027 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 49.7 mt -135.1 147.9 49.66 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 123.833 0.853 . . . . 0.0 109.557 176.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.536 HG21 HG21 ' A' ' 109' ' ' THR . 18.4 tt -153.54 143.66 14.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 N-CA-C 107.313 -1.365 . . . . 0.0 107.313 173.441 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' SER . . . . . 0.478 ' HB3' ' HA2' ' A' ' 143' ' ' GLY . 44.1 t -150.68 152.89 34.63 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-O 121.876 0.846 . . . . 0.0 110.97 -175.378 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.595 ' HB2' ' HB3' ' A' ' 107' ' ' PHE . 8.7 m-85 -125.26 108.71 12.0 Favored 'General case' 0 CA--C 1.543 0.708 0 CA-C-N 113.524 -1.671 . . . . 0.0 107.499 -164.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 97.48 -4.33 61.9 Favored Glycine 0 C--N 1.348 1.243 0 CA-C-N 116.149 -0.478 . . . . 0.0 112.821 -173.339 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 171.14 -152.64 18.77 Favored Glycine 0 C--N 1.347 1.163 0 CA-C-O 118.744 -1.031 . . . . 0.0 111.295 -179.625 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.478 ' HA2' ' HB3' ' A' ' 139' ' ' SER . . . -119.6 170.2 13.99 Favored Glycine 0 C--N 1.357 1.743 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 173.338 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' TRP . . . . . 0.601 ' HE3' ' HB3' ' A' ' 108' ' ' HIS . 41.6 t-105 -60.23 108.88 0.86 Allowed 'General case' 0 N--CA 1.483 1.188 0 CA-C-O 121.671 0.748 . . . . 0.0 110.728 176.291 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . 0.632 ' HA ' HG21 ' A' ' 229' ' ' THR . 0.0 OUTLIER -145.54 135.1 23.26 Favored 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 114.903 -1.044 . . . . 0.0 108.824 171.007 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' LEU . . . . . 0.603 HD22 ' HB3' ' A' ' 103' ' ' LYS . 13.6 mt -144.69 10.29 1.38 Allowed 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 123.67 0.788 . . . . 0.0 110.586 168.607 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 14.3 tt0 75.37 -18.5 0.44 Allowed 'General case' 0 N--CA 1.498 1.942 0 C-N-CA 124.67 1.188 . . . . 0.0 111.431 177.071 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . 0.411 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -77.65 138.47 21.66 Favored Glycine 0 C--N 1.346 1.119 0 C-N-CA 123.4 0.524 . . . . 0.0 113.135 -169.478 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -130.1 142.03 50.64 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 124.306 1.042 . . . . 0.0 108.399 -178.565 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' TRP . . . . . . . . . . . . . 43.2 t90 -73.19 137.34 44.99 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 122.719 0.407 . . . . 0.0 110.759 172.357 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 54.3 tttm -92.85 133.57 35.94 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 123.776 0.83 . . . . 0.0 109.225 174.368 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -66.85 146.42 54.44 Favored 'General case' 0 N--CA 1.479 1.012 0 CA-C-O 121.118 0.485 . . . . 0.0 111.826 178.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 92.56 -12.89 68.72 Favored Glycine 0 C--N 1.348 1.237 0 CA-C-N 115.027 -0.988 . . . . 0.0 112.921 -177.571 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 29.7 mm-40 -94.07 131.83 39.18 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 123.045 0.538 . . . . 0.0 111.696 -173.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -76.06 123.78 26.34 Favored 'General case' 0 C--O 1.245 0.863 0 N-CA-C 107.008 -1.478 . . . . 0.0 107.008 162.489 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -91.13 158.76 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 -168.544 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . 0.408 ' OE1' ' HG2' ' A' ' 171' ' ' GLN . 13.9 mm100 -100.58 133.61 44.77 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 123.32 0.648 . . . . 0.0 109.297 179.561 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 46.2 t -107.84 102.35 13.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 107.164 -1.421 . . . . 0.0 107.164 177.516 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.539 HD22 ' HB3' ' A' ' 169' ' ' ALA . 1.8 tm? -74.93 78.42 2.16 Favored 'General case' 0 CA--C 1.546 0.796 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 -175.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -72.05 110.18 6.36 Favored 'General case' 0 C--O 1.242 0.699 0 CA-C-N 114.129 -1.396 . . . . 0.0 111.004 -168.359 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . 0.53 HD11 ' HB1' ' A' ' 83' ' ' ALA . 29.9 mt -81.55 83.89 6.89 Favored 'General case' 0 C--O 1.24 0.599 0 CA-C-N 115.099 -0.955 . . . . 0.0 109.182 177.371 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 29.7 mm-40 -68.74 126.92 93.2 Favored Pre-proline 0 CA--C 1.552 1.031 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 174.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -61.77 115.76 3.01 Favored 'Trans proline' 0 C--N 1.384 2.4 0 C-N-CA 123.231 2.621 . . . . 0.0 112.503 -174.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 81.61 10.99 83.62 Favored Glycine 0 C--N 1.351 1.388 0 CA-C-N 115.485 -0.78 . . . . 0.0 113.467 -179.36 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 49.5 mttp -128.54 172.45 11.16 Favored 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 123.395 0.678 . . . . 0.0 110.9 -178.41 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -74.03 156.59 87.74 Favored Pre-proline 0 CA--C 1.555 1.159 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.989 173.826 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 15.8 Cg_exo -68.79 137.38 38.25 Favored 'Trans proline' 0 C--N 1.375 1.937 0 C-N-CA 122.581 2.187 . . . . 0.0 112.568 178.179 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 69.5 mtp180 -117.06 105.75 12.63 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 176.396 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . 0.539 ' HB3' HD22 ' A' ' 159' ' ' LEU . . . -86.04 103.3 14.6 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-O 121.034 0.445 . . . . 0.0 110.559 -176.797 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 42.8 t -94.63 129.71 44.46 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.718 0 C-N-CA 124.288 1.035 . . . . 0.0 111.269 -164.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . 0.408 ' HG2' ' OE1' ' A' ' 157' ' ' GLN . 20.6 mt-30 -79.3 121.37 25.01 Favored 'General case' 0 C--N 1.354 0.767 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 178.627 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 41.9 p -140.34 124.76 17.84 Favored 'General case' 0 C--O 1.237 0.436 0 C-N-CA 122.92 0.488 . . . . 0.0 109.753 -173.064 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 62.2 tttp -70.17 127.58 92.16 Favored Pre-proline 0 CA--C 1.547 0.862 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 171.487 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_exo -57.91 126.4 21.57 Favored 'Trans proline' 0 C--N 1.379 2.175 0 C-N-CA 122.686 2.257 . . . . 0.0 112.767 -179.574 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -98.34 178.44 31.6 Favored Glycine 0 C--N 1.337 0.638 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.391 176.488 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 5.3 mp -141.3 146.3 36.58 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 123.501 0.72 . . . . 0.0 109.267 176.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 177' ' ' PHE . . . . . 0.674 ' HE1' HG12 ' A' ' 223' ' ' VAL . 22.3 m-85 -93.47 121.63 35.07 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 176.551 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 57.1 tptt -86.29 95.87 9.77 Favored 'General case' 0 CA--C 1.541 0.596 0 O-C-N 123.783 0.677 . . . . 0.0 109.201 177.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 179' ' ' THR . . . . . 0.467 HG21 ' H ' ' A' ' 181' ' ' ALA . 23.0 m -110.47 150.6 28.63 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 176.383 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 24.7 p30 -61.75 -24.35 66.76 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 123.578 0.751 . . . . 0.0 111.914 175.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . 0.467 ' H ' HG21 ' A' ' 179' ' ' THR . . . -74.18 -39.91 62.87 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.274 1.03 . . . . 0.0 111.388 174.579 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 169.25 -174.16 43.67 Favored Glycine 0 C--N 1.341 0.841 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.569 -177.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 13.2 t -97.78 134.55 40.78 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 175.2 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . 0.557 ' HB ' ' HB2' ' A' ' 177' ' ' PHE . 23.6 mt -104.65 160.02 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 177.905 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -99.09 124.23 8.16 Favored Glycine 0 C--N 1.349 1.279 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 179.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . 0.43 ' HA ' ' HA ' ' A' ' 225' ' ' ALA . . . -147.98 -165.56 2.3 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-O 121.22 0.533 . . . . 0.0 112.395 -161.753 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 187' ' ' VAL . . . . . . . . . . . . . 4.7 p -158.39 131.12 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.728 0 C-N-CA 124.615 1.166 . . . . 0.0 108.9 175.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 7.1 m -111.42 103.5 11.87 Favored 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 123.118 0.567 . . . . 0.0 110.168 176.557 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 4.3 pp -125.67 141.63 51.92 Favored 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 123.37 0.668 . . . . 0.0 109.224 179.586 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -113.53 104.49 12.31 Favored 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 168.102 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 191' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -163.07 -178.3 5.96 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 124.143 0.977 . . . . 0.0 108.725 -170.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 31.4 m -52.11 122.34 23.21 Favored Pre-proline 0 CA--C 1.549 0.939 0 CA-C-O 118.542 -0.742 . . . . 0.0 109.86 170.406 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . 0.477 ' HB2' ' HG3' ' B' ' 254' ' ' ARG . 29.4 Cg_endo -61.57 91.31 0.11 Allowed 'Trans proline' 0 C--N 1.378 2.129 0 C-N-CA 122.695 2.263 . . . . 0.0 112.155 -173.905 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -60.02 123.28 32.62 Favored Glycine 0 C--N 1.348 1.219 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 172.43 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 195' ' ' THR . . . . . 0.762 HG23 ' HG2' ' A' ' 85' ' ' ARG . 8.8 t -54.22 144.37 20.24 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-O 121.663 0.744 . . . . 0.0 112.035 -173.207 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 196' ' ' SER . . . . . 0.47 ' HA ' ' HD2' ' A' ' 211' ' ' TYR . 13.4 m -72.28 95.56 1.72 Allowed 'General case' 0 C--O 1.242 0.688 0 CA-C-N 115.077 -0.965 . . . . 0.0 111.406 -169.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . 0.415 ' H ' ' HB3' ' A' ' 211' ' ' TYR . . . 133.63 4.94 2.99 Favored Glycine 0 C--N 1.34 0.753 0 CA-C-N 115.279 -0.873 . . . . 0.0 111.663 -176.684 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 72.0 m -56.32 131.81 75.86 Favored Pre-proline 0 C--N 1.361 1.101 0 C-N-CA 123.143 0.577 . . . . 0.0 110.229 171.089 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -64.23 111.67 1.67 Allowed 'Trans proline' 0 C--N 1.372 1.777 0 C-N-CA 122.209 1.939 . . . . 0.0 111.635 -176.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 200' ' ' ILE . . . . . 0.423 HD13 ' HA ' ' A' ' 211' ' ' TYR . 55.3 mt -77.93 111.69 15.04 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.414 0 N-CA-C 107.964 -1.125 . . . . 0.0 107.964 174.32 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 201' ' ' ILE . . . . . 0.429 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 63.5 mt -112.28 148.51 15.33 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.61 0 C-N-CA 124.741 1.216 . . . . 0.0 108.739 -174.545 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -71.55 160.49 32.61 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 123.802 0.841 . . . . 0.0 108.871 171.823 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 203' ' ' LYS . . . . . 0.587 ' HZ3' ' HB2' ' A' ' 203' ' ' LYS . 3.7 ttmp? -70.17 -13.18 62.07 Favored 'General case' 0 N--CA 1.483 1.195 0 C-N-CA 123.343 0.657 . . . . 0.0 111.358 -178.841 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 27.1 mtpp -89.23 15.11 9.46 Favored 'General case' 0 CA--C 1.552 1.052 0 C-N-CA 123.9 0.88 . . . . 0.0 111.788 175.499 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 70.53 22.9 77.94 Favored Glycine 0 C--N 1.356 1.642 0 O-C-N 123.102 0.251 . . . . 0.0 113.316 176.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 22.1 ttpt -112.62 112.84 24.65 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 124.715 1.206 . . . . 0.0 108.261 -176.585 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . 0.429 ' HA ' ' HA ' ' A' ' 201' ' ' ILE . 7.4 p -56.61 141.64 13.19 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 CA-C-N 118.953 0.797 . . . . 0.0 110.714 179.057 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 6.0 m -119.02 -33.9 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 C-N-CA 122.606 0.363 . . . . 0.0 110.363 178.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . . . . . . . . . . . -175.82 -167.13 34.33 Favored Glycine 0 C--N 1.349 1.304 0 O-C-N 123.197 0.311 . . . . 0.0 113.819 -174.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . 0.491 ' HB2' ' SD ' ' A' ' 110' ' ' MET . 87.3 mt -117.29 156.2 28.2 Favored 'General case' 0 C--O 1.255 1.356 0 C-N-CA 124.196 0.998 . . . . 0.0 109.916 175.107 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 211' ' ' TYR . . . . . 0.47 ' HD2' ' HA ' ' A' ' 196' ' ' SER . 37.8 t80 -73.33 116.09 13.47 Favored 'General case' 0 C--N 1.35 0.63 0 CA-C-N 114.644 -1.162 . . . . 0.0 109.251 178.561 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 212' ' ' GLY . . . . . 0.683 ' HA2' ' HE1' ' A' ' 110' ' ' MET . . . -73.99 -142.74 0.7 Allowed Glycine 0 C--N 1.339 0.731 0 O-C-N 124.051 0.844 . . . . 0.0 114.272 -174.291 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 213' ' ' ASN . . . . . 0.481 ' HB3' ' HD1' ' A' ' 112' ' ' HIS . 3.9 p30 -127.96 159.23 35.62 Favored 'General case' 0 C--O 1.239 0.503 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 -177.27 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 173.62 -136.03 3.47 Favored Glycine 0 N--CA 1.438 -1.227 0 N-CA-C 109.646 -1.381 . . . . 0.0 109.646 178.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 215' ' ' VAL . . . . . 0.552 ' HA ' ' HG2' ' B' ' 253' ' ' LYS . 11.3 p -170.0 170.75 0.16 Allowed 'Isoleucine or valine' 0 C--O 1.242 0.683 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 -172.163 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 216' ' ' VAL . . . . . 0.607 HG23 ' H2 ' ' B' ' 251' ' ' BEZ . 35.7 m -70.28 112.6 5.25 Favored 'Isoleucine or valine' 0 CA--C 1.557 1.221 0 CA-C-O 121.882 0.848 . . . . 0.0 108.908 168.548 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 217' ' ' THR . . . . . . . . . . . . . 8.3 m -119.69 171.84 8.1 Favored 'General case' 0 C--O 1.254 1.323 0 C-N-CA 124.661 1.184 . . . . 0.0 108.393 -174.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 22.2 ttt180 73.46 -74.68 0.08 Allowed 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 124.636 1.174 . . . . 0.0 110.327 -179.205 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 35.8 p -148.06 -0.47 0.6 Allowed 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 123.651 0.78 . . . . 0.0 111.297 -178.298 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 220' ' ' GLY . . . . . 0.425 ' HA2' ' HB ' ' A' ' 216' ' ' VAL . . . 134.27 12.55 1.42 Allowed Glycine 0 C--N 1.351 1.386 0 CA-C-O 120.0 -0.334 . . . . 0.0 113.048 -174.586 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . 0.473 ' O ' HG22 ' A' ' 223' ' ' VAL . . . -78.61 139.99 38.5 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 123.023 0.529 . . . . 0.0 109.597 178.449 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 222' ' ' TYR . . . . . . . . . . . . . 37.8 m-85 -78.81 99.21 6.61 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 123.614 0.766 . . . . 0.0 109.532 -176.093 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . 0.674 HG12 ' HE1' ' A' ' 177' ' ' PHE . 39.1 t -118.91 111.31 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 123.142 0.577 . . . . 0.0 110.148 -169.167 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 16.5 m -137.54 159.57 41.58 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.242 1.017 . . . . 0.0 110.554 -171.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . 0.43 ' HA ' ' HA ' ' A' ' 186' ' ' ALA . . . -70.93 171.92 9.89 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 123.921 0.888 . . . . 0.0 112.309 -179.009 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 226' ' ' ILE . . . . . . . . . . . . . 39.3 mt -127.22 124.47 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.183 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 173.298 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -114.18 109.67 18.77 Favored 'General case' 0 N--CA 1.487 1.402 0 CA-C-N 118.019 0.372 . . . . 0.0 110.525 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 -92.89 168.97 10.81 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 123.673 0.789 . . . . 0.0 111.37 -176.477 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.632 HG21 ' HA ' ' A' ' 145' ' ' LYS . 97.4 m -64.41 108.37 1.61 Allowed 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.602 0.761 . . . . 0.0 111.089 -174.736 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 16.2 mm-40 -156.34 12.98 0.29 Allowed 'General case' 0 N--CA 1.484 1.245 0 C-N-CA 123.645 0.778 . . . . 0.0 112.173 -176.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 231' ' ' LYS . . . . . 0.524 ' HA ' ' HE2' ' A' ' 231' ' ' LYS . 11.1 mmpt? -96.52 -92.33 0.22 Allowed 'General case' 0 N--CA 1.486 1.334 0 CA-C-N 119.103 0.865 . . . . 0.0 111.955 -174.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 66.8 p -89.21 113.08 24.25 Favored 'General case' 0 C--N 1.353 0.754 0 CA-C-N 118.735 0.698 . . . . 0.0 112.255 -169.362 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 233' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -86.78 -13.74 10.54 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.312 0 CA-C-N 114.612 -1.176 . . . . 0.0 109.362 166.508 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 234' ' ' GLU . . . . . 0.573 ' HG2' ' H ' ' A' ' 235' ' ' ASP 0.275 1.4 pm0 40.14 -87.46 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 127.574 2.35 . . . . 0.0 114.811 -178.897 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . 0.573 ' H ' ' HG2' ' A' ' 234' ' ' GLU . 29.8 t70 -141.01 18.49 2.29 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 123.175 0.59 . . . . 0.0 110.043 -172.592 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 236' ' ' ASN . . . . . . . . . . . . . 31.9 t30 -76.62 107.45 4.73 Favored Pre-proline 0 CA--C 1.555 1.146 0 C-N-CA 124.276 1.031 . . . . 0.0 110.429 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_endo -85.08 83.73 1.48 Allowed 'Trans proline' 0 C--N 1.377 2.048 0 C-N-CA 122.604 2.202 . . . . 0.0 111.955 -176.106 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 238' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -104.36 121.52 43.54 Favored 'General case' 0 N--CA 1.477 0.889 0 C-N-CA 123.49 0.716 . . . . 0.0 110.459 -179.752 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 239' ' ' ILE . . . . . . . . . . . . . 9.7 tt -84.88 -52.56 12.27 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.069 0 C-N-CA 123.154 0.581 . . . . 0.0 110.035 176.834 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.556 1.178 0 C-N-CA 123.54 0.736 . . . . 0.0 110.248 179.579 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 251' ' ' BEZ . . . . . 0.607 ' H2 ' HG23 ' A' ' 216' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 253' ' ' LYS . . . . . 0.552 ' HG2' ' HA ' ' A' ' 215' ' ' VAL . 0.1 OUTLIER -83.31 159.66 21.85 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.744 0.818 . . . . 0.0 110.082 173.763 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 254' ' ' ARG . . . . . 0.477 ' HG3' ' HB2' ' A' ' 193' ' ' PRO . 63.0 mtt-85 -72.95 -68.82 0.45 Allowed 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 176.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 255' ' ' M9P . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.93 0 CA-C-O 119.34 -0.7 . . . . 0.0 111.663 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 52.6 p -170.88 117.39 0.48 Allowed 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 124.351 1.061 . . . . 0.0 108.552 176.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -131.98 -59.83 0.93 Allowed 'General case' 0 N--CA 1.482 1.173 0 C-N-CA 122.877 0.471 . . . . 0.0 111.054 -177.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -163.48 20.74 0.08 Allowed 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 123.901 0.88 . . . . 0.0 109.406 -171.778 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 21.1 p-10 -142.84 58.83 1.43 Allowed 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 114.426 -1.261 . . . . 0.0 108.938 -162.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.476 ' HG ' ' HG2' ' A' ' 88' ' ' GLN . 2.9 mp -134.32 117.73 16.72 Favored 'General case' 0 C--O 1.207 -1.149 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 173.143 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.476 ' HB3' ' HE3' ' A' ' 87' ' ' LYS . 37.4 tt0 -114.48 156.26 24.89 Favored 'General case' 0 N--CA 1.495 1.789 0 CA-C-N 119.745 1.157 . . . . 0.0 112.202 -175.645 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 81.6 mt -95.77 143.07 27.32 Favored 'General case' 0 N--CA 1.481 1.121 0 C-N-CA 124.161 0.984 . . . . 0.0 113.011 178.446 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 -131.34 116.3 17.39 Favored 'General case' 0 N--CA 1.483 1.18 0 C-N-CA 124.283 1.033 . . . . 0.0 108.637 172.349 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.512 ' HA ' ' HA ' ' A' ' 84' ' ' TYR . 36.7 ptt85 -62.33 110.66 1.71 Allowed 'General case' 0 N--CA 1.487 1.407 0 CA-C-N 119.503 1.047 . . . . 0.0 110.17 173.671 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . 0.491 ' HB2' HD13 ' A' ' 161' ' ' LEU . . . -91.5 -28.3 17.69 Favored 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 123.552 0.741 . . . . 0.0 110.457 -177.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -160.22 175.05 13.34 Favored 'General case' 0 C--O 1.239 0.504 0 C-N-CA 123.808 0.843 . . . . 0.0 110.613 -179.366 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -102.66 170.1 8.23 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 124.044 0.938 . . . . 0.0 109.947 175.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.631 HG23 ' HA2' ' A' ' 82' ' ' GLY . 82.0 t -72.22 101.54 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.626 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 167.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 31.0 ttmt -169.08 140.79 2.49 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -169.589 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 28.6 t90 -102.45 122.3 44.05 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 122.745 0.418 . . . . 0.0 110.064 179.313 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -81.33 146.18 30.5 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 124.08 0.952 . . . . 0.0 110.889 171.713 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -73.95 0.89 12.09 Favored 'General case' 0 N--CA 1.483 1.182 0 C-N-CA 124.325 1.05 . . . . 0.0 112.607 176.758 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 23.9 mt-30 -75.96 14.95 0.6 Allowed 'General case' 0 CA--C 1.555 1.143 0 C-N-CA 124.325 1.05 . . . . 0.0 112.966 -176.169 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.454 ' HB1' ' HB2' ' A' ' 171' ' ' GLN . . . -52.99 90.64 0.01 OUTLIER 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 124.367 1.067 . . . . 0.0 113.255 -168.594 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -62.56 131.94 50.75 Favored 'General case' 0 C--N 1.353 0.745 0 C-N-CA 124.46 1.104 . . . . 0.0 110.64 -178.876 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 3.0 mp -75.37 111.0 11.11 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 -173.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 19.1 m -142.13 179.35 6.95 Favored 'General case' 0 C--O 1.246 0.885 0 C-N-CA 124.663 1.185 . . . . 0.0 109.208 -175.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.433 ' HA2' ' O ' ' A' ' 188' ' ' SER . . . 88.27 84.75 1.23 Allowed Glycine 0 C--N 1.341 0.823 0 N-CA-C 111.306 -0.717 . . . . 0.0 111.306 -176.821 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 50.4 m -150.3 -28.13 0.23 Allowed 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.14 0.576 . . . . 0.0 111.555 -177.471 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 9.3 p -66.14 126.55 92.15 Favored Pre-proline 0 CA--C 1.553 1.086 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 177.612 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -75.82 -165.3 0.29 Allowed 'Trans proline' 0 C--N 1.377 2.061 0 C-N-CA 123.214 2.609 . . . . 0.0 113.452 -172.587 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.404 HD12 ' HG ' ' A' ' 176' ' ' LEU . 36.3 mm -63.17 111.82 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.953 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 177.833 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.603 HD22 ' HB2' ' A' ' 218' ' ' ARG . 0.3 OUTLIER -109.59 160.33 16.35 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.218 -172.249 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.424 ' H ' HD23 ' A' ' 29' ' ' LEU . 65.6 m -94.54 149.12 21.56 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 123.119 0.568 . . . . 0.0 110.05 171.608 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 17.6 tt -139.31 160.55 28.58 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.593 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 27.7 m -93.9 105.91 17.91 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 108.693 -0.855 . . . . 0.0 108.693 178.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 10.8 tp -73.71 148.55 8.49 Favored 'Isoleucine or valine' 0 C--O 1.246 0.903 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 169.803 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' SER . . . . . 0.505 ' HB2' ' HB2' ' A' ' 38' ' ' SER . 50.4 m -138.48 138.7 38.34 Favored 'General case' 0 C--O 1.242 0.695 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 178.302 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -60.41 156.47 15.92 Favored 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 123.499 0.72 . . . . 0.0 111.105 -174.61 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.8 t70 77.85 21.35 0.94 Allowed 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 125.317 1.447 . . . . 0.0 110.727 -179.01 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 78.7 38.49 23.87 Favored Glycine 0 C--N 1.35 1.317 0 CA-C-N 115.556 -0.747 . . . . 0.0 113.755 174.021 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.505 ' HB2' ' HB2' ' A' ' 34' ' ' SER . 28.4 m -107.33 150.36 26.78 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 122.937 0.495 . . . . 0.0 109.793 175.589 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 5.4 ptm -160.65 123.8 3.37 Favored 'General case' 0 N--CA 1.481 1.107 0 CA-C-O 120.901 0.382 . . . . 0.0 111.723 -175.041 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.457 ' HA ' HG13 ' A' ' 215' ' ' VAL . 15.7 p -177.42 -176.17 0.6 Allowed 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 124.549 1.139 . . . . 0.0 109.434 -178.525 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 1.4 mp -92.13 131.09 40.16 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 N-CA-C 105.796 -1.928 . . . . 0.0 105.796 156.283 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 49.3 pttt -52.98 89.76 0.01 OUTLIER 'General case' 0 CA--C 1.551 0.986 0 C-N-CA 124.531 1.132 . . . . 0.0 112.048 -177.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 64.0 m-20 -158.13 149.82 21.53 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.462 1.505 . . . . 0.0 108.329 -177.251 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -68.69 108.62 3.46 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 123.328 0.651 . . . . 0.0 110.234 -179.605 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -91.46 121.88 33.56 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 122.978 0.511 . . . . 0.0 109.954 176.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.422 ' HG2' ' NH1' ' B' ' 255' ' ' M9P . 0.4 OUTLIER -170.12 124.09 0.73 Allowed 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 175.683 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.458 ' HB3' ' HA ' ' B' ' 254' ' ' ARG . 8.4 tp10 -159.39 93.95 1.15 Allowed 'General case' 0 C--O 1.24 0.58 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 178.646 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 8.4 pt20 -103.43 99.31 9.14 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 123.947 0.899 . . . . 0.0 109.563 176.644 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.401 ' OG1' ' HD3' ' B' ' 254' ' ' ARG . 28.0 m -71.29 -78.08 0.08 Allowed 'General case' 0 CA--C 1.547 0.827 0 C-N-CA 123.52 0.728 . . . . 0.0 110.662 -175.927 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 57.8 tp -175.18 127.21 0.27 Allowed 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 123.017 0.527 . . . . 0.0 109.889 -177.498 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -76.04 -155.7 5.9 Favored Glycine 0 C--N 1.346 1.122 0 O-C-N 123.436 0.46 . . . . 0.0 112.273 171.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -143.79 -64.26 0.02 OUTLIER Glycine 0 N--CA 1.467 0.767 0 N-CA-C 111.696 -0.562 . . . . 0.0 111.696 -178.459 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 80.48 -72.16 2.71 Favored Glycine 0 C--N 1.341 0.823 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 -175.076 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 98.45 156.84 29.63 Favored Glycine 0 C--N 1.342 0.906 0 C-N-CA 122.917 0.294 . . . . 0.0 112.644 177.224 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.428 ' HB3' ' HA2' ' A' ' 59' ' ' GLY . 15.2 t 59.83 33.23 21.63 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 124.72 1.208 . . . . 0.0 111.366 177.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 119.71 -37.31 3.16 Favored Glycine 0 C--N 1.343 0.947 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.891 -178.302 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 149.07 -12.72 1.09 Allowed Glycine 0 C--N 1.35 1.309 0 CA-C-O 119.949 -0.362 . . . . 0.0 113.049 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -168.32 35.68 0.2 Allowed Glycine 0 C--N 1.349 1.288 0 N-CA-C 112.074 -0.41 . . . . 0.0 112.074 -179.449 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.428 ' HA2' ' HB3' ' A' ' 55' ' ' SER . . . 83.76 -61.93 4.67 Favored Glycine 0 C--N 1.351 1.363 0 N-CA-C 112.46 -0.256 . . . . 0.0 112.46 -178.494 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -170.26 -62.45 0.02 OUTLIER 'General case' 0 C--O 1.236 0.39 0 N-CA-C 107.073 -1.454 . . . . 0.0 107.073 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -114.41 -61.32 1.76 Allowed 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 114.829 -1.078 . . . . 0.0 108.923 171.378 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -148.73 13.2 0.91 Allowed 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 123.494 0.717 . . . . 0.0 111.006 -178.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -81.45 71.72 2.88 Favored Glycine 0 C--N 1.35 1.334 0 N-CA-C 113.729 0.252 . . . . 0.0 113.729 -173.844 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.2 t -85.71 64.91 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.808 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 175.455 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -37.22 130.31 0.89 Allowed 'General case' 0 N--CA 1.481 1.089 0 C-N-CA 125.836 1.655 . . . . 0.0 112.096 -178.376 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 29.0 m0 -69.63 158.42 35.35 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.037 -173.141 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.569 ' HB2' ' H ' ' A' ' 80' ' ' GLU . 1.0 OUTLIER -82.83 71.33 9.93 Favored 'General case' 0 CA--C 1.54 0.574 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 -168.866 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 16.3 t -106.9 112.52 63.32 Favored Pre-proline 0 CA--C 1.545 0.782 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 -174.493 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -57.27 -32.96 95.16 Favored 'Trans proline' 0 C--N 1.375 1.938 0 C-N-CA 123.516 2.811 . . . . 0.0 114.276 -170.642 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 36.3 p -128.7 147.44 64.36 Favored Pre-proline 0 CA--C 1.55 0.976 0 C-N-CA 123.751 0.821 . . . . 0.0 110.787 -179.352 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_exo -53.87 -44.24 50.93 Favored 'Trans proline' 0 CA--C 1.573 2.467 0 C-N-CA 123.675 2.916 . . . . 0.0 117.035 174.326 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.86 -51.61 10.72 Favored 'Trans proline' 0 C--N 1.399 3.214 0 C-N-CA 122.16 1.907 . . . . 0.0 116.544 -176.274 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_endo -82.84 169.77 13.05 Favored 'Trans proline' 0 C--N 1.386 2.534 0 CA-C-N 122.322 1.865 . . . . 0.0 112.827 178.136 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 11.7 p -163.49 -36.52 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 C-N-CA 124.38 1.072 . . . . 0.0 108.386 172.576 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 52.17 -99.55 0.04 OUTLIER Glycine 0 C--N 1.352 1.458 0 O-C-N 124.702 1.251 . . . . 0.0 114.227 172.427 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -159.86 -58.11 0.06 Allowed 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 124.227 1.011 . . . . 0.0 108.897 -174.028 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -112.95 37.31 3.16 Favored 'General case' 0 N--CA 1.472 0.632 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.381 -178.48 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 11.1 mm-40 -71.67 83.39 0.87 Allowed 'General case' 0 N--CA 1.479 0.991 0 CA-C-O 121.547 0.689 . . . . 0.0 110.486 171.195 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 6.4 mp -117.76 131.96 56.52 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 114.877 -1.056 . . . . 0.0 108.255 168.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.569 ' H ' ' HB2' ' A' ' 67' ' ' ASP . 37.8 tt0 -70.27 -11.93 61.24 Favored 'General case' 0 CA--C 1.549 0.926 0 C-N-CA 125.459 1.504 . . . . 0.0 110.5 177.574 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . 0.412 ' HB2' ' O ' ' A' ' 102' ' ' TYR . 0.5 OUTLIER 66.89 -179.53 0.21 Allowed 'General case' 0 C--N 1.352 0.71 0 C-N-CA 126.559 1.944 . . . . 0.0 112.478 170.806 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.631 ' HA2' HG23 ' A' ' 14' ' ' VAL . . . 128.84 -157.9 21.7 Favored Glycine 0 C--O 1.248 1.031 0 CA-C-N 115.364 -0.834 . . . . 0.0 111.384 -177.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . 0.623 ' HB2' HD12 ' A' ' 161' ' ' LEU . . . -90.35 107.06 18.91 Favored 'General case' 0 CA--C 1.54 0.57 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -179.228 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . 0.512 ' HA ' ' HA ' ' A' ' 10' ' ' ARG . 7.4 m-85 -92.51 176.23 6.54 Favored 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 123.18 0.592 . . . . 0.0 109.405 177.455 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . 0.631 ' HA ' ' HA ' ' A' ' 99' ' ' ALA . 53.8 ttp180 -138.36 121.82 17.22 Favored 'General case' 0 C--O 1.239 0.54 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 -174.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.402 HG22 HD12 ' A' ' 119' ' ' LEU . 41.7 mt -90.67 116.04 31.16 Favored 'Isoleucine or valine' 0 C--O 1.25 1.116 0 CA-C-O 121.607 0.718 . . . . 0.0 110.134 -172.257 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.603 ' HE3' ' HD2' ' A' ' 89' ' ' LYS . 48.3 pttt -105.35 142.13 35.65 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 168.564 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . 0.629 ' HB2' HD13 ' A' ' 97' ' ' ILE . 18.0 tm0? -84.44 106.48 16.06 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 104.534 -2.395 . . . . 0.0 104.534 165.784 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . 0.603 ' HD2' ' HE3' ' A' ' 87' ' ' LYS . 78.6 tttt -119.41 104.09 10.04 Favored 'General case' 0 C--O 1.241 0.613 0 C-N-CA 123.666 0.786 . . . . 0.0 110.36 -167.203 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -72.32 155.31 51.36 Favored Glycine 0 C--O 1.243 0.701 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 167.474 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 22.2 mm -79.41 62.15 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.563 1.442 0 CA-C-N 118.174 0.987 . . . . 0.0 109.067 -176.102 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 1.6 tm? 170.16 -40.1 0.0 OUTLIER 'General case' 0 CA--C 1.556 1.204 0 C-N-CA 126.347 1.859 . . . . 0.0 107.556 -168.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -137.96 151.66 21.45 Favored Glycine 0 C--N 1.369 2.379 0 N-CA-C 114.926 0.731 . . . . 0.0 114.926 -166.576 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -111.89 142.81 43.81 Favored 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 125.037 1.335 . . . . 0.0 110.738 -179.167 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 49.5 m -150.52 96.67 2.41 Favored 'General case' 0 N--CA 1.477 0.915 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 168.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.52 HE22 ' HB3' ' A' ' 163' ' ' PRO . 35.8 tt0 -62.48 140.25 58.6 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 123.237 0.615 . . . . 0.0 111.243 -178.605 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.629 HD13 ' HB2' ' A' ' 88' ' ' GLN . 8.5 pt -132.76 -24.68 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 N-CA-C 112.604 0.594 . . . . 0.0 112.604 -173.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 178.85 -149.4 8.86 Favored Glycine 0 C--N 1.345 1.074 0 C-N-CA 120.847 -0.692 . . . . 0.0 113.031 179.484 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.631 ' HA ' ' HA ' ' A' ' 85' ' ' ARG . . . -143.59 178.11 8.01 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 124.44 1.096 . . . . 0.0 109.805 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -176.89 140.84 5.13 Favored Glycine 0 C--N 1.34 0.796 0 CA-C-O 119.826 -0.43 . . . . 0.0 112.123 174.042 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.589 ' HB ' ' HG3' ' A' ' 199' ' ' PRO . 3.3 p -89.36 127.14 42.22 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.942 0 CA-C-N 117.422 0.611 . . . . 0.0 111.001 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.45 ' HD2' ' HB2' ' A' ' 107' ' ' PHE . 29.4 t80 -98.05 136.77 37.83 Favored 'General case' 0 N--CA 1.477 0.881 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 169.562 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.437 ' HD2' HG22 ' A' ' 14' ' ' VAL . 35.2 tttp -169.02 154.23 6.01 Favored 'General case' 0 N--CA 1.47 0.57 0 O-C-N 123.69 0.618 . . . . 0.0 110.071 171.927 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 11.8 tp10 72.86 17.28 4.35 Favored 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 124.684 1.194 . . . . 0.0 110.752 171.301 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 80.51 18.01 72.02 Favored Glycine 0 C--N 1.345 1.033 0 CA-C-N 115.925 -0.58 . . . . 0.0 113.303 -176.159 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' THR . . . . . 0.471 HG22 ' HD2' ' A' ' 108' ' ' HIS . 2.7 t -139.54 134.8 32.69 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 123.013 0.525 . . . . 0.0 110.584 176.662 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' PHE . . . . . 0.551 ' HB3' ' HB2' ' A' ' 140' ' ' TYR . 38.3 t80 -88.55 118.81 28.47 Favored 'General case' 0 C--N 1.349 0.579 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 174.716 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . 0.471 ' HD2' HG22 ' A' ' 106' ' ' THR . 4.1 p80 -133.45 114.1 13.27 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 123.051 0.54 . . . . 0.0 109.969 -175.267 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 11.5 t -136.17 -172.89 3.24 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 124.187 0.995 . . . . 0.0 110.359 -176.081 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' MET . . . . . 0.414 ' SD ' ' HE1' ' A' ' 112' ' ' HIS . 1.0 OUTLIER -67.14 152.57 45.51 Favored 'General case' 0 N--CA 1.479 1.02 0 C-N-CA 124.189 0.996 . . . . 0.0 110.702 171.542 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 84.1 t90 -74.0 -47.65 35.71 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 122.848 0.459 . . . . 0.0 110.654 -178.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . 0.414 ' HE1' ' SD ' ' A' ' 110' ' ' MET . 22.1 p-80 -59.78 -15.46 20.57 Favored 'General case' 0 N--CA 1.489 1.506 0 C-N-CA 124.38 1.072 . . . . 0.0 113.755 -170.035 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.471 ' O ' HD11 ' A' ' 97' ' ' ILE . 23.2 m -57.62 -27.53 29.84 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 C-N-CA 123.185 0.594 . . . . 0.0 111.032 178.695 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 10.8 t -135.5 165.22 26.03 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.163 0.985 . . . . 0.0 109.263 177.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 14.7 tpp180 -92.74 16.03 13.21 Favored 'General case' 0 N--CA 1.484 1.252 0 CA-C-O 121.642 0.734 . . . . 0.0 109.887 176.048 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 98.72 42.23 2.94 Favored Glycine 0 C--N 1.347 1.153 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 -177.169 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -106.79 167.56 9.79 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 123.608 0.763 . . . . 0.0 110.621 -179.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.409 HG22 ' HA ' ' A' ' 127' ' ' GLU . 7.3 p -84.93 137.73 20.33 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.006 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.408 178.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.402 HD12 HG22 ' A' ' 86' ' ' ILE . 1.8 mm? -84.37 -177.97 6.78 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 124.429 1.092 . . . . 0.0 111.1 -178.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 47.9 mtm -145.23 164.87 30.02 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 124.165 0.986 . . . . 0.0 111.119 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.401 ' HA ' ' HG3' ' A' ' 7' ' ' GLU . 12.0 t-160 -164.92 111.28 0.97 Allowed 'General case' 0 C--O 1.239 0.536 0 N-CA-C 106.497 -1.668 . . . . 0.0 106.497 171.454 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 73.1 tttt 70.55 20.34 5.88 Favored 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 124.131 0.972 . . . . 0.0 110.802 -179.739 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 93.13 -19.95 49.06 Favored Glycine 0 C--N 1.344 0.985 0 CA-C-N 114.811 -1.086 . . . . 0.0 113.334 -172.134 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 38.8 ttmt -77.37 119.6 21.21 Favored 'General case' 0 C--N 1.36 1.027 0 CA-C-N 117.509 0.654 . . . . 0.0 109.76 -179.135 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 3.6 mpt_? -59.68 143.8 49.7 Favored 'General case' 0 CA--C 1.551 1.014 0 C-N-CA 124.383 1.073 . . . . 0.0 111.75 177.306 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 57.9 mt -119.1 109.05 25.45 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 176.367 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . 0.409 ' HA ' HG22 ' A' ' 118' ' ' VAL . 10.8 pt-20 -80.01 134.42 56.39 Favored Pre-proline 0 CA--C 1.557 1.241 0 C-N-CA 124.42 1.088 . . . . 0.0 112.997 -167.793 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -76.3 110.38 3.05 Favored 'Trans proline' 0 C--N 1.383 2.357 0 C-N-CA 123.023 2.482 . . . . 0.0 111.365 176.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 34.1 p -85.6 -27.46 25.46 Favored 'General case' 0 N--CA 1.479 1.0 0 C-N-CA 123.315 0.646 . . . . 0.0 111.416 -179.362 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.509 ' HB3' ' HG ' ' A' ' 139' ' ' SER . 69.9 t-105 -147.86 153.9 39.72 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 123.706 0.802 . . . . 0.0 109.127 -178.538 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -155.99 118.28 4.08 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 123.196 0.599 . . . . 0.0 110.089 175.443 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 12.8 t0 -117.14 106.95 13.89 Favored 'General case' 0 N--CA 1.475 0.793 0 C-N-CA 124.312 1.045 . . . . 0.0 108.555 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 21.5 t -76.88 -16.42 14.7 Favored 'Isoleucine or valine' 0 CA--C 1.565 1.543 0 C-N-CA 123.263 0.625 . . . . 0.0 111.643 -174.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -79.16 -43.04 24.75 Favored 'General case' 0 N--CA 1.492 1.66 0 C-N-CA 123.203 0.601 . . . . 0.0 111.06 -175.859 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 11.8 mptt -78.19 -15.55 58.72 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 170.189 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 11.1 t0 58.69 61.86 2.09 Favored 'General case' 0 C--N 1.356 0.888 0 O-C-N 124.834 1.334 . . . . 0.0 108.512 -170.37 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . 0.482 HD13 ' HB1' ' A' ' 227' ' ' ALA . 87.0 mt -139.66 131.97 28.35 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 123.973 0.909 . . . . 0.0 109.607 176.808 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.419 HG22 ' HE1' ' A' ' 140' ' ' TYR . 20.2 tt -119.7 138.08 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.18 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 171.451 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' SER . . . . . 0.509 ' HG ' ' HB3' ' A' ' 130' ' ' TRP . 21.0 p -133.3 147.77 51.9 Favored 'General case' 0 CA--C 1.544 0.733 0 CA-C-O 121.827 0.822 . . . . 0.0 112.113 -171.501 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.551 ' HB2' ' HB3' ' A' ' 107' ' ' PHE . 17.5 m-85 -132.25 112.02 11.89 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.333 1.453 . . . . 0.0 108.476 -162.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.62 20.49 63.77 Favored Glycine 0 N--CA 1.474 1.229 0 O-C-N 123.084 0.24 . . . . 0.0 112.625 -176.029 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 157.04 -160.71 30.62 Favored Glycine 0 C--N 1.34 0.8 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 177.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.684 ' HA3' ' HB2' ' A' ' 232' ' ' SER . . . -98.75 -175.81 32.31 Favored Glycine 0 C--N 1.346 1.119 0 CA-C-N 117.348 0.574 . . . . 0.0 111.732 171.575 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' TRP . . . . . 0.574 ' CD1' ' HA ' ' A' ' 229' ' ' THR . 47.6 t-105 -61.78 107.64 0.87 Allowed 'General case' 0 C--N 1.352 0.707 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 167.828 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 38.6 ttpt -150.52 112.16 4.48 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-O 121.197 0.523 . . . . 0.0 110.791 -172.201 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' LEU . . . . . . . . . . . . . 1.6 pp -146.19 -2.37 0.7 Allowed 'General case' 0 N--CA 1.48 1.036 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.728 169.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 79.44 -22.86 0.26 Allowed 'General case' 0 N--CA 1.484 1.232 0 C-N-CA 126.108 1.763 . . . . 0.0 113.338 166.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -70.11 157.51 53.51 Favored Glycine 0 C--N 1.355 1.59 0 CA-C-N 118.055 0.389 . . . . 0.0 112.842 -175.149 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -141.12 154.05 45.7 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.097 0.559 . . . . 0.0 110.093 -173.026 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' TRP . . . . . 0.509 ' HB2' HG11 ' A' ' 208' ' ' VAL . 25.7 t90 -68.81 133.78 48.8 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 122.712 0.405 . . . . 0.0 110.107 169.709 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 60.2 tttm -86.33 97.5 10.45 Favored 'General case' 0 CA--C 1.549 0.921 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 171.246 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -59.06 109.91 0.94 Allowed 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 124.548 1.139 . . . . 0.0 112.144 -170.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 123.39 -9.24 8.83 Favored Glycine 0 N--CA 1.475 1.253 0 CA-C-N 115.764 -0.653 . . . . 0.0 112.056 -175.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . 0.48 ' HB3' ' HE3' ' A' ' 203' ' ' LYS . 62.3 mm-40 -101.17 163.25 12.37 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 123.424 0.689 . . . . 0.0 110.256 174.36 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 13.2 mp0 -82.57 146.2 29.3 Favored 'General case' 0 N--CA 1.477 0.919 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 172.071 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 29.6 m -89.8 140.55 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.558 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 25.5 mm-40 -99.66 128.26 45.76 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 178.293 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.494 ' HB ' ' HB ' ' A' ' 170' ' ' VAL . 58.0 t -98.97 103.18 14.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 -176.709 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -80.8 72.57 7.78 Favored 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 106.946 -1.501 . . . . 0.0 106.946 178.084 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -77.13 130.01 36.77 Favored 'General case' 0 C--N 1.343 0.321 0 CA-C-N 113.496 -1.684 . . . . 0.0 110.647 -173.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . 0.623 HD12 ' HB2' ' A' ' 83' ' ' ALA . 45.6 mt -95.93 108.91 21.33 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 177.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . 0.401 ' HA ' ' HD3' ' A' ' 163' ' ' PRO . 57.9 mt-10 -90.26 115.29 63.7 Favored Pre-proline 0 CA--C 1.544 0.728 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 167.499 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . 0.52 ' HB3' HE22 ' A' ' 96' ' ' GLN . 35.5 Cg_exo -61.55 116.05 3.17 Favored 'Trans proline' 0 C--N 1.372 1.811 0 C-N-CA 123.41 2.74 . . . . 0.0 112.259 -176.71 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 109.53 -23.72 21.69 Favored Glycine 0 C--N 1.341 0.851 0 CA-C-N 115.518 -0.765 . . . . 0.0 112.203 -176.035 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 11.8 mmpt? -105.76 173.94 6.1 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 123.902 0.881 . . . . 0.0 111.532 -172.11 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -67.77 161.84 63.13 Favored Pre-proline 0 CA--C 1.558 1.287 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.021 168.573 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_exo -56.83 138.85 87.36 Favored 'Trans proline' 0 C--N 1.378 2.114 0 C-N-CA 122.968 2.445 . . . . 0.0 111.979 172.05 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 17.1 mmt85 -121.28 97.7 5.64 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 123.681 0.792 . . . . 0.0 109.692 -171.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -79.24 132.72 36.59 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 175.489 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . 0.494 ' HB ' ' HB ' ' A' ' 158' ' ' VAL . 95.5 t -129.8 122.06 53.84 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.163 0 C-N-CA 123.196 0.599 . . . . 0.0 110.266 -178.478 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . 0.454 ' HB2' ' HB1' ' A' ' 20' ' ' ALA . 11.5 tt0 -80.82 110.58 16.47 Favored 'General case' 0 N--CA 1.48 1.03 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 -179.867 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 6.9 m -126.73 137.22 53.22 Favored 'General case' 0 C--O 1.238 0.499 0 CA-C-O 121.023 0.44 . . . . 0.0 109.954 -179.563 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . 0.406 ' H ' ' HA3' ' A' ' 24' ' ' GLY . 47.3 mttp -83.17 153.62 66.36 Favored Pre-proline 0 C--O 1.246 0.883 0 C-N-CA 124.115 0.966 . . . . 0.0 108.981 177.555 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . 0.46 ' HA ' ' O ' ' A' ' 186' ' ' ALA . 87.3 Cg_exo -49.73 125.99 15.47 Favored 'Trans proline' 0 C--N 1.381 2.252 0 C-N-CA 122.914 2.41 . . . . 0.0 113.36 179.627 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . 0.486 ' H ' ' C ' ' A' ' 186' ' ' ALA . . . -141.11 131.76 5.04 Favored Glycine 0 CA--C 1.541 1.662 0 CA-C-O 122.292 0.94 . . . . 0.0 114.616 178.444 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.56 HD11 ' HB ' ' A' ' 183' ' ' THR . 0.6 OUTLIER -139.31 155.09 47.95 Favored 'General case' 0 C--O 1.242 0.705 0 O-C-N 121.714 -0.874 . . . . 0.0 111.493 -170.292 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 177' ' ' PHE . . . . . 0.43 ' HZ ' ' HB3' ' A' ' 225' ' ' ALA . 3.1 p90 -124.13 139.32 54.04 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 113.696 -1.593 . . . . 0.0 109.781 -175.546 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 178' ' ' LYS . . . . . 0.441 ' HZ2' ' HB3' ' A' ' 178' ' ' LYS . 3.5 ttpm? -85.01 121.36 27.69 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 124.407 1.083 . . . . 0.0 110.167 -173.376 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 77.8 p -117.78 170.61 8.65 Favored 'General case' 0 C--O 1.243 0.731 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 164.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 10.5 t30 -66.21 -26.66 67.49 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 123.072 0.549 . . . . 0.0 109.91 173.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -68.76 -33.66 74.27 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 123.971 0.908 . . . . 0.0 111.055 173.178 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 150.66 172.43 19.81 Favored Glycine 0 C--N 1.35 1.323 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.341 175.325 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 183' ' ' THR . . . . . 0.56 ' HB ' HD11 ' A' ' 176' ' ' LEU . 44.5 p -75.83 95.8 3.56 Favored 'General case' 0 CA--C 1.545 0.782 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 174.723 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 20.3 pt -107.76 141.11 23.83 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 124.292 1.037 . . . . 0.0 110.378 -170.628 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 185' ' ' GLY . . . . . 0.565 ' HA2' ' HA ' ' A' ' 225' ' ' ALA . . . 115.92 173.61 17.35 Favored Glycine 0 N--CA 1.476 1.351 0 CA-C-O 119.432 -0.649 . . . . 0.0 112.612 -178.593 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . 0.486 ' C ' ' H ' ' A' ' 175' ' ' GLY . . . -175.55 40.58 0.01 OUTLIER 'General case' 0 C--O 1.206 -1.225 0 C-N-CA 123.328 0.651 . . . . 0.0 109.882 178.836 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 187' ' ' VAL . . . . . 0.569 HG13 ' HB3' ' A' ' 224' ' ' SER . 2.4 p -164.39 100.42 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.552 1.036 0 O-C-N 120.412 -1.43 . . . . 0.0 108.893 172.857 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 188' ' ' SER . . . . . 0.433 ' O ' ' HA2' ' A' ' 24' ' ' GLY . 80.3 p -118.13 125.67 50.71 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 123.17 0.588 . . . . 0.0 110.266 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 3.6 pp -150.73 -177.81 6.2 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-O 121.095 0.474 . . . . 0.0 110.958 176.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -138.8 103.42 4.82 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 166.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 191' ' ' PHE . . . . . . . . . . . . . 29.9 t80 -168.15 -179.61 4.15 Favored 'General case' 0 N--CA 1.486 1.326 0 C-N-CA 122.787 0.435 . . . . 0.0 109.934 -172.256 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 36.6 m -49.05 117.93 7.0 Favored Pre-proline 0 CA--C 1.554 1.125 0 C-N-CA 124.656 1.183 . . . . 0.0 111.585 175.259 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -69.2 99.79 0.71 Allowed 'Trans proline' 0 C--N 1.378 2.09 0 C-N-CA 122.421 2.081 . . . . 0.0 112.111 -179.347 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -60.93 130.94 48.4 Favored Glycine 0 C--N 1.348 1.22 0 N-CA-C 110.589 -1.005 . . . . 0.0 110.589 170.104 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 195' ' ' THR . . . . . 0.437 HG22 ' O ' ' A' ' 161' ' ' LEU . 12.6 t -59.45 140.37 56.25 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 123.202 0.601 . . . . 0.0 112.004 -169.811 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -69.47 104.08 2.21 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 123.961 0.904 . . . . 0.0 110.826 -165.026 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . 0.462 ' HA2' HD12 ' A' ' 210' ' ' LEU . . . 135.66 -7.2 4.22 Favored Glycine 0 C--O 1.24 0.525 0 CA-C-N 115.097 -0.956 . . . . 0.0 111.384 -172.526 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 69.6 m -60.99 124.93 82.28 Favored Pre-proline 0 CA--C 1.548 0.897 0 C-N-CA 123.802 0.841 . . . . 0.0 109.554 169.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . 0.589 ' HG3' ' HB ' ' A' ' 101' ' ' VAL . 2.9 Cg_exo -73.13 153.52 51.78 Favored 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 122.409 2.073 . . . . 0.0 111.553 -177.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 200' ' ' ILE . . . . . 0.49 HG23 ' HA ' ' A' ' 158' ' ' VAL . 9.7 pt -108.54 129.4 63.05 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 169.084 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 201' ' ' ILE . . . . . 0.428 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 66.4 mt -115.29 152.89 16.88 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.912 0 C-N-CA 125.165 1.386 . . . . 0.0 108.187 -178.252 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -84.9 162.03 19.62 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 175.139 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 203' ' ' LYS . . . . . 0.48 ' HE3' ' HB3' ' A' ' 154' ' ' GLU . 18.5 ptpt -61.98 -24.07 66.79 Favored 'General case' 0 N--CA 1.482 1.154 0 C-N-CA 123.316 0.646 . . . . 0.0 111.765 179.283 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 50.5 tttp -69.48 -21.62 63.69 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 124.012 0.925 . . . . 0.0 111.33 179.567 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 109.14 -12.61 34.06 Favored Glycine 0 C--N 1.349 1.269 0 CA-C-N 116.188 -0.46 . . . . 0.0 113.082 179.351 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 44.7 mmtm -88.51 138.98 30.94 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 177.505 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . 0.428 ' HA ' ' HA ' ' A' ' 201' ' ' ILE . 21.4 t -63.36 151.08 8.86 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.936 0 C-N-CA 123.566 0.746 . . . . 0.0 110.867 -176.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 208' ' ' VAL . . . . . 0.509 HG11 ' HB2' ' A' ' 150' ' ' TRP . 54.8 t -100.35 -52.48 8.65 Favored 'Isoleucine or valine' 0 C--O 1.241 0.656 0 C-N-CA 124.415 1.086 . . . . 0.0 109.02 173.083 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . . . . . . . . . . . 171.35 -121.79 0.92 Allowed Glycine 0 C--N 1.345 1.053 0 CA-C-N 114.582 -1.19 . . . . 0.0 111.495 -176.248 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . 0.527 ' HB2' ' CH2' ' A' ' 144' ' ' TRP . 9.0 tt -142.03 139.6 32.38 Favored 'General case' 0 CA--C 1.549 0.926 0 CA-C-N 117.481 0.641 . . . . 0.0 110.426 -175.842 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 79.5 t80 -71.64 109.31 5.48 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 123.922 0.889 . . . . 0.0 108.807 174.126 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -76.79 -138.74 0.92 Allowed Glycine 0 C--N 1.34 0.776 0 O-C-N 123.632 0.583 . . . . 0.0 114.455 -170.115 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 213' ' ' ASN . . . . . . . . . . . . . 81.0 m-20 -74.74 85.47 2.16 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 123.294 0.638 . . . . 0.0 109.93 -176.028 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . -72.32 73.22 0.92 Allowed Glycine 0 C--N 1.355 1.593 0 C-N-CA 123.69 0.662 . . . . 0.0 111.571 175.213 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 215' ' ' VAL . . . . . 0.693 ' HA ' ' HD3' ' B' ' 253' ' ' LYS . 54.7 t -84.37 147.24 5.8 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 C-N-CA 123.282 0.633 . . . . 0.0 111.1 -170.128 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 216' ' ' VAL . . . . . 0.511 ' HB ' ' HA2' ' A' ' 220' ' ' GLY . 14.7 m -68.34 111.95 3.0 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.109 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 165.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 217' ' ' THR . . . . . 0.567 HG23 HD13 ' A' ' 29' ' ' LEU . 13.5 t -125.09 159.89 30.36 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 122.686 0.394 . . . . 0.0 110.977 -179.043 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 218' ' ' ARG . . . . . 0.603 ' HB2' HD22 ' A' ' 29' ' ' LEU . 65.0 ttt180 66.45 -74.25 0.06 Allowed 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 124.924 1.289 . . . . 0.0 109.799 -170.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 16.6 p -131.3 -36.89 1.27 Allowed 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 124.02 0.928 . . . . 0.0 109.903 175.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 220' ' ' GLY . . . . . 0.511 ' HA2' ' HB ' ' A' ' 216' ' ' VAL . . . -176.78 11.83 0.03 OUTLIER Glycine 0 C--N 1.358 1.781 0 CA-C-O 119.341 -0.699 . . . . 0.0 114.64 -178.103 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . 0.447 ' O ' HG21 ' A' ' 217' ' ' THR . . . -70.95 119.23 14.76 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 117.664 0.732 . . . . 0.0 109.939 -175.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 222' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -76.92 95.69 4.17 Favored 'General case' 0 N--CA 1.473 0.71 0 CA-C-O 121.64 0.733 . . . . 0.0 109.975 -177.636 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 96.5 t -116.67 135.88 55.56 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.092 -179.26 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 224' ' ' SER . . . . . 0.569 ' HB3' HG13 ' A' ' 187' ' ' VAL . 35.2 t -131.18 155.74 46.53 Favored 'General case' 0 C--O 1.243 0.752 0 C-N-CA 124.324 1.05 . . . . 0.0 111.102 -164.73 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . 0.565 ' HA ' ' HA2' ' A' ' 185' ' ' GLY . . . -97.49 121.27 39.2 Favored 'General case' 0 N--CA 1.467 0.388 0 C-N-CA 123.76 0.824 . . . . 0.0 109.319 174.818 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 226' ' ' ILE . . . . . 0.432 HG21 HD12 ' A' ' 200' ' ' ILE . 7.1 mt -64.77 114.18 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 CA-C-O 120.857 0.36 . . . . 0.0 110.501 174.451 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 227' ' ' ALA . . . . . 0.482 ' HB1' HD13 ' A' ' 137' ' ' LEU . . . -76.79 113.13 14.12 Favored 'General case' 0 C--O 1.239 0.501 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 168.444 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . 0.422 ' HG3' ' HG3' ' A' ' 230' ' ' GLU . 29.7 pt20 -93.39 156.24 16.9 Favored 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 123.782 0.833 . . . . 0.0 109.474 -174.36 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.574 ' HA ' ' CD1' ' A' ' 144' ' ' TRP . 40.7 m -80.11 107.43 12.89 Favored 'General case' 0 C--N 1.347 0.487 0 CA-C-O 121.605 0.717 . . . . 0.0 111.536 179.389 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 230' ' ' GLU . . . . . 0.422 ' HG3' ' HG3' ' A' ' 228' ' ' GLN . 40.5 mt-10 -125.22 88.42 2.88 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 107.049 -1.463 . . . . 0.0 107.049 171.433 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 231' ' ' LYS . . . . . 0.47 ' HA ' ' O ' ' A' ' 144' ' ' TRP . 54.6 pttt -57.73 107.92 0.51 Allowed 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.329 -178.64 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 232' ' ' SER . . . . . 0.684 ' HB2' ' HA3' ' A' ' 143' ' ' GLY . 13.9 m -80.79 91.91 6.0 Favored 'General case' 0 C--O 1.239 0.527 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 -175.401 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 233' ' ' ILE . . . . . . . . . . . . . 6.6 tt -137.62 99.15 1.61 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.721 0 C-N-CA 124.588 1.155 . . . . 0.0 108.062 -176.66 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 234' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -90.3 35.94 0.87 Allowed 'General case' 0 N--CA 1.478 0.957 0 CA-C-N 114.859 -1.064 . . . . 0.0 111.156 -176.361 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 13.6 p-10 -58.34 -35.04 71.32 Favored 'General case' 0 N--CA 1.479 0.983 0 C-N-CA 124.062 0.945 . . . . 0.0 110.029 175.177 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 236' ' ' ASN . . . . . . . . . . . . . 50.0 m-80 -113.68 106.35 53.97 Favored Pre-proline 0 CA--C 1.537 0.459 0 CA-C-N 114.594 -1.185 . . . . 0.0 107.84 165.335 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -60.7 -49.99 7.53 Favored 'Trans proline' 0 C--N 1.374 1.912 0 C-N-CA 122.125 1.884 . . . . 0.0 110.009 167.362 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 238' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 -136.42 145.49 45.34 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 125.239 1.415 . . . . 0.0 107.769 173.529 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 239' ' ' ILE . . . . . . . . . . . . . 12.9 tt -154.18 70.53 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 CA-C-O 122.886 1.327 . . . . 0.0 108.549 175.722 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 . . . . . 0 C--O 1.247 0.956 0 CA-C-N 114.59 -1.186 . . . . 0.0 108.781 -174.069 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 251' ' ' BEZ . . . . . 0.466 ' H6 ' HG21 ' A' ' 216' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 253' ' ' LYS . . . . . 0.693 ' HD3' ' HA ' ' A' ' 215' ' ' VAL . 54.0 pttt -67.0 146.1 54.71 Favored 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 124.02 0.928 . . . . 0.0 111.625 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 254' ' ' ARG . . . . . 0.458 ' HA ' ' HB3' ' A' ' 47' ' ' GLU . 22.5 mtm-85 -84.87 24.82 1.0 Allowed 'General case' 0 N--CA 1.489 1.48 0 C-N-CA 123.943 0.897 . . . . 0.0 110.925 171.204 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 255' ' ' M9P . . . . . 0.422 ' NH1' ' HG2' ' A' ' 46' ' ' GLU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.678 0 N-CA-C 112.288 -0.325 . . . . 0.0 112.288 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.536 ' HB3' ' HB3' ' A' ' 117' ' ' ALA . 42.9 t -167.73 -62.73 0.03 OUTLIER 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 123.922 0.889 . . . . 0.0 110.061 177.823 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -165.22 -170.96 2.04 Favored 'General case' 0 N--CA 1.482 1.143 0 C-N-CA 124.233 1.013 . . . . 0.0 110.169 -178.068 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -155.9 47.42 0.49 Allowed 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 124.246 1.018 . . . . 0.0 108.356 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 22.3 m-20 -144.33 -18.38 0.55 Allowed 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 113.229 0.826 . . . . 0.0 113.229 -158.478 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.656 ' HB2' ' HG ' ' A' ' 119' ' ' LEU . 1.9 mt -75.88 92.12 3.06 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 118.143 0.429 . . . . 0.0 111.124 -158.436 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -77.2 141.06 40.25 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.969 0.89 . . . . 0.0 111.575 -174.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . 0.467 ' HB3' ' CE2' ' A' ' 84' ' ' TYR . 11.3 mp -83.69 115.38 22.15 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 113.587 -1.642 . . . . 0.0 107.586 175.416 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -111.6 126.37 54.93 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 108.374 -0.972 . . . . 0.0 108.374 179.37 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.603 HH22 ' HB3' ' A' ' 13' ' ' ASP . 60.8 ttt85 -75.03 129.19 37.2 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 120.527 0.203 . . . . 0.0 110.539 -177.469 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . 0.474 ' HB1' ' HG3' ' A' ' 85' ' ' ARG . . . -104.23 -35.07 8.13 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 123.177 0.591 . . . . 0.0 109.96 175.149 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -177.72 -160.95 0.05 Allowed 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 124.421 1.088 . . . . 0.0 110.59 -175.218 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.603 ' HB3' HH22 ' A' ' 10' ' ' ARG . 6.8 p-10 -126.56 170.03 12.46 Favored 'General case' 0 N--CA 1.476 0.87 0 C-N-CA 124.149 0.98 . . . . 0.0 109.847 171.568 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 60.2 t -73.66 104.4 2.5 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.861 -177.414 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 59.2 pttt -164.81 146.29 7.94 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 124.278 1.031 . . . . 0.0 108.804 -178.464 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 24.7 t90 -84.11 113.92 21.4 Favored 'General case' 0 CA--C 1.544 0.713 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 177.395 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 38.2 mm-40 -67.89 147.11 52.94 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 123.557 0.743 . . . . 0.0 111.54 174.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -70.44 -2.46 13.9 Favored 'General case' 0 CA--C 1.556 1.18 0 C-N-CA 125.153 1.381 . . . . 0.0 111.807 175.593 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . 0.52 ' HB2' ' H ' ' A' ' 169' ' ' ALA . 12.9 mm100 -80.14 14.11 2.02 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 124.532 1.133 . . . . 0.0 112.585 -174.355 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -53.89 100.32 0.03 OUTLIER 'General case' 0 C--N 1.364 1.196 0 C-N-CA 124.605 1.162 . . . . 0.0 112.92 -168.743 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.6 mm-40 -82.74 121.88 27.45 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.165 179.294 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 3.6 mp -78.62 103.5 5.66 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.807 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 63.5 m -142.64 -171.59 3.46 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 125.403 1.481 . . . . 0.0 107.2 174.163 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.419 ' HA3' ' H ' ' A' ' 173' ' ' LYS . . . 133.67 148.66 5.9 Favored Glycine 0 N--CA 1.468 0.828 0 N-CA-C 114.887 0.715 . . . . 0.0 114.887 169.37 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.471 ' HB2' ' HB2' ' A' ' 173' ' ' LYS . 15.4 t 65.57 97.98 0.05 OUTLIER 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 125.07 1.348 . . . . 0.0 111.733 173.317 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 15.6 m -111.29 160.96 27.27 Favored Pre-proline 0 CA--C 1.553 1.069 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 169.291 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -57.28 158.59 18.05 Favored 'Trans proline' 0 C--N 1.384 2.418 0 C-N-CA 122.715 2.277 . . . . 0.0 113.074 -176.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 35.5 mm -57.74 120.87 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 123.63 0.772 . . . . 0.0 110.334 -177.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.506 HD21 ' HE1' ' A' ' 177' ' ' PHE . 38.1 tp -98.85 143.12 29.53 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 115.096 -0.957 . . . . 0.0 110.145 -170.343 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.475 ' HG ' ' HB3' ' A' ' 178' ' ' LYS . 50.4 m -123.06 116.46 23.54 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 122.872 0.469 . . . . 0.0 109.766 -175.789 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 14.4 pt -138.29 173.48 12.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 C-N-CA 124.149 0.98 . . . . 0.0 110.155 178.475 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 36.4 p -93.85 125.26 38.37 Favored 'General case' 0 C--N 1.353 0.736 0 C-N-CA 122.787 0.435 . . . . 0.0 109.92 -173.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 10.6 tp -65.15 128.55 28.07 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.001 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 170.058 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 24.8 t -108.47 103.61 12.78 Favored 'General case' 0 C--O 1.267 2.005 0 CA-C-O 121.437 0.637 . . . . 0.0 109.567 -176.251 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 68.26 -79.57 0.04 OUTLIER 'General case' 0 C--N 1.357 0.914 0 CA-C-N 113.179 -1.828 . . . . 0.0 111.282 176.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -144.37 -72.84 0.27 Allowed 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.873 0.869 . . . . 0.0 109.26 -177.799 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -97.95 4.95 61.32 Favored Glycine 0 C--N 1.347 1.171 0 CA-C-O 118.812 -0.993 . . . . 0.0 114.227 -174.325 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 35.8 t -107.04 164.33 12.24 Favored 'General case' 0 C--N 1.359 1.021 0 CA-C-N 119.026 1.413 . . . . 0.0 107.967 172.405 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 39.7 ttp -164.24 126.47 2.36 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 178.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.457 ' HA ' HG11 ' A' ' 215' ' ' VAL . 68.3 m -150.95 -178.91 6.87 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 123.53 0.732 . . . . 0.0 110.968 -173.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.766 HD11 HG22 ' A' ' 217' ' ' THR . 2.3 mp -83.95 97.88 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 N-CA-C 105.729 -1.952 . . . . 0.0 105.729 163.255 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 13.2 mptt 57.64 -86.24 0.02 OUTLIER 'General case' 0 CA--C 1.55 0.952 0 C-N-CA 124.139 0.976 . . . . 0.0 108.731 -165.226 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 8.7 t30 -140.54 140.05 35.15 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 123.553 0.741 . . . . 0.0 109.318 172.001 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -154.86 121.64 5.45 Favored 'General case' 0 CA--C 1.537 0.458 0 N-CA-C 106.406 -1.702 . . . . 0.0 106.406 179.204 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.3 tp10 -163.09 136.28 5.7 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 122.836 0.454 . . . . 0.0 110.33 -177.067 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -143.31 135.54 27.05 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 123.336 0.654 . . . . 0.0 110.987 179.563 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 28.7 mm-40 -80.43 93.85 6.08 Favored 'General case' 0 C--O 1.243 0.719 0 C-N-CA 123.628 0.771 . . . . 0.0 109.454 169.193 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 51.8 tt0 -76.26 150.45 36.99 Favored 'General case' 0 N--CA 1.475 0.796 0 N-CA-C 109.114 -0.698 . . . . 0.0 109.114 174.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 95.0 m -147.08 124.47 11.62 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 123.142 0.577 . . . . 0.0 109.947 179.553 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.451 HD23 ' HB2' ' A' ' 163' ' ' PRO . 61.0 tp -164.41 -70.12 0.04 OUTLIER 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 175.207 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 70.1 -133.3 24.31 Favored Glycine 0 CA--C 1.531 1.058 0 CA-C-N 115.388 -0.824 . . . . 0.0 112.929 -175.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 155.26 -24.81 0.6 Allowed Glycine 0 C--N 1.348 1.241 0 C-N-CA 122.941 0.305 . . . . 0.0 113.285 177.254 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -77.12 79.15 1.35 Allowed Glycine 0 C--N 1.341 0.831 0 C-N-CA 123.68 0.657 . . . . 0.0 112.755 -179.254 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 62.44 -157.92 36.39 Favored Glycine 0 C--N 1.351 1.406 0 O-C-N 124.103 0.531 . . . . 0.0 112.811 -177.429 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 25.7 t -143.77 39.74 1.38 Allowed 'General case' 0 N--CA 1.476 0.869 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 176.464 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 80.1 -69.22 3.14 Favored Glycine 0 C--N 1.352 1.454 0 CA-C-N 115.405 -0.816 . . . . 0.0 113.522 173.514 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -65.37 98.55 0.33 Allowed Glycine 0 C--N 1.348 1.231 0 O-C-N 124.089 0.523 . . . . 0.0 113.243 -178.82 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.537 ' HA3' ' HB3' ' A' ' 62' ' ' ALA . . . 149.44 -29.2 1.19 Allowed Glycine 0 N--CA 1.466 0.68 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 -173.55 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 68.91 -84.72 0.21 Allowed Glycine 0 C--N 1.355 1.637 0 O-C-N 124.455 0.738 . . . . 0.0 113.776 169.45 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . 0.407 ' HA ' ' HE2' ' A' ' 122' ' ' LYS . 13.7 mt-10 -82.73 -26.46 31.93 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.268 0.627 . . . . 0.0 110.74 -179.655 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -98.75 -65.25 0.97 Allowed 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 123.712 0.805 . . . . 0.0 109.87 -175.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.537 ' HB3' ' HA3' ' A' ' 58' ' ' GLY . . . -97.2 48.03 1.04 Allowed 'General case' 0 N--CA 1.481 1.107 0 CA-C-O 121.559 0.695 . . . . 0.0 110.813 179.679 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -149.8 -105.66 0.34 Allowed Glycine 0 C--N 1.338 0.663 0 N-CA-C 109.239 -1.545 . . . . 0.0 109.239 174.507 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.755 HG22 ' HB2' ' A' ' 122' ' ' LYS . 2.4 m -140.75 -166.41 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 C-N-CA 123.803 0.841 . . . . 0.0 109.201 172.214 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.409 HD22 ' HE3' ' A' ' 122' ' ' LYS . 2.1 tm? -145.53 132.56 20.31 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 107.656 -1.238 . . . . 0.0 107.656 -178.21 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . 0.613 ' HE1' ' HB3' ' A' ' 122' ' ' LYS . 1.1 m0 -89.92 109.3 20.33 Favored 'General case' 0 C--N 1.361 1.072 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 174.563 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -69.48 109.53 4.28 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 171.275 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 18.3 m -125.63 160.75 54.47 Favored Pre-proline 0 N--CA 1.479 1.0 0 C-N-CA 123.277 0.631 . . . . 0.0 110.52 -173.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -64.84 163.59 27.53 Favored 'Trans proline' 0 C--N 1.375 1.933 0 C-N-CA 122.373 2.049 . . . . 0.0 112.61 174.037 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 56.8 p -103.85 160.46 26.02 Favored Pre-proline 0 CA--C 1.557 1.249 0 C-N-CA 123.778 0.831 . . . . 0.0 109.821 178.226 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_endo -43.66 -35.36 6.33 Favored 'Trans proline' 0 CA--C 1.575 2.567 0 C-N-CA 124.722 3.614 . . . . 0.0 117.224 176.506 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_exo -48.35 152.1 4.06 Favored 'Trans proline' 0 C--N 1.402 3.348 0 C-N-CA 122.289 1.993 . . . . 0.0 113.968 165.239 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_exo -59.3 83.15 0.06 OUTLIER 'Trans proline' 0 C--N 1.383 2.385 0 C-N-CA 123.348 2.699 . . . . 0.0 114.009 -177.156 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 5.7 m -141.53 -174.33 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 C-N-CA 125.326 1.45 . . . . 0.0 109.073 174.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 122.32 49.55 0.25 Allowed Glycine 0 C--N 1.349 1.273 0 N-CA-C 111.343 -0.703 . . . . 0.0 111.343 -177.279 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 17.6 pttp -82.39 -62.49 1.6 Allowed 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 123.423 0.689 . . . . 0.0 111.696 -169.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -174.38 19.26 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.244 0 C-N-CA 124.002 0.921 . . . . 0.0 110.25 -173.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -91.66 12.67 20.37 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 124.538 1.135 . . . . 0.0 111.514 -172.635 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.646 HD13 ' HA2' ' A' ' 105' ' ' GLY . 0.3 OUTLIER -73.72 67.94 1.2 Allowed 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 124.362 1.065 . . . . 0.0 112.43 -173.963 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.406 ' HG3' ' HH ' ' A' ' 84' ' ' TYR . 11.9 tp10 52.96 77.87 0.15 Allowed 'General case' 0 C--O 1.244 0.765 0 C-N-CA 125.35 1.46 . . . . 0.0 112.366 176.43 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . 0.509 ' HB2' ' HA ' ' A' ' 103' ' ' LYS . 8.2 p-10 -119.87 146.76 45.45 Favored 'General case' 0 C--O 1.245 0.861 0 CA-C-N 114.633 -1.167 . . . . 0.0 109.579 -179.268 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 159.52 -163.73 33.66 Favored Glycine 0 C--N 1.343 0.917 0 CA-C-N 116.031 -0.531 . . . . 0.0 113.396 178.536 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -89.84 123.99 34.29 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 124.137 0.975 . . . . 0.0 109.232 -177.451 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . 0.467 ' CE2' ' HB3' ' A' ' 8' ' ' LEU . 4.0 m-85 -126.09 151.38 47.29 Favored 'General case' 0 N--CA 1.48 1.034 0 C-N-CA 123.723 0.809 . . . . 0.0 112.09 -166.566 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . 0.504 ' HA ' ' HA ' ' A' ' 99' ' ' ALA . 25.3 mtm180 -113.71 131.02 56.33 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 124.817 1.247 . . . . 0.0 107.897 167.371 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 25.7 mt -94.33 124.55 46.85 Favored 'Isoleucine or valine' 0 C--O 1.249 1.048 0 CA-C-O 121.684 0.754 . . . . 0.0 110.513 -179.401 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.498 ' HD3' ' HB3' ' A' ' 94' ' ' TYR . 1.7 ttmp? -105.72 136.68 44.88 Favored 'General case' 0 C--O 1.213 -0.816 0 C-N-CA 126.114 1.766 . . . . 0.0 108.305 177.599 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 22.9 tm0? -83.07 106.98 15.33 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 104.435 -2.431 . . . . 0.0 104.435 166.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 1.9 tmtp? -118.49 95.21 4.77 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-N 114.975 -1.011 . . . . 0.0 108.298 -166.577 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -82.48 150.52 28.53 Favored Glycine 0 C--O 1.248 1.012 0 N-CA-C 108.911 -1.675 . . . . 0.0 108.911 166.562 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 16.1 mm -80.2 59.63 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.265 0 CA-C-O 121.614 0.721 . . . . 0.0 109.07 -177.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 4.6 pp 168.55 -20.59 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 126.331 1.853 . . . . 0.0 110.433 -173.662 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -157.36 145.51 12.08 Favored Glycine 0 C--N 1.37 2.462 0 CA-C-O 119.841 -0.422 . . . . 0.0 113.239 -174.703 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . 0.498 ' HB3' ' HD3' ' A' ' 87' ' ' LYS . 28.3 m-85 -130.56 147.67 52.27 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-N 117.434 0.617 . . . . 0.0 111.192 -171.177 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 25.1 t -151.18 149.83 29.92 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 123.806 0.843 . . . . 0.0 109.447 175.2 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . . . . . . . . . 22.2 tp60 -94.83 111.22 23.01 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 108.858 -0.794 . . . . 0.0 108.858 177.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.428 HD12 ' HB3' ' A' ' 6' ' ' LEU . 28.6 pt -106.33 -16.86 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 N-CA-C 113.375 0.88 . . . . 0.0 113.375 -173.222 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 170.35 -146.32 9.76 Favored Glycine 0 N--CA 1.472 1.044 0 C-N-CA 120.453 -0.879 . . . . 0.0 113.193 173.604 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.504 ' HA ' ' HA ' ' A' ' 85' ' ' ARG . . . -149.32 176.36 10.62 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 123.684 0.794 . . . . 0.0 110.787 177.904 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -166.81 -170.52 31.81 Favored Glycine 0 C--N 1.344 1.02 0 N-CA-C 111.368 -0.693 . . . . 0.0 111.368 178.12 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 6.2 p -142.83 117.4 4.34 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.728 0 C-N-CA 124.034 0.934 . . . . 0.0 109.278 178.432 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 3.0 t80 -88.5 136.71 32.86 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 171.313 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.509 ' HA ' ' HB2' ' A' ' 81' ' ' ASP . 17.2 tptp -160.12 153.47 22.14 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 110.41 -0.219 . . . . 0.0 110.41 177.244 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 71.52 -85.47 0.03 OUTLIER 'General case' 0 CA--C 1.55 0.981 0 C-N-CA 124.868 1.267 . . . . 0.0 110.576 169.651 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . 0.646 ' HA2' HD13 ' A' ' 79' ' ' LEU . . . -155.88 24.81 0.56 Allowed Glycine 0 N--CA 1.469 0.889 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 174.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' THR . . . . . 0.727 HG23 ' HA3' ' A' ' 141' ' ' GLY . 7.0 p -147.03 151.75 37.45 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.377 1.071 . . . . 0.0 110.011 -167.865 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' PHE . . . . . 0.508 ' HB3' ' HB3' ' A' ' 140' ' ' TYR . 31.4 t80 -104.63 139.16 39.88 Favored 'General case' 0 N--CA 1.484 1.235 0 N-CA-C 108.031 -1.099 . . . . 0.0 108.031 174.02 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . 0.419 ' HB3' ' CZ3' ' A' ' 144' ' ' TRP . 78.0 m-70 -132.35 113.58 13.36 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 123.549 0.74 . . . . 0.0 110.173 -175.555 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 9.0 t -136.47 -177.8 4.88 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 122.761 0.424 . . . . 0.0 110.673 177.495 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' MET . . . . . 0.496 ' SD ' ' HE1' ' A' ' 112' ' ' HIS . 3.3 mtp -89.52 152.42 21.44 Favored 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 123.677 0.791 . . . . 0.0 110.195 178.656 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 53.9 t90 -73.45 -39.13 65.2 Favored 'General case' 0 CA--C 1.542 0.642 0 O-C-N 123.634 0.584 . . . . 0.0 110.365 -175.848 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . 0.496 ' HE1' ' SD ' ' A' ' 110' ' ' MET . 18.6 p-80 -65.87 -8.39 21.76 Favored 'General case' 0 N--CA 1.49 1.555 0 C-N-CA 124.474 1.11 . . . . 0.0 113.087 -172.665 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 95.1 t -58.08 -37.97 64.82 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.977 0 C-N-CA 123.366 0.666 . . . . 0.0 110.1 178.231 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.401 ' HB ' ' OG ' ' A' ' 2' ' ' SER . 17.5 p -147.78 -163.08 1.69 Allowed 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 124.448 1.099 . . . . 0.0 109.989 169.435 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.452 ' HB3' ' HB2' ' A' ' 2' ' ' SER . 17.8 tpp180 -90.83 5.23 49.26 Favored 'General case' 0 CA--C 1.559 1.296 0 C-N-CA 123.562 0.745 . . . . 0.0 111.152 176.248 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 107.1 63.49 0.59 Allowed Glycine 0 C--N 1.35 1.329 0 N-CA-C 111.799 -0.52 . . . . 0.0 111.799 -178.364 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . 0.582 ' HB2' HD13 ' A' ' 6' ' ' LEU . . . -95.33 168.39 10.75 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 123.811 0.844 . . . . 0.0 111.823 -179.363 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.418 HG22 ' HA ' ' A' ' 127' ' ' GLU . 14.9 p -86.5 141.41 14.44 Favored 'Isoleucine or valine' 0 C--O 1.245 0.845 0 N-CA-C 108.369 -0.975 . . . . 0.0 108.369 165.565 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.656 ' HG ' ' HB2' ' A' ' 6' ' ' LEU . 6.4 mp -102.03 174.62 5.85 Favored 'General case' 0 C--O 1.222 -0.35 0 C-N-CA 124.072 0.949 . . . . 0.0 111.291 -173.667 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 25.4 mmt -121.78 165.71 15.43 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 125.36 1.464 . . . . 0.0 108.752 177.194 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 12.1 t-80 -170.03 97.44 0.28 Allowed 'General case' 0 C--O 1.246 0.879 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 166.435 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.755 ' HB2' HG22 ' A' ' 64' ' ' VAL . 49.1 tttm 56.87 37.63 28.92 Favored 'General case' 0 N--CA 1.489 1.483 0 CA-C-O 121.91 0.862 . . . . 0.0 110.889 173.358 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 101.38 -12.09 58.37 Favored Glycine 0 C--N 1.348 1.22 0 CA-C-O 119.135 -0.814 . . . . 0.0 114.349 177.007 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 53.4 mtpt -102.56 135.18 44.65 Favored 'General case' 0 N--CA 1.49 1.569 0 CA-C-N 118.155 0.977 . . . . 0.0 110.712 178.506 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . 0.435 ' HA ' ' O ' ' A' ' 119' ' ' LEU . 0.1 OUTLIER -85.21 122.79 29.9 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 123.196 0.599 . . . . 0.0 110.82 177.667 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.515 HG23 ' HB2' ' A' ' 140' ' ' TYR . 1.8 mp -87.13 100.07 9.38 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.917 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 172.606 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . 0.418 ' HA ' HG22 ' A' ' 118' ' ' VAL . 36.5 tt0 -92.42 104.63 11.61 Favored Pre-proline 0 CA--C 1.545 0.787 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.371 -177.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 12.9 Cg_exo -68.69 98.2 0.58 Allowed 'Trans proline' 0 C--N 1.374 1.905 0 C-N-CA 122.534 2.156 . . . . 0.0 112.195 -175.697 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 6.4 p -69.08 -24.66 64.17 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 123.797 0.839 . . . . 0.0 111.231 176.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.549 ' HB2' ' HA2' ' A' ' 142' ' ' GLY . 59.7 t-105 -107.32 138.43 43.52 Favored 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 108.712 -0.848 . . . . 0.0 108.712 171.334 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -155.35 120.89 4.99 Favored 'General case' 0 C--O 1.238 0.494 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 176.393 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -143.07 114.08 7.7 Favored 'General case' 0 CA--C 1.544 0.728 0 CA-C-O 120.879 0.371 . . . . 0.0 110.98 -178.099 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 14.2 p -77.45 -17.43 14.29 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.309 0 C-N-CA 124.219 1.008 . . . . 0.0 112.423 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 65.4 mttm -71.73 -45.52 61.5 Favored 'General case' 0 N--CA 1.485 1.306 0 C-N-CA 123.177 0.591 . . . . 0.0 110.735 -173.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . 0.601 ' HG2' ' HG2' ' A' ' 230' ' ' GLU . 4.6 mptp? -88.64 -10.06 49.92 Favored 'General case' 0 N--CA 1.477 0.898 0 C-N-CA 124.653 1.181 . . . . 0.0 109.897 174.876 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 56.1 t0 63.02 46.11 4.92 Favored 'General case' 0 C--N 1.36 1.037 0 O-C-N 124.549 1.156 . . . . 0.0 109.426 -177.124 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 96.2 mt -136.71 127.67 27.61 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.696 0.798 . . . . 0.0 110.392 -179.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 17.8 tt -124.14 136.81 59.18 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 175.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 80.5 p -148.58 146.0 28.07 Favored 'General case' 0 N--CA 1.475 0.796 0 CA-C-O 121.843 0.83 . . . . 0.0 113.146 -171.162 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.515 ' HB2' HG23 ' A' ' 126' ' ' ILE . 81.3 t80 -84.6 122.17 28.66 Favored 'General case' 0 N--CA 1.473 0.695 0 CA-C-N 114.446 -1.252 . . . . 0.0 108.396 172.601 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . 0.727 ' HA3' HG23 ' A' ' 106' ' ' THR . . . 123.69 -82.47 0.35 Allowed Glycine 0 C--N 1.34 0.801 0 O-C-N 124.281 0.988 . . . . 0.0 111.637 177.676 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . 0.549 ' HA2' ' HB2' ' A' ' 130' ' ' TRP . . . 147.57 84.09 0.05 OUTLIER Glycine 0 C--O 1.24 0.495 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 172.683 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 146.94 176.34 20.62 Favored Glycine 0 C--O 1.241 0.565 0 N-CA-C 111.233 -0.747 . . . . 0.0 111.233 177.312 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' TRP . . . . . 0.549 ' HH2' HD11 ' A' ' 210' ' ' LEU . 69.2 t-105 -110.16 109.21 19.64 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 166.491 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 28.7 mmmt -108.98 107.43 17.79 Favored 'General case' 0 N--CA 1.471 0.621 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -175.412 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' LEU . . . . . . . . . . . . . 60.2 mt -162.63 -45.74 0.04 OUTLIER 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 126.909 2.084 . . . . 0.0 106.784 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 63.89 22.88 13.17 Favored 'General case' 0 N--CA 1.482 1.128 0 C-N-CA 125.256 1.422 . . . . 0.0 112.758 176.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . 0.422 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -76.98 165.96 53.76 Favored Glycine 0 C--N 1.352 1.455 0 CA-C-N 116.262 -0.427 . . . . 0.0 113.017 179.543 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 22.2 tt0 -123.69 96.62 5.03 Favored 'General case' 0 C--O 1.239 0.506 0 C-N-CA 123.485 0.714 . . . . 0.0 109.26 -174.401 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' TRP . . . . . 0.54 ' HA ' ' HB ' ' A' ' 208' ' ' VAL . 29.1 t90 -55.63 116.05 2.68 Favored 'General case' 0 N--CA 1.481 1.098 0 O-C-N 123.308 0.38 . . . . 0.0 111.185 171.33 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 65.9 mttm -94.5 100.3 12.31 Favored 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 123.848 0.859 . . . . 0.0 109.419 -178.366 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -68.21 141.02 56.08 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 124.658 1.183 . . . . 0.0 111.918 -175.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 83.8 -23.56 6.63 Favored Glycine 0 C--N 1.351 1.389 0 CA-C-N 116.47 -0.332 . . . . 0.0 113.518 177.314 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -97.02 151.53 19.63 Favored 'General case' 0 C--O 1.24 0.57 0 C-N-CA 124.546 1.138 . . . . 0.0 108.53 -179.578 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . 0.426 ' HA ' ' HA ' ' A' ' 173' ' ' LYS . 1.2 pm0 -63.6 121.96 15.16 Favored 'General case' 0 C--N 1.345 0.406 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 176.051 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 33.9 m -89.93 179.51 0.5 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.537 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 174.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.47 133.4 51.21 Favored 'General case' 0 C--O 1.217 -0.641 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -175.87 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.437 ' O ' ' HA ' ' A' ' 169' ' ' ALA . 86.3 t -107.77 119.35 57.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 -176.795 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -93.1 77.43 4.63 Favored 'General case' 0 CA--C 1.54 0.584 0 N-CA-C 106.665 -1.605 . . . . 0.0 106.665 172.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -77.9 111.87 14.2 Favored 'General case' 0 CA--C 1.539 0.534 0 CA-C-N 114.69 -1.141 . . . . 0.0 111.006 -169.347 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 89.0 mt -79.1 102.61 8.52 Favored 'General case' 0 C--O 1.244 0.805 0 C-N-CA 123.993 0.917 . . . . 0.0 110.195 179.541 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . 0.518 ' HB2' ' HB2' ' A' ' 193' ' ' PRO . 39.1 tt0 -74.82 126.66 88.16 Favored Pre-proline 0 CA--C 1.541 0.614 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 173.124 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . 0.451 ' HB2' HD23 ' A' ' 50' ' ' LEU . 36.5 Cg_endo -64.13 116.03 3.48 Favored 'Trans proline' 0 C--N 1.376 1.988 0 C-N-CA 121.911 1.741 . . . . 0.0 110.375 173.753 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 113.1 -28.01 9.11 Favored Glycine 0 C--N 1.344 1.006 0 CA-C-O 119.583 -0.565 . . . . 0.0 113.816 177.369 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -136.47 -173.48 3.43 Favored 'General case' 0 N--CA 1.49 1.552 0 CA-C-N 117.986 0.893 . . . . 0.0 112.154 -175.08 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -60.0 161.27 12.88 Favored Pre-proline 0 CA--C 1.554 1.116 0 C-N-CA 124.983 1.313 . . . . 0.0 112.319 175.861 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -77.2 157.4 33.65 Favored 'Trans proline' 0 C--N 1.373 1.823 0 C-N-CA 122.016 1.811 . . . . 0.0 111.759 173.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . 0.506 HH11 ' HG3' ' A' ' 193' ' ' PRO . 58.7 mtp180 -124.58 131.97 53.46 Favored 'General case' 0 C--O 1.238 0.489 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.257 173.773 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . 0.52 ' H ' ' HB2' ' A' ' 19' ' ' GLN . . . -80.02 133.83 36.18 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.053 176.633 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 63.0 t -134.21 117.8 26.05 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.131 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 174.436 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 55.1 mt-30 -81.75 126.28 31.63 Favored 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 108.245 -1.021 . . . . 0.0 108.245 174.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 4.9 t -152.72 132.44 13.16 Favored 'General case' 0 CA--C 1.54 0.561 0 O-C-N 123.571 0.544 . . . . 0.0 111.738 -174.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . 0.471 ' HB2' ' HB2' ' A' ' 25' ' ' SER . 64.0 mttp -75.6 138.13 70.57 Favored Pre-proline 0 N--CA 1.475 0.782 0 C-N-CA 123.146 0.578 . . . . 0.0 110.069 171.69 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_endo -61.78 163.27 19.27 Favored 'Trans proline' 0 C--N 1.379 2.134 0 C-N-CA 123.091 2.527 . . . . 0.0 113.728 178.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -144.45 169.89 26.3 Favored Glycine 0 N--CA 1.468 0.785 0 N-CA-C 110.399 -1.08 . . . . 0.0 110.399 178.217 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 6.5 mp -124.34 152.13 43.5 Favored 'General case' 0 N--CA 1.488 1.463 0 CA-C-N 118.681 1.24 . . . . 0.0 111.887 -176.511 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 177' ' ' PHE . . . . . 0.506 ' HE1' HD21 ' A' ' 29' ' ' LEU . 68.4 m-85 -96.53 122.42 39.41 Favored 'General case' 0 C--N 1.344 0.356 0 CA-C-N 114.756 -1.111 . . . . 0.0 109.593 173.831 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 178' ' ' LYS . . . . . 0.475 ' HB3' ' HG ' ' A' ' 30' ' ' SER . 61.0 tttp -85.47 90.07 7.86 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 167.032 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 23.0 m -104.14 158.79 16.2 Favored 'General case' 0 C--O 1.242 0.689 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 -179.352 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -61.6 -34.88 76.4 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 122.356 0.262 . . . . 0.0 110.471 177.506 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -63.79 -33.85 76.59 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 123.572 0.749 . . . . 0.0 111.155 175.442 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 151.25 -169.13 30.88 Favored Glycine 0 C--N 1.342 0.888 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.97 177.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 183' ' ' THR . . . . . 0.45 ' HA ' ' O ' ' A' ' 177' ' ' PHE . 16.9 p -87.25 119.19 27.23 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 122.986 0.514 . . . . 0.0 109.776 176.522 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . 0.47 ' HB ' ' HB2' ' A' ' 177' ' ' PHE . 65.5 mt -103.01 144.51 13.69 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 124.223 1.009 . . . . 0.0 108.504 -176.833 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -99.23 120.24 6.79 Favored Glycine 0 C--N 1.345 1.038 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 -175.223 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . 0.414 ' HA ' ' HA ' ' A' ' 225' ' ' ALA . . . -146.93 -160.65 1.19 Allowed 'General case' 0 N--CA 1.465 0.294 0 C-N-CA 123.413 0.685 . . . . 0.0 111.102 -163.689 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 187' ' ' VAL . . . . . 0.415 ' HB ' HD12 ' A' ' 226' ' ' ILE . 3.7 p -132.22 103.86 7.13 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.989 0 C-N-CA 124.029 0.932 . . . . 0.0 108.498 169.552 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 188' ' ' SER . . . . . 0.515 ' HA ' HG13 ' A' ' 223' ' ' VAL . 15.6 t -76.96 100.65 5.68 Favored 'General case' 0 C--O 1.243 0.753 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.501 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -152.44 155.66 37.96 Favored 'General case' 0 C--N 1.358 0.939 0 CA-C-O 121.365 0.603 . . . . 0.0 110.689 -168.531 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 190' ' ' ASP . . . . . 0.627 ' HA ' ' HB2' ' A' ' 221' ' ' ALA . 16.6 t70 -69.08 162.76 26.26 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 124.869 1.267 . . . . 0.0 109.859 176.048 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 191' ' ' PHE . . . . . 0.519 ' HB3' ' H ' ' A' ' 222' ' ' TYR . 9.6 p90 -74.23 123.92 25.43 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-O 121.958 0.885 . . . . 0.0 110.522 -168.409 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 50.8 m -104.62 158.96 30.88 Favored Pre-proline 0 CA--C 1.547 0.854 0 CA-C-N 114.23 -1.35 . . . . 0.0 110.445 -174.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . 0.518 ' HB2' ' HB2' ' A' ' 162' ' ' GLU . 73.7 Cg_endo -72.78 69.69 3.62 Favored 'Trans proline' 0 C--N 1.372 1.8 0 C-N-CA 122.786 2.324 . . . . 0.0 112.2 173.44 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -154.01 146.63 15.02 Favored Glycine 0 C--N 1.347 1.145 0 CA-C-N 116.178 -0.465 . . . . 0.0 112.46 -177.42 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 25.3 p -110.39 156.37 20.87 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 123.684 0.793 . . . . 0.0 109.469 176.32 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.63 107.2 0.77 Allowed 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 123.858 0.863 . . . . 0.0 110.069 -175.557 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 132.6 -9.55 5.26 Favored Glycine 0 C--N 1.342 0.89 0 CA-C-N 114.749 -1.114 . . . . 0.0 112.338 -172.19 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 54.2 m -63.91 120.12 60.92 Favored Pre-proline 0 CA--C 1.55 0.953 0 C-N-CA 123.351 0.66 . . . . 0.0 109.553 173.48 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -60.39 125.29 17.04 Favored 'Trans proline' 0 C--N 1.375 1.949 0 C-N-CA 122.836 2.357 . . . . 0.0 112.292 -173.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 55.5 mt -88.22 107.56 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 173.665 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 201' ' ' ILE . . . . . 0.809 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 25.9 mt -97.06 176.55 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.044 0 C-N-CA 124.524 1.13 . . . . 0.0 108.942 -175.839 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 202' ' ' ASP . . . . . 0.413 ' N ' HG23 ' A' ' 201' ' ' ILE . 9.2 t70 -102.93 174.22 5.97 Favored 'General case' 0 C--O 1.24 0.604 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 169.886 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 2.4 mppt? -70.46 -28.74 65.25 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 123.84 0.856 . . . . 0.0 109.051 174.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp -81.96 1.6 34.65 Favored 'General case' 0 N--CA 1.477 0.878 0 C-N-CA 123.958 0.903 . . . . 0.0 111.927 178.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 90.96 -4.82 81.84 Favored Glycine 0 C--N 1.351 1.403 0 CA-C-O 119.965 -0.353 . . . . 0.0 113.562 177.249 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 31.3 mmtp -78.25 108.89 11.9 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 122.931 0.492 . . . . 0.0 110.064 179.651 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . 0.809 ' HA ' ' HA ' ' A' ' 201' ' ' ILE . 4.8 p -63.66 103.06 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.053 0 CA-C-O 121.437 0.636 . . . . 0.0 110.218 177.076 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 208' ' ' VAL . . . . . 0.54 ' HB ' ' HA ' ' A' ' 150' ' ' TRP . 27.2 m -81.68 -18.37 11.43 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.987 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.287 -169.782 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . . . . . . . . . . . 170.89 -138.84 5.15 Favored Glycine 0 C--N 1.344 0.99 0 CA-C-N 115.446 -0.797 . . . . 0.0 112.351 179.506 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . 0.549 HD11 ' HH2' ' A' ' 144' ' ' TRP . 4.9 tt -153.41 154.13 33.85 Favored 'General case' 0 CA--C 1.549 0.904 0 C-N-CA 123.864 0.866 . . . . 0.0 109.825 -168.219 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -67.97 114.42 6.5 Favored 'General case' 0 N--CA 1.481 1.12 0 C-N-CA 123.885 0.874 . . . . 0.0 109.868 -178.78 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -74.65 -136.67 0.44 Allowed Glycine 0 CA--C 1.528 0.895 0 O-C-N 124.349 1.031 . . . . 0.0 114.754 -169.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 213' ' ' ASN . . . . . . . . . . . . . 49.0 t-20 -123.99 135.15 53.44 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 -175.164 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 214' ' ' GLY . . . . . 0.513 ' HA3' ' HA ' ' A' ' 224' ' ' SER . . . -164.37 -152.42 6.96 Favored Glycine 0 CA--C 1.506 -0.528 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.918 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 215' ' ' VAL . . . . . 0.457 HG11 ' HA ' ' A' ' 40' ' ' SER . 7.4 p -162.76 157.09 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 123.02 0.528 . . . . 0.0 110.445 -171.412 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 216' ' ' VAL . . . . . 0.46 ' HA ' ' HA ' ' A' ' 222' ' ' TYR . 93.0 t -70.93 116.38 12.36 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 C-N-CA 123.891 0.877 . . . . 0.0 109.064 174.553 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 217' ' ' THR . . . . . 0.766 HG22 HD11 ' A' ' 41' ' ' ILE . 72.9 p -130.68 163.48 27.12 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 125.256 1.423 . . . . 0.0 109.525 -173.572 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 10.1 ttp180 54.31 76.57 0.23 Allowed 'General case' 0 CA--C 1.561 1.367 0 C-N-CA 123.133 0.573 . . . . 0.0 111.957 161.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 45.1 m 71.91 -5.69 1.64 Allowed 'General case' 0 N--CA 1.492 1.663 0 C-N-CA 124.901 1.28 . . . . 0.0 114.393 176.21 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . 118.27 43.82 0.54 Allowed Glycine 0 C--N 1.357 1.71 0 CA-C-N 118.583 0.629 . . . . 0.0 112.909 176.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . 0.627 ' HB2' ' HA ' ' A' ' 190' ' ' ASP . . . -130.39 120.91 24.99 Favored 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 124.712 1.205 . . . . 0.0 109.578 -178.611 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 222' ' ' TYR . . . . . 0.519 ' H ' ' HB3' ' A' ' 191' ' ' PHE . 11.0 p90 -86.3 127.45 34.78 Favored 'General case' 0 C--N 1.351 0.665 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 -169.643 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . 0.515 HG13 ' HA ' ' A' ' 188' ' ' SER . 96.4 t -113.49 132.95 60.95 Favored 'Isoleucine or valine' 0 C--O 1.241 0.633 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 176.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 224' ' ' SER . . . . . 0.513 ' HA ' ' HA3' ' A' ' 214' ' ' GLY . 35.8 t -136.3 158.74 43.71 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 124.199 0.999 . . . . 0.0 109.959 -168.898 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . 0.414 ' HA ' ' HA ' ' A' ' 186' ' ' ALA . . . -68.73 166.51 17.28 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 123.708 0.803 . . . . 0.0 111.234 175.232 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 226' ' ' ILE . . . . . 0.415 HD12 ' HB ' ' A' ' 187' ' ' VAL . 70.9 mt -108.71 111.56 36.55 Favored 'Isoleucine or valine' 0 C--O 1.243 0.731 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 168.634 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -74.62 131.83 41.25 Favored 'General case' 0 C--N 1.345 0.381 0 N-CA-C 107.516 -1.291 . . . . 0.0 107.516 169.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -111.39 171.12 7.67 Favored 'General case' 0 C--O 1.248 1.01 0 C-N-CA 123.626 0.77 . . . . 0.0 109.371 -177.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.466 ' HA ' ' CD1' ' A' ' 144' ' ' TRP . 87.1 m -66.94 115.31 6.53 Favored 'General case' 0 CA--C 1.544 0.738 0 O-C-N 123.59 0.556 . . . . 0.0 110.618 178.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 230' ' ' GLU . . . . . 0.601 ' HG2' ' HG2' ' A' ' 135' ' ' LYS . 10.0 tp10 -117.0 62.75 0.73 Allowed 'General case' 0 C--O 1.242 0.68 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 175.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 24.3 pttm -66.97 157.45 33.33 Favored 'General case' 0 N--CA 1.472 0.662 0 CA-C-N 114.985 -1.007 . . . . 0.0 112.911 -165.733 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 19.8 p -50.51 106.55 0.13 Allowed 'General case' 0 CA--C 1.549 0.926 0 CA-C-N 113.935 -1.484 . . . . 0.0 112.132 -178.074 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 233' ' ' ILE . . . . . 0.426 ' O ' HG12 ' A' ' 233' ' ' ILE . 1.4 tt -90.14 7.37 4.07 Favored 'Isoleucine or valine' 0 CA--C 1.562 1.426 0 C-N-CA 124.309 1.044 . . . . 0.0 110.341 176.158 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 234' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 64.86 31.83 11.28 Favored 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 124.486 1.115 . . . . 0.0 110.815 -174.261 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -62.05 -51.49 67.75 Favored 'General case' 0 N--CA 1.479 0.999 0 C-N-CA 123.86 0.864 . . . . 0.0 108.678 171.016 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 236' ' ' ASN . . . . . . . . . . . . . 4.7 p-10 -74.94 149.02 85.13 Favored Pre-proline 0 C--O 1.244 0.779 0 CA-C-N 114.039 -1.437 . . . . 0.0 109.174 168.014 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 16.3 Cg_endo -57.97 142.48 96.66 Favored 'Trans proline' 0 C--N 1.376 2.018 0 C-N-CA 121.848 1.699 . . . . 0.0 111.311 175.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 238' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -65.5 -27.55 68.56 Favored 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 123.505 0.722 . . . . 0.0 110.951 -178.051 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 239' ' ' ILE . . . . . . . . . . . . . 3.8 mp -79.41 -6.87 9.96 Favored 'Isoleucine or valine' 0 CA--C 1.568 1.638 0 C-N-CA 124.358 1.063 . . . . 0.0 109.698 -179.241 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 . . . . . 0 C--O 1.254 1.323 0 C-N-CA 125.152 1.381 . . . . 0.0 110.594 177.27 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 251' ' ' BEZ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 253' ' ' LYS . . . . . . . . . . . . . 5.0 tppp? -57.73 91.23 0.01 OUTLIER 'General case' 0 CA--C 1.55 0.979 0 C-N-CA 123.79 0.836 . . . . 0.0 112.124 -176.397 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 254' ' ' ARG . . . . . . . . . . . . . 26.1 mtp180 -79.22 -15.45 58.01 Favored 'General case' 0 N--CA 1.482 1.151 0 CA-C-N 114.363 -1.289 . . . . 0.0 109.964 172.026 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 255' ' ' M9P . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.563 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 41.6 t -166.32 -52.44 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 123.335 0.654 . . . . 0.0 109.663 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 67.41 43.18 2.01 Favored 'General case' 0 N--CA 1.484 1.25 0 C-N-CA 123.962 0.905 . . . . 0.0 111.848 173.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -165.2 23.62 0.05 Allowed 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 123.142 0.577 . . . . 0.0 110.365 -175.489 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . 0.568 ' HA ' ' HE2' ' A' ' 120' ' ' MET . 8.9 p30 -175.55 64.73 0.02 OUTLIER 'General case' 0 C--N 1.344 0.367 0 C-N-CA 124.734 1.214 . . . . 0.0 108.069 -173.099 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.663 ' HB2' HD12 ' A' ' 119' ' ' LEU . 15.6 mt -79.58 177.52 8.81 Favored 'General case' 0 C--O 1.213 -0.868 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 168.078 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 17.3 tt0 -152.39 142.35 22.15 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-N 119.104 0.866 . . . . 0.0 111.56 171.15 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . 0.443 ' HB3' ' CD2' ' A' ' 84' ' ' TYR . 89.3 mt -87.9 114.37 24.45 Favored 'General case' 0 C--O 1.24 0.56 0 CA-C-N 114.012 -1.449 . . . . 0.0 110.007 175.029 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -106.79 117.75 34.87 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 173.583 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 21.2 ptt180 -58.98 121.77 12.04 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 122.83 0.452 . . . . 0.0 110.08 177.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -113.8 -33.83 5.67 Favored 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 122.609 0.364 . . . . 0.0 110.676 -176.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -169.17 -172.16 1.46 Allowed 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 123.938 0.895 . . . . 0.0 109.9 -179.096 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -102.04 160.29 14.63 Favored 'General case' 0 C--O 1.245 0.83 0 N-CA-C 107.818 -1.178 . . . . 0.0 107.818 169.208 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 99.7 t -72.38 100.09 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 170.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 63.7 tttt -155.54 127.74 7.68 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 115.126 -0.943 . . . . 0.0 108.725 -166.111 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . 0.47 ' HE1' ' HG2' ' A' ' 157' ' ' GLN . 40.6 t90 -69.74 121.64 17.62 Favored 'General case' 0 C--O 1.236 0.375 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 167.802 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.479 ' HB3' ' H ' ' A' ' 169' ' ' ALA . 9.4 tp10 -92.74 134.35 35.13 Favored 'General case' 0 C--O 1.238 0.486 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 173.11 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -72.25 0.24 10.38 Favored 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 124.171 0.988 . . . . 0.0 113.093 -173.276 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . 0.472 ' HG2' ' HG3' ' A' ' 17' ' ' GLU . 11.6 mm-40 -74.77 47.73 0.34 Allowed 'General case' 0 CA--C 1.557 1.212 0 C-N-CA 124.326 1.05 . . . . 0.0 111.185 175.206 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.446 ' HA ' ' O ' ' A' ' 169' ' ' ALA . . . -73.87 89.29 1.85 Allowed 'General case' 0 C--N 1.352 0.697 0 C-N-CA 123.915 0.886 . . . . 0.0 110.098 -176.644 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -88.19 141.26 28.7 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 114.762 -1.108 . . . . 0.0 109.196 179.638 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 44.4 mm -76.11 102.58 3.11 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.424 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 173.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 47.5 m -121.7 -71.85 0.71 Allowed 'General case' 0 CA--C 1.538 0.497 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.502 -167.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.479 ' HA3' HG21 ' A' ' 172' ' ' THR . . . -85.01 133.05 11.49 Favored Glycine 0 C--N 1.353 1.482 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 174.332 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.546 ' HA ' ' HB2' ' A' ' 173' ' ' LYS . 62.2 p -163.62 10.46 0.05 Allowed 'General case' 0 N--CA 1.481 1.085 0 CA-C-N 117.477 0.638 . . . . 0.0 112.106 -178.112 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 20.7 p -94.12 145.51 29.91 Favored Pre-proline 0 CA--C 1.55 0.962 0 C-N-CA 123.0 0.52 . . . . 0.0 110.245 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -89.45 -82.87 0.0 OUTLIER 'Trans proline' 0 C--N 1.379 2.144 0 C-N-CA 123.005 2.47 . . . . 0.0 114.29 -175.461 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.415 ' HA ' ' O ' ' A' ' 176' ' ' LEU . 33.0 mm -101.93 130.68 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 C-N-CA 122.788 0.435 . . . . 0.0 111.173 -169.84 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.691 HD21 HG22 ' A' ' 217' ' ' THR . 0.0 OUTLIER -139.19 161.37 37.58 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 123.613 0.765 . . . . 0.0 110.586 170.96 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 34.2 p -88.59 144.46 26.3 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 123.171 0.588 . . . . 0.0 111.45 -178.318 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 10.4 tt -155.37 152.63 8.72 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.175 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -178.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 3.9 m -97.99 109.42 22.18 Favored 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 123.153 0.581 . . . . 0.0 110.794 -173.076 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 18.1 tt -90.6 141.83 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 O-C-N 121.771 -0.581 . . . . 0.0 110.123 178.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 25.1 m -143.79 151.5 40.03 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 123.217 0.607 . . . . 0.0 111.05 -177.061 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 54.61 25.9 6.83 Favored 'General case' 0 N--CA 1.487 1.418 0 C-N-CA 124.338 1.055 . . . . 0.0 112.307 175.114 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.8 t70 73.35 -60.82 0.52 Allowed 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 125.759 1.624 . . . . 0.0 111.378 -173.648 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -89.21 -34.31 8.85 Favored Glycine 0 C--N 1.348 1.234 0 N-CA-C 114.713 0.645 . . . . 0.0 114.713 -173.523 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 24.4 t -87.34 105.11 17.02 Favored 'General case' 0 N--CA 1.484 1.261 0 CA-C-N 117.428 0.614 . . . . 0.0 109.398 -167.629 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' MET . . . . . 0.497 ' HE1' ' HE1' ' A' ' 177' ' ' PHE . 43.5 ttp -125.41 131.18 52.97 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 122.656 0.382 . . . . 0.0 110.278 -171.412 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.555 ' HB3' ' HE2' ' B' ' 253' ' ' LYS . 72.4 m -155.76 -178.36 7.24 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 125.179 1.392 . . . . 0.0 109.177 -175.318 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.52 HG12 HG11 ' A' ' 215' ' ' VAL . 44.8 mm -80.62 150.02 4.9 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.821 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 159.512 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 45.4 pttt -67.61 76.24 0.18 Allowed 'General case' 0 CA--C 1.556 1.189 0 CA-C-O 122.172 0.987 . . . . 0.0 109.839 167.128 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 -148.12 -168.03 2.97 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 124.906 1.282 . . . . 0.0 108.813 -178.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -134.93 160.26 38.84 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 123.381 0.672 . . . . 0.0 109.439 -179.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -111.12 133.1 53.74 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 123.788 0.835 . . . . 0.0 109.761 177.288 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -106.41 -41.38 5.31 Favored 'General case' 0 N--CA 1.475 0.783 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 174.452 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 48.3 mm-40 63.39 -168.73 0.2 Allowed 'General case' 0 C--N 1.352 0.708 0 C-N-CA 125.215 1.406 . . . . 0.0 113.523 175.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.465 HE21 ' HB3' ' A' ' 96' ' ' GLN . 0.3 OUTLIER -146.94 152.78 39.22 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 124.157 0.983 . . . . 0.0 109.198 -174.086 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 13.1 t -85.11 -11.38 55.3 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 123.247 0.619 . . . . 0.0 110.334 176.112 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 67.1 mt -56.4 131.11 47.44 Favored 'General case' 0 C--N 1.355 0.818 0 C-N-CA 124.449 1.1 . . . . 0.0 112.1 -176.179 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -153.38 -101.8 0.21 Allowed Glycine 0 C--N 1.335 0.498 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 175.131 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -83.3 76.99 2.17 Favored Glycine 0 C--N 1.343 0.946 0 N-CA-C 111.42 -0.672 . . . . 0.0 111.42 175.386 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -67.15 87.89 0.15 Allowed Glycine 0 C--N 1.348 1.221 0 C-N-CA 123.01 0.338 . . . . 0.0 112.681 -179.207 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 128.83 -144.03 14.98 Favored Glycine 0 C--N 1.342 0.884 0 N-CA-C 111.306 -0.718 . . . . 0.0 111.306 -177.431 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 43.4 m -74.36 84.45 1.94 Allowed 'General case' 0 CA--C 1.552 1.033 0 C-N-CA 123.128 0.571 . . . . 0.0 110.656 -179.184 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -78.9 -32.31 40.76 Favored Glycine 0 C--N 1.348 1.22 0 CA-C-N 115.373 -0.83 . . . . 0.0 112.431 177.468 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -118.23 -149.4 8.74 Favored Glycine 0 C--N 1.346 1.111 0 N-CA-C 111.743 -0.543 . . . . 0.0 111.743 176.566 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -92.96 -70.22 1.14 Allowed Glycine 0 C--N 1.343 0.939 0 N-CA-C 111.692 -0.563 . . . . 0.0 111.692 177.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 130.32 -41.39 1.54 Allowed Glycine 0 C--N 1.345 1.064 0 C-N-CA 123.054 0.359 . . . . 0.0 112.652 176.355 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.7 tm-20 -82.78 80.78 8.76 Favored 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 123.231 0.612 . . . . 0.0 109.369 -174.118 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 67.8 t80 49.55 -74.9 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.896 0 C-N-CA 126.831 2.052 . . . . 0.0 114.106 172.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -61.06 -14.13 21.67 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 124.222 1.009 . . . . 0.0 112.873 178.201 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -114.62 47.12 1.07 Allowed Glycine 0 C--N 1.342 0.863 0 CA-C-O 119.671 -0.516 . . . . 0.0 113.005 178.842 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.755 HG22 ' HG3' ' A' ' 122' ' ' LYS . 29.9 m -89.1 0.55 7.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 CA-C-N 118.756 1.278 . . . . 0.0 112.175 178.392 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.44 ' HB3' ' HB2' ' A' ' 122' ' ' LYS . 3.2 tt -166.92 -90.05 0.02 OUTLIER 'General case' 0 C--N 1.361 1.086 0 C-N-CA 123.392 0.677 . . . . 0.0 110.271 162.519 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . 0.614 ' CD1' ' HD3' ' A' ' 122' ' ' LYS . 66.9 p-90 -59.1 122.68 14.37 Favored 'General case' 0 C--N 1.377 1.764 0 N-CA-C 112.458 0.54 . . . . 0.0 112.458 -160.134 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.43 ' O ' ' HD3' ' A' ' 69' ' ' PRO . 5.0 p-10 -79.08 119.3 22.0 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-N 115.075 -0.966 . . . . 0.0 109.009 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.523 ' HB ' ' HZ3' ' A' ' 66' ' ' TRP . 2.0 p -89.95 103.14 5.74 Favored Pre-proline 0 CA--C 1.56 1.344 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.439 170.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.43 ' HD3' ' O ' ' A' ' 67' ' ' ASP . 23.5 Cg_exo -69.14 -22.96 34.19 Favored 'Trans proline' 0 C--N 1.382 2.291 0 C-N-CA 122.814 2.343 . . . . 0.0 112.702 174.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 33.1 m -78.63 178.03 2.48 Favored Pre-proline 0 CA--C 1.562 1.408 0 C-N-CA 123.746 0.819 . . . . 0.0 110.21 175.473 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -54.72 157.26 12.91 Favored 'Trans proline' 0 C--N 1.383 2.363 0 C-N-CA 122.169 1.913 . . . . 0.0 112.1 165.336 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_exo -41.52 140.85 1.57 Allowed 'Trans proline' 0 C--N 1.385 2.457 0 C-N-CA 124.25 3.3 . . . . 0.0 114.155 179.553 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -23.59 80.71 0.0 OUTLIER 'Trans proline' 0 C--N 1.392 2.842 1 C-N-CA 126.454 4.77 . . . . 0.0 116.423 -165.76 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 35.1 m -74.24 -36.98 44.89 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.167 179.584 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -89.75 -84.53 1.33 Allowed Glycine 0 C--N 1.346 1.089 0 N-CA-C 110.496 -1.042 . . . . 0.0 110.496 173.507 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . 0.442 ' HG3' ' H ' ' A' ' 77' ' ' ALA . 18.4 ptpt -162.09 -62.35 0.05 OUTLIER 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 123.359 0.664 . . . . 0.0 110.697 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.442 ' H ' ' HG3' ' A' ' 76' ' ' LYS . . . -163.39 82.91 0.47 Allowed 'General case' 0 C--O 1.237 0.408 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 -173.293 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -71.11 135.48 47.7 Favored 'General case' 0 CA--C 1.546 0.812 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.287 178.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.652 HD23 ' H ' ' A' ' 105' ' ' GLY . 6.3 mp -84.48 117.8 23.89 Favored 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 124.074 0.95 . . . . 0.0 109.321 -171.31 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -71.5 84.94 0.84 Allowed 'General case' 0 N--CA 1.482 1.159 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -55.42 106.19 0.22 Allowed 'General case' 0 CA--C 1.549 0.907 0 C-N-CA 124.624 1.17 . . . . 0.0 110.857 -178.021 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -177.41 -169.01 37.97 Favored Glycine 0 C--N 1.355 1.615 0 N-CA-C 115.198 0.839 . . . . 0.0 115.198 -175.502 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -97.85 122.65 41.21 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 124.479 1.112 . . . . 0.0 110.803 -176.051 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . 0.443 ' CD2' ' HB3' ' A' ' 8' ' ' LEU . 3.4 m-85 -117.42 154.8 30.73 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 123.498 0.719 . . . . 0.0 110.613 -175.383 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . 0.514 ' HG2' HG21 ' A' ' 195' ' ' THR . 22.1 mtm180 -99.17 127.91 45.22 Favored 'General case' 0 C--O 1.243 0.76 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 166.196 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.432 HG12 HD23 ' A' ' 8' ' ' LEU . 22.4 mt -92.12 129.7 42.35 Favored 'Isoleucine or valine' 0 C--O 1.25 1.13 0 CA-C-O 121.658 0.742 . . . . 0.0 109.346 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -117.37 154.17 31.78 Favored 'General case' 0 C--O 1.216 -0.675 0 CA-C-N 114.302 -1.317 . . . . 0.0 109.666 177.351 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 6.3 tp-100 -85.58 107.17 17.37 Favored 'General case' 0 C--O 1.243 0.719 0 N-CA-C 104.807 -2.294 . . . . 0.0 104.807 163.58 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.4 tttp -88.55 98.17 11.5 Favored 'General case' 0 C--O 1.242 0.679 0 CA-C-N 114.706 -1.134 . . . . 0.0 108.522 -173.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -71.54 131.94 19.83 Favored Glycine 0 N--CA 1.439 -1.141 0 N-CA-C 108.021 -2.032 . . . . 0.0 108.021 161.267 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 33.1 mm -62.57 -12.87 10.03 Favored 'Isoleucine or valine' 0 CA--C 1.566 1.584 0 C-N-CA 123.171 0.588 . . . . 0.0 110.569 -178.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 2.3 pp -111.93 -18.27 12.7 Favored 'General case' 0 CA--C 1.562 1.414 0 C-N-CA 123.974 0.91 . . . . 0.0 112.889 168.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -160.81 127.18 1.72 Allowed Glycine 0 N--CA 1.488 2.132 0 N-CA-C 114.763 0.665 . . . . 0.0 114.763 -172.25 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 9.2 m-85 -84.16 160.37 20.87 Favored 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 123.409 0.684 . . . . 0.0 111.635 -178.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 37.9 t -148.42 139.21 22.95 Favored 'General case' 0 C--O 1.207 -1.169 0 C-N-CA 124.616 1.167 . . . . 0.0 108.325 169.696 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.465 ' HB3' HE21 ' A' ' 48' ' ' GLN . 9.5 tt0 -90.68 125.61 35.72 Favored 'General case' 0 N--CA 1.493 1.71 0 CA-C-N 119.461 1.028 . . . . 0.0 109.64 -178.687 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 27.6 pt -124.02 -8.62 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 N-CA-C 112.559 0.578 . . . . 0.0 112.559 -172.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 160.92 -139.39 6.02 Favored Glycine 0 C--N 1.343 0.926 0 C-N-CA 120.903 -0.665 . . . . 0.0 113.05 170.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.492 ' HB2' HG23 ' A' ' 195' ' ' THR . . . -153.19 168.72 25.0 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 123.515 0.726 . . . . 0.0 111.786 -178.159 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -174.51 154.17 18.2 Favored Glycine 0 C--N 1.345 1.071 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.903 177.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 28.1 m -97.85 126.86 50.7 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 CA-C-N 117.607 0.703 . . . . 0.0 110.678 -179.346 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 24.3 t80 -100.76 106.4 17.81 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.482 ' HB3' ' O ' ' A' ' 106' ' ' THR . 14.2 tmtt? -100.87 149.85 23.45 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 -172.144 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -62.31 96.15 0.07 Allowed 'General case' 0 CA--C 1.56 1.348 0 CA-C-O 121.982 0.896 . . . . 0.0 111.713 -178.06 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . 0.652 ' H ' HD23 ' A' ' 79' ' ' LEU . . . 104.58 -9.01 48.11 Favored Glycine 0 C--N 1.342 0.882 0 CA-C-N 115.29 -0.868 . . . . 0.0 112.867 177.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' THR . . . . . 0.482 ' O ' ' HB3' ' A' ' 103' ' ' LYS . 54.6 m -151.21 124.25 8.7 Favored 'General case' 0 CA--C 1.547 0.854 0 CA-C-N 117.363 0.581 . . . . 0.0 110.314 -175.402 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' PHE . . . . . 0.632 ' HB3' ' HB3' ' A' ' 140' ' ' TYR . 27.4 t80 -96.35 133.66 40.45 Favored 'General case' 0 CA--C 1.545 0.786 0 O-C-N 121.461 -0.774 . . . . 0.0 110.075 176.244 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . 0.465 ' HB3' ' HE3' ' A' ' 144' ' ' TRP . 32.1 m170 -133.34 115.89 15.44 Favored 'General case' 0 N--CA 1.48 1.04 0 C-N-CA 124.113 0.965 . . . . 0.0 110.707 -178.48 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' THR . . . . . 0.606 HG21 ' HB ' ' A' ' 138' ' ' ILE . 10.1 t -136.87 -176.39 4.35 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 122.749 0.42 . . . . 0.0 110.736 174.466 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' MET . . . . . 0.625 ' HA ' ' HA ' ' A' ' 137' ' ' LEU . 34.6 mtp -93.78 163.15 13.64 Favored 'General case' 0 C--O 1.24 0.558 0 C-N-CA 123.785 0.834 . . . . 0.0 111.098 169.626 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' TRP . . . . . 0.629 ' HA ' HG13 ' A' ' 138' ' ' ILE . 83.9 t90 -80.23 -38.36 31.19 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 123.523 0.729 . . . . 0.0 111.62 -175.908 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . 0.434 ' CE1' ' SD ' ' A' ' 110' ' ' MET . 1.1 p-80 -64.07 -9.42 16.17 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 125.03 1.332 . . . . 0.0 113.933 -169.162 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 33.9 m -57.36 -36.4 52.62 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.911 0 O-C-N 123.471 0.482 . . . . 0.0 110.278 176.424 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.404 HG22 ' H ' ' A' ' 115' ' ' ARG . 0.7 OUTLIER -152.74 -151.6 0.39 Allowed 'General case' 0 CA--C 1.56 1.334 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 175.022 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.404 ' H ' HG22 ' A' ' 114' ' ' THR . 55.8 ttt85 -99.4 32.73 2.67 Favored 'General case' 0 CA--C 1.557 1.227 0 C-N-CA 123.64 0.776 . . . . 0.0 110.112 176.251 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.483 ' HA2' HD13 ' A' ' 138' ' ' ILE . . . 85.0 53.29 3.2 Favored Glycine 0 C--N 1.346 1.131 0 N-CA-C 111.848 -0.501 . . . . 0.0 111.848 -176.338 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -94.83 169.43 10.15 Favored 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 123.513 0.725 . . . . 0.0 112.251 -174.034 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.534 HG22 ' HA ' ' A' ' 127' ' ' GLU . 7.1 p -91.69 142.83 12.46 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.073 0 CA-C-N 114.962 -1.017 . . . . 0.0 111.281 -176.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.663 HD12 ' HB2' ' A' ' 6' ' ' LEU . 2.9 mm? -93.48 152.87 18.79 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 124.236 1.015 . . . . 0.0 110.779 -174.517 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' MET . . . . . 0.568 ' HE2' ' HA ' ' A' ' 5' ' ' ASP . 32.5 mmt -110.32 158.2 18.68 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 169.581 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 80.3 t60 -161.95 96.54 1.01 Allowed 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 175.204 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.755 ' HG3' HG22 ' A' ' 64' ' ' VAL . 77.7 tttt 59.23 31.17 20.99 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 123.774 0.83 . . . . 0.0 111.085 176.088 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 101.63 -11.23 57.87 Favored Glycine 0 C--N 1.355 1.587 0 CA-C-N 115.945 -0.571 . . . . 0.0 113.553 -179.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 49.9 tttm -90.2 127.23 36.07 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 123.122 0.569 . . . . 0.0 109.612 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . 0.557 ' HG3' ' HE1' ' A' ' 120' ' ' MET . 28.2 ttm-85 -89.66 101.25 13.94 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 123.444 0.698 . . . . 0.0 109.518 179.0 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 68.7 mt -85.2 99.92 7.81 Favored 'Isoleucine or valine' 0 C--O 1.239 0.542 0 C-N-CA 123.837 0.855 . . . . 0.0 109.949 178.646 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . 0.534 ' HA ' HG22 ' A' ' 118' ' ' VAL . 0.3 OUTLIER -74.1 149.91 87.54 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.177 174.979 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_endo -79.59 152.95 23.18 Favored 'Trans proline' 0 C--N 1.366 1.499 0 C-N-CA 122.115 1.877 . . . . 0.0 111.8 167.587 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 95.3 p -89.36 -26.8 20.87 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 122.874 0.47 . . . . 0.0 110.131 171.744 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 74.7 t-105 -165.88 156.12 12.78 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 123.497 0.719 . . . . 0.0 109.665 179.344 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . 0.415 ' HB1' ' HD1' ' A' ' 111' ' ' TRP . . . -133.95 118.62 18.08 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.574 0.75 . . . . 0.0 109.024 172.664 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 22.5 t0 -90.09 104.41 16.98 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 124.288 1.035 . . . . 0.0 108.269 175.318 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 45.7 t -75.79 -26.79 18.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 122.929 0.492 . . . . 0.0 111.08 -176.428 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 26.6 mtpp -73.14 -51.47 17.79 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.351 0.661 . . . . 0.0 111.358 -175.158 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 42.8 mtpt -85.73 -4.14 59.08 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 115.45 -0.795 . . . . 0.0 111.554 -179.255 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 37.0 t0 65.22 56.77 0.98 Allowed 'General case' 0 CA--C 1.552 1.025 0 O-C-N 124.554 1.159 . . . . 0.0 109.621 175.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . 0.625 ' HA ' ' HA ' ' A' ' 110' ' ' MET . 62.6 mt -143.49 137.58 28.62 Favored 'General case' 0 N--CA 1.478 0.958 0 O-C-N 121.482 -0.762 . . . . 0.0 110.329 -177.701 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.629 HG13 ' HA ' ' A' ' 111' ' ' TRP . 84.8 mt -111.99 149.44 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.376 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 169.305 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' SER . . . . . 0.409 ' HB2' ' O ' ' A' ' 142' ' ' GLY . 33.5 p -145.44 148.44 33.3 Favored 'General case' 0 C--O 1.241 0.65 0 C-N-CA 123.374 0.67 . . . . 0.0 110.519 -172.545 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.632 ' HB3' ' HB3' ' A' ' 107' ' ' PHE . 37.5 t80 -144.27 120.01 10.51 Favored 'General case' 0 N--CA 1.466 0.333 0 C-N-CA 124.662 1.185 . . . . 0.0 108.705 178.004 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 86.25 3.69 84.51 Favored Glycine 0 C--N 1.345 1.054 0 O-C-N 123.572 0.545 . . . . 0.0 112.725 -178.003 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . 0.409 ' O ' ' HB2' ' A' ' 139' ' ' SER . . . 147.28 148.82 4.83 Favored Glycine 0 C--N 1.344 0.995 0 N-CA-C 110.386 -1.085 . . . . 0.0 110.386 -177.884 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -67.83 169.71 37.88 Favored Glycine 0 C--N 1.348 1.234 0 C-N-CA 123.126 0.393 . . . . 0.0 112.608 -179.562 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' TRP . . . . . 0.636 ' HZ2' ' HA2' ' A' ' 209' ' ' GLY . 57.1 t-105 -58.43 105.54 0.3 Allowed 'General case' 0 CA--C 1.555 1.135 0 CA-C-O 121.209 0.528 . . . . 0.0 110.977 -177.517 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . 0.625 ' HA ' ' HB ' ' A' ' 229' ' ' THR . 50.1 tttm -163.82 126.97 2.59 Favored 'General case' 0 CA--C 1.54 0.562 0 CA-C-N 115.04 -0.982 . . . . 0.0 109.433 176.513 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' LEU . . . . . 0.466 ' H ' ' HB ' ' A' ' 229' ' ' THR . 79.5 mt -141.8 -2.74 1.17 Allowed 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 125.744 1.618 . . . . 0.0 110.219 179.727 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 29.2 tt0 86.69 18.53 0.09 Allowed 'General case' 0 N--CA 1.5 2.043 0 C-N-CA 125.355 1.462 . . . . 0.0 110.848 171.197 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . 0.554 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -85.15 117.72 4.59 Favored Glycine 0 N--CA 1.434 -1.489 0 CA-C-N 115.376 -0.829 . . . . 0.0 113.466 173.578 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -116.04 95.12 4.95 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 124.06 0.944 . . . . 0.0 110.175 -175.311 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' TRP . . . . . 0.603 ' HZ2' ' HG3' ' A' ' 174' ' ' PRO . 35.8 t90 -82.86 146.97 28.6 Favored 'General case' 0 CA--C 1.553 1.095 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.27 168.313 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . 0.401 ' HB3' ' HG2' ' A' ' 154' ' ' GLU . 22.5 tptp -112.67 128.79 56.49 Favored 'General case' 0 N--CA 1.476 0.841 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 177.095 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -63.13 99.69 0.19 Allowed 'General case' 0 N--CA 1.483 1.221 0 C-N-CA 123.494 0.718 . . . . 0.0 111.059 -179.214 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 143.54 -23.25 2.18 Favored Glycine 0 C--N 1.341 0.851 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.345 -177.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . 0.401 ' HG2' ' HB3' ' A' ' 151' ' ' LYS . 32.7 mm-40 -75.91 133.58 40.48 Favored 'General case' 0 C--O 1.24 0.581 0 C-N-CA 123.324 0.65 . . . . 0.0 111.604 -179.452 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . 0.531 ' HG2' ' HG2' ' A' ' 173' ' ' LYS . 35.8 mt-10 -74.84 101.62 4.44 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 174.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 9.7 p -114.72 145.83 19.99 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 123.257 0.623 . . . . 0.0 109.577 -168.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . 0.47 ' HG2' ' HE1' ' A' ' 16' ' ' TRP . 1.8 mp0 -93.34 141.19 28.72 Favored 'General case' 0 C--O 1.217 -0.641 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 -172.541 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.576 HG11 ' HH ' ' A' ' 211' ' ' TYR . 46.9 t -101.2 116.11 44.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 177.019 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -72.08 86.37 1.04 Allowed 'General case' 0 CA--C 1.548 0.869 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 176.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -88.44 139.13 30.8 Favored 'General case' 0 C--O 1.249 1.044 0 CA-C-N 114.181 -1.372 . . . . 0.0 110.738 -174.453 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 35.2 mt -112.7 84.29 1.96 Allowed 'General case' 0 C--O 1.245 0.854 0 C-N-CA 124.718 1.207 . . . . 0.0 108.936 -178.891 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . 0.668 ' HB2' ' HB2' ' A' ' 165' ' ' LYS . 44.2 mt-10 -75.98 143.48 74.21 Favored Pre-proline 0 CA--C 1.547 0.855 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 176.183 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . 0.483 ' HD3' ' NH2' ' B' ' 254' ' ' ARG . 74.5 Cg_endo -70.35 114.12 3.69 Favored 'Trans proline' 0 C--N 1.374 1.897 0 C-N-CA 122.209 1.939 . . . . 0.0 110.591 -177.785 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 90.85 -11.24 72.54 Favored Glycine 0 C--N 1.34 0.76 0 CA-C-N 115.954 -0.566 . . . . 0.0 113.42 179.022 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . 0.668 ' HB2' ' HB2' ' A' ' 162' ' ' GLU . 47.5 mmtm -104.53 147.83 27.17 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 176.096 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -58.85 149.5 64.42 Favored Pre-proline 0 CA--C 1.554 1.111 0 O-C-N 123.553 0.533 . . . . 0.0 111.832 179.399 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo -56.56 118.09 4.87 Favored 'Trans proline' 0 C--N 1.376 1.994 0 C-N-CA 122.497 2.131 . . . . 0.0 110.348 171.442 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 16.0 ptt180 -135.25 134.09 39.64 Favored 'General case' 0 N--CA 1.47 0.556 0 CA-C-O 120.825 0.345 . . . . 0.0 110.202 -176.606 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . 0.479 ' H ' ' HB3' ' A' ' 17' ' ' GLU . . . -97.75 105.24 17.35 Favored 'General case' 0 C--O 1.225 -0.219 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.557 -177.691 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 27.7 m -97.64 133.63 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.234 0 C-N-CA 123.663 0.785 . . . . 0.0 110.125 -174.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . 0.408 ' HA ' ' HA ' ' A' ' 157' ' ' GLN . 37.3 tt0 -77.75 128.41 33.99 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-O 121.656 0.741 . . . . 0.0 110.328 -171.593 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 172' ' ' THR . . . . . 0.552 HG23 HG11 ' A' ' 187' ' ' VAL . 68.7 m -128.08 123.3 34.21 Favored 'General case' 0 C--O 1.246 0.908 0 CA-C-N 113.842 -1.526 . . . . 0.0 109.448 -175.205 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . 0.546 ' HB2' ' HA ' ' A' ' 25' ' ' SER . 27.5 mtpp -76.15 141.61 70.95 Favored Pre-proline 0 CA--C 1.544 0.743 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 168.808 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . 0.603 ' HG3' ' HZ2' ' A' ' 150' ' ' TRP . 39.4 Cg_exo -55.37 122.95 12.64 Favored 'Trans proline' 0 C--N 1.371 1.74 0 C-N-CA 122.511 2.14 . . . . 0.0 113.66 -171.481 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . 0.435 ' H ' ' C ' ' A' ' 186' ' ' ALA . . . -117.26 127.33 7.34 Favored Glycine 0 N--CA 1.482 1.723 0 CA-C-O 121.606 0.559 . . . . 0.0 113.594 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.453 ' N ' HD22 ' A' ' 176' ' ' LEU . 0.4 OUTLIER -132.01 127.97 37.35 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 121.914 0.864 . . . . 0.0 109.52 -169.031 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 177' ' ' PHE . . . . . 0.497 ' HE1' ' HE1' ' A' ' 39' ' ' MET . 0.1 OUTLIER -102.58 138.94 38.83 Favored 'General case' 0 C--O 1.245 0.86 0 CA-C-N 114.069 -1.423 . . . . 0.0 110.494 -169.505 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 58.5 tptt -86.0 124.89 32.95 Favored 'General case' 0 C--O 1.243 0.716 0 C-N-CA 124.585 1.154 . . . . 0.0 109.953 -178.552 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 68.9 p -120.53 175.86 5.78 Favored 'General case' 0 C--O 1.242 0.697 0 C-N-CA 123.31 0.644 . . . . 0.0 109.612 169.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 -68.07 -21.37 64.98 Favored 'General case' 0 CA--C 1.546 0.806 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.206 172.694 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -78.65 -53.04 7.58 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 123.724 0.81 . . . . 0.0 110.301 176.011 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 177.48 176.97 45.98 Favored Glycine 0 C--N 1.344 0.999 0 CA-C-N 115.623 -0.717 . . . . 0.0 112.331 -178.742 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 15.5 m -93.91 104.32 16.38 Favored 'General case' 0 CA--C 1.542 0.663 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 176.421 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -123.63 161.09 26.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 C-N-CA 123.455 0.702 . . . . 0.0 109.732 -174.122 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . 113.48 178.41 19.37 Favored Glycine 0 N--CA 1.47 0.912 0 CA-C-O 119.802 -0.443 . . . . 0.0 113.074 176.401 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . 0.435 ' C ' ' H ' ' A' ' 175' ' ' GLY . . . -173.22 38.12 0.01 OUTLIER 'General case' 0 C--N 1.364 1.222 0 C-N-CA 123.75 0.82 . . . . 0.0 110.967 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 187' ' ' VAL . . . . . 0.552 HG11 HG23 ' A' ' 172' ' ' THR . 58.5 t -155.1 117.51 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 C-N-CA 125.146 1.378 . . . . 0.0 107.48 171.539 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 188' ' ' SER . . . . . 0.52 ' HA ' HG11 ' A' ' 223' ' ' VAL . 68.4 m -129.83 86.2 2.38 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-O 121.877 0.846 . . . . 0.0 108.747 170.531 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 32.4 tp -106.38 103.77 13.31 Favored 'General case' 0 CA--C 1.543 0.687 0 CA-C-N 113.907 -1.497 . . . . 0.0 110.231 -173.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 190' ' ' ASP . . . . . 0.7 ' HA ' ' HA ' ' A' ' 221' ' ' ALA . 11.0 p-10 -90.52 102.04 14.78 Favored 'General case' 0 N--CA 1.478 0.934 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 175.348 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 191' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 179.41 -174.88 0.23 Allowed 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 125.981 1.713 . . . . 0.0 108.254 -174.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 9.5 m -51.19 119.89 13.25 Favored Pre-proline 0 CA--C 1.551 0.994 0 O-C-N 123.872 0.733 . . . . 0.0 109.801 172.627 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_exo -48.01 132.61 22.73 Favored 'Trans proline' 0 C--N 1.379 2.138 0 C-N-CA 123.471 2.781 . . . . 0.0 114.226 -171.024 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -67.0 167.18 39.37 Favored Glycine 0 C--N 1.348 1.232 0 CA-C-N 115.633 -0.712 . . . . 0.0 112.085 175.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 195' ' ' THR . . . . . 0.514 HG21 ' HG2' ' A' ' 85' ' ' ARG . 1.4 m -89.99 103.77 16.41 Favored 'General case' 0 CA--C 1.54 0.559 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -173.617 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 43.6 t -51.72 85.08 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.09 0 C-N-CA 125.285 1.434 . . . . 0.0 113.389 -170.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 126.03 16.01 2.74 Favored Glycine 0 C--N 1.355 1.586 0 CA-C-N 115.253 -0.885 . . . . 0.0 113.083 179.123 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 84.2 p -82.81 155.86 67.87 Favored Pre-proline 0 N--CA 1.483 1.21 0 CA-C-N 117.477 0.638 . . . . 0.0 110.156 178.082 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -74.15 142.64 31.02 Favored 'Trans proline' 0 C--N 1.386 2.535 0 C-N-CA 122.308 2.006 . . . . 0.0 113.157 -178.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 62.6 mt -108.59 113.57 44.37 Favored 'Isoleucine or valine' 0 C--O 1.255 1.36 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 175.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 201' ' ' ILE . . . . . 0.581 HG12 ' HA ' ' A' ' 208' ' ' VAL . 14.3 mt -117.24 134.95 59.19 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.085 0 CA-C-N 114.822 -1.081 . . . . 0.0 110.799 -167.445 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -68.37 162.82 24.5 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 125.06 1.344 . . . . 0.0 110.704 174.454 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 63.2 tttm -67.45 -15.54 63.73 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 124.6 1.16 . . . . 0.0 112.061 -173.049 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 21.6 ptmt -94.15 4.01 54.48 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 123.232 0.613 . . . . 0.0 112.147 177.387 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 80.41 38.87 16.39 Favored Glycine 0 C--N 1.351 1.393 0 C-N-CA 122.9 0.286 . . . . 0.0 112.856 -178.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 58.0 tttp -128.78 167.1 17.78 Favored 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 124.272 1.029 . . . . 0.0 109.758 -174.341 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . 0.554 ' O ' ' HA3' ' A' ' 148' ' ' GLY . 89.5 t 95.64 -74.91 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.146 0 C-N-CA 125.719 1.608 . . . . 0.0 110.157 171.079 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 208' ' ' VAL . . . . . 0.581 ' HA ' HG12 ' A' ' 201' ' ' ILE . 3.2 m 63.1 22.37 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 CA-C-O 122.484 1.135 . . . . 0.0 109.787 166.414 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.636 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . -83.08 128.85 8.72 Favored Glycine 0 C--N 1.347 1.18 0 CA-C-N 113.376 -1.738 . . . . 0.0 109.353 -172.456 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 87.4 mt -65.65 173.28 2.87 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-N 117.908 0.854 . . . . 0.0 111.287 -165.47 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 211' ' ' TYR . . . . . 0.576 ' HH ' HG11 ' A' ' 158' ' ' VAL . 6.3 m-85 -56.56 157.78 4.97 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.824 163.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 212' ' ' GLY . . . . . 0.594 ' HA3' ' HB2' ' A' ' 225' ' ' ALA . . . -105.87 -141.18 10.38 Favored Glycine 0 C--O 1.24 0.492 0 N-CA-C 111.264 -0.735 . . . . 0.0 111.264 173.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 213' ' ' ASN . . . . . . . . . . . . . 23.5 p-10 -100.13 130.47 46.27 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 -176.327 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . -176.45 -135.96 2.27 Favored Glycine 0 C--N 1.337 0.617 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.962 176.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 215' ' ' VAL . . . . . 0.641 HG21 ' HD3' ' B' ' 253' ' ' LYS . 7.4 p 176.06 162.85 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 C-N-CA 125.415 1.486 . . . . 0.0 107.936 -171.485 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 216' ' ' VAL . . . . . 0.685 ' HA ' ' HA ' ' A' ' 222' ' ' TYR . 7.8 p -75.07 110.27 9.5 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.498 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 161.167 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 217' ' ' THR . . . . . 0.691 HG22 HD21 ' A' ' 29' ' ' LEU . 53.2 m -87.69 141.82 28.31 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.992 0.917 . . . . 0.0 110.19 -178.448 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 218' ' ' ARG . . . . . 0.445 ' HG3' HG21 ' A' ' 217' ' ' THR . 57.3 mtp180 62.71 8.6 3.09 Favored 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 124.093 0.957 . . . . 0.0 111.574 -175.047 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 68.0 m 62.75 26.31 15.55 Favored 'General case' 0 C--N 1.359 1.006 0 C-N-CA 124.734 1.214 . . . . 0.0 112.077 -176.224 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . -153.88 -19.4 0.05 OUTLIER Glycine 0 C--N 1.349 1.277 0 CA-C-N 116.637 -0.256 . . . . 0.0 113.653 179.29 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . 0.7 ' HA ' ' HA ' ' A' ' 190' ' ' ASP . . . -113.87 89.65 3.14 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 123.333 0.653 . . . . 0.0 109.757 -175.576 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 222' ' ' TYR . . . . . 0.685 ' HA ' ' HA ' ' A' ' 216' ' ' VAL . 50.2 t80 -69.15 118.2 11.75 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 123.149 0.58 . . . . 0.0 110.453 -177.45 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . 0.52 HG11 ' HA ' ' A' ' 188' ' ' SER . 21.5 m -123.05 145.43 29.95 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.731 0 C-N-CA 123.507 0.723 . . . . 0.0 110.687 -179.039 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 70.2 m -158.7 159.78 35.67 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 124.915 1.286 . . . . 0.0 108.757 178.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . 0.594 ' HB2' ' HA3' ' A' ' 212' ' ' GLY . . . -76.64 -169.06 1.14 Allowed 'General case' 0 N--CA 1.482 1.147 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 167.239 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 226' ' ' ILE . . . . . . . . . . . . . 54.9 mt -127.83 106.34 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.12 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 174.5 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -85.14 92.03 8.28 Favored 'General case' 0 C--O 1.239 0.551 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 177.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 20.1 pt20 -92.31 158.88 15.87 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-N 115.248 -0.887 . . . . 0.0 108.813 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.625 ' HB ' ' HA ' ' A' ' 145' ' ' LYS . 30.5 p -69.12 107.44 3.19 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-O 121.589 0.709 . . . . 0.0 110.738 -161.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -168.75 79.59 0.14 Allowed 'General case' 0 N--CA 1.451 -0.401 0 N-CA-C 106.366 -1.716 . . . . 0.0 106.366 -171.801 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 231' ' ' LYS . . . . . 0.405 ' HD3' ' H ' ' A' ' 144' ' ' TRP . 59.1 tttp -145.85 -78.82 0.18 Allowed 'General case' 0 N--CA 1.48 1.07 0 CA-C-N 115.912 -0.585 . . . . 0.0 112.297 167.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 68.0 p -93.37 -174.73 3.6 Favored 'General case' 0 N--CA 1.485 1.312 0 CA-C-N 118.884 0.765 . . . . 0.0 112.036 -174.098 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 233' ' ' ILE . . . . . . . . . . . . . 31.2 pt -123.15 13.17 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 C-N-CA 123.809 0.844 . . . . 0.0 109.475 167.123 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 234' ' ' GLU . . . . . . . . . . . . . 4.0 mp0 47.62 -86.84 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.36 0 C-N-CA 125.377 1.471 . . . . 0.0 111.139 -170.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 24.8 m-20 -141.48 0.82 1.51 Allowed 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 123.497 0.719 . . . . 0.0 112.06 -179.165 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 236' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -72.25 141.79 83.91 Favored Pre-proline 0 N--CA 1.482 1.152 0 CA-C-N 118.461 0.573 . . . . 0.0 110.003 179.517 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_exo -63.13 125.72 16.4 Favored 'Trans proline' 0 C--N 1.367 1.544 0 C-N-CA 122.41 2.074 . . . . 0.0 110.781 172.26 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 238' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -84.68 -23.87 29.23 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 123.47 0.708 . . . . 0.0 110.16 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 239' ' ' ILE . . . . . . . . . . . . . 3.6 mp 57.77 85.38 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.36 1.045 0 C-N-CA 125.014 1.325 . . . . 0.0 108.577 -170.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.248 1.004 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -173.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 251' ' ' BEZ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 253' ' ' LYS . . . . . 0.641 ' HD3' HG21 ' A' ' 215' ' ' VAL . 28.7 mmtp -138.71 -59.1 0.61 Allowed 'General case' 0 C--O 1.239 0.522 0 C-N-CA 124.703 1.201 . . . . 0.0 109.967 175.275 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 254' ' ' ARG . . . . . 0.483 ' NH2' ' HD3' ' A' ' 163' ' ' PRO . 16.8 mmt85 77.26 -49.8 0.53 Allowed 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 125.725 1.61 . . . . 0.0 109.282 -156.203 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 255' ' ' M9P . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.674 0 N-CA-C 111.795 -0.522 . . . . 0.0 111.795 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 70.4 m -139.55 134.08 31.67 Favored 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 123.836 0.854 . . . . 0.0 109.386 177.004 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.426 ' HB1' ' NE2' ' A' ' 88' ' ' GLN . . . -140.6 172.76 12.26 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 123.27 0.628 . . . . 0.0 110.674 -179.742 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.58 41.11 1.06 Allowed 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 124.186 0.994 . . . . 0.0 109.798 -171.415 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . 0.49 ' HA ' ' HG2' ' A' ' 120' ' ' MET . 7.1 m-20 -153.86 52.53 0.7 Allowed 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 -163.168 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.633 ' HB2' ' HG ' ' A' ' 119' ' ' LEU . 7.9 mt -95.18 89.36 5.49 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 177.113 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.691 ' HB3' ' HD2' ' A' ' 89' ' ' LYS . 11.8 pt-20 -78.7 147.26 33.55 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-O 121.446 0.641 . . . . 0.0 111.771 -173.63 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 41.9 mt -98.02 113.71 25.65 Favored 'General case' 0 C--O 1.238 0.489 0 CA-C-N 114.281 -1.327 . . . . 0.0 108.9 179.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -109.47 144.56 37.56 Favored 'General case' 0 N--CA 1.482 1.132 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 171.383 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 18.0 ttm-85 -69.24 129.09 38.85 Favored 'General case' 0 C--O 1.24 0.604 0 CA-C-O 121.169 0.509 . . . . 0.0 111.476 -173.09 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . 0.571 ' HB3' ' HB2' ' A' ' 85' ' ' ARG . . . -103.21 -37.62 7.62 Favored 'General case' 0 C--O 1.239 0.531 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.13 178.983 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . 0.433 ' HB3' ' HB2' ' A' ' 83' ' ' ALA . . . -165.87 170.3 13.96 Favored 'General case' 0 N--CA 1.474 0.733 0 CA-C-O 121.595 0.712 . . . . 0.0 111.456 -176.523 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -111.55 145.94 38.21 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 171.074 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 59.7 t -74.26 97.75 1.09 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.919 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 -179.29 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 24.1 ttmm -175.13 111.66 0.13 Allowed 'General case' 0 C--O 1.239 0.507 0 C-N-CA 125.615 1.566 . . . . 0.0 107.271 178.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . 0.518 ' HE1' ' HB2' ' A' ' 169' ' ' ALA . 34.7 t90 -93.5 95.01 8.99 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 122.086 0.155 . . . . 0.0 111.07 -178.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -159.68 64.36 0.37 Allowed 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 148.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -89.61 -62.06 1.56 Allowed 'General case' 0 N--CA 1.481 1.111 0 CA-C-O 121.242 0.544 . . . . 0.0 112.192 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . 0.43 ' H ' ' HB3' ' A' ' 169' ' ' ALA . 23.0 mt-30 -150.88 47.74 0.86 Allowed 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 124.203 1.001 . . . . 0.0 109.606 -168.575 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -48.77 95.42 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 113.556 0.947 . . . . 0.0 113.556 -172.368 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -136.48 164.5 28.01 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 125.631 1.572 . . . . 0.0 108.864 -177.532 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.594 HG23 ' HB2' ' A' ' 171' ' ' GLN . 0.2 OUTLIER -122.57 140.3 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.242 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 177.464 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 63.1 m -139.84 -57.82 0.56 Allowed 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -68.93 118.67 9.04 Favored Glycine 0 C--N 1.349 1.28 0 N-CA-C 114.469 0.547 . . . . 0.0 114.469 -168.628 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 68.0 m -164.31 24.32 0.07 Allowed 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 124.864 1.266 . . . . 0.0 109.572 -173.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.616 ' HB2' ' HB2' ' A' ' 188' ' ' SER . 18.4 m -73.88 161.53 78.19 Favored Pre-proline 0 CA--C 1.555 1.163 0 C-N-CA 123.323 0.649 . . . . 0.0 110.701 -177.549 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_exo -71.77 -173.68 1.09 Allowed 'Trans proline' 0 C--N 1.378 2.1 0 C-N-CA 122.471 2.114 . . . . 0.0 112.874 174.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.5 HD12 ' HB2' ' A' ' 176' ' ' LEU . 27.3 mm -76.14 140.91 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.461 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 14.0 mt -131.07 132.24 44.76 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 122.796 0.438 . . . . 0.0 111.605 -168.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.401 ' HA ' ' HB3' ' A' ' 178' ' ' LYS . 49.3 m -69.97 135.15 49.1 Favored 'General case' 0 C--N 1.35 0.62 0 O-C-N 124.098 0.874 . . . . 0.0 111.096 179.493 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 19.6 tt -142.62 141.26 27.79 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.744 0 C-N-CA 123.829 0.852 . . . . 0.0 109.205 -177.655 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 56.0 p -99.42 109.6 22.16 Favored 'General case' 0 CA--C 1.555 1.154 0 C-N-CA 123.24 0.616 . . . . 0.0 110.168 -176.546 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 1.5 mp -80.75 120.31 32.1 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 C-N-CA 123.687 0.795 . . . . 0.0 109.038 176.33 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 26.0 m -97.71 122.78 41.19 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 124.254 1.022 . . . . 0.0 110.094 -178.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 67.57 12.4 8.86 Favored 'General case' 0 N--CA 1.493 1.677 0 C-N-CA 124.358 1.063 . . . . 0.0 112.383 171.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 61.73 24.86 14.88 Favored 'General case' 0 N--CA 1.491 1.618 0 C-N-CA 124.436 1.094 . . . . 0.0 112.113 -177.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -143.03 -42.97 0.05 OUTLIER Glycine 0 C--N 1.338 0.683 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 -178.712 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 39.4 t -93.66 162.93 13.75 Favored 'General case' 0 C--O 1.241 0.609 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 175.092 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 20.9 ptm -161.73 134.77 6.18 Favored 'General case' 0 C--O 1.241 0.609 0 C-N-CA 122.829 0.452 . . . . 0.0 110.065 -175.694 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 28.5 p -173.26 -179.07 1.86 Allowed 'General case' 0 C--O 1.221 -0.43 0 C-N-CA 123.786 0.835 . . . . 0.0 109.422 179.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.743 HD11 HG21 ' A' ' 217' ' ' THR . 28.3 mm -72.12 151.03 8.46 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.971 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 165.593 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 15.3 ptmt -42.62 140.0 1.41 Allowed 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 124.968 1.307 . . . . 0.0 112.104 171.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 65.07 85.57 0.14 Allowed 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 124.999 1.319 . . . . 0.0 108.952 -160.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -86.18 26.91 0.97 Allowed 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 123.86 0.864 . . . . 0.0 113.125 -169.156 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -56.1 134.94 53.06 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 123.671 0.788 . . . . 0.0 110.772 172.461 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -82.61 173.86 11.56 Favored 'General case' 0 N--CA 1.482 1.157 0 C-N-CA 123.931 0.893 . . . . 0.0 112.003 -174.258 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -144.59 142.07 29.89 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 124.158 0.983 . . . . 0.0 109.708 174.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 17.7 pt20 -155.09 -179.43 8.06 Favored 'General case' 0 N--CA 1.479 1.02 0 C-N-CA 123.998 0.919 . . . . 0.0 109.341 176.24 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.45 HG21 HE21 ' A' ' 96' ' ' GLN . 15.4 t -165.26 175.07 9.55 Favored 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 122.817 0.447 . . . . 0.0 110.239 -179.49 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 34.4 tp -60.94 133.72 56.38 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.673 0.789 . . . . 0.0 110.449 176.677 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.53 -162.59 35.02 Favored Glycine 0 C--N 1.34 0.788 0 O-C-N 123.508 0.505 . . . . 0.0 112.971 177.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 91.65 36.9 6.29 Favored Glycine 0 C--N 1.337 0.629 0 C-N-CA 123.069 0.366 . . . . 0.0 112.336 -179.117 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -77.96 63.64 3.49 Favored Glycine 0 C--N 1.353 1.479 0 C-N-CA 123.372 0.511 . . . . 0.0 112.291 -178.717 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -167.93 151.5 18.79 Favored Glycine 0 C--O 1.246 0.882 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -178.509 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 32.7 t -68.88 121.1 15.88 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 123.042 0.537 . . . . 0.0 110.342 -176.628 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 126.09 -27.19 5.14 Favored Glycine 0 C--N 1.343 0.924 0 N-CA-C 111.31 -0.716 . . . . 0.0 111.31 -177.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 126.24 -29.41 4.57 Favored Glycine 0 C--N 1.353 1.481 0 CA-C-O 119.906 -0.385 . . . . 0.0 112.645 178.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 62.4 49.76 71.03 Favored Glycine 0 C--N 1.353 1.502 0 C-N-CA 123.48 0.562 . . . . 0.0 113.692 175.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -120.04 -140.73 6.18 Favored Glycine 0 N--CA 1.472 1.048 0 N-CA-C 112.115 -0.394 . . . . 0.0 112.115 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . 0.513 ' HB2' ' HZ2' ' A' ' 89' ' ' LYS . 19.5 tp10 -108.54 89.67 3.06 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 123.522 0.729 . . . . 0.0 109.324 -179.502 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 5.5 p90 -121.54 80.15 1.64 Allowed 'General case' 0 CA--C 1.543 0.707 0 CA-C-N 114.946 -1.025 . . . . 0.0 109.099 -179.269 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . 61.5 26.42 16.16 Favored 'General case' 0 N--CA 1.481 1.119 0 C-N-CA 124.339 1.055 . . . . 0.0 111.491 -175.161 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.506 ' HA3' ' HG3' ' A' ' 122' ' ' LYS . . . 99.39 179.16 31.22 Favored Glycine 0 C--N 1.353 1.507 0 CA-C-N 115.614 -0.721 . . . . 0.0 113.722 -178.854 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.414 ' HB ' ' H ' ' A' ' 65' ' ' LEU . 4.6 t -92.67 -92.66 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.556 1.176 0 C-N-CA 124.724 1.21 . . . . 0.0 110.194 177.761 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.448 ' N ' ' HD2' ' A' ' 122' ' ' LYS . 24.0 tp -167.98 132.34 1.74 Allowed 'General case' 0 C--N 1.37 1.464 0 C-N-CA 123.928 0.891 . . . . 0.0 109.563 -177.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 18.1 m0 -96.93 175.17 6.43 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 123.91 0.884 . . . . 0.0 111.898 -178.73 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.523 ' HB2' ' HB3' ' A' ' 79' ' ' LEU . 33.9 t70 -93.45 82.14 4.42 Favored 'General case' 0 N--CA 1.478 0.973 0 CA-C-N 115.229 -0.896 . . . . 0.0 108.934 170.004 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 35.8 m -92.37 147.39 34.37 Favored Pre-proline 0 CA--C 1.549 0.916 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.162 -175.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -60.66 83.85 0.08 OUTLIER 'Trans proline' 0 C--N 1.377 2.051 0 C-N-CA 122.53 2.153 . . . . 0.0 111.206 169.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 22.2 t -91.13 123.41 64.52 Favored Pre-proline 0 CA--C 1.541 0.608 0 C-N-CA 123.925 0.89 . . . . 0.0 110.084 -174.108 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -56.92 151.21 50.54 Favored 'Trans proline' 0 C--N 1.374 1.916 0 C-N-CA 122.932 2.421 . . . . 0.0 112.413 177.24 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_exo -44.58 -45.85 12.74 Favored 'Trans proline' 0 CA--C 1.572 2.401 0 C-N-CA 123.853 3.035 . . . . 0.0 116.899 -175.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_exo -65.02 -31.34 55.66 Favored 'Trans proline' 0 C--N 1.397 3.131 0 CA-C-N 121.999 1.75 . . . . 0.0 113.367 176.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 23.5 t -86.21 -36.95 11.15 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.918 0 C-N-CA 123.587 0.755 . . . . 0.0 111.084 -173.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -64.13 133.4 39.71 Favored Glycine 0 C--N 1.35 1.357 0 O-C-N 124.015 0.822 . . . . 0.0 114.119 -170.627 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 60.2 mttm -130.64 -82.89 0.54 Allowed 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 122.843 0.457 . . . . 0.0 110.398 -173.392 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -166.31 27.33 0.04 OUTLIER 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 123.9 0.88 . . . . 0.0 109.657 -170.67 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -57.21 -23.54 48.55 Favored 'General case' 0 N--CA 1.491 1.615 0 C-N-CA 125.699 1.6 . . . . 0.0 114.904 -164.164 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.523 ' HB3' ' HB2' ' A' ' 67' ' ' ASP . 12.2 tp -173.67 -37.41 0.01 OUTLIER 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 105.625 -1.991 . . . . 0.0 105.625 173.627 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -44.43 83.17 0.0 OUTLIER 'General case' 0 CA--C 1.552 1.054 0 CA-C-N 112.579 -2.1 . . . . 0.0 111.901 154.737 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . 0.463 ' H ' ' HA ' ' A' ' 103' ' ' LYS . 4.5 m-20 61.21 71.13 0.57 Allowed 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 124.345 1.058 . . . . 0.0 110.923 179.689 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -129.23 137.97 9.94 Favored Glycine 0 C--N 1.338 0.66 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 174.835 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . 0.433 ' HB2' ' HB3' ' A' ' 12' ' ' ALA . . . -89.21 120.64 30.76 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 178.544 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 47.6 m-85 -112.55 171.47 7.5 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-O 121.603 0.716 . . . . 0.0 111.127 -176.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . 0.571 ' HB2' ' HB3' ' A' ' 11' ' ' ALA . 44.4 ttm105 -131.77 122.83 26.48 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 -177.104 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.456 ' H ' ' HA ' ' A' ' 99' ' ' ALA . 24.5 mt -83.29 133.18 29.67 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 -175.856 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.599 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 76.8 tttt -137.88 131.18 30.61 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 114.743 -1.117 . . . . 0.0 108.405 -170.205 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . 0.426 ' NE2' ' HB1' ' A' ' 3' ' ' ALA . 0.0 OUTLIER -82.55 130.11 35.05 Favored 'General case' 0 C--O 1.245 0.822 0 N-CA-C 106.753 -1.573 . . . . 0.0 106.753 176.315 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . 0.691 ' HD2' ' HB3' ' A' ' 7' ' ' GLU . 48.3 tttp -123.11 135.72 54.49 Favored 'General case' 0 CA--C 1.549 0.914 0 CA-C-N 114.573 -1.194 . . . . 0.0 112.264 -162.024 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . 0.525 ' O ' ' HG2' ' A' ' 89' ' ' LYS . . . -91.83 162.11 27.43 Favored Glycine 0 C--O 1.207 -1.569 0 N-CA-C 106.464 -2.654 . . . . 0.0 106.464 149.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 31.1 mm -54.99 -18.74 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.195 0 CA-C-N 121.333 2.566 . . . . 0.0 114.47 -167.444 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 66.5 mt -86.1 -38.21 18.02 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.385 -0.822 . . . . 0.0 110.464 167.524 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.443 ' HA2' ' HG3' ' A' ' 89' ' ' LYS . . . 145.29 -167.63 27.36 Favored Glycine 0 N--CA 1.477 1.399 0 CA-C-O 118.348 -1.251 . . . . 0.0 110.381 176.608 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . 0.527 ' H ' ' HE2' ' A' ' 87' ' ' LYS 0.285 3.0 p90 178.68 -79.51 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.728 0 C-N-CA 123.838 0.855 . . . . 0.0 112.276 146.488 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 93.6 p -117.45 135.07 54.16 Favored 'General case' 0 N--CA 1.504 2.246 0 CA-C-N 120.384 1.447 . . . . 0.0 112.444 -161.328 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.599 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 5.1 pp0? -81.58 148.48 29.09 Favored 'General case' 0 N--CA 1.485 1.317 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 177.109 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 26.0 pt -133.18 -28.6 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 C-N-CA 123.354 0.662 . . . . 0.0 112.037 -171.758 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -167.41 -155.38 9.15 Favored Glycine 0 C--N 1.344 1.012 0 CA-C-O 119.803 -0.443 . . . . 0.0 112.237 -176.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.566 ' HA ' ' HA ' ' A' ' 85' ' ' ARG . . . -154.96 171.97 18.85 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 123.544 0.738 . . . . 0.0 110.507 -178.24 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -178.92 151.42 10.3 Favored Glycine 0 C--N 1.347 1.151 0 O-C-N 123.135 0.272 . . . . 0.0 112.594 179.487 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 14.9 p -89.15 138.17 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 122.93 0.492 . . . . 0.0 109.908 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -118.28 138.63 52.24 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 170.43 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.463 ' HA ' ' H ' ' A' ' 81' ' ' ASP . 64.4 tttp -135.14 105.9 6.53 Favored 'General case' 0 C--O 1.238 0.472 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 176.395 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 29.3 mt-10 63.39 -87.14 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.167 0 C-N-CA 125.031 1.332 . . . . 0.0 112.251 171.516 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -126.11 11.05 7.33 Favored Glycine 0 C--N 1.349 1.27 0 CA-C-O 120.163 -0.243 . . . . 0.0 113.025 -176.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 15.2 t -132.89 131.36 40.85 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 122.96 0.504 . . . . 0.0 110.094 -177.317 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 30.9 t80 -115.49 131.56 56.89 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 123.258 0.623 . . . . 0.0 109.805 -175.322 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 80.7 m-70 -135.15 123.5 23.22 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 123.058 0.543 . . . . 0.0 110.56 -177.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' THR . . . . . 0.599 HG23 HG22 ' A' ' 138' ' ' ILE . 1.9 t -139.35 175.24 9.73 Favored 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 123.245 0.618 . . . . 0.0 111.911 -179.324 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' MET . . . . . . . . . . . . . 8.0 mmt -75.07 150.1 38.97 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 124.36 1.064 . . . . 0.0 109.561 172.212 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 76.0 t90 -78.89 -43.98 23.75 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 123.071 0.549 . . . . 0.0 111.854 -169.282 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -65.76 -6.58 12.17 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 114.312 1.227 . . . . 0.0 114.312 -172.273 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 19.7 m -60.35 -40.4 83.85 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 176.455 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 90.0 m -164.5 140.0 5.82 Favored 'General case' 0 CA--C 1.551 1.017 0 C-N-CA 126.287 1.835 . . . . 0.0 107.396 171.299 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 32.8 mtt180 -80.85 33.08 0.32 Allowed 'General case' 0 N--CA 1.485 1.305 0 N-CA-C 114.152 1.167 . . . . 0.0 114.152 -166.45 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 107.27 62.15 0.57 Allowed Glycine 0 C--N 1.346 1.091 0 O-C-N 122.085 -0.384 . . . . 0.0 112.656 178.225 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -122.78 168.23 12.5 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 123.441 0.696 . . . . 0.0 110.064 174.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 87.9 t -75.44 144.43 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.802 0 C-N-CA 123.99 0.916 . . . . 0.0 110.96 -177.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.729 ' HB2' ' HB ' ' A' ' 126' ' ' ILE . 5.2 mp -111.16 161.17 16.23 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 123.077 0.551 . . . . 0.0 111.831 178.853 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' MET . . . . . 0.49 ' HG2' ' HA ' ' A' ' 5' ' ' ASP . 19.6 mmt -110.7 106.99 16.4 Favored 'General case' 0 C--O 1.241 0.619 0 CA-C-O 121.935 0.874 . . . . 0.0 110.1 179.191 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.541 ' HB2' HD12 ' A' ' 126' ' ' ILE . 13.9 t60 -104.13 95.07 5.73 Favored 'General case' 0 CA--C 1.542 0.663 0 N-CA-C 107.929 -1.137 . . . . 0.0 107.929 169.17 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.506 ' HG3' ' HA3' ' A' ' 63' ' ' GLY . 65.5 tttp 44.43 65.31 1.08 Allowed 'General case' 0 CA--C 1.554 1.115 0 C-N-CA 124.893 1.277 . . . . 0.0 112.76 176.109 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 80.73 -27.29 2.98 Favored Glycine 0 CA--C 1.531 1.076 0 CA-C-N 115.047 -0.979 . . . . 0.0 113.881 -179.576 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 94.7 mttt -85.36 154.34 21.94 Favored 'General case' 0 C--N 1.35 0.598 0 CA-C-N 117.395 0.598 . . . . 0.0 109.476 179.124 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 33.8 ptt85 -92.22 160.34 15.21 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-O 121.008 0.432 . . . . 0.0 110.367 178.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.729 ' HB ' ' HB2' ' A' ' 119' ' ' LEU . 80.8 mt -128.52 111.46 23.75 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 171.709 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -93.81 108.66 36.32 Favored Pre-proline 0 CA--C 1.546 0.818 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 178.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -56.7 103.65 0.13 Allowed 'Trans proline' 0 C--N 1.377 2.072 0 C-N-CA 122.884 2.389 . . . . 0.0 112.193 -178.42 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 86.5 p -74.9 -17.23 60.61 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 123.173 0.589 . . . . 0.0 111.277 -177.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 30.4 t-105 -143.26 149.92 38.55 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 -178.663 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -166.59 120.41 1.07 Allowed 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 122.98 0.512 . . . . 0.0 110.72 176.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -120.99 120.83 36.56 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.077 0.951 . . . . 0.0 109.265 171.643 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.476 HG11 ' HG3' ' A' ' 134' ' ' LYS . 4.6 p -69.05 -38.97 79.02 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 CA-C-N 114.657 -1.156 . . . . 0.0 111.844 -178.473 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.476 ' HG3' HG11 ' A' ' 133' ' ' VAL . 97.1 mttt -82.52 -27.95 31.39 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 123.307 0.643 . . . . 0.0 112.218 -173.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . 0.487 ' HB3' HD12 ' A' ' 137' ' ' LEU . 33.5 mmtp -71.83 -27.74 63.1 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 167.661 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . 0.405 ' HB3' HD21 ' A' ' 213' ' ' ASN . 8.9 t70 56.64 58.61 4.03 Favored 'General case' 0 CA--C 1.538 0.494 0 O-C-N 125.27 1.606 . . . . 0.0 109.37 -167.878 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . 0.487 HD12 ' HB3' ' A' ' 135' ' ' LYS . 6.6 mt -144.1 121.98 12.0 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 113.6 -1.637 . . . . 0.0 109.223 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.599 HG22 HG23 ' A' ' 109' ' ' THR . 9.2 tt -121.85 133.32 68.6 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 174.16 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 73.4 m -146.6 165.51 29.29 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-O 122.138 0.97 . . . . 0.0 112.575 -169.798 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 46.4 t80 -133.44 128.69 36.02 Favored 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 125.778 1.631 . . . . 0.0 107.764 175.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 102.29 -4.01 51.3 Favored Glycine 0 C--N 1.345 1.029 0 O-C-N 123.671 0.607 . . . . 0.0 112.324 -175.363 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 147.17 -165.58 28.58 Favored Glycine 0 C--N 1.349 1.272 0 N-CA-C 111.392 -0.683 . . . . 0.0 111.392 179.324 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -77.95 -173.64 41.34 Favored Glycine 0 C--N 1.353 1.501 0 CA-C-O 118.98 -0.9 . . . . 0.0 111.059 172.42 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' TRP . . . . . 0.522 ' HZ2' ' HA2' ' A' ' 209' ' ' GLY . 5.1 t-105 -55.0 108.01 0.36 Allowed 'General case' 0 N--CA 1.477 0.909 0 CA-C-N 118.267 1.033 . . . . 0.0 109.986 176.856 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 30.7 tptt -144.5 133.35 22.49 Favored 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 113.725 -1.579 . . . . 0.0 107.617 -174.463 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' LEU . . . . . . . . . . . . . 32.9 tp -153.37 -86.75 0.06 Allowed 'General case' 0 CA--C 1.534 0.345 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 174.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 161.31 38.23 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.078 0 C-N-CA 125.362 1.465 . . . . 0.0 109.384 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -126.29 119.78 3.52 Favored Glycine 0 C--N 1.336 0.583 0 CA-C-N 115.879 -0.6 . . . . 0.0 113.279 -172.234 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 5.0 mp0 -113.78 100.34 8.38 Favored 'General case' 0 N--CA 1.474 0.751 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 179.457 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' TRP . . . . . 0.5 ' HZ2' ' HG3' ' A' ' 174' ' ' PRO . 28.8 t90 -71.28 130.23 40.88 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 174.752 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 18.2 ttmm -87.29 106.87 18.22 Favored 'General case' 0 C--O 1.242 0.673 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 176.184 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -62.19 104.14 0.45 Allowed 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.122 0.969 . . . . 0.0 111.688 -173.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 141.68 -38.15 1.53 Allowed Glycine 0 C--N 1.347 1.176 0 CA-C-N 116.58 -0.282 . . . . 0.0 112.989 178.026 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 -72.51 152.9 41.62 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 123.054 0.542 . . . . 0.0 111.805 -178.338 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -69.73 120.06 14.92 Favored 'General case' 0 C--O 1.244 0.786 0 N-CA-C 108.258 -1.015 . . . . 0.0 108.258 169.042 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . 0.502 HG23 HG23 ' A' ' 208' ' ' VAL . 8.9 p -119.17 151.31 21.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.474 0 N-CA-C 108.974 -0.751 . . . . 0.0 108.974 -173.292 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . 0.45 ' HA ' ' HA ' ' A' ' 171' ' ' GLN . 0.0 OUTLIER -99.77 141.05 33.09 Favored 'General case' 0 N--CA 1.478 0.954 0 CA-C-O 121.081 0.467 . . . . 0.0 110.704 -168.779 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 89.7 t -117.6 131.35 70.59 Favored 'Isoleucine or valine' 0 C--O 1.245 0.825 0 C-N-CA 124.075 0.95 . . . . 0.0 108.444 170.258 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 44.6 mt -73.8 86.99 1.73 Allowed 'General case' 0 CA--C 1.544 0.717 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 171.356 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . 0.581 ' HB1' ' HB2' ' A' ' 168' ' ' ARG . . . -64.13 98.61 0.23 Allowed 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 123.357 0.663 . . . . 0.0 110.82 -176.882 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . 0.617 ' H ' ' HA2' ' A' ' 194' ' ' GLY . 71.6 mt -70.78 88.22 0.72 Allowed 'General case' 0 C--O 1.241 0.631 0 C-N-CA 124.549 1.139 . . . . 0.0 111.229 -173.9 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -85.34 119.08 71.96 Favored Pre-proline 0 CA--C 1.553 1.09 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.316 174.326 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_exo -59.0 115.78 2.8 Favored 'Trans proline' 0 C--N 1.379 2.167 0 C-N-CA 123.115 2.543 . . . . 0.0 113.322 -176.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 113.79 -15.26 21.7 Favored Glycine 0 N--CA 1.471 0.969 0 CA-C-O 119.348 -0.695 . . . . 0.0 113.663 174.073 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -123.21 -169.62 1.97 Allowed 'General case' 0 C--N 1.355 0.814 0 CA-C-N 117.63 0.715 . . . . 0.0 109.787 -177.249 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 -70.46 162.24 71.62 Favored Pre-proline 0 CA--C 1.563 1.445 0 CA-C-N 114.695 -1.139 . . . . 0.0 109.359 161.482 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_exo -71.17 135.54 27.34 Favored 'Trans proline' 0 C--N 1.365 1.414 0 C-N-CA 121.95 1.767 . . . . 0.0 111.934 172.284 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . 0.581 ' HB2' ' HB1' ' A' ' 160' ' ' ALA . 85.7 mtt180 -70.88 109.26 4.93 Favored 'General case' 0 CA--C 1.546 0.801 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 171.745 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . 0.518 ' HB2' ' HE1' ' A' ' 16' ' ' TRP . . . -75.78 102.11 5.33 Favored 'General case' 0 N--CA 1.474 0.725 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -179.483 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . 0.427 HG21 ' CE2' ' A' ' 191' ' ' PHE . 40.6 t -120.99 116.3 49.41 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 C-N-CA 122.52 0.328 . . . . 0.0 111.158 -170.02 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . 0.594 ' HB2' HG23 ' A' ' 22' ' ' ILE . 26.6 mt-30 -83.91 142.41 30.58 Favored 'General case' 0 C--O 1.243 0.751 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 173.565 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 5.6 t -152.38 136.28 16.34 Favored 'General case' 0 C--O 1.242 0.694 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.652 -168.736 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . 0.519 ' HD3' ' HD2' ' A' ' 174' ' ' PRO . 4.5 tppp? -72.33 126.04 91.17 Favored Pre-proline 0 CA--C 1.543 0.696 0 C-N-CA 123.557 0.743 . . . . 0.0 109.554 175.471 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . 0.519 ' HD2' ' HD3' ' A' ' 173' ' ' LYS . 9.2 Cg_endo -48.05 139.14 21.04 Favored 'Trans proline' 0 C--N 1.374 1.912 0 C-N-CA 123.739 2.96 . . . . 0.0 113.475 172.689 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . 0.624 ' H ' ' HA ' ' A' ' 187' ' ' VAL . . . -118.09 -172.77 15.84 Favored Glycine 0 C--O 1.237 0.293 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 175.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.5 ' HB2' HD12 ' A' ' 28' ' ' ILE . 5.5 mp -138.47 152.36 48.24 Favored 'General case' 0 N--CA 1.479 0.983 0 CA-C-N 117.8 0.8 . . . . 0.0 110.11 178.588 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 177' ' ' PHE . . . . . 0.649 ' HB2' ' HB ' ' A' ' 184' ' ' ILE . 35.7 m-85 -92.18 123.58 35.63 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.531 0.732 . . . . 0.0 109.85 176.571 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 178' ' ' LYS . . . . . 0.401 ' HB3' ' HA ' ' A' ' 30' ' ' SER . 23.8 ttmm -86.57 94.87 9.56 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 172.383 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 63.0 m -103.1 153.68 20.05 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 123.469 0.708 . . . . 0.0 110.621 -173.536 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 7.0 t30 -80.14 64.93 5.12 Favored 'General case' 0 N--CA 1.48 1.044 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 173.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -175.47 -38.83 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.569 1.548 . . . . 0.0 108.706 -176.495 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 170.49 -144.17 8.23 Favored Glycine 0 C--N 1.341 0.86 0 CA-C-N 114.862 -1.063 . . . . 0.0 111.143 -178.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 10.2 m -127.13 131.87 50.7 Favored 'General case' 0 CA--C 1.548 0.866 0 C-N-CA 123.319 0.648 . . . . 0.0 109.546 179.075 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . 0.649 ' HB ' ' HB2' ' A' ' 177' ' ' PHE . 31.4 mt -107.16 163.28 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 C-N-CA 124.152 0.981 . . . . 0.0 108.561 -179.537 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -99.89 132.34 10.9 Favored Glycine 0 N--CA 1.478 1.488 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . 0.68 ' HA ' ' HA ' ' A' ' 225' ' ' ALA . . . -154.51 -159.02 0.91 Allowed 'General case' 0 N--CA 1.474 0.751 0 CA-C-O 121.083 0.468 . . . . 0.0 112.105 -164.122 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 187' ' ' VAL . . . . . 0.624 ' HA ' ' H ' ' A' ' 175' ' ' GLY . 10.4 p -149.25 135.46 12.18 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 C-N-CA 123.98 0.912 . . . . 0.0 108.731 167.446 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 188' ' ' SER . . . . . 0.616 ' HB2' ' HB2' ' A' ' 26' ' ' SER . 11.9 p -106.38 101.87 11.31 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 123.679 0.792 . . . . 0.0 110.009 -173.322 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 65.5 tp -127.15 109.95 12.39 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 123.969 0.908 . . . . 0.0 110.786 -168.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 190' ' ' ASP . . . . . 0.469 ' HA ' ' HA ' ' A' ' 221' ' ' ALA . 13.5 p-10 -96.25 102.74 14.57 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 167.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 191' ' ' PHE . . . . . 0.427 ' CE2' HG21 ' A' ' 170' ' ' VAL . 50.5 t80 179.68 174.96 0.79 Allowed 'General case' 0 CA--C 1.551 0.985 0 CA-C-N 114.985 -1.007 . . . . 0.0 108.541 -168.117 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 33.6 m -86.87 96.17 0.51 Allowed Pre-proline 0 CA--C 1.554 1.114 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 169.548 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . 0.453 ' HG3' ' HB2' ' A' ' 222' ' ' TYR . 10.0 Cg_endo -93.1 -164.76 0.12 Allowed 'Trans proline' 0 C--N 1.373 1.828 0 C-N-CA 123.266 2.644 . . . . 0.0 114.055 -165.587 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 194' ' ' GLY . . . . . 0.617 ' HA2' ' H ' ' A' ' 161' ' ' LEU . . . -82.11 153.73 32.71 Favored Glycine 0 C--N 1.35 1.32 0 CA-C-N 115.053 -0.976 . . . . 0.0 112.793 176.395 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 2.8 m -70.87 155.08 41.24 Favored 'General case' 0 CA--C 1.554 1.128 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 174.201 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 4.1 m -63.67 87.41 0.04 OUTLIER 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 123.493 0.717 . . . . 0.0 112.428 -168.405 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 134.35 17.81 0.96 Allowed Glycine 0 N--CA 1.469 0.883 0 CA-C-N 114.797 -1.092 . . . . 0.0 111.823 -175.43 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 42.6 t -62.09 138.31 95.86 Favored Pre-proline 0 CA--C 1.545 0.762 0 C-N-CA 124.777 1.231 . . . . 0.0 111.388 177.246 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -71.9 129.79 15.86 Favored 'Trans proline' 0 C--N 1.37 1.71 0 C-N-CA 122.039 1.826 . . . . 0.0 112.259 179.371 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 22.9 mt -100.71 120.5 50.28 Favored 'Isoleucine or valine' 0 C--O 1.238 0.473 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 173.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 201' ' ' ILE . . . . . 0.465 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 56.5 mt -113.55 160.57 12.98 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.942 0 N-CA-C 107.826 -1.176 . . . . 0.0 107.826 178.221 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -99.6 169.27 9.4 Favored 'General case' 0 N--CA 1.478 0.942 0 O-C-N 121.739 -0.601 . . . . 0.0 110.539 176.188 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 7.3 ptpp? -58.66 -26.57 63.93 Favored 'General case' 0 CA--C 1.55 0.957 0 C-N-CA 124.207 1.003 . . . . 0.0 111.497 174.221 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 51.2 tptt -67.0 -20.62 65.91 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 124.064 0.946 . . . . 0.0 111.401 179.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 98.82 -14.1 61.88 Favored Glycine 0 C--N 1.345 1.078 0 N-CA-C 111.791 -0.524 . . . . 0.0 111.791 -175.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -85.79 136.89 33.14 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 123.96 0.904 . . . . 0.0 109.705 179.042 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . 0.465 ' HA ' ' HA ' ' A' ' 201' ' ' ILE . 13.7 p -67.88 151.95 9.95 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 123.627 0.771 . . . . 0.0 110.101 -179.629 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 208' ' ' VAL . . . . . 0.502 HG23 HG23 ' A' ' 156' ' ' VAL . 28.8 m -127.49 -26.62 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 CA-C-O 118.683 -0.675 . . . . 0.0 112.568 -179.211 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.522 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . 171.72 -147.03 9.82 Favored Glycine 0 C--N 1.36 1.871 0 C-N-CA 119.202 -1.475 . . . . 0.0 116.618 176.128 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 50.6 mt -129.65 143.33 50.77 Favored 'General case' 0 N--CA 1.491 1.623 0 C-N-CA 124.45 1.1 . . . . 0.0 111.804 -175.06 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 47.7 t80 -117.5 105.74 12.41 Favored 'General case' 0 C--O 1.236 0.386 0 C-N-CA 124.951 1.3 . . . . 0.0 108.505 -177.025 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . 172.86 71.49 0.05 OUTLIER Glycine 0 N--CA 1.442 -0.906 0 N-CA-C 111.348 -0.701 . . . . 0.0 111.348 160.286 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 213' ' ' ASN . . . . . 0.609 ' HB2' ' HB1' ' A' ' 225' ' ' ALA . 2.8 m120 -140.17 79.62 1.72 Allowed 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 175.308 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 169.17 -152.63 20.41 Favored Glycine 0 C--O 1.247 0.927 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.756 -176.265 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 215' ' ' VAL . . . . . 0.466 HG23 ' HE2' ' B' ' 253' ' ' LYS . 9.9 p -163.24 171.02 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.832 0 CA-C-N 116.905 0.353 . . . . 0.0 111.831 -166.476 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 216' ' ' VAL . . . . . . . . . . . . . 14.4 p -69.0 128.42 32.44 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.048 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 167.021 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 217' ' ' THR . . . . . 0.743 HG21 HD11 ' A' ' 41' ' ' ILE . 47.7 m -138.12 169.27 18.09 Favored 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 124.98 1.312 . . . . 0.0 108.848 -170.817 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 59.9 ttt180 69.22 -83.99 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 123.69 0.796 . . . . 0.0 111.526 168.099 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 23.2 p -163.27 42.36 0.11 Allowed 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 124.216 1.006 . . . . 0.0 109.011 -174.191 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . 101.39 37.89 3.42 Favored Glycine 0 C--N 1.345 1.069 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.149 -178.562 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . 0.469 ' HA ' ' HA ' ' A' ' 190' ' ' ASP . . . -118.96 100.61 7.48 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 123.802 0.841 . . . . 0.0 109.234 -172.479 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 222' ' ' TYR . . . . . 0.453 ' HB2' ' HG3' ' A' ' 193' ' ' PRO . 69.7 m-85 -77.4 97.81 5.05 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-O 121.601 0.715 . . . . 0.0 109.212 -177.003 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 45.7 t -97.52 113.71 32.72 Favored 'Isoleucine or valine' 0 C--O 1.235 0.29 0 CA-C-N 114.398 -1.273 . . . . 0.0 107.957 -178.708 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 8.8 t -130.91 154.58 47.95 Favored 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 124.737 1.215 . . . . 0.0 109.367 -173.025 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . 0.68 ' HA ' ' HA ' ' A' ' 186' ' ' ALA . . . -84.03 152.43 24.41 Favored 'General case' 0 C--O 1.247 0.947 0 CA-C-O 120.949 0.404 . . . . 0.0 110.545 178.545 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 226' ' ' ILE . . . . . . . . . . . . . 8.5 pt -114.53 93.14 2.37 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.806 0 CA-C-O 121.914 0.864 . . . . 0.0 109.855 -176.394 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 227' ' ' ALA . . . . . 0.43 ' O ' ' HA3' ' A' ' 209' ' ' GLY . . . -80.69 119.38 23.23 Favored 'General case' 0 N--CA 1.48 1.027 0 CA-C-N 114.939 -1.028 . . . . 0.0 111.108 -172.006 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . 0.423 HE21 ' HB3' ' A' ' 150' ' ' TRP . 4.0 pt20 -93.81 152.9 18.59 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 123.902 0.881 . . . . 0.0 109.188 177.621 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.416 ' HA ' ' NE1' ' A' ' 144' ' ' TRP . 87.4 m -65.06 122.36 16.85 Favored 'General case' 0 N--CA 1.477 0.907 0 CA-C-O 121.005 0.431 . . . . 0.0 111.872 -170.131 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 30.2 mt-10 -84.69 -41.73 15.99 Favored 'General case' 0 CA--C 1.543 0.694 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.313 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 231' ' ' LYS . . . . . 0.647 ' HB3' ' HZ3' ' A' ' 231' ' ' LYS . 0.0 OUTLIER 61.99 95.11 0.04 OUTLIER 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 124.9 1.28 . . . . 0.0 110.742 -177.284 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 85.2 p -89.07 138.56 31.31 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-O 119.124 -0.465 . . . . 0.0 110.97 178.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 233' ' ' ILE . . . . . . . . . . . . . 7.0 tt 66.87 -32.84 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.627 0 C-N-CA 127.838 2.455 . . . . 0.0 115.921 167.089 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 234' ' ' GLU . . . . . 0.507 ' HB3' ' HD3' ' A' ' 231' ' ' LYS . 30.4 tt0 -59.57 -26.56 65.49 Favored 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 124.352 1.061 . . . . 0.0 113.001 -169.56 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . 0.59 ' HB3' ' HE2' ' A' ' 231' ' ' LYS . 6.4 p-10 -54.68 -28.85 50.61 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 124.147 0.979 . . . . 0.0 111.654 178.221 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 236' ' ' ASN . . . . . . . . . . . . . 5.4 p30 -114.84 107.33 50.56 Favored Pre-proline 0 CA--C 1.561 1.386 0 C-N-CA 124.192 0.997 . . . . 0.0 108.734 169.274 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_exo -69.81 88.75 0.54 Allowed 'Trans proline' 0 C--N 1.379 2.151 0 C-N-CA 122.706 2.27 . . . . 0.0 111.662 175.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 238' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 -93.92 -59.52 1.96 Allowed 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 123.403 0.681 . . . . 0.0 110.282 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 239' ' ' ILE . . . . . . . . . . . . . 37.2 pt -113.45 -39.08 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 C-N-CA 123.028 0.531 . . . . 0.0 112.187 -172.571 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 23.9 mm-40 . . . . . 0 CA--C 1.558 1.25 0 C-N-CA 124.547 1.139 . . . . 0.0 111.206 -177.048 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 251' ' ' BEZ . . . . . 0.604 ' H6 ' ' HB2' ' B' ' 253' ' ' LYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 253' ' ' LYS . . . . . 0.604 ' HB2' ' H6 ' ' B' ' 251' ' ' BEZ . 1.0 OUTLIER -71.44 78.77 0.77 Allowed 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 124.721 1.208 . . . . 0.0 111.202 -175.551 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 254' ' ' ARG . . . . . 0.448 ' HG2' HH11 ' B' ' 254' ' ' ARG . 7.2 mmt-85 -79.45 164.49 23.92 Favored 'General case' 0 C--O 1.244 0.767 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 172.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 255' ' ' M9P . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.384 0 N-CA-C 111.302 -0.719 . . . . 0.0 111.302 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 27.6 t -141.02 111.41 6.81 Favored 'General case' 0 C--N 1.353 0.72 0 C-N-CA 123.078 0.551 . . . . 0.0 110.386 -174.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 61.29 15.65 6.65 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 124.79 1.236 . . . . 0.0 114.214 171.567 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -128.84 20.39 5.99 Favored 'General case' 0 N--CA 1.476 0.869 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 -177.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -123.94 10.41 8.86 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 126.109 1.764 . . . . 0.0 107.242 -177.18 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.496 ' HB2' HD11 ' A' ' 119' ' ' LEU . 16.9 mt -67.73 166.51 15.12 Favored 'General case' 0 C--O 1.201 -1.461 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 -174.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -154.6 146.7 23.68 Favored 'General case' 0 C--O 1.247 0.968 0 CA-C-N 118.7 0.682 . . . . 0.0 110.144 176.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . 0.568 ' HB2' ' CD2' ' A' ' 121' ' ' HIS . 83.7 mt -87.54 125.45 34.34 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 115.032 -0.985 . . . . 0.0 109.933 172.536 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 22.7 tt0 -104.18 125.27 50.34 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 124.893 1.277 . . . . 0.0 108.275 178.391 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 15.5 ttt180 -60.24 109.35 0.96 Allowed 'General case' 0 N--CA 1.477 0.917 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 -179.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . 0.406 ' HB3' ' HG3' ' A' ' 85' ' ' ARG . . . -106.56 -43.88 4.62 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 122.487 0.315 . . . . 0.0 111.267 -170.113 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -174.25 172.91 3.16 Favored 'General case' 0 N--CA 1.477 0.913 0 O-C-N 124.095 0.872 . . . . 0.0 110.409 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -87.12 144.62 26.78 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 162.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 61.9 t -72.06 100.6 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.003 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 176.778 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 26.8 ttpp -172.05 103.49 0.17 Allowed 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 124.483 1.113 . . . . 0.0 108.884 -175.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . 0.526 ' NE1' ' HB1' ' A' ' 169' ' ' ALA . 92.4 t90 -80.59 94.78 6.36 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 123.224 0.61 . . . . 0.0 110.351 -179.244 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -157.81 57.62 0.48 Allowed 'General case' 0 CA--C 1.557 1.217 0 C-N-CA 123.195 0.598 . . . . 0.0 111.587 157.232 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -92.3 -63.42 1.24 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.445 -0.784 . . . . 0.0 112.689 177.675 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . 0.715 ' H ' ' HB2' ' A' ' 169' ' ' ALA . 48.8 mt-30 -153.09 43.8 0.63 Allowed 'General case' 0 N--CA 1.489 1.477 0 CA-C-N 114.693 -1.14 . . . . 0.0 111.248 -158.199 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -35.05 99.78 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.014 0 C-N-CA 125.537 1.535 . . . . 0.0 114.486 -175.135 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -126.52 118.48 24.99 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 123.748 0.819 . . . . 0.0 110.163 -176.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.529 ' HA ' ' HB2' ' A' ' 171' ' ' GLN . 0.2 OUTLIER -76.16 143.87 12.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 CA-C-O 121.052 0.453 . . . . 0.0 111.872 -174.478 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 77.2 p -154.35 156.71 37.39 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 124.558 1.143 . . . . 0.0 109.654 -178.502 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 160.25 103.82 0.19 Allowed Glycine 0 C--N 1.339 0.747 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -174.293 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.408 ' H ' ' HB3' ' A' ' 189' ' ' LEU . 29.4 t -109.72 -70.27 0.82 Allowed 'General case' 0 N--CA 1.478 0.961 0 CA-C-N 117.566 0.683 . . . . 0.0 111.342 -168.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 26.5 m -123.49 85.68 52.52 Favored Pre-proline 0 CA--C 1.551 1.014 0 C-N-CA 123.3 0.64 . . . . 0.0 109.526 -172.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 82.3 Cg_exo -45.41 -49.76 10.01 Favored 'Trans proline' 0 C--N 1.39 2.761 0 C-N-CA 124.293 3.329 . . . . 0.0 114.162 -173.149 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 49.1 mm -104.01 117.04 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 175.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.554 HD13 ' HB2' ' A' ' 218' ' ' ARG . 0.5 OUTLIER -138.26 128.52 25.95 Favored 'General case' 0 N--CA 1.478 0.942 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 -177.232 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 60.1 p -79.24 159.24 27.39 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 122.949 0.5 . . . . 0.0 111.195 179.088 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 16.0 tt -150.68 159.62 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 -177.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 35.3 m -94.88 110.81 22.65 Favored 'General case' 0 C--O 1.241 0.622 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 176.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 45.5 mm -72.12 115.75 12.98 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 173.673 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' SER . . . . . 0.481 ' HB2' ' HB3' ' A' ' 38' ' ' SER . 15.5 m -79.65 117.63 20.74 Favored 'General case' 0 C--O 1.241 0.627 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 170.641 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -60.37 -8.49 2.69 Favored 'General case' 0 N--CA 1.491 1.608 0 C-N-CA 124.473 1.109 . . . . 0.0 113.491 -169.206 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -65.79 -13.75 60.05 Favored 'General case' 0 CA--C 1.551 1.0 0 C-N-CA 124.756 1.222 . . . . 0.0 112.24 172.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.04 14.39 26.66 Favored Glycine 0 C--N 1.347 1.141 0 N-CA-C 111.693 -0.563 . . . . 0.0 111.693 -171.249 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.481 ' HB3' ' HB2' ' A' ' 34' ' ' SER . 23.1 t -109.03 164.97 11.95 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.496 0.719 . . . . 0.0 110.481 -179.303 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 68.3 mtp -133.29 134.71 44.23 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 123.518 0.727 . . . . 0.0 109.808 -179.015 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 13.3 p -169.44 174.4 6.0 Favored 'General case' 0 C--N 1.353 0.749 0 CA-C-O 121.436 0.636 . . . . 0.0 112.611 -175.185 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.622 HD12 HG21 ' A' ' 217' ' ' THR . 50.7 mm -89.44 152.33 3.35 Favored 'Isoleucine or valine' 0 C--O 1.241 0.635 0 N-CA-C 107.0 -1.482 . . . . 0.0 107.0 160.062 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 47.6 mtmt -72.65 75.74 1.1 Allowed 'General case' 0 CA--C 1.55 0.977 0 CA-C-O 121.665 0.745 . . . . 0.0 110.51 177.195 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 36.0 t30 -173.05 143.42 1.15 Allowed 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 126.079 1.752 . . . . 0.0 107.667 -176.504 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.473 ' HA ' ' HB2' ' B' ' 253' ' ' LYS . 12.5 pt-20 -148.5 150.53 33.56 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 122.537 0.335 . . . . 0.0 111.155 177.961 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -166.91 172.96 9.8 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 124.425 1.09 . . . . 0.0 109.866 179.419 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -65.44 119.3 10.76 Favored 'General case' 0 CA--C 1.558 1.28 0 N-CA-C 113.578 0.955 . . . . 0.0 113.578 -171.644 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.443 ' HG3' ' HNE' ' B' ' 255' ' ' M9P . 6.1 mm-40 -83.11 76.12 9.87 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 124.482 1.113 . . . . 0.0 109.82 173.022 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 75.5 mt-30 -117.59 104.11 10.71 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.055 -0.975 . . . . 0.0 110.097 -178.318 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 2.2 t -133.38 175.58 9.29 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 125.06 1.344 . . . . 0.0 107.794 171.119 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 53.4 tp -150.77 128.21 11.41 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 176.346 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -90.0 -122.89 2.41 Favored Glycine 0 C--N 1.345 1.079 0 N-CA-C 110.891 -0.884 . . . . 0.0 110.891 173.094 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -100.72 -144.82 16.19 Favored Glycine 0 C--N 1.337 0.629 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 168.352 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.25 42.94 96.02 Favored Glycine 0 C--N 1.348 1.197 0 CA-C-N 116.874 0.337 . . . . 0.0 113.897 173.326 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -170.98 -121.99 0.61 Allowed Glycine 0 C--N 1.339 0.718 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 178.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 11.0 t 67.85 165.04 0.23 Allowed 'General case' 0 N--CA 1.485 1.312 0 C-N-CA 125.337 1.455 . . . . 0.0 112.681 176.549 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -77.34 -17.74 78.95 Favored Glycine 0 C--N 1.348 1.23 0 CA-C-N 115.552 -0.749 . . . . 0.0 113.073 179.272 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -68.39 98.6 0.52 Allowed Glycine 0 C--N 1.346 1.123 0 N-CA-C 112.283 -0.327 . . . . 0.0 112.283 176.608 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -76.61 -137.76 0.81 Allowed Glycine 0 CA--C 1.531 1.073 0 N-CA-C 112.184 -0.366 . . . . 0.0 112.184 175.063 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 71.12 -76.88 0.58 Allowed Glycine 0 C--N 1.346 1.11 0 N-CA-C 111.364 -0.694 . . . . 0.0 111.364 -176.276 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 23.9 mm-40 -81.13 -22.88 38.71 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 123.711 0.804 . . . . 0.0 110.929 172.274 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 48.3 p90 40.86 95.94 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.831 0 C-N-CA 126.672 1.989 . . . . 0.0 114.14 177.445 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . 69.4 8.8 6.98 Favored 'General case' 0 N--CA 1.487 1.414 0 C-N-CA 124.823 1.249 . . . . 0.0 112.854 177.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 87.21 -57.12 4.57 Favored Glycine 0 C--N 1.349 1.299 0 N-CA-C 111.746 -0.542 . . . . 0.0 111.746 -178.308 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 8.8 p 44.37 50.84 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.568 1.639 0 C-N-CA 126.43 1.892 . . . . 0.0 112.945 172.231 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -159.18 97.85 1.4 Allowed 'General case' 0 N--CA 1.485 1.31 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 -178.385 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . 0.527 ' NE1' ' HG3' ' A' ' 122' ' ' LYS . 1.1 p90 -168.99 60.46 0.05 Allowed 'General case' 0 N--CA 1.49 1.572 0 C-N-CA 123.791 0.837 . . . . 0.0 110.674 -179.044 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.459 ' HB2' ' HZ3' ' A' ' 122' ' ' LYS . 15.1 m-20 177.59 -141.82 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.933 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 -171.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.407 ' H ' ' HB3' ' A' ' 67' ' ' ASP . 6.1 m -52.99 123.25 32.46 Favored Pre-proline 0 CA--C 1.566 1.592 0 CA-C-N 114.898 -1.046 . . . . 0.0 110.831 153.45 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_exo -60.28 -34.41 93.77 Favored 'Trans proline' 0 C--N 1.377 2.071 0 C-N-CA 122.801 2.334 . . . . 0.0 112.384 171.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 53.5 m -86.96 171.44 10.0 Favored Pre-proline 0 CA--C 1.554 1.13 0 C-N-CA 124.077 0.951 . . . . 0.0 110.022 174.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 76.7 Cg_exo -53.4 147.6 36.65 Favored 'Trans proline' 0 C--N 1.384 2.395 0 C-N-CA 122.349 2.033 . . . . 0.0 112.066 166.435 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 97.2 Cg_exo -47.56 111.16 0.38 Allowed 'Trans proline' 0 C--N 1.377 2.071 0 C-N-CA 123.46 2.774 . . . . 0.0 113.399 177.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_endo -71.06 -179.93 3.89 Favored 'Trans proline' 0 C--N 1.379 2.147 0 C-N-CA 123.261 2.64 . . . . 0.0 112.845 -178.418 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 41.2 t -64.66 -43.04 96.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 123.021 0.528 . . . . 0.0 110.067 -179.83 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -66.53 -43.77 91.54 Favored Glycine 0 C--N 1.348 1.248 0 CA-C-N 115.38 -0.827 . . . . 0.0 112.553 176.44 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 64.1 pttt 47.3 15.97 0.05 Allowed 'General case' 0 N--CA 1.503 2.193 0 C-N-CA 126.632 1.973 . . . . 0.0 115.247 176.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -74.79 -23.67 58.54 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 123.664 0.786 . . . . 0.0 110.571 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -70.61 104.92 2.95 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 123.608 0.763 . . . . 0.0 109.62 173.355 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.406 HD13 ' OH ' ' A' ' 102' ' ' TYR . 88.6 mt -135.08 134.34 40.21 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 124.568 1.147 . . . . 0.0 108.236 178.229 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -95.01 145.24 25.08 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 121.525 0.679 . . . . 0.0 110.572 -177.432 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . 0.517 ' HB2' ' HA ' ' A' ' 103' ' ' LYS . 38.5 p-10 -127.93 169.76 13.6 Favored 'General case' 0 CA--C 1.537 0.449 0 CA-C-N 114.449 -1.25 . . . . 0.0 112.271 -172.473 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 142.27 -162.82 27.2 Favored Glycine 0 C--N 1.345 1.06 0 CA-C-N 115.296 -0.866 . . . . 0.0 112.256 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . 0.482 ' HB2' HD13 ' A' ' 161' ' ' LEU . . . -85.76 123.26 30.93 Favored 'General case' 0 N--CA 1.477 0.88 0 C-N-CA 123.67 0.788 . . . . 0.0 109.865 177.587 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 15.0 m-85 -129.79 140.43 51.04 Favored 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 123.356 0.663 . . . . 0.0 110.686 -176.145 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . 0.512 ' HD3' HE22 ' A' ' 96' ' ' GLN . 80.7 mtt85 -88.09 128.8 35.42 Favored 'General case' 0 N--CA 1.479 0.997 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 173.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 53.3 mt -91.02 122.03 42.0 Favored 'Isoleucine or valine' 0 C--O 1.247 0.957 0 CA-C-O 121.432 0.634 . . . . 0.0 110.209 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.545 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 34.4 mtmm -114.84 146.96 40.5 Favored 'General case' 0 C--O 1.216 -0.675 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.316 174.657 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 19.7 tm0? -87.05 107.15 18.3 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 105.872 -1.899 . . . . 0.0 105.872 165.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 50.0 mtpt -114.38 94.04 4.62 Favored 'General case' 0 C--O 1.241 0.641 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 -176.078 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -70.28 137.9 28.5 Favored Glycine 0 C--O 1.242 0.619 0 N-CA-C 108.221 -1.951 . . . . 0.0 108.221 165.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 2.9 mp -75.13 68.9 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.566 1.584 0 N-CA-C 107.103 -1.443 . . . . 0.0 107.103 176.854 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 3.9 pp 170.5 -38.16 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.468 0 C-N-CA 126.435 1.894 . . . . 0.0 109.834 -165.549 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -161.66 134.33 3.48 Favored Glycine 0 C--N 1.353 1.492 0 CA-C-N 115.994 -0.548 . . . . 0.0 112.201 -174.417 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 8.2 m-85 -123.25 131.65 53.75 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.75 0.82 . . . . 0.0 109.756 -167.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 53.6 m -148.65 146.32 28.13 Favored 'General case' 0 N--CA 1.483 1.21 0 C-N-CA 123.956 0.902 . . . . 0.0 109.383 176.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.545 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 61.9 tt0 -92.52 144.08 25.7 Favored 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 123.127 0.571 . . . . 0.0 110.904 178.312 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 25.5 pt -128.34 -26.4 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 C-N-CA 123.138 0.575 . . . . 0.0 112.158 -173.255 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . 0.426 ' HA2' ' HB ' ' A' ' 195' ' ' THR . . . -177.52 -149.54 7.93 Favored Glycine 0 C--N 1.349 1.271 0 C-N-CA 121.144 -0.55 . . . . 0.0 113.263 -177.643 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -157.23 175.47 13.98 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 124.119 0.967 . . . . 0.0 110.969 -176.447 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -178.21 -171.18 41.28 Favored Glycine 0 C--N 1.346 1.117 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.646 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 34.7 t -135.64 127.0 44.92 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.065 0 CA-C-O 121.552 0.691 . . . . 0.0 111.023 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . 0.406 ' OH ' HD13 ' A' ' 79' ' ' LEU . 8.5 t80 -91.03 145.0 25.07 Favored 'General case' 0 CA--C 1.548 0.874 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 170.698 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.517 ' HA ' ' HB2' ' A' ' 81' ' ' ASP . 20.1 tptp -152.65 118.14 5.3 Favored 'General case' 0 N--CA 1.483 1.196 0 CA-C-N 119.168 0.895 . . . . 0.0 111.667 177.303 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 52.3 43.2 30.99 Favored 'General case' 0 N--CA 1.486 1.344 0 C-N-CA 124.629 1.171 . . . . 0.0 113.262 166.286 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 96.31 -33.76 5.42 Favored Glycine 0 C--N 1.348 1.244 0 CA-C-N 115.935 -0.575 . . . . 0.0 112.947 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 60.5 p -88.88 118.93 28.94 Favored 'General case' 0 CA--C 1.542 0.639 0 CA-C-N 117.023 0.412 . . . . 0.0 110.433 -178.213 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' PHE . . . . . 0.415 ' CE2' ' HG ' ' A' ' 119' ' ' LEU . 23.1 t80 -95.23 115.25 27.18 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 176.638 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . 0.603 ' HB2' ' HE3' ' A' ' 144' ' ' TRP . 1.0 OUTLIER -136.2 121.2 18.81 Favored 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 122.698 0.399 . . . . 0.0 110.808 -176.703 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 14.7 t -135.88 -179.71 5.82 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 122.999 0.52 . . . . 0.0 112.035 -169.09 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' MET . . . . . 0.567 ' HE1' ' HA2' ' A' ' 212' ' ' GLY . 0.0 OUTLIER -72.72 141.52 48.17 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 124.839 1.256 . . . . 0.0 110.023 171.247 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 80.7 t90 -76.03 -53.01 9.0 Favored 'General case' 0 N--CA 1.483 1.202 0 CA-C-O 119.328 -0.367 . . . . 0.0 111.616 -174.482 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . 0.617 ' HE1' ' HA ' ' A' ' 213' ' ' ASN . 3.4 p-80 -65.35 -2.88 3.48 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 114.119 1.155 . . . . 0.0 114.119 -170.437 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 78.1 t -58.07 -39.58 73.22 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.934 0 CA-C-O 121.524 0.678 . . . . 0.0 109.705 167.639 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.531 HG23 ' H ' ' A' ' 116' ' ' GLY . 9.4 t -138.6 -168.48 2.41 Favored 'General case' 0 CA--C 1.555 1.161 0 CA-C-N 114.607 -1.179 . . . . 0.0 109.765 -178.492 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 31.5 ttt180 -93.03 14.94 16.26 Favored 'General case' 0 CA--C 1.561 1.401 0 C-N-CA 124.063 0.945 . . . . 0.0 110.951 177.316 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.531 ' H ' HG23 ' A' ' 114' ' ' THR . . . 80.17 40.7 13.2 Favored Glycine 0 C--N 1.346 1.084 0 N-CA-C 111.816 -0.513 . . . . 0.0 111.816 -175.167 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -120.23 -169.89 1.88 Allowed 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 123.336 0.654 . . . . 0.0 111.543 -173.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 48.9 t -75.36 136.93 23.94 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 N-CA-C 114.184 1.179 . . . . 0.0 114.184 -159.854 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.496 HD11 ' HB2' ' A' ' 6' ' ' LEU . 3.7 mm? -103.13 151.63 22.36 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 124.89 1.276 . . . . 0.0 110.616 174.505 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 38.1 mmt -104.1 151.45 23.26 Favored 'General case' 0 C--O 1.262 1.744 0 C-N-CA 124.57 1.148 . . . . 0.0 108.197 173.284 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.568 ' CD2' ' HB2' ' A' ' 8' ' ' LEU . 0.1 OUTLIER -143.52 92.45 2.36 Favored 'General case' 0 CA--C 1.538 0.495 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 165.072 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.527 ' HG3' ' NE1' ' A' ' 66' ' ' TRP . 10.1 mtmp? 56.72 28.45 14.24 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 124.591 1.157 . . . . 0.0 112.619 -174.614 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 100.66 -8.91 58.45 Favored Glycine 0 C--N 1.347 1.176 0 CA-C-O 119.683 -0.509 . . . . 0.0 113.229 -176.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 61.2 tttm -72.94 114.55 11.22 Favored 'General case' 0 C--N 1.357 0.901 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 171.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 47.1 ttp180 -82.86 86.13 6.98 Favored 'General case' 0 C--O 1.241 0.605 0 C-N-CA 124.258 1.023 . . . . 0.0 109.271 -174.368 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.443 HG13 ' HB2' ' A' ' 119' ' ' LEU . 23.8 pt -91.71 100.49 11.3 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 CA-C-O 122.334 1.064 . . . . 0.0 109.346 -177.71 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -94.22 126.79 47.14 Favored Pre-proline 0 CA--C 1.546 0.789 0 CA-C-N 113.972 -1.467 . . . . 0.0 110.063 -175.382 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . 0.405 ' HB3' HG23 ' A' ' 138' ' ' ILE . 88.0 Cg_exo -49.53 119.5 4.72 Favored 'Trans proline' 0 C--N 1.373 1.865 0 C-N-CA 123.266 2.644 . . . . 0.0 113.834 175.666 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 59.1 p -82.13 -10.41 59.19 Favored 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 123.799 0.84 . . . . 0.0 110.51 174.425 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.688 ' HB3' ' HB2' ' A' ' 139' ' ' SER . 64.8 t-105 -155.79 152.77 28.86 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 124.912 1.285 . . . . 0.0 109.096 178.176 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -161.86 120.48 2.33 Favored 'General case' 0 C--O 1.241 0.622 0 C-N-CA 124.152 0.981 . . . . 0.0 108.546 169.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -108.84 112.5 24.79 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 123.324 0.65 . . . . 0.0 109.627 176.652 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 11.5 t -75.47 -17.47 15.8 Favored 'Isoleucine or valine' 0 CA--C 1.557 1.228 0 C-N-CA 123.139 0.576 . . . . 0.0 110.159 179.316 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 23.4 ttmm -59.62 -51.5 69.55 Favored 'General case' 0 C--N 1.358 0.974 0 C-N-CA 124.486 1.114 . . . . 0.0 112.359 -174.584 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 79.6 tttt -109.79 4.9 22.2 Favored 'General case' 0 N--CA 1.485 1.291 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 172.606 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . 0.437 ' O ' ' HE3' ' A' ' 110' ' ' MET . 15.6 t70 67.96 71.15 0.33 Allowed 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 124.341 1.056 . . . . 0.0 111.368 170.175 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 47.8 mt -147.43 160.29 42.73 Favored 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 124.317 1.047 . . . . 0.0 110.278 178.043 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.405 HG23 ' HB3' ' A' ' 128' ' ' PRO . 38.0 mt -132.24 150.72 33.83 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 C-N-CA 125.739 1.615 . . . . 0.0 108.214 -176.675 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' SER . . . . . 0.688 ' HB2' ' HB3' ' A' ' 130' ' ' TRP . 20.4 m -145.36 143.98 30.44 Favored 'General case' 0 CA--C 1.554 1.123 0 C-N-CA 123.81 0.844 . . . . 0.0 110.887 -179.393 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 19.8 t80 -139.35 128.98 24.52 Favored 'General case' 0 N--CA 1.48 1.029 0 C-N-CA 125.544 1.538 . . . . 0.0 107.942 178.207 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.03 2.51 88.83 Favored Glycine 0 C--N 1.35 1.347 0 O-C-N 123.848 0.717 . . . . 0.0 113.178 179.336 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 165.09 -153.49 23.69 Favored Glycine 0 C--N 1.339 0.725 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -173.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -105.62 173.47 20.24 Favored Glycine 0 C--N 1.343 0.968 0 CA-C-N 117.122 0.461 . . . . 0.0 112.034 174.66 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' TRP . . . . . 0.603 ' HE3' ' HB2' ' A' ' 108' ' ' HIS . 36.2 t-105 -66.6 110.51 3.22 Favored 'General case' 0 C--O 1.245 0.853 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 170.064 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . 0.532 ' HA ' ' HB ' ' A' ' 229' ' ' THR . 0.1 OUTLIER -150.49 146.34 26.55 Favored 'General case' 0 CA--C 1.538 0.499 0 CA-C-O 121.6 0.714 . . . . 0.0 110.475 171.345 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' LEU . . . . . 0.514 HD13 ' HA2' ' A' ' 209' ' ' GLY . 72.7 mt -144.06 2.21 1.15 Allowed 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 125.997 1.719 . . . . 0.0 108.099 170.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 36.6 mt-10 71.07 36.2 1.47 Allowed 'General case' 0 C--N 1.372 1.564 0 C-N-CA 124.157 0.983 . . . . 0.0 111.421 171.045 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . 0.517 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -149.94 156.51 26.78 Favored Glycine 0 C--N 1.347 1.174 0 CA-C-O 121.436 0.465 . . . . 0.0 113.932 -177.613 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -151.12 131.29 13.53 Favored 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 124.022 0.929 . . . . 0.0 109.224 -176.071 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' TRP . . . . . 0.505 ' HE1' ' HB3' ' A' ' 174' ' ' PRO . 50.8 t-105 -91.7 143.78 26.19 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 122.985 0.514 . . . . 0.0 110.027 170.599 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 26.5 tptp -131.14 139.44 49.8 Favored 'General case' 0 CA--C 1.536 0.412 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 169.101 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -44.27 147.11 0.58 Allowed 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 126.165 1.786 . . . . 0.0 113.73 -178.162 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 152.12 -84.7 0.15 Allowed Glycine 0 C--N 1.342 0.867 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.804 179.389 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -88.73 -174.88 4.71 Favored 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 124.446 1.099 . . . . 0.0 110.538 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 11.6 mp0 -63.97 130.95 46.1 Favored 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 169.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 13.0 p -90.53 148.0 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 166.444 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 7.9 mm100 -103.72 140.5 37.52 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -170.24 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.574 HG23 HG12 ' A' ' 200' ' ' ILE . 19.1 t -127.63 120.02 53.35 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 176.139 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.599 ' HB3' ' HG2' ' A' ' 199' ' ' PRO . 0.2 OUTLIER -81.39 86.18 6.33 Favored 'General case' 0 CA--C 1.558 1.269 0 N-CA-C 107.481 -1.304 . . . . 0.0 107.481 174.249 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . 0.425 ' HB1' ' HB2' ' A' ' 168' ' ' ARG . . . -68.97 104.99 2.24 Favored 'General case' 0 N--CA 1.481 1.121 0 C-N-CA 123.263 0.625 . . . . 0.0 112.089 -172.43 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . 0.482 HD13 ' HB2' ' A' ' 83' ' ' ALA . 74.9 mt -75.42 83.8 2.52 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 174.359 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 15.0 tp10 -70.25 119.75 74.02 Favored Pre-proline 0 CA--C 1.551 1.017 0 CA-C-N 114.886 -1.052 . . . . 0.0 110.176 -176.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . 0.447 ' HG3' HG21 ' A' ' 195' ' ' THR . 63.5 Cg_exo -55.43 114.1 1.72 Allowed 'Trans proline' 0 C--N 1.377 2.045 0 C-N-CA 123.132 2.554 . . . . 0.0 113.378 -178.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 75.99 22.08 74.9 Favored Glycine 0 C--N 1.344 1.019 0 O-C-N 123.724 0.64 . . . . 0.0 113.418 175.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 54.1 tptt -151.69 156.88 41.25 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -174.434 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -58.28 148.21 64.08 Favored Pre-proline 0 CA--C 1.558 1.259 0 C-N-CA 123.034 0.534 . . . . 0.0 112.312 177.594 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -59.62 146.89 94.04 Favored 'Trans proline' 0 C--N 1.379 2.134 0 C-N-CA 123.213 2.609 . . . . 0.0 113.233 179.048 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . 0.425 ' HB2' ' HB1' ' A' ' 160' ' ' ALA . 80.9 mtp180 -123.91 110.54 14.96 Favored 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 123.804 0.842 . . . . 0.0 108.828 -172.465 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . 0.715 ' HB2' ' H ' ' A' ' 19' ' ' GLN . . . -78.84 106.37 10.81 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-O 120.808 0.337 . . . . 0.0 110.701 -178.662 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 21.9 t -105.64 139.19 27.57 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.894 0 C-N-CA 123.176 0.591 . . . . 0.0 109.778 -178.023 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . 0.529 ' HB2' ' HA ' ' A' ' 22' ' ' ILE . 11.2 mt-30 -97.09 102.87 14.73 Favored 'General case' 0 C--N 1.348 0.53 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 170.335 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 172' ' ' THR . . . . . 0.477 ' HB ' HD13 ' A' ' 189' ' ' LEU . 71.4 p -101.71 124.06 46.73 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -178.816 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 28.1 mtpp -71.03 133.17 86.06 Favored Pre-proline 0 CA--C 1.546 0.806 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 174.049 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . 0.505 ' HB3' ' HE1' ' A' ' 150' ' ' TRP . 37.7 Cg_endo -64.1 123.53 12.03 Favored 'Trans proline' 0 C--N 1.377 2.053 0 C-N-CA 122.288 1.992 . . . . 0.0 111.776 -169.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -100.0 -173.94 30.37 Favored Glycine 0 N--CA 1.45 -0.428 0 CA-C-N 114.956 -1.02 . . . . 0.0 112.229 177.064 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 5.6 mp -148.73 145.84 27.82 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.096 0.958 . . . . 0.0 109.172 178.476 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 177' ' ' PHE . . . . . 0.73 ' HB2' ' HB ' ' A' ' 184' ' ' ILE . 59.1 m-85 -92.71 122.67 35.35 Favored 'General case' 0 C--O 1.245 0.866 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 167.705 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 77.8 tttt -95.21 104.8 16.7 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 114.809 -1.087 . . . . 0.0 109.187 177.063 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 36.4 p -132.81 156.98 46.14 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 169.481 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 10.3 t30 -56.61 -38.74 72.47 Favored 'General case' 0 N--CA 1.484 1.232 0 C-N-CA 123.874 0.87 . . . . 0.0 112.892 -169.078 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -94.93 -35.68 11.91 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 123.067 0.547 . . . . 0.0 110.8 178.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -112.94 118.19 4.5 Favored Glycine 0 C--N 1.347 1.153 0 CA-C-N 116.279 -0.419 . . . . 0.0 113.859 -169.319 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 30.2 m -98.57 100.88 12.16 Favored 'General case' 0 CA--C 1.538 0.507 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 163.167 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . 0.73 ' HB ' ' HB2' ' A' ' 177' ' ' PHE . 46.9 mt -104.17 149.73 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 C-N-CA 123.512 0.725 . . . . 0.0 109.07 -169.546 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -99.17 124.6 8.29 Favored Glycine 0 C--N 1.349 1.305 0 N-CA-C 109.808 -1.317 . . . . 0.0 109.808 -179.577 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . 0.668 ' HA ' ' HA ' ' A' ' 225' ' ' ALA . . . -140.27 -174.66 4.0 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 114.125 1.157 . . . . 0.0 114.125 -159.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 187' ' ' VAL . . . . . 0.417 HG12 ' HB ' ' A' ' 172' ' ' THR . 98.4 t -126.27 99.86 6.14 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.641 0 N-CA-C 105.683 -1.969 . . . . 0.0 105.683 171.183 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 188' ' ' SER . . . . . 0.554 ' HA ' HG12 ' A' ' 223' ' ' VAL . 60.6 p -113.64 79.64 1.27 Allowed 'General case' 0 C--O 1.243 0.731 0 CA-C-O 122.243 1.021 . . . . 0.0 111.044 -171.343 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 189' ' ' LEU . . . . . 0.477 HD13 ' HB ' ' A' ' 172' ' ' THR . 0.0 OUTLIER -151.49 178.9 8.83 Favored 'General case' 0 N--CA 1.477 0.923 0 CA-C-N 114.596 -1.184 . . . . 0.0 111.528 175.723 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -80.03 102.33 9.21 Favored 'General case' 0 CA--C 1.542 0.635 0 N-CA-C 107.307 -1.368 . . . . 0.0 107.307 171.622 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 191' ' ' PHE . . . . . 0.701 ' HB3' ' HB2' ' A' ' 222' ' ' TYR . 69.5 t80 -106.58 164.22 12.24 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 124.32 1.048 . . . . 0.0 109.53 -174.269 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 16.8 m -58.79 155.15 32.7 Favored Pre-proline 0 CA--C 1.561 1.394 0 C-N-CA 124.748 1.219 . . . . 0.0 112.134 178.297 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_exo -64.84 10.91 0.12 Allowed 'Trans proline' 0 C--N 1.381 2.263 0 C-N-CA 123.123 2.548 . . . . 0.0 115.342 171.555 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 194' ' ' GLY . . . . . 0.442 ' HA2' ' HD3' ' A' ' 163' ' ' PRO . . . -50.05 134.13 27.72 Favored Glycine 0 CA--C 1.54 1.643 0 C-N-CA 123.621 0.629 . . . . 0.0 112.995 168.712 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 195' ' ' THR . . . . . 0.447 HG21 ' HG3' ' A' ' 163' ' ' PRO . 6.6 p -75.34 151.39 38.25 Favored 'General case' 0 CA--C 1.552 1.03 0 C-N-CA 124.285 1.034 . . . . 0.0 113.381 -169.919 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -62.98 128.91 38.03 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 124.333 1.053 . . . . 0.0 111.213 -172.643 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . 0.4 ' O ' HD23 ' A' ' 210' ' ' LEU . . . 96.68 8.19 57.35 Favored Glycine 0 C--N 1.34 0.755 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 -167.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 198' ' ' SER . . . . . 0.403 ' OG ' ' HA ' ' A' ' 160' ' ' ALA . 34.0 t -57.15 119.06 28.31 Favored Pre-proline 0 CA--C 1.557 1.243 0 C-N-CA 123.684 0.793 . . . . 0.0 109.839 164.278 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . 0.599 ' HG2' ' HB3' ' A' ' 159' ' ' LEU . 19.6 Cg_endo -58.04 131.63 44.61 Favored 'Trans proline' 0 C--N 1.377 2.033 0 C-N-CA 123.171 2.581 . . . . 0.0 113.832 -170.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 200' ' ' ILE . . . . . 0.574 HG12 HG23 ' A' ' 158' ' ' VAL . 18.9 mt -97.98 130.87 46.1 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.754 0 C-N-CA 123.988 0.915 . . . . 0.0 109.062 171.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 201' ' ' ILE . . . . . . . . . . . . . 50.3 mt -123.03 169.55 14.26 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.369 0 C-N-CA 124.706 1.202 . . . . 0.0 108.525 179.045 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -108.55 155.82 20.21 Favored 'General case' 0 N--CA 1.483 1.177 0 C-N-CA 124.346 1.058 . . . . 0.0 108.867 173.258 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 18.7 ptmt -66.4 -19.5 65.82 Favored 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 -170.578 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 45.3 mttp -73.99 -17.4 61.0 Favored 'General case' 0 N--CA 1.488 1.443 0 CA-C-N 117.911 0.323 . . . . 0.0 110.739 176.011 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 115.4 -16.45 17.16 Favored Glycine 0 C--N 1.351 1.362 0 N-CA-C 111.898 -0.481 . . . . 0.0 111.898 -176.066 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 1.2 tpmt? -73.21 119.2 17.12 Favored 'General case' 0 C--O 1.219 -0.502 0 C-N-CA 123.985 0.914 . . . . 0.0 109.239 -177.676 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . 0.517 ' O ' ' HA3' ' A' ' 148' ' ' GLY . 12.7 p -64.02 150.23 10.13 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.926 0 C-N-CA 122.798 0.439 . . . . 0.0 110.239 176.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 208' ' ' VAL . . . . . 0.475 ' HB ' HG22 ' A' ' 200' ' ' ILE . 93.4 t -106.26 -49.84 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 177.542 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.514 ' HA2' HD13 ' A' ' 146' ' ' LEU . . . 161.33 -117.49 0.77 Allowed Glycine 0 N--CA 1.441 -1.014 0 CA-C-N 114.876 -1.056 . . . . 0.0 112.986 178.709 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . 0.569 ' HG ' ' CH2' ' A' ' 144' ' ' TRP . 69.2 mt -124.37 166.43 15.96 Favored 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 123.406 0.683 . . . . 0.0 111.841 -177.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -69.9 112.65 6.46 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-N 114.213 -1.358 . . . . 0.0 107.602 167.608 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 212' ' ' GLY . . . . . 0.567 ' HA2' ' HE1' ' A' ' 110' ' ' MET . . . -74.5 -145.66 1.07 Allowed Glycine 0 C--N 1.341 0.814 0 N-CA-C 115.984 1.154 . . . . 0.0 115.984 -163.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 213' ' ' ASN . . . . . 0.617 ' HA ' ' HE1' ' A' ' 112' ' ' HIS . 14.2 p30 -100.66 123.56 45.04 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 121.295 0.569 . . . . 0.0 110.716 -166.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 177.49 -134.31 2.44 Favored Glycine 0 N--CA 1.442 -0.906 0 CA-C-N 114.736 -1.12 . . . . 0.0 111.293 178.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 215' ' ' VAL . . . . . . . . . . . . . 10.0 p -176.55 178.09 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 -165.133 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 216' ' ' VAL . . . . . 0.57 HG11 ' HB2' ' B' ' 254' ' ' ARG . 6.7 m -75.35 110.36 10.08 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.024 0 O-C-N 121.159 -0.963 . . . . 0.0 108.922 160.213 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 217' ' ' THR . . . . . 0.622 HG21 HD12 ' A' ' 41' ' ' ILE . 13.4 m -104.14 177.02 4.96 Favored 'General case' 0 CA--C 1.548 0.886 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 175.86 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 218' ' ' ARG . . . . . 0.554 ' HB2' HD13 ' A' ' 29' ' ' LEU . 71.0 ttt-85 63.38 30.98 15.42 Favored 'General case' 0 N--CA 1.491 1.604 0 CA-C-O 121.98 0.895 . . . . 0.0 110.119 176.096 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 19.6 m 68.33 17.32 9.24 Favored 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 125.47 1.508 . . . . 0.0 113.203 177.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . 153.14 -6.87 0.44 Allowed Glycine 0 C--N 1.355 1.618 0 N-CA-C 115.05 0.78 . . . . 0.0 115.05 174.779 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . 0.453 ' HB1' ' HB3' ' A' ' 218' ' ' ARG . . . -78.58 125.97 30.1 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 123.205 0.602 . . . . 0.0 110.167 -179.816 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 222' ' ' TYR . . . . . 0.701 ' HB2' ' HB3' ' A' ' 191' ' ' PHE . 11.6 m-85 -65.97 102.03 0.74 Allowed 'General case' 0 N--CA 1.481 1.087 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 178.216 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . 0.554 HG12 ' HA ' ' A' ' 188' ' ' SER . 92.4 t -124.64 108.54 20.46 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.922 0 C-N-CA 124.296 1.038 . . . . 0.0 109.469 -176.726 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 50.6 m -142.1 159.0 43.11 Favored 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 123.871 0.868 . . . . 0.0 109.451 -178.571 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . 0.668 ' HA ' ' HA ' ' A' ' 186' ' ' ALA . . . -65.12 -171.36 0.07 Allowed 'General case' 0 N--CA 1.482 1.155 0 N-CA-C 113.349 0.87 . . . . 0.0 113.349 -174.809 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 226' ' ' ILE . . . . . . . . . . . . . 46.5 mt -118.29 105.84 18.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 172.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -80.34 99.72 8.05 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 122.965 0.506 . . . . 0.0 109.857 -178.713 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 18.2 pt20 -94.25 162.14 13.97 Favored 'General case' 0 N--CA 1.484 1.235 0 C-N-CA 123.929 0.892 . . . . 0.0 110.184 -178.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.532 ' HB ' ' HA ' ' A' ' 145' ' ' LYS . 24.6 p -90.06 121.83 32.49 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 122.669 0.388 . . . . 0.0 111.284 -170.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -139.65 -21.0 0.91 Allowed 'General case' 0 N--CA 1.483 1.221 0 C-N-CA 123.464 0.706 . . . . 0.0 112.284 -166.695 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 2.4 mptp? -82.33 -80.42 0.16 Allowed 'General case' 0 N--CA 1.488 1.463 0 CA-C-N 117.921 0.328 . . . . 0.0 110.453 -164.165 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 232' ' ' SER . . . . . 0.408 ' HB2' ' HD2' ' A' ' 145' ' ' LYS . 73.0 m -76.46 93.5 3.53 Favored 'General case' 0 C--N 1.36 1.03 0 CA-C-N 118.304 0.502 . . . . 0.0 109.788 171.566 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 233' ' ' ILE . . . . . . . . . . . . . 33.2 pt -69.99 -34.59 60.44 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.671 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.328 177.342 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 234' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 52.46 27.56 5.09 Favored 'General case' 0 N--CA 1.493 1.703 0 C-N-CA 125.068 1.347 . . . . 0.0 111.696 179.408 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -103.81 -11.79 17.33 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 124.718 1.207 . . . . 0.0 111.506 -168.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 236' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 -59.57 134.28 88.95 Favored Pre-proline 0 CA--C 1.55 0.965 0 C-N-CA 122.731 0.413 . . . . 0.0 110.888 -175.283 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -68.64 89.29 0.42 Allowed 'Trans proline' 0 C--N 1.373 1.825 0 C-N-CA 122.252 1.968 . . . . 0.0 110.36 174.374 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 238' ' ' GLU . . . . . . . . . . . . . 16.2 tp10 -66.29 -80.46 0.04 OUTLIER 'General case' 0 CA--C 1.549 0.92 0 CA-C-N 115.123 -0.944 . . . . 0.0 111.148 -170.352 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 239' ' ' ILE . . . . . . . . . . . . . 8.2 tp -95.96 -23.47 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.135 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 174.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 . . . . . 0 C--O 1.25 1.101 0 C-N-CA 124.808 1.243 . . . . 0.0 108.101 -177.604 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 251' ' ' BEZ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 253' ' ' LYS . . . . . 0.473 ' HB2' ' HA ' ' A' ' 44' ' ' GLU . 18.3 tptm -126.41 57.21 1.42 Allowed 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 107.907 -1.146 . . . . 0.0 107.907 165.39 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 254' ' ' ARG . . . . . 0.57 ' HB2' HG11 ' A' ' 216' ' ' VAL . 18.2 mmm180 -68.44 149.33 49.44 Favored 'General case' 0 C--O 1.241 0.633 0 CA-C-N 113.991 -1.459 . . . . 0.0 109.746 173.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 255' ' ' M9P . . . . . 0.443 ' HNE' ' HG3' ' A' ' 47' ' ' GLU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.879 0 CA-C-O 120.801 0.112 . . . . 0.0 113.237 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.638 ' HA ' ' HG3' ' A' ' 88' ' ' GLN . 38.2 t -77.53 154.02 32.83 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 123.733 0.813 . . . . 0.0 110.549 177.936 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -154.03 -74.92 0.12 Allowed 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 122.458 0.303 . . . . 0.0 110.463 173.043 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.538 ' O ' HG22 ' A' ' 118' ' ' VAL . . . -162.7 8.06 0.06 Allowed 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 112.175 0.435 . . . . 0.0 112.175 -175.774 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -123.37 83.92 2.2 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 177.223 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.713 ' HA ' ' HA ' ' A' ' 88' ' ' GLN . 4.8 mp -125.07 98.79 5.83 Favored 'General case' 0 N--CA 1.481 1.122 0 CA-C-O 119.333 -0.365 . . . . 0.0 111.559 -173.663 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 30.3 tt0 -81.58 144.84 30.98 Favored 'General case' 0 C--O 1.252 1.207 0 CA-C-O 121.979 0.895 . . . . 0.0 111.197 -175.125 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . 0.553 HD23 HD12 ' A' ' 119' ' ' LEU . 53.9 mt -85.31 115.3 22.98 Favored 'General case' 0 C--O 1.242 0.706 0 CA-C-N 113.556 -1.656 . . . . 0.0 109.752 176.04 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -104.03 125.96 50.78 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 171.319 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 47.0 ptt85 -67.17 129.39 39.76 Favored 'General case' 0 N--CA 1.478 0.958 0 CA-C-N 118.36 0.527 . . . . 0.0 109.76 178.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . 0.423 ' HB3' HD12 ' A' ' 161' ' ' LEU . . . -121.69 -21.35 6.18 Favored 'General case' 0 N--CA 1.479 0.983 0 C-N-CA 122.746 0.418 . . . . 0.0 111.239 -176.366 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . 0.662 ' HB2' ' HB3' ' A' ' 83' ' ' ALA . . . -164.01 161.4 22.63 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 121.639 0.733 . . . . 0.0 111.058 178.592 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -93.71 155.84 17.02 Favored 'General case' 0 C--O 1.245 0.826 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 161.31 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.591 HG22 ' HA2' ' A' ' 82' ' ' GLY . 85.9 t -67.21 103.35 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 175.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 58.8 tttp -168.55 133.32 1.64 Allowed 'General case' 0 C--O 1.239 0.528 0 CA-C-N 115.123 -0.944 . . . . 0.0 108.617 -170.308 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 23.3 t90 -74.61 114.01 12.54 Favored 'General case' 0 CA--C 1.542 0.655 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 167.504 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.567 ' HB3' ' HB3' ' A' ' 169' ' ' ALA . 39.6 tt0 -72.25 145.42 47.94 Favored 'General case' 0 CA--C 1.548 0.888 0 C-N-CA 123.344 0.658 . . . . 0.0 109.825 176.825 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -78.32 -2.73 39.48 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 123.878 0.871 . . . . 0.0 112.716 -172.579 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 31.6 mm-40 -87.08 43.44 1.1 Allowed 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 122.99 0.516 . . . . 0.0 110.152 -175.616 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -60.4 101.27 0.12 Allowed 'General case' 0 C--N 1.354 0.788 0 C-N-CA 124.775 1.23 . . . . 0.0 110.803 -174.603 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -105.37 117.44 34.02 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 124.236 1.014 . . . . 0.0 109.496 -173.662 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.488 HD12 ' HB2' ' A' ' 171' ' ' GLN . 43.4 mm -76.55 127.43 37.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 C-N-CA 123.025 0.53 . . . . 0.0 110.063 -172.82 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 29.2 m -148.25 -171.55 3.86 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 124.149 0.98 . . . . 0.0 110.796 -172.604 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 133.4 66.28 0.08 OUTLIER Glycine 0 C--N 1.347 1.185 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.456 ' H ' ' HA ' ' A' ' 189' ' ' LEU . 13.1 m -66.62 -52.6 43.36 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-N 114.648 -0.776 . . . . 0.0 111.845 -167.308 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.429 ' HB2' ' OG ' ' A' ' 188' ' ' SER . 14.8 m -95.26 144.12 27.26 Favored Pre-proline 0 CA--C 1.552 1.048 0 C-N-CA 123.119 0.568 . . . . 0.0 110.525 -172.747 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -84.97 -161.06 0.12 Allowed 'Trans proline' 0 C--N 1.378 2.113 0 C-N-CA 123.0 2.467 . . . . 0.0 112.623 174.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 45.3 mm -63.05 133.72 28.68 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 168.405 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.488 HD12 HG23 ' A' ' 217' ' ' THR . 0.2 OUTLIER -143.75 163.72 32.53 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 123.719 0.808 . . . . 0.0 109.639 -163.428 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.3 t -108.65 145.84 34.34 Favored 'General case' 0 N--CA 1.479 1.013 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 172.699 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.427 HD11 ' CE2' ' A' ' 177' ' ' PHE . 14.9 tt -135.27 154.38 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 C-N-CA 123.4 0.68 . . . . 0.0 109.336 -174.143 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 34.7 p -95.35 103.77 15.65 Favored 'General case' 0 C--O 1.243 0.713 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 171.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.427 ' HA ' ' HA ' ' A' ' 39' ' ' MET . 15.7 tt -91.05 117.53 34.47 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.764 179.432 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' SER . . . . . 0.606 ' HB3' ' HB3' ' A' ' 38' ' ' SER . 35.5 t -82.97 118.52 23.55 Favored 'General case' 0 C--O 1.242 0.662 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.003 -178.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -52.84 -28.15 21.55 Favored 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 125.3 1.44 . . . . 0.0 112.474 -177.682 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -48.22 -41.26 26.94 Favored 'General case' 0 CA--C 1.55 0.957 0 C-N-CA 125.265 1.426 . . . . 0.0 111.884 174.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 145.68 9.89 0.28 Allowed Glycine 0 C--N 1.34 0.791 0 CA-C-N 114.929 -1.032 . . . . 0.0 111.942 178.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.606 ' HB3' ' HB3' ' A' ' 34' ' ' SER . 32.7 t -109.82 164.2 12.79 Favored 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 123.537 0.735 . . . . 0.0 110.334 -173.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' MET . . . . . 0.427 ' HA ' ' HA ' ' A' ' 33' ' ' ILE . 22.3 ptm -153.67 127.64 8.95 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 123.439 0.696 . . . . 0.0 109.133 173.604 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 17.7 p -169.46 169.82 8.68 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 123.091 0.556 . . . . 0.0 110.862 -175.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.0 mp -78.69 124.32 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 N-CA-C 104.815 -2.291 . . . . 0.0 104.815 157.699 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . 0.64 ' HB2' ' HZ3' ' A' ' 42' ' ' LYS . 0.0 OUTLIER -61.43 79.02 0.01 OUTLIER 'General case' 0 CA--C 1.558 1.278 0 C-N-CA 124.238 1.015 . . . . 0.0 112.824 -170.957 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 92.5 m-20 -130.5 173.65 10.65 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 125.017 1.327 . . . . 0.0 109.088 -177.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -72.23 143.08 48.94 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 123.54 0.736 . . . . 0.0 110.755 177.063 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -115.41 149.29 38.22 Favored 'General case' 0 N--CA 1.473 0.678 0 C-N-CA 123.207 0.603 . . . . 0.0 110.594 177.593 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -145.19 152.2 39.62 Favored 'General case' 0 C--O 1.242 0.694 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 177.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -101.1 -176.43 3.16 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 123.209 0.603 . . . . 0.0 110.501 176.605 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.461 ' N ' HE21 ' A' ' 48' ' ' GLN . 0.0 OUTLIER -164.68 175.46 9.73 Favored 'General case' 0 N--CA 1.486 1.346 0 C-N-CA 124.426 1.09 . . . . 0.0 109.874 -176.609 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.583 ' HB ' ' HA ' ' A' ' 95' ' ' SER . 13.4 t -135.0 146.72 49.32 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 123.589 0.756 . . . . 0.0 109.188 171.535 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.434 ' HB3' ' OE1' ' A' ' 96' ' ' GLN . 29.5 tp -167.13 68.8 0.09 Allowed 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 175.828 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -173.87 142.89 6.76 Favored Glycine 0 C--N 1.342 0.888 0 CA-C-N 114.175 -1.375 . . . . 0.0 110.617 -177.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -115.89 -58.22 0.33 Allowed Glycine 0 C--N 1.348 1.205 0 CA-C-N 117.465 0.632 . . . . 0.0 112.472 -175.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.519 ' HA3' ' HZ2' ' A' ' 89' ' ' LYS . . . 59.56 52.64 51.87 Favored Glycine 0 C--N 1.356 1.682 0 C-N-CA 123.251 0.453 . . . . 0.0 112.192 -179.407 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 100.89 -133.08 11.17 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 110.55 -1.02 . . . . 0.0 110.55 -169.742 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 38.4 t -163.37 -36.7 0.04 OUTLIER 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 123.429 0.692 . . . . 0.0 110.502 179.546 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -72.96 -15.01 78.44 Favored Glycine 0 C--N 1.357 1.726 0 O-C-N 123.579 0.549 . . . . 0.0 114.337 -176.392 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 70.85 -98.51 0.7 Allowed Glycine 0 C--N 1.346 1.136 0 N-CA-C 112.324 -0.311 . . . . 0.0 112.324 -177.566 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -87.38 71.69 2.64 Favored Glycine 0 C--N 1.348 1.215 0 N-CA-C 111.205 -0.758 . . . . 0.0 111.205 177.184 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -67.82 88.98 0.19 Allowed Glycine 0 C--N 1.346 1.095 0 C-N-CA 122.964 0.316 . . . . 0.0 113.133 -178.109 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -74.95 -51.0 14.84 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 123.346 0.659 . . . . 0.0 109.542 176.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 89.2 t80 -76.46 105.18 7.37 Favored 'General case' 0 C--O 1.24 0.595 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 174.491 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . 65.7 114.55 0.03 OUTLIER 'General case' 0 CA--C 1.546 0.816 0 O-C-N 124.384 1.052 . . . . 0.0 110.512 -170.222 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -57.35 150.61 29.54 Favored Glycine 0 CA--C 1.533 1.176 0 CA-C-N 115.769 -0.65 . . . . 0.0 112.968 176.512 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.487 ' HB ' ' HG3' ' A' ' 122' ' ' LYS . 4.6 t -81.93 20.46 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 C-N-CA 124.356 1.062 . . . . 0.0 111.883 -169.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 3.3 tm? 74.33 102.69 0.07 Allowed 'General case' 0 N--CA 1.484 1.274 0 C-N-CA 124.85 1.26 . . . . 0.0 110.043 173.76 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . 0.458 ' CD1' ' HD2' ' A' ' 122' ' ' LYS . 30.2 m-90 -80.13 142.18 35.03 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 123.755 0.822 . . . . 0.0 109.712 178.103 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 27.1 t0 -83.68 75.84 10.03 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-O 121.759 0.79 . . . . 0.0 109.077 -178.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.409 ' HA ' ' O ' ' A' ' 78' ' ' GLU . 6.4 m -107.15 101.37 37.84 Favored Pre-proline 0 CA--C 1.554 1.098 0 CA-C-N 114.75 -1.114 . . . . 0.0 111.19 -173.562 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.628 ' HG3' ' HB3' ' A' ' 80' ' ' GLU . 73.7 Cg_endo -75.02 -46.38 0.24 Allowed 'Trans proline' 0 C--N 1.377 2.04 0 C-N-CA 122.274 1.982 . . . . 0.0 111.489 174.644 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 9.0 p -92.1 128.8 43.9 Favored Pre-proline 0 CA--C 1.547 0.843 0 C-N-CA 124.197 0.999 . . . . 0.0 110.072 178.678 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -58.39 151.28 62.15 Favored 'Trans proline' 0 C--N 1.374 1.901 0 C-N-CA 123.232 2.621 . . . . 0.0 113.296 168.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 66.8 Cg_exo -50.58 -47.0 26.72 Favored 'Trans proline' 0 C--N 1.384 2.41 0 C-N-CA 123.686 2.924 . . . . 0.0 115.703 176.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_exo -70.72 128.36 15.04 Favored 'Trans proline' 0 C--N 1.389 2.665 0 CA-C-N 121.884 1.709 . . . . 0.0 111.35 175.586 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 39.7 t 54.18 85.77 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.315 0 C-N-CA 125.009 1.324 . . . . 0.0 111.648 -177.543 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 168.64 124.82 0.75 Allowed Glycine 0 C--N 1.34 0.788 0 N-CA-C 111.034 -0.827 . . . . 0.0 111.034 -179.189 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 65.8 mttm -83.26 -27.66 29.71 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 123.286 0.635 . . . . 0.0 110.887 -176.565 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -89.3 151.81 21.9 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 123.611 0.764 . . . . 0.0 111.069 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.409 ' O ' ' HA ' ' A' ' 68' ' ' VAL . 3.9 tm-20 -126.21 -69.46 0.77 Allowed 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 174.328 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.423 HD11 ' CE1' ' A' ' 121' ' ' HIS . 7.9 tt -84.88 128.17 34.49 Favored 'General case' 0 C--O 1.244 0.764 0 N-CA-C 106.685 -1.598 . . . . 0.0 106.685 170.533 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.628 ' HB3' ' HG3' ' A' ' 69' ' ' PRO . 8.7 pt-20 -68.01 148.0 51.63 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-O 121.178 0.513 . . . . 0.0 111.661 -175.155 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -72.27 136.42 46.29 Favored 'General case' 0 C--O 1.239 0.524 0 CA-C-N 115.74 -0.663 . . . . 0.0 109.552 173.13 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.591 ' HA2' HG22 ' A' ' 14' ' ' VAL . . . 163.28 -175.05 39.6 Favored Glycine 0 C--N 1.34 0.79 0 O-C-N 123.167 0.292 . . . . 0.0 112.574 -173.106 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . 0.662 ' HB3' ' HB2' ' A' ' 12' ' ' ALA . . . -93.18 110.17 21.68 Favored 'General case' 0 C--O 1.244 0.789 0 CA-C-O 121.102 0.477 . . . . 0.0 110.503 -177.761 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 18.1 m-85 -107.41 136.92 46.39 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 176.731 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.68 131.79 36.82 Favored 'General case' 0 C--O 1.245 0.837 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 175.183 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.507 HD11 ' HE2' ' A' ' 107' ' ' PHE . 38.0 mt -90.58 111.46 23.54 Favored 'Isoleucine or valine' 0 C--O 1.273 2.3 0 CA-C-O 122.559 1.171 . . . . 0.0 110.482 -176.426 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.621 ' HZ1' ' HB3' ' A' ' 94' ' ' TYR . 7.1 tmtm? -116.73 130.89 57.0 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-N 112.857 -1.974 . . . . 0.0 107.061 179.075 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . 0.713 ' HA ' ' HA ' ' A' ' 6' ' ' LEU . 21.0 tm0? -79.86 111.08 15.84 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 106.838 -1.541 . . . . 0.0 106.838 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . 0.519 ' HZ2' ' HA3' ' A' ' 53' ' ' GLY . 35.0 ttmt -117.1 93.61 4.25 Favored 'General case' 0 C--O 1.238 0.458 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 -178.277 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -104.51 144.61 15.86 Favored Glycine 0 CA--C 1.496 -1.152 0 CA-C-N 114.158 -1.383 . . . . 0.0 110.953 -176.263 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 2.9 mp -65.3 -15.34 18.27 Favored 'Isoleucine or valine' 0 CA--C 1.566 1.589 0 C-N-CA 125.087 1.355 . . . . 0.0 109.675 179.735 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 1.1 pp -118.43 0.31 11.6 Favored 'General case' 0 CA--C 1.557 1.229 0 N-CA-C 113.467 0.914 . . . . 0.0 113.467 175.658 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 175.67 154.45 11.43 Favored Glycine 0 N--CA 1.488 2.128 0 CA-C-N 119.289 0.95 . . . . 0.0 114.185 -175.048 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . 0.621 ' HB3' ' HZ1' ' A' ' 87' ' ' LYS . 75.4 m-85 -130.71 125.39 33.79 Favored 'General case' 0 N--CA 1.487 1.405 0 C-N-CA 123.421 0.688 . . . . 0.0 112.086 -171.89 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.583 ' HA ' ' HB ' ' A' ' 49' ' ' THR . 39.8 m -135.66 157.36 47.06 Favored 'General case' 0 N--CA 1.492 1.675 0 C-N-CA 124.794 1.237 . . . . 0.0 110.734 171.506 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.442 ' H ' ' HA ' ' A' ' 49' ' ' THR . 11.7 pt20 -100.19 148.89 24.12 Favored 'General case' 0 N--CA 1.496 1.875 0 N-CA-C 107.977 -1.12 . . . . 0.0 107.977 158.366 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.629 HD13 ' HB2' ' A' ' 88' ' ' GLN . 0.0 OUTLIER -132.17 -39.01 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 CA-C-N 119.629 1.104 . . . . 0.0 111.305 179.167 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -175.59 -145.99 5.68 Favored Glycine 0 C--N 1.347 1.143 0 C-N-CA 119.652 -1.261 . . . . 0.0 114.199 -171.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -158.64 175.28 13.85 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 123.488 0.715 . . . . 0.0 111.449 -177.048 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -172.25 176.47 45.25 Favored Glycine 0 C--N 1.344 0.993 0 CA-C-N 115.401 -0.818 . . . . 0.0 111.539 -178.608 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 47.2 t -123.12 125.93 72.81 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.012 0 C-N-CA 122.866 0.466 . . . . 0.0 111.028 -175.325 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 39.4 t80 -85.34 144.63 27.94 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 167.092 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.611 ' HG3' ' HG3' ' A' ' 104' ' ' GLU . 22.9 tptm -157.0 133.83 10.19 Favored 'General case' 0 C--O 1.239 0.518 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 173.665 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.611 ' HG3' ' HG3' ' A' ' 103' ' ' LYS . 29.5 mt-10 62.6 -91.83 0.03 OUTLIER 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 124.983 1.313 . . . . 0.0 111.569 176.062 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -143.89 31.26 1.88 Allowed Glycine 0 C--N 1.341 0.831 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.4 t -146.28 129.4 16.55 Favored 'General case' 0 C--O 1.241 0.653 0 C-N-CA 123.694 0.798 . . . . 0.0 110.614 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' PHE . . . . . 0.507 ' HE2' HD11 ' A' ' 86' ' ' ILE . 67.2 t80 -94.92 104.01 15.89 Favored 'General case' 0 C--N 1.345 0.386 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 171.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . 0.532 ' CE1' ' HB3' ' A' ' 103' ' ' LYS . 1.5 p-80 -107.8 121.08 44.01 Favored 'General case' 0 C--N 1.325 -0.481 0 C-N-CA 123.247 0.619 . . . . 0.0 109.492 -178.862 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 8.6 t -136.62 179.77 6.17 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 123.839 0.856 . . . . 0.0 111.241 -172.52 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' MET . . . . . 0.449 ' SD ' ' O ' ' A' ' 212' ' ' GLY . 27.7 ttm -74.92 150.42 39.12 Favored 'General case' 0 CA--C 1.547 0.86 0 C-N-CA 125.463 1.505 . . . . 0.0 109.94 173.204 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 86.8 t90 -73.61 -56.32 5.16 Favored 'General case' 0 N--CA 1.494 1.747 0 CA-C-N 118.32 0.509 . . . . 0.0 111.967 -168.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . 0.407 ' CD2' ' HBA' ' B' ' 255' ' ' M9P . 1.2 p-80 -68.69 2.96 2.12 Favored 'General case' 0 N--CA 1.485 1.314 0 N-CA-C 114.332 1.234 . . . . 0.0 114.332 -171.358 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 23.0 m -60.32 -38.64 78.27 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 167.273 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 12.0 t -122.48 174.24 7.17 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 124.663 1.185 . . . . 0.0 108.498 178.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 50.7 ttt-85 -93.14 31.26 1.48 Allowed 'General case' 0 N--CA 1.485 1.275 0 CA-C-O 121.326 0.584 . . . . 0.0 109.588 -179.005 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 73.74 35.43 54.91 Favored Glycine 0 C--N 1.348 1.234 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 -167.22 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -122.36 -163.31 1.07 Allowed 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 123.663 0.785 . . . . 0.0 111.782 -168.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.667 HG23 ' HG3' ' A' ' 125' ' ' ARG . 2.0 m -89.21 156.56 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.127 0 C-N-CA 123.359 0.664 . . . . 0.0 110.822 -172.413 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.553 HD12 HD23 ' A' ' 8' ' ' LEU . 54.8 mt -110.46 174.78 5.7 Favored 'General case' 0 CA--C 1.551 1.018 0 C-N-CA 124.357 1.063 . . . . 0.0 109.586 170.758 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 23.5 mmt -124.63 137.6 54.36 Favored 'General case' 0 C--O 1.25 1.093 0 C-N-CA 123.534 0.734 . . . . 0.0 110.165 -176.026 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.446 ' NE2' ' HD1' ' A' ' 66' ' ' TRP . 77.6 t60 -130.88 95.85 3.93 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 168.002 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.487 ' HG3' ' HB ' ' A' ' 64' ' ' VAL . 0.1 OUTLIER 62.93 20.44 12.25 Favored 'General case' 0 N--CA 1.495 1.811 0 C-N-CA 124.513 1.125 . . . . 0.0 111.523 -168.461 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 88.52 14.65 61.31 Favored Glycine 0 C--N 1.345 1.054 0 CA-C-O 119.7 -0.5 . . . . 0.0 112.682 -172.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -82.18 129.5 34.85 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 169.072 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . 0.667 ' HG3' HG23 ' A' ' 118' ' ' VAL . 35.8 ttm180 -78.59 98.71 6.25 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 124.794 1.237 . . . . 0.0 111.217 -173.619 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.415 HD11 ' HB2' ' A' ' 121' ' ' HIS . 18.4 mt -89.08 95.48 5.44 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.693 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 175.751 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -91.68 141.57 25.84 Favored Pre-proline 0 N--CA 1.487 1.422 0 C-N-CA 122.732 0.413 . . . . 0.0 110.256 -179.212 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -73.42 153.8 50.36 Favored 'Trans proline' 0 C--N 1.382 2.307 0 C-N-CA 122.924 2.416 . . . . 0.0 114.791 -170.786 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 66.4 p -101.88 -32.45 10.22 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 123.97 0.908 . . . . 0.0 110.209 172.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 72.4 t-105 -130.38 149.71 51.94 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 124.059 0.944 . . . . 0.0 109.355 -177.76 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -156.77 125.69 5.93 Favored 'General case' 0 C--O 1.241 0.654 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 175.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -141.75 110.16 6.0 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 123.108 0.563 . . . . 0.0 109.896 179.717 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 3.5 t -77.09 -17.02 14.56 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.286 0 C-N-CA 123.654 0.782 . . . . 0.0 111.307 -176.552 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 58.3 mttp -65.21 -53.79 39.36 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 123.697 0.799 . . . . 0.0 110.903 -176.53 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 47.6 mmtm -82.93 -17.38 43.81 Favored 'General case' 0 N--CA 1.478 0.934 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.181 172.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 11.5 t70 60.49 66.74 0.9 Allowed 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 125.865 1.666 . . . . 0.0 109.44 -173.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . 0.413 HD21 ' HA ' ' A' ' 110' ' ' MET . 51.8 mt -143.63 123.94 13.83 Favored 'General case' 0 CA--C 1.547 0.844 0 CA-C-N 113.673 -1.603 . . . . 0.0 108.7 -179.17 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 16.8 tt -118.7 138.79 48.26 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 176.076 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 35.0 t -134.37 151.76 51.4 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 121.785 0.802 . . . . 0.0 111.797 -175.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 18.8 m-85 -124.25 102.77 7.87 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 113.784 -1.553 . . . . 0.0 107.423 -169.754 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 97.09 -1.98 61.22 Favored Glycine 0 C--N 1.346 1.092 0 O-C-N 123.776 0.672 . . . . 0.0 113.366 -177.09 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . -175.69 -150.54 8.06 Favored Glycine 0 C--N 1.347 1.155 0 CA-C-O 119.503 -0.61 . . . . 0.0 111.986 -177.52 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -116.83 -179.43 17.79 Favored Glycine 0 C--N 1.352 1.419 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 171.185 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' TRP . . . . . 0.525 ' HA ' ' HB2' ' A' ' 108' ' ' HIS . 54.1 t-105 -70.61 105.15 3.03 Favored 'General case' 0 N--CA 1.476 0.867 0 CA-C-N 118.655 1.227 . . . . 0.0 108.782 175.964 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 19.2 ptmt -138.41 121.55 16.86 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 122.944 0.498 . . . . 0.0 110.944 -171.058 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' LEU . . . . . . . . . . . . . 46.1 mt -153.17 -33.13 0.12 Allowed 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 125.586 1.554 . . . . 0.0 107.928 172.609 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 71.65 101.55 0.07 Allowed 'General case' 0 C--N 1.362 1.12 0 C-N-CA 126.166 1.786 . . . . 0.0 110.545 -179.048 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . 0.451 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -167.75 148.03 12.37 Favored Glycine 0 C--O 1.242 0.655 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 178.218 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -151.66 108.57 3.53 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -177.193 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' TRP . . . . . 0.546 ' HB2' HG21 ' A' ' 208' ' ' VAL . 81.5 t90 -65.9 123.95 21.2 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-O 120.762 0.315 . . . . 0.0 110.692 172.775 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -151.52 90.49 1.57 Allowed 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 160.567 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . 0.44 ' HG3' ' H ' ' A' ' 154' ' ' GLU . 12.0 tp10 -131.81 142.91 49.86 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 115.133 -0.94 . . . . 0.0 109.285 178.793 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -64.19 -30.42 77.75 Favored Glycine 0 C--N 1.349 1.287 0 N-CA-C 111.404 -0.678 . . . . 0.0 111.404 173.158 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . 0.44 ' H ' ' HG3' ' A' ' 152' ' ' GLU . 29.9 mt-10 -81.22 173.34 12.61 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 124.786 1.234 . . . . 0.0 110.003 172.566 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . 0.505 ' HB2' ' HB3' ' A' ' 171' ' ' GLN . 4.4 mp0 -67.31 166.76 13.71 Favored 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 123.738 0.815 . . . . 0.0 112.41 -173.394 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 15.0 p -92.67 141.47 14.58 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.167 172.117 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 20.4 mp0 -99.22 131.51 45.2 Favored 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -173.392 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 41.4 t -133.95 102.06 4.2 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 -178.432 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.419 ' HA ' ' HA ' ' A' ' 169' ' ' ALA . 2.3 pt? -76.3 85.5 3.08 Favored 'General case' 0 CA--C 1.545 0.768 0 CA-C-O 122.386 1.089 . . . . 0.0 108.893 176.004 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -64.65 114.53 4.48 Favored 'General case' 0 C--O 1.239 0.549 0 CA-C-N 114.221 -1.354 . . . . 0.0 108.64 178.441 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . 0.423 HD12 ' HB3' ' A' ' 11' ' ' ALA . 84.6 mt -69.0 94.49 0.64 Allowed 'General case' 0 C--O 1.239 0.503 0 O-C-N 123.655 0.597 . . . . 0.0 109.913 -172.312 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -65.28 112.6 8.74 Favored Pre-proline 0 CA--C 1.548 0.889 0 CA-C-N 114.267 -1.333 . . . . 0.0 109.436 -177.479 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -61.31 115.91 3.05 Favored 'Trans proline' 0 C--N 1.375 1.933 0 C-N-CA 122.503 2.135 . . . . 0.0 112.522 -171.405 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 93.12 -6.42 75.96 Favored Glycine 0 C--N 1.348 1.196 0 CA-C-N 114.966 -1.016 . . . . 0.0 113.883 177.542 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 61.3 mttm -128.07 -179.3 4.91 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 123.626 0.77 . . . . 0.0 109.207 -176.691 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -61.38 160.7 22.54 Favored Pre-proline 0 CA--C 1.558 1.26 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 164.302 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . 0.447 ' HG3' ' HB3' ' A' ' 12' ' ' ALA . 30.9 Cg_exo -61.93 -172.53 0.11 Allowed 'Trans proline' 0 C--N 1.375 1.951 0 C-N-CA 122.361 2.041 . . . . 0.0 114.491 -178.309 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 20.0 ttm-85 -138.13 99.46 3.88 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 171.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . 0.567 ' HB3' ' HB3' ' A' ' 17' ' ' GLU . . . -73.39 107.2 5.56 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.341 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 77.2 t -112.11 123.94 68.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 C-N-CA 123.493 0.717 . . . . 0.0 110.069 -176.584 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . 0.505 ' HB3' ' HB2' ' A' ' 155' ' ' GLU . 20.9 mt-30 -93.03 118.29 31.02 Favored 'General case' 0 C--N 1.341 0.217 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 175.362 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 172' ' ' THR . . . . . 0.669 HG21 HG21 ' A' ' 187' ' ' VAL . 5.9 t -126.29 142.8 51.39 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 123.206 0.603 . . . . 0.0 109.471 176.511 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -75.89 156.89 84.21 Favored Pre-proline 0 CA--C 1.561 1.368 0 CA-C-N 115.993 -0.548 . . . . 0.0 109.612 178.058 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -69.43 124.55 11.33 Favored 'Trans proline' 0 C--N 1.375 1.939 0 C-N-CA 122.178 1.919 . . . . 0.0 112.708 -177.492 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -158.78 139.38 6.22 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 108.74 -1.744 . . . . 0.0 108.74 175.238 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.722 ' HG ' ' HB2' ' A' ' 186' ' ' ALA 0.264 0.0 OUTLIER -175.8 -169.97 0.37 Allowed 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 123.949 0.899 . . . . 0.0 110.754 178.95 . . . . . . . . 4 4 . 1 . 008 nuclear orig full ' A' A ' 177' ' ' PHE . . . . . 0.46 ' HA ' ' O ' ' A' ' 29' ' ' LEU . 79.3 m-85 -91.8 158.3 16.41 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 114.863 -1.062 . . . . 0.0 111.118 -152.28 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -133.36 109.48 9.38 Favored 'General case' 0 C--O 1.239 0.523 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 170.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 1.2 m -140.55 170.18 16.26 Favored 'General case' 0 N--CA 1.479 1.018 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 175.118 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 36.1 t30 -59.85 102.43 0.16 Allowed 'General case' 0 CA--C 1.548 0.892 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 168.324 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . 79.22 1.24 2.34 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 125.415 1.486 . . . . 0.0 111.492 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -123.86 54.2 0.73 Allowed Glycine 0 C--N 1.348 1.225 0 N-CA-C 111.409 -0.676 . . . . 0.0 111.409 178.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 84.6 m -110.21 98.16 7.48 Favored 'General case' 0 CA--C 1.536 0.441 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 175.452 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . 0.513 ' O ' ' HB3' ' A' ' 176' ' ' LEU . 3.6 mp -125.13 152.82 31.93 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 178.569 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -127.62 116.98 2.52 Favored Glycine 0 C--N 1.377 2.851 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 172.066 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . 0.722 ' HB2' ' HG ' ' A' ' 176' ' ' LEU . . . -161.87 -149.34 0.16 Allowed 'General case' 0 C--N 1.373 1.598 0 CA-C-N 119.056 1.428 . . . . 0.0 111.9 -159.225 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 187' ' ' VAL . . . . . 0.669 HG21 HG21 ' A' ' 172' ' ' THR . 0.4 OUTLIER -91.57 117.77 35.54 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.971 0 C-N-CA 124.288 1.035 . . . . 0.0 110.028 -176.228 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 188' ' ' SER . . . . . 0.429 ' OG ' ' HB2' ' A' ' 26' ' ' SER . 10.6 t -130.44 90.78 2.98 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 123.406 0.682 . . . . 0.0 109.861 -174.123 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 189' ' ' LEU . . . . . 0.456 ' HA ' ' H ' ' A' ' 25' ' ' SER . 1.7 pp -136.91 -175.0 3.89 Favored 'General case' 0 N--CA 1.489 1.524 0 C-N-CA 123.423 0.689 . . . . 0.0 112.081 -174.292 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -135.19 119.29 17.57 Favored 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 124.238 1.015 . . . . 0.0 108.982 171.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 191' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -149.15 -178.89 6.64 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 123.223 0.609 . . . . 0.0 111.916 -178.711 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 42.3 m -60.71 157.09 40.72 Favored Pre-proline 0 CA--C 1.555 1.161 0 C-N-CA 124.787 1.235 . . . . 0.0 111.28 176.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 3.8 Cg_exo -34.58 91.23 0.01 OUTLIER 'Trans proline' 0 C--N 1.393 2.881 0 C-N-CA 125.236 3.957 . . . . 0.0 115.225 -178.018 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -74.08 134.48 18.5 Favored Glycine 0 C--N 1.35 1.325 0 CA-C-N 114.582 -1.19 . . . . 0.0 112.394 -179.669 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 40.7 p -82.72 122.75 28.57 Favored 'General case' 0 C--O 1.244 0.796 0 C-N-CA 123.752 0.821 . . . . 0.0 110.097 178.013 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 18.1 m -62.45 88.08 0.03 OUTLIER 'General case' 0 C--N 1.363 1.17 0 C-N-CA 123.591 0.756 . . . . 0.0 110.847 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . 0.457 ' O ' HD21 ' A' ' 210' ' ' LEU . . . 129.12 21.14 1.37 Allowed Glycine 0 CA--C 1.523 0.553 0 CA-C-N 114.897 -1.047 . . . . 0.0 112.574 -179.276 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 198' ' ' SER . . . . . 0.457 ' HG ' ' HB3' ' A' ' 211' ' ' TYR . 32.2 p -70.18 123.64 89.23 Favored Pre-proline 0 N--CA 1.478 0.951 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 172.758 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 198' ' ' SER . 32.1 Cg_exo -58.71 141.88 98.13 Favored 'Trans proline' 0 C--N 1.374 1.918 0 C-N-CA 122.9 2.4 . . . . 0.0 114.368 -168.538 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 200' ' ' ILE . . . . . 0.497 HD11 HG12 ' A' ' 226' ' ' ILE . 47.8 mt -110.8 118.96 58.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.325 0 C-N-CA 124.851 1.26 . . . . 0.0 108.754 175.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 201' ' ' ILE . . . . . 0.587 HG12 HG23 ' A' ' 207' ' ' VAL . 24.0 mt -113.02 143.47 22.64 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.377 0 C-N-CA 124.563 1.145 . . . . 0.0 110.029 -176.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 202' ' ' ASP . . . . . 0.401 ' O ' HG21 ' A' ' 201' ' ' ILE . 43.5 t0 -84.83 153.6 22.84 Favored 'General case' 0 N--CA 1.486 1.357 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 170.21 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 84.0 tttt -48.33 -27.29 2.45 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 124.689 1.196 . . . . 0.0 113.96 -172.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . 0.506 ' H ' ' HD2' ' A' ' 204' ' ' LYS . 9.7 mptt -64.1 -20.09 65.71 Favored 'General case' 0 N--CA 1.484 1.227 0 C-N-CA 124.27 1.028 . . . . 0.0 111.78 -177.448 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 101.6 5.85 50.9 Favored Glycine 0 C--N 1.345 1.033 0 CA-C-N 116.361 -0.382 . . . . 0.0 112.676 -177.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 39.8 tttm -106.61 140.74 39.01 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 123.162 0.585 . . . . 0.0 109.618 -179.762 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . 0.587 HG23 HG12 ' A' ' 201' ' ' ILE . 61.9 t -82.63 123.98 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 123.208 0.603 . . . . 0.0 111.41 -168.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 208' ' ' VAL . . . . . 0.546 HG21 ' HB2' ' A' ' 150' ' ' TRP . 45.6 t -69.46 -52.56 31.39 Favored 'Isoleucine or valine' 0 C--O 1.239 0.548 0 O-C-N 124.574 1.171 . . . . 0.0 110.48 173.714 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.518 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . 177.71 -134.24 2.4 Favored Glycine 0 C--N 1.348 1.2 0 CA-C-N 115.157 -0.928 . . . . 0.0 113.694 -175.892 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . 0.457 HD21 ' O ' ' A' ' 197' ' ' GLY . 86.1 mt -131.44 152.64 50.5 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 123.836 0.854 . . . . 0.0 110.926 -176.793 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 211' ' ' TYR . . . . . 0.457 ' HB3' ' HG ' ' A' ' 198' ' ' SER . 51.1 t80 -102.15 104.54 15.15 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 123.861 0.864 . . . . 0.0 108.986 175.696 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 212' ' ' GLY . . . . . 0.449 ' O ' ' SD ' ' A' ' 110' ' ' MET . . . 169.72 74.27 0.04 OUTLIER Glycine 0 C--N 1.337 0.632 0 C-N-CA 120.892 -0.67 . . . . 0.0 113.424 161.514 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 213' ' ' ASN . . . . . 0.68 ' H ' ' HB3' ' A' ' 224' ' ' SER . 71.7 m-20 -146.09 81.96 1.6 Allowed 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 170.368 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 178.03 -121.58 0.78 Allowed Glycine 0 N--CA 1.445 -0.714 0 CA-C-N 114.71 -1.132 . . . . 0.0 111.839 178.303 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 215' ' ' VAL . . . . . 0.484 HG22 ' HG2' ' B' ' 253' ' ' LYS . 10.2 p -172.81 165.61 0.24 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.843 0 C-N-CA 122.883 0.473 . . . . 0.0 109.955 -164.015 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 216' ' ' VAL . . . . . . . . . . . . . 27.7 m -77.45 107.7 9.46 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.137 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 158.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 217' ' ' THR . . . . . 0.488 HG23 HD12 ' A' ' 29' ' ' LEU . 74.6 m -82.41 144.03 30.79 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 123.998 0.919 . . . . 0.0 109.351 -179.751 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 13.6 mmm180 63.81 17.54 10.56 Favored 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 124.03 0.932 . . . . 0.0 110.077 -169.633 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 35.5 m 61.33 31.95 19.23 Favored 'General case' 0 C--N 1.364 1.239 0 C-N-CA 125.536 1.534 . . . . 0.0 112.175 -175.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . -157.93 -52.85 0.01 OUTLIER Glycine 0 C--N 1.352 1.464 0 CA-C-O 120.019 -0.323 . . . . 0.0 113.358 -179.122 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -69.71 114.22 7.71 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 123.185 0.594 . . . . 0.0 111.562 -172.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 222' ' ' TYR . . . . . . . . . . . . . 7.5 m-85 -68.11 98.06 0.75 Allowed 'General case' 0 CA--C 1.551 1.0 0 C-N-CA 123.0 0.52 . . . . 0.0 110.272 179.063 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 94.9 t -127.5 127.17 68.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 C-N-CA 123.798 0.839 . . . . 0.0 110.089 -171.445 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 224' ' ' SER . . . . . 0.68 ' HB3' ' H ' ' A' ' 213' ' ' ASN . 58.5 m -153.75 159.06 41.82 Favored 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 123.237 0.615 . . . . 0.0 111.384 -171.026 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . . . . . . . . . . . -80.03 145.15 32.65 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.352 1.061 . . . . 0.0 110.986 177.451 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 226' ' ' ILE . . . . . 0.663 HG13 ' HB1' ' A' ' 186' ' ' ALA . 85.3 mt -78.85 102.89 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 174.065 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 227' ' ' ALA . . . . . 0.428 ' O ' ' HA3' ' A' ' 209' ' ' GLY . . . -77.76 101.75 6.83 Favored 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 177.757 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 49.0 mt-30 -89.87 169.37 11.3 Favored 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 123.088 0.555 . . . . 0.0 110.098 -171.316 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.432 ' HA ' ' CD1' ' A' ' 144' ' ' TRP . 71.4 p -80.05 123.41 27.82 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 123.079 0.552 . . . . 0.0 111.506 -177.566 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -99.6 -24.18 14.82 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 123.244 0.618 . . . . 0.0 109.504 167.886 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 13.4 ptpt 68.72 157.06 0.14 Allowed 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 127.392 2.277 . . . . 0.0 113.098 174.132 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 22.4 m -61.02 138.33 58.19 Favored 'General case' 0 CA--C 1.543 0.678 0 CA-C-N 115.536 -0.756 . . . . 0.0 110.64 166.58 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 233' ' ' ILE . . . . . . . . . . . . . 13.4 tt -162.09 -33.29 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 C-N-CA 124.003 0.921 . . . . 0.0 108.996 -178.254 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 234' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 55.54 36.13 26.55 Favored 'General case' 0 C--N 1.364 1.209 0 C-N-CA 124.677 1.191 . . . . 0.0 109.898 175.86 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 10.1 p-10 -60.96 -25.06 66.56 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 125.04 1.336 . . . . 0.0 112.178 -174.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 236' ' ' ASN . . . . . . . . . . . . . 31.9 t30 -54.3 121.29 30.57 Favored Pre-proline 0 CA--C 1.55 0.956 0 C-N-CA 124.742 1.217 . . . . 0.0 110.442 169.247 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -68.8 98.53 0.6 Allowed 'Trans proline' 0 C--N 1.375 1.942 0 C-N-CA 121.93 1.753 . . . . 0.0 111.035 175.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 238' ' ' GLU . . . . . . . . . . . . . 48.0 mt-10 -99.26 32.3 2.78 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 123.982 0.913 . . . . 0.0 110.069 -179.26 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 239' ' ' ILE . . . . . 0.472 HG13 ' HG3' ' A' ' 240' ' ' GLU . 38.2 pt -62.91 -30.5 49.7 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 C-N-CA 123.986 0.915 . . . . 0.0 112.543 -176.249 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . 0.472 ' HG3' HG13 ' A' ' 239' ' ' ILE . 42.2 mt-10 . . . . . 0 CA--C 1.55 0.974 0 C-N-CA 124.323 1.049 . . . . 0.0 108.961 177.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 251' ' ' BEZ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 253' ' ' LYS . . . . . 0.484 ' HG2' HG22 ' A' ' 215' ' ' VAL . 1.5 tmtp? 70.49 -71.03 0.14 Allowed 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 125.385 1.474 . . . . 0.0 110.872 176.326 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 254' ' ' ARG . . . . . 0.41 ' O ' ' HD3' ' B' ' 253' ' ' LYS . 41.5 mtp85 69.85 171.67 0.31 Allowed 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 124.816 1.246 . . . . 0.0 113.254 175.083 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 255' ' ' M9P . . . . . 0.407 ' HBA' ' CD2' ' A' ' 112' ' ' HIS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.634 0 N-CA-C 111.466 -0.654 . . . . 0.0 111.466 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.47 ' HA ' HD23 ' A' ' 6' ' ' LEU . 24.0 p -102.12 102.85 13.37 Favored 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 123.063 0.545 . . . . 0.0 109.946 178.537 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.426 ' O ' ' HB3' ' A' ' 117' ' ' ALA . . . -103.99 -158.99 0.69 Allowed 'General case' 0 N--CA 1.482 1.165 0 C-N-CA 123.769 0.828 . . . . 0.0 109.225 176.46 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -102.81 18.03 22.47 Favored 'General case' 0 N--CA 1.478 0.937 0 O-C-N 121.851 -0.531 . . . . 0.0 109.652 -175.027 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . 0.49 ' HB2' ' NE2' ' A' ' 88' ' ' GLN . 6.2 m-20 -126.02 26.88 6.45 Favored 'General case' 0 C--O 1.237 0.444 0 C-N-CA 124.525 1.13 . . . . 0.0 108.976 -169.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.47 HD23 ' HA ' ' A' ' 2' ' ' SER . 83.7 mt -75.8 93.56 3.17 Favored 'General case' 0 C--O 1.215 -0.739 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.085 -173.172 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.446 ' HA ' ' O ' ' A' ' 120' ' ' MET . 23.2 tt0 -83.54 135.19 34.73 Favored 'General case' 0 N--CA 1.475 0.796 0 O-C-N 122.139 -0.351 . . . . 0.0 111.326 -179.651 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -102.1 138.89 38.46 Favored 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.337 177.096 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 19.1 pt-20 -143.33 144.51 32.12 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.802 0.841 . . . . 0.0 109.096 176.182 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . 0.506 ' NH2' ' HB3' ' A' ' 13' ' ' ASP . 50.7 ttt180 -63.41 120.73 12.21 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 112.286 0.476 . . . . 0.0 112.286 -165.603 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . 0.643 ' HB2' ' HG3' ' A' ' 85' ' ' ARG . . . -84.64 -45.89 12.05 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 124.108 0.963 . . . . 0.0 109.896 173.081 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -170.95 -178.21 2.44 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-N 115.178 -0.919 . . . . 0.0 112.006 -173.733 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.506 ' HB3' ' NH2' ' A' ' 10' ' ' ARG . 10.4 p-10 -103.63 164.77 11.46 Favored 'General case' 0 CA--C 1.54 0.571 0 CA-C-N 114.121 -1.4 . . . . 0.0 108.571 165.373 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 53.0 t -88.11 101.44 11.61 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.856 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 179.03 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 62.7 tttp -172.73 113.74 0.27 Allowed 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 124.42 1.088 . . . . 0.0 108.187 -177.738 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 79.8 t90 -100.95 91.71 4.7 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 122.503 0.321 . . . . 0.0 110.465 -176.714 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -158.27 58.05 0.46 Allowed 'General case' 0 CA--C 1.549 0.931 0 C-N-CA 123.593 0.757 . . . . 0.0 109.746 162.114 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -86.93 -56.04 3.57 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 122.833 0.453 . . . . 0.0 111.17 179.052 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . 0.591 ' H ' ' HB2' ' A' ' 169' ' ' ALA . 0.0 OUTLIER -148.38 4.35 0.69 Allowed 'General case' 0 N--CA 1.484 1.267 0 C-N-CA 123.186 0.595 . . . . 0.0 111.396 -173.615 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . 13.71 81.55 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 126.521 1.928 . . . . 0.0 114.228 -168.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.464 ' O ' ' HG2' ' A' ' 171' ' ' GLN . 34.2 tt0 -101.97 147.44 26.55 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 114.306 -1.316 . . . . 0.0 109.221 -176.503 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 9.4 tp -93.03 149.05 4.34 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.798 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 174.348 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.516 ' HB3' HD21 ' A' ' 189' ' ' LEU . 69.1 m -91.73 -174.67 3.92 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 123.642 0.777 . . . . 0.0 111.455 178.341 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -87.23 -41.88 6.43 Favored Glycine 0 C--N 1.347 1.194 0 CA-C-N 115.436 -0.802 . . . . 0.0 111.28 178.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 35.5 m 63.0 87.47 0.1 Allowed 'General case' 0 C--N 1.358 0.968 0 C-N-CA 124.299 1.039 . . . . 0.0 110.219 177.836 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.539 ' HB2' ' HB3' ' A' ' 188' ' ' SER . 17.2 m -85.49 156.31 59.26 Favored Pre-proline 0 CA--C 1.555 1.147 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.988 -174.672 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -65.63 -168.56 0.13 Allowed 'Trans proline' 0 C--N 1.376 2.018 0 C-N-CA 123.244 2.63 . . . . 0.0 112.448 167.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 35.0 mm -66.14 138.37 23.14 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.267 0 CA-C-O 120.811 0.339 . . . . 0.0 110.662 -174.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.557 HD22 HG21 ' A' ' 217' ' ' THR . 4.3 mt -114.85 161.46 18.21 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 123.282 0.633 . . . . 0.0 110.564 175.167 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 30.4 t -112.24 114.65 27.56 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 178.579 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 12.9 tt -113.62 160.56 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 C-N-CA 124.649 1.18 . . . . 0.0 108.306 -174.793 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 82.2 p -93.89 104.96 17.0 Favored 'General case' 0 C--N 1.363 1.164 0 CA-C-N 119.845 1.202 . . . . 0.0 108.184 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.786 HG23 ' HA ' ' A' ' 179' ' ' THR . 3.5 tp -107.86 154.65 8.91 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 C-N-CA 125.887 1.675 . . . . 0.0 107.549 -176.62 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 9.1 p -157.27 161.91 39.18 Favored 'General case' 0 C--O 1.249 1.061 0 C-N-CA 123.264 0.626 . . . . 0.0 110.547 -171.743 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -58.29 158.02 7.76 Favored 'General case' 0 N--CA 1.481 1.103 0 C-N-CA 124.594 1.158 . . . . 0.0 111.505 -175.548 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 30.7 t70 78.39 14.55 1.38 Allowed 'General case' 0 N--CA 1.491 1.616 0 C-N-CA 124.911 1.284 . . . . 0.0 110.396 178.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 73.98 34.23 56.05 Favored Glycine 0 C--N 1.356 1.644 0 CA-C-N 115.343 -0.844 . . . . 0.0 112.265 -178.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 47.5 t -99.54 143.87 29.29 Favored 'General case' 0 N--CA 1.469 0.522 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -175.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' MET . . . . . 0.424 ' HB3' HD13 ' A' ' 33' ' ' ILE . 19.3 ptm -163.03 154.24 17.23 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 122.571 0.348 . . . . 0.0 111.053 -177.087 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 35.5 p -176.29 -179.09 1.03 Allowed 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 125.035 1.334 . . . . 0.0 108.96 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.419 HG21 ' O ' ' A' ' 216' ' ' VAL . 10.4 tp -107.17 96.72 4.86 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 172.309 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 7.5 mtpm? 50.77 31.0 5.47 Favored 'General case' 0 CA--C 1.559 1.318 0 C-N-CA 124.247 1.019 . . . . 0.0 113.082 170.729 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 41.8 t-20 79.15 -30.02 0.14 Allowed 'General case' 0 N--CA 1.502 2.132 0 C-N-CA 125.885 1.674 . . . . 0.0 111.959 -174.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -58.54 107.36 0.49 Allowed 'General case' 0 CA--C 1.55 0.949 0 C-N-CA 125.533 1.533 . . . . 0.0 112.86 -171.005 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.701 ' HB2' ' HG2' ' B' ' 253' ' ' LYS . 22.6 pt-20 -162.52 176.0 10.88 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.419 0.687 . . . . 0.0 110.684 172.471 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.431 ' H ' ' HB3' ' B' ' 253' ' ' LYS . 12.9 pt-20 -158.76 -172.5 3.85 Favored 'General case' 0 C--O 1.245 0.854 0 C-N-CA 123.714 0.806 . . . . 0.0 110.225 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.406 ' HB3' ' NH2' ' B' ' 255' ' ' M9P . 7.8 pt-20 -146.67 151.33 37.05 Favored 'General case' 0 C--O 1.244 0.787 0 C-N-CA 124.211 1.004 . . . . 0.0 109.164 179.855 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.464 ' OE1' ' HB3' ' A' ' 163' ' ' PRO . 35.8 tt0 -109.13 157.85 18.35 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 123.096 0.558 . . . . 0.0 111.214 -169.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' THR . . . . . 0.48 HG23 ' HG ' ' A' ' 50' ' ' LEU . 12.3 t -80.75 -151.8 0.08 Allowed 'General case' 0 CA--C 1.563 1.46 0 C-N-CA 124.326 1.05 . . . . 0.0 109.725 170.687 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.48 ' HG ' HG23 ' A' ' 49' ' ' THR . 78.1 mt 77.65 -98.85 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 125.143 1.377 . . . . 0.0 111.534 172.669 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 119.28 -145.09 18.0 Favored Glycine 0 C--N 1.342 0.904 0 N-CA-C 111.826 -0.51 . . . . 0.0 111.826 -173.465 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -158.74 -142.54 3.42 Favored Glycine 0 C--N 1.339 0.724 0 N-CA-C 111.058 -0.817 . . . . 0.0 111.058 177.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 153.39 141.24 3.23 Favored Glycine 0 C--N 1.341 0.825 0 N-CA-C 111.543 -0.623 . . . . 0.0 111.543 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -155.87 154.28 25.4 Favored Glycine 0 C--N 1.343 0.944 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 179.083 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.688 ' HB2' ' HA ' ' A' ' 72' ' ' PRO . 68.0 m -121.57 156.96 31.79 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 123.631 0.772 . . . . 0.0 110.956 -179.378 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.4 ' HA3' ' HG2' ' A' ' 80' ' ' GLU . . . -145.28 -136.17 2.95 Favored Glycine 0 C--N 1.346 1.123 0 CA-C-O 119.586 -0.563 . . . . 0.0 111.94 -174.829 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -177.7 45.74 0.1 OUTLIER Glycine 0 C--N 1.347 1.166 0 CA-C-N 117.057 0.429 . . . . 0.0 112.137 178.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -76.55 -55.9 4.44 Favored Glycine 0 C--N 1.348 1.216 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 -178.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.62 79.78 0.44 Allowed Glycine 0 C--N 1.344 0.984 0 CA-C-N 114.996 -0.602 . . . . 0.0 113.266 170.084 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -75.46 -12.5 60.25 Favored 'General case' 0 N--CA 1.483 1.22 0 C-N-CA 122.948 0.499 . . . . 0.0 111.094 174.627 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 26.7 m-85 65.2 -177.12 0.18 Allowed 'General case' 0 N--CA 1.49 1.56 0 C-N-CA 125.288 1.435 . . . . 0.0 112.645 172.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . 67.42 -76.67 0.05 Allowed 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 124.984 1.314 . . . . 0.0 112.021 177.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -165.14 -178.27 38.25 Favored Glycine 0 N--CA 1.469 0.889 0 CA-C-O 119.081 -0.844 . . . . 0.0 111.269 179.295 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . 0.413 ' O ' ' HD3' ' A' ' 122' ' ' LYS . 9.9 p 47.92 46.35 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.951 0 CA-C-O 123.508 1.623 . . . . 0.0 110.715 178.039 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 3.2 pp -117.53 118.92 33.49 Favored 'General case' 0 C--N 1.339 0.128 0 CA-C-N 113.759 -1.564 . . . . 0.0 109.636 -174.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . 0.517 ' CD1' ' HG2' ' A' ' 122' ' ' LYS . 8.4 m95 -127.24 70.88 1.31 Allowed 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 104.726 -2.324 . . . . 0.0 104.726 168.426 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -170.92 70.24 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 105.521 -2.029 . . . . 0.0 105.521 -179.703 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 3.2 t -115.4 139.15 24.23 Favored Pre-proline 0 CA--C 1.538 0.518 0 CA-C-N 113.953 -1.476 . . . . 0.0 108.346 -168.074 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -60.05 81.21 0.06 OUTLIER 'Trans proline' 0 C--N 1.38 2.187 0 C-N-CA 122.708 2.272 . . . . 0.0 111.673 171.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 35.4 t -128.23 141.2 40.55 Favored Pre-proline 0 C--O 1.241 0.642 0 CA-C-N 113.985 -1.461 . . . . 0.0 108.403 -176.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_endo -44.73 122.95 4.43 Favored 'Trans proline' 0 C--N 1.377 2.078 0 C-N-CA 123.263 2.642 . . . . 0.0 112.545 176.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.688 ' HA ' ' HB2' ' A' ' 55' ' ' SER . 76.2 Cg_exo -43.41 -41.23 10.41 Favored 'Trans proline' 0 CA--C 1.568 2.204 0 C-N-CA 124.047 3.165 . . . . 0.0 116.464 177.123 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_exo -51.94 -23.78 17.45 Favored 'Trans proline' 0 C--N 1.395 3.004 0 C-N-CA 122.861 2.374 . . . . 0.0 116.029 173.152 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 81.2 t -61.52 -57.58 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.214 0 C-N-CA 122.985 0.514 . . . . 0.0 109.74 175.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 55.67 54.83 32.18 Favored Glycine 0 C--N 1.346 1.128 0 O-C-N 123.83 0.706 . . . . 0.0 114.031 175.088 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 57.6 pttt -86.6 44.41 1.15 Allowed 'General case' 0 N--CA 1.483 1.213 0 C-N-CA 123.253 0.621 . . . . 0.0 111.918 -173.303 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . 59.92 33.0 21.45 Favored 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 124.712 1.205 . . . . 0.0 112.322 174.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 59.3 mt-10 -66.24 134.06 51.9 Favored 'General case' 0 CA--C 1.544 0.74 0 N-CA-C 112.461 0.541 . . . . 0.0 112.461 -174.708 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.411 ' HB2' ' CD2' ' A' ' 121' ' ' HIS . 0.8 OUTLIER -89.5 66.73 7.43 Favored 'General case' 0 CA--C 1.548 0.867 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 170.951 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.4 ' HG2' ' HA3' ' A' ' 56' ' ' GLY . 22.0 tp10 -80.45 -83.07 0.11 Allowed 'General case' 0 CA--C 1.553 1.067 0 CA-C-N 113.445 -1.707 . . . . 0.0 111.022 175.127 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -175.43 162.66 2.89 Favored 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 123.92 0.888 . . . . 0.0 109.909 -168.584 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.43 ' HA3' ' HA ' ' A' ' 13' ' ' ASP . . . 93.49 -147.54 18.63 Favored Glycine 0 C--N 1.344 0.984 0 C-N-CA 123.076 0.369 . . . . 0.0 113.34 177.199 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -84.44 138.22 32.94 Favored 'General case' 0 N--CA 1.48 1.062 0 C-N-CA 123.493 0.717 . . . . 0.0 110.155 -177.397 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 12.0 m-85 -125.74 140.02 53.04 Favored 'General case' 0 N--CA 1.494 1.761 0 C-N-CA 123.334 0.654 . . . . 0.0 111.324 -179.061 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . 0.643 ' HG3' ' HB2' ' A' ' 11' ' ' ALA . 58.2 mtt-85 -85.41 122.21 29.23 Favored 'General case' 0 C--O 1.239 0.521 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 169.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.467 HD11 HD11 ' A' ' 119' ' ' LEU . 62.6 mt -98.3 119.82 46.82 Favored 'Isoleucine or valine' 0 C--O 1.253 1.237 0 CA-C-O 121.589 0.709 . . . . 0.0 109.394 175.299 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.423 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 58.4 pttt -111.12 146.9 36.0 Favored 'General case' 0 C--O 1.239 0.548 0 CA-C-N 114.26 -1.336 . . . . 0.0 108.477 174.001 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . 0.49 ' NE2' ' HB2' ' A' ' 5' ' ' ASP . 0.1 OUTLIER -83.09 107.81 15.92 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 104.294 -2.484 . . . . 0.0 104.294 166.31 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . 0.489 ' O ' ' HB3' ' A' ' 5' ' ' ASP . 28.8 ttpt -117.34 96.92 5.64 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -175.506 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -67.11 154.2 52.86 Favored Glycine 0 C--N 1.339 0.725 0 N-CA-C 107.436 -2.266 . . . . 0.0 107.436 166.097 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 20.1 mm -78.86 63.93 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.39 0 CA-C-N 118.637 1.219 . . . . 0.0 108.926 -173.265 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 22.3 tp 167.81 -32.62 0.0 OUTLIER 'General case' 0 CA--C 1.562 1.431 0 C-N-CA 125.535 1.534 . . . . 0.0 109.854 -166.336 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -145.36 149.14 21.25 Favored Glycine 0 C--N 1.369 2.39 0 N-CA-C 114.265 0.466 . . . . 0.0 114.265 -171.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -124.98 133.36 53.04 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 124.614 1.166 . . . . 0.0 110.33 -169.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 44.7 m -151.45 103.19 2.96 Favored 'General case' 0 N--CA 1.493 1.705 0 CA-C-N 118.602 0.637 . . . . 0.0 112.085 176.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.423 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 43.7 mt-30 -53.76 120.39 6.19 Favored 'General case' 0 N--CA 1.495 1.818 0 C-N-CA 123.489 0.716 . . . . 0.0 111.215 173.446 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.5 pp -122.54 -13.07 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 C-N-CA 123.806 0.842 . . . . 0.0 112.061 -176.645 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 174.87 -152.51 13.96 Favored Glycine 0 C--N 1.342 0.903 0 CA-C-O 119.637 -0.535 . . . . 0.0 112.313 174.619 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -156.36 164.3 38.46 Favored 'General case' 0 C--O 1.241 0.652 0 C-N-CA 123.384 0.674 . . . . 0.0 110.973 -176.594 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -158.31 149.94 20.46 Favored Glycine 0 C--N 1.339 0.731 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 177.209 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 37.2 t -96.14 118.91 43.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 C-N-CA 123.328 0.651 . . . . 0.0 110.192 -176.576 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 85.5 t80 -94.93 126.9 40.58 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 171.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.415 ' HA ' ' HD2' ' A' ' 103' ' ' LYS . 42.7 tptt -133.55 114.5 13.64 Favored 'General case' 0 C--O 1.239 0.548 0 C-N-CA 123.28 0.632 . . . . 0.0 109.565 175.054 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 68.52 -78.14 0.05 OUTLIER 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 125.282 1.433 . . . . 0.0 112.415 169.185 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -147.46 32.43 1.36 Allowed Glycine 0 N--CA 1.465 0.569 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 176.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 44.6 m -136.84 124.86 22.82 Favored 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 124.21 1.004 . . . . 0.0 109.563 178.331 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' PHE . . . . . 0.457 ' HZ ' HD13 ' A' ' 86' ' ' ILE . 57.0 t80 -110.13 118.05 35.35 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 172.634 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . 0.592 ' HE2' HD12 ' A' ' 137' ' ' LEU . 60.5 t60 -123.69 114.82 20.47 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 122.809 0.443 . . . . 0.0 109.97 -178.654 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 9.0 t -114.14 -165.71 1.03 Allowed 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 124.338 1.055 . . . . 0.0 109.525 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' MET . . . . . 0.591 ' HA ' ' HA ' ' A' ' 137' ' ' LEU . 13.6 mtp -107.43 160.56 15.55 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 124.13 0.972 . . . . 0.0 110.033 177.075 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 11.6 t90 -80.79 -31.47 35.74 Favored 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 122.645 0.378 . . . . 0.0 111.512 -175.561 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . 0.44 ' HE2' ' HB3' ' A' ' 196' ' ' SER . 46.1 p-80 -75.02 -18.02 60.41 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.639 -0.663 . . . . 0.0 111.051 174.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 68.7 t -81.98 -44.02 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.523 0.729 . . . . 0.0 109.519 173.675 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 90.1 m -135.16 108.3 7.7 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 107.752 -1.203 . . . . 0.0 107.752 -178.767 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 19.3 ptp180 -85.69 33.33 0.58 Allowed 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 123.298 0.639 . . . . 0.0 112.211 -172.533 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 91.74 27.76 16.06 Favored Glycine 0 N--CA 1.47 0.912 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -170.083 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . 0.426 ' HB3' ' O ' ' A' ' 3' ' ' ALA . . . -94.41 -178.92 4.74 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.065 0.946 . . . . 0.0 110.971 -177.189 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 70.2 t -100.3 133.25 43.99 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 123.404 0.681 . . . . 0.0 110.47 -176.341 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.514 ' HB2' ' HB ' ' A' ' 126' ' ' ILE . 2.4 mm? -92.01 162.31 14.43 Favored 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 124.155 0.982 . . . . 0.0 110.049 172.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' MET . . . . . 0.446 ' O ' ' HA ' ' A' ' 7' ' ' GLU . 23.5 mmt -139.25 136.79 35.33 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 124.066 0.947 . . . . 0.0 110.458 -171.609 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.411 ' CD2' ' HB2' ' A' ' 79' ' ' LEU . 56.8 t60 -169.38 137.0 1.8 Allowed 'General case' 0 N--CA 1.476 0.825 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 153.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.517 ' HG2' ' CD1' ' A' ' 66' ' ' TRP . 85.5 mttt 70.45 9.69 7.0 Favored 'General case' 0 N--CA 1.503 2.208 0 C-N-CA 124.238 1.015 . . . . 0.0 111.753 -178.45 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 83.46 -4.95 79.96 Favored Glycine 0 C--N 1.349 1.266 0 CA-C-O 119.953 -0.359 . . . . 0.0 112.519 -167.289 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 31.0 mmmt -72.64 117.61 14.54 Favored 'General case' 0 C--O 1.248 0.998 0 C-N-CA 123.512 0.725 . . . . 0.0 109.123 175.593 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 85.3 mtm180 -87.4 96.05 10.23 Favored 'General case' 0 C--O 1.237 0.418 0 O-C-N 124.665 1.228 . . . . 0.0 108.869 -179.122 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.514 ' HB ' ' HB2' ' A' ' 119' ' ' LEU . 97.2 mt -75.19 114.78 15.65 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.664 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.271 -179.069 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -92.91 146.9 32.92 Favored Pre-proline 0 CA--C 1.548 0.875 0 C-N-CA 124.126 0.97 . . . . 0.0 110.63 -174.554 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_exo -67.9 101.01 0.65 Allowed 'Trans proline' 0 C--N 1.367 1.528 0 C-N-CA 122.088 1.859 . . . . 0.0 110.866 169.336 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 22.7 t -64.33 -31.25 72.38 Favored 'General case' 0 N--CA 1.483 1.216 0 CA-C-O 121.271 0.558 . . . . 0.0 109.877 177.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 75.0 t-105 -150.7 156.33 41.11 Favored 'General case' 0 CA--C 1.543 0.695 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 165.306 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -136.76 120.09 16.86 Favored 'General case' 0 N--CA 1.467 0.419 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 176.278 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 27.3 m-20 -95.13 106.78 18.81 Favored 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 124.394 1.078 . . . . 0.0 109.247 175.518 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 60.3 t -75.59 -41.87 41.58 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.659 0 C-N-CA 123.141 0.577 . . . . 0.0 110.351 178.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 55.7 tttm -73.76 -34.98 64.95 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.954 -175.242 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 13.6 tppt? -80.88 -18.78 46.12 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 123.096 0.558 . . . . 0.0 110.797 176.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 26.3 t70 62.5 48.32 4.58 Favored 'General case' 0 N--CA 1.481 1.083 0 CA-C-O 122.72 1.248 . . . . 0.0 110.379 -175.4 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . 0.592 HD12 ' HE2' ' A' ' 108' ' ' HIS . 74.8 mt -149.98 138.6 20.76 Favored 'General case' 0 N--CA 1.476 0.838 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.155 -176.899 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 5.8 mt -112.22 145.02 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 C-N-CA 123.384 0.674 . . . . 0.0 110.416 175.206 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' SER . . . . . 0.403 ' HB3' ' O ' ' A' ' 142' ' ' GLY . 34.6 m -118.64 141.61 48.43 Favored 'General case' 0 CA--C 1.557 1.217 0 C-N-CA 125.015 1.326 . . . . 0.0 110.945 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 19.6 t80 -135.38 142.13 45.64 Favored 'General case' 0 N--CA 1.488 1.472 0 C-N-CA 124.835 1.254 . . . . 0.0 108.515 173.203 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.26 -60.5 4.7 Favored Glycine 0 C--N 1.352 1.42 0 N-CA-C 111.254 -0.738 . . . . 0.0 111.254 -176.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . 0.403 ' O ' ' HB3' ' A' ' 139' ' ' SER . . . -148.28 -171.82 17.57 Favored Glycine 0 C--O 1.242 0.635 0 N-CA-C 109.871 -1.292 . . . . 0.0 109.871 172.394 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -77.46 -177.17 46.06 Favored Glycine 0 C--N 1.337 0.627 0 N-CA-C 112.13 -0.388 . . . . 0.0 112.13 175.333 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' TRP . . . . . 0.487 ' HB2' ' CE1' ' A' ' 108' ' ' HIS . 13.4 t-105 -69.78 111.6 5.65 Favored 'General case' 0 C--O 1.243 0.756 0 O-C-N 122.585 -0.362 . . . . 0.0 110.44 177.19 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 23.0 pttm -135.64 152.34 51.12 Favored 'General case' 0 N--CA 1.466 0.334 0 O-C-N 124.092 0.87 . . . . 0.0 110.308 173.015 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' LEU . . . . . 0.407 HD11 ' CH2' ' A' ' 144' ' ' TRP . 4.1 mt 174.63 -8.89 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.945 0 C-N-CA 127.158 2.183 . . . . 0.0 108.207 178.521 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.452 ' N ' HG23 ' A' ' 229' ' ' THR . 7.6 mm-40 60.0 70.93 0.6 Allowed 'General case' 0 C--N 1.365 1.269 0 C-N-CA 125.387 1.475 . . . . 0.0 110.66 173.377 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -104.15 159.23 16.48 Favored Glycine 0 N--CA 1.444 -0.789 0 CA-C-N 114.069 -1.423 . . . . 0.0 113.998 -177.204 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -129.35 93.01 3.46 Favored 'General case' 0 C--O 1.243 0.742 0 C-N-CA 123.856 0.862 . . . . 0.0 109.142 178.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' TRP . . . . . . . . . . . . . 25.2 t90 -74.24 120.63 20.07 Favored 'General case' 0 C--O 1.238 0.498 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 173.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 20.4 mttm -85.15 94.68 8.93 Favored 'General case' 0 C--O 1.243 0.722 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 176.695 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -66.39 97.15 0.4 Allowed 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 123.671 0.788 . . . . 0.0 109.053 -176.961 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 143.27 -49.33 0.72 Allowed Glycine 0 C--N 1.341 0.842 0 CA-C-N 115.371 -0.832 . . . . 0.0 111.365 -178.357 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -85.33 157.94 20.41 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 122.889 0.476 . . . . 0.0 112.042 -175.659 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . 0.469 ' HA ' ' HA ' ' A' ' 173' ' ' LYS . 0.8 OUTLIER -62.5 131.1 48.0 Favored 'General case' 0 C--N 1.351 0.654 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.926 177.918 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . 0.461 HG13 HD13 ' A' ' 226' ' ' ILE . 34.0 m -93.25 159.11 2.83 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.562 179.421 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 25.2 mp0 -113.02 130.36 56.17 Favored 'General case' 0 C--O 1.215 -0.727 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -172.079 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 44.6 t -133.99 137.07 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -174.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -92.57 96.53 10.26 Favored 'General case' 0 CA--C 1.545 0.777 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 169.269 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -64.91 104.02 0.8 Allowed 'General case' 0 C--O 1.24 0.603 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.243 -178.565 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . 0.615 HD22 ' HB3' ' A' ' 167' ' ' PRO . 78.0 mt -69.01 84.74 0.33 Allowed 'General case' 0 C--O 1.241 0.641 0 C-N-CA 123.704 0.802 . . . . 0.0 108.873 177.109 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 28.3 tt0 -74.9 134.11 75.34 Favored Pre-proline 0 CA--C 1.545 0.767 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.297 -177.085 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . 0.464 ' HB3' ' OE1' ' A' ' 48' ' ' GLN . 93.1 Cg_exo -46.25 112.59 0.48 Allowed 'Trans proline' 0 C--N 1.382 2.342 0 C-N-CA 123.53 2.82 . . . . 0.0 113.881 178.198 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 63.79 27.87 71.78 Favored Glycine 0 C--N 1.35 1.356 0 O-C-N 123.903 0.752 . . . . 0.0 113.819 173.703 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 53.0 tptt -146.49 173.21 12.51 Favored 'General case' 0 C--O 1.245 0.837 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 -176.03 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -56.87 151.09 34.6 Favored Pre-proline 0 CA--C 1.558 1.28 0 C-N-CA 123.701 0.8 . . . . 0.0 112.595 177.317 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . 0.615 ' HB3' HD22 ' A' ' 161' ' ' LEU . 6.9 Cg_exo -74.86 92.42 0.97 Allowed 'Trans proline' 0 C--N 1.372 1.789 0 C-N-CA 123.249 2.632 . . . . 0.0 110.188 171.393 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 31.7 ttp-105 -75.68 122.08 23.45 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.065 -170.211 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . 0.591 ' HB2' ' H ' ' A' ' 19' ' ' GLN . . . -68.77 105.36 2.29 Favored 'General case' 0 CA--C 1.538 0.505 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.934 179.606 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 18.8 t -129.24 135.01 62.85 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.095 0 C-N-CA 124.866 1.266 . . . . 0.0 108.257 176.353 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . 0.464 ' HG2' ' O ' ' A' ' 21' ' ' GLU . 27.3 pt20 -117.07 126.73 53.3 Favored 'General case' 0 N--CA 1.478 0.933 0 C-N-CA 123.651 0.781 . . . . 0.0 110.318 -176.122 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 172' ' ' THR . . . . . 0.48 HG22 HG13 ' A' ' 187' ' ' VAL . 5.4 t -118.0 143.13 46.65 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 124.207 1.003 . . . . 0.0 110.911 -173.006 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 155' ' ' GLU . 37.2 ttmt -85.46 142.07 37.26 Favored Pre-proline 0 N--CA 1.479 0.983 0 CA-C-O 118.549 -0.738 . . . . 0.0 109.334 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . 0.552 ' HA ' ' O ' ' A' ' 186' ' ' ALA . 89.6 Cg_exo -47.32 122.69 6.85 Favored 'Trans proline' 0 C--N 1.396 3.04 0 C-N-CA 123.116 2.544 . . . . 0.0 114.562 -175.244 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . 0.469 ' H ' ' C ' ' A' ' 186' ' ' ALA . . . -135.47 139.59 10.91 Favored Glycine 0 CA--C 1.541 1.679 0 CA-C-N 115.159 -0.928 . . . . 0.0 114.543 179.342 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.419 ' N ' HD22 ' A' ' 176' ' ' LEU . 0.3 OUTLIER -132.22 162.5 30.77 Favored 'General case' 0 C--O 1.241 0.619 0 O-C-N 121.551 -0.97 . . . . 0.0 110.18 -171.412 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 177' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -138.51 139.53 38.79 Favored 'General case' 0 C--O 1.242 0.668 0 CA-C-N 114.141 -1.391 . . . . 0.0 109.727 -167.334 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 178' ' ' LYS . . . . . 0.415 ' HE3' ' HB3' ' A' ' 178' ' ' LYS . 1.3 tmmt? -69.07 120.77 15.45 Favored 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 124.481 1.112 . . . . 0.0 111.648 -165.488 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 179' ' ' THR . . . . . 0.786 ' HA ' HG23 ' A' ' 33' ' ' ILE . 7.4 m -90.09 165.4 14.02 Favored 'General case' 0 CA--C 1.551 1.01 0 C-N-CA 125.89 1.676 . . . . 0.0 109.787 177.619 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 180' ' ' ASN . . . . . 0.555 ' ND2' HG21 ' A' ' 33' ' ' ILE . 63.4 m-80 -64.53 -35.14 79.99 Favored 'General case' 0 N--CA 1.487 1.384 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 170.82 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -75.62 -48.22 23.14 Favored 'General case' 0 CA--C 1.54 0.566 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.977 175.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . 0.572 ' H ' ' HB ' ' A' ' 179' ' ' THR . . . -165.73 -94.43 0.1 OUTLIER Glycine 0 C--N 1.345 1.045 0 CA-C-O 119.756 -0.469 . . . . 0.0 112.638 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 7.5 t -163.46 135.83 5.21 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 124.719 1.208 . . . . 0.0 109.354 178.092 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -132.98 155.73 41.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 122.898 0.479 . . . . 0.0 109.814 177.052 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . 129.83 177.58 14.96 Favored Glycine 0 C--N 1.343 0.935 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 173.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . 0.552 ' O ' ' HA ' ' A' ' 174' ' ' PRO . . . -171.66 38.85 0.02 OUTLIER 'General case' 0 C--O 1.193 -1.901 0 C-N-CA 123.486 0.715 . . . . 0.0 110.329 177.867 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 187' ' ' VAL . . . . . 0.48 HG13 HG22 ' A' ' 172' ' ' THR . 95.1 t -153.15 125.22 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 120.012 -1.68 . . . . 0.0 107.648 167.399 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 188' ' ' SER . . . . . 0.605 ' HA ' HG13 ' A' ' 223' ' ' VAL . 73.6 m -132.54 91.13 2.88 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 168.115 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 189' ' ' LEU . . . . . 0.516 HD21 ' HB3' ' A' ' 23' ' ' SER . 0.5 OUTLIER -126.97 104.36 7.96 Favored 'General case' 0 N--CA 1.48 1.039 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 -176.285 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 190' ' ' ASP . . . . . 0.666 ' HA ' ' HA ' ' A' ' 221' ' ' ALA . 8.0 p-10 -85.72 103.16 14.25 Favored 'General case' 0 C--N 1.356 0.865 0 CA-C-O 121.875 0.845 . . . . 0.0 109.992 -179.243 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 191' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -174.19 172.92 3.19 Favored 'General case' 0 N--CA 1.475 0.776 0 CA-C-N 115.059 -0.973 . . . . 0.0 108.541 -167.393 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 44.5 p -58.3 121.91 55.51 Favored Pre-proline 0 CA--C 1.548 0.883 0 C-N-CA 123.127 0.571 . . . . 0.0 110.614 175.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_endo -61.16 127.66 22.81 Favored 'Trans proline' 0 C--N 1.376 2.021 0 C-N-CA 122.246 1.964 . . . . 0.0 112.661 -178.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -72.41 173.44 46.43 Favored Glycine 0 C--N 1.35 1.326 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 162.099 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 7.4 m -80.66 135.78 36.09 Favored 'General case' 0 CA--C 1.562 1.416 0 CA-C-N 118.626 1.213 . . . . 0.0 111.334 -172.532 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 196' ' ' SER . . . . . 0.44 ' HB3' ' HE2' ' A' ' 112' ' ' HIS . 0.8 OUTLIER -65.19 88.44 0.08 Allowed 'General case' 0 C--N 1.367 1.339 0 C-N-CA 124.13 0.972 . . . . 0.0 111.304 -171.641 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . 0.624 ' HA2' HD21 ' A' ' 210' ' ' LEU . . . 144.59 9.58 0.36 Allowed Glycine 0 C--N 1.335 0.499 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.984 -175.908 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 198' ' ' SER . . . . . 0.406 ' O ' ' HB2' ' A' ' 211' ' ' TYR . 39.3 m -57.36 132.09 81.31 Favored Pre-proline 0 CA--C 1.556 1.208 0 C-N-CA 122.942 0.497 . . . . 0.0 109.838 166.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -69.91 137.44 35.02 Favored 'Trans proline' 0 C--N 1.369 1.621 0 C-N-CA 121.965 1.777 . . . . 0.0 111.108 174.072 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 39.9 mt -91.92 119.6 39.61 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 N-CA-C 107.923 -1.139 . . . . 0.0 107.923 170.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 201' ' ' ILE . . . . . 0.641 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 46.7 mt -103.61 168.87 2.19 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.483 0 C-N-CA 125.632 1.573 . . . . 0.0 109.786 179.768 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -104.6 167.19 9.89 Favored 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 124.752 1.221 . . . . 0.0 109.402 178.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 18.5 ptpt -55.11 -29.24 57.24 Favored 'General case' 0 N--CA 1.481 1.106 0 C-N-CA 124.626 1.17 . . . . 0.0 112.444 177.762 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 52.9 mtmt -82.33 10.57 6.75 Favored 'General case' 0 N--CA 1.481 1.11 0 C-N-CA 123.324 0.65 . . . . 0.0 112.277 -179.072 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 70.0 19.73 75.68 Favored Glycine 0 C--N 1.356 1.669 0 N-CA-C 112.115 -0.394 . . . . 0.0 112.115 -177.235 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 62.4 tttp -110.73 121.14 44.59 Favored 'General case' 0 C--O 1.212 -0.892 0 C-N-CA 124.381 1.072 . . . . 0.0 108.662 -176.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . 0.641 ' HA ' ' HA ' ' A' ' 201' ' ' ILE . 7.1 p -53.9 139.67 11.87 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.092 0 C-N-CA 123.191 0.596 . . . . 0.0 111.687 178.092 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 3.6 m -98.34 -35.43 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.854 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 170.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.581 ' HA3' ' HA ' ' A' ' 228' ' ' GLN . . . 166.86 -138.18 5.05 Favored Glycine 0 C--N 1.348 1.226 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.268 -178.229 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . 0.624 HD21 ' HA2' ' A' ' 197' ' ' GLY . 5.1 tt -122.58 154.01 38.52 Favored 'General case' 0 CA--C 1.545 0.779 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 -172.122 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 211' ' ' TYR . . . . . 0.442 ' N ' HD22 ' A' ' 210' ' ' LEU . 10.2 t80 -62.45 142.19 58.01 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 123.592 0.757 . . . . 0.0 109.956 178.467 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -77.45 -157.83 9.26 Favored Glycine 0 N--CA 1.475 1.298 0 CA-C-N 118.103 0.41 . . . . 0.0 112.622 178.392 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 213' ' ' ASN . . . . . . . . . . . . . 14.7 t-20 -81.92 85.59 6.66 Favored 'General case' 0 N--CA 1.477 0.904 0 N-CA-C 108.442 -0.948 . . . . 0.0 108.442 -176.658 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . -71.66 123.3 9.87 Favored Glycine 0 C--N 1.347 1.174 0 CA-C-N 114.789 -1.096 . . . . 0.0 112.008 177.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 215' ' ' VAL . . . . . 0.689 ' HA ' ' HE3' ' B' ' 253' ' ' LYS . 21.7 t -134.59 143.56 37.44 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.672 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 173.63 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 216' ' ' VAL . . . . . 0.568 ' HB ' ' HA2' ' A' ' 220' ' ' GLY . 15.4 m -87.98 111.3 22.01 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.891 0 CA-C-O 121.781 0.8 . . . . 0.0 109.536 -178.718 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 217' ' ' THR . . . . . 0.557 HG21 HD22 ' A' ' 29' ' ' LEU . 38.8 m -107.74 162.53 13.9 Favored 'General case' 0 N--CA 1.475 0.825 0 C-N-CA 124.329 1.052 . . . . 0.0 109.659 -170.692 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 20.3 ttm180 71.45 -73.77 0.09 Allowed 'General case' 0 N--CA 1.492 1.646 0 C-N-CA 124.217 1.007 . . . . 0.0 109.592 -177.065 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 41.1 m -140.96 -43.86 0.39 Allowed 'General case' 0 CA--C 1.547 0.838 0 C-N-CA 124.519 1.127 . . . . 0.0 109.19 178.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 220' ' ' GLY . . . . . 0.568 ' HA2' ' HB ' ' A' ' 216' ' ' VAL . . . -169.04 27.65 0.13 Allowed Glycine 0 C--N 1.348 1.218 0 CA-C-N 115.49 -0.777 . . . . 0.0 112.181 -175.744 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . 0.666 ' HA ' ' HA ' ' A' ' 190' ' ' ASP . . . -80.32 96.11 6.55 Favored 'General case' 0 N--CA 1.465 0.317 0 C-N-CA 123.684 0.794 . . . . 0.0 110.607 179.717 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 222' ' ' TYR . . . . . . . . . . . . . 12.3 t80 -66.61 95.9 0.36 Allowed 'General case' 0 CA--C 1.554 1.123 0 CA-C-N 114.804 -1.089 . . . . 0.0 109.543 -176.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . 0.605 HG13 ' HA ' ' A' ' 188' ' ' SER . 35.3 m -114.59 140.14 37.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 C-N-CA 123.81 0.844 . . . . 0.0 109.774 -177.157 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 33.1 t -152.16 160.68 43.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.623 -169.598 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . . . . . . . . . . . -81.64 -175.02 5.32 Favored 'General case' 0 CA--C 1.546 0.792 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.643 164.43 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 226' ' ' ILE . . . . . 0.461 HD13 HG13 ' A' ' 156' ' ' VAL . 78.2 mt -133.57 116.44 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 176.005 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -95.78 137.2 35.18 Favored 'General case' 0 C--O 1.233 0.196 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 176.015 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . 0.581 ' HA ' ' HA3' ' A' ' 209' ' ' GLY . 29.0 pt20 -120.26 174.3 6.59 Favored 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 175.318 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.474 ' HA ' ' CD1' ' A' ' 144' ' ' TRP . 39.4 p -66.14 107.71 2.02 Favored 'General case' 0 CA--C 1.546 0.825 0 CA-C-O 121.208 0.528 . . . . 0.0 110.802 -176.502 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 230' ' ' GLU . . . . . 0.473 ' HG2' ' O ' ' A' ' 228' ' ' GLN . 26.7 mm-40 -108.06 -30.16 8.58 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 124.425 1.09 . . . . 0.0 112.437 -168.384 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 29.8 mmtp -107.06 -99.78 0.35 Allowed 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 113.477 0.917 . . . . 0.0 113.477 -160.38 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 64.3 p -76.45 89.44 3.24 Favored 'General case' 0 C--N 1.361 1.093 0 CA-C-O 121.958 0.885 . . . . 0.0 110.672 -165.207 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 233' ' ' ILE . . . . . . . . . . . . . 12.4 tt -116.76 -23.85 3.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 C-N-CA 125.18 1.392 . . . . 0.0 108.207 178.015 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 234' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER 58.07 58.43 3.56 Favored 'General case' 0 C--O 1.242 0.693 0 C-N-CA 125.417 1.487 . . . . 0.0 110.133 -173.872 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -90.72 17.84 7.16 Favored 'General case' 0 CA--C 1.551 0.992 0 CA-C-N 113.639 -1.619 . . . . 0.0 109.578 176.407 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 236' ' ' ASN . . . . . . . . . . . . . 30.1 t30 -48.1 118.47 6.49 Favored Pre-proline 0 C--N 1.36 1.03 0 C-N-CA 124.392 1.077 . . . . 0.0 109.494 173.336 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_endo -57.39 82.78 0.04 OUTLIER 'Trans proline' 0 C--N 1.378 2.094 0 C-N-CA 123.455 2.77 . . . . 0.0 113.083 -174.891 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 238' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -110.75 -14.96 13.93 Favored 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 124.182 0.993 . . . . 0.0 111.232 -178.316 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 239' ' ' ILE . . . . . . . . . . . . . 9.0 tt -64.83 -38.45 82.76 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 C-N-CA 123.758 0.823 . . . . 0.0 110.755 176.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 2.8 pp20? . . . . . 0 C--O 1.251 1.144 0 C-N-CA 123.717 0.807 . . . . 0.0 110.027 171.205 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 251' ' ' BEZ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 253' ' ' LYS . . . . . 0.701 ' HG2' ' HB2' ' A' ' 45' ' ' GLU . 21.8 tptm -138.57 131.89 30.23 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.095 -174.202 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 254' ' ' ARG . . . . . 0.423 HH12 ' NE2' ' A' ' 96' ' ' GLN . 28.6 mmm180 -105.68 -9.28 17.4 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 124.483 1.113 . . . . 0.0 110.356 171.905 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 255' ' ' M9P . . . . . 0.471 ' HA ' ' HE2' ' B' ' 253' ' ' LYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.71 ' H3 ' HD13 ' A' ' 138' ' ' ILE . . . . . . . . 0 N--CA 1.481 1.663 0 N-CA-C 111.754 -0.538 . . . . 0.0 111.754 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 41.1 p 172.14 152.92 0.07 Allowed 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 125.267 1.427 . . . . 0.0 108.392 -171.277 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.5 ' HB3' ' HB ' ' A' ' 114' ' ' THR . . . -162.57 -61.38 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.753 0 CA-C-N 119.256 0.935 . . . . 0.0 111.317 176.406 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -150.76 -62.01 0.19 Allowed 'General case' 0 N--CA 1.477 0.875 0 C-N-CA 123.287 0.635 . . . . 0.0 110.054 -173.131 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . 0.723 ' HA ' ' HG3' ' A' ' 120' ' ' MET . 32.6 t70 -144.5 76.92 1.52 Allowed 'General case' 0 CA--C 1.528 0.113 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 -172.386 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.508 HD22 HG21 ' A' ' 114' ' ' THR . 5.8 mp -117.56 124.4 48.57 Favored 'General case' 0 N--CA 1.488 1.471 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.051 -179.283 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.79 ' HB2' ' HD3' ' A' ' 89' ' ' LYS . 14.5 tp10 -80.9 134.54 35.76 Favored 'General case' 0 C--O 1.252 1.229 0 CA-C-N 118.06 0.391 . . . . 0.0 110.449 178.023 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . 0.459 ' HB2' HD12 ' A' ' 119' ' ' LEU . 18.1 tp -87.16 113.34 22.81 Favored 'General case' 0 CA--C 1.542 0.649 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 171.027 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -104.87 143.64 32.87 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 125.826 1.65 . . . . 0.0 108.176 -173.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.8 ptt-85 -76.29 147.16 38.42 Favored 'General case' 0 N--CA 1.481 1.104 0 CA-C-N 118.336 0.516 . . . . 0.0 110.505 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . 0.641 ' HB2' ' HG3' ' A' ' 85' ' ' ARG . . . -125.89 -51.12 1.57 Allowed 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 169.2 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -166.65 175.34 8.0 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.012 0.925 . . . . 0.0 110.279 -177.038 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -98.59 159.44 14.95 Favored 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 108.401 -0.962 . . . . 0.0 108.401 164.11 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 83.4 t -88.39 103.18 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 CA-C-O 121.545 0.688 . . . . 0.0 111.281 -176.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 2.4 ptpp? -155.98 158.67 38.28 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 124.891 1.277 . . . . 0.0 107.97 168.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 10.6 t90 -67.83 105.43 1.96 Allowed 'General case' 0 CA--C 1.549 0.923 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.26 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.563 ' HB3' ' HB2' ' A' ' 169' ' ' ALA . 2.6 tm-20 -70.35 145.03 51.45 Favored 'General case' 0 CA--C 1.554 1.127 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 170.496 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -75.65 -19.45 59.16 Favored 'General case' 0 N--CA 1.481 1.117 0 N-CA-C 113.885 1.069 . . . . 0.0 113.885 -165.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 6.6 tp60 -94.1 53.37 1.74 Allowed 'General case' 0 N--CA 1.476 0.828 0 CA-C-O 121.46 0.648 . . . . 0.0 110.592 -168.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.592 ' HB3' ' HB2' ' A' ' 171' ' ' GLN . . . -56.04 91.24 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 124.558 1.143 . . . . 0.0 111.843 178.34 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -62.74 126.51 27.59 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 124.851 1.261 . . . . 0.0 110.746 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 50.4 mm -77.08 109.16 11.3 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.613 0 C-N-CA 123.073 0.549 . . . . 0.0 109.609 -178.256 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.1 m -135.38 -174.78 3.72 Favored 'General case' 0 CA--C 1.551 1.015 0 C-N-CA 124.038 0.935 . . . . 0.0 110.026 -179.436 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.11 73.1 1.1 Allowed Glycine 0 C--N 1.349 1.259 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 -172.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.8 m -124.57 1.93 8.27 Favored 'General case' 0 N--CA 1.478 0.963 0 C-N-CA 122.971 0.508 . . . . 0.0 112.291 -164.636 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 13.7 m -120.45 137.88 26.7 Favored Pre-proline 0 CA--C 1.55 0.957 0 C-N-CA 123.291 0.636 . . . . 0.0 109.675 -176.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -82.43 -155.82 0.06 OUTLIER 'Trans proline' 0 C--N 1.379 2.151 0 C-N-CA 123.204 2.603 . . . . 0.0 112.253 179.506 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 48.6 mm -66.32 121.05 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 123.16 0.584 . . . . 0.0 110.632 -178.749 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.2 mt -105.53 164.87 11.55 Favored 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 124.658 1.183 . . . . 0.0 111.752 -175.139 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 39.4 m -122.46 116.18 23.52 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 123.5 0.72 . . . . 0.0 109.542 176.122 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.487 HD13 HG13 ' A' ' 223' ' ' VAL . 62.5 mt -116.24 145.09 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 C-N-CA 124.292 1.037 . . . . 0.0 108.561 178.391 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 35.9 p -93.56 105.13 17.21 Favored 'General case' 0 CA--C 1.543 0.703 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.125 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 9.2 tp -69.91 141.14 17.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 C-N-CA 124.159 0.983 . . . . 0.0 110.403 175.019 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 34.3 t -135.47 140.17 44.64 Favored 'General case' 0 C--O 1.242 0.701 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 176.788 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 65.14 15.98 10.3 Favored 'General case' 0 CA--C 1.563 1.476 0 C-N-CA 123.893 0.877 . . . . 0.0 111.133 174.756 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 58.12 32.65 22.27 Favored 'General case' 0 N--CA 1.49 1.545 0 C-N-CA 124.744 1.218 . . . . 0.0 111.67 -179.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -169.55 -44.41 0.03 OUTLIER Glycine 0 C--N 1.348 1.236 0 CA-C-N 116.32 -0.4 . . . . 0.0 112.669 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 25.6 m -89.15 106.2 18.29 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -176.373 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 27.3 mtm -88.05 162.59 16.71 Favored 'General case' 0 N--CA 1.476 0.873 0 O-C-N 121.909 -0.494 . . . . 0.0 110.856 -176.21 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 39.1 m -147.51 148.56 31.34 Favored 'General case' 0 C--O 1.238 0.492 0 C-N-CA 123.707 0.803 . . . . 0.0 109.379 -178.553 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 9.1 tp -96.12 151.7 3.97 Favored 'Isoleucine or valine' 0 C--O 1.239 0.55 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 169.326 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 50.2 mtmt -81.93 40.92 0.63 Allowed 'General case' 0 CA--C 1.558 1.261 0 C-N-CA 123.532 0.733 . . . . 0.0 111.222 175.31 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 7.8 t30 -167.49 75.34 0.14 Allowed 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 125.047 1.339 . . . . 0.0 107.661 176.518 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -75.29 117.66 17.34 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 177.398 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -168.95 154.97 6.49 Favored 'General case' 0 C--O 1.245 0.827 0 C-N-CA 123.912 0.885 . . . . 0.0 109.398 177.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 26.0 mm-40 65.38 161.57 0.13 Allowed 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 125.577 1.551 . . . . 0.0 113.796 176.185 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -133.19 173.19 11.71 Favored 'General case' 0 CA--C 1.549 0.919 0 CA-C-N 114.824 -1.08 . . . . 0.0 108.851 -177.487 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.443 ' HB2' ' NH1' ' B' ' 254' ' ' ARG . 29.6 pt20 -75.25 -179.09 4.24 Favored 'General case' 0 N--CA 1.477 0.893 0 C-N-CA 124.467 1.107 . . . . 0.0 111.873 175.241 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 37.9 p -116.32 -164.65 0.98 Allowed 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 124.238 1.015 . . . . 0.0 108.995 -178.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 2.3 pp -67.73 167.97 12.26 Favored 'General case' 0 C--O 1.244 0.764 0 CA-C-O 121.559 0.695 . . . . 0.0 111.803 175.149 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -82.2 -97.49 0.48 Allowed Glycine 0 C--O 1.224 -0.499 0 CA-C-N 114.648 -1.16 . . . . 0.0 112.435 174.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -128.97 -35.02 0.49 Allowed Glycine 0 N--CA 1.468 0.768 0 N-CA-C 111.645 -0.582 . . . . 0.0 111.645 -178.246 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 102.79 47.74 1.34 Allowed Glycine 0 C--N 1.354 1.564 0 C-N-CA 123.033 0.349 . . . . 0.0 112.481 176.188 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -70.57 123.88 12.04 Favored Glycine 0 C--N 1.346 1.112 0 C-N-CA 123.465 0.555 . . . . 0.0 111.929 178.256 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 39.1 t -80.19 158.7 26.21 Favored 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 124.343 1.057 . . . . 0.0 110.707 -178.208 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -73.02 90.45 0.59 Allowed Glycine 0 C--N 1.347 1.144 0 CA-C-N 116.309 -0.405 . . . . 0.0 112.543 -178.103 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -65.44 -48.8 65.05 Favored Glycine 0 C--N 1.35 1.315 0 O-C-N 123.881 0.4 . . . . 0.0 112.221 177.368 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 70.53 -114.89 5.65 Favored Glycine 0 C--N 1.354 1.548 0 O-C-N 123.77 0.335 . . . . 0.0 112.497 178.659 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 136.94 -143.28 14.54 Favored Glycine 0 C--N 1.346 1.112 0 N-CA-C 111.396 -0.682 . . . . 0.0 111.396 -179.694 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 -92.07 -5.49 52.74 Favored 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 123.824 0.85 . . . . 0.0 110.835 174.427 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 56.5 t80 75.47 -3.54 2.56 Favored 'General case' 0 N--CA 1.488 1.458 0 C-N-CA 125.48 1.512 . . . . 0.0 112.176 177.319 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -72.45 -38.64 68.23 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 123.391 0.676 . . . . 0.0 110.571 177.504 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 137.61 108.36 0.85 Allowed Glycine 0 C--N 1.344 1.006 0 CA-C-N 115.685 -0.689 . . . . 0.0 112.148 176.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 36.0 t -71.63 -86.29 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.565 1.532 0 C-N-CA 123.548 0.739 . . . . 0.0 109.197 178.264 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.597 HD21 ' HG2' ' A' ' 78' ' ' GLU . 33.6 tp 174.92 146.92 0.07 Allowed 'General case' 0 N--CA 1.483 1.182 0 C-N-CA 126.888 2.075 . . . . 0.0 106.172 171.772 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 6.7 m0 -91.2 62.43 4.76 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 118.526 0.603 . . . . 0.0 111.651 -176.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 8.6 t0 179.15 70.64 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.266 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 173.096 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 14.5 m -129.52 109.41 17.5 Favored Pre-proline 0 CA--C 1.555 1.152 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.443 -169.101 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.531 ' HD3' ' HG3' ' A' ' 80' ' ' GLU . 87.6 Cg_endo -81.9 -33.04 0.66 Allowed 'Trans proline' 0 C--N 1.38 2.222 0 C-N-CA 123.03 2.487 . . . . 0.0 112.247 177.051 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 51.1 m -129.83 152.64 80.2 Favored Pre-proline 0 CA--C 1.544 0.727 0 C-N-CA 125.395 1.478 . . . . 0.0 107.684 173.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 22.7 Cg_endo -59.11 109.54 0.55 Allowed 'Trans proline' 0 C--N 1.376 2.005 0 C-N-CA 122.574 2.183 . . . . 0.0 111.564 175.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -78.25 164.15 27.01 Favored 'Trans proline' 0 C--N 1.38 2.214 0 C-N-CA 122.809 2.339 . . . . 0.0 111.961 -176.083 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -79.99 55.28 5.58 Favored 'Trans proline' 0 CA--C 1.558 1.716 0 C-N-CA 122.768 2.312 . . . . 0.0 111.542 171.461 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 9.3 p 37.86 75.69 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 C-N-CA 126.125 1.77 . . . . 0.0 112.355 -171.494 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -90.23 -131.89 4.8 Favored Glycine 0 C--N 1.342 0.884 0 CA-C-N 115.201 -0.909 . . . . 0.0 111.909 -178.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 25.3 pttm 178.76 -22.84 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 125.112 1.365 . . . . 0.0 110.168 -179.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -94.17 1.33 56.08 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 123.444 0.698 . . . . 0.0 112.607 -176.088 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.597 ' HG2' HD21 ' A' ' 65' ' ' LEU . 8.7 pm0 -82.62 72.78 9.69 Favored 'General case' 0 N--CA 1.479 0.993 0 CA-C-O 122.206 1.003 . . . . 0.0 111.165 -179.292 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.438 HD21 HD23 ' A' ' 65' ' ' LEU . 4.1 mm? -105.45 81.57 1.71 Allowed 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 106.86 -1.533 . . . . 0.0 106.86 168.13 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.531 ' HG3' ' HD3' ' A' ' 69' ' ' PRO . 29.6 mm-40 -71.09 -38.7 72.39 Favored 'General case' 0 C--O 1.243 0.738 0 CA-C-N 114.563 -1.198 . . . . 0.0 111.742 -171.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 70.02 125.58 0.03 OUTLIER 'General case' 0 CA--C 1.549 0.939 0 O-C-N 125.008 1.443 . . . . 0.0 109.731 -161.517 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -166.16 166.33 38.7 Favored Glycine 0 C--N 1.34 0.802 0 CA-C-N 115.805 -0.634 . . . . 0.0 113.455 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . 0.64 ' HB3' HD13 ' A' ' 161' ' ' LEU . . . -86.3 118.14 25.55 Favored 'General case' 0 C--O 1.243 0.719 0 CA-C-N 114.117 -1.041 . . . . 0.0 108.701 175.096 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 79.9 m-85 -118.46 142.4 47.6 Favored 'General case' 0 C--O 1.216 -0.676 0 C-N-CA 123.09 0.556 . . . . 0.0 109.622 -179.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . 0.641 ' HG3' ' HB2' ' A' ' 11' ' ' ALA . 54.9 mtt-85 -92.29 137.0 32.73 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 174.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 51.6 mt -102.37 121.3 53.26 Favored 'Isoleucine or valine' 0 C--O 1.26 1.629 0 CA-C-O 121.673 0.749 . . . . 0.0 110.151 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.467 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 22.7 pttm -122.82 144.79 48.96 Favored 'General case' 0 C--N 1.349 0.554 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.823 177.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.18 119.65 24.33 Favored 'General case' 0 C--O 1.249 1.027 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 173.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . 0.79 ' HD3' ' HB2' ' A' ' 7' ' ' GLU . 53.2 pttt -115.31 152.74 32.23 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.686 -172.318 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -100.93 103.2 2.55 Favored Glycine 0 C--N 1.347 1.157 0 N-CA-C 106.135 -2.786 . . . . 0.0 106.135 160.414 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 4.8 tp 19.36 29.66 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.58 2.118 0 C-N-CA 129.298 3.039 . . . . 0.0 116.882 -167.542 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.438 ' N ' ' HD2' ' A' ' 89' ' ' LYS . 0.7 OUTLIER -177.41 -57.27 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.873 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 -169.77 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 177.05 161.89 26.52 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 114.732 0.653 . . . . 0.0 114.732 -177.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 53.2 p90 -165.8 -48.0 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 124.308 1.043 . . . . 0.0 112.05 156.17 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 12.6 t -152.72 149.83 28.8 Favored 'General case' 0 N--CA 1.495 1.783 0 CA-C-N 119.63 1.105 . . . . 0.0 112.067 -175.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' GLN . . . . . 0.467 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 0.8 OUTLIER -95.38 142.31 27.91 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 124.417 1.087 . . . . 0.0 110.445 -179.782 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.436 HD11 HD23 ' A' ' 6' ' ' LEU . 1.3 pp -133.49 -7.66 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 N-CA-C 113.575 0.954 . . . . 0.0 113.575 -175.052 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 175.92 -148.92 9.58 Favored Glycine 0 N--CA 1.475 1.242 0 CA-C-N 118.359 0.527 . . . . 0.0 113.017 173.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -156.41 176.06 13.19 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 123.585 0.754 . . . . 0.0 110.985 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -172.87 135.3 3.27 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -177.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.467 HG23 ' HB3' ' A' ' 199' ' ' PRO . 71.3 t -95.65 110.67 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 C-N-CA 123.285 0.634 . . . . 0.0 109.328 -177.447 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 17.7 t80 -77.66 134.51 38.14 Favored 'General case' 0 CA--C 1.536 0.439 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -179.468 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' LYS . . . . . 0.728 ' HZ2' HG23 ' A' ' 207' ' ' VAL . 35.5 mmtm -118.64 157.65 27.0 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 124.96 1.304 . . . . 0.0 109.045 -179.583 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -53.76 100.18 0.03 OUTLIER 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 123.86 0.864 . . . . 0.0 112.176 -173.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 83.55 -9.97 60.57 Favored Glycine 0 C--N 1.351 1.386 0 CA-C-N 115.48 -0.782 . . . . 0.0 113.766 178.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 20.3 p -123.81 120.45 32.65 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 124.038 0.935 . . . . 0.0 111.02 -175.121 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' PHE . . . . . 0.683 ' HB3' ' HB3' ' A' ' 140' ' ' TYR . 37.2 t80 -84.42 122.6 29.19 Favored 'General case' 0 N--CA 1.48 1.027 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 176.483 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 5.3 t-80 -132.97 102.3 5.57 Favored 'General case' 0 CA--C 1.554 1.129 0 C-N-CA 123.776 0.83 . . . . 0.0 110.434 -167.111 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' THR . . . . . 0.46 HG23 ' HB ' ' A' ' 138' ' ' ILE . 10.2 t -136.74 177.19 8.05 Favored 'General case' 0 N--CA 1.488 1.457 0 C-N-CA 123.889 0.876 . . . . 0.0 111.135 -178.601 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' MET . . . . . 0.474 ' HA ' ' HA ' ' A' ' 137' ' ' LEU . 44.2 mtp -93.55 157.14 16.34 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 124.296 1.038 . . . . 0.0 109.148 173.536 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 79.7 t90 -80.46 -61.88 1.84 Allowed 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 112.28 0.474 . . . . 0.0 112.28 -166.149 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 2.3 p-80 -73.97 3.93 6.12 Favored 'General case' 0 N--CA 1.5 2.048 0 N-CA-C 114.009 1.114 . . . . 0.0 114.009 -167.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 40.7 t -42.99 -41.6 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.279 0 C-N-CA 123.734 0.814 . . . . 0.0 110.29 161.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.508 HG21 HD22 ' A' ' 6' ' ' LEU . 0.2 OUTLIER -153.29 -163.03 1.59 Allowed 'General case' 0 CA--C 1.558 1.286 0 C-N-CA 125.267 1.427 . . . . 0.0 109.207 170.395 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 77.5 mtp180 -66.01 -26.65 67.63 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 113.362 0.875 . . . . 0.0 113.362 -172.747 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 93.78 62.84 1.07 Allowed Glycine 0 CA--C 1.53 0.983 0 O-C-N 123.205 0.316 . . . . 0.0 113.715 178.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -141.98 -85.66 0.17 Allowed 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 112.461 0.541 . . . . 0.0 112.461 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 26.6 t -110.98 109.0 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 123.359 0.663 . . . . 0.0 112.331 -169.028 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.506 HD11 HD12 ' A' ' 126' ' ' ILE . 1.3 tm? -91.33 152.06 20.61 Favored 'General case' 0 C--O 1.212 -0.908 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 169.108 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' MET . . . . . 0.723 ' HG3' ' HA ' ' A' ' 5' ' ' ASP . 45.7 mmm -135.01 138.85 44.36 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 124.06 0.944 . . . . 0.0 108.717 -172.755 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' HIS . . . . . 0.515 ' O ' ' HG2' ' A' ' 122' ' ' LYS . 18.5 t-160 -167.53 141.84 3.68 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -177.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.515 ' HG2' ' O ' ' A' ' 121' ' ' HIS . 32.8 pttt 68.92 3.12 3.84 Favored 'General case' 0 N--CA 1.501 2.086 0 C-N-CA 125.649 1.579 . . . . 0.0 112.766 176.194 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 99.96 -0.76 56.35 Favored Glycine 0 C--N 1.351 1.362 0 C-N-CA 123.144 0.402 . . . . 0.0 113.084 -174.282 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -118.45 152.93 34.97 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 123.813 0.845 . . . . 0.0 110.744 179.482 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' ARG . . . . . 0.439 ' HB3' ' SD ' ' A' ' 120' ' ' MET . 20.8 ptp180 -93.07 164.67 13.18 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.11 -179.276 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.506 HD12 HD11 ' A' ' 119' ' ' LEU . 27.5 mt -142.8 122.97 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 C-N-CA 125.628 1.571 . . . . 0.0 107.086 -172.396 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 44.8 mt-10 -125.73 132.69 24.39 Favored Pre-proline 0 N--CA 1.474 0.758 0 N-CA-C 108.604 -0.888 . . . . 0.0 108.604 175.427 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . 0.524 ' HA ' ' HB2' ' A' ' 140' ' ' TYR . 96.9 Cg_endo -73.78 157.65 47.62 Favored 'Trans proline' 0 C--N 1.373 1.86 0 C-N-CA 122.934 2.423 . . . . 0.0 113.943 -168.806 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' SER . . . . . 0.499 ' H ' ' HA ' ' A' ' 140' ' ' TYR . 28.8 p -76.77 -27.62 55.37 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-N 114.884 -1.053 . . . . 0.0 109.623 172.385 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 67.6 t-105 -152.5 144.94 24.07 Favored 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 123.314 0.645 . . . . 0.0 110.21 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -136.72 121.19 18.22 Favored 'General case' 0 C--O 1.241 0.613 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 171.566 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -114.13 109.09 17.88 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 123.437 0.695 . . . . 0.0 109.467 -173.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 17.1 t -77.44 -19.38 14.15 Favored 'Isoleucine or valine' 0 CA--C 1.562 1.407 0 C-N-CA 123.9 0.88 . . . . 0.0 111.304 -175.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 2.8 mptp? -69.46 -51.31 37.27 Favored 'General case' 0 N--CA 1.487 1.419 0 C-N-CA 123.461 0.704 . . . . 0.0 109.557 -177.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 31.9 mmtp -84.13 -20.08 33.1 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-N 115.088 -0.96 . . . . 0.0 110.346 178.681 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 14.2 t70 65.5 63.57 0.62 Allowed 'General case' 0 C--O 1.24 0.595 0 C-N-CA 125.56 1.544 . . . . 0.0 110.607 -175.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' LEU . . . . . 0.474 ' HA ' ' HA ' ' A' ' 110' ' ' MET . 1.5 mp -143.77 172.64 12.56 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.802 174.461 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.71 HD13 ' H3 ' ' A' ' 1' ' ' GLY . 21.6 mt -141.46 131.33 25.15 Favored 'Isoleucine or valine' 0 C--O 1.245 0.868 0 C-N-CA 125.952 1.701 . . . . 0.0 108.08 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 29.9 p -136.48 123.09 20.98 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 124.13 0.972 . . . . 0.0 110.282 -177.566 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.683 ' HB3' ' HB3' ' A' ' 107' ' ' PHE . 47.8 t80 -109.68 123.97 50.41 Favored 'General case' 0 N--CA 1.464 0.24 0 C-N-CA 124.626 1.17 . . . . 0.0 108.06 172.79 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 113.91 0.4 24.23 Favored Glycine 0 N--CA 1.474 1.19 0 O-C-N 123.885 0.741 . . . . 0.0 111.98 -173.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 147.46 -141.74 9.58 Favored Glycine 0 C--N 1.346 1.125 0 N-CA-C 109.944 -1.262 . . . . 0.0 109.944 177.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.781 ' HA3' ' HB2' ' A' ' 232' ' ' SER . . . -97.45 -175.06 34.19 Favored Glycine 0 C--N 1.345 1.058 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 164.285 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' TRP . . . . . 0.602 ' HZ2' ' HA2' ' A' ' 209' ' ' GLY . 7.4 t90 -69.76 104.02 2.32 Favored 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 177.279 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . 0.59 ' HB3' ' HA ' ' A' ' 231' ' ' LYS . 11.7 pttt -164.87 113.85 1.08 Allowed 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 123.7 0.8 . . . . 0.0 109.692 -177.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' LEU . . . . . 0.679 HD21 ' HD2' ' A' ' 103' ' ' LYS . 0.0 OUTLIER 167.62 -33.12 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 C-N-CA 125.178 1.391 . . . . 0.0 110.602 161.409 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.572 ' HG2' ' HE2' ' A' ' 103' ' ' LYS . 31.6 mt-10 -62.3 -81.91 0.02 OUTLIER 'General case' 0 C--N 1.367 1.353 0 O-C-N 123.714 0.634 . . . . 0.0 111.057 -166.139 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . 0.444 ' O ' ' HB ' ' A' ' 229' ' ' THR . . . 177.66 -174.26 46.75 Favored Glycine 0 C--N 1.341 0.813 0 O-C-N 123.464 0.477 . . . . 0.0 111.963 -178.097 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -124.85 107.37 10.83 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 -172.765 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' TRP . . . . . . . . . . . . . 27.5 t90 -54.89 135.57 48.0 Favored 'General case' 0 N--CA 1.477 0.923 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.625 172.161 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . 0.43 ' HZ3' ' HE3' ' A' ' 206' ' ' LYS . 53.6 mmtt -84.48 101.8 12.33 Favored 'General case' 0 C--O 1.239 0.508 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 179.042 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -62.65 107.72 1.01 Allowed 'General case' 0 CA--C 1.546 0.803 0 O-C-N 124.022 0.826 . . . . 0.0 109.765 -172.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 134.16 -31.62 2.77 Favored Glycine 0 C--N 1.34 0.803 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.688 -176.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -82.81 156.34 23.71 Favored 'General case' 0 C--O 1.242 0.708 0 C-N-CA 123.349 0.66 . . . . 0.0 109.48 178.559 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 10.0 pm0 -64.02 142.93 58.23 Favored 'General case' 0 C--O 1.243 0.731 0 O-C-N 124.207 0.942 . . . . 0.0 109.956 174.442 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . 0.406 ' HB ' HG21 ' A' ' 200' ' ' ILE . 15.8 m -92.48 142.34 13.26 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 CA-C-O 121.184 0.516 . . . . 0.0 109.822 174.552 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' GLN . . . . . 0.469 HE22 ' HB2' ' A' ' 171' ' ' GLN . 9.9 tp-100 -101.32 144.96 29.52 Favored 'General case' 0 N--CA 1.454 -0.235 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 173.008 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.597 ' HB ' ' HB ' ' A' ' 170' ' ' VAL . 49.1 t -128.03 146.02 34.28 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 123.445 0.698 . . . . 0.0 110.014 -174.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' LEU . . . . . 0.415 ' HB2' ' HG2' ' A' ' 199' ' ' PRO . 33.7 mt -97.04 85.55 3.76 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 160.82 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -64.16 100.5 0.34 Allowed 'General case' 0 C--O 1.237 0.403 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 -179.233 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' LEU . . . . . 0.64 HD13 ' HB3' ' A' ' 83' ' ' ALA . 70.6 mt -78.03 80.28 4.47 Favored 'General case' 0 C--O 1.242 0.691 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.628 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 10.1 mm-40 -61.59 125.3 84.26 Favored Pre-proline 0 CA--C 1.555 1.151 0 CA-C-N 113.412 -1.722 . . . . 0.0 110.074 -176.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . 0.414 ' HB3' ' NH2' ' B' ' 254' ' ' ARG . 18.4 Cg_endo -58.1 112.8 1.28 Allowed 'Trans proline' 0 C--N 1.382 2.293 0 C-N-CA 122.875 2.383 . . . . 0.0 112.626 -174.006 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 67.06 26.87 73.31 Favored Glycine 0 C--N 1.349 1.305 0 O-C-N 124.139 0.9 . . . . 0.0 113.291 176.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 49.8 mtpt -131.54 -172.49 2.87 Favored 'General case' 0 C--O 1.242 0.703 0 C-N-CA 124.282 1.033 . . . . 0.0 109.306 -176.533 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -72.48 141.7 83.23 Favored Pre-proline 0 CA--C 1.555 1.139 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.053 170.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_exo -67.48 122.33 9.54 Favored 'Trans proline' 0 C--N 1.368 1.577 0 C-N-CA 122.522 2.148 . . . . 0.0 111.006 170.384 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 56.6 mtp180 -105.51 167.6 9.65 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 123.912 0.885 . . . . 0.0 110.549 -178.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 169' ' ' ALA . . . . . 0.563 ' HB2' ' HB3' ' A' ' 17' ' ' GLU . . . -102.24 151.21 22.49 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 109.408 -0.589 . . . . 0.0 109.408 170.493 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . 0.597 ' HB ' ' HB ' ' A' ' 158' ' ' VAL . 95.5 t -136.17 117.08 18.51 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.239 0 C-N-CA 123.276 0.63 . . . . 0.0 110.286 175.159 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . 0.592 ' HB2' ' HB3' ' A' ' 20' ' ' ALA . 65.0 tt0 -94.81 111.24 23.03 Favored 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 172.441 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 4.5 t -140.52 140.53 35.27 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-O 121.001 0.429 . . . . 0.0 110.742 -174.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 21.5 ptmt -75.61 152.43 85.27 Favored Pre-proline 0 CA--C 1.55 0.953 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.961 177.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -70.3 143.54 48.52 Favored 'Trans proline' 0 C--N 1.374 1.909 0 C-N-CA 122.314 2.009 . . . . 0.0 112.692 171.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -132.84 155.55 21.67 Favored Glycine 0 N--CA 1.467 0.729 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 170.406 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.487 ' HG ' ' HA2' ' A' ' 185' ' ' GLY . 6.5 mp -116.81 157.17 26.02 Favored 'General case' 0 N--CA 1.482 1.143 0 CA-C-N 119.019 1.409 . . . . 0.0 109.231 -174.562 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 177' ' ' PHE . . . . . . . . . . . . . 50.2 p90 -137.02 149.55 47.53 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.802 175.301 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 60.1 tttp -97.78 128.01 44.13 Favored 'General case' 0 C--O 1.239 0.547 0 CA-C-N 115.577 -0.738 . . . . 0.0 109.977 -177.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 75.5 p -123.48 171.82 9.19 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.017 0.927 . . . . 0.0 109.355 168.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -65.94 -27.07 67.9 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 123.564 0.746 . . . . 0.0 110.607 174.334 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -68.65 -40.71 80.08 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 123.757 0.823 . . . . 0.0 110.602 175.455 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 158.22 -175.9 35.31 Favored Glycine 0 C--N 1.35 1.346 0 CA-C-N 115.831 -0.622 . . . . 0.0 112.423 177.634 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 8.5 t -77.98 115.42 17.71 Favored 'General case' 0 CA--C 1.543 0.695 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 172.55 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 52.8 mt -104.5 138.95 26.98 Favored 'Isoleucine or valine' 0 C--O 1.246 0.909 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -177.504 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 185' ' ' GLY . . . . . 0.487 ' HA2' ' HG ' ' A' ' 176' ' ' LEU . . . -100.45 119.43 6.51 Favored Glycine 0 C--N 1.349 1.291 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -175.121 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . 0.494 ' HA ' ' H ' ' A' ' 226' ' ' ILE . . . -144.94 -156.85 0.74 Allowed 'General case' 0 C--O 1.235 0.323 0 C-N-CA 123.837 0.855 . . . . 0.0 109.928 -165.694 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 187' ' ' VAL . . . . . 0.547 HG12 ' HB3' ' A' ' 224' ' ' SER . 2.4 p -135.77 123.06 34.98 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 C-N-CA 123.648 0.779 . . . . 0.0 109.285 175.085 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 41.6 m -117.75 115.29 24.72 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 123.779 0.832 . . . . 0.0 109.262 -176.796 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 189' ' ' LEU . . . . . 0.417 HD11 ' HB3' ' A' ' 191' ' ' PHE . 0.5 OUTLIER -149.44 164.0 36.22 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 124.065 0.946 . . . . 0.0 110.962 -175.44 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -101.52 104.1 14.99 Favored 'General case' 0 CA--C 1.541 0.634 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 170.246 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 191' ' ' PHE . . . . . 0.417 ' HB3' HD11 ' A' ' 189' ' ' LEU . 67.9 t80 -154.11 166.58 32.62 Favored 'General case' 0 N--CA 1.484 1.238 0 C-N-CA 123.217 0.607 . . . . 0.0 110.486 -171.79 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 48.8 m -69.53 156.25 92.01 Favored Pre-proline 0 CA--C 1.559 1.295 0 C-N-CA 124.952 1.301 . . . . 0.0 112.631 -178.713 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 193' ' ' PRO . . . . . 0.515 ' HA ' ' CE1' ' A' ' 222' ' ' TYR . 39.7 Cg_endo -64.24 99.18 0.28 Allowed 'Trans proline' 0 C--N 1.387 2.554 0 C-N-CA 123.009 2.473 . . . . 0.0 113.02 176.392 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -70.47 -136.39 0.12 Allowed Glycine 0 C--N 1.361 1.918 0 C-N-CA 123.745 0.688 . . . . 0.0 112.596 177.749 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 25.4 p -124.79 143.94 50.54 Favored 'General case' 0 N--CA 1.489 1.501 0 CA-C-N 118.979 1.39 . . . . 0.0 112.245 169.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 14.1 m -73.88 83.19 1.68 Allowed 'General case' 0 C--N 1.354 0.765 0 C-N-CA 123.645 0.778 . . . . 0.0 110.305 170.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 127.98 19.86 1.73 Allowed Glycine 0 C--N 1.339 0.747 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.536 -170.275 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 33.4 t -65.49 140.23 97.53 Favored Pre-proline 0 CA--C 1.554 1.108 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 164.118 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 199' ' ' PRO . . . . . 0.467 ' HB3' HG23 ' A' ' 101' ' ' VAL . 65.7 Cg_endo -81.04 131.85 8.1 Favored 'Trans proline' 0 C--N 1.374 1.881 0 C-N-CA 121.647 1.565 . . . . 0.0 113.374 179.016 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 200' ' ' ILE . . . . . 0.406 HG21 ' HB ' ' A' ' 156' ' ' VAL . 43.9 mt -87.43 117.91 32.33 Favored 'Isoleucine or valine' 0 C--O 1.248 1.002 0 CA-C-O 121.962 0.887 . . . . 0.0 108.739 163.091 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 201' ' ' ILE . . . . . . . . . . . . . 80.4 mt -102.87 136.49 35.12 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.812 0 CA-C-N 113.248 -1.796 . . . . 0.0 107.54 172.421 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 202' ' ' ASP . . . . . 0.518 ' HB3' ' HB2' ' A' ' 206' ' ' LYS . 19.1 t70 -73.31 148.56 43.41 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 167.415 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 60.6 pttt -60.38 -18.96 53.85 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 -172.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 86.1 tttt -67.52 -21.34 65.49 Favored 'General case' 0 CA--C 1.557 1.247 0 C-N-CA 123.546 0.738 . . . . 0.0 111.766 177.497 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 108.27 3.32 33.37 Favored Glycine 0 N--CA 1.471 0.967 0 C-N-CA 123.3 0.476 . . . . 0.0 111.949 -171.691 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 206' ' ' LYS . . . . . 0.518 ' HB2' ' HB3' ' A' ' 202' ' ' ASP . 46.4 mttm -74.45 136.22 42.3 Favored 'General case' 0 C--O 1.205 -1.244 0 C-N-CA 123.985 0.914 . . . . 0.0 109.428 173.436 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 207' ' ' VAL . . . . . 0.728 HG23 ' HZ2' ' A' ' 103' ' ' LYS . 7.5 p -86.68 135.91 24.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 N-CA-C 106.403 -1.702 . . . . 0.0 106.403 163.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 30.9 m -135.8 -21.08 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 N-CA-C 113.153 0.797 . . . . 0.0 113.153 -168.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 209' ' ' GLY . . . . . 0.602 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . 178.4 -151.37 10.47 Favored Glycine 0 C--N 1.35 1.329 0 C-N-CA 119.751 -1.214 . . . . 0.0 115.815 -176.116 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 210' ' ' LEU . . . . . 0.449 HD11 HD21 ' A' ' 137' ' ' LEU . 33.6 mt -130.82 133.74 46.22 Favored 'General case' 0 C--N 1.365 1.241 0 CA-C-O 121.88 0.848 . . . . 0.0 112.366 -175.751 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 64.0 t80 -94.09 133.96 37.03 Favored 'General case' 0 C--O 1.241 0.655 0 C-N-CA 126.409 1.884 . . . . 0.0 108.223 168.061 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -137.38 -138.05 3.69 Favored Glycine 0 C--O 1.229 -0.189 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 177.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 213' ' ' ASN . . . . . 0.449 ' HA ' ' HA ' ' A' ' 224' ' ' SER . 9.2 t30 -156.79 101.09 1.95 Allowed 'General case' 0 C--O 1.237 0.396 0 C-N-CA 125.694 1.598 . . . . 0.0 107.05 170.666 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . -56.22 -56.39 24.5 Favored Glycine 0 C--N 1.342 0.894 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 172.782 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 215' ' ' VAL . . . . . . . . . . . . . 3.4 m -162.2 -172.74 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 C-N-CA 125.241 1.416 . . . . 0.0 108.952 176.057 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 216' ' ' VAL . . . . . 0.503 HG22 ' HD3' ' B' ' 253' ' ' LYS . 3.4 m -117.83 129.89 73.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 168.135 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 217' ' ' THR . . . . . 0.416 HG23 ' H ' ' A' ' 218' ' ' ARG . 4.9 m -126.69 -178.9 4.54 Favored 'General case' 0 CA--C 1.552 1.031 0 N-CA-C 107.829 -1.175 . . . . 0.0 107.829 -178.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 218' ' ' ARG . . . . . 0.416 ' H ' HG23 ' A' ' 217' ' ' THR . 10.9 ttt85 64.19 25.57 13.66 Favored 'General case' 0 N--CA 1.496 1.863 0 CA-C-O 122.393 1.092 . . . . 0.0 110.879 171.367 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 10.2 t 69.9 2.07 3.72 Favored 'General case' 0 N--CA 1.489 1.507 0 C-N-CA 125.412 1.485 . . . . 0.0 112.975 176.501 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 220' ' ' GLY . . . . . 0.405 ' HA2' ' H5 ' ' B' ' 251' ' ' BEZ . . . 159.64 45.81 0.02 OUTLIER Glycine 0 C--N 1.349 1.263 0 CA-C-N 117.706 0.23 . . . . 0.0 112.572 -177.447 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -122.69 121.45 36.41 Favored 'General case' 0 C--O 1.238 0.478 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 176.048 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 222' ' ' TYR . . . . . 0.515 ' CE1' ' HA ' ' A' ' 193' ' ' PRO . 56.6 t80 -69.8 101.29 1.68 Allowed 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 125.136 1.374 . . . . 0.0 109.059 179.282 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 223' ' ' VAL . . . . . 0.487 HG13 HD13 ' A' ' 31' ' ' ILE . 8.2 t -96.89 98.56 7.68 Favored 'Isoleucine or valine' 0 C--O 1.249 1.039 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 -176.467 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 224' ' ' SER . . . . . 0.547 ' HB3' HG12 ' A' ' 187' ' ' VAL . 38.0 t -97.3 155.19 16.98 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 125.144 1.378 . . . . 0.0 109.744 179.059 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 225' ' ' ALA . . . . . . . . . . . . . . . -104.83 131.38 52.38 Favored 'General case' 0 C--O 1.241 0.626 0 C-N-CA 123.449 0.7 . . . . 0.0 109.675 176.428 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 226' ' ' ILE . . . . . 0.494 ' H ' ' HA ' ' A' ' 186' ' ' ALA . 78.8 mt -77.98 95.04 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.352 0.68 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 173.196 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 227' ' ' ALA . . . . . 0.412 ' O ' ' HA3' ' A' ' 209' ' ' GLY . . . -85.18 147.18 26.73 Favored 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 172.632 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 3.7 pt20 -147.54 153.56 39.63 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 123.918 0.887 . . . . 0.0 109.446 -169.246 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.444 ' HB ' ' O ' ' A' ' 148' ' ' GLY . 89.4 m -69.0 109.28 3.88 Favored 'General case' 0 CA--C 1.545 0.764 0 CA-C-O 121.161 0.505 . . . . 0.0 109.817 179.242 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 230' ' ' GLU . . . . . 0.412 ' O ' ' HG2' ' A' ' 231' ' ' LYS . 38.3 mt-10 -98.01 -11.83 22.58 Favored 'General case' 0 N--CA 1.481 1.081 0 CA-C-N 114.916 -1.038 . . . . 0.0 111.302 -175.193 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 231' ' ' LYS . . . . . 0.59 ' HA ' ' HB3' ' A' ' 145' ' ' LYS . 11.7 pttm 66.78 128.48 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 127.06 2.144 . . . . 0.0 112.189 -177.51 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 232' ' ' SER . . . . . 0.781 ' HB2' ' HA3' ' A' ' 143' ' ' GLY . 30.1 m -144.03 93.38 2.44 Favored 'General case' 0 C--N 1.351 0.659 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 172.814 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 233' ' ' ILE . . . . . . . . . . . . . 6.4 tt -75.08 -24.68 17.9 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.057 0 CA-C-N 114.767 -1.106 . . . . 0.0 110.725 179.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 234' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 78.9 -39.87 0.24 Allowed 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 126.431 1.893 . . . . 0.0 111.945 -178.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -60.12 -56.89 16.05 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 123.642 0.777 . . . . 0.0 110.522 176.196 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 236' ' ' ASN . . . . . . . . . . . . . 38.7 m-20 -107.54 106.38 58.3 Favored Pre-proline 0 N--CA 1.477 0.908 0 C-N-CA 123.428 0.691 . . . . 0.0 110.045 -176.629 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_exo -73.3 136.27 23.94 Favored 'Trans proline' 0 C--N 1.374 1.908 0 C-N-CA 122.623 2.215 . . . . 0.0 110.577 170.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 238' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -84.98 39.3 0.76 Allowed 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 123.778 0.831 . . . . 0.0 112.634 -170.19 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 239' ' ' ILE . . . . . . . . . . . . . 49.8 mm 73.92 -51.93 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 C-N-CA 126.05 1.74 . . . . 0.0 110.946 -177.537 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 . . . . . 0 CA--C 1.556 1.191 0 C-N-CA 123.818 0.847 . . . . 0.0 109.726 174.907 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 251' ' ' BEZ . . . . . 0.405 ' H5 ' ' HA2' ' A' ' 220' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 252' ' ' NLE . . . . . 0.546 ' HD2' ' H ' ' B' ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 253' ' ' LYS . . . . . 0.503 ' HD3' HG22 ' A' ' 216' ' ' VAL . 24.8 pttm -144.95 177.04 9.04 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.125 0.57 . . . . 0.0 111.544 -172.705 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 254' ' ' ARG . . . . . 0.443 ' NH1' ' HB2' ' A' ' 48' ' ' GLN . 38.3 mmt180 -115.78 -169.46 1.59 Allowed 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 124.544 1.137 . . . . 0.0 109.003 172.292 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 255' ' ' M9P . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.238 0 CA-C-O 120.857 0.361 . . . . 0.0 111.626 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -170.95 11.37 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 123.736 0.814 . . . . 0.0 109.669 -170.836 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ASP . . . . . 0.414 ' H ' HD12 ' A' ' 6' ' ' LEU . 13.0 m-20 -158.25 82.33 0.84 Allowed 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 -169.967 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.414 HD12 ' H ' ' A' ' 5' ' ' ASP . 7.4 mp -117.01 109.65 17.27 Favored 'General case' 0 C--O 1.202 -1.432 0 O-C-N 121.474 -0.766 . . . . 0.0 110.284 -175.221 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.618 ' HB2' ' HD3' ' A' ' 89' ' ' LYS . 37.3 tp10 -83.68 145.46 28.76 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.551 -0.718 . . . . 0.0 110.627 -176.304 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.451 HD21 ' CZ ' ' A' ' 107' ' ' PHE . 81.6 mt -89.32 114.66 26.08 Favored 'General case' 0 CA--C 1.547 0.856 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.508 171.177 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -112.28 107.88 16.89 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 125.108 1.363 . . . . 0.0 108.274 178.802 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 15.9 ttp180 -67.75 125.05 25.02 Favored 'General case' 0 N--CA 1.481 1.102 0 CA-C-N 118.441 0.564 . . . . 0.0 111.616 -172.088 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.543 ' HB2' ' HG3' ' A' ' 85' ' ' ARG . . . -89.06 -40.54 12.89 Favored 'General case' 0 C--N 1.347 0.473 0 C-N-CA 124.02 0.928 . . . . 0.0 109.986 177.188 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -166.09 -176.25 3.67 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 115.08 -0.964 . . . . 0.0 110.776 -173.783 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 65.2 m-20 -110.22 146.78 35.01 Favored 'General case' 0 C--O 1.242 0.696 0 C-N-CA 124.085 0.954 . . . . 0.0 108.838 171.401 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.435 HG11 HG12 ' A' ' 208' ' ' VAL . 94.6 t -78.86 101.01 3.97 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 CA-C-O 121.503 0.668 . . . . 0.0 109.469 -177.171 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 33.8 ttpt -167.96 109.74 0.59 Allowed 'General case' 0 C--O 1.247 0.966 0 N-CA-C 105.247 -2.131 . . . . 0.0 105.247 175.767 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' TRP . . . . . 0.442 ' NE1' ' HB1' ' A' ' 169' ' ' ALA . 68.2 t90 -80.3 90.57 5.56 Favored 'General case' 0 CA--C 1.539 0.553 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 -177.153 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -157.88 60.46 0.47 Allowed 'General case' 0 CA--C 1.543 0.677 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 158.046 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.601 ' HB3' ' HB2' ' A' ' 169' ' ' ALA . 12.6 t70 -90.6 -58.93 2.32 Favored 'General case' 0 CA--C 1.554 1.134 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.775 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' GLN . . . . . 0.698 ' H ' ' HB3' ' A' ' 169' ' ' ALA . 81.3 mt-30 -150.28 4.27 0.52 Allowed 'General case' 0 N--CA 1.5 2.027 0 N-CA-C 113.953 1.094 . . . . 0.0 113.953 -172.485 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . 11.84 70.91 0.01 OUTLIER 'General case' 0 N--CA 1.506 2.365 0 C-N-CA 126.549 1.94 . . . . 0.0 115.484 -169.053 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -88.22 123.59 33.0 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 123.603 0.761 . . . . 0.0 109.9 -176.253 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 30.8 mm -75.58 134.87 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 C-N-CA 123.045 0.538 . . . . 0.0 110.187 -176.789 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 78.5 p -174.84 -162.46 0.12 Allowed 'General case' 0 CA--C 1.55 0.949 0 O-C-N 124.581 1.176 . . . . 0.0 109.954 172.696 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.653 ' HA3' ' H ' ' A' ' 173' ' ' LYS . . . 102.77 178.49 26.86 Favored Glycine 0 C--N 1.349 1.259 0 CA-C-O 119.522 -0.599 . . . . 0.0 111.805 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 44.0 t 64.02 98.17 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 124.212 1.005 . . . . 0.0 111.176 176.287 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 28.8 t -140.63 148.83 54.73 Favored Pre-proline 0 N--CA 1.479 0.993 0 CA-C-O 118.406 -0.807 . . . . 0.0 109.345 -176.995 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_exo -42.63 138.12 3.7 Favored 'Trans proline' 0 C--N 1.391 2.81 0 C-N-CA 123.87 3.046 . . . . 0.0 113.785 177.243 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.678 HD12 ' HB2' ' A' ' 176' ' ' LEU . 31.0 mm -63.52 111.13 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 -175.728 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.689 ' HB3' HG21 ' A' ' 217' ' ' THR . 13.6 mt -94.11 142.33 27.52 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 115.373 -0.83 . . . . 0.0 111.732 -167.69 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 60.4 p -85.52 140.8 30.36 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 123.358 0.663 . . . . 0.0 110.316 177.474 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.739 HG21 ' HD2' ' A' ' 177' ' ' PHE . 14.6 tt -148.39 138.6 16.7 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.794 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 -172.372 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 39.4 p -102.27 117.05 33.93 Favored 'General case' 0 CA--C 1.547 0.855 0 O-C-N 121.881 -0.512 . . . . 0.0 110.997 -170.794 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.602 ' HA ' ' HG3' ' A' ' 39' ' ' MET . 10.6 tp -61.25 145.11 13.09 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.077 0 C-N-CA 124.902 1.281 . . . . 0.0 112.208 -177.949 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 47.5 m -152.25 130.91 12.31 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 124.103 0.961 . . . . 0.0 110.068 -176.041 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 60.71 19.24 9.32 Favored 'General case' 0 CA--C 1.566 1.586 0 C-N-CA 123.479 0.712 . . . . 0.0 111.437 174.761 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 24.3 t70 76.05 -55.55 0.6 Allowed 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 125.617 1.567 . . . . 0.0 112.318 -178.359 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -89.0 -20.27 47.23 Favored Glycine 0 N--CA 1.475 1.268 0 N-CA-C 115.002 0.761 . . . . 0.0 115.002 -175.359 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 66.5 m -106.0 165.49 11.17 Favored 'General case' 0 N--CA 1.478 0.941 0 CA-C-N 117.646 0.723 . . . . 0.0 110.252 -177.688 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' MET . . . . . 0.602 ' HG3' ' HA ' ' A' ' 33' ' ' ILE . 3.7 mpp? -138.99 168.31 20.11 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 123.808 0.843 . . . . 0.0 108.861 168.901 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.841 ' HA ' HG11 ' A' ' 215' ' ' VAL . 64.5 m -150.39 -179.47 7.24 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 124.788 1.235 . . . . 0.0 108.282 167.975 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 41.7 mm -99.0 96.51 5.08 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 N-CA-C 108.261 -1.015 . . . . 0.0 108.261 167.417 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER 53.16 -79.63 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.154 0 C-N-CA 125.999 1.72 . . . . 0.0 112.164 -176.579 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 4.4 p30 -136.27 87.08 2.27 Favored 'General case' 0 CA--C 1.551 0.985 0 C-N-CA 124.486 1.115 . . . . 0.0 108.94 178.073 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -100.67 148.09 25.26 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.81 -172.215 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 . . . . . 0 N--CA 1.475 0.793 0 C-N-CA 124.17 0.988 . . . . 0.0 110.97 176.947 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 12.4 p-10 . . . . . 0 CA--C 1.54 0.587 0 CA-C-O 120.92 0.39 . . . . 0.0 111.298 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 169.0 -154.32 23.83 Favored Glycine 0 C--O 1.258 1.61 0 CA-C-N 115.34 -0.846 . . . . 0.0 111.85 -175.148 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -81.75 108.74 15.54 Favored 'General case' 0 C--O 1.237 0.445 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 176.364 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' TYR . . . . . 0.427 ' CD1' ' HB3' ' A' ' 8' ' ' LEU . 47.0 m-85 -102.91 156.56 17.58 Favored 'General case' 0 N--CA 1.469 0.479 0 C-N-CA 123.643 0.777 . . . . 0.0 110.704 -179.3 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' ARG . . . . . 0.543 ' HG3' ' HB2' ' A' ' 11' ' ' ALA . 60.0 mtt180 -103.06 132.57 49.23 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 106.09 -1.818 . . . . 0.0 106.09 166.36 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.521 ' H ' ' HA ' ' A' ' 99' ' ' ALA . 12.9 mt -91.84 107.83 19.31 Favored 'Isoleucine or valine' 0 C--O 1.256 1.434 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 171.388 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.879 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 19.3 ptmt -99.27 139.2 35.27 Favored 'General case' 0 N--CA 1.441 -0.907 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 169.827 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -82.85 105.99 14.31 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 105.192 -2.151 . . . . 0.0 105.192 168.271 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' LYS . . . . . 0.618 ' HD3' ' HB2' ' A' ' 7' ' ' GLU . 60.0 tttt -113.67 98.5 7.08 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-N 114.562 -1.199 . . . . 0.0 108.082 -177.541 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -66.33 154.78 51.68 Favored Glycine 0 C--O 1.246 0.903 0 N-CA-C 108.279 -1.929 . . . . 0.0 108.279 160.557 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 22.8 mm -68.19 -6.24 5.27 Favored 'Isoleucine or valine' 0 CA--C 1.572 1.796 0 CA-C-N 117.728 0.764 . . . . 0.0 110.483 -176.518 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 1.1 pp -134.52 25.44 3.76 Favored 'General case' 0 CA--C 1.564 1.507 0 C-N-CA 124.585 1.154 . . . . 0.0 111.901 172.318 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -164.98 133.07 2.85 Favored Glycine 0 N--CA 1.486 1.968 0 CA-C-N 117.869 0.304 . . . . 0.0 113.357 -178.416 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 71.6 m-85 -122.69 120.19 32.92 Favored 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 124.082 0.953 . . . . 0.0 110.015 -174.789 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 37.3 p -152.75 109.24 3.42 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 122.965 0.506 . . . . 0.0 110.75 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.879 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 39.9 tt0 -74.1 140.53 45.34 Favored 'General case' 0 N--CA 1.485 1.3 0 CA-C-N 118.227 0.467 . . . . 0.0 110.705 179.046 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 1.6 pp -134.59 -16.25 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 N-CA-C 112.993 0.738 . . . . 0.0 112.993 -174.699 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -165.31 -157.75 10.05 Favored Glycine 0 C--N 1.342 0.867 0 C-N-CA 121.498 -0.382 . . . . 0.0 112.529 179.239 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.521 ' HA ' ' H ' ' A' ' 86' ' ' ILE . . . -146.01 170.81 15.89 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 123.489 0.716 . . . . 0.0 110.367 176.813 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -161.9 156.18 27.65 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 -179.294 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 24.1 t -118.15 114.0 43.82 Favored 'Isoleucine or valine' 0 C--O 1.241 0.608 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -175.969 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.466 ' CD2' ' HB2' ' A' ' 107' ' ' PHE . 0.4 OUTLIER -105.2 121.78 44.56 Favored 'General case' 0 N--CA 1.478 0.943 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 174.049 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.698 ' HB2' HD11 ' A' ' 146' ' ' LEU . 4.6 mmmp? -146.6 150.46 35.53 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 174.451 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 66.13 -84.28 0.03 OUTLIER 'General case' 0 CA--C 1.548 0.866 0 O-C-N 124.929 1.393 . . . . 0.0 110.49 173.684 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -154.59 21.27 0.62 Allowed Glycine 0 C--N 1.337 0.61 0 N-CA-C 111.816 -0.514 . . . . 0.0 111.816 178.579 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 97.1 m -142.65 135.1 27.75 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 123.583 0.753 . . . . 0.0 110.499 -175.753 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' PHE . . . . . 0.676 ' HB3' ' HB3' ' A' ' 140' ' ' TYR . 36.2 t80 -109.31 104.98 14.19 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 124.554 1.142 . . . . 0.0 109.363 175.635 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 42.1 p-80 -100.46 126.69 46.9 Favored 'General case' 0 C--O 1.239 0.521 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 173.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 13.8 t -137.77 -162.0 1.24 Allowed 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.319 176.938 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 110' ' ' MET . . . . . 0.522 ' HA ' ' HA ' ' A' ' 137' ' ' LEU . 1.9 ttm -115.84 150.2 37.37 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.949 1.3 . . . . 0.0 109.817 -173.896 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 21.3 t90 -78.88 -42.76 26.51 Favored 'General case' 0 CA--C 1.553 1.077 0 C-N-CA 122.72 0.408 . . . . 0.0 110.777 -175.766 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 1.8 p-80 -71.47 3.47 3.82 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 113.807 1.04 . . . . 0.0 113.807 -175.393 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.7 m -53.95 -40.26 44.21 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.096 0 CA-C-N 118.273 0.488 . . . . 0.0 110.591 175.123 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 11.2 m -148.29 -83.61 0.11 Allowed 'General case' 0 CA--C 1.553 1.088 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 167.673 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 41.9 ttm180 -135.73 28.22 3.28 Favored 'General case' 0 N--CA 1.489 1.482 0 CA-C-O 121.696 0.76 . . . . 0.0 109.284 179.487 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.632 ' HA2' HD11 ' A' ' 138' ' ' ILE . . . 58.83 36.71 88.41 Favored Glycine 0 C--N 1.348 1.231 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 -166.963 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -79.02 175.31 10.7 Favored 'General case' 0 C--O 1.246 0.873 0 C-N-CA 124.161 0.985 . . . . 0.0 111.761 -169.428 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.6 m -72.83 142.36 15.21 Favored 'Isoleucine or valine' 0 C--O 1.244 0.782 0 CA-C-O 121.37 0.605 . . . . 0.0 109.784 -176.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.4 HD11 HD13 ' A' ' 86' ' ' ILE . 3.4 mm? -88.12 177.24 6.96 Favored 'General case' 0 CA--C 1.548 0.869 0 CA-C-N 114.676 -1.147 . . . . 0.0 110.099 171.357 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 120' ' ' MET . . . . . 0.467 ' HA ' ' O ' ' A' ' 124' ' ' LYS . 9.1 ptp -159.04 155.76 28.03 Favored 'General case' 0 C--O 1.253 1.274 0 C-N-CA 123.874 0.87 . . . . 0.0 110.399 178.544 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.436 ' CE1' ' HB2' ' A' ' 8' ' ' LEU . 0.1 OUTLIER -153.19 104.13 2.77 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 114.727 -1.124 . . . . 0.0 108.134 -179.238 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt 61.74 30.08 18.27 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 123.844 0.715 . . . . 0.0 110.024 -175.246 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 83.94 -5.06 81.02 Favored Glycine 0 C--N 1.347 1.142 0 CA-C-O 119.012 -0.882 . . . . 0.0 114.185 -177.45 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' LYS . . . . . 0.467 ' O ' ' HA ' ' A' ' 120' ' ' MET . 21.6 ttmm -69.21 114.21 7.27 Favored 'General case' 0 C--N 1.357 0.924 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 170.65 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 36.2 ttm-85 -80.21 95.36 6.26 Favored 'General case' 0 CA--C 1.538 0.499 0 O-C-N 123.895 0.747 . . . . 0.0 109.36 -171.799 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 74.6 mt -80.14 93.74 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 C-N-CA 123.918 0.887 . . . . 0.0 108.701 -177.093 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -94.02 128.95 39.2 Favored Pre-proline 0 CA--C 1.542 0.636 0 CA-C-O 118.768 -0.634 . . . . 0.0 109.556 -177.117 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_exo -51.09 142.78 33.93 Favored 'Trans proline' 0 C--N 1.384 2.42 0 C-N-CA 123.419 2.746 . . . . 0.0 114.516 -176.88 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 54.7 p -97.8 -10.69 24.36 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 123.558 0.743 . . . . 0.0 110.429 172.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.677 ' HB3' ' HB2' ' A' ' 139' ' ' SER . 35.9 t-105 -155.38 147.18 23.26 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.647 1.179 . . . . 0.0 107.869 176.007 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.401 ' HA ' ' HA ' ' A' ' 138' ' ' ILE . . . -154.79 119.97 4.98 Favored 'General case' 0 C--O 1.237 0.436 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 170.669 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -109.7 112.24 24.19 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 123.859 0.864 . . . . 0.0 108.684 176.77 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 18.2 t -77.43 -27.4 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 C-N-CA 122.512 0.325 . . . . 0.0 110.739 -176.368 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 52.5 tttp -67.31 -49.39 64.38 Favored 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.022 0.529 . . . . 0.0 111.996 -172.442 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -80.19 -23.0 41.29 Favored 'General case' 0 N--CA 1.485 1.284 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 169.028 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 18.8 t70 74.46 55.37 0.09 Allowed 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 125.367 1.467 . . . . 0.0 110.202 176.631 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 137' ' ' LEU . . . . . 0.522 ' HA ' ' HA ' ' A' ' 110' ' ' MET . 4.6 mp -133.8 174.89 9.97 Favored 'General case' 0 CA--C 1.541 0.604 0 CA-C-N 115.074 -0.966 . . . . 0.0 111.368 172.616 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.632 HD11 ' HA2' ' A' ' 116' ' ' GLY . 78.9 mt -139.9 150.94 21.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 125.318 1.447 . . . . 0.0 108.327 -176.549 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 139' ' ' SER . . . . . 0.677 ' HB2' ' HB3' ' A' ' 130' ' ' TRP . 19.6 m -134.44 141.64 46.86 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 123.585 0.754 . . . . 0.0 109.563 171.507 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.676 ' HB3' ' HB3' ' A' ' 107' ' ' PHE . 83.4 t80 -128.79 142.16 51.07 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 177.241 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 90.48 -5.86 82.43 Favored Glycine 0 CA--C 1.531 1.044 0 N-CA-C 112.28 -0.328 . . . . 0.0 112.28 -173.701 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 146.87 -139.37 7.92 Favored Glycine 0 C--N 1.342 0.904 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -178.5 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -90.15 165.25 31.47 Favored Glycine 0 C--N 1.344 1.006 0 N-CA-C 110.157 -1.177 . . . . 0.0 110.157 167.16 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 144' ' ' TRP . . . . . 0.549 ' HZ2' ' HA2' ' A' ' 209' ' ' GLY . 7.0 t90 -61.11 105.58 0.5 Allowed 'General case' 0 CA--C 1.548 0.893 0 CA-C-O 121.281 0.562 . . . . 0.0 110.601 174.772 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.88 156.28 48.07 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 115.352 -0.84 . . . . 0.0 109.386 176.022 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 146' ' ' LEU . . . . . 0.698 HD11 ' HB2' ' A' ' 103' ' ' LYS . 5.7 mt 169.24 -25.46 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.535 0 O-C-N 125.625 1.828 . . . . 0.0 109.015 -174.43 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 67.49 83.78 0.16 Allowed 'General case' 0 C--N 1.362 1.111 0 C-N-CA 125.185 1.394 . . . . 0.0 109.035 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -164.34 86.25 0.1 Allowed Glycine 0 C--N 1.337 0.599 0 CA-C-N 115.045 -0.979 . . . . 0.0 110.849 -170.292 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 28.1 tt0 -103.45 122.61 45.25 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 124.739 1.216 . . . . 0.0 109.327 177.317 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 150' ' ' TRP . . . . . . . . . . . . . 42.3 t90 -68.71 129.28 39.47 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 172.038 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 22.9 pttm -86.38 110.18 19.52 Favored 'General case' 0 CA--C 1.553 1.088 0 CA-C-O 121.408 0.623 . . . . 0.0 109.872 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -66.92 112.37 4.28 Favored 'General case' 0 N--CA 1.483 1.203 0 CA-C-O 121.609 0.718 . . . . 0.0 111.068 -178.036 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 153.81 -41.83 0.64 Allowed Glycine 0 N--CA 1.465 0.628 0 N-CA-C 110.191 -1.163 . . . . 0.0 110.191 -176.636 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 3.8 mp0 -88.55 -179.29 6.02 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 124.617 1.167 . . . . 0.0 109.907 175.907 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -73.23 142.34 47.28 Favored 'General case' 0 C--O 1.242 0.669 0 C-N-CA 122.976 0.51 . . . . 0.0 110.05 172.673 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 5.0 p -91.68 139.2 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 170.771 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 157' ' ' GLN . . . . . 0.434 HE22 ' HG2' ' A' ' 171' ' ' GLN . 5.8 mm100 -112.17 131.75 55.29 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 -176.963 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 53.7 t -126.21 124.08 65.05 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.642 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -177.698 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.46 ' HB2' ' HD2' ' A' ' 199' ' ' PRO . 51.1 mt -73.54 78.35 1.46 Allowed 'General case' 0 C--N 1.351 0.642 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 164.225 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -63.53 99.1 0.2 Allowed 'General case' 0 C--N 1.349 0.557 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -179.552 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 68.6 mt -72.16 95.95 1.73 Allowed 'General case' 0 C--O 1.24 0.563 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 179.719 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 162' ' ' GLU . . . . . 0.402 ' HB2' ' HB2' ' A' ' 165' ' ' LYS . 42.9 mt-10 -62.47 139.09 96.63 Favored Pre-proline 0 CA--C 1.556 1.204 0 CA-C-N 115.249 -0.887 . . . . 0.0 109.775 178.866 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_exo -54.48 111.55 0.75 Allowed 'Trans proline' 0 C--N 1.38 2.219 0 C-N-CA 123.16 2.573 . . . . 0.0 113.862 -173.485 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 63.49 19.17 62.09 Favored Glycine 0 C--N 1.355 1.622 0 O-C-N 123.572 0.545 . . . . 0.0 113.784 179.067 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 165' ' ' LYS . . . . . 0.402 ' HB2' ' HB2' ' A' ' 162' ' ' GLU . 56.7 mtpt -129.31 178.55 6.36 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 124.473 1.109 . . . . 0.0 110.348 -173.97 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -52.81 155.68 3.9 Favored Pre-proline 0 CA--C 1.559 1.291 0 CA-C-N 114.759 -1.109 . . . . 0.0 112.31 169.531 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -69.52 168.74 20.37 Favored 'Trans proline' 0 C--N 1.371 1.711 0 C-N-CA 122.235 1.957 . . . . 0.0 110.932 168.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 16.2 ttm180 -137.09 109.88 7.59 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 172.614 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 169' ' ' ALA . . . . . 0.698 ' HB3' ' H ' ' A' ' 19' ' ' GLN . . . -69.4 105.88 2.75 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 172.076 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 24.8 t -113.75 128.23 70.74 Favored 'Isoleucine or valine' 0 C--O 1.24 0.586 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 -178.185 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 171' ' ' GLN . . . . . 0.434 ' HG2' HE22 ' A' ' 157' ' ' GLN . 14.6 mt-30 -83.73 103.84 13.35 Favored 'General case' 0 C--O 1.237 0.42 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 168.488 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 11.9 p -106.4 124.25 49.3 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 178.397 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 173' ' ' LYS . . . . . 0.653 ' H ' ' HA3' ' A' ' 24' ' ' GLY . 50.1 mttm -78.78 132.86 63.32 Favored Pre-proline 0 CA--C 1.548 0.884 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 171.244 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -59.37 171.92 2.2 Favored 'Trans proline' 0 C--N 1.377 2.061 0 C-N-CA 123.38 2.72 . . . . 0.0 114.242 -172.855 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -164.67 -177.12 37.03 Favored Glycine 0 C--N 1.335 0.512 0 CA-C-N 114.786 -1.097 . . . . 0.0 111.011 -179.644 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.678 ' HB2' HD12 ' A' ' 28' ' ' ILE . 69.6 mt -131.82 159.52 38.28 Favored 'General case' 0 N--CA 1.485 1.319 0 CA-C-N 117.414 0.607 . . . . 0.0 110.07 -174.89 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 177' ' ' PHE . . . . . 0.739 ' HD2' HG21 ' A' ' 31' ' ' ILE . 0.2 OUTLIER -141.18 125.3 17.32 Favored 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 123.101 0.56 . . . . 0.0 110.839 176.047 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 178' ' ' LYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 183' ' ' THR . 10.3 ptpp? -95.02 123.08 38.3 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 123.375 0.67 . . . . 0.0 111.028 -173.189 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 52.3 p -95.4 -173.44 2.91 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.771 0.828 . . . . 0.0 109.391 169.739 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 30.3 p-10 -68.9 -22.75 64.15 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 123.003 0.521 . . . . 0.0 110.764 171.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -77.87 -51.28 10.7 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 123.99 0.916 . . . . 0.0 110.322 176.787 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 164.46 -177.63 40.03 Favored Glycine 0 C--N 1.342 0.897 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.587 -179.713 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 183' ' ' THR . . . . . 0.48 ' HA ' ' HA ' ' A' ' 178' ' ' LYS . 13.2 t -80.23 136.71 36.52 Favored 'General case' 0 CA--C 1.544 0.749 0 CA-C-O 121.317 0.58 . . . . 0.0 110.735 -177.798 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 184' ' ' ILE . . . . . 0.414 ' HB ' ' CE1' ' A' ' 177' ' ' PHE . 14.9 mt -119.01 161.27 18.21 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.866 0 C-N-CA 124.9 1.28 . . . . 0.0 107.546 -177.087 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -100.74 138.78 14.05 Favored Glycine 0 C--N 1.349 1.281 0 N-CA-C 112.319 -0.312 . . . . 0.0 112.319 -176.257 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.497 ' HB2' ' CE1' ' A' ' 177' ' ' PHE . . . -162.63 -169.95 2.25 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-O 122.029 0.919 . . . . 0.0 112.543 -169.616 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 187' ' ' VAL . . . . . . . . . . . . . 2.0 p -105.41 100.98 11.69 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.999 0 CA-C-N 113.76 -1.564 . . . . 0.0 107.317 156.513 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 65.8 p -98.38 111.44 23.78 Favored 'General case' 0 C--O 1.24 0.56 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 172.195 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 46.0 tp -146.22 138.41 25.15 Favored 'General case' 0 N--CA 1.485 1.306 0 CA-C-O 120.881 0.372 . . . . 0.0 111.811 -177.593 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 190' ' ' ASP . . . . . 0.471 ' HA ' ' HA ' ' A' ' 221' ' ' ALA . 32.7 t70 -81.92 103.23 11.42 Favored 'General case' 0 C--N 1.351 0.658 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 170.504 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 191' ' ' PHE . . . . . 0.54 ' HB3' ' HE1' ' A' ' 222' ' ' TYR . 68.2 t80 -177.23 166.71 2.36 Favored 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 124.71 1.204 . . . . 0.0 108.659 -173.655 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 33.7 p -64.94 117.04 35.05 Favored Pre-proline 0 CA--C 1.557 1.22 0 C-N-CA 123.639 0.776 . . . . 0.0 111.234 177.318 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -62.45 140.7 83.54 Favored 'Trans proline' 0 C--N 1.378 2.109 0 C-N-CA 123.078 2.519 . . . . 0.0 112.855 176.638 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -84.09 -176.24 51.09 Favored Glycine 0 C--N 1.344 0.977 0 N-CA-C 111.051 -0.819 . . . . 0.0 111.051 168.726 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 62.5 p -77.39 131.7 38.17 Favored 'General case' 0 CA--C 1.551 0.991 0 CA-C-N 117.149 0.474 . . . . 0.0 110.725 178.072 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -63.57 100.14 0.25 Allowed 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.561 0.744 . . . . 0.0 109.776 -176.833 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 140.05 -1.22 2.19 Favored Glycine 0 C--N 1.341 0.86 0 CA-C-N 114.519 -1.219 . . . . 0.0 112.148 -174.282 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 198' ' ' SER . . . . . 0.455 ' HB2' ' HD2' ' A' ' 211' ' ' TYR . 48.9 m -57.43 138.6 81.18 Favored Pre-proline 0 CA--C 1.558 1.277 0 C-N-CA 123.495 0.718 . . . . 0.0 111.512 173.889 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 199' ' ' PRO . . . . . 0.46 ' HD2' ' HB2' ' A' ' 159' ' ' LEU . 17.3 Cg_exo -67.05 132.81 29.04 Favored 'Trans proline' 0 C--N 1.38 2.203 0 C-N-CA 123.268 2.645 . . . . 0.0 113.492 -177.37 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 200' ' ' ILE . . . . . 0.449 HD13 HG23 ' A' ' 226' ' ' ILE . 16.6 mt -98.81 110.12 25.51 Favored 'Isoleucine or valine' 0 C--O 1.241 0.618 0 CA-C-O 121.982 0.896 . . . . 0.0 109.666 172.421 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 201' ' ' ILE . . . . . . . . . . . . . 47.0 mt -108.91 148.75 12.56 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.894 0 CA-C-N 114.644 -1.162 . . . . 0.0 108.082 177.769 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 202' ' ' ASP . . . . . 0.573 ' H ' ' HB ' ' A' ' 207' ' ' VAL . 18.1 t70 -89.51 160.21 16.85 Favored 'General case' 0 N--CA 1.48 1.075 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 172.215 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 83.1 tttt -63.37 -15.48 57.61 Favored 'General case' 0 CA--C 1.555 1.141 0 N-CA-C 113.479 0.918 . . . . 0.0 113.479 -170.487 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 7.9 mtpm? -76.42 -1.02 24.94 Favored 'General case' 0 N--CA 1.485 1.318 0 N-CA-C 112.502 0.556 . . . . 0.0 112.502 176.961 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 82.7 7.01 87.97 Favored Glycine 0 C--N 1.349 1.283 0 CA-C-O 120.913 0.174 . . . . 0.0 112.695 -178.734 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -117.2 164.09 15.31 Favored 'General case' 0 N--CA 1.475 0.793 0 C-N-CA 124.733 1.213 . . . . 0.0 108.714 174.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 207' ' ' VAL . . . . . 0.573 ' HB ' ' H ' ' A' ' 202' ' ' ASP . 57.4 t 90.77 160.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.254 0 C-N-CA 125.905 1.682 . . . . 0.0 108.562 -171.662 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 208' ' ' VAL . . . . . 0.585 HG21 ' HB3' ' A' ' 146' ' ' LEU . 1.8 m -174.34 13.8 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 C-N-CA 124.444 1.098 . . . . 0.0 109.666 -144.391 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.549 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . -64.87 -154.78 0.15 Allowed Glycine 0 C--N 1.354 1.549 0 C-N-CA 124.105 0.86 . . . . 0.0 115.013 -177.098 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 210' ' ' LEU . . . . . 0.474 HD13 HD23 ' A' ' 137' ' ' LEU . 6.0 tt -142.12 133.4 26.34 Favored 'General case' 0 C--O 1.242 0.691 0 O-C-N 122.048 -0.678 . . . . 0.0 110.588 -172.399 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 211' ' ' TYR . . . . . 0.455 ' HD2' ' HB2' ' A' ' 198' ' ' SER . 0.4 OUTLIER -102.49 108.56 19.91 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 124.844 1.258 . . . . 0.0 108.935 175.208 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 212' ' ' GLY . . . . . 0.519 ' O ' ' SD ' ' A' ' 110' ' ' MET . . . 171.22 70.05 0.04 OUTLIER Glycine 0 C--N 1.345 1.081 0 C-N-CA 120.65 -0.786 . . . . 0.0 114.719 156.061 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 213' ' ' ASN . . . . . 0.669 ' HB2' ' HB3' ' A' ' 225' ' ' ALA . 18.5 m120 -131.76 81.85 2.0 Allowed 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 172.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 160.57 -152.38 23.08 Favored Glycine 0 C--O 1.242 0.619 0 CA-C-N 113.965 -1.471 . . . . 0.0 111.341 -178.231 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 215' ' ' VAL . . . . . 0.841 HG11 ' HA ' ' A' ' 40' ' ' SER . 15.8 m -152.57 -173.94 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.213 0 C-N-CA 123.45 0.7 . . . . 0.0 111.235 -167.345 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 216' ' ' VAL . . . . . 0.489 ' HB ' ' HA2' ' A' ' 220' ' ' GLY . 17.0 m -85.15 113.0 22.9 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.771 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 164.706 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 217' ' ' THR . . . . . 0.689 HG21 ' HB3' ' A' ' 29' ' ' LEU . 23.5 m -102.81 158.99 15.88 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 123.944 0.898 . . . . 0.0 109.644 -174.806 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 2.5 tpm_? 69.89 -74.63 0.08 Allowed 'General case' 0 CA--C 1.552 1.023 0 C-N-CA 124.957 1.303 . . . . 0.0 110.095 -176.932 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 21.8 t -164.42 26.21 0.07 Allowed 'General case' 0 CA--C 1.551 1.007 0 C-N-CA 123.856 0.862 . . . . 0.0 110.148 175.83 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 220' ' ' GLY . . . . . 0.489 ' HA2' ' HB ' ' A' ' 216' ' ' VAL . . . 141.98 -6.88 2.35 Favored Glycine 0 N--CA 1.477 1.418 0 CA-C-O 119.884 -0.398 . . . . 0.0 113.72 -179.086 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 221' ' ' ALA . . . . . 0.471 ' HA ' ' HA ' ' A' ' 190' ' ' ASP . . . -70.76 97.83 1.44 Allowed 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.943 0.897 . . . . 0.0 110.044 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 222' ' ' TYR . . . . . 0.54 ' HE1' ' HB3' ' A' ' 191' ' ' PHE . 15.8 p90 -66.1 124.72 23.37 Favored 'General case' 0 CA--C 1.544 0.715 0 CA-C-O 121.534 0.683 . . . . 0.0 110.88 -171.08 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 223' ' ' VAL . . . . . 0.637 HG11 ' HB3' ' A' ' 177' ' ' PHE . 62.1 t -123.92 115.66 45.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 173.721 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 67.9 m -142.71 141.85 31.88 Favored 'General case' 0 N--CA 1.48 1.06 0 O-C-N 123.855 0.722 . . . . 0.0 110.312 176.062 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 225' ' ' ALA . . . . . 0.669 ' HB3' ' HB2' ' A' ' 213' ' ' ASN . . . -75.31 153.29 37.96 Favored 'General case' 0 C--O 1.244 0.782 0 C-N-CA 123.087 0.555 . . . . 0.0 112.238 -174.656 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 226' ' ' ILE . . . . . 0.449 HG23 HD13 ' A' ' 200' ' ' ILE . 88.9 mt -91.4 103.06 14.12 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.623 0 CA-C-N 114.758 -1.11 . . . . 0.0 109.748 -176.594 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -96.07 152.65 18.34 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 122.895 0.478 . . . . 0.0 109.952 178.36 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -148.19 168.55 22.17 Favored 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 124.515 1.126 . . . . 0.0 109.736 -172.118 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 229' ' ' THR . . . . . 0.425 HG22 ' NE1' ' A' ' 144' ' ' TRP . 59.0 p -66.88 110.61 3.38 Favored 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 123.006 0.522 . . . . 0.0 110.527 -176.232 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -116.97 -24.37 7.63 Favored 'General case' 0 N--CA 1.482 1.169 0 C-N-CA 123.418 0.687 . . . . 0.0 111.406 -172.34 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 23.3 mmtp -91.88 -141.02 0.19 Allowed 'General case' 0 CA--C 1.566 1.561 0 C-N-CA 122.974 0.51 . . . . 0.0 109.682 -172.409 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 70.0 p . . . . . 0 N--CA 1.479 0.998 0 C-N-CA 124.221 1.009 . . . . 0.0 108.873 -167.555 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.889 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -131.99 2.09 3.97 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 124.05 0.94 . . . . 0.0 109.742 -175.14 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -127.34 80.65 1.97 Allowed 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 114.526 -1.216 . . . . 0.0 108.14 -168.708 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 5.0 mp -127.05 101.97 6.77 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 -178.922 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.425 ' HA ' ' HB2' ' A' ' 120' ' ' MET . 10.7 mm-40 -78.65 146.59 33.97 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 123.244 0.618 . . . . 0.0 110.979 -172.403 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.555 HD21 HD13 ' A' ' 119' ' ' LEU . 30.4 mt -90.58 114.39 26.62 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-N 115.042 -0.981 . . . . 0.0 109.14 171.849 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.417 ' HB2' ' HD2' ' A' ' 87' ' ' LYS . 31.4 tt0 -103.52 120.28 40.54 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 124.503 1.121 . . . . 0.0 108.328 -176.455 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 26.3 ptt180 -59.76 132.69 54.74 Favored 'General case' 0 N--CA 1.475 0.817 0 C-N-CA 122.859 0.464 . . . . 0.0 110.893 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.447 ' HB2' ' HG3' ' A' ' 85' ' ' ARG . . . -121.27 -43.18 2.43 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 122.379 0.272 . . . . 0.0 111.362 -177.046 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . 178.37 -158.45 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 124.184 0.994 . . . . 0.0 110.041 -173.703 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -128.01 164.67 21.86 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 123.777 0.831 . . . . 0.0 108.85 168.503 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 53.9 t -75.45 102.36 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 N-CA-C 109.414 -0.588 . . . . 0.0 109.414 177.444 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 4.5 ptpp? -167.89 146.23 4.56 Favored 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 124.633 1.173 . . . . 0.0 108.557 174.294 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 28.8 t90 -78.99 110.7 14.48 Favored 'General case' 0 CA--C 1.547 0.844 0 O-C-N 123.533 0.52 . . . . 0.0 111.402 -172.505 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -73.68 145.43 45.26 Favored 'General case' 0 CA--C 1.544 0.737 0 CA-C-O 121.66 0.743 . . . . 0.0 111.506 172.427 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -68.01 -1.62 6.14 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 125.47 1.508 . . . . 0.0 112.967 -177.072 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 22.8 mm-40 -80.2 50.4 1.24 Allowed 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 123.766 0.826 . . . . 0.0 111.112 -178.306 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.428 ' HA ' ' O ' ' A' ' 169' ' ' ALA . . . -73.32 84.02 1.42 Allowed 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 124.615 1.166 . . . . 0.0 111.464 -174.67 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 38.8 mt-10 -103.57 123.12 46.35 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 124.031 0.932 . . . . 0.0 110.425 -175.895 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 9.6 tp -76.91 132.68 32.41 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.134 0 C-N-CA 122.47 0.308 . . . . 0.0 110.763 -177.904 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 95.7 p -148.68 -35.71 0.19 Allowed 'General case' 0 N--CA 1.484 1.275 0 N-CA-C 112.14 0.422 . . . . 0.0 112.14 175.567 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -53.39 98.1 0.03 OUTLIER Glycine 0 C--N 1.353 1.476 0 N-CA-C 113.917 0.327 . . . . 0.0 113.917 178.45 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 40.7 p -103.9 -68.72 0.83 Allowed 'General case' 0 CA--C 1.547 0.865 0 C-N-CA 124.014 0.926 . . . . 0.0 111.468 -172.762 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 20.0 m -72.98 126.08 90.7 Favored Pre-proline 0 N--CA 1.477 0.88 0 C-N-CA 123.598 0.759 . . . . 0.0 111.381 -171.12 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -70.85 -74.27 0.01 OUTLIER 'Trans proline' 0 C--N 1.366 1.467 0 C-N-CA 122.13 1.887 . . . . 0.0 111.59 167.825 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 51.0 mm -90.55 121.12 40.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.913 0 C-N-CA 123.26 0.624 . . . . 0.0 111.448 -167.89 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.409 HD22 HG22 ' A' ' 217' ' ' THR . 17.2 mt -143.37 133.48 24.34 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 123.737 0.815 . . . . 0.0 110.333 174.068 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 35.0 p -97.07 140.02 32.21 Favored 'General case' 0 N--CA 1.477 0.892 0 C-N-CA 123.851 0.86 . . . . 0.0 110.538 179.189 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 39.5 mt -131.53 160.58 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 124.265 1.026 . . . . 0.0 108.594 -178.96 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 66.7 p -96.03 114.33 26.03 Favored 'General case' 0 C--N 1.367 1.327 0 CA-C-N 118.889 0.768 . . . . 0.0 109.001 176.102 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 8.8 mm -55.93 125.89 12.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 C-N-CA 123.987 0.915 . . . . 0.0 109.934 175.712 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 5.8 m -117.42 135.53 53.82 Favored 'General case' 0 C--O 1.252 1.224 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.322 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 30.4 tt0 60.3 28.82 18.46 Favored 'General case' 0 CA--C 1.558 1.263 0 C-N-CA 124.725 1.21 . . . . 0.0 110.791 178.878 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 3.8 p30 46.5 30.05 1.02 Allowed 'General case' 0 N--CA 1.493 1.708 0 C-N-CA 125.631 1.572 . . . . 0.0 113.109 -174.584 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -145.13 -63.7 0.02 OUTLIER Glycine 0 C--N 1.353 1.515 0 CA-C-N 116.562 -0.29 . . . . 0.0 112.487 -177.67 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 38.8 t -105.85 125.97 51.62 Favored 'General case' 0 N--CA 1.486 1.361 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 -172.242 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 1.8 mpp? -88.8 136.95 32.74 Favored 'General case' 0 CA--C 1.546 0.823 0 O-C-N 121.875 -0.515 . . . . 0.0 111.472 -173.745 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.5 m -125.15 164.12 20.95 Favored 'General case' 0 N--CA 1.482 1.125 0 C-N-CA 124.622 1.169 . . . . 0.0 109.915 176.961 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.529 ' H ' HG21 ' A' ' 215' ' ' VAL . 7.5 tp -93.07 92.51 3.74 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.845 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 -177.937 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 42.5 mmtm 57.88 -74.78 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.336 0 C-N-CA 123.382 0.673 . . . . 0.0 109.831 -161.238 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 5.2 p30 -147.32 118.16 7.62 Favored 'General case' 0 CA--C 1.552 1.045 0 C-N-CA 124.608 1.163 . . . . 0.0 110.034 175.181 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -174.13 130.78 0.39 Allowed 'General case' 0 N--CA 1.492 1.629 0 C-N-CA 123.685 0.794 . . . . 0.0 109.176 171.275 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 CA--C 1.554 1.108 0 C-N-CA 123.42 0.688 . . . . 0.0 110.104 -178.275 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.684 ' HB2' ' HD2' ' A' ' 103' ' ' LYS . 8.2 p-10 . . . . . 0 CA--C 1.54 0.57 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 168.32 178.92 40.4 Favored Glycine 0 C--N 1.339 0.699 0 CA-C-N 115.973 -0.558 . . . . 0.0 112.42 177.268 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' ALA . . . . . 0.558 ' HB1' HD11 ' A' ' 161' ' ' LEU . . . -88.32 125.07 34.5 Favored 'General case' 0 CA--C 1.549 0.911 0 C-N-CA 123.947 0.899 . . . . 0.0 109.79 176.717 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 -122.12 148.46 44.87 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 123.596 0.758 . . . . 0.0 109.963 -177.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' ARG . . . . . 0.781 ' HG2' HG21 ' A' ' 195' ' ' THR . 37.3 mtm-85 -95.99 124.43 39.99 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 166.05 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.486 ' H ' ' HA ' ' A' ' 99' ' ' ALA . 27.8 mt -90.65 131.05 38.83 Favored 'Isoleucine or valine' 0 C--O 1.26 1.656 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.437 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 0.2 OUTLIER -124.67 140.83 52.58 Favored 'General case' 0 N--CA 1.45 -0.459 0 CA-C-N 114.504 -1.226 . . . . 0.0 108.684 -174.224 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -84.76 104.09 14.42 Favored 'General case' 0 C--N 1.344 0.331 0 N-CA-C 104.581 -2.377 . . . . 0.0 104.581 175.549 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 14.4 tmtt? -120.64 98.27 5.95 Favored 'General case' 0 CA--C 1.518 -0.288 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 -170.409 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -79.91 152.47 35.01 Favored Glycine 0 C--O 1.242 0.644 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 170.359 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 2.3 mp -78.46 70.26 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.13 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 174.969 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 58.7 tp 167.29 -41.4 0.0 OUTLIER 'General case' 0 CA--C 1.554 1.123 0 C-N-CA 126.388 1.875 . . . . 0.0 109.029 -167.04 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -148.22 161.02 28.53 Favored Glycine 0 C--N 1.365 2.174 0 N-CA-C 114.8 0.68 . . . . 0.0 114.8 -169.56 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 77.4 m-85 -132.12 129.33 39.73 Favored 'General case' 0 N--CA 1.481 1.095 0 C-N-CA 124.049 0.94 . . . . 0.0 110.427 -172.93 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 24.5 m -145.42 153.75 41.53 Favored 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 124.652 1.181 . . . . 0.0 108.254 175.173 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.437 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 1.5 pp0? -96.15 146.72 24.43 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-N 118.738 0.699 . . . . 0.0 109.242 168.509 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.46 HD11 HG22 ' A' ' 86' ' ' ILE . 1.6 pp -136.71 -10.03 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 177.443 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' GLY . . . . . 0.552 ' HA3' HG12 ' A' ' 113' ' ' VAL . . . 168.26 -147.06 11.01 Favored Glycine 0 C--N 1.348 1.241 0 C-N-CA 121.003 -0.618 . . . . 0.0 113.19 174.049 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.486 ' HA ' ' H ' ' A' ' 86' ' ' ILE . . . -154.33 153.76 32.2 Favored 'General case' 0 C--O 1.24 0.603 0 C-N-CA 123.663 0.785 . . . . 0.0 111.196 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -155.75 157.18 27.58 Favored Glycine 0 C--N 1.338 0.665 0 CA-C-N 114.937 -1.029 . . . . 0.0 111.209 178.748 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 53.1 t -120.82 120.69 63.16 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.778 0 C-N-CA 123.528 0.731 . . . . 0.0 111.517 -169.376 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.531 ' HB3' ' HA ' ' A' ' 81' ' ' ASP . 10.6 m-85 -74.36 135.81 42.47 Favored 'General case' 0 N--CA 1.482 1.163 0 N-CA-C 107.861 -1.163 . . . . 0.0 107.861 165.037 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.684 ' HD2' ' HB2' ' A' ' 81' ' ' ASP . 29.3 tptt -172.4 149.71 2.23 Favored 'General case' 0 N--CA 1.483 1.177 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 171.322 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 60.21 20.14 9.52 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 124.494 1.118 . . . . 0.0 112.048 -178.771 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 80.09 17.06 75.32 Favored Glycine 0 C--N 1.346 1.115 0 CA-C-N 116.036 -0.529 . . . . 0.0 114.377 -178.011 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 18.8 p -140.07 137.18 34.36 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.604 0.762 . . . . 0.0 109.716 -176.316 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' PHE . . . . . 0.602 ' HB3' ' HB2' ' A' ' 140' ' ' TYR . 42.2 t80 -89.87 103.43 16.09 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 120.937 0.399 . . . . 0.0 111.131 -175.084 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 108' ' ' HIS . . . . . 0.613 ' HB3' ' HE3' ' A' ' 144' ' ' TRP . 18.6 m170 -100.4 114.25 27.65 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 124.488 1.115 . . . . 0.0 110.563 -176.857 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 109' ' ' THR . . . . . 0.592 HG23 HG23 ' A' ' 138' ' ' ILE . 3.9 t -135.71 175.44 9.59 Favored 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 118.758 0.708 . . . . 0.0 112.158 -177.86 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 110' ' ' MET . . . . . 0.499 ' SD ' ' HB2' ' A' ' 210' ' ' LEU . 79.2 mmm -87.95 154.47 20.48 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 123.886 0.874 . . . . 0.0 109.014 172.807 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 111' ' ' TRP . . . . . 0.416 ' CE2' HG22 ' A' ' 133' ' ' VAL . 50.2 t90 -71.52 -45.74 61.58 Favored 'General case' 0 N--CA 1.486 1.338 0 CA-C-N 118.159 0.436 . . . . 0.0 111.504 -170.611 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 4.3 p-80 -51.52 -21.09 2.21 Favored 'General case' 0 N--CA 1.488 1.465 0 C-N-CA 124.769 1.228 . . . . 0.0 114.247 -173.146 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.552 HG12 ' HA3' ' A' ' 98' ' ' GLY . 16.6 m -59.85 -44.14 93.53 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 CA-C-O 121.43 0.633 . . . . 0.0 110.265 -178.603 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 9.0 t -113.76 168.51 9.72 Favored 'General case' 0 C--O 1.238 0.488 0 C-N-CA 123.905 0.882 . . . . 0.0 109.212 -179.45 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 92.9 mtt180 -95.95 33.43 1.7 Allowed 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 124.194 0.997 . . . . 0.0 109.132 178.146 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 68.81 38.85 85.82 Favored Glycine 0 C--N 1.362 1.983 0 CA-C-N 115.158 -0.928 . . . . 0.0 111.528 -174.193 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -127.83 -179.96 5.23 Favored 'General case' 0 C--O 1.244 0.763 0 C-N-CA 123.647 0.779 . . . . 0.0 110.955 -171.106 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.2 p -75.4 139.65 18.71 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.211 0 CA-C-N 114.716 -1.129 . . . . 0.0 111.963 -176.329 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.555 HD13 HD21 ' A' ' 8' ' ' LEU . 58.3 mt -97.9 -177.78 3.87 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 124.084 0.953 . . . . 0.0 110.77 177.812 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 120' ' ' MET . . . . . 0.425 ' HB2' ' HA ' ' A' ' 7' ' ' GLU . 23.2 mmt -133.49 147.9 51.67 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 125.308 1.443 . . . . 0.0 109.762 -176.557 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.777 ' HB2' HD11 ' A' ' 126' ' ' ILE . 34.9 t-80 -151.03 96.63 2.35 Favored 'General case' 0 CA--C 1.54 0.595 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 25.5 ttpp 57.69 29.77 17.83 Favored 'General case' 0 N--CA 1.496 1.826 0 C-N-CA 124.186 0.995 . . . . 0.0 111.117 -175.693 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 94.95 -3.53 67.3 Favored Glycine 0 C--N 1.345 1.043 0 CA-C-N 115.768 -0.651 . . . . 0.0 113.47 -179.628 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -94.92 122.45 37.57 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 122.92 0.488 . . . . 0.0 109.92 177.792 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 91.0 mtm-85 -69.39 146.01 52.41 Favored 'General case' 0 C--O 1.243 0.734 0 C-N-CA 123.774 0.83 . . . . 0.0 111.976 178.774 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.777 HD11 ' HB2' ' A' ' 121' ' ' HIS . 5.0 mt -127.19 112.41 28.51 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.801 0 C-N-CA 123.791 0.836 . . . . 0.0 109.225 -179.0 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -83.01 139.36 42.68 Favored Pre-proline 0 CA--C 1.554 1.104 0 C-N-CA 123.838 0.855 . . . . 0.0 110.025 179.007 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -75.61 148.7 33.34 Favored 'Trans proline' 0 C--N 1.379 2.181 0 C-N-CA 122.808 2.339 . . . . 0.0 112.482 179.462 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 32.5 p -109.23 -32.35 7.23 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 124.031 0.932 . . . . 0.0 110.707 177.709 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 4.5 t-105 -132.87 144.03 49.91 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 107.624 -1.251 . . . . 0.0 107.624 -176.698 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -160.53 123.53 3.37 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.205 0.602 . . . . 0.0 110.222 178.488 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 41.4 m-20 -123.32 105.23 9.67 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 124.345 1.058 . . . . 0.0 108.552 167.892 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.416 HG22 ' CE2' ' A' ' 111' ' ' TRP . 16.7 t -68.24 -33.39 60.36 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.884 0 C-N-CA 123.53 0.732 . . . . 0.0 109.313 175.164 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -72.01 -33.13 67.82 Favored 'General case' 0 CA--C 1.547 0.863 0 CA-C-N 114.347 -1.297 . . . . 0.0 111.926 -179.177 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -97.07 -7.47 32.7 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 122.946 0.498 . . . . 0.0 111.792 179.586 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 27.5 t70 60.85 47.52 7.69 Favored 'General case' 0 CA--C 1.548 0.873 0 CA-C-O 122.449 1.118 . . . . 0.0 110.604 -178.027 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 49.7 mt -135.1 147.9 49.66 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 123.833 0.853 . . . . 0.0 109.557 176.675 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.592 HG23 HG23 ' A' ' 109' ' ' THR . 18.4 tt -153.54 143.66 14.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 N-CA-C 107.313 -1.365 . . . . 0.0 107.313 173.441 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 139' ' ' SER . . . . . 0.479 ' HB3' ' HA2' ' A' ' 143' ' ' GLY . 44.1 t -150.68 152.89 34.63 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-O 121.876 0.846 . . . . 0.0 110.97 -175.378 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.602 ' HB2' ' HB3' ' A' ' 107' ' ' PHE . 8.7 m-85 -125.26 108.71 12.0 Favored 'General case' 0 CA--C 1.543 0.708 0 CA-C-N 113.524 -1.671 . . . . 0.0 107.499 -164.933 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 97.48 -4.33 61.9 Favored Glycine 0 C--N 1.348 1.243 0 CA-C-N 116.149 -0.478 . . . . 0.0 112.821 -173.339 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 171.14 -152.64 18.77 Favored Glycine 0 C--N 1.347 1.163 0 CA-C-O 118.744 -1.031 . . . . 0.0 111.295 -179.625 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.479 ' HA2' ' HB3' ' A' ' 139' ' ' SER . . . -119.6 170.2 13.99 Favored Glycine 0 C--N 1.357 1.743 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 173.338 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 144' ' ' TRP . . . . . 0.613 ' HE3' ' HB3' ' A' ' 108' ' ' HIS . 41.6 t-105 -60.23 108.88 0.86 Allowed 'General case' 0 N--CA 1.483 1.188 0 CA-C-O 121.671 0.748 . . . . 0.0 110.728 176.291 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 145' ' ' LYS . . . . . 0.676 ' HA ' HG23 ' A' ' 229' ' ' THR . 0.0 OUTLIER -145.54 135.1 23.26 Favored 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 114.903 -1.044 . . . . 0.0 108.824 171.007 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 146' ' ' LEU . . . . . 0.601 HD21 ' HB3' ' A' ' 103' ' ' LYS . 13.6 mt -144.69 10.29 1.38 Allowed 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 123.67 0.788 . . . . 0.0 110.586 168.607 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.442 ' H ' HG21 ' A' ' 229' ' ' THR . 14.3 tt0 75.37 -18.5 0.44 Allowed 'General case' 0 N--CA 1.498 1.942 0 C-N-CA 124.67 1.188 . . . . 0.0 111.431 177.071 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 148' ' ' GLY . . . . . 0.43 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -77.65 138.47 21.66 Favored Glycine 0 C--N 1.346 1.119 0 C-N-CA 123.4 0.524 . . . . 0.0 113.135 -169.478 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -130.1 142.03 50.64 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 124.306 1.042 . . . . 0.0 108.399 -178.565 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 150' ' ' TRP . . . . . . . . . . . . . 43.2 t90 -73.19 137.34 44.99 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 122.719 0.407 . . . . 0.0 110.759 172.357 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 54.3 tttm -92.85 133.57 35.94 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 123.776 0.83 . . . . 0.0 109.225 174.368 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -66.85 146.42 54.44 Favored 'General case' 0 N--CA 1.479 1.012 0 CA-C-O 121.118 0.485 . . . . 0.0 111.826 178.951 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 92.56 -12.89 68.72 Favored Glycine 0 C--N 1.348 1.237 0 CA-C-N 115.027 -0.988 . . . . 0.0 112.921 -177.571 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 29.7 mm-40 -94.07 131.83 39.18 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 123.045 0.538 . . . . 0.0 111.696 -173.836 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -76.06 123.78 26.34 Favored 'General case' 0 C--O 1.245 0.863 0 N-CA-C 107.008 -1.478 . . . . 0.0 107.008 162.489 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -91.13 158.76 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 -168.544 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 157' ' ' GLN . . . . . 0.412 ' OE1' ' HG2' ' A' ' 171' ' ' GLN . 13.9 mm100 -100.58 133.61 44.77 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 123.32 0.648 . . . . 0.0 109.297 179.561 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 46.2 t -107.84 102.35 13.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 107.164 -1.421 . . . . 0.0 107.164 177.516 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.557 HD23 ' HB2' ' A' ' 169' ' ' ALA . 1.8 tm? -74.93 78.42 2.16 Favored 'General case' 0 CA--C 1.546 0.796 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 -175.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -72.05 110.18 6.36 Favored 'General case' 0 C--O 1.242 0.699 0 CA-C-N 114.129 -1.396 . . . . 0.0 111.004 -168.359 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 161' ' ' LEU . . . . . 0.558 HD11 ' HB1' ' A' ' 83' ' ' ALA . 29.9 mt -81.55 83.89 6.89 Favored 'General case' 0 C--O 1.24 0.599 0 CA-C-N 115.099 -0.955 . . . . 0.0 109.182 177.371 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 29.7 mm-40 -68.74 126.92 93.2 Favored Pre-proline 0 CA--C 1.552 1.031 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 174.837 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -61.77 115.76 3.01 Favored 'Trans proline' 0 C--N 1.384 2.4 0 C-N-CA 123.231 2.621 . . . . 0.0 112.503 -174.935 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 81.61 10.99 83.62 Favored Glycine 0 C--N 1.351 1.388 0 CA-C-N 115.485 -0.78 . . . . 0.0 113.467 -179.36 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 49.5 mttp -128.54 172.45 11.16 Favored 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 123.395 0.678 . . . . 0.0 110.9 -178.41 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 25.5 p30 -74.03 156.59 87.74 Favored Pre-proline 0 CA--C 1.555 1.159 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.989 173.826 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 15.8 Cg_exo -68.79 137.38 38.25 Favored 'Trans proline' 0 C--N 1.375 1.937 0 C-N-CA 122.581 2.187 . . . . 0.0 112.568 178.179 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 69.5 mtp180 -117.06 105.75 12.63 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 176.396 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 169' ' ' ALA . . . . . 0.557 ' HB2' HD23 ' A' ' 159' ' ' LEU . . . -86.04 103.3 14.6 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-O 121.034 0.445 . . . . 0.0 110.559 -176.797 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 42.8 t -94.63 129.71 44.46 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.718 0 C-N-CA 124.288 1.035 . . . . 0.0 111.269 -164.626 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 171' ' ' GLN . . . . . 0.412 ' HG2' ' OE1' ' A' ' 157' ' ' GLN . 20.6 mt-30 -79.3 121.37 25.01 Favored 'General case' 0 C--N 1.354 0.767 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 178.627 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 41.9 p -140.34 124.76 17.84 Favored 'General case' 0 C--O 1.237 0.436 0 C-N-CA 122.92 0.488 . . . . 0.0 109.753 -173.064 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 62.2 tttp -70.17 127.58 92.16 Favored Pre-proline 0 CA--C 1.547 0.862 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 171.487 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_exo -57.91 126.4 21.57 Favored 'Trans proline' 0 C--N 1.379 2.175 0 C-N-CA 122.686 2.257 . . . . 0.0 112.767 -179.574 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 175' ' ' GLY . . . . . 0.431 ' H ' ' HA ' ' A' ' 187' ' ' VAL . . . -98.34 178.44 31.6 Favored Glycine 0 C--N 1.337 0.638 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.391 176.488 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 5.3 mp -141.3 146.3 36.58 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 123.501 0.72 . . . . 0.0 109.267 176.351 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 177' ' ' PHE . . . . . 0.7 ' HE1' HG12 ' A' ' 223' ' ' VAL . 22.3 m-85 -93.47 121.63 35.07 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 176.551 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 57.1 tptt -86.29 95.87 9.77 Favored 'General case' 0 CA--C 1.541 0.596 0 O-C-N 123.783 0.677 . . . . 0.0 109.201 177.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 179' ' ' THR . . . . . 0.524 HG22 ' H ' ' A' ' 181' ' ' ALA . 23.0 m -110.47 150.6 28.63 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 176.383 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 24.7 p30 -61.75 -24.35 66.76 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 123.578 0.751 . . . . 0.0 111.914 175.871 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 181' ' ' ALA . . . . . 0.524 ' H ' HG22 ' A' ' 179' ' ' THR . . . -74.18 -39.91 62.87 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.274 1.03 . . . . 0.0 111.388 174.579 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 169.25 -174.16 43.67 Favored Glycine 0 C--N 1.341 0.841 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.569 -177.581 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 13.2 t -97.78 134.55 40.78 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 175.2 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 184' ' ' ILE . . . . . 0.556 ' HB ' ' HB2' ' A' ' 177' ' ' PHE . 23.6 mt -104.65 160.02 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 177.905 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -99.09 124.23 8.16 Favored Glycine 0 C--N 1.349 1.279 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 179.808 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.428 ' HA ' ' HA ' ' A' ' 225' ' ' ALA . . . -147.98 -165.56 2.3 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-O 121.22 0.533 . . . . 0.0 112.395 -161.753 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 187' ' ' VAL . . . . . 0.431 ' HA ' ' H ' ' A' ' 175' ' ' GLY . 4.7 p -158.39 131.12 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.728 0 C-N-CA 124.615 1.166 . . . . 0.0 108.9 175.671 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 7.1 m -111.42 103.5 11.87 Favored 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 123.118 0.567 . . . . 0.0 110.168 176.557 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 4.3 pp -125.67 141.63 51.92 Favored 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 123.37 0.668 . . . . 0.0 109.224 179.586 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -113.53 104.49 12.31 Favored 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 168.102 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 191' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -163.07 -178.3 5.96 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 124.143 0.977 . . . . 0.0 108.725 -170.71 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 31.4 m -52.11 122.34 23.21 Favored Pre-proline 0 CA--C 1.549 0.939 0 CA-C-O 118.542 -0.742 . . . . 0.0 109.86 170.406 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -61.57 91.31 0.11 Allowed 'Trans proline' 0 C--N 1.378 2.129 0 C-N-CA 122.695 2.263 . . . . 0.0 112.155 -173.905 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -60.02 123.28 32.62 Favored Glycine 0 C--N 1.348 1.219 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 172.43 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 195' ' ' THR . . . . . 0.781 HG21 ' HG2' ' A' ' 85' ' ' ARG . 8.8 t -54.22 144.37 20.24 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-O 121.663 0.744 . . . . 0.0 112.035 -173.207 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 196' ' ' SER . . . . . 0.468 ' HA ' ' HD2' ' A' ' 211' ' ' TYR . 13.4 m -72.28 95.56 1.72 Allowed 'General case' 0 C--O 1.242 0.688 0 CA-C-N 115.077 -0.965 . . . . 0.0 111.406 -169.872 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 197' ' ' GLY . . . . . 0.496 ' H ' ' HB3' ' A' ' 211' ' ' TYR . . . 133.63 4.94 2.99 Favored Glycine 0 C--N 1.34 0.753 0 CA-C-N 115.279 -0.873 . . . . 0.0 111.663 -176.684 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 72.0 m -56.32 131.81 75.86 Favored Pre-proline 0 C--N 1.361 1.101 0 C-N-CA 123.143 0.577 . . . . 0.0 110.229 171.089 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -64.23 111.67 1.67 Allowed 'Trans proline' 0 C--N 1.372 1.777 0 C-N-CA 122.209 1.939 . . . . 0.0 111.635 -176.899 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 55.3 mt -77.93 111.69 15.04 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.414 0 N-CA-C 107.964 -1.125 . . . . 0.0 107.964 174.32 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 201' ' ' ILE . . . . . 0.424 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 63.5 mt -112.28 148.51 15.33 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.61 0 C-N-CA 124.741 1.216 . . . . 0.0 108.739 -174.545 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -71.55 160.49 32.61 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 123.802 0.841 . . . . 0.0 108.871 171.823 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 3.7 ttmp? -70.17 -13.18 62.07 Favored 'General case' 0 N--CA 1.483 1.195 0 C-N-CA 123.343 0.657 . . . . 0.0 111.358 -178.841 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 27.1 mtpp -89.23 15.11 9.46 Favored 'General case' 0 CA--C 1.552 1.052 0 C-N-CA 123.9 0.88 . . . . 0.0 111.788 175.499 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 70.53 22.9 77.94 Favored Glycine 0 C--N 1.356 1.642 0 O-C-N 123.102 0.251 . . . . 0.0 113.316 176.762 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 206' ' ' LYS . . . . . 0.405 ' HE2' ' HB3' ' A' ' 206' ' ' LYS . 22.1 ttpt -112.62 112.84 24.65 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 124.715 1.206 . . . . 0.0 108.261 -176.585 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 207' ' ' VAL . . . . . 0.43 ' O ' ' HA3' ' A' ' 148' ' ' GLY . 7.4 p -56.61 141.64 13.19 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 CA-C-N 118.953 0.797 . . . . 0.0 110.714 179.057 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 6.0 m -119.02 -33.9 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 C-N-CA 122.606 0.363 . . . . 0.0 110.363 178.868 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 209' ' ' GLY . . . . . . . . . . . . . . . -175.82 -167.13 34.33 Favored Glycine 0 C--N 1.349 1.304 0 O-C-N 123.197 0.311 . . . . 0.0 113.819 -174.96 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 210' ' ' LEU . . . . . 0.499 ' HB2' ' SD ' ' A' ' 110' ' ' MET . 87.3 mt -117.29 156.2 28.2 Favored 'General case' 0 C--O 1.255 1.356 0 C-N-CA 124.196 0.998 . . . . 0.0 109.916 175.107 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 211' ' ' TYR . . . . . 0.496 ' HB3' ' H ' ' A' ' 197' ' ' GLY . 37.8 t80 -73.33 116.09 13.47 Favored 'General case' 0 C--N 1.35 0.63 0 CA-C-N 114.644 -1.162 . . . . 0.0 109.251 178.561 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -73.99 -142.74 0.7 Allowed Glycine 0 C--N 1.339 0.731 0 O-C-N 124.051 0.844 . . . . 0.0 114.272 -174.291 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 213' ' ' ASN . . . . . . . . . . . . . 3.9 p30 -127.96 159.23 35.62 Favored 'General case' 0 C--O 1.239 0.503 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 -177.27 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 173.62 -136.03 3.47 Favored Glycine 0 N--CA 1.438 -1.227 0 N-CA-C 109.646 -1.381 . . . . 0.0 109.646 178.351 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 215' ' ' VAL . . . . . 0.529 HG21 ' H ' ' A' ' 41' ' ' ILE . 11.3 p -170.0 170.75 0.16 Allowed 'Isoleucine or valine' 0 C--O 1.242 0.683 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 -172.163 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 216' ' ' VAL . . . . . 0.478 ' HA ' ' O ' ' A' ' 221' ' ' ALA . 35.7 m -70.28 112.6 5.25 Favored 'Isoleucine or valine' 0 CA--C 1.557 1.221 0 CA-C-O 121.882 0.848 . . . . 0.0 108.908 168.548 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 217' ' ' THR . . . . . 0.409 HG22 HD22 ' A' ' 29' ' ' LEU . 8.3 m -119.69 171.84 8.1 Favored 'General case' 0 C--O 1.254 1.323 0 C-N-CA 124.661 1.184 . . . . 0.0 108.393 -174.747 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 22.2 ttt180 73.46 -74.68 0.08 Allowed 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 124.636 1.174 . . . . 0.0 110.327 -179.205 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 35.8 p -148.06 -0.47 0.6 Allowed 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 123.651 0.78 . . . . 0.0 111.297 -178.298 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 220' ' ' GLY . . . . . 0.429 ' HA2' ' HB ' ' A' ' 216' ' ' VAL . . . 134.27 12.55 1.42 Allowed Glycine 0 C--N 1.351 1.386 0 CA-C-O 120.0 -0.334 . . . . 0.0 113.048 -174.586 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 221' ' ' ALA . . . . . 0.492 ' O ' HG23 ' A' ' 223' ' ' VAL . . . -78.61 139.99 38.5 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 123.023 0.529 . . . . 0.0 109.597 178.449 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 222' ' ' TYR . . . . . . . . . . . . . 37.8 m-85 -78.81 99.21 6.61 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 123.614 0.766 . . . . 0.0 109.532 -176.093 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 223' ' ' VAL . . . . . 0.7 HG12 ' HE1' ' A' ' 177' ' ' PHE . 39.1 t -118.91 111.31 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 123.142 0.577 . . . . 0.0 110.148 -169.167 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 16.5 m -137.54 159.57 41.58 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.242 1.017 . . . . 0.0 110.554 -171.854 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 225' ' ' ALA . . . . . 0.428 ' HA ' ' HA ' ' A' ' 186' ' ' ALA . . . -70.93 171.92 9.89 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 123.921 0.888 . . . . 0.0 112.309 -179.009 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 226' ' ' ILE . . . . . . . . . . . . . 39.3 mt -127.22 124.47 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.183 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 173.298 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -114.18 109.67 18.77 Favored 'General case' 0 N--CA 1.487 1.402 0 CA-C-N 118.019 0.372 . . . . 0.0 110.525 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 -92.89 168.97 10.81 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 123.673 0.789 . . . . 0.0 111.37 -176.477 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 229' ' ' THR . . . . . 0.676 HG23 ' HA ' ' A' ' 145' ' ' LYS . 97.4 m -64.41 108.37 1.61 Allowed 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.602 0.761 . . . . 0.0 111.089 -174.736 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 16.2 mm-40 -156.34 12.98 0.29 Allowed 'General case' 0 N--CA 1.484 1.245 0 C-N-CA 123.645 0.778 . . . . 0.0 112.173 -176.695 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 231' ' ' LYS . . . . . 0.538 ' HE2' ' HA ' ' A' ' 231' ' ' LYS . 11.1 mmpt? -96.52 -92.33 0.22 Allowed 'General case' 0 N--CA 1.486 1.334 0 CA-C-N 119.103 0.865 . . . . 0.0 111.955 -174.897 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 66.8 p . . . . . 0 C--N 1.353 0.754 0 CA-C-N 118.735 0.698 . . . . 0.0 112.255 -169.362 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.173 0 CA-C-O 120.997 0.427 . . . . 0.0 111.054 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -163.48 20.74 0.08 Allowed 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 123.901 0.88 . . . . 0.0 109.406 -171.778 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 21.1 p-10 -142.84 58.83 1.43 Allowed 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 114.426 -1.261 . . . . 0.0 108.938 -162.866 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.466 ' HG ' ' HG2' ' A' ' 88' ' ' GLN . 2.9 mp -134.32 117.73 16.72 Favored 'General case' 0 C--O 1.207 -1.149 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 173.143 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.493 ' HB3' ' HE3' ' A' ' 87' ' ' LYS . 37.4 tt0 -114.48 156.26 24.89 Favored 'General case' 0 N--CA 1.495 1.789 0 CA-C-N 119.745 1.157 . . . . 0.0 112.202 -175.645 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 81.6 mt -95.77 143.07 27.32 Favored 'General case' 0 N--CA 1.481 1.121 0 C-N-CA 124.161 0.984 . . . . 0.0 113.011 178.446 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 -131.34 116.3 17.39 Favored 'General case' 0 N--CA 1.483 1.18 0 C-N-CA 124.283 1.033 . . . . 0.0 108.637 172.349 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.508 ' HA ' ' HA ' ' A' ' 84' ' ' TYR . 36.7 ptt85 -62.33 110.66 1.71 Allowed 'General case' 0 N--CA 1.487 1.407 0 CA-C-N 119.503 1.047 . . . . 0.0 110.17 173.671 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.49 ' HB3' HD13 ' A' ' 161' ' ' LEU . . . -91.5 -28.3 17.69 Favored 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 123.552 0.741 . . . . 0.0 110.457 -177.748 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -160.22 175.05 13.34 Favored 'General case' 0 C--O 1.239 0.504 0 C-N-CA 123.808 0.843 . . . . 0.0 110.613 -179.366 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -102.66 170.1 8.23 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 124.044 0.938 . . . . 0.0 109.947 175.883 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.645 HG23 ' HA2' ' A' ' 82' ' ' GLY . 82.0 t -72.22 101.54 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.626 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 167.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 31.0 ttmt -169.08 140.79 2.49 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -169.589 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 28.6 t90 -102.45 122.3 44.05 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 122.745 0.418 . . . . 0.0 110.064 179.313 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -81.33 146.18 30.5 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 124.08 0.952 . . . . 0.0 110.889 171.713 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -73.95 0.89 12.09 Favored 'General case' 0 N--CA 1.483 1.182 0 C-N-CA 124.325 1.05 . . . . 0.0 112.607 176.758 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 72.2 mt-30 -75.96 14.95 0.6 Allowed 'General case' 0 CA--C 1.555 1.143 0 C-N-CA 124.325 1.05 . . . . 0.0 112.966 -176.169 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.525 ' HB1' ' HB2' ' A' ' 171' ' ' GLN . . . -52.99 90.64 0.01 OUTLIER 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 124.367 1.067 . . . . 0.0 113.255 -168.594 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -62.56 131.94 50.75 Favored 'General case' 0 C--N 1.353 0.745 0 C-N-CA 124.46 1.104 . . . . 0.0 110.64 -178.876 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 3.0 mp -75.37 111.0 11.11 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 -173.975 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 19.1 m -142.13 179.35 6.95 Favored 'General case' 0 C--O 1.246 0.885 0 C-N-CA 124.663 1.185 . . . . 0.0 109.208 -175.836 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.474 ' HA3' ' H ' ' A' ' 173' ' ' LYS . . . 88.27 84.75 1.23 Allowed Glycine 0 C--N 1.341 0.823 0 N-CA-C 111.306 -0.717 . . . . 0.0 111.306 -176.821 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 50.4 m -150.3 -28.13 0.23 Allowed 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.14 0.576 . . . . 0.0 111.555 -177.471 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 9.3 p -66.14 126.55 92.15 Favored Pre-proline 0 CA--C 1.553 1.086 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 177.612 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -75.82 -165.3 0.29 Allowed 'Trans proline' 0 C--N 1.377 2.061 0 C-N-CA 123.214 2.609 . . . . 0.0 113.452 -172.587 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 36.3 mm -63.17 111.82 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.953 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 177.833 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.635 HD21 ' HB2' ' A' ' 218' ' ' ARG . 0.3 OUTLIER -109.59 160.33 16.35 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.218 -172.249 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.427 ' H ' HD23 ' A' ' 29' ' ' LEU . 65.6 m -94.54 149.12 21.56 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 123.119 0.568 . . . . 0.0 110.05 171.608 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 17.6 tt -139.31 160.55 28.58 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.593 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 27.7 m -93.9 105.91 17.91 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 108.693 -0.855 . . . . 0.0 108.693 178.945 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 10.8 tp -73.71 148.55 8.49 Favored 'Isoleucine or valine' 0 C--O 1.246 0.903 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 169.803 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.561 ' HB2' ' HB2' ' A' ' 38' ' ' SER . 50.4 m -138.48 138.7 38.34 Favored 'General case' 0 C--O 1.242 0.695 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 178.302 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -60.41 156.47 15.92 Favored 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 123.499 0.72 . . . . 0.0 111.105 -174.61 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.8 t70 77.85 21.35 0.94 Allowed 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 125.317 1.447 . . . . 0.0 110.727 -179.01 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 78.7 38.49 23.87 Favored Glycine 0 C--N 1.35 1.317 0 CA-C-N 115.556 -0.747 . . . . 0.0 113.755 174.021 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' SER . . . . . 0.561 ' HB2' ' HB2' ' A' ' 34' ' ' SER . 28.4 m -107.33 150.36 26.78 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 122.937 0.495 . . . . 0.0 109.793 175.589 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 5.4 ptm -160.65 123.8 3.37 Favored 'General case' 0 N--CA 1.481 1.107 0 CA-C-O 120.901 0.382 . . . . 0.0 111.723 -175.041 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.509 ' HA ' HG11 ' A' ' 215' ' ' VAL . 15.7 p -177.42 -176.17 0.6 Allowed 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 124.549 1.139 . . . . 0.0 109.434 -178.525 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 1.4 mp -92.13 131.09 40.16 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 N-CA-C 105.796 -1.928 . . . . 0.0 105.796 156.283 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 49.3 pttt -52.98 89.76 0.01 OUTLIER 'General case' 0 CA--C 1.551 0.986 0 C-N-CA 124.531 1.132 . . . . 0.0 112.048 -177.785 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 64.0 m-20 -158.13 149.82 21.53 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.462 1.505 . . . . 0.0 108.329 -177.251 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -68.69 108.62 3.46 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 123.328 0.651 . . . . 0.0 110.234 -179.605 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 . . . . . 0 CA--C 1.537 0.457 0 C-N-CA 122.978 0.511 . . . . 0.0 109.954 176.566 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.413 ' HB2' ' O ' ' A' ' 102' ' ' TYR . 0.5 OUTLIER . . . . . 0 N--CA 1.47 0.562 0 CA-C-O 121.265 0.555 . . . . 0.0 112.478 . . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.645 ' HA2' HG23 ' A' ' 14' ' ' VAL . . . 128.84 -157.9 21.7 Favored Glycine 0 C--O 1.248 1.031 0 CA-C-N 115.364 -0.834 . . . . 0.0 111.384 -177.948 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' ALA . . . . . 0.667 ' HB1' HD11 ' A' ' 161' ' ' LEU . . . -90.35 107.06 18.91 Favored 'General case' 0 CA--C 1.54 0.57 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -179.228 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' TYR . . . . . 0.508 ' HA ' ' HA ' ' A' ' 10' ' ' ARG . 7.4 m-85 -92.51 176.23 6.54 Favored 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 123.18 0.592 . . . . 0.0 109.405 177.455 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' ARG . . . . . 0.626 ' HA ' ' HA ' ' A' ' 99' ' ' ALA . 53.8 ttp180 -138.36 121.82 17.22 Favored 'General case' 0 C--O 1.239 0.54 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 -174.979 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 41.7 mt -90.67 116.04 31.16 Favored 'Isoleucine or valine' 0 C--O 1.25 1.116 0 CA-C-O 121.607 0.718 . . . . 0.0 110.134 -172.257 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.609 ' HE3' ' HD2' ' A' ' 89' ' ' LYS . 48.3 pttt -105.35 142.13 35.65 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 168.564 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' GLN . . . . . 0.612 ' HB2' HD13 ' A' ' 97' ' ' ILE . 18.0 tm0? -84.44 106.48 16.06 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 104.534 -2.395 . . . . 0.0 104.534 165.784 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' LYS . . . . . 0.609 ' HD2' ' HE3' ' A' ' 87' ' ' LYS . 78.6 tttt -119.41 104.09 10.04 Favored 'General case' 0 C--O 1.241 0.613 0 C-N-CA 123.666 0.786 . . . . 0.0 110.36 -167.203 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -72.32 155.31 51.36 Favored Glycine 0 C--O 1.243 0.701 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 167.474 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 22.2 mm -79.41 62.15 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.563 1.442 0 CA-C-N 118.174 0.987 . . . . 0.0 109.067 -176.102 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 1.6 tm? 170.16 -40.1 0.0 OUTLIER 'General case' 0 CA--C 1.556 1.204 0 C-N-CA 126.347 1.859 . . . . 0.0 107.556 -168.848 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -137.96 151.66 21.45 Favored Glycine 0 C--N 1.369 2.379 0 N-CA-C 114.926 0.731 . . . . 0.0 114.926 -166.576 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -111.89 142.81 43.81 Favored 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 125.037 1.335 . . . . 0.0 110.738 -179.167 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 49.5 m -150.52 96.67 2.41 Favored 'General case' 0 N--CA 1.477 0.915 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 168.641 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.51 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 29.6 tt0 -62.48 140.25 58.6 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 123.237 0.615 . . . . 0.0 111.243 -178.605 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.612 HD13 ' HB2' ' A' ' 88' ' ' GLN . 8.5 pt -132.76 -24.68 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 N-CA-C 112.604 0.594 . . . . 0.0 112.604 -173.765 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 178.85 -149.4 8.86 Favored Glycine 0 C--N 1.345 1.074 0 C-N-CA 120.847 -0.692 . . . . 0.0 113.031 179.484 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.626 ' HA ' ' HA ' ' A' ' 85' ' ' ARG . . . -143.59 178.11 8.01 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 124.44 1.096 . . . . 0.0 109.805 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -176.89 140.84 5.13 Favored Glycine 0 C--N 1.34 0.796 0 CA-C-O 119.826 -0.43 . . . . 0.0 112.123 174.042 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.599 ' HB ' ' HG3' ' A' ' 199' ' ' PRO . 3.3 p -89.36 127.14 42.22 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.942 0 CA-C-N 117.422 0.611 . . . . 0.0 111.001 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' TYR . . . . . 0.443 ' HD2' ' HB2' ' A' ' 107' ' ' PHE . 29.4 t80 -98.05 136.77 37.83 Favored 'General case' 0 N--CA 1.477 0.881 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 169.562 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.435 ' HD2' HG21 ' A' ' 14' ' ' VAL . 35.2 tttp -169.02 154.23 6.01 Favored 'General case' 0 N--CA 1.47 0.57 0 O-C-N 123.69 0.618 . . . . 0.0 110.071 171.927 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 11.8 tp10 72.86 17.28 4.35 Favored 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 124.684 1.194 . . . . 0.0 110.752 171.301 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 80.51 18.01 72.02 Favored Glycine 0 C--N 1.345 1.033 0 CA-C-N 115.925 -0.58 . . . . 0.0 113.303 -176.159 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' THR . . . . . 0.468 HG23 ' HD2' ' A' ' 108' ' ' HIS . 2.7 t -139.54 134.8 32.69 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 123.013 0.525 . . . . 0.0 110.584 176.662 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 107' ' ' PHE . . . . . 0.556 ' HB3' ' HB2' ' A' ' 140' ' ' TYR . 38.3 t80 -88.55 118.81 28.47 Favored 'General case' 0 C--N 1.349 0.579 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 174.716 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 108' ' ' HIS . . . . . 0.468 ' HD2' HG23 ' A' ' 106' ' ' THR . 4.1 p80 -133.45 114.1 13.27 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 123.051 0.54 . . . . 0.0 109.969 -175.267 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 11.5 t -136.17 -172.89 3.24 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 124.187 0.995 . . . . 0.0 110.359 -176.081 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' MET . . . . . 0.414 ' SD ' ' HE1' ' A' ' 112' ' ' HIS . 1.0 OUTLIER -67.14 152.57 45.51 Favored 'General case' 0 N--CA 1.479 1.02 0 C-N-CA 124.189 0.996 . . . . 0.0 110.702 171.542 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 84.1 t90 -74.0 -47.65 35.71 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 122.848 0.459 . . . . 0.0 110.654 -178.791 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 112' ' ' HIS . . . . . 0.414 ' HE1' ' SD ' ' A' ' 110' ' ' MET . 22.1 p-80 -59.78 -15.46 20.57 Favored 'General case' 0 N--CA 1.489 1.506 0 C-N-CA 124.38 1.072 . . . . 0.0 113.755 -170.035 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.5 ' O ' HD12 ' A' ' 97' ' ' ILE . 23.2 m -57.62 -27.53 29.84 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 C-N-CA 123.185 0.594 . . . . 0.0 111.032 178.695 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 10.8 t -135.5 165.22 26.03 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.163 0.985 . . . . 0.0 109.263 177.922 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 14.7 tpp180 -92.74 16.03 13.21 Favored 'General case' 0 N--CA 1.484 1.252 0 CA-C-O 121.642 0.734 . . . . 0.0 109.887 176.048 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 98.72 42.23 2.94 Favored Glycine 0 C--N 1.347 1.153 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 -177.169 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -106.79 167.56 9.79 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 123.608 0.763 . . . . 0.0 110.621 -179.646 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.43 HG23 ' HA ' ' A' ' 127' ' ' GLU . 7.3 p -84.93 137.73 20.33 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.006 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.408 178.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 1.8 mm? -84.37 -177.97 6.78 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 124.429 1.092 . . . . 0.0 111.1 -178.96 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 47.9 mtm -145.23 164.87 30.02 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 124.165 0.986 . . . . 0.0 111.119 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 12.0 t-160 -164.92 111.28 0.97 Allowed 'General case' 0 C--O 1.239 0.536 0 N-CA-C 106.497 -1.668 . . . . 0.0 106.497 171.454 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 73.1 tttt 70.55 20.34 5.88 Favored 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 124.131 0.972 . . . . 0.0 110.802 -179.739 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 93.13 -19.95 49.06 Favored Glycine 0 C--N 1.344 0.985 0 CA-C-N 114.811 -1.086 . . . . 0.0 113.334 -172.134 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 38.8 ttmt -77.37 119.6 21.21 Favored 'General case' 0 C--N 1.36 1.027 0 CA-C-N 117.509 0.654 . . . . 0.0 109.76 -179.135 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 3.6 mpt_? -59.68 143.8 49.7 Favored 'General case' 0 CA--C 1.551 1.014 0 C-N-CA 124.383 1.073 . . . . 0.0 111.75 177.306 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 57.9 mt -119.1 109.05 25.45 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 176.367 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 127' ' ' GLU . . . . . 0.43 ' HA ' HG23 ' A' ' 118' ' ' VAL . 10.8 pt-20 -80.01 134.42 56.39 Favored Pre-proline 0 CA--C 1.557 1.241 0 C-N-CA 124.42 1.088 . . . . 0.0 112.997 -167.793 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 127' ' ' GLU . 3.7 Cg_exo -76.3 110.38 3.05 Favored 'Trans proline' 0 C--N 1.383 2.357 0 C-N-CA 123.023 2.482 . . . . 0.0 111.365 176.845 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 34.1 p -85.6 -27.46 25.46 Favored 'General case' 0 N--CA 1.479 1.0 0 C-N-CA 123.315 0.646 . . . . 0.0 111.416 -179.362 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 69.9 t-105 -147.86 153.9 39.72 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 123.706 0.802 . . . . 0.0 109.127 -178.538 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -155.99 118.28 4.08 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 123.196 0.599 . . . . 0.0 110.089 175.443 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 12.8 t0 -117.14 106.95 13.89 Favored 'General case' 0 N--CA 1.475 0.793 0 C-N-CA 124.312 1.045 . . . . 0.0 108.555 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 21.5 t -76.88 -16.42 14.7 Favored 'Isoleucine or valine' 0 CA--C 1.565 1.543 0 C-N-CA 123.263 0.625 . . . . 0.0 111.643 -174.977 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -79.16 -43.04 24.75 Favored 'General case' 0 N--CA 1.492 1.66 0 C-N-CA 123.203 0.601 . . . . 0.0 111.06 -175.859 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 11.8 mptt -78.19 -15.55 58.72 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 170.189 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 11.1 t0 58.69 61.86 2.09 Favored 'General case' 0 C--N 1.356 0.888 0 O-C-N 124.834 1.334 . . . . 0.0 108.512 -170.37 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 137' ' ' LEU . . . . . 0.506 HD11 ' HB1' ' A' ' 227' ' ' ALA . 87.0 mt -139.66 131.97 28.35 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 123.973 0.909 . . . . 0.0 109.607 176.808 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.403 HG22 ' O ' ' A' ' 110' ' ' MET . 20.2 tt -119.7 138.08 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.18 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 171.451 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 21.0 p -133.3 147.77 51.9 Favored 'General case' 0 CA--C 1.544 0.733 0 CA-C-O 121.827 0.822 . . . . 0.0 112.113 -171.501 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.556 ' HB2' ' HB3' ' A' ' 107' ' ' PHE . 17.5 m-85 -132.25 112.02 11.89 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.333 1.453 . . . . 0.0 108.476 -162.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.62 20.49 63.77 Favored Glycine 0 N--CA 1.474 1.229 0 O-C-N 123.084 0.24 . . . . 0.0 112.625 -176.029 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 157.04 -160.71 30.62 Favored Glycine 0 C--N 1.34 0.8 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 177.809 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.706 ' HA3' ' HB2' ' A' ' 232' ' ' SER . . . -98.75 -175.81 32.31 Favored Glycine 0 C--N 1.346 1.119 0 CA-C-N 117.348 0.574 . . . . 0.0 111.732 171.575 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 144' ' ' TRP . . . . . 0.581 ' CD1' ' HA ' ' A' ' 229' ' ' THR . 47.6 t-105 -61.78 107.64 0.87 Allowed 'General case' 0 C--N 1.352 0.707 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 167.828 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 38.6 ttpt -150.52 112.16 4.48 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-O 121.197 0.523 . . . . 0.0 110.791 -172.201 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 146' ' ' LEU . . . . . . . . . . . . . 1.6 pp -146.19 -2.37 0.7 Allowed 'General case' 0 N--CA 1.48 1.036 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.728 169.877 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 79.44 -22.86 0.26 Allowed 'General case' 0 N--CA 1.484 1.232 0 C-N-CA 126.108 1.763 . . . . 0.0 113.338 166.795 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -70.11 157.51 53.51 Favored Glycine 0 C--N 1.355 1.59 0 CA-C-N 118.055 0.389 . . . . 0.0 112.842 -175.149 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -141.12 154.05 45.7 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.097 0.559 . . . . 0.0 110.093 -173.026 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 150' ' ' TRP . . . . . 0.553 ' HB2' HG13 ' A' ' 208' ' ' VAL . 25.7 t90 -68.81 133.78 48.8 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 122.712 0.405 . . . . 0.0 110.107 169.709 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 60.2 tttm -86.33 97.5 10.45 Favored 'General case' 0 CA--C 1.549 0.921 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 171.246 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -59.06 109.91 0.94 Allowed 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 124.548 1.139 . . . . 0.0 112.144 -170.86 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 123.39 -9.24 8.83 Favored Glycine 0 N--CA 1.475 1.253 0 CA-C-N 115.764 -0.653 . . . . 0.0 112.056 -175.96 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 154' ' ' GLU . . . . . 0.477 ' HB3' ' HE3' ' A' ' 203' ' ' LYS . 62.3 mm-40 -101.17 163.25 12.37 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 123.424 0.689 . . . . 0.0 110.256 174.36 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 13.2 mp0 -82.57 146.2 29.3 Favored 'General case' 0 N--CA 1.477 0.919 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 172.071 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 29.6 m -89.8 140.55 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.558 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 10.4 mm100 -99.66 128.26 45.76 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 178.293 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.506 ' HA ' HG22 ' A' ' 200' ' ' ILE . 58.0 t -98.97 103.18 14.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 -176.709 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -80.8 72.57 7.78 Favored 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 106.946 -1.501 . . . . 0.0 106.946 178.084 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -77.13 130.01 36.77 Favored 'General case' 0 C--N 1.343 0.321 0 CA-C-N 113.496 -1.684 . . . . 0.0 110.647 -173.671 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 161' ' ' LEU . . . . . 0.667 HD11 ' HB1' ' A' ' 83' ' ' ALA . 45.6 mt -95.93 108.91 21.33 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 177.961 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 57.9 mt-10 -90.26 115.29 63.7 Favored Pre-proline 0 CA--C 1.544 0.728 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 167.499 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo -61.55 116.05 3.17 Favored 'Trans proline' 0 C--N 1.372 1.811 0 C-N-CA 123.41 2.74 . . . . 0.0 112.259 -176.71 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 109.53 -23.72 21.69 Favored Glycine 0 C--N 1.341 0.851 0 CA-C-N 115.518 -0.765 . . . . 0.0 112.203 -176.035 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 11.8 mmpt? -105.76 173.94 6.1 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 123.902 0.881 . . . . 0.0 111.532 -172.11 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 12.4 p30 -67.77 161.84 63.13 Favored Pre-proline 0 CA--C 1.558 1.287 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.021 168.573 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_exo -56.83 138.85 87.36 Favored 'Trans proline' 0 C--N 1.378 2.114 0 C-N-CA 122.968 2.445 . . . . 0.0 111.979 172.05 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 17.1 mmt85 -121.28 97.7 5.64 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 123.681 0.792 . . . . 0.0 109.692 -171.86 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -79.24 132.72 36.59 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 175.489 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.494 ' HB ' ' HB ' ' A' ' 158' ' ' VAL . 95.5 t -129.8 122.06 53.84 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.163 0 C-N-CA 123.196 0.599 . . . . 0.0 110.266 -178.478 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 171' ' ' GLN . . . . . 0.525 ' HB2' ' HB1' ' A' ' 20' ' ' ALA . 11.5 tt0 -80.82 110.58 16.47 Favored 'General case' 0 N--CA 1.48 1.03 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 -179.867 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 6.9 m -126.73 137.22 53.22 Favored 'General case' 0 C--O 1.238 0.499 0 CA-C-O 121.023 0.44 . . . . 0.0 109.954 -179.563 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 173' ' ' LYS . . . . . 0.474 ' H ' ' HA3' ' A' ' 24' ' ' GLY . 47.3 mttp -83.17 153.62 66.36 Favored Pre-proline 0 C--O 1.246 0.883 0 C-N-CA 124.115 0.966 . . . . 0.0 108.981 177.555 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 174' ' ' PRO . . . . . 0.489 ' HA ' ' O ' ' A' ' 186' ' ' ALA . 87.3 Cg_exo -49.73 125.99 15.47 Favored 'Trans proline' 0 C--N 1.381 2.252 0 C-N-CA 122.914 2.41 . . . . 0.0 113.36 179.627 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 175' ' ' GLY . . . . . 0.543 ' H ' ' C ' ' A' ' 186' ' ' ALA . . . -141.11 131.76 5.04 Favored Glycine 0 CA--C 1.541 1.662 0 CA-C-O 122.292 0.94 . . . . 0.0 114.616 178.444 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.579 HD12 ' HB ' ' A' ' 183' ' ' THR . 0.6 OUTLIER -139.31 155.09 47.95 Favored 'General case' 0 C--O 1.242 0.705 0 O-C-N 121.714 -0.874 . . . . 0.0 111.493 -170.292 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 177' ' ' PHE . . . . . 0.429 ' HZ ' ' HB2' ' A' ' 225' ' ' ALA . 3.1 p90 -124.13 139.32 54.04 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 113.696 -1.593 . . . . 0.0 109.781 -175.546 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 3.5 ttpm? -85.01 121.36 27.69 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 124.407 1.083 . . . . 0.0 110.167 -173.376 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 77.8 p -117.78 170.61 8.65 Favored 'General case' 0 C--O 1.243 0.731 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 164.905 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 10.5 t30 -66.21 -26.66 67.49 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 123.072 0.549 . . . . 0.0 109.91 173.807 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -68.76 -33.66 74.27 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 123.971 0.908 . . . . 0.0 111.055 173.178 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 150.66 172.43 19.81 Favored Glycine 0 C--N 1.35 1.323 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.341 175.325 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 183' ' ' THR . . . . . 0.579 ' HB ' HD12 ' A' ' 176' ' ' LEU . 44.5 p -75.83 95.8 3.56 Favored 'General case' 0 CA--C 1.545 0.782 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 174.723 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 20.3 pt -107.76 141.11 23.83 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 124.292 1.037 . . . . 0.0 110.378 -170.628 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 185' ' ' GLY . . . . . 0.613 ' HA2' ' HA ' ' A' ' 225' ' ' ALA . . . 115.92 173.61 17.35 Favored Glycine 0 N--CA 1.476 1.351 0 CA-C-O 119.432 -0.649 . . . . 0.0 112.612 -178.593 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.543 ' C ' ' H ' ' A' ' 175' ' ' GLY . . . -175.55 40.58 0.01 OUTLIER 'General case' 0 C--O 1.206 -1.225 0 C-N-CA 123.328 0.651 . . . . 0.0 109.882 178.836 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 187' ' ' VAL . . . . . 0.561 HG13 ' HB3' ' A' ' 224' ' ' SER . 2.4 p -164.39 100.42 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.552 1.036 0 O-C-N 120.412 -1.43 . . . . 0.0 108.893 172.857 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 188' ' ' SER . . . . . 0.433 ' O ' ' HA2' ' A' ' 24' ' ' GLY . 80.3 p -118.13 125.67 50.71 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 123.17 0.588 . . . . 0.0 110.266 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 3.6 pp -150.73 -177.81 6.2 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-O 121.095 0.474 . . . . 0.0 110.958 176.773 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -138.8 103.42 4.82 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 166.749 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 191' ' ' PHE . . . . . . . . . . . . . 29.9 t80 -168.15 -179.61 4.15 Favored 'General case' 0 N--CA 1.486 1.326 0 C-N-CA 122.787 0.435 . . . . 0.0 109.934 -172.256 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 36.6 m -49.05 117.93 7.0 Favored Pre-proline 0 CA--C 1.554 1.125 0 C-N-CA 124.656 1.183 . . . . 0.0 111.585 175.259 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -69.2 99.79 0.71 Allowed 'Trans proline' 0 C--N 1.378 2.09 0 C-N-CA 122.421 2.081 . . . . 0.0 112.111 -179.347 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -60.93 130.94 48.4 Favored Glycine 0 C--N 1.348 1.22 0 N-CA-C 110.589 -1.005 . . . . 0.0 110.589 170.104 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 195' ' ' THR . . . . . 0.451 HG22 ' O ' ' A' ' 161' ' ' LEU . 12.6 t -59.45 140.37 56.25 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 123.202 0.601 . . . . 0.0 112.004 -169.811 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -69.47 104.08 2.21 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 123.961 0.904 . . . . 0.0 110.826 -165.026 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 197' ' ' GLY . . . . . 0.487 ' HA2' HD11 ' A' ' 210' ' ' LEU . . . 135.66 -7.2 4.22 Favored Glycine 0 C--O 1.24 0.525 0 CA-C-N 115.097 -0.956 . . . . 0.0 111.384 -172.526 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 69.6 m -60.99 124.93 82.28 Favored Pre-proline 0 CA--C 1.548 0.897 0 C-N-CA 123.802 0.841 . . . . 0.0 109.554 169.661 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 199' ' ' PRO . . . . . 0.599 ' HG3' ' HB ' ' A' ' 101' ' ' VAL . 2.9 Cg_exo -73.13 153.52 51.78 Favored 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 122.409 2.073 . . . . 0.0 111.553 -177.977 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 200' ' ' ILE . . . . . 0.506 HG22 ' HA ' ' A' ' 158' ' ' VAL . 9.7 pt -108.54 129.4 63.05 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 169.084 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 201' ' ' ILE . . . . . 0.438 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 66.4 mt -115.29 152.89 16.88 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.912 0 C-N-CA 125.165 1.386 . . . . 0.0 108.187 -178.252 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -84.9 162.03 19.62 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 175.139 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 203' ' ' LYS . . . . . 0.477 ' HE3' ' HB3' ' A' ' 154' ' ' GLU . 18.5 ptpt -61.98 -24.07 66.79 Favored 'General case' 0 N--CA 1.482 1.154 0 C-N-CA 123.316 0.646 . . . . 0.0 111.765 179.283 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 50.5 tttp -69.48 -21.62 63.69 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 124.012 0.925 . . . . 0.0 111.33 179.567 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 109.14 -12.61 34.06 Favored Glycine 0 C--N 1.349 1.269 0 CA-C-N 116.188 -0.46 . . . . 0.0 113.082 179.351 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 44.7 mmtm -88.51 138.98 30.94 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 177.505 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 207' ' ' VAL . . . . . 0.438 ' HA ' ' HA ' ' A' ' 201' ' ' ILE . 21.4 t -63.36 151.08 8.86 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.936 0 C-N-CA 123.566 0.746 . . . . 0.0 110.867 -176.914 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 208' ' ' VAL . . . . . 0.553 HG13 ' HB2' ' A' ' 150' ' ' TRP . 54.8 t -100.35 -52.48 8.65 Favored 'Isoleucine or valine' 0 C--O 1.241 0.656 0 C-N-CA 124.415 1.086 . . . . 0.0 109.02 173.083 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 209' ' ' GLY . . . . . . . . . . . . . . . 171.35 -121.79 0.92 Allowed Glycine 0 C--N 1.345 1.053 0 CA-C-N 114.582 -1.19 . . . . 0.0 111.495 -176.248 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 210' ' ' LEU . . . . . 0.544 ' HB2' ' CH2' ' A' ' 144' ' ' TRP . 9.0 tt -142.03 139.6 32.38 Favored 'General case' 0 CA--C 1.549 0.926 0 CA-C-N 117.481 0.641 . . . . 0.0 110.426 -175.842 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 79.5 t80 -71.64 109.31 5.48 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 123.922 0.889 . . . . 0.0 108.807 174.126 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -76.79 -138.74 0.92 Allowed Glycine 0 C--N 1.34 0.776 0 O-C-N 123.632 0.583 . . . . 0.0 114.455 -170.115 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 213' ' ' ASN . . . . . . . . . . . . . 81.0 m-20 -74.74 85.47 2.16 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 123.294 0.638 . . . . 0.0 109.93 -176.028 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . -72.32 73.22 0.92 Allowed Glycine 0 C--N 1.355 1.593 0 C-N-CA 123.69 0.662 . . . . 0.0 111.571 175.213 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 215' ' ' VAL . . . . . 0.509 HG11 ' HA ' ' A' ' 40' ' ' SER . 54.7 t -84.37 147.24 5.8 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 C-N-CA 123.282 0.633 . . . . 0.0 111.1 -170.128 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 216' ' ' VAL . . . . . 0.518 ' HB ' ' HA2' ' A' ' 220' ' ' GLY . 14.7 m -68.34 111.95 3.0 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.109 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 165.873 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 217' ' ' THR . . . . . 0.587 HG23 HD13 ' A' ' 29' ' ' LEU . 13.5 t -125.09 159.89 30.36 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 122.686 0.394 . . . . 0.0 110.977 -179.043 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 218' ' ' ARG . . . . . 0.635 ' HB2' HD21 ' A' ' 29' ' ' LEU . 65.0 ttt180 66.45 -74.25 0.06 Allowed 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 124.924 1.289 . . . . 0.0 109.799 -170.991 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 16.6 p -131.3 -36.89 1.27 Allowed 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 124.02 0.928 . . . . 0.0 109.903 175.873 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 220' ' ' GLY . . . . . 0.518 ' HA2' ' HB ' ' A' ' 216' ' ' VAL . . . -176.78 11.83 0.03 OUTLIER Glycine 0 C--N 1.358 1.781 0 CA-C-O 119.341 -0.699 . . . . 0.0 114.64 -178.103 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 221' ' ' ALA . . . . . 0.47 ' O ' HG22 ' A' ' 217' ' ' THR . . . -70.95 119.23 14.76 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 117.664 0.732 . . . . 0.0 109.939 -175.917 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 222' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -76.92 95.69 4.17 Favored 'General case' 0 N--CA 1.473 0.71 0 CA-C-O 121.64 0.733 . . . . 0.0 109.975 -177.636 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 96.5 t -116.67 135.88 55.56 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.092 -179.26 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 224' ' ' SER . . . . . 0.561 ' HB3' HG13 ' A' ' 187' ' ' VAL . 35.2 t -131.18 155.74 46.53 Favored 'General case' 0 C--O 1.243 0.752 0 C-N-CA 124.324 1.05 . . . . 0.0 111.102 -164.73 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 225' ' ' ALA . . . . . 0.613 ' HA ' ' HA2' ' A' ' 185' ' ' GLY . . . -97.49 121.27 39.2 Favored 'General case' 0 N--CA 1.467 0.388 0 C-N-CA 123.76 0.824 . . . . 0.0 109.319 174.818 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 226' ' ' ILE . . . . . 0.439 HG23 HD11 ' A' ' 200' ' ' ILE . 7.1 mt -64.77 114.18 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 CA-C-O 120.857 0.36 . . . . 0.0 110.501 174.451 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 227' ' ' ALA . . . . . 0.506 ' HB1' HD11 ' A' ' 137' ' ' LEU . . . -76.79 113.13 14.12 Favored 'General case' 0 C--O 1.239 0.501 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 168.444 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 228' ' ' GLN . . . . . 0.433 ' HG3' ' HG3' ' A' ' 230' ' ' GLU . 29.7 pt20 -93.39 156.24 16.9 Favored 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 123.782 0.833 . . . . 0.0 109.474 -174.36 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 229' ' ' THR . . . . . 0.581 ' HA ' ' CD1' ' A' ' 144' ' ' TRP . 40.7 m -80.11 107.43 12.89 Favored 'General case' 0 C--N 1.347 0.487 0 CA-C-O 121.605 0.717 . . . . 0.0 111.536 179.389 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 230' ' ' GLU . . . . . 0.433 ' HG3' ' HG3' ' A' ' 228' ' ' GLN . 40.5 mt-10 -125.22 88.42 2.88 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 107.049 -1.463 . . . . 0.0 107.049 171.433 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 231' ' ' LYS . . . . . 0.449 ' HA ' ' O ' ' A' ' 144' ' ' TRP . 54.6 pttt -57.73 107.92 0.51 Allowed 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.329 -178.64 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 232' ' ' SER . . . . . 0.706 ' HB2' ' HA3' ' A' ' 143' ' ' GLY . 13.9 m . . . . . 0 C--O 1.239 0.527 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 -175.401 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.143 0 CA-C-O 120.898 0.38 . . . . 0.0 110.169 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -155.9 47.42 0.49 Allowed 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 124.246 1.018 . . . . 0.0 108.356 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 22.3 m-20 -144.33 -18.38 0.55 Allowed 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 113.229 0.826 . . . . 0.0 113.229 -158.478 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.659 ' HB2' ' HG ' ' A' ' 119' ' ' LEU . 1.9 mt -75.88 92.12 3.06 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 118.143 0.429 . . . . 0.0 111.124 -158.436 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -77.2 141.06 40.25 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.969 0.89 . . . . 0.0 111.575 -174.677 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.475 ' HB3' ' CE2' ' A' ' 84' ' ' TYR . 11.3 mp -83.69 115.38 22.15 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 113.587 -1.642 . . . . 0.0 107.586 175.416 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -111.6 126.37 54.93 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 108.374 -0.972 . . . . 0.0 108.374 179.37 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.617 HH22 ' HB3' ' A' ' 13' ' ' ASP . 60.8 ttt85 -75.03 129.19 37.2 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 120.527 0.203 . . . . 0.0 110.539 -177.469 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.474 ' HB2' ' HG3' ' A' ' 85' ' ' ARG . . . -104.23 -35.07 8.13 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 123.177 0.591 . . . . 0.0 109.96 175.149 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -177.72 -160.95 0.05 Allowed 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 124.421 1.088 . . . . 0.0 110.59 -175.218 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ASP . . . . . 0.617 ' HB3' HH22 ' A' ' 10' ' ' ARG . 6.8 p-10 -126.56 170.03 12.46 Favored 'General case' 0 N--CA 1.476 0.87 0 C-N-CA 124.149 0.98 . . . . 0.0 109.847 171.568 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 60.2 t -73.66 104.4 2.5 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.861 -177.414 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 59.2 pttt -164.81 146.29 7.94 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 124.278 1.031 . . . . 0.0 108.804 -178.464 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 24.7 t90 -84.11 113.92 21.4 Favored 'General case' 0 CA--C 1.544 0.713 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 177.395 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 38.2 mm-40 -67.89 147.11 52.94 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 123.557 0.743 . . . . 0.0 111.54 174.846 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -70.44 -2.46 13.9 Favored 'General case' 0 CA--C 1.556 1.18 0 C-N-CA 125.153 1.381 . . . . 0.0 111.807 175.593 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' GLN . . . . . 0.559 ' HB2' ' H ' ' A' ' 169' ' ' ALA . 12.9 mm100 -80.14 14.11 2.02 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 124.532 1.133 . . . . 0.0 112.585 -174.355 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -53.89 100.32 0.03 OUTLIER 'General case' 0 C--N 1.364 1.196 0 C-N-CA 124.605 1.162 . . . . 0.0 112.92 -168.743 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.6 mm-40 -82.74 121.88 27.45 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.165 179.294 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 3.6 mp -78.62 103.5 5.66 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.807 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 63.5 m -142.64 -171.59 3.46 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 125.403 1.481 . . . . 0.0 107.2 174.163 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.427 ' HA3' ' H ' ' A' ' 173' ' ' LYS . . . 133.67 148.66 5.9 Favored Glycine 0 N--CA 1.468 0.828 0 N-CA-C 114.887 0.715 . . . . 0.0 114.887 169.37 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' SER . . . . . 0.496 ' HB2' ' HB2' ' A' ' 173' ' ' LYS . 15.4 t 65.57 97.98 0.05 OUTLIER 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 125.07 1.348 . . . . 0.0 111.733 173.317 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 15.6 m -111.29 160.96 27.27 Favored Pre-proline 0 CA--C 1.553 1.069 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 169.291 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -57.28 158.59 18.05 Favored 'Trans proline' 0 C--N 1.384 2.418 0 C-N-CA 122.715 2.277 . . . . 0.0 113.074 -176.684 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 35.5 mm -57.74 120.87 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 123.63 0.772 . . . . 0.0 110.334 -177.901 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.517 HD23 ' HE1' ' A' ' 177' ' ' PHE . 38.1 tp -98.85 143.12 29.53 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 115.096 -0.957 . . . . 0.0 110.145 -170.343 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 50.4 m -123.06 116.46 23.54 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 122.872 0.469 . . . . 0.0 109.766 -175.789 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 14.4 pt -138.29 173.48 12.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 C-N-CA 124.149 0.98 . . . . 0.0 110.155 178.475 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 36.4 p -93.85 125.26 38.37 Favored 'General case' 0 C--N 1.353 0.736 0 C-N-CA 122.787 0.435 . . . . 0.0 109.92 -173.769 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 10.6 tp -65.15 128.55 28.07 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.001 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 170.058 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 24.8 t -108.47 103.61 12.78 Favored 'General case' 0 C--O 1.267 2.005 0 CA-C-O 121.437 0.637 . . . . 0.0 109.567 -176.251 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 68.26 -79.57 0.04 OUTLIER 'General case' 0 C--N 1.357 0.914 0 CA-C-N 113.179 -1.828 . . . . 0.0 111.282 176.863 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -144.37 -72.84 0.27 Allowed 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.873 0.869 . . . . 0.0 109.26 -177.799 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -97.95 4.95 61.32 Favored Glycine 0 C--N 1.347 1.171 0 CA-C-O 118.812 -0.993 . . . . 0.0 114.227 -174.325 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 35.8 t -107.04 164.33 12.24 Favored 'General case' 0 C--N 1.359 1.021 0 CA-C-N 119.026 1.413 . . . . 0.0 107.967 172.405 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' MET . . . . . 0.437 ' HE1' ' CE2' ' A' ' 177' ' ' PHE . 39.7 ttp -164.24 126.47 2.36 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 178.85 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.466 ' HA ' HG11 ' A' ' 215' ' ' VAL . 68.3 m -150.95 -178.91 6.87 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 123.53 0.732 . . . . 0.0 110.968 -173.947 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.796 HD11 HG22 ' A' ' 217' ' ' THR . 2.3 mp -83.95 97.88 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 N-CA-C 105.729 -1.952 . . . . 0.0 105.729 163.255 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 13.2 mptt 57.64 -86.24 0.02 OUTLIER 'General case' 0 CA--C 1.55 0.952 0 C-N-CA 124.139 0.976 . . . . 0.0 108.731 -165.226 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 8.7 t30 -140.54 140.05 35.15 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 123.553 0.741 . . . . 0.0 109.318 172.001 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -154.86 121.64 5.45 Favored 'General case' 0 CA--C 1.537 0.458 0 N-CA-C 106.406 -1.702 . . . . 0.0 106.406 179.204 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.3 tp10 . . . . . 0 N--CA 1.476 0.863 0 C-N-CA 122.836 0.454 . . . . 0.0 110.33 -177.067 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.514 ' HB2' ' HA ' ' A' ' 103' ' ' LYS . 8.2 p-10 . . . . . 0 C--O 1.245 0.861 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 159.52 -163.73 33.66 Favored Glycine 0 C--N 1.343 0.917 0 CA-C-N 116.031 -0.531 . . . . 0.0 113.396 178.536 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' ALA . . . . . 0.431 ' HB1' HD21 ' A' ' 161' ' ' LEU . . . -89.84 123.99 34.29 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 124.137 0.975 . . . . 0.0 109.232 -177.451 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' TYR . . . . . 0.475 ' CE2' ' HB3' ' A' ' 8' ' ' LEU . 4.0 m-85 -126.09 151.38 47.29 Favored 'General case' 0 N--CA 1.48 1.034 0 C-N-CA 123.723 0.809 . . . . 0.0 112.09 -166.566 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' ARG . . . . . 0.476 ' HA ' ' HA ' ' A' ' 99' ' ' ALA . 25.3 mtm180 -113.71 131.02 56.33 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 124.817 1.247 . . . . 0.0 107.897 167.371 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 25.7 mt -94.33 124.55 46.85 Favored 'Isoleucine or valine' 0 C--O 1.249 1.048 0 CA-C-O 121.684 0.754 . . . . 0.0 110.513 -179.401 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.482 ' HD3' ' HB3' ' A' ' 94' ' ' TYR . 1.7 ttmp? -105.72 136.68 44.88 Favored 'General case' 0 C--O 1.213 -0.816 0 C-N-CA 126.114 1.766 . . . . 0.0 108.305 177.599 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 22.9 tm0? -83.07 106.98 15.33 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 104.435 -2.431 . . . . 0.0 104.435 166.69 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 1.9 tmtp? -118.49 95.21 4.77 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-N 114.975 -1.011 . . . . 0.0 108.298 -166.577 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -82.48 150.52 28.53 Favored Glycine 0 C--O 1.248 1.012 0 N-CA-C 108.911 -1.675 . . . . 0.0 108.911 166.562 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 16.1 mm -80.2 59.63 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.265 0 CA-C-O 121.614 0.721 . . . . 0.0 109.07 -177.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 4.6 pp 168.55 -20.59 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 126.331 1.853 . . . . 0.0 110.433 -173.662 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -157.36 145.51 12.08 Favored Glycine 0 C--N 1.37 2.462 0 CA-C-O 119.841 -0.422 . . . . 0.0 113.239 -174.703 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' TYR . . . . . 0.482 ' HB3' ' HD3' ' A' ' 87' ' ' LYS . 28.3 m-85 -130.56 147.67 52.27 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-N 117.434 0.617 . . . . 0.0 111.192 -171.177 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 25.1 t -151.18 149.83 29.92 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 123.806 0.843 . . . . 0.0 109.447 175.2 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' GLN . . . . . . . . . . . . . 22.2 tp60 -94.83 111.22 23.01 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 108.858 -0.794 . . . . 0.0 108.858 177.9 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.444 HD11 ' HB3' ' A' ' 6' ' ' LEU . 28.6 pt -106.33 -16.86 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 N-CA-C 113.375 0.88 . . . . 0.0 113.375 -173.222 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 170.35 -146.32 9.76 Favored Glycine 0 N--CA 1.472 1.044 0 C-N-CA 120.453 -0.879 . . . . 0.0 113.193 173.604 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.476 ' HA ' ' HA ' ' A' ' 85' ' ' ARG . . . -149.32 176.36 10.62 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 123.684 0.794 . . . . 0.0 110.787 177.904 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -166.81 -170.52 31.81 Favored Glycine 0 C--N 1.344 1.02 0 N-CA-C 111.368 -0.693 . . . . 0.0 111.368 178.12 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 6.2 p -142.83 117.4 4.34 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.728 0 C-N-CA 124.034 0.934 . . . . 0.0 109.278 178.432 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 3.0 t80 -88.5 136.71 32.86 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 171.313 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.514 ' HA ' ' HB2' ' A' ' 81' ' ' ASP . 17.2 tptp -160.12 153.47 22.14 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 110.41 -0.219 . . . . 0.0 110.41 177.244 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 71.52 -85.47 0.03 OUTLIER 'General case' 0 CA--C 1.55 0.981 0 C-N-CA 124.868 1.267 . . . . 0.0 110.576 169.651 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -155.88 24.81 0.56 Allowed Glycine 0 N--CA 1.469 0.889 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 174.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 106' ' ' THR . . . . . 0.746 HG22 ' HA3' ' A' ' 141' ' ' GLY . 7.0 p -147.03 151.75 37.45 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.377 1.071 . . . . 0.0 110.011 -167.865 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 107' ' ' PHE . . . . . 0.518 ' HB3' ' HB3' ' A' ' 140' ' ' TYR . 31.4 t80 -104.63 139.16 39.88 Favored 'General case' 0 N--CA 1.484 1.235 0 N-CA-C 108.031 -1.099 . . . . 0.0 108.031 174.02 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 108' ' ' HIS . . . . . 0.436 ' HB3' ' CZ3' ' A' ' 144' ' ' TRP . 78.0 m-70 -132.35 113.58 13.36 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 123.549 0.74 . . . . 0.0 110.173 -175.555 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 9.0 t -136.47 -177.8 4.88 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 122.761 0.424 . . . . 0.0 110.673 177.495 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 110' ' ' MET . . . . . . . . . . . . . 3.3 mtp -89.52 152.42 21.44 Favored 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 123.677 0.791 . . . . 0.0 110.195 178.656 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 53.9 t90 -73.45 -39.13 65.2 Favored 'General case' 0 CA--C 1.542 0.642 0 O-C-N 123.634 0.584 . . . . 0.0 110.365 -175.848 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 30.1 p80 -65.87 -8.39 21.76 Favored 'General case' 0 N--CA 1.49 1.555 0 C-N-CA 124.474 1.11 . . . . 0.0 113.087 -172.665 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 95.1 t -58.08 -37.97 64.82 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.977 0 C-N-CA 123.366 0.666 . . . . 0.0 110.1 178.231 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 17.5 p -147.78 -163.08 1.69 Allowed 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 124.448 1.099 . . . . 0.0 109.989 169.435 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.8 tpp180 -90.83 5.23 49.26 Favored 'General case' 0 CA--C 1.559 1.296 0 C-N-CA 123.562 0.745 . . . . 0.0 111.152 176.248 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 107.1 63.49 0.59 Allowed Glycine 0 C--N 1.35 1.329 0 N-CA-C 111.799 -0.52 . . . . 0.0 111.799 -178.364 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 117' ' ' ALA . . . . . 0.591 ' HB3' HD11 ' A' ' 6' ' ' LEU . . . -95.33 168.39 10.75 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 123.811 0.844 . . . . 0.0 111.823 -179.363 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.42 HG23 ' HA ' ' A' ' 127' ' ' GLU . 14.9 p -86.5 141.41 14.44 Favored 'Isoleucine or valine' 0 C--O 1.245 0.845 0 N-CA-C 108.369 -0.975 . . . . 0.0 108.369 165.565 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.659 ' HG ' ' HB2' ' A' ' 6' ' ' LEU . 6.4 mp -102.03 174.62 5.85 Favored 'General case' 0 C--O 1.222 -0.35 0 C-N-CA 124.072 0.949 . . . . 0.0 111.291 -173.667 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 25.4 mmt -121.78 165.71 15.43 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 125.36 1.464 . . . . 0.0 108.752 177.194 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 12.1 t-80 -170.03 97.44 0.28 Allowed 'General case' 0 C--O 1.246 0.879 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 166.435 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 49.1 tttm 56.87 37.63 28.92 Favored 'General case' 0 N--CA 1.489 1.483 0 CA-C-O 121.91 0.862 . . . . 0.0 110.889 173.358 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 101.38 -12.09 58.37 Favored Glycine 0 C--N 1.348 1.22 0 CA-C-O 119.135 -0.814 . . . . 0.0 114.349 177.007 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 53.4 mtpt -102.56 135.18 44.65 Favored 'General case' 0 N--CA 1.49 1.569 0 CA-C-N 118.155 0.977 . . . . 0.0 110.712 178.506 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 125' ' ' ARG . . . . . 0.434 ' HA ' ' O ' ' A' ' 119' ' ' LEU . 0.1 OUTLIER -85.21 122.79 29.9 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 123.196 0.599 . . . . 0.0 110.82 177.667 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.519 HG23 ' HB2' ' A' ' 140' ' ' TYR . 1.8 mp -87.13 100.07 9.38 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.917 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 172.606 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 127' ' ' GLU . . . . . 0.42 ' HA ' HG23 ' A' ' 118' ' ' VAL . 36.5 tt0 -92.42 104.63 11.61 Favored Pre-proline 0 CA--C 1.545 0.787 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.371 -177.735 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 12.9 Cg_exo -68.69 98.2 0.58 Allowed 'Trans proline' 0 C--N 1.374 1.905 0 C-N-CA 122.534 2.156 . . . . 0.0 112.195 -175.697 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 6.4 p -69.08 -24.66 64.17 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 123.797 0.839 . . . . 0.0 111.231 176.912 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.578 ' HB2' ' HA2' ' A' ' 142' ' ' GLY . 59.7 t-105 -107.32 138.43 43.52 Favored 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 108.712 -0.848 . . . . 0.0 108.712 171.334 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -155.35 120.89 4.99 Favored 'General case' 0 C--O 1.238 0.494 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 176.393 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -143.07 114.08 7.7 Favored 'General case' 0 CA--C 1.544 0.728 0 CA-C-O 120.879 0.371 . . . . 0.0 110.98 -178.099 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 14.2 p -77.45 -17.43 14.29 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.309 0 C-N-CA 124.219 1.008 . . . . 0.0 112.423 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 65.4 mttm -71.73 -45.52 61.5 Favored 'General case' 0 N--CA 1.485 1.306 0 C-N-CA 123.177 0.591 . . . . 0.0 110.735 -173.225 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' LYS . . . . . 0.599 ' HG2' ' HG2' ' A' ' 230' ' ' GLU . 4.6 mptp? -88.64 -10.06 49.92 Favored 'General case' 0 N--CA 1.477 0.898 0 C-N-CA 124.653 1.181 . . . . 0.0 109.897 174.876 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 56.1 t0 63.02 46.11 4.92 Favored 'General case' 0 C--N 1.36 1.037 0 O-C-N 124.549 1.156 . . . . 0.0 109.426 -177.124 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 96.2 mt -136.71 127.67 27.61 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.696 0.798 . . . . 0.0 110.392 -179.486 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 17.8 tt -124.14 136.81 59.18 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 175.773 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 80.5 p -148.58 146.0 28.07 Favored 'General case' 0 N--CA 1.475 0.796 0 CA-C-O 121.843 0.83 . . . . 0.0 113.146 -171.162 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.519 ' HB2' HG23 ' A' ' 126' ' ' ILE . 81.3 t80 -84.6 122.17 28.66 Favored 'General case' 0 N--CA 1.473 0.695 0 CA-C-N 114.446 -1.252 . . . . 0.0 108.396 172.601 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.746 ' HA3' HG22 ' A' ' 106' ' ' THR . . . 123.69 -82.47 0.35 Allowed Glycine 0 C--N 1.34 0.801 0 O-C-N 124.281 0.988 . . . . 0.0 111.637 177.676 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 142' ' ' GLY . . . . . 0.578 ' HA2' ' HB2' ' A' ' 130' ' ' TRP . . . 147.57 84.09 0.05 OUTLIER Glycine 0 C--O 1.24 0.495 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 172.683 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 146.94 176.34 20.62 Favored Glycine 0 C--O 1.241 0.565 0 N-CA-C 111.233 -0.747 . . . . 0.0 111.233 177.312 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 144' ' ' TRP . . . . . 0.593 ' HH2' HD13 ' A' ' 210' ' ' LEU . 69.2 t-105 -110.16 109.21 19.64 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 166.491 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 28.7 mmmt -108.98 107.43 17.79 Favored 'General case' 0 N--CA 1.471 0.621 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -175.412 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 146' ' ' LEU . . . . . 0.423 HD22 HG11 ' A' ' 207' ' ' VAL . 60.2 mt -162.63 -45.74 0.04 OUTLIER 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 126.909 2.084 . . . . 0.0 106.784 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 63.89 22.88 13.17 Favored 'General case' 0 N--CA 1.482 1.128 0 C-N-CA 125.256 1.422 . . . . 0.0 112.758 176.895 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 148' ' ' GLY . . . . . 0.434 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -76.98 165.96 53.76 Favored Glycine 0 C--N 1.352 1.455 0 CA-C-N 116.262 -0.427 . . . . 0.0 113.017 179.543 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 22.2 tt0 -123.69 96.62 5.03 Favored 'General case' 0 C--O 1.239 0.506 0 C-N-CA 123.485 0.714 . . . . 0.0 109.26 -174.401 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 150' ' ' TRP . . . . . 0.527 ' HA ' ' HB ' ' A' ' 208' ' ' VAL . 29.1 t90 -55.63 116.05 2.68 Favored 'General case' 0 N--CA 1.481 1.098 0 O-C-N 123.308 0.38 . . . . 0.0 111.185 171.33 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 65.9 mttm -94.5 100.3 12.31 Favored 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 123.848 0.859 . . . . 0.0 109.419 -178.366 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -68.21 141.02 56.08 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 124.658 1.183 . . . . 0.0 111.918 -175.972 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 83.8 -23.56 6.63 Favored Glycine 0 C--N 1.351 1.389 0 CA-C-N 116.47 -0.332 . . . . 0.0 113.518 177.314 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -97.02 151.53 19.63 Favored 'General case' 0 C--O 1.24 0.57 0 C-N-CA 124.546 1.138 . . . . 0.0 108.53 -179.578 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 155' ' ' GLU . . . . . 0.424 ' HA ' ' HA ' ' A' ' 173' ' ' LYS . 1.2 pm0 -63.6 121.96 15.16 Favored 'General case' 0 C--N 1.345 0.406 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 176.051 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 33.9 m -89.93 179.51 0.5 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.537 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 174.807 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.47 133.4 51.21 Favored 'General case' 0 C--O 1.217 -0.641 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -175.87 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.451 ' O ' ' HA ' ' A' ' 169' ' ' ALA . 86.3 t -107.77 119.35 57.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 -176.795 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -93.1 77.43 4.63 Favored 'General case' 0 CA--C 1.54 0.584 0 N-CA-C 106.665 -1.605 . . . . 0.0 106.665 172.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -77.9 111.87 14.2 Favored 'General case' 0 CA--C 1.539 0.534 0 CA-C-N 114.69 -1.141 . . . . 0.0 111.006 -169.347 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 161' ' ' LEU . . . . . 0.431 HD21 ' HB1' ' A' ' 83' ' ' ALA . 89.0 mt -79.1 102.61 8.52 Favored 'General case' 0 C--O 1.244 0.805 0 C-N-CA 123.993 0.917 . . . . 0.0 110.195 179.541 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 162' ' ' GLU . . . . . 0.516 ' HB2' ' HB2' ' A' ' 193' ' ' PRO . 39.1 tt0 -74.82 126.66 88.16 Favored Pre-proline 0 CA--C 1.541 0.614 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 173.124 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -64.13 116.03 3.48 Favored 'Trans proline' 0 C--N 1.376 1.988 0 C-N-CA 121.911 1.741 . . . . 0.0 110.375 173.753 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 113.1 -28.01 9.11 Favored Glycine 0 C--N 1.344 1.006 0 CA-C-O 119.583 -0.565 . . . . 0.0 113.816 177.369 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -136.47 -173.48 3.43 Favored 'General case' 0 N--CA 1.49 1.552 0 CA-C-N 117.986 0.893 . . . . 0.0 112.154 -175.08 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -60.0 161.27 12.88 Favored Pre-proline 0 CA--C 1.554 1.116 0 C-N-CA 124.983 1.313 . . . . 0.0 112.319 175.861 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -77.2 157.4 33.65 Favored 'Trans proline' 0 C--N 1.373 1.823 0 C-N-CA 122.016 1.811 . . . . 0.0 111.759 173.826 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 168' ' ' ARG . . . . . 0.517 HH11 ' HG3' ' A' ' 193' ' ' PRO . 58.7 mtp180 -124.58 131.97 53.46 Favored 'General case' 0 C--O 1.238 0.489 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.257 173.773 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 169' ' ' ALA . . . . . 0.559 ' H ' ' HB2' ' A' ' 19' ' ' GLN . . . -80.02 133.83 36.18 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.053 176.633 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 63.0 t -134.21 117.8 26.05 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.131 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 174.436 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 55.1 mt-30 -81.75 126.28 31.63 Favored 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 108.245 -1.021 . . . . 0.0 108.245 174.85 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 4.9 t -152.72 132.44 13.16 Favored 'General case' 0 CA--C 1.54 0.561 0 O-C-N 123.571 0.544 . . . . 0.0 111.738 -174.887 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 173' ' ' LYS . . . . . 0.496 ' HB2' ' HB2' ' A' ' 25' ' ' SER . 64.0 mttp -75.6 138.13 70.57 Favored Pre-proline 0 N--CA 1.475 0.782 0 C-N-CA 123.146 0.578 . . . . 0.0 110.069 171.69 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_endo -61.78 163.27 19.27 Favored 'Trans proline' 0 C--N 1.379 2.134 0 C-N-CA 123.091 2.527 . . . . 0.0 113.728 178.427 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -144.45 169.89 26.3 Favored Glycine 0 N--CA 1.468 0.785 0 N-CA-C 110.399 -1.08 . . . . 0.0 110.399 178.217 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 6.5 mp -124.34 152.13 43.5 Favored 'General case' 0 N--CA 1.488 1.463 0 CA-C-N 118.681 1.24 . . . . 0.0 111.887 -176.511 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 177' ' ' PHE . . . . . 0.517 ' HE1' HD23 ' A' ' 29' ' ' LEU . 68.4 m-85 -96.53 122.42 39.41 Favored 'General case' 0 C--N 1.344 0.356 0 CA-C-N 114.756 -1.111 . . . . 0.0 109.593 173.831 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 61.0 tttp -85.47 90.07 7.86 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 167.032 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 23.0 m -104.14 158.79 16.2 Favored 'General case' 0 C--O 1.242 0.689 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 -179.352 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -61.6 -34.88 76.4 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 122.356 0.262 . . . . 0.0 110.471 177.506 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -63.79 -33.85 76.59 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 123.572 0.749 . . . . 0.0 111.155 175.442 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 151.25 -169.13 30.88 Favored Glycine 0 C--N 1.342 0.888 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.97 177.891 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 183' ' ' THR . . . . . 0.453 ' HA ' ' O ' ' A' ' 177' ' ' PHE . 16.9 p -87.25 119.19 27.23 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 122.986 0.514 . . . . 0.0 109.776 176.522 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 184' ' ' ILE . . . . . 0.461 ' HB ' ' HB2' ' A' ' 177' ' ' PHE . 65.5 mt -103.01 144.51 13.69 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 124.223 1.009 . . . . 0.0 108.504 -176.833 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -99.23 120.24 6.79 Favored Glycine 0 C--N 1.345 1.038 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 -175.223 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.403 ' HA ' ' HA ' ' A' ' 225' ' ' ALA . . . -146.93 -160.65 1.19 Allowed 'General case' 0 N--CA 1.465 0.294 0 C-N-CA 123.413 0.685 . . . . 0.0 111.102 -163.689 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 187' ' ' VAL . . . . . 0.416 ' HB ' HD11 ' A' ' 226' ' ' ILE . 3.7 p -132.22 103.86 7.13 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.989 0 C-N-CA 124.029 0.932 . . . . 0.0 108.498 169.552 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 188' ' ' SER . . . . . 0.46 ' HA ' HG13 ' A' ' 223' ' ' VAL . 15.6 t -76.96 100.65 5.68 Favored 'General case' 0 C--O 1.243 0.753 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.501 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 189' ' ' LEU . . . . . 0.4 HD13 ' N ' ' A' ' 190' ' ' ASP . 0.8 OUTLIER -152.44 155.66 37.96 Favored 'General case' 0 C--N 1.358 0.939 0 CA-C-O 121.365 0.603 . . . . 0.0 110.689 -168.531 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 190' ' ' ASP . . . . . 0.645 ' HA ' ' HB1' ' A' ' 221' ' ' ALA . 16.6 t70 -69.08 162.76 26.26 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 124.869 1.267 . . . . 0.0 109.859 176.048 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 191' ' ' PHE . . . . . 0.536 ' HB3' ' H ' ' A' ' 222' ' ' TYR . 9.6 p90 -74.23 123.92 25.43 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-O 121.958 0.885 . . . . 0.0 110.522 -168.409 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 50.8 m -104.62 158.96 30.88 Favored Pre-proline 0 CA--C 1.547 0.854 0 CA-C-N 114.23 -1.35 . . . . 0.0 110.445 -174.457 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 193' ' ' PRO . . . . . 0.517 ' HG3' HH11 ' A' ' 168' ' ' ARG . 73.7 Cg_endo -72.78 69.69 3.62 Favored 'Trans proline' 0 C--N 1.372 1.8 0 C-N-CA 122.786 2.324 . . . . 0.0 112.2 173.44 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -154.01 146.63 15.02 Favored Glycine 0 C--N 1.347 1.145 0 CA-C-N 116.178 -0.465 . . . . 0.0 112.46 -177.42 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 25.3 p -110.39 156.37 20.87 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 123.684 0.793 . . . . 0.0 109.469 176.32 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.63 107.2 0.77 Allowed 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 123.858 0.863 . . . . 0.0 110.069 -175.557 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 132.6 -9.55 5.26 Favored Glycine 0 C--N 1.342 0.89 0 CA-C-N 114.749 -1.114 . . . . 0.0 112.338 -172.19 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 54.2 m -63.91 120.12 60.92 Favored Pre-proline 0 CA--C 1.55 0.953 0 C-N-CA 123.351 0.66 . . . . 0.0 109.553 173.48 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -60.39 125.29 17.04 Favored 'Trans proline' 0 C--N 1.375 1.949 0 C-N-CA 122.836 2.357 . . . . 0.0 112.292 -173.765 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 55.5 mt -88.22 107.56 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 173.665 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 201' ' ' ILE . . . . . 0.8 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 25.9 mt -97.06 176.55 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.044 0 C-N-CA 124.524 1.13 . . . . 0.0 108.942 -175.839 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -102.93 174.22 5.97 Favored 'General case' 0 C--O 1.24 0.604 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 169.886 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 2.4 mppt? -70.46 -28.74 65.25 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 123.84 0.856 . . . . 0.0 109.051 174.96 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp -81.96 1.6 34.65 Favored 'General case' 0 N--CA 1.477 0.878 0 C-N-CA 123.958 0.903 . . . . 0.0 111.927 178.836 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 90.96 -4.82 81.84 Favored Glycine 0 C--N 1.351 1.403 0 CA-C-O 119.965 -0.353 . . . . 0.0 113.562 177.249 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 31.3 mmtp -78.25 108.89 11.9 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 122.931 0.492 . . . . 0.0 110.064 179.651 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 207' ' ' VAL . . . . . 0.8 ' HA ' ' HA ' ' A' ' 201' ' ' ILE . 4.8 p -63.66 103.06 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.053 0 CA-C-O 121.437 0.636 . . . . 0.0 110.218 177.076 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 208' ' ' VAL . . . . . 0.527 ' HB ' ' HA ' ' A' ' 150' ' ' TRP . 27.2 m -81.68 -18.37 11.43 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.987 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.287 -169.782 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 209' ' ' GLY . . . . . . . . . . . . . . . 170.89 -138.84 5.15 Favored Glycine 0 C--N 1.344 0.99 0 CA-C-N 115.446 -0.797 . . . . 0.0 112.351 179.506 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 210' ' ' LEU . . . . . 0.593 HD13 ' HH2' ' A' ' 144' ' ' TRP . 4.9 tt -153.41 154.13 33.85 Favored 'General case' 0 CA--C 1.549 0.904 0 C-N-CA 123.864 0.866 . . . . 0.0 109.825 -168.219 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -67.97 114.42 6.5 Favored 'General case' 0 N--CA 1.481 1.12 0 C-N-CA 123.885 0.874 . . . . 0.0 109.868 -178.78 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -74.65 -136.67 0.44 Allowed Glycine 0 CA--C 1.528 0.895 0 O-C-N 124.349 1.031 . . . . 0.0 114.754 -169.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 213' ' ' ASN . . . . . 0.404 ' H ' ' HB3' ' A' ' 225' ' ' ALA . 49.0 t-20 -123.99 135.15 53.44 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 -175.164 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 214' ' ' GLY . . . . . 0.507 ' HA3' ' HA ' ' A' ' 224' ' ' SER . . . -164.37 -152.42 6.96 Favored Glycine 0 CA--C 1.506 -0.528 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.918 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 215' ' ' VAL . . . . . 0.466 HG11 ' HA ' ' A' ' 40' ' ' SER . 7.4 p -162.76 157.09 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 123.02 0.528 . . . . 0.0 110.445 -171.412 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 216' ' ' VAL . . . . . 0.46 ' HA ' ' HA ' ' A' ' 222' ' ' TYR . 93.0 t -70.93 116.38 12.36 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 C-N-CA 123.891 0.877 . . . . 0.0 109.064 174.553 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 217' ' ' THR . . . . . 0.796 HG22 HD11 ' A' ' 41' ' ' ILE . 72.9 p -130.68 163.48 27.12 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 125.256 1.423 . . . . 0.0 109.525 -173.572 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 10.1 ttp180 54.31 76.57 0.23 Allowed 'General case' 0 CA--C 1.561 1.367 0 C-N-CA 123.133 0.573 . . . . 0.0 111.957 161.96 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 45.1 m 71.91 -5.69 1.64 Allowed 'General case' 0 N--CA 1.492 1.663 0 C-N-CA 124.901 1.28 . . . . 0.0 114.393 176.21 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . 118.27 43.82 0.54 Allowed Glycine 0 C--N 1.357 1.71 0 CA-C-N 118.583 0.629 . . . . 0.0 112.909 176.942 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 221' ' ' ALA . . . . . 0.645 ' HB1' ' HA ' ' A' ' 190' ' ' ASP . . . -130.39 120.91 24.99 Favored 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 124.712 1.205 . . . . 0.0 109.578 -178.611 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 222' ' ' TYR . . . . . 0.536 ' H ' ' HB3' ' A' ' 191' ' ' PHE . 11.0 p90 -86.3 127.45 34.78 Favored 'General case' 0 C--N 1.351 0.665 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 -169.643 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 223' ' ' VAL . . . . . 0.46 HG13 ' HA ' ' A' ' 188' ' ' SER . 96.4 t -113.49 132.95 60.95 Favored 'Isoleucine or valine' 0 C--O 1.241 0.633 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 176.988 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 224' ' ' SER . . . . . 0.507 ' HA ' ' HA3' ' A' ' 214' ' ' GLY . 35.8 t -136.3 158.74 43.71 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 124.199 0.999 . . . . 0.0 109.959 -168.898 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 225' ' ' ALA . . . . . 0.404 ' HB3' ' H ' ' A' ' 213' ' ' ASN . . . -68.73 166.51 17.28 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 123.708 0.803 . . . . 0.0 111.234 175.232 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 226' ' ' ILE . . . . . 0.416 HD11 ' HB ' ' A' ' 187' ' ' VAL . 70.9 mt -108.71 111.56 36.55 Favored 'Isoleucine or valine' 0 C--O 1.243 0.731 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 168.634 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -74.62 131.83 41.25 Favored 'General case' 0 C--N 1.345 0.381 0 N-CA-C 107.516 -1.291 . . . . 0.0 107.516 169.828 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 14.1 pt20 -111.39 171.12 7.67 Favored 'General case' 0 C--O 1.248 1.01 0 C-N-CA 123.626 0.77 . . . . 0.0 109.371 -177.754 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 229' ' ' THR . . . . . 0.474 ' HA ' ' CD1' ' A' ' 144' ' ' TRP . 87.1 m -66.94 115.31 6.53 Favored 'General case' 0 CA--C 1.544 0.738 0 O-C-N 123.59 0.556 . . . . 0.0 110.618 178.912 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 230' ' ' GLU . . . . . 0.599 ' HG2' ' HG2' ' A' ' 135' ' ' LYS . 10.0 tp10 -117.0 62.75 0.73 Allowed 'General case' 0 C--O 1.242 0.68 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 175.921 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 24.3 pttm -66.97 157.45 33.33 Favored 'General case' 0 N--CA 1.472 0.662 0 CA-C-N 114.985 -1.007 . . . . 0.0 112.911 -165.733 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 19.8 p . . . . . 0 CA--C 1.549 0.926 0 CA-C-N 113.935 -1.484 . . . . 0.0 112.132 -178.074 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.25 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -165.2 23.62 0.05 Allowed 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 123.142 0.577 . . . . 0.0 110.365 -175.489 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 8.9 p30 -175.55 64.73 0.02 OUTLIER 'General case' 0 C--N 1.344 0.367 0 C-N-CA 124.734 1.214 . . . . 0.0 108.069 -173.099 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.683 ' HB2' HD13 ' A' ' 119' ' ' LEU . 15.6 mt -79.58 177.52 8.81 Favored 'General case' 0 C--O 1.213 -0.868 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 168.078 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 17.3 tt0 -152.39 142.35 22.15 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-N 119.104 0.866 . . . . 0.0 111.56 171.15 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.448 ' HB3' ' CD2' ' A' ' 84' ' ' TYR . 89.3 mt -87.9 114.37 24.45 Favored 'General case' 0 C--O 1.24 0.56 0 CA-C-N 114.012 -1.449 . . . . 0.0 110.007 175.029 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -106.79 117.75 34.87 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 173.583 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 21.2 ptt180 -58.98 121.77 12.04 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 122.83 0.452 . . . . 0.0 110.08 177.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -113.8 -33.83 5.67 Favored 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 122.609 0.364 . . . . 0.0 110.676 -176.806 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -169.17 -172.16 1.46 Allowed 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 123.938 0.895 . . . . 0.0 109.9 -179.096 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -102.04 160.29 14.63 Favored 'General case' 0 C--O 1.245 0.83 0 N-CA-C 107.818 -1.178 . . . . 0.0 107.818 169.208 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 99.7 t -72.38 100.09 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 170.887 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 63.7 tttt -155.54 127.74 7.68 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 115.126 -0.943 . . . . 0.0 108.725 -166.111 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' TRP . . . . . 0.5 ' HE1' ' HG2' ' A' ' 157' ' ' GLN . 40.6 t90 -69.74 121.64 17.62 Favored 'General case' 0 C--O 1.236 0.375 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 167.802 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.504 ' HG3' ' HG2' ' A' ' 19' ' ' GLN . 9.4 tp10 -92.74 134.35 35.13 Favored 'General case' 0 C--O 1.238 0.486 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 173.11 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -72.25 0.24 10.38 Favored 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 124.171 0.988 . . . . 0.0 113.093 -173.276 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' GLN . . . . . 0.504 ' HG2' ' HG3' ' A' ' 17' ' ' GLU . 11.6 mm-40 -74.77 47.73 0.34 Allowed 'General case' 0 CA--C 1.557 1.212 0 C-N-CA 124.326 1.05 . . . . 0.0 111.185 175.206 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.431 ' HA ' ' O ' ' A' ' 169' ' ' ALA . . . -73.87 89.29 1.85 Allowed 'General case' 0 C--N 1.352 0.697 0 C-N-CA 123.915 0.886 . . . . 0.0 110.098 -176.644 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -88.19 141.26 28.7 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 114.762 -1.108 . . . . 0.0 109.196 179.638 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 44.4 mm -76.11 102.58 3.11 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.424 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 173.745 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 47.5 m -121.7 -71.85 0.71 Allowed 'General case' 0 CA--C 1.538 0.497 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.502 -167.853 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.487 ' HA3' HG23 ' A' ' 172' ' ' THR . . . -85.01 133.05 11.49 Favored Glycine 0 C--N 1.353 1.482 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 174.332 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' SER . . . . . 0.546 ' HA ' ' HB2' ' A' ' 173' ' ' LYS . 62.2 p -163.62 10.46 0.05 Allowed 'General case' 0 N--CA 1.481 1.085 0 CA-C-N 117.477 0.638 . . . . 0.0 112.106 -178.112 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.422 ' HA ' ' HD3' ' A' ' 27' ' ' PRO . 20.7 p -94.12 145.51 29.91 Favored Pre-proline 0 CA--C 1.55 0.962 0 C-N-CA 123.0 0.52 . . . . 0.0 110.245 179.838 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 26' ' ' SER . 31.5 Cg_endo -89.45 -82.87 0.0 OUTLIER 'Trans proline' 0 C--N 1.379 2.144 0 C-N-CA 123.005 2.47 . . . . 0.0 114.29 -175.461 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.419 ' HA ' ' O ' ' A' ' 176' ' ' LEU . 33.0 mm -101.93 130.68 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 C-N-CA 122.788 0.435 . . . . 0.0 111.173 -169.84 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.702 HD23 HG21 ' A' ' 217' ' ' THR . 0.0 OUTLIER -139.19 161.37 37.58 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 123.613 0.765 . . . . 0.0 110.586 170.96 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 34.2 p -88.59 144.46 26.3 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 123.171 0.588 . . . . 0.0 111.45 -178.318 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.404 HG23 HG22 ' A' ' 179' ' ' THR . 10.4 tt -155.37 152.63 8.72 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.175 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -178.745 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 3.9 m -97.99 109.42 22.18 Favored 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 123.153 0.581 . . . . 0.0 110.794 -173.076 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 18.1 tt -90.6 141.83 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 O-C-N 121.771 -0.581 . . . . 0.0 110.123 178.851 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 25.1 m -143.79 151.5 40.03 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 123.217 0.607 . . . . 0.0 111.05 -177.061 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 54.61 25.9 6.83 Favored 'General case' 0 N--CA 1.487 1.418 0 C-N-CA 124.338 1.055 . . . . 0.0 112.307 175.114 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.8 t70 73.35 -60.82 0.52 Allowed 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 125.759 1.624 . . . . 0.0 111.378 -173.648 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -89.21 -34.31 8.85 Favored Glycine 0 C--N 1.348 1.234 0 N-CA-C 114.713 0.645 . . . . 0.0 114.713 -173.523 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 24.4 t -87.34 105.11 17.02 Favored 'General case' 0 N--CA 1.484 1.261 0 CA-C-N 117.428 0.614 . . . . 0.0 109.398 -167.629 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' MET . . . . . 0.5 ' HE2' ' HB3' ' A' ' 39' ' ' MET . 43.5 ttp -125.41 131.18 52.97 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 122.656 0.382 . . . . 0.0 110.278 -171.412 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 72.4 m -155.76 -178.36 7.24 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 125.179 1.392 . . . . 0.0 109.177 -175.318 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.601 HG12 HG11 ' A' ' 215' ' ' VAL . 44.8 mm -80.62 150.02 4.9 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.821 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 159.512 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 45.4 pttt -67.61 76.24 0.18 Allowed 'General case' 0 CA--C 1.556 1.189 0 CA-C-O 122.172 0.987 . . . . 0.0 109.839 167.128 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 -148.12 -168.03 2.97 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 124.906 1.282 . . . . 0.0 108.813 -178.601 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -134.93 160.26 38.84 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 123.381 0.672 . . . . 0.0 109.439 -179.84 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.471 0.624 0 C-N-CA 123.788 0.835 . . . . 0.0 109.761 177.288 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 20.9 t70 . . . . . 0 CA--C 1.549 0.907 0 CA-C-O 119.932 -0.08 . . . . 0.0 110.857 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -177.41 -169.01 37.97 Favored Glycine 0 C--N 1.355 1.615 0 N-CA-C 115.198 0.839 . . . . 0.0 115.198 -175.502 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -97.85 122.65 41.21 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 124.479 1.112 . . . . 0.0 110.803 -176.051 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' TYR . . . . . 0.448 ' CD2' ' HB3' ' A' ' 8' ' ' LEU . 3.4 m-85 -117.42 154.8 30.73 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 123.498 0.719 . . . . 0.0 110.613 -175.383 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' ARG . . . . . 0.525 ' HG2' HG21 ' A' ' 195' ' ' THR . 22.1 mtm180 -99.17 127.91 45.22 Favored 'General case' 0 C--O 1.243 0.76 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 166.196 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.446 HG12 HD23 ' A' ' 8' ' ' LEU . 22.4 mt -92.12 129.7 42.35 Favored 'Isoleucine or valine' 0 C--O 1.25 1.13 0 CA-C-O 121.658 0.742 . . . . 0.0 109.346 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -117.37 154.17 31.78 Favored 'General case' 0 C--O 1.216 -0.675 0 CA-C-N 114.302 -1.317 . . . . 0.0 109.666 177.351 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.8 tp60 -85.58 107.17 17.37 Favored 'General case' 0 C--O 1.243 0.719 0 N-CA-C 104.807 -2.294 . . . . 0.0 104.807 163.58 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.4 tttp -88.55 98.17 11.5 Favored 'General case' 0 C--O 1.242 0.679 0 CA-C-N 114.706 -1.134 . . . . 0.0 108.522 -173.822 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -71.54 131.94 19.83 Favored Glycine 0 N--CA 1.439 -1.141 0 N-CA-C 108.021 -2.032 . . . . 0.0 108.021 161.267 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 33.1 mm -62.57 -12.87 10.03 Favored 'Isoleucine or valine' 0 CA--C 1.566 1.584 0 C-N-CA 123.171 0.588 . . . . 0.0 110.569 -178.819 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 2.3 pp -111.93 -18.27 12.7 Favored 'General case' 0 CA--C 1.562 1.414 0 C-N-CA 123.974 0.91 . . . . 0.0 112.889 168.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -160.81 127.18 1.72 Allowed Glycine 0 N--CA 1.488 2.132 0 N-CA-C 114.763 0.665 . . . . 0.0 114.763 -172.25 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 9.2 m-85 -84.16 160.37 20.87 Favored 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 123.409 0.684 . . . . 0.0 111.635 -178.682 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 37.9 t -148.42 139.21 22.95 Favored 'General case' 0 C--O 1.207 -1.169 0 C-N-CA 124.616 1.167 . . . . 0.0 108.325 169.696 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' GLN . . . . . . . . . . . . . 9.5 tt0 -90.68 125.61 35.72 Favored 'General case' 0 N--CA 1.493 1.71 0 CA-C-N 119.461 1.028 . . . . 0.0 109.64 -178.687 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 27.6 pt -124.02 -8.62 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 N-CA-C 112.559 0.578 . . . . 0.0 112.559 -172.952 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 160.92 -139.39 6.02 Favored Glycine 0 C--N 1.343 0.926 0 C-N-CA 120.903 -0.665 . . . . 0.0 113.05 170.95 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.476 ' HB2' HG22 ' A' ' 195' ' ' THR . . . -153.19 168.72 25.0 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 123.515 0.726 . . . . 0.0 111.786 -178.159 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -174.51 154.17 18.2 Favored Glycine 0 C--N 1.345 1.071 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.903 177.859 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 28.1 m -97.85 126.86 50.7 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 CA-C-N 117.607 0.703 . . . . 0.0 110.678 -179.346 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 24.3 t80 -100.76 106.4 17.81 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.489 ' HB3' ' O ' ' A' ' 106' ' ' THR . 14.2 tmtt? -100.87 149.85 23.45 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 -172.144 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -62.31 96.15 0.07 Allowed 'General case' 0 CA--C 1.56 1.348 0 CA-C-O 121.982 0.896 . . . . 0.0 111.713 -178.06 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 104.58 -9.01 48.11 Favored Glycine 0 C--N 1.342 0.882 0 CA-C-N 115.29 -0.868 . . . . 0.0 112.867 177.91 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 106' ' ' THR . . . . . 0.489 ' O ' ' HB3' ' A' ' 103' ' ' LYS . 54.6 m -151.21 124.25 8.7 Favored 'General case' 0 CA--C 1.547 0.854 0 CA-C-N 117.363 0.581 . . . . 0.0 110.314 -175.402 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 107' ' ' PHE . . . . . 0.635 ' HB3' ' HB3' ' A' ' 140' ' ' TYR . 27.4 t80 -96.35 133.66 40.45 Favored 'General case' 0 CA--C 1.545 0.786 0 O-C-N 121.461 -0.774 . . . . 0.0 110.075 176.244 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 108' ' ' HIS . . . . . 0.449 ' HB3' ' HE3' ' A' ' 144' ' ' TRP . 32.1 m170 -133.34 115.89 15.44 Favored 'General case' 0 N--CA 1.48 1.04 0 C-N-CA 124.113 0.965 . . . . 0.0 110.707 -178.48 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 109' ' ' THR . . . . . 0.621 HG23 ' HB ' ' A' ' 138' ' ' ILE . 10.1 t -136.87 -176.39 4.35 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 122.749 0.42 . . . . 0.0 110.736 174.466 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 110' ' ' MET . . . . . 0.627 ' HA ' ' HA ' ' A' ' 137' ' ' LEU . 34.6 mtp -93.78 163.15 13.64 Favored 'General case' 0 C--O 1.24 0.558 0 C-N-CA 123.785 0.834 . . . . 0.0 111.098 169.626 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 111' ' ' TRP . . . . . 0.61 ' HA ' HG13 ' A' ' 138' ' ' ILE . 83.9 t90 -80.23 -38.36 31.19 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 123.523 0.729 . . . . 0.0 111.62 -175.908 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 112' ' ' HIS . . . . . 0.434 ' CE1' ' SD ' ' A' ' 110' ' ' MET . 1.1 p-80 -64.07 -9.42 16.17 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 125.03 1.332 . . . . 0.0 113.933 -169.162 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 33.9 m -57.36 -36.4 52.62 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.911 0 O-C-N 123.471 0.482 . . . . 0.0 110.278 176.424 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -152.74 -151.6 0.39 Allowed 'General case' 0 CA--C 1.56 1.334 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 175.022 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 55.8 ttt85 -99.4 32.73 2.67 Favored 'General case' 0 CA--C 1.557 1.227 0 C-N-CA 123.64 0.776 . . . . 0.0 110.112 176.251 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.51 ' HA2' HD11 ' A' ' 138' ' ' ILE . . . 85.0 53.29 3.2 Favored Glycine 0 C--N 1.346 1.131 0 N-CA-C 111.848 -0.501 . . . . 0.0 111.848 -176.338 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -94.83 169.43 10.15 Favored 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 123.513 0.725 . . . . 0.0 112.251 -174.034 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.562 HG23 ' HA ' ' A' ' 127' ' ' GLU . 7.1 p -91.69 142.83 12.46 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.073 0 CA-C-N 114.962 -1.017 . . . . 0.0 111.281 -176.92 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.683 HD13 ' HB2' ' A' ' 6' ' ' LEU . 2.9 mm? -93.48 152.87 18.79 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 124.236 1.015 . . . . 0.0 110.779 -174.517 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 120' ' ' MET . . . . . 0.657 ' HE1' ' HG3' ' A' ' 125' ' ' ARG . 32.5 mmt -110.32 158.2 18.68 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 169.581 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 80.3 t60 -161.95 96.54 1.01 Allowed 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 175.204 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 77.7 tttt 59.23 31.17 20.99 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 123.774 0.83 . . . . 0.0 111.085 176.088 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 101.63 -11.23 57.87 Favored Glycine 0 C--N 1.355 1.587 0 CA-C-N 115.945 -0.571 . . . . 0.0 113.553 -179.466 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 49.9 tttm -90.2 127.23 36.07 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 123.122 0.569 . . . . 0.0 109.612 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' ARG . . . . . 0.657 ' HG3' ' HE1' ' A' ' 120' ' ' MET . 28.2 ttm-85 -89.66 101.25 13.94 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 123.444 0.698 . . . . 0.0 109.518 179.0 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 68.7 mt -85.2 99.92 7.81 Favored 'Isoleucine or valine' 0 C--O 1.239 0.542 0 C-N-CA 123.837 0.855 . . . . 0.0 109.949 178.646 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 127' ' ' GLU . . . . . 0.562 ' HA ' HG23 ' A' ' 118' ' ' VAL . 0.3 OUTLIER -74.1 149.91 87.54 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.177 174.979 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_endo -79.59 152.95 23.18 Favored 'Trans proline' 0 C--N 1.366 1.499 0 C-N-CA 122.115 1.877 . . . . 0.0 111.8 167.587 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 95.3 p -89.36 -26.8 20.87 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 122.874 0.47 . . . . 0.0 110.131 171.744 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 74.7 t-105 -165.88 156.12 12.78 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 123.497 0.719 . . . . 0.0 109.665 179.344 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 131' ' ' ALA . . . . . 0.428 ' HB1' ' HD1' ' A' ' 111' ' ' TRP . . . -133.95 118.62 18.08 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.574 0.75 . . . . 0.0 109.024 172.664 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 22.5 t0 -90.09 104.41 16.98 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 124.288 1.035 . . . . 0.0 108.269 175.318 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 45.7 t -75.79 -26.79 18.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 122.929 0.492 . . . . 0.0 111.08 -176.428 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 26.6 mtpp -73.14 -51.47 17.79 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.351 0.661 . . . . 0.0 111.358 -175.158 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 42.8 mtpt -85.73 -4.14 59.08 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 115.45 -0.795 . . . . 0.0 111.554 -179.255 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 37.0 t0 65.22 56.77 0.98 Allowed 'General case' 0 CA--C 1.552 1.025 0 O-C-N 124.554 1.159 . . . . 0.0 109.621 175.894 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 137' ' ' LEU . . . . . 0.627 ' HA ' ' HA ' ' A' ' 110' ' ' MET . 62.6 mt -143.49 137.58 28.62 Favored 'General case' 0 N--CA 1.478 0.958 0 O-C-N 121.482 -0.762 . . . . 0.0 110.329 -177.701 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.621 ' HB ' HG23 ' A' ' 109' ' ' THR . 84.8 mt -111.99 149.44 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.376 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 169.305 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 139' ' ' SER . . . . . 0.421 ' HB2' ' O ' ' A' ' 142' ' ' GLY . 33.5 p -145.44 148.44 33.3 Favored 'General case' 0 C--O 1.241 0.65 0 C-N-CA 123.374 0.67 . . . . 0.0 110.519 -172.545 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.635 ' HB3' ' HB3' ' A' ' 107' ' ' PHE . 37.5 t80 -144.27 120.01 10.51 Favored 'General case' 0 N--CA 1.466 0.333 0 C-N-CA 124.662 1.185 . . . . 0.0 108.705 178.004 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 86.25 3.69 84.51 Favored Glycine 0 C--N 1.345 1.054 0 O-C-N 123.572 0.545 . . . . 0.0 112.725 -178.003 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 142' ' ' GLY . . . . . 0.421 ' O ' ' HB2' ' A' ' 139' ' ' SER . . . 147.28 148.82 4.83 Favored Glycine 0 C--N 1.344 0.995 0 N-CA-C 110.386 -1.085 . . . . 0.0 110.386 -177.884 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -67.83 169.71 37.88 Favored Glycine 0 C--N 1.348 1.234 0 C-N-CA 123.126 0.393 . . . . 0.0 112.608 -179.562 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 144' ' ' TRP . . . . . 0.644 ' HZ2' ' HA2' ' A' ' 209' ' ' GLY . 57.1 t-105 -58.43 105.54 0.3 Allowed 'General case' 0 CA--C 1.555 1.135 0 CA-C-O 121.209 0.528 . . . . 0.0 110.977 -177.517 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 145' ' ' LYS . . . . . 0.643 ' HA ' ' HB ' ' A' ' 229' ' ' THR . 50.1 tttm -163.82 126.97 2.59 Favored 'General case' 0 CA--C 1.54 0.562 0 CA-C-N 115.04 -0.982 . . . . 0.0 109.433 176.513 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 146' ' ' LEU . . . . . 0.444 ' H ' ' HB ' ' A' ' 229' ' ' THR . 79.5 mt -141.8 -2.74 1.17 Allowed 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 125.744 1.618 . . . . 0.0 110.219 179.727 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 29.2 tt0 86.69 18.53 0.09 Allowed 'General case' 0 N--CA 1.5 2.043 0 C-N-CA 125.355 1.462 . . . . 0.0 110.848 171.197 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 148' ' ' GLY . . . . . 0.577 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -85.15 117.72 4.59 Favored Glycine 0 N--CA 1.434 -1.489 0 CA-C-N 115.376 -0.829 . . . . 0.0 113.466 173.578 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -116.04 95.12 4.95 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 124.06 0.944 . . . . 0.0 110.175 -175.311 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 150' ' ' TRP . . . . . 0.608 ' HZ2' ' HG3' ' A' ' 174' ' ' PRO . 35.8 t90 -82.86 146.97 28.6 Favored 'General case' 0 CA--C 1.553 1.095 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.27 168.313 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.414 ' HB3' ' HG2' ' A' ' 154' ' ' GLU . 22.5 tptp -112.67 128.79 56.49 Favored 'General case' 0 N--CA 1.476 0.841 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 177.095 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -63.13 99.69 0.19 Allowed 'General case' 0 N--CA 1.483 1.221 0 C-N-CA 123.494 0.718 . . . . 0.0 111.059 -179.214 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 143.54 -23.25 2.18 Favored Glycine 0 C--N 1.341 0.851 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.345 -177.828 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 154' ' ' GLU . . . . . 0.414 ' HG2' ' HB3' ' A' ' 151' ' ' LYS . 32.7 mm-40 -75.91 133.58 40.48 Favored 'General case' 0 C--O 1.24 0.581 0 C-N-CA 123.324 0.65 . . . . 0.0 111.604 -179.452 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 155' ' ' GLU . . . . . 0.536 ' HG2' ' HG2' ' A' ' 173' ' ' LYS . 35.8 mt-10 -74.84 101.62 4.44 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 174.845 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 9.7 p -114.72 145.83 19.99 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 123.257 0.623 . . . . 0.0 109.577 -168.972 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 157' ' ' GLN . . . . . 0.5 ' HG2' ' HE1' ' A' ' 16' ' ' TRP . 25.2 mp0 -93.34 141.19 28.72 Favored 'General case' 0 C--O 1.217 -0.641 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 -172.541 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.465 ' O ' ' HA ' ' A' ' 169' ' ' ALA . 46.9 t -101.2 116.11 44.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 177.019 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -72.08 86.37 1.04 Allowed 'General case' 0 CA--C 1.548 0.869 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 176.647 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -88.44 139.13 30.8 Favored 'General case' 0 C--O 1.249 1.044 0 CA-C-N 114.181 -1.372 . . . . 0.0 110.738 -174.453 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 35.2 mt -112.7 84.29 1.96 Allowed 'General case' 0 C--O 1.245 0.854 0 C-N-CA 124.718 1.207 . . . . 0.0 108.936 -178.891 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 162' ' ' GLU . . . . . 0.675 ' HB2' ' HB2' ' A' ' 165' ' ' LYS . 44.2 mt-10 -75.98 143.48 74.21 Favored Pre-proline 0 CA--C 1.547 0.855 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 176.183 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -70.35 114.12 3.69 Favored 'Trans proline' 0 C--N 1.374 1.897 0 C-N-CA 122.209 1.939 . . . . 0.0 110.591 -177.785 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 90.85 -11.24 72.54 Favored Glycine 0 C--N 1.34 0.76 0 CA-C-N 115.954 -0.566 . . . . 0.0 113.42 179.022 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 165' ' ' LYS . . . . . 0.675 ' HB2' ' HB2' ' A' ' 162' ' ' GLU . 47.5 mmtm -104.53 147.83 27.17 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 176.096 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -58.85 149.5 64.42 Favored Pre-proline 0 CA--C 1.554 1.111 0 O-C-N 123.553 0.533 . . . . 0.0 111.832 179.399 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo -56.56 118.09 4.87 Favored 'Trans proline' 0 C--N 1.376 1.994 0 C-N-CA 122.497 2.131 . . . . 0.0 110.348 171.442 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 16.0 ptt180 -135.25 134.09 39.64 Favored 'General case' 0 N--CA 1.47 0.556 0 CA-C-O 120.825 0.345 . . . . 0.0 110.202 -176.606 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 169' ' ' ALA . . . . . 0.487 ' H ' ' HB3' ' A' ' 17' ' ' GLU . . . -97.75 105.24 17.35 Favored 'General case' 0 C--O 1.225 -0.219 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.557 -177.691 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 27.7 m -97.64 133.63 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.234 0 C-N-CA 123.663 0.785 . . . . 0.0 110.125 -174.84 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 171' ' ' GLN . . . . . 0.42 ' HA ' ' HA ' ' A' ' 157' ' ' GLN . 27.7 tt0 -77.75 128.41 33.99 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-O 121.656 0.741 . . . . 0.0 110.328 -171.593 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 172' ' ' THR . . . . . 0.583 HG21 HG13 ' A' ' 187' ' ' VAL . 68.7 m -128.08 123.3 34.21 Favored 'General case' 0 C--O 1.246 0.908 0 CA-C-N 113.842 -1.526 . . . . 0.0 109.448 -175.205 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 173' ' ' LYS . . . . . 0.546 ' HB2' ' HA ' ' A' ' 25' ' ' SER . 27.5 mtpp -76.15 141.61 70.95 Favored Pre-proline 0 CA--C 1.544 0.743 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 168.808 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 174' ' ' PRO . . . . . 0.608 ' HG3' ' HZ2' ' A' ' 150' ' ' TRP . 39.4 Cg_exo -55.37 122.95 12.64 Favored 'Trans proline' 0 C--N 1.371 1.74 0 C-N-CA 122.511 2.14 . . . . 0.0 113.66 -171.481 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 175' ' ' GLY . . . . . 0.484 ' H ' ' C ' ' A' ' 186' ' ' ALA . . . -117.26 127.33 7.34 Favored Glycine 0 N--CA 1.482 1.723 0 CA-C-O 121.606 0.559 . . . . 0.0 113.594 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.459 ' N ' HD23 ' A' ' 176' ' ' LEU . 0.4 OUTLIER -132.01 127.97 37.35 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 121.914 0.864 . . . . 0.0 109.52 -169.031 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 177' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -102.58 138.94 38.83 Favored 'General case' 0 C--O 1.245 0.86 0 CA-C-N 114.069 -1.423 . . . . 0.0 110.494 -169.505 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 58.5 tptt -86.0 124.89 32.95 Favored 'General case' 0 C--O 1.243 0.716 0 C-N-CA 124.585 1.154 . . . . 0.0 109.953 -178.552 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 179' ' ' THR . . . . . 0.404 HG22 HG23 ' A' ' 31' ' ' ILE . 68.9 p -120.53 175.86 5.78 Favored 'General case' 0 C--O 1.242 0.697 0 C-N-CA 123.31 0.644 . . . . 0.0 109.612 169.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 -68.07 -21.37 64.98 Favored 'General case' 0 CA--C 1.546 0.806 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.206 172.694 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -78.65 -53.04 7.58 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 123.724 0.81 . . . . 0.0 110.301 176.011 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 177.48 176.97 45.98 Favored Glycine 0 C--N 1.344 0.999 0 CA-C-N 115.623 -0.717 . . . . 0.0 112.331 -178.742 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 15.5 m -93.91 104.32 16.38 Favored 'General case' 0 CA--C 1.542 0.663 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 176.421 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 184' ' ' ILE . . . . . 0.483 HD13 ' H ' ' A' ' 184' ' ' ILE . 0.2 OUTLIER -123.63 161.09 26.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 C-N-CA 123.455 0.702 . . . . 0.0 109.732 -174.122 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . 113.48 178.41 19.37 Favored Glycine 0 N--CA 1.47 0.912 0 CA-C-O 119.802 -0.443 . . . . 0.0 113.074 176.401 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.484 ' C ' ' H ' ' A' ' 175' ' ' GLY . . . -173.22 38.12 0.01 OUTLIER 'General case' 0 C--N 1.364 1.222 0 C-N-CA 123.75 0.82 . . . . 0.0 110.967 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 187' ' ' VAL . . . . . 0.583 HG13 HG21 ' A' ' 172' ' ' THR . 58.5 t -155.1 117.51 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 C-N-CA 125.146 1.378 . . . . 0.0 107.48 171.539 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 188' ' ' SER . . . . . 0.546 ' HA ' HG12 ' A' ' 223' ' ' VAL . 68.4 m -129.83 86.2 2.38 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-O 121.877 0.846 . . . . 0.0 108.747 170.531 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 32.4 tp -106.38 103.77 13.31 Favored 'General case' 0 CA--C 1.543 0.687 0 CA-C-N 113.907 -1.497 . . . . 0.0 110.231 -173.88 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 190' ' ' ASP . . . . . 0.711 ' HA ' ' HA ' ' A' ' 221' ' ' ALA . 11.0 p-10 -90.52 102.04 14.78 Favored 'General case' 0 N--CA 1.478 0.934 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 175.348 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 191' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 179.41 -174.88 0.23 Allowed 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 125.981 1.713 . . . . 0.0 108.254 -174.879 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 9.5 m -51.19 119.89 13.25 Favored Pre-proline 0 CA--C 1.551 0.994 0 O-C-N 123.872 0.733 . . . . 0.0 109.801 172.627 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_exo -48.01 132.61 22.73 Favored 'Trans proline' 0 C--N 1.379 2.138 0 C-N-CA 123.471 2.781 . . . . 0.0 114.226 -171.024 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -67.0 167.18 39.37 Favored Glycine 0 C--N 1.348 1.232 0 CA-C-N 115.633 -0.712 . . . . 0.0 112.085 175.069 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 195' ' ' THR . . . . . 0.525 HG21 ' HG2' ' A' ' 85' ' ' ARG . 1.4 m -89.99 103.77 16.41 Favored 'General case' 0 CA--C 1.54 0.559 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -173.617 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 43.6 t -51.72 85.08 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.09 0 C-N-CA 125.285 1.434 . . . . 0.0 113.389 -170.924 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 126.03 16.01 2.74 Favored Glycine 0 C--N 1.355 1.586 0 CA-C-N 115.253 -0.885 . . . . 0.0 113.083 179.123 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 84.2 p -82.81 155.86 67.87 Favored Pre-proline 0 N--CA 1.483 1.21 0 CA-C-N 117.477 0.638 . . . . 0.0 110.156 178.082 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -74.15 142.64 31.02 Favored 'Trans proline' 0 C--N 1.386 2.535 0 C-N-CA 122.308 2.006 . . . . 0.0 113.157 -178.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 62.6 mt -108.59 113.57 44.37 Favored 'Isoleucine or valine' 0 C--O 1.255 1.36 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 175.833 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 201' ' ' ILE . . . . . 0.607 HG12 ' HA ' ' A' ' 208' ' ' VAL . 14.3 mt -117.24 134.95 59.19 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.085 0 CA-C-N 114.822 -1.081 . . . . 0.0 110.799 -167.445 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -68.37 162.82 24.5 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 125.06 1.344 . . . . 0.0 110.704 174.454 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 63.2 tttm -67.45 -15.54 63.73 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 124.6 1.16 . . . . 0.0 112.061 -173.049 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 21.6 ptmt -94.15 4.01 54.48 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 123.232 0.613 . . . . 0.0 112.147 177.387 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 80.41 38.87 16.39 Favored Glycine 0 C--N 1.351 1.393 0 C-N-CA 122.9 0.286 . . . . 0.0 112.856 -178.851 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 58.0 tttp -128.78 167.1 17.78 Favored 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 124.272 1.029 . . . . 0.0 109.758 -174.341 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 207' ' ' VAL . . . . . 0.577 ' O ' ' HA3' ' A' ' 148' ' ' GLY . 89.5 t 95.64 -74.91 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.146 0 C-N-CA 125.719 1.608 . . . . 0.0 110.157 171.079 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 208' ' ' VAL . . . . . 0.607 ' HA ' HG12 ' A' ' 201' ' ' ILE . 3.2 m 63.1 22.37 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 CA-C-O 122.484 1.135 . . . . 0.0 109.787 166.414 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.644 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . -83.08 128.85 8.72 Favored Glycine 0 C--N 1.347 1.18 0 CA-C-N 113.376 -1.738 . . . . 0.0 109.353 -172.456 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 87.4 mt -65.65 173.28 2.87 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-N 117.908 0.854 . . . . 0.0 111.287 -165.47 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 211' ' ' TYR . . . . . 0.457 ' CZ ' HG11 ' A' ' 158' ' ' VAL . 6.3 m-85 -56.56 157.78 4.97 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.824 163.742 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 212' ' ' GLY . . . . . 0.612 ' HA3' ' HB3' ' A' ' 225' ' ' ALA . . . -105.87 -141.18 10.38 Favored Glycine 0 C--O 1.24 0.492 0 N-CA-C 111.264 -0.735 . . . . 0.0 111.264 173.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 213' ' ' ASN . . . . . . . . . . . . . 23.5 p-10 -100.13 130.47 46.27 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 -176.327 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . -176.45 -135.96 2.27 Favored Glycine 0 C--N 1.337 0.617 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.962 176.909 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 215' ' ' VAL . . . . . 0.601 HG11 HG12 ' A' ' 41' ' ' ILE . 7.4 p 176.06 162.85 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 C-N-CA 125.415 1.486 . . . . 0.0 107.936 -171.485 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 216' ' ' VAL . . . . . 0.661 ' HA ' ' HA ' ' A' ' 222' ' ' TYR . 7.8 p -75.07 110.27 9.5 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.498 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 161.167 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 217' ' ' THR . . . . . 0.702 HG21 HD23 ' A' ' 29' ' ' LEU . 53.2 m -87.69 141.82 28.31 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.992 0.917 . . . . 0.0 110.19 -178.448 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 218' ' ' ARG . . . . . 0.46 ' HG3' HG22 ' A' ' 217' ' ' THR . 57.3 mtp180 62.71 8.6 3.09 Favored 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 124.093 0.957 . . . . 0.0 111.574 -175.047 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 68.0 m 62.75 26.31 15.55 Favored 'General case' 0 C--N 1.359 1.006 0 C-N-CA 124.734 1.214 . . . . 0.0 112.077 -176.224 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . -153.88 -19.4 0.05 OUTLIER Glycine 0 C--N 1.349 1.277 0 CA-C-N 116.637 -0.256 . . . . 0.0 113.653 179.29 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 221' ' ' ALA . . . . . 0.711 ' HA ' ' HA ' ' A' ' 190' ' ' ASP . . . -113.87 89.65 3.14 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 123.333 0.653 . . . . 0.0 109.757 -175.576 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 222' ' ' TYR . . . . . 0.661 ' HA ' ' HA ' ' A' ' 216' ' ' VAL . 50.2 t80 -69.15 118.2 11.75 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 123.149 0.58 . . . . 0.0 110.453 -177.45 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 223' ' ' VAL . . . . . 0.546 HG12 ' HA ' ' A' ' 188' ' ' SER . 21.5 m -123.05 145.43 29.95 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.731 0 C-N-CA 123.507 0.723 . . . . 0.0 110.687 -179.039 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 70.2 m -158.7 159.78 35.67 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 124.915 1.286 . . . . 0.0 108.757 178.483 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 225' ' ' ALA . . . . . 0.612 ' HB3' ' HA3' ' A' ' 212' ' ' GLY . . . -76.64 -169.06 1.14 Allowed 'General case' 0 N--CA 1.482 1.147 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 167.239 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 226' ' ' ILE . . . . . . . . . . . . . 54.9 mt -127.83 106.34 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.12 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 174.5 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -85.14 92.03 8.28 Favored 'General case' 0 C--O 1.239 0.551 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 177.652 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 20.1 pt20 -92.31 158.88 15.87 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-N 115.248 -0.887 . . . . 0.0 108.813 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 229' ' ' THR . . . . . 0.643 ' HB ' ' HA ' ' A' ' 145' ' ' LYS . 30.5 p -69.12 107.44 3.19 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-O 121.589 0.709 . . . . 0.0 110.738 -161.957 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -168.75 79.59 0.14 Allowed 'General case' 0 N--CA 1.451 -0.401 0 N-CA-C 106.366 -1.716 . . . . 0.0 106.366 -171.801 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 231' ' ' LYS . . . . . 0.413 ' HD3' ' H ' ' A' ' 144' ' ' TRP . 59.1 tttp -145.85 -78.82 0.18 Allowed 'General case' 0 N--CA 1.48 1.07 0 CA-C-N 115.912 -0.585 . . . . 0.0 112.297 167.986 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 68.0 p . . . . . 0 N--CA 1.485 1.312 0 CA-C-N 118.884 0.765 . . . . 0.0 112.036 -174.098 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.724 0 CA-C-O 120.98 0.419 . . . . 0.0 110.674 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.58 41.11 1.06 Allowed 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 124.186 0.994 . . . . 0.0 109.798 -171.415 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' ASP . . . . . 0.489 ' HA ' ' HG2' ' A' ' 120' ' ' MET . 7.1 m-20 -153.86 52.53 0.7 Allowed 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 -163.168 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.633 ' HB2' ' HG ' ' A' ' 119' ' ' LEU . 7.9 mt -95.18 89.36 5.49 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 177.113 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.707 ' HB3' ' HD2' ' A' ' 89' ' ' LYS . 11.8 pt-20 -78.7 147.26 33.55 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-O 121.446 0.641 . . . . 0.0 111.771 -173.63 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 41.9 mt -98.02 113.71 25.65 Favored 'General case' 0 C--O 1.238 0.489 0 CA-C-N 114.281 -1.327 . . . . 0.0 108.9 179.77 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -109.47 144.56 37.56 Favored 'General case' 0 N--CA 1.482 1.132 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 171.383 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 18.0 ttm-85 -69.24 129.09 38.85 Favored 'General case' 0 C--O 1.24 0.604 0 CA-C-O 121.169 0.509 . . . . 0.0 111.476 -173.09 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.593 ' HB2' ' HB2' ' A' ' 85' ' ' ARG . . . -103.21 -37.62 7.62 Favored 'General case' 0 C--O 1.239 0.531 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.13 178.983 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ALA . . . . . 0.428 ' HB3' ' HB3' ' A' ' 83' ' ' ALA . . . -165.87 170.3 13.96 Favored 'General case' 0 N--CA 1.474 0.733 0 CA-C-O 121.595 0.712 . . . . 0.0 111.456 -176.523 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -111.55 145.94 38.21 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 171.074 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 59.7 t -74.26 97.75 1.09 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.919 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 -179.29 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 24.1 ttmm -175.13 111.66 0.13 Allowed 'General case' 0 C--O 1.239 0.507 0 C-N-CA 125.615 1.566 . . . . 0.0 107.271 178.727 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' TRP . . . . . 0.513 ' HE1' ' HB1' ' A' ' 169' ' ' ALA . 34.7 t90 -93.5 95.01 8.99 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 122.086 0.155 . . . . 0.0 111.07 -178.985 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -159.68 64.36 0.37 Allowed 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 148.935 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -89.61 -62.06 1.56 Allowed 'General case' 0 N--CA 1.481 1.111 0 CA-C-O 121.242 0.544 . . . . 0.0 112.192 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' GLN . . . . . 0.494 ' H ' ' HB3' ' A' ' 169' ' ' ALA . 71.5 mt-30 -150.88 47.74 0.86 Allowed 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 124.203 1.001 . . . . 0.0 109.606 -168.575 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -48.77 95.42 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 113.556 0.947 . . . . 0.0 113.556 -172.368 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -136.48 164.5 28.01 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 125.631 1.572 . . . . 0.0 108.864 -177.532 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.606 HG22 ' HB2' ' A' ' 171' ' ' GLN . 0.2 OUTLIER -122.57 140.3 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.242 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 177.464 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 63.1 m -139.84 -57.82 0.56 Allowed 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -68.93 118.67 9.04 Favored Glycine 0 C--N 1.349 1.28 0 N-CA-C 114.469 0.547 . . . . 0.0 114.469 -168.628 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 68.0 m -164.31 24.32 0.07 Allowed 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 124.864 1.266 . . . . 0.0 109.572 -173.912 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.629 ' HB2' ' HB2' ' A' ' 188' ' ' SER . 18.4 m -73.88 161.53 78.19 Favored Pre-proline 0 CA--C 1.555 1.163 0 C-N-CA 123.323 0.649 . . . . 0.0 110.701 -177.549 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_exo -71.77 -173.68 1.09 Allowed 'Trans proline' 0 C--N 1.378 2.1 0 C-N-CA 122.471 2.114 . . . . 0.0 112.874 174.017 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.55 HD12 ' HB2' ' A' ' 176' ' ' LEU . 27.3 mm -76.14 140.91 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.461 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.406 ' HB3' HG21 ' A' ' 217' ' ' THR . 14.0 mt -131.07 132.24 44.76 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 122.796 0.438 . . . . 0.0 111.605 -168.734 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 178' ' ' LYS . 49.3 m -69.97 135.15 49.1 Favored 'General case' 0 C--N 1.35 0.62 0 O-C-N 124.098 0.874 . . . . 0.0 111.096 179.493 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 19.6 tt -142.62 141.26 27.79 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.744 0 C-N-CA 123.829 0.852 . . . . 0.0 109.205 -177.655 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 56.0 p -99.42 109.6 22.16 Favored 'General case' 0 CA--C 1.555 1.154 0 C-N-CA 123.24 0.616 . . . . 0.0 110.168 -176.546 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 1.5 mp -80.75 120.31 32.1 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 C-N-CA 123.687 0.795 . . . . 0.0 109.038 176.33 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 26.0 m -97.71 122.78 41.19 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 124.254 1.022 . . . . 0.0 110.094 -178.967 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 67.57 12.4 8.86 Favored 'General case' 0 N--CA 1.493 1.677 0 C-N-CA 124.358 1.063 . . . . 0.0 112.383 171.761 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 61.73 24.86 14.88 Favored 'General case' 0 N--CA 1.491 1.618 0 C-N-CA 124.436 1.094 . . . . 0.0 112.113 -177.762 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -143.03 -42.97 0.05 OUTLIER Glycine 0 C--N 1.338 0.683 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 -178.712 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 39.4 t -93.66 162.93 13.75 Favored 'General case' 0 C--O 1.241 0.609 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 175.092 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 20.9 ptm -161.73 134.77 6.18 Favored 'General case' 0 C--O 1.241 0.609 0 C-N-CA 122.829 0.452 . . . . 0.0 110.065 -175.694 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 28.5 p -173.26 -179.07 1.86 Allowed 'General case' 0 C--O 1.221 -0.43 0 C-N-CA 123.786 0.835 . . . . 0.0 109.422 179.702 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.755 HD11 HG23 ' A' ' 217' ' ' THR . 28.3 mm -72.12 151.03 8.46 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.971 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 165.593 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 15.3 ptmt -42.62 140.0 1.41 Allowed 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 124.968 1.307 . . . . 0.0 112.104 171.785 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 65.07 85.57 0.14 Allowed 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 124.999 1.319 . . . . 0.0 108.952 -160.761 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -86.18 26.91 0.97 Allowed 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 123.86 0.864 . . . . 0.0 113.125 -169.156 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 . . . . . 0 N--CA 1.48 1.07 0 C-N-CA 123.671 0.788 . . . . 0.0 110.772 172.461 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 . . . . . 0 N--CA 1.476 0.873 0 CA-C-O 121.548 0.689 . . . . 0.0 110.923 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -129.23 137.97 9.94 Favored Glycine 0 C--N 1.338 0.66 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 174.835 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' ALA . . . . . 0.428 ' HB3' ' HB3' ' A' ' 12' ' ' ALA . . . -89.21 120.64 30.76 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 178.544 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 47.6 m-85 -112.55 171.47 7.5 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-O 121.603 0.716 . . . . 0.0 111.127 -176.75 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' ARG . . . . . 0.593 ' HB2' ' HB2' ' A' ' 11' ' ' ALA . 44.4 ttm105 -131.77 122.83 26.48 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 -177.104 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.465 ' H ' ' HA ' ' A' ' 99' ' ' ALA . 24.5 mt -83.29 133.18 29.67 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 -175.856 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.597 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 76.8 tttt -137.88 131.18 30.61 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 114.743 -1.117 . . . . 0.0 108.405 -170.205 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.55 130.11 35.05 Favored 'General case' 0 C--O 1.245 0.822 0 N-CA-C 106.753 -1.573 . . . . 0.0 106.753 176.315 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' LYS . . . . . 0.707 ' HD2' ' HB3' ' A' ' 7' ' ' GLU . 48.3 tttp -123.11 135.72 54.49 Favored 'General case' 0 CA--C 1.549 0.914 0 CA-C-N 114.573 -1.194 . . . . 0.0 112.264 -162.024 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' GLY . . . . . 0.55 ' O ' ' HG2' ' A' ' 89' ' ' LYS . . . -91.83 162.11 27.43 Favored Glycine 0 C--O 1.207 -1.569 0 N-CA-C 106.464 -2.654 . . . . 0.0 106.464 149.837 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 31.1 mm -54.99 -18.74 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.195 0 CA-C-N 121.333 2.566 . . . . 0.0 114.47 -167.444 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 66.5 mt -86.1 -38.21 18.02 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.385 -0.822 . . . . 0.0 110.464 167.524 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.444 ' HA2' ' HG3' ' A' ' 89' ' ' LYS . . . 145.29 -167.63 27.36 Favored Glycine 0 N--CA 1.477 1.399 0 CA-C-O 118.348 -1.251 . . . . 0.0 110.381 176.608 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' TYR . . . . . 0.583 ' H ' ' HE2' ' A' ' 87' ' ' LYS 0.285 3.0 p90 178.68 -79.51 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.728 0 C-N-CA 123.838 0.855 . . . . 0.0 112.276 146.488 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 93.6 p -117.45 135.07 54.16 Favored 'General case' 0 N--CA 1.504 2.246 0 CA-C-N 120.384 1.447 . . . . 0.0 112.444 -161.328 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.597 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 5.1 pp0? -81.58 148.48 29.09 Favored 'General case' 0 N--CA 1.485 1.317 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 177.109 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 26.0 pt -133.18 -28.6 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 C-N-CA 123.354 0.662 . . . . 0.0 112.037 -171.758 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -167.41 -155.38 9.15 Favored Glycine 0 C--N 1.344 1.012 0 CA-C-O 119.803 -0.443 . . . . 0.0 112.237 -176.389 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.545 ' HA ' ' HA ' ' A' ' 85' ' ' ARG . . . -154.96 171.97 18.85 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 123.544 0.738 . . . . 0.0 110.507 -178.24 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -178.92 151.42 10.3 Favored Glycine 0 C--N 1.347 1.151 0 O-C-N 123.135 0.272 . . . . 0.0 112.594 179.487 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.446 HG12 HD11 ' A' ' 210' ' ' LEU . 14.9 p -89.15 138.17 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 122.93 0.492 . . . . 0.0 109.908 179.671 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -118.28 138.63 52.24 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 170.43 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -135.14 105.9 6.53 Favored 'General case' 0 C--O 1.238 0.472 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 176.395 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 29.3 mt-10 63.39 -87.14 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.167 0 C-N-CA 125.031 1.332 . . . . 0.0 112.251 171.516 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -126.11 11.05 7.33 Favored Glycine 0 C--N 1.349 1.27 0 CA-C-O 120.163 -0.243 . . . . 0.0 113.025 -176.96 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 15.2 t -132.89 131.36 40.85 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 122.96 0.504 . . . . 0.0 110.094 -177.317 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 30.9 t80 -115.49 131.56 56.89 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 123.258 0.623 . . . . 0.0 109.805 -175.322 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 80.7 m-70 -135.15 123.5 23.22 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 123.058 0.543 . . . . 0.0 110.56 -177.876 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' THR . . . . . 0.682 HG23 HG23 ' A' ' 138' ' ' ILE . 1.9 t -139.35 175.24 9.73 Favored 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 123.245 0.618 . . . . 0.0 111.911 -179.324 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 110' ' ' MET . . . . . . . . . . . . . 8.0 mmt -75.07 150.1 38.97 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 124.36 1.064 . . . . 0.0 109.561 172.212 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' TRP . . . . . 0.413 ' HA ' HG22 ' A' ' 138' ' ' ILE . 76.0 t90 -78.89 -43.98 23.75 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 123.071 0.549 . . . . 0.0 111.854 -169.282 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -65.76 -6.58 12.17 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 114.312 1.227 . . . . 0.0 114.312 -172.273 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 19.7 m -60.35 -40.4 83.85 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 176.455 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 90.0 m -164.5 140.0 5.82 Favored 'General case' 0 CA--C 1.551 1.017 0 C-N-CA 126.287 1.835 . . . . 0.0 107.396 171.299 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 32.8 mtt180 -80.85 33.08 0.32 Allowed 'General case' 0 N--CA 1.485 1.305 0 N-CA-C 114.152 1.167 . . . . 0.0 114.152 -166.45 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 107.27 62.15 0.57 Allowed Glycine 0 C--N 1.346 1.091 0 O-C-N 122.085 -0.384 . . . . 0.0 112.656 178.225 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -122.78 168.23 12.5 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 123.441 0.696 . . . . 0.0 110.064 174.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 87.9 t -75.44 144.43 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.802 0 C-N-CA 123.99 0.916 . . . . 0.0 110.96 -177.888 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.735 ' HB2' ' HB ' ' A' ' 126' ' ' ILE . 5.2 mp -111.16 161.17 16.23 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 123.077 0.551 . . . . 0.0 111.831 178.853 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 120' ' ' MET . . . . . 0.489 ' HG2' ' HA ' ' A' ' 5' ' ' ASP . 19.6 mmt -110.7 106.99 16.4 Favored 'General case' 0 C--O 1.241 0.619 0 CA-C-O 121.935 0.874 . . . . 0.0 110.1 179.191 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.558 ' HB2' HD11 ' A' ' 126' ' ' ILE . 13.9 t60 -104.13 95.07 5.73 Favored 'General case' 0 CA--C 1.542 0.663 0 N-CA-C 107.929 -1.137 . . . . 0.0 107.929 169.17 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 65.5 tttp 44.43 65.31 1.08 Allowed 'General case' 0 CA--C 1.554 1.115 0 C-N-CA 124.893 1.277 . . . . 0.0 112.76 176.109 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 80.73 -27.29 2.98 Favored Glycine 0 CA--C 1.531 1.076 0 CA-C-N 115.047 -0.979 . . . . 0.0 113.881 -179.576 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 94.7 mttt -85.36 154.34 21.94 Favored 'General case' 0 C--N 1.35 0.598 0 CA-C-N 117.395 0.598 . . . . 0.0 109.476 179.124 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 33.8 ptt85 -92.22 160.34 15.21 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-O 121.008 0.432 . . . . 0.0 110.367 178.52 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.735 ' HB ' ' HB2' ' A' ' 119' ' ' LEU . 80.8 mt -128.52 111.46 23.75 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 171.709 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -93.81 108.66 36.32 Favored Pre-proline 0 CA--C 1.546 0.818 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 178.7 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -56.7 103.65 0.13 Allowed 'Trans proline' 0 C--N 1.377 2.072 0 C-N-CA 122.884 2.389 . . . . 0.0 112.193 -178.42 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 86.5 p -74.9 -17.23 60.61 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 123.173 0.589 . . . . 0.0 111.277 -177.762 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 30.4 t-105 -143.26 149.92 38.55 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 -178.663 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -166.59 120.41 1.07 Allowed 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 122.98 0.512 . . . . 0.0 110.72 176.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -120.99 120.83 36.56 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.077 0.951 . . . . 0.0 109.265 171.643 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.493 HG13 ' HG3' ' A' ' 134' ' ' LYS . 4.6 p -69.05 -38.97 79.02 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 CA-C-N 114.657 -1.156 . . . . 0.0 111.844 -178.473 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.493 ' HG3' HG13 ' A' ' 133' ' ' VAL . 97.1 mttt -82.52 -27.95 31.39 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 123.307 0.643 . . . . 0.0 112.218 -173.994 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 135' ' ' LYS . . . . . 0.508 ' HB3' HD12 ' A' ' 137' ' ' LEU . 33.5 mmtp -71.83 -27.74 63.1 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 167.661 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 8.9 t70 56.64 58.61 4.03 Favored 'General case' 0 CA--C 1.538 0.494 0 O-C-N 125.27 1.606 . . . . 0.0 109.37 -167.878 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 137' ' ' LEU . . . . . 0.508 HD12 ' HB3' ' A' ' 135' ' ' LYS . 6.6 mt -144.1 121.98 12.0 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 113.6 -1.637 . . . . 0.0 109.223 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.682 HG23 HG23 ' A' ' 109' ' ' THR . 9.2 tt -121.85 133.32 68.6 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 174.16 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 73.4 m -146.6 165.51 29.29 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-O 122.138 0.97 . . . . 0.0 112.575 -169.798 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 46.4 t80 -133.44 128.69 36.02 Favored 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 125.778 1.631 . . . . 0.0 107.764 175.439 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 102.29 -4.01 51.3 Favored Glycine 0 C--N 1.345 1.029 0 O-C-N 123.671 0.607 . . . . 0.0 112.324 -175.363 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 147.17 -165.58 28.58 Favored Glycine 0 C--N 1.349 1.272 0 N-CA-C 111.392 -0.683 . . . . 0.0 111.392 179.324 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -77.95 -173.64 41.34 Favored Glycine 0 C--N 1.353 1.501 0 CA-C-O 118.98 -0.9 . . . . 0.0 111.059 172.42 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 144' ' ' TRP . . . . . 0.529 ' HZ2' ' HA2' ' A' ' 209' ' ' GLY . 5.1 t-105 -55.0 108.01 0.36 Allowed 'General case' 0 N--CA 1.477 0.909 0 CA-C-N 118.267 1.033 . . . . 0.0 109.986 176.856 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 30.7 tptt -144.5 133.35 22.49 Favored 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 113.725 -1.579 . . . . 0.0 107.617 -174.463 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 146' ' ' LEU . . . . . . . . . . . . . 32.9 tp -153.37 -86.75 0.06 Allowed 'General case' 0 CA--C 1.534 0.345 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 174.389 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 161.31 38.23 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.078 0 C-N-CA 125.362 1.465 . . . . 0.0 109.384 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -126.29 119.78 3.52 Favored Glycine 0 C--N 1.336 0.583 0 CA-C-N 115.879 -0.6 . . . . 0.0 113.279 -172.234 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 5.0 mp0 -113.78 100.34 8.38 Favored 'General case' 0 N--CA 1.474 0.751 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 179.457 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 150' ' ' TRP . . . . . 0.483 ' HZ2' ' HG3' ' A' ' 174' ' ' PRO . 28.8 t90 -71.28 130.23 40.88 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 174.752 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 18.2 ttmm -87.29 106.87 18.22 Favored 'General case' 0 C--O 1.242 0.673 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 176.184 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -62.19 104.14 0.45 Allowed 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.122 0.969 . . . . 0.0 111.688 -173.155 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 141.68 -38.15 1.53 Allowed Glycine 0 C--N 1.347 1.176 0 CA-C-N 116.58 -0.282 . . . . 0.0 112.989 178.026 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 -72.51 152.9 41.62 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 123.054 0.542 . . . . 0.0 111.805 -178.338 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -69.73 120.06 14.92 Favored 'General case' 0 C--O 1.244 0.786 0 N-CA-C 108.258 -1.015 . . . . 0.0 108.258 169.042 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.51 HG21 HG21 ' A' ' 208' ' ' VAL . 8.9 p -119.17 151.31 21.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.474 0 N-CA-C 108.974 -0.751 . . . . 0.0 108.974 -173.292 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 157' ' ' GLN . . . . . 0.44 ' HA ' ' HA ' ' A' ' 171' ' ' GLN . 0.0 OUTLIER -99.77 141.05 33.09 Favored 'General case' 0 N--CA 1.478 0.954 0 CA-C-O 121.081 0.467 . . . . 0.0 110.704 -168.779 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 89.7 t -117.6 131.35 70.59 Favored 'Isoleucine or valine' 0 C--O 1.245 0.825 0 C-N-CA 124.075 0.95 . . . . 0.0 108.444 170.258 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.401 HD12 ' HG2' ' A' ' 199' ' ' PRO . 44.6 mt -73.8 86.99 1.73 Allowed 'General case' 0 CA--C 1.544 0.717 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 171.356 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 160' ' ' ALA . . . . . 0.586 ' HB3' ' HB2' ' A' ' 168' ' ' ARG . . . -64.13 98.61 0.23 Allowed 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 123.357 0.663 . . . . 0.0 110.82 -176.882 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 161' ' ' LEU . . . . . 0.645 ' H ' ' HA2' ' A' ' 194' ' ' GLY . 71.6 mt -70.78 88.22 0.72 Allowed 'General case' 0 C--O 1.241 0.631 0 C-N-CA 124.549 1.139 . . . . 0.0 111.229 -173.9 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -85.34 119.08 71.96 Favored Pre-proline 0 CA--C 1.553 1.09 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.316 174.326 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_exo -59.0 115.78 2.8 Favored 'Trans proline' 0 C--N 1.379 2.167 0 C-N-CA 123.115 2.543 . . . . 0.0 113.322 -176.841 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 113.79 -15.26 21.7 Favored Glycine 0 N--CA 1.471 0.969 0 CA-C-O 119.348 -0.695 . . . . 0.0 113.663 174.073 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -123.21 -169.62 1.97 Allowed 'General case' 0 C--N 1.355 0.814 0 CA-C-N 117.63 0.715 . . . . 0.0 109.787 -177.249 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 10.7 p30 -70.46 162.24 71.62 Favored Pre-proline 0 CA--C 1.563 1.445 0 CA-C-N 114.695 -1.139 . . . . 0.0 109.359 161.482 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_exo -71.17 135.54 27.34 Favored 'Trans proline' 0 C--N 1.365 1.414 0 C-N-CA 121.95 1.767 . . . . 0.0 111.934 172.284 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 168' ' ' ARG . . . . . 0.586 ' HB2' ' HB3' ' A' ' 160' ' ' ALA . 85.7 mtt180 -70.88 109.26 4.93 Favored 'General case' 0 CA--C 1.546 0.801 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 171.745 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 169' ' ' ALA . . . . . 0.513 ' HB1' ' HE1' ' A' ' 16' ' ' TRP . . . -75.78 102.11 5.33 Favored 'General case' 0 N--CA 1.474 0.725 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -179.483 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.443 HG21 ' CE2' ' A' ' 191' ' ' PHE . 40.6 t -120.99 116.3 49.41 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 C-N-CA 122.52 0.328 . . . . 0.0 111.158 -170.02 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 171' ' ' GLN . . . . . 0.606 ' HB2' HG22 ' A' ' 22' ' ' ILE . 26.6 mt-30 -83.91 142.41 30.58 Favored 'General case' 0 C--O 1.243 0.751 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 173.565 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 5.6 t -152.38 136.28 16.34 Favored 'General case' 0 C--O 1.242 0.694 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.652 -168.736 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 173' ' ' LYS . . . . . 0.501 ' HD3' ' HD2' ' A' ' 174' ' ' PRO . 4.5 tppp? -72.33 126.04 91.17 Favored Pre-proline 0 CA--C 1.543 0.696 0 C-N-CA 123.557 0.743 . . . . 0.0 109.554 175.471 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 174' ' ' PRO . . . . . 0.501 ' HD2' ' HD3' ' A' ' 173' ' ' LYS . 9.2 Cg_endo -48.05 139.14 21.04 Favored 'Trans proline' 0 C--N 1.374 1.912 0 C-N-CA 123.739 2.96 . . . . 0.0 113.475 172.689 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 175' ' ' GLY . . . . . 0.695 ' H ' ' HA ' ' A' ' 187' ' ' VAL . . . -118.09 -172.77 15.84 Favored Glycine 0 C--O 1.237 0.293 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 175.938 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.55 ' HB2' HD12 ' A' ' 28' ' ' ILE . 5.5 mp -138.47 152.36 48.24 Favored 'General case' 0 N--CA 1.479 0.983 0 CA-C-N 117.8 0.8 . . . . 0.0 110.11 178.588 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 177' ' ' PHE . . . . . 0.652 ' HB2' ' HB ' ' A' ' 184' ' ' ILE . 35.7 m-85 -92.18 123.58 35.63 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.531 0.732 . . . . 0.0 109.85 176.571 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 178' ' ' LYS . . . . . 0.409 ' O ' ' HA ' ' A' ' 30' ' ' SER . 23.8 ttmm -86.57 94.87 9.56 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 172.383 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 63.0 m -103.1 153.68 20.05 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 123.469 0.708 . . . . 0.0 110.621 -173.536 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 7.0 t30 -80.14 64.93 5.12 Favored 'General case' 0 N--CA 1.48 1.044 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 173.776 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -175.47 -38.83 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.569 1.548 . . . . 0.0 108.706 -176.495 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 170.49 -144.17 8.23 Favored Glycine 0 C--N 1.341 0.86 0 CA-C-N 114.862 -1.063 . . . . 0.0 111.143 -178.929 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 10.2 m -127.13 131.87 50.7 Favored 'General case' 0 CA--C 1.548 0.866 0 C-N-CA 123.319 0.648 . . . . 0.0 109.546 179.075 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 184' ' ' ILE . . . . . 0.652 ' HB ' ' HB2' ' A' ' 177' ' ' PHE . 31.4 mt -107.16 163.28 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 C-N-CA 124.152 0.981 . . . . 0.0 108.561 -179.537 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -99.89 132.34 10.9 Favored Glycine 0 N--CA 1.478 1.488 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.677 ' HA ' ' HA ' ' A' ' 225' ' ' ALA . . . -154.51 -159.02 0.91 Allowed 'General case' 0 N--CA 1.474 0.751 0 CA-C-O 121.083 0.468 . . . . 0.0 112.105 -164.122 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 187' ' ' VAL . . . . . 0.695 ' HA ' ' H ' ' A' ' 175' ' ' GLY . 10.4 p -149.25 135.46 12.18 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 C-N-CA 123.98 0.912 . . . . 0.0 108.731 167.446 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 188' ' ' SER . . . . . 0.629 ' HB2' ' HB2' ' A' ' 26' ' ' SER . 11.9 p -106.38 101.87 11.31 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 123.679 0.792 . . . . 0.0 110.009 -173.322 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 65.5 tp -127.15 109.95 12.39 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 123.969 0.908 . . . . 0.0 110.786 -168.525 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 190' ' ' ASP . . . . . 0.48 ' HA ' ' HA ' ' A' ' 221' ' ' ALA . 13.5 p-10 -96.25 102.74 14.57 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 167.968 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 191' ' ' PHE . . . . . 0.443 ' CE2' HG21 ' A' ' 170' ' ' VAL . 50.5 t80 179.68 174.96 0.79 Allowed 'General case' 0 CA--C 1.551 0.985 0 CA-C-N 114.985 -1.007 . . . . 0.0 108.541 -168.117 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 33.6 m -86.87 96.17 0.51 Allowed Pre-proline 0 CA--C 1.554 1.114 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 169.548 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 193' ' ' PRO . . . . . 0.457 ' HG3' ' HB2' ' A' ' 222' ' ' TYR . 10.0 Cg_endo -93.1 -164.76 0.12 Allowed 'Trans proline' 0 C--N 1.373 1.828 0 C-N-CA 123.266 2.644 . . . . 0.0 114.055 -165.587 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 194' ' ' GLY . . . . . 0.645 ' HA2' ' H ' ' A' ' 161' ' ' LEU . . . -82.11 153.73 32.71 Favored Glycine 0 C--N 1.35 1.32 0 CA-C-N 115.053 -0.976 . . . . 0.0 112.793 176.395 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 2.8 m -70.87 155.08 41.24 Favored 'General case' 0 CA--C 1.554 1.128 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 174.201 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 4.1 m -63.67 87.41 0.04 OUTLIER 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 123.493 0.717 . . . . 0.0 112.428 -168.405 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 134.35 17.81 0.96 Allowed Glycine 0 N--CA 1.469 0.883 0 CA-C-N 114.797 -1.092 . . . . 0.0 111.823 -175.43 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 42.6 t -62.09 138.31 95.86 Favored Pre-proline 0 CA--C 1.545 0.762 0 C-N-CA 124.777 1.231 . . . . 0.0 111.388 177.246 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 199' ' ' PRO . . . . . 0.401 ' HG2' HD12 ' A' ' 159' ' ' LEU . 74.1 Cg_endo -71.9 129.79 15.86 Favored 'Trans proline' 0 C--N 1.37 1.71 0 C-N-CA 122.039 1.826 . . . . 0.0 112.259 179.371 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 22.9 mt -100.71 120.5 50.28 Favored 'Isoleucine or valine' 0 C--O 1.238 0.473 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 173.96 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 201' ' ' ILE . . . . . 0.49 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 56.5 mt -113.55 160.57 12.98 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.942 0 N-CA-C 107.826 -1.176 . . . . 0.0 107.826 178.221 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -99.6 169.27 9.4 Favored 'General case' 0 N--CA 1.478 0.942 0 O-C-N 121.739 -0.601 . . . . 0.0 110.539 176.188 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 7.3 ptpp? -58.66 -26.57 63.93 Favored 'General case' 0 CA--C 1.55 0.957 0 C-N-CA 124.207 1.003 . . . . 0.0 111.497 174.221 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 51.2 tptt -67.0 -20.62 65.91 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 124.064 0.946 . . . . 0.0 111.401 179.863 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 98.82 -14.1 61.88 Favored Glycine 0 C--N 1.345 1.078 0 N-CA-C 111.791 -0.524 . . . . 0.0 111.791 -175.881 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -85.79 136.89 33.14 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 123.96 0.904 . . . . 0.0 109.705 179.042 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 207' ' ' VAL . . . . . 0.49 ' HA ' ' HA ' ' A' ' 201' ' ' ILE . 13.7 p -67.88 151.95 9.95 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 123.627 0.771 . . . . 0.0 110.101 -179.629 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 208' ' ' VAL . . . . . 0.51 HG21 HG21 ' A' ' 156' ' ' VAL . 28.8 m -127.49 -26.62 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 CA-C-O 118.683 -0.675 . . . . 0.0 112.568 -179.211 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.529 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . 171.72 -147.03 9.82 Favored Glycine 0 C--N 1.36 1.871 0 C-N-CA 119.202 -1.475 . . . . 0.0 116.618 176.128 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 210' ' ' LEU . . . . . 0.446 HD11 HG12 ' A' ' 101' ' ' VAL . 50.6 mt -129.65 143.33 50.77 Favored 'General case' 0 N--CA 1.491 1.623 0 C-N-CA 124.45 1.1 . . . . 0.0 111.804 -175.06 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 47.7 t80 -117.5 105.74 12.41 Favored 'General case' 0 C--O 1.236 0.386 0 C-N-CA 124.951 1.3 . . . . 0.0 108.505 -177.025 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . 172.86 71.49 0.05 OUTLIER Glycine 0 N--CA 1.442 -0.906 0 N-CA-C 111.348 -0.701 . . . . 0.0 111.348 160.286 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 213' ' ' ASN . . . . . 0.672 ' HB2' ' HB3' ' A' ' 225' ' ' ALA . 3.4 m-80 -140.17 79.62 1.72 Allowed 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 175.308 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 169.17 -152.63 20.41 Favored Glycine 0 C--O 1.247 0.927 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.756 -176.265 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 215' ' ' VAL . . . . . . . . . . . . . 9.9 p -163.24 171.02 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.832 0 CA-C-N 116.905 0.353 . . . . 0.0 111.831 -166.476 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 216' ' ' VAL . . . . . . . . . . . . . 14.4 p -69.0 128.42 32.44 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.048 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 167.021 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 217' ' ' THR . . . . . 0.755 HG23 HD11 ' A' ' 41' ' ' ILE . 47.7 m -138.12 169.27 18.09 Favored 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 124.98 1.312 . . . . 0.0 108.848 -170.817 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 218' ' ' ARG . . . . . 0.405 ' HB3' ' HB3' ' A' ' 221' ' ' ALA . 59.9 ttt180 69.22 -83.99 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 123.69 0.796 . . . . 0.0 111.526 168.099 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 23.2 p -163.27 42.36 0.11 Allowed 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 124.216 1.006 . . . . 0.0 109.011 -174.191 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . 101.39 37.89 3.42 Favored Glycine 0 C--N 1.345 1.069 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.149 -178.562 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 221' ' ' ALA . . . . . 0.48 ' HA ' ' HA ' ' A' ' 190' ' ' ASP . . . -118.96 100.61 7.48 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 123.802 0.841 . . . . 0.0 109.234 -172.479 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 222' ' ' TYR . . . . . 0.457 ' HB2' ' HG3' ' A' ' 193' ' ' PRO . 69.7 m-85 -77.4 97.81 5.05 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-O 121.601 0.715 . . . . 0.0 109.212 -177.003 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 45.7 t -97.52 113.71 32.72 Favored 'Isoleucine or valine' 0 C--O 1.235 0.29 0 CA-C-N 114.398 -1.273 . . . . 0.0 107.957 -178.708 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 8.8 t -130.91 154.58 47.95 Favored 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 124.737 1.215 . . . . 0.0 109.367 -173.025 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 225' ' ' ALA . . . . . 0.677 ' HA ' ' HA ' ' A' ' 186' ' ' ALA . . . -84.03 152.43 24.41 Favored 'General case' 0 C--O 1.247 0.947 0 CA-C-O 120.949 0.404 . . . . 0.0 110.545 178.545 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 226' ' ' ILE . . . . . . . . . . . . . 8.5 pt -114.53 93.14 2.37 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.806 0 CA-C-O 121.914 0.864 . . . . 0.0 109.855 -176.394 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 227' ' ' ALA . . . . . 0.434 ' O ' ' HA3' ' A' ' 209' ' ' GLY . . . -80.69 119.38 23.23 Favored 'General case' 0 N--CA 1.48 1.027 0 CA-C-N 114.939 -1.028 . . . . 0.0 111.108 -172.006 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 228' ' ' GLN . . . . . 0.431 ' HB3' ' HB3' ' A' ' 150' ' ' TRP . 13.7 pt20 -93.81 152.9 18.59 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 123.902 0.881 . . . . 0.0 109.188 177.621 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 229' ' ' THR . . . . . 0.422 ' HA ' ' NE1' ' A' ' 144' ' ' TRP . 87.4 m -65.06 122.36 16.85 Favored 'General case' 0 N--CA 1.477 0.907 0 CA-C-O 121.005 0.431 . . . . 0.0 111.872 -170.131 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 30.2 mt-10 -84.69 -41.73 15.99 Favored 'General case' 0 CA--C 1.543 0.694 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.313 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 61.99 95.11 0.04 OUTLIER 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 124.9 1.28 . . . . 0.0 110.742 -177.284 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 85.2 p . . . . . 0 N--CA 1.476 0.858 0 CA-C-O 119.124 -0.465 . . . . 0.0 110.97 178.446 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.394 0 N-CA-C 114.214 1.191 . . . . 0.0 114.214 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -128.84 20.39 5.99 Favored 'General case' 0 N--CA 1.476 0.869 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 -177.905 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -123.94 10.41 8.86 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 126.109 1.764 . . . . 0.0 107.242 -177.18 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.521 ' HB2' HD13 ' A' ' 119' ' ' LEU . 16.9 mt -67.73 166.51 15.12 Favored 'General case' 0 C--O 1.201 -1.461 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 -174.955 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -154.6 146.7 23.68 Favored 'General case' 0 C--O 1.247 0.968 0 CA-C-N 118.7 0.682 . . . . 0.0 110.144 176.952 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.58 ' HB2' ' CD2' ' A' ' 121' ' ' HIS . 83.7 mt -87.54 125.45 34.34 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 115.032 -0.985 . . . . 0.0 109.933 172.536 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 22.7 tt0 -104.18 125.27 50.34 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 124.893 1.277 . . . . 0.0 108.275 178.391 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 15.5 ttt180 -60.24 109.35 0.96 Allowed 'General case' 0 N--CA 1.477 0.917 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 -179.849 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.458 ' HB2' ' HG3' ' A' ' 85' ' ' ARG . . . -106.56 -43.88 4.62 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 122.487 0.315 . . . . 0.0 111.267 -170.113 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -174.25 172.91 3.16 Favored 'General case' 0 N--CA 1.477 0.913 0 O-C-N 124.095 0.872 . . . . 0.0 110.409 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -87.12 144.62 26.78 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 162.808 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 61.9 t -72.06 100.6 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.003 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 176.778 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 26.8 ttpp -172.05 103.49 0.17 Allowed 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 124.483 1.113 . . . . 0.0 108.884 -175.992 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' TRP . . . . . 0.532 ' NE1' ' HB1' ' A' ' 169' ' ' ALA . 92.4 t90 -80.59 94.78 6.36 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 123.224 0.61 . . . . 0.0 110.351 -179.244 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -157.81 57.62 0.48 Allowed 'General case' 0 CA--C 1.557 1.217 0 C-N-CA 123.195 0.598 . . . . 0.0 111.587 157.232 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.406 ' H ' ' HB2' ' A' ' 169' ' ' ALA . 4.8 m-20 -92.3 -63.42 1.24 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.445 -0.784 . . . . 0.0 112.689 177.675 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' GLN . . . . . 0.808 ' H ' ' HB3' ' A' ' 169' ' ' ALA . 48.8 mt-30 -153.09 43.8 0.63 Allowed 'General case' 0 N--CA 1.489 1.477 0 CA-C-N 114.693 -1.14 . . . . 0.0 111.248 -158.199 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -35.05 99.78 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.014 0 C-N-CA 125.537 1.535 . . . . 0.0 114.486 -175.135 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -126.52 118.48 24.99 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 123.748 0.819 . . . . 0.0 110.163 -176.972 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.543 ' HA ' ' HB2' ' A' ' 171' ' ' GLN . 0.2 OUTLIER -76.16 143.87 12.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 CA-C-O 121.052 0.453 . . . . 0.0 111.872 -174.478 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 77.2 p -154.35 156.71 37.39 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 124.558 1.143 . . . . 0.0 109.654 -178.502 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 160.25 103.82 0.19 Allowed Glycine 0 C--N 1.339 0.747 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -174.293 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' SER . . . . . 0.405 ' H ' ' HB3' ' A' ' 189' ' ' LEU . 29.4 t -109.72 -70.27 0.82 Allowed 'General case' 0 N--CA 1.478 0.961 0 CA-C-N 117.566 0.683 . . . . 0.0 111.342 -168.935 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 26.5 m -123.49 85.68 52.52 Favored Pre-proline 0 CA--C 1.551 1.014 0 C-N-CA 123.3 0.64 . . . . 0.0 109.526 -172.891 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 82.3 Cg_exo -45.41 -49.76 10.01 Favored 'Trans proline' 0 C--N 1.39 2.761 0 C-N-CA 124.293 3.329 . . . . 0.0 114.162 -173.149 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 49.1 mm -104.01 117.04 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 175.936 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.578 HD11 ' HB2' ' A' ' 218' ' ' ARG . 0.5 OUTLIER -138.26 128.52 25.95 Favored 'General case' 0 N--CA 1.478 0.942 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 -177.232 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 60.1 p -79.24 159.24 27.39 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 122.949 0.5 . . . . 0.0 111.195 179.088 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 16.0 tt -150.68 159.62 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 -177.793 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 35.3 m -94.88 110.81 22.65 Favored 'General case' 0 C--O 1.241 0.622 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 176.949 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 45.5 mm -72.12 115.75 12.98 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 173.673 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.491 ' HB2' ' HB3' ' A' ' 38' ' ' SER . 15.5 m -79.65 117.63 20.74 Favored 'General case' 0 C--O 1.241 0.627 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 170.641 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -60.37 -8.49 2.69 Favored 'General case' 0 N--CA 1.491 1.608 0 C-N-CA 124.473 1.109 . . . . 0.0 113.491 -169.206 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -65.79 -13.75 60.05 Favored 'General case' 0 CA--C 1.551 1.0 0 C-N-CA 124.756 1.222 . . . . 0.0 112.24 172.823 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.04 14.39 26.66 Favored Glycine 0 C--N 1.347 1.141 0 N-CA-C 111.693 -0.563 . . . . 0.0 111.693 -171.249 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' SER . . . . . 0.491 ' HB3' ' HB2' ' A' ' 34' ' ' SER . 23.1 t -109.03 164.97 11.95 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.496 0.719 . . . . 0.0 110.481 -179.303 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 68.3 mtp -133.29 134.71 44.23 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 123.518 0.727 . . . . 0.0 109.808 -179.015 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 13.3 p -169.44 174.4 6.0 Favored 'General case' 0 C--N 1.353 0.749 0 CA-C-O 121.436 0.636 . . . . 0.0 112.611 -175.185 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.635 HD11 HG23 ' A' ' 217' ' ' THR . 50.7 mm -89.44 152.33 3.35 Favored 'Isoleucine or valine' 0 C--O 1.241 0.635 0 N-CA-C 107.0 -1.482 . . . . 0.0 107.0 160.062 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 47.6 mtmt -72.65 75.74 1.1 Allowed 'General case' 0 CA--C 1.55 0.977 0 CA-C-O 121.665 0.745 . . . . 0.0 110.51 177.195 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 36.0 t30 -173.05 143.42 1.15 Allowed 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 126.079 1.752 . . . . 0.0 107.667 -176.504 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -148.5 150.53 33.56 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 122.537 0.335 . . . . 0.0 111.155 177.961 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 . . . . . 0 N--CA 1.473 0.682 0 C-N-CA 124.425 1.09 . . . . 0.0 109.866 179.419 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.532 ' HB2' ' HA ' ' A' ' 103' ' ' LYS . 38.5 p-10 . . . . . 0 CA--C 1.537 0.449 0 N-CA-C 112.271 0.471 . . . . 0.0 112.271 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 142.27 -162.82 27.2 Favored Glycine 0 C--N 1.345 1.06 0 CA-C-N 115.296 -0.866 . . . . 0.0 112.256 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' ALA . . . . . 0.512 ' HB1' HD11 ' A' ' 161' ' ' LEU . . . -85.76 123.26 30.93 Favored 'General case' 0 N--CA 1.477 0.88 0 C-N-CA 123.67 0.788 . . . . 0.0 109.865 177.587 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 15.0 m-85 -129.79 140.43 51.04 Favored 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 123.356 0.663 . . . . 0.0 110.686 -176.145 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' ARG . . . . . 0.527 ' HD3' HE22 ' A' ' 96' ' ' GLN . 80.7 mtt85 -88.09 128.8 35.42 Favored 'General case' 0 N--CA 1.479 0.997 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 173.994 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.411 ' H ' ' HA ' ' A' ' 99' ' ' ALA . 53.3 mt -91.02 122.03 42.0 Favored 'Isoleucine or valine' 0 C--O 1.247 0.957 0 CA-C-O 121.432 0.634 . . . . 0.0 110.209 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.561 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 34.4 mtmm -114.84 146.96 40.5 Favored 'General case' 0 C--O 1.216 -0.675 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.316 174.657 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 19.7 tm0? -87.05 107.15 18.3 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 105.872 -1.899 . . . . 0.0 105.872 165.848 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' LYS . . . . . 0.405 ' HD2' ' HE2' ' A' ' 87' ' ' LYS . 50.0 mtpt -114.38 94.04 4.62 Favored 'General case' 0 C--O 1.241 0.641 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 -176.078 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -70.28 137.9 28.5 Favored Glycine 0 C--O 1.242 0.619 0 N-CA-C 108.221 -1.951 . . . . 0.0 108.221 165.816 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 2.9 mp -75.13 68.9 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.566 1.584 0 N-CA-C 107.103 -1.443 . . . . 0.0 107.103 176.854 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 3.9 pp 170.5 -38.16 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.468 0 C-N-CA 126.435 1.894 . . . . 0.0 109.834 -165.549 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -161.66 134.33 3.48 Favored Glycine 0 C--N 1.353 1.492 0 CA-C-N 115.994 -0.548 . . . . 0.0 112.201 -174.417 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 8.2 m-85 -123.25 131.65 53.75 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.75 0.82 . . . . 0.0 109.756 -167.806 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 53.6 m -148.65 146.32 28.13 Favored 'General case' 0 N--CA 1.483 1.21 0 C-N-CA 123.956 0.902 . . . . 0.0 109.383 176.969 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.561 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 61.9 tt0 -92.52 144.08 25.7 Favored 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 123.127 0.571 . . . . 0.0 110.904 178.312 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 25.5 pt -128.34 -26.4 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 C-N-CA 123.138 0.575 . . . . 0.0 112.158 -173.255 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' GLY . . . . . 0.421 ' HA2' ' HB ' ' A' ' 195' ' ' THR . . . -177.52 -149.54 7.93 Favored Glycine 0 C--N 1.349 1.271 0 C-N-CA 121.144 -0.55 . . . . 0.0 113.263 -177.643 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.411 ' HA ' ' H ' ' A' ' 86' ' ' ILE . . . -157.23 175.47 13.98 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 124.119 0.967 . . . . 0.0 110.969 -176.447 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -178.21 -171.18 41.28 Favored Glycine 0 C--N 1.346 1.117 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.646 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 34.7 t -135.64 127.0 44.92 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.065 0 CA-C-O 121.552 0.691 . . . . 0.0 111.023 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -91.03 145.0 25.07 Favored 'General case' 0 CA--C 1.548 0.874 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 170.698 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.532 ' HA ' ' HB2' ' A' ' 81' ' ' ASP . 20.1 tptp -152.65 118.14 5.3 Favored 'General case' 0 N--CA 1.483 1.196 0 CA-C-N 119.168 0.895 . . . . 0.0 111.667 177.303 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 52.3 43.2 30.99 Favored 'General case' 0 N--CA 1.486 1.344 0 C-N-CA 124.629 1.171 . . . . 0.0 113.262 166.286 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 96.31 -33.76 5.42 Favored Glycine 0 C--N 1.348 1.244 0 CA-C-N 115.935 -0.575 . . . . 0.0 112.947 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 60.5 p -88.88 118.93 28.94 Favored 'General case' 0 CA--C 1.542 0.639 0 CA-C-N 117.023 0.412 . . . . 0.0 110.433 -178.213 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' PHE . . . . . 0.429 ' CE2' ' HG ' ' A' ' 119' ' ' LEU . 23.1 t80 -95.23 115.25 27.18 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 176.638 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 108' ' ' HIS . . . . . 0.618 ' HB2' ' HE3' ' A' ' 144' ' ' TRP . 1.0 OUTLIER -136.2 121.2 18.81 Favored 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 122.698 0.399 . . . . 0.0 110.808 -176.703 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 14.7 t -135.88 -179.71 5.82 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 122.999 0.52 . . . . 0.0 112.035 -169.09 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 110' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -72.72 141.52 48.17 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 124.839 1.256 . . . . 0.0 110.023 171.247 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 80.7 t90 -76.03 -53.01 9.0 Favored 'General case' 0 N--CA 1.483 1.202 0 CA-C-O 119.328 -0.367 . . . . 0.0 111.616 -174.482 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 112' ' ' HIS . . . . . 0.62 ' HE1' ' HA ' ' A' ' 213' ' ' ASN . 3.4 p-80 -65.35 -2.88 3.48 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 114.119 1.155 . . . . 0.0 114.119 -170.437 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.405 HG13 ' HA3' ' A' ' 98' ' ' GLY . 78.1 t -58.07 -39.58 73.22 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.934 0 CA-C-O 121.524 0.678 . . . . 0.0 109.705 167.639 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.618 HG23 ' H ' ' A' ' 116' ' ' GLY . 9.4 t -138.6 -168.48 2.41 Favored 'General case' 0 CA--C 1.555 1.161 0 CA-C-N 114.607 -1.179 . . . . 0.0 109.765 -178.492 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 31.5 ttt180 -93.03 14.94 16.26 Favored 'General case' 0 CA--C 1.561 1.401 0 C-N-CA 124.063 0.945 . . . . 0.0 110.951 177.316 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.618 ' H ' HG23 ' A' ' 114' ' ' THR . . . 80.17 40.7 13.2 Favored Glycine 0 C--N 1.346 1.084 0 N-CA-C 111.816 -0.513 . . . . 0.0 111.816 -175.167 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -120.23 -169.89 1.88 Allowed 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 123.336 0.654 . . . . 0.0 111.543 -173.705 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 48.9 t -75.36 136.93 23.94 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 N-CA-C 114.184 1.179 . . . . 0.0 114.184 -159.854 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.521 HD13 ' HB2' ' A' ' 6' ' ' LEU . 3.7 mm? -103.13 151.63 22.36 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 124.89 1.276 . . . . 0.0 110.616 174.505 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 38.1 mmt -104.1 151.45 23.26 Favored 'General case' 0 C--O 1.262 1.744 0 C-N-CA 124.57 1.148 . . . . 0.0 108.197 173.284 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.58 ' CD2' ' HB2' ' A' ' 8' ' ' LEU . 0.1 OUTLIER -143.52 92.45 2.36 Favored 'General case' 0 CA--C 1.538 0.495 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 165.072 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 10.1 mtmp? 56.72 28.45 14.24 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 124.591 1.157 . . . . 0.0 112.619 -174.614 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 100.66 -8.91 58.45 Favored Glycine 0 C--N 1.347 1.176 0 CA-C-O 119.683 -0.509 . . . . 0.0 113.229 -176.904 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 61.2 tttm -72.94 114.55 11.22 Favored 'General case' 0 C--N 1.357 0.901 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 171.92 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 47.1 ttp180 -82.86 86.13 6.98 Favored 'General case' 0 C--O 1.241 0.605 0 C-N-CA 124.258 1.023 . . . . 0.0 109.271 -174.368 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.461 HG13 ' HB2' ' A' ' 119' ' ' LEU . 23.8 pt -91.71 100.49 11.3 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 CA-C-O 122.334 1.064 . . . . 0.0 109.346 -177.71 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -94.22 126.79 47.14 Favored Pre-proline 0 CA--C 1.546 0.789 0 CA-C-N 113.972 -1.467 . . . . 0.0 110.063 -175.382 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.401 ' HB3' HG23 ' A' ' 138' ' ' ILE . 88.0 Cg_exo -49.53 119.5 4.72 Favored 'Trans proline' 0 C--N 1.373 1.865 0 C-N-CA 123.266 2.644 . . . . 0.0 113.834 175.666 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 59.1 p -82.13 -10.41 59.19 Favored 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 123.799 0.84 . . . . 0.0 110.51 174.425 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.703 ' HB3' ' HB2' ' A' ' 139' ' ' SER . 64.8 t-105 -155.79 152.77 28.86 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 124.912 1.285 . . . . 0.0 109.096 178.176 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -161.86 120.48 2.33 Favored 'General case' 0 C--O 1.241 0.622 0 C-N-CA 124.152 0.981 . . . . 0.0 108.546 169.897 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -108.84 112.5 24.79 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 123.324 0.65 . . . . 0.0 109.627 176.652 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 11.5 t -75.47 -17.47 15.8 Favored 'Isoleucine or valine' 0 CA--C 1.557 1.228 0 C-N-CA 123.139 0.576 . . . . 0.0 110.159 179.316 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 23.4 ttmm -59.62 -51.5 69.55 Favored 'General case' 0 C--N 1.358 0.974 0 C-N-CA 124.486 1.114 . . . . 0.0 112.359 -174.584 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 79.6 tttt -109.79 4.9 22.2 Favored 'General case' 0 N--CA 1.485 1.291 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 172.606 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 15.6 t70 67.96 71.15 0.33 Allowed 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 124.341 1.056 . . . . 0.0 111.368 170.175 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 47.8 mt -147.43 160.29 42.73 Favored 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 124.317 1.047 . . . . 0.0 110.278 178.043 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.449 HD11 ' HA2' ' A' ' 116' ' ' GLY . 38.0 mt -132.24 150.72 33.83 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 C-N-CA 125.739 1.615 . . . . 0.0 108.214 -176.675 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 139' ' ' SER . . . . . 0.703 ' HB2' ' HB3' ' A' ' 130' ' ' TRP . 20.4 m -145.36 143.98 30.44 Favored 'General case' 0 CA--C 1.554 1.123 0 C-N-CA 123.81 0.844 . . . . 0.0 110.887 -179.393 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 19.8 t80 -139.35 128.98 24.52 Favored 'General case' 0 N--CA 1.48 1.029 0 C-N-CA 125.544 1.538 . . . . 0.0 107.942 178.207 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.03 2.51 88.83 Favored Glycine 0 C--N 1.35 1.347 0 O-C-N 123.848 0.717 . . . . 0.0 113.178 179.336 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 165.09 -153.49 23.69 Favored Glycine 0 C--N 1.339 0.725 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -173.96 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -105.62 173.47 20.24 Favored Glycine 0 C--N 1.343 0.968 0 CA-C-N 117.122 0.461 . . . . 0.0 112.034 174.66 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 144' ' ' TRP . . . . . 0.618 ' HE3' ' HB2' ' A' ' 108' ' ' HIS . 36.2 t-105 -66.6 110.51 3.22 Favored 'General case' 0 C--O 1.245 0.853 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 170.064 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 145' ' ' LYS . . . . . 0.516 ' HA ' ' HB ' ' A' ' 229' ' ' THR . 0.1 OUTLIER -150.49 146.34 26.55 Favored 'General case' 0 CA--C 1.538 0.499 0 CA-C-O 121.6 0.714 . . . . 0.0 110.475 171.345 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 146' ' ' LEU . . . . . 0.518 HD12 ' HA2' ' A' ' 209' ' ' GLY . 72.7 mt -144.06 2.21 1.15 Allowed 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 125.997 1.719 . . . . 0.0 108.099 170.932 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 36.6 mt-10 71.07 36.2 1.47 Allowed 'General case' 0 C--N 1.372 1.564 0 C-N-CA 124.157 0.983 . . . . 0.0 111.421 171.045 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 148' ' ' GLY . . . . . 0.532 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -149.94 156.51 26.78 Favored Glycine 0 C--N 1.347 1.174 0 CA-C-O 121.436 0.465 . . . . 0.0 113.932 -177.613 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -151.12 131.29 13.53 Favored 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 124.022 0.929 . . . . 0.0 109.224 -176.071 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 150' ' ' TRP . . . . . 0.567 ' HE1' ' HB3' ' A' ' 174' ' ' PRO . 50.8 t-105 -91.7 143.78 26.19 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 122.985 0.514 . . . . 0.0 110.027 170.599 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 26.5 tptp -131.14 139.44 49.8 Favored 'General case' 0 CA--C 1.536 0.412 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 169.101 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -44.27 147.11 0.58 Allowed 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 126.165 1.786 . . . . 0.0 113.73 -178.162 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 152.12 -84.7 0.15 Allowed Glycine 0 C--N 1.342 0.867 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.804 179.389 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -88.73 -174.88 4.71 Favored 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 124.446 1.099 . . . . 0.0 110.538 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 11.6 mp0 -63.97 130.95 46.1 Favored 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 169.67 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 13.0 p -90.53 148.0 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 166.444 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 157' ' ' GLN . . . . . 0.63 HE21 ' HB3' ' A' ' 203' ' ' LYS . 41.8 mm-40 -103.72 140.5 37.52 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -170.24 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.568 HG22 HG12 ' A' ' 200' ' ' ILE . 19.1 t -127.63 120.02 53.35 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 176.139 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.601 ' HB3' ' HG2' ' A' ' 199' ' ' PRO . 0.2 OUTLIER -81.39 86.18 6.33 Favored 'General case' 0 CA--C 1.558 1.269 0 N-CA-C 107.481 -1.304 . . . . 0.0 107.481 174.249 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 160' ' ' ALA . . . . . 0.422 ' HA ' ' OG ' ' A' ' 198' ' ' SER . . . -68.97 104.99 2.24 Favored 'General case' 0 N--CA 1.481 1.121 0 C-N-CA 123.263 0.625 . . . . 0.0 112.089 -172.43 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 161' ' ' LEU . . . . . 0.512 HD11 ' HB1' ' A' ' 83' ' ' ALA . 74.9 mt -75.42 83.8 2.52 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 174.359 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 15.0 tp10 -70.25 119.75 74.02 Favored Pre-proline 0 CA--C 1.551 1.017 0 CA-C-N 114.886 -1.052 . . . . 0.0 110.176 -176.931 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 163' ' ' PRO . . . . . 0.487 ' HG3' HG23 ' A' ' 195' ' ' THR . 63.5 Cg_exo -55.43 114.1 1.72 Allowed 'Trans proline' 0 C--N 1.377 2.045 0 C-N-CA 123.132 2.554 . . . . 0.0 113.378 -178.928 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 75.99 22.08 74.9 Favored Glycine 0 C--N 1.344 1.019 0 O-C-N 123.724 0.64 . . . . 0.0 113.418 175.386 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 54.1 tptt -151.69 156.88 41.25 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -174.434 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 20.3 p30 -58.28 148.21 64.08 Favored Pre-proline 0 CA--C 1.558 1.259 0 C-N-CA 123.034 0.534 . . . . 0.0 112.312 177.594 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -59.62 146.89 94.04 Favored 'Trans proline' 0 C--N 1.379 2.134 0 C-N-CA 123.213 2.609 . . . . 0.0 113.233 179.048 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 168' ' ' ARG . . . . . 0.413 ' HB2' ' HB3' ' A' ' 160' ' ' ALA . 80.9 mtp180 -123.91 110.54 14.96 Favored 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 123.804 0.842 . . . . 0.0 108.828 -172.465 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 169' ' ' ALA . . . . . 0.808 ' HB3' ' H ' ' A' ' 19' ' ' GLN . . . -78.84 106.37 10.81 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-O 120.808 0.337 . . . . 0.0 110.701 -178.662 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 21.9 t -105.64 139.19 27.57 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.894 0 C-N-CA 123.176 0.591 . . . . 0.0 109.778 -178.023 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 171' ' ' GLN . . . . . 0.543 ' HB2' ' HA ' ' A' ' 22' ' ' ILE . 11.2 mt-30 -97.09 102.87 14.73 Favored 'General case' 0 C--N 1.348 0.53 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 170.335 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 172' ' ' THR . . . . . 0.519 ' HB ' HD11 ' A' ' 189' ' ' LEU . 71.4 p -101.71 124.06 46.73 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -178.816 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 28.1 mtpp -71.03 133.17 86.06 Favored Pre-proline 0 CA--C 1.546 0.806 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 174.049 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 174' ' ' PRO . . . . . 0.567 ' HB3' ' HE1' ' A' ' 150' ' ' TRP . 37.7 Cg_endo -64.1 123.53 12.03 Favored 'Trans proline' 0 C--N 1.377 2.053 0 C-N-CA 122.288 1.992 . . . . 0.0 111.776 -169.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -100.0 -173.94 30.37 Favored Glycine 0 N--CA 1.45 -0.428 0 CA-C-N 114.956 -1.02 . . . . 0.0 112.229 177.064 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 5.6 mp -148.73 145.84 27.82 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.096 0.958 . . . . 0.0 109.172 178.476 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 177' ' ' PHE . . . . . 0.729 ' HB2' ' HB ' ' A' ' 184' ' ' ILE . 59.1 m-85 -92.71 122.67 35.35 Favored 'General case' 0 C--O 1.245 0.866 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 167.705 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 77.8 tttt -95.21 104.8 16.7 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 114.809 -1.087 . . . . 0.0 109.187 177.063 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 36.4 p -132.81 156.98 46.14 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 169.481 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 10.3 t30 -56.61 -38.74 72.47 Favored 'General case' 0 N--CA 1.484 1.232 0 C-N-CA 123.874 0.87 . . . . 0.0 112.892 -169.078 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -94.93 -35.68 11.91 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 123.067 0.547 . . . . 0.0 110.8 178.906 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -112.94 118.19 4.5 Favored Glycine 0 C--N 1.347 1.153 0 CA-C-N 116.279 -0.419 . . . . 0.0 113.859 -169.319 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 30.2 m -98.57 100.88 12.16 Favored 'General case' 0 CA--C 1.538 0.507 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 163.167 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 184' ' ' ILE . . . . . 0.729 ' HB ' ' HB2' ' A' ' 177' ' ' PHE . 46.9 mt -104.17 149.73 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 C-N-CA 123.512 0.725 . . . . 0.0 109.07 -169.546 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -99.17 124.6 8.29 Favored Glycine 0 C--N 1.349 1.305 0 N-CA-C 109.808 -1.317 . . . . 0.0 109.808 -179.577 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.657 ' HA ' ' HA ' ' A' ' 225' ' ' ALA . . . -140.27 -174.66 4.0 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 114.125 1.157 . . . . 0.0 114.125 -159.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 187' ' ' VAL . . . . . . . . . . . . . 98.4 t -126.27 99.86 6.14 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.641 0 N-CA-C 105.683 -1.969 . . . . 0.0 105.683 171.183 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 188' ' ' SER . . . . . 0.559 ' HA ' HG13 ' A' ' 223' ' ' VAL . 60.6 p -113.64 79.64 1.27 Allowed 'General case' 0 C--O 1.243 0.731 0 CA-C-O 122.243 1.021 . . . . 0.0 111.044 -171.343 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 189' ' ' LEU . . . . . 0.519 HD11 ' HB ' ' A' ' 172' ' ' THR . 0.0 OUTLIER -151.49 178.9 8.83 Favored 'General case' 0 N--CA 1.477 0.923 0 CA-C-N 114.596 -1.184 . . . . 0.0 111.528 175.723 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -80.03 102.33 9.21 Favored 'General case' 0 CA--C 1.542 0.635 0 N-CA-C 107.307 -1.368 . . . . 0.0 107.307 171.622 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 191' ' ' PHE . . . . . 0.73 ' HB3' ' HB2' ' A' ' 222' ' ' TYR . 69.5 t80 -106.58 164.22 12.24 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 124.32 1.048 . . . . 0.0 109.53 -174.269 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 16.8 m -58.79 155.15 32.7 Favored Pre-proline 0 CA--C 1.561 1.394 0 C-N-CA 124.748 1.219 . . . . 0.0 112.134 178.297 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_exo -64.84 10.91 0.12 Allowed 'Trans proline' 0 C--N 1.381 2.263 0 C-N-CA 123.123 2.548 . . . . 0.0 115.342 171.555 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 194' ' ' GLY . . . . . 0.458 ' HA2' ' HD3' ' A' ' 163' ' ' PRO . . . -50.05 134.13 27.72 Favored Glycine 0 CA--C 1.54 1.643 0 C-N-CA 123.621 0.629 . . . . 0.0 112.995 168.712 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 195' ' ' THR . . . . . 0.487 HG23 ' HG3' ' A' ' 163' ' ' PRO . 6.6 p -75.34 151.39 38.25 Favored 'General case' 0 CA--C 1.552 1.03 0 C-N-CA 124.285 1.034 . . . . 0.0 113.381 -169.919 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -62.98 128.91 38.03 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 124.333 1.053 . . . . 0.0 111.213 -172.643 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 197' ' ' GLY . . . . . 0.422 ' O ' HD22 ' A' ' 210' ' ' LEU . . . 96.68 8.19 57.35 Favored Glycine 0 C--N 1.34 0.755 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 -167.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 198' ' ' SER . . . . . 0.422 ' OG ' ' HA ' ' A' ' 160' ' ' ALA . 34.0 t -57.15 119.06 28.31 Favored Pre-proline 0 CA--C 1.557 1.243 0 C-N-CA 123.684 0.793 . . . . 0.0 109.839 164.278 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 199' ' ' PRO . . . . . 0.601 ' HG2' ' HB3' ' A' ' 159' ' ' LEU . 19.6 Cg_endo -58.04 131.63 44.61 Favored 'Trans proline' 0 C--N 1.377 2.033 0 C-N-CA 123.171 2.581 . . . . 0.0 113.832 -170.924 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 200' ' ' ILE . . . . . 0.568 HG12 HG22 ' A' ' 158' ' ' VAL . 18.9 mt -97.98 130.87 46.1 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.754 0 C-N-CA 123.988 0.915 . . . . 0.0 109.062 171.903 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 201' ' ' ILE . . . . . . . . . . . . . 50.3 mt -123.03 169.55 14.26 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.369 0 C-N-CA 124.706 1.202 . . . . 0.0 108.525 179.045 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -108.55 155.82 20.21 Favored 'General case' 0 N--CA 1.483 1.177 0 C-N-CA 124.346 1.058 . . . . 0.0 108.867 173.258 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 203' ' ' LYS . . . . . 0.63 ' HB3' HE21 ' A' ' 157' ' ' GLN . 18.7 ptmt -66.4 -19.5 65.82 Favored 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 -170.578 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 45.3 mttp -73.99 -17.4 61.0 Favored 'General case' 0 N--CA 1.488 1.443 0 CA-C-N 117.911 0.323 . . . . 0.0 110.739 176.011 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 115.4 -16.45 17.16 Favored Glycine 0 C--N 1.351 1.362 0 N-CA-C 111.898 -0.481 . . . . 0.0 111.898 -176.066 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 206' ' ' LYS . . . . . 0.423 ' HE3' ' HA ' ' A' ' 206' ' ' LYS . 1.2 tpmt? -73.21 119.2 17.12 Favored 'General case' 0 C--O 1.219 -0.502 0 C-N-CA 123.985 0.914 . . . . 0.0 109.239 -177.676 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 207' ' ' VAL . . . . . 0.532 ' O ' ' HA3' ' A' ' 148' ' ' GLY . 12.7 p -64.02 150.23 10.13 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.926 0 C-N-CA 122.798 0.439 . . . . 0.0 110.239 176.916 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 208' ' ' VAL . . . . . 0.502 ' HB ' HG22 ' A' ' 200' ' ' ILE . 93.4 t -106.26 -49.84 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 177.542 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.518 ' HA2' HD12 ' A' ' 146' ' ' LEU . . . 161.33 -117.49 0.77 Allowed Glycine 0 N--CA 1.441 -1.014 0 CA-C-N 114.876 -1.056 . . . . 0.0 112.986 178.709 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 210' ' ' LEU . . . . . 0.58 ' HG ' ' CH2' ' A' ' 144' ' ' TRP . 69.2 mt -124.37 166.43 15.96 Favored 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 123.406 0.683 . . . . 0.0 111.841 -177.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -69.9 112.65 6.46 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-N 114.213 -1.358 . . . . 0.0 107.602 167.608 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -74.5 -145.66 1.07 Allowed Glycine 0 C--N 1.341 0.814 0 N-CA-C 115.984 1.154 . . . . 0.0 115.984 -163.849 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 213' ' ' ASN . . . . . 0.62 ' HA ' ' HE1' ' A' ' 112' ' ' HIS . 14.2 p30 -100.66 123.56 45.04 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 121.295 0.569 . . . . 0.0 110.716 -166.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 177.49 -134.31 2.44 Favored Glycine 0 N--CA 1.442 -0.906 0 CA-C-N 114.736 -1.12 . . . . 0.0 111.293 178.922 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 215' ' ' VAL . . . . . 0.423 HG22 ' N ' ' A' ' 216' ' ' VAL . 10.0 p -176.55 178.09 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 -165.133 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 216' ' ' VAL . . . . . 0.423 ' N ' HG22 ' A' ' 215' ' ' VAL . 6.7 m -75.35 110.36 10.08 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.024 0 O-C-N 121.159 -0.963 . . . . 0.0 108.922 160.213 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 217' ' ' THR . . . . . 0.635 HG23 HD11 ' A' ' 41' ' ' ILE . 13.4 m -104.14 177.02 4.96 Favored 'General case' 0 CA--C 1.548 0.886 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 175.86 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 218' ' ' ARG . . . . . 0.578 ' HB2' HD11 ' A' ' 29' ' ' LEU . 71.0 ttt-85 63.38 30.98 15.42 Favored 'General case' 0 N--CA 1.491 1.604 0 CA-C-O 121.98 0.895 . . . . 0.0 110.119 176.096 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 19.6 m 68.33 17.32 9.24 Favored 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 125.47 1.508 . . . . 0.0 113.203 177.807 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . 153.14 -6.87 0.44 Allowed Glycine 0 C--N 1.355 1.618 0 N-CA-C 115.05 0.78 . . . . 0.0 115.05 174.779 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 221' ' ' ALA . . . . . 0.463 ' HB3' ' HB3' ' A' ' 218' ' ' ARG . . . -78.58 125.97 30.1 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 123.205 0.602 . . . . 0.0 110.167 -179.816 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 222' ' ' TYR . . . . . 0.73 ' HB2' ' HB3' ' A' ' 191' ' ' PHE . 11.6 m-85 -65.97 102.03 0.74 Allowed 'General case' 0 N--CA 1.481 1.087 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 178.216 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 223' ' ' VAL . . . . . 0.559 HG13 ' HA ' ' A' ' 188' ' ' SER . 92.4 t -124.64 108.54 20.46 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.922 0 C-N-CA 124.296 1.038 . . . . 0.0 109.469 -176.726 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 50.6 m -142.1 159.0 43.11 Favored 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 123.871 0.868 . . . . 0.0 109.451 -178.571 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 225' ' ' ALA . . . . . 0.657 ' HA ' ' HA ' ' A' ' 186' ' ' ALA . . . -65.12 -171.36 0.07 Allowed 'General case' 0 N--CA 1.482 1.155 0 N-CA-C 113.349 0.87 . . . . 0.0 113.349 -174.809 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 226' ' ' ILE . . . . . . . . . . . . . 46.5 mt -118.29 105.84 18.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 172.786 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -80.34 99.72 8.05 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 122.965 0.506 . . . . 0.0 109.857 -178.713 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 18.2 pt20 -94.25 162.14 13.97 Favored 'General case' 0 N--CA 1.484 1.235 0 C-N-CA 123.929 0.892 . . . . 0.0 110.184 -178.813 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 229' ' ' THR . . . . . 0.516 ' HB ' ' HA ' ' A' ' 145' ' ' LYS . 24.6 p -90.06 121.83 32.49 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 122.669 0.388 . . . . 0.0 111.284 -170.856 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -139.65 -21.0 0.91 Allowed 'General case' 0 N--CA 1.483 1.221 0 C-N-CA 123.464 0.706 . . . . 0.0 112.284 -166.695 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 2.4 mptp? -82.33 -80.42 0.16 Allowed 'General case' 0 N--CA 1.488 1.463 0 CA-C-N 117.921 0.328 . . . . 0.0 110.453 -164.165 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 232' ' ' SER . . . . . 0.41 ' HB2' ' HD2' ' A' ' 145' ' ' LYS . 73.0 m . . . . . 0 C--N 1.36 1.03 0 CA-C-N 118.304 0.502 . . . . 0.0 109.788 171.566 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.95 0 CA-C-O 119.541 -0.266 . . . . 0.0 110.463 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.554 ' O ' HG22 ' A' ' 118' ' ' VAL . . . -162.7 8.06 0.06 Allowed 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 112.175 0.435 . . . . 0.0 112.175 -175.774 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -123.37 83.92 2.2 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 177.223 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.693 ' HA ' ' HA ' ' A' ' 88' ' ' GLN . 4.8 mp -125.07 98.79 5.83 Favored 'General case' 0 N--CA 1.481 1.122 0 CA-C-O 119.333 -0.365 . . . . 0.0 111.559 -173.663 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 30.3 tt0 -81.58 144.84 30.98 Favored 'General case' 0 C--O 1.252 1.207 0 CA-C-O 121.979 0.895 . . . . 0.0 111.197 -175.125 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.634 HD21 HD13 ' A' ' 119' ' ' LEU . 53.9 mt -85.31 115.3 22.98 Favored 'General case' 0 C--O 1.242 0.706 0 CA-C-N 113.556 -1.656 . . . . 0.0 109.752 176.04 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -104.03 125.96 50.78 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 171.319 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 47.0 ptt85 -67.17 129.39 39.76 Favored 'General case' 0 N--CA 1.478 0.958 0 CA-C-N 118.36 0.527 . . . . 0.0 109.76 178.66 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.41 ' HB3' HD13 ' A' ' 161' ' ' LEU . . . -121.69 -21.35 6.18 Favored 'General case' 0 N--CA 1.479 0.983 0 C-N-CA 122.746 0.418 . . . . 0.0 111.239 -176.366 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ALA . . . . . 0.668 ' HB3' ' HB3' ' A' ' 83' ' ' ALA . . . -164.01 161.4 22.63 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 121.639 0.733 . . . . 0.0 111.058 178.592 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -93.71 155.84 17.02 Favored 'General case' 0 C--O 1.245 0.826 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 161.31 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.592 HG23 ' HA2' ' A' ' 82' ' ' GLY . 85.9 t -67.21 103.35 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 175.931 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 58.8 tttp -168.55 133.32 1.64 Allowed 'General case' 0 C--O 1.239 0.528 0 CA-C-N 115.123 -0.944 . . . . 0.0 108.617 -170.308 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 23.3 t90 -74.61 114.01 12.54 Favored 'General case' 0 CA--C 1.542 0.655 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 167.504 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.565 ' HB3' ' HB2' ' A' ' 169' ' ' ALA . 39.6 tt0 -72.25 145.42 47.94 Favored 'General case' 0 CA--C 1.548 0.888 0 C-N-CA 123.344 0.658 . . . . 0.0 109.825 176.825 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -78.32 -2.73 39.48 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 123.878 0.871 . . . . 0.0 112.716 -172.579 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 31.6 mm-40 -87.08 43.44 1.1 Allowed 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 122.99 0.516 . . . . 0.0 110.152 -175.616 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -60.4 101.27 0.12 Allowed 'General case' 0 C--N 1.354 0.788 0 C-N-CA 124.775 1.23 . . . . 0.0 110.803 -174.603 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -105.37 117.44 34.02 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 124.236 1.014 . . . . 0.0 109.496 -173.662 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.513 HD13 ' HB2' ' A' ' 171' ' ' GLN . 43.4 mm -76.55 127.43 37.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 C-N-CA 123.025 0.53 . . . . 0.0 110.063 -172.82 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.433 ' HG ' ' HE2' ' A' ' 191' ' ' PHE . 29.2 m -148.25 -171.55 3.86 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 124.149 0.98 . . . . 0.0 110.796 -172.604 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 133.4 66.28 0.08 OUTLIER Glycine 0 C--N 1.347 1.185 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' SER . . . . . 0.515 ' H ' ' HA ' ' A' ' 189' ' ' LEU . 13.1 m -66.62 -52.6 43.36 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-N 114.648 -0.776 . . . . 0.0 111.845 -167.308 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.446 ' HB2' ' OG ' ' A' ' 188' ' ' SER . 14.8 m -95.26 144.12 27.26 Favored Pre-proline 0 CA--C 1.552 1.048 0 C-N-CA 123.119 0.568 . . . . 0.0 110.525 -172.747 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -84.97 -161.06 0.12 Allowed 'Trans proline' 0 C--N 1.378 2.113 0 C-N-CA 123.0 2.467 . . . . 0.0 112.623 174.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 45.3 mm -63.05 133.72 28.68 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 168.405 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.529 HD13 HG21 ' A' ' 217' ' ' THR . 0.2 OUTLIER -143.75 163.72 32.53 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 123.719 0.808 . . . . 0.0 109.639 -163.428 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.3 t -108.65 145.84 34.34 Favored 'General case' 0 N--CA 1.479 1.013 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 172.699 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.447 HD12 ' CE2' ' A' ' 177' ' ' PHE . 14.9 tt -135.27 154.38 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 C-N-CA 123.4 0.68 . . . . 0.0 109.336 -174.143 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 34.7 p -95.35 103.77 15.65 Favored 'General case' 0 C--O 1.243 0.713 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 171.628 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.45 ' HA ' ' HA ' ' A' ' 39' ' ' MET . 15.7 tt -91.05 117.53 34.47 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.764 179.432 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.615 ' HB3' ' HB3' ' A' ' 38' ' ' SER . 35.5 t -82.97 118.52 23.55 Favored 'General case' 0 C--O 1.242 0.662 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.003 -178.919 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -52.84 -28.15 21.55 Favored 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 125.3 1.44 . . . . 0.0 112.474 -177.682 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -48.22 -41.26 26.94 Favored 'General case' 0 CA--C 1.55 0.957 0 C-N-CA 125.265 1.426 . . . . 0.0 111.884 174.965 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 145.68 9.89 0.28 Allowed Glycine 0 C--N 1.34 0.791 0 CA-C-N 114.929 -1.032 . . . . 0.0 111.942 178.507 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' SER . . . . . 0.615 ' HB3' ' HB3' ' A' ' 34' ' ' SER . 32.7 t -109.82 164.2 12.79 Favored 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 123.537 0.735 . . . . 0.0 110.334 -173.945 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' MET . . . . . 0.45 ' HA ' ' HA ' ' A' ' 33' ' ' ILE . 22.3 ptm -153.67 127.64 8.95 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 123.439 0.696 . . . . 0.0 109.133 173.604 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 17.7 p -169.46 169.82 8.68 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 123.091 0.556 . . . . 0.0 110.862 -175.921 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.0 mp -78.69 124.32 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 N-CA-C 104.815 -2.291 . . . . 0.0 104.815 157.699 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.43 79.02 0.01 OUTLIER 'General case' 0 CA--C 1.558 1.278 0 C-N-CA 124.238 1.015 . . . . 0.0 112.824 -170.957 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 92.5 m-20 -130.5 173.65 10.65 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 125.017 1.327 . . . . 0.0 109.088 -177.943 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -72.23 143.08 48.94 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 123.54 0.736 . . . . 0.0 110.755 177.063 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 . . . . . 0 N--CA 1.473 0.678 0 C-N-CA 123.207 0.603 . . . . 0.0 110.594 177.593 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.411 ' HB2' ' HA ' ' A' ' 103' ' ' LYS . 6.3 p-10 . . . . . 0 C--O 1.239 0.524 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.592 ' HA2' HG23 ' A' ' 14' ' ' VAL . . . 163.28 -175.05 39.6 Favored Glycine 0 C--N 1.34 0.79 0 O-C-N 123.167 0.292 . . . . 0.0 112.574 -173.106 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' ALA . . . . . 0.668 ' HB3' ' HB3' ' A' ' 12' ' ' ALA . . . -93.18 110.17 21.68 Favored 'General case' 0 C--O 1.244 0.789 0 CA-C-O 121.102 0.477 . . . . 0.0 110.503 -177.761 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 18.1 m-85 -107.41 136.92 46.39 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 176.731 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.68 131.79 36.82 Favored 'General case' 0 C--O 1.245 0.837 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 175.183 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.533 HD11 ' HE2' ' A' ' 107' ' ' PHE . 38.0 mt -90.58 111.46 23.54 Favored 'Isoleucine or valine' 0 C--O 1.273 2.3 0 CA-C-O 122.559 1.171 . . . . 0.0 110.482 -176.426 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.417 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 7.1 tmtm? -116.73 130.89 57.0 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-N 112.857 -1.974 . . . . 0.0 107.061 179.075 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' GLN . . . . . 0.693 ' HA ' ' HA ' ' A' ' 6' ' ' LEU . 21.0 tm0? -79.86 111.08 15.84 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 106.838 -1.541 . . . . 0.0 106.838 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' LYS . . . . . 0.432 ' HE3' ' HB2' ' A' ' 89' ' ' LYS . 35.0 ttmt -117.1 93.61 4.25 Favored 'General case' 0 C--O 1.238 0.458 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 -178.277 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -104.51 144.61 15.86 Favored Glycine 0 CA--C 1.496 -1.152 0 CA-C-N 114.158 -1.383 . . . . 0.0 110.953 -176.263 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 2.9 mp -65.3 -15.34 18.27 Favored 'Isoleucine or valine' 0 CA--C 1.566 1.589 0 C-N-CA 125.087 1.355 . . . . 0.0 109.675 179.735 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 1.1 pp -118.43 0.31 11.6 Favored 'General case' 0 CA--C 1.557 1.229 0 N-CA-C 113.467 0.914 . . . . 0.0 113.467 175.658 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 175.67 154.45 11.43 Favored Glycine 0 N--CA 1.488 2.128 0 CA-C-N 119.289 0.95 . . . . 0.0 114.185 -175.048 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 75.4 m-85 -130.71 125.39 33.79 Favored 'General case' 0 N--CA 1.487 1.405 0 C-N-CA 123.421 0.688 . . . . 0.0 112.086 -171.89 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 39.8 m -135.66 157.36 47.06 Favored 'General case' 0 N--CA 1.492 1.675 0 C-N-CA 124.794 1.237 . . . . 0.0 110.734 171.506 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.417 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 11.7 pt20 -100.19 148.89 24.12 Favored 'General case' 0 N--CA 1.496 1.875 0 N-CA-C 107.977 -1.12 . . . . 0.0 107.977 158.366 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.649 HD11 ' HB2' ' A' ' 88' ' ' GLN . 0.0 OUTLIER -132.17 -39.01 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 CA-C-N 119.629 1.104 . . . . 0.0 111.305 179.167 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -175.59 -145.99 5.68 Favored Glycine 0 C--N 1.347 1.143 0 C-N-CA 119.652 -1.261 . . . . 0.0 114.199 -171.996 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -158.64 175.28 13.85 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 123.488 0.715 . . . . 0.0 111.449 -177.048 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -172.25 176.47 45.25 Favored Glycine 0 C--N 1.344 0.993 0 CA-C-N 115.401 -0.818 . . . . 0.0 111.539 -178.608 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.447 HG11 HD11 ' A' ' 146' ' ' LEU . 47.2 t -123.12 125.93 72.81 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.012 0 C-N-CA 122.866 0.466 . . . . 0.0 111.028 -175.325 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 39.4 t80 -85.34 144.63 27.94 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 167.092 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.603 ' HG3' ' HG3' ' A' ' 104' ' ' GLU . 22.9 tptm -157.0 133.83 10.19 Favored 'General case' 0 C--O 1.239 0.518 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 173.665 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.603 ' HG3' ' HG3' ' A' ' 103' ' ' LYS . 29.5 mt-10 62.6 -91.83 0.03 OUTLIER 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 124.983 1.313 . . . . 0.0 111.569 176.062 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -143.89 31.26 1.88 Allowed Glycine 0 C--N 1.341 0.831 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.4 t -146.28 129.4 16.55 Favored 'General case' 0 C--O 1.241 0.653 0 C-N-CA 123.694 0.798 . . . . 0.0 110.614 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' PHE . . . . . 0.533 ' HE2' HD11 ' A' ' 86' ' ' ILE . 67.2 t80 -94.92 104.01 15.89 Favored 'General case' 0 C--N 1.345 0.386 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 171.916 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' HIS . . . . . 0.541 ' CE1' ' HB3' ' A' ' 103' ' ' LYS . 1.5 p-80 -107.8 121.08 44.01 Favored 'General case' 0 C--N 1.325 -0.481 0 C-N-CA 123.247 0.619 . . . . 0.0 109.492 -178.862 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 8.6 t -136.62 179.77 6.17 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 123.839 0.856 . . . . 0.0 111.241 -172.52 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 110' ' ' MET . . . . . 0.449 ' SD ' ' O ' ' A' ' 212' ' ' GLY . 27.7 ttm -74.92 150.42 39.12 Favored 'General case' 0 CA--C 1.547 0.86 0 C-N-CA 125.463 1.505 . . . . 0.0 109.94 173.204 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 111' ' ' TRP . . . . . 0.407 ' HA ' HG22 ' A' ' 138' ' ' ILE . 86.8 t90 -73.61 -56.32 5.16 Favored 'General case' 0 N--CA 1.494 1.747 0 CA-C-N 118.32 0.509 . . . . 0.0 111.967 -168.474 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 1.2 p-80 -68.69 2.96 2.12 Favored 'General case' 0 N--CA 1.485 1.314 0 N-CA-C 114.332 1.234 . . . . 0.0 114.332 -171.358 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.412 HG21 HD12 ' A' ' 86' ' ' ILE . 23.0 m -60.32 -38.64 78.27 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 167.273 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 12.0 t -122.48 174.24 7.17 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 124.663 1.185 . . . . 0.0 108.498 178.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 50.7 ttt-85 -93.14 31.26 1.48 Allowed 'General case' 0 N--CA 1.485 1.275 0 CA-C-O 121.326 0.584 . . . . 0.0 109.588 -179.005 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.418 ' HA2' HD12 ' A' ' 138' ' ' ILE . . . 73.74 35.43 54.91 Favored Glycine 0 C--N 1.348 1.234 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 -167.22 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -122.36 -163.31 1.07 Allowed 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 123.663 0.785 . . . . 0.0 111.782 -168.833 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.698 HG21 ' HG3' ' A' ' 125' ' ' ARG . 2.0 m -89.21 156.56 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.127 0 C-N-CA 123.359 0.664 . . . . 0.0 110.822 -172.413 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.634 HD13 HD21 ' A' ' 8' ' ' LEU . 54.8 mt -110.46 174.78 5.7 Favored 'General case' 0 CA--C 1.551 1.018 0 C-N-CA 124.357 1.063 . . . . 0.0 109.586 170.758 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 23.5 mmt -124.63 137.6 54.36 Favored 'General case' 0 C--O 1.25 1.093 0 C-N-CA 123.534 0.734 . . . . 0.0 110.165 -176.026 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.446 ' HB2' HD11 ' A' ' 126' ' ' ILE . 77.6 t60 -130.88 95.85 3.93 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 168.002 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 62.93 20.44 12.25 Favored 'General case' 0 N--CA 1.495 1.811 0 C-N-CA 124.513 1.125 . . . . 0.0 111.523 -168.461 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 88.52 14.65 61.31 Favored Glycine 0 C--N 1.345 1.054 0 CA-C-O 119.7 -0.5 . . . . 0.0 112.682 -172.946 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -82.18 129.5 34.85 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 169.072 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 125' ' ' ARG . . . . . 0.698 ' HG3' HG21 ' A' ' 118' ' ' VAL . 35.8 ttm180 -78.59 98.71 6.25 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 124.794 1.237 . . . . 0.0 111.217 -173.619 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.446 HD11 ' HB2' ' A' ' 121' ' ' HIS . 18.4 mt -89.08 95.48 5.44 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.693 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 175.751 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -91.68 141.57 25.84 Favored Pre-proline 0 N--CA 1.487 1.422 0 C-N-CA 122.732 0.413 . . . . 0.0 110.256 -179.212 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -73.42 153.8 50.36 Favored 'Trans proline' 0 C--N 1.382 2.307 0 C-N-CA 122.924 2.416 . . . . 0.0 114.791 -170.786 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 66.4 p -101.88 -32.45 10.22 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 123.97 0.908 . . . . 0.0 110.209 172.766 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 72.4 t-105 -130.38 149.71 51.94 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 124.059 0.944 . . . . 0.0 109.355 -177.76 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -156.77 125.69 5.93 Favored 'General case' 0 C--O 1.241 0.654 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 175.78 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -141.75 110.16 6.0 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 123.108 0.563 . . . . 0.0 109.896 179.717 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 3.5 t -77.09 -17.02 14.56 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.286 0 C-N-CA 123.654 0.782 . . . . 0.0 111.307 -176.552 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 58.3 mttp -65.21 -53.79 39.36 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 123.697 0.799 . . . . 0.0 110.903 -176.53 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 47.6 mmtm -82.93 -17.38 43.81 Favored 'General case' 0 N--CA 1.478 0.934 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.181 172.654 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 11.5 t70 60.49 66.74 0.9 Allowed 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 125.865 1.666 . . . . 0.0 109.44 -173.66 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 51.8 mt -143.63 123.94 13.83 Favored 'General case' 0 CA--C 1.547 0.844 0 CA-C-N 113.673 -1.603 . . . . 0.0 108.7 -179.17 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.418 HD12 ' HA2' ' A' ' 116' ' ' GLY . 16.8 tt -118.7 138.79 48.26 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 176.076 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 35.0 t -134.37 151.76 51.4 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 121.785 0.802 . . . . 0.0 111.797 -175.914 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 18.8 m-85 -124.25 102.77 7.87 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 113.784 -1.553 . . . . 0.0 107.423 -169.754 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 97.09 -1.98 61.22 Favored Glycine 0 C--N 1.346 1.092 0 O-C-N 123.776 0.672 . . . . 0.0 113.366 -177.09 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . -175.69 -150.54 8.06 Favored Glycine 0 C--N 1.347 1.155 0 CA-C-O 119.503 -0.61 . . . . 0.0 111.986 -177.52 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -116.83 -179.43 17.79 Favored Glycine 0 C--N 1.352 1.419 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 171.185 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 144' ' ' TRP . . . . . 0.527 ' HA ' ' HB2' ' A' ' 108' ' ' HIS . 54.1 t-105 -70.61 105.15 3.03 Favored 'General case' 0 N--CA 1.476 0.867 0 CA-C-N 118.655 1.227 . . . . 0.0 108.782 175.964 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 19.2 ptmt -138.41 121.55 16.86 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 122.944 0.498 . . . . 0.0 110.944 -171.058 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 146' ' ' LEU . . . . . 0.447 HD11 HG11 ' A' ' 101' ' ' VAL . 46.1 mt -153.17 -33.13 0.12 Allowed 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 125.586 1.554 . . . . 0.0 107.928 172.609 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 71.65 101.55 0.07 Allowed 'General case' 0 C--N 1.362 1.12 0 C-N-CA 126.166 1.786 . . . . 0.0 110.545 -179.048 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 148' ' ' GLY . . . . . 0.455 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -167.75 148.03 12.37 Favored Glycine 0 C--O 1.242 0.655 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 178.218 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -151.66 108.57 3.53 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -177.193 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 150' ' ' TRP . . . . . 0.605 ' HB2' HG21 ' A' ' 208' ' ' VAL . 81.5 t90 -65.9 123.95 21.2 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-O 120.762 0.315 . . . . 0.0 110.692 172.775 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -151.52 90.49 1.57 Allowed 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 160.567 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 152' ' ' GLU . . . . . 0.5 ' HG3' ' H ' ' A' ' 154' ' ' GLU . 12.0 tp10 -131.81 142.91 49.86 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 115.133 -0.94 . . . . 0.0 109.285 178.793 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -64.19 -30.42 77.75 Favored Glycine 0 C--N 1.349 1.287 0 N-CA-C 111.404 -0.678 . . . . 0.0 111.404 173.158 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 154' ' ' GLU . . . . . 0.5 ' H ' ' HG3' ' A' ' 152' ' ' GLU . 29.9 mt-10 -81.22 173.34 12.61 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 124.786 1.234 . . . . 0.0 110.003 172.566 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 155' ' ' GLU . . . . . 0.495 ' HB2' ' HB3' ' A' ' 171' ' ' GLN . 4.4 mp0 -67.31 166.76 13.71 Favored 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 123.738 0.815 . . . . 0.0 112.41 -173.394 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 15.0 p -92.67 141.47 14.58 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.167 172.117 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 157' ' ' GLN . . . . . 0.41 ' HG3' ' HG2' ' A' ' 171' ' ' GLN . 20.4 mp0 -99.22 131.51 45.2 Favored 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -173.392 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 41.4 t -133.95 102.06 4.2 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 -178.432 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.531 ' H ' HD23 ' A' ' 159' ' ' LEU . 2.3 pt? -76.3 85.5 3.08 Favored 'General case' 0 CA--C 1.545 0.768 0 CA-C-O 122.386 1.089 . . . . 0.0 108.893 176.004 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -64.65 114.53 4.48 Favored 'General case' 0 C--O 1.239 0.549 0 CA-C-N 114.221 -1.354 . . . . 0.0 108.64 178.441 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 161' ' ' LEU . . . . . 0.41 HD13 ' HB3' ' A' ' 11' ' ' ALA . 84.6 mt -69.0 94.49 0.64 Allowed 'General case' 0 C--O 1.239 0.503 0 O-C-N 123.655 0.597 . . . . 0.0 109.913 -172.312 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -65.28 112.6 8.74 Favored Pre-proline 0 CA--C 1.548 0.889 0 CA-C-N 114.267 -1.333 . . . . 0.0 109.436 -177.479 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -61.31 115.91 3.05 Favored 'Trans proline' 0 C--N 1.375 1.933 0 C-N-CA 122.503 2.135 . . . . 0.0 112.522 -171.405 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 93.12 -6.42 75.96 Favored Glycine 0 C--N 1.348 1.196 0 CA-C-N 114.966 -1.016 . . . . 0.0 113.883 177.542 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 61.3 mttm -128.07 -179.3 4.91 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 123.626 0.77 . . . . 0.0 109.207 -176.691 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -61.38 160.7 22.54 Favored Pre-proline 0 CA--C 1.558 1.26 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 164.302 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 167' ' ' PRO . . . . . 0.498 ' HG3' ' HB2' ' A' ' 12' ' ' ALA . 30.9 Cg_exo -61.93 -172.53 0.11 Allowed 'Trans proline' 0 C--N 1.375 1.951 0 C-N-CA 122.361 2.041 . . . . 0.0 114.491 -178.309 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 20.0 ttm-85 -138.13 99.46 3.88 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 171.902 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 169' ' ' ALA . . . . . 0.565 ' HB2' ' HB3' ' A' ' 17' ' ' GLU . . . -73.39 107.2 5.56 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.341 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 77.2 t -112.11 123.94 68.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 C-N-CA 123.493 0.717 . . . . 0.0 110.069 -176.584 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 171' ' ' GLN . . . . . 0.513 ' HB2' HD13 ' A' ' 22' ' ' ILE . 20.9 mt-30 -93.03 118.29 31.02 Favored 'General case' 0 C--N 1.341 0.217 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 175.362 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 172' ' ' THR . . . . . 0.723 HG21 HG23 ' A' ' 187' ' ' VAL . 5.9 t -126.29 142.8 51.39 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 123.206 0.603 . . . . 0.0 109.471 176.511 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -75.89 156.89 84.21 Favored Pre-proline 0 CA--C 1.561 1.368 0 CA-C-N 115.993 -0.548 . . . . 0.0 109.612 178.058 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -69.43 124.55 11.33 Favored 'Trans proline' 0 C--N 1.375 1.939 0 C-N-CA 122.178 1.919 . . . . 0.0 112.708 -177.492 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -158.78 139.38 6.22 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 108.74 -1.744 . . . . 0.0 108.74 175.238 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.749 ' HG ' ' HB3' ' A' ' 186' ' ' ALA 0.264 0.0 OUTLIER -175.8 -169.97 0.37 Allowed 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 123.949 0.899 . . . . 0.0 110.754 178.95 . . . . . . . . 4 4 . 1 . 008 nuclear build core ' A' A ' 177' ' ' PHE . . . . . 0.449 ' HA ' ' O ' ' A' ' 29' ' ' LEU . 79.3 m-85 -91.8 158.3 16.41 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 114.863 -1.062 . . . . 0.0 111.118 -152.28 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -133.36 109.48 9.38 Favored 'General case' 0 C--O 1.239 0.523 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 170.881 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 1.2 m -140.55 170.18 16.26 Favored 'General case' 0 N--CA 1.479 1.018 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 175.118 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 36.1 t30 -59.85 102.43 0.16 Allowed 'General case' 0 CA--C 1.548 0.892 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 168.324 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . 79.22 1.24 2.34 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 125.415 1.486 . . . . 0.0 111.492 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -123.86 54.2 0.73 Allowed Glycine 0 C--N 1.348 1.225 0 N-CA-C 111.409 -0.676 . . . . 0.0 111.409 178.547 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 84.6 m -110.21 98.16 7.48 Favored 'General case' 0 CA--C 1.536 0.441 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 175.452 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 184' ' ' ILE . . . . . 0.514 ' O ' ' HB3' ' A' ' 176' ' ' LEU . 3.6 mp -125.13 152.82 31.93 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 178.569 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -127.62 116.98 2.52 Favored Glycine 0 C--N 1.377 2.851 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 172.066 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.749 ' HB3' ' HG ' ' A' ' 176' ' ' LEU . . . -161.87 -149.34 0.16 Allowed 'General case' 0 C--N 1.373 1.598 0 CA-C-N 119.056 1.428 . . . . 0.0 111.9 -159.225 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 187' ' ' VAL . . . . . 0.723 HG23 HG21 ' A' ' 172' ' ' THR . 0.4 OUTLIER -91.57 117.77 35.54 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.971 0 C-N-CA 124.288 1.035 . . . . 0.0 110.028 -176.228 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 188' ' ' SER . . . . . 0.446 ' OG ' ' HB2' ' A' ' 26' ' ' SER . 10.6 t -130.44 90.78 2.98 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 123.406 0.682 . . . . 0.0 109.861 -174.123 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 189' ' ' LEU . . . . . 0.515 ' HA ' ' H ' ' A' ' 25' ' ' SER . 1.7 pp -136.91 -175.0 3.89 Favored 'General case' 0 N--CA 1.489 1.524 0 C-N-CA 123.423 0.689 . . . . 0.0 112.081 -174.292 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -135.19 119.29 17.57 Favored 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 124.238 1.015 . . . . 0.0 108.982 171.73 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 191' ' ' PHE . . . . . 0.433 ' HE2' ' HG ' ' A' ' 23' ' ' SER . 9.6 m-85 -149.15 -178.89 6.64 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 123.223 0.609 . . . . 0.0 111.916 -178.711 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 42.3 m -60.71 157.09 40.72 Favored Pre-proline 0 CA--C 1.555 1.161 0 C-N-CA 124.787 1.235 . . . . 0.0 111.28 176.839 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 3.8 Cg_exo -34.58 91.23 0.01 OUTLIER 'Trans proline' 0 C--N 1.393 2.881 0 C-N-CA 125.236 3.957 . . . . 0.0 115.225 -178.018 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -74.08 134.48 18.5 Favored Glycine 0 C--N 1.35 1.325 0 CA-C-N 114.582 -1.19 . . . . 0.0 112.394 -179.669 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 40.7 p -82.72 122.75 28.57 Favored 'General case' 0 C--O 1.244 0.796 0 C-N-CA 123.752 0.821 . . . . 0.0 110.097 178.013 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 18.1 m -62.45 88.08 0.03 OUTLIER 'General case' 0 C--N 1.363 1.17 0 C-N-CA 123.591 0.756 . . . . 0.0 110.847 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 197' ' ' GLY . . . . . 0.468 ' O ' HD22 ' A' ' 210' ' ' LEU . . . 129.12 21.14 1.37 Allowed Glycine 0 CA--C 1.523 0.553 0 CA-C-N 114.897 -1.047 . . . . 0.0 112.574 -179.276 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 198' ' ' SER . . . . . 0.444 ' HA ' ' HD3' ' A' ' 199' ' ' PRO . 32.2 p -70.18 123.64 89.23 Favored Pre-proline 0 N--CA 1.478 0.951 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 172.758 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 199' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' A' ' 198' ' ' SER . 32.1 Cg_exo -58.71 141.88 98.13 Favored 'Trans proline' 0 C--N 1.374 1.918 0 C-N-CA 122.9 2.4 . . . . 0.0 114.368 -168.538 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 200' ' ' ILE . . . . . 0.513 HD13 HG12 ' A' ' 226' ' ' ILE . 47.8 mt -110.8 118.96 58.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.325 0 C-N-CA 124.851 1.26 . . . . 0.0 108.754 175.922 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 201' ' ' ILE . . . . . 0.592 HG12 HG22 ' A' ' 207' ' ' VAL . 24.0 mt -113.02 143.47 22.64 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.377 0 C-N-CA 124.563 1.145 . . . . 0.0 110.029 -176.959 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -84.83 153.6 22.84 Favored 'General case' 0 N--CA 1.486 1.357 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 170.21 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 84.0 tttt -48.33 -27.29 2.45 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 124.689 1.196 . . . . 0.0 113.96 -172.884 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 204' ' ' LYS . . . . . 0.582 ' H ' ' HD2' ' A' ' 204' ' ' LYS . 9.7 mptt -64.1 -20.09 65.71 Favored 'General case' 0 N--CA 1.484 1.227 0 C-N-CA 124.27 1.028 . . . . 0.0 111.78 -177.448 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 101.6 5.85 50.9 Favored Glycine 0 C--N 1.345 1.033 0 CA-C-N 116.361 -0.382 . . . . 0.0 112.676 -177.881 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 39.8 tttm -106.61 140.74 39.01 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 123.162 0.585 . . . . 0.0 109.618 -179.762 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 207' ' ' VAL . . . . . 0.592 HG22 HG12 ' A' ' 201' ' ' ILE . 61.9 t -82.63 123.98 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 123.208 0.603 . . . . 0.0 111.41 -168.976 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 208' ' ' VAL . . . . . 0.605 HG21 ' HB2' ' A' ' 150' ' ' TRP . 45.6 t -69.46 -52.56 31.39 Favored 'Isoleucine or valine' 0 C--O 1.239 0.548 0 O-C-N 124.574 1.171 . . . . 0.0 110.48 173.714 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.519 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . 177.71 -134.24 2.4 Favored Glycine 0 C--N 1.348 1.2 0 CA-C-N 115.157 -0.928 . . . . 0.0 113.694 -175.892 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 210' ' ' LEU . . . . . 0.468 HD22 ' O ' ' A' ' 197' ' ' GLY . 86.1 mt -131.44 152.64 50.5 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 123.836 0.854 . . . . 0.0 110.926 -176.793 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 51.1 t80 -102.15 104.54 15.15 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 123.861 0.864 . . . . 0.0 108.986 175.696 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 212' ' ' GLY . . . . . 0.449 ' O ' ' SD ' ' A' ' 110' ' ' MET . . . 169.72 74.27 0.04 OUTLIER Glycine 0 C--N 1.337 0.632 0 C-N-CA 120.892 -0.67 . . . . 0.0 113.424 161.514 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 213' ' ' ASN . . . . . 0.705 ' H ' ' HB3' ' A' ' 224' ' ' SER . 71.7 m-20 -146.09 81.96 1.6 Allowed 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 170.368 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 178.03 -121.58 0.78 Allowed Glycine 0 N--CA 1.445 -0.714 0 CA-C-N 114.71 -1.132 . . . . 0.0 111.839 178.303 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 215' ' ' VAL . . . . . . . . . . . . . 10.2 p -172.81 165.61 0.24 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.843 0 C-N-CA 122.883 0.473 . . . . 0.0 109.955 -164.015 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 216' ' ' VAL . . . . . . . . . . . . . 27.7 m -77.45 107.7 9.46 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.137 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 158.949 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 217' ' ' THR . . . . . 0.529 HG21 HD13 ' A' ' 29' ' ' LEU . 74.6 m -82.41 144.03 30.79 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 123.998 0.919 . . . . 0.0 109.351 -179.751 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 13.6 mmm180 63.81 17.54 10.56 Favored 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 124.03 0.932 . . . . 0.0 110.077 -169.633 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 35.5 m 61.33 31.95 19.23 Favored 'General case' 0 C--N 1.364 1.239 0 C-N-CA 125.536 1.534 . . . . 0.0 112.175 -175.903 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . -157.93 -52.85 0.01 OUTLIER Glycine 0 C--N 1.352 1.464 0 CA-C-O 120.019 -0.323 . . . . 0.0 113.358 -179.122 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -69.71 114.22 7.71 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 123.185 0.594 . . . . 0.0 111.562 -172.911 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 222' ' ' TYR . . . . . . . . . . . . . 7.5 m-85 -68.11 98.06 0.75 Allowed 'General case' 0 CA--C 1.551 1.0 0 C-N-CA 123.0 0.52 . . . . 0.0 110.272 179.063 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 94.9 t -127.5 127.17 68.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 C-N-CA 123.798 0.839 . . . . 0.0 110.089 -171.445 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 224' ' ' SER . . . . . 0.705 ' HB3' ' H ' ' A' ' 213' ' ' ASN . 58.5 m -153.75 159.06 41.82 Favored 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 123.237 0.615 . . . . 0.0 111.384 -171.026 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 225' ' ' ALA . . . . . . . . . . . . . . . -80.03 145.15 32.65 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.352 1.061 . . . . 0.0 110.986 177.451 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 226' ' ' ILE . . . . . 0.637 HG13 ' HB1' ' A' ' 186' ' ' ALA . 85.3 mt -78.85 102.89 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 174.065 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 227' ' ' ALA . . . . . 0.435 ' O ' ' HA3' ' A' ' 209' ' ' GLY . . . -77.76 101.75 6.83 Favored 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 177.757 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 49.0 mt-30 -89.87 169.37 11.3 Favored 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 123.088 0.555 . . . . 0.0 110.098 -171.316 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 229' ' ' THR . . . . . 0.43 ' HA ' ' CD1' ' A' ' 144' ' ' TRP . 71.4 p -80.05 123.41 27.82 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 123.079 0.552 . . . . 0.0 111.506 -177.566 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -99.6 -24.18 14.82 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 123.244 0.618 . . . . 0.0 109.504 167.886 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 13.4 ptpt 68.72 157.06 0.14 Allowed 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 127.392 2.277 . . . . 0.0 113.098 174.132 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 22.4 m . . . . . 0 CA--C 1.543 0.678 0 CA-C-N 115.536 -0.756 . . . . 0.0 110.64 166.58 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.432 ' O ' ' HB1' ' A' ' 117' ' ' ALA . . . . . . . . 0 N--CA 1.482 1.165 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -102.81 18.03 22.47 Favored 'General case' 0 N--CA 1.478 0.937 0 O-C-N 121.851 -0.531 . . . . 0.0 109.652 -175.027 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' ASP . . . . . 0.5 ' HB3' ' O ' ' A' ' 89' ' ' LYS . 6.2 m-20 -126.02 26.88 6.45 Favored 'General case' 0 C--O 1.237 0.444 0 C-N-CA 124.525 1.13 . . . . 0.0 108.976 -169.888 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.424 ' O ' HD13 ' A' ' 119' ' ' LEU . 83.7 mt -75.8 93.56 3.17 Favored 'General case' 0 C--O 1.215 -0.739 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.085 -173.172 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.446 ' HA ' ' O ' ' A' ' 120' ' ' MET . 23.2 tt0 -83.54 135.19 34.73 Favored 'General case' 0 N--CA 1.475 0.796 0 O-C-N 122.139 -0.351 . . . . 0.0 111.326 -179.651 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.475 ' H ' HD23 ' A' ' 8' ' ' LEU . 2.6 pt? -102.1 138.89 38.46 Favored 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.337 177.096 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 19.1 pt-20 -143.33 144.51 32.12 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.802 0.841 . . . . 0.0 109.096 176.182 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ARG . . . . . 0.517 ' NH2' ' HB3' ' A' ' 13' ' ' ASP . 50.7 ttt180 -63.41 120.73 12.21 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 112.286 0.476 . . . . 0.0 112.286 -165.603 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.706 ' HB2' ' HG3' ' A' ' 85' ' ' ARG . . . -84.64 -45.89 12.05 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 124.108 0.963 . . . . 0.0 109.896 173.081 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -170.95 -178.21 2.44 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-N 115.178 -0.919 . . . . 0.0 112.006 -173.733 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ASP . . . . . 0.517 ' HB3' ' NH2' ' A' ' 10' ' ' ARG . 10.4 p-10 -103.63 164.77 11.46 Favored 'General case' 0 CA--C 1.54 0.571 0 CA-C-N 114.121 -1.4 . . . . 0.0 108.571 165.373 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 53.0 t -88.11 101.44 11.61 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.856 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 179.03 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 62.7 tttp -172.73 113.74 0.27 Allowed 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 124.42 1.088 . . . . 0.0 108.187 -177.738 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 79.8 t90 -100.95 91.71 4.7 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 122.503 0.321 . . . . 0.0 110.465 -176.714 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -158.27 58.05 0.46 Allowed 'General case' 0 CA--C 1.549 0.931 0 C-N-CA 123.593 0.757 . . . . 0.0 109.746 162.114 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.425 ' HB3' ' H ' ' A' ' 169' ' ' ALA . 8.0 t70 -86.93 -56.04 3.57 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 122.833 0.453 . . . . 0.0 111.17 179.052 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' GLN . . . . . 0.656 ' H ' ' HB3' ' A' ' 169' ' ' ALA . 10.1 tm0? -148.38 4.35 0.69 Allowed 'General case' 0 N--CA 1.484 1.267 0 C-N-CA 123.186 0.595 . . . . 0.0 111.396 -173.615 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . 13.71 81.55 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 126.521 1.928 . . . . 0.0 114.228 -168.422 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.472 ' O ' ' HG2' ' A' ' 171' ' ' GLN . 34.2 tt0 -101.97 147.44 26.55 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 114.306 -1.316 . . . . 0.0 109.221 -176.503 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 9.4 tp -93.03 149.05 4.34 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.798 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 174.348 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' SER . . . . . 0.559 ' HB3' HD23 ' A' ' 189' ' ' LEU . 69.1 m -91.73 -174.67 3.92 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 123.642 0.777 . . . . 0.0 111.455 178.341 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -87.23 -41.88 6.43 Favored Glycine 0 C--N 1.347 1.194 0 CA-C-N 115.436 -0.802 . . . . 0.0 111.28 178.912 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 35.5 m 63.0 87.47 0.1 Allowed 'General case' 0 C--N 1.358 0.968 0 C-N-CA 124.299 1.039 . . . . 0.0 110.219 177.836 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.553 ' HB2' ' HB3' ' A' ' 188' ' ' SER . 17.2 m -85.49 156.31 59.26 Favored Pre-proline 0 CA--C 1.555 1.147 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.988 -174.672 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -65.63 -168.56 0.13 Allowed 'Trans proline' 0 C--N 1.376 2.018 0 C-N-CA 123.244 2.63 . . . . 0.0 112.448 167.946 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 35.0 mm -66.14 138.37 23.14 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.267 0 CA-C-O 120.811 0.339 . . . . 0.0 110.662 -174.981 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.563 HD22 HG22 ' A' ' 217' ' ' THR . 4.3 mt -114.85 161.46 18.21 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 123.282 0.633 . . . . 0.0 110.564 175.167 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 30.4 t -112.24 114.65 27.56 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 178.579 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 12.9 tt -113.62 160.56 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 C-N-CA 124.649 1.18 . . . . 0.0 108.306 -174.793 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 82.2 p -93.89 104.96 17.0 Favored 'General case' 0 C--N 1.363 1.164 0 CA-C-N 119.845 1.202 . . . . 0.0 108.184 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.807 HG21 ' HA ' ' A' ' 179' ' ' THR . 3.5 tp -107.86 154.65 8.91 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 C-N-CA 125.887 1.675 . . . . 0.0 107.549 -176.62 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 9.1 p -157.27 161.91 39.18 Favored 'General case' 0 C--O 1.249 1.061 0 C-N-CA 123.264 0.626 . . . . 0.0 110.547 -171.743 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -58.29 158.02 7.76 Favored 'General case' 0 N--CA 1.481 1.103 0 C-N-CA 124.594 1.158 . . . . 0.0 111.505 -175.548 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 30.7 t70 78.39 14.55 1.38 Allowed 'General case' 0 N--CA 1.491 1.616 0 C-N-CA 124.911 1.284 . . . . 0.0 110.396 178.871 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 73.98 34.23 56.05 Favored Glycine 0 C--N 1.356 1.644 0 CA-C-N 115.343 -0.844 . . . . 0.0 112.265 -178.834 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 47.5 t -99.54 143.87 29.29 Favored 'General case' 0 N--CA 1.469 0.522 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -175.718 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 19.3 ptm -163.03 154.24 17.23 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 122.571 0.348 . . . . 0.0 111.053 -177.087 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 35.5 p -176.29 -179.09 1.03 Allowed 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 125.035 1.334 . . . . 0.0 108.96 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.415 HG21 ' O ' ' A' ' 216' ' ' VAL . 10.4 tp -107.17 96.72 4.86 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 172.309 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 7.5 mtpm? 50.77 31.0 5.47 Favored 'General case' 0 CA--C 1.559 1.318 0 C-N-CA 124.247 1.019 . . . . 0.0 113.082 170.729 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 41.8 t-20 79.15 -30.02 0.14 Allowed 'General case' 0 N--CA 1.502 2.132 0 C-N-CA 125.885 1.674 . . . . 0.0 111.959 -174.697 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -58.54 107.36 0.49 Allowed 'General case' 0 CA--C 1.55 0.949 0 C-N-CA 125.533 1.533 . . . . 0.0 112.86 -171.005 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 . . . . . 0 N--CA 1.474 0.759 0 C-N-CA 123.419 0.687 . . . . 0.0 110.684 172.471 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.609 ' N ' ' HH ' ' A' ' 84' ' ' TYR . 18.9 t70 . . . . . 0 N--CA 1.487 1.413 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.421 ' HA3' ' HA ' ' A' ' 13' ' ' ASP . . . 93.49 -147.54 18.63 Favored Glycine 0 C--N 1.344 0.984 0 C-N-CA 123.076 0.369 . . . . 0.0 113.34 177.199 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -84.44 138.22 32.94 Favored 'General case' 0 N--CA 1.48 1.062 0 C-N-CA 123.493 0.717 . . . . 0.0 110.155 -177.397 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' TYR . . . . . 0.609 ' HH ' ' N ' ' A' ' 81' ' ' ASP . 12.0 m-85 -125.74 140.02 53.04 Favored 'General case' 0 N--CA 1.494 1.761 0 C-N-CA 123.334 0.654 . . . . 0.0 111.324 -179.061 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' ARG . . . . . 0.706 ' HG3' ' HB2' ' A' ' 11' ' ' ALA . 58.2 mtt-85 -85.41 122.21 29.23 Favored 'General case' 0 C--O 1.239 0.521 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 169.958 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.48 HD11 ' HZ ' ' A' ' 107' ' ' PHE . 62.6 mt -98.3 119.82 46.82 Favored 'Isoleucine or valine' 0 C--O 1.253 1.237 0 CA-C-O 121.589 0.709 . . . . 0.0 109.394 175.299 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.442 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 58.4 pttt -111.12 146.9 36.0 Favored 'General case' 0 C--O 1.239 0.548 0 CA-C-N 114.26 -1.336 . . . . 0.0 108.477 174.001 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -83.09 107.81 15.92 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 104.294 -2.484 . . . . 0.0 104.294 166.31 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' LYS . . . . . 0.5 ' O ' ' HB3' ' A' ' 5' ' ' ASP . 28.8 ttpt -117.34 96.92 5.64 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -175.506 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -67.11 154.2 52.86 Favored Glycine 0 C--N 1.339 0.725 0 N-CA-C 107.436 -2.266 . . . . 0.0 107.436 166.097 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 20.1 mm -78.86 63.93 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.39 0 CA-C-N 118.637 1.219 . . . . 0.0 108.926 -173.265 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 22.3 tp 167.81 -32.62 0.0 OUTLIER 'General case' 0 CA--C 1.562 1.431 0 C-N-CA 125.535 1.534 . . . . 0.0 109.854 -166.336 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -145.36 149.14 21.25 Favored Glycine 0 C--N 1.369 2.39 0 N-CA-C 114.265 0.466 . . . . 0.0 114.265 -171.935 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -124.98 133.36 53.04 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 124.614 1.166 . . . . 0.0 110.33 -169.885 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 44.7 m -151.45 103.19 2.96 Favored 'General case' 0 N--CA 1.493 1.705 0 CA-C-N 118.602 0.637 . . . . 0.0 112.085 176.724 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.442 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 43.7 mt-30 -53.76 120.39 6.19 Favored 'General case' 0 N--CA 1.495 1.818 0 C-N-CA 123.489 0.716 . . . . 0.0 111.215 173.446 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.5 pp -122.54 -13.07 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 C-N-CA 123.806 0.842 . . . . 0.0 112.061 -176.645 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 174.87 -152.51 13.96 Favored Glycine 0 C--N 1.342 0.903 0 CA-C-O 119.637 -0.535 . . . . 0.0 112.313 174.619 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -156.36 164.3 38.46 Favored 'General case' 0 C--O 1.241 0.652 0 C-N-CA 123.384 0.674 . . . . 0.0 110.973 -176.594 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -158.31 149.94 20.46 Favored Glycine 0 C--N 1.339 0.731 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 177.209 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 37.2 t -96.14 118.91 43.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 C-N-CA 123.328 0.651 . . . . 0.0 110.192 -176.576 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 85.5 t80 -94.93 126.9 40.58 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 171.371 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.441 ' HD2' ' HA ' ' A' ' 103' ' ' LYS . 42.7 tptt -133.55 114.5 13.64 Favored 'General case' 0 C--O 1.239 0.548 0 C-N-CA 123.28 0.632 . . . . 0.0 109.565 175.054 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 68.52 -78.14 0.05 OUTLIER 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 125.282 1.433 . . . . 0.0 112.415 169.185 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -147.46 32.43 1.36 Allowed Glycine 0 N--CA 1.465 0.569 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 176.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 44.6 m -136.84 124.86 22.82 Favored 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 124.21 1.004 . . . . 0.0 109.563 178.331 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' PHE . . . . . 0.48 ' HZ ' HD11 ' A' ' 86' ' ' ILE . 57.0 t80 -110.13 118.05 35.35 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 172.634 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 108' ' ' HIS . . . . . 0.527 ' NE2' ' HB3' ' A' ' 137' ' ' LEU . 60.5 t60 -123.69 114.82 20.47 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 122.809 0.443 . . . . 0.0 109.97 -178.654 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 9.0 t -114.14 -165.71 1.03 Allowed 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 124.338 1.055 . . . . 0.0 109.525 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' MET . . . . . 0.589 ' HA ' ' HA ' ' A' ' 137' ' ' LEU . 13.6 mtp -107.43 160.56 15.55 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 124.13 0.972 . . . . 0.0 110.033 177.075 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 11.6 t90 -80.79 -31.47 35.74 Favored 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 122.645 0.378 . . . . 0.0 111.512 -175.561 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 46.1 p-80 -75.02 -18.02 60.41 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.639 -0.663 . . . . 0.0 111.051 174.981 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 68.7 t -81.98 -44.02 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.523 0.729 . . . . 0.0 109.519 173.675 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 90.1 m -135.16 108.3 7.7 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 107.752 -1.203 . . . . 0.0 107.752 -178.767 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 19.3 ptp180 -85.69 33.33 0.58 Allowed 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 123.298 0.639 . . . . 0.0 112.211 -172.533 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 91.74 27.76 16.06 Favored Glycine 0 N--CA 1.47 0.912 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -170.083 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 117' ' ' ALA . . . . . 0.432 ' HB1' ' O ' ' A' ' 3' ' ' ALA . . . -94.41 -178.92 4.74 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.065 0.946 . . . . 0.0 110.971 -177.189 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 70.2 t -100.3 133.25 43.99 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 123.404 0.681 . . . . 0.0 110.47 -176.341 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.541 ' HB2' ' HB ' ' A' ' 126' ' ' ILE . 2.4 mm? -92.01 162.31 14.43 Favored 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 124.155 0.982 . . . . 0.0 110.049 172.946 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 120' ' ' MET . . . . . 0.446 ' O ' ' HA ' ' A' ' 7' ' ' GLU . 23.5 mmt -139.25 136.79 35.33 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 124.066 0.947 . . . . 0.0 110.458 -171.609 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 14.7 t-80 -169.38 137.0 1.8 Allowed 'General case' 0 N--CA 1.476 0.825 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 153.956 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 85.5 mttt 70.45 9.69 7.0 Favored 'General case' 0 N--CA 1.503 2.208 0 C-N-CA 124.238 1.015 . . . . 0.0 111.753 -178.45 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 83.46 -4.95 79.96 Favored Glycine 0 C--N 1.349 1.266 0 CA-C-O 119.953 -0.359 . . . . 0.0 112.519 -167.289 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 31.0 mmmt -72.64 117.61 14.54 Favored 'General case' 0 C--O 1.248 0.998 0 C-N-CA 123.512 0.725 . . . . 0.0 109.123 175.593 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 85.3 mtm180 -87.4 96.05 10.23 Favored 'General case' 0 C--O 1.237 0.418 0 O-C-N 124.665 1.228 . . . . 0.0 108.869 -179.122 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.541 ' HB ' ' HB2' ' A' ' 119' ' ' LEU . 97.2 mt -75.19 114.78 15.65 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.664 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.271 -179.069 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -92.91 146.9 32.92 Favored Pre-proline 0 CA--C 1.548 0.875 0 C-N-CA 124.126 0.97 . . . . 0.0 110.63 -174.554 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_exo -67.9 101.01 0.65 Allowed 'Trans proline' 0 C--N 1.367 1.528 0 C-N-CA 122.088 1.859 . . . . 0.0 110.866 169.336 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 22.7 t -64.33 -31.25 72.38 Favored 'General case' 0 N--CA 1.483 1.216 0 CA-C-O 121.271 0.558 . . . . 0.0 109.877 177.19 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 75.0 t-105 -150.7 156.33 41.11 Favored 'General case' 0 CA--C 1.543 0.695 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 165.306 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -136.76 120.09 16.86 Favored 'General case' 0 N--CA 1.467 0.419 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 176.278 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 27.3 m-20 -95.13 106.78 18.81 Favored 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 124.394 1.078 . . . . 0.0 109.247 175.518 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 60.3 t -75.59 -41.87 41.58 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.659 0 C-N-CA 123.141 0.577 . . . . 0.0 110.351 178.74 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 55.7 tttm -73.76 -34.98 64.95 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.954 -175.242 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 13.6 tppt? -80.88 -18.78 46.12 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 123.096 0.558 . . . . 0.0 110.797 176.935 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 26.3 t70 62.5 48.32 4.58 Favored 'General case' 0 N--CA 1.481 1.083 0 CA-C-O 122.72 1.248 . . . . 0.0 110.379 -175.4 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 137' ' ' LEU . . . . . 0.589 ' HA ' ' HA ' ' A' ' 110' ' ' MET . 74.8 mt -149.98 138.6 20.76 Favored 'General case' 0 N--CA 1.476 0.838 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.155 -176.899 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 5.8 mt -112.22 145.02 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 C-N-CA 123.384 0.674 . . . . 0.0 110.416 175.206 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 139' ' ' SER . . . . . 0.415 ' HB3' ' O ' ' A' ' 142' ' ' GLY . 34.6 m -118.64 141.61 48.43 Favored 'General case' 0 CA--C 1.557 1.217 0 C-N-CA 125.015 1.326 . . . . 0.0 110.945 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 19.6 t80 -135.38 142.13 45.64 Favored 'General case' 0 N--CA 1.488 1.472 0 C-N-CA 124.835 1.254 . . . . 0.0 108.515 173.203 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.26 -60.5 4.7 Favored Glycine 0 C--N 1.352 1.42 0 N-CA-C 111.254 -0.738 . . . . 0.0 111.254 -176.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 142' ' ' GLY . . . . . 0.415 ' O ' ' HB3' ' A' ' 139' ' ' SER . . . -148.28 -171.82 17.57 Favored Glycine 0 C--O 1.242 0.635 0 N-CA-C 109.871 -1.292 . . . . 0.0 109.871 172.394 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -77.46 -177.17 46.06 Favored Glycine 0 C--N 1.337 0.627 0 N-CA-C 112.13 -0.388 . . . . 0.0 112.13 175.333 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 144' ' ' TRP . . . . . 0.501 ' HB2' ' CE1' ' A' ' 108' ' ' HIS . 13.4 t-105 -69.78 111.6 5.65 Favored 'General case' 0 C--O 1.243 0.756 0 O-C-N 122.585 -0.362 . . . . 0.0 110.44 177.19 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 145' ' ' LYS . . . . . 0.412 ' HB3' ' O ' ' A' ' 232' ' ' SER . 23.0 pttm -135.64 152.34 51.12 Favored 'General case' 0 N--CA 1.466 0.334 0 O-C-N 124.092 0.87 . . . . 0.0 110.308 173.015 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 146' ' ' LEU . . . . . 0.443 ' H ' ' H ' ' A' ' 147' ' ' GLU . 4.1 mt 174.63 -8.89 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.945 0 C-N-CA 127.158 2.183 . . . . 0.0 108.207 178.521 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.46 ' N ' HG21 ' A' ' 229' ' ' THR . 7.6 mm-40 60.0 70.93 0.6 Allowed 'General case' 0 C--N 1.365 1.269 0 C-N-CA 125.387 1.475 . . . . 0.0 110.66 173.377 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -104.15 159.23 16.48 Favored Glycine 0 N--CA 1.444 -0.789 0 CA-C-N 114.069 -1.423 . . . . 0.0 113.998 -177.204 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -129.35 93.01 3.46 Favored 'General case' 0 C--O 1.243 0.742 0 C-N-CA 123.856 0.862 . . . . 0.0 109.142 178.795 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 150' ' ' TRP . . . . . . . . . . . . . 25.2 t90 -74.24 120.63 20.07 Favored 'General case' 0 C--O 1.238 0.498 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 173.655 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 20.4 mttm -85.15 94.68 8.93 Favored 'General case' 0 C--O 1.243 0.722 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 176.695 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -66.39 97.15 0.4 Allowed 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 123.671 0.788 . . . . 0.0 109.053 -176.961 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 143.27 -49.33 0.72 Allowed Glycine 0 C--N 1.341 0.842 0 CA-C-N 115.371 -0.832 . . . . 0.0 111.365 -178.357 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -85.33 157.94 20.41 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 122.889 0.476 . . . . 0.0 112.042 -175.659 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 155' ' ' GLU . . . . . 0.467 ' HA ' ' HA ' ' A' ' 173' ' ' LYS . 0.8 OUTLIER -62.5 131.1 48.0 Favored 'General case' 0 C--N 1.351 0.654 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.926 177.918 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.53 HG11 HD13 ' A' ' 226' ' ' ILE . 34.0 m -93.25 159.11 2.83 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.562 179.421 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 25.2 mp0 -113.02 130.36 56.17 Favored 'General case' 0 C--O 1.215 -0.727 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -172.079 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 44.6 t -133.99 137.07 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -174.863 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.582 ' H ' HD23 ' A' ' 159' ' ' LEU . 2.2 pt? -92.57 96.53 10.26 Favored 'General case' 0 CA--C 1.545 0.777 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 169.269 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -64.91 104.02 0.8 Allowed 'General case' 0 C--O 1.24 0.603 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.243 -178.565 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 161' ' ' LEU . . . . . 0.613 HD23 ' HB3' ' A' ' 167' ' ' PRO . 78.0 mt -69.01 84.74 0.33 Allowed 'General case' 0 C--O 1.241 0.641 0 C-N-CA 123.704 0.802 . . . . 0.0 108.873 177.109 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 28.3 tt0 -74.9 134.11 75.34 Favored Pre-proline 0 CA--C 1.545 0.767 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.297 -177.085 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_exo -46.25 112.59 0.48 Allowed 'Trans proline' 0 C--N 1.382 2.342 0 C-N-CA 123.53 2.82 . . . . 0.0 113.881 178.198 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 63.79 27.87 71.78 Favored Glycine 0 C--N 1.35 1.356 0 O-C-N 123.903 0.752 . . . . 0.0 113.819 173.703 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 53.0 tptt -146.49 173.21 12.51 Favored 'General case' 0 C--O 1.245 0.837 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 -176.03 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -56.87 151.09 34.6 Favored Pre-proline 0 CA--C 1.558 1.28 0 C-N-CA 123.701 0.8 . . . . 0.0 112.595 177.317 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 167' ' ' PRO . . . . . 0.613 ' HB3' HD23 ' A' ' 161' ' ' LEU . 6.9 Cg_exo -74.86 92.42 0.97 Allowed 'Trans proline' 0 C--N 1.372 1.789 0 C-N-CA 123.249 2.632 . . . . 0.0 110.188 171.393 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 31.7 ttp-105 -75.68 122.08 23.45 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.065 -170.211 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 169' ' ' ALA . . . . . 0.656 ' HB3' ' H ' ' A' ' 19' ' ' GLN . . . -68.77 105.36 2.29 Favored 'General case' 0 CA--C 1.538 0.505 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.934 179.606 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 18.8 t -129.24 135.01 62.85 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.095 0 C-N-CA 124.866 1.266 . . . . 0.0 108.257 176.353 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 171' ' ' GLN . . . . . 0.472 ' HG2' ' O ' ' A' ' 21' ' ' GLU . 27.3 pt20 -117.07 126.73 53.3 Favored 'General case' 0 N--CA 1.478 0.933 0 C-N-CA 123.651 0.781 . . . . 0.0 110.318 -176.122 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 172' ' ' THR . . . . . 0.527 HG21 HG13 ' A' ' 187' ' ' VAL . 5.4 t -118.0 143.13 46.65 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 124.207 1.003 . . . . 0.0 110.911 -173.006 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 173' ' ' LYS . . . . . 0.467 ' HA ' ' HA ' ' A' ' 155' ' ' GLU . 37.2 ttmt -85.46 142.07 37.26 Favored Pre-proline 0 N--CA 1.479 0.983 0 CA-C-O 118.549 -0.738 . . . . 0.0 109.334 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 174' ' ' PRO . . . . . 0.577 ' HA ' ' O ' ' A' ' 186' ' ' ALA . 89.6 Cg_exo -47.32 122.69 6.85 Favored 'Trans proline' 0 C--N 1.396 3.04 0 C-N-CA 123.116 2.544 . . . . 0.0 114.562 -175.244 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 175' ' ' GLY . . . . . 0.526 ' H ' ' C ' ' A' ' 186' ' ' ALA . . . -135.47 139.59 10.91 Favored Glycine 0 CA--C 1.541 1.679 0 CA-C-N 115.159 -0.928 . . . . 0.0 114.543 179.342 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.434 ' N ' HD23 ' A' ' 176' ' ' LEU . 0.3 OUTLIER -132.22 162.5 30.77 Favored 'General case' 0 C--O 1.241 0.619 0 O-C-N 121.551 -0.97 . . . . 0.0 110.18 -171.412 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 177' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -138.51 139.53 38.79 Favored 'General case' 0 C--O 1.242 0.668 0 CA-C-N 114.141 -1.391 . . . . 0.0 109.727 -167.334 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 178' ' ' LYS . . . . . 0.435 ' HE3' ' HB3' ' A' ' 178' ' ' LYS . 1.3 tmmt? -69.07 120.77 15.45 Favored 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 124.481 1.112 . . . . 0.0 111.648 -165.488 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 179' ' ' THR . . . . . 0.807 ' HA ' HG21 ' A' ' 33' ' ' ILE . 7.4 m -90.09 165.4 14.02 Favored 'General case' 0 CA--C 1.551 1.01 0 C-N-CA 125.89 1.676 . . . . 0.0 109.787 177.619 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 180' ' ' ASN . . . . . 0.411 ' OD1' HG23 ' A' ' 33' ' ' ILE . 31.1 m120 -64.53 -35.14 79.99 Favored 'General case' 0 N--CA 1.487 1.384 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 170.82 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 181' ' ' ALA . . . . . 0.4 ' H ' HG22 ' A' ' 179' ' ' THR . . . -75.62 -48.22 23.14 Favored 'General case' 0 CA--C 1.54 0.566 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.977 175.798 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 182' ' ' GLY . . . . . 0.682 ' H ' ' HB ' ' A' ' 179' ' ' THR . . . -165.73 -94.43 0.1 OUTLIER Glycine 0 C--N 1.345 1.045 0 CA-C-O 119.756 -0.469 . . . . 0.0 112.638 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 7.5 t -163.46 135.83 5.21 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 124.719 1.208 . . . . 0.0 109.354 178.092 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -132.98 155.73 41.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 122.898 0.479 . . . . 0.0 109.814 177.052 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . 129.83 177.58 14.96 Favored Glycine 0 C--N 1.343 0.935 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 173.905 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.577 ' O ' ' HA ' ' A' ' 174' ' ' PRO . . . -171.66 38.85 0.02 OUTLIER 'General case' 0 C--O 1.193 -1.901 0 C-N-CA 123.486 0.715 . . . . 0.0 110.329 177.867 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 187' ' ' VAL . . . . . 0.527 HG13 HG21 ' A' ' 172' ' ' THR . 95.1 t -153.15 125.22 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 120.012 -1.68 . . . . 0.0 107.648 167.399 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 188' ' ' SER . . . . . 0.635 ' HA ' HG12 ' A' ' 223' ' ' VAL . 73.6 m -132.54 91.13 2.88 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 168.115 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 189' ' ' LEU . . . . . 0.559 HD23 ' HB3' ' A' ' 23' ' ' SER . 0.5 OUTLIER -126.97 104.36 7.96 Favored 'General case' 0 N--CA 1.48 1.039 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 -176.285 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 190' ' ' ASP . . . . . 0.681 ' HA ' ' HA ' ' A' ' 221' ' ' ALA . 8.0 p-10 -85.72 103.16 14.25 Favored 'General case' 0 C--N 1.356 0.865 0 CA-C-O 121.875 0.845 . . . . 0.0 109.992 -179.243 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 191' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -174.19 172.92 3.19 Favored 'General case' 0 N--CA 1.475 0.776 0 CA-C-N 115.059 -0.973 . . . . 0.0 108.541 -167.393 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 44.5 p -58.3 121.91 55.51 Favored Pre-proline 0 CA--C 1.548 0.883 0 C-N-CA 123.127 0.571 . . . . 0.0 110.614 175.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_endo -61.16 127.66 22.81 Favored 'Trans proline' 0 C--N 1.376 2.021 0 C-N-CA 122.246 1.964 . . . . 0.0 112.661 -178.874 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -72.41 173.44 46.43 Favored Glycine 0 C--N 1.35 1.326 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 162.099 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 7.4 m -80.66 135.78 36.09 Favored 'General case' 0 CA--C 1.562 1.416 0 CA-C-N 118.626 1.213 . . . . 0.0 111.334 -172.532 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -65.19 88.44 0.08 Allowed 'General case' 0 C--N 1.367 1.339 0 C-N-CA 124.13 0.972 . . . . 0.0 111.304 -171.641 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 197' ' ' GLY . . . . . 0.645 ' HA2' HD21 ' A' ' 210' ' ' LEU . . . 144.59 9.58 0.36 Allowed Glycine 0 C--N 1.335 0.499 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.984 -175.908 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 198' ' ' SER . . . . . 0.431 ' O ' ' HB2' ' A' ' 211' ' ' TYR . 39.3 m -57.36 132.09 81.31 Favored Pre-proline 0 CA--C 1.556 1.208 0 C-N-CA 122.942 0.497 . . . . 0.0 109.838 166.983 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -69.91 137.44 35.02 Favored 'Trans proline' 0 C--N 1.369 1.621 0 C-N-CA 121.965 1.777 . . . . 0.0 111.108 174.072 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 39.9 mt -91.92 119.6 39.61 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 N-CA-C 107.923 -1.139 . . . . 0.0 107.923 170.732 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 201' ' ' ILE . . . . . 0.642 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 46.7 mt -103.61 168.87 2.19 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.483 0 C-N-CA 125.632 1.573 . . . . 0.0 109.786 179.768 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -104.6 167.19 9.89 Favored 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 124.752 1.221 . . . . 0.0 109.402 178.935 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 18.5 ptpt -55.11 -29.24 57.24 Favored 'General case' 0 N--CA 1.481 1.106 0 C-N-CA 124.626 1.17 . . . . 0.0 112.444 177.762 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 52.9 mtmt -82.33 10.57 6.75 Favored 'General case' 0 N--CA 1.481 1.11 0 C-N-CA 123.324 0.65 . . . . 0.0 112.277 -179.072 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 70.0 19.73 75.68 Favored Glycine 0 C--N 1.356 1.669 0 N-CA-C 112.115 -0.394 . . . . 0.0 112.115 -177.235 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 62.4 tttp -110.73 121.14 44.59 Favored 'General case' 0 C--O 1.212 -0.892 0 C-N-CA 124.381 1.072 . . . . 0.0 108.662 -176.904 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 207' ' ' VAL . . . . . 0.642 ' HA ' ' HA ' ' A' ' 201' ' ' ILE . 7.1 p -53.9 139.67 11.87 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.092 0 C-N-CA 123.191 0.596 . . . . 0.0 111.687 178.092 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 3.6 m -98.34 -35.43 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.854 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 170.618 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.555 ' HA3' ' HA ' ' A' ' 228' ' ' GLN . . . 166.86 -138.18 5.05 Favored Glycine 0 C--N 1.348 1.226 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.268 -178.229 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 210' ' ' LEU . . . . . 0.645 HD21 ' HA2' ' A' ' 197' ' ' GLY . 5.1 tt -122.58 154.01 38.52 Favored 'General case' 0 CA--C 1.545 0.779 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 -172.122 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 211' ' ' TYR . . . . . 0.461 ' N ' HD23 ' A' ' 210' ' ' LEU . 10.2 t80 -62.45 142.19 58.01 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 123.592 0.757 . . . . 0.0 109.956 178.467 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -77.45 -157.83 9.26 Favored Glycine 0 N--CA 1.475 1.298 0 CA-C-N 118.103 0.41 . . . . 0.0 112.622 178.392 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 213' ' ' ASN . . . . . . . . . . . . . 14.7 t-20 -81.92 85.59 6.66 Favored 'General case' 0 N--CA 1.477 0.904 0 N-CA-C 108.442 -0.948 . . . . 0.0 108.442 -176.658 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . -71.66 123.3 9.87 Favored Glycine 0 C--N 1.347 1.174 0 CA-C-N 114.789 -1.096 . . . . 0.0 112.008 177.719 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 215' ' ' VAL . . . . . . . . . . . . . 21.7 t -134.59 143.56 37.44 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.672 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 173.63 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 216' ' ' VAL . . . . . 0.563 ' HB ' ' HA2' ' A' ' 220' ' ' GLY . 15.4 m -87.98 111.3 22.01 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.891 0 CA-C-O 121.781 0.8 . . . . 0.0 109.536 -178.718 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 217' ' ' THR . . . . . 0.563 HG22 HD22 ' A' ' 29' ' ' LEU . 38.8 m -107.74 162.53 13.9 Favored 'General case' 0 N--CA 1.475 0.825 0 C-N-CA 124.329 1.052 . . . . 0.0 109.659 -170.692 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 20.3 ttm180 71.45 -73.77 0.09 Allowed 'General case' 0 N--CA 1.492 1.646 0 C-N-CA 124.217 1.007 . . . . 0.0 109.592 -177.065 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 41.1 m -140.96 -43.86 0.39 Allowed 'General case' 0 CA--C 1.547 0.838 0 C-N-CA 124.519 1.127 . . . . 0.0 109.19 178.833 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 220' ' ' GLY . . . . . 0.563 ' HA2' ' HB ' ' A' ' 216' ' ' VAL . . . -169.04 27.65 0.13 Allowed Glycine 0 C--N 1.348 1.218 0 CA-C-N 115.49 -0.777 . . . . 0.0 112.181 -175.744 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 221' ' ' ALA . . . . . 0.681 ' HA ' ' HA ' ' A' ' 190' ' ' ASP . . . -80.32 96.11 6.55 Favored 'General case' 0 N--CA 1.465 0.317 0 C-N-CA 123.684 0.794 . . . . 0.0 110.607 179.717 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 222' ' ' TYR . . . . . . . . . . . . . 12.3 t80 -66.61 95.9 0.36 Allowed 'General case' 0 CA--C 1.554 1.123 0 CA-C-N 114.804 -1.089 . . . . 0.0 109.543 -176.873 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 223' ' ' VAL . . . . . 0.635 HG12 ' HA ' ' A' ' 188' ' ' SER . 35.3 m -114.59 140.14 37.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 C-N-CA 123.81 0.844 . . . . 0.0 109.774 -177.157 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 33.1 t -152.16 160.68 43.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.623 -169.598 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 225' ' ' ALA . . . . . . . . . . . . . . . -81.64 -175.02 5.32 Favored 'General case' 0 CA--C 1.546 0.792 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.643 164.43 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 226' ' ' ILE . . . . . 0.53 HD13 HG11 ' A' ' 156' ' ' VAL . 78.2 mt -133.57 116.44 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 176.005 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -95.78 137.2 35.18 Favored 'General case' 0 C--O 1.233 0.196 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 176.015 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 228' ' ' GLN . . . . . 0.555 ' HA ' ' HA3' ' A' ' 209' ' ' GLY . 29.0 pt20 -120.26 174.3 6.59 Favored 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 175.318 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 229' ' ' THR . . . . . 0.464 ' HA ' ' CD1' ' A' ' 144' ' ' TRP . 39.4 p -66.14 107.71 2.02 Favored 'General case' 0 CA--C 1.546 0.825 0 CA-C-O 121.208 0.528 . . . . 0.0 110.802 -176.502 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 230' ' ' GLU . . . . . 0.482 ' HG2' ' O ' ' A' ' 228' ' ' GLN . 26.7 mm-40 -108.06 -30.16 8.58 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 124.425 1.09 . . . . 0.0 112.437 -168.384 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 29.8 mmtp -107.06 -99.78 0.35 Allowed 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 113.477 0.917 . . . . 0.0 113.477 -160.38 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 232' ' ' SER . . . . . 0.412 ' O ' ' HB3' ' A' ' 145' ' ' LYS . 64.3 p . . . . . 0 C--N 1.361 1.093 0 CA-C-O 121.958 0.885 . . . . 0.0 110.672 -165.207 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.529 ' HB3' HD11 ' A' ' 6' ' ' LEU . . . . . . . . 0 N--CA 1.494 1.753 0 N-CA-C 111.317 0.117 . . . . 0.0 111.317 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -150.76 -62.01 0.19 Allowed 'General case' 0 N--CA 1.477 0.875 0 C-N-CA 123.287 0.635 . . . . 0.0 110.054 -173.131 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' ASP . . . . . 0.732 ' HA ' ' HG3' ' A' ' 120' ' ' MET . 32.6 t70 -144.5 76.92 1.52 Allowed 'General case' 0 CA--C 1.528 0.113 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 -172.386 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.529 HD11 ' HB3' ' A' ' 3' ' ' ALA . 5.8 mp -117.56 124.4 48.57 Favored 'General case' 0 N--CA 1.488 1.471 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.051 -179.283 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.794 ' HB2' ' HD3' ' A' ' 89' ' ' LYS . 14.5 tp10 -80.9 134.54 35.76 Favored 'General case' 0 C--O 1.252 1.229 0 CA-C-N 118.06 0.391 . . . . 0.0 110.449 178.023 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.462 ' HB2' HD11 ' A' ' 119' ' ' LEU . 18.1 tp -87.16 113.34 22.81 Favored 'General case' 0 CA--C 1.542 0.649 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 171.027 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -104.87 143.64 32.87 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 125.826 1.65 . . . . 0.0 108.176 -173.754 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.8 ptt-85 -76.29 147.16 38.42 Favored 'General case' 0 N--CA 1.481 1.104 0 CA-C-N 118.336 0.516 . . . . 0.0 110.505 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.656 ' HB2' ' HG3' ' A' ' 85' ' ' ARG . . . -125.89 -51.12 1.57 Allowed 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 169.2 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -166.65 175.34 8.0 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.012 0.925 . . . . 0.0 110.279 -177.038 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -98.59 159.44 14.95 Favored 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 108.401 -0.962 . . . . 0.0 108.401 164.11 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 83.4 t -88.39 103.18 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 CA-C-O 121.545 0.688 . . . . 0.0 111.281 -176.977 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 2.4 ptpp? -155.98 158.67 38.28 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 124.891 1.277 . . . . 0.0 107.97 168.695 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 10.6 t90 -67.83 105.43 1.96 Allowed 'General case' 0 CA--C 1.549 0.923 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.26 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.57 ' HB3' ' HB2' ' A' ' 169' ' ' ALA . 2.6 tm-20 -70.35 145.03 51.45 Favored 'General case' 0 CA--C 1.554 1.127 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 170.496 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -75.65 -19.45 59.16 Favored 'General case' 0 N--CA 1.481 1.117 0 N-CA-C 113.885 1.069 . . . . 0.0 113.885 -165.994 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 6.6 tp60 -94.1 53.37 1.74 Allowed 'General case' 0 N--CA 1.476 0.828 0 CA-C-O 121.46 0.648 . . . . 0.0 110.592 -168.819 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.617 ' HB1' ' HB2' ' A' ' 171' ' ' GLN . . . -56.04 91.24 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 124.558 1.143 . . . . 0.0 111.843 178.34 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -62.74 126.51 27.59 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 124.851 1.261 . . . . 0.0 110.746 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 50.4 mm -77.08 109.16 11.3 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.613 0 C-N-CA 123.073 0.549 . . . . 0.0 109.609 -178.256 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.1 m -135.38 -174.78 3.72 Favored 'General case' 0 CA--C 1.551 1.015 0 C-N-CA 124.038 0.935 . . . . 0.0 110.026 -179.436 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.413 ' H ' ' HB3' ' A' ' 189' ' ' LEU . . . 98.11 73.1 1.1 Allowed Glycine 0 C--N 1.349 1.259 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 -172.861 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.8 m -124.57 1.93 8.27 Favored 'General case' 0 N--CA 1.478 0.963 0 C-N-CA 122.971 0.508 . . . . 0.0 112.291 -164.636 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 13.7 m -120.45 137.88 26.7 Favored Pre-proline 0 CA--C 1.55 0.957 0 C-N-CA 123.291 0.636 . . . . 0.0 109.675 -176.727 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -82.43 -155.82 0.06 OUTLIER 'Trans proline' 0 C--N 1.379 2.151 0 C-N-CA 123.204 2.603 . . . . 0.0 112.253 179.506 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 48.6 mm -66.32 121.05 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 123.16 0.584 . . . . 0.0 110.632 -178.749 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.2 mt -105.53 164.87 11.55 Favored 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 124.658 1.183 . . . . 0.0 111.752 -175.139 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 39.4 m -122.46 116.18 23.52 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 123.5 0.72 . . . . 0.0 109.542 176.122 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.509 HD11 HG11 ' A' ' 223' ' ' VAL . 62.5 mt -116.24 145.09 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 C-N-CA 124.292 1.037 . . . . 0.0 108.561 178.391 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 35.9 p -93.56 105.13 17.21 Favored 'General case' 0 CA--C 1.543 0.703 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.125 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 9.2 tp -69.91 141.14 17.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 C-N-CA 124.159 0.983 . . . . 0.0 110.403 175.019 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 34.3 t -135.47 140.17 44.64 Favored 'General case' 0 C--O 1.242 0.701 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 176.788 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 65.14 15.98 10.3 Favored 'General case' 0 CA--C 1.563 1.476 0 C-N-CA 123.893 0.877 . . . . 0.0 111.133 174.756 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 58.12 32.65 22.27 Favored 'General case' 0 N--CA 1.49 1.545 0 C-N-CA 124.744 1.218 . . . . 0.0 111.67 -179.0 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -169.55 -44.41 0.03 OUTLIER Glycine 0 C--N 1.348 1.236 0 CA-C-N 116.32 -0.4 . . . . 0.0 112.669 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 25.6 m -89.15 106.2 18.29 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -176.373 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 27.3 mtm -88.05 162.59 16.71 Favored 'General case' 0 N--CA 1.476 0.873 0 O-C-N 121.909 -0.494 . . . . 0.0 110.856 -176.21 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 39.1 m -147.51 148.56 31.34 Favored 'General case' 0 C--O 1.238 0.492 0 C-N-CA 123.707 0.803 . . . . 0.0 109.379 -178.553 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 9.1 tp -96.12 151.7 3.97 Favored 'Isoleucine or valine' 0 C--O 1.239 0.55 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 169.326 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 50.2 mtmt -81.93 40.92 0.63 Allowed 'General case' 0 CA--C 1.558 1.261 0 C-N-CA 123.532 0.733 . . . . 0.0 111.222 175.31 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 7.8 t30 -167.49 75.34 0.14 Allowed 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 125.047 1.339 . . . . 0.0 107.661 176.518 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -75.29 117.66 17.34 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 177.398 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 . . . . . 0 C--O 1.245 0.827 0 C-N-CA 123.912 0.885 . . . . 0.0 109.398 177.939 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 CA--C 1.549 0.939 0 CA-C-O 121.458 0.647 . . . . 0.0 109.731 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -166.16 166.33 38.7 Favored Glycine 0 C--N 1.34 0.802 0 CA-C-N 115.805 -0.634 . . . . 0.0 113.455 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' ALA . . . . . 0.68 ' HB1' HD11 ' A' ' 161' ' ' LEU . . . -86.3 118.14 25.55 Favored 'General case' 0 C--O 1.243 0.719 0 CA-C-N 114.117 -1.041 . . . . 0.0 108.701 175.096 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 79.9 m-85 -118.46 142.4 47.6 Favored 'General case' 0 C--O 1.216 -0.676 0 C-N-CA 123.09 0.556 . . . . 0.0 109.622 -179.429 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' ARG . . . . . 0.656 ' HG3' ' HB2' ' A' ' 11' ' ' ALA . 54.9 mtt-85 -92.29 137.0 32.73 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 174.931 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.404 ' H ' ' HA ' ' A' ' 99' ' ' ALA . 51.6 mt -102.37 121.3 53.26 Favored 'Isoleucine or valine' 0 C--O 1.26 1.629 0 CA-C-O 121.673 0.749 . . . . 0.0 110.151 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.489 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 22.7 pttm -122.82 144.79 48.96 Favored 'General case' 0 C--N 1.349 0.554 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.823 177.851 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 4.8 mm-40 -82.18 119.65 24.33 Favored 'General case' 0 C--O 1.249 1.027 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 173.869 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' LYS . . . . . 0.794 ' HD3' ' HB2' ' A' ' 7' ' ' GLU . 53.2 pttt -115.31 152.74 32.23 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.686 -172.318 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -100.93 103.2 2.55 Favored Glycine 0 C--N 1.347 1.157 0 N-CA-C 106.135 -2.786 . . . . 0.0 106.135 160.414 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 4.8 tp 19.36 29.66 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.58 2.118 0 C-N-CA 129.298 3.039 . . . . 0.0 116.882 -167.542 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.444 ' N ' ' HD2' ' A' ' 89' ' ' LYS . 0.7 OUTLIER -177.41 -57.27 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.873 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 -169.77 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 177.05 161.89 26.52 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 114.732 0.653 . . . . 0.0 114.732 -177.604 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 53.2 p90 -165.8 -48.0 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 124.308 1.043 . . . . 0.0 112.05 156.17 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 12.6 t -152.72 149.83 28.8 Favored 'General case' 0 N--CA 1.495 1.783 0 CA-C-N 119.63 1.105 . . . . 0.0 112.067 -175.82 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' GLN . . . . . 0.489 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 21.0 tm0? -95.38 142.31 27.91 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 124.417 1.087 . . . . 0.0 110.445 -179.782 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.485 HD11 HD23 ' A' ' 6' ' ' LEU . 1.3 pp -133.49 -7.66 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 N-CA-C 113.575 0.954 . . . . 0.0 113.575 -175.052 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 175.92 -148.92 9.58 Favored Glycine 0 N--CA 1.475 1.242 0 CA-C-N 118.359 0.527 . . . . 0.0 113.017 173.837 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.404 ' HA ' ' H ' ' A' ' 86' ' ' ILE . . . -156.41 176.06 13.19 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 123.585 0.754 . . . . 0.0 110.985 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -172.87 135.3 3.27 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -177.761 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.491 HG21 ' HB3' ' A' ' 199' ' ' PRO . 71.3 t -95.65 110.67 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 C-N-CA 123.285 0.634 . . . . 0.0 109.328 -177.447 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 17.7 t80 -77.66 134.51 38.14 Favored 'General case' 0 CA--C 1.536 0.439 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -179.468 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' LYS . . . . . 0.66 ' HD2' HD21 ' A' ' 146' ' ' LEU . 35.5 mmtm -118.64 157.65 27.0 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 124.96 1.304 . . . . 0.0 109.045 -179.583 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -53.76 100.18 0.03 OUTLIER 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 123.86 0.864 . . . . 0.0 112.176 -173.429 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 83.55 -9.97 60.57 Favored Glycine 0 C--N 1.351 1.386 0 CA-C-N 115.48 -0.782 . . . . 0.0 113.766 178.649 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 20.3 p -123.81 120.45 32.65 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 124.038 0.935 . . . . 0.0 111.02 -175.121 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' PHE . . . . . 0.702 ' HB3' ' HB3' ' A' ' 140' ' ' TYR . 37.2 t80 -84.42 122.6 29.19 Favored 'General case' 0 N--CA 1.48 1.027 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 176.483 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 5.3 t-80 -132.97 102.3 5.57 Favored 'General case' 0 CA--C 1.554 1.129 0 C-N-CA 123.776 0.83 . . . . 0.0 110.434 -167.111 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' THR . . . . . 0.485 HG23 ' HB ' ' A' ' 138' ' ' ILE . 10.2 t -136.74 177.19 8.05 Favored 'General case' 0 N--CA 1.488 1.457 0 C-N-CA 123.889 0.876 . . . . 0.0 111.135 -178.601 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 110' ' ' MET . . . . . 0.476 ' HA ' ' HA ' ' A' ' 137' ' ' LEU . 44.2 mtp -93.55 157.14 16.34 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 124.296 1.038 . . . . 0.0 109.148 173.536 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 79.7 t90 -80.46 -61.88 1.84 Allowed 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 112.28 0.474 . . . . 0.0 112.28 -166.149 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 2.3 p-80 -73.97 3.93 6.12 Favored 'General case' 0 N--CA 1.5 2.048 0 N-CA-C 114.009 1.114 . . . . 0.0 114.009 -167.836 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 40.7 t -42.99 -41.6 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.279 0 C-N-CA 123.734 0.814 . . . . 0.0 110.29 161.676 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.526 HG21 HD21 ' A' ' 6' ' ' LEU . 0.2 OUTLIER -153.29 -163.03 1.59 Allowed 'General case' 0 CA--C 1.558 1.286 0 C-N-CA 125.267 1.427 . . . . 0.0 109.207 170.395 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 77.5 mtp180 -66.01 -26.65 67.63 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 113.362 0.875 . . . . 0.0 113.362 -172.747 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 93.78 62.84 1.07 Allowed Glycine 0 CA--C 1.53 0.983 0 O-C-N 123.205 0.316 . . . . 0.0 113.715 178.878 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -141.98 -85.66 0.17 Allowed 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 112.461 0.541 . . . . 0.0 112.461 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 26.6 t -110.98 109.0 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 123.359 0.663 . . . . 0.0 112.331 -169.028 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.515 HD12 HD12 ' A' ' 126' ' ' ILE . 1.3 tm? -91.33 152.06 20.61 Favored 'General case' 0 C--O 1.212 -0.908 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 169.108 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 120' ' ' MET . . . . . 0.732 ' HG3' ' HA ' ' A' ' 5' ' ' ASP . 45.7 mmm -135.01 138.85 44.36 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 124.06 0.944 . . . . 0.0 108.717 -172.755 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 121' ' ' HIS . . . . . 0.518 ' O ' ' HG2' ' A' ' 122' ' ' LYS . 18.5 t-160 -167.53 141.84 3.68 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -177.869 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.518 ' HG2' ' O ' ' A' ' 121' ' ' HIS . 32.8 pttt 68.92 3.12 3.84 Favored 'General case' 0 N--CA 1.501 2.086 0 C-N-CA 125.649 1.579 . . . . 0.0 112.766 176.194 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 99.96 -0.76 56.35 Favored Glycine 0 C--N 1.351 1.362 0 C-N-CA 123.144 0.402 . . . . 0.0 113.084 -174.282 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -118.45 152.93 34.97 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 123.813 0.845 . . . . 0.0 110.744 179.482 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 125' ' ' ARG . . . . . 0.444 ' HB3' ' SD ' ' A' ' 120' ' ' MET . 20.8 ptp180 -93.07 164.67 13.18 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.11 -179.276 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.515 HD12 HD12 ' A' ' 119' ' ' LEU . 27.5 mt -142.8 122.97 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 C-N-CA 125.628 1.571 . . . . 0.0 107.086 -172.396 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 44.8 mt-10 -125.73 132.69 24.39 Favored Pre-proline 0 N--CA 1.474 0.758 0 N-CA-C 108.604 -0.888 . . . . 0.0 108.604 175.427 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.48 ' HA ' ' HB2' ' A' ' 140' ' ' TYR . 96.9 Cg_endo -73.78 157.65 47.62 Favored 'Trans proline' 0 C--N 1.373 1.86 0 C-N-CA 122.934 2.423 . . . . 0.0 113.943 -168.806 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 129' ' ' SER . . . . . 0.558 ' H ' ' HA ' ' A' ' 140' ' ' TYR . 28.8 p -76.77 -27.62 55.37 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-N 114.884 -1.053 . . . . 0.0 109.623 172.385 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 67.6 t-105 -152.5 144.94 24.07 Favored 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 123.314 0.645 . . . . 0.0 110.21 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -136.72 121.19 18.22 Favored 'General case' 0 C--O 1.241 0.613 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 171.566 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -114.13 109.09 17.88 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 123.437 0.695 . . . . 0.0 109.467 -173.571 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 17.1 t -77.44 -19.38 14.15 Favored 'Isoleucine or valine' 0 CA--C 1.562 1.407 0 C-N-CA 123.9 0.88 . . . . 0.0 111.304 -175.884 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 2.8 mptp? -69.46 -51.31 37.27 Favored 'General case' 0 N--CA 1.487 1.419 0 C-N-CA 123.461 0.704 . . . . 0.0 109.557 -177.899 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 31.9 mmtp -84.13 -20.08 33.1 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-N 115.088 -0.96 . . . . 0.0 110.346 178.681 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 14.2 t70 65.5 63.57 0.62 Allowed 'General case' 0 C--O 1.24 0.595 0 C-N-CA 125.56 1.544 . . . . 0.0 110.607 -175.745 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 137' ' ' LEU . . . . . 0.495 HD21 HD12 ' A' ' 210' ' ' LEU . 1.5 mp -143.77 172.64 12.56 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.802 174.461 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.485 ' HB ' HG23 ' A' ' 109' ' ' THR . 21.6 mt -141.46 131.33 25.15 Favored 'Isoleucine or valine' 0 C--O 1.245 0.868 0 C-N-CA 125.952 1.701 . . . . 0.0 108.08 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 29.9 p -136.48 123.09 20.98 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 124.13 0.972 . . . . 0.0 110.282 -177.566 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.702 ' HB3' ' HB3' ' A' ' 107' ' ' PHE . 47.8 t80 -109.68 123.97 50.41 Favored 'General case' 0 N--CA 1.464 0.24 0 C-N-CA 124.626 1.17 . . . . 0.0 108.06 172.79 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 113.91 0.4 24.23 Favored Glycine 0 N--CA 1.474 1.19 0 O-C-N 123.885 0.741 . . . . 0.0 111.98 -173.996 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 147.46 -141.74 9.58 Favored Glycine 0 C--N 1.346 1.125 0 N-CA-C 109.944 -1.262 . . . . 0.0 109.944 177.734 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.809 ' HA3' ' HB2' ' A' ' 232' ' ' SER . . . -97.45 -175.06 34.19 Favored Glycine 0 C--N 1.345 1.058 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 164.285 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 144' ' ' TRP . . . . . 0.609 ' HZ2' ' HA2' ' A' ' 209' ' ' GLY . 7.4 t90 -69.76 104.02 2.32 Favored 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 177.279 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 145' ' ' LYS . . . . . 0.616 ' HB3' ' HA ' ' A' ' 231' ' ' LYS . 11.7 pttt -164.87 113.85 1.08 Allowed 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 123.7 0.8 . . . . 0.0 109.692 -177.964 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 146' ' ' LEU . . . . . 0.66 HD21 ' HD2' ' A' ' 103' ' ' LYS . 0.0 OUTLIER 167.62 -33.12 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 C-N-CA 125.178 1.391 . . . . 0.0 110.602 161.409 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.569 ' HG2' ' HE2' ' A' ' 103' ' ' LYS . 31.6 mt-10 -62.3 -81.91 0.02 OUTLIER 'General case' 0 C--N 1.367 1.353 0 O-C-N 123.714 0.634 . . . . 0.0 111.057 -166.139 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 148' ' ' GLY . . . . . 0.424 ' O ' ' HB ' ' A' ' 229' ' ' THR . . . 177.66 -174.26 46.75 Favored Glycine 0 C--N 1.341 0.813 0 O-C-N 123.464 0.477 . . . . 0.0 111.963 -178.097 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -124.85 107.37 10.83 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 -172.765 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 150' ' ' TRP . . . . . . . . . . . . . 27.5 t90 -54.89 135.57 48.0 Favored 'General case' 0 N--CA 1.477 0.923 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.625 172.161 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 53.6 mmtt -84.48 101.8 12.33 Favored 'General case' 0 C--O 1.239 0.508 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 179.042 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -62.65 107.72 1.01 Allowed 'General case' 0 CA--C 1.546 0.803 0 O-C-N 124.022 0.826 . . . . 0.0 109.765 -172.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 134.16 -31.62 2.77 Favored Glycine 0 C--N 1.34 0.803 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.688 -176.955 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -82.81 156.34 23.71 Favored 'General case' 0 C--O 1.242 0.708 0 C-N-CA 123.349 0.66 . . . . 0.0 109.48 178.559 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 10.0 pm0 -64.02 142.93 58.23 Favored 'General case' 0 C--O 1.243 0.731 0 O-C-N 124.207 0.942 . . . . 0.0 109.956 174.442 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 15.8 m -92.48 142.34 13.26 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 CA-C-O 121.184 0.516 . . . . 0.0 109.822 174.552 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 157' ' ' GLN . . . . . 0.482 HE22 ' HB2' ' A' ' 171' ' ' GLN . 9.9 tp-100 -101.32 144.96 29.52 Favored 'General case' 0 N--CA 1.454 -0.235 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 173.008 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.594 ' HB ' ' HB ' ' A' ' 170' ' ' VAL . 49.1 t -128.03 146.02 34.28 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 123.445 0.698 . . . . 0.0 110.014 -174.924 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 159' ' ' LEU . . . . . 0.424 ' HB2' ' HG2' ' A' ' 199' ' ' PRO . 33.7 mt -97.04 85.55 3.76 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 160.82 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -64.16 100.5 0.34 Allowed 'General case' 0 C--O 1.237 0.403 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 -179.233 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 161' ' ' LEU . . . . . 0.68 HD11 ' HB1' ' A' ' 83' ' ' ALA . 70.6 mt -78.03 80.28 4.47 Favored 'General case' 0 C--O 1.242 0.691 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.628 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 162' ' ' GLU . . . . . 0.425 ' HB2' ' HB2' ' A' ' 165' ' ' LYS . 10.1 mm-40 -61.59 125.3 84.26 Favored Pre-proline 0 CA--C 1.555 1.151 0 CA-C-N 113.412 -1.722 . . . . 0.0 110.074 -176.972 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -58.1 112.8 1.28 Allowed 'Trans proline' 0 C--N 1.382 2.293 0 C-N-CA 122.875 2.383 . . . . 0.0 112.626 -174.006 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 67.06 26.87 73.31 Favored Glycine 0 C--N 1.349 1.305 0 O-C-N 124.139 0.9 . . . . 0.0 113.291 176.612 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 165' ' ' LYS . . . . . 0.425 ' HB2' ' HB2' ' A' ' 162' ' ' GLU . 49.8 mtpt -131.54 -172.49 2.87 Favored 'General case' 0 C--O 1.242 0.703 0 C-N-CA 124.282 1.033 . . . . 0.0 109.306 -176.533 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -72.48 141.7 83.23 Favored Pre-proline 0 CA--C 1.555 1.139 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.053 170.879 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_exo -67.48 122.33 9.54 Favored 'Trans proline' 0 C--N 1.368 1.577 0 C-N-CA 122.522 2.148 . . . . 0.0 111.006 170.384 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 56.6 mtp180 -105.51 167.6 9.65 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 123.912 0.885 . . . . 0.0 110.549 -178.844 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 169' ' ' ALA . . . . . 0.57 ' HB2' ' HB3' ' A' ' 17' ' ' GLU . . . -102.24 151.21 22.49 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 109.408 -0.589 . . . . 0.0 109.408 170.493 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.594 ' HB ' ' HB ' ' A' ' 158' ' ' VAL . 95.5 t -136.17 117.08 18.51 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.239 0 C-N-CA 123.276 0.63 . . . . 0.0 110.286 175.159 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 171' ' ' GLN . . . . . 0.617 ' HB2' ' HB1' ' A' ' 20' ' ' ALA . 65.0 tt0 -94.81 111.24 23.03 Favored 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 172.441 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 4.5 t -140.52 140.53 35.27 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-O 121.001 0.429 . . . . 0.0 110.742 -174.88 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 21.5 ptmt -75.61 152.43 85.27 Favored Pre-proline 0 CA--C 1.55 0.953 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.961 177.954 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -70.3 143.54 48.52 Favored 'Trans proline' 0 C--N 1.374 1.909 0 C-N-CA 122.314 2.009 . . . . 0.0 112.692 171.502 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -132.84 155.55 21.67 Favored Glycine 0 N--CA 1.467 0.729 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 170.406 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.49 ' HG ' ' HA2' ' A' ' 185' ' ' GLY . 6.5 mp -116.81 157.17 26.02 Favored 'General case' 0 N--CA 1.482 1.143 0 CA-C-N 119.019 1.409 . . . . 0.0 109.231 -174.562 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 177' ' ' PHE . . . . . . . . . . . . . 50.2 p90 -137.02 149.55 47.53 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.802 175.301 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 60.1 tttp -97.78 128.01 44.13 Favored 'General case' 0 C--O 1.239 0.547 0 CA-C-N 115.577 -0.738 . . . . 0.0 109.977 -177.781 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 75.5 p -123.48 171.82 9.19 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.017 0.927 . . . . 0.0 109.355 168.862 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -65.94 -27.07 67.9 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 123.564 0.746 . . . . 0.0 110.607 174.334 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -68.65 -40.71 80.08 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 123.757 0.823 . . . . 0.0 110.602 175.455 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 158.22 -175.9 35.31 Favored Glycine 0 C--N 1.35 1.346 0 CA-C-N 115.831 -0.622 . . . . 0.0 112.423 177.634 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 8.5 t -77.98 115.42 17.71 Favored 'General case' 0 CA--C 1.543 0.695 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 172.55 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 52.8 mt -104.5 138.95 26.98 Favored 'Isoleucine or valine' 0 C--O 1.246 0.909 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -177.504 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 185' ' ' GLY . . . . . 0.49 ' HA2' ' HG ' ' A' ' 176' ' ' LEU . . . -100.45 119.43 6.51 Favored Glycine 0 C--N 1.349 1.291 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -175.121 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 186' ' ' ALA . . . . . 0.563 ' HA ' ' H ' ' A' ' 226' ' ' ILE . . . -144.94 -156.85 0.74 Allowed 'General case' 0 C--O 1.235 0.323 0 C-N-CA 123.837 0.855 . . . . 0.0 109.928 -165.694 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 187' ' ' VAL . . . . . 0.544 HG13 ' HB3' ' A' ' 224' ' ' SER . 2.4 p -135.77 123.06 34.98 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 C-N-CA 123.648 0.779 . . . . 0.0 109.285 175.085 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 41.6 m -117.75 115.29 24.72 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 123.779 0.832 . . . . 0.0 109.262 -176.796 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 189' ' ' LEU . . . . . 0.421 HD13 ' HB3' ' A' ' 191' ' ' PHE . 0.5 OUTLIER -149.44 164.0 36.22 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 124.065 0.946 . . . . 0.0 110.962 -175.44 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -101.52 104.1 14.99 Favored 'General case' 0 CA--C 1.541 0.634 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 170.246 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 191' ' ' PHE . . . . . 0.421 ' HB3' HD13 ' A' ' 189' ' ' LEU . 67.9 t80 -154.11 166.58 32.62 Favored 'General case' 0 N--CA 1.484 1.238 0 C-N-CA 123.217 0.607 . . . . 0.0 110.486 -171.79 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 48.8 m -69.53 156.25 92.01 Favored Pre-proline 0 CA--C 1.559 1.295 0 C-N-CA 124.952 1.301 . . . . 0.0 112.631 -178.713 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 193' ' ' PRO . . . . . 0.537 ' HA ' ' CE1' ' A' ' 222' ' ' TYR . 39.7 Cg_endo -64.24 99.18 0.28 Allowed 'Trans proline' 0 C--N 1.387 2.554 0 C-N-CA 123.009 2.473 . . . . 0.0 113.02 176.392 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -70.47 -136.39 0.12 Allowed Glycine 0 C--N 1.361 1.918 0 C-N-CA 123.745 0.688 . . . . 0.0 112.596 177.749 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 25.4 p -124.79 143.94 50.54 Favored 'General case' 0 N--CA 1.489 1.501 0 CA-C-N 118.979 1.39 . . . . 0.0 112.245 169.715 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 14.1 m -73.88 83.19 1.68 Allowed 'General case' 0 C--N 1.354 0.765 0 C-N-CA 123.645 0.778 . . . . 0.0 110.305 170.729 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 127.98 19.86 1.73 Allowed Glycine 0 C--N 1.339 0.747 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.536 -170.275 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 33.4 t -65.49 140.23 97.53 Favored Pre-proline 0 CA--C 1.554 1.108 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 164.118 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 199' ' ' PRO . . . . . 0.491 ' HB3' HG21 ' A' ' 101' ' ' VAL . 65.7 Cg_endo -81.04 131.85 8.1 Favored 'Trans proline' 0 C--N 1.374 1.881 0 C-N-CA 121.647 1.565 . . . . 0.0 113.374 179.016 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 43.9 mt -87.43 117.91 32.33 Favored 'Isoleucine or valine' 0 C--O 1.248 1.002 0 CA-C-O 121.962 0.887 . . . . 0.0 108.739 163.091 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 201' ' ' ILE . . . . . . . . . . . . . 80.4 mt -102.87 136.49 35.12 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.812 0 CA-C-N 113.248 -1.796 . . . . 0.0 107.54 172.421 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 202' ' ' ASP . . . . . 0.529 ' HB3' ' HB2' ' A' ' 206' ' ' LYS . 19.1 t70 -73.31 148.56 43.41 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 167.415 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 60.6 pttt -60.38 -18.96 53.85 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 -172.837 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 86.1 tttt -67.52 -21.34 65.49 Favored 'General case' 0 CA--C 1.557 1.247 0 C-N-CA 123.546 0.738 . . . . 0.0 111.766 177.497 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 108.27 3.32 33.37 Favored Glycine 0 N--CA 1.471 0.967 0 C-N-CA 123.3 0.476 . . . . 0.0 111.949 -171.691 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 206' ' ' LYS . . . . . 0.529 ' HB2' ' HB3' ' A' ' 202' ' ' ASP . 46.4 mttm -74.45 136.22 42.3 Favored 'General case' 0 C--O 1.205 -1.244 0 C-N-CA 123.985 0.914 . . . . 0.0 109.428 173.436 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 7.5 p -86.68 135.91 24.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 N-CA-C 106.403 -1.702 . . . . 0.0 106.403 163.962 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 30.9 m -135.8 -21.08 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 N-CA-C 113.153 0.797 . . . . 0.0 113.153 -168.852 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 209' ' ' GLY . . . . . 0.609 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . 178.4 -151.37 10.47 Favored Glycine 0 C--N 1.35 1.329 0 C-N-CA 119.751 -1.214 . . . . 0.0 115.815 -176.116 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 210' ' ' LEU . . . . . 0.495 HD12 HD21 ' A' ' 137' ' ' LEU . 33.6 mt -130.82 133.74 46.22 Favored 'General case' 0 C--N 1.365 1.241 0 CA-C-O 121.88 0.848 . . . . 0.0 112.366 -175.751 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 64.0 t80 -94.09 133.96 37.03 Favored 'General case' 0 C--O 1.241 0.655 0 C-N-CA 126.409 1.884 . . . . 0.0 108.223 168.061 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -137.38 -138.05 3.69 Favored Glycine 0 C--O 1.229 -0.189 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 177.816 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 213' ' ' ASN . . . . . 0.403 ' HB2' ' CZ ' ' A' ' 222' ' ' TYR . 9.2 t30 -156.79 101.09 1.95 Allowed 'General case' 0 C--O 1.237 0.396 0 C-N-CA 125.694 1.598 . . . . 0.0 107.05 170.666 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . -56.22 -56.39 24.5 Favored Glycine 0 C--N 1.342 0.894 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 172.782 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 215' ' ' VAL . . . . . . . . . . . . . 3.4 m -162.2 -172.74 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 C-N-CA 125.241 1.416 . . . . 0.0 108.952 176.057 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 216' ' ' VAL . . . . . 0.462 HG12 ' HA ' ' A' ' 222' ' ' TYR . 3.4 m -117.83 129.89 73.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 168.135 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 217' ' ' THR . . . . . 0.451 HG22 ' H ' ' A' ' 218' ' ' ARG . 4.9 m -126.69 -178.9 4.54 Favored 'General case' 0 CA--C 1.552 1.031 0 N-CA-C 107.829 -1.175 . . . . 0.0 107.829 -178.928 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 218' ' ' ARG . . . . . 0.451 ' H ' HG22 ' A' ' 217' ' ' THR . 10.9 ttt85 64.19 25.57 13.66 Favored 'General case' 0 N--CA 1.496 1.863 0 CA-C-O 122.393 1.092 . . . . 0.0 110.879 171.367 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 10.2 t 69.9 2.07 3.72 Favored 'General case' 0 N--CA 1.489 1.507 0 C-N-CA 125.412 1.485 . . . . 0.0 112.975 176.501 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . 159.64 45.81 0.02 OUTLIER Glycine 0 C--N 1.349 1.263 0 CA-C-N 117.706 0.23 . . . . 0.0 112.572 -177.447 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -122.69 121.45 36.41 Favored 'General case' 0 C--O 1.238 0.478 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 176.048 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 222' ' ' TYR . . . . . 0.537 ' CE1' ' HA ' ' A' ' 193' ' ' PRO . 56.6 t80 -69.8 101.29 1.68 Allowed 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 125.136 1.374 . . . . 0.0 109.059 179.282 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 223' ' ' VAL . . . . . 0.509 HG11 HD11 ' A' ' 31' ' ' ILE . 8.2 t -96.89 98.56 7.68 Favored 'Isoleucine or valine' 0 C--O 1.249 1.039 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 -176.467 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 224' ' ' SER . . . . . 0.544 ' HB3' HG13 ' A' ' 187' ' ' VAL . 38.0 t -97.3 155.19 16.98 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 125.144 1.378 . . . . 0.0 109.744 179.059 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 225' ' ' ALA . . . . . . . . . . . . . . . -104.83 131.38 52.38 Favored 'General case' 0 C--O 1.241 0.626 0 C-N-CA 123.449 0.7 . . . . 0.0 109.675 176.428 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 226' ' ' ILE . . . . . 0.563 ' H ' ' HA ' ' A' ' 186' ' ' ALA . 78.8 mt -77.98 95.04 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.352 0.68 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 173.196 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 227' ' ' ALA . . . . . 0.419 ' O ' ' HA3' ' A' ' 209' ' ' GLY . . . -85.18 147.18 26.73 Favored 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 172.632 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 13.1 pt20 -147.54 153.56 39.63 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 123.918 0.887 . . . . 0.0 109.446 -169.246 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 229' ' ' THR . . . . . 0.424 ' HB ' ' O ' ' A' ' 148' ' ' GLY . 89.4 m -69.0 109.28 3.88 Favored 'General case' 0 CA--C 1.545 0.764 0 CA-C-O 121.161 0.505 . . . . 0.0 109.817 179.242 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 230' ' ' GLU . . . . . 0.411 ' O ' ' HG2' ' A' ' 231' ' ' LYS . 38.3 mt-10 -98.01 -11.83 22.58 Favored 'General case' 0 N--CA 1.481 1.081 0 CA-C-N 114.916 -1.038 . . . . 0.0 111.302 -175.193 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 231' ' ' LYS . . . . . 0.616 ' HA ' ' HB3' ' A' ' 145' ' ' LYS . 11.7 pttm 66.78 128.48 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 127.06 2.144 . . . . 0.0 112.189 -177.51 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 232' ' ' SER . . . . . 0.809 ' HB2' ' HA3' ' A' ' 143' ' ' GLY . 30.1 m . . . . . 0 C--N 1.351 0.659 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 172.814 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.652 0 CA-C-O 119.869 -0.406 . . . . 0.0 112.614 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.8 m -60.24 -42.05 94.42 Favored 'General case' 0 N--CA 1.48 1.04 0 C-N-CA 123.405 0.682 . . . . 0.0 111.605 -178.462 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 56.93 39.06 29.7 Favored 'General case' 0 N--CA 1.484 1.238 0 O-C-N 124.34 1.025 . . . . 0.0 111.626 175.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -170.95 11.37 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 123.736 0.814 . . . . 0.0 109.669 -170.836 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ASP . . . . . 0.414 ' H ' HD12 ' A' ' 6' ' ' LEU . 13.0 m-20 -158.25 82.33 0.84 Allowed 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 -169.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.414 HD12 ' H ' ' A' ' 5' ' ' ASP . 7.4 mp -117.01 109.65 17.27 Favored 'General case' 0 C--O 1.202 -1.432 0 O-C-N 121.474 -0.766 . . . . 0.0 110.284 -175.221 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.618 ' HB2' ' HD3' ' A' ' 89' ' ' LYS . 37.3 tp10 -83.68 145.46 28.76 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.551 -0.718 . . . . 0.0 110.627 -176.304 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.451 HD21 ' CZ ' ' A' ' 107' ' ' PHE . 81.6 mt -89.32 114.66 26.08 Favored 'General case' 0 CA--C 1.547 0.856 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.508 171.177 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -112.28 107.88 16.89 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 125.108 1.363 . . . . 0.0 108.274 178.802 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 15.9 ttp180 -67.75 125.05 25.02 Favored 'General case' 0 N--CA 1.481 1.102 0 CA-C-N 118.441 0.564 . . . . 0.0 111.616 -172.088 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.543 ' HB2' ' HG3' ' A' ' 85' ' ' ARG . . . -89.06 -40.54 12.89 Favored 'General case' 0 C--N 1.347 0.473 0 C-N-CA 124.02 0.928 . . . . 0.0 109.986 177.188 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -166.09 -176.25 3.67 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 115.08 -0.964 . . . . 0.0 110.776 -173.783 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 65.2 m-20 -110.22 146.78 35.01 Favored 'General case' 0 C--O 1.242 0.696 0 C-N-CA 124.085 0.954 . . . . 0.0 108.838 171.401 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.435 HG11 HG12 ' A' ' 208' ' ' VAL . 94.6 t -78.86 101.01 3.97 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 CA-C-O 121.503 0.668 . . . . 0.0 109.469 -177.171 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 33.8 ttpt -167.96 109.74 0.59 Allowed 'General case' 0 C--O 1.247 0.966 0 N-CA-C 105.247 -2.131 . . . . 0.0 105.247 175.767 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' TRP . . . . . 0.442 ' NE1' ' HB1' ' A' ' 169' ' ' ALA . 68.2 t90 -80.3 90.57 5.56 Favored 'General case' 0 CA--C 1.539 0.553 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 -177.153 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -157.88 60.46 0.47 Allowed 'General case' 0 CA--C 1.543 0.677 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 158.046 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.601 ' HB3' ' HB2' ' A' ' 169' ' ' ALA . 12.6 t70 -90.6 -58.93 2.32 Favored 'General case' 0 CA--C 1.554 1.134 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.775 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLN . . . . . 0.698 ' H ' ' HB3' ' A' ' 169' ' ' ALA . 81.3 mt-30 -150.28 4.27 0.52 Allowed 'General case' 0 N--CA 1.5 2.027 0 N-CA-C 113.953 1.094 . . . . 0.0 113.953 -172.485 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . 11.84 70.91 0.01 OUTLIER 'General case' 0 N--CA 1.506 2.365 0 C-N-CA 126.549 1.94 . . . . 0.0 115.484 -169.053 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -88.22 123.59 33.0 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 123.603 0.761 . . . . 0.0 109.9 -176.253 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 30.8 mm -75.58 134.87 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 C-N-CA 123.045 0.538 . . . . 0.0 110.187 -176.789 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 78.5 p -174.84 -162.46 0.12 Allowed 'General case' 0 CA--C 1.55 0.949 0 O-C-N 124.581 1.176 . . . . 0.0 109.954 172.696 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.653 ' HA3' ' H ' ' A' ' 173' ' ' LYS . . . 102.77 178.49 26.86 Favored Glycine 0 C--N 1.349 1.259 0 CA-C-O 119.522 -0.599 . . . . 0.0 111.805 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 44.0 t 64.02 98.17 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 124.212 1.005 . . . . 0.0 111.176 176.287 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 28.8 t -140.63 148.83 54.73 Favored Pre-proline 0 N--CA 1.479 0.993 0 CA-C-O 118.406 -0.807 . . . . 0.0 109.345 -176.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_exo -42.63 138.12 3.7 Favored 'Trans proline' 0 C--N 1.391 2.81 0 C-N-CA 123.87 3.046 . . . . 0.0 113.785 177.243 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.678 HD12 ' HB2' ' A' ' 176' ' ' LEU . 31.0 mm -63.52 111.13 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 -175.728 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.689 ' HB3' HG21 ' A' ' 217' ' ' THR . 13.6 mt -94.11 142.33 27.52 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 115.373 -0.83 . . . . 0.0 111.732 -167.69 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 60.4 p -85.52 140.8 30.36 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 123.358 0.663 . . . . 0.0 110.316 177.474 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.739 HG21 ' HD2' ' A' ' 177' ' ' PHE . 14.6 tt -148.39 138.6 16.7 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.794 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 -172.372 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 39.4 p -102.27 117.05 33.93 Favored 'General case' 0 CA--C 1.547 0.855 0 O-C-N 121.881 -0.512 . . . . 0.0 110.997 -170.794 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.602 ' HA ' ' HG3' ' A' ' 39' ' ' MET . 10.6 tp -61.25 145.11 13.09 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.077 0 C-N-CA 124.902 1.281 . . . . 0.0 112.208 -177.949 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 47.5 m -152.25 130.91 12.31 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 124.103 0.961 . . . . 0.0 110.068 -176.041 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 60.71 19.24 9.32 Favored 'General case' 0 CA--C 1.566 1.586 0 C-N-CA 123.479 0.712 . . . . 0.0 111.437 174.761 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 24.3 t70 76.05 -55.55 0.6 Allowed 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 125.617 1.567 . . . . 0.0 112.318 -178.359 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -89.0 -20.27 47.23 Favored Glycine 0 N--CA 1.475 1.268 0 N-CA-C 115.002 0.761 . . . . 0.0 115.002 -175.359 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 66.5 m -106.0 165.49 11.17 Favored 'General case' 0 N--CA 1.478 0.941 0 CA-C-N 117.646 0.723 . . . . 0.0 110.252 -177.688 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' MET . . . . . 0.602 ' HG3' ' HA ' ' A' ' 33' ' ' ILE . 3.7 mpp? -138.99 168.31 20.11 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 123.808 0.843 . . . . 0.0 108.861 168.901 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.841 ' HA ' HG11 ' A' ' 215' ' ' VAL . 64.5 m -150.39 -179.47 7.24 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 124.788 1.235 . . . . 0.0 108.282 167.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 41.7 mm -99.0 96.51 5.08 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 N-CA-C 108.261 -1.015 . . . . 0.0 108.261 167.417 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER 53.16 -79.63 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.154 0 C-N-CA 125.999 1.72 . . . . 0.0 112.164 -176.579 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 4.4 p30 -136.27 87.08 2.27 Favored 'General case' 0 CA--C 1.551 0.985 0 C-N-CA 124.486 1.115 . . . . 0.0 108.94 178.073 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -100.67 148.09 25.26 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.81 -172.215 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -85.27 178.08 7.61 Favored 'General case' 0 N--CA 1.475 0.793 0 C-N-CA 124.17 0.988 . . . . 0.0 110.97 176.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -152.44 146.01 24.96 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 123.347 0.659 . . . . 0.0 110.422 -176.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 -138.91 148.43 43.59 Favored 'General case' 0 C--O 1.244 0.791 0 C-N-CA 123.714 0.806 . . . . 0.0 110.134 -179.336 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 29.5 pt20 -71.21 146.76 48.86 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 123.572 0.749 . . . . 0.0 110.057 171.084 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.498 HG23 ' HB3' ' A' ' 163' ' ' PRO . 56.5 m -77.21 -39.19 49.58 Favored 'General case' 0 CA--C 1.554 1.109 0 C-N-CA 123.372 0.669 . . . . 0.0 110.997 178.409 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.424 ' HA ' ' H ' ' A' ' 96' ' ' GLN . 44.8 tp 68.54 132.61 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 125.814 1.645 . . . . 0.0 112.187 -175.914 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -143.85 157.37 27.04 Favored Glycine 0 C--N 1.353 1.514 0 N-CA-C 111.419 -0.672 . . . . 0.0 111.419 -178.871 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -112.84 -33.81 1.97 Allowed Glycine 0 C--N 1.348 1.218 0 CA-C-O 119.823 -0.432 . . . . 0.0 114.051 -168.496 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -62.95 153.82 44.53 Favored Glycine 0 N--CA 1.477 1.401 0 C-N-CA 123.241 0.448 . . . . 0.0 113.523 -176.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.49 ' HA2' ' HZ2' ' A' ' 66' ' ' TRP . . . 92.75 81.6 1.48 Allowed Glycine 0 C--N 1.339 0.729 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 -171.489 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 77.7 p -69.59 154.12 42.47 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 123.325 0.65 . . . . 0.0 112.001 -177.69 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -80.2 -9.27 86.79 Favored Glycine 0 C--N 1.347 1.187 0 CA-C-N 115.611 -0.722 . . . . 0.0 113.563 178.854 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -67.22 84.56 0.13 Allowed Glycine 0 C--N 1.349 1.264 0 N-CA-C 112.028 -0.429 . . . . 0.0 112.028 177.001 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 73.5 35.83 55.31 Favored Glycine 0 C--N 1.35 1.34 0 N-CA-C 112.064 -0.414 . . . . 0.0 112.064 -173.09 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -62.04 -26.83 67.9 Favored Glycine 0 C--N 1.356 1.659 0 O-C-N 123.828 0.369 . . . . 0.0 113.538 -175.728 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.594 ' HG3' ' H ' ' A' ' 61' ' ' PHE . 9.6 pt-20 -90.48 -69.53 0.72 Allowed 'General case' 0 CA--C 1.549 0.912 0 CA-C-O 118.908 -0.568 . . . . 0.0 110.695 172.13 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.594 ' H ' ' HG3' ' A' ' 60' ' ' GLU . 74.2 t80 48.3 -86.23 0.01 OUTLIER 'General case' 0 CA--C 1.557 1.25 0 C-N-CA 124.966 1.306 . . . . 0.0 111.716 -176.639 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -177.31 -52.36 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 125.307 1.443 . . . . 0.0 108.273 -178.008 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 174.71 93.73 0.09 OUTLIER Glycine 0 C--N 1.342 0.861 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 178.232 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.566 ' HB ' ' HD2' ' A' ' 122' ' ' LYS . 1.8 t -90.94 -11.15 9.82 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.277 0 C-N-CA 123.59 0.756 . . . . 0.0 110.04 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.455 ' N ' ' HG3' ' A' ' 122' ' ' LYS . 3.9 mm? 69.29 129.96 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 125.813 1.645 . . . . 0.0 114.302 176.135 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' TRP . . . . . 0.559 ' CD1' ' HG2' ' A' ' 122' ' ' LYS . 68.3 m95 -92.79 79.19 4.74 Favored 'General case' 0 N--CA 1.482 1.164 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 166.732 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 30.5 t70 179.64 69.58 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 106.497 -1.668 . . . . 0.0 106.497 161.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 6.4 m -126.2 100.91 29.14 Favored Pre-proline 0 CA--C 1.553 1.093 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.99 -171.881 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -70.98 -47.08 0.6 Allowed 'Trans proline' 0 C--N 1.374 1.888 0 C-N-CA 122.333 2.022 . . . . 0.0 111.314 165.192 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 44.0 m -109.38 171.83 4.12 Favored Pre-proline 0 CA--C 1.561 1.376 0 C-N-CA 124.985 1.314 . . . . 0.0 108.789 171.588 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -52.65 146.27 35.24 Favored 'Trans proline' 0 C--N 1.386 2.511 0 C-N-CA 122.56 2.174 . . . . 0.0 111.788 171.448 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_exo -42.78 104.14 0.05 OUTLIER 'Trans proline' 0 C--N 1.39 2.717 0 C-N-CA 124.164 3.243 . . . . 0.0 114.321 -172.59 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -82.05 39.03 0.79 Allowed 'Trans proline' 0 C--N 1.376 1.982 0 C-N-CA 124.184 3.256 . . . . 0.0 113.444 -173.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 42.9 t 68.24 8.61 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.567 1.599 0 C-N-CA 124.27 1.028 . . . . 0.0 110.974 174.758 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -64.81 -45.75 91.71 Favored Glycine 0 C--N 1.362 1.976 0 CA-C-N 116.345 -0.388 . . . . 0.0 112.777 -175.347 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 38.3 ttmt 71.99 0.96 3.73 Favored 'General case' 0 CA--C 1.562 1.431 0 C-N-CA 125.135 1.374 . . . . 0.0 113.085 168.485 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -142.08 11.58 1.98 Allowed 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.803 -0.56 . . . . 0.0 112.444 -173.459 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -75.41 123.3 25.16 Favored 'General case' 0 CA--C 1.55 0.977 0 CA-C-O 121.313 0.578 . . . . 0.0 109.6 -179.419 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 1.2 pp -128.83 119.09 23.86 Favored 'General case' 0 N--CA 1.473 0.678 0 C-N-CA 124.254 1.022 . . . . 0.0 109.738 -173.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -84.12 61.77 6.69 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 124.325 1.05 . . . . 0.0 108.617 176.671 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 12.4 p-10 -66.8 142.95 57.18 Favored 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 114.03 -1.441 . . . . 0.0 111.298 -169.799 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 169.0 -154.32 23.83 Favored Glycine 0 C--O 1.258 1.61 0 CA-C-N 115.34 -0.846 . . . . 0.0 111.85 -175.148 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -81.75 108.74 15.54 Favored 'General case' 0 C--O 1.237 0.445 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 176.364 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' TYR . . . . . 0.427 ' CD1' ' HB3' ' A' ' 8' ' ' LEU . 47.0 m-85 -102.91 156.56 17.58 Favored 'General case' 0 N--CA 1.469 0.479 0 C-N-CA 123.643 0.777 . . . . 0.0 110.704 -179.3 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' ARG . . . . . 0.543 ' HG3' ' HB2' ' A' ' 11' ' ' ALA . 60.0 mtt180 -103.06 132.57 49.23 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 106.09 -1.818 . . . . 0.0 106.09 166.36 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.521 ' H ' ' HA ' ' A' ' 99' ' ' ALA . 12.9 mt -91.84 107.83 19.31 Favored 'Isoleucine or valine' 0 C--O 1.256 1.434 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 171.388 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.879 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 19.3 ptmt -99.27 139.2 35.27 Favored 'General case' 0 N--CA 1.441 -0.907 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 169.827 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -82.85 105.99 14.31 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 105.192 -2.151 . . . . 0.0 105.192 168.271 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' LYS . . . . . 0.618 ' HD3' ' HB2' ' A' ' 7' ' ' GLU . 60.0 tttt -113.67 98.5 7.08 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-N 114.562 -1.199 . . . . 0.0 108.082 -177.541 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -66.33 154.78 51.68 Favored Glycine 0 C--O 1.246 0.903 0 N-CA-C 108.279 -1.929 . . . . 0.0 108.279 160.557 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 22.8 mm -68.19 -6.24 5.27 Favored 'Isoleucine or valine' 0 CA--C 1.572 1.796 0 CA-C-N 117.728 0.764 . . . . 0.0 110.483 -176.518 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 1.1 pp -134.52 25.44 3.76 Favored 'General case' 0 CA--C 1.564 1.507 0 C-N-CA 124.585 1.154 . . . . 0.0 111.901 172.318 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -164.98 133.07 2.85 Favored Glycine 0 N--CA 1.486 1.968 0 CA-C-N 117.869 0.304 . . . . 0.0 113.357 -178.416 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 71.6 m-85 -122.69 120.19 32.92 Favored 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 124.082 0.953 . . . . 0.0 110.015 -174.789 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 37.3 p -152.75 109.24 3.42 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 122.965 0.506 . . . . 0.0 110.75 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.879 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 39.9 tt0 -74.1 140.53 45.34 Favored 'General case' 0 N--CA 1.485 1.3 0 CA-C-N 118.227 0.467 . . . . 0.0 110.705 179.046 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 1.6 pp -134.59 -16.25 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 N-CA-C 112.993 0.738 . . . . 0.0 112.993 -174.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -165.31 -157.75 10.05 Favored Glycine 0 C--N 1.342 0.867 0 C-N-CA 121.498 -0.382 . . . . 0.0 112.529 179.239 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.521 ' HA ' ' H ' ' A' ' 86' ' ' ILE . . . -146.01 170.81 15.89 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 123.489 0.716 . . . . 0.0 110.367 176.813 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -161.9 156.18 27.65 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 -179.294 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 24.1 t -118.15 114.0 43.82 Favored 'Isoleucine or valine' 0 C--O 1.241 0.608 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -175.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.466 ' CD2' ' HB2' ' A' ' 107' ' ' PHE . 0.4 OUTLIER -105.2 121.78 44.56 Favored 'General case' 0 N--CA 1.478 0.943 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 174.049 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.698 ' HB2' HD11 ' A' ' 146' ' ' LEU . 4.6 mmmp? -146.6 150.46 35.53 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 174.451 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 66.13 -84.28 0.03 OUTLIER 'General case' 0 CA--C 1.548 0.866 0 O-C-N 124.929 1.393 . . . . 0.0 110.49 173.684 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -154.59 21.27 0.62 Allowed Glycine 0 C--N 1.337 0.61 0 N-CA-C 111.816 -0.514 . . . . 0.0 111.816 178.579 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 97.1 m -142.65 135.1 27.75 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 123.583 0.753 . . . . 0.0 110.499 -175.753 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' PHE . . . . . 0.676 ' HB3' ' HB3' ' A' ' 140' ' ' TYR . 36.2 t80 -109.31 104.98 14.19 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 124.554 1.142 . . . . 0.0 109.363 175.635 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 42.1 p-80 -100.46 126.69 46.9 Favored 'General case' 0 C--O 1.239 0.521 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 173.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 13.8 t -137.77 -162.0 1.24 Allowed 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.319 176.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' MET . . . . . 0.522 ' HA ' ' HA ' ' A' ' 137' ' ' LEU . 1.9 ttm -115.84 150.2 37.37 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.949 1.3 . . . . 0.0 109.817 -173.896 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 21.3 t90 -78.88 -42.76 26.51 Favored 'General case' 0 CA--C 1.553 1.077 0 C-N-CA 122.72 0.408 . . . . 0.0 110.777 -175.766 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 1.8 p-80 -71.47 3.47 3.82 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 113.807 1.04 . . . . 0.0 113.807 -175.393 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.7 m -53.95 -40.26 44.21 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.096 0 CA-C-N 118.273 0.488 . . . . 0.0 110.591 175.123 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 11.2 m -148.29 -83.61 0.11 Allowed 'General case' 0 CA--C 1.553 1.088 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 167.673 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 41.9 ttm180 -135.73 28.22 3.28 Favored 'General case' 0 N--CA 1.489 1.482 0 CA-C-O 121.696 0.76 . . . . 0.0 109.284 179.487 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.632 ' HA2' HD11 ' A' ' 138' ' ' ILE . . . 58.83 36.71 88.41 Favored Glycine 0 C--N 1.348 1.231 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 -166.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -79.02 175.31 10.7 Favored 'General case' 0 C--O 1.246 0.873 0 C-N-CA 124.161 0.985 . . . . 0.0 111.761 -169.428 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.6 m -72.83 142.36 15.21 Favored 'Isoleucine or valine' 0 C--O 1.244 0.782 0 CA-C-O 121.37 0.605 . . . . 0.0 109.784 -176.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.4 HD11 HD13 ' A' ' 86' ' ' ILE . 3.4 mm? -88.12 177.24 6.96 Favored 'General case' 0 CA--C 1.548 0.869 0 CA-C-N 114.676 -1.147 . . . . 0.0 110.099 171.357 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' MET . . . . . 0.467 ' HA ' ' O ' ' A' ' 124' ' ' LYS . 9.1 ptp -159.04 155.76 28.03 Favored 'General case' 0 C--O 1.253 1.274 0 C-N-CA 123.874 0.87 . . . . 0.0 110.399 178.544 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.436 ' CE1' ' HB2' ' A' ' 8' ' ' LEU . 0.1 OUTLIER -153.19 104.13 2.77 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 114.727 -1.124 . . . . 0.0 108.134 -179.238 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.566 ' HD2' ' HB ' ' A' ' 64' ' ' VAL . 70.5 mmtt 61.74 30.08 18.27 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 123.844 0.715 . . . . 0.0 110.024 -175.246 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.442 ' HA3' ' O ' ' A' ' 60' ' ' GLU . . . 83.94 -5.06 81.02 Favored Glycine 0 C--N 1.347 1.142 0 CA-C-O 119.012 -0.882 . . . . 0.0 114.185 -177.45 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' LYS . . . . . 0.467 ' O ' ' HA ' ' A' ' 120' ' ' MET . 21.6 ttmm -69.21 114.21 7.27 Favored 'General case' 0 C--N 1.357 0.924 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 170.65 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 36.2 ttm-85 -80.21 95.36 6.26 Favored 'General case' 0 CA--C 1.538 0.499 0 O-C-N 123.895 0.747 . . . . 0.0 109.36 -171.799 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 74.6 mt -80.14 93.74 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 C-N-CA 123.918 0.887 . . . . 0.0 108.701 -177.093 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -94.02 128.95 39.2 Favored Pre-proline 0 CA--C 1.542 0.636 0 CA-C-O 118.768 -0.634 . . . . 0.0 109.556 -177.117 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_exo -51.09 142.78 33.93 Favored 'Trans proline' 0 C--N 1.384 2.42 0 C-N-CA 123.419 2.746 . . . . 0.0 114.516 -176.88 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 54.7 p -97.8 -10.69 24.36 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 123.558 0.743 . . . . 0.0 110.429 172.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.677 ' HB3' ' HB2' ' A' ' 139' ' ' SER . 35.9 t-105 -155.38 147.18 23.26 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.647 1.179 . . . . 0.0 107.869 176.007 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.401 ' HA ' ' HA ' ' A' ' 138' ' ' ILE . . . -154.79 119.97 4.98 Favored 'General case' 0 C--O 1.237 0.436 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 170.669 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -109.7 112.24 24.19 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 123.859 0.864 . . . . 0.0 108.684 176.77 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 18.2 t -77.43 -27.4 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 C-N-CA 122.512 0.325 . . . . 0.0 110.739 -176.368 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 52.5 tttp -67.31 -49.39 64.38 Favored 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.022 0.529 . . . . 0.0 111.996 -172.442 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -80.19 -23.0 41.29 Favored 'General case' 0 N--CA 1.485 1.284 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 169.028 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 18.8 t70 74.46 55.37 0.09 Allowed 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 125.367 1.467 . . . . 0.0 110.202 176.631 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' LEU . . . . . 0.522 ' HA ' ' HA ' ' A' ' 110' ' ' MET . 4.6 mp -133.8 174.89 9.97 Favored 'General case' 0 CA--C 1.541 0.604 0 CA-C-N 115.074 -0.966 . . . . 0.0 111.368 172.616 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.632 HD11 ' HA2' ' A' ' 116' ' ' GLY . 78.9 mt -139.9 150.94 21.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 125.318 1.447 . . . . 0.0 108.327 -176.549 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 139' ' ' SER . . . . . 0.677 ' HB2' ' HB3' ' A' ' 130' ' ' TRP . 19.6 m -134.44 141.64 46.86 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 123.585 0.754 . . . . 0.0 109.563 171.507 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.676 ' HB3' ' HB3' ' A' ' 107' ' ' PHE . 83.4 t80 -128.79 142.16 51.07 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 177.241 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 90.48 -5.86 82.43 Favored Glycine 0 CA--C 1.531 1.044 0 N-CA-C 112.28 -0.328 . . . . 0.0 112.28 -173.701 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 142' ' ' GLY . . . . . 0.485 ' HA3' ' O ' ' A' ' 233' ' ' ILE . . . 146.87 -139.37 7.92 Favored Glycine 0 C--N 1.342 0.904 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -178.5 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -90.15 165.25 31.47 Favored Glycine 0 C--N 1.344 1.006 0 N-CA-C 110.157 -1.177 . . . . 0.0 110.157 167.16 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 144' ' ' TRP . . . . . 0.549 ' HZ2' ' HA2' ' A' ' 209' ' ' GLY . 7.0 t90 -61.11 105.58 0.5 Allowed 'General case' 0 CA--C 1.548 0.893 0 CA-C-O 121.281 0.562 . . . . 0.0 110.601 174.772 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 145' ' ' LYS . . . . . 0.601 ' HG2' ' HA ' ' A' ' 233' ' ' ILE . 0.0 OUTLIER -137.88 156.28 48.07 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 115.352 -0.84 . . . . 0.0 109.386 176.022 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 146' ' ' LEU . . . . . 0.698 HD11 ' HB2' ' A' ' 103' ' ' LYS . 5.7 mt 169.24 -25.46 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.535 0 O-C-N 125.625 1.828 . . . . 0.0 109.015 -174.43 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 67.49 83.78 0.16 Allowed 'General case' 0 C--N 1.362 1.111 0 C-N-CA 125.185 1.394 . . . . 0.0 109.035 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -164.34 86.25 0.1 Allowed Glycine 0 C--N 1.337 0.599 0 CA-C-N 115.045 -0.979 . . . . 0.0 110.849 -170.292 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 28.1 tt0 -103.45 122.61 45.25 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 124.739 1.216 . . . . 0.0 109.327 177.317 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 150' ' ' TRP . . . . . . . . . . . . . 42.3 t90 -68.71 129.28 39.47 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 172.038 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 22.9 pttm -86.38 110.18 19.52 Favored 'General case' 0 CA--C 1.553 1.088 0 CA-C-O 121.408 0.623 . . . . 0.0 109.872 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -66.92 112.37 4.28 Favored 'General case' 0 N--CA 1.483 1.203 0 CA-C-O 121.609 0.718 . . . . 0.0 111.068 -178.036 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 153.81 -41.83 0.64 Allowed Glycine 0 N--CA 1.465 0.628 0 N-CA-C 110.191 -1.163 . . . . 0.0 110.191 -176.636 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 3.8 mp0 -88.55 -179.29 6.02 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 124.617 1.167 . . . . 0.0 109.907 175.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -73.23 142.34 47.28 Favored 'General case' 0 C--O 1.242 0.669 0 C-N-CA 122.976 0.51 . . . . 0.0 110.05 172.673 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 5.0 p -91.68 139.2 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 170.771 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 157' ' ' GLN . . . . . 0.434 HE22 ' HG2' ' A' ' 171' ' ' GLN . 5.8 mm100 -112.17 131.75 55.29 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 -176.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 53.7 t -126.21 124.08 65.05 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.642 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -177.698 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.46 ' HB2' ' HD2' ' A' ' 199' ' ' PRO . 51.1 mt -73.54 78.35 1.46 Allowed 'General case' 0 C--N 1.351 0.642 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 164.225 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -63.53 99.1 0.2 Allowed 'General case' 0 C--N 1.349 0.557 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -179.552 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 68.6 mt -72.16 95.95 1.73 Allowed 'General case' 0 C--O 1.24 0.563 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 179.719 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 162' ' ' GLU . . . . . 0.402 ' HB2' ' HB2' ' A' ' 165' ' ' LYS . 42.9 mt-10 -62.47 139.09 96.63 Favored Pre-proline 0 CA--C 1.556 1.204 0 CA-C-N 115.249 -0.887 . . . . 0.0 109.775 178.866 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 163' ' ' PRO . . . . . 0.498 ' HB3' HG23 ' A' ' 49' ' ' THR . 63.1 Cg_exo -54.48 111.55 0.75 Allowed 'Trans proline' 0 C--N 1.38 2.219 0 C-N-CA 123.16 2.573 . . . . 0.0 113.862 -173.485 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 63.49 19.17 62.09 Favored Glycine 0 C--N 1.355 1.622 0 O-C-N 123.572 0.545 . . . . 0.0 113.784 179.067 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 165' ' ' LYS . . . . . 0.402 ' HB2' ' HB2' ' A' ' 162' ' ' GLU . 56.7 mtpt -129.31 178.55 6.36 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 124.473 1.109 . . . . 0.0 110.348 -173.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -52.81 155.68 3.9 Favored Pre-proline 0 CA--C 1.559 1.291 0 CA-C-N 114.759 -1.109 . . . . 0.0 112.31 169.531 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -69.52 168.74 20.37 Favored 'Trans proline' 0 C--N 1.371 1.711 0 C-N-CA 122.235 1.957 . . . . 0.0 110.932 168.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 16.2 ttm180 -137.09 109.88 7.59 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 172.614 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 169' ' ' ALA . . . . . 0.698 ' HB3' ' H ' ' A' ' 19' ' ' GLN . . . -69.4 105.88 2.75 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 172.076 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 24.8 t -113.75 128.23 70.74 Favored 'Isoleucine or valine' 0 C--O 1.24 0.586 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 -178.185 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 171' ' ' GLN . . . . . 0.434 ' HG2' HE22 ' A' ' 157' ' ' GLN . 14.6 mt-30 -83.73 103.84 13.35 Favored 'General case' 0 C--O 1.237 0.42 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 168.488 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 11.9 p -106.4 124.25 49.3 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 178.397 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 173' ' ' LYS . . . . . 0.653 ' H ' ' HA3' ' A' ' 24' ' ' GLY . 50.1 mttm -78.78 132.86 63.32 Favored Pre-proline 0 CA--C 1.548 0.884 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 171.244 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -59.37 171.92 2.2 Favored 'Trans proline' 0 C--N 1.377 2.061 0 C-N-CA 123.38 2.72 . . . . 0.0 114.242 -172.855 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -164.67 -177.12 37.03 Favored Glycine 0 C--N 1.335 0.512 0 CA-C-N 114.786 -1.097 . . . . 0.0 111.011 -179.644 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.678 ' HB2' HD12 ' A' ' 28' ' ' ILE . 69.6 mt -131.82 159.52 38.28 Favored 'General case' 0 N--CA 1.485 1.319 0 CA-C-N 117.414 0.607 . . . . 0.0 110.07 -174.89 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 177' ' ' PHE . . . . . 0.739 ' HD2' HG21 ' A' ' 31' ' ' ILE . 0.2 OUTLIER -141.18 125.3 17.32 Favored 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 123.101 0.56 . . . . 0.0 110.839 176.047 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 178' ' ' LYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 183' ' ' THR . 10.3 ptpp? -95.02 123.08 38.3 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 123.375 0.67 . . . . 0.0 111.028 -173.189 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 52.3 p -95.4 -173.44 2.91 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.771 0.828 . . . . 0.0 109.391 169.739 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 30.3 p-10 -68.9 -22.75 64.15 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 123.003 0.521 . . . . 0.0 110.764 171.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -77.87 -51.28 10.7 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 123.99 0.916 . . . . 0.0 110.322 176.787 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 164.46 -177.63 40.03 Favored Glycine 0 C--N 1.342 0.897 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.587 -179.713 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 183' ' ' THR . . . . . 0.48 ' HA ' ' HA ' ' A' ' 178' ' ' LYS . 13.2 t -80.23 136.71 36.52 Favored 'General case' 0 CA--C 1.544 0.749 0 CA-C-O 121.317 0.58 . . . . 0.0 110.735 -177.798 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 184' ' ' ILE . . . . . 0.414 ' HB ' ' CE1' ' A' ' 177' ' ' PHE . 14.9 mt -119.01 161.27 18.21 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.866 0 C-N-CA 124.9 1.28 . . . . 0.0 107.546 -177.087 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -100.74 138.78 14.05 Favored Glycine 0 C--N 1.349 1.281 0 N-CA-C 112.319 -0.312 . . . . 0.0 112.319 -176.257 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.497 ' HB2' ' CE1' ' A' ' 177' ' ' PHE . . . -162.63 -169.95 2.25 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-O 122.029 0.919 . . . . 0.0 112.543 -169.616 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 187' ' ' VAL . . . . . . . . . . . . . 2.0 p -105.41 100.98 11.69 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.999 0 CA-C-N 113.76 -1.564 . . . . 0.0 107.317 156.513 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 65.8 p -98.38 111.44 23.78 Favored 'General case' 0 C--O 1.24 0.56 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 172.195 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 46.0 tp -146.22 138.41 25.15 Favored 'General case' 0 N--CA 1.485 1.306 0 CA-C-O 120.881 0.372 . . . . 0.0 111.811 -177.593 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 190' ' ' ASP . . . . . 0.471 ' HA ' ' HA ' ' A' ' 221' ' ' ALA . 32.7 t70 -81.92 103.23 11.42 Favored 'General case' 0 C--N 1.351 0.658 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 170.504 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 191' ' ' PHE . . . . . 0.54 ' HB3' ' HE1' ' A' ' 222' ' ' TYR . 68.2 t80 -177.23 166.71 2.36 Favored 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 124.71 1.204 . . . . 0.0 108.659 -173.655 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 33.7 p -64.94 117.04 35.05 Favored Pre-proline 0 CA--C 1.557 1.22 0 C-N-CA 123.639 0.776 . . . . 0.0 111.234 177.318 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 193' ' ' PRO . . . . . 0.579 ' HG2' ' HG3' ' B' ' 254' ' ' ARG . 30.0 Cg_endo -62.45 140.7 83.54 Favored 'Trans proline' 0 C--N 1.378 2.109 0 C-N-CA 123.078 2.519 . . . . 0.0 112.855 176.638 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -84.09 -176.24 51.09 Favored Glycine 0 C--N 1.344 0.977 0 N-CA-C 111.051 -0.819 . . . . 0.0 111.051 168.726 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 62.5 p -77.39 131.7 38.17 Favored 'General case' 0 CA--C 1.551 0.991 0 CA-C-N 117.149 0.474 . . . . 0.0 110.725 178.072 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -63.57 100.14 0.25 Allowed 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.561 0.744 . . . . 0.0 109.776 -176.833 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 140.05 -1.22 2.19 Favored Glycine 0 C--N 1.341 0.86 0 CA-C-N 114.519 -1.219 . . . . 0.0 112.148 -174.282 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 198' ' ' SER . . . . . 0.455 ' HB2' ' HD2' ' A' ' 211' ' ' TYR . 48.9 m -57.43 138.6 81.18 Favored Pre-proline 0 CA--C 1.558 1.277 0 C-N-CA 123.495 0.718 . . . . 0.0 111.512 173.889 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 199' ' ' PRO . . . . . 0.46 ' HD2' ' HB2' ' A' ' 159' ' ' LEU . 17.3 Cg_exo -67.05 132.81 29.04 Favored 'Trans proline' 0 C--N 1.38 2.203 0 C-N-CA 123.268 2.645 . . . . 0.0 113.492 -177.37 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 200' ' ' ILE . . . . . 0.449 HD13 HG23 ' A' ' 226' ' ' ILE . 16.6 mt -98.81 110.12 25.51 Favored 'Isoleucine or valine' 0 C--O 1.241 0.618 0 CA-C-O 121.982 0.896 . . . . 0.0 109.666 172.421 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 201' ' ' ILE . . . . . . . . . . . . . 47.0 mt -108.91 148.75 12.56 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.894 0 CA-C-N 114.644 -1.162 . . . . 0.0 108.082 177.769 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 202' ' ' ASP . . . . . 0.573 ' H ' ' HB ' ' A' ' 207' ' ' VAL . 18.1 t70 -89.51 160.21 16.85 Favored 'General case' 0 N--CA 1.48 1.075 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 172.215 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 83.1 tttt -63.37 -15.48 57.61 Favored 'General case' 0 CA--C 1.555 1.141 0 N-CA-C 113.479 0.918 . . . . 0.0 113.479 -170.487 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 7.9 mtpm? -76.42 -1.02 24.94 Favored 'General case' 0 N--CA 1.485 1.318 0 N-CA-C 112.502 0.556 . . . . 0.0 112.502 176.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 82.7 7.01 87.97 Favored Glycine 0 C--N 1.349 1.283 0 CA-C-O 120.913 0.174 . . . . 0.0 112.695 -178.734 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -117.2 164.09 15.31 Favored 'General case' 0 N--CA 1.475 0.793 0 C-N-CA 124.733 1.213 . . . . 0.0 108.714 174.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.573 ' HB ' ' H ' ' A' ' 202' ' ' ASP . 57.4 t 90.77 160.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.254 0 C-N-CA 125.905 1.682 . . . . 0.0 108.562 -171.662 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 208' ' ' VAL . . . . . 0.585 HG21 ' HB3' ' A' ' 146' ' ' LEU . 1.8 m -174.34 13.8 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 C-N-CA 124.444 1.098 . . . . 0.0 109.666 -144.391 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.549 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . -64.87 -154.78 0.15 Allowed Glycine 0 C--N 1.354 1.549 0 C-N-CA 124.105 0.86 . . . . 0.0 115.013 -177.098 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 210' ' ' LEU . . . . . 0.474 HD13 HD23 ' A' ' 137' ' ' LEU . 6.0 tt -142.12 133.4 26.34 Favored 'General case' 0 C--O 1.242 0.691 0 O-C-N 122.048 -0.678 . . . . 0.0 110.588 -172.399 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 211' ' ' TYR . . . . . 0.455 ' HD2' ' HB2' ' A' ' 198' ' ' SER . 0.4 OUTLIER -102.49 108.56 19.91 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 124.844 1.258 . . . . 0.0 108.935 175.208 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 212' ' ' GLY . . . . . 0.519 ' O ' ' SD ' ' A' ' 110' ' ' MET . . . 171.22 70.05 0.04 OUTLIER Glycine 0 C--N 1.345 1.081 0 C-N-CA 120.65 -0.786 . . . . 0.0 114.719 156.061 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 213' ' ' ASN . . . . . 0.669 ' HB2' ' HB3' ' A' ' 225' ' ' ALA . 18.5 m120 -131.76 81.85 2.0 Allowed 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 172.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 160.57 -152.38 23.08 Favored Glycine 0 C--O 1.242 0.619 0 CA-C-N 113.965 -1.471 . . . . 0.0 111.341 -178.231 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 215' ' ' VAL . . . . . 0.841 HG11 ' HA ' ' A' ' 40' ' ' SER . 15.8 m -152.57 -173.94 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.213 0 C-N-CA 123.45 0.7 . . . . 0.0 111.235 -167.345 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 216' ' ' VAL . . . . . 0.489 ' HB ' ' HA2' ' A' ' 220' ' ' GLY . 17.0 m -85.15 113.0 22.9 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.771 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 164.706 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 217' ' ' THR . . . . . 0.689 HG21 ' HB3' ' A' ' 29' ' ' LEU . 23.5 m -102.81 158.99 15.88 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 123.944 0.898 . . . . 0.0 109.644 -174.806 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 2.5 tpm_? 69.89 -74.63 0.08 Allowed 'General case' 0 CA--C 1.552 1.023 0 C-N-CA 124.957 1.303 . . . . 0.0 110.095 -176.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 21.8 t -164.42 26.21 0.07 Allowed 'General case' 0 CA--C 1.551 1.007 0 C-N-CA 123.856 0.862 . . . . 0.0 110.148 175.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 220' ' ' GLY . . . . . 0.489 ' HA2' ' HB ' ' A' ' 216' ' ' VAL . . . 141.98 -6.88 2.35 Favored Glycine 0 N--CA 1.477 1.418 0 CA-C-O 119.884 -0.398 . . . . 0.0 113.72 -179.086 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 221' ' ' ALA . . . . . 0.471 ' HA ' ' HA ' ' A' ' 190' ' ' ASP . . . -70.76 97.83 1.44 Allowed 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.943 0.897 . . . . 0.0 110.044 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 222' ' ' TYR . . . . . 0.54 ' HE1' ' HB3' ' A' ' 191' ' ' PHE . 15.8 p90 -66.1 124.72 23.37 Favored 'General case' 0 CA--C 1.544 0.715 0 CA-C-O 121.534 0.683 . . . . 0.0 110.88 -171.08 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 223' ' ' VAL . . . . . 0.637 HG11 ' HB3' ' A' ' 177' ' ' PHE . 62.1 t -123.92 115.66 45.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 173.721 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 67.9 m -142.71 141.85 31.88 Favored 'General case' 0 N--CA 1.48 1.06 0 O-C-N 123.855 0.722 . . . . 0.0 110.312 176.062 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 225' ' ' ALA . . . . . 0.669 ' HB3' ' HB2' ' A' ' 213' ' ' ASN . . . -75.31 153.29 37.96 Favored 'General case' 0 C--O 1.244 0.782 0 C-N-CA 123.087 0.555 . . . . 0.0 112.238 -174.656 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 226' ' ' ILE . . . . . 0.449 HG23 HD13 ' A' ' 200' ' ' ILE . 88.9 mt -91.4 103.06 14.12 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.623 0 CA-C-N 114.758 -1.11 . . . . 0.0 109.748 -176.594 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -96.07 152.65 18.34 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 122.895 0.478 . . . . 0.0 109.952 178.36 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -148.19 168.55 22.17 Favored 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 124.515 1.126 . . . . 0.0 109.736 -172.118 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 229' ' ' THR . . . . . 0.425 HG22 ' NE1' ' A' ' 144' ' ' TRP . 59.0 p -66.88 110.61 3.38 Favored 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 123.006 0.522 . . . . 0.0 110.527 -176.232 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -116.97 -24.37 7.63 Favored 'General case' 0 N--CA 1.482 1.169 0 C-N-CA 123.418 0.687 . . . . 0.0 111.406 -172.34 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 23.3 mmtp -91.88 -141.02 0.19 Allowed 'General case' 0 CA--C 1.566 1.561 0 C-N-CA 122.974 0.51 . . . . 0.0 109.682 -172.409 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 70.0 p -158.13 178.39 10.25 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 124.221 1.009 . . . . 0.0 108.873 -167.555 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 233' ' ' ILE . . . . . 0.601 ' HA ' ' HG2' ' A' ' 145' ' ' LYS . 82.1 mt -53.79 -42.7 53.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 CA-C-N 118.391 0.541 . . . . 0.0 110.467 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 234' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 174.07 -72.52 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 125.363 1.465 . . . . 0.0 107.237 174.187 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -104.38 -38.89 6.65 Favored 'General case' 0 C--O 1.238 0.467 0 C-N-CA 124.852 1.261 . . . . 0.0 108.282 174.321 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 236' ' ' ASN . . . . . 0.411 ' HB2' ' HB ' ' A' ' 233' ' ' ILE . 17.0 m120 -67.73 152.79 96.01 Favored Pre-proline 0 CA--C 1.548 0.902 0 CA-C-N 114.882 -1.054 . . . . 0.0 109.776 172.625 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -60.38 -177.48 0.16 Allowed 'Trans proline' 0 C--N 1.381 2.263 0 C-N-CA 123.549 2.833 . . . . 0.0 113.5 177.803 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 238' ' ' GLU . . . . . 0.467 ' HG3' ' H ' ' A' ' 239' ' ' ILE . 4.9 pt-20 -51.31 -49.04 62.1 Favored 'General case' 0 CA--C 1.555 1.151 0 C-N-CA 123.498 0.719 . . . . 0.0 110.703 172.274 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 239' ' ' ILE . . . . . 0.467 ' H ' ' HG3' ' A' ' 238' ' ' GLU . 6.5 tp -153.07 -45.08 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 C-N-CA 124.521 1.128 . . . . 0.0 108.123 176.123 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 . . . . . 0 C--O 1.248 1.019 0 C-N-CA 124.088 0.955 . . . . 0.0 108.616 -179.507 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 251' ' ' BEZ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 253' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 68.51 -76.08 0.06 Allowed 'General case' 0 C--N 1.359 0.994 0 C-N-CA 124.818 1.247 . . . . 0.0 109.872 -169.377 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 254' ' ' ARG . . . . . 0.579 ' HG3' ' HG2' ' A' ' 193' ' ' PRO . 5.4 mmp_? 73.5 -30.27 0.21 Allowed 'General case' 0 N--CA 1.496 1.831 0 C-N-CA 125.749 1.619 . . . . 0.0 112.085 -172.678 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 255' ' ' M9P . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.888 0 N-CA-C 112.794 -0.123 . . . . 0.0 112.794 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 39.0 t -144.0 152.57 41.22 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 123.707 0.803 . . . . 0.0 109.42 179.419 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.43 151.74 37.91 Favored 'General case' 0 N--CA 1.477 0.889 0 C-N-CA 123.538 0.735 . . . . 0.0 109.431 -179.343 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -131.99 2.09 3.97 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 124.05 0.94 . . . . 0.0 109.742 -175.14 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -127.34 80.65 1.97 Allowed 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 114.526 -1.216 . . . . 0.0 108.14 -168.708 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 5.0 mp -127.05 101.97 6.77 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 -178.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.425 ' HA ' ' HB2' ' A' ' 120' ' ' MET . 10.7 mm-40 -78.65 146.59 33.97 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 123.244 0.618 . . . . 0.0 110.979 -172.403 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.555 HD21 HD13 ' A' ' 119' ' ' LEU . 30.4 mt -90.58 114.39 26.62 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-N 115.042 -0.981 . . . . 0.0 109.14 171.849 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.417 ' HB2' ' HD2' ' A' ' 87' ' ' LYS . 31.4 tt0 -103.52 120.28 40.54 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 124.503 1.121 . . . . 0.0 108.328 -176.455 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 26.3 ptt180 -59.76 132.69 54.74 Favored 'General case' 0 N--CA 1.475 0.817 0 C-N-CA 122.859 0.464 . . . . 0.0 110.893 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.447 ' HB2' ' HG3' ' A' ' 85' ' ' ARG . . . -121.27 -43.18 2.43 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 122.379 0.272 . . . . 0.0 111.362 -177.046 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . 178.37 -158.45 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 124.184 0.994 . . . . 0.0 110.041 -173.703 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -128.01 164.67 21.86 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 123.777 0.831 . . . . 0.0 108.85 168.503 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 53.9 t -75.45 102.36 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 N-CA-C 109.414 -0.588 . . . . 0.0 109.414 177.444 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 4.5 ptpp? -167.89 146.23 4.56 Favored 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 124.633 1.173 . . . . 0.0 108.557 174.294 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 28.8 t90 -78.99 110.7 14.48 Favored 'General case' 0 CA--C 1.547 0.844 0 O-C-N 123.533 0.52 . . . . 0.0 111.402 -172.505 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -73.68 145.43 45.26 Favored 'General case' 0 CA--C 1.544 0.737 0 CA-C-O 121.66 0.743 . . . . 0.0 111.506 172.427 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -68.01 -1.62 6.14 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 125.47 1.508 . . . . 0.0 112.967 -177.072 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 22.8 mm-40 -80.2 50.4 1.24 Allowed 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 123.766 0.826 . . . . 0.0 111.112 -178.306 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.428 ' HA ' ' O ' ' A' ' 169' ' ' ALA . . . -73.32 84.02 1.42 Allowed 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 124.615 1.166 . . . . 0.0 111.464 -174.67 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 38.8 mt-10 -103.57 123.12 46.35 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 124.031 0.932 . . . . 0.0 110.425 -175.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 9.6 tp -76.91 132.68 32.41 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.134 0 C-N-CA 122.47 0.308 . . . . 0.0 110.763 -177.904 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 95.7 p -148.68 -35.71 0.19 Allowed 'General case' 0 N--CA 1.484 1.275 0 N-CA-C 112.14 0.422 . . . . 0.0 112.14 175.567 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -53.39 98.1 0.03 OUTLIER Glycine 0 C--N 1.353 1.476 0 N-CA-C 113.917 0.327 . . . . 0.0 113.917 178.45 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 40.7 p -103.9 -68.72 0.83 Allowed 'General case' 0 CA--C 1.547 0.865 0 C-N-CA 124.014 0.926 . . . . 0.0 111.468 -172.762 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 20.0 m -72.98 126.08 90.7 Favored Pre-proline 0 N--CA 1.477 0.88 0 C-N-CA 123.598 0.759 . . . . 0.0 111.381 -171.12 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -70.85 -74.27 0.01 OUTLIER 'Trans proline' 0 C--N 1.366 1.467 0 C-N-CA 122.13 1.887 . . . . 0.0 111.59 167.825 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 51.0 mm -90.55 121.12 40.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.913 0 C-N-CA 123.26 0.624 . . . . 0.0 111.448 -167.89 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.409 HD22 HG22 ' A' ' 217' ' ' THR . 17.2 mt -143.37 133.48 24.34 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 123.737 0.815 . . . . 0.0 110.333 174.068 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 35.0 p -97.07 140.02 32.21 Favored 'General case' 0 N--CA 1.477 0.892 0 C-N-CA 123.851 0.86 . . . . 0.0 110.538 179.189 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 39.5 mt -131.53 160.58 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 124.265 1.026 . . . . 0.0 108.594 -178.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 66.7 p -96.03 114.33 26.03 Favored 'General case' 0 C--N 1.367 1.327 0 CA-C-N 118.889 0.768 . . . . 0.0 109.001 176.102 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 8.8 mm -55.93 125.89 12.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 C-N-CA 123.987 0.915 . . . . 0.0 109.934 175.712 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 5.8 m -117.42 135.53 53.82 Favored 'General case' 0 C--O 1.252 1.224 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.322 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 30.4 tt0 60.3 28.82 18.46 Favored 'General case' 0 CA--C 1.558 1.263 0 C-N-CA 124.725 1.21 . . . . 0.0 110.791 178.878 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 3.8 p30 46.5 30.05 1.02 Allowed 'General case' 0 N--CA 1.493 1.708 0 C-N-CA 125.631 1.572 . . . . 0.0 113.109 -174.584 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -145.13 -63.7 0.02 OUTLIER Glycine 0 C--N 1.353 1.515 0 CA-C-N 116.562 -0.29 . . . . 0.0 112.487 -177.67 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 38.8 t -105.85 125.97 51.62 Favored 'General case' 0 N--CA 1.486 1.361 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 -172.242 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 1.8 mpp? -88.8 136.95 32.74 Favored 'General case' 0 CA--C 1.546 0.823 0 O-C-N 121.875 -0.515 . . . . 0.0 111.472 -173.745 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.5 m -125.15 164.12 20.95 Favored 'General case' 0 N--CA 1.482 1.125 0 C-N-CA 124.622 1.169 . . . . 0.0 109.915 176.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.529 ' H ' HG21 ' A' ' 215' ' ' VAL . 7.5 tp -93.07 92.51 3.74 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.845 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 -177.937 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 42.5 mmtm 57.88 -74.78 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.336 0 C-N-CA 123.382 0.673 . . . . 0.0 109.831 -161.238 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 5.2 p30 -147.32 118.16 7.62 Favored 'General case' 0 CA--C 1.552 1.045 0 C-N-CA 124.608 1.163 . . . . 0.0 110.034 175.181 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -174.13 130.78 0.39 Allowed 'General case' 0 N--CA 1.492 1.629 0 C-N-CA 123.685 0.794 . . . . 0.0 109.176 171.275 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.418 ' HA ' ' NZ ' ' B' ' 253' ' ' LYS . 0.5 OUTLIER -166.52 27.51 0.04 OUTLIER 'General case' 0 CA--C 1.554 1.108 0 C-N-CA 123.42 0.688 . . . . 0.0 110.104 -178.275 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -105.65 125.21 50.72 Favored 'General case' 0 N--CA 1.483 1.18 0 C-N-CA 122.989 0.515 . . . . 0.0 111.246 -176.868 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -173.59 139.72 0.75 Allowed 'General case' 0 N--CA 1.478 0.952 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 171.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 27.7 tt0 -158.06 79.91 0.84 Allowed 'General case' 0 C--O 1.24 0.555 0 CA-C-O 121.14 0.495 . . . . 0.0 109.673 178.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 93.4 m -81.69 135.09 35.52 Favored 'General case' 0 CA--C 1.537 0.473 0 N-CA-C 108.577 -0.898 . . . . 0.0 108.577 165.685 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 8.1 mp -72.77 90.92 1.44 Allowed 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 123.159 0.583 . . . . 0.0 109.652 -178.915 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -63.17 150.78 48.81 Favored Glycine 0 C--N 1.35 1.327 0 CA-C-N 114.854 -1.066 . . . . 0.0 112.488 177.075 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 99.11 -31.08 8.66 Favored Glycine 0 C--N 1.34 0.796 0 N-CA-C 111.501 -0.64 . . . . 0.0 111.501 -172.713 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 128.72 -50.42 0.89 Allowed Glycine 0 C--N 1.349 1.256 0 N-CA-C 110.67 -0.972 . . . . 0.0 110.67 -176.873 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 145.82 -34.27 1.47 Allowed Glycine 0 C--N 1.349 1.305 0 O-C-N 123.666 0.274 . . . . 0.0 112.459 177.355 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 75.0 p -77.37 -22.74 51.27 Favored 'General case' 0 CA--C 1.555 1.136 0 C-N-CA 123.584 0.754 . . . . 0.0 111.787 -178.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 93.0 -50.79 2.51 Favored Glycine 0 C--N 1.35 1.316 0 C-N-CA 122.864 0.269 . . . . 0.0 112.894 177.506 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.41 ' HA3' ' HB2' ' A' ' 60' ' ' GLU . . . 137.35 146.53 5.12 Favored Glycine 0 C--N 1.347 1.174 0 N-CA-C 111.52 -0.632 . . . . 0.0 111.52 -178.891 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -74.84 -84.74 0.32 Allowed Glycine 0 C--N 1.35 1.315 0 CA-C-N 117.13 0.465 . . . . 0.0 112.011 -178.681 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -71.09 -15.37 74.35 Favored Glycine 0 C--N 1.347 1.165 0 O-C-N 123.567 0.216 . . . . 0.0 112.682 174.558 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.424 ' O ' HG22 ' A' ' 64' ' ' VAL . 36.6 mt-10 -71.14 -10.3 59.52 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 124.283 1.033 . . . . 0.0 112.349 179.212 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 81.8 t80 -65.98 117.14 7.91 Favored 'General case' 0 N--CA 1.478 0.937 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 173.886 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . 70.12 -65.43 0.32 Allowed 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 124.971 1.308 . . . . 0.0 110.476 -174.42 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -76.28 75.9 1.53 Allowed Glycine 0 C--N 1.344 1.013 0 N-CA-C 112.042 -0.423 . . . . 0.0 112.042 175.304 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.424 HG22 ' O ' ' A' ' 60' ' ' GLU . 5.0 t -85.18 60.7 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.116 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 178.777 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -45.36 132.32 7.82 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 124.686 1.194 . . . . 0.0 112.573 -169.808 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' TRP . . . . . 0.606 ' HE1' ' HB2' ' A' ' 122' ' ' LYS . 62.8 m95 -111.65 179.82 3.91 Favored 'General case' 0 C--O 1.243 0.713 0 C-N-CA 123.611 0.764 . . . . 0.0 111.242 -177.223 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -77.41 85.76 3.81 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 114.984 -1.007 . . . . 0.0 108.773 173.23 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 46.3 t -122.69 96.81 45.06 Favored Pre-proline 0 CA--C 1.551 0.995 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 175.893 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 11.9 Cg_exo -74.05 -27.6 11.8 Favored 'Trans proline' 0 C--N 1.379 2.17 0 C-N-CA 123.483 2.789 . . . . 0.0 111.853 172.822 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 52.1 p -69.07 162.21 66.95 Favored Pre-proline 0 CA--C 1.551 0.991 0 C-N-CA 123.733 0.813 . . . . 0.0 110.292 175.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 81.3 Cg_exo -47.2 149.07 4.05 Favored 'Trans proline' 0 C--N 1.377 2.027 0 C-N-CA 122.785 2.323 . . . . 0.0 113.492 171.463 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 80.3 Cg_exo -51.02 160.13 2.14 Favored 'Trans proline' 0 C--N 1.384 2.424 0 C-N-CA 123.563 2.842 . . . . 0.0 113.395 176.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_exo -45.7 84.05 0.01 OUTLIER 'Trans proline' 0 C--N 1.389 2.706 0 C-N-CA 124.332 3.354 . . . . 0.0 114.697 -179.121 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 26.8 m -137.64 -36.32 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 C-N-CA 124.441 1.096 . . . . 0.0 109.951 178.641 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -102.57 -37.97 3.12 Favored Glycine 0 C--N 1.348 1.241 0 CA-C-N 116.034 -0.53 . . . . 0.0 112.524 -178.815 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 55.7 tptt -157.34 -42.49 0.07 Allowed 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 122.891 0.476 . . . . 0.0 111.824 -179.171 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . 74.25 110.83 0.07 Allowed 'General case' 0 N--CA 1.491 1.606 0 C-N-CA 124.827 1.251 . . . . 0.0 109.625 -166.898 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -83.96 150.97 25.31 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 123.044 0.537 . . . . 0.0 111.024 -176.245 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 2.6 pp -100.29 -177.99 3.68 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 123.88 0.872 . . . . 0.0 110.074 174.647 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 -112.77 -170.97 1.77 Allowed 'General case' 0 N--CA 1.483 1.208 0 C-N-CA 123.34 0.656 . . . . 0.0 109.586 -176.868 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.684 ' HB2' ' HD2' ' A' ' 103' ' ' LYS . 8.2 p-10 -135.84 129.28 32.16 Favored 'General case' 0 CA--C 1.54 0.57 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 163.771 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 168.32 178.92 40.4 Favored Glycine 0 C--N 1.339 0.699 0 CA-C-N 115.973 -0.558 . . . . 0.0 112.42 177.268 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ALA . . . . . 0.558 ' HB1' HD11 ' A' ' 161' ' ' LEU . . . -88.32 125.07 34.5 Favored 'General case' 0 CA--C 1.549 0.911 0 C-N-CA 123.947 0.899 . . . . 0.0 109.79 176.717 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 -122.12 148.46 44.87 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 123.596 0.758 . . . . 0.0 109.963 -177.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' ARG . . . . . 0.781 ' HG2' HG21 ' A' ' 195' ' ' THR . 37.3 mtm-85 -95.99 124.43 39.99 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 166.05 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.486 ' H ' ' HA ' ' A' ' 99' ' ' ALA . 27.8 mt -90.65 131.05 38.83 Favored 'Isoleucine or valine' 0 C--O 1.26 1.656 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.437 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 0.2 OUTLIER -124.67 140.83 52.58 Favored 'General case' 0 N--CA 1.45 -0.459 0 CA-C-N 114.504 -1.226 . . . . 0.0 108.684 -174.224 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -84.76 104.09 14.42 Favored 'General case' 0 C--N 1.344 0.331 0 N-CA-C 104.581 -2.377 . . . . 0.0 104.581 175.549 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 14.4 tmtt? -120.64 98.27 5.95 Favored 'General case' 0 CA--C 1.518 -0.288 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 -170.409 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -79.91 152.47 35.01 Favored Glycine 0 C--O 1.242 0.644 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 170.359 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 2.3 mp -78.46 70.26 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.13 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 174.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 58.7 tp 167.29 -41.4 0.0 OUTLIER 'General case' 0 CA--C 1.554 1.123 0 C-N-CA 126.388 1.875 . . . . 0.0 109.029 -167.04 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -148.22 161.02 28.53 Favored Glycine 0 C--N 1.365 2.174 0 N-CA-C 114.8 0.68 . . . . 0.0 114.8 -169.56 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 77.4 m-85 -132.12 129.33 39.73 Favored 'General case' 0 N--CA 1.481 1.095 0 C-N-CA 124.049 0.94 . . . . 0.0 110.427 -172.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 24.5 m -145.42 153.75 41.53 Favored 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 124.652 1.181 . . . . 0.0 108.254 175.173 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.437 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 1.5 pp0? -96.15 146.72 24.43 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-N 118.738 0.699 . . . . 0.0 109.242 168.509 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.46 HD11 HG22 ' A' ' 86' ' ' ILE . 1.6 pp -136.71 -10.03 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 177.443 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' GLY . . . . . 0.552 ' HA3' HG12 ' A' ' 113' ' ' VAL . . . 168.26 -147.06 11.01 Favored Glycine 0 C--N 1.348 1.241 0 C-N-CA 121.003 -0.618 . . . . 0.0 113.19 174.049 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.486 ' HA ' ' H ' ' A' ' 86' ' ' ILE . . . -154.33 153.76 32.2 Favored 'General case' 0 C--O 1.24 0.603 0 C-N-CA 123.663 0.785 . . . . 0.0 111.196 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -155.75 157.18 27.58 Favored Glycine 0 C--N 1.338 0.665 0 CA-C-N 114.937 -1.029 . . . . 0.0 111.209 178.748 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 53.1 t -120.82 120.69 63.16 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.778 0 C-N-CA 123.528 0.731 . . . . 0.0 111.517 -169.376 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.531 ' HB3' ' HA ' ' A' ' 81' ' ' ASP . 10.6 m-85 -74.36 135.81 42.47 Favored 'General case' 0 N--CA 1.482 1.163 0 N-CA-C 107.861 -1.163 . . . . 0.0 107.861 165.037 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.684 ' HD2' ' HB2' ' A' ' 81' ' ' ASP . 29.3 tptt -172.4 149.71 2.23 Favored 'General case' 0 N--CA 1.483 1.177 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 171.322 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 60.21 20.14 9.52 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 124.494 1.118 . . . . 0.0 112.048 -178.771 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 80.09 17.06 75.32 Favored Glycine 0 C--N 1.346 1.115 0 CA-C-N 116.036 -0.529 . . . . 0.0 114.377 -178.011 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 18.8 p -140.07 137.18 34.36 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.604 0.762 . . . . 0.0 109.716 -176.316 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' PHE . . . . . 0.602 ' HB3' ' HB2' ' A' ' 140' ' ' TYR . 42.2 t80 -89.87 103.43 16.09 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 120.937 0.399 . . . . 0.0 111.131 -175.084 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' HIS . . . . . 0.613 ' HB3' ' HE3' ' A' ' 144' ' ' TRP . 18.6 m170 -100.4 114.25 27.65 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 124.488 1.115 . . . . 0.0 110.563 -176.857 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' THR . . . . . 0.592 HG23 HG23 ' A' ' 138' ' ' ILE . 3.9 t -135.71 175.44 9.59 Favored 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 118.758 0.708 . . . . 0.0 112.158 -177.86 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' MET . . . . . 0.499 ' SD ' ' HB2' ' A' ' 210' ' ' LEU . 79.2 mmm -87.95 154.47 20.48 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 123.886 0.874 . . . . 0.0 109.014 172.807 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 111' ' ' TRP . . . . . 0.416 ' CE2' HG22 ' A' ' 133' ' ' VAL . 50.2 t90 -71.52 -45.74 61.58 Favored 'General case' 0 N--CA 1.486 1.338 0 CA-C-N 118.159 0.436 . . . . 0.0 111.504 -170.611 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 4.3 p-80 -51.52 -21.09 2.21 Favored 'General case' 0 N--CA 1.488 1.465 0 C-N-CA 124.769 1.228 . . . . 0.0 114.247 -173.146 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.552 HG12 ' HA3' ' A' ' 98' ' ' GLY . 16.6 m -59.85 -44.14 93.53 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 CA-C-O 121.43 0.633 . . . . 0.0 110.265 -178.603 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 9.0 t -113.76 168.51 9.72 Favored 'General case' 0 C--O 1.238 0.488 0 C-N-CA 123.905 0.882 . . . . 0.0 109.212 -179.45 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 92.9 mtt180 -95.95 33.43 1.7 Allowed 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 124.194 0.997 . . . . 0.0 109.132 178.146 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 68.81 38.85 85.82 Favored Glycine 0 C--N 1.362 1.983 0 CA-C-N 115.158 -0.928 . . . . 0.0 111.528 -174.193 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -127.83 -179.96 5.23 Favored 'General case' 0 C--O 1.244 0.763 0 C-N-CA 123.647 0.779 . . . . 0.0 110.955 -171.106 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.2 p -75.4 139.65 18.71 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.211 0 CA-C-N 114.716 -1.129 . . . . 0.0 111.963 -176.329 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.555 HD13 HD21 ' A' ' 8' ' ' LEU . 58.3 mt -97.9 -177.78 3.87 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 124.084 0.953 . . . . 0.0 110.77 177.812 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 120' ' ' MET . . . . . 0.425 ' HB2' ' HA ' ' A' ' 7' ' ' GLU . 23.2 mmt -133.49 147.9 51.67 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 125.308 1.443 . . . . 0.0 109.762 -176.557 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.777 ' HB2' HD11 ' A' ' 126' ' ' ILE . 34.9 t-80 -151.03 96.63 2.35 Favored 'General case' 0 CA--C 1.54 0.595 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.606 ' HB2' ' HE1' ' A' ' 66' ' ' TRP . 25.5 ttpp 57.69 29.77 17.83 Favored 'General case' 0 N--CA 1.496 1.826 0 C-N-CA 124.186 0.995 . . . . 0.0 111.117 -175.693 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 94.95 -3.53 67.3 Favored Glycine 0 C--N 1.345 1.043 0 CA-C-N 115.768 -0.651 . . . . 0.0 113.47 -179.628 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -94.92 122.45 37.57 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 122.92 0.488 . . . . 0.0 109.92 177.792 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 91.0 mtm-85 -69.39 146.01 52.41 Favored 'General case' 0 C--O 1.243 0.734 0 C-N-CA 123.774 0.83 . . . . 0.0 111.976 178.774 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.777 HD11 ' HB2' ' A' ' 121' ' ' HIS . 5.0 mt -127.19 112.41 28.51 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.801 0 C-N-CA 123.791 0.836 . . . . 0.0 109.225 -179.0 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -83.01 139.36 42.68 Favored Pre-proline 0 CA--C 1.554 1.104 0 C-N-CA 123.838 0.855 . . . . 0.0 110.025 179.007 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -75.61 148.7 33.34 Favored 'Trans proline' 0 C--N 1.379 2.181 0 C-N-CA 122.808 2.339 . . . . 0.0 112.482 179.462 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 32.5 p -109.23 -32.35 7.23 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 124.031 0.932 . . . . 0.0 110.707 177.709 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 4.5 t-105 -132.87 144.03 49.91 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 107.624 -1.251 . . . . 0.0 107.624 -176.698 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -160.53 123.53 3.37 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.205 0.602 . . . . 0.0 110.222 178.488 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 41.4 m-20 -123.32 105.23 9.67 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 124.345 1.058 . . . . 0.0 108.552 167.892 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.416 HG22 ' CE2' ' A' ' 111' ' ' TRP . 16.7 t -68.24 -33.39 60.36 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.884 0 C-N-CA 123.53 0.732 . . . . 0.0 109.313 175.164 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -72.01 -33.13 67.82 Favored 'General case' 0 CA--C 1.547 0.863 0 CA-C-N 114.347 -1.297 . . . . 0.0 111.926 -179.177 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -97.07 -7.47 32.7 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 122.946 0.498 . . . . 0.0 111.792 179.586 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 27.5 t70 60.85 47.52 7.69 Favored 'General case' 0 CA--C 1.548 0.873 0 CA-C-O 122.449 1.118 . . . . 0.0 110.604 -178.027 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 49.7 mt -135.1 147.9 49.66 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 123.833 0.853 . . . . 0.0 109.557 176.675 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.592 HG23 HG23 ' A' ' 109' ' ' THR . 18.4 tt -153.54 143.66 14.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 N-CA-C 107.313 -1.365 . . . . 0.0 107.313 173.441 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 139' ' ' SER . . . . . 0.479 ' HB3' ' HA2' ' A' ' 143' ' ' GLY . 44.1 t -150.68 152.89 34.63 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-O 121.876 0.846 . . . . 0.0 110.97 -175.378 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.602 ' HB2' ' HB3' ' A' ' 107' ' ' PHE . 8.7 m-85 -125.26 108.71 12.0 Favored 'General case' 0 CA--C 1.543 0.708 0 CA-C-N 113.524 -1.671 . . . . 0.0 107.499 -164.933 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 97.48 -4.33 61.9 Favored Glycine 0 C--N 1.348 1.243 0 CA-C-N 116.149 -0.478 . . . . 0.0 112.821 -173.339 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 171.14 -152.64 18.77 Favored Glycine 0 C--N 1.347 1.163 0 CA-C-O 118.744 -1.031 . . . . 0.0 111.295 -179.625 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.479 ' HA2' ' HB3' ' A' ' 139' ' ' SER . . . -119.6 170.2 13.99 Favored Glycine 0 C--N 1.357 1.743 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 173.338 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 144' ' ' TRP . . . . . 0.613 ' HE3' ' HB3' ' A' ' 108' ' ' HIS . 41.6 t-105 -60.23 108.88 0.86 Allowed 'General case' 0 N--CA 1.483 1.188 0 CA-C-O 121.671 0.748 . . . . 0.0 110.728 176.291 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 145' ' ' LYS . . . . . 0.676 ' HA ' HG23 ' A' ' 229' ' ' THR . 0.0 OUTLIER -145.54 135.1 23.26 Favored 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 114.903 -1.044 . . . . 0.0 108.824 171.007 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 146' ' ' LEU . . . . . 0.601 HD21 ' HB3' ' A' ' 103' ' ' LYS . 13.6 mt -144.69 10.29 1.38 Allowed 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 123.67 0.788 . . . . 0.0 110.586 168.607 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.442 ' H ' HG21 ' A' ' 229' ' ' THR . 14.3 tt0 75.37 -18.5 0.44 Allowed 'General case' 0 N--CA 1.498 1.942 0 C-N-CA 124.67 1.188 . . . . 0.0 111.431 177.071 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.43 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -77.65 138.47 21.66 Favored Glycine 0 C--N 1.346 1.119 0 C-N-CA 123.4 0.524 . . . . 0.0 113.135 -169.478 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -130.1 142.03 50.64 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 124.306 1.042 . . . . 0.0 108.399 -178.565 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 150' ' ' TRP . . . . . . . . . . . . . 43.2 t90 -73.19 137.34 44.99 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 122.719 0.407 . . . . 0.0 110.759 172.357 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 54.3 tttm -92.85 133.57 35.94 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 123.776 0.83 . . . . 0.0 109.225 174.368 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -66.85 146.42 54.44 Favored 'General case' 0 N--CA 1.479 1.012 0 CA-C-O 121.118 0.485 . . . . 0.0 111.826 178.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 92.56 -12.89 68.72 Favored Glycine 0 C--N 1.348 1.237 0 CA-C-N 115.027 -0.988 . . . . 0.0 112.921 -177.571 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 29.7 mm-40 -94.07 131.83 39.18 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 123.045 0.538 . . . . 0.0 111.696 -173.836 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -76.06 123.78 26.34 Favored 'General case' 0 C--O 1.245 0.863 0 N-CA-C 107.008 -1.478 . . . . 0.0 107.008 162.489 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -91.13 158.76 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 -168.544 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 157' ' ' GLN . . . . . 0.412 ' OE1' ' HG2' ' A' ' 171' ' ' GLN . 13.9 mm100 -100.58 133.61 44.77 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 123.32 0.648 . . . . 0.0 109.297 179.561 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 46.2 t -107.84 102.35 13.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 107.164 -1.421 . . . . 0.0 107.164 177.516 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.557 HD23 ' HB2' ' A' ' 169' ' ' ALA . 1.8 tm? -74.93 78.42 2.16 Favored 'General case' 0 CA--C 1.546 0.796 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 -175.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -72.05 110.18 6.36 Favored 'General case' 0 C--O 1.242 0.699 0 CA-C-N 114.129 -1.396 . . . . 0.0 111.004 -168.359 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 161' ' ' LEU . . . . . 0.558 HD11 ' HB1' ' A' ' 83' ' ' ALA . 29.9 mt -81.55 83.89 6.89 Favored 'General case' 0 C--O 1.24 0.599 0 CA-C-N 115.099 -0.955 . . . . 0.0 109.182 177.371 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 29.7 mm-40 -68.74 126.92 93.2 Favored Pre-proline 0 CA--C 1.552 1.031 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 174.837 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -61.77 115.76 3.01 Favored 'Trans proline' 0 C--N 1.384 2.4 0 C-N-CA 123.231 2.621 . . . . 0.0 112.503 -174.935 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 81.61 10.99 83.62 Favored Glycine 0 C--N 1.351 1.388 0 CA-C-N 115.485 -0.78 . . . . 0.0 113.467 -179.36 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 49.5 mttp -128.54 172.45 11.16 Favored 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 123.395 0.678 . . . . 0.0 110.9 -178.41 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 25.5 p30 -74.03 156.59 87.74 Favored Pre-proline 0 CA--C 1.555 1.159 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.989 173.826 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 15.8 Cg_exo -68.79 137.38 38.25 Favored 'Trans proline' 0 C--N 1.375 1.937 0 C-N-CA 122.581 2.187 . . . . 0.0 112.568 178.179 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 69.5 mtp180 -117.06 105.75 12.63 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 176.396 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 169' ' ' ALA . . . . . 0.557 ' HB2' HD23 ' A' ' 159' ' ' LEU . . . -86.04 103.3 14.6 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-O 121.034 0.445 . . . . 0.0 110.559 -176.797 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 42.8 t -94.63 129.71 44.46 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.718 0 C-N-CA 124.288 1.035 . . . . 0.0 111.269 -164.626 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 171' ' ' GLN . . . . . 0.412 ' HG2' ' OE1' ' A' ' 157' ' ' GLN . 20.6 mt-30 -79.3 121.37 25.01 Favored 'General case' 0 C--N 1.354 0.767 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 178.627 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 41.9 p -140.34 124.76 17.84 Favored 'General case' 0 C--O 1.237 0.436 0 C-N-CA 122.92 0.488 . . . . 0.0 109.753 -173.064 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 62.2 tttp -70.17 127.58 92.16 Favored Pre-proline 0 CA--C 1.547 0.862 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 171.487 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_exo -57.91 126.4 21.57 Favored 'Trans proline' 0 C--N 1.379 2.175 0 C-N-CA 122.686 2.257 . . . . 0.0 112.767 -179.574 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 175' ' ' GLY . . . . . 0.431 ' H ' ' HA ' ' A' ' 187' ' ' VAL . . . -98.34 178.44 31.6 Favored Glycine 0 C--N 1.337 0.638 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.391 176.488 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 5.3 mp -141.3 146.3 36.58 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 123.501 0.72 . . . . 0.0 109.267 176.351 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 177' ' ' PHE . . . . . 0.7 ' HE1' HG12 ' A' ' 223' ' ' VAL . 22.3 m-85 -93.47 121.63 35.07 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 176.551 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 57.1 tptt -86.29 95.87 9.77 Favored 'General case' 0 CA--C 1.541 0.596 0 O-C-N 123.783 0.677 . . . . 0.0 109.201 177.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 179' ' ' THR . . . . . 0.524 HG22 ' H ' ' A' ' 181' ' ' ALA . 23.0 m -110.47 150.6 28.63 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 176.383 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 24.7 p30 -61.75 -24.35 66.76 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 123.578 0.751 . . . . 0.0 111.914 175.871 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 181' ' ' ALA . . . . . 0.524 ' H ' HG22 ' A' ' 179' ' ' THR . . . -74.18 -39.91 62.87 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.274 1.03 . . . . 0.0 111.388 174.579 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 169.25 -174.16 43.67 Favored Glycine 0 C--N 1.341 0.841 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.569 -177.581 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 13.2 t -97.78 134.55 40.78 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 175.2 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 184' ' ' ILE . . . . . 0.556 ' HB ' ' HB2' ' A' ' 177' ' ' PHE . 23.6 mt -104.65 160.02 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 177.905 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -99.09 124.23 8.16 Favored Glycine 0 C--N 1.349 1.279 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 179.808 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.428 ' HA ' ' HA ' ' A' ' 225' ' ' ALA . . . -147.98 -165.56 2.3 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-O 121.22 0.533 . . . . 0.0 112.395 -161.753 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 187' ' ' VAL . . . . . 0.431 ' HA ' ' H ' ' A' ' 175' ' ' GLY . 4.7 p -158.39 131.12 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.728 0 C-N-CA 124.615 1.166 . . . . 0.0 108.9 175.671 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 7.1 m -111.42 103.5 11.87 Favored 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 123.118 0.567 . . . . 0.0 110.168 176.557 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 4.3 pp -125.67 141.63 51.92 Favored 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 123.37 0.668 . . . . 0.0 109.224 179.586 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -113.53 104.49 12.31 Favored 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 168.102 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 191' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -163.07 -178.3 5.96 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 124.143 0.977 . . . . 0.0 108.725 -170.71 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 31.4 m -52.11 122.34 23.21 Favored Pre-proline 0 CA--C 1.549 0.939 0 CA-C-O 118.542 -0.742 . . . . 0.0 109.86 170.406 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 193' ' ' PRO . . . . . 0.493 ' HB2' ' HG3' ' B' ' 254' ' ' ARG . 29.4 Cg_endo -61.57 91.31 0.11 Allowed 'Trans proline' 0 C--N 1.378 2.129 0 C-N-CA 122.695 2.263 . . . . 0.0 112.155 -173.905 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -60.02 123.28 32.62 Favored Glycine 0 C--N 1.348 1.219 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 172.43 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 195' ' ' THR . . . . . 0.781 HG21 ' HG2' ' A' ' 85' ' ' ARG . 8.8 t -54.22 144.37 20.24 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-O 121.663 0.744 . . . . 0.0 112.035 -173.207 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 196' ' ' SER . . . . . 0.468 ' HA ' ' HD2' ' A' ' 211' ' ' TYR . 13.4 m -72.28 95.56 1.72 Allowed 'General case' 0 C--O 1.242 0.688 0 CA-C-N 115.077 -0.965 . . . . 0.0 111.406 -169.872 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 197' ' ' GLY . . . . . 0.496 ' H ' ' HB3' ' A' ' 211' ' ' TYR . . . 133.63 4.94 2.99 Favored Glycine 0 C--N 1.34 0.753 0 CA-C-N 115.279 -0.873 . . . . 0.0 111.663 -176.684 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 72.0 m -56.32 131.81 75.86 Favored Pre-proline 0 C--N 1.361 1.101 0 C-N-CA 123.143 0.577 . . . . 0.0 110.229 171.089 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -64.23 111.67 1.67 Allowed 'Trans proline' 0 C--N 1.372 1.777 0 C-N-CA 122.209 1.939 . . . . 0.0 111.635 -176.899 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 55.3 mt -77.93 111.69 15.04 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.414 0 N-CA-C 107.964 -1.125 . . . . 0.0 107.964 174.32 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 201' ' ' ILE . . . . . 0.424 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 63.5 mt -112.28 148.51 15.33 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.61 0 C-N-CA 124.741 1.216 . . . . 0.0 108.739 -174.545 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -71.55 160.49 32.61 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 123.802 0.841 . . . . 0.0 108.871 171.823 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 3.7 ttmp? -70.17 -13.18 62.07 Favored 'General case' 0 N--CA 1.483 1.195 0 C-N-CA 123.343 0.657 . . . . 0.0 111.358 -178.841 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 27.1 mtpp -89.23 15.11 9.46 Favored 'General case' 0 CA--C 1.552 1.052 0 C-N-CA 123.9 0.88 . . . . 0.0 111.788 175.499 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 70.53 22.9 77.94 Favored Glycine 0 C--N 1.356 1.642 0 O-C-N 123.102 0.251 . . . . 0.0 113.316 176.762 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 206' ' ' LYS . . . . . 0.405 ' HE2' ' HB3' ' A' ' 206' ' ' LYS . 22.1 ttpt -112.62 112.84 24.65 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 124.715 1.206 . . . . 0.0 108.261 -176.585 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.43 ' O ' ' HA3' ' A' ' 148' ' ' GLY . 7.4 p -56.61 141.64 13.19 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 CA-C-N 118.953 0.797 . . . . 0.0 110.714 179.057 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 6.0 m -119.02 -33.9 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 C-N-CA 122.606 0.363 . . . . 0.0 110.363 178.868 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 209' ' ' GLY . . . . . . . . . . . . . . . -175.82 -167.13 34.33 Favored Glycine 0 C--N 1.349 1.304 0 O-C-N 123.197 0.311 . . . . 0.0 113.819 -174.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 210' ' ' LEU . . . . . 0.499 ' HB2' ' SD ' ' A' ' 110' ' ' MET . 87.3 mt -117.29 156.2 28.2 Favored 'General case' 0 C--O 1.255 1.356 0 C-N-CA 124.196 0.998 . . . . 0.0 109.916 175.107 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 211' ' ' TYR . . . . . 0.496 ' HB3' ' H ' ' A' ' 197' ' ' GLY . 37.8 t80 -73.33 116.09 13.47 Favored 'General case' 0 C--N 1.35 0.63 0 CA-C-N 114.644 -1.162 . . . . 0.0 109.251 178.561 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -73.99 -142.74 0.7 Allowed Glycine 0 C--N 1.339 0.731 0 O-C-N 124.051 0.844 . . . . 0.0 114.272 -174.291 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 213' ' ' ASN . . . . . . . . . . . . . 3.9 p30 -127.96 159.23 35.62 Favored 'General case' 0 C--O 1.239 0.503 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 -177.27 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 173.62 -136.03 3.47 Favored Glycine 0 N--CA 1.438 -1.227 0 N-CA-C 109.646 -1.381 . . . . 0.0 109.646 178.351 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 215' ' ' VAL . . . . . 0.568 ' HA ' ' HG2' ' B' ' 253' ' ' LYS . 11.3 p -170.0 170.75 0.16 Allowed 'Isoleucine or valine' 0 C--O 1.242 0.683 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 -172.163 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 216' ' ' VAL . . . . . 0.613 HG21 ' H2 ' ' B' ' 251' ' ' BEZ . 35.7 m -70.28 112.6 5.25 Favored 'Isoleucine or valine' 0 CA--C 1.557 1.221 0 CA-C-O 121.882 0.848 . . . . 0.0 108.908 168.548 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 217' ' ' THR . . . . . 0.409 HG22 HD22 ' A' ' 29' ' ' LEU . 8.3 m -119.69 171.84 8.1 Favored 'General case' 0 C--O 1.254 1.323 0 C-N-CA 124.661 1.184 . . . . 0.0 108.393 -174.747 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 22.2 ttt180 73.46 -74.68 0.08 Allowed 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 124.636 1.174 . . . . 0.0 110.327 -179.205 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 35.8 p -148.06 -0.47 0.6 Allowed 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 123.651 0.78 . . . . 0.0 111.297 -178.298 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 220' ' ' GLY . . . . . 0.429 ' HA2' ' HB ' ' A' ' 216' ' ' VAL . . . 134.27 12.55 1.42 Allowed Glycine 0 C--N 1.351 1.386 0 CA-C-O 120.0 -0.334 . . . . 0.0 113.048 -174.586 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 221' ' ' ALA . . . . . 0.492 ' O ' HG23 ' A' ' 223' ' ' VAL . . . -78.61 139.99 38.5 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 123.023 0.529 . . . . 0.0 109.597 178.449 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 222' ' ' TYR . . . . . . . . . . . . . 37.8 m-85 -78.81 99.21 6.61 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 123.614 0.766 . . . . 0.0 109.532 -176.093 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 223' ' ' VAL . . . . . 0.7 HG12 ' HE1' ' A' ' 177' ' ' PHE . 39.1 t -118.91 111.31 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 123.142 0.577 . . . . 0.0 110.148 -169.167 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 16.5 m -137.54 159.57 41.58 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.242 1.017 . . . . 0.0 110.554 -171.854 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 225' ' ' ALA . . . . . 0.428 ' HA ' ' HA ' ' A' ' 186' ' ' ALA . . . -70.93 171.92 9.89 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 123.921 0.888 . . . . 0.0 112.309 -179.009 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 226' ' ' ILE . . . . . . . . . . . . . 39.3 mt -127.22 124.47 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.183 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 173.298 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -114.18 109.67 18.77 Favored 'General case' 0 N--CA 1.487 1.402 0 CA-C-N 118.019 0.372 . . . . 0.0 110.525 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 -92.89 168.97 10.81 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 123.673 0.789 . . . . 0.0 111.37 -176.477 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 229' ' ' THR . . . . . 0.676 HG23 ' HA ' ' A' ' 145' ' ' LYS . 97.4 m -64.41 108.37 1.61 Allowed 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.602 0.761 . . . . 0.0 111.089 -174.736 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 16.2 mm-40 -156.34 12.98 0.29 Allowed 'General case' 0 N--CA 1.484 1.245 0 C-N-CA 123.645 0.778 . . . . 0.0 112.173 -176.695 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 231' ' ' LYS . . . . . 0.538 ' HE2' ' HA ' ' A' ' 231' ' ' LYS . 11.1 mmpt? -96.52 -92.33 0.22 Allowed 'General case' 0 N--CA 1.486 1.334 0 CA-C-N 119.103 0.865 . . . . 0.0 111.955 -174.897 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 66.8 p -89.21 113.08 24.25 Favored 'General case' 0 C--N 1.353 0.754 0 CA-C-N 118.735 0.698 . . . . 0.0 112.255 -169.362 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 233' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -86.78 -13.74 10.54 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.312 0 CA-C-N 114.612 -1.176 . . . . 0.0 109.362 166.508 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 234' ' ' GLU . . . . . 0.57 ' HG2' ' H ' ' A' ' 235' ' ' ASP 0.275 1.4 pm0 40.14 -87.46 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 127.574 2.35 . . . . 0.0 114.811 -178.897 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 235' ' ' ASP . . . . . 0.57 ' H ' ' HG2' ' A' ' 234' ' ' GLU . 29.8 t70 -141.01 18.49 2.29 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 123.175 0.59 . . . . 0.0 110.043 -172.592 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 236' ' ' ASN . . . . . . . . . . . . . 31.9 t30 -76.62 107.45 4.73 Favored Pre-proline 0 CA--C 1.555 1.146 0 C-N-CA 124.276 1.031 . . . . 0.0 110.429 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_endo -85.08 83.73 1.48 Allowed 'Trans proline' 0 C--N 1.377 2.048 0 C-N-CA 122.604 2.202 . . . . 0.0 111.955 -176.106 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 238' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -104.36 121.52 43.54 Favored 'General case' 0 N--CA 1.477 0.889 0 C-N-CA 123.49 0.716 . . . . 0.0 110.459 -179.752 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 239' ' ' ILE . . . . . . . . . . . . . 9.7 tt -84.88 -52.56 12.27 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.069 0 C-N-CA 123.154 0.581 . . . . 0.0 110.035 176.834 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.556 1.178 0 C-N-CA 123.54 0.736 . . . . 0.0 110.248 179.579 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 251' ' ' BEZ . . . . . 0.613 ' H2 ' HG21 ' A' ' 216' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 253' ' ' LYS . . . . . 0.568 ' HG2' ' HA ' ' A' ' 215' ' ' VAL . 0.1 OUTLIER -83.31 159.66 21.85 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.744 0.818 . . . . 0.0 110.082 173.763 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 254' ' ' ARG . . . . . 0.493 ' HG3' ' HB2' ' A' ' 193' ' ' PRO . 63.0 mtt-85 -72.95 -68.82 0.45 Allowed 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 176.899 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 255' ' ' M9P . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.93 0 CA-C-O 119.34 -0.7 . . . . 0.0 111.663 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 52.6 p -170.88 117.39 0.48 Allowed 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 124.351 1.061 . . . . 0.0 108.552 176.641 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -131.98 -59.83 0.93 Allowed 'General case' 0 N--CA 1.482 1.173 0 C-N-CA 122.877 0.471 . . . . 0.0 111.054 -177.853 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -163.48 20.74 0.08 Allowed 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 123.901 0.88 . . . . 0.0 109.406 -171.778 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 21.1 p-10 -142.84 58.83 1.43 Allowed 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 114.426 -1.261 . . . . 0.0 108.938 -162.866 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.466 ' HG ' ' HG2' ' A' ' 88' ' ' GLN . 2.9 mp -134.32 117.73 16.72 Favored 'General case' 0 C--O 1.207 -1.149 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 173.143 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.493 ' HB3' ' HE3' ' A' ' 87' ' ' LYS . 37.4 tt0 -114.48 156.26 24.89 Favored 'General case' 0 N--CA 1.495 1.789 0 CA-C-N 119.745 1.157 . . . . 0.0 112.202 -175.645 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 81.6 mt -95.77 143.07 27.32 Favored 'General case' 0 N--CA 1.481 1.121 0 C-N-CA 124.161 0.984 . . . . 0.0 113.011 178.446 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 -131.34 116.3 17.39 Favored 'General case' 0 N--CA 1.483 1.18 0 C-N-CA 124.283 1.033 . . . . 0.0 108.637 172.349 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.508 ' HA ' ' HA ' ' A' ' 84' ' ' TYR . 36.7 ptt85 -62.33 110.66 1.71 Allowed 'General case' 0 N--CA 1.487 1.407 0 CA-C-N 119.503 1.047 . . . . 0.0 110.17 173.671 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.49 ' HB3' HD13 ' A' ' 161' ' ' LEU . . . -91.5 -28.3 17.69 Favored 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 123.552 0.741 . . . . 0.0 110.457 -177.748 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -160.22 175.05 13.34 Favored 'General case' 0 C--O 1.239 0.504 0 C-N-CA 123.808 0.843 . . . . 0.0 110.613 -179.366 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -102.66 170.1 8.23 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 124.044 0.938 . . . . 0.0 109.947 175.883 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.645 HG23 ' HA2' ' A' ' 82' ' ' GLY . 82.0 t -72.22 101.54 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.626 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 167.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 31.0 ttmt -169.08 140.79 2.49 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -169.589 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 28.6 t90 -102.45 122.3 44.05 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 122.745 0.418 . . . . 0.0 110.064 179.313 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -81.33 146.18 30.5 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 124.08 0.952 . . . . 0.0 110.889 171.713 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -73.95 0.89 12.09 Favored 'General case' 0 N--CA 1.483 1.182 0 C-N-CA 124.325 1.05 . . . . 0.0 112.607 176.758 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 72.2 mt-30 -75.96 14.95 0.6 Allowed 'General case' 0 CA--C 1.555 1.143 0 C-N-CA 124.325 1.05 . . . . 0.0 112.966 -176.169 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.525 ' HB1' ' HB2' ' A' ' 171' ' ' GLN . . . -52.99 90.64 0.01 OUTLIER 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 124.367 1.067 . . . . 0.0 113.255 -168.594 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -62.56 131.94 50.75 Favored 'General case' 0 C--N 1.353 0.745 0 C-N-CA 124.46 1.104 . . . . 0.0 110.64 -178.876 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 3.0 mp -75.37 111.0 11.11 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 -173.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 19.1 m -142.13 179.35 6.95 Favored 'General case' 0 C--O 1.246 0.885 0 C-N-CA 124.663 1.185 . . . . 0.0 109.208 -175.836 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.474 ' HA3' ' H ' ' A' ' 173' ' ' LYS . . . 88.27 84.75 1.23 Allowed Glycine 0 C--N 1.341 0.823 0 N-CA-C 111.306 -0.717 . . . . 0.0 111.306 -176.821 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 50.4 m -150.3 -28.13 0.23 Allowed 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.14 0.576 . . . . 0.0 111.555 -177.471 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 9.3 p -66.14 126.55 92.15 Favored Pre-proline 0 CA--C 1.553 1.086 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 177.612 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -75.82 -165.3 0.29 Allowed 'Trans proline' 0 C--N 1.377 2.061 0 C-N-CA 123.214 2.609 . . . . 0.0 113.452 -172.587 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 36.3 mm -63.17 111.82 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.953 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 177.833 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.635 HD21 ' HB2' ' A' ' 218' ' ' ARG . 0.3 OUTLIER -109.59 160.33 16.35 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.218 -172.249 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.427 ' H ' HD23 ' A' ' 29' ' ' LEU . 65.6 m -94.54 149.12 21.56 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 123.119 0.568 . . . . 0.0 110.05 171.608 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 17.6 tt -139.31 160.55 28.58 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.593 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 27.7 m -93.9 105.91 17.91 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 108.693 -0.855 . . . . 0.0 108.693 178.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 10.8 tp -73.71 148.55 8.49 Favored 'Isoleucine or valine' 0 C--O 1.246 0.903 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 169.803 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.561 ' HB2' ' HB2' ' A' ' 38' ' ' SER . 50.4 m -138.48 138.7 38.34 Favored 'General case' 0 C--O 1.242 0.695 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 178.302 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -60.41 156.47 15.92 Favored 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 123.499 0.72 . . . . 0.0 111.105 -174.61 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.8 t70 77.85 21.35 0.94 Allowed 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 125.317 1.447 . . . . 0.0 110.727 -179.01 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 78.7 38.49 23.87 Favored Glycine 0 C--N 1.35 1.317 0 CA-C-N 115.556 -0.747 . . . . 0.0 113.755 174.021 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.561 ' HB2' ' HB2' ' A' ' 34' ' ' SER . 28.4 m -107.33 150.36 26.78 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 122.937 0.495 . . . . 0.0 109.793 175.589 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 5.4 ptm -160.65 123.8 3.37 Favored 'General case' 0 N--CA 1.481 1.107 0 CA-C-O 120.901 0.382 . . . . 0.0 111.723 -175.041 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.509 ' HA ' HG11 ' A' ' 215' ' ' VAL . 15.7 p -177.42 -176.17 0.6 Allowed 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 124.549 1.139 . . . . 0.0 109.434 -178.525 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 1.4 mp -92.13 131.09 40.16 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 N-CA-C 105.796 -1.928 . . . . 0.0 105.796 156.283 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 49.3 pttt -52.98 89.76 0.01 OUTLIER 'General case' 0 CA--C 1.551 0.986 0 C-N-CA 124.531 1.132 . . . . 0.0 112.048 -177.785 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 64.0 m-20 -158.13 149.82 21.53 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.462 1.505 . . . . 0.0 108.329 -177.251 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -68.69 108.62 3.46 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 123.328 0.651 . . . . 0.0 110.234 -179.605 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -91.46 121.88 33.56 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 122.978 0.511 . . . . 0.0 109.954 176.566 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.423 ' HG2' ' NH1' ' B' ' 255' ' ' M9P . 0.4 OUTLIER -170.12 124.09 0.73 Allowed 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 175.683 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.462 ' HB3' ' HA ' ' B' ' 254' ' ' ARG . 8.4 tp10 -159.39 93.95 1.15 Allowed 'General case' 0 C--O 1.24 0.58 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 178.646 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 8.4 pt20 -103.43 99.31 9.14 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 123.947 0.899 . . . . 0.0 109.563 176.644 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.409 ' OG1' ' HD3' ' B' ' 254' ' ' ARG . 28.0 m -71.29 -78.08 0.08 Allowed 'General case' 0 CA--C 1.547 0.827 0 C-N-CA 123.52 0.728 . . . . 0.0 110.662 -175.927 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 57.8 tp -175.18 127.21 0.27 Allowed 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 123.017 0.527 . . . . 0.0 109.889 -177.498 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -76.04 -155.7 5.9 Favored Glycine 0 C--N 1.346 1.122 0 O-C-N 123.436 0.46 . . . . 0.0 112.273 171.905 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -143.79 -64.26 0.02 OUTLIER Glycine 0 N--CA 1.467 0.767 0 N-CA-C 111.696 -0.562 . . . . 0.0 111.696 -178.459 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 80.48 -72.16 2.71 Favored Glycine 0 C--N 1.341 0.823 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 -175.076 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 98.45 156.84 29.63 Favored Glycine 0 C--N 1.342 0.906 0 C-N-CA 122.917 0.294 . . . . 0.0 112.644 177.224 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.423 ' HB3' ' HA2' ' A' ' 59' ' ' GLY . 15.2 t 59.83 33.23 21.63 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 124.72 1.208 . . . . 0.0 111.366 177.866 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 119.71 -37.31 3.16 Favored Glycine 0 C--N 1.343 0.947 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.891 -178.302 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 149.07 -12.72 1.09 Allowed Glycine 0 C--N 1.35 1.309 0 CA-C-O 119.949 -0.362 . . . . 0.0 113.049 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -168.32 35.68 0.2 Allowed Glycine 0 C--N 1.349 1.288 0 N-CA-C 112.074 -0.41 . . . . 0.0 112.074 -179.449 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.423 ' HA2' ' HB3' ' A' ' 55' ' ' SER . . . 83.76 -61.93 4.67 Favored Glycine 0 C--N 1.351 1.363 0 N-CA-C 112.46 -0.256 . . . . 0.0 112.46 -178.494 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -170.26 -62.45 0.02 OUTLIER 'General case' 0 C--O 1.236 0.39 0 N-CA-C 107.073 -1.454 . . . . 0.0 107.073 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -114.41 -61.32 1.76 Allowed 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 114.829 -1.078 . . . . 0.0 108.923 171.378 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -148.73 13.2 0.91 Allowed 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 123.494 0.717 . . . . 0.0 111.006 -178.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -81.45 71.72 2.88 Favored Glycine 0 C--N 1.35 1.334 0 N-CA-C 113.729 0.252 . . . . 0.0 113.729 -173.844 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.414 ' H ' ' HG3' ' A' ' 122' ' ' LYS . 14.2 t -85.71 64.91 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.808 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 175.455 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -37.22 130.31 0.89 Allowed 'General case' 0 N--CA 1.481 1.089 0 C-N-CA 125.836 1.655 . . . . 0.0 112.096 -178.376 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 29.0 m0 -69.63 158.42 35.35 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.037 -173.141 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.603 ' HB2' ' H ' ' A' ' 80' ' ' GLU . 1.0 OUTLIER -82.83 71.33 9.93 Favored 'General case' 0 CA--C 1.54 0.574 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 -168.866 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.409 HG22 ' HB3' ' A' ' 78' ' ' GLU . 16.3 t -106.9 112.52 63.32 Favored Pre-proline 0 CA--C 1.545 0.782 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 -174.493 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -57.27 -32.96 95.16 Favored 'Trans proline' 0 C--N 1.375 1.938 0 C-N-CA 123.516 2.811 . . . . 0.0 114.276 -170.642 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 36.3 p -128.7 147.44 64.36 Favored Pre-proline 0 CA--C 1.55 0.976 0 C-N-CA 123.751 0.821 . . . . 0.0 110.787 -179.352 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_exo -53.87 -44.24 50.93 Favored 'Trans proline' 0 CA--C 1.573 2.467 0 C-N-CA 123.675 2.916 . . . . 0.0 117.035 174.326 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.86 -51.61 10.72 Favored 'Trans proline' 0 C--N 1.399 3.214 0 C-N-CA 122.16 1.907 . . . . 0.0 116.544 -176.274 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_endo -82.84 169.77 13.05 Favored 'Trans proline' 0 C--N 1.386 2.534 0 CA-C-N 122.322 1.865 . . . . 0.0 112.827 178.136 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 11.7 p -163.49 -36.52 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 C-N-CA 124.38 1.072 . . . . 0.0 108.386 172.576 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 52.17 -99.55 0.04 OUTLIER Glycine 0 C--N 1.352 1.458 0 O-C-N 124.702 1.251 . . . . 0.0 114.227 172.427 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -159.86 -58.11 0.06 Allowed 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 124.227 1.011 . . . . 0.0 108.897 -174.028 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -112.95 37.31 3.16 Favored 'General case' 0 N--CA 1.472 0.632 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.381 -178.48 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.409 ' HB3' HG22 ' A' ' 68' ' ' VAL . 11.1 mm-40 -71.67 83.39 0.87 Allowed 'General case' 0 N--CA 1.479 0.991 0 CA-C-O 121.547 0.689 . . . . 0.0 110.486 171.195 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 6.4 mp -117.76 131.96 56.52 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 114.877 -1.056 . . . . 0.0 108.255 168.804 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.603 ' H ' ' HB2' ' A' ' 67' ' ' ASP . 37.8 tt0 -70.27 -11.93 61.24 Favored 'General case' 0 CA--C 1.549 0.926 0 C-N-CA 125.459 1.504 . . . . 0.0 110.5 177.574 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.413 ' HB2' ' O ' ' A' ' 102' ' ' TYR . 0.5 OUTLIER 66.89 -179.53 0.21 Allowed 'General case' 0 C--N 1.352 0.71 0 C-N-CA 126.559 1.944 . . . . 0.0 112.478 170.806 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.645 ' HA2' HG23 ' A' ' 14' ' ' VAL . . . 128.84 -157.9 21.7 Favored Glycine 0 C--O 1.248 1.031 0 CA-C-N 115.364 -0.834 . . . . 0.0 111.384 -177.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ALA . . . . . 0.667 ' HB1' HD11 ' A' ' 161' ' ' LEU . . . -90.35 107.06 18.91 Favored 'General case' 0 CA--C 1.54 0.57 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -179.228 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' TYR . . . . . 0.508 ' HA ' ' HA ' ' A' ' 10' ' ' ARG . 7.4 m-85 -92.51 176.23 6.54 Favored 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 123.18 0.592 . . . . 0.0 109.405 177.455 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' ARG . . . . . 0.626 ' HA ' ' HA ' ' A' ' 99' ' ' ALA . 53.8 ttp180 -138.36 121.82 17.22 Favored 'General case' 0 C--O 1.239 0.54 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 -174.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 41.7 mt -90.67 116.04 31.16 Favored 'Isoleucine or valine' 0 C--O 1.25 1.116 0 CA-C-O 121.607 0.718 . . . . 0.0 110.134 -172.257 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.609 ' HE3' ' HD2' ' A' ' 89' ' ' LYS . 48.3 pttt -105.35 142.13 35.65 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 168.564 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' GLN . . . . . 0.612 ' HB2' HD13 ' A' ' 97' ' ' ILE . 18.0 tm0? -84.44 106.48 16.06 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 104.534 -2.395 . . . . 0.0 104.534 165.784 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' LYS . . . . . 0.609 ' HD2' ' HE3' ' A' ' 87' ' ' LYS . 78.6 tttt -119.41 104.09 10.04 Favored 'General case' 0 C--O 1.241 0.613 0 C-N-CA 123.666 0.786 . . . . 0.0 110.36 -167.203 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -72.32 155.31 51.36 Favored Glycine 0 C--O 1.243 0.701 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 167.474 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 22.2 mm -79.41 62.15 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.563 1.442 0 CA-C-N 118.174 0.987 . . . . 0.0 109.067 -176.102 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 1.6 tm? 170.16 -40.1 0.0 OUTLIER 'General case' 0 CA--C 1.556 1.204 0 C-N-CA 126.347 1.859 . . . . 0.0 107.556 -168.848 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -137.96 151.66 21.45 Favored Glycine 0 C--N 1.369 2.379 0 N-CA-C 114.926 0.731 . . . . 0.0 114.926 -166.576 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -111.89 142.81 43.81 Favored 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 125.037 1.335 . . . . 0.0 110.738 -179.167 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 49.5 m -150.52 96.67 2.41 Favored 'General case' 0 N--CA 1.477 0.915 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 168.641 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.555 HE22 ' HB3' ' A' ' 163' ' ' PRO . 35.8 tt0 -62.48 140.25 58.6 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 123.237 0.615 . . . . 0.0 111.243 -178.605 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.612 HD13 ' HB2' ' A' ' 88' ' ' GLN . 8.5 pt -132.76 -24.68 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 N-CA-C 112.604 0.594 . . . . 0.0 112.604 -173.765 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 178.85 -149.4 8.86 Favored Glycine 0 C--N 1.345 1.074 0 C-N-CA 120.847 -0.692 . . . . 0.0 113.031 179.484 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.626 ' HA ' ' HA ' ' A' ' 85' ' ' ARG . . . -143.59 178.11 8.01 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 124.44 1.096 . . . . 0.0 109.805 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -176.89 140.84 5.13 Favored Glycine 0 C--N 1.34 0.796 0 CA-C-O 119.826 -0.43 . . . . 0.0 112.123 174.042 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.599 ' HB ' ' HG3' ' A' ' 199' ' ' PRO . 3.3 p -89.36 127.14 42.22 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.942 0 CA-C-N 117.422 0.611 . . . . 0.0 111.001 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.443 ' HD2' ' HB2' ' A' ' 107' ' ' PHE . 29.4 t80 -98.05 136.77 37.83 Favored 'General case' 0 N--CA 1.477 0.881 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 169.562 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.435 ' HD2' HG21 ' A' ' 14' ' ' VAL . 35.2 tttp -169.02 154.23 6.01 Favored 'General case' 0 N--CA 1.47 0.57 0 O-C-N 123.69 0.618 . . . . 0.0 110.071 171.927 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 11.8 tp10 72.86 17.28 4.35 Favored 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 124.684 1.194 . . . . 0.0 110.752 171.301 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 80.51 18.01 72.02 Favored Glycine 0 C--N 1.345 1.033 0 CA-C-N 115.925 -0.58 . . . . 0.0 113.303 -176.159 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' THR . . . . . 0.468 HG23 ' HD2' ' A' ' 108' ' ' HIS . 2.7 t -139.54 134.8 32.69 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 123.013 0.525 . . . . 0.0 110.584 176.662 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 107' ' ' PHE . . . . . 0.556 ' HB3' ' HB2' ' A' ' 140' ' ' TYR . 38.3 t80 -88.55 118.81 28.47 Favored 'General case' 0 C--N 1.349 0.579 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 174.716 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' HIS . . . . . 0.468 ' HD2' HG23 ' A' ' 106' ' ' THR . 4.1 p80 -133.45 114.1 13.27 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 123.051 0.54 . . . . 0.0 109.969 -175.267 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 11.5 t -136.17 -172.89 3.24 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 124.187 0.995 . . . . 0.0 110.359 -176.081 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' MET . . . . . 0.414 ' SD ' ' HE1' ' A' ' 112' ' ' HIS . 1.0 OUTLIER -67.14 152.57 45.51 Favored 'General case' 0 N--CA 1.479 1.02 0 C-N-CA 124.189 0.996 . . . . 0.0 110.702 171.542 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 84.1 t90 -74.0 -47.65 35.71 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 122.848 0.459 . . . . 0.0 110.654 -178.791 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' HIS . . . . . 0.414 ' HE1' ' SD ' ' A' ' 110' ' ' MET . 22.1 p-80 -59.78 -15.46 20.57 Favored 'General case' 0 N--CA 1.489 1.506 0 C-N-CA 124.38 1.072 . . . . 0.0 113.755 -170.035 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.5 ' O ' HD12 ' A' ' 97' ' ' ILE . 23.2 m -57.62 -27.53 29.84 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 C-N-CA 123.185 0.594 . . . . 0.0 111.032 178.695 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 10.8 t -135.5 165.22 26.03 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.163 0.985 . . . . 0.0 109.263 177.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 14.7 tpp180 -92.74 16.03 13.21 Favored 'General case' 0 N--CA 1.484 1.252 0 CA-C-O 121.642 0.734 . . . . 0.0 109.887 176.048 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 98.72 42.23 2.94 Favored Glycine 0 C--N 1.347 1.153 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 -177.169 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -106.79 167.56 9.79 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 123.608 0.763 . . . . 0.0 110.621 -179.646 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.43 HG23 ' HA ' ' A' ' 127' ' ' GLU . 7.3 p -84.93 137.73 20.33 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.006 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.408 178.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 1.8 mm? -84.37 -177.97 6.78 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 124.429 1.092 . . . . 0.0 111.1 -178.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 47.9 mtm -145.23 164.87 30.02 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 124.165 0.986 . . . . 0.0 111.119 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 12.0 t-160 -164.92 111.28 0.97 Allowed 'General case' 0 C--O 1.239 0.536 0 N-CA-C 106.497 -1.668 . . . . 0.0 106.497 171.454 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.414 ' HG3' ' H ' ' A' ' 64' ' ' VAL . 73.1 tttt 70.55 20.34 5.88 Favored 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 124.131 0.972 . . . . 0.0 110.802 -179.739 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 93.13 -19.95 49.06 Favored Glycine 0 C--N 1.344 0.985 0 CA-C-N 114.811 -1.086 . . . . 0.0 113.334 -172.134 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 38.8 ttmt -77.37 119.6 21.21 Favored 'General case' 0 C--N 1.36 1.027 0 CA-C-N 117.509 0.654 . . . . 0.0 109.76 -179.135 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 3.6 mpt_? -59.68 143.8 49.7 Favored 'General case' 0 CA--C 1.551 1.014 0 C-N-CA 124.383 1.073 . . . . 0.0 111.75 177.306 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 57.9 mt -119.1 109.05 25.45 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 176.367 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' GLU . . . . . 0.43 ' HA ' HG23 ' A' ' 118' ' ' VAL . 10.8 pt-20 -80.01 134.42 56.39 Favored Pre-proline 0 CA--C 1.557 1.241 0 C-N-CA 124.42 1.088 . . . . 0.0 112.997 -167.793 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 127' ' ' GLU . 3.7 Cg_exo -76.3 110.38 3.05 Favored 'Trans proline' 0 C--N 1.383 2.357 0 C-N-CA 123.023 2.482 . . . . 0.0 111.365 176.845 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 34.1 p -85.6 -27.46 25.46 Favored 'General case' 0 N--CA 1.479 1.0 0 C-N-CA 123.315 0.646 . . . . 0.0 111.416 -179.362 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 69.9 t-105 -147.86 153.9 39.72 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 123.706 0.802 . . . . 0.0 109.127 -178.538 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -155.99 118.28 4.08 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 123.196 0.599 . . . . 0.0 110.089 175.443 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 12.8 t0 -117.14 106.95 13.89 Favored 'General case' 0 N--CA 1.475 0.793 0 C-N-CA 124.312 1.045 . . . . 0.0 108.555 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 21.5 t -76.88 -16.42 14.7 Favored 'Isoleucine or valine' 0 CA--C 1.565 1.543 0 C-N-CA 123.263 0.625 . . . . 0.0 111.643 -174.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -79.16 -43.04 24.75 Favored 'General case' 0 N--CA 1.492 1.66 0 C-N-CA 123.203 0.601 . . . . 0.0 111.06 -175.859 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 11.8 mptt -78.19 -15.55 58.72 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 170.189 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 11.1 t0 58.69 61.86 2.09 Favored 'General case' 0 C--N 1.356 0.888 0 O-C-N 124.834 1.334 . . . . 0.0 108.512 -170.37 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' LEU . . . . . 0.506 HD11 ' HB1' ' A' ' 227' ' ' ALA . 87.0 mt -139.66 131.97 28.35 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 123.973 0.909 . . . . 0.0 109.607 176.808 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.403 HG22 ' O ' ' A' ' 110' ' ' MET . 20.2 tt -119.7 138.08 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.18 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 171.451 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 21.0 p -133.3 147.77 51.9 Favored 'General case' 0 CA--C 1.544 0.733 0 CA-C-O 121.827 0.822 . . . . 0.0 112.113 -171.501 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.556 ' HB2' ' HB3' ' A' ' 107' ' ' PHE . 17.5 m-85 -132.25 112.02 11.89 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.333 1.453 . . . . 0.0 108.476 -162.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.62 20.49 63.77 Favored Glycine 0 N--CA 1.474 1.229 0 O-C-N 123.084 0.24 . . . . 0.0 112.625 -176.029 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 157.04 -160.71 30.62 Favored Glycine 0 C--N 1.34 0.8 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 177.809 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.706 ' HA3' ' HB2' ' A' ' 232' ' ' SER . . . -98.75 -175.81 32.31 Favored Glycine 0 C--N 1.346 1.119 0 CA-C-N 117.348 0.574 . . . . 0.0 111.732 171.575 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 144' ' ' TRP . . . . . 0.581 ' CD1' ' HA ' ' A' ' 229' ' ' THR . 47.6 t-105 -61.78 107.64 0.87 Allowed 'General case' 0 C--N 1.352 0.707 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 167.828 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 38.6 ttpt -150.52 112.16 4.48 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-O 121.197 0.523 . . . . 0.0 110.791 -172.201 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 146' ' ' LEU . . . . . . . . . . . . . 1.6 pp -146.19 -2.37 0.7 Allowed 'General case' 0 N--CA 1.48 1.036 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.728 169.877 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 79.44 -22.86 0.26 Allowed 'General case' 0 N--CA 1.484 1.232 0 C-N-CA 126.108 1.763 . . . . 0.0 113.338 166.795 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -70.11 157.51 53.51 Favored Glycine 0 C--N 1.355 1.59 0 CA-C-N 118.055 0.389 . . . . 0.0 112.842 -175.149 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -141.12 154.05 45.7 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.097 0.559 . . . . 0.0 110.093 -173.026 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 150' ' ' TRP . . . . . 0.553 ' HB2' HG13 ' A' ' 208' ' ' VAL . 25.7 t90 -68.81 133.78 48.8 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 122.712 0.405 . . . . 0.0 110.107 169.709 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 60.2 tttm -86.33 97.5 10.45 Favored 'General case' 0 CA--C 1.549 0.921 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 171.246 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -59.06 109.91 0.94 Allowed 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 124.548 1.139 . . . . 0.0 112.144 -170.86 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 123.39 -9.24 8.83 Favored Glycine 0 N--CA 1.475 1.253 0 CA-C-N 115.764 -0.653 . . . . 0.0 112.056 -175.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 154' ' ' GLU . . . . . 0.477 ' HB3' ' HE3' ' A' ' 203' ' ' LYS . 62.3 mm-40 -101.17 163.25 12.37 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 123.424 0.689 . . . . 0.0 110.256 174.36 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 13.2 mp0 -82.57 146.2 29.3 Favored 'General case' 0 N--CA 1.477 0.919 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 172.071 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 29.6 m -89.8 140.55 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.558 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 10.4 mm100 -99.66 128.26 45.76 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 178.293 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.506 ' HA ' HG22 ' A' ' 200' ' ' ILE . 58.0 t -98.97 103.18 14.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 -176.709 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -80.8 72.57 7.78 Favored 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 106.946 -1.501 . . . . 0.0 106.946 178.084 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -77.13 130.01 36.77 Favored 'General case' 0 C--N 1.343 0.321 0 CA-C-N 113.496 -1.684 . . . . 0.0 110.647 -173.671 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 161' ' ' LEU . . . . . 0.667 HD11 ' HB1' ' A' ' 83' ' ' ALA . 45.6 mt -95.93 108.91 21.33 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 177.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 57.9 mt-10 -90.26 115.29 63.7 Favored Pre-proline 0 CA--C 1.544 0.728 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 167.499 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 163' ' ' PRO . . . . . 0.555 ' HB3' HE22 ' A' ' 96' ' ' GLN . 35.5 Cg_exo -61.55 116.05 3.17 Favored 'Trans proline' 0 C--N 1.372 1.811 0 C-N-CA 123.41 2.74 . . . . 0.0 112.259 -176.71 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 109.53 -23.72 21.69 Favored Glycine 0 C--N 1.341 0.851 0 CA-C-N 115.518 -0.765 . . . . 0.0 112.203 -176.035 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 11.8 mmpt? -105.76 173.94 6.1 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 123.902 0.881 . . . . 0.0 111.532 -172.11 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 12.4 p30 -67.77 161.84 63.13 Favored Pre-proline 0 CA--C 1.558 1.287 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.021 168.573 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_exo -56.83 138.85 87.36 Favored 'Trans proline' 0 C--N 1.378 2.114 0 C-N-CA 122.968 2.445 . . . . 0.0 111.979 172.05 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 17.1 mmt85 -121.28 97.7 5.64 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 123.681 0.792 . . . . 0.0 109.692 -171.86 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -79.24 132.72 36.59 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 175.489 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.494 ' HB ' ' HB ' ' A' ' 158' ' ' VAL . 95.5 t -129.8 122.06 53.84 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.163 0 C-N-CA 123.196 0.599 . . . . 0.0 110.266 -178.478 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 171' ' ' GLN . . . . . 0.525 ' HB2' ' HB1' ' A' ' 20' ' ' ALA . 11.5 tt0 -80.82 110.58 16.47 Favored 'General case' 0 N--CA 1.48 1.03 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 -179.867 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 6.9 m -126.73 137.22 53.22 Favored 'General case' 0 C--O 1.238 0.499 0 CA-C-O 121.023 0.44 . . . . 0.0 109.954 -179.563 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 173' ' ' LYS . . . . . 0.474 ' H ' ' HA3' ' A' ' 24' ' ' GLY . 47.3 mttp -83.17 153.62 66.36 Favored Pre-proline 0 C--O 1.246 0.883 0 C-N-CA 124.115 0.966 . . . . 0.0 108.981 177.555 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 174' ' ' PRO . . . . . 0.489 ' HA ' ' O ' ' A' ' 186' ' ' ALA . 87.3 Cg_exo -49.73 125.99 15.47 Favored 'Trans proline' 0 C--N 1.381 2.252 0 C-N-CA 122.914 2.41 . . . . 0.0 113.36 179.627 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 175' ' ' GLY . . . . . 0.543 ' H ' ' C ' ' A' ' 186' ' ' ALA . . . -141.11 131.76 5.04 Favored Glycine 0 CA--C 1.541 1.662 0 CA-C-O 122.292 0.94 . . . . 0.0 114.616 178.444 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.579 HD12 ' HB ' ' A' ' 183' ' ' THR . 0.6 OUTLIER -139.31 155.09 47.95 Favored 'General case' 0 C--O 1.242 0.705 0 O-C-N 121.714 -0.874 . . . . 0.0 111.493 -170.292 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 177' ' ' PHE . . . . . 0.429 ' HZ ' ' HB2' ' A' ' 225' ' ' ALA . 3.1 p90 -124.13 139.32 54.04 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 113.696 -1.593 . . . . 0.0 109.781 -175.546 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 3.5 ttpm? -85.01 121.36 27.69 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 124.407 1.083 . . . . 0.0 110.167 -173.376 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 77.8 p -117.78 170.61 8.65 Favored 'General case' 0 C--O 1.243 0.731 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 164.905 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 10.5 t30 -66.21 -26.66 67.49 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 123.072 0.549 . . . . 0.0 109.91 173.807 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -68.76 -33.66 74.27 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 123.971 0.908 . . . . 0.0 111.055 173.178 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 150.66 172.43 19.81 Favored Glycine 0 C--N 1.35 1.323 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.341 175.325 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 183' ' ' THR . . . . . 0.579 ' HB ' HD12 ' A' ' 176' ' ' LEU . 44.5 p -75.83 95.8 3.56 Favored 'General case' 0 CA--C 1.545 0.782 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 174.723 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 20.3 pt -107.76 141.11 23.83 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 124.292 1.037 . . . . 0.0 110.378 -170.628 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 185' ' ' GLY . . . . . 0.613 ' HA2' ' HA ' ' A' ' 225' ' ' ALA . . . 115.92 173.61 17.35 Favored Glycine 0 N--CA 1.476 1.351 0 CA-C-O 119.432 -0.649 . . . . 0.0 112.612 -178.593 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.543 ' C ' ' H ' ' A' ' 175' ' ' GLY . . . -175.55 40.58 0.01 OUTLIER 'General case' 0 C--O 1.206 -1.225 0 C-N-CA 123.328 0.651 . . . . 0.0 109.882 178.836 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 187' ' ' VAL . . . . . 0.561 HG13 ' HB3' ' A' ' 224' ' ' SER . 2.4 p -164.39 100.42 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.552 1.036 0 O-C-N 120.412 -1.43 . . . . 0.0 108.893 172.857 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 188' ' ' SER . . . . . 0.433 ' O ' ' HA2' ' A' ' 24' ' ' GLY . 80.3 p -118.13 125.67 50.71 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 123.17 0.588 . . . . 0.0 110.266 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 3.6 pp -150.73 -177.81 6.2 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-O 121.095 0.474 . . . . 0.0 110.958 176.773 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -138.8 103.42 4.82 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 166.749 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 191' ' ' PHE . . . . . . . . . . . . . 29.9 t80 -168.15 -179.61 4.15 Favored 'General case' 0 N--CA 1.486 1.326 0 C-N-CA 122.787 0.435 . . . . 0.0 109.934 -172.256 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 36.6 m -49.05 117.93 7.0 Favored Pre-proline 0 CA--C 1.554 1.125 0 C-N-CA 124.656 1.183 . . . . 0.0 111.585 175.259 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -69.2 99.79 0.71 Allowed 'Trans proline' 0 C--N 1.378 2.09 0 C-N-CA 122.421 2.081 . . . . 0.0 112.111 -179.347 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -60.93 130.94 48.4 Favored Glycine 0 C--N 1.348 1.22 0 N-CA-C 110.589 -1.005 . . . . 0.0 110.589 170.104 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 195' ' ' THR . . . . . 0.451 HG22 ' O ' ' A' ' 161' ' ' LEU . 12.6 t -59.45 140.37 56.25 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 123.202 0.601 . . . . 0.0 112.004 -169.811 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -69.47 104.08 2.21 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 123.961 0.904 . . . . 0.0 110.826 -165.026 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 197' ' ' GLY . . . . . 0.487 ' HA2' HD11 ' A' ' 210' ' ' LEU . . . 135.66 -7.2 4.22 Favored Glycine 0 C--O 1.24 0.525 0 CA-C-N 115.097 -0.956 . . . . 0.0 111.384 -172.526 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 69.6 m -60.99 124.93 82.28 Favored Pre-proline 0 CA--C 1.548 0.897 0 C-N-CA 123.802 0.841 . . . . 0.0 109.554 169.661 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 199' ' ' PRO . . . . . 0.599 ' HG3' ' HB ' ' A' ' 101' ' ' VAL . 2.9 Cg_exo -73.13 153.52 51.78 Favored 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 122.409 2.073 . . . . 0.0 111.553 -177.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 200' ' ' ILE . . . . . 0.506 HG22 ' HA ' ' A' ' 158' ' ' VAL . 9.7 pt -108.54 129.4 63.05 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 169.084 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 201' ' ' ILE . . . . . 0.438 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 66.4 mt -115.29 152.89 16.88 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.912 0 C-N-CA 125.165 1.386 . . . . 0.0 108.187 -178.252 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -84.9 162.03 19.62 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 175.139 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 203' ' ' LYS . . . . . 0.477 ' HE3' ' HB3' ' A' ' 154' ' ' GLU . 18.5 ptpt -61.98 -24.07 66.79 Favored 'General case' 0 N--CA 1.482 1.154 0 C-N-CA 123.316 0.646 . . . . 0.0 111.765 179.283 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 50.5 tttp -69.48 -21.62 63.69 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 124.012 0.925 . . . . 0.0 111.33 179.567 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 109.14 -12.61 34.06 Favored Glycine 0 C--N 1.349 1.269 0 CA-C-N 116.188 -0.46 . . . . 0.0 113.082 179.351 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 44.7 mmtm -88.51 138.98 30.94 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 177.505 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.438 ' HA ' ' HA ' ' A' ' 201' ' ' ILE . 21.4 t -63.36 151.08 8.86 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.936 0 C-N-CA 123.566 0.746 . . . . 0.0 110.867 -176.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 208' ' ' VAL . . . . . 0.553 HG13 ' HB2' ' A' ' 150' ' ' TRP . 54.8 t -100.35 -52.48 8.65 Favored 'Isoleucine or valine' 0 C--O 1.241 0.656 0 C-N-CA 124.415 1.086 . . . . 0.0 109.02 173.083 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 209' ' ' GLY . . . . . . . . . . . . . . . 171.35 -121.79 0.92 Allowed Glycine 0 C--N 1.345 1.053 0 CA-C-N 114.582 -1.19 . . . . 0.0 111.495 -176.248 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 210' ' ' LEU . . . . . 0.544 ' HB2' ' CH2' ' A' ' 144' ' ' TRP . 9.0 tt -142.03 139.6 32.38 Favored 'General case' 0 CA--C 1.549 0.926 0 CA-C-N 117.481 0.641 . . . . 0.0 110.426 -175.842 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 79.5 t80 -71.64 109.31 5.48 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 123.922 0.889 . . . . 0.0 108.807 174.126 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -76.79 -138.74 0.92 Allowed Glycine 0 C--N 1.34 0.776 0 O-C-N 123.632 0.583 . . . . 0.0 114.455 -170.115 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 213' ' ' ASN . . . . . . . . . . . . . 81.0 m-20 -74.74 85.47 2.16 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 123.294 0.638 . . . . 0.0 109.93 -176.028 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . -72.32 73.22 0.92 Allowed Glycine 0 C--N 1.355 1.593 0 C-N-CA 123.69 0.662 . . . . 0.0 111.571 175.213 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 215' ' ' VAL . . . . . 0.704 ' HA ' ' HD3' ' B' ' 253' ' ' LYS . 54.7 t -84.37 147.24 5.8 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 C-N-CA 123.282 0.633 . . . . 0.0 111.1 -170.128 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 216' ' ' VAL . . . . . 0.518 ' HB ' ' HA2' ' A' ' 220' ' ' GLY . 14.7 m -68.34 111.95 3.0 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.109 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 165.873 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 217' ' ' THR . . . . . 0.587 HG23 HD13 ' A' ' 29' ' ' LEU . 13.5 t -125.09 159.89 30.36 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 122.686 0.394 . . . . 0.0 110.977 -179.043 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 218' ' ' ARG . . . . . 0.635 ' HB2' HD21 ' A' ' 29' ' ' LEU . 65.0 ttt180 66.45 -74.25 0.06 Allowed 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 124.924 1.289 . . . . 0.0 109.799 -170.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 16.6 p -131.3 -36.89 1.27 Allowed 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 124.02 0.928 . . . . 0.0 109.903 175.873 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 220' ' ' GLY . . . . . 0.518 ' HA2' ' HB ' ' A' ' 216' ' ' VAL . . . -176.78 11.83 0.03 OUTLIER Glycine 0 C--N 1.358 1.781 0 CA-C-O 119.341 -0.699 . . . . 0.0 114.64 -178.103 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 221' ' ' ALA . . . . . 0.47 ' O ' HG22 ' A' ' 217' ' ' THR . . . -70.95 119.23 14.76 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 117.664 0.732 . . . . 0.0 109.939 -175.917 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 222' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -76.92 95.69 4.17 Favored 'General case' 0 N--CA 1.473 0.71 0 CA-C-O 121.64 0.733 . . . . 0.0 109.975 -177.636 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 96.5 t -116.67 135.88 55.56 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.092 -179.26 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 224' ' ' SER . . . . . 0.561 ' HB3' HG13 ' A' ' 187' ' ' VAL . 35.2 t -131.18 155.74 46.53 Favored 'General case' 0 C--O 1.243 0.752 0 C-N-CA 124.324 1.05 . . . . 0.0 111.102 -164.73 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 225' ' ' ALA . . . . . 0.613 ' HA ' ' HA2' ' A' ' 185' ' ' GLY . . . -97.49 121.27 39.2 Favored 'General case' 0 N--CA 1.467 0.388 0 C-N-CA 123.76 0.824 . . . . 0.0 109.319 174.818 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 226' ' ' ILE . . . . . 0.439 HG23 HD11 ' A' ' 200' ' ' ILE . 7.1 mt -64.77 114.18 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 CA-C-O 120.857 0.36 . . . . 0.0 110.501 174.451 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 227' ' ' ALA . . . . . 0.506 ' HB1' HD11 ' A' ' 137' ' ' LEU . . . -76.79 113.13 14.12 Favored 'General case' 0 C--O 1.239 0.501 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 168.444 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 228' ' ' GLN . . . . . 0.433 ' HG3' ' HG3' ' A' ' 230' ' ' GLU . 29.7 pt20 -93.39 156.24 16.9 Favored 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 123.782 0.833 . . . . 0.0 109.474 -174.36 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 229' ' ' THR . . . . . 0.581 ' HA ' ' CD1' ' A' ' 144' ' ' TRP . 40.7 m -80.11 107.43 12.89 Favored 'General case' 0 C--N 1.347 0.487 0 CA-C-O 121.605 0.717 . . . . 0.0 111.536 179.389 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 230' ' ' GLU . . . . . 0.433 ' HG3' ' HG3' ' A' ' 228' ' ' GLN . 40.5 mt-10 -125.22 88.42 2.88 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 107.049 -1.463 . . . . 0.0 107.049 171.433 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 231' ' ' LYS . . . . . 0.449 ' HA ' ' O ' ' A' ' 144' ' ' TRP . 54.6 pttt -57.73 107.92 0.51 Allowed 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.329 -178.64 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 232' ' ' SER . . . . . 0.706 ' HB2' ' HA3' ' A' ' 143' ' ' GLY . 13.9 m -80.79 91.91 6.0 Favored 'General case' 0 C--O 1.239 0.527 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 -175.401 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 233' ' ' ILE . . . . . . . . . . . . . 6.6 tt -137.62 99.15 1.61 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.721 0 C-N-CA 124.588 1.155 . . . . 0.0 108.062 -176.66 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 234' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -90.3 35.94 0.87 Allowed 'General case' 0 N--CA 1.478 0.957 0 CA-C-N 114.859 -1.064 . . . . 0.0 111.156 -176.361 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 13.6 p-10 -58.34 -35.04 71.32 Favored 'General case' 0 N--CA 1.479 0.983 0 C-N-CA 124.062 0.945 . . . . 0.0 110.029 175.177 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 236' ' ' ASN . . . . . . . . . . . . . 50.0 m-80 -113.68 106.35 53.97 Favored Pre-proline 0 CA--C 1.537 0.459 0 CA-C-N 114.594 -1.185 . . . . 0.0 107.84 165.335 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -60.7 -49.99 7.53 Favored 'Trans proline' 0 C--N 1.374 1.912 0 C-N-CA 122.125 1.884 . . . . 0.0 110.009 167.362 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 238' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 -136.42 145.49 45.34 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 125.239 1.415 . . . . 0.0 107.769 173.529 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 239' ' ' ILE . . . . . . . . . . . . . 12.9 tt -154.18 70.53 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 CA-C-O 122.886 1.327 . . . . 0.0 108.549 175.722 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 . . . . . 0 C--O 1.247 0.956 0 CA-C-N 114.59 -1.186 . . . . 0.0 108.781 -174.069 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 251' ' ' BEZ . . . . . 0.472 ' H6 ' HG21 ' A' ' 216' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 253' ' ' LYS . . . . . 0.704 ' HD3' ' HA ' ' A' ' 215' ' ' VAL . 54.0 pttt -67.0 146.1 54.71 Favored 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 124.02 0.928 . . . . 0.0 111.625 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 254' ' ' ARG . . . . . 0.462 ' HA ' ' HB3' ' A' ' 47' ' ' GLU . 22.5 mtm-85 -84.87 24.82 1.0 Allowed 'General case' 0 N--CA 1.489 1.48 0 C-N-CA 123.943 0.897 . . . . 0.0 110.925 171.204 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 255' ' ' M9P . . . . . 0.423 ' NH1' ' HG2' ' A' ' 46' ' ' GLU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.678 0 N-CA-C 112.288 -0.325 . . . . 0.0 112.288 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.534 ' HB3' ' HB2' ' A' ' 117' ' ' ALA . 42.9 t -167.73 -62.73 0.03 OUTLIER 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 123.922 0.889 . . . . 0.0 110.061 177.823 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -165.22 -170.96 2.04 Favored 'General case' 0 N--CA 1.482 1.143 0 C-N-CA 124.233 1.013 . . . . 0.0 110.169 -178.068 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -155.9 47.42 0.49 Allowed 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 124.246 1.018 . . . . 0.0 108.356 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 22.3 m-20 -144.33 -18.38 0.55 Allowed 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 113.229 0.826 . . . . 0.0 113.229 -158.478 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.659 ' HB2' ' HG ' ' A' ' 119' ' ' LEU . 1.9 mt -75.88 92.12 3.06 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 118.143 0.429 . . . . 0.0 111.124 -158.436 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -77.2 141.06 40.25 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.969 0.89 . . . . 0.0 111.575 -174.677 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.475 ' HB3' ' CE2' ' A' ' 84' ' ' TYR . 11.3 mp -83.69 115.38 22.15 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 113.587 -1.642 . . . . 0.0 107.586 175.416 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -111.6 126.37 54.93 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 108.374 -0.972 . . . . 0.0 108.374 179.37 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.617 HH22 ' HB3' ' A' ' 13' ' ' ASP . 60.8 ttt85 -75.03 129.19 37.2 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 120.527 0.203 . . . . 0.0 110.539 -177.469 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.474 ' HB2' ' HG3' ' A' ' 85' ' ' ARG . . . -104.23 -35.07 8.13 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 123.177 0.591 . . . . 0.0 109.96 175.149 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -177.72 -160.95 0.05 Allowed 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 124.421 1.088 . . . . 0.0 110.59 -175.218 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.617 ' HB3' HH22 ' A' ' 10' ' ' ARG . 6.8 p-10 -126.56 170.03 12.46 Favored 'General case' 0 N--CA 1.476 0.87 0 C-N-CA 124.149 0.98 . . . . 0.0 109.847 171.568 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 60.2 t -73.66 104.4 2.5 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.861 -177.414 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 59.2 pttt -164.81 146.29 7.94 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 124.278 1.031 . . . . 0.0 108.804 -178.464 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 24.7 t90 -84.11 113.92 21.4 Favored 'General case' 0 CA--C 1.544 0.713 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 177.395 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 38.2 mm-40 -67.89 147.11 52.94 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 123.557 0.743 . . . . 0.0 111.54 174.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -70.44 -2.46 13.9 Favored 'General case' 0 CA--C 1.556 1.18 0 C-N-CA 125.153 1.381 . . . . 0.0 111.807 175.593 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLN . . . . . 0.559 ' HB2' ' H ' ' A' ' 169' ' ' ALA . 12.9 mm100 -80.14 14.11 2.02 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 124.532 1.133 . . . . 0.0 112.585 -174.355 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -53.89 100.32 0.03 OUTLIER 'General case' 0 C--N 1.364 1.196 0 C-N-CA 124.605 1.162 . . . . 0.0 112.92 -168.743 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.6 mm-40 -82.74 121.88 27.45 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.165 179.294 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 3.6 mp -78.62 103.5 5.66 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.807 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 63.5 m -142.64 -171.59 3.46 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 125.403 1.481 . . . . 0.0 107.2 174.163 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.427 ' HA3' ' H ' ' A' ' 173' ' ' LYS . . . 133.67 148.66 5.9 Favored Glycine 0 N--CA 1.468 0.828 0 N-CA-C 114.887 0.715 . . . . 0.0 114.887 169.37 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.496 ' HB2' ' HB2' ' A' ' 173' ' ' LYS . 15.4 t 65.57 97.98 0.05 OUTLIER 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 125.07 1.348 . . . . 0.0 111.733 173.317 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 15.6 m -111.29 160.96 27.27 Favored Pre-proline 0 CA--C 1.553 1.069 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 169.291 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -57.28 158.59 18.05 Favored 'Trans proline' 0 C--N 1.384 2.418 0 C-N-CA 122.715 2.277 . . . . 0.0 113.074 -176.684 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 35.5 mm -57.74 120.87 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 123.63 0.772 . . . . 0.0 110.334 -177.901 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.517 HD23 ' HE1' ' A' ' 177' ' ' PHE . 38.1 tp -98.85 143.12 29.53 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 115.096 -0.957 . . . . 0.0 110.145 -170.343 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 50.4 m -123.06 116.46 23.54 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 122.872 0.469 . . . . 0.0 109.766 -175.789 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 14.4 pt -138.29 173.48 12.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 C-N-CA 124.149 0.98 . . . . 0.0 110.155 178.475 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 36.4 p -93.85 125.26 38.37 Favored 'General case' 0 C--N 1.353 0.736 0 C-N-CA 122.787 0.435 . . . . 0.0 109.92 -173.769 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 10.6 tp -65.15 128.55 28.07 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.001 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 170.058 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 24.8 t -108.47 103.61 12.78 Favored 'General case' 0 C--O 1.267 2.005 0 CA-C-O 121.437 0.637 . . . . 0.0 109.567 -176.251 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 68.26 -79.57 0.04 OUTLIER 'General case' 0 C--N 1.357 0.914 0 CA-C-N 113.179 -1.828 . . . . 0.0 111.282 176.863 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -144.37 -72.84 0.27 Allowed 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.873 0.869 . . . . 0.0 109.26 -177.799 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -97.95 4.95 61.32 Favored Glycine 0 C--N 1.347 1.171 0 CA-C-O 118.812 -0.993 . . . . 0.0 114.227 -174.325 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 35.8 t -107.04 164.33 12.24 Favored 'General case' 0 C--N 1.359 1.021 0 CA-C-N 119.026 1.413 . . . . 0.0 107.967 172.405 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' MET . . . . . 0.437 ' HE1' ' CE2' ' A' ' 177' ' ' PHE . 39.7 ttp -164.24 126.47 2.36 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 178.85 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.466 ' HA ' HG11 ' A' ' 215' ' ' VAL . 68.3 m -150.95 -178.91 6.87 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 123.53 0.732 . . . . 0.0 110.968 -173.947 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.796 HD11 HG22 ' A' ' 217' ' ' THR . 2.3 mp -83.95 97.88 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 N-CA-C 105.729 -1.952 . . . . 0.0 105.729 163.255 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 13.2 mptt 57.64 -86.24 0.02 OUTLIER 'General case' 0 CA--C 1.55 0.952 0 C-N-CA 124.139 0.976 . . . . 0.0 108.731 -165.226 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 8.7 t30 -140.54 140.05 35.15 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 123.553 0.741 . . . . 0.0 109.318 172.001 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -154.86 121.64 5.45 Favored 'General case' 0 CA--C 1.537 0.458 0 N-CA-C 106.406 -1.702 . . . . 0.0 106.406 179.204 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.3 tp10 -163.09 136.28 5.7 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 122.836 0.454 . . . . 0.0 110.33 -177.067 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -143.31 135.54 27.05 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 123.336 0.654 . . . . 0.0 110.987 179.563 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 28.7 mm-40 -80.43 93.85 6.08 Favored 'General case' 0 C--O 1.243 0.719 0 C-N-CA 123.628 0.771 . . . . 0.0 109.454 169.193 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 51.8 tt0 -76.26 150.45 36.99 Favored 'General case' 0 N--CA 1.475 0.796 0 N-CA-C 109.114 -0.698 . . . . 0.0 109.114 174.814 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 95.0 m -147.08 124.47 11.62 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 123.142 0.577 . . . . 0.0 109.947 179.553 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.455 HD23 ' HB2' ' A' ' 163' ' ' PRO . 61.0 tp -164.41 -70.12 0.04 OUTLIER 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 175.207 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 70.1 -133.3 24.31 Favored Glycine 0 CA--C 1.531 1.058 0 CA-C-N 115.388 -0.824 . . . . 0.0 112.929 -175.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 155.26 -24.81 0.6 Allowed Glycine 0 C--N 1.348 1.241 0 C-N-CA 122.941 0.305 . . . . 0.0 113.285 177.254 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -77.12 79.15 1.35 Allowed Glycine 0 C--N 1.341 0.831 0 C-N-CA 123.68 0.657 . . . . 0.0 112.755 -179.254 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 62.44 -157.92 36.39 Favored Glycine 0 C--N 1.351 1.406 0 O-C-N 124.103 0.531 . . . . 0.0 112.811 -177.429 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 25.7 t -143.77 39.74 1.38 Allowed 'General case' 0 N--CA 1.476 0.869 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 176.464 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 80.1 -69.22 3.14 Favored Glycine 0 C--N 1.352 1.454 0 CA-C-N 115.405 -0.816 . . . . 0.0 113.522 173.514 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -65.37 98.55 0.33 Allowed Glycine 0 C--N 1.348 1.231 0 O-C-N 124.089 0.523 . . . . 0.0 113.243 -178.82 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.574 ' HA3' ' HB3' ' A' ' 62' ' ' ALA . . . 149.44 -29.2 1.19 Allowed Glycine 0 N--CA 1.466 0.68 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 -173.55 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 68.91 -84.72 0.21 Allowed Glycine 0 C--N 1.355 1.637 0 O-C-N 124.455 0.738 . . . . 0.0 113.776 169.45 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.418 ' HA ' ' HE2' ' A' ' 122' ' ' LYS . 13.7 mt-10 -82.73 -26.46 31.93 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.268 0.627 . . . . 0.0 110.74 -179.655 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -98.75 -65.25 0.97 Allowed 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 123.712 0.805 . . . . 0.0 109.87 -175.831 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.574 ' HB3' ' HA3' ' A' ' 58' ' ' GLY . . . -97.2 48.03 1.04 Allowed 'General case' 0 N--CA 1.481 1.107 0 CA-C-O 121.559 0.695 . . . . 0.0 110.813 179.679 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -149.8 -105.66 0.34 Allowed Glycine 0 C--N 1.338 0.663 0 N-CA-C 109.239 -1.545 . . . . 0.0 109.239 174.507 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.772 HG23 ' HB2' ' A' ' 122' ' ' LYS . 2.4 m -140.75 -166.41 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 C-N-CA 123.803 0.841 . . . . 0.0 109.201 172.214 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.468 HD22 ' HE3' ' A' ' 122' ' ' LYS . 2.1 tm? -145.53 132.56 20.31 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 107.656 -1.238 . . . . 0.0 107.656 -178.21 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' TRP . . . . . 0.628 ' HE1' ' HB3' ' A' ' 122' ' ' LYS . 1.1 m0 -89.92 109.3 20.33 Favored 'General case' 0 C--N 1.361 1.072 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 174.563 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -69.48 109.53 4.28 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 171.275 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 18.3 m -125.63 160.75 54.47 Favored Pre-proline 0 N--CA 1.479 1.0 0 C-N-CA 123.277 0.631 . . . . 0.0 110.52 -173.945 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -64.84 163.59 27.53 Favored 'Trans proline' 0 C--N 1.375 1.933 0 C-N-CA 122.373 2.049 . . . . 0.0 112.61 174.037 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 56.8 p -103.85 160.46 26.02 Favored Pre-proline 0 CA--C 1.557 1.249 0 C-N-CA 123.778 0.831 . . . . 0.0 109.821 178.226 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_endo -43.66 -35.36 6.33 Favored 'Trans proline' 0 CA--C 1.575 2.567 0 C-N-CA 124.722 3.614 . . . . 0.0 117.224 176.506 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_exo -48.35 152.1 4.06 Favored 'Trans proline' 0 C--N 1.402 3.348 0 C-N-CA 122.289 1.993 . . . . 0.0 113.968 165.239 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_exo -59.3 83.15 0.06 OUTLIER 'Trans proline' 0 C--N 1.383 2.385 0 C-N-CA 123.348 2.699 . . . . 0.0 114.009 -177.156 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 5.7 m -141.53 -174.33 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 C-N-CA 125.326 1.45 . . . . 0.0 109.073 174.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 122.32 49.55 0.25 Allowed Glycine 0 C--N 1.349 1.273 0 N-CA-C 111.343 -0.703 . . . . 0.0 111.343 -177.279 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 17.6 pttp -82.39 -62.49 1.6 Allowed 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 123.423 0.689 . . . . 0.0 111.696 -169.83 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -174.38 19.26 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.244 0 C-N-CA 124.002 0.921 . . . . 0.0 110.25 -173.777 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -91.66 12.67 20.37 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 124.538 1.135 . . . . 0.0 111.514 -172.635 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.673 HD11 ' HA2' ' A' ' 105' ' ' GLY . 0.3 OUTLIER -73.72 67.94 1.2 Allowed 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 124.362 1.065 . . . . 0.0 112.43 -173.963 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 11.9 tp10 52.96 77.87 0.15 Allowed 'General case' 0 C--O 1.244 0.765 0 C-N-CA 125.35 1.46 . . . . 0.0 112.366 176.43 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.514 ' HB2' ' HA ' ' A' ' 103' ' ' LYS . 8.2 p-10 -119.87 146.76 45.45 Favored 'General case' 0 C--O 1.245 0.861 0 CA-C-N 114.633 -1.167 . . . . 0.0 109.579 -179.268 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 159.52 -163.73 33.66 Favored Glycine 0 C--N 1.343 0.917 0 CA-C-N 116.031 -0.531 . . . . 0.0 113.396 178.536 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ALA . . . . . 0.431 ' HB1' HD21 ' A' ' 161' ' ' LEU . . . -89.84 123.99 34.29 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 124.137 0.975 . . . . 0.0 109.232 -177.451 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' TYR . . . . . 0.475 ' CE2' ' HB3' ' A' ' 8' ' ' LEU . 4.0 m-85 -126.09 151.38 47.29 Favored 'General case' 0 N--CA 1.48 1.034 0 C-N-CA 123.723 0.809 . . . . 0.0 112.09 -166.566 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' ARG . . . . . 0.476 ' HA ' ' HA ' ' A' ' 99' ' ' ALA . 25.3 mtm180 -113.71 131.02 56.33 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 124.817 1.247 . . . . 0.0 107.897 167.371 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 25.7 mt -94.33 124.55 46.85 Favored 'Isoleucine or valine' 0 C--O 1.249 1.048 0 CA-C-O 121.684 0.754 . . . . 0.0 110.513 -179.401 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.482 ' HD3' ' HB3' ' A' ' 94' ' ' TYR . 1.7 ttmp? -105.72 136.68 44.88 Favored 'General case' 0 C--O 1.213 -0.816 0 C-N-CA 126.114 1.766 . . . . 0.0 108.305 177.599 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 22.9 tm0? -83.07 106.98 15.33 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 104.435 -2.431 . . . . 0.0 104.435 166.69 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 1.9 tmtp? -118.49 95.21 4.77 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-N 114.975 -1.011 . . . . 0.0 108.298 -166.577 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -82.48 150.52 28.53 Favored Glycine 0 C--O 1.248 1.012 0 N-CA-C 108.911 -1.675 . . . . 0.0 108.911 166.562 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 16.1 mm -80.2 59.63 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.265 0 CA-C-O 121.614 0.721 . . . . 0.0 109.07 -177.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 4.6 pp 168.55 -20.59 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 126.331 1.853 . . . . 0.0 110.433 -173.662 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -157.36 145.51 12.08 Favored Glycine 0 C--N 1.37 2.462 0 CA-C-O 119.841 -0.422 . . . . 0.0 113.239 -174.703 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' TYR . . . . . 0.482 ' HB3' ' HD3' ' A' ' 87' ' ' LYS . 28.3 m-85 -130.56 147.67 52.27 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-N 117.434 0.617 . . . . 0.0 111.192 -171.177 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 25.1 t -151.18 149.83 29.92 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 123.806 0.843 . . . . 0.0 109.447 175.2 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' GLN . . . . . . . . . . . . . 22.2 tp60 -94.83 111.22 23.01 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 108.858 -0.794 . . . . 0.0 108.858 177.9 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.444 HD11 ' HB3' ' A' ' 6' ' ' LEU . 28.6 pt -106.33 -16.86 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 N-CA-C 113.375 0.88 . . . . 0.0 113.375 -173.222 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 170.35 -146.32 9.76 Favored Glycine 0 N--CA 1.472 1.044 0 C-N-CA 120.453 -0.879 . . . . 0.0 113.193 173.604 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.476 ' HA ' ' HA ' ' A' ' 85' ' ' ARG . . . -149.32 176.36 10.62 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 123.684 0.794 . . . . 0.0 110.787 177.904 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -166.81 -170.52 31.81 Favored Glycine 0 C--N 1.344 1.02 0 N-CA-C 111.368 -0.693 . . . . 0.0 111.368 178.12 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 6.2 p -142.83 117.4 4.34 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.728 0 C-N-CA 124.034 0.934 . . . . 0.0 109.278 178.432 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 3.0 t80 -88.5 136.71 32.86 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 171.313 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.514 ' HA ' ' HB2' ' A' ' 81' ' ' ASP . 17.2 tptp -160.12 153.47 22.14 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 110.41 -0.219 . . . . 0.0 110.41 177.244 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 71.52 -85.47 0.03 OUTLIER 'General case' 0 CA--C 1.55 0.981 0 C-N-CA 124.868 1.267 . . . . 0.0 110.576 169.651 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' GLY . . . . . 0.673 ' HA2' HD11 ' A' ' 79' ' ' LEU . . . -155.88 24.81 0.56 Allowed Glycine 0 N--CA 1.469 0.889 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 174.947 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' THR . . . . . 0.746 HG22 ' HA3' ' A' ' 141' ' ' GLY . 7.0 p -147.03 151.75 37.45 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.377 1.071 . . . . 0.0 110.011 -167.865 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 107' ' ' PHE . . . . . 0.518 ' HB3' ' HB3' ' A' ' 140' ' ' TYR . 31.4 t80 -104.63 139.16 39.88 Favored 'General case' 0 N--CA 1.484 1.235 0 N-CA-C 108.031 -1.099 . . . . 0.0 108.031 174.02 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' HIS . . . . . 0.436 ' HB3' ' CZ3' ' A' ' 144' ' ' TRP . 78.0 m-70 -132.35 113.58 13.36 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 123.549 0.74 . . . . 0.0 110.173 -175.555 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 9.0 t -136.47 -177.8 4.88 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 122.761 0.424 . . . . 0.0 110.673 177.495 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' MET . . . . . 0.506 ' SD ' ' HE1' ' A' ' 112' ' ' HIS . 3.3 mtp -89.52 152.42 21.44 Favored 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 123.677 0.791 . . . . 0.0 110.195 178.656 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 53.9 t90 -73.45 -39.13 65.2 Favored 'General case' 0 CA--C 1.542 0.642 0 O-C-N 123.634 0.584 . . . . 0.0 110.365 -175.848 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' HIS . . . . . 0.506 ' HE1' ' SD ' ' A' ' 110' ' ' MET . 18.6 p-80 -65.87 -8.39 21.76 Favored 'General case' 0 N--CA 1.49 1.555 0 C-N-CA 124.474 1.11 . . . . 0.0 113.087 -172.665 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 95.1 t -58.08 -37.97 64.82 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.977 0 C-N-CA 123.366 0.666 . . . . 0.0 110.1 178.231 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.4 ' HB ' ' OG ' ' A' ' 2' ' ' SER . 17.5 p -147.78 -163.08 1.69 Allowed 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 124.448 1.099 . . . . 0.0 109.989 169.435 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.441 ' HB3' ' HB2' ' A' ' 2' ' ' SER . 17.8 tpp180 -90.83 5.23 49.26 Favored 'General case' 0 CA--C 1.559 1.296 0 C-N-CA 123.562 0.745 . . . . 0.0 111.152 176.248 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 107.1 63.49 0.59 Allowed Glycine 0 C--N 1.35 1.329 0 N-CA-C 111.799 -0.52 . . . . 0.0 111.799 -178.364 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' ALA . . . . . 0.591 ' HB3' HD11 ' A' ' 6' ' ' LEU . . . -95.33 168.39 10.75 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 123.811 0.844 . . . . 0.0 111.823 -179.363 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.42 HG23 ' HA ' ' A' ' 127' ' ' GLU . 14.9 p -86.5 141.41 14.44 Favored 'Isoleucine or valine' 0 C--O 1.245 0.845 0 N-CA-C 108.369 -0.975 . . . . 0.0 108.369 165.565 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.659 ' HG ' ' HB2' ' A' ' 6' ' ' LEU . 6.4 mp -102.03 174.62 5.85 Favored 'General case' 0 C--O 1.222 -0.35 0 C-N-CA 124.072 0.949 . . . . 0.0 111.291 -173.667 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 25.4 mmt -121.78 165.71 15.43 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 125.36 1.464 . . . . 0.0 108.752 177.194 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 50.6 t60 -170.03 97.44 0.28 Allowed 'General case' 0 C--O 1.246 0.879 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 166.435 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.772 ' HB2' HG23 ' A' ' 64' ' ' VAL . 49.1 tttm 56.87 37.63 28.92 Favored 'General case' 0 N--CA 1.489 1.483 0 CA-C-O 121.91 0.862 . . . . 0.0 110.889 173.358 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 101.38 -12.09 58.37 Favored Glycine 0 C--N 1.348 1.22 0 CA-C-O 119.135 -0.814 . . . . 0.0 114.349 177.007 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 53.4 mtpt -102.56 135.18 44.65 Favored 'General case' 0 N--CA 1.49 1.569 0 CA-C-N 118.155 0.977 . . . . 0.0 110.712 178.506 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' ARG . . . . . 0.434 ' HA ' ' O ' ' A' ' 119' ' ' LEU . 0.1 OUTLIER -85.21 122.79 29.9 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 123.196 0.599 . . . . 0.0 110.82 177.667 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.519 HG23 ' HB2' ' A' ' 140' ' ' TYR . 1.8 mp -87.13 100.07 9.38 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.917 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 172.606 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' GLU . . . . . 0.42 ' HA ' HG23 ' A' ' 118' ' ' VAL . 36.5 tt0 -92.42 104.63 11.61 Favored Pre-proline 0 CA--C 1.545 0.787 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.371 -177.735 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 12.9 Cg_exo -68.69 98.2 0.58 Allowed 'Trans proline' 0 C--N 1.374 1.905 0 C-N-CA 122.534 2.156 . . . . 0.0 112.195 -175.697 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 6.4 p -69.08 -24.66 64.17 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 123.797 0.839 . . . . 0.0 111.231 176.912 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.578 ' HB2' ' HA2' ' A' ' 142' ' ' GLY . 59.7 t-105 -107.32 138.43 43.52 Favored 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 108.712 -0.848 . . . . 0.0 108.712 171.334 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -155.35 120.89 4.99 Favored 'General case' 0 C--O 1.238 0.494 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 176.393 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -143.07 114.08 7.7 Favored 'General case' 0 CA--C 1.544 0.728 0 CA-C-O 120.879 0.371 . . . . 0.0 110.98 -178.099 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 14.2 p -77.45 -17.43 14.29 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.309 0 C-N-CA 124.219 1.008 . . . . 0.0 112.423 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 65.4 mttm -71.73 -45.52 61.5 Favored 'General case' 0 N--CA 1.485 1.306 0 C-N-CA 123.177 0.591 . . . . 0.0 110.735 -173.225 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' LYS . . . . . 0.599 ' HG2' ' HG2' ' A' ' 230' ' ' GLU . 4.6 mptp? -88.64 -10.06 49.92 Favored 'General case' 0 N--CA 1.477 0.898 0 C-N-CA 124.653 1.181 . . . . 0.0 109.897 174.876 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 56.1 t0 63.02 46.11 4.92 Favored 'General case' 0 C--N 1.36 1.037 0 O-C-N 124.549 1.156 . . . . 0.0 109.426 -177.124 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 96.2 mt -136.71 127.67 27.61 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.696 0.798 . . . . 0.0 110.392 -179.486 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 17.8 tt -124.14 136.81 59.18 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 175.773 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 80.5 p -148.58 146.0 28.07 Favored 'General case' 0 N--CA 1.475 0.796 0 CA-C-O 121.843 0.83 . . . . 0.0 113.146 -171.162 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.519 ' HB2' HG23 ' A' ' 126' ' ' ILE . 81.3 t80 -84.6 122.17 28.66 Favored 'General case' 0 N--CA 1.473 0.695 0 CA-C-N 114.446 -1.252 . . . . 0.0 108.396 172.601 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.746 ' HA3' HG22 ' A' ' 106' ' ' THR . . . 123.69 -82.47 0.35 Allowed Glycine 0 C--N 1.34 0.801 0 O-C-N 124.281 0.988 . . . . 0.0 111.637 177.676 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 142' ' ' GLY . . . . . 0.578 ' HA2' ' HB2' ' A' ' 130' ' ' TRP . . . 147.57 84.09 0.05 OUTLIER Glycine 0 C--O 1.24 0.495 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 172.683 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 146.94 176.34 20.62 Favored Glycine 0 C--O 1.241 0.565 0 N-CA-C 111.233 -0.747 . . . . 0.0 111.233 177.312 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 144' ' ' TRP . . . . . 0.593 ' HH2' HD13 ' A' ' 210' ' ' LEU . 69.2 t-105 -110.16 109.21 19.64 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 166.491 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 28.7 mmmt -108.98 107.43 17.79 Favored 'General case' 0 N--CA 1.471 0.621 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -175.412 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 146' ' ' LEU . . . . . 0.423 HD22 HG11 ' A' ' 207' ' ' VAL . 60.2 mt -162.63 -45.74 0.04 OUTLIER 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 126.909 2.084 . . . . 0.0 106.784 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 63.89 22.88 13.17 Favored 'General case' 0 N--CA 1.482 1.128 0 C-N-CA 125.256 1.422 . . . . 0.0 112.758 176.895 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.434 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -76.98 165.96 53.76 Favored Glycine 0 C--N 1.352 1.455 0 CA-C-N 116.262 -0.427 . . . . 0.0 113.017 179.543 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 22.2 tt0 -123.69 96.62 5.03 Favored 'General case' 0 C--O 1.239 0.506 0 C-N-CA 123.485 0.714 . . . . 0.0 109.26 -174.401 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 150' ' ' TRP . . . . . 0.527 ' HA ' ' HB ' ' A' ' 208' ' ' VAL . 29.1 t90 -55.63 116.05 2.68 Favored 'General case' 0 N--CA 1.481 1.098 0 O-C-N 123.308 0.38 . . . . 0.0 111.185 171.33 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 65.9 mttm -94.5 100.3 12.31 Favored 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 123.848 0.859 . . . . 0.0 109.419 -178.366 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -68.21 141.02 56.08 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 124.658 1.183 . . . . 0.0 111.918 -175.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 83.8 -23.56 6.63 Favored Glycine 0 C--N 1.351 1.389 0 CA-C-N 116.47 -0.332 . . . . 0.0 113.518 177.314 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -97.02 151.53 19.63 Favored 'General case' 0 C--O 1.24 0.57 0 C-N-CA 124.546 1.138 . . . . 0.0 108.53 -179.578 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 155' ' ' GLU . . . . . 0.424 ' HA ' ' HA ' ' A' ' 173' ' ' LYS . 1.2 pm0 -63.6 121.96 15.16 Favored 'General case' 0 C--N 1.345 0.406 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 176.051 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 33.9 m -89.93 179.51 0.5 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.537 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 174.807 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.47 133.4 51.21 Favored 'General case' 0 C--O 1.217 -0.641 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -175.87 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.451 ' O ' ' HA ' ' A' ' 169' ' ' ALA . 86.3 t -107.77 119.35 57.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 -176.795 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -93.1 77.43 4.63 Favored 'General case' 0 CA--C 1.54 0.584 0 N-CA-C 106.665 -1.605 . . . . 0.0 106.665 172.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -77.9 111.87 14.2 Favored 'General case' 0 CA--C 1.539 0.534 0 CA-C-N 114.69 -1.141 . . . . 0.0 111.006 -169.347 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 161' ' ' LEU . . . . . 0.431 HD21 ' HB1' ' A' ' 83' ' ' ALA . 89.0 mt -79.1 102.61 8.52 Favored 'General case' 0 C--O 1.244 0.805 0 C-N-CA 123.993 0.917 . . . . 0.0 110.195 179.541 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 162' ' ' GLU . . . . . 0.516 ' HB2' ' HB2' ' A' ' 193' ' ' PRO . 39.1 tt0 -74.82 126.66 88.16 Favored Pre-proline 0 CA--C 1.541 0.614 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 173.124 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 163' ' ' PRO . . . . . 0.455 ' HB2' HD23 ' A' ' 50' ' ' LEU . 36.5 Cg_endo -64.13 116.03 3.48 Favored 'Trans proline' 0 C--N 1.376 1.988 0 C-N-CA 121.911 1.741 . . . . 0.0 110.375 173.753 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 113.1 -28.01 9.11 Favored Glycine 0 C--N 1.344 1.006 0 CA-C-O 119.583 -0.565 . . . . 0.0 113.816 177.369 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -136.47 -173.48 3.43 Favored 'General case' 0 N--CA 1.49 1.552 0 CA-C-N 117.986 0.893 . . . . 0.0 112.154 -175.08 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -60.0 161.27 12.88 Favored Pre-proline 0 CA--C 1.554 1.116 0 C-N-CA 124.983 1.313 . . . . 0.0 112.319 175.861 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -77.2 157.4 33.65 Favored 'Trans proline' 0 C--N 1.373 1.823 0 C-N-CA 122.016 1.811 . . . . 0.0 111.759 173.826 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 168' ' ' ARG . . . . . 0.517 HH11 ' HG3' ' A' ' 193' ' ' PRO . 58.7 mtp180 -124.58 131.97 53.46 Favored 'General case' 0 C--O 1.238 0.489 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.257 173.773 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 169' ' ' ALA . . . . . 0.559 ' H ' ' HB2' ' A' ' 19' ' ' GLN . . . -80.02 133.83 36.18 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.053 176.633 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 63.0 t -134.21 117.8 26.05 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.131 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 174.436 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 55.1 mt-30 -81.75 126.28 31.63 Favored 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 108.245 -1.021 . . . . 0.0 108.245 174.85 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 4.9 t -152.72 132.44 13.16 Favored 'General case' 0 CA--C 1.54 0.561 0 O-C-N 123.571 0.544 . . . . 0.0 111.738 -174.887 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 173' ' ' LYS . . . . . 0.496 ' HB2' ' HB2' ' A' ' 25' ' ' SER . 64.0 mttp -75.6 138.13 70.57 Favored Pre-proline 0 N--CA 1.475 0.782 0 C-N-CA 123.146 0.578 . . . . 0.0 110.069 171.69 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_endo -61.78 163.27 19.27 Favored 'Trans proline' 0 C--N 1.379 2.134 0 C-N-CA 123.091 2.527 . . . . 0.0 113.728 178.427 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -144.45 169.89 26.3 Favored Glycine 0 N--CA 1.468 0.785 0 N-CA-C 110.399 -1.08 . . . . 0.0 110.399 178.217 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 6.5 mp -124.34 152.13 43.5 Favored 'General case' 0 N--CA 1.488 1.463 0 CA-C-N 118.681 1.24 . . . . 0.0 111.887 -176.511 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 177' ' ' PHE . . . . . 0.517 ' HE1' HD23 ' A' ' 29' ' ' LEU . 68.4 m-85 -96.53 122.42 39.41 Favored 'General case' 0 C--N 1.344 0.356 0 CA-C-N 114.756 -1.111 . . . . 0.0 109.593 173.831 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 61.0 tttp -85.47 90.07 7.86 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 167.032 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 23.0 m -104.14 158.79 16.2 Favored 'General case' 0 C--O 1.242 0.689 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 -179.352 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -61.6 -34.88 76.4 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 122.356 0.262 . . . . 0.0 110.471 177.506 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -63.79 -33.85 76.59 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 123.572 0.749 . . . . 0.0 111.155 175.442 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 151.25 -169.13 30.88 Favored Glycine 0 C--N 1.342 0.888 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.97 177.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 183' ' ' THR . . . . . 0.453 ' HA ' ' O ' ' A' ' 177' ' ' PHE . 16.9 p -87.25 119.19 27.23 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 122.986 0.514 . . . . 0.0 109.776 176.522 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 184' ' ' ILE . . . . . 0.461 ' HB ' ' HB2' ' A' ' 177' ' ' PHE . 65.5 mt -103.01 144.51 13.69 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 124.223 1.009 . . . . 0.0 108.504 -176.833 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -99.23 120.24 6.79 Favored Glycine 0 C--N 1.345 1.038 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 -175.223 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.403 ' HA ' ' HA ' ' A' ' 225' ' ' ALA . . . -146.93 -160.65 1.19 Allowed 'General case' 0 N--CA 1.465 0.294 0 C-N-CA 123.413 0.685 . . . . 0.0 111.102 -163.689 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 187' ' ' VAL . . . . . 0.416 ' HB ' HD11 ' A' ' 226' ' ' ILE . 3.7 p -132.22 103.86 7.13 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.989 0 C-N-CA 124.029 0.932 . . . . 0.0 108.498 169.552 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 188' ' ' SER . . . . . 0.46 ' HA ' HG13 ' A' ' 223' ' ' VAL . 15.6 t -76.96 100.65 5.68 Favored 'General case' 0 C--O 1.243 0.753 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.501 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 189' ' ' LEU . . . . . 0.4 HD13 ' N ' ' A' ' 190' ' ' ASP . 0.8 OUTLIER -152.44 155.66 37.96 Favored 'General case' 0 C--N 1.358 0.939 0 CA-C-O 121.365 0.603 . . . . 0.0 110.689 -168.531 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 190' ' ' ASP . . . . . 0.645 ' HA ' ' HB1' ' A' ' 221' ' ' ALA . 16.6 t70 -69.08 162.76 26.26 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 124.869 1.267 . . . . 0.0 109.859 176.048 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 191' ' ' PHE . . . . . 0.536 ' HB3' ' H ' ' A' ' 222' ' ' TYR . 9.6 p90 -74.23 123.92 25.43 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-O 121.958 0.885 . . . . 0.0 110.522 -168.409 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 50.8 m -104.62 158.96 30.88 Favored Pre-proline 0 CA--C 1.547 0.854 0 CA-C-N 114.23 -1.35 . . . . 0.0 110.445 -174.457 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 193' ' ' PRO . . . . . 0.517 ' HG3' HH11 ' A' ' 168' ' ' ARG . 73.7 Cg_endo -72.78 69.69 3.62 Favored 'Trans proline' 0 C--N 1.372 1.8 0 C-N-CA 122.786 2.324 . . . . 0.0 112.2 173.44 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -154.01 146.63 15.02 Favored Glycine 0 C--N 1.347 1.145 0 CA-C-N 116.178 -0.465 . . . . 0.0 112.46 -177.42 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 25.3 p -110.39 156.37 20.87 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 123.684 0.793 . . . . 0.0 109.469 176.32 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.63 107.2 0.77 Allowed 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 123.858 0.863 . . . . 0.0 110.069 -175.557 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 132.6 -9.55 5.26 Favored Glycine 0 C--N 1.342 0.89 0 CA-C-N 114.749 -1.114 . . . . 0.0 112.338 -172.19 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 54.2 m -63.91 120.12 60.92 Favored Pre-proline 0 CA--C 1.55 0.953 0 C-N-CA 123.351 0.66 . . . . 0.0 109.553 173.48 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -60.39 125.29 17.04 Favored 'Trans proline' 0 C--N 1.375 1.949 0 C-N-CA 122.836 2.357 . . . . 0.0 112.292 -173.765 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 55.5 mt -88.22 107.56 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 173.665 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 201' ' ' ILE . . . . . 0.8 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 25.9 mt -97.06 176.55 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.044 0 C-N-CA 124.524 1.13 . . . . 0.0 108.942 -175.839 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -102.93 174.22 5.97 Favored 'General case' 0 C--O 1.24 0.604 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 169.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 2.4 mppt? -70.46 -28.74 65.25 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 123.84 0.856 . . . . 0.0 109.051 174.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp -81.96 1.6 34.65 Favored 'General case' 0 N--CA 1.477 0.878 0 C-N-CA 123.958 0.903 . . . . 0.0 111.927 178.836 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 90.96 -4.82 81.84 Favored Glycine 0 C--N 1.351 1.403 0 CA-C-O 119.965 -0.353 . . . . 0.0 113.562 177.249 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 31.3 mmtp -78.25 108.89 11.9 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 122.931 0.492 . . . . 0.0 110.064 179.651 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.8 ' HA ' ' HA ' ' A' ' 201' ' ' ILE . 4.8 p -63.66 103.06 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.053 0 CA-C-O 121.437 0.636 . . . . 0.0 110.218 177.076 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 208' ' ' VAL . . . . . 0.527 ' HB ' ' HA ' ' A' ' 150' ' ' TRP . 27.2 m -81.68 -18.37 11.43 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.987 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.287 -169.782 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 209' ' ' GLY . . . . . . . . . . . . . . . 170.89 -138.84 5.15 Favored Glycine 0 C--N 1.344 0.99 0 CA-C-N 115.446 -0.797 . . . . 0.0 112.351 179.506 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 210' ' ' LEU . . . . . 0.593 HD13 ' HH2' ' A' ' 144' ' ' TRP . 4.9 tt -153.41 154.13 33.85 Favored 'General case' 0 CA--C 1.549 0.904 0 C-N-CA 123.864 0.866 . . . . 0.0 109.825 -168.219 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -67.97 114.42 6.5 Favored 'General case' 0 N--CA 1.481 1.12 0 C-N-CA 123.885 0.874 . . . . 0.0 109.868 -178.78 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -74.65 -136.67 0.44 Allowed Glycine 0 CA--C 1.528 0.895 0 O-C-N 124.349 1.031 . . . . 0.0 114.754 -169.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 213' ' ' ASN . . . . . 0.404 ' H ' ' HB3' ' A' ' 225' ' ' ALA . 49.0 t-20 -123.99 135.15 53.44 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 -175.164 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 214' ' ' GLY . . . . . 0.507 ' HA3' ' HA ' ' A' ' 224' ' ' SER . . . -164.37 -152.42 6.96 Favored Glycine 0 CA--C 1.506 -0.528 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.918 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 215' ' ' VAL . . . . . 0.466 HG11 ' HA ' ' A' ' 40' ' ' SER . 7.4 p -162.76 157.09 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 123.02 0.528 . . . . 0.0 110.445 -171.412 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 216' ' ' VAL . . . . . 0.46 ' HA ' ' HA ' ' A' ' 222' ' ' TYR . 93.0 t -70.93 116.38 12.36 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 C-N-CA 123.891 0.877 . . . . 0.0 109.064 174.553 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 217' ' ' THR . . . . . 0.796 HG22 HD11 ' A' ' 41' ' ' ILE . 72.9 p -130.68 163.48 27.12 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 125.256 1.423 . . . . 0.0 109.525 -173.572 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 10.1 ttp180 54.31 76.57 0.23 Allowed 'General case' 0 CA--C 1.561 1.367 0 C-N-CA 123.133 0.573 . . . . 0.0 111.957 161.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 45.1 m 71.91 -5.69 1.64 Allowed 'General case' 0 N--CA 1.492 1.663 0 C-N-CA 124.901 1.28 . . . . 0.0 114.393 176.21 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . 118.27 43.82 0.54 Allowed Glycine 0 C--N 1.357 1.71 0 CA-C-N 118.583 0.629 . . . . 0.0 112.909 176.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 221' ' ' ALA . . . . . 0.645 ' HB1' ' HA ' ' A' ' 190' ' ' ASP . . . -130.39 120.91 24.99 Favored 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 124.712 1.205 . . . . 0.0 109.578 -178.611 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 222' ' ' TYR . . . . . 0.536 ' H ' ' HB3' ' A' ' 191' ' ' PHE . 11.0 p90 -86.3 127.45 34.78 Favored 'General case' 0 C--N 1.351 0.665 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 -169.643 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 223' ' ' VAL . . . . . 0.46 HG13 ' HA ' ' A' ' 188' ' ' SER . 96.4 t -113.49 132.95 60.95 Favored 'Isoleucine or valine' 0 C--O 1.241 0.633 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 176.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 224' ' ' SER . . . . . 0.507 ' HA ' ' HA3' ' A' ' 214' ' ' GLY . 35.8 t -136.3 158.74 43.71 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 124.199 0.999 . . . . 0.0 109.959 -168.898 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 225' ' ' ALA . . . . . 0.404 ' HB3' ' H ' ' A' ' 213' ' ' ASN . . . -68.73 166.51 17.28 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 123.708 0.803 . . . . 0.0 111.234 175.232 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 226' ' ' ILE . . . . . 0.416 HD11 ' HB ' ' A' ' 187' ' ' VAL . 70.9 mt -108.71 111.56 36.55 Favored 'Isoleucine or valine' 0 C--O 1.243 0.731 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 168.634 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -74.62 131.83 41.25 Favored 'General case' 0 C--N 1.345 0.381 0 N-CA-C 107.516 -1.291 . . . . 0.0 107.516 169.828 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 14.1 pt20 -111.39 171.12 7.67 Favored 'General case' 0 C--O 1.248 1.01 0 C-N-CA 123.626 0.77 . . . . 0.0 109.371 -177.754 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 229' ' ' THR . . . . . 0.474 ' HA ' ' CD1' ' A' ' 144' ' ' TRP . 87.1 m -66.94 115.31 6.53 Favored 'General case' 0 CA--C 1.544 0.738 0 O-C-N 123.59 0.556 . . . . 0.0 110.618 178.912 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 230' ' ' GLU . . . . . 0.599 ' HG2' ' HG2' ' A' ' 135' ' ' LYS . 10.0 tp10 -117.0 62.75 0.73 Allowed 'General case' 0 C--O 1.242 0.68 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 175.921 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 24.3 pttm -66.97 157.45 33.33 Favored 'General case' 0 N--CA 1.472 0.662 0 CA-C-N 114.985 -1.007 . . . . 0.0 112.911 -165.733 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 19.8 p -50.51 106.55 0.13 Allowed 'General case' 0 CA--C 1.549 0.926 0 CA-C-N 113.935 -1.484 . . . . 0.0 112.132 -178.074 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 233' ' ' ILE . . . . . 0.448 ' O ' HG12 ' A' ' 233' ' ' ILE . 1.4 tt -90.14 7.37 4.07 Favored 'Isoleucine or valine' 0 CA--C 1.562 1.426 0 C-N-CA 124.309 1.044 . . . . 0.0 110.341 176.158 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 234' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 64.86 31.83 11.28 Favored 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 124.486 1.115 . . . . 0.0 110.815 -174.261 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -62.05 -51.49 67.75 Favored 'General case' 0 N--CA 1.479 0.999 0 C-N-CA 123.86 0.864 . . . . 0.0 108.678 171.016 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 236' ' ' ASN . . . . . . . . . . . . . 4.7 p-10 -74.94 149.02 85.13 Favored Pre-proline 0 C--O 1.244 0.779 0 CA-C-N 114.039 -1.437 . . . . 0.0 109.174 168.014 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 16.3 Cg_endo -57.97 142.48 96.66 Favored 'Trans proline' 0 C--N 1.376 2.018 0 C-N-CA 121.848 1.699 . . . . 0.0 111.311 175.768 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 238' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -65.5 -27.55 68.56 Favored 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 123.505 0.722 . . . . 0.0 110.951 -178.051 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 239' ' ' ILE . . . . . 0.452 HD12 ' H ' ' A' ' 239' ' ' ILE . 3.8 mp -79.41 -6.87 9.96 Favored 'Isoleucine or valine' 0 CA--C 1.568 1.638 0 C-N-CA 124.358 1.063 . . . . 0.0 109.698 -179.241 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 . . . . . 0 C--O 1.254 1.323 0 C-N-CA 125.152 1.381 . . . . 0.0 110.594 177.27 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 251' ' ' BEZ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 253' ' ' LYS . . . . . . . . . . . . . 5.0 tppp? -57.73 91.23 0.01 OUTLIER 'General case' 0 CA--C 1.55 0.979 0 C-N-CA 123.79 0.836 . . . . 0.0 112.124 -176.397 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 254' ' ' ARG . . . . . . . . . . . . . 26.1 mtp180 -79.22 -15.45 58.01 Favored 'General case' 0 N--CA 1.482 1.151 0 CA-C-N 114.363 -1.289 . . . . 0.0 109.964 172.026 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 255' ' ' M9P . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.563 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 41.6 t -166.32 -52.44 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 123.335 0.654 . . . . 0.0 109.663 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 67.41 43.18 2.01 Favored 'General case' 0 N--CA 1.484 1.25 0 C-N-CA 123.962 0.905 . . . . 0.0 111.848 173.84 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -165.2 23.62 0.05 Allowed 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 123.142 0.577 . . . . 0.0 110.365 -175.489 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 8.9 p30 -175.55 64.73 0.02 OUTLIER 'General case' 0 C--N 1.344 0.367 0 C-N-CA 124.734 1.214 . . . . 0.0 108.069 -173.099 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.683 ' HB2' HD13 ' A' ' 119' ' ' LEU . 15.6 mt -79.58 177.52 8.81 Favored 'General case' 0 C--O 1.213 -0.868 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 168.078 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 17.3 tt0 -152.39 142.35 22.15 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-N 119.104 0.866 . . . . 0.0 111.56 171.15 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.448 ' HB3' ' CD2' ' A' ' 84' ' ' TYR . 89.3 mt -87.9 114.37 24.45 Favored 'General case' 0 C--O 1.24 0.56 0 CA-C-N 114.012 -1.449 . . . . 0.0 110.007 175.029 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -106.79 117.75 34.87 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 173.583 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 21.2 ptt180 -58.98 121.77 12.04 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 122.83 0.452 . . . . 0.0 110.08 177.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -113.8 -33.83 5.67 Favored 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 122.609 0.364 . . . . 0.0 110.676 -176.806 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -169.17 -172.16 1.46 Allowed 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 123.938 0.895 . . . . 0.0 109.9 -179.096 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -102.04 160.29 14.63 Favored 'General case' 0 C--O 1.245 0.83 0 N-CA-C 107.818 -1.178 . . . . 0.0 107.818 169.208 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 99.7 t -72.38 100.09 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 170.887 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 63.7 tttt -155.54 127.74 7.68 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 115.126 -0.943 . . . . 0.0 108.725 -166.111 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' TRP . . . . . 0.5 ' HE1' ' HG2' ' A' ' 157' ' ' GLN . 40.6 t90 -69.74 121.64 17.62 Favored 'General case' 0 C--O 1.236 0.375 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 167.802 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.504 ' HG3' ' HG2' ' A' ' 19' ' ' GLN . 9.4 tp10 -92.74 134.35 35.13 Favored 'General case' 0 C--O 1.238 0.486 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 173.11 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -72.25 0.24 10.38 Favored 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 124.171 0.988 . . . . 0.0 113.093 -173.276 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLN . . . . . 0.504 ' HG2' ' HG3' ' A' ' 17' ' ' GLU . 11.6 mm-40 -74.77 47.73 0.34 Allowed 'General case' 0 CA--C 1.557 1.212 0 C-N-CA 124.326 1.05 . . . . 0.0 111.185 175.206 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.431 ' HA ' ' O ' ' A' ' 169' ' ' ALA . . . -73.87 89.29 1.85 Allowed 'General case' 0 C--N 1.352 0.697 0 C-N-CA 123.915 0.886 . . . . 0.0 110.098 -176.644 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -88.19 141.26 28.7 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 114.762 -1.108 . . . . 0.0 109.196 179.638 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 44.4 mm -76.11 102.58 3.11 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.424 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 173.745 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 47.5 m -121.7 -71.85 0.71 Allowed 'General case' 0 CA--C 1.538 0.497 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.502 -167.853 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.487 ' HA3' HG23 ' A' ' 172' ' ' THR . . . -85.01 133.05 11.49 Favored Glycine 0 C--N 1.353 1.482 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 174.332 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.546 ' HA ' ' HB2' ' A' ' 173' ' ' LYS . 62.2 p -163.62 10.46 0.05 Allowed 'General case' 0 N--CA 1.481 1.085 0 CA-C-N 117.477 0.638 . . . . 0.0 112.106 -178.112 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.422 ' HA ' ' HD3' ' A' ' 27' ' ' PRO . 20.7 p -94.12 145.51 29.91 Favored Pre-proline 0 CA--C 1.55 0.962 0 C-N-CA 123.0 0.52 . . . . 0.0 110.245 179.838 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 26' ' ' SER . 31.5 Cg_endo -89.45 -82.87 0.0 OUTLIER 'Trans proline' 0 C--N 1.379 2.144 0 C-N-CA 123.005 2.47 . . . . 0.0 114.29 -175.461 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.419 ' HA ' ' O ' ' A' ' 176' ' ' LEU . 33.0 mm -101.93 130.68 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 C-N-CA 122.788 0.435 . . . . 0.0 111.173 -169.84 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.702 HD23 HG21 ' A' ' 217' ' ' THR . 0.0 OUTLIER -139.19 161.37 37.58 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 123.613 0.765 . . . . 0.0 110.586 170.96 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 34.2 p -88.59 144.46 26.3 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 123.171 0.588 . . . . 0.0 111.45 -178.318 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.404 HG23 HG22 ' A' ' 179' ' ' THR . 10.4 tt -155.37 152.63 8.72 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.175 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -178.745 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 3.9 m -97.99 109.42 22.18 Favored 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 123.153 0.581 . . . . 0.0 110.794 -173.076 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 18.1 tt -90.6 141.83 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 O-C-N 121.771 -0.581 . . . . 0.0 110.123 178.851 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 25.1 m -143.79 151.5 40.03 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 123.217 0.607 . . . . 0.0 111.05 -177.061 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 54.61 25.9 6.83 Favored 'General case' 0 N--CA 1.487 1.418 0 C-N-CA 124.338 1.055 . . . . 0.0 112.307 175.114 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.8 t70 73.35 -60.82 0.52 Allowed 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 125.759 1.624 . . . . 0.0 111.378 -173.648 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -89.21 -34.31 8.85 Favored Glycine 0 C--N 1.348 1.234 0 N-CA-C 114.713 0.645 . . . . 0.0 114.713 -173.523 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 24.4 t -87.34 105.11 17.02 Favored 'General case' 0 N--CA 1.484 1.261 0 CA-C-N 117.428 0.614 . . . . 0.0 109.398 -167.629 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' MET . . . . . 0.5 ' HE2' ' HB3' ' A' ' 39' ' ' MET . 43.5 ttp -125.41 131.18 52.97 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 122.656 0.382 . . . . 0.0 110.278 -171.412 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.555 ' HB3' ' HE2' ' B' ' 253' ' ' LYS . 72.4 m -155.76 -178.36 7.24 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 125.179 1.392 . . . . 0.0 109.177 -175.318 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.601 HG12 HG11 ' A' ' 215' ' ' VAL . 44.8 mm -80.62 150.02 4.9 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.821 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 159.512 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 45.4 pttt -67.61 76.24 0.18 Allowed 'General case' 0 CA--C 1.556 1.189 0 CA-C-O 122.172 0.987 . . . . 0.0 109.839 167.128 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 -148.12 -168.03 2.97 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 124.906 1.282 . . . . 0.0 108.813 -178.601 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -134.93 160.26 38.84 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 123.381 0.672 . . . . 0.0 109.439 -179.84 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -111.12 133.1 53.74 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 123.788 0.835 . . . . 0.0 109.761 177.288 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -106.41 -41.38 5.31 Favored 'General case' 0 N--CA 1.475 0.783 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 174.452 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 48.3 mm-40 63.39 -168.73 0.2 Allowed 'General case' 0 C--N 1.352 0.708 0 C-N-CA 125.215 1.406 . . . . 0.0 113.523 175.653 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -146.94 152.78 39.22 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 124.157 0.983 . . . . 0.0 109.198 -174.086 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 13.1 t -85.11 -11.38 55.3 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 123.247 0.619 . . . . 0.0 110.334 176.112 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 67.1 mt -56.4 131.11 47.44 Favored 'General case' 0 C--N 1.355 0.818 0 C-N-CA 124.449 1.1 . . . . 0.0 112.1 -176.179 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -153.38 -101.8 0.21 Allowed Glycine 0 C--N 1.335 0.498 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 175.131 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -83.3 76.99 2.17 Favored Glycine 0 C--N 1.343 0.946 0 N-CA-C 111.42 -0.672 . . . . 0.0 111.42 175.386 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -67.15 87.89 0.15 Allowed Glycine 0 C--N 1.348 1.221 0 C-N-CA 123.01 0.338 . . . . 0.0 112.681 -179.207 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 128.83 -144.03 14.98 Favored Glycine 0 C--N 1.342 0.884 0 N-CA-C 111.306 -0.718 . . . . 0.0 111.306 -177.431 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 43.4 m -74.36 84.45 1.94 Allowed 'General case' 0 CA--C 1.552 1.033 0 C-N-CA 123.128 0.571 . . . . 0.0 110.656 -179.184 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -78.9 -32.31 40.76 Favored Glycine 0 C--N 1.348 1.22 0 CA-C-N 115.373 -0.83 . . . . 0.0 112.431 177.468 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -118.23 -149.4 8.74 Favored Glycine 0 C--N 1.346 1.111 0 N-CA-C 111.743 -0.543 . . . . 0.0 111.743 176.566 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -92.96 -70.22 1.14 Allowed Glycine 0 C--N 1.343 0.939 0 N-CA-C 111.692 -0.563 . . . . 0.0 111.692 177.846 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 130.32 -41.39 1.54 Allowed Glycine 0 C--N 1.345 1.064 0 C-N-CA 123.054 0.359 . . . . 0.0 112.652 176.355 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.7 tm-20 -82.78 80.78 8.76 Favored 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 123.231 0.612 . . . . 0.0 109.369 -174.118 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 67.8 t80 49.55 -74.9 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.896 0 C-N-CA 126.831 2.052 . . . . 0.0 114.106 172.811 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -61.06 -14.13 21.67 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 124.222 1.009 . . . . 0.0 112.873 178.201 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -114.62 47.12 1.07 Allowed Glycine 0 C--N 1.342 0.863 0 CA-C-O 119.671 -0.516 . . . . 0.0 113.005 178.842 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.798 HG23 ' HG3' ' A' ' 122' ' ' LYS . 29.9 m -89.1 0.55 7.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 CA-C-N 118.756 1.278 . . . . 0.0 112.175 178.392 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.429 ' HB3' ' HB2' ' A' ' 122' ' ' LYS . 3.2 tt -166.92 -90.05 0.02 OUTLIER 'General case' 0 C--N 1.361 1.086 0 C-N-CA 123.392 0.677 . . . . 0.0 110.271 162.519 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' TRP . . . . . 0.64 ' CD1' ' HD3' ' A' ' 122' ' ' LYS . 66.9 p-90 -59.1 122.68 14.37 Favored 'General case' 0 C--N 1.377 1.764 0 N-CA-C 112.458 0.54 . . . . 0.0 112.458 -160.134 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.434 ' O ' ' HD3' ' A' ' 69' ' ' PRO . 5.0 p-10 -79.08 119.3 22.0 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-N 115.075 -0.966 . . . . 0.0 109.009 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.538 ' HB ' ' HZ3' ' A' ' 66' ' ' TRP . 2.0 p -89.95 103.14 5.74 Favored Pre-proline 0 CA--C 1.56 1.344 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.439 170.956 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.434 ' HD3' ' O ' ' A' ' 67' ' ' ASP . 23.5 Cg_exo -69.14 -22.96 34.19 Favored 'Trans proline' 0 C--N 1.382 2.291 0 C-N-CA 122.814 2.343 . . . . 0.0 112.702 174.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 33.1 m -78.63 178.03 2.48 Favored Pre-proline 0 CA--C 1.562 1.408 0 C-N-CA 123.746 0.819 . . . . 0.0 110.21 175.473 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -54.72 157.26 12.91 Favored 'Trans proline' 0 C--N 1.383 2.363 0 C-N-CA 122.169 1.913 . . . . 0.0 112.1 165.336 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_exo -41.52 140.85 1.57 Allowed 'Trans proline' 0 C--N 1.385 2.457 0 C-N-CA 124.25 3.3 . . . . 0.0 114.155 179.553 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -23.59 80.71 0.0 OUTLIER 'Trans proline' 0 C--N 1.392 2.842 1 C-N-CA 126.454 4.77 . . . . 0.0 116.423 -165.76 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 35.1 m -74.24 -36.98 44.89 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.167 179.584 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -89.75 -84.53 1.33 Allowed Glycine 0 C--N 1.346 1.089 0 N-CA-C 110.496 -1.042 . . . . 0.0 110.496 173.507 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' LYS . . . . . 0.467 ' HG3' ' H ' ' A' ' 77' ' ' ALA . 18.4 ptpt -162.09 -62.35 0.05 OUTLIER 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 123.359 0.664 . . . . 0.0 110.697 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.467 ' H ' ' HG3' ' A' ' 76' ' ' LYS . . . -163.39 82.91 0.47 Allowed 'General case' 0 C--O 1.237 0.408 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 -173.293 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -71.11 135.48 47.7 Favored 'General case' 0 CA--C 1.546 0.812 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.287 178.927 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.723 HD22 ' H ' ' A' ' 105' ' ' GLY . 6.3 mp -84.48 117.8 23.89 Favored 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 124.074 0.95 . . . . 0.0 109.321 -171.31 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -71.5 84.94 0.84 Allowed 'General case' 0 N--CA 1.482 1.159 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -55.42 106.19 0.22 Allowed 'General case' 0 CA--C 1.549 0.907 0 C-N-CA 124.624 1.17 . . . . 0.0 110.857 -178.021 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -177.41 -169.01 37.97 Favored Glycine 0 C--N 1.355 1.615 0 N-CA-C 115.198 0.839 . . . . 0.0 115.198 -175.502 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -97.85 122.65 41.21 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 124.479 1.112 . . . . 0.0 110.803 -176.051 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' TYR . . . . . 0.448 ' CD2' ' HB3' ' A' ' 8' ' ' LEU . 3.4 m-85 -117.42 154.8 30.73 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 123.498 0.719 . . . . 0.0 110.613 -175.383 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' ARG . . . . . 0.525 ' HG2' HG21 ' A' ' 195' ' ' THR . 22.1 mtm180 -99.17 127.91 45.22 Favored 'General case' 0 C--O 1.243 0.76 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 166.196 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.446 HG12 HD23 ' A' ' 8' ' ' LEU . 22.4 mt -92.12 129.7 42.35 Favored 'Isoleucine or valine' 0 C--O 1.25 1.13 0 CA-C-O 121.658 0.742 . . . . 0.0 109.346 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -117.37 154.17 31.78 Favored 'General case' 0 C--O 1.216 -0.675 0 CA-C-N 114.302 -1.317 . . . . 0.0 109.666 177.351 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.8 tp60 -85.58 107.17 17.37 Favored 'General case' 0 C--O 1.243 0.719 0 N-CA-C 104.807 -2.294 . . . . 0.0 104.807 163.58 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.4 tttp -88.55 98.17 11.5 Favored 'General case' 0 C--O 1.242 0.679 0 CA-C-N 114.706 -1.134 . . . . 0.0 108.522 -173.822 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -71.54 131.94 19.83 Favored Glycine 0 N--CA 1.439 -1.141 0 N-CA-C 108.021 -2.032 . . . . 0.0 108.021 161.267 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 33.1 mm -62.57 -12.87 10.03 Favored 'Isoleucine or valine' 0 CA--C 1.566 1.584 0 C-N-CA 123.171 0.588 . . . . 0.0 110.569 -178.819 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 2.3 pp -111.93 -18.27 12.7 Favored 'General case' 0 CA--C 1.562 1.414 0 C-N-CA 123.974 0.91 . . . . 0.0 112.889 168.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -160.81 127.18 1.72 Allowed Glycine 0 N--CA 1.488 2.132 0 N-CA-C 114.763 0.665 . . . . 0.0 114.763 -172.25 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 9.2 m-85 -84.16 160.37 20.87 Favored 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 123.409 0.684 . . . . 0.0 111.635 -178.682 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 37.9 t -148.42 139.21 22.95 Favored 'General case' 0 C--O 1.207 -1.169 0 C-N-CA 124.616 1.167 . . . . 0.0 108.325 169.696 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' GLN . . . . . . . . . . . . . 9.5 tt0 -90.68 125.61 35.72 Favored 'General case' 0 N--CA 1.493 1.71 0 CA-C-N 119.461 1.028 . . . . 0.0 109.64 -178.687 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 27.6 pt -124.02 -8.62 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 N-CA-C 112.559 0.578 . . . . 0.0 112.559 -172.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 160.92 -139.39 6.02 Favored Glycine 0 C--N 1.343 0.926 0 C-N-CA 120.903 -0.665 . . . . 0.0 113.05 170.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.476 ' HB2' HG22 ' A' ' 195' ' ' THR . . . -153.19 168.72 25.0 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 123.515 0.726 . . . . 0.0 111.786 -178.159 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -174.51 154.17 18.2 Favored Glycine 0 C--N 1.345 1.071 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.903 177.859 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 28.1 m -97.85 126.86 50.7 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 CA-C-N 117.607 0.703 . . . . 0.0 110.678 -179.346 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 24.3 t80 -100.76 106.4 17.81 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.489 ' HB3' ' O ' ' A' ' 106' ' ' THR . 14.2 tmtt? -100.87 149.85 23.45 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 -172.144 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -62.31 96.15 0.07 Allowed 'General case' 0 CA--C 1.56 1.348 0 CA-C-O 121.982 0.896 . . . . 0.0 111.713 -178.06 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' GLY . . . . . 0.723 ' H ' HD22 ' A' ' 79' ' ' LEU . . . 104.58 -9.01 48.11 Favored Glycine 0 C--N 1.342 0.882 0 CA-C-N 115.29 -0.868 . . . . 0.0 112.867 177.91 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' THR . . . . . 0.489 ' O ' ' HB3' ' A' ' 103' ' ' LYS . 54.6 m -151.21 124.25 8.7 Favored 'General case' 0 CA--C 1.547 0.854 0 CA-C-N 117.363 0.581 . . . . 0.0 110.314 -175.402 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 107' ' ' PHE . . . . . 0.635 ' HB3' ' HB3' ' A' ' 140' ' ' TYR . 27.4 t80 -96.35 133.66 40.45 Favored 'General case' 0 CA--C 1.545 0.786 0 O-C-N 121.461 -0.774 . . . . 0.0 110.075 176.244 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' HIS . . . . . 0.449 ' HB3' ' HE3' ' A' ' 144' ' ' TRP . 32.1 m170 -133.34 115.89 15.44 Favored 'General case' 0 N--CA 1.48 1.04 0 C-N-CA 124.113 0.965 . . . . 0.0 110.707 -178.48 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 109' ' ' THR . . . . . 0.621 HG23 ' HB ' ' A' ' 138' ' ' ILE . 10.1 t -136.87 -176.39 4.35 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 122.749 0.42 . . . . 0.0 110.736 174.466 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' MET . . . . . 0.627 ' HA ' ' HA ' ' A' ' 137' ' ' LEU . 34.6 mtp -93.78 163.15 13.64 Favored 'General case' 0 C--O 1.24 0.558 0 C-N-CA 123.785 0.834 . . . . 0.0 111.098 169.626 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 111' ' ' TRP . . . . . 0.61 ' HA ' HG13 ' A' ' 138' ' ' ILE . 83.9 t90 -80.23 -38.36 31.19 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 123.523 0.729 . . . . 0.0 111.62 -175.908 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' HIS . . . . . 0.434 ' CE1' ' SD ' ' A' ' 110' ' ' MET . 1.1 p-80 -64.07 -9.42 16.17 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 125.03 1.332 . . . . 0.0 113.933 -169.162 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 33.9 m -57.36 -36.4 52.62 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.911 0 O-C-N 123.471 0.482 . . . . 0.0 110.278 176.424 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -152.74 -151.6 0.39 Allowed 'General case' 0 CA--C 1.56 1.334 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 175.022 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 55.8 ttt85 -99.4 32.73 2.67 Favored 'General case' 0 CA--C 1.557 1.227 0 C-N-CA 123.64 0.776 . . . . 0.0 110.112 176.251 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.51 ' HA2' HD11 ' A' ' 138' ' ' ILE . . . 85.0 53.29 3.2 Favored Glycine 0 C--N 1.346 1.131 0 N-CA-C 111.848 -0.501 . . . . 0.0 111.848 -176.338 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -94.83 169.43 10.15 Favored 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 123.513 0.725 . . . . 0.0 112.251 -174.034 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.562 HG23 ' HA ' ' A' ' 127' ' ' GLU . 7.1 p -91.69 142.83 12.46 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.073 0 CA-C-N 114.962 -1.017 . . . . 0.0 111.281 -176.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.683 HD13 ' HB2' ' A' ' 6' ' ' LEU . 2.9 mm? -93.48 152.87 18.79 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 124.236 1.015 . . . . 0.0 110.779 -174.517 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 120' ' ' MET . . . . . 0.657 ' HE1' ' HG3' ' A' ' 125' ' ' ARG . 32.5 mmt -110.32 158.2 18.68 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 169.581 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 80.3 t60 -161.95 96.54 1.01 Allowed 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 175.204 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.798 ' HG3' HG23 ' A' ' 64' ' ' VAL . 77.7 tttt 59.23 31.17 20.99 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 123.774 0.83 . . . . 0.0 111.085 176.088 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 101.63 -11.23 57.87 Favored Glycine 0 C--N 1.355 1.587 0 CA-C-N 115.945 -0.571 . . . . 0.0 113.553 -179.466 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 49.9 tttm -90.2 127.23 36.07 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 123.122 0.569 . . . . 0.0 109.612 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' ARG . . . . . 0.657 ' HG3' ' HE1' ' A' ' 120' ' ' MET . 28.2 ttm-85 -89.66 101.25 13.94 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 123.444 0.698 . . . . 0.0 109.518 179.0 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 68.7 mt -85.2 99.92 7.81 Favored 'Isoleucine or valine' 0 C--O 1.239 0.542 0 C-N-CA 123.837 0.855 . . . . 0.0 109.949 178.646 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 127' ' ' GLU . . . . . 0.562 ' HA ' HG23 ' A' ' 118' ' ' VAL . 0.3 OUTLIER -74.1 149.91 87.54 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.177 174.979 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_endo -79.59 152.95 23.18 Favored 'Trans proline' 0 C--N 1.366 1.499 0 C-N-CA 122.115 1.877 . . . . 0.0 111.8 167.587 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 95.3 p -89.36 -26.8 20.87 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 122.874 0.47 . . . . 0.0 110.131 171.744 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 74.7 t-105 -165.88 156.12 12.78 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 123.497 0.719 . . . . 0.0 109.665 179.344 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 131' ' ' ALA . . . . . 0.428 ' HB1' ' HD1' ' A' ' 111' ' ' TRP . . . -133.95 118.62 18.08 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.574 0.75 . . . . 0.0 109.024 172.664 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 22.5 t0 -90.09 104.41 16.98 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 124.288 1.035 . . . . 0.0 108.269 175.318 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 45.7 t -75.79 -26.79 18.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 122.929 0.492 . . . . 0.0 111.08 -176.428 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 26.6 mtpp -73.14 -51.47 17.79 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.351 0.661 . . . . 0.0 111.358 -175.158 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 42.8 mtpt -85.73 -4.14 59.08 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 115.45 -0.795 . . . . 0.0 111.554 -179.255 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 37.0 t0 65.22 56.77 0.98 Allowed 'General case' 0 CA--C 1.552 1.025 0 O-C-N 124.554 1.159 . . . . 0.0 109.621 175.894 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 137' ' ' LEU . . . . . 0.627 ' HA ' ' HA ' ' A' ' 110' ' ' MET . 62.6 mt -143.49 137.58 28.62 Favored 'General case' 0 N--CA 1.478 0.958 0 O-C-N 121.482 -0.762 . . . . 0.0 110.329 -177.701 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.621 ' HB ' HG23 ' A' ' 109' ' ' THR . 84.8 mt -111.99 149.44 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.376 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 169.305 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 139' ' ' SER . . . . . 0.421 ' HB2' ' O ' ' A' ' 142' ' ' GLY . 33.5 p -145.44 148.44 33.3 Favored 'General case' 0 C--O 1.241 0.65 0 C-N-CA 123.374 0.67 . . . . 0.0 110.519 -172.545 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.635 ' HB3' ' HB3' ' A' ' 107' ' ' PHE . 37.5 t80 -144.27 120.01 10.51 Favored 'General case' 0 N--CA 1.466 0.333 0 C-N-CA 124.662 1.185 . . . . 0.0 108.705 178.004 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 86.25 3.69 84.51 Favored Glycine 0 C--N 1.345 1.054 0 O-C-N 123.572 0.545 . . . . 0.0 112.725 -178.003 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 142' ' ' GLY . . . . . 0.421 ' O ' ' HB2' ' A' ' 139' ' ' SER . . . 147.28 148.82 4.83 Favored Glycine 0 C--N 1.344 0.995 0 N-CA-C 110.386 -1.085 . . . . 0.0 110.386 -177.884 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -67.83 169.71 37.88 Favored Glycine 0 C--N 1.348 1.234 0 C-N-CA 123.126 0.393 . . . . 0.0 112.608 -179.562 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 144' ' ' TRP . . . . . 0.644 ' HZ2' ' HA2' ' A' ' 209' ' ' GLY . 57.1 t-105 -58.43 105.54 0.3 Allowed 'General case' 0 CA--C 1.555 1.135 0 CA-C-O 121.209 0.528 . . . . 0.0 110.977 -177.517 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 145' ' ' LYS . . . . . 0.643 ' HA ' ' HB ' ' A' ' 229' ' ' THR . 50.1 tttm -163.82 126.97 2.59 Favored 'General case' 0 CA--C 1.54 0.562 0 CA-C-N 115.04 -0.982 . . . . 0.0 109.433 176.513 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 146' ' ' LEU . . . . . 0.444 ' H ' ' HB ' ' A' ' 229' ' ' THR . 79.5 mt -141.8 -2.74 1.17 Allowed 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 125.744 1.618 . . . . 0.0 110.219 179.727 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 29.2 tt0 86.69 18.53 0.09 Allowed 'General case' 0 N--CA 1.5 2.043 0 C-N-CA 125.355 1.462 . . . . 0.0 110.848 171.197 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.577 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -85.15 117.72 4.59 Favored Glycine 0 N--CA 1.434 -1.489 0 CA-C-N 115.376 -0.829 . . . . 0.0 113.466 173.578 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -116.04 95.12 4.95 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 124.06 0.944 . . . . 0.0 110.175 -175.311 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 150' ' ' TRP . . . . . 0.608 ' HZ2' ' HG3' ' A' ' 174' ' ' PRO . 35.8 t90 -82.86 146.97 28.6 Favored 'General case' 0 CA--C 1.553 1.095 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.27 168.313 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.414 ' HB3' ' HG2' ' A' ' 154' ' ' GLU . 22.5 tptp -112.67 128.79 56.49 Favored 'General case' 0 N--CA 1.476 0.841 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 177.095 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -63.13 99.69 0.19 Allowed 'General case' 0 N--CA 1.483 1.221 0 C-N-CA 123.494 0.718 . . . . 0.0 111.059 -179.214 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 143.54 -23.25 2.18 Favored Glycine 0 C--N 1.341 0.851 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.345 -177.828 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 154' ' ' GLU . . . . . 0.414 ' HG2' ' HB3' ' A' ' 151' ' ' LYS . 32.7 mm-40 -75.91 133.58 40.48 Favored 'General case' 0 C--O 1.24 0.581 0 C-N-CA 123.324 0.65 . . . . 0.0 111.604 -179.452 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 155' ' ' GLU . . . . . 0.536 ' HG2' ' HG2' ' A' ' 173' ' ' LYS . 35.8 mt-10 -74.84 101.62 4.44 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 174.845 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 9.7 p -114.72 145.83 19.99 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 123.257 0.623 . . . . 0.0 109.577 -168.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 157' ' ' GLN . . . . . 0.5 ' HG2' ' HE1' ' A' ' 16' ' ' TRP . 25.2 mp0 -93.34 141.19 28.72 Favored 'General case' 0 C--O 1.217 -0.641 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 -172.541 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.465 ' O ' ' HA ' ' A' ' 169' ' ' ALA . 46.9 t -101.2 116.11 44.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 177.019 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -72.08 86.37 1.04 Allowed 'General case' 0 CA--C 1.548 0.869 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 176.647 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -88.44 139.13 30.8 Favored 'General case' 0 C--O 1.249 1.044 0 CA-C-N 114.181 -1.372 . . . . 0.0 110.738 -174.453 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 35.2 mt -112.7 84.29 1.96 Allowed 'General case' 0 C--O 1.245 0.854 0 C-N-CA 124.718 1.207 . . . . 0.0 108.936 -178.891 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 162' ' ' GLU . . . . . 0.675 ' HB2' ' HB2' ' A' ' 165' ' ' LYS . 44.2 mt-10 -75.98 143.48 74.21 Favored Pre-proline 0 CA--C 1.547 0.855 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 176.183 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 163' ' ' PRO . . . . . 0.506 ' HD3' ' NH2' ' B' ' 254' ' ' ARG . 74.5 Cg_endo -70.35 114.12 3.69 Favored 'Trans proline' 0 C--N 1.374 1.897 0 C-N-CA 122.209 1.939 . . . . 0.0 110.591 -177.785 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 90.85 -11.24 72.54 Favored Glycine 0 C--N 1.34 0.76 0 CA-C-N 115.954 -0.566 . . . . 0.0 113.42 179.022 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 165' ' ' LYS . . . . . 0.675 ' HB2' ' HB2' ' A' ' 162' ' ' GLU . 47.5 mmtm -104.53 147.83 27.17 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 176.096 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -58.85 149.5 64.42 Favored Pre-proline 0 CA--C 1.554 1.111 0 O-C-N 123.553 0.533 . . . . 0.0 111.832 179.399 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo -56.56 118.09 4.87 Favored 'Trans proline' 0 C--N 1.376 1.994 0 C-N-CA 122.497 2.131 . . . . 0.0 110.348 171.442 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 16.0 ptt180 -135.25 134.09 39.64 Favored 'General case' 0 N--CA 1.47 0.556 0 CA-C-O 120.825 0.345 . . . . 0.0 110.202 -176.606 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 169' ' ' ALA . . . . . 0.487 ' H ' ' HB3' ' A' ' 17' ' ' GLU . . . -97.75 105.24 17.35 Favored 'General case' 0 C--O 1.225 -0.219 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.557 -177.691 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 27.7 m -97.64 133.63 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.234 0 C-N-CA 123.663 0.785 . . . . 0.0 110.125 -174.84 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 171' ' ' GLN . . . . . 0.42 ' HA ' ' HA ' ' A' ' 157' ' ' GLN . 27.7 tt0 -77.75 128.41 33.99 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-O 121.656 0.741 . . . . 0.0 110.328 -171.593 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 172' ' ' THR . . . . . 0.583 HG21 HG13 ' A' ' 187' ' ' VAL . 68.7 m -128.08 123.3 34.21 Favored 'General case' 0 C--O 1.246 0.908 0 CA-C-N 113.842 -1.526 . . . . 0.0 109.448 -175.205 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 173' ' ' LYS . . . . . 0.546 ' HB2' ' HA ' ' A' ' 25' ' ' SER . 27.5 mtpp -76.15 141.61 70.95 Favored Pre-proline 0 CA--C 1.544 0.743 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 168.808 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 174' ' ' PRO . . . . . 0.608 ' HG3' ' HZ2' ' A' ' 150' ' ' TRP . 39.4 Cg_exo -55.37 122.95 12.64 Favored 'Trans proline' 0 C--N 1.371 1.74 0 C-N-CA 122.511 2.14 . . . . 0.0 113.66 -171.481 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 175' ' ' GLY . . . . . 0.484 ' H ' ' C ' ' A' ' 186' ' ' ALA . . . -117.26 127.33 7.34 Favored Glycine 0 N--CA 1.482 1.723 0 CA-C-O 121.606 0.559 . . . . 0.0 113.594 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.459 ' N ' HD23 ' A' ' 176' ' ' LEU . 0.4 OUTLIER -132.01 127.97 37.35 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 121.914 0.864 . . . . 0.0 109.52 -169.031 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 177' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -102.58 138.94 38.83 Favored 'General case' 0 C--O 1.245 0.86 0 CA-C-N 114.069 -1.423 . . . . 0.0 110.494 -169.505 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 58.5 tptt -86.0 124.89 32.95 Favored 'General case' 0 C--O 1.243 0.716 0 C-N-CA 124.585 1.154 . . . . 0.0 109.953 -178.552 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 179' ' ' THR . . . . . 0.404 HG22 HG23 ' A' ' 31' ' ' ILE . 68.9 p -120.53 175.86 5.78 Favored 'General case' 0 C--O 1.242 0.697 0 C-N-CA 123.31 0.644 . . . . 0.0 109.612 169.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 -68.07 -21.37 64.98 Favored 'General case' 0 CA--C 1.546 0.806 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.206 172.694 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -78.65 -53.04 7.58 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 123.724 0.81 . . . . 0.0 110.301 176.011 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 177.48 176.97 45.98 Favored Glycine 0 C--N 1.344 0.999 0 CA-C-N 115.623 -0.717 . . . . 0.0 112.331 -178.742 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 15.5 m -93.91 104.32 16.38 Favored 'General case' 0 CA--C 1.542 0.663 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 176.421 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 184' ' ' ILE . . . . . 0.483 HD13 ' H ' ' A' ' 184' ' ' ILE . 0.2 OUTLIER -123.63 161.09 26.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 C-N-CA 123.455 0.702 . . . . 0.0 109.732 -174.122 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . 113.48 178.41 19.37 Favored Glycine 0 N--CA 1.47 0.912 0 CA-C-O 119.802 -0.443 . . . . 0.0 113.074 176.401 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.484 ' C ' ' H ' ' A' ' 175' ' ' GLY . . . -173.22 38.12 0.01 OUTLIER 'General case' 0 C--N 1.364 1.222 0 C-N-CA 123.75 0.82 . . . . 0.0 110.967 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 187' ' ' VAL . . . . . 0.583 HG13 HG21 ' A' ' 172' ' ' THR . 58.5 t -155.1 117.51 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 C-N-CA 125.146 1.378 . . . . 0.0 107.48 171.539 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 188' ' ' SER . . . . . 0.546 ' HA ' HG12 ' A' ' 223' ' ' VAL . 68.4 m -129.83 86.2 2.38 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-O 121.877 0.846 . . . . 0.0 108.747 170.531 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 32.4 tp -106.38 103.77 13.31 Favored 'General case' 0 CA--C 1.543 0.687 0 CA-C-N 113.907 -1.497 . . . . 0.0 110.231 -173.88 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 190' ' ' ASP . . . . . 0.711 ' HA ' ' HA ' ' A' ' 221' ' ' ALA . 11.0 p-10 -90.52 102.04 14.78 Favored 'General case' 0 N--CA 1.478 0.934 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 175.348 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 191' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 179.41 -174.88 0.23 Allowed 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 125.981 1.713 . . . . 0.0 108.254 -174.879 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 9.5 m -51.19 119.89 13.25 Favored Pre-proline 0 CA--C 1.551 0.994 0 O-C-N 123.872 0.733 . . . . 0.0 109.801 172.627 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_exo -48.01 132.61 22.73 Favored 'Trans proline' 0 C--N 1.379 2.138 0 C-N-CA 123.471 2.781 . . . . 0.0 114.226 -171.024 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -67.0 167.18 39.37 Favored Glycine 0 C--N 1.348 1.232 0 CA-C-N 115.633 -0.712 . . . . 0.0 112.085 175.069 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 195' ' ' THR . . . . . 0.525 HG21 ' HG2' ' A' ' 85' ' ' ARG . 1.4 m -89.99 103.77 16.41 Favored 'General case' 0 CA--C 1.54 0.559 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -173.617 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 43.6 t -51.72 85.08 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.09 0 C-N-CA 125.285 1.434 . . . . 0.0 113.389 -170.924 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 126.03 16.01 2.74 Favored Glycine 0 C--N 1.355 1.586 0 CA-C-N 115.253 -0.885 . . . . 0.0 113.083 179.123 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 84.2 p -82.81 155.86 67.87 Favored Pre-proline 0 N--CA 1.483 1.21 0 CA-C-N 117.477 0.638 . . . . 0.0 110.156 178.082 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -74.15 142.64 31.02 Favored 'Trans proline' 0 C--N 1.386 2.535 0 C-N-CA 122.308 2.006 . . . . 0.0 113.157 -178.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 62.6 mt -108.59 113.57 44.37 Favored 'Isoleucine or valine' 0 C--O 1.255 1.36 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 175.833 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 201' ' ' ILE . . . . . 0.607 HG12 ' HA ' ' A' ' 208' ' ' VAL . 14.3 mt -117.24 134.95 59.19 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.085 0 CA-C-N 114.822 -1.081 . . . . 0.0 110.799 -167.445 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -68.37 162.82 24.5 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 125.06 1.344 . . . . 0.0 110.704 174.454 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 63.2 tttm -67.45 -15.54 63.73 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 124.6 1.16 . . . . 0.0 112.061 -173.049 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 21.6 ptmt -94.15 4.01 54.48 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 123.232 0.613 . . . . 0.0 112.147 177.387 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 80.41 38.87 16.39 Favored Glycine 0 C--N 1.351 1.393 0 C-N-CA 122.9 0.286 . . . . 0.0 112.856 -178.851 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 58.0 tttp -128.78 167.1 17.78 Favored 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 124.272 1.029 . . . . 0.0 109.758 -174.341 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.577 ' O ' ' HA3' ' A' ' 148' ' ' GLY . 89.5 t 95.64 -74.91 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.146 0 C-N-CA 125.719 1.608 . . . . 0.0 110.157 171.079 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 208' ' ' VAL . . . . . 0.607 ' HA ' HG12 ' A' ' 201' ' ' ILE . 3.2 m 63.1 22.37 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 CA-C-O 122.484 1.135 . . . . 0.0 109.787 166.414 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.644 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . -83.08 128.85 8.72 Favored Glycine 0 C--N 1.347 1.18 0 CA-C-N 113.376 -1.738 . . . . 0.0 109.353 -172.456 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 87.4 mt -65.65 173.28 2.87 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-N 117.908 0.854 . . . . 0.0 111.287 -165.47 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 211' ' ' TYR . . . . . 0.457 ' CZ ' HG11 ' A' ' 158' ' ' VAL . 6.3 m-85 -56.56 157.78 4.97 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.824 163.742 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 212' ' ' GLY . . . . . 0.612 ' HA3' ' HB3' ' A' ' 225' ' ' ALA . . . -105.87 -141.18 10.38 Favored Glycine 0 C--O 1.24 0.492 0 N-CA-C 111.264 -0.735 . . . . 0.0 111.264 173.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 213' ' ' ASN . . . . . . . . . . . . . 23.5 p-10 -100.13 130.47 46.27 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 -176.327 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . -176.45 -135.96 2.27 Favored Glycine 0 C--N 1.337 0.617 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.962 176.909 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 215' ' ' VAL . . . . . 0.734 HG23 ' HD3' ' B' ' 253' ' ' LYS . 7.4 p 176.06 162.85 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 C-N-CA 125.415 1.486 . . . . 0.0 107.936 -171.485 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 216' ' ' VAL . . . . . 0.661 ' HA ' ' HA ' ' A' ' 222' ' ' TYR . 7.8 p -75.07 110.27 9.5 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.498 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 161.167 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 217' ' ' THR . . . . . 0.702 HG21 HD23 ' A' ' 29' ' ' LEU . 53.2 m -87.69 141.82 28.31 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.992 0.917 . . . . 0.0 110.19 -178.448 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 218' ' ' ARG . . . . . 0.46 ' HG3' HG22 ' A' ' 217' ' ' THR . 57.3 mtp180 62.71 8.6 3.09 Favored 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 124.093 0.957 . . . . 0.0 111.574 -175.047 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 68.0 m 62.75 26.31 15.55 Favored 'General case' 0 C--N 1.359 1.006 0 C-N-CA 124.734 1.214 . . . . 0.0 112.077 -176.224 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . -153.88 -19.4 0.05 OUTLIER Glycine 0 C--N 1.349 1.277 0 CA-C-N 116.637 -0.256 . . . . 0.0 113.653 179.29 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 221' ' ' ALA . . . . . 0.711 ' HA ' ' HA ' ' A' ' 190' ' ' ASP . . . -113.87 89.65 3.14 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 123.333 0.653 . . . . 0.0 109.757 -175.576 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 222' ' ' TYR . . . . . 0.661 ' HA ' ' HA ' ' A' ' 216' ' ' VAL . 50.2 t80 -69.15 118.2 11.75 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 123.149 0.58 . . . . 0.0 110.453 -177.45 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 223' ' ' VAL . . . . . 0.546 HG12 ' HA ' ' A' ' 188' ' ' SER . 21.5 m -123.05 145.43 29.95 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.731 0 C-N-CA 123.507 0.723 . . . . 0.0 110.687 -179.039 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 70.2 m -158.7 159.78 35.67 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 124.915 1.286 . . . . 0.0 108.757 178.483 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 225' ' ' ALA . . . . . 0.612 ' HB3' ' HA3' ' A' ' 212' ' ' GLY . . . -76.64 -169.06 1.14 Allowed 'General case' 0 N--CA 1.482 1.147 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 167.239 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 226' ' ' ILE . . . . . . . . . . . . . 54.9 mt -127.83 106.34 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.12 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 174.5 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -85.14 92.03 8.28 Favored 'General case' 0 C--O 1.239 0.551 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 177.652 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 20.1 pt20 -92.31 158.88 15.87 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-N 115.248 -0.887 . . . . 0.0 108.813 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 229' ' ' THR . . . . . 0.643 ' HB ' ' HA ' ' A' ' 145' ' ' LYS . 30.5 p -69.12 107.44 3.19 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-O 121.589 0.709 . . . . 0.0 110.738 -161.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -168.75 79.59 0.14 Allowed 'General case' 0 N--CA 1.451 -0.401 0 N-CA-C 106.366 -1.716 . . . . 0.0 106.366 -171.801 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 231' ' ' LYS . . . . . 0.413 ' HD3' ' H ' ' A' ' 144' ' ' TRP . 59.1 tttp -145.85 -78.82 0.18 Allowed 'General case' 0 N--CA 1.48 1.07 0 CA-C-N 115.912 -0.585 . . . . 0.0 112.297 167.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 68.0 p -93.37 -174.73 3.6 Favored 'General case' 0 N--CA 1.485 1.312 0 CA-C-N 118.884 0.765 . . . . 0.0 112.036 -174.098 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 233' ' ' ILE . . . . . . . . . . . . . 31.2 pt -123.15 13.17 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 C-N-CA 123.809 0.844 . . . . 0.0 109.475 167.123 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 234' ' ' GLU . . . . . . . . . . . . . 4.0 mp0 47.62 -86.84 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.36 0 C-N-CA 125.377 1.471 . . . . 0.0 111.139 -170.778 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 24.8 m-20 -141.48 0.82 1.51 Allowed 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 123.497 0.719 . . . . 0.0 112.06 -179.165 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 236' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -72.25 141.79 83.91 Favored Pre-proline 0 N--CA 1.482 1.152 0 CA-C-N 118.461 0.573 . . . . 0.0 110.003 179.517 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_exo -63.13 125.72 16.4 Favored 'Trans proline' 0 C--N 1.367 1.544 0 C-N-CA 122.41 2.074 . . . . 0.0 110.781 172.26 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 238' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -84.68 -23.87 29.23 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 123.47 0.708 . . . . 0.0 110.16 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 239' ' ' ILE . . . . . . . . . . . . . 3.6 mp 57.77 85.38 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.36 1.045 0 C-N-CA 125.014 1.325 . . . . 0.0 108.577 -170.925 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.248 1.004 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -173.887 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 251' ' ' BEZ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 253' ' ' LYS . . . . . 0.734 ' HD3' HG23 ' A' ' 215' ' ' VAL . 28.7 mmtp -138.71 -59.1 0.61 Allowed 'General case' 0 C--O 1.239 0.522 0 C-N-CA 124.703 1.201 . . . . 0.0 109.967 175.275 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 254' ' ' ARG . . . . . 0.506 ' NH2' ' HD3' ' A' ' 163' ' ' PRO . 16.8 mmt85 77.26 -49.8 0.53 Allowed 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 125.725 1.61 . . . . 0.0 109.282 -156.203 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 255' ' ' M9P . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.674 0 N-CA-C 111.795 -0.522 . . . . 0.0 111.795 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 70.4 m -139.55 134.08 31.67 Favored 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 123.836 0.854 . . . . 0.0 109.386 177.004 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -140.6 172.76 12.26 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 123.27 0.628 . . . . 0.0 110.674 -179.742 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.58 41.11 1.06 Allowed 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 124.186 0.994 . . . . 0.0 109.798 -171.415 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ASP . . . . . 0.489 ' HA ' ' HG2' ' A' ' 120' ' ' MET . 7.1 m-20 -153.86 52.53 0.7 Allowed 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 -163.168 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.633 ' HB2' ' HG ' ' A' ' 119' ' ' LEU . 7.9 mt -95.18 89.36 5.49 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 177.113 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.707 ' HB3' ' HD2' ' A' ' 89' ' ' LYS . 11.8 pt-20 -78.7 147.26 33.55 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-O 121.446 0.641 . . . . 0.0 111.771 -173.63 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 41.9 mt -98.02 113.71 25.65 Favored 'General case' 0 C--O 1.238 0.489 0 CA-C-N 114.281 -1.327 . . . . 0.0 108.9 179.77 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -109.47 144.56 37.56 Favored 'General case' 0 N--CA 1.482 1.132 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 171.383 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 18.0 ttm-85 -69.24 129.09 38.85 Favored 'General case' 0 C--O 1.24 0.604 0 CA-C-O 121.169 0.509 . . . . 0.0 111.476 -173.09 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.593 ' HB2' ' HB2' ' A' ' 85' ' ' ARG . . . -103.21 -37.62 7.62 Favored 'General case' 0 C--O 1.239 0.531 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.13 178.983 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.428 ' HB3' ' HB3' ' A' ' 83' ' ' ALA . . . -165.87 170.3 13.96 Favored 'General case' 0 N--CA 1.474 0.733 0 CA-C-O 121.595 0.712 . . . . 0.0 111.456 -176.523 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -111.55 145.94 38.21 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 171.074 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 59.7 t -74.26 97.75 1.09 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.919 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 -179.29 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 24.1 ttmm -175.13 111.66 0.13 Allowed 'General case' 0 C--O 1.239 0.507 0 C-N-CA 125.615 1.566 . . . . 0.0 107.271 178.727 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' TRP . . . . . 0.513 ' HE1' ' HB1' ' A' ' 169' ' ' ALA . 34.7 t90 -93.5 95.01 8.99 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 122.086 0.155 . . . . 0.0 111.07 -178.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -159.68 64.36 0.37 Allowed 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 148.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -89.61 -62.06 1.56 Allowed 'General case' 0 N--CA 1.481 1.111 0 CA-C-O 121.242 0.544 . . . . 0.0 112.192 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLN . . . . . 0.494 ' H ' ' HB3' ' A' ' 169' ' ' ALA . 71.5 mt-30 -150.88 47.74 0.86 Allowed 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 124.203 1.001 . . . . 0.0 109.606 -168.575 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -48.77 95.42 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 113.556 0.947 . . . . 0.0 113.556 -172.368 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -136.48 164.5 28.01 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 125.631 1.572 . . . . 0.0 108.864 -177.532 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.606 HG22 ' HB2' ' A' ' 171' ' ' GLN . 0.2 OUTLIER -122.57 140.3 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.242 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 177.464 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 63.1 m -139.84 -57.82 0.56 Allowed 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -68.93 118.67 9.04 Favored Glycine 0 C--N 1.349 1.28 0 N-CA-C 114.469 0.547 . . . . 0.0 114.469 -168.628 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 68.0 m -164.31 24.32 0.07 Allowed 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 124.864 1.266 . . . . 0.0 109.572 -173.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.629 ' HB2' ' HB2' ' A' ' 188' ' ' SER . 18.4 m -73.88 161.53 78.19 Favored Pre-proline 0 CA--C 1.555 1.163 0 C-N-CA 123.323 0.649 . . . . 0.0 110.701 -177.549 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_exo -71.77 -173.68 1.09 Allowed 'Trans proline' 0 C--N 1.378 2.1 0 C-N-CA 122.471 2.114 . . . . 0.0 112.874 174.017 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.55 HD12 ' HB2' ' A' ' 176' ' ' LEU . 27.3 mm -76.14 140.91 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.461 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.406 ' HB3' HG21 ' A' ' 217' ' ' THR . 14.0 mt -131.07 132.24 44.76 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 122.796 0.438 . . . . 0.0 111.605 -168.734 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 178' ' ' LYS . 49.3 m -69.97 135.15 49.1 Favored 'General case' 0 C--N 1.35 0.62 0 O-C-N 124.098 0.874 . . . . 0.0 111.096 179.493 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 19.6 tt -142.62 141.26 27.79 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.744 0 C-N-CA 123.829 0.852 . . . . 0.0 109.205 -177.655 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 56.0 p -99.42 109.6 22.16 Favored 'General case' 0 CA--C 1.555 1.154 0 C-N-CA 123.24 0.616 . . . . 0.0 110.168 -176.546 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 1.5 mp -80.75 120.31 32.1 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 C-N-CA 123.687 0.795 . . . . 0.0 109.038 176.33 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 26.0 m -97.71 122.78 41.19 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 124.254 1.022 . . . . 0.0 110.094 -178.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 67.57 12.4 8.86 Favored 'General case' 0 N--CA 1.493 1.677 0 C-N-CA 124.358 1.063 . . . . 0.0 112.383 171.761 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 61.73 24.86 14.88 Favored 'General case' 0 N--CA 1.491 1.618 0 C-N-CA 124.436 1.094 . . . . 0.0 112.113 -177.762 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -143.03 -42.97 0.05 OUTLIER Glycine 0 C--N 1.338 0.683 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 -178.712 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 39.4 t -93.66 162.93 13.75 Favored 'General case' 0 C--O 1.241 0.609 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 175.092 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 20.9 ptm -161.73 134.77 6.18 Favored 'General case' 0 C--O 1.241 0.609 0 C-N-CA 122.829 0.452 . . . . 0.0 110.065 -175.694 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 28.5 p -173.26 -179.07 1.86 Allowed 'General case' 0 C--O 1.221 -0.43 0 C-N-CA 123.786 0.835 . . . . 0.0 109.422 179.702 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.755 HD11 HG23 ' A' ' 217' ' ' THR . 28.3 mm -72.12 151.03 8.46 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.971 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 165.593 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 15.3 ptmt -42.62 140.0 1.41 Allowed 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 124.968 1.307 . . . . 0.0 112.104 171.785 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 65.07 85.57 0.14 Allowed 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 124.999 1.319 . . . . 0.0 108.952 -160.761 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -86.18 26.91 0.97 Allowed 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 123.86 0.864 . . . . 0.0 113.125 -169.156 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -56.1 134.94 53.06 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 123.671 0.788 . . . . 0.0 110.772 172.461 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -82.61 173.86 11.56 Favored 'General case' 0 N--CA 1.482 1.157 0 C-N-CA 123.931 0.893 . . . . 0.0 112.003 -174.258 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -144.59 142.07 29.89 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 124.158 0.983 . . . . 0.0 109.708 174.735 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 17.7 pt20 -155.09 -179.43 8.06 Favored 'General case' 0 N--CA 1.479 1.02 0 C-N-CA 123.998 0.919 . . . . 0.0 109.341 176.24 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 15.4 t -165.26 175.07 9.55 Favored 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 122.817 0.447 . . . . 0.0 110.239 -179.49 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 34.4 tp -60.94 133.72 56.38 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.673 0.789 . . . . 0.0 110.449 176.677 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.53 -162.59 35.02 Favored Glycine 0 C--N 1.34 0.788 0 O-C-N 123.508 0.505 . . . . 0.0 112.971 177.805 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 91.65 36.9 6.29 Favored Glycine 0 C--N 1.337 0.629 0 C-N-CA 123.069 0.366 . . . . 0.0 112.336 -179.117 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -77.96 63.64 3.49 Favored Glycine 0 C--N 1.353 1.479 0 C-N-CA 123.372 0.511 . . . . 0.0 112.291 -178.717 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -167.93 151.5 18.79 Favored Glycine 0 C--O 1.246 0.882 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -178.509 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 32.7 t -68.88 121.1 15.88 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 123.042 0.537 . . . . 0.0 110.342 -176.628 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 126.09 -27.19 5.14 Favored Glycine 0 C--N 1.343 0.924 0 N-CA-C 111.31 -0.716 . . . . 0.0 111.31 -177.908 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 126.24 -29.41 4.57 Favored Glycine 0 C--N 1.353 1.481 0 CA-C-O 119.906 -0.385 . . . . 0.0 112.645 178.882 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 62.4 49.76 71.03 Favored Glycine 0 C--N 1.353 1.502 0 C-N-CA 123.48 0.562 . . . . 0.0 113.692 175.847 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -120.04 -140.73 6.18 Favored Glycine 0 N--CA 1.472 1.048 0 N-CA-C 112.115 -0.394 . . . . 0.0 112.115 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 19.5 tp10 -108.54 89.67 3.06 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 123.522 0.729 . . . . 0.0 109.324 -179.502 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 5.5 p90 -121.54 80.15 1.64 Allowed 'General case' 0 CA--C 1.543 0.707 0 CA-C-N 114.946 -1.025 . . . . 0.0 109.099 -179.269 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . 61.5 26.42 16.16 Favored 'General case' 0 N--CA 1.481 1.119 0 C-N-CA 124.339 1.055 . . . . 0.0 111.491 -175.161 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.511 ' HA3' ' HG3' ' A' ' 122' ' ' LYS . . . 99.39 179.16 31.22 Favored Glycine 0 C--N 1.353 1.507 0 CA-C-N 115.614 -0.721 . . . . 0.0 113.722 -178.854 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.414 ' HB ' ' H ' ' A' ' 65' ' ' LEU . 4.6 t -92.67 -92.66 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.556 1.176 0 C-N-CA 124.724 1.21 . . . . 0.0 110.194 177.761 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.461 ' N ' ' HD2' ' A' ' 122' ' ' LYS . 24.0 tp -167.98 132.34 1.74 Allowed 'General case' 0 C--N 1.37 1.464 0 C-N-CA 123.928 0.891 . . . . 0.0 109.563 -177.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' TRP . . . . . 0.466 ' HD1' ' CE1' ' A' ' 121' ' ' HIS . 18.1 m0 -96.93 175.17 6.43 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 123.91 0.884 . . . . 0.0 111.898 -178.73 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.531 ' HB2' HD23 ' A' ' 79' ' ' LEU . 33.9 t70 -93.45 82.14 4.42 Favored 'General case' 0 N--CA 1.478 0.973 0 CA-C-N 115.229 -0.896 . . . . 0.0 108.934 170.004 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 35.8 m -92.37 147.39 34.37 Favored Pre-proline 0 CA--C 1.549 0.916 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.162 -175.581 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -60.66 83.85 0.08 OUTLIER 'Trans proline' 0 C--N 1.377 2.051 0 C-N-CA 122.53 2.153 . . . . 0.0 111.206 169.62 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 22.2 t -91.13 123.41 64.52 Favored Pre-proline 0 CA--C 1.541 0.608 0 C-N-CA 123.925 0.89 . . . . 0.0 110.084 -174.108 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -56.92 151.21 50.54 Favored 'Trans proline' 0 C--N 1.374 1.916 0 C-N-CA 122.932 2.421 . . . . 0.0 112.413 177.24 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_exo -44.58 -45.85 12.74 Favored 'Trans proline' 0 CA--C 1.572 2.401 0 C-N-CA 123.853 3.035 . . . . 0.0 116.899 -175.905 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_exo -65.02 -31.34 55.66 Favored 'Trans proline' 0 C--N 1.397 3.131 0 CA-C-N 121.999 1.75 . . . . 0.0 113.367 176.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 23.5 t -86.21 -36.95 11.15 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.918 0 C-N-CA 123.587 0.755 . . . . 0.0 111.084 -173.671 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -64.13 133.4 39.71 Favored Glycine 0 C--N 1.35 1.357 0 O-C-N 124.015 0.822 . . . . 0.0 114.119 -170.627 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 60.2 mttm -130.64 -82.89 0.54 Allowed 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 122.843 0.457 . . . . 0.0 110.398 -173.392 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -166.31 27.33 0.04 OUTLIER 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 123.9 0.88 . . . . 0.0 109.657 -170.67 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -57.21 -23.54 48.55 Favored 'General case' 0 N--CA 1.491 1.615 0 C-N-CA 125.699 1.6 . . . . 0.0 114.904 -164.164 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.531 HD23 ' HB2' ' A' ' 67' ' ' ASP . 12.2 tp -173.67 -37.41 0.01 OUTLIER 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 105.625 -1.991 . . . . 0.0 105.625 173.627 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -44.43 83.17 0.0 OUTLIER 'General case' 0 CA--C 1.552 1.054 0 CA-C-N 112.579 -2.1 . . . . 0.0 111.901 154.737 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.534 ' H ' ' HA ' ' A' ' 103' ' ' LYS . 4.5 m-20 61.21 71.13 0.57 Allowed 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 124.345 1.058 . . . . 0.0 110.923 179.689 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -129.23 137.97 9.94 Favored Glycine 0 C--N 1.338 0.66 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 174.835 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ALA . . . . . 0.428 ' HB3' ' HB3' ' A' ' 12' ' ' ALA . . . -89.21 120.64 30.76 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 178.544 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 47.6 m-85 -112.55 171.47 7.5 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-O 121.603 0.716 . . . . 0.0 111.127 -176.75 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' ARG . . . . . 0.593 ' HB2' ' HB2' ' A' ' 11' ' ' ALA . 44.4 ttm105 -131.77 122.83 26.48 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 -177.104 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.465 ' H ' ' HA ' ' A' ' 99' ' ' ALA . 24.5 mt -83.29 133.18 29.67 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 -175.856 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.597 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 76.8 tttt -137.88 131.18 30.61 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 114.743 -1.117 . . . . 0.0 108.405 -170.205 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.55 130.11 35.05 Favored 'General case' 0 C--O 1.245 0.822 0 N-CA-C 106.753 -1.573 . . . . 0.0 106.753 176.315 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' LYS . . . . . 0.707 ' HD2' ' HB3' ' A' ' 7' ' ' GLU . 48.3 tttp -123.11 135.72 54.49 Favored 'General case' 0 CA--C 1.549 0.914 0 CA-C-N 114.573 -1.194 . . . . 0.0 112.264 -162.024 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' GLY . . . . . 0.55 ' O ' ' HG2' ' A' ' 89' ' ' LYS . . . -91.83 162.11 27.43 Favored Glycine 0 C--O 1.207 -1.569 0 N-CA-C 106.464 -2.654 . . . . 0.0 106.464 149.837 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 31.1 mm -54.99 -18.74 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.195 0 CA-C-N 121.333 2.566 . . . . 0.0 114.47 -167.444 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 66.5 mt -86.1 -38.21 18.02 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.385 -0.822 . . . . 0.0 110.464 167.524 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.444 ' HA2' ' HG3' ' A' ' 89' ' ' LYS . . . 145.29 -167.63 27.36 Favored Glycine 0 N--CA 1.477 1.399 0 CA-C-O 118.348 -1.251 . . . . 0.0 110.381 176.608 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' TYR . . . . . 0.583 ' H ' ' HE2' ' A' ' 87' ' ' LYS 0.285 3.0 p90 178.68 -79.51 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.728 0 C-N-CA 123.838 0.855 . . . . 0.0 112.276 146.488 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 93.6 p -117.45 135.07 54.16 Favored 'General case' 0 N--CA 1.504 2.246 0 CA-C-N 120.384 1.447 . . . . 0.0 112.444 -161.328 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.597 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 0.0 OUTLIER -81.58 148.48 29.09 Favored 'General case' 0 N--CA 1.485 1.317 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 177.109 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 26.0 pt -133.18 -28.6 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 C-N-CA 123.354 0.662 . . . . 0.0 112.037 -171.758 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -167.41 -155.38 9.15 Favored Glycine 0 C--N 1.344 1.012 0 CA-C-O 119.803 -0.443 . . . . 0.0 112.237 -176.389 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.545 ' HA ' ' HA ' ' A' ' 85' ' ' ARG . . . -154.96 171.97 18.85 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 123.544 0.738 . . . . 0.0 110.507 -178.24 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -178.92 151.42 10.3 Favored Glycine 0 C--N 1.347 1.151 0 O-C-N 123.135 0.272 . . . . 0.0 112.594 179.487 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.446 HG12 HD11 ' A' ' 210' ' ' LEU . 14.9 p -89.15 138.17 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 122.93 0.492 . . . . 0.0 109.908 179.671 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -118.28 138.63 52.24 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 170.43 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.534 ' HA ' ' H ' ' A' ' 81' ' ' ASP . 64.4 tttp -135.14 105.9 6.53 Favored 'General case' 0 C--O 1.238 0.472 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 176.395 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 29.3 mt-10 63.39 -87.14 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.167 0 C-N-CA 125.031 1.332 . . . . 0.0 112.251 171.516 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -126.11 11.05 7.33 Favored Glycine 0 C--N 1.349 1.27 0 CA-C-O 120.163 -0.243 . . . . 0.0 113.025 -176.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 15.2 t -132.89 131.36 40.85 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 122.96 0.504 . . . . 0.0 110.094 -177.317 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 30.9 t80 -115.49 131.56 56.89 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 123.258 0.623 . . . . 0.0 109.805 -175.322 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 80.7 m-70 -135.15 123.5 23.22 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 123.058 0.543 . . . . 0.0 110.56 -177.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' THR . . . . . 0.682 HG23 HG23 ' A' ' 138' ' ' ILE . 1.9 t -139.35 175.24 9.73 Favored 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 123.245 0.618 . . . . 0.0 111.911 -179.324 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' MET . . . . . . . . . . . . . 8.0 mmt -75.07 150.1 38.97 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 124.36 1.064 . . . . 0.0 109.561 172.212 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' TRP . . . . . 0.413 ' HA ' HG22 ' A' ' 138' ' ' ILE . 76.0 t90 -78.89 -43.98 23.75 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 123.071 0.549 . . . . 0.0 111.854 -169.282 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -65.76 -6.58 12.17 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 114.312 1.227 . . . . 0.0 114.312 -172.273 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 19.7 m -60.35 -40.4 83.85 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 176.455 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 90.0 m -164.5 140.0 5.82 Favored 'General case' 0 CA--C 1.551 1.017 0 C-N-CA 126.287 1.835 . . . . 0.0 107.396 171.299 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 32.8 mtt180 -80.85 33.08 0.32 Allowed 'General case' 0 N--CA 1.485 1.305 0 N-CA-C 114.152 1.167 . . . . 0.0 114.152 -166.45 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 107.27 62.15 0.57 Allowed Glycine 0 C--N 1.346 1.091 0 O-C-N 122.085 -0.384 . . . . 0.0 112.656 178.225 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -122.78 168.23 12.5 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 123.441 0.696 . . . . 0.0 110.064 174.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 87.9 t -75.44 144.43 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.802 0 C-N-CA 123.99 0.916 . . . . 0.0 110.96 -177.888 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.735 ' HB2' ' HB ' ' A' ' 126' ' ' ILE . 5.2 mp -111.16 161.17 16.23 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 123.077 0.551 . . . . 0.0 111.831 178.853 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' MET . . . . . 0.489 ' HG2' ' HA ' ' A' ' 5' ' ' ASP . 19.6 mmt -110.7 106.99 16.4 Favored 'General case' 0 C--O 1.241 0.619 0 CA-C-O 121.935 0.874 . . . . 0.0 110.1 179.191 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.558 ' HB2' HD11 ' A' ' 126' ' ' ILE . 7.1 t-80 -104.13 95.07 5.73 Favored 'General case' 0 CA--C 1.542 0.663 0 N-CA-C 107.929 -1.137 . . . . 0.0 107.929 169.17 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.511 ' HG3' ' HA3' ' A' ' 63' ' ' GLY . 65.5 tttp 44.43 65.31 1.08 Allowed 'General case' 0 CA--C 1.554 1.115 0 C-N-CA 124.893 1.277 . . . . 0.0 112.76 176.109 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 80.73 -27.29 2.98 Favored Glycine 0 CA--C 1.531 1.076 0 CA-C-N 115.047 -0.979 . . . . 0.0 113.881 -179.576 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 94.7 mttt -85.36 154.34 21.94 Favored 'General case' 0 C--N 1.35 0.598 0 CA-C-N 117.395 0.598 . . . . 0.0 109.476 179.124 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 33.8 ptt85 -92.22 160.34 15.21 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-O 121.008 0.432 . . . . 0.0 110.367 178.52 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.735 ' HB ' ' HB2' ' A' ' 119' ' ' LEU . 80.8 mt -128.52 111.46 23.75 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 171.709 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -93.81 108.66 36.32 Favored Pre-proline 0 CA--C 1.546 0.818 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 178.7 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -56.7 103.65 0.13 Allowed 'Trans proline' 0 C--N 1.377 2.072 0 C-N-CA 122.884 2.389 . . . . 0.0 112.193 -178.42 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 86.5 p -74.9 -17.23 60.61 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 123.173 0.589 . . . . 0.0 111.277 -177.762 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 30.4 t-105 -143.26 149.92 38.55 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 -178.663 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -166.59 120.41 1.07 Allowed 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 122.98 0.512 . . . . 0.0 110.72 176.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -120.99 120.83 36.56 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.077 0.951 . . . . 0.0 109.265 171.643 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.493 HG13 ' HG3' ' A' ' 134' ' ' LYS . 4.6 p -69.05 -38.97 79.02 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 CA-C-N 114.657 -1.156 . . . . 0.0 111.844 -178.473 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.493 ' HG3' HG13 ' A' ' 133' ' ' VAL . 97.1 mttt -82.52 -27.95 31.39 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 123.307 0.643 . . . . 0.0 112.218 -173.994 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 135' ' ' LYS . . . . . 0.508 ' HB3' HD12 ' A' ' 137' ' ' LEU . 33.5 mmtp -71.83 -27.74 63.1 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 167.661 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 8.9 t70 56.64 58.61 4.03 Favored 'General case' 0 CA--C 1.538 0.494 0 O-C-N 125.27 1.606 . . . . 0.0 109.37 -167.878 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' LEU . . . . . 0.508 HD12 ' HB3' ' A' ' 135' ' ' LYS . 6.6 mt -144.1 121.98 12.0 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 113.6 -1.637 . . . . 0.0 109.223 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.682 HG23 HG23 ' A' ' 109' ' ' THR . 9.2 tt -121.85 133.32 68.6 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 174.16 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 73.4 m -146.6 165.51 29.29 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-O 122.138 0.97 . . . . 0.0 112.575 -169.798 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 46.4 t80 -133.44 128.69 36.02 Favored 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 125.778 1.631 . . . . 0.0 107.764 175.439 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 102.29 -4.01 51.3 Favored Glycine 0 C--N 1.345 1.029 0 O-C-N 123.671 0.607 . . . . 0.0 112.324 -175.363 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 147.17 -165.58 28.58 Favored Glycine 0 C--N 1.349 1.272 0 N-CA-C 111.392 -0.683 . . . . 0.0 111.392 179.324 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -77.95 -173.64 41.34 Favored Glycine 0 C--N 1.353 1.501 0 CA-C-O 118.98 -0.9 . . . . 0.0 111.059 172.42 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 144' ' ' TRP . . . . . 0.529 ' HZ2' ' HA2' ' A' ' 209' ' ' GLY . 5.1 t-105 -55.0 108.01 0.36 Allowed 'General case' 0 N--CA 1.477 0.909 0 CA-C-N 118.267 1.033 . . . . 0.0 109.986 176.856 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 30.7 tptt -144.5 133.35 22.49 Favored 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 113.725 -1.579 . . . . 0.0 107.617 -174.463 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 146' ' ' LEU . . . . . . . . . . . . . 32.9 tp -153.37 -86.75 0.06 Allowed 'General case' 0 CA--C 1.534 0.345 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 174.389 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 161.31 38.23 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.078 0 C-N-CA 125.362 1.465 . . . . 0.0 109.384 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -126.29 119.78 3.52 Favored Glycine 0 C--N 1.336 0.583 0 CA-C-N 115.879 -0.6 . . . . 0.0 113.279 -172.234 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 5.0 mp0 -113.78 100.34 8.38 Favored 'General case' 0 N--CA 1.474 0.751 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 179.457 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 150' ' ' TRP . . . . . 0.483 ' HZ2' ' HG3' ' A' ' 174' ' ' PRO . 28.8 t90 -71.28 130.23 40.88 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 174.752 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 18.2 ttmm -87.29 106.87 18.22 Favored 'General case' 0 C--O 1.242 0.673 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 176.184 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -62.19 104.14 0.45 Allowed 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.122 0.969 . . . . 0.0 111.688 -173.155 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 141.68 -38.15 1.53 Allowed Glycine 0 C--N 1.347 1.176 0 CA-C-N 116.58 -0.282 . . . . 0.0 112.989 178.026 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 -72.51 152.9 41.62 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 123.054 0.542 . . . . 0.0 111.805 -178.338 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -69.73 120.06 14.92 Favored 'General case' 0 C--O 1.244 0.786 0 N-CA-C 108.258 -1.015 . . . . 0.0 108.258 169.042 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.51 HG21 HG21 ' A' ' 208' ' ' VAL . 8.9 p -119.17 151.31 21.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.474 0 N-CA-C 108.974 -0.751 . . . . 0.0 108.974 -173.292 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 157' ' ' GLN . . . . . 0.44 ' HA ' ' HA ' ' A' ' 171' ' ' GLN . 0.0 OUTLIER -99.77 141.05 33.09 Favored 'General case' 0 N--CA 1.478 0.954 0 CA-C-O 121.081 0.467 . . . . 0.0 110.704 -168.779 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 89.7 t -117.6 131.35 70.59 Favored 'Isoleucine or valine' 0 C--O 1.245 0.825 0 C-N-CA 124.075 0.95 . . . . 0.0 108.444 170.258 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.401 HD12 ' HG2' ' A' ' 199' ' ' PRO . 44.6 mt -73.8 86.99 1.73 Allowed 'General case' 0 CA--C 1.544 0.717 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 171.356 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 160' ' ' ALA . . . . . 0.586 ' HB3' ' HB2' ' A' ' 168' ' ' ARG . . . -64.13 98.61 0.23 Allowed 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 123.357 0.663 . . . . 0.0 110.82 -176.882 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 161' ' ' LEU . . . . . 0.645 ' H ' ' HA2' ' A' ' 194' ' ' GLY . 71.6 mt -70.78 88.22 0.72 Allowed 'General case' 0 C--O 1.241 0.631 0 C-N-CA 124.549 1.139 . . . . 0.0 111.229 -173.9 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -85.34 119.08 71.96 Favored Pre-proline 0 CA--C 1.553 1.09 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.316 174.326 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_exo -59.0 115.78 2.8 Favored 'Trans proline' 0 C--N 1.379 2.167 0 C-N-CA 123.115 2.543 . . . . 0.0 113.322 -176.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 113.79 -15.26 21.7 Favored Glycine 0 N--CA 1.471 0.969 0 CA-C-O 119.348 -0.695 . . . . 0.0 113.663 174.073 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -123.21 -169.62 1.97 Allowed 'General case' 0 C--N 1.355 0.814 0 CA-C-N 117.63 0.715 . . . . 0.0 109.787 -177.249 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 10.7 p30 -70.46 162.24 71.62 Favored Pre-proline 0 CA--C 1.563 1.445 0 CA-C-N 114.695 -1.139 . . . . 0.0 109.359 161.482 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_exo -71.17 135.54 27.34 Favored 'Trans proline' 0 C--N 1.365 1.414 0 C-N-CA 121.95 1.767 . . . . 0.0 111.934 172.284 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 168' ' ' ARG . . . . . 0.586 ' HB2' ' HB3' ' A' ' 160' ' ' ALA . 85.7 mtt180 -70.88 109.26 4.93 Favored 'General case' 0 CA--C 1.546 0.801 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 171.745 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 169' ' ' ALA . . . . . 0.513 ' HB1' ' HE1' ' A' ' 16' ' ' TRP . . . -75.78 102.11 5.33 Favored 'General case' 0 N--CA 1.474 0.725 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -179.483 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.443 HG21 ' CE2' ' A' ' 191' ' ' PHE . 40.6 t -120.99 116.3 49.41 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 C-N-CA 122.52 0.328 . . . . 0.0 111.158 -170.02 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 171' ' ' GLN . . . . . 0.606 ' HB2' HG22 ' A' ' 22' ' ' ILE . 26.6 mt-30 -83.91 142.41 30.58 Favored 'General case' 0 C--O 1.243 0.751 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 173.565 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 5.6 t -152.38 136.28 16.34 Favored 'General case' 0 C--O 1.242 0.694 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.652 -168.736 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 173' ' ' LYS . . . . . 0.501 ' HD3' ' HD2' ' A' ' 174' ' ' PRO . 4.5 tppp? -72.33 126.04 91.17 Favored Pre-proline 0 CA--C 1.543 0.696 0 C-N-CA 123.557 0.743 . . . . 0.0 109.554 175.471 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 174' ' ' PRO . . . . . 0.501 ' HD2' ' HD3' ' A' ' 173' ' ' LYS . 9.2 Cg_endo -48.05 139.14 21.04 Favored 'Trans proline' 0 C--N 1.374 1.912 0 C-N-CA 123.739 2.96 . . . . 0.0 113.475 172.689 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 175' ' ' GLY . . . . . 0.695 ' H ' ' HA ' ' A' ' 187' ' ' VAL . . . -118.09 -172.77 15.84 Favored Glycine 0 C--O 1.237 0.293 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 175.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.55 ' HB2' HD12 ' A' ' 28' ' ' ILE . 5.5 mp -138.47 152.36 48.24 Favored 'General case' 0 N--CA 1.479 0.983 0 CA-C-N 117.8 0.8 . . . . 0.0 110.11 178.588 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 177' ' ' PHE . . . . . 0.652 ' HB2' ' HB ' ' A' ' 184' ' ' ILE . 35.7 m-85 -92.18 123.58 35.63 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.531 0.732 . . . . 0.0 109.85 176.571 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 178' ' ' LYS . . . . . 0.409 ' O ' ' HA ' ' A' ' 30' ' ' SER . 23.8 ttmm -86.57 94.87 9.56 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 172.383 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 63.0 m -103.1 153.68 20.05 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 123.469 0.708 . . . . 0.0 110.621 -173.536 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 7.0 t30 -80.14 64.93 5.12 Favored 'General case' 0 N--CA 1.48 1.044 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 173.776 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -175.47 -38.83 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.569 1.548 . . . . 0.0 108.706 -176.495 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 170.49 -144.17 8.23 Favored Glycine 0 C--N 1.341 0.86 0 CA-C-N 114.862 -1.063 . . . . 0.0 111.143 -178.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 10.2 m -127.13 131.87 50.7 Favored 'General case' 0 CA--C 1.548 0.866 0 C-N-CA 123.319 0.648 . . . . 0.0 109.546 179.075 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 184' ' ' ILE . . . . . 0.652 ' HB ' ' HB2' ' A' ' 177' ' ' PHE . 31.4 mt -107.16 163.28 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 C-N-CA 124.152 0.981 . . . . 0.0 108.561 -179.537 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -99.89 132.34 10.9 Favored Glycine 0 N--CA 1.478 1.488 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.677 ' HA ' ' HA ' ' A' ' 225' ' ' ALA . . . -154.51 -159.02 0.91 Allowed 'General case' 0 N--CA 1.474 0.751 0 CA-C-O 121.083 0.468 . . . . 0.0 112.105 -164.122 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 187' ' ' VAL . . . . . 0.695 ' HA ' ' H ' ' A' ' 175' ' ' GLY . 10.4 p -149.25 135.46 12.18 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 C-N-CA 123.98 0.912 . . . . 0.0 108.731 167.446 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 188' ' ' SER . . . . . 0.629 ' HB2' ' HB2' ' A' ' 26' ' ' SER . 11.9 p -106.38 101.87 11.31 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 123.679 0.792 . . . . 0.0 110.009 -173.322 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 65.5 tp -127.15 109.95 12.39 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 123.969 0.908 . . . . 0.0 110.786 -168.525 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 190' ' ' ASP . . . . . 0.48 ' HA ' ' HA ' ' A' ' 221' ' ' ALA . 13.5 p-10 -96.25 102.74 14.57 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 167.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 191' ' ' PHE . . . . . 0.443 ' CE2' HG21 ' A' ' 170' ' ' VAL . 50.5 t80 179.68 174.96 0.79 Allowed 'General case' 0 CA--C 1.551 0.985 0 CA-C-N 114.985 -1.007 . . . . 0.0 108.541 -168.117 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 33.6 m -86.87 96.17 0.51 Allowed Pre-proline 0 CA--C 1.554 1.114 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 169.548 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 193' ' ' PRO . . . . . 0.457 ' HG3' ' HB2' ' A' ' 222' ' ' TYR . 10.0 Cg_endo -93.1 -164.76 0.12 Allowed 'Trans proline' 0 C--N 1.373 1.828 0 C-N-CA 123.266 2.644 . . . . 0.0 114.055 -165.587 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 194' ' ' GLY . . . . . 0.645 ' HA2' ' H ' ' A' ' 161' ' ' LEU . . . -82.11 153.73 32.71 Favored Glycine 0 C--N 1.35 1.32 0 CA-C-N 115.053 -0.976 . . . . 0.0 112.793 176.395 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 2.8 m -70.87 155.08 41.24 Favored 'General case' 0 CA--C 1.554 1.128 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 174.201 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 4.1 m -63.67 87.41 0.04 OUTLIER 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 123.493 0.717 . . . . 0.0 112.428 -168.405 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 134.35 17.81 0.96 Allowed Glycine 0 N--CA 1.469 0.883 0 CA-C-N 114.797 -1.092 . . . . 0.0 111.823 -175.43 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 42.6 t -62.09 138.31 95.86 Favored Pre-proline 0 CA--C 1.545 0.762 0 C-N-CA 124.777 1.231 . . . . 0.0 111.388 177.246 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 199' ' ' PRO . . . . . 0.401 ' HG2' HD12 ' A' ' 159' ' ' LEU . 74.1 Cg_endo -71.9 129.79 15.86 Favored 'Trans proline' 0 C--N 1.37 1.71 0 C-N-CA 122.039 1.826 . . . . 0.0 112.259 179.371 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 22.9 mt -100.71 120.5 50.28 Favored 'Isoleucine or valine' 0 C--O 1.238 0.473 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 173.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 201' ' ' ILE . . . . . 0.49 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 56.5 mt -113.55 160.57 12.98 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.942 0 N-CA-C 107.826 -1.176 . . . . 0.0 107.826 178.221 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -99.6 169.27 9.4 Favored 'General case' 0 N--CA 1.478 0.942 0 O-C-N 121.739 -0.601 . . . . 0.0 110.539 176.188 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 7.3 ptpp? -58.66 -26.57 63.93 Favored 'General case' 0 CA--C 1.55 0.957 0 C-N-CA 124.207 1.003 . . . . 0.0 111.497 174.221 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 51.2 tptt -67.0 -20.62 65.91 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 124.064 0.946 . . . . 0.0 111.401 179.863 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 98.82 -14.1 61.88 Favored Glycine 0 C--N 1.345 1.078 0 N-CA-C 111.791 -0.524 . . . . 0.0 111.791 -175.881 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -85.79 136.89 33.14 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 123.96 0.904 . . . . 0.0 109.705 179.042 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.49 ' HA ' ' HA ' ' A' ' 201' ' ' ILE . 13.7 p -67.88 151.95 9.95 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 123.627 0.771 . . . . 0.0 110.101 -179.629 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 208' ' ' VAL . . . . . 0.51 HG21 HG21 ' A' ' 156' ' ' VAL . 28.8 m -127.49 -26.62 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 CA-C-O 118.683 -0.675 . . . . 0.0 112.568 -179.211 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.529 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . 171.72 -147.03 9.82 Favored Glycine 0 C--N 1.36 1.871 0 C-N-CA 119.202 -1.475 . . . . 0.0 116.618 176.128 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 210' ' ' LEU . . . . . 0.446 HD11 HG12 ' A' ' 101' ' ' VAL . 50.6 mt -129.65 143.33 50.77 Favored 'General case' 0 N--CA 1.491 1.623 0 C-N-CA 124.45 1.1 . . . . 0.0 111.804 -175.06 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 47.7 t80 -117.5 105.74 12.41 Favored 'General case' 0 C--O 1.236 0.386 0 C-N-CA 124.951 1.3 . . . . 0.0 108.505 -177.025 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . 172.86 71.49 0.05 OUTLIER Glycine 0 N--CA 1.442 -0.906 0 N-CA-C 111.348 -0.701 . . . . 0.0 111.348 160.286 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 213' ' ' ASN . . . . . 0.672 ' HB2' ' HB3' ' A' ' 225' ' ' ALA . 3.4 m-80 -140.17 79.62 1.72 Allowed 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 175.308 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 169.17 -152.63 20.41 Favored Glycine 0 C--O 1.247 0.927 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.756 -176.265 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 215' ' ' VAL . . . . . 0.491 HG21 ' HE2' ' B' ' 253' ' ' LYS . 9.9 p -163.24 171.02 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.832 0 CA-C-N 116.905 0.353 . . . . 0.0 111.831 -166.476 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 216' ' ' VAL . . . . . . . . . . . . . 14.4 p -69.0 128.42 32.44 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.048 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 167.021 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 217' ' ' THR . . . . . 0.755 HG23 HD11 ' A' ' 41' ' ' ILE . 47.7 m -138.12 169.27 18.09 Favored 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 124.98 1.312 . . . . 0.0 108.848 -170.817 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 218' ' ' ARG . . . . . 0.405 ' HB3' ' HB3' ' A' ' 221' ' ' ALA . 59.9 ttt180 69.22 -83.99 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 123.69 0.796 . . . . 0.0 111.526 168.099 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 23.2 p -163.27 42.36 0.11 Allowed 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 124.216 1.006 . . . . 0.0 109.011 -174.191 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . 101.39 37.89 3.42 Favored Glycine 0 C--N 1.345 1.069 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.149 -178.562 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 221' ' ' ALA . . . . . 0.48 ' HA ' ' HA ' ' A' ' 190' ' ' ASP . . . -118.96 100.61 7.48 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 123.802 0.841 . . . . 0.0 109.234 -172.479 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 222' ' ' TYR . . . . . 0.457 ' HB2' ' HG3' ' A' ' 193' ' ' PRO . 69.7 m-85 -77.4 97.81 5.05 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-O 121.601 0.715 . . . . 0.0 109.212 -177.003 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 45.7 t -97.52 113.71 32.72 Favored 'Isoleucine or valine' 0 C--O 1.235 0.29 0 CA-C-N 114.398 -1.273 . . . . 0.0 107.957 -178.708 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 8.8 t -130.91 154.58 47.95 Favored 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 124.737 1.215 . . . . 0.0 109.367 -173.025 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 225' ' ' ALA . . . . . 0.677 ' HA ' ' HA ' ' A' ' 186' ' ' ALA . . . -84.03 152.43 24.41 Favored 'General case' 0 C--O 1.247 0.947 0 CA-C-O 120.949 0.404 . . . . 0.0 110.545 178.545 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 226' ' ' ILE . . . . . . . . . . . . . 8.5 pt -114.53 93.14 2.37 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.806 0 CA-C-O 121.914 0.864 . . . . 0.0 109.855 -176.394 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 227' ' ' ALA . . . . . 0.434 ' O ' ' HA3' ' A' ' 209' ' ' GLY . . . -80.69 119.38 23.23 Favored 'General case' 0 N--CA 1.48 1.027 0 CA-C-N 114.939 -1.028 . . . . 0.0 111.108 -172.006 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 228' ' ' GLN . . . . . 0.431 ' HB3' ' HB3' ' A' ' 150' ' ' TRP . 13.7 pt20 -93.81 152.9 18.59 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 123.902 0.881 . . . . 0.0 109.188 177.621 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 229' ' ' THR . . . . . 0.422 ' HA ' ' NE1' ' A' ' 144' ' ' TRP . 87.4 m -65.06 122.36 16.85 Favored 'General case' 0 N--CA 1.477 0.907 0 CA-C-O 121.005 0.431 . . . . 0.0 111.872 -170.131 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 30.2 mt-10 -84.69 -41.73 15.99 Favored 'General case' 0 CA--C 1.543 0.694 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.313 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 231' ' ' LYS . . . . . 0.592 ' HE2' ' HB3' ' A' ' 235' ' ' ASP . 0.0 OUTLIER 61.99 95.11 0.04 OUTLIER 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 124.9 1.28 . . . . 0.0 110.742 -177.284 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 85.2 p -89.07 138.56 31.31 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-O 119.124 -0.465 . . . . 0.0 110.97 178.446 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 233' ' ' ILE . . . . . . . . . . . . . 7.0 tt 66.87 -32.84 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.627 0 C-N-CA 127.838 2.455 . . . . 0.0 115.921 167.089 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 234' ' ' GLU . . . . . 0.518 ' HB3' ' HD3' ' A' ' 231' ' ' LYS . 30.4 tt0 -59.57 -26.56 65.49 Favored 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 124.352 1.061 . . . . 0.0 113.001 -169.56 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 235' ' ' ASP . . . . . 0.592 ' HB3' ' HE2' ' A' ' 231' ' ' LYS . 6.4 p-10 -54.68 -28.85 50.61 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 124.147 0.979 . . . . 0.0 111.654 178.221 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 236' ' ' ASN . . . . . . . . . . . . . 5.4 p30 -114.84 107.33 50.56 Favored Pre-proline 0 CA--C 1.561 1.386 0 C-N-CA 124.192 0.997 . . . . 0.0 108.734 169.274 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_exo -69.81 88.75 0.54 Allowed 'Trans proline' 0 C--N 1.379 2.151 0 C-N-CA 122.706 2.27 . . . . 0.0 111.662 175.803 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 238' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 -93.92 -59.52 1.96 Allowed 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 123.403 0.681 . . . . 0.0 110.282 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 239' ' ' ILE . . . . . . . . . . . . . 37.2 pt -113.45 -39.08 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 C-N-CA 123.028 0.531 . . . . 0.0 112.187 -172.571 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 23.9 mm-40 . . . . . 0 CA--C 1.558 1.25 0 C-N-CA 124.547 1.139 . . . . 0.0 111.206 -177.048 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 251' ' ' BEZ . . . . . 0.601 ' H6 ' ' HB2' ' B' ' 253' ' ' LYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 253' ' ' LYS . . . . . 0.601 ' HB2' ' H6 ' ' B' ' 251' ' ' BEZ . 1.0 OUTLIER -71.44 78.77 0.77 Allowed 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 124.721 1.208 . . . . 0.0 111.202 -175.551 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 254' ' ' ARG . . . . . 0.46 ' HG2' HH11 ' B' ' 254' ' ' ARG . 7.2 mmt-85 -79.45 164.49 23.92 Favored 'General case' 0 C--O 1.244 0.767 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 172.917 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 255' ' ' M9P . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.384 0 N-CA-C 111.302 -0.719 . . . . 0.0 111.302 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 27.6 t -141.02 111.41 6.81 Favored 'General case' 0 C--N 1.353 0.72 0 C-N-CA 123.078 0.551 . . . . 0.0 110.386 -174.63 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 61.29 15.65 6.65 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 124.79 1.236 . . . . 0.0 114.214 171.567 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -128.84 20.39 5.99 Favored 'General case' 0 N--CA 1.476 0.869 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 -177.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -123.94 10.41 8.86 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 126.109 1.764 . . . . 0.0 107.242 -177.18 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.521 ' HB2' HD13 ' A' ' 119' ' ' LEU . 16.9 mt -67.73 166.51 15.12 Favored 'General case' 0 C--O 1.201 -1.461 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 -174.955 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -154.6 146.7 23.68 Favored 'General case' 0 C--O 1.247 0.968 0 CA-C-N 118.7 0.682 . . . . 0.0 110.144 176.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.58 ' HB2' ' CD2' ' A' ' 121' ' ' HIS . 83.7 mt -87.54 125.45 34.34 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 115.032 -0.985 . . . . 0.0 109.933 172.536 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 22.7 tt0 -104.18 125.27 50.34 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 124.893 1.277 . . . . 0.0 108.275 178.391 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 15.5 ttt180 -60.24 109.35 0.96 Allowed 'General case' 0 N--CA 1.477 0.917 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 -179.849 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.458 ' HB2' ' HG3' ' A' ' 85' ' ' ARG . . . -106.56 -43.88 4.62 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 122.487 0.315 . . . . 0.0 111.267 -170.113 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -174.25 172.91 3.16 Favored 'General case' 0 N--CA 1.477 0.913 0 O-C-N 124.095 0.872 . . . . 0.0 110.409 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -87.12 144.62 26.78 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 162.808 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 61.9 t -72.06 100.6 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.003 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 176.778 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 26.8 ttpp -172.05 103.49 0.17 Allowed 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 124.483 1.113 . . . . 0.0 108.884 -175.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' TRP . . . . . 0.532 ' NE1' ' HB1' ' A' ' 169' ' ' ALA . 92.4 t90 -80.59 94.78 6.36 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 123.224 0.61 . . . . 0.0 110.351 -179.244 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -157.81 57.62 0.48 Allowed 'General case' 0 CA--C 1.557 1.217 0 C-N-CA 123.195 0.598 . . . . 0.0 111.587 157.232 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.406 ' H ' ' HB2' ' A' ' 169' ' ' ALA . 4.8 m-20 -92.3 -63.42 1.24 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.445 -0.784 . . . . 0.0 112.689 177.675 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLN . . . . . 0.808 ' H ' ' HB3' ' A' ' 169' ' ' ALA . 48.8 mt-30 -153.09 43.8 0.63 Allowed 'General case' 0 N--CA 1.489 1.477 0 CA-C-N 114.693 -1.14 . . . . 0.0 111.248 -158.199 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -35.05 99.78 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.014 0 C-N-CA 125.537 1.535 . . . . 0.0 114.486 -175.135 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -126.52 118.48 24.99 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 123.748 0.819 . . . . 0.0 110.163 -176.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.543 ' HA ' ' HB2' ' A' ' 171' ' ' GLN . 0.2 OUTLIER -76.16 143.87 12.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 CA-C-O 121.052 0.453 . . . . 0.0 111.872 -174.478 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 77.2 p -154.35 156.71 37.39 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 124.558 1.143 . . . . 0.0 109.654 -178.502 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 160.25 103.82 0.19 Allowed Glycine 0 C--N 1.339 0.747 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -174.293 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.405 ' H ' ' HB3' ' A' ' 189' ' ' LEU . 29.4 t -109.72 -70.27 0.82 Allowed 'General case' 0 N--CA 1.478 0.961 0 CA-C-N 117.566 0.683 . . . . 0.0 111.342 -168.935 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 26.5 m -123.49 85.68 52.52 Favored Pre-proline 0 CA--C 1.551 1.014 0 C-N-CA 123.3 0.64 . . . . 0.0 109.526 -172.891 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 82.3 Cg_exo -45.41 -49.76 10.01 Favored 'Trans proline' 0 C--N 1.39 2.761 0 C-N-CA 124.293 3.329 . . . . 0.0 114.162 -173.149 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 49.1 mm -104.01 117.04 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 175.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.578 HD11 ' HB2' ' A' ' 218' ' ' ARG . 0.5 OUTLIER -138.26 128.52 25.95 Favored 'General case' 0 N--CA 1.478 0.942 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 -177.232 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 60.1 p -79.24 159.24 27.39 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 122.949 0.5 . . . . 0.0 111.195 179.088 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 16.0 tt -150.68 159.62 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 -177.793 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 35.3 m -94.88 110.81 22.65 Favored 'General case' 0 C--O 1.241 0.622 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 176.949 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 45.5 mm -72.12 115.75 12.98 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 173.673 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.491 ' HB2' ' HB3' ' A' ' 38' ' ' SER . 15.5 m -79.65 117.63 20.74 Favored 'General case' 0 C--O 1.241 0.627 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 170.641 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -60.37 -8.49 2.69 Favored 'General case' 0 N--CA 1.491 1.608 0 C-N-CA 124.473 1.109 . . . . 0.0 113.491 -169.206 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -65.79 -13.75 60.05 Favored 'General case' 0 CA--C 1.551 1.0 0 C-N-CA 124.756 1.222 . . . . 0.0 112.24 172.823 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.04 14.39 26.66 Favored Glycine 0 C--N 1.347 1.141 0 N-CA-C 111.693 -0.563 . . . . 0.0 111.693 -171.249 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.491 ' HB3' ' HB2' ' A' ' 34' ' ' SER . 23.1 t -109.03 164.97 11.95 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.496 0.719 . . . . 0.0 110.481 -179.303 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 68.3 mtp -133.29 134.71 44.23 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 123.518 0.727 . . . . 0.0 109.808 -179.015 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.417 ' HB3' ' HE3' ' B' ' 253' ' ' LYS . 13.3 p -169.44 174.4 6.0 Favored 'General case' 0 C--N 1.353 0.749 0 CA-C-O 121.436 0.636 . . . . 0.0 112.611 -175.185 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.635 HD11 HG23 ' A' ' 217' ' ' THR . 50.7 mm -89.44 152.33 3.35 Favored 'Isoleucine or valine' 0 C--O 1.241 0.635 0 N-CA-C 107.0 -1.482 . . . . 0.0 107.0 160.062 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 47.6 mtmt -72.65 75.74 1.1 Allowed 'General case' 0 CA--C 1.55 0.977 0 CA-C-O 121.665 0.745 . . . . 0.0 110.51 177.195 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 36.0 t30 -173.05 143.42 1.15 Allowed 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 126.079 1.752 . . . . 0.0 107.667 -176.504 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.475 ' HA ' ' HB2' ' B' ' 253' ' ' LYS . 12.5 pt-20 -148.5 150.53 33.56 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 122.537 0.335 . . . . 0.0 111.155 177.961 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -166.91 172.96 9.8 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 124.425 1.09 . . . . 0.0 109.866 179.419 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -65.44 119.3 10.76 Favored 'General case' 0 CA--C 1.558 1.28 0 N-CA-C 113.578 0.955 . . . . 0.0 113.578 -171.644 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -83.11 76.12 9.87 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 124.482 1.113 . . . . 0.0 109.82 173.022 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 75.5 mt-30 -117.59 104.11 10.71 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.055 -0.975 . . . . 0.0 110.097 -178.318 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.402 HG23 ' HB3' ' A' ' 96' ' ' GLN . 2.2 t -133.38 175.58 9.29 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 125.06 1.344 . . . . 0.0 107.794 171.119 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 53.4 tp -150.77 128.21 11.41 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 176.346 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -90.0 -122.89 2.41 Favored Glycine 0 C--N 1.345 1.079 0 N-CA-C 110.891 -0.884 . . . . 0.0 110.891 173.094 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -100.72 -144.82 16.19 Favored Glycine 0 C--N 1.337 0.629 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 168.352 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.25 42.94 96.02 Favored Glycine 0 C--N 1.348 1.197 0 CA-C-N 116.874 0.337 . . . . 0.0 113.897 173.326 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -170.98 -121.99 0.61 Allowed Glycine 0 C--N 1.339 0.718 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 178.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 11.0 t 67.85 165.04 0.23 Allowed 'General case' 0 N--CA 1.485 1.312 0 C-N-CA 125.337 1.455 . . . . 0.0 112.681 176.549 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -77.34 -17.74 78.95 Favored Glycine 0 C--N 1.348 1.23 0 CA-C-N 115.552 -0.749 . . . . 0.0 113.073 179.272 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -68.39 98.6 0.52 Allowed Glycine 0 C--N 1.346 1.123 0 N-CA-C 112.283 -0.327 . . . . 0.0 112.283 176.608 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -76.61 -137.76 0.81 Allowed Glycine 0 CA--C 1.531 1.073 0 N-CA-C 112.184 -0.366 . . . . 0.0 112.184 175.063 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 71.12 -76.88 0.58 Allowed Glycine 0 C--N 1.346 1.11 0 N-CA-C 111.364 -0.694 . . . . 0.0 111.364 -176.276 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 23.9 mm-40 -81.13 -22.88 38.71 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 123.711 0.804 . . . . 0.0 110.929 172.274 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 48.3 p90 40.86 95.94 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.831 0 C-N-CA 126.672 1.989 . . . . 0.0 114.14 177.445 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . 69.4 8.8 6.98 Favored 'General case' 0 N--CA 1.487 1.414 0 C-N-CA 124.823 1.249 . . . . 0.0 112.854 177.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 87.21 -57.12 4.57 Favored Glycine 0 C--N 1.349 1.299 0 N-CA-C 111.746 -0.542 . . . . 0.0 111.746 -178.308 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 8.8 p 44.37 50.84 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.568 1.639 0 C-N-CA 126.43 1.892 . . . . 0.0 112.945 172.231 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -159.18 97.85 1.4 Allowed 'General case' 0 N--CA 1.485 1.31 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 -178.385 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' TRP . . . . . 0.533 ' NE1' ' HG3' ' A' ' 122' ' ' LYS . 1.1 p90 -168.99 60.46 0.05 Allowed 'General case' 0 N--CA 1.49 1.572 0 C-N-CA 123.791 0.837 . . . . 0.0 110.674 -179.044 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ASP . . . . . 0.492 ' HB3' ' H ' ' A' ' 68' ' ' VAL . 15.1 m-20 177.59 -141.82 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.933 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 -171.893 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.492 ' H ' ' HB3' ' A' ' 67' ' ' ASP . 6.1 m -52.99 123.25 32.46 Favored Pre-proline 0 CA--C 1.566 1.592 0 CA-C-N 114.898 -1.046 . . . . 0.0 110.831 153.45 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_exo -60.28 -34.41 93.77 Favored 'Trans proline' 0 C--N 1.377 2.071 0 C-N-CA 122.801 2.334 . . . . 0.0 112.384 171.69 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 53.5 m -86.96 171.44 10.0 Favored Pre-proline 0 CA--C 1.554 1.13 0 C-N-CA 124.077 0.951 . . . . 0.0 110.022 174.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 76.7 Cg_exo -53.4 147.6 36.65 Favored 'Trans proline' 0 C--N 1.384 2.395 0 C-N-CA 122.349 2.033 . . . . 0.0 112.066 166.435 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 97.2 Cg_exo -47.56 111.16 0.38 Allowed 'Trans proline' 0 C--N 1.377 2.071 0 C-N-CA 123.46 2.774 . . . . 0.0 113.399 177.565 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' PRO . . . . . 0.407 ' HG2' ' H ' ' A' ' 76' ' ' LYS . 70.5 Cg_endo -71.06 -179.93 3.89 Favored 'Trans proline' 0 C--N 1.379 2.147 0 C-N-CA 123.261 2.64 . . . . 0.0 112.845 -178.418 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 41.2 t -64.66 -43.04 96.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 123.021 0.528 . . . . 0.0 110.067 -179.83 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -66.53 -43.77 91.54 Favored Glycine 0 C--N 1.348 1.248 0 CA-C-N 115.38 -0.827 . . . . 0.0 112.553 176.44 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' LYS . . . . . 0.407 ' H ' ' HG2' ' A' ' 73' ' ' PRO . 64.1 pttt 47.3 15.97 0.05 Allowed 'General case' 0 N--CA 1.503 2.193 0 C-N-CA 126.632 1.973 . . . . 0.0 115.247 176.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -74.79 -23.67 58.54 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 123.664 0.786 . . . . 0.0 110.571 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -70.61 104.92 2.95 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 123.608 0.763 . . . . 0.0 109.62 173.355 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.424 HD13 ' OH ' ' A' ' 102' ' ' TYR . 88.6 mt -135.08 134.34 40.21 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 124.568 1.147 . . . . 0.0 108.236 178.229 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -95.01 145.24 25.08 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 121.525 0.679 . . . . 0.0 110.572 -177.432 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.532 ' HB2' ' HA ' ' A' ' 103' ' ' LYS . 38.5 p-10 -127.93 169.76 13.6 Favored 'General case' 0 CA--C 1.537 0.449 0 CA-C-N 114.449 -1.25 . . . . 0.0 112.271 -172.473 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 142.27 -162.82 27.2 Favored Glycine 0 C--N 1.345 1.06 0 CA-C-N 115.296 -0.866 . . . . 0.0 112.256 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' ALA . . . . . 0.512 ' HB1' HD11 ' A' ' 161' ' ' LEU . . . -85.76 123.26 30.93 Favored 'General case' 0 N--CA 1.477 0.88 0 C-N-CA 123.67 0.788 . . . . 0.0 109.865 177.587 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 15.0 m-85 -129.79 140.43 51.04 Favored 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 123.356 0.663 . . . . 0.0 110.686 -176.145 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' ARG . . . . . 0.527 ' HD3' HE22 ' A' ' 96' ' ' GLN . 80.7 mtt85 -88.09 128.8 35.42 Favored 'General case' 0 N--CA 1.479 0.997 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 173.994 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.411 ' H ' ' HA ' ' A' ' 99' ' ' ALA . 53.3 mt -91.02 122.03 42.0 Favored 'Isoleucine or valine' 0 C--O 1.247 0.957 0 CA-C-O 121.432 0.634 . . . . 0.0 110.209 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.561 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 34.4 mtmm -114.84 146.96 40.5 Favored 'General case' 0 C--O 1.216 -0.675 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.316 174.657 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 19.7 tm0? -87.05 107.15 18.3 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 105.872 -1.899 . . . . 0.0 105.872 165.848 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' LYS . . . . . 0.405 ' HD2' ' HE2' ' A' ' 87' ' ' LYS . 50.0 mtpt -114.38 94.04 4.62 Favored 'General case' 0 C--O 1.241 0.641 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 -176.078 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -70.28 137.9 28.5 Favored Glycine 0 C--O 1.242 0.619 0 N-CA-C 108.221 -1.951 . . . . 0.0 108.221 165.816 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 2.9 mp -75.13 68.9 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.566 1.584 0 N-CA-C 107.103 -1.443 . . . . 0.0 107.103 176.854 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 3.9 pp 170.5 -38.16 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.468 0 C-N-CA 126.435 1.894 . . . . 0.0 109.834 -165.549 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -161.66 134.33 3.48 Favored Glycine 0 C--N 1.353 1.492 0 CA-C-N 115.994 -0.548 . . . . 0.0 112.201 -174.417 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 8.2 m-85 -123.25 131.65 53.75 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.75 0.82 . . . . 0.0 109.756 -167.806 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 53.6 m -148.65 146.32 28.13 Favored 'General case' 0 N--CA 1.483 1.21 0 C-N-CA 123.956 0.902 . . . . 0.0 109.383 176.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.561 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 61.9 tt0 -92.52 144.08 25.7 Favored 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 123.127 0.571 . . . . 0.0 110.904 178.312 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 25.5 pt -128.34 -26.4 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 C-N-CA 123.138 0.575 . . . . 0.0 112.158 -173.255 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' GLY . . . . . 0.421 ' HA2' ' HB ' ' A' ' 195' ' ' THR . . . -177.52 -149.54 7.93 Favored Glycine 0 C--N 1.349 1.271 0 C-N-CA 121.144 -0.55 . . . . 0.0 113.263 -177.643 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.411 ' HA ' ' H ' ' A' ' 86' ' ' ILE . . . -157.23 175.47 13.98 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 124.119 0.967 . . . . 0.0 110.969 -176.447 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -178.21 -171.18 41.28 Favored Glycine 0 C--N 1.346 1.117 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.646 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 34.7 t -135.64 127.0 44.92 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.065 0 CA-C-O 121.552 0.691 . . . . 0.0 111.023 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' TYR . . . . . 0.424 ' OH ' HD13 ' A' ' 79' ' ' LEU . 8.5 t80 -91.03 145.0 25.07 Favored 'General case' 0 CA--C 1.548 0.874 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 170.698 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.532 ' HA ' ' HB2' ' A' ' 81' ' ' ASP . 20.1 tptp -152.65 118.14 5.3 Favored 'General case' 0 N--CA 1.483 1.196 0 CA-C-N 119.168 0.895 . . . . 0.0 111.667 177.303 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 52.3 43.2 30.99 Favored 'General case' 0 N--CA 1.486 1.344 0 C-N-CA 124.629 1.171 . . . . 0.0 113.262 166.286 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 96.31 -33.76 5.42 Favored Glycine 0 C--N 1.348 1.244 0 CA-C-N 115.935 -0.575 . . . . 0.0 112.947 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 60.5 p -88.88 118.93 28.94 Favored 'General case' 0 CA--C 1.542 0.639 0 CA-C-N 117.023 0.412 . . . . 0.0 110.433 -178.213 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' PHE . . . . . 0.429 ' CE2' ' HG ' ' A' ' 119' ' ' LEU . 23.1 t80 -95.23 115.25 27.18 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 176.638 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 108' ' ' HIS . . . . . 0.618 ' HB2' ' HE3' ' A' ' 144' ' ' TRP . 1.0 OUTLIER -136.2 121.2 18.81 Favored 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 122.698 0.399 . . . . 0.0 110.808 -176.703 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 14.7 t -135.88 -179.71 5.82 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 122.999 0.52 . . . . 0.0 112.035 -169.09 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -72.72 141.52 48.17 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 124.839 1.256 . . . . 0.0 110.023 171.247 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 80.7 t90 -76.03 -53.01 9.0 Favored 'General case' 0 N--CA 1.483 1.202 0 CA-C-O 119.328 -0.367 . . . . 0.0 111.616 -174.482 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' HIS . . . . . 0.62 ' HE1' ' HA ' ' A' ' 213' ' ' ASN . 3.4 p-80 -65.35 -2.88 3.48 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 114.119 1.155 . . . . 0.0 114.119 -170.437 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.405 HG13 ' HA3' ' A' ' 98' ' ' GLY . 78.1 t -58.07 -39.58 73.22 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.934 0 CA-C-O 121.524 0.678 . . . . 0.0 109.705 167.639 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.618 HG23 ' H ' ' A' ' 116' ' ' GLY . 9.4 t -138.6 -168.48 2.41 Favored 'General case' 0 CA--C 1.555 1.161 0 CA-C-N 114.607 -1.179 . . . . 0.0 109.765 -178.492 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 31.5 ttt180 -93.03 14.94 16.26 Favored 'General case' 0 CA--C 1.561 1.401 0 C-N-CA 124.063 0.945 . . . . 0.0 110.951 177.316 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.618 ' H ' HG23 ' A' ' 114' ' ' THR . . . 80.17 40.7 13.2 Favored Glycine 0 C--N 1.346 1.084 0 N-CA-C 111.816 -0.513 . . . . 0.0 111.816 -175.167 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -120.23 -169.89 1.88 Allowed 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 123.336 0.654 . . . . 0.0 111.543 -173.705 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 48.9 t -75.36 136.93 23.94 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 N-CA-C 114.184 1.179 . . . . 0.0 114.184 -159.854 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.521 HD13 ' HB2' ' A' ' 6' ' ' LEU . 3.7 mm? -103.13 151.63 22.36 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 124.89 1.276 . . . . 0.0 110.616 174.505 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 38.1 mmt -104.1 151.45 23.26 Favored 'General case' 0 C--O 1.262 1.744 0 C-N-CA 124.57 1.148 . . . . 0.0 108.197 173.284 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.58 ' CD2' ' HB2' ' A' ' 8' ' ' LEU . 0.1 OUTLIER -143.52 92.45 2.36 Favored 'General case' 0 CA--C 1.538 0.495 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 165.072 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.533 ' HG3' ' NE1' ' A' ' 66' ' ' TRP . 10.1 mtmp? 56.72 28.45 14.24 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 124.591 1.157 . . . . 0.0 112.619 -174.614 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 100.66 -8.91 58.45 Favored Glycine 0 C--N 1.347 1.176 0 CA-C-O 119.683 -0.509 . . . . 0.0 113.229 -176.904 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 61.2 tttm -72.94 114.55 11.22 Favored 'General case' 0 C--N 1.357 0.901 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 171.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 47.1 ttp180 -82.86 86.13 6.98 Favored 'General case' 0 C--O 1.241 0.605 0 C-N-CA 124.258 1.023 . . . . 0.0 109.271 -174.368 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.461 HG13 ' HB2' ' A' ' 119' ' ' LEU . 23.8 pt -91.71 100.49 11.3 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 CA-C-O 122.334 1.064 . . . . 0.0 109.346 -177.71 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -94.22 126.79 47.14 Favored Pre-proline 0 CA--C 1.546 0.789 0 CA-C-N 113.972 -1.467 . . . . 0.0 110.063 -175.382 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.401 ' HB3' HG23 ' A' ' 138' ' ' ILE . 88.0 Cg_exo -49.53 119.5 4.72 Favored 'Trans proline' 0 C--N 1.373 1.865 0 C-N-CA 123.266 2.644 . . . . 0.0 113.834 175.666 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 59.1 p -82.13 -10.41 59.19 Favored 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 123.799 0.84 . . . . 0.0 110.51 174.425 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.703 ' HB3' ' HB2' ' A' ' 139' ' ' SER . 64.8 t-105 -155.79 152.77 28.86 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 124.912 1.285 . . . . 0.0 109.096 178.176 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -161.86 120.48 2.33 Favored 'General case' 0 C--O 1.241 0.622 0 C-N-CA 124.152 0.981 . . . . 0.0 108.546 169.897 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -108.84 112.5 24.79 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 123.324 0.65 . . . . 0.0 109.627 176.652 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 11.5 t -75.47 -17.47 15.8 Favored 'Isoleucine or valine' 0 CA--C 1.557 1.228 0 C-N-CA 123.139 0.576 . . . . 0.0 110.159 179.316 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 23.4 ttmm -59.62 -51.5 69.55 Favored 'General case' 0 C--N 1.358 0.974 0 C-N-CA 124.486 1.114 . . . . 0.0 112.359 -174.584 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 79.6 tttt -109.79 4.9 22.2 Favored 'General case' 0 N--CA 1.485 1.291 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 172.606 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 15.6 t70 67.96 71.15 0.33 Allowed 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 124.341 1.056 . . . . 0.0 111.368 170.175 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 47.8 mt -147.43 160.29 42.73 Favored 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 124.317 1.047 . . . . 0.0 110.278 178.043 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.449 HD11 ' HA2' ' A' ' 116' ' ' GLY . 38.0 mt -132.24 150.72 33.83 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 C-N-CA 125.739 1.615 . . . . 0.0 108.214 -176.675 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 139' ' ' SER . . . . . 0.703 ' HB2' ' HB3' ' A' ' 130' ' ' TRP . 20.4 m -145.36 143.98 30.44 Favored 'General case' 0 CA--C 1.554 1.123 0 C-N-CA 123.81 0.844 . . . . 0.0 110.887 -179.393 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 19.8 t80 -139.35 128.98 24.52 Favored 'General case' 0 N--CA 1.48 1.029 0 C-N-CA 125.544 1.538 . . . . 0.0 107.942 178.207 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.03 2.51 88.83 Favored Glycine 0 C--N 1.35 1.347 0 O-C-N 123.848 0.717 . . . . 0.0 113.178 179.336 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 165.09 -153.49 23.69 Favored Glycine 0 C--N 1.339 0.725 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -173.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -105.62 173.47 20.24 Favored Glycine 0 C--N 1.343 0.968 0 CA-C-N 117.122 0.461 . . . . 0.0 112.034 174.66 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 144' ' ' TRP . . . . . 0.618 ' HE3' ' HB2' ' A' ' 108' ' ' HIS . 36.2 t-105 -66.6 110.51 3.22 Favored 'General case' 0 C--O 1.245 0.853 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 170.064 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 145' ' ' LYS . . . . . 0.516 ' HA ' ' HB ' ' A' ' 229' ' ' THR . 0.1 OUTLIER -150.49 146.34 26.55 Favored 'General case' 0 CA--C 1.538 0.499 0 CA-C-O 121.6 0.714 . . . . 0.0 110.475 171.345 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 146' ' ' LEU . . . . . 0.518 HD12 ' HA2' ' A' ' 209' ' ' GLY . 72.7 mt -144.06 2.21 1.15 Allowed 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 125.997 1.719 . . . . 0.0 108.099 170.932 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 36.6 mt-10 71.07 36.2 1.47 Allowed 'General case' 0 C--N 1.372 1.564 0 C-N-CA 124.157 0.983 . . . . 0.0 111.421 171.045 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.532 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -149.94 156.51 26.78 Favored Glycine 0 C--N 1.347 1.174 0 CA-C-O 121.436 0.465 . . . . 0.0 113.932 -177.613 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -151.12 131.29 13.53 Favored 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 124.022 0.929 . . . . 0.0 109.224 -176.071 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 150' ' ' TRP . . . . . 0.567 ' HE1' ' HB3' ' A' ' 174' ' ' PRO . 50.8 t-105 -91.7 143.78 26.19 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 122.985 0.514 . . . . 0.0 110.027 170.599 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 26.5 tptp -131.14 139.44 49.8 Favored 'General case' 0 CA--C 1.536 0.412 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 169.101 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -44.27 147.11 0.58 Allowed 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 126.165 1.786 . . . . 0.0 113.73 -178.162 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 152.12 -84.7 0.15 Allowed Glycine 0 C--N 1.342 0.867 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.804 179.389 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -88.73 -174.88 4.71 Favored 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 124.446 1.099 . . . . 0.0 110.538 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 11.6 mp0 -63.97 130.95 46.1 Favored 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 169.67 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 13.0 p -90.53 148.0 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 166.444 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 157' ' ' GLN . . . . . 0.63 HE21 ' HB3' ' A' ' 203' ' ' LYS . 41.8 mm-40 -103.72 140.5 37.52 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -170.24 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.568 HG22 HG12 ' A' ' 200' ' ' ILE . 19.1 t -127.63 120.02 53.35 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 176.139 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.601 ' HB3' ' HG2' ' A' ' 199' ' ' PRO . 0.2 OUTLIER -81.39 86.18 6.33 Favored 'General case' 0 CA--C 1.558 1.269 0 N-CA-C 107.481 -1.304 . . . . 0.0 107.481 174.249 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 160' ' ' ALA . . . . . 0.422 ' HA ' ' OG ' ' A' ' 198' ' ' SER . . . -68.97 104.99 2.24 Favored 'General case' 0 N--CA 1.481 1.121 0 C-N-CA 123.263 0.625 . . . . 0.0 112.089 -172.43 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 161' ' ' LEU . . . . . 0.512 HD11 ' HB1' ' A' ' 83' ' ' ALA . 74.9 mt -75.42 83.8 2.52 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 174.359 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 15.0 tp10 -70.25 119.75 74.02 Favored Pre-proline 0 CA--C 1.551 1.017 0 CA-C-N 114.886 -1.052 . . . . 0.0 110.176 -176.931 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 163' ' ' PRO . . . . . 0.487 ' HG3' HG23 ' A' ' 195' ' ' THR . 63.5 Cg_exo -55.43 114.1 1.72 Allowed 'Trans proline' 0 C--N 1.377 2.045 0 C-N-CA 123.132 2.554 . . . . 0.0 113.378 -178.928 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 75.99 22.08 74.9 Favored Glycine 0 C--N 1.344 1.019 0 O-C-N 123.724 0.64 . . . . 0.0 113.418 175.386 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 54.1 tptt -151.69 156.88 41.25 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -174.434 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 20.3 p30 -58.28 148.21 64.08 Favored Pre-proline 0 CA--C 1.558 1.259 0 C-N-CA 123.034 0.534 . . . . 0.0 112.312 177.594 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -59.62 146.89 94.04 Favored 'Trans proline' 0 C--N 1.379 2.134 0 C-N-CA 123.213 2.609 . . . . 0.0 113.233 179.048 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 168' ' ' ARG . . . . . 0.413 ' HB2' ' HB3' ' A' ' 160' ' ' ALA . 80.9 mtp180 -123.91 110.54 14.96 Favored 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 123.804 0.842 . . . . 0.0 108.828 -172.465 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 169' ' ' ALA . . . . . 0.808 ' HB3' ' H ' ' A' ' 19' ' ' GLN . . . -78.84 106.37 10.81 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-O 120.808 0.337 . . . . 0.0 110.701 -178.662 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 21.9 t -105.64 139.19 27.57 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.894 0 C-N-CA 123.176 0.591 . . . . 0.0 109.778 -178.023 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 171' ' ' GLN . . . . . 0.543 ' HB2' ' HA ' ' A' ' 22' ' ' ILE . 11.2 mt-30 -97.09 102.87 14.73 Favored 'General case' 0 C--N 1.348 0.53 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 170.335 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 172' ' ' THR . . . . . 0.519 ' HB ' HD11 ' A' ' 189' ' ' LEU . 71.4 p -101.71 124.06 46.73 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -178.816 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 28.1 mtpp -71.03 133.17 86.06 Favored Pre-proline 0 CA--C 1.546 0.806 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 174.049 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 174' ' ' PRO . . . . . 0.567 ' HB3' ' HE1' ' A' ' 150' ' ' TRP . 37.7 Cg_endo -64.1 123.53 12.03 Favored 'Trans proline' 0 C--N 1.377 2.053 0 C-N-CA 122.288 1.992 . . . . 0.0 111.776 -169.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -100.0 -173.94 30.37 Favored Glycine 0 N--CA 1.45 -0.428 0 CA-C-N 114.956 -1.02 . . . . 0.0 112.229 177.064 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 5.6 mp -148.73 145.84 27.82 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.096 0.958 . . . . 0.0 109.172 178.476 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 177' ' ' PHE . . . . . 0.729 ' HB2' ' HB ' ' A' ' 184' ' ' ILE . 59.1 m-85 -92.71 122.67 35.35 Favored 'General case' 0 C--O 1.245 0.866 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 167.705 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 77.8 tttt -95.21 104.8 16.7 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 114.809 -1.087 . . . . 0.0 109.187 177.063 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 36.4 p -132.81 156.98 46.14 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 169.481 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 10.3 t30 -56.61 -38.74 72.47 Favored 'General case' 0 N--CA 1.484 1.232 0 C-N-CA 123.874 0.87 . . . . 0.0 112.892 -169.078 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -94.93 -35.68 11.91 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 123.067 0.547 . . . . 0.0 110.8 178.906 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -112.94 118.19 4.5 Favored Glycine 0 C--N 1.347 1.153 0 CA-C-N 116.279 -0.419 . . . . 0.0 113.859 -169.319 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 30.2 m -98.57 100.88 12.16 Favored 'General case' 0 CA--C 1.538 0.507 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 163.167 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 184' ' ' ILE . . . . . 0.729 ' HB ' ' HB2' ' A' ' 177' ' ' PHE . 46.9 mt -104.17 149.73 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 C-N-CA 123.512 0.725 . . . . 0.0 109.07 -169.546 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -99.17 124.6 8.29 Favored Glycine 0 C--N 1.349 1.305 0 N-CA-C 109.808 -1.317 . . . . 0.0 109.808 -179.577 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.657 ' HA ' ' HA ' ' A' ' 225' ' ' ALA . . . -140.27 -174.66 4.0 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 114.125 1.157 . . . . 0.0 114.125 -159.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 187' ' ' VAL . . . . . . . . . . . . . 98.4 t -126.27 99.86 6.14 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.641 0 N-CA-C 105.683 -1.969 . . . . 0.0 105.683 171.183 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 188' ' ' SER . . . . . 0.559 ' HA ' HG13 ' A' ' 223' ' ' VAL . 60.6 p -113.64 79.64 1.27 Allowed 'General case' 0 C--O 1.243 0.731 0 CA-C-O 122.243 1.021 . . . . 0.0 111.044 -171.343 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 189' ' ' LEU . . . . . 0.519 HD11 ' HB ' ' A' ' 172' ' ' THR . 0.0 OUTLIER -151.49 178.9 8.83 Favored 'General case' 0 N--CA 1.477 0.923 0 CA-C-N 114.596 -1.184 . . . . 0.0 111.528 175.723 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -80.03 102.33 9.21 Favored 'General case' 0 CA--C 1.542 0.635 0 N-CA-C 107.307 -1.368 . . . . 0.0 107.307 171.622 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 191' ' ' PHE . . . . . 0.73 ' HB3' ' HB2' ' A' ' 222' ' ' TYR . 69.5 t80 -106.58 164.22 12.24 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 124.32 1.048 . . . . 0.0 109.53 -174.269 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 16.8 m -58.79 155.15 32.7 Favored Pre-proline 0 CA--C 1.561 1.394 0 C-N-CA 124.748 1.219 . . . . 0.0 112.134 178.297 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_exo -64.84 10.91 0.12 Allowed 'Trans proline' 0 C--N 1.381 2.263 0 C-N-CA 123.123 2.548 . . . . 0.0 115.342 171.555 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 194' ' ' GLY . . . . . 0.458 ' HA2' ' HD3' ' A' ' 163' ' ' PRO . . . -50.05 134.13 27.72 Favored Glycine 0 CA--C 1.54 1.643 0 C-N-CA 123.621 0.629 . . . . 0.0 112.995 168.712 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 195' ' ' THR . . . . . 0.487 HG23 ' HG3' ' A' ' 163' ' ' PRO . 6.6 p -75.34 151.39 38.25 Favored 'General case' 0 CA--C 1.552 1.03 0 C-N-CA 124.285 1.034 . . . . 0.0 113.381 -169.919 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -62.98 128.91 38.03 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 124.333 1.053 . . . . 0.0 111.213 -172.643 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 197' ' ' GLY . . . . . 0.422 ' O ' HD22 ' A' ' 210' ' ' LEU . . . 96.68 8.19 57.35 Favored Glycine 0 C--N 1.34 0.755 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 -167.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 198' ' ' SER . . . . . 0.422 ' OG ' ' HA ' ' A' ' 160' ' ' ALA . 34.0 t -57.15 119.06 28.31 Favored Pre-proline 0 CA--C 1.557 1.243 0 C-N-CA 123.684 0.793 . . . . 0.0 109.839 164.278 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 199' ' ' PRO . . . . . 0.601 ' HG2' ' HB3' ' A' ' 159' ' ' LEU . 19.6 Cg_endo -58.04 131.63 44.61 Favored 'Trans proline' 0 C--N 1.377 2.033 0 C-N-CA 123.171 2.581 . . . . 0.0 113.832 -170.924 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 200' ' ' ILE . . . . . 0.568 HG12 HG22 ' A' ' 158' ' ' VAL . 18.9 mt -97.98 130.87 46.1 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.754 0 C-N-CA 123.988 0.915 . . . . 0.0 109.062 171.903 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 201' ' ' ILE . . . . . . . . . . . . . 50.3 mt -123.03 169.55 14.26 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.369 0 C-N-CA 124.706 1.202 . . . . 0.0 108.525 179.045 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -108.55 155.82 20.21 Favored 'General case' 0 N--CA 1.483 1.177 0 C-N-CA 124.346 1.058 . . . . 0.0 108.867 173.258 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 203' ' ' LYS . . . . . 0.63 ' HB3' HE21 ' A' ' 157' ' ' GLN . 18.7 ptmt -66.4 -19.5 65.82 Favored 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 -170.578 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 45.3 mttp -73.99 -17.4 61.0 Favored 'General case' 0 N--CA 1.488 1.443 0 CA-C-N 117.911 0.323 . . . . 0.0 110.739 176.011 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 115.4 -16.45 17.16 Favored Glycine 0 C--N 1.351 1.362 0 N-CA-C 111.898 -0.481 . . . . 0.0 111.898 -176.066 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 206' ' ' LYS . . . . . 0.423 ' HE3' ' HA ' ' A' ' 206' ' ' LYS . 1.2 tpmt? -73.21 119.2 17.12 Favored 'General case' 0 C--O 1.219 -0.502 0 C-N-CA 123.985 0.914 . . . . 0.0 109.239 -177.676 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.532 ' O ' ' HA3' ' A' ' 148' ' ' GLY . 12.7 p -64.02 150.23 10.13 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.926 0 C-N-CA 122.798 0.439 . . . . 0.0 110.239 176.916 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 208' ' ' VAL . . . . . 0.502 ' HB ' HG22 ' A' ' 200' ' ' ILE . 93.4 t -106.26 -49.84 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 177.542 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.518 ' HA2' HD12 ' A' ' 146' ' ' LEU . . . 161.33 -117.49 0.77 Allowed Glycine 0 N--CA 1.441 -1.014 0 CA-C-N 114.876 -1.056 . . . . 0.0 112.986 178.709 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 210' ' ' LEU . . . . . 0.58 ' HG ' ' CH2' ' A' ' 144' ' ' TRP . 69.2 mt -124.37 166.43 15.96 Favored 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 123.406 0.683 . . . . 0.0 111.841 -177.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -69.9 112.65 6.46 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-N 114.213 -1.358 . . . . 0.0 107.602 167.608 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -74.5 -145.66 1.07 Allowed Glycine 0 C--N 1.341 0.814 0 N-CA-C 115.984 1.154 . . . . 0.0 115.984 -163.849 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 213' ' ' ASN . . . . . 0.62 ' HA ' ' HE1' ' A' ' 112' ' ' HIS . 14.2 p30 -100.66 123.56 45.04 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 121.295 0.569 . . . . 0.0 110.716 -166.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 177.49 -134.31 2.44 Favored Glycine 0 N--CA 1.442 -0.906 0 CA-C-N 114.736 -1.12 . . . . 0.0 111.293 178.922 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 215' ' ' VAL . . . . . 0.423 HG22 ' N ' ' A' ' 216' ' ' VAL . 10.0 p -176.55 178.09 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 -165.133 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 216' ' ' VAL . . . . . 0.589 HG13 ' HB2' ' B' ' 254' ' ' ARG . 6.7 m -75.35 110.36 10.08 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.024 0 O-C-N 121.159 -0.963 . . . . 0.0 108.922 160.213 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 217' ' ' THR . . . . . 0.635 HG23 HD11 ' A' ' 41' ' ' ILE . 13.4 m -104.14 177.02 4.96 Favored 'General case' 0 CA--C 1.548 0.886 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 175.86 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 218' ' ' ARG . . . . . 0.578 ' HB2' HD11 ' A' ' 29' ' ' LEU . 71.0 ttt-85 63.38 30.98 15.42 Favored 'General case' 0 N--CA 1.491 1.604 0 CA-C-O 121.98 0.895 . . . . 0.0 110.119 176.096 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 19.6 m 68.33 17.32 9.24 Favored 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 125.47 1.508 . . . . 0.0 113.203 177.807 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . 153.14 -6.87 0.44 Allowed Glycine 0 C--N 1.355 1.618 0 N-CA-C 115.05 0.78 . . . . 0.0 115.05 174.779 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 221' ' ' ALA . . . . . 0.463 ' HB3' ' HB3' ' A' ' 218' ' ' ARG . . . -78.58 125.97 30.1 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 123.205 0.602 . . . . 0.0 110.167 -179.816 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 222' ' ' TYR . . . . . 0.73 ' HB2' ' HB3' ' A' ' 191' ' ' PHE . 11.6 m-85 -65.97 102.03 0.74 Allowed 'General case' 0 N--CA 1.481 1.087 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 178.216 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 223' ' ' VAL . . . . . 0.559 HG13 ' HA ' ' A' ' 188' ' ' SER . 92.4 t -124.64 108.54 20.46 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.922 0 C-N-CA 124.296 1.038 . . . . 0.0 109.469 -176.726 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 50.6 m -142.1 159.0 43.11 Favored 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 123.871 0.868 . . . . 0.0 109.451 -178.571 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 225' ' ' ALA . . . . . 0.657 ' HA ' ' HA ' ' A' ' 186' ' ' ALA . . . -65.12 -171.36 0.07 Allowed 'General case' 0 N--CA 1.482 1.155 0 N-CA-C 113.349 0.87 . . . . 0.0 113.349 -174.809 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 226' ' ' ILE . . . . . . . . . . . . . 46.5 mt -118.29 105.84 18.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 172.786 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -80.34 99.72 8.05 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 122.965 0.506 . . . . 0.0 109.857 -178.713 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 18.2 pt20 -94.25 162.14 13.97 Favored 'General case' 0 N--CA 1.484 1.235 0 C-N-CA 123.929 0.892 . . . . 0.0 110.184 -178.813 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 229' ' ' THR . . . . . 0.516 ' HB ' ' HA ' ' A' ' 145' ' ' LYS . 24.6 p -90.06 121.83 32.49 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 122.669 0.388 . . . . 0.0 111.284 -170.856 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -139.65 -21.0 0.91 Allowed 'General case' 0 N--CA 1.483 1.221 0 C-N-CA 123.464 0.706 . . . . 0.0 112.284 -166.695 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 2.4 mptp? -82.33 -80.42 0.16 Allowed 'General case' 0 N--CA 1.488 1.463 0 CA-C-N 117.921 0.328 . . . . 0.0 110.453 -164.165 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 232' ' ' SER . . . . . 0.41 ' HB2' ' HD2' ' A' ' 145' ' ' LYS . 73.0 m -76.46 93.5 3.53 Favored 'General case' 0 C--N 1.36 1.03 0 CA-C-N 118.304 0.502 . . . . 0.0 109.788 171.566 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 233' ' ' ILE . . . . . . . . . . . . . 33.2 pt -69.99 -34.59 60.44 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.671 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.328 177.342 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 234' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 52.46 27.56 5.09 Favored 'General case' 0 N--CA 1.493 1.703 0 C-N-CA 125.068 1.347 . . . . 0.0 111.696 179.408 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -103.81 -11.79 17.33 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 124.718 1.207 . . . . 0.0 111.506 -168.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 236' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 -59.57 134.28 88.95 Favored Pre-proline 0 CA--C 1.55 0.965 0 C-N-CA 122.731 0.413 . . . . 0.0 110.888 -175.283 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -68.64 89.29 0.42 Allowed 'Trans proline' 0 C--N 1.373 1.825 0 C-N-CA 122.252 1.968 . . . . 0.0 110.36 174.374 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 238' ' ' GLU . . . . . . . . . . . . . 16.2 tp10 -66.29 -80.46 0.04 OUTLIER 'General case' 0 CA--C 1.549 0.92 0 CA-C-N 115.123 -0.944 . . . . 0.0 111.148 -170.352 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 239' ' ' ILE . . . . . . . . . . . . . 8.2 tp -95.96 -23.47 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.135 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 174.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 . . . . . 0 C--O 1.25 1.101 0 C-N-CA 124.808 1.243 . . . . 0.0 108.101 -177.604 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 251' ' ' BEZ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 253' ' ' LYS . . . . . 0.475 ' HB2' ' HA ' ' A' ' 44' ' ' GLU . 18.3 tptm -126.41 57.21 1.42 Allowed 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 107.907 -1.146 . . . . 0.0 107.907 165.39 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 254' ' ' ARG . . . . . 0.589 ' HB2' HG13 ' A' ' 216' ' ' VAL . 18.2 mmm180 -68.44 149.33 49.44 Favored 'General case' 0 C--O 1.241 0.633 0 CA-C-N 113.991 -1.459 . . . . 0.0 109.746 173.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 255' ' ' M9P . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.879 0 CA-C-O 120.801 0.112 . . . . 0.0 113.237 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.655 ' HA ' ' HG3' ' A' ' 88' ' ' GLN . 38.2 t -77.53 154.02 32.83 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 123.733 0.813 . . . . 0.0 110.549 177.936 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -154.03 -74.92 0.12 Allowed 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 122.458 0.303 . . . . 0.0 110.463 173.043 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.554 ' O ' HG22 ' A' ' 118' ' ' VAL . . . -162.7 8.06 0.06 Allowed 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 112.175 0.435 . . . . 0.0 112.175 -175.774 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -123.37 83.92 2.2 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 177.223 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.693 ' HA ' ' HA ' ' A' ' 88' ' ' GLN . 4.8 mp -125.07 98.79 5.83 Favored 'General case' 0 N--CA 1.481 1.122 0 CA-C-O 119.333 -0.365 . . . . 0.0 111.559 -173.663 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 30.3 tt0 -81.58 144.84 30.98 Favored 'General case' 0 C--O 1.252 1.207 0 CA-C-O 121.979 0.895 . . . . 0.0 111.197 -175.125 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.634 HD21 HD13 ' A' ' 119' ' ' LEU . 53.9 mt -85.31 115.3 22.98 Favored 'General case' 0 C--O 1.242 0.706 0 CA-C-N 113.556 -1.656 . . . . 0.0 109.752 176.04 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -104.03 125.96 50.78 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 171.319 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 47.0 ptt85 -67.17 129.39 39.76 Favored 'General case' 0 N--CA 1.478 0.958 0 CA-C-N 118.36 0.527 . . . . 0.0 109.76 178.66 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.41 ' HB3' HD13 ' A' ' 161' ' ' LEU . . . -121.69 -21.35 6.18 Favored 'General case' 0 N--CA 1.479 0.983 0 C-N-CA 122.746 0.418 . . . . 0.0 111.239 -176.366 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ALA . . . . . 0.668 ' HB3' ' HB3' ' A' ' 83' ' ' ALA . . . -164.01 161.4 22.63 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 121.639 0.733 . . . . 0.0 111.058 178.592 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -93.71 155.84 17.02 Favored 'General case' 0 C--O 1.245 0.826 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 161.31 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.592 HG23 ' HA2' ' A' ' 82' ' ' GLY . 85.9 t -67.21 103.35 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 175.931 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 58.8 tttp -168.55 133.32 1.64 Allowed 'General case' 0 C--O 1.239 0.528 0 CA-C-N 115.123 -0.944 . . . . 0.0 108.617 -170.308 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 23.3 t90 -74.61 114.01 12.54 Favored 'General case' 0 CA--C 1.542 0.655 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 167.504 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.565 ' HB3' ' HB2' ' A' ' 169' ' ' ALA . 39.6 tt0 -72.25 145.42 47.94 Favored 'General case' 0 CA--C 1.548 0.888 0 C-N-CA 123.344 0.658 . . . . 0.0 109.825 176.825 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -78.32 -2.73 39.48 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 123.878 0.871 . . . . 0.0 112.716 -172.579 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 31.6 mm-40 -87.08 43.44 1.1 Allowed 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 122.99 0.516 . . . . 0.0 110.152 -175.616 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -60.4 101.27 0.12 Allowed 'General case' 0 C--N 1.354 0.788 0 C-N-CA 124.775 1.23 . . . . 0.0 110.803 -174.603 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -105.37 117.44 34.02 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 124.236 1.014 . . . . 0.0 109.496 -173.662 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.513 HD13 ' HB2' ' A' ' 171' ' ' GLN . 43.4 mm -76.55 127.43 37.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 C-N-CA 123.025 0.53 . . . . 0.0 110.063 -172.82 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.433 ' HG ' ' HE2' ' A' ' 191' ' ' PHE . 29.2 m -148.25 -171.55 3.86 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 124.149 0.98 . . . . 0.0 110.796 -172.604 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 133.4 66.28 0.08 OUTLIER Glycine 0 C--N 1.347 1.185 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.515 ' H ' ' HA ' ' A' ' 189' ' ' LEU . 13.1 m -66.62 -52.6 43.36 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-N 114.648 -0.776 . . . . 0.0 111.845 -167.308 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.446 ' HB2' ' OG ' ' A' ' 188' ' ' SER . 14.8 m -95.26 144.12 27.26 Favored Pre-proline 0 CA--C 1.552 1.048 0 C-N-CA 123.119 0.568 . . . . 0.0 110.525 -172.747 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -84.97 -161.06 0.12 Allowed 'Trans proline' 0 C--N 1.378 2.113 0 C-N-CA 123.0 2.467 . . . . 0.0 112.623 174.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 45.3 mm -63.05 133.72 28.68 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 168.405 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.529 HD13 HG21 ' A' ' 217' ' ' THR . 0.2 OUTLIER -143.75 163.72 32.53 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 123.719 0.808 . . . . 0.0 109.639 -163.428 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.3 t -108.65 145.84 34.34 Favored 'General case' 0 N--CA 1.479 1.013 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 172.699 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.447 HD12 ' CE2' ' A' ' 177' ' ' PHE . 14.9 tt -135.27 154.38 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 C-N-CA 123.4 0.68 . . . . 0.0 109.336 -174.143 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 34.7 p -95.35 103.77 15.65 Favored 'General case' 0 C--O 1.243 0.713 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 171.628 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.45 ' HA ' ' HA ' ' A' ' 39' ' ' MET . 15.7 tt -91.05 117.53 34.47 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.764 179.432 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.615 ' HB3' ' HB3' ' A' ' 38' ' ' SER . 35.5 t -82.97 118.52 23.55 Favored 'General case' 0 C--O 1.242 0.662 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.003 -178.919 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -52.84 -28.15 21.55 Favored 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 125.3 1.44 . . . . 0.0 112.474 -177.682 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -48.22 -41.26 26.94 Favored 'General case' 0 CA--C 1.55 0.957 0 C-N-CA 125.265 1.426 . . . . 0.0 111.884 174.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 145.68 9.89 0.28 Allowed Glycine 0 C--N 1.34 0.791 0 CA-C-N 114.929 -1.032 . . . . 0.0 111.942 178.507 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.615 ' HB3' ' HB3' ' A' ' 34' ' ' SER . 32.7 t -109.82 164.2 12.79 Favored 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 123.537 0.735 . . . . 0.0 110.334 -173.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' MET . . . . . 0.45 ' HA ' ' HA ' ' A' ' 33' ' ' ILE . 22.3 ptm -153.67 127.64 8.95 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 123.439 0.696 . . . . 0.0 109.133 173.604 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 17.7 p -169.46 169.82 8.68 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 123.091 0.556 . . . . 0.0 110.862 -175.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.0 mp -78.69 124.32 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 N-CA-C 104.815 -2.291 . . . . 0.0 104.815 157.699 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.43 79.02 0.01 OUTLIER 'General case' 0 CA--C 1.558 1.278 0 C-N-CA 124.238 1.015 . . . . 0.0 112.824 -170.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 92.5 m-20 -130.5 173.65 10.65 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 125.017 1.327 . . . . 0.0 109.088 -177.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -72.23 143.08 48.94 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 123.54 0.736 . . . . 0.0 110.755 177.063 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -115.41 149.29 38.22 Favored 'General case' 0 N--CA 1.473 0.678 0 C-N-CA 123.207 0.603 . . . . 0.0 110.594 177.593 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -145.19 152.2 39.62 Favored 'General case' 0 C--O 1.242 0.694 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 177.892 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -101.1 -176.43 3.16 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 123.209 0.603 . . . . 0.0 110.501 176.605 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.482 HE21 ' N ' ' A' ' 48' ' ' GLN . 0.0 OUTLIER -164.68 175.46 9.73 Favored 'General case' 0 N--CA 1.486 1.346 0 C-N-CA 124.426 1.09 . . . . 0.0 109.874 -176.609 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.583 ' HB ' ' HA ' ' A' ' 95' ' ' SER . 13.4 t -135.0 146.72 49.32 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 123.589 0.756 . . . . 0.0 109.188 171.535 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.438 ' HB3' ' OE1' ' A' ' 96' ' ' GLN . 29.5 tp -167.13 68.8 0.09 Allowed 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 175.828 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -173.87 142.89 6.76 Favored Glycine 0 C--N 1.342 0.888 0 CA-C-N 114.175 -1.375 . . . . 0.0 110.617 -177.873 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -115.89 -58.22 0.33 Allowed Glycine 0 C--N 1.348 1.205 0 CA-C-N 117.465 0.632 . . . . 0.0 112.472 -175.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 59.56 52.64 51.87 Favored Glycine 0 C--N 1.356 1.682 0 C-N-CA 123.251 0.453 . . . . 0.0 112.192 -179.407 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 100.89 -133.08 11.17 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 110.55 -1.02 . . . . 0.0 110.55 -169.742 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 38.4 t -163.37 -36.7 0.04 OUTLIER 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 123.429 0.692 . . . . 0.0 110.502 179.546 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -72.96 -15.01 78.44 Favored Glycine 0 C--N 1.357 1.726 0 O-C-N 123.579 0.549 . . . . 0.0 114.337 -176.392 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 70.85 -98.51 0.7 Allowed Glycine 0 C--N 1.346 1.136 0 N-CA-C 112.324 -0.311 . . . . 0.0 112.324 -177.566 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -87.38 71.69 2.64 Favored Glycine 0 C--N 1.348 1.215 0 N-CA-C 111.205 -0.758 . . . . 0.0 111.205 177.184 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -67.82 88.98 0.19 Allowed Glycine 0 C--N 1.346 1.095 0 C-N-CA 122.964 0.316 . . . . 0.0 113.133 -178.109 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -74.95 -51.0 14.84 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 123.346 0.659 . . . . 0.0 109.542 176.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 89.2 t80 -76.46 105.18 7.37 Favored 'General case' 0 C--O 1.24 0.595 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 174.491 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . 65.7 114.55 0.03 OUTLIER 'General case' 0 CA--C 1.546 0.816 0 O-C-N 124.384 1.052 . . . . 0.0 110.512 -170.222 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -57.35 150.61 29.54 Favored Glycine 0 CA--C 1.533 1.176 0 CA-C-N 115.769 -0.65 . . . . 0.0 112.968 176.512 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.477 ' HB ' ' HG3' ' A' ' 122' ' ' LYS . 4.6 t -81.93 20.46 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 C-N-CA 124.356 1.062 . . . . 0.0 111.883 -169.913 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 3.3 tm? 74.33 102.69 0.07 Allowed 'General case' 0 N--CA 1.484 1.274 0 C-N-CA 124.85 1.26 . . . . 0.0 110.043 173.76 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' TRP . . . . . 0.467 ' CD1' ' HD2' ' A' ' 122' ' ' LYS . 30.2 m-90 -80.13 142.18 35.03 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 123.755 0.822 . . . . 0.0 109.712 178.103 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 27.1 t0 -83.68 75.84 10.03 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-O 121.759 0.79 . . . . 0.0 109.077 -178.833 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.411 ' HA ' ' O ' ' A' ' 78' ' ' GLU . 6.4 m -107.15 101.37 37.84 Favored Pre-proline 0 CA--C 1.554 1.098 0 CA-C-N 114.75 -1.114 . . . . 0.0 111.19 -173.562 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.64 ' HG3' ' HB3' ' A' ' 80' ' ' GLU . 73.7 Cg_endo -75.02 -46.38 0.24 Allowed 'Trans proline' 0 C--N 1.377 2.04 0 C-N-CA 122.274 1.982 . . . . 0.0 111.489 174.644 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 9.0 p -92.1 128.8 43.9 Favored Pre-proline 0 CA--C 1.547 0.843 0 C-N-CA 124.197 0.999 . . . . 0.0 110.072 178.678 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -58.39 151.28 62.15 Favored 'Trans proline' 0 C--N 1.374 1.901 0 C-N-CA 123.232 2.621 . . . . 0.0 113.296 168.654 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 66.8 Cg_exo -50.58 -47.0 26.72 Favored 'Trans proline' 0 C--N 1.384 2.41 0 C-N-CA 123.686 2.924 . . . . 0.0 115.703 176.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_exo -70.72 128.36 15.04 Favored 'Trans proline' 0 C--N 1.389 2.665 0 CA-C-N 121.884 1.709 . . . . 0.0 111.35 175.586 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 39.7 t 54.18 85.77 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.315 0 C-N-CA 125.009 1.324 . . . . 0.0 111.648 -177.543 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 168.64 124.82 0.75 Allowed Glycine 0 C--N 1.34 0.788 0 N-CA-C 111.034 -0.827 . . . . 0.0 111.034 -179.189 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 65.8 mttm -83.26 -27.66 29.71 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 123.286 0.635 . . . . 0.0 110.887 -176.565 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -89.3 151.81 21.9 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 123.611 0.764 . . . . 0.0 111.069 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.411 ' O ' ' HA ' ' A' ' 68' ' ' VAL . 3.9 tm-20 -126.21 -69.46 0.77 Allowed 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 174.328 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.431 HD12 ' CE1' ' A' ' 121' ' ' HIS . 7.9 tt -84.88 128.17 34.49 Favored 'General case' 0 C--O 1.244 0.764 0 N-CA-C 106.685 -1.598 . . . . 0.0 106.685 170.533 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.64 ' HB3' ' HG3' ' A' ' 69' ' ' PRO . 8.7 pt-20 -68.01 148.0 51.63 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-O 121.178 0.513 . . . . 0.0 111.661 -175.155 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.411 ' HB2' ' HA ' ' A' ' 103' ' ' LYS . 6.3 p-10 -72.27 136.42 46.29 Favored 'General case' 0 C--O 1.239 0.524 0 CA-C-N 115.74 -0.663 . . . . 0.0 109.552 173.13 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.592 ' HA2' HG23 ' A' ' 14' ' ' VAL . . . 163.28 -175.05 39.6 Favored Glycine 0 C--N 1.34 0.79 0 O-C-N 123.167 0.292 . . . . 0.0 112.574 -173.106 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' ALA . . . . . 0.668 ' HB3' ' HB3' ' A' ' 12' ' ' ALA . . . -93.18 110.17 21.68 Favored 'General case' 0 C--O 1.244 0.789 0 CA-C-O 121.102 0.477 . . . . 0.0 110.503 -177.761 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 18.1 m-85 -107.41 136.92 46.39 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 176.731 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.68 131.79 36.82 Favored 'General case' 0 C--O 1.245 0.837 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 175.183 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.533 HD11 ' HE2' ' A' ' 107' ' ' PHE . 38.0 mt -90.58 111.46 23.54 Favored 'Isoleucine or valine' 0 C--O 1.273 2.3 0 CA-C-O 122.559 1.171 . . . . 0.0 110.482 -176.426 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.473 ' HZ1' ' HB3' ' A' ' 94' ' ' TYR . 7.1 tmtm? -116.73 130.89 57.0 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-N 112.857 -1.974 . . . . 0.0 107.061 179.075 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' GLN . . . . . 0.693 ' HA ' ' HA ' ' A' ' 6' ' ' LEU . 21.0 tm0? -79.86 111.08 15.84 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 106.838 -1.541 . . . . 0.0 106.838 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' LYS . . . . . 0.432 ' HE3' ' HB2' ' A' ' 89' ' ' LYS . 35.0 ttmt -117.1 93.61 4.25 Favored 'General case' 0 C--O 1.238 0.458 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 -178.277 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -104.51 144.61 15.86 Favored Glycine 0 CA--C 1.496 -1.152 0 CA-C-N 114.158 -1.383 . . . . 0.0 110.953 -176.263 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 2.9 mp -65.3 -15.34 18.27 Favored 'Isoleucine or valine' 0 CA--C 1.566 1.589 0 C-N-CA 125.087 1.355 . . . . 0.0 109.675 179.735 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 1.1 pp -118.43 0.31 11.6 Favored 'General case' 0 CA--C 1.557 1.229 0 N-CA-C 113.467 0.914 . . . . 0.0 113.467 175.658 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 175.67 154.45 11.43 Favored Glycine 0 N--CA 1.488 2.128 0 CA-C-N 119.289 0.95 . . . . 0.0 114.185 -175.048 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' TYR . . . . . 0.473 ' HB3' ' HZ1' ' A' ' 87' ' ' LYS . 75.4 m-85 -130.71 125.39 33.79 Favored 'General case' 0 N--CA 1.487 1.405 0 C-N-CA 123.421 0.688 . . . . 0.0 112.086 -171.89 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.583 ' HA ' ' HB ' ' A' ' 49' ' ' THR . 39.8 m -135.66 157.36 47.06 Favored 'General case' 0 N--CA 1.492 1.675 0 C-N-CA 124.794 1.237 . . . . 0.0 110.734 171.506 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.471 ' H ' ' HA ' ' A' ' 49' ' ' THR . 11.7 pt20 -100.19 148.89 24.12 Favored 'General case' 0 N--CA 1.496 1.875 0 N-CA-C 107.977 -1.12 . . . . 0.0 107.977 158.366 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.649 HD11 ' HB2' ' A' ' 88' ' ' GLN . 0.0 OUTLIER -132.17 -39.01 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 CA-C-N 119.629 1.104 . . . . 0.0 111.305 179.167 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -175.59 -145.99 5.68 Favored Glycine 0 C--N 1.347 1.143 0 C-N-CA 119.652 -1.261 . . . . 0.0 114.199 -171.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -158.64 175.28 13.85 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 123.488 0.715 . . . . 0.0 111.449 -177.048 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -172.25 176.47 45.25 Favored Glycine 0 C--N 1.344 0.993 0 CA-C-N 115.401 -0.818 . . . . 0.0 111.539 -178.608 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.447 HG11 HD11 ' A' ' 146' ' ' LEU . 47.2 t -123.12 125.93 72.81 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.012 0 C-N-CA 122.866 0.466 . . . . 0.0 111.028 -175.325 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 39.4 t80 -85.34 144.63 27.94 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 167.092 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.603 ' HG3' ' HG3' ' A' ' 104' ' ' GLU . 22.9 tptm -157.0 133.83 10.19 Favored 'General case' 0 C--O 1.239 0.518 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 173.665 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.603 ' HG3' ' HG3' ' A' ' 103' ' ' LYS . 29.5 mt-10 62.6 -91.83 0.03 OUTLIER 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 124.983 1.313 . . . . 0.0 111.569 176.062 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -143.89 31.26 1.88 Allowed Glycine 0 C--N 1.341 0.831 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.4 t -146.28 129.4 16.55 Favored 'General case' 0 C--O 1.241 0.653 0 C-N-CA 123.694 0.798 . . . . 0.0 110.614 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' PHE . . . . . 0.533 ' HE2' HD11 ' A' ' 86' ' ' ILE . 67.2 t80 -94.92 104.01 15.89 Favored 'General case' 0 C--N 1.345 0.386 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 171.916 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' HIS . . . . . 0.541 ' CE1' ' HB3' ' A' ' 103' ' ' LYS . 1.5 p-80 -107.8 121.08 44.01 Favored 'General case' 0 C--N 1.325 -0.481 0 C-N-CA 123.247 0.619 . . . . 0.0 109.492 -178.862 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 8.6 t -136.62 179.77 6.17 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 123.839 0.856 . . . . 0.0 111.241 -172.52 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' MET . . . . . 0.449 ' SD ' ' O ' ' A' ' 212' ' ' GLY . 27.7 ttm -74.92 150.42 39.12 Favored 'General case' 0 CA--C 1.547 0.86 0 C-N-CA 125.463 1.505 . . . . 0.0 109.94 173.204 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 111' ' ' TRP . . . . . 0.407 ' HA ' HG22 ' A' ' 138' ' ' ILE . 86.8 t90 -73.61 -56.32 5.16 Favored 'General case' 0 N--CA 1.494 1.747 0 CA-C-N 118.32 0.509 . . . . 0.0 111.967 -168.474 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 1.2 p-80 -68.69 2.96 2.12 Favored 'General case' 0 N--CA 1.485 1.314 0 N-CA-C 114.332 1.234 . . . . 0.0 114.332 -171.358 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.412 HG21 HD12 ' A' ' 86' ' ' ILE . 23.0 m -60.32 -38.64 78.27 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 167.273 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 12.0 t -122.48 174.24 7.17 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 124.663 1.185 . . . . 0.0 108.498 178.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 50.7 ttt-85 -93.14 31.26 1.48 Allowed 'General case' 0 N--CA 1.485 1.275 0 CA-C-O 121.326 0.584 . . . . 0.0 109.588 -179.005 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.418 ' HA2' HD12 ' A' ' 138' ' ' ILE . . . 73.74 35.43 54.91 Favored Glycine 0 C--N 1.348 1.234 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 -167.22 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -122.36 -163.31 1.07 Allowed 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 123.663 0.785 . . . . 0.0 111.782 -168.833 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.698 HG21 ' HG3' ' A' ' 125' ' ' ARG . 2.0 m -89.21 156.56 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.127 0 C-N-CA 123.359 0.664 . . . . 0.0 110.822 -172.413 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.634 HD13 HD21 ' A' ' 8' ' ' LEU . 54.8 mt -110.46 174.78 5.7 Favored 'General case' 0 CA--C 1.551 1.018 0 C-N-CA 124.357 1.063 . . . . 0.0 109.586 170.758 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 23.5 mmt -124.63 137.6 54.36 Favored 'General case' 0 C--O 1.25 1.093 0 C-N-CA 123.534 0.734 . . . . 0.0 110.165 -176.026 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.45 ' NE2' ' HD1' ' A' ' 66' ' ' TRP . 77.6 t60 -130.88 95.85 3.93 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 168.002 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.477 ' HG3' ' HB ' ' A' ' 64' ' ' VAL . 0.1 OUTLIER 62.93 20.44 12.25 Favored 'General case' 0 N--CA 1.495 1.811 0 C-N-CA 124.513 1.125 . . . . 0.0 111.523 -168.461 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 88.52 14.65 61.31 Favored Glycine 0 C--N 1.345 1.054 0 CA-C-O 119.7 -0.5 . . . . 0.0 112.682 -172.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -82.18 129.5 34.85 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 169.072 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 125' ' ' ARG . . . . . 0.698 ' HG3' HG21 ' A' ' 118' ' ' VAL . 35.8 ttm180 -78.59 98.71 6.25 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 124.794 1.237 . . . . 0.0 111.217 -173.619 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.446 HD11 ' HB2' ' A' ' 121' ' ' HIS . 18.4 mt -89.08 95.48 5.44 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.693 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 175.751 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -91.68 141.57 25.84 Favored Pre-proline 0 N--CA 1.487 1.422 0 C-N-CA 122.732 0.413 . . . . 0.0 110.256 -179.212 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -73.42 153.8 50.36 Favored 'Trans proline' 0 C--N 1.382 2.307 0 C-N-CA 122.924 2.416 . . . . 0.0 114.791 -170.786 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 66.4 p -101.88 -32.45 10.22 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 123.97 0.908 . . . . 0.0 110.209 172.766 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 72.4 t-105 -130.38 149.71 51.94 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 124.059 0.944 . . . . 0.0 109.355 -177.76 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -156.77 125.69 5.93 Favored 'General case' 0 C--O 1.241 0.654 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 175.78 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -141.75 110.16 6.0 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 123.108 0.563 . . . . 0.0 109.896 179.717 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 3.5 t -77.09 -17.02 14.56 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.286 0 C-N-CA 123.654 0.782 . . . . 0.0 111.307 -176.552 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 58.3 mttp -65.21 -53.79 39.36 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 123.697 0.799 . . . . 0.0 110.903 -176.53 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 47.6 mmtm -82.93 -17.38 43.81 Favored 'General case' 0 N--CA 1.478 0.934 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.181 172.654 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 11.5 t70 60.49 66.74 0.9 Allowed 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 125.865 1.666 . . . . 0.0 109.44 -173.66 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 51.8 mt -143.63 123.94 13.83 Favored 'General case' 0 CA--C 1.547 0.844 0 CA-C-N 113.673 -1.603 . . . . 0.0 108.7 -179.17 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.418 HD12 ' HA2' ' A' ' 116' ' ' GLY . 16.8 tt -118.7 138.79 48.26 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 176.076 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 35.0 t -134.37 151.76 51.4 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 121.785 0.802 . . . . 0.0 111.797 -175.914 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 18.8 m-85 -124.25 102.77 7.87 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 113.784 -1.553 . . . . 0.0 107.423 -169.754 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 97.09 -1.98 61.22 Favored Glycine 0 C--N 1.346 1.092 0 O-C-N 123.776 0.672 . . . . 0.0 113.366 -177.09 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . -175.69 -150.54 8.06 Favored Glycine 0 C--N 1.347 1.155 0 CA-C-O 119.503 -0.61 . . . . 0.0 111.986 -177.52 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -116.83 -179.43 17.79 Favored Glycine 0 C--N 1.352 1.419 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 171.185 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 144' ' ' TRP . . . . . 0.527 ' HA ' ' HB2' ' A' ' 108' ' ' HIS . 54.1 t-105 -70.61 105.15 3.03 Favored 'General case' 0 N--CA 1.476 0.867 0 CA-C-N 118.655 1.227 . . . . 0.0 108.782 175.964 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 19.2 ptmt -138.41 121.55 16.86 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 122.944 0.498 . . . . 0.0 110.944 -171.058 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 146' ' ' LEU . . . . . 0.447 HD11 HG11 ' A' ' 101' ' ' VAL . 46.1 mt -153.17 -33.13 0.12 Allowed 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 125.586 1.554 . . . . 0.0 107.928 172.609 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 71.65 101.55 0.07 Allowed 'General case' 0 C--N 1.362 1.12 0 C-N-CA 126.166 1.786 . . . . 0.0 110.545 -179.048 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.455 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -167.75 148.03 12.37 Favored Glycine 0 C--O 1.242 0.655 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 178.218 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -151.66 108.57 3.53 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -177.193 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 150' ' ' TRP . . . . . 0.605 ' HB2' HG21 ' A' ' 208' ' ' VAL . 81.5 t90 -65.9 123.95 21.2 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-O 120.762 0.315 . . . . 0.0 110.692 172.775 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -151.52 90.49 1.57 Allowed 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 160.567 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 152' ' ' GLU . . . . . 0.5 ' HG3' ' H ' ' A' ' 154' ' ' GLU . 12.0 tp10 -131.81 142.91 49.86 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 115.133 -0.94 . . . . 0.0 109.285 178.793 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -64.19 -30.42 77.75 Favored Glycine 0 C--N 1.349 1.287 0 N-CA-C 111.404 -0.678 . . . . 0.0 111.404 173.158 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 154' ' ' GLU . . . . . 0.5 ' H ' ' HG3' ' A' ' 152' ' ' GLU . 29.9 mt-10 -81.22 173.34 12.61 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 124.786 1.234 . . . . 0.0 110.003 172.566 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 155' ' ' GLU . . . . . 0.495 ' HB2' ' HB3' ' A' ' 171' ' ' GLN . 4.4 mp0 -67.31 166.76 13.71 Favored 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 123.738 0.815 . . . . 0.0 112.41 -173.394 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 15.0 p -92.67 141.47 14.58 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.167 172.117 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 157' ' ' GLN . . . . . 0.41 ' HG3' ' HG2' ' A' ' 171' ' ' GLN . 20.4 mp0 -99.22 131.51 45.2 Favored 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -173.392 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 41.4 t -133.95 102.06 4.2 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 -178.432 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.531 ' H ' HD23 ' A' ' 159' ' ' LEU . 2.3 pt? -76.3 85.5 3.08 Favored 'General case' 0 CA--C 1.545 0.768 0 CA-C-O 122.386 1.089 . . . . 0.0 108.893 176.004 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -64.65 114.53 4.48 Favored 'General case' 0 C--O 1.239 0.549 0 CA-C-N 114.221 -1.354 . . . . 0.0 108.64 178.441 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 161' ' ' LEU . . . . . 0.41 HD13 ' HB3' ' A' ' 11' ' ' ALA . 84.6 mt -69.0 94.49 0.64 Allowed 'General case' 0 C--O 1.239 0.503 0 O-C-N 123.655 0.597 . . . . 0.0 109.913 -172.312 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -65.28 112.6 8.74 Favored Pre-proline 0 CA--C 1.548 0.889 0 CA-C-N 114.267 -1.333 . . . . 0.0 109.436 -177.479 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -61.31 115.91 3.05 Favored 'Trans proline' 0 C--N 1.375 1.933 0 C-N-CA 122.503 2.135 . . . . 0.0 112.522 -171.405 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 93.12 -6.42 75.96 Favored Glycine 0 C--N 1.348 1.196 0 CA-C-N 114.966 -1.016 . . . . 0.0 113.883 177.542 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 61.3 mttm -128.07 -179.3 4.91 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 123.626 0.77 . . . . 0.0 109.207 -176.691 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -61.38 160.7 22.54 Favored Pre-proline 0 CA--C 1.558 1.26 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 164.302 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 167' ' ' PRO . . . . . 0.498 ' HG3' ' HB2' ' A' ' 12' ' ' ALA . 30.9 Cg_exo -61.93 -172.53 0.11 Allowed 'Trans proline' 0 C--N 1.375 1.951 0 C-N-CA 122.361 2.041 . . . . 0.0 114.491 -178.309 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 20.0 ttm-85 -138.13 99.46 3.88 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 171.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 169' ' ' ALA . . . . . 0.565 ' HB2' ' HB3' ' A' ' 17' ' ' GLU . . . -73.39 107.2 5.56 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.341 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 77.2 t -112.11 123.94 68.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 C-N-CA 123.493 0.717 . . . . 0.0 110.069 -176.584 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 171' ' ' GLN . . . . . 0.513 ' HB2' HD13 ' A' ' 22' ' ' ILE . 20.9 mt-30 -93.03 118.29 31.02 Favored 'General case' 0 C--N 1.341 0.217 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 175.362 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 172' ' ' THR . . . . . 0.723 HG21 HG23 ' A' ' 187' ' ' VAL . 5.9 t -126.29 142.8 51.39 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 123.206 0.603 . . . . 0.0 109.471 176.511 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -75.89 156.89 84.21 Favored Pre-proline 0 CA--C 1.561 1.368 0 CA-C-N 115.993 -0.548 . . . . 0.0 109.612 178.058 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -69.43 124.55 11.33 Favored 'Trans proline' 0 C--N 1.375 1.939 0 C-N-CA 122.178 1.919 . . . . 0.0 112.708 -177.492 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -158.78 139.38 6.22 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 108.74 -1.744 . . . . 0.0 108.74 175.238 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.749 ' HG ' ' HB3' ' A' ' 186' ' ' ALA 0.264 0.0 OUTLIER -175.8 -169.97 0.37 Allowed 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 123.949 0.899 . . . . 0.0 110.754 178.95 . . . . . . . . 4 4 . 1 . 008 nuclear build full ' A' A ' 177' ' ' PHE . . . . . 0.449 ' HA ' ' O ' ' A' ' 29' ' ' LEU . 79.3 m-85 -91.8 158.3 16.41 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 114.863 -1.062 . . . . 0.0 111.118 -152.28 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -133.36 109.48 9.38 Favored 'General case' 0 C--O 1.239 0.523 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 170.881 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 1.2 m -140.55 170.18 16.26 Favored 'General case' 0 N--CA 1.479 1.018 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 175.118 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 36.1 t30 -59.85 102.43 0.16 Allowed 'General case' 0 CA--C 1.548 0.892 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 168.324 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . 79.22 1.24 2.34 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 125.415 1.486 . . . . 0.0 111.492 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -123.86 54.2 0.73 Allowed Glycine 0 C--N 1.348 1.225 0 N-CA-C 111.409 -0.676 . . . . 0.0 111.409 178.547 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 84.6 m -110.21 98.16 7.48 Favored 'General case' 0 CA--C 1.536 0.441 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 175.452 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 184' ' ' ILE . . . . . 0.514 ' O ' ' HB3' ' A' ' 176' ' ' LEU . 3.6 mp -125.13 152.82 31.93 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 178.569 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -127.62 116.98 2.52 Favored Glycine 0 C--N 1.377 2.851 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 172.066 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.749 ' HB3' ' HG ' ' A' ' 176' ' ' LEU . . . -161.87 -149.34 0.16 Allowed 'General case' 0 C--N 1.373 1.598 0 CA-C-N 119.056 1.428 . . . . 0.0 111.9 -159.225 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 187' ' ' VAL . . . . . 0.723 HG23 HG21 ' A' ' 172' ' ' THR . 0.4 OUTLIER -91.57 117.77 35.54 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.971 0 C-N-CA 124.288 1.035 . . . . 0.0 110.028 -176.228 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 188' ' ' SER . . . . . 0.446 ' OG ' ' HB2' ' A' ' 26' ' ' SER . 10.6 t -130.44 90.78 2.98 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 123.406 0.682 . . . . 0.0 109.861 -174.123 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 189' ' ' LEU . . . . . 0.515 ' HA ' ' H ' ' A' ' 25' ' ' SER . 1.7 pp -136.91 -175.0 3.89 Favored 'General case' 0 N--CA 1.489 1.524 0 C-N-CA 123.423 0.689 . . . . 0.0 112.081 -174.292 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -135.19 119.29 17.57 Favored 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 124.238 1.015 . . . . 0.0 108.982 171.73 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 191' ' ' PHE . . . . . 0.433 ' HE2' ' HG ' ' A' ' 23' ' ' SER . 9.6 m-85 -149.15 -178.89 6.64 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 123.223 0.609 . . . . 0.0 111.916 -178.711 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 42.3 m -60.71 157.09 40.72 Favored Pre-proline 0 CA--C 1.555 1.161 0 C-N-CA 124.787 1.235 . . . . 0.0 111.28 176.839 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 193' ' ' PRO . . . . . 0.41 ' HB3' HH12 ' B' ' 254' ' ' ARG . 3.8 Cg_exo -34.58 91.23 0.01 OUTLIER 'Trans proline' 0 C--N 1.393 2.881 0 C-N-CA 125.236 3.957 . . . . 0.0 115.225 -178.018 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -74.08 134.48 18.5 Favored Glycine 0 C--N 1.35 1.325 0 CA-C-N 114.582 -1.19 . . . . 0.0 112.394 -179.669 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 40.7 p -82.72 122.75 28.57 Favored 'General case' 0 C--O 1.244 0.796 0 C-N-CA 123.752 0.821 . . . . 0.0 110.097 178.013 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 18.1 m -62.45 88.08 0.03 OUTLIER 'General case' 0 C--N 1.363 1.17 0 C-N-CA 123.591 0.756 . . . . 0.0 110.847 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 197' ' ' GLY . . . . . 0.468 ' O ' HD22 ' A' ' 210' ' ' LEU . . . 129.12 21.14 1.37 Allowed Glycine 0 CA--C 1.523 0.553 0 CA-C-N 114.897 -1.047 . . . . 0.0 112.574 -179.276 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 198' ' ' SER . . . . . 0.444 ' HA ' ' HD3' ' A' ' 199' ' ' PRO . 32.2 p -70.18 123.64 89.23 Favored Pre-proline 0 N--CA 1.478 0.951 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 172.758 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 199' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' A' ' 198' ' ' SER . 32.1 Cg_exo -58.71 141.88 98.13 Favored 'Trans proline' 0 C--N 1.374 1.918 0 C-N-CA 122.9 2.4 . . . . 0.0 114.368 -168.538 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 200' ' ' ILE . . . . . 0.513 HD13 HG12 ' A' ' 226' ' ' ILE . 47.8 mt -110.8 118.96 58.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.325 0 C-N-CA 124.851 1.26 . . . . 0.0 108.754 175.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 201' ' ' ILE . . . . . 0.592 HG12 HG22 ' A' ' 207' ' ' VAL . 24.0 mt -113.02 143.47 22.64 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.377 0 C-N-CA 124.563 1.145 . . . . 0.0 110.029 -176.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -84.83 153.6 22.84 Favored 'General case' 0 N--CA 1.486 1.357 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 170.21 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 84.0 tttt -48.33 -27.29 2.45 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 124.689 1.196 . . . . 0.0 113.96 -172.884 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 204' ' ' LYS . . . . . 0.582 ' H ' ' HD2' ' A' ' 204' ' ' LYS . 9.7 mptt -64.1 -20.09 65.71 Favored 'General case' 0 N--CA 1.484 1.227 0 C-N-CA 124.27 1.028 . . . . 0.0 111.78 -177.448 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 101.6 5.85 50.9 Favored Glycine 0 C--N 1.345 1.033 0 CA-C-N 116.361 -0.382 . . . . 0.0 112.676 -177.881 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 39.8 tttm -106.61 140.74 39.01 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 123.162 0.585 . . . . 0.0 109.618 -179.762 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.592 HG22 HG12 ' A' ' 201' ' ' ILE . 61.9 t -82.63 123.98 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 123.208 0.603 . . . . 0.0 111.41 -168.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 208' ' ' VAL . . . . . 0.605 HG21 ' HB2' ' A' ' 150' ' ' TRP . 45.6 t -69.46 -52.56 31.39 Favored 'Isoleucine or valine' 0 C--O 1.239 0.548 0 O-C-N 124.574 1.171 . . . . 0.0 110.48 173.714 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.519 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . 177.71 -134.24 2.4 Favored Glycine 0 C--N 1.348 1.2 0 CA-C-N 115.157 -0.928 . . . . 0.0 113.694 -175.892 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 210' ' ' LEU . . . . . 0.468 HD22 ' O ' ' A' ' 197' ' ' GLY . 86.1 mt -131.44 152.64 50.5 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 123.836 0.854 . . . . 0.0 110.926 -176.793 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 51.1 t80 -102.15 104.54 15.15 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 123.861 0.864 . . . . 0.0 108.986 175.696 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 212' ' ' GLY . . . . . 0.449 ' O ' ' SD ' ' A' ' 110' ' ' MET . . . 169.72 74.27 0.04 OUTLIER Glycine 0 C--N 1.337 0.632 0 C-N-CA 120.892 -0.67 . . . . 0.0 113.424 161.514 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 213' ' ' ASN . . . . . 0.705 ' H ' ' HB3' ' A' ' 224' ' ' SER . 71.7 m-20 -146.09 81.96 1.6 Allowed 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 170.368 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 178.03 -121.58 0.78 Allowed Glycine 0 N--CA 1.445 -0.714 0 CA-C-N 114.71 -1.132 . . . . 0.0 111.839 178.303 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 215' ' ' VAL . . . . . 0.516 HG23 ' HG2' ' B' ' 253' ' ' LYS . 10.2 p -172.81 165.61 0.24 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.843 0 C-N-CA 122.883 0.473 . . . . 0.0 109.955 -164.015 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 216' ' ' VAL . . . . . . . . . . . . . 27.7 m -77.45 107.7 9.46 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.137 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 158.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 217' ' ' THR . . . . . 0.529 HG21 HD13 ' A' ' 29' ' ' LEU . 74.6 m -82.41 144.03 30.79 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 123.998 0.919 . . . . 0.0 109.351 -179.751 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 13.6 mmm180 63.81 17.54 10.56 Favored 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 124.03 0.932 . . . . 0.0 110.077 -169.633 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 35.5 m 61.33 31.95 19.23 Favored 'General case' 0 C--N 1.364 1.239 0 C-N-CA 125.536 1.534 . . . . 0.0 112.175 -175.903 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . -157.93 -52.85 0.01 OUTLIER Glycine 0 C--N 1.352 1.464 0 CA-C-O 120.019 -0.323 . . . . 0.0 113.358 -179.122 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -69.71 114.22 7.71 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 123.185 0.594 . . . . 0.0 111.562 -172.911 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 222' ' ' TYR . . . . . . . . . . . . . 7.5 m-85 -68.11 98.06 0.75 Allowed 'General case' 0 CA--C 1.551 1.0 0 C-N-CA 123.0 0.52 . . . . 0.0 110.272 179.063 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 94.9 t -127.5 127.17 68.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 C-N-CA 123.798 0.839 . . . . 0.0 110.089 -171.445 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 224' ' ' SER . . . . . 0.705 ' HB3' ' H ' ' A' ' 213' ' ' ASN . 58.5 m -153.75 159.06 41.82 Favored 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 123.237 0.615 . . . . 0.0 111.384 -171.026 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 225' ' ' ALA . . . . . . . . . . . . . . . -80.03 145.15 32.65 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.352 1.061 . . . . 0.0 110.986 177.451 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 226' ' ' ILE . . . . . 0.637 HG13 ' HB1' ' A' ' 186' ' ' ALA . 85.3 mt -78.85 102.89 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 174.065 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 227' ' ' ALA . . . . . 0.435 ' O ' ' HA3' ' A' ' 209' ' ' GLY . . . -77.76 101.75 6.83 Favored 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 177.757 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 49.0 mt-30 -89.87 169.37 11.3 Favored 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 123.088 0.555 . . . . 0.0 110.098 -171.316 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 229' ' ' THR . . . . . 0.43 ' HA ' ' CD1' ' A' ' 144' ' ' TRP . 71.4 p -80.05 123.41 27.82 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 123.079 0.552 . . . . 0.0 111.506 -177.566 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -99.6 -24.18 14.82 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 123.244 0.618 . . . . 0.0 109.504 167.886 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 13.4 ptpt 68.72 157.06 0.14 Allowed 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 127.392 2.277 . . . . 0.0 113.098 174.132 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 22.4 m -61.02 138.33 58.19 Favored 'General case' 0 CA--C 1.543 0.678 0 CA-C-N 115.536 -0.756 . . . . 0.0 110.64 166.58 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 233' ' ' ILE . . . . . . . . . . . . . 13.4 tt -162.09 -33.29 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 C-N-CA 124.003 0.921 . . . . 0.0 108.996 -178.254 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 234' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 55.54 36.13 26.55 Favored 'General case' 0 C--N 1.364 1.209 0 C-N-CA 124.677 1.191 . . . . 0.0 109.898 175.86 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 10.1 p-10 -60.96 -25.06 66.56 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 125.04 1.336 . . . . 0.0 112.178 -174.782 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 236' ' ' ASN . . . . . . . . . . . . . 31.9 t30 -54.3 121.29 30.57 Favored Pre-proline 0 CA--C 1.55 0.956 0 C-N-CA 124.742 1.217 . . . . 0.0 110.442 169.247 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -68.8 98.53 0.6 Allowed 'Trans proline' 0 C--N 1.375 1.942 0 C-N-CA 121.93 1.753 . . . . 0.0 111.035 175.815 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 238' ' ' GLU . . . . . . . . . . . . . 48.0 mt-10 -99.26 32.3 2.78 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 123.982 0.913 . . . . 0.0 110.069 -179.26 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 239' ' ' ILE . . . . . 0.48 HG13 ' HG3' ' A' ' 240' ' ' GLU . 38.2 pt -62.91 -30.5 49.7 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 C-N-CA 123.986 0.915 . . . . 0.0 112.543 -176.249 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 240' ' ' GLU . . . . . 0.48 ' HG3' HG13 ' A' ' 239' ' ' ILE . 42.2 mt-10 . . . . . 0 CA--C 1.55 0.974 0 C-N-CA 124.323 1.049 . . . . 0.0 108.961 177.87 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 251' ' ' BEZ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 253' ' ' LYS . . . . . 0.516 ' HG2' HG23 ' A' ' 215' ' ' VAL . 1.5 tmtp? 70.49 -71.03 0.14 Allowed 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 125.385 1.474 . . . . 0.0 110.872 176.326 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 254' ' ' ARG . . . . . 0.412 ' O ' ' HD3' ' B' ' 253' ' ' LYS . 41.5 mtp85 69.85 171.67 0.31 Allowed 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 124.816 1.246 . . . . 0.0 113.254 175.083 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 255' ' ' M9P . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.634 0 N-CA-C 111.466 -0.654 . . . . 0.0 111.466 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.488 ' HA ' HD21 ' A' ' 6' ' ' LEU . 24.0 p -102.12 102.85 13.37 Favored 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 123.063 0.545 . . . . 0.0 109.946 178.537 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.432 ' O ' ' HB1' ' A' ' 117' ' ' ALA . . . -103.99 -158.99 0.69 Allowed 'General case' 0 N--CA 1.482 1.165 0 C-N-CA 123.769 0.828 . . . . 0.0 109.225 176.46 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -102.81 18.03 22.47 Favored 'General case' 0 N--CA 1.478 0.937 0 O-C-N 121.851 -0.531 . . . . 0.0 109.652 -175.027 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ASP . . . . . 0.5 ' HB3' ' O ' ' A' ' 89' ' ' LYS . 6.2 m-20 -126.02 26.88 6.45 Favored 'General case' 0 C--O 1.237 0.444 0 C-N-CA 124.525 1.13 . . . . 0.0 108.976 -169.888 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.488 HD21 ' HA ' ' A' ' 2' ' ' SER . 83.7 mt -75.8 93.56 3.17 Favored 'General case' 0 C--O 1.215 -0.739 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.085 -173.172 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.446 ' HA ' ' O ' ' A' ' 120' ' ' MET . 23.2 tt0 -83.54 135.19 34.73 Favored 'General case' 0 N--CA 1.475 0.796 0 O-C-N 122.139 -0.351 . . . . 0.0 111.326 -179.651 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.475 ' H ' HD23 ' A' ' 8' ' ' LEU . 2.6 pt? -102.1 138.89 38.46 Favored 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.337 177.096 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 19.1 pt-20 -143.33 144.51 32.12 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.802 0.841 . . . . 0.0 109.096 176.182 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.517 ' NH2' ' HB3' ' A' ' 13' ' ' ASP . 50.7 ttt180 -63.41 120.73 12.21 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 112.286 0.476 . . . . 0.0 112.286 -165.603 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.706 ' HB2' ' HG3' ' A' ' 85' ' ' ARG . . . -84.64 -45.89 12.05 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 124.108 0.963 . . . . 0.0 109.896 173.081 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -170.95 -178.21 2.44 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-N 115.178 -0.919 . . . . 0.0 112.006 -173.733 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.517 ' HB3' ' NH2' ' A' ' 10' ' ' ARG . 10.4 p-10 -103.63 164.77 11.46 Favored 'General case' 0 CA--C 1.54 0.571 0 CA-C-N 114.121 -1.4 . . . . 0.0 108.571 165.373 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 53.0 t -88.11 101.44 11.61 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.856 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 179.03 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 62.7 tttp -172.73 113.74 0.27 Allowed 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 124.42 1.088 . . . . 0.0 108.187 -177.738 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 79.8 t90 -100.95 91.71 4.7 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 122.503 0.321 . . . . 0.0 110.465 -176.714 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -158.27 58.05 0.46 Allowed 'General case' 0 CA--C 1.549 0.931 0 C-N-CA 123.593 0.757 . . . . 0.0 109.746 162.114 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.425 ' HB3' ' H ' ' A' ' 169' ' ' ALA . 8.0 t70 -86.93 -56.04 3.57 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 122.833 0.453 . . . . 0.0 111.17 179.052 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLN . . . . . 0.656 ' H ' ' HB3' ' A' ' 169' ' ' ALA . 10.1 tm0? -148.38 4.35 0.69 Allowed 'General case' 0 N--CA 1.484 1.267 0 C-N-CA 123.186 0.595 . . . . 0.0 111.396 -173.615 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . 13.71 81.55 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 126.521 1.928 . . . . 0.0 114.228 -168.422 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.472 ' O ' ' HG2' ' A' ' 171' ' ' GLN . 34.2 tt0 -101.97 147.44 26.55 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 114.306 -1.316 . . . . 0.0 109.221 -176.503 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 9.4 tp -93.03 149.05 4.34 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.798 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 174.348 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.559 ' HB3' HD23 ' A' ' 189' ' ' LEU . 69.1 m -91.73 -174.67 3.92 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 123.642 0.777 . . . . 0.0 111.455 178.341 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -87.23 -41.88 6.43 Favored Glycine 0 C--N 1.347 1.194 0 CA-C-N 115.436 -0.802 . . . . 0.0 111.28 178.912 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 35.5 m 63.0 87.47 0.1 Allowed 'General case' 0 C--N 1.358 0.968 0 C-N-CA 124.299 1.039 . . . . 0.0 110.219 177.836 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.553 ' HB2' ' HB3' ' A' ' 188' ' ' SER . 17.2 m -85.49 156.31 59.26 Favored Pre-proline 0 CA--C 1.555 1.147 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.988 -174.672 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -65.63 -168.56 0.13 Allowed 'Trans proline' 0 C--N 1.376 2.018 0 C-N-CA 123.244 2.63 . . . . 0.0 112.448 167.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 35.0 mm -66.14 138.37 23.14 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.267 0 CA-C-O 120.811 0.339 . . . . 0.0 110.662 -174.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.563 HD22 HG22 ' A' ' 217' ' ' THR . 4.3 mt -114.85 161.46 18.21 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 123.282 0.633 . . . . 0.0 110.564 175.167 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 30.4 t -112.24 114.65 27.56 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 178.579 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 12.9 tt -113.62 160.56 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 C-N-CA 124.649 1.18 . . . . 0.0 108.306 -174.793 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 82.2 p -93.89 104.96 17.0 Favored 'General case' 0 C--N 1.363 1.164 0 CA-C-N 119.845 1.202 . . . . 0.0 108.184 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.807 HG21 ' HA ' ' A' ' 179' ' ' THR . 3.5 tp -107.86 154.65 8.91 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 C-N-CA 125.887 1.675 . . . . 0.0 107.549 -176.62 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 9.1 p -157.27 161.91 39.18 Favored 'General case' 0 C--O 1.249 1.061 0 C-N-CA 123.264 0.626 . . . . 0.0 110.547 -171.743 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -58.29 158.02 7.76 Favored 'General case' 0 N--CA 1.481 1.103 0 C-N-CA 124.594 1.158 . . . . 0.0 111.505 -175.548 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 30.7 t70 78.39 14.55 1.38 Allowed 'General case' 0 N--CA 1.491 1.616 0 C-N-CA 124.911 1.284 . . . . 0.0 110.396 178.871 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 73.98 34.23 56.05 Favored Glycine 0 C--N 1.356 1.644 0 CA-C-N 115.343 -0.844 . . . . 0.0 112.265 -178.834 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 47.5 t -99.54 143.87 29.29 Favored 'General case' 0 N--CA 1.469 0.522 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -175.718 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 19.3 ptm -163.03 154.24 17.23 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 122.571 0.348 . . . . 0.0 111.053 -177.087 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 35.5 p -176.29 -179.09 1.03 Allowed 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 125.035 1.334 . . . . 0.0 108.96 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.415 HG21 ' O ' ' A' ' 216' ' ' VAL . 10.4 tp -107.17 96.72 4.86 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 172.309 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 7.5 mtpm? 50.77 31.0 5.47 Favored 'General case' 0 CA--C 1.559 1.318 0 C-N-CA 124.247 1.019 . . . . 0.0 113.082 170.729 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 41.8 t-20 79.15 -30.02 0.14 Allowed 'General case' 0 N--CA 1.502 2.132 0 C-N-CA 125.885 1.674 . . . . 0.0 111.959 -174.697 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -58.54 107.36 0.49 Allowed 'General case' 0 CA--C 1.55 0.949 0 C-N-CA 125.533 1.533 . . . . 0.0 112.86 -171.005 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.715 ' HB2' ' HG2' ' B' ' 253' ' ' LYS . 22.6 pt-20 -162.52 176.0 10.88 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.419 0.687 . . . . 0.0 110.684 172.471 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' GLU . . . . . 0.473 ' H ' ' HB3' ' B' ' 253' ' ' LYS . 12.9 pt-20 -158.76 -172.5 3.85 Favored 'General case' 0 C--O 1.245 0.854 0 C-N-CA 123.714 0.806 . . . . 0.0 110.225 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.412 ' HB3' ' NH2' ' B' ' 255' ' ' M9P . 7.8 pt-20 -146.67 151.33 37.05 Favored 'General case' 0 C--O 1.244 0.787 0 C-N-CA 124.211 1.004 . . . . 0.0 109.164 179.855 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.472 ' OE1' ' HB3' ' A' ' 163' ' ' PRO . 35.8 tt0 -109.13 157.85 18.35 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 123.096 0.558 . . . . 0.0 111.214 -169.932 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' THR . . . . . 0.51 HG23 ' HG ' ' A' ' 50' ' ' LEU . 12.3 t -80.75 -151.8 0.08 Allowed 'General case' 0 CA--C 1.563 1.46 0 C-N-CA 124.326 1.05 . . . . 0.0 109.725 170.687 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.51 ' HG ' HG23 ' A' ' 49' ' ' THR . 78.1 mt 77.65 -98.85 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 125.143 1.377 . . . . 0.0 111.534 172.669 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 119.28 -145.09 18.0 Favored Glycine 0 C--N 1.342 0.904 0 N-CA-C 111.826 -0.51 . . . . 0.0 111.826 -173.465 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -158.74 -142.54 3.42 Favored Glycine 0 C--N 1.339 0.724 0 N-CA-C 111.058 -0.817 . . . . 0.0 111.058 177.909 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 153.39 141.24 3.23 Favored Glycine 0 C--N 1.341 0.825 0 N-CA-C 111.543 -0.623 . . . . 0.0 111.543 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -155.87 154.28 25.4 Favored Glycine 0 C--N 1.343 0.944 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 179.083 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.725 ' HB2' ' HA ' ' A' ' 72' ' ' PRO . 68.0 m -121.57 156.96 31.79 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 123.631 0.772 . . . . 0.0 110.956 -179.378 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.41 ' HA3' ' HG2' ' A' ' 80' ' ' GLU . . . -145.28 -136.17 2.95 Favored Glycine 0 C--N 1.346 1.123 0 CA-C-O 119.586 -0.563 . . . . 0.0 111.94 -174.829 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -177.7 45.74 0.1 OUTLIER Glycine 0 C--N 1.347 1.166 0 CA-C-N 117.057 0.429 . . . . 0.0 112.137 178.494 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -76.55 -55.9 4.44 Favored Glycine 0 C--N 1.348 1.216 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 -178.903 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.62 79.78 0.44 Allowed Glycine 0 C--N 1.344 0.984 0 CA-C-N 114.996 -0.602 . . . . 0.0 113.266 170.084 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -75.46 -12.5 60.25 Favored 'General case' 0 N--CA 1.483 1.22 0 C-N-CA 122.948 0.499 . . . . 0.0 111.094 174.627 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 26.7 m-85 65.2 -177.12 0.18 Allowed 'General case' 0 N--CA 1.49 1.56 0 C-N-CA 125.288 1.435 . . . . 0.0 112.645 172.884 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . 67.42 -76.67 0.05 Allowed 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 124.984 1.314 . . . . 0.0 112.021 177.801 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -165.14 -178.27 38.25 Favored Glycine 0 N--CA 1.469 0.889 0 CA-C-O 119.081 -0.844 . . . . 0.0 111.269 179.295 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.432 HG22 ' HD3' ' A' ' 122' ' ' LYS . 9.9 p 47.92 46.35 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.951 0 CA-C-O 123.508 1.623 . . . . 0.0 110.715 178.039 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 3.2 pp -117.53 118.92 33.49 Favored 'General case' 0 C--N 1.339 0.128 0 CA-C-N 113.759 -1.564 . . . . 0.0 109.636 -174.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' TRP . . . . . 0.531 ' CD1' ' HG2' ' A' ' 122' ' ' LYS . 8.4 m95 -127.24 70.88 1.31 Allowed 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 104.726 -2.324 . . . . 0.0 104.726 168.426 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -170.92 70.24 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 105.521 -2.029 . . . . 0.0 105.521 -179.703 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 3.2 t -115.4 139.15 24.23 Favored Pre-proline 0 CA--C 1.538 0.518 0 CA-C-N 113.953 -1.476 . . . . 0.0 108.346 -168.074 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -60.05 81.21 0.06 OUTLIER 'Trans proline' 0 C--N 1.38 2.187 0 C-N-CA 122.708 2.272 . . . . 0.0 111.673 171.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 35.4 t -128.23 141.2 40.55 Favored Pre-proline 0 C--O 1.241 0.642 0 CA-C-N 113.985 -1.461 . . . . 0.0 108.403 -176.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_endo -44.73 122.95 4.43 Favored 'Trans proline' 0 C--N 1.377 2.078 0 C-N-CA 123.263 2.642 . . . . 0.0 112.545 176.848 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 0.725 ' HA ' ' HB2' ' A' ' 55' ' ' SER . 76.2 Cg_exo -43.41 -41.23 10.41 Favored 'Trans proline' 0 CA--C 1.568 2.204 0 C-N-CA 124.047 3.165 . . . . 0.0 116.464 177.123 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_exo -51.94 -23.78 17.45 Favored 'Trans proline' 0 C--N 1.395 3.004 0 C-N-CA 122.861 2.374 . . . . 0.0 116.029 173.152 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 81.2 t -61.52 -57.58 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.214 0 C-N-CA 122.985 0.514 . . . . 0.0 109.74 175.705 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 55.67 54.83 32.18 Favored Glycine 0 C--N 1.346 1.128 0 O-C-N 123.83 0.706 . . . . 0.0 114.031 175.088 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 57.6 pttt -86.6 44.41 1.15 Allowed 'General case' 0 N--CA 1.483 1.213 0 C-N-CA 123.253 0.621 . . . . 0.0 111.918 -173.303 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . 59.92 33.0 21.45 Favored 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 124.712 1.205 . . . . 0.0 112.322 174.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 59.3 mt-10 -66.24 134.06 51.9 Favored 'General case' 0 CA--C 1.544 0.74 0 N-CA-C 112.461 0.541 . . . . 0.0 112.461 -174.708 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -89.5 66.73 7.43 Favored 'General case' 0 CA--C 1.548 0.867 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 170.951 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.41 ' HG2' ' HA3' ' A' ' 56' ' ' GLY . 22.0 tp10 -80.45 -83.07 0.11 Allowed 'General case' 0 CA--C 1.553 1.067 0 CA-C-N 113.445 -1.707 . . . . 0.0 111.022 175.127 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -175.43 162.66 2.89 Favored 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 123.92 0.888 . . . . 0.0 109.909 -168.584 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.421 ' HA3' ' HA ' ' A' ' 13' ' ' ASP . . . 93.49 -147.54 18.63 Favored Glycine 0 C--N 1.344 0.984 0 C-N-CA 123.076 0.369 . . . . 0.0 113.34 177.199 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -84.44 138.22 32.94 Favored 'General case' 0 N--CA 1.48 1.062 0 C-N-CA 123.493 0.717 . . . . 0.0 110.155 -177.397 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 12.0 m-85 -125.74 140.02 53.04 Favored 'General case' 0 N--CA 1.494 1.761 0 C-N-CA 123.334 0.654 . . . . 0.0 111.324 -179.061 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' ARG . . . . . 0.706 ' HG3' ' HB2' ' A' ' 11' ' ' ALA . 58.2 mtt-85 -85.41 122.21 29.23 Favored 'General case' 0 C--O 1.239 0.521 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 169.958 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.48 HD11 ' HZ ' ' A' ' 107' ' ' PHE . 62.6 mt -98.3 119.82 46.82 Favored 'Isoleucine or valine' 0 C--O 1.253 1.237 0 CA-C-O 121.589 0.709 . . . . 0.0 109.394 175.299 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.442 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 58.4 pttt -111.12 146.9 36.0 Favored 'General case' 0 C--O 1.239 0.548 0 CA-C-N 114.26 -1.336 . . . . 0.0 108.477 174.001 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -83.09 107.81 15.92 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 104.294 -2.484 . . . . 0.0 104.294 166.31 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' LYS . . . . . 0.5 ' O ' ' HB3' ' A' ' 5' ' ' ASP . 28.8 ttpt -117.34 96.92 5.64 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -175.506 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -67.11 154.2 52.86 Favored Glycine 0 C--N 1.339 0.725 0 N-CA-C 107.436 -2.266 . . . . 0.0 107.436 166.097 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 20.1 mm -78.86 63.93 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.39 0 CA-C-N 118.637 1.219 . . . . 0.0 108.926 -173.265 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 22.3 tp 167.81 -32.62 0.0 OUTLIER 'General case' 0 CA--C 1.562 1.431 0 C-N-CA 125.535 1.534 . . . . 0.0 109.854 -166.336 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -145.36 149.14 21.25 Favored Glycine 0 C--N 1.369 2.39 0 N-CA-C 114.265 0.466 . . . . 0.0 114.265 -171.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -124.98 133.36 53.04 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 124.614 1.166 . . . . 0.0 110.33 -169.885 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 44.7 m -151.45 103.19 2.96 Favored 'General case' 0 N--CA 1.493 1.705 0 CA-C-N 118.602 0.637 . . . . 0.0 112.085 176.724 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.442 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 43.7 mt-30 -53.76 120.39 6.19 Favored 'General case' 0 N--CA 1.495 1.818 0 C-N-CA 123.489 0.716 . . . . 0.0 111.215 173.446 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.5 pp -122.54 -13.07 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 C-N-CA 123.806 0.842 . . . . 0.0 112.061 -176.645 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 174.87 -152.51 13.96 Favored Glycine 0 C--N 1.342 0.903 0 CA-C-O 119.637 -0.535 . . . . 0.0 112.313 174.619 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -156.36 164.3 38.46 Favored 'General case' 0 C--O 1.241 0.652 0 C-N-CA 123.384 0.674 . . . . 0.0 110.973 -176.594 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -158.31 149.94 20.46 Favored Glycine 0 C--N 1.339 0.731 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 177.209 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 37.2 t -96.14 118.91 43.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 C-N-CA 123.328 0.651 . . . . 0.0 110.192 -176.576 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 85.5 t80 -94.93 126.9 40.58 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 171.371 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.441 ' HD2' ' HA ' ' A' ' 103' ' ' LYS . 42.7 tptt -133.55 114.5 13.64 Favored 'General case' 0 C--O 1.239 0.548 0 C-N-CA 123.28 0.632 . . . . 0.0 109.565 175.054 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 68.52 -78.14 0.05 OUTLIER 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 125.282 1.433 . . . . 0.0 112.415 169.185 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -147.46 32.43 1.36 Allowed Glycine 0 N--CA 1.465 0.569 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 176.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 44.6 m -136.84 124.86 22.82 Favored 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 124.21 1.004 . . . . 0.0 109.563 178.331 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' PHE . . . . . 0.48 ' HZ ' HD11 ' A' ' 86' ' ' ILE . 57.0 t80 -110.13 118.05 35.35 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 172.634 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' HIS . . . . . 0.527 ' NE2' ' HB3' ' A' ' 137' ' ' LEU . 60.5 t60 -123.69 114.82 20.47 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 122.809 0.443 . . . . 0.0 109.97 -178.654 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 9.0 t -114.14 -165.71 1.03 Allowed 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 124.338 1.055 . . . . 0.0 109.525 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' MET . . . . . 0.589 ' HA ' ' HA ' ' A' ' 137' ' ' LEU . 13.6 mtp -107.43 160.56 15.55 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 124.13 0.972 . . . . 0.0 110.033 177.075 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 11.6 t90 -80.79 -31.47 35.74 Favored 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 122.645 0.378 . . . . 0.0 111.512 -175.561 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 46.1 p-80 -75.02 -18.02 60.41 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.639 -0.663 . . . . 0.0 111.051 174.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 68.7 t -81.98 -44.02 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.523 0.729 . . . . 0.0 109.519 173.675 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 90.1 m -135.16 108.3 7.7 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 107.752 -1.203 . . . . 0.0 107.752 -178.767 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 19.3 ptp180 -85.69 33.33 0.58 Allowed 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 123.298 0.639 . . . . 0.0 112.211 -172.533 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 91.74 27.76 16.06 Favored Glycine 0 N--CA 1.47 0.912 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -170.083 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' ALA . . . . . 0.432 ' HB1' ' O ' ' A' ' 3' ' ' ALA . . . -94.41 -178.92 4.74 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.065 0.946 . . . . 0.0 110.971 -177.189 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 70.2 t -100.3 133.25 43.99 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 123.404 0.681 . . . . 0.0 110.47 -176.341 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.541 ' HB2' ' HB ' ' A' ' 126' ' ' ILE . 2.4 mm? -92.01 162.31 14.43 Favored 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 124.155 0.982 . . . . 0.0 110.049 172.946 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 120' ' ' MET . . . . . 0.446 ' O ' ' HA ' ' A' ' 7' ' ' GLU . 23.5 mmt -139.25 136.79 35.33 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 124.066 0.947 . . . . 0.0 110.458 -171.609 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 14.7 t-80 -169.38 137.0 1.8 Allowed 'General case' 0 N--CA 1.476 0.825 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 153.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.531 ' HG2' ' CD1' ' A' ' 66' ' ' TRP . 85.5 mttt 70.45 9.69 7.0 Favored 'General case' 0 N--CA 1.503 2.208 0 C-N-CA 124.238 1.015 . . . . 0.0 111.753 -178.45 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 83.46 -4.95 79.96 Favored Glycine 0 C--N 1.349 1.266 0 CA-C-O 119.953 -0.359 . . . . 0.0 112.519 -167.289 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 31.0 mmmt -72.64 117.61 14.54 Favored 'General case' 0 C--O 1.248 0.998 0 C-N-CA 123.512 0.725 . . . . 0.0 109.123 175.593 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 85.3 mtm180 -87.4 96.05 10.23 Favored 'General case' 0 C--O 1.237 0.418 0 O-C-N 124.665 1.228 . . . . 0.0 108.869 -179.122 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.541 ' HB ' ' HB2' ' A' ' 119' ' ' LEU . 97.2 mt -75.19 114.78 15.65 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.664 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.271 -179.069 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -92.91 146.9 32.92 Favored Pre-proline 0 CA--C 1.548 0.875 0 C-N-CA 124.126 0.97 . . . . 0.0 110.63 -174.554 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_exo -67.9 101.01 0.65 Allowed 'Trans proline' 0 C--N 1.367 1.528 0 C-N-CA 122.088 1.859 . . . . 0.0 110.866 169.336 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 22.7 t -64.33 -31.25 72.38 Favored 'General case' 0 N--CA 1.483 1.216 0 CA-C-O 121.271 0.558 . . . . 0.0 109.877 177.19 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 75.0 t-105 -150.7 156.33 41.11 Favored 'General case' 0 CA--C 1.543 0.695 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 165.306 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -136.76 120.09 16.86 Favored 'General case' 0 N--CA 1.467 0.419 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 176.278 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 27.3 m-20 -95.13 106.78 18.81 Favored 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 124.394 1.078 . . . . 0.0 109.247 175.518 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 60.3 t -75.59 -41.87 41.58 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.659 0 C-N-CA 123.141 0.577 . . . . 0.0 110.351 178.74 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 55.7 tttm -73.76 -34.98 64.95 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.954 -175.242 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 13.6 tppt? -80.88 -18.78 46.12 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 123.096 0.558 . . . . 0.0 110.797 176.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 26.3 t70 62.5 48.32 4.58 Favored 'General case' 0 N--CA 1.481 1.083 0 CA-C-O 122.72 1.248 . . . . 0.0 110.379 -175.4 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' LEU . . . . . 0.589 ' HA ' ' HA ' ' A' ' 110' ' ' MET . 74.8 mt -149.98 138.6 20.76 Favored 'General case' 0 N--CA 1.476 0.838 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.155 -176.899 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 5.8 mt -112.22 145.02 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 C-N-CA 123.384 0.674 . . . . 0.0 110.416 175.206 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 139' ' ' SER . . . . . 0.415 ' HB3' ' O ' ' A' ' 142' ' ' GLY . 34.6 m -118.64 141.61 48.43 Favored 'General case' 0 CA--C 1.557 1.217 0 C-N-CA 125.015 1.326 . . . . 0.0 110.945 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 19.6 t80 -135.38 142.13 45.64 Favored 'General case' 0 N--CA 1.488 1.472 0 C-N-CA 124.835 1.254 . . . . 0.0 108.515 173.203 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.26 -60.5 4.7 Favored Glycine 0 C--N 1.352 1.42 0 N-CA-C 111.254 -0.738 . . . . 0.0 111.254 -176.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 142' ' ' GLY . . . . . 0.415 ' O ' ' HB3' ' A' ' 139' ' ' SER . . . -148.28 -171.82 17.57 Favored Glycine 0 C--O 1.242 0.635 0 N-CA-C 109.871 -1.292 . . . . 0.0 109.871 172.394 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -77.46 -177.17 46.06 Favored Glycine 0 C--N 1.337 0.627 0 N-CA-C 112.13 -0.388 . . . . 0.0 112.13 175.333 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 144' ' ' TRP . . . . . 0.501 ' HB2' ' CE1' ' A' ' 108' ' ' HIS . 13.4 t-105 -69.78 111.6 5.65 Favored 'General case' 0 C--O 1.243 0.756 0 O-C-N 122.585 -0.362 . . . . 0.0 110.44 177.19 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 145' ' ' LYS . . . . . 0.412 ' HB3' ' O ' ' A' ' 232' ' ' SER . 23.0 pttm -135.64 152.34 51.12 Favored 'General case' 0 N--CA 1.466 0.334 0 O-C-N 124.092 0.87 . . . . 0.0 110.308 173.015 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 146' ' ' LEU . . . . . 0.443 ' H ' ' H ' ' A' ' 147' ' ' GLU . 4.1 mt 174.63 -8.89 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.945 0 C-N-CA 127.158 2.183 . . . . 0.0 108.207 178.521 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.46 ' N ' HG21 ' A' ' 229' ' ' THR . 7.6 mm-40 60.0 70.93 0.6 Allowed 'General case' 0 C--N 1.365 1.269 0 C-N-CA 125.387 1.475 . . . . 0.0 110.66 173.377 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -104.15 159.23 16.48 Favored Glycine 0 N--CA 1.444 -0.789 0 CA-C-N 114.069 -1.423 . . . . 0.0 113.998 -177.204 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -129.35 93.01 3.46 Favored 'General case' 0 C--O 1.243 0.742 0 C-N-CA 123.856 0.862 . . . . 0.0 109.142 178.795 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 150' ' ' TRP . . . . . . . . . . . . . 25.2 t90 -74.24 120.63 20.07 Favored 'General case' 0 C--O 1.238 0.498 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 173.655 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 20.4 mttm -85.15 94.68 8.93 Favored 'General case' 0 C--O 1.243 0.722 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 176.695 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -66.39 97.15 0.4 Allowed 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 123.671 0.788 . . . . 0.0 109.053 -176.961 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 143.27 -49.33 0.72 Allowed Glycine 0 C--N 1.341 0.842 0 CA-C-N 115.371 -0.832 . . . . 0.0 111.365 -178.357 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -85.33 157.94 20.41 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 122.889 0.476 . . . . 0.0 112.042 -175.659 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 155' ' ' GLU . . . . . 0.467 ' HA ' ' HA ' ' A' ' 173' ' ' LYS . 0.8 OUTLIER -62.5 131.1 48.0 Favored 'General case' 0 C--N 1.351 0.654 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.926 177.918 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.53 HG11 HD13 ' A' ' 226' ' ' ILE . 34.0 m -93.25 159.11 2.83 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.562 179.421 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 25.2 mp0 -113.02 130.36 56.17 Favored 'General case' 0 C--O 1.215 -0.727 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -172.079 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 44.6 t -133.99 137.07 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -174.863 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.582 ' H ' HD23 ' A' ' 159' ' ' LEU . 2.2 pt? -92.57 96.53 10.26 Favored 'General case' 0 CA--C 1.545 0.777 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 169.269 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -64.91 104.02 0.8 Allowed 'General case' 0 C--O 1.24 0.603 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.243 -178.565 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 161' ' ' LEU . . . . . 0.613 HD23 ' HB3' ' A' ' 167' ' ' PRO . 78.0 mt -69.01 84.74 0.33 Allowed 'General case' 0 C--O 1.241 0.641 0 C-N-CA 123.704 0.802 . . . . 0.0 108.873 177.109 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 28.3 tt0 -74.9 134.11 75.34 Favored Pre-proline 0 CA--C 1.545 0.767 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.297 -177.085 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 163' ' ' PRO . . . . . 0.472 ' HB3' ' OE1' ' A' ' 48' ' ' GLN . 93.1 Cg_exo -46.25 112.59 0.48 Allowed 'Trans proline' 0 C--N 1.382 2.342 0 C-N-CA 123.53 2.82 . . . . 0.0 113.881 178.198 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 63.79 27.87 71.78 Favored Glycine 0 C--N 1.35 1.356 0 O-C-N 123.903 0.752 . . . . 0.0 113.819 173.703 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 53.0 tptt -146.49 173.21 12.51 Favored 'General case' 0 C--O 1.245 0.837 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 -176.03 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -56.87 151.09 34.6 Favored Pre-proline 0 CA--C 1.558 1.28 0 C-N-CA 123.701 0.8 . . . . 0.0 112.595 177.317 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 167' ' ' PRO . . . . . 0.613 ' HB3' HD23 ' A' ' 161' ' ' LEU . 6.9 Cg_exo -74.86 92.42 0.97 Allowed 'Trans proline' 0 C--N 1.372 1.789 0 C-N-CA 123.249 2.632 . . . . 0.0 110.188 171.393 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 31.7 ttp-105 -75.68 122.08 23.45 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.065 -170.211 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 169' ' ' ALA . . . . . 0.656 ' HB3' ' H ' ' A' ' 19' ' ' GLN . . . -68.77 105.36 2.29 Favored 'General case' 0 CA--C 1.538 0.505 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.934 179.606 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 18.8 t -129.24 135.01 62.85 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.095 0 C-N-CA 124.866 1.266 . . . . 0.0 108.257 176.353 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 171' ' ' GLN . . . . . 0.472 ' HG2' ' O ' ' A' ' 21' ' ' GLU . 27.3 pt20 -117.07 126.73 53.3 Favored 'General case' 0 N--CA 1.478 0.933 0 C-N-CA 123.651 0.781 . . . . 0.0 110.318 -176.122 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 172' ' ' THR . . . . . 0.527 HG21 HG13 ' A' ' 187' ' ' VAL . 5.4 t -118.0 143.13 46.65 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 124.207 1.003 . . . . 0.0 110.911 -173.006 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 173' ' ' LYS . . . . . 0.467 ' HA ' ' HA ' ' A' ' 155' ' ' GLU . 37.2 ttmt -85.46 142.07 37.26 Favored Pre-proline 0 N--CA 1.479 0.983 0 CA-C-O 118.549 -0.738 . . . . 0.0 109.334 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 174' ' ' PRO . . . . . 0.577 ' HA ' ' O ' ' A' ' 186' ' ' ALA . 89.6 Cg_exo -47.32 122.69 6.85 Favored 'Trans proline' 0 C--N 1.396 3.04 0 C-N-CA 123.116 2.544 . . . . 0.0 114.562 -175.244 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 175' ' ' GLY . . . . . 0.526 ' H ' ' C ' ' A' ' 186' ' ' ALA . . . -135.47 139.59 10.91 Favored Glycine 0 CA--C 1.541 1.679 0 CA-C-N 115.159 -0.928 . . . . 0.0 114.543 179.342 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.434 ' N ' HD23 ' A' ' 176' ' ' LEU . 0.3 OUTLIER -132.22 162.5 30.77 Favored 'General case' 0 C--O 1.241 0.619 0 O-C-N 121.551 -0.97 . . . . 0.0 110.18 -171.412 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 177' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -138.51 139.53 38.79 Favored 'General case' 0 C--O 1.242 0.668 0 CA-C-N 114.141 -1.391 . . . . 0.0 109.727 -167.334 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 178' ' ' LYS . . . . . 0.435 ' HE3' ' HB3' ' A' ' 178' ' ' LYS . 1.3 tmmt? -69.07 120.77 15.45 Favored 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 124.481 1.112 . . . . 0.0 111.648 -165.488 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 179' ' ' THR . . . . . 0.807 ' HA ' HG21 ' A' ' 33' ' ' ILE . 7.4 m -90.09 165.4 14.02 Favored 'General case' 0 CA--C 1.551 1.01 0 C-N-CA 125.89 1.676 . . . . 0.0 109.787 177.619 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 180' ' ' ASN . . . . . 0.411 ' OD1' HG23 ' A' ' 33' ' ' ILE . 31.1 m120 -64.53 -35.14 79.99 Favored 'General case' 0 N--CA 1.487 1.384 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 170.82 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 181' ' ' ALA . . . . . 0.4 ' H ' HG22 ' A' ' 179' ' ' THR . . . -75.62 -48.22 23.14 Favored 'General case' 0 CA--C 1.54 0.566 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.977 175.798 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 182' ' ' GLY . . . . . 0.682 ' H ' ' HB ' ' A' ' 179' ' ' THR . . . -165.73 -94.43 0.1 OUTLIER Glycine 0 C--N 1.345 1.045 0 CA-C-O 119.756 -0.469 . . . . 0.0 112.638 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 7.5 t -163.46 135.83 5.21 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 124.719 1.208 . . . . 0.0 109.354 178.092 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -132.98 155.73 41.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 122.898 0.479 . . . . 0.0 109.814 177.052 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . 129.83 177.58 14.96 Favored Glycine 0 C--N 1.343 0.935 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 173.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.577 ' O ' ' HA ' ' A' ' 174' ' ' PRO . . . -171.66 38.85 0.02 OUTLIER 'General case' 0 C--O 1.193 -1.901 0 C-N-CA 123.486 0.715 . . . . 0.0 110.329 177.867 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 187' ' ' VAL . . . . . 0.527 HG13 HG21 ' A' ' 172' ' ' THR . 95.1 t -153.15 125.22 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 120.012 -1.68 . . . . 0.0 107.648 167.399 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 188' ' ' SER . . . . . 0.635 ' HA ' HG12 ' A' ' 223' ' ' VAL . 73.6 m -132.54 91.13 2.88 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 168.115 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 189' ' ' LEU . . . . . 0.559 HD23 ' HB3' ' A' ' 23' ' ' SER . 0.5 OUTLIER -126.97 104.36 7.96 Favored 'General case' 0 N--CA 1.48 1.039 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 -176.285 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 190' ' ' ASP . . . . . 0.681 ' HA ' ' HA ' ' A' ' 221' ' ' ALA . 8.0 p-10 -85.72 103.16 14.25 Favored 'General case' 0 C--N 1.356 0.865 0 CA-C-O 121.875 0.845 . . . . 0.0 109.992 -179.243 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 191' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -174.19 172.92 3.19 Favored 'General case' 0 N--CA 1.475 0.776 0 CA-C-N 115.059 -0.973 . . . . 0.0 108.541 -167.393 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 44.5 p -58.3 121.91 55.51 Favored Pre-proline 0 CA--C 1.548 0.883 0 C-N-CA 123.127 0.571 . . . . 0.0 110.614 175.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_endo -61.16 127.66 22.81 Favored 'Trans proline' 0 C--N 1.376 2.021 0 C-N-CA 122.246 1.964 . . . . 0.0 112.661 -178.874 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -72.41 173.44 46.43 Favored Glycine 0 C--N 1.35 1.326 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 162.099 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 7.4 m -80.66 135.78 36.09 Favored 'General case' 0 CA--C 1.562 1.416 0 CA-C-N 118.626 1.213 . . . . 0.0 111.334 -172.532 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -65.19 88.44 0.08 Allowed 'General case' 0 C--N 1.367 1.339 0 C-N-CA 124.13 0.972 . . . . 0.0 111.304 -171.641 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 197' ' ' GLY . . . . . 0.645 ' HA2' HD21 ' A' ' 210' ' ' LEU . . . 144.59 9.58 0.36 Allowed Glycine 0 C--N 1.335 0.499 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.984 -175.908 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 198' ' ' SER . . . . . 0.431 ' O ' ' HB2' ' A' ' 211' ' ' TYR . 39.3 m -57.36 132.09 81.31 Favored Pre-proline 0 CA--C 1.556 1.208 0 C-N-CA 122.942 0.497 . . . . 0.0 109.838 166.983 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -69.91 137.44 35.02 Favored 'Trans proline' 0 C--N 1.369 1.621 0 C-N-CA 121.965 1.777 . . . . 0.0 111.108 174.072 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 39.9 mt -91.92 119.6 39.61 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 N-CA-C 107.923 -1.139 . . . . 0.0 107.923 170.732 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 201' ' ' ILE . . . . . 0.642 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 46.7 mt -103.61 168.87 2.19 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.483 0 C-N-CA 125.632 1.573 . . . . 0.0 109.786 179.768 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -104.6 167.19 9.89 Favored 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 124.752 1.221 . . . . 0.0 109.402 178.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 18.5 ptpt -55.11 -29.24 57.24 Favored 'General case' 0 N--CA 1.481 1.106 0 C-N-CA 124.626 1.17 . . . . 0.0 112.444 177.762 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 52.9 mtmt -82.33 10.57 6.75 Favored 'General case' 0 N--CA 1.481 1.11 0 C-N-CA 123.324 0.65 . . . . 0.0 112.277 -179.072 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 70.0 19.73 75.68 Favored Glycine 0 C--N 1.356 1.669 0 N-CA-C 112.115 -0.394 . . . . 0.0 112.115 -177.235 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 62.4 tttp -110.73 121.14 44.59 Favored 'General case' 0 C--O 1.212 -0.892 0 C-N-CA 124.381 1.072 . . . . 0.0 108.662 -176.904 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 207' ' ' VAL . . . . . 0.642 ' HA ' ' HA ' ' A' ' 201' ' ' ILE . 7.1 p -53.9 139.67 11.87 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.092 0 C-N-CA 123.191 0.596 . . . . 0.0 111.687 178.092 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 3.6 m -98.34 -35.43 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.854 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 170.618 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.555 ' HA3' ' HA ' ' A' ' 228' ' ' GLN . . . 166.86 -138.18 5.05 Favored Glycine 0 C--N 1.348 1.226 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.268 -178.229 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 210' ' ' LEU . . . . . 0.645 HD21 ' HA2' ' A' ' 197' ' ' GLY . 5.1 tt -122.58 154.01 38.52 Favored 'General case' 0 CA--C 1.545 0.779 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 -172.122 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 211' ' ' TYR . . . . . 0.461 ' N ' HD23 ' A' ' 210' ' ' LEU . 10.2 t80 -62.45 142.19 58.01 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 123.592 0.757 . . . . 0.0 109.956 178.467 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -77.45 -157.83 9.26 Favored Glycine 0 N--CA 1.475 1.298 0 CA-C-N 118.103 0.41 . . . . 0.0 112.622 178.392 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 213' ' ' ASN . . . . . . . . . . . . . 14.7 t-20 -81.92 85.59 6.66 Favored 'General case' 0 N--CA 1.477 0.904 0 N-CA-C 108.442 -0.948 . . . . 0.0 108.442 -176.658 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . -71.66 123.3 9.87 Favored Glycine 0 C--N 1.347 1.174 0 CA-C-N 114.789 -1.096 . . . . 0.0 112.008 177.719 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 215' ' ' VAL . . . . . 0.706 ' HA ' ' HE3' ' B' ' 253' ' ' LYS . 21.7 t -134.59 143.56 37.44 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.672 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 173.63 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 216' ' ' VAL . . . . . 0.563 ' HB ' ' HA2' ' A' ' 220' ' ' GLY . 15.4 m -87.98 111.3 22.01 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.891 0 CA-C-O 121.781 0.8 . . . . 0.0 109.536 -178.718 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 217' ' ' THR . . . . . 0.563 HG22 HD22 ' A' ' 29' ' ' LEU . 38.8 m -107.74 162.53 13.9 Favored 'General case' 0 N--CA 1.475 0.825 0 C-N-CA 124.329 1.052 . . . . 0.0 109.659 -170.692 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 20.3 ttm180 71.45 -73.77 0.09 Allowed 'General case' 0 N--CA 1.492 1.646 0 C-N-CA 124.217 1.007 . . . . 0.0 109.592 -177.065 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 41.1 m -140.96 -43.86 0.39 Allowed 'General case' 0 CA--C 1.547 0.838 0 C-N-CA 124.519 1.127 . . . . 0.0 109.19 178.833 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 220' ' ' GLY . . . . . 0.563 ' HA2' ' HB ' ' A' ' 216' ' ' VAL . . . -169.04 27.65 0.13 Allowed Glycine 0 C--N 1.348 1.218 0 CA-C-N 115.49 -0.777 . . . . 0.0 112.181 -175.744 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 221' ' ' ALA . . . . . 0.681 ' HA ' ' HA ' ' A' ' 190' ' ' ASP . . . -80.32 96.11 6.55 Favored 'General case' 0 N--CA 1.465 0.317 0 C-N-CA 123.684 0.794 . . . . 0.0 110.607 179.717 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 222' ' ' TYR . . . . . . . . . . . . . 12.3 t80 -66.61 95.9 0.36 Allowed 'General case' 0 CA--C 1.554 1.123 0 CA-C-N 114.804 -1.089 . . . . 0.0 109.543 -176.873 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 223' ' ' VAL . . . . . 0.635 HG12 ' HA ' ' A' ' 188' ' ' SER . 35.3 m -114.59 140.14 37.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 C-N-CA 123.81 0.844 . . . . 0.0 109.774 -177.157 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 33.1 t -152.16 160.68 43.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.623 -169.598 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 225' ' ' ALA . . . . . . . . . . . . . . . -81.64 -175.02 5.32 Favored 'General case' 0 CA--C 1.546 0.792 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.643 164.43 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 226' ' ' ILE . . . . . 0.53 HD13 HG11 ' A' ' 156' ' ' VAL . 78.2 mt -133.57 116.44 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 176.005 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -95.78 137.2 35.18 Favored 'General case' 0 C--O 1.233 0.196 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 176.015 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 228' ' ' GLN . . . . . 0.555 ' HA ' ' HA3' ' A' ' 209' ' ' GLY . 29.0 pt20 -120.26 174.3 6.59 Favored 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 175.318 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 229' ' ' THR . . . . . 0.464 ' HA ' ' CD1' ' A' ' 144' ' ' TRP . 39.4 p -66.14 107.71 2.02 Favored 'General case' 0 CA--C 1.546 0.825 0 CA-C-O 121.208 0.528 . . . . 0.0 110.802 -176.502 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 230' ' ' GLU . . . . . 0.482 ' HG2' ' O ' ' A' ' 228' ' ' GLN . 26.7 mm-40 -108.06 -30.16 8.58 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 124.425 1.09 . . . . 0.0 112.437 -168.384 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 29.8 mmtp -107.06 -99.78 0.35 Allowed 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 113.477 0.917 . . . . 0.0 113.477 -160.38 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 232' ' ' SER . . . . . 0.412 ' O ' ' HB3' ' A' ' 145' ' ' LYS . 64.3 p -76.45 89.44 3.24 Favored 'General case' 0 C--N 1.361 1.093 0 CA-C-O 121.958 0.885 . . . . 0.0 110.672 -165.207 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 233' ' ' ILE . . . . . . . . . . . . . 12.4 tt -116.76 -23.85 3.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 C-N-CA 125.18 1.392 . . . . 0.0 108.207 178.015 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 234' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER 58.07 58.43 3.56 Favored 'General case' 0 C--O 1.242 0.693 0 C-N-CA 125.417 1.487 . . . . 0.0 110.133 -173.872 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -90.72 17.84 7.16 Favored 'General case' 0 CA--C 1.551 0.992 0 CA-C-N 113.639 -1.619 . . . . 0.0 109.578 176.407 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 236' ' ' ASN . . . . . . . . . . . . . 30.1 t30 -48.1 118.47 6.49 Favored Pre-proline 0 C--N 1.36 1.03 0 C-N-CA 124.392 1.077 . . . . 0.0 109.494 173.336 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_endo -57.39 82.78 0.04 OUTLIER 'Trans proline' 0 C--N 1.378 2.094 0 C-N-CA 123.455 2.77 . . . . 0.0 113.083 -174.891 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 238' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -110.75 -14.96 13.93 Favored 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 124.182 0.993 . . . . 0.0 111.232 -178.316 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 239' ' ' ILE . . . . . . . . . . . . . 9.0 tt -64.83 -38.45 82.76 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 C-N-CA 123.758 0.823 . . . . 0.0 110.755 176.744 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 2.8 pp20? . . . . . 0 C--O 1.251 1.144 0 C-N-CA 123.717 0.807 . . . . 0.0 110.027 171.205 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 251' ' ' BEZ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 253' ' ' LYS . . . . . 0.715 ' HG2' ' HB2' ' A' ' 45' ' ' GLU . 21.8 tptm -138.57 131.89 30.23 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.095 -174.202 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 254' ' ' ARG . . . . . 0.44 HH12 ' NE2' ' A' ' 96' ' ' GLN . 28.6 mmm180 -105.68 -9.28 17.4 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 124.483 1.113 . . . . 0.0 110.356 171.905 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 255' ' ' M9P . . . . . 0.412 ' NH2' ' HB3' ' A' ' 47' ' ' GLU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.454 ' H2 ' HD12 ' A' ' 138' ' ' ILE . . . . . . . . 0 N--CA 1.481 1.663 0 N-CA-C 111.754 -0.538 . . . . 0.0 111.754 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 41.1 p 172.14 152.92 0.07 Allowed 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 125.267 1.427 . . . . 0.0 108.392 -171.277 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.529 ' HB3' HD11 ' A' ' 6' ' ' LEU . . . -162.57 -61.38 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.753 0 CA-C-N 119.256 0.935 . . . . 0.0 111.317 176.406 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -150.76 -62.01 0.19 Allowed 'General case' 0 N--CA 1.477 0.875 0 C-N-CA 123.287 0.635 . . . . 0.0 110.054 -173.131 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ASP . . . . . 0.732 ' HA ' ' HG3' ' A' ' 120' ' ' MET . 32.6 t70 -144.5 76.92 1.52 Allowed 'General case' 0 CA--C 1.528 0.113 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 -172.386 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.529 HD11 ' HB3' ' A' ' 3' ' ' ALA . 5.8 mp -117.56 124.4 48.57 Favored 'General case' 0 N--CA 1.488 1.471 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.051 -179.283 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.794 ' HB2' ' HD3' ' A' ' 89' ' ' LYS . 14.5 tp10 -80.9 134.54 35.76 Favored 'General case' 0 C--O 1.252 1.229 0 CA-C-N 118.06 0.391 . . . . 0.0 110.449 178.023 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.462 ' HB2' HD11 ' A' ' 119' ' ' LEU . 18.1 tp -87.16 113.34 22.81 Favored 'General case' 0 CA--C 1.542 0.649 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 171.027 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -104.87 143.64 32.87 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 125.826 1.65 . . . . 0.0 108.176 -173.754 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.8 ptt-85 -76.29 147.16 38.42 Favored 'General case' 0 N--CA 1.481 1.104 0 CA-C-N 118.336 0.516 . . . . 0.0 110.505 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.656 ' HB2' ' HG3' ' A' ' 85' ' ' ARG . . . -125.89 -51.12 1.57 Allowed 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 169.2 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -166.65 175.34 8.0 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.012 0.925 . . . . 0.0 110.279 -177.038 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -98.59 159.44 14.95 Favored 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 108.401 -0.962 . . . . 0.0 108.401 164.11 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 83.4 t -88.39 103.18 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 CA-C-O 121.545 0.688 . . . . 0.0 111.281 -176.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 2.4 ptpp? -155.98 158.67 38.28 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 124.891 1.277 . . . . 0.0 107.97 168.695 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 10.6 t90 -67.83 105.43 1.96 Allowed 'General case' 0 CA--C 1.549 0.923 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.26 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.57 ' HB3' ' HB2' ' A' ' 169' ' ' ALA . 2.6 tm-20 -70.35 145.03 51.45 Favored 'General case' 0 CA--C 1.554 1.127 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 170.496 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -75.65 -19.45 59.16 Favored 'General case' 0 N--CA 1.481 1.117 0 N-CA-C 113.885 1.069 . . . . 0.0 113.885 -165.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 6.6 tp60 -94.1 53.37 1.74 Allowed 'General case' 0 N--CA 1.476 0.828 0 CA-C-O 121.46 0.648 . . . . 0.0 110.592 -168.819 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.617 ' HB1' ' HB2' ' A' ' 171' ' ' GLN . . . -56.04 91.24 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 124.558 1.143 . . . . 0.0 111.843 178.34 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -62.74 126.51 27.59 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 124.851 1.261 . . . . 0.0 110.746 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 50.4 mm -77.08 109.16 11.3 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.613 0 C-N-CA 123.073 0.549 . . . . 0.0 109.609 -178.256 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.1 m -135.38 -174.78 3.72 Favored 'General case' 0 CA--C 1.551 1.015 0 C-N-CA 124.038 0.935 . . . . 0.0 110.026 -179.436 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.413 ' H ' ' HB3' ' A' ' 189' ' ' LEU . . . 98.11 73.1 1.1 Allowed Glycine 0 C--N 1.349 1.259 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 -172.861 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.8 m -124.57 1.93 8.27 Favored 'General case' 0 N--CA 1.478 0.963 0 C-N-CA 122.971 0.508 . . . . 0.0 112.291 -164.636 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 13.7 m -120.45 137.88 26.7 Favored Pre-proline 0 CA--C 1.55 0.957 0 C-N-CA 123.291 0.636 . . . . 0.0 109.675 -176.727 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -82.43 -155.82 0.06 OUTLIER 'Trans proline' 0 C--N 1.379 2.151 0 C-N-CA 123.204 2.603 . . . . 0.0 112.253 179.506 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 48.6 mm -66.32 121.05 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 123.16 0.584 . . . . 0.0 110.632 -178.749 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.2 mt -105.53 164.87 11.55 Favored 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 124.658 1.183 . . . . 0.0 111.752 -175.139 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 39.4 m -122.46 116.18 23.52 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 123.5 0.72 . . . . 0.0 109.542 176.122 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.509 HD11 HG11 ' A' ' 223' ' ' VAL . 62.5 mt -116.24 145.09 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 C-N-CA 124.292 1.037 . . . . 0.0 108.561 178.391 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 35.9 p -93.56 105.13 17.21 Favored 'General case' 0 CA--C 1.543 0.703 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.125 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 9.2 tp -69.91 141.14 17.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 C-N-CA 124.159 0.983 . . . . 0.0 110.403 175.019 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 34.3 t -135.47 140.17 44.64 Favored 'General case' 0 C--O 1.242 0.701 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 176.788 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 65.14 15.98 10.3 Favored 'General case' 0 CA--C 1.563 1.476 0 C-N-CA 123.893 0.877 . . . . 0.0 111.133 174.756 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 58.12 32.65 22.27 Favored 'General case' 0 N--CA 1.49 1.545 0 C-N-CA 124.744 1.218 . . . . 0.0 111.67 -179.0 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -169.55 -44.41 0.03 OUTLIER Glycine 0 C--N 1.348 1.236 0 CA-C-N 116.32 -0.4 . . . . 0.0 112.669 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 25.6 m -89.15 106.2 18.29 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -176.373 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 27.3 mtm -88.05 162.59 16.71 Favored 'General case' 0 N--CA 1.476 0.873 0 O-C-N 121.909 -0.494 . . . . 0.0 110.856 -176.21 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 39.1 m -147.51 148.56 31.34 Favored 'General case' 0 C--O 1.238 0.492 0 C-N-CA 123.707 0.803 . . . . 0.0 109.379 -178.553 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 9.1 tp -96.12 151.7 3.97 Favored 'Isoleucine or valine' 0 C--O 1.239 0.55 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 169.326 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 50.2 mtmt -81.93 40.92 0.63 Allowed 'General case' 0 CA--C 1.558 1.261 0 C-N-CA 123.532 0.733 . . . . 0.0 111.222 175.31 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 7.8 t30 -167.49 75.34 0.14 Allowed 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 125.047 1.339 . . . . 0.0 107.661 176.518 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -75.29 117.66 17.34 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 177.398 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -168.95 154.97 6.49 Favored 'General case' 0 C--O 1.245 0.827 0 C-N-CA 123.912 0.885 . . . . 0.0 109.398 177.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 26.0 mm-40 65.38 161.57 0.13 Allowed 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 125.577 1.551 . . . . 0.0 113.796 176.185 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -133.19 173.19 11.71 Favored 'General case' 0 CA--C 1.549 0.919 0 CA-C-N 114.824 -1.08 . . . . 0.0 108.851 -177.487 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.443 ' HB2' ' NH1' ' B' ' 254' ' ' ARG . 29.6 pt20 -75.25 -179.09 4.24 Favored 'General case' 0 N--CA 1.477 0.893 0 C-N-CA 124.467 1.107 . . . . 0.0 111.873 175.241 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 37.9 p -116.32 -164.65 0.98 Allowed 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 124.238 1.015 . . . . 0.0 108.995 -178.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 2.3 pp -67.73 167.97 12.26 Favored 'General case' 0 C--O 1.244 0.764 0 CA-C-O 121.559 0.695 . . . . 0.0 111.803 175.149 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -82.2 -97.49 0.48 Allowed Glycine 0 C--O 1.224 -0.499 0 CA-C-N 114.648 -1.16 . . . . 0.0 112.435 174.571 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -128.97 -35.02 0.49 Allowed Glycine 0 N--CA 1.468 0.768 0 N-CA-C 111.645 -0.582 . . . . 0.0 111.645 -178.246 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 102.79 47.74 1.34 Allowed Glycine 0 C--N 1.354 1.564 0 C-N-CA 123.033 0.349 . . . . 0.0 112.481 176.188 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -70.57 123.88 12.04 Favored Glycine 0 C--N 1.346 1.112 0 C-N-CA 123.465 0.555 . . . . 0.0 111.929 178.256 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 39.1 t -80.19 158.7 26.21 Favored 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 124.343 1.057 . . . . 0.0 110.707 -178.208 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -73.02 90.45 0.59 Allowed Glycine 0 C--N 1.347 1.144 0 CA-C-N 116.309 -0.405 . . . . 0.0 112.543 -178.103 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -65.44 -48.8 65.05 Favored Glycine 0 C--N 1.35 1.315 0 O-C-N 123.881 0.4 . . . . 0.0 112.221 177.368 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 70.53 -114.89 5.65 Favored Glycine 0 C--N 1.354 1.548 0 O-C-N 123.77 0.335 . . . . 0.0 112.497 178.659 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 136.94 -143.28 14.54 Favored Glycine 0 C--N 1.346 1.112 0 N-CA-C 111.396 -0.682 . . . . 0.0 111.396 -179.694 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 -92.07 -5.49 52.74 Favored 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 123.824 0.85 . . . . 0.0 110.835 174.427 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 56.5 t80 75.47 -3.54 2.56 Favored 'General case' 0 N--CA 1.488 1.458 0 C-N-CA 125.48 1.512 . . . . 0.0 112.176 177.319 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -72.45 -38.64 68.23 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 123.391 0.676 . . . . 0.0 110.571 177.504 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 137.61 108.36 0.85 Allowed Glycine 0 C--N 1.344 1.006 0 CA-C-N 115.685 -0.689 . . . . 0.0 112.148 176.715 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 36.0 t -71.63 -86.29 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.565 1.532 0 C-N-CA 123.548 0.739 . . . . 0.0 109.197 178.264 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.606 HD23 ' HG2' ' A' ' 78' ' ' GLU . 33.6 tp 174.92 146.92 0.07 Allowed 'General case' 0 N--CA 1.483 1.182 0 C-N-CA 126.888 2.075 . . . . 0.0 106.172 171.772 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 6.7 m0 -91.2 62.43 4.76 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 118.526 0.603 . . . . 0.0 111.651 -176.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 8.6 t0 179.15 70.64 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.266 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 173.096 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 14.5 m -129.52 109.41 17.5 Favored Pre-proline 0 CA--C 1.555 1.152 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.443 -169.101 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.552 ' HD3' ' HG3' ' A' ' 80' ' ' GLU . 87.6 Cg_endo -81.9 -33.04 0.66 Allowed 'Trans proline' 0 C--N 1.38 2.222 0 C-N-CA 123.03 2.487 . . . . 0.0 112.247 177.051 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 51.1 m -129.83 152.64 80.2 Favored Pre-proline 0 CA--C 1.544 0.727 0 C-N-CA 125.395 1.478 . . . . 0.0 107.684 173.894 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 22.7 Cg_endo -59.11 109.54 0.55 Allowed 'Trans proline' 0 C--N 1.376 2.005 0 C-N-CA 122.574 2.183 . . . . 0.0 111.564 175.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -78.25 164.15 27.01 Favored 'Trans proline' 0 C--N 1.38 2.214 0 C-N-CA 122.809 2.339 . . . . 0.0 111.961 -176.083 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -79.99 55.28 5.58 Favored 'Trans proline' 0 CA--C 1.558 1.716 0 C-N-CA 122.768 2.312 . . . . 0.0 111.542 171.461 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 9.3 p 37.86 75.69 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 C-N-CA 126.125 1.77 . . . . 0.0 112.355 -171.494 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -90.23 -131.89 4.8 Favored Glycine 0 C--N 1.342 0.884 0 CA-C-N 115.201 -0.909 . . . . 0.0 111.909 -178.869 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 25.3 pttm 178.76 -22.84 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 125.112 1.365 . . . . 0.0 110.168 -179.159 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -94.17 1.33 56.08 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 123.444 0.698 . . . . 0.0 112.607 -176.088 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.606 ' HG2' HD23 ' A' ' 65' ' ' LEU . 8.7 pm0 -82.62 72.78 9.69 Favored 'General case' 0 N--CA 1.479 0.993 0 CA-C-O 122.206 1.003 . . . . 0.0 111.165 -179.292 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.423 HD22 HD21 ' A' ' 65' ' ' LEU . 4.1 mm? -105.45 81.57 1.71 Allowed 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 106.86 -1.533 . . . . 0.0 106.86 168.13 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.552 ' HG3' ' HD3' ' A' ' 69' ' ' PRO . 29.6 mm-40 -71.09 -38.7 72.39 Favored 'General case' 0 C--O 1.243 0.738 0 CA-C-N 114.563 -1.198 . . . . 0.0 111.742 -171.904 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 70.02 125.58 0.03 OUTLIER 'General case' 0 CA--C 1.549 0.939 0 O-C-N 125.008 1.443 . . . . 0.0 109.731 -161.517 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -166.16 166.33 38.7 Favored Glycine 0 C--N 1.34 0.802 0 CA-C-N 115.805 -0.634 . . . . 0.0 113.455 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' ALA . . . . . 0.68 ' HB1' HD11 ' A' ' 161' ' ' LEU . . . -86.3 118.14 25.55 Favored 'General case' 0 C--O 1.243 0.719 0 CA-C-N 114.117 -1.041 . . . . 0.0 108.701 175.096 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 79.9 m-85 -118.46 142.4 47.6 Favored 'General case' 0 C--O 1.216 -0.676 0 C-N-CA 123.09 0.556 . . . . 0.0 109.622 -179.429 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' ARG . . . . . 0.656 ' HG3' ' HB2' ' A' ' 11' ' ' ALA . 54.9 mtt-85 -92.29 137.0 32.73 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 174.931 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.404 ' H ' ' HA ' ' A' ' 99' ' ' ALA . 51.6 mt -102.37 121.3 53.26 Favored 'Isoleucine or valine' 0 C--O 1.26 1.629 0 CA-C-O 121.673 0.749 . . . . 0.0 110.151 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.489 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 22.7 pttm -122.82 144.79 48.96 Favored 'General case' 0 C--N 1.349 0.554 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.823 177.851 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 4.8 mm-40 -82.18 119.65 24.33 Favored 'General case' 0 C--O 1.249 1.027 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 173.869 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' LYS . . . . . 0.794 ' HD3' ' HB2' ' A' ' 7' ' ' GLU . 53.2 pttt -115.31 152.74 32.23 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.686 -172.318 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -100.93 103.2 2.55 Favored Glycine 0 C--N 1.347 1.157 0 N-CA-C 106.135 -2.786 . . . . 0.0 106.135 160.414 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 4.8 tp 19.36 29.66 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.58 2.118 0 C-N-CA 129.298 3.039 . . . . 0.0 116.882 -167.542 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.444 ' N ' ' HD2' ' A' ' 89' ' ' LYS . 0.7 OUTLIER -177.41 -57.27 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.873 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 -169.77 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 177.05 161.89 26.52 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 114.732 0.653 . . . . 0.0 114.732 -177.604 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 53.2 p90 -165.8 -48.0 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 124.308 1.043 . . . . 0.0 112.05 156.17 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 12.6 t -152.72 149.83 28.8 Favored 'General case' 0 N--CA 1.495 1.783 0 CA-C-N 119.63 1.105 . . . . 0.0 112.067 -175.82 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' GLN . . . . . 0.489 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 21.0 tm0? -95.38 142.31 27.91 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 124.417 1.087 . . . . 0.0 110.445 -179.782 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.485 HD11 HD23 ' A' ' 6' ' ' LEU . 1.3 pp -133.49 -7.66 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 N-CA-C 113.575 0.954 . . . . 0.0 113.575 -175.052 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 175.92 -148.92 9.58 Favored Glycine 0 N--CA 1.475 1.242 0 CA-C-N 118.359 0.527 . . . . 0.0 113.017 173.837 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.404 ' HA ' ' H ' ' A' ' 86' ' ' ILE . . . -156.41 176.06 13.19 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 123.585 0.754 . . . . 0.0 110.985 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -172.87 135.3 3.27 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -177.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.491 HG21 ' HB3' ' A' ' 199' ' ' PRO . 71.3 t -95.65 110.67 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 C-N-CA 123.285 0.634 . . . . 0.0 109.328 -177.447 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 17.7 t80 -77.66 134.51 38.14 Favored 'General case' 0 CA--C 1.536 0.439 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -179.468 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' LYS . . . . . 0.66 ' HD2' HD21 ' A' ' 146' ' ' LEU . 35.5 mmtm -118.64 157.65 27.0 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 124.96 1.304 . . . . 0.0 109.045 -179.583 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -53.76 100.18 0.03 OUTLIER 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 123.86 0.864 . . . . 0.0 112.176 -173.429 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 83.55 -9.97 60.57 Favored Glycine 0 C--N 1.351 1.386 0 CA-C-N 115.48 -0.782 . . . . 0.0 113.766 178.649 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 20.3 p -123.81 120.45 32.65 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 124.038 0.935 . . . . 0.0 111.02 -175.121 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' PHE . . . . . 0.702 ' HB3' ' HB3' ' A' ' 140' ' ' TYR . 37.2 t80 -84.42 122.6 29.19 Favored 'General case' 0 N--CA 1.48 1.027 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 176.483 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 5.3 t-80 -132.97 102.3 5.57 Favored 'General case' 0 CA--C 1.554 1.129 0 C-N-CA 123.776 0.83 . . . . 0.0 110.434 -167.111 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' THR . . . . . 0.485 HG23 ' HB ' ' A' ' 138' ' ' ILE . 10.2 t -136.74 177.19 8.05 Favored 'General case' 0 N--CA 1.488 1.457 0 C-N-CA 123.889 0.876 . . . . 0.0 111.135 -178.601 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' MET . . . . . 0.476 ' HA ' ' HA ' ' A' ' 137' ' ' LEU . 44.2 mtp -93.55 157.14 16.34 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 124.296 1.038 . . . . 0.0 109.148 173.536 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 79.7 t90 -80.46 -61.88 1.84 Allowed 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 112.28 0.474 . . . . 0.0 112.28 -166.149 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 2.3 p-80 -73.97 3.93 6.12 Favored 'General case' 0 N--CA 1.5 2.048 0 N-CA-C 114.009 1.114 . . . . 0.0 114.009 -167.836 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 40.7 t -42.99 -41.6 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.279 0 C-N-CA 123.734 0.814 . . . . 0.0 110.29 161.676 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.526 HG21 HD21 ' A' ' 6' ' ' LEU . 0.2 OUTLIER -153.29 -163.03 1.59 Allowed 'General case' 0 CA--C 1.558 1.286 0 C-N-CA 125.267 1.427 . . . . 0.0 109.207 170.395 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 77.5 mtp180 -66.01 -26.65 67.63 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 113.362 0.875 . . . . 0.0 113.362 -172.747 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 93.78 62.84 1.07 Allowed Glycine 0 CA--C 1.53 0.983 0 O-C-N 123.205 0.316 . . . . 0.0 113.715 178.878 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -141.98 -85.66 0.17 Allowed 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 112.461 0.541 . . . . 0.0 112.461 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 26.6 t -110.98 109.0 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 123.359 0.663 . . . . 0.0 112.331 -169.028 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.515 HD12 HD12 ' A' ' 126' ' ' ILE . 1.3 tm? -91.33 152.06 20.61 Favored 'General case' 0 C--O 1.212 -0.908 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 169.108 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 120' ' ' MET . . . . . 0.732 ' HG3' ' HA ' ' A' ' 5' ' ' ASP . 45.7 mmm -135.01 138.85 44.36 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 124.06 0.944 . . . . 0.0 108.717 -172.755 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' HIS . . . . . 0.518 ' O ' ' HG2' ' A' ' 122' ' ' LYS . 18.5 t-160 -167.53 141.84 3.68 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -177.869 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.518 ' HG2' ' O ' ' A' ' 121' ' ' HIS . 32.8 pttt 68.92 3.12 3.84 Favored 'General case' 0 N--CA 1.501 2.086 0 C-N-CA 125.649 1.579 . . . . 0.0 112.766 176.194 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 99.96 -0.76 56.35 Favored Glycine 0 C--N 1.351 1.362 0 C-N-CA 123.144 0.402 . . . . 0.0 113.084 -174.282 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -118.45 152.93 34.97 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 123.813 0.845 . . . . 0.0 110.744 179.482 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' ARG . . . . . 0.444 ' HB3' ' SD ' ' A' ' 120' ' ' MET . 20.8 ptp180 -93.07 164.67 13.18 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.11 -179.276 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.515 HD12 HD12 ' A' ' 119' ' ' LEU . 27.5 mt -142.8 122.97 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 C-N-CA 125.628 1.571 . . . . 0.0 107.086 -172.396 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 44.8 mt-10 -125.73 132.69 24.39 Favored Pre-proline 0 N--CA 1.474 0.758 0 N-CA-C 108.604 -0.888 . . . . 0.0 108.604 175.427 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.48 ' HA ' ' HB2' ' A' ' 140' ' ' TYR . 96.9 Cg_endo -73.78 157.65 47.62 Favored 'Trans proline' 0 C--N 1.373 1.86 0 C-N-CA 122.934 2.423 . . . . 0.0 113.943 -168.806 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' SER . . . . . 0.558 ' H ' ' HA ' ' A' ' 140' ' ' TYR . 28.8 p -76.77 -27.62 55.37 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-N 114.884 -1.053 . . . . 0.0 109.623 172.385 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 67.6 t-105 -152.5 144.94 24.07 Favored 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 123.314 0.645 . . . . 0.0 110.21 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -136.72 121.19 18.22 Favored 'General case' 0 C--O 1.241 0.613 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 171.566 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -114.13 109.09 17.88 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 123.437 0.695 . . . . 0.0 109.467 -173.571 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 17.1 t -77.44 -19.38 14.15 Favored 'Isoleucine or valine' 0 CA--C 1.562 1.407 0 C-N-CA 123.9 0.88 . . . . 0.0 111.304 -175.884 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 2.8 mptp? -69.46 -51.31 37.27 Favored 'General case' 0 N--CA 1.487 1.419 0 C-N-CA 123.461 0.704 . . . . 0.0 109.557 -177.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 31.9 mmtp -84.13 -20.08 33.1 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-N 115.088 -0.96 . . . . 0.0 110.346 178.681 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 14.2 t70 65.5 63.57 0.62 Allowed 'General case' 0 C--O 1.24 0.595 0 C-N-CA 125.56 1.544 . . . . 0.0 110.607 -175.745 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' LEU . . . . . 0.495 HD21 HD12 ' A' ' 210' ' ' LEU . 1.5 mp -143.77 172.64 12.56 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.802 174.461 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.485 ' HB ' HG23 ' A' ' 109' ' ' THR . 21.6 mt -141.46 131.33 25.15 Favored 'Isoleucine or valine' 0 C--O 1.245 0.868 0 C-N-CA 125.952 1.701 . . . . 0.0 108.08 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 29.9 p -136.48 123.09 20.98 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 124.13 0.972 . . . . 0.0 110.282 -177.566 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.702 ' HB3' ' HB3' ' A' ' 107' ' ' PHE . 47.8 t80 -109.68 123.97 50.41 Favored 'General case' 0 N--CA 1.464 0.24 0 C-N-CA 124.626 1.17 . . . . 0.0 108.06 172.79 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 113.91 0.4 24.23 Favored Glycine 0 N--CA 1.474 1.19 0 O-C-N 123.885 0.741 . . . . 0.0 111.98 -173.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 147.46 -141.74 9.58 Favored Glycine 0 C--N 1.346 1.125 0 N-CA-C 109.944 -1.262 . . . . 0.0 109.944 177.734 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.809 ' HA3' ' HB2' ' A' ' 232' ' ' SER . . . -97.45 -175.06 34.19 Favored Glycine 0 C--N 1.345 1.058 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 164.285 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 144' ' ' TRP . . . . . 0.609 ' HZ2' ' HA2' ' A' ' 209' ' ' GLY . 7.4 t90 -69.76 104.02 2.32 Favored 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 177.279 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 145' ' ' LYS . . . . . 0.616 ' HB3' ' HA ' ' A' ' 231' ' ' LYS . 11.7 pttt -164.87 113.85 1.08 Allowed 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 123.7 0.8 . . . . 0.0 109.692 -177.964 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 146' ' ' LEU . . . . . 0.66 HD21 ' HD2' ' A' ' 103' ' ' LYS . 0.0 OUTLIER 167.62 -33.12 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 C-N-CA 125.178 1.391 . . . . 0.0 110.602 161.409 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.569 ' HG2' ' HE2' ' A' ' 103' ' ' LYS . 31.6 mt-10 -62.3 -81.91 0.02 OUTLIER 'General case' 0 C--N 1.367 1.353 0 O-C-N 123.714 0.634 . . . . 0.0 111.057 -166.139 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 148' ' ' GLY . . . . . 0.424 ' O ' ' HB ' ' A' ' 229' ' ' THR . . . 177.66 -174.26 46.75 Favored Glycine 0 C--N 1.341 0.813 0 O-C-N 123.464 0.477 . . . . 0.0 111.963 -178.097 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -124.85 107.37 10.83 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 -172.765 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 150' ' ' TRP . . . . . . . . . . . . . 27.5 t90 -54.89 135.57 48.0 Favored 'General case' 0 N--CA 1.477 0.923 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.625 172.161 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 53.6 mmtt -84.48 101.8 12.33 Favored 'General case' 0 C--O 1.239 0.508 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 179.042 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -62.65 107.72 1.01 Allowed 'General case' 0 CA--C 1.546 0.803 0 O-C-N 124.022 0.826 . . . . 0.0 109.765 -172.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 134.16 -31.62 2.77 Favored Glycine 0 C--N 1.34 0.803 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.688 -176.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -82.81 156.34 23.71 Favored 'General case' 0 C--O 1.242 0.708 0 C-N-CA 123.349 0.66 . . . . 0.0 109.48 178.559 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 10.0 pm0 -64.02 142.93 58.23 Favored 'General case' 0 C--O 1.243 0.731 0 O-C-N 124.207 0.942 . . . . 0.0 109.956 174.442 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 15.8 m -92.48 142.34 13.26 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 CA-C-O 121.184 0.516 . . . . 0.0 109.822 174.552 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 157' ' ' GLN . . . . . 0.482 HE22 ' HB2' ' A' ' 171' ' ' GLN . 9.9 tp-100 -101.32 144.96 29.52 Favored 'General case' 0 N--CA 1.454 -0.235 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 173.008 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.594 ' HB ' ' HB ' ' A' ' 170' ' ' VAL . 49.1 t -128.03 146.02 34.28 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 123.445 0.698 . . . . 0.0 110.014 -174.924 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 159' ' ' LEU . . . . . 0.424 ' HB2' ' HG2' ' A' ' 199' ' ' PRO . 33.7 mt -97.04 85.55 3.76 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 160.82 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -64.16 100.5 0.34 Allowed 'General case' 0 C--O 1.237 0.403 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 -179.233 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 161' ' ' LEU . . . . . 0.68 HD11 ' HB1' ' A' ' 83' ' ' ALA . 70.6 mt -78.03 80.28 4.47 Favored 'General case' 0 C--O 1.242 0.691 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.628 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 162' ' ' GLU . . . . . 0.425 ' HB2' ' HB2' ' A' ' 165' ' ' LYS . 10.1 mm-40 -61.59 125.3 84.26 Favored Pre-proline 0 CA--C 1.555 1.151 0 CA-C-N 113.412 -1.722 . . . . 0.0 110.074 -176.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 163' ' ' PRO . . . . . 0.413 ' HB3' ' NH2' ' B' ' 254' ' ' ARG . 18.4 Cg_endo -58.1 112.8 1.28 Allowed 'Trans proline' 0 C--N 1.382 2.293 0 C-N-CA 122.875 2.383 . . . . 0.0 112.626 -174.006 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 67.06 26.87 73.31 Favored Glycine 0 C--N 1.349 1.305 0 O-C-N 124.139 0.9 . . . . 0.0 113.291 176.612 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 165' ' ' LYS . . . . . 0.425 ' HB2' ' HB2' ' A' ' 162' ' ' GLU . 49.8 mtpt -131.54 -172.49 2.87 Favored 'General case' 0 C--O 1.242 0.703 0 C-N-CA 124.282 1.033 . . . . 0.0 109.306 -176.533 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -72.48 141.7 83.23 Favored Pre-proline 0 CA--C 1.555 1.139 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.053 170.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_exo -67.48 122.33 9.54 Favored 'Trans proline' 0 C--N 1.368 1.577 0 C-N-CA 122.522 2.148 . . . . 0.0 111.006 170.384 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 56.6 mtp180 -105.51 167.6 9.65 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 123.912 0.885 . . . . 0.0 110.549 -178.844 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 169' ' ' ALA . . . . . 0.57 ' HB2' ' HB3' ' A' ' 17' ' ' GLU . . . -102.24 151.21 22.49 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 109.408 -0.589 . . . . 0.0 109.408 170.493 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.594 ' HB ' ' HB ' ' A' ' 158' ' ' VAL . 95.5 t -136.17 117.08 18.51 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.239 0 C-N-CA 123.276 0.63 . . . . 0.0 110.286 175.159 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 171' ' ' GLN . . . . . 0.617 ' HB2' ' HB1' ' A' ' 20' ' ' ALA . 65.0 tt0 -94.81 111.24 23.03 Favored 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 172.441 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 4.5 t -140.52 140.53 35.27 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-O 121.001 0.429 . . . . 0.0 110.742 -174.88 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 21.5 ptmt -75.61 152.43 85.27 Favored Pre-proline 0 CA--C 1.55 0.953 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.961 177.954 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -70.3 143.54 48.52 Favored 'Trans proline' 0 C--N 1.374 1.909 0 C-N-CA 122.314 2.009 . . . . 0.0 112.692 171.502 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -132.84 155.55 21.67 Favored Glycine 0 N--CA 1.467 0.729 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 170.406 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.49 ' HG ' ' HA2' ' A' ' 185' ' ' GLY . 6.5 mp -116.81 157.17 26.02 Favored 'General case' 0 N--CA 1.482 1.143 0 CA-C-N 119.019 1.409 . . . . 0.0 109.231 -174.562 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 177' ' ' PHE . . . . . . . . . . . . . 50.2 p90 -137.02 149.55 47.53 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.802 175.301 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 60.1 tttp -97.78 128.01 44.13 Favored 'General case' 0 C--O 1.239 0.547 0 CA-C-N 115.577 -0.738 . . . . 0.0 109.977 -177.781 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 75.5 p -123.48 171.82 9.19 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.017 0.927 . . . . 0.0 109.355 168.862 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -65.94 -27.07 67.9 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 123.564 0.746 . . . . 0.0 110.607 174.334 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -68.65 -40.71 80.08 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 123.757 0.823 . . . . 0.0 110.602 175.455 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 158.22 -175.9 35.31 Favored Glycine 0 C--N 1.35 1.346 0 CA-C-N 115.831 -0.622 . . . . 0.0 112.423 177.634 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 8.5 t -77.98 115.42 17.71 Favored 'General case' 0 CA--C 1.543 0.695 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 172.55 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 52.8 mt -104.5 138.95 26.98 Favored 'Isoleucine or valine' 0 C--O 1.246 0.909 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -177.504 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 185' ' ' GLY . . . . . 0.49 ' HA2' ' HG ' ' A' ' 176' ' ' LEU . . . -100.45 119.43 6.51 Favored Glycine 0 C--N 1.349 1.291 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -175.121 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.563 ' HA ' ' H ' ' A' ' 226' ' ' ILE . . . -144.94 -156.85 0.74 Allowed 'General case' 0 C--O 1.235 0.323 0 C-N-CA 123.837 0.855 . . . . 0.0 109.928 -165.694 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 187' ' ' VAL . . . . . 0.544 HG13 ' HB3' ' A' ' 224' ' ' SER . 2.4 p -135.77 123.06 34.98 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 C-N-CA 123.648 0.779 . . . . 0.0 109.285 175.085 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 41.6 m -117.75 115.29 24.72 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 123.779 0.832 . . . . 0.0 109.262 -176.796 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 189' ' ' LEU . . . . . 0.421 HD13 ' HB3' ' A' ' 191' ' ' PHE . 0.5 OUTLIER -149.44 164.0 36.22 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 124.065 0.946 . . . . 0.0 110.962 -175.44 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -101.52 104.1 14.99 Favored 'General case' 0 CA--C 1.541 0.634 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 170.246 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 191' ' ' PHE . . . . . 0.421 ' HB3' HD13 ' A' ' 189' ' ' LEU . 67.9 t80 -154.11 166.58 32.62 Favored 'General case' 0 N--CA 1.484 1.238 0 C-N-CA 123.217 0.607 . . . . 0.0 110.486 -171.79 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 48.8 m -69.53 156.25 92.01 Favored Pre-proline 0 CA--C 1.559 1.295 0 C-N-CA 124.952 1.301 . . . . 0.0 112.631 -178.713 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 193' ' ' PRO . . . . . 0.537 ' HA ' ' CE1' ' A' ' 222' ' ' TYR . 39.7 Cg_endo -64.24 99.18 0.28 Allowed 'Trans proline' 0 C--N 1.387 2.554 0 C-N-CA 123.009 2.473 . . . . 0.0 113.02 176.392 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -70.47 -136.39 0.12 Allowed Glycine 0 C--N 1.361 1.918 0 C-N-CA 123.745 0.688 . . . . 0.0 112.596 177.749 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 25.4 p -124.79 143.94 50.54 Favored 'General case' 0 N--CA 1.489 1.501 0 CA-C-N 118.979 1.39 . . . . 0.0 112.245 169.715 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 14.1 m -73.88 83.19 1.68 Allowed 'General case' 0 C--N 1.354 0.765 0 C-N-CA 123.645 0.778 . . . . 0.0 110.305 170.729 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 127.98 19.86 1.73 Allowed Glycine 0 C--N 1.339 0.747 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.536 -170.275 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 33.4 t -65.49 140.23 97.53 Favored Pre-proline 0 CA--C 1.554 1.108 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 164.118 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 199' ' ' PRO . . . . . 0.491 ' HB3' HG21 ' A' ' 101' ' ' VAL . 65.7 Cg_endo -81.04 131.85 8.1 Favored 'Trans proline' 0 C--N 1.374 1.881 0 C-N-CA 121.647 1.565 . . . . 0.0 113.374 179.016 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 43.9 mt -87.43 117.91 32.33 Favored 'Isoleucine or valine' 0 C--O 1.248 1.002 0 CA-C-O 121.962 0.887 . . . . 0.0 108.739 163.091 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 201' ' ' ILE . . . . . . . . . . . . . 80.4 mt -102.87 136.49 35.12 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.812 0 CA-C-N 113.248 -1.796 . . . . 0.0 107.54 172.421 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 202' ' ' ASP . . . . . 0.529 ' HB3' ' HB2' ' A' ' 206' ' ' LYS . 19.1 t70 -73.31 148.56 43.41 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 167.415 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 60.6 pttt -60.38 -18.96 53.85 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 -172.837 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 86.1 tttt -67.52 -21.34 65.49 Favored 'General case' 0 CA--C 1.557 1.247 0 C-N-CA 123.546 0.738 . . . . 0.0 111.766 177.497 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 108.27 3.32 33.37 Favored Glycine 0 N--CA 1.471 0.967 0 C-N-CA 123.3 0.476 . . . . 0.0 111.949 -171.691 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 206' ' ' LYS . . . . . 0.529 ' HB2' ' HB3' ' A' ' 202' ' ' ASP . 46.4 mttm -74.45 136.22 42.3 Favored 'General case' 0 C--O 1.205 -1.244 0 C-N-CA 123.985 0.914 . . . . 0.0 109.428 173.436 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 7.5 p -86.68 135.91 24.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 N-CA-C 106.403 -1.702 . . . . 0.0 106.403 163.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 30.9 m -135.8 -21.08 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 N-CA-C 113.153 0.797 . . . . 0.0 113.153 -168.852 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 209' ' ' GLY . . . . . 0.609 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . 178.4 -151.37 10.47 Favored Glycine 0 C--N 1.35 1.329 0 C-N-CA 119.751 -1.214 . . . . 0.0 115.815 -176.116 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 210' ' ' LEU . . . . . 0.495 HD12 HD21 ' A' ' 137' ' ' LEU . 33.6 mt -130.82 133.74 46.22 Favored 'General case' 0 C--N 1.365 1.241 0 CA-C-O 121.88 0.848 . . . . 0.0 112.366 -175.751 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 64.0 t80 -94.09 133.96 37.03 Favored 'General case' 0 C--O 1.241 0.655 0 C-N-CA 126.409 1.884 . . . . 0.0 108.223 168.061 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -137.38 -138.05 3.69 Favored Glycine 0 C--O 1.229 -0.189 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 177.816 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 213' ' ' ASN . . . . . 0.403 ' HB2' ' CZ ' ' A' ' 222' ' ' TYR . 9.2 t30 -156.79 101.09 1.95 Allowed 'General case' 0 C--O 1.237 0.396 0 C-N-CA 125.694 1.598 . . . . 0.0 107.05 170.666 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . -56.22 -56.39 24.5 Favored Glycine 0 C--N 1.342 0.894 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 172.782 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 215' ' ' VAL . . . . . . . . . . . . . 3.4 m -162.2 -172.74 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 C-N-CA 125.241 1.416 . . . . 0.0 108.952 176.057 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 216' ' ' VAL . . . . . 0.518 HG22 ' HD3' ' B' ' 253' ' ' LYS . 3.4 m -117.83 129.89 73.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 168.135 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 217' ' ' THR . . . . . 0.451 HG22 ' H ' ' A' ' 218' ' ' ARG . 4.9 m -126.69 -178.9 4.54 Favored 'General case' 0 CA--C 1.552 1.031 0 N-CA-C 107.829 -1.175 . . . . 0.0 107.829 -178.928 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 218' ' ' ARG . . . . . 0.451 ' H ' HG22 ' A' ' 217' ' ' THR . 10.9 ttt85 64.19 25.57 13.66 Favored 'General case' 0 N--CA 1.496 1.863 0 CA-C-O 122.393 1.092 . . . . 0.0 110.879 171.367 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 10.2 t 69.9 2.07 3.72 Favored 'General case' 0 N--CA 1.489 1.507 0 C-N-CA 125.412 1.485 . . . . 0.0 112.975 176.501 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 220' ' ' GLY . . . . . 0.421 ' HA2' ' H5 ' ' B' ' 251' ' ' BEZ . . . 159.64 45.81 0.02 OUTLIER Glycine 0 C--N 1.349 1.263 0 CA-C-N 117.706 0.23 . . . . 0.0 112.572 -177.447 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -122.69 121.45 36.41 Favored 'General case' 0 C--O 1.238 0.478 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 176.048 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 222' ' ' TYR . . . . . 0.537 ' CE1' ' HA ' ' A' ' 193' ' ' PRO . 56.6 t80 -69.8 101.29 1.68 Allowed 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 125.136 1.374 . . . . 0.0 109.059 179.282 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 223' ' ' VAL . . . . . 0.509 HG11 HD11 ' A' ' 31' ' ' ILE . 8.2 t -96.89 98.56 7.68 Favored 'Isoleucine or valine' 0 C--O 1.249 1.039 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 -176.467 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 224' ' ' SER . . . . . 0.544 ' HB3' HG13 ' A' ' 187' ' ' VAL . 38.0 t -97.3 155.19 16.98 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 125.144 1.378 . . . . 0.0 109.744 179.059 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 225' ' ' ALA . . . . . . . . . . . . . . . -104.83 131.38 52.38 Favored 'General case' 0 C--O 1.241 0.626 0 C-N-CA 123.449 0.7 . . . . 0.0 109.675 176.428 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 226' ' ' ILE . . . . . 0.563 ' H ' ' HA ' ' A' ' 186' ' ' ALA . 78.8 mt -77.98 95.04 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.352 0.68 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 173.196 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 227' ' ' ALA . . . . . 0.419 ' O ' ' HA3' ' A' ' 209' ' ' GLY . . . -85.18 147.18 26.73 Favored 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 172.632 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 13.1 pt20 -147.54 153.56 39.63 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 123.918 0.887 . . . . 0.0 109.446 -169.246 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 229' ' ' THR . . . . . 0.424 ' HB ' ' O ' ' A' ' 148' ' ' GLY . 89.4 m -69.0 109.28 3.88 Favored 'General case' 0 CA--C 1.545 0.764 0 CA-C-O 121.161 0.505 . . . . 0.0 109.817 179.242 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 230' ' ' GLU . . . . . 0.411 ' O ' ' HG2' ' A' ' 231' ' ' LYS . 38.3 mt-10 -98.01 -11.83 22.58 Favored 'General case' 0 N--CA 1.481 1.081 0 CA-C-N 114.916 -1.038 . . . . 0.0 111.302 -175.193 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 231' ' ' LYS . . . . . 0.616 ' HA ' ' HB3' ' A' ' 145' ' ' LYS . 11.7 pttm 66.78 128.48 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 127.06 2.144 . . . . 0.0 112.189 -177.51 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 232' ' ' SER . . . . . 0.809 ' HB2' ' HA3' ' A' ' 143' ' ' GLY . 30.1 m -144.03 93.38 2.44 Favored 'General case' 0 C--N 1.351 0.659 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 172.814 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 233' ' ' ILE . . . . . . . . . . . . . 6.4 tt -75.08 -24.68 17.9 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.057 0 CA-C-N 114.767 -1.106 . . . . 0.0 110.725 179.616 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 234' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 78.9 -39.87 0.24 Allowed 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 126.431 1.893 . . . . 0.0 111.945 -178.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -60.12 -56.89 16.05 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 123.642 0.777 . . . . 0.0 110.522 176.196 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 236' ' ' ASN . . . . . . . . . . . . . 38.7 m-20 -107.54 106.38 58.3 Favored Pre-proline 0 N--CA 1.477 0.908 0 C-N-CA 123.428 0.691 . . . . 0.0 110.045 -176.629 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_exo -73.3 136.27 23.94 Favored 'Trans proline' 0 C--N 1.374 1.908 0 C-N-CA 122.623 2.215 . . . . 0.0 110.577 170.655 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 238' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -84.98 39.3 0.76 Allowed 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 123.778 0.831 . . . . 0.0 112.634 -170.19 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 239' ' ' ILE . . . . . . . . . . . . . 49.8 mm 73.92 -51.93 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 C-N-CA 126.05 1.74 . . . . 0.0 110.946 -177.537 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 . . . . . 0 CA--C 1.556 1.191 0 C-N-CA 123.818 0.847 . . . . 0.0 109.726 174.907 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 251' ' ' BEZ . . . . . 0.421 ' H5 ' ' HA2' ' A' ' 220' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 252' ' ' NLE . . . . . 0.506 ' HD2' ' HN2' ' B' ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 253' ' ' LYS . . . . . 0.518 ' HD3' HG22 ' A' ' 216' ' ' VAL . 24.8 pttm -144.95 177.04 9.04 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.125 0.57 . . . . 0.0 111.544 -172.705 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 254' ' ' ARG . . . . . 0.443 ' NH1' ' HB2' ' A' ' 48' ' ' GLN . 38.3 mmt180 -115.78 -169.46 1.59 Allowed 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 124.544 1.137 . . . . 0.0 109.003 172.292 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 255' ' ' M9P . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.238 0 CA-C-O 120.857 0.361 . . . . 0.0 111.626 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -170.95 11.37 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 123.736 0.814 . . . . 0.0 109.669 -170.836 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . 0.414 ' H ' HD12 ' A' ' 6' ' ' LEU . 13.0 m-20 -158.25 82.33 0.84 Allowed 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 -169.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.414 HD12 ' H ' ' A' ' 5' ' ' ASP . 7.4 mp -117.01 109.65 17.27 Favored 'General case' 0 C--O 1.202 -1.432 0 O-C-N 121.474 -0.766 . . . . 0.0 110.284 -175.221 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.618 ' HB2' ' HD3' ' A' ' 89' ' ' LYS . 37.3 tp10 -83.68 145.46 28.76 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.551 -0.718 . . . . 0.0 110.627 -176.304 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.455 ' HB2' ' CD2' ' A' ' 121' ' ' HIS . 81.6 mt -89.32 114.66 26.08 Favored 'General case' 0 CA--C 1.547 0.856 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.508 171.177 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -112.28 107.88 16.89 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 125.108 1.363 . . . . 0.0 108.274 178.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 15.9 ttp180 -67.75 125.05 25.02 Favored 'General case' 0 N--CA 1.481 1.102 0 CA-C-N 118.441 0.564 . . . . 0.0 111.616 -172.088 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.543 ' HB2' ' HG3' ' A' ' 85' ' ' ARG . . . -89.06 -40.54 12.89 Favored 'General case' 0 C--N 1.347 0.473 0 C-N-CA 124.02 0.928 . . . . 0.0 109.986 177.188 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -166.09 -176.25 3.67 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 115.08 -0.964 . . . . 0.0 110.776 -173.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 65.2 m-20 -110.22 146.78 35.01 Favored 'General case' 0 C--O 1.242 0.696 0 C-N-CA 124.085 0.954 . . . . 0.0 108.838 171.401 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.435 HG11 HG12 ' A' ' 208' ' ' VAL . 94.6 t -78.86 101.01 3.97 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 CA-C-O 121.503 0.668 . . . . 0.0 109.469 -177.171 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 33.8 ttpt -167.96 109.74 0.59 Allowed 'General case' 0 C--O 1.247 0.966 0 N-CA-C 105.247 -2.131 . . . . 0.0 105.247 175.767 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . 0.442 ' NE1' ' HB1' ' A' ' 169' ' ' ALA . 68.2 t90 -80.3 90.57 5.56 Favored 'General case' 0 CA--C 1.539 0.553 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 -177.153 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -157.88 60.46 0.47 Allowed 'General case' 0 CA--C 1.543 0.677 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 158.046 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.601 ' HB3' ' HB2' ' A' ' 169' ' ' ALA . 12.6 t70 -90.6 -58.93 2.32 Favored 'General case' 0 CA--C 1.554 1.134 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.775 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . 0.698 ' H ' ' HB3' ' A' ' 169' ' ' ALA . 17.7 mt-30 -150.28 4.27 0.52 Allowed 'General case' 0 N--CA 1.5 2.027 0 N-CA-C 113.953 1.094 . . . . 0.0 113.953 -172.485 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . 11.84 70.91 0.01 OUTLIER 'General case' 0 N--CA 1.506 2.365 0 C-N-CA 126.549 1.94 . . . . 0.0 115.484 -169.053 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -88.22 123.59 33.0 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 123.603 0.761 . . . . 0.0 109.9 -176.253 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 30.8 mm -75.58 134.87 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 C-N-CA 123.045 0.538 . . . . 0.0 110.187 -176.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 78.5 p -174.84 -162.46 0.12 Allowed 'General case' 0 CA--C 1.55 0.949 0 O-C-N 124.581 1.176 . . . . 0.0 109.954 172.696 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.653 ' HA3' ' H ' ' A' ' 173' ' ' LYS . . . 102.77 178.49 26.86 Favored Glycine 0 C--N 1.349 1.259 0 CA-C-O 119.522 -0.599 . . . . 0.0 111.805 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 44.0 t 64.02 98.17 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 124.212 1.005 . . . . 0.0 111.176 176.287 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 28.8 t -140.63 148.83 54.73 Favored Pre-proline 0 N--CA 1.479 0.993 0 CA-C-O 118.406 -0.807 . . . . 0.0 109.345 -176.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_exo -42.63 138.12 3.7 Favored 'Trans proline' 0 C--N 1.391 2.81 0 C-N-CA 123.87 3.046 . . . . 0.0 113.785 177.243 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.678 HD12 ' HB2' ' A' ' 176' ' ' LEU . 31.0 mm -63.52 111.13 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 -175.728 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.689 ' HB3' HG21 ' A' ' 217' ' ' THR . 13.6 mt -94.11 142.33 27.52 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 115.373 -0.83 . . . . 0.0 111.732 -167.69 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 60.4 p -85.52 140.8 30.36 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 123.358 0.663 . . . . 0.0 110.316 177.474 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.739 HG21 ' HD2' ' A' ' 177' ' ' PHE . 14.6 tt -148.39 138.6 16.7 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.794 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 -172.372 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 39.4 p -102.27 117.05 33.93 Favored 'General case' 0 CA--C 1.547 0.855 0 O-C-N 121.881 -0.512 . . . . 0.0 110.997 -170.794 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.602 ' HA ' ' HG3' ' A' ' 39' ' ' MET . 10.6 tp -61.25 145.11 13.09 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.077 0 C-N-CA 124.902 1.281 . . . . 0.0 112.208 -177.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 47.5 m -152.25 130.91 12.31 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 124.103 0.961 . . . . 0.0 110.068 -176.041 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 60.71 19.24 9.32 Favored 'General case' 0 CA--C 1.566 1.586 0 C-N-CA 123.479 0.712 . . . . 0.0 111.437 174.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 24.3 t70 76.05 -55.55 0.6 Allowed 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 125.617 1.567 . . . . 0.0 112.318 -178.359 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -89.0 -20.27 47.23 Favored Glycine 0 N--CA 1.475 1.268 0 N-CA-C 115.002 0.761 . . . . 0.0 115.002 -175.359 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 66.5 m -106.0 165.49 11.17 Favored 'General case' 0 N--CA 1.478 0.941 0 CA-C-N 117.646 0.723 . . . . 0.0 110.252 -177.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . 0.602 ' HG3' ' HA ' ' A' ' 33' ' ' ILE . 3.7 mpp? -138.99 168.31 20.11 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 123.808 0.843 . . . . 0.0 108.861 168.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.841 ' HA ' HG11 ' A' ' 215' ' ' VAL . 64.5 m -150.39 -179.47 7.24 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 124.788 1.235 . . . . 0.0 108.282 167.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 41.7 mm -99.0 96.51 5.08 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 N-CA-C 108.261 -1.015 . . . . 0.0 108.261 167.417 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER 53.16 -79.63 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.154 0 C-N-CA 125.999 1.72 . . . . 0.0 112.164 -176.579 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 4.4 p30 -136.27 87.08 2.27 Favored 'General case' 0 CA--C 1.551 0.985 0 C-N-CA 124.486 1.115 . . . . 0.0 108.94 178.073 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -100.67 148.09 25.26 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.81 -172.215 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 . . . . . 0 N--CA 1.475 0.793 0 C-N-CA 124.17 0.988 . . . . 0.0 110.97 176.947 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 12.4 p-10 . . . . . 0 CA--C 1.54 0.587 0 CA-C-O 120.92 0.39 . . . . 0.0 111.298 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 169.0 -154.32 23.83 Favored Glycine 0 C--O 1.258 1.61 0 CA-C-N 115.34 -0.846 . . . . 0.0 111.85 -175.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -81.75 108.74 15.54 Favored 'General case' 0 C--O 1.237 0.445 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 176.364 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' TYR . . . . . 0.427 ' CD1' ' HB3' ' A' ' 8' ' ' LEU . 47.0 m-85 -102.91 156.56 17.58 Favored 'General case' 0 N--CA 1.469 0.479 0 C-N-CA 123.643 0.777 . . . . 0.0 110.704 -179.3 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' ARG . . . . . 0.543 ' HG3' ' HB2' ' A' ' 11' ' ' ALA . 60.0 mtt180 -103.06 132.57 49.23 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 106.09 -1.818 . . . . 0.0 106.09 166.36 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.521 ' H ' ' HA ' ' A' ' 99' ' ' ALA . 12.9 mt -91.84 107.83 19.31 Favored 'Isoleucine or valine' 0 C--O 1.256 1.434 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 171.388 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.879 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 19.3 ptmt -99.27 139.2 35.27 Favored 'General case' 0 N--CA 1.441 -0.907 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 169.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -82.85 105.99 14.31 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 105.192 -2.151 . . . . 0.0 105.192 168.271 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . 0.618 ' HD3' ' HB2' ' A' ' 7' ' ' GLU . 60.0 tttt -113.67 98.5 7.08 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-N 114.562 -1.199 . . . . 0.0 108.082 -177.541 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -66.33 154.78 51.68 Favored Glycine 0 C--O 1.246 0.903 0 N-CA-C 108.279 -1.929 . . . . 0.0 108.279 160.557 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 22.8 mm -68.19 -6.24 5.27 Favored 'Isoleucine or valine' 0 CA--C 1.572 1.796 0 CA-C-N 117.728 0.764 . . . . 0.0 110.483 -176.518 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 1.1 pp -134.52 25.44 3.76 Favored 'General case' 0 CA--C 1.564 1.507 0 C-N-CA 124.585 1.154 . . . . 0.0 111.901 172.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -164.98 133.07 2.85 Favored Glycine 0 N--CA 1.486 1.968 0 CA-C-N 117.869 0.304 . . . . 0.0 113.357 -178.416 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 71.6 m-85 -122.69 120.19 32.92 Favored 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 124.082 0.953 . . . . 0.0 110.015 -174.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 37.3 p -152.75 109.24 3.42 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 122.965 0.506 . . . . 0.0 110.75 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.879 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 39.9 tt0 -74.1 140.53 45.34 Favored 'General case' 0 N--CA 1.485 1.3 0 CA-C-N 118.227 0.467 . . . . 0.0 110.705 179.046 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 1.6 pp -134.59 -16.25 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 N-CA-C 112.993 0.738 . . . . 0.0 112.993 -174.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -165.31 -157.75 10.05 Favored Glycine 0 C--N 1.342 0.867 0 C-N-CA 121.498 -0.382 . . . . 0.0 112.529 179.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.521 ' HA ' ' H ' ' A' ' 86' ' ' ILE . . . -146.01 170.81 15.89 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 123.489 0.716 . . . . 0.0 110.367 176.813 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -161.9 156.18 27.65 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 -179.294 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 24.1 t -118.15 114.0 43.82 Favored 'Isoleucine or valine' 0 C--O 1.241 0.608 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -175.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.466 ' CD2' ' HB2' ' A' ' 107' ' ' PHE . 0.4 OUTLIER -105.2 121.78 44.56 Favored 'General case' 0 N--CA 1.478 0.943 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 174.049 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.698 ' HB2' HD11 ' A' ' 146' ' ' LEU . 4.6 mmmp? -146.6 150.46 35.53 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 174.451 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 66.13 -84.28 0.03 OUTLIER 'General case' 0 CA--C 1.548 0.866 0 O-C-N 124.929 1.393 . . . . 0.0 110.49 173.684 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -154.59 21.27 0.62 Allowed Glycine 0 C--N 1.337 0.61 0 N-CA-C 111.816 -0.514 . . . . 0.0 111.816 178.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 97.1 m -142.65 135.1 27.75 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 123.583 0.753 . . . . 0.0 110.499 -175.753 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' PHE . . . . . 0.676 ' HB3' ' HB3' ' A' ' 140' ' ' TYR . 36.2 t80 -109.31 104.98 14.19 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 124.554 1.142 . . . . 0.0 109.363 175.635 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 42.1 p-80 -100.46 126.69 46.9 Favored 'General case' 0 C--O 1.239 0.521 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 173.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 13.8 t -137.77 -162.0 1.24 Allowed 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.319 176.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' MET . . . . . 0.522 ' HA ' ' HA ' ' A' ' 137' ' ' LEU . 1.9 ttm -115.84 150.2 37.37 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.949 1.3 . . . . 0.0 109.817 -173.896 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 21.3 t90 -78.88 -42.76 26.51 Favored 'General case' 0 CA--C 1.553 1.077 0 C-N-CA 122.72 0.408 . . . . 0.0 110.777 -175.766 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 1.8 p-80 -71.47 3.47 3.82 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 113.807 1.04 . . . . 0.0 113.807 -175.393 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.7 m -53.95 -40.26 44.21 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.096 0 CA-C-N 118.273 0.488 . . . . 0.0 110.591 175.123 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 11.2 m -148.29 -83.61 0.11 Allowed 'General case' 0 CA--C 1.553 1.088 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 167.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 41.9 ttm180 -135.73 28.22 3.28 Favored 'General case' 0 N--CA 1.489 1.482 0 CA-C-O 121.696 0.76 . . . . 0.0 109.284 179.487 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.632 ' HA2' HD11 ' A' ' 138' ' ' ILE . . . 58.83 36.71 88.41 Favored Glycine 0 C--N 1.348 1.231 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 -166.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -79.02 175.31 10.7 Favored 'General case' 0 C--O 1.246 0.873 0 C-N-CA 124.161 0.985 . . . . 0.0 111.761 -169.428 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.6 m -72.83 142.36 15.21 Favored 'Isoleucine or valine' 0 C--O 1.244 0.782 0 CA-C-O 121.37 0.605 . . . . 0.0 109.784 -176.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.4 HD11 HD13 ' A' ' 86' ' ' ILE . 3.4 mm? -88.12 177.24 6.96 Favored 'General case' 0 CA--C 1.548 0.869 0 CA-C-N 114.676 -1.147 . . . . 0.0 110.099 171.357 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' MET . . . . . 0.467 ' HA ' ' O ' ' A' ' 124' ' ' LYS . 9.1 ptp -159.04 155.76 28.03 Favored 'General case' 0 C--O 1.253 1.274 0 C-N-CA 123.874 0.87 . . . . 0.0 110.399 178.544 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.455 ' CD2' ' HB2' ' A' ' 8' ' ' LEU . 0.1 OUTLIER -153.19 104.13 2.77 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 114.727 -1.124 . . . . 0.0 108.134 -179.238 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt 61.74 30.08 18.27 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 123.844 0.715 . . . . 0.0 110.024 -175.246 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 83.94 -5.06 81.02 Favored Glycine 0 C--N 1.347 1.142 0 CA-C-O 119.012 -0.882 . . . . 0.0 114.185 -177.45 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . 0.467 ' O ' ' HA ' ' A' ' 120' ' ' MET . 21.6 ttmm -69.21 114.21 7.27 Favored 'General case' 0 C--N 1.357 0.924 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 170.65 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 36.2 ttm-85 -80.21 95.36 6.26 Favored 'General case' 0 CA--C 1.538 0.499 0 O-C-N 123.895 0.747 . . . . 0.0 109.36 -171.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 74.6 mt -80.14 93.74 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 C-N-CA 123.918 0.887 . . . . 0.0 108.701 -177.093 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -94.02 128.95 39.2 Favored Pre-proline 0 CA--C 1.542 0.636 0 CA-C-O 118.768 -0.634 . . . . 0.0 109.556 -177.117 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_exo -51.09 142.78 33.93 Favored 'Trans proline' 0 C--N 1.384 2.42 0 C-N-CA 123.419 2.746 . . . . 0.0 114.516 -176.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 54.7 p -97.8 -10.69 24.36 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 123.558 0.743 . . . . 0.0 110.429 172.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.677 ' HB3' ' HB2' ' A' ' 139' ' ' SER . 35.9 t-105 -155.38 147.18 23.26 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.647 1.179 . . . . 0.0 107.869 176.007 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.401 ' HA ' ' HA ' ' A' ' 138' ' ' ILE . . . -154.79 119.97 4.98 Favored 'General case' 0 C--O 1.237 0.436 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 170.669 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -109.7 112.24 24.19 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 123.859 0.864 . . . . 0.0 108.684 176.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 18.2 t -77.43 -27.4 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 C-N-CA 122.512 0.325 . . . . 0.0 110.739 -176.368 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 52.5 tttp -67.31 -49.39 64.38 Favored 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.022 0.529 . . . . 0.0 111.996 -172.442 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -80.19 -23.0 41.29 Favored 'General case' 0 N--CA 1.485 1.284 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 169.028 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 18.8 t70 74.46 55.37 0.09 Allowed 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 125.367 1.467 . . . . 0.0 110.202 176.631 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.522 ' HA ' ' HA ' ' A' ' 110' ' ' MET . 4.6 mp -133.8 174.89 9.97 Favored 'General case' 0 CA--C 1.541 0.604 0 CA-C-N 115.074 -0.966 . . . . 0.0 111.368 172.616 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.632 HD11 ' HA2' ' A' ' 116' ' ' GLY . 78.9 mt -139.9 150.94 21.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 125.318 1.447 . . . . 0.0 108.327 -176.549 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . 0.677 ' HB2' ' HB3' ' A' ' 130' ' ' TRP . 19.6 m -134.44 141.64 46.86 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 123.585 0.754 . . . . 0.0 109.563 171.507 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.676 ' HB3' ' HB3' ' A' ' 107' ' ' PHE . 83.4 t80 -128.79 142.16 51.07 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 177.241 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 90.48 -5.86 82.43 Favored Glycine 0 CA--C 1.531 1.044 0 N-CA-C 112.28 -0.328 . . . . 0.0 112.28 -173.701 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 146.87 -139.37 7.92 Favored Glycine 0 C--N 1.342 0.904 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -178.5 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -90.15 165.25 31.47 Favored Glycine 0 C--N 1.344 1.006 0 N-CA-C 110.157 -1.177 . . . . 0.0 110.157 167.16 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' TRP . . . . . 0.549 ' HZ2' ' HA2' ' A' ' 209' ' ' GLY . 7.0 t90 -61.11 105.58 0.5 Allowed 'General case' 0 CA--C 1.548 0.893 0 CA-C-O 121.281 0.562 . . . . 0.0 110.601 174.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -137.88 156.28 48.07 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 115.352 -0.84 . . . . 0.0 109.386 176.022 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' LEU . . . . . 0.698 HD11 ' HB2' ' A' ' 103' ' ' LYS . 5.7 mt 169.24 -25.46 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.535 0 O-C-N 125.625 1.828 . . . . 0.0 109.015 -174.43 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 67.49 83.78 0.16 Allowed 'General case' 0 C--N 1.362 1.111 0 C-N-CA 125.185 1.394 . . . . 0.0 109.035 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -164.34 86.25 0.1 Allowed Glycine 0 C--N 1.337 0.599 0 CA-C-N 115.045 -0.979 . . . . 0.0 110.849 -170.292 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 28.1 tt0 -103.45 122.61 45.25 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 124.739 1.216 . . . . 0.0 109.327 177.317 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' TRP . . . . . . . . . . . . . 42.3 t90 -68.71 129.28 39.47 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 172.038 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 22.9 pttm -86.38 110.18 19.52 Favored 'General case' 0 CA--C 1.553 1.088 0 CA-C-O 121.408 0.623 . . . . 0.0 109.872 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -66.92 112.37 4.28 Favored 'General case' 0 N--CA 1.483 1.203 0 CA-C-O 121.609 0.718 . . . . 0.0 111.068 -178.036 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 153.81 -41.83 0.64 Allowed Glycine 0 N--CA 1.465 0.628 0 N-CA-C 110.191 -1.163 . . . . 0.0 110.191 -176.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 3.8 mp0 -88.55 -179.29 6.02 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 124.617 1.167 . . . . 0.0 109.907 175.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -73.23 142.34 47.28 Favored 'General case' 0 C--O 1.242 0.669 0 C-N-CA 122.976 0.51 . . . . 0.0 110.05 172.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 5.0 p -91.68 139.2 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 170.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 10.9 mm-40 -112.17 131.75 55.29 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 -176.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 53.7 t -126.21 124.08 65.05 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.642 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -177.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.46 ' HB2' ' HD2' ' A' ' 199' ' ' PRO . 51.1 mt -73.54 78.35 1.46 Allowed 'General case' 0 C--N 1.351 0.642 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 164.225 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -63.53 99.1 0.2 Allowed 'General case' 0 C--N 1.349 0.557 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -179.552 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 68.6 mt -72.16 95.95 1.73 Allowed 'General case' 0 C--O 1.24 0.563 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 179.719 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . 0.402 ' HB2' ' HB2' ' A' ' 165' ' ' LYS . 42.9 mt-10 -62.47 139.09 96.63 Favored Pre-proline 0 CA--C 1.556 1.204 0 CA-C-N 115.249 -0.887 . . . . 0.0 109.775 178.866 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_exo -54.48 111.55 0.75 Allowed 'Trans proline' 0 C--N 1.38 2.219 0 C-N-CA 123.16 2.573 . . . . 0.0 113.862 -173.485 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 63.49 19.17 62.09 Favored Glycine 0 C--N 1.355 1.622 0 O-C-N 123.572 0.545 . . . . 0.0 113.784 179.067 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . 0.402 ' HB2' ' HB2' ' A' ' 162' ' ' GLU . 56.7 mtpt -129.31 178.55 6.36 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 124.473 1.109 . . . . 0.0 110.348 -173.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -52.81 155.68 3.9 Favored Pre-proline 0 CA--C 1.559 1.291 0 CA-C-N 114.759 -1.109 . . . . 0.0 112.31 169.531 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -69.52 168.74 20.37 Favored 'Trans proline' 0 C--N 1.371 1.711 0 C-N-CA 122.235 1.957 . . . . 0.0 110.932 168.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 16.2 ttm180 -137.09 109.88 7.59 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 172.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . 0.698 ' HB3' ' H ' ' A' ' 19' ' ' GLN . . . -69.4 105.88 2.75 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 172.076 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 24.8 t -113.75 128.23 70.74 Favored 'Isoleucine or valine' 0 C--O 1.24 0.586 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 -178.185 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 14.6 mt-30 -83.73 103.84 13.35 Favored 'General case' 0 C--O 1.237 0.42 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 168.488 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 11.9 p -106.4 124.25 49.3 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 178.397 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . 0.653 ' H ' ' HA3' ' A' ' 24' ' ' GLY . 50.1 mttm -78.78 132.86 63.32 Favored Pre-proline 0 CA--C 1.548 0.884 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 171.244 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -59.37 171.92 2.2 Favored 'Trans proline' 0 C--N 1.377 2.061 0 C-N-CA 123.38 2.72 . . . . 0.0 114.242 -172.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -164.67 -177.12 37.03 Favored Glycine 0 C--N 1.335 0.512 0 CA-C-N 114.786 -1.097 . . . . 0.0 111.011 -179.644 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.678 ' HB2' HD12 ' A' ' 28' ' ' ILE . 69.6 mt -131.82 159.52 38.28 Favored 'General case' 0 N--CA 1.485 1.319 0 CA-C-N 117.414 0.607 . . . . 0.0 110.07 -174.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 177' ' ' PHE . . . . . 0.739 ' HD2' HG21 ' A' ' 31' ' ' ILE . 0.2 OUTLIER -141.18 125.3 17.32 Favored 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 123.101 0.56 . . . . 0.0 110.839 176.047 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 178' ' ' LYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 183' ' ' THR . 10.3 ptpp? -95.02 123.08 38.3 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 123.375 0.67 . . . . 0.0 111.028 -173.189 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 52.3 p -95.4 -173.44 2.91 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.771 0.828 . . . . 0.0 109.391 169.739 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 30.3 p-10 -68.9 -22.75 64.15 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 123.003 0.521 . . . . 0.0 110.764 171.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -77.87 -51.28 10.7 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 123.99 0.916 . . . . 0.0 110.322 176.787 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 164.46 -177.63 40.03 Favored Glycine 0 C--N 1.342 0.897 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.587 -179.713 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 183' ' ' THR . . . . . 0.48 ' HA ' ' HA ' ' A' ' 178' ' ' LYS . 13.2 t -80.23 136.71 36.52 Favored 'General case' 0 CA--C 1.544 0.749 0 CA-C-O 121.317 0.58 . . . . 0.0 110.735 -177.798 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . 0.414 ' HB ' ' CE1' ' A' ' 177' ' ' PHE . 14.9 mt -119.01 161.27 18.21 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.866 0 C-N-CA 124.9 1.28 . . . . 0.0 107.546 -177.087 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -100.74 138.78 14.05 Favored Glycine 0 C--N 1.349 1.281 0 N-CA-C 112.319 -0.312 . . . . 0.0 112.319 -176.257 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.497 ' HB2' ' CE1' ' A' ' 177' ' ' PHE . . . -162.63 -169.95 2.25 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-O 122.029 0.919 . . . . 0.0 112.543 -169.616 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 187' ' ' VAL . . . . . . . . . . . . . 2.0 p -105.41 100.98 11.69 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.999 0 CA-C-N 113.76 -1.564 . . . . 0.0 107.317 156.513 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 65.8 p -98.38 111.44 23.78 Favored 'General case' 0 C--O 1.24 0.56 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 172.195 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 46.0 tp -146.22 138.41 25.15 Favored 'General case' 0 N--CA 1.485 1.306 0 CA-C-O 120.881 0.372 . . . . 0.0 111.811 -177.593 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 190' ' ' ASP . . . . . 0.471 ' HA ' ' HA ' ' A' ' 221' ' ' ALA . 32.7 t70 -81.92 103.23 11.42 Favored 'General case' 0 C--N 1.351 0.658 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 170.504 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 191' ' ' PHE . . . . . 0.54 ' HB3' ' HE1' ' A' ' 222' ' ' TYR . 68.2 t80 -177.23 166.71 2.36 Favored 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 124.71 1.204 . . . . 0.0 108.659 -173.655 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 33.7 p -64.94 117.04 35.05 Favored Pre-proline 0 CA--C 1.557 1.22 0 C-N-CA 123.639 0.776 . . . . 0.0 111.234 177.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -62.45 140.7 83.54 Favored 'Trans proline' 0 C--N 1.378 2.109 0 C-N-CA 123.078 2.519 . . . . 0.0 112.855 176.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -84.09 -176.24 51.09 Favored Glycine 0 C--N 1.344 0.977 0 N-CA-C 111.051 -0.819 . . . . 0.0 111.051 168.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 62.5 p -77.39 131.7 38.17 Favored 'General case' 0 CA--C 1.551 0.991 0 CA-C-N 117.149 0.474 . . . . 0.0 110.725 178.072 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -63.57 100.14 0.25 Allowed 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.561 0.744 . . . . 0.0 109.776 -176.833 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 140.05 -1.22 2.19 Favored Glycine 0 C--N 1.341 0.86 0 CA-C-N 114.519 -1.219 . . . . 0.0 112.148 -174.282 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 198' ' ' SER . . . . . 0.455 ' HB2' ' HD2' ' A' ' 211' ' ' TYR . 48.9 m -57.43 138.6 81.18 Favored Pre-proline 0 CA--C 1.558 1.277 0 C-N-CA 123.495 0.718 . . . . 0.0 111.512 173.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 199' ' ' PRO . . . . . 0.46 ' HD2' ' HB2' ' A' ' 159' ' ' LEU . 17.3 Cg_exo -67.05 132.81 29.04 Favored 'Trans proline' 0 C--N 1.38 2.203 0 C-N-CA 123.268 2.645 . . . . 0.0 113.492 -177.37 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 200' ' ' ILE . . . . . 0.449 HD13 HG23 ' A' ' 226' ' ' ILE . 16.6 mt -98.81 110.12 25.51 Favored 'Isoleucine or valine' 0 C--O 1.241 0.618 0 CA-C-O 121.982 0.896 . . . . 0.0 109.666 172.421 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 201' ' ' ILE . . . . . . . . . . . . . 47.0 mt -108.91 148.75 12.56 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.894 0 CA-C-N 114.644 -1.162 . . . . 0.0 108.082 177.769 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 202' ' ' ASP . . . . . 0.573 ' H ' ' HB ' ' A' ' 207' ' ' VAL . 18.1 t70 -89.51 160.21 16.85 Favored 'General case' 0 N--CA 1.48 1.075 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 172.215 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 83.1 tttt -63.37 -15.48 57.61 Favored 'General case' 0 CA--C 1.555 1.141 0 N-CA-C 113.479 0.918 . . . . 0.0 113.479 -170.487 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 7.9 mtpm? -76.42 -1.02 24.94 Favored 'General case' 0 N--CA 1.485 1.318 0 N-CA-C 112.502 0.556 . . . . 0.0 112.502 176.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 82.7 7.01 87.97 Favored Glycine 0 C--N 1.349 1.283 0 CA-C-O 120.913 0.174 . . . . 0.0 112.695 -178.734 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -117.2 164.09 15.31 Favored 'General case' 0 N--CA 1.475 0.793 0 C-N-CA 124.733 1.213 . . . . 0.0 108.714 174.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 207' ' ' VAL . . . . . 0.573 ' HB ' ' H ' ' A' ' 202' ' ' ASP . 57.4 t 90.77 160.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.254 0 C-N-CA 125.905 1.682 . . . . 0.0 108.562 -171.662 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 208' ' ' VAL . . . . . 0.585 HG21 ' HB3' ' A' ' 146' ' ' LEU . 1.8 m -174.34 13.8 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 C-N-CA 124.444 1.098 . . . . 0.0 109.666 -144.391 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.549 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . -64.87 -154.78 0.15 Allowed Glycine 0 C--N 1.354 1.549 0 C-N-CA 124.105 0.86 . . . . 0.0 115.013 -177.098 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 210' ' ' LEU . . . . . 0.474 HD13 HD23 ' A' ' 137' ' ' LEU . 6.0 tt -142.12 133.4 26.34 Favored 'General case' 0 C--O 1.242 0.691 0 O-C-N 122.048 -0.678 . . . . 0.0 110.588 -172.399 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 211' ' ' TYR . . . . . 0.455 ' HD2' ' HB2' ' A' ' 198' ' ' SER . 0.4 OUTLIER -102.49 108.56 19.91 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 124.844 1.258 . . . . 0.0 108.935 175.208 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 212' ' ' GLY . . . . . 0.519 ' O ' ' SD ' ' A' ' 110' ' ' MET . . . 171.22 70.05 0.04 OUTLIER Glycine 0 C--N 1.345 1.081 0 C-N-CA 120.65 -0.786 . . . . 0.0 114.719 156.061 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 213' ' ' ASN . . . . . 0.669 ' HB2' ' HB3' ' A' ' 225' ' ' ALA . 18.5 m120 -131.76 81.85 2.0 Allowed 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 172.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 160.57 -152.38 23.08 Favored Glycine 0 C--O 1.242 0.619 0 CA-C-N 113.965 -1.471 . . . . 0.0 111.341 -178.231 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 215' ' ' VAL . . . . . 0.841 HG11 ' HA ' ' A' ' 40' ' ' SER . 15.8 m -152.57 -173.94 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.213 0 C-N-CA 123.45 0.7 . . . . 0.0 111.235 -167.345 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 216' ' ' VAL . . . . . 0.489 ' HB ' ' HA2' ' A' ' 220' ' ' GLY . 17.0 m -85.15 113.0 22.9 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.771 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 164.706 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 217' ' ' THR . . . . . 0.689 HG21 ' HB3' ' A' ' 29' ' ' LEU . 23.5 m -102.81 158.99 15.88 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 123.944 0.898 . . . . 0.0 109.644 -174.806 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 2.5 tpm_? 69.89 -74.63 0.08 Allowed 'General case' 0 CA--C 1.552 1.023 0 C-N-CA 124.957 1.303 . . . . 0.0 110.095 -176.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 21.8 t -164.42 26.21 0.07 Allowed 'General case' 0 CA--C 1.551 1.007 0 C-N-CA 123.856 0.862 . . . . 0.0 110.148 175.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 220' ' ' GLY . . . . . 0.489 ' HA2' ' HB ' ' A' ' 216' ' ' VAL . . . 141.98 -6.88 2.35 Favored Glycine 0 N--CA 1.477 1.418 0 CA-C-O 119.884 -0.398 . . . . 0.0 113.72 -179.086 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 221' ' ' ALA . . . . . 0.471 ' HA ' ' HA ' ' A' ' 190' ' ' ASP . . . -70.76 97.83 1.44 Allowed 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.943 0.897 . . . . 0.0 110.044 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 222' ' ' TYR . . . . . 0.54 ' HE1' ' HB3' ' A' ' 191' ' ' PHE . 15.8 p90 -66.1 124.72 23.37 Favored 'General case' 0 CA--C 1.544 0.715 0 CA-C-O 121.534 0.683 . . . . 0.0 110.88 -171.08 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . 0.637 HG11 ' HB3' ' A' ' 177' ' ' PHE . 62.1 t -123.92 115.66 45.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 173.721 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 67.9 m -142.71 141.85 31.88 Favored 'General case' 0 N--CA 1.48 1.06 0 O-C-N 123.855 0.722 . . . . 0.0 110.312 176.062 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . 0.669 ' HB3' ' HB2' ' A' ' 213' ' ' ASN . . . -75.31 153.29 37.96 Favored 'General case' 0 C--O 1.244 0.782 0 C-N-CA 123.087 0.555 . . . . 0.0 112.238 -174.656 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 226' ' ' ILE . . . . . 0.449 HG23 HD13 ' A' ' 200' ' ' ILE . 88.9 mt -91.4 103.06 14.12 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.623 0 CA-C-N 114.758 -1.11 . . . . 0.0 109.748 -176.594 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -96.07 152.65 18.34 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 122.895 0.478 . . . . 0.0 109.952 178.36 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -148.19 168.55 22.17 Favored 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 124.515 1.126 . . . . 0.0 109.736 -172.118 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . 0.425 HG22 ' NE1' ' A' ' 144' ' ' TRP . 59.0 p -66.88 110.61 3.38 Favored 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 123.006 0.522 . . . . 0.0 110.527 -176.232 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -116.97 -24.37 7.63 Favored 'General case' 0 N--CA 1.482 1.169 0 C-N-CA 123.418 0.687 . . . . 0.0 111.406 -172.34 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 23.3 mmtp -91.88 -141.02 0.19 Allowed 'General case' 0 CA--C 1.566 1.561 0 C-N-CA 122.974 0.51 . . . . 0.0 109.682 -172.409 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 70.0 p . . . . . 0 N--CA 1.479 0.998 0 C-N-CA 124.221 1.009 . . . . 0.0 108.873 -167.555 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.889 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -131.99 2.09 3.97 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 124.05 0.94 . . . . 0.0 109.742 -175.14 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -127.34 80.65 1.97 Allowed 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 114.526 -1.216 . . . . 0.0 108.14 -168.708 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 5.0 mp -127.05 101.97 6.77 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 -178.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.425 ' HA ' ' HB2' ' A' ' 120' ' ' MET . 10.7 mm-40 -78.65 146.59 33.97 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 123.244 0.618 . . . . 0.0 110.979 -172.403 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.555 HD21 HD13 ' A' ' 119' ' ' LEU . 30.4 mt -90.58 114.39 26.62 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-N 115.042 -0.981 . . . . 0.0 109.14 171.849 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.417 ' HB2' ' HD2' ' A' ' 87' ' ' LYS . 31.4 tt0 -103.52 120.28 40.54 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 124.503 1.121 . . . . 0.0 108.328 -176.455 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 26.3 ptt180 -59.76 132.69 54.74 Favored 'General case' 0 N--CA 1.475 0.817 0 C-N-CA 122.859 0.464 . . . . 0.0 110.893 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.447 ' HB2' ' HG3' ' A' ' 85' ' ' ARG . . . -121.27 -43.18 2.43 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 122.379 0.272 . . . . 0.0 111.362 -177.046 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . 178.37 -158.45 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 124.184 0.994 . . . . 0.0 110.041 -173.703 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -128.01 164.67 21.86 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 123.777 0.831 . . . . 0.0 108.85 168.503 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 53.9 t -75.45 102.36 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 N-CA-C 109.414 -0.588 . . . . 0.0 109.414 177.444 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 4.5 ptpp? -167.89 146.23 4.56 Favored 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 124.633 1.173 . . . . 0.0 108.557 174.294 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 28.8 t90 -78.99 110.7 14.48 Favored 'General case' 0 CA--C 1.547 0.844 0 O-C-N 123.533 0.52 . . . . 0.0 111.402 -172.505 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -73.68 145.43 45.26 Favored 'General case' 0 CA--C 1.544 0.737 0 CA-C-O 121.66 0.743 . . . . 0.0 111.506 172.427 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -68.01 -1.62 6.14 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 125.47 1.508 . . . . 0.0 112.967 -177.072 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 22.8 mm-40 -80.2 50.4 1.24 Allowed 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 123.766 0.826 . . . . 0.0 111.112 -178.306 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.428 ' HA ' ' O ' ' A' ' 169' ' ' ALA . . . -73.32 84.02 1.42 Allowed 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 124.615 1.166 . . . . 0.0 111.464 -174.67 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 38.8 mt-10 -103.57 123.12 46.35 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 124.031 0.932 . . . . 0.0 110.425 -175.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 9.6 tp -76.91 132.68 32.41 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.134 0 C-N-CA 122.47 0.308 . . . . 0.0 110.763 -177.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 95.7 p -148.68 -35.71 0.19 Allowed 'General case' 0 N--CA 1.484 1.275 0 N-CA-C 112.14 0.422 . . . . 0.0 112.14 175.567 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -53.39 98.1 0.03 OUTLIER Glycine 0 C--N 1.353 1.476 0 N-CA-C 113.917 0.327 . . . . 0.0 113.917 178.45 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 40.7 p -103.9 -68.72 0.83 Allowed 'General case' 0 CA--C 1.547 0.865 0 C-N-CA 124.014 0.926 . . . . 0.0 111.468 -172.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 20.0 m -72.98 126.08 90.7 Favored Pre-proline 0 N--CA 1.477 0.88 0 C-N-CA 123.598 0.759 . . . . 0.0 111.381 -171.12 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -70.85 -74.27 0.01 OUTLIER 'Trans proline' 0 C--N 1.366 1.467 0 C-N-CA 122.13 1.887 . . . . 0.0 111.59 167.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 51.0 mm -90.55 121.12 40.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.913 0 C-N-CA 123.26 0.624 . . . . 0.0 111.448 -167.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.409 HD22 HG22 ' A' ' 217' ' ' THR . 17.2 mt -143.37 133.48 24.34 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 123.737 0.815 . . . . 0.0 110.333 174.068 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 35.0 p -97.07 140.02 32.21 Favored 'General case' 0 N--CA 1.477 0.892 0 C-N-CA 123.851 0.86 . . . . 0.0 110.538 179.189 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 39.5 mt -131.53 160.58 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 124.265 1.026 . . . . 0.0 108.594 -178.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 66.7 p -96.03 114.33 26.03 Favored 'General case' 0 C--N 1.367 1.327 0 CA-C-N 118.889 0.768 . . . . 0.0 109.001 176.102 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 8.8 mm -55.93 125.89 12.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 C-N-CA 123.987 0.915 . . . . 0.0 109.934 175.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 5.8 m -117.42 135.53 53.82 Favored 'General case' 0 C--O 1.252 1.224 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.322 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 30.4 tt0 60.3 28.82 18.46 Favored 'General case' 0 CA--C 1.558 1.263 0 C-N-CA 124.725 1.21 . . . . 0.0 110.791 178.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 3.8 p30 46.5 30.05 1.02 Allowed 'General case' 0 N--CA 1.493 1.708 0 C-N-CA 125.631 1.572 . . . . 0.0 113.109 -174.584 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -145.13 -63.7 0.02 OUTLIER Glycine 0 C--N 1.353 1.515 0 CA-C-N 116.562 -0.29 . . . . 0.0 112.487 -177.67 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 38.8 t -105.85 125.97 51.62 Favored 'General case' 0 N--CA 1.486 1.361 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 -172.242 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 1.8 mpp? -88.8 136.95 32.74 Favored 'General case' 0 CA--C 1.546 0.823 0 O-C-N 121.875 -0.515 . . . . 0.0 111.472 -173.745 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.5 m -125.15 164.12 20.95 Favored 'General case' 0 N--CA 1.482 1.125 0 C-N-CA 124.622 1.169 . . . . 0.0 109.915 176.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.529 ' H ' HG21 ' A' ' 215' ' ' VAL . 7.5 tp -93.07 92.51 3.74 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.845 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 -177.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 42.5 mmtm 57.88 -74.78 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.336 0 C-N-CA 123.382 0.673 . . . . 0.0 109.831 -161.238 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 5.2 p30 -147.32 118.16 7.62 Favored 'General case' 0 CA--C 1.552 1.045 0 C-N-CA 124.608 1.163 . . . . 0.0 110.034 175.181 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -174.13 130.78 0.39 Allowed 'General case' 0 N--CA 1.492 1.629 0 C-N-CA 123.685 0.794 . . . . 0.0 109.176 171.275 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 CA--C 1.554 1.108 0 C-N-CA 123.42 0.688 . . . . 0.0 110.104 -178.275 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.684 ' HB2' ' HD2' ' A' ' 103' ' ' LYS . 8.2 p-10 . . . . . 0 CA--C 1.54 0.57 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 168.32 178.92 40.4 Favored Glycine 0 C--N 1.339 0.699 0 CA-C-N 115.973 -0.558 . . . . 0.0 112.42 177.268 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . 0.558 ' HB1' HD11 ' A' ' 161' ' ' LEU . . . -88.32 125.07 34.5 Favored 'General case' 0 CA--C 1.549 0.911 0 C-N-CA 123.947 0.899 . . . . 0.0 109.79 176.717 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 -122.12 148.46 44.87 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 123.596 0.758 . . . . 0.0 109.963 -177.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' ARG . . . . . 0.781 ' HG2' HG21 ' A' ' 195' ' ' THR . 37.3 mtm-85 -95.99 124.43 39.99 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 166.05 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.486 ' H ' ' HA ' ' A' ' 99' ' ' ALA . 27.8 mt -90.65 131.05 38.83 Favored 'Isoleucine or valine' 0 C--O 1.26 1.656 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.437 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 0.2 OUTLIER -124.67 140.83 52.58 Favored 'General case' 0 N--CA 1.45 -0.459 0 CA-C-N 114.504 -1.226 . . . . 0.0 108.684 -174.224 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -84.76 104.09 14.42 Favored 'General case' 0 C--N 1.344 0.331 0 N-CA-C 104.581 -2.377 . . . . 0.0 104.581 175.549 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 14.4 tmtt? -120.64 98.27 5.95 Favored 'General case' 0 CA--C 1.518 -0.288 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 -170.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -79.91 152.47 35.01 Favored Glycine 0 C--O 1.242 0.644 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 170.359 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 2.3 mp -78.46 70.26 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.13 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 174.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 58.7 tp 167.29 -41.4 0.0 OUTLIER 'General case' 0 CA--C 1.554 1.123 0 C-N-CA 126.388 1.875 . . . . 0.0 109.029 -167.04 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -148.22 161.02 28.53 Favored Glycine 0 C--N 1.365 2.174 0 N-CA-C 114.8 0.68 . . . . 0.0 114.8 -169.56 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 77.4 m-85 -132.12 129.33 39.73 Favored 'General case' 0 N--CA 1.481 1.095 0 C-N-CA 124.049 0.94 . . . . 0.0 110.427 -172.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 24.5 m -145.42 153.75 41.53 Favored 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 124.652 1.181 . . . . 0.0 108.254 175.173 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.437 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 1.5 pp0? -96.15 146.72 24.43 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-N 118.738 0.699 . . . . 0.0 109.242 168.509 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.46 HD11 HG22 ' A' ' 86' ' ' ILE . 1.6 pp -136.71 -10.03 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 177.443 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . 0.552 ' HA3' HG12 ' A' ' 113' ' ' VAL . . . 168.26 -147.06 11.01 Favored Glycine 0 C--N 1.348 1.241 0 C-N-CA 121.003 -0.618 . . . . 0.0 113.19 174.049 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.486 ' HA ' ' H ' ' A' ' 86' ' ' ILE . . . -154.33 153.76 32.2 Favored 'General case' 0 C--O 1.24 0.603 0 C-N-CA 123.663 0.785 . . . . 0.0 111.196 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -155.75 157.18 27.58 Favored Glycine 0 C--N 1.338 0.665 0 CA-C-N 114.937 -1.029 . . . . 0.0 111.209 178.748 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 53.1 t -120.82 120.69 63.16 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.778 0 C-N-CA 123.528 0.731 . . . . 0.0 111.517 -169.376 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.531 ' HB3' ' HA ' ' A' ' 81' ' ' ASP . 10.6 m-85 -74.36 135.81 42.47 Favored 'General case' 0 N--CA 1.482 1.163 0 N-CA-C 107.861 -1.163 . . . . 0.0 107.861 165.037 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.684 ' HD2' ' HB2' ' A' ' 81' ' ' ASP . 29.3 tptt -172.4 149.71 2.23 Favored 'General case' 0 N--CA 1.483 1.177 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 171.322 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 60.21 20.14 9.52 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 124.494 1.118 . . . . 0.0 112.048 -178.771 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 80.09 17.06 75.32 Favored Glycine 0 C--N 1.346 1.115 0 CA-C-N 116.036 -0.529 . . . . 0.0 114.377 -178.011 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 18.8 p -140.07 137.18 34.36 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.604 0.762 . . . . 0.0 109.716 -176.316 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' PHE . . . . . 0.602 ' HB3' ' HB2' ' A' ' 140' ' ' TYR . 42.2 t80 -89.87 103.43 16.09 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 120.937 0.399 . . . . 0.0 111.131 -175.084 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . 0.613 ' HB3' ' HE3' ' A' ' 144' ' ' TRP . 18.6 m170 -100.4 114.25 27.65 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 124.488 1.115 . . . . 0.0 110.563 -176.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . 0.592 HG23 HG23 ' A' ' 138' ' ' ILE . 3.9 t -135.71 175.44 9.59 Favored 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 118.758 0.708 . . . . 0.0 112.158 -177.86 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' MET . . . . . 0.499 ' SD ' ' HB2' ' A' ' 210' ' ' LEU . 79.2 mmm -87.95 154.47 20.48 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 123.886 0.874 . . . . 0.0 109.014 172.807 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' TRP . . . . . 0.416 ' CE2' HG22 ' A' ' 133' ' ' VAL . 50.2 t90 -71.52 -45.74 61.58 Favored 'General case' 0 N--CA 1.486 1.338 0 CA-C-N 118.159 0.436 . . . . 0.0 111.504 -170.611 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 4.3 p-80 -51.52 -21.09 2.21 Favored 'General case' 0 N--CA 1.488 1.465 0 C-N-CA 124.769 1.228 . . . . 0.0 114.247 -173.146 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.552 HG12 ' HA3' ' A' ' 98' ' ' GLY . 16.6 m -59.85 -44.14 93.53 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 CA-C-O 121.43 0.633 . . . . 0.0 110.265 -178.603 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 9.0 t -113.76 168.51 9.72 Favored 'General case' 0 C--O 1.238 0.488 0 C-N-CA 123.905 0.882 . . . . 0.0 109.212 -179.45 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 92.9 mtt180 -95.95 33.43 1.7 Allowed 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 124.194 0.997 . . . . 0.0 109.132 178.146 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 68.81 38.85 85.82 Favored Glycine 0 C--N 1.362 1.983 0 CA-C-N 115.158 -0.928 . . . . 0.0 111.528 -174.193 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -127.83 -179.96 5.23 Favored 'General case' 0 C--O 1.244 0.763 0 C-N-CA 123.647 0.779 . . . . 0.0 110.955 -171.106 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.2 p -75.4 139.65 18.71 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.211 0 CA-C-N 114.716 -1.129 . . . . 0.0 111.963 -176.329 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.555 HD13 HD21 ' A' ' 8' ' ' LEU . 58.3 mt -97.9 -177.78 3.87 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 124.084 0.953 . . . . 0.0 110.77 177.812 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' MET . . . . . 0.425 ' HB2' ' HA ' ' A' ' 7' ' ' GLU . 23.2 mmt -133.49 147.9 51.67 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 125.308 1.443 . . . . 0.0 109.762 -176.557 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.777 ' HB2' HD11 ' A' ' 126' ' ' ILE . 34.9 t-80 -151.03 96.63 2.35 Favored 'General case' 0 CA--C 1.54 0.595 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 25.5 ttpp 57.69 29.77 17.83 Favored 'General case' 0 N--CA 1.496 1.826 0 C-N-CA 124.186 0.995 . . . . 0.0 111.117 -175.693 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 94.95 -3.53 67.3 Favored Glycine 0 C--N 1.345 1.043 0 CA-C-N 115.768 -0.651 . . . . 0.0 113.47 -179.628 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -94.92 122.45 37.57 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 122.92 0.488 . . . . 0.0 109.92 177.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 91.0 mtm-85 -69.39 146.01 52.41 Favored 'General case' 0 C--O 1.243 0.734 0 C-N-CA 123.774 0.83 . . . . 0.0 111.976 178.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.777 HD11 ' HB2' ' A' ' 121' ' ' HIS . 5.0 mt -127.19 112.41 28.51 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.801 0 C-N-CA 123.791 0.836 . . . . 0.0 109.225 -179.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -83.01 139.36 42.68 Favored Pre-proline 0 CA--C 1.554 1.104 0 C-N-CA 123.838 0.855 . . . . 0.0 110.025 179.007 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -75.61 148.7 33.34 Favored 'Trans proline' 0 C--N 1.379 2.181 0 C-N-CA 122.808 2.339 . . . . 0.0 112.482 179.462 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 32.5 p -109.23 -32.35 7.23 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 124.031 0.932 . . . . 0.0 110.707 177.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 4.5 t-105 -132.87 144.03 49.91 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 107.624 -1.251 . . . . 0.0 107.624 -176.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -160.53 123.53 3.37 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.205 0.602 . . . . 0.0 110.222 178.488 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 41.4 m-20 -123.32 105.23 9.67 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 124.345 1.058 . . . . 0.0 108.552 167.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.416 HG22 ' CE2' ' A' ' 111' ' ' TRP . 16.7 t -68.24 -33.39 60.36 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.884 0 C-N-CA 123.53 0.732 . . . . 0.0 109.313 175.164 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -72.01 -33.13 67.82 Favored 'General case' 0 CA--C 1.547 0.863 0 CA-C-N 114.347 -1.297 . . . . 0.0 111.926 -179.177 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -97.07 -7.47 32.7 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 122.946 0.498 . . . . 0.0 111.792 179.586 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 27.5 t70 60.85 47.52 7.69 Favored 'General case' 0 CA--C 1.548 0.873 0 CA-C-O 122.449 1.118 . . . . 0.0 110.604 -178.027 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 49.7 mt -135.1 147.9 49.66 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 123.833 0.853 . . . . 0.0 109.557 176.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.592 HG23 HG23 ' A' ' 109' ' ' THR . 18.4 tt -153.54 143.66 14.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 N-CA-C 107.313 -1.365 . . . . 0.0 107.313 173.441 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . 0.479 ' HB3' ' HA2' ' A' ' 143' ' ' GLY . 44.1 t -150.68 152.89 34.63 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-O 121.876 0.846 . . . . 0.0 110.97 -175.378 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.602 ' HB2' ' HB3' ' A' ' 107' ' ' PHE . 8.7 m-85 -125.26 108.71 12.0 Favored 'General case' 0 CA--C 1.543 0.708 0 CA-C-N 113.524 -1.671 . . . . 0.0 107.499 -164.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 97.48 -4.33 61.9 Favored Glycine 0 C--N 1.348 1.243 0 CA-C-N 116.149 -0.478 . . . . 0.0 112.821 -173.339 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 171.14 -152.64 18.77 Favored Glycine 0 C--N 1.347 1.163 0 CA-C-O 118.744 -1.031 . . . . 0.0 111.295 -179.625 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.479 ' HA2' ' HB3' ' A' ' 139' ' ' SER . . . -119.6 170.2 13.99 Favored Glycine 0 C--N 1.357 1.743 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 173.338 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' TRP . . . . . 0.613 ' HE3' ' HB3' ' A' ' 108' ' ' HIS . 41.6 t-105 -60.23 108.88 0.86 Allowed 'General case' 0 N--CA 1.483 1.188 0 CA-C-O 121.671 0.748 . . . . 0.0 110.728 176.291 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . 0.676 ' HA ' HG23 ' A' ' 229' ' ' THR . 0.0 OUTLIER -145.54 135.1 23.26 Favored 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 114.903 -1.044 . . . . 0.0 108.824 171.007 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' LEU . . . . . 0.601 HD21 ' HB3' ' A' ' 103' ' ' LYS . 13.6 mt -144.69 10.29 1.38 Allowed 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 123.67 0.788 . . . . 0.0 110.586 168.607 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.442 ' H ' HG21 ' A' ' 229' ' ' THR . 14.3 tt0 75.37 -18.5 0.44 Allowed 'General case' 0 N--CA 1.498 1.942 0 C-N-CA 124.67 1.188 . . . . 0.0 111.431 177.071 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . 0.43 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -77.65 138.47 21.66 Favored Glycine 0 C--N 1.346 1.119 0 C-N-CA 123.4 0.524 . . . . 0.0 113.135 -169.478 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -130.1 142.03 50.64 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 124.306 1.042 . . . . 0.0 108.399 -178.565 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' TRP . . . . . . . . . . . . . 43.2 t90 -73.19 137.34 44.99 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 122.719 0.407 . . . . 0.0 110.759 172.357 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 54.3 tttm -92.85 133.57 35.94 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 123.776 0.83 . . . . 0.0 109.225 174.368 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -66.85 146.42 54.44 Favored 'General case' 0 N--CA 1.479 1.012 0 CA-C-O 121.118 0.485 . . . . 0.0 111.826 178.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 92.56 -12.89 68.72 Favored Glycine 0 C--N 1.348 1.237 0 CA-C-N 115.027 -0.988 . . . . 0.0 112.921 -177.571 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 29.7 mm-40 -94.07 131.83 39.18 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 123.045 0.538 . . . . 0.0 111.696 -173.836 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -76.06 123.78 26.34 Favored 'General case' 0 C--O 1.245 0.863 0 N-CA-C 107.008 -1.478 . . . . 0.0 107.008 162.489 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -91.13 158.76 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 -168.544 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . 0.412 ' OE1' ' HG2' ' A' ' 171' ' ' GLN . 13.9 mm100 -100.58 133.61 44.77 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 123.32 0.648 . . . . 0.0 109.297 179.561 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 46.2 t -107.84 102.35 13.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 107.164 -1.421 . . . . 0.0 107.164 177.516 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.557 HD23 ' HB2' ' A' ' 169' ' ' ALA . 1.8 tm? -74.93 78.42 2.16 Favored 'General case' 0 CA--C 1.546 0.796 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 -175.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -72.05 110.18 6.36 Favored 'General case' 0 C--O 1.242 0.699 0 CA-C-N 114.129 -1.396 . . . . 0.0 111.004 -168.359 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . 0.558 HD11 ' HB1' ' A' ' 83' ' ' ALA . 29.9 mt -81.55 83.89 6.89 Favored 'General case' 0 C--O 1.24 0.599 0 CA-C-N 115.099 -0.955 . . . . 0.0 109.182 177.371 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 29.7 mm-40 -68.74 126.92 93.2 Favored Pre-proline 0 CA--C 1.552 1.031 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 174.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -61.77 115.76 3.01 Favored 'Trans proline' 0 C--N 1.384 2.4 0 C-N-CA 123.231 2.621 . . . . 0.0 112.503 -174.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 81.61 10.99 83.62 Favored Glycine 0 C--N 1.351 1.388 0 CA-C-N 115.485 -0.78 . . . . 0.0 113.467 -179.36 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 49.5 mttp -128.54 172.45 11.16 Favored 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 123.395 0.678 . . . . 0.0 110.9 -178.41 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -74.03 156.59 87.74 Favored Pre-proline 0 CA--C 1.555 1.159 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.989 173.826 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 15.8 Cg_exo -68.79 137.38 38.25 Favored 'Trans proline' 0 C--N 1.375 1.937 0 C-N-CA 122.581 2.187 . . . . 0.0 112.568 178.179 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 69.5 mtp180 -117.06 105.75 12.63 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 176.396 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . 0.557 ' HB2' HD23 ' A' ' 159' ' ' LEU . . . -86.04 103.3 14.6 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-O 121.034 0.445 . . . . 0.0 110.559 -176.797 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 42.8 t -94.63 129.71 44.46 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.718 0 C-N-CA 124.288 1.035 . . . . 0.0 111.269 -164.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 171' ' ' GLN . . . . . 0.412 ' HG2' ' OE1' ' A' ' 157' ' ' GLN . 20.6 mt-30 -79.3 121.37 25.01 Favored 'General case' 0 C--N 1.354 0.767 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 178.627 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 41.9 p -140.34 124.76 17.84 Favored 'General case' 0 C--O 1.237 0.436 0 C-N-CA 122.92 0.488 . . . . 0.0 109.753 -173.064 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 62.2 tttp -70.17 127.58 92.16 Favored Pre-proline 0 CA--C 1.547 0.862 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 171.487 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_exo -57.91 126.4 21.57 Favored 'Trans proline' 0 C--N 1.379 2.175 0 C-N-CA 122.686 2.257 . . . . 0.0 112.767 -179.574 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . 0.431 ' H ' ' HA ' ' A' ' 187' ' ' VAL . . . -98.34 178.44 31.6 Favored Glycine 0 C--N 1.337 0.638 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.391 176.488 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 5.3 mp -141.3 146.3 36.58 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 123.501 0.72 . . . . 0.0 109.267 176.351 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 177' ' ' PHE . . . . . 0.7 ' HE1' HG12 ' A' ' 223' ' ' VAL . 22.3 m-85 -93.47 121.63 35.07 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 176.551 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 57.1 tptt -86.29 95.87 9.77 Favored 'General case' 0 CA--C 1.541 0.596 0 O-C-N 123.783 0.677 . . . . 0.0 109.201 177.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . 0.524 HG22 ' H ' ' A' ' 181' ' ' ALA . 23.0 m -110.47 150.6 28.63 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 176.383 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 24.7 p30 -61.75 -24.35 66.76 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 123.578 0.751 . . . . 0.0 111.914 175.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . 0.524 ' H ' HG22 ' A' ' 179' ' ' THR . . . -74.18 -39.91 62.87 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.274 1.03 . . . . 0.0 111.388 174.579 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 169.25 -174.16 43.67 Favored Glycine 0 C--N 1.341 0.841 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.569 -177.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 13.2 t -97.78 134.55 40.78 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 175.2 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . 0.556 ' HB ' ' HB2' ' A' ' 177' ' ' PHE . 23.6 mt -104.65 160.02 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 177.905 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -99.09 124.23 8.16 Favored Glycine 0 C--N 1.349 1.279 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 179.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.428 ' HA ' ' HA ' ' A' ' 225' ' ' ALA . . . -147.98 -165.56 2.3 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-O 121.22 0.533 . . . . 0.0 112.395 -161.753 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 187' ' ' VAL . . . . . 0.431 ' HA ' ' H ' ' A' ' 175' ' ' GLY . 4.7 p -158.39 131.12 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.728 0 C-N-CA 124.615 1.166 . . . . 0.0 108.9 175.671 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 7.1 m -111.42 103.5 11.87 Favored 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 123.118 0.567 . . . . 0.0 110.168 176.557 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 4.3 pp -125.67 141.63 51.92 Favored 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 123.37 0.668 . . . . 0.0 109.224 179.586 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -113.53 104.49 12.31 Favored 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 168.102 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 191' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -163.07 -178.3 5.96 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 124.143 0.977 . . . . 0.0 108.725 -170.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 31.4 m -52.11 122.34 23.21 Favored Pre-proline 0 CA--C 1.549 0.939 0 CA-C-O 118.542 -0.742 . . . . 0.0 109.86 170.406 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -61.57 91.31 0.11 Allowed 'Trans proline' 0 C--N 1.378 2.129 0 C-N-CA 122.695 2.263 . . . . 0.0 112.155 -173.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -60.02 123.28 32.62 Favored Glycine 0 C--N 1.348 1.219 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 172.43 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 195' ' ' THR . . . . . 0.781 HG21 ' HG2' ' A' ' 85' ' ' ARG . 8.8 t -54.22 144.37 20.24 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-O 121.663 0.744 . . . . 0.0 112.035 -173.207 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 196' ' ' SER . . . . . 0.468 ' HA ' ' HD2' ' A' ' 211' ' ' TYR . 13.4 m -72.28 95.56 1.72 Allowed 'General case' 0 C--O 1.242 0.688 0 CA-C-N 115.077 -0.965 . . . . 0.0 111.406 -169.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 197' ' ' GLY . . . . . 0.496 ' H ' ' HB3' ' A' ' 211' ' ' TYR . . . 133.63 4.94 2.99 Favored Glycine 0 C--N 1.34 0.753 0 CA-C-N 115.279 -0.873 . . . . 0.0 111.663 -176.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 72.0 m -56.32 131.81 75.86 Favored Pre-proline 0 C--N 1.361 1.101 0 C-N-CA 123.143 0.577 . . . . 0.0 110.229 171.089 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -64.23 111.67 1.67 Allowed 'Trans proline' 0 C--N 1.372 1.777 0 C-N-CA 122.209 1.939 . . . . 0.0 111.635 -176.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 55.3 mt -77.93 111.69 15.04 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.414 0 N-CA-C 107.964 -1.125 . . . . 0.0 107.964 174.32 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 201' ' ' ILE . . . . . 0.424 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 63.5 mt -112.28 148.51 15.33 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.61 0 C-N-CA 124.741 1.216 . . . . 0.0 108.739 -174.545 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -71.55 160.49 32.61 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 123.802 0.841 . . . . 0.0 108.871 171.823 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 3.7 ttmp? -70.17 -13.18 62.07 Favored 'General case' 0 N--CA 1.483 1.195 0 C-N-CA 123.343 0.657 . . . . 0.0 111.358 -178.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 27.1 mtpp -89.23 15.11 9.46 Favored 'General case' 0 CA--C 1.552 1.052 0 C-N-CA 123.9 0.88 . . . . 0.0 111.788 175.499 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 70.53 22.9 77.94 Favored Glycine 0 C--N 1.356 1.642 0 O-C-N 123.102 0.251 . . . . 0.0 113.316 176.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 206' ' ' LYS . . . . . 0.405 ' HE2' ' HB3' ' A' ' 206' ' ' LYS . 22.1 ttpt -112.62 112.84 24.65 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 124.715 1.206 . . . . 0.0 108.261 -176.585 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 207' ' ' VAL . . . . . 0.43 ' O ' ' HA3' ' A' ' 148' ' ' GLY . 7.4 p -56.61 141.64 13.19 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 CA-C-N 118.953 0.797 . . . . 0.0 110.714 179.057 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 6.0 m -119.02 -33.9 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 C-N-CA 122.606 0.363 . . . . 0.0 110.363 178.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . . . . . . . . . . . -175.82 -167.13 34.33 Favored Glycine 0 C--N 1.349 1.304 0 O-C-N 123.197 0.311 . . . . 0.0 113.819 -174.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 210' ' ' LEU . . . . . 0.499 ' HB2' ' SD ' ' A' ' 110' ' ' MET . 87.3 mt -117.29 156.2 28.2 Favored 'General case' 0 C--O 1.255 1.356 0 C-N-CA 124.196 0.998 . . . . 0.0 109.916 175.107 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 211' ' ' TYR . . . . . 0.496 ' HB3' ' H ' ' A' ' 197' ' ' GLY . 37.8 t80 -73.33 116.09 13.47 Favored 'General case' 0 C--N 1.35 0.63 0 CA-C-N 114.644 -1.162 . . . . 0.0 109.251 178.561 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -73.99 -142.74 0.7 Allowed Glycine 0 C--N 1.339 0.731 0 O-C-N 124.051 0.844 . . . . 0.0 114.272 -174.291 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 213' ' ' ASN . . . . . . . . . . . . . 3.9 p30 -127.96 159.23 35.62 Favored 'General case' 0 C--O 1.239 0.503 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 -177.27 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 173.62 -136.03 3.47 Favored Glycine 0 N--CA 1.438 -1.227 0 N-CA-C 109.646 -1.381 . . . . 0.0 109.646 178.351 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 215' ' ' VAL . . . . . 0.529 HG21 ' H ' ' A' ' 41' ' ' ILE . 11.3 p -170.0 170.75 0.16 Allowed 'Isoleucine or valine' 0 C--O 1.242 0.683 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 -172.163 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 216' ' ' VAL . . . . . 0.478 ' HA ' ' O ' ' A' ' 221' ' ' ALA . 35.7 m -70.28 112.6 5.25 Favored 'Isoleucine or valine' 0 CA--C 1.557 1.221 0 CA-C-O 121.882 0.848 . . . . 0.0 108.908 168.548 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 217' ' ' THR . . . . . 0.409 HG22 HD22 ' A' ' 29' ' ' LEU . 8.3 m -119.69 171.84 8.1 Favored 'General case' 0 C--O 1.254 1.323 0 C-N-CA 124.661 1.184 . . . . 0.0 108.393 -174.747 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 22.2 ttt180 73.46 -74.68 0.08 Allowed 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 124.636 1.174 . . . . 0.0 110.327 -179.205 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 35.8 p -148.06 -0.47 0.6 Allowed 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 123.651 0.78 . . . . 0.0 111.297 -178.298 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 220' ' ' GLY . . . . . 0.429 ' HA2' ' HB ' ' A' ' 216' ' ' VAL . . . 134.27 12.55 1.42 Allowed Glycine 0 C--N 1.351 1.386 0 CA-C-O 120.0 -0.334 . . . . 0.0 113.048 -174.586 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 221' ' ' ALA . . . . . 0.492 ' O ' HG23 ' A' ' 223' ' ' VAL . . . -78.61 139.99 38.5 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 123.023 0.529 . . . . 0.0 109.597 178.449 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 222' ' ' TYR . . . . . . . . . . . . . 37.8 m-85 -78.81 99.21 6.61 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 123.614 0.766 . . . . 0.0 109.532 -176.093 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . 0.7 HG12 ' HE1' ' A' ' 177' ' ' PHE . 39.1 t -118.91 111.31 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 123.142 0.577 . . . . 0.0 110.148 -169.167 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 16.5 m -137.54 159.57 41.58 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.242 1.017 . . . . 0.0 110.554 -171.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . 0.428 ' HA ' ' HA ' ' A' ' 186' ' ' ALA . . . -70.93 171.92 9.89 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 123.921 0.888 . . . . 0.0 112.309 -179.009 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 226' ' ' ILE . . . . . . . . . . . . . 39.3 mt -127.22 124.47 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.183 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 173.298 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -114.18 109.67 18.77 Favored 'General case' 0 N--CA 1.487 1.402 0 CA-C-N 118.019 0.372 . . . . 0.0 110.525 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 -92.89 168.97 10.81 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 123.673 0.789 . . . . 0.0 111.37 -176.477 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . 0.676 HG23 ' HA ' ' A' ' 145' ' ' LYS . 97.4 m -64.41 108.37 1.61 Allowed 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.602 0.761 . . . . 0.0 111.089 -174.736 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 16.2 mm-40 -156.34 12.98 0.29 Allowed 'General case' 0 N--CA 1.484 1.245 0 C-N-CA 123.645 0.778 . . . . 0.0 112.173 -176.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 231' ' ' LYS . . . . . 0.538 ' HA ' ' HE2' ' A' ' 231' ' ' LYS . 11.1 mmpt? -96.52 -92.33 0.22 Allowed 'General case' 0 N--CA 1.486 1.334 0 CA-C-N 119.103 0.865 . . . . 0.0 111.955 -174.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 66.8 p . . . . . 0 C--N 1.353 0.754 0 CA-C-N 118.735 0.698 . . . . 0.0 112.255 -169.362 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.173 0 CA-C-O 120.997 0.427 . . . . 0.0 111.054 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -163.48 20.74 0.08 Allowed 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 123.901 0.88 . . . . 0.0 109.406 -171.778 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 21.1 p-10 -142.84 58.83 1.43 Allowed 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 114.426 -1.261 . . . . 0.0 108.938 -162.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.466 ' HG ' ' HG2' ' A' ' 88' ' ' GLN . 2.9 mp -134.32 117.73 16.72 Favored 'General case' 0 C--O 1.207 -1.149 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 173.143 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.493 ' HB3' ' HE3' ' A' ' 87' ' ' LYS . 37.4 tt0 -114.48 156.26 24.89 Favored 'General case' 0 N--CA 1.495 1.789 0 CA-C-N 119.745 1.157 . . . . 0.0 112.202 -175.645 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 81.6 mt -95.77 143.07 27.32 Favored 'General case' 0 N--CA 1.481 1.121 0 C-N-CA 124.161 0.984 . . . . 0.0 113.011 178.446 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 -131.34 116.3 17.39 Favored 'General case' 0 N--CA 1.483 1.18 0 C-N-CA 124.283 1.033 . . . . 0.0 108.637 172.349 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.508 ' HA ' ' HA ' ' A' ' 84' ' ' TYR . 36.7 ptt85 -62.33 110.66 1.71 Allowed 'General case' 0 N--CA 1.487 1.407 0 CA-C-N 119.503 1.047 . . . . 0.0 110.17 173.671 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.49 ' HB3' HD13 ' A' ' 161' ' ' LEU . . . -91.5 -28.3 17.69 Favored 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 123.552 0.741 . . . . 0.0 110.457 -177.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -160.22 175.05 13.34 Favored 'General case' 0 C--O 1.239 0.504 0 C-N-CA 123.808 0.843 . . . . 0.0 110.613 -179.366 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -102.66 170.1 8.23 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 124.044 0.938 . . . . 0.0 109.947 175.883 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.645 HG23 ' HA2' ' A' ' 82' ' ' GLY . 82.0 t -72.22 101.54 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.626 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 167.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 31.0 ttmt -169.08 140.79 2.49 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -169.589 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 28.6 t90 -102.45 122.3 44.05 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 122.745 0.418 . . . . 0.0 110.064 179.313 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -81.33 146.18 30.5 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 124.08 0.952 . . . . 0.0 110.889 171.713 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -73.95 0.89 12.09 Favored 'General case' 0 N--CA 1.483 1.182 0 C-N-CA 124.325 1.05 . . . . 0.0 112.607 176.758 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 23.9 mt-30 -75.96 14.95 0.6 Allowed 'General case' 0 CA--C 1.555 1.143 0 C-N-CA 124.325 1.05 . . . . 0.0 112.966 -176.169 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.525 ' HB1' ' HB2' ' A' ' 171' ' ' GLN . . . -52.99 90.64 0.01 OUTLIER 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 124.367 1.067 . . . . 0.0 113.255 -168.594 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -62.56 131.94 50.75 Favored 'General case' 0 C--N 1.353 0.745 0 C-N-CA 124.46 1.104 . . . . 0.0 110.64 -178.876 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 3.0 mp -75.37 111.0 11.11 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 -173.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 19.1 m -142.13 179.35 6.95 Favored 'General case' 0 C--O 1.246 0.885 0 C-N-CA 124.663 1.185 . . . . 0.0 109.208 -175.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.474 ' HA3' ' H ' ' A' ' 173' ' ' LYS . . . 88.27 84.75 1.23 Allowed Glycine 0 C--N 1.341 0.823 0 N-CA-C 111.306 -0.717 . . . . 0.0 111.306 -176.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 50.4 m -150.3 -28.13 0.23 Allowed 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.14 0.576 . . . . 0.0 111.555 -177.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 9.3 p -66.14 126.55 92.15 Favored Pre-proline 0 CA--C 1.553 1.086 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 177.612 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -75.82 -165.3 0.29 Allowed 'Trans proline' 0 C--N 1.377 2.061 0 C-N-CA 123.214 2.609 . . . . 0.0 113.452 -172.587 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 36.3 mm -63.17 111.82 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.953 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 177.833 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.635 HD21 ' HB2' ' A' ' 218' ' ' ARG . 0.3 OUTLIER -109.59 160.33 16.35 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.218 -172.249 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.427 ' H ' HD23 ' A' ' 29' ' ' LEU . 65.6 m -94.54 149.12 21.56 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 123.119 0.568 . . . . 0.0 110.05 171.608 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 17.6 tt -139.31 160.55 28.58 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.593 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 27.7 m -93.9 105.91 17.91 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 108.693 -0.855 . . . . 0.0 108.693 178.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 10.8 tp -73.71 148.55 8.49 Favored 'Isoleucine or valine' 0 C--O 1.246 0.903 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 169.803 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.561 ' HB2' ' HB2' ' A' ' 38' ' ' SER . 50.4 m -138.48 138.7 38.34 Favored 'General case' 0 C--O 1.242 0.695 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 178.302 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -60.41 156.47 15.92 Favored 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 123.499 0.72 . . . . 0.0 111.105 -174.61 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.8 t70 77.85 21.35 0.94 Allowed 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 125.317 1.447 . . . . 0.0 110.727 -179.01 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 78.7 38.49 23.87 Favored Glycine 0 C--N 1.35 1.317 0 CA-C-N 115.556 -0.747 . . . . 0.0 113.755 174.021 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . 0.561 ' HB2' ' HB2' ' A' ' 34' ' ' SER . 28.4 m -107.33 150.36 26.78 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 122.937 0.495 . . . . 0.0 109.793 175.589 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 5.4 ptm -160.65 123.8 3.37 Favored 'General case' 0 N--CA 1.481 1.107 0 CA-C-O 120.901 0.382 . . . . 0.0 111.723 -175.041 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.509 ' HA ' HG11 ' A' ' 215' ' ' VAL . 15.7 p -177.42 -176.17 0.6 Allowed 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 124.549 1.139 . . . . 0.0 109.434 -178.525 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 1.4 mp -92.13 131.09 40.16 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 N-CA-C 105.796 -1.928 . . . . 0.0 105.796 156.283 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 49.3 pttt -52.98 89.76 0.01 OUTLIER 'General case' 0 CA--C 1.551 0.986 0 C-N-CA 124.531 1.132 . . . . 0.0 112.048 -177.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 64.0 m-20 -158.13 149.82 21.53 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.462 1.505 . . . . 0.0 108.329 -177.251 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -68.69 108.62 3.46 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 123.328 0.651 . . . . 0.0 110.234 -179.605 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 . . . . . 0 CA--C 1.537 0.457 0 C-N-CA 122.978 0.511 . . . . 0.0 109.954 176.566 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.413 ' HB2' ' O ' ' A' ' 102' ' ' TYR . 0.5 OUTLIER . . . . . 0 N--CA 1.47 0.562 0 CA-C-O 121.265 0.555 . . . . 0.0 112.478 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.645 ' HA2' HG23 ' A' ' 14' ' ' VAL . . . 128.84 -157.9 21.7 Favored Glycine 0 C--O 1.248 1.031 0 CA-C-N 115.364 -0.834 . . . . 0.0 111.384 -177.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . 0.667 ' HB1' HD11 ' A' ' 161' ' ' LEU . . . -90.35 107.06 18.91 Favored 'General case' 0 CA--C 1.54 0.57 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -179.228 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' TYR . . . . . 0.508 ' HA ' ' HA ' ' A' ' 10' ' ' ARG . 7.4 m-85 -92.51 176.23 6.54 Favored 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 123.18 0.592 . . . . 0.0 109.405 177.455 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' ARG . . . . . 0.626 ' HA ' ' HA ' ' A' ' 99' ' ' ALA . 53.8 ttp180 -138.36 121.82 17.22 Favored 'General case' 0 C--O 1.239 0.54 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 -174.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 41.7 mt -90.67 116.04 31.16 Favored 'Isoleucine or valine' 0 C--O 1.25 1.116 0 CA-C-O 121.607 0.718 . . . . 0.0 110.134 -172.257 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.609 ' HE3' ' HD2' ' A' ' 89' ' ' LYS . 48.3 pttt -105.35 142.13 35.65 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 168.564 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . 0.612 ' HB2' HD13 ' A' ' 97' ' ' ILE . 18.0 tm0? -84.44 106.48 16.06 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 104.534 -2.395 . . . . 0.0 104.534 165.784 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . 0.609 ' HD2' ' HE3' ' A' ' 87' ' ' LYS . 78.6 tttt -119.41 104.09 10.04 Favored 'General case' 0 C--O 1.241 0.613 0 C-N-CA 123.666 0.786 . . . . 0.0 110.36 -167.203 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -72.32 155.31 51.36 Favored Glycine 0 C--O 1.243 0.701 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 167.474 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 22.2 mm -79.41 62.15 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.563 1.442 0 CA-C-N 118.174 0.987 . . . . 0.0 109.067 -176.102 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 1.6 tm? 170.16 -40.1 0.0 OUTLIER 'General case' 0 CA--C 1.556 1.204 0 C-N-CA 126.347 1.859 . . . . 0.0 107.556 -168.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -137.96 151.66 21.45 Favored Glycine 0 C--N 1.369 2.379 0 N-CA-C 114.926 0.731 . . . . 0.0 114.926 -166.576 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -111.89 142.81 43.81 Favored 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 125.037 1.335 . . . . 0.0 110.738 -179.167 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 49.5 m -150.52 96.67 2.41 Favored 'General case' 0 N--CA 1.477 0.915 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 168.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.555 HE22 ' HB3' ' A' ' 163' ' ' PRO . 35.8 tt0 -62.48 140.25 58.6 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 123.237 0.615 . . . . 0.0 111.243 -178.605 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.612 HD13 ' HB2' ' A' ' 88' ' ' GLN . 8.5 pt -132.76 -24.68 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 N-CA-C 112.604 0.594 . . . . 0.0 112.604 -173.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 178.85 -149.4 8.86 Favored Glycine 0 C--N 1.345 1.074 0 C-N-CA 120.847 -0.692 . . . . 0.0 113.031 179.484 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.626 ' HA ' ' HA ' ' A' ' 85' ' ' ARG . . . -143.59 178.11 8.01 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 124.44 1.096 . . . . 0.0 109.805 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -176.89 140.84 5.13 Favored Glycine 0 C--N 1.34 0.796 0 CA-C-O 119.826 -0.43 . . . . 0.0 112.123 174.042 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.599 ' HB ' ' HG3' ' A' ' 199' ' ' PRO . 3.3 p -89.36 127.14 42.22 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.942 0 CA-C-N 117.422 0.611 . . . . 0.0 111.001 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . 0.443 ' HD2' ' HB2' ' A' ' 107' ' ' PHE . 29.4 t80 -98.05 136.77 37.83 Favored 'General case' 0 N--CA 1.477 0.881 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 169.562 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.435 ' HD2' HG21 ' A' ' 14' ' ' VAL . 35.2 tttp -169.02 154.23 6.01 Favored 'General case' 0 N--CA 1.47 0.57 0 O-C-N 123.69 0.618 . . . . 0.0 110.071 171.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 11.8 tp10 72.86 17.28 4.35 Favored 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 124.684 1.194 . . . . 0.0 110.752 171.301 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 80.51 18.01 72.02 Favored Glycine 0 C--N 1.345 1.033 0 CA-C-N 115.925 -0.58 . . . . 0.0 113.303 -176.159 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . 0.468 HG23 ' HD2' ' A' ' 108' ' ' HIS . 2.7 t -139.54 134.8 32.69 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 123.013 0.525 . . . . 0.0 110.584 176.662 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' PHE . . . . . 0.556 ' HB3' ' HB2' ' A' ' 140' ' ' TYR . 38.3 t80 -88.55 118.81 28.47 Favored 'General case' 0 C--N 1.349 0.579 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 174.716 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . 0.468 ' HD2' HG23 ' A' ' 106' ' ' THR . 4.1 p80 -133.45 114.1 13.27 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 123.051 0.54 . . . . 0.0 109.969 -175.267 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 11.5 t -136.17 -172.89 3.24 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 124.187 0.995 . . . . 0.0 110.359 -176.081 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' MET . . . . . 0.414 ' SD ' ' HE1' ' A' ' 112' ' ' HIS . 1.0 OUTLIER -67.14 152.57 45.51 Favored 'General case' 0 N--CA 1.479 1.02 0 C-N-CA 124.189 0.996 . . . . 0.0 110.702 171.542 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 84.1 t90 -74.0 -47.65 35.71 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 122.848 0.459 . . . . 0.0 110.654 -178.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . 0.414 ' HE1' ' SD ' ' A' ' 110' ' ' MET . 22.1 p-80 -59.78 -15.46 20.57 Favored 'General case' 0 N--CA 1.489 1.506 0 C-N-CA 124.38 1.072 . . . . 0.0 113.755 -170.035 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.5 ' O ' HD12 ' A' ' 97' ' ' ILE . 23.2 m -57.62 -27.53 29.84 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 C-N-CA 123.185 0.594 . . . . 0.0 111.032 178.695 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 10.8 t -135.5 165.22 26.03 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.163 0.985 . . . . 0.0 109.263 177.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 14.7 tpp180 -92.74 16.03 13.21 Favored 'General case' 0 N--CA 1.484 1.252 0 CA-C-O 121.642 0.734 . . . . 0.0 109.887 176.048 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 98.72 42.23 2.94 Favored Glycine 0 C--N 1.347 1.153 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 -177.169 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -106.79 167.56 9.79 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 123.608 0.763 . . . . 0.0 110.621 -179.646 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.43 HG23 ' HA ' ' A' ' 127' ' ' GLU . 7.3 p -84.93 137.73 20.33 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.006 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.408 178.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 1.8 mm? -84.37 -177.97 6.78 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 124.429 1.092 . . . . 0.0 111.1 -178.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 47.9 mtm -145.23 164.87 30.02 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 124.165 0.986 . . . . 0.0 111.119 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 12.0 t-160 -164.92 111.28 0.97 Allowed 'General case' 0 C--O 1.239 0.536 0 N-CA-C 106.497 -1.668 . . . . 0.0 106.497 171.454 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 73.1 tttt 70.55 20.34 5.88 Favored 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 124.131 0.972 . . . . 0.0 110.802 -179.739 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 93.13 -19.95 49.06 Favored Glycine 0 C--N 1.344 0.985 0 CA-C-N 114.811 -1.086 . . . . 0.0 113.334 -172.134 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 38.8 ttmt -77.37 119.6 21.21 Favored 'General case' 0 C--N 1.36 1.027 0 CA-C-N 117.509 0.654 . . . . 0.0 109.76 -179.135 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 3.6 mpt_? -59.68 143.8 49.7 Favored 'General case' 0 CA--C 1.551 1.014 0 C-N-CA 124.383 1.073 . . . . 0.0 111.75 177.306 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 57.9 mt -119.1 109.05 25.45 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 176.367 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . 0.43 ' HA ' HG23 ' A' ' 118' ' ' VAL . 10.8 pt-20 -80.01 134.42 56.39 Favored Pre-proline 0 CA--C 1.557 1.241 0 C-N-CA 124.42 1.088 . . . . 0.0 112.997 -167.793 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 127' ' ' GLU . 3.7 Cg_exo -76.3 110.38 3.05 Favored 'Trans proline' 0 C--N 1.383 2.357 0 C-N-CA 123.023 2.482 . . . . 0.0 111.365 176.845 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 34.1 p -85.6 -27.46 25.46 Favored 'General case' 0 N--CA 1.479 1.0 0 C-N-CA 123.315 0.646 . . . . 0.0 111.416 -179.362 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 69.9 t-105 -147.86 153.9 39.72 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 123.706 0.802 . . . . 0.0 109.127 -178.538 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -155.99 118.28 4.08 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 123.196 0.599 . . . . 0.0 110.089 175.443 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 12.8 t0 -117.14 106.95 13.89 Favored 'General case' 0 N--CA 1.475 0.793 0 C-N-CA 124.312 1.045 . . . . 0.0 108.555 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 21.5 t -76.88 -16.42 14.7 Favored 'Isoleucine or valine' 0 CA--C 1.565 1.543 0 C-N-CA 123.263 0.625 . . . . 0.0 111.643 -174.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -79.16 -43.04 24.75 Favored 'General case' 0 N--CA 1.492 1.66 0 C-N-CA 123.203 0.601 . . . . 0.0 111.06 -175.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 11.8 mptt -78.19 -15.55 58.72 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 170.189 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 11.1 t0 58.69 61.86 2.09 Favored 'General case' 0 C--N 1.356 0.888 0 O-C-N 124.834 1.334 . . . . 0.0 108.512 -170.37 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.506 HD11 ' HB1' ' A' ' 227' ' ' ALA . 87.0 mt -139.66 131.97 28.35 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 123.973 0.909 . . . . 0.0 109.607 176.808 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.403 HG22 ' O ' ' A' ' 110' ' ' MET . 20.2 tt -119.7 138.08 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.18 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 171.451 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 21.0 p -133.3 147.77 51.9 Favored 'General case' 0 CA--C 1.544 0.733 0 CA-C-O 121.827 0.822 . . . . 0.0 112.113 -171.501 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.556 ' HB2' ' HB3' ' A' ' 107' ' ' PHE . 17.5 m-85 -132.25 112.02 11.89 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.333 1.453 . . . . 0.0 108.476 -162.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.62 20.49 63.77 Favored Glycine 0 N--CA 1.474 1.229 0 O-C-N 123.084 0.24 . . . . 0.0 112.625 -176.029 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 157.04 -160.71 30.62 Favored Glycine 0 C--N 1.34 0.8 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 177.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.706 ' HA3' ' HB2' ' A' ' 232' ' ' SER . . . -98.75 -175.81 32.31 Favored Glycine 0 C--N 1.346 1.119 0 CA-C-N 117.348 0.574 . . . . 0.0 111.732 171.575 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' TRP . . . . . 0.581 ' CD1' ' HA ' ' A' ' 229' ' ' THR . 47.6 t-105 -61.78 107.64 0.87 Allowed 'General case' 0 C--N 1.352 0.707 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 167.828 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 38.6 ttpt -150.52 112.16 4.48 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-O 121.197 0.523 . . . . 0.0 110.791 -172.201 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' LEU . . . . . . . . . . . . . 1.6 pp -146.19 -2.37 0.7 Allowed 'General case' 0 N--CA 1.48 1.036 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.728 169.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 79.44 -22.86 0.26 Allowed 'General case' 0 N--CA 1.484 1.232 0 C-N-CA 126.108 1.763 . . . . 0.0 113.338 166.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -70.11 157.51 53.51 Favored Glycine 0 C--N 1.355 1.59 0 CA-C-N 118.055 0.389 . . . . 0.0 112.842 -175.149 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -141.12 154.05 45.7 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.097 0.559 . . . . 0.0 110.093 -173.026 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' TRP . . . . . 0.553 ' HB2' HG13 ' A' ' 208' ' ' VAL . 25.7 t90 -68.81 133.78 48.8 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 122.712 0.405 . . . . 0.0 110.107 169.709 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 60.2 tttm -86.33 97.5 10.45 Favored 'General case' 0 CA--C 1.549 0.921 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 171.246 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -59.06 109.91 0.94 Allowed 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 124.548 1.139 . . . . 0.0 112.144 -170.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 123.39 -9.24 8.83 Favored Glycine 0 N--CA 1.475 1.253 0 CA-C-N 115.764 -0.653 . . . . 0.0 112.056 -175.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . 0.477 ' HB3' ' HE3' ' A' ' 203' ' ' LYS . 62.3 mm-40 -101.17 163.25 12.37 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 123.424 0.689 . . . . 0.0 110.256 174.36 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 13.2 mp0 -82.57 146.2 29.3 Favored 'General case' 0 N--CA 1.477 0.919 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 172.071 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 29.6 m -89.8 140.55 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.558 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 25.5 mm-40 -99.66 128.26 45.76 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 178.293 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.506 ' HA ' HG22 ' A' ' 200' ' ' ILE . 58.0 t -98.97 103.18 14.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 -176.709 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -80.8 72.57 7.78 Favored 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 106.946 -1.501 . . . . 0.0 106.946 178.084 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -77.13 130.01 36.77 Favored 'General case' 0 C--N 1.343 0.321 0 CA-C-N 113.496 -1.684 . . . . 0.0 110.647 -173.671 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . 0.667 HD11 ' HB1' ' A' ' 83' ' ' ALA . 45.6 mt -95.93 108.91 21.33 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 177.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 57.9 mt-10 -90.26 115.29 63.7 Favored Pre-proline 0 CA--C 1.544 0.728 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 167.499 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . 0.555 ' HB3' HE22 ' A' ' 96' ' ' GLN . 35.5 Cg_exo -61.55 116.05 3.17 Favored 'Trans proline' 0 C--N 1.372 1.811 0 C-N-CA 123.41 2.74 . . . . 0.0 112.259 -176.71 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 109.53 -23.72 21.69 Favored Glycine 0 C--N 1.341 0.851 0 CA-C-N 115.518 -0.765 . . . . 0.0 112.203 -176.035 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 11.8 mmpt? -105.76 173.94 6.1 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 123.902 0.881 . . . . 0.0 111.532 -172.11 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -67.77 161.84 63.13 Favored Pre-proline 0 CA--C 1.558 1.287 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.021 168.573 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_exo -56.83 138.85 87.36 Favored 'Trans proline' 0 C--N 1.378 2.114 0 C-N-CA 122.968 2.445 . . . . 0.0 111.979 172.05 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 17.1 mmt85 -121.28 97.7 5.64 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 123.681 0.792 . . . . 0.0 109.692 -171.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -79.24 132.72 36.59 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 175.489 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.494 ' HB ' ' HB ' ' A' ' 158' ' ' VAL . 95.5 t -129.8 122.06 53.84 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.163 0 C-N-CA 123.196 0.599 . . . . 0.0 110.266 -178.478 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 171' ' ' GLN . . . . . 0.525 ' HB2' ' HB1' ' A' ' 20' ' ' ALA . 11.5 tt0 -80.82 110.58 16.47 Favored 'General case' 0 N--CA 1.48 1.03 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 -179.867 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 6.9 m -126.73 137.22 53.22 Favored 'General case' 0 C--O 1.238 0.499 0 CA-C-O 121.023 0.44 . . . . 0.0 109.954 -179.563 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . 0.474 ' H ' ' HA3' ' A' ' 24' ' ' GLY . 47.3 mttp -83.17 153.62 66.36 Favored Pre-proline 0 C--O 1.246 0.883 0 C-N-CA 124.115 0.966 . . . . 0.0 108.981 177.555 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 174' ' ' PRO . . . . . 0.489 ' HA ' ' O ' ' A' ' 186' ' ' ALA . 87.3 Cg_exo -49.73 125.99 15.47 Favored 'Trans proline' 0 C--N 1.381 2.252 0 C-N-CA 122.914 2.41 . . . . 0.0 113.36 179.627 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . 0.543 ' H ' ' C ' ' A' ' 186' ' ' ALA . . . -141.11 131.76 5.04 Favored Glycine 0 CA--C 1.541 1.662 0 CA-C-O 122.292 0.94 . . . . 0.0 114.616 178.444 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.579 HD12 ' HB ' ' A' ' 183' ' ' THR . 0.6 OUTLIER -139.31 155.09 47.95 Favored 'General case' 0 C--O 1.242 0.705 0 O-C-N 121.714 -0.874 . . . . 0.0 111.493 -170.292 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 177' ' ' PHE . . . . . 0.429 ' HZ ' ' HB2' ' A' ' 225' ' ' ALA . 3.1 p90 -124.13 139.32 54.04 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 113.696 -1.593 . . . . 0.0 109.781 -175.546 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 3.5 ttpm? -85.01 121.36 27.69 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 124.407 1.083 . . . . 0.0 110.167 -173.376 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 77.8 p -117.78 170.61 8.65 Favored 'General case' 0 C--O 1.243 0.731 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 164.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 10.5 t30 -66.21 -26.66 67.49 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 123.072 0.549 . . . . 0.0 109.91 173.807 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -68.76 -33.66 74.27 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 123.971 0.908 . . . . 0.0 111.055 173.178 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 150.66 172.43 19.81 Favored Glycine 0 C--N 1.35 1.323 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.341 175.325 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 183' ' ' THR . . . . . 0.579 ' HB ' HD12 ' A' ' 176' ' ' LEU . 44.5 p -75.83 95.8 3.56 Favored 'General case' 0 CA--C 1.545 0.782 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 174.723 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 20.3 pt -107.76 141.11 23.83 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 124.292 1.037 . . . . 0.0 110.378 -170.628 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 185' ' ' GLY . . . . . 0.613 ' HA2' ' HA ' ' A' ' 225' ' ' ALA . . . 115.92 173.61 17.35 Favored Glycine 0 N--CA 1.476 1.351 0 CA-C-O 119.432 -0.649 . . . . 0.0 112.612 -178.593 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.543 ' C ' ' H ' ' A' ' 175' ' ' GLY . . . -175.55 40.58 0.01 OUTLIER 'General case' 0 C--O 1.206 -1.225 0 C-N-CA 123.328 0.651 . . . . 0.0 109.882 178.836 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 187' ' ' VAL . . . . . 0.561 HG13 ' HB3' ' A' ' 224' ' ' SER . 2.4 p -164.39 100.42 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.552 1.036 0 O-C-N 120.412 -1.43 . . . . 0.0 108.893 172.857 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 188' ' ' SER . . . . . 0.433 ' O ' ' HA2' ' A' ' 24' ' ' GLY . 80.3 p -118.13 125.67 50.71 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 123.17 0.588 . . . . 0.0 110.266 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 3.6 pp -150.73 -177.81 6.2 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-O 121.095 0.474 . . . . 0.0 110.958 176.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -138.8 103.42 4.82 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 166.749 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 191' ' ' PHE . . . . . . . . . . . . . 29.9 t80 -168.15 -179.61 4.15 Favored 'General case' 0 N--CA 1.486 1.326 0 C-N-CA 122.787 0.435 . . . . 0.0 109.934 -172.256 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 36.6 m -49.05 117.93 7.0 Favored Pre-proline 0 CA--C 1.554 1.125 0 C-N-CA 124.656 1.183 . . . . 0.0 111.585 175.259 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -69.2 99.79 0.71 Allowed 'Trans proline' 0 C--N 1.378 2.09 0 C-N-CA 122.421 2.081 . . . . 0.0 112.111 -179.347 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -60.93 130.94 48.4 Favored Glycine 0 C--N 1.348 1.22 0 N-CA-C 110.589 -1.005 . . . . 0.0 110.589 170.104 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 195' ' ' THR . . . . . 0.451 HG22 ' O ' ' A' ' 161' ' ' LEU . 12.6 t -59.45 140.37 56.25 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 123.202 0.601 . . . . 0.0 112.004 -169.811 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -69.47 104.08 2.21 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 123.961 0.904 . . . . 0.0 110.826 -165.026 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 197' ' ' GLY . . . . . 0.487 ' HA2' HD11 ' A' ' 210' ' ' LEU . . . 135.66 -7.2 4.22 Favored Glycine 0 C--O 1.24 0.525 0 CA-C-N 115.097 -0.956 . . . . 0.0 111.384 -172.526 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 69.6 m -60.99 124.93 82.28 Favored Pre-proline 0 CA--C 1.548 0.897 0 C-N-CA 123.802 0.841 . . . . 0.0 109.554 169.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 199' ' ' PRO . . . . . 0.599 ' HG3' ' HB ' ' A' ' 101' ' ' VAL . 2.9 Cg_exo -73.13 153.52 51.78 Favored 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 122.409 2.073 . . . . 0.0 111.553 -177.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 200' ' ' ILE . . . . . 0.506 HG22 ' HA ' ' A' ' 158' ' ' VAL . 9.7 pt -108.54 129.4 63.05 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 169.084 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 201' ' ' ILE . . . . . 0.438 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 66.4 mt -115.29 152.89 16.88 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.912 0 C-N-CA 125.165 1.386 . . . . 0.0 108.187 -178.252 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -84.9 162.03 19.62 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 175.139 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 203' ' ' LYS . . . . . 0.477 ' HE3' ' HB3' ' A' ' 154' ' ' GLU . 18.5 ptpt -61.98 -24.07 66.79 Favored 'General case' 0 N--CA 1.482 1.154 0 C-N-CA 123.316 0.646 . . . . 0.0 111.765 179.283 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 50.5 tttp -69.48 -21.62 63.69 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 124.012 0.925 . . . . 0.0 111.33 179.567 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 109.14 -12.61 34.06 Favored Glycine 0 C--N 1.349 1.269 0 CA-C-N 116.188 -0.46 . . . . 0.0 113.082 179.351 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 44.7 mmtm -88.51 138.98 30.94 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 177.505 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 207' ' ' VAL . . . . . 0.438 ' HA ' ' HA ' ' A' ' 201' ' ' ILE . 21.4 t -63.36 151.08 8.86 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.936 0 C-N-CA 123.566 0.746 . . . . 0.0 110.867 -176.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 208' ' ' VAL . . . . . 0.553 HG13 ' HB2' ' A' ' 150' ' ' TRP . 54.8 t -100.35 -52.48 8.65 Favored 'Isoleucine or valine' 0 C--O 1.241 0.656 0 C-N-CA 124.415 1.086 . . . . 0.0 109.02 173.083 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . . . . . . . . . . . 171.35 -121.79 0.92 Allowed Glycine 0 C--N 1.345 1.053 0 CA-C-N 114.582 -1.19 . . . . 0.0 111.495 -176.248 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 210' ' ' LEU . . . . . 0.544 ' HB2' ' CH2' ' A' ' 144' ' ' TRP . 9.0 tt -142.03 139.6 32.38 Favored 'General case' 0 CA--C 1.549 0.926 0 CA-C-N 117.481 0.641 . . . . 0.0 110.426 -175.842 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 79.5 t80 -71.64 109.31 5.48 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 123.922 0.889 . . . . 0.0 108.807 174.126 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -76.79 -138.74 0.92 Allowed Glycine 0 C--N 1.34 0.776 0 O-C-N 123.632 0.583 . . . . 0.0 114.455 -170.115 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 213' ' ' ASN . . . . . . . . . . . . . 81.0 m-20 -74.74 85.47 2.16 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 123.294 0.638 . . . . 0.0 109.93 -176.028 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . -72.32 73.22 0.92 Allowed Glycine 0 C--N 1.355 1.593 0 C-N-CA 123.69 0.662 . . . . 0.0 111.571 175.213 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 215' ' ' VAL . . . . . 0.509 HG11 ' HA ' ' A' ' 40' ' ' SER . 54.7 t -84.37 147.24 5.8 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 C-N-CA 123.282 0.633 . . . . 0.0 111.1 -170.128 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 216' ' ' VAL . . . . . 0.518 ' HB ' ' HA2' ' A' ' 220' ' ' GLY . 14.7 m -68.34 111.95 3.0 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.109 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 165.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 217' ' ' THR . . . . . 0.587 HG23 HD13 ' A' ' 29' ' ' LEU . 13.5 t -125.09 159.89 30.36 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 122.686 0.394 . . . . 0.0 110.977 -179.043 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 218' ' ' ARG . . . . . 0.635 ' HB2' HD21 ' A' ' 29' ' ' LEU . 65.0 ttt180 66.45 -74.25 0.06 Allowed 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 124.924 1.289 . . . . 0.0 109.799 -170.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 16.6 p -131.3 -36.89 1.27 Allowed 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 124.02 0.928 . . . . 0.0 109.903 175.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 220' ' ' GLY . . . . . 0.518 ' HA2' ' HB ' ' A' ' 216' ' ' VAL . . . -176.78 11.83 0.03 OUTLIER Glycine 0 C--N 1.358 1.781 0 CA-C-O 119.341 -0.699 . . . . 0.0 114.64 -178.103 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 221' ' ' ALA . . . . . 0.47 ' O ' HG22 ' A' ' 217' ' ' THR . . . -70.95 119.23 14.76 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 117.664 0.732 . . . . 0.0 109.939 -175.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 222' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -76.92 95.69 4.17 Favored 'General case' 0 N--CA 1.473 0.71 0 CA-C-O 121.64 0.733 . . . . 0.0 109.975 -177.636 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 96.5 t -116.67 135.88 55.56 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.092 -179.26 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 224' ' ' SER . . . . . 0.561 ' HB3' HG13 ' A' ' 187' ' ' VAL . 35.2 t -131.18 155.74 46.53 Favored 'General case' 0 C--O 1.243 0.752 0 C-N-CA 124.324 1.05 . . . . 0.0 111.102 -164.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . 0.613 ' HA ' ' HA2' ' A' ' 185' ' ' GLY . . . -97.49 121.27 39.2 Favored 'General case' 0 N--CA 1.467 0.388 0 C-N-CA 123.76 0.824 . . . . 0.0 109.319 174.818 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 226' ' ' ILE . . . . . 0.439 HG23 HD11 ' A' ' 200' ' ' ILE . 7.1 mt -64.77 114.18 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 CA-C-O 120.857 0.36 . . . . 0.0 110.501 174.451 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 227' ' ' ALA . . . . . 0.506 ' HB1' HD11 ' A' ' 137' ' ' LEU . . . -76.79 113.13 14.12 Favored 'General case' 0 C--O 1.239 0.501 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 168.444 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . 0.433 ' HG3' ' HG3' ' A' ' 230' ' ' GLU . 29.7 pt20 -93.39 156.24 16.9 Favored 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 123.782 0.833 . . . . 0.0 109.474 -174.36 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . 0.581 ' HA ' ' CD1' ' A' ' 144' ' ' TRP . 40.7 m -80.11 107.43 12.89 Favored 'General case' 0 C--N 1.347 0.487 0 CA-C-O 121.605 0.717 . . . . 0.0 111.536 179.389 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 230' ' ' GLU . . . . . 0.433 ' HG3' ' HG3' ' A' ' 228' ' ' GLN . 40.5 mt-10 -125.22 88.42 2.88 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 107.049 -1.463 . . . . 0.0 107.049 171.433 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 231' ' ' LYS . . . . . 0.449 ' HA ' ' O ' ' A' ' 144' ' ' TRP . 54.6 pttt -57.73 107.92 0.51 Allowed 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.329 -178.64 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 232' ' ' SER . . . . . 0.706 ' HB2' ' HA3' ' A' ' 143' ' ' GLY . 13.9 m . . . . . 0 C--O 1.239 0.527 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 -175.401 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.143 0 CA-C-O 120.898 0.38 . . . . 0.0 110.169 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -155.9 47.42 0.49 Allowed 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 124.246 1.018 . . . . 0.0 108.356 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 22.3 m-20 -144.33 -18.38 0.55 Allowed 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 113.229 0.826 . . . . 0.0 113.229 -158.478 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.659 ' HB2' ' HG ' ' A' ' 119' ' ' LEU . 1.9 mt -75.88 92.12 3.06 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 118.143 0.429 . . . . 0.0 111.124 -158.436 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -77.2 141.06 40.25 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.969 0.89 . . . . 0.0 111.575 -174.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.475 ' HB3' ' CE2' ' A' ' 84' ' ' TYR . 11.3 mp -83.69 115.38 22.15 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 113.587 -1.642 . . . . 0.0 107.586 175.416 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -111.6 126.37 54.93 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 108.374 -0.972 . . . . 0.0 108.374 179.37 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.617 HH22 ' HB3' ' A' ' 13' ' ' ASP . 60.8 ttt85 -75.03 129.19 37.2 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 120.527 0.203 . . . . 0.0 110.539 -177.469 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.474 ' HB2' ' HG3' ' A' ' 85' ' ' ARG . . . -104.23 -35.07 8.13 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 123.177 0.591 . . . . 0.0 109.96 175.149 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -177.72 -160.95 0.05 Allowed 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 124.421 1.088 . . . . 0.0 110.59 -175.218 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . 0.617 ' HB3' HH22 ' A' ' 10' ' ' ARG . 6.8 p-10 -126.56 170.03 12.46 Favored 'General case' 0 N--CA 1.476 0.87 0 C-N-CA 124.149 0.98 . . . . 0.0 109.847 171.568 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 60.2 t -73.66 104.4 2.5 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.861 -177.414 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 59.2 pttt -164.81 146.29 7.94 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 124.278 1.031 . . . . 0.0 108.804 -178.464 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 24.7 t90 -84.11 113.92 21.4 Favored 'General case' 0 CA--C 1.544 0.713 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 177.395 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 38.2 mm-40 -67.89 147.11 52.94 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 123.557 0.743 . . . . 0.0 111.54 174.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -70.44 -2.46 13.9 Favored 'General case' 0 CA--C 1.556 1.18 0 C-N-CA 125.153 1.381 . . . . 0.0 111.807 175.593 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . 0.559 ' HB2' ' H ' ' A' ' 169' ' ' ALA . 12.9 mm100 -80.14 14.11 2.02 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 124.532 1.133 . . . . 0.0 112.585 -174.355 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -53.89 100.32 0.03 OUTLIER 'General case' 0 C--N 1.364 1.196 0 C-N-CA 124.605 1.162 . . . . 0.0 112.92 -168.743 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.6 mm-40 -82.74 121.88 27.45 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.165 179.294 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 3.6 mp -78.62 103.5 5.66 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.807 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 63.5 m -142.64 -171.59 3.46 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 125.403 1.481 . . . . 0.0 107.2 174.163 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.427 ' HA3' ' H ' ' A' ' 173' ' ' LYS . . . 133.67 148.66 5.9 Favored Glycine 0 N--CA 1.468 0.828 0 N-CA-C 114.887 0.715 . . . . 0.0 114.887 169.37 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.496 ' HB2' ' HB2' ' A' ' 173' ' ' LYS . 15.4 t 65.57 97.98 0.05 OUTLIER 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 125.07 1.348 . . . . 0.0 111.733 173.317 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 15.6 m -111.29 160.96 27.27 Favored Pre-proline 0 CA--C 1.553 1.069 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 169.291 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -57.28 158.59 18.05 Favored 'Trans proline' 0 C--N 1.384 2.418 0 C-N-CA 122.715 2.277 . . . . 0.0 113.074 -176.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 35.5 mm -57.74 120.87 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 123.63 0.772 . . . . 0.0 110.334 -177.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.517 HD23 ' HE1' ' A' ' 177' ' ' PHE . 38.1 tp -98.85 143.12 29.53 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 115.096 -0.957 . . . . 0.0 110.145 -170.343 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 50.4 m -123.06 116.46 23.54 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 122.872 0.469 . . . . 0.0 109.766 -175.789 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 14.4 pt -138.29 173.48 12.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 C-N-CA 124.149 0.98 . . . . 0.0 110.155 178.475 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 36.4 p -93.85 125.26 38.37 Favored 'General case' 0 C--N 1.353 0.736 0 C-N-CA 122.787 0.435 . . . . 0.0 109.92 -173.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 10.6 tp -65.15 128.55 28.07 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.001 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 170.058 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 24.8 t -108.47 103.61 12.78 Favored 'General case' 0 C--O 1.267 2.005 0 CA-C-O 121.437 0.637 . . . . 0.0 109.567 -176.251 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 68.26 -79.57 0.04 OUTLIER 'General case' 0 C--N 1.357 0.914 0 CA-C-N 113.179 -1.828 . . . . 0.0 111.282 176.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -144.37 -72.84 0.27 Allowed 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.873 0.869 . . . . 0.0 109.26 -177.799 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -97.95 4.95 61.32 Favored Glycine 0 C--N 1.347 1.171 0 CA-C-O 118.812 -0.993 . . . . 0.0 114.227 -174.325 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 35.8 t -107.04 164.33 12.24 Favored 'General case' 0 C--N 1.359 1.021 0 CA-C-N 119.026 1.413 . . . . 0.0 107.967 172.405 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . 0.437 ' HE1' ' CE2' ' A' ' 177' ' ' PHE . 39.7 ttp -164.24 126.47 2.36 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 178.85 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.466 ' HA ' HG11 ' A' ' 215' ' ' VAL . 68.3 m -150.95 -178.91 6.87 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 123.53 0.732 . . . . 0.0 110.968 -173.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.796 HD11 HG22 ' A' ' 217' ' ' THR . 2.3 mp -83.95 97.88 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 N-CA-C 105.729 -1.952 . . . . 0.0 105.729 163.255 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 13.2 mptt 57.64 -86.24 0.02 OUTLIER 'General case' 0 CA--C 1.55 0.952 0 C-N-CA 124.139 0.976 . . . . 0.0 108.731 -165.226 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 8.7 t30 -140.54 140.05 35.15 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 123.553 0.741 . . . . 0.0 109.318 172.001 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -154.86 121.64 5.45 Favored 'General case' 0 CA--C 1.537 0.458 0 N-CA-C 106.406 -1.702 . . . . 0.0 106.406 179.204 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.3 tp10 . . . . . 0 N--CA 1.476 0.863 0 C-N-CA 122.836 0.454 . . . . 0.0 110.33 -177.067 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.514 ' HB2' ' HA ' ' A' ' 103' ' ' LYS . 8.2 p-10 . . . . . 0 C--O 1.245 0.861 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 159.52 -163.73 33.66 Favored Glycine 0 C--N 1.343 0.917 0 CA-C-N 116.031 -0.531 . . . . 0.0 113.396 178.536 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . 0.431 ' HB1' HD21 ' A' ' 161' ' ' LEU . . . -89.84 123.99 34.29 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 124.137 0.975 . . . . 0.0 109.232 -177.451 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' TYR . . . . . 0.475 ' CE2' ' HB3' ' A' ' 8' ' ' LEU . 4.0 m-85 -126.09 151.38 47.29 Favored 'General case' 0 N--CA 1.48 1.034 0 C-N-CA 123.723 0.809 . . . . 0.0 112.09 -166.566 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' ARG . . . . . 0.476 ' HA ' ' HA ' ' A' ' 99' ' ' ALA . 25.3 mtm180 -113.71 131.02 56.33 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 124.817 1.247 . . . . 0.0 107.897 167.371 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 25.7 mt -94.33 124.55 46.85 Favored 'Isoleucine or valine' 0 C--O 1.249 1.048 0 CA-C-O 121.684 0.754 . . . . 0.0 110.513 -179.401 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.482 ' HD3' ' HB3' ' A' ' 94' ' ' TYR . 1.7 ttmp? -105.72 136.68 44.88 Favored 'General case' 0 C--O 1.213 -0.816 0 C-N-CA 126.114 1.766 . . . . 0.0 108.305 177.599 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 22.9 tm0? -83.07 106.98 15.33 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 104.435 -2.431 . . . . 0.0 104.435 166.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 1.9 tmtp? -118.49 95.21 4.77 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-N 114.975 -1.011 . . . . 0.0 108.298 -166.577 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -82.48 150.52 28.53 Favored Glycine 0 C--O 1.248 1.012 0 N-CA-C 108.911 -1.675 . . . . 0.0 108.911 166.562 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 16.1 mm -80.2 59.63 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.265 0 CA-C-O 121.614 0.721 . . . . 0.0 109.07 -177.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 4.6 pp 168.55 -20.59 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 126.331 1.853 . . . . 0.0 110.433 -173.662 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -157.36 145.51 12.08 Favored Glycine 0 C--N 1.37 2.462 0 CA-C-O 119.841 -0.422 . . . . 0.0 113.239 -174.703 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . 0.482 ' HB3' ' HD3' ' A' ' 87' ' ' LYS . 28.3 m-85 -130.56 147.67 52.27 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-N 117.434 0.617 . . . . 0.0 111.192 -171.177 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 25.1 t -151.18 149.83 29.92 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 123.806 0.843 . . . . 0.0 109.447 175.2 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . . . . . . . . . 22.2 tp60 -94.83 111.22 23.01 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 108.858 -0.794 . . . . 0.0 108.858 177.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.444 HD11 ' HB3' ' A' ' 6' ' ' LEU . 28.6 pt -106.33 -16.86 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 N-CA-C 113.375 0.88 . . . . 0.0 113.375 -173.222 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 170.35 -146.32 9.76 Favored Glycine 0 N--CA 1.472 1.044 0 C-N-CA 120.453 -0.879 . . . . 0.0 113.193 173.604 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.476 ' HA ' ' HA ' ' A' ' 85' ' ' ARG . . . -149.32 176.36 10.62 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 123.684 0.794 . . . . 0.0 110.787 177.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -166.81 -170.52 31.81 Favored Glycine 0 C--N 1.344 1.02 0 N-CA-C 111.368 -0.693 . . . . 0.0 111.368 178.12 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 6.2 p -142.83 117.4 4.34 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.728 0 C-N-CA 124.034 0.934 . . . . 0.0 109.278 178.432 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 3.0 t80 -88.5 136.71 32.86 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 171.313 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.514 ' HA ' ' HB2' ' A' ' 81' ' ' ASP . 17.2 tptp -160.12 153.47 22.14 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 110.41 -0.219 . . . . 0.0 110.41 177.244 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 71.52 -85.47 0.03 OUTLIER 'General case' 0 CA--C 1.55 0.981 0 C-N-CA 124.868 1.267 . . . . 0.0 110.576 169.651 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -155.88 24.81 0.56 Allowed Glycine 0 N--CA 1.469 0.889 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 174.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . 0.746 HG22 ' HA3' ' A' ' 141' ' ' GLY . 7.0 p -147.03 151.75 37.45 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.377 1.071 . . . . 0.0 110.011 -167.865 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' PHE . . . . . 0.518 ' HB3' ' HB3' ' A' ' 140' ' ' TYR . 31.4 t80 -104.63 139.16 39.88 Favored 'General case' 0 N--CA 1.484 1.235 0 N-CA-C 108.031 -1.099 . . . . 0.0 108.031 174.02 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . 0.436 ' HB3' ' CZ3' ' A' ' 144' ' ' TRP . 78.0 m-70 -132.35 113.58 13.36 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 123.549 0.74 . . . . 0.0 110.173 -175.555 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 9.0 t -136.47 -177.8 4.88 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 122.761 0.424 . . . . 0.0 110.673 177.495 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' MET . . . . . 0.506 ' SD ' ' HE1' ' A' ' 112' ' ' HIS . 3.3 mtp -89.52 152.42 21.44 Favored 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 123.677 0.791 . . . . 0.0 110.195 178.656 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 53.9 t90 -73.45 -39.13 65.2 Favored 'General case' 0 CA--C 1.542 0.642 0 O-C-N 123.634 0.584 . . . . 0.0 110.365 -175.848 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . 0.506 ' HE1' ' SD ' ' A' ' 110' ' ' MET . 18.6 p-80 -65.87 -8.39 21.76 Favored 'General case' 0 N--CA 1.49 1.555 0 C-N-CA 124.474 1.11 . . . . 0.0 113.087 -172.665 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 95.1 t -58.08 -37.97 64.82 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.977 0 C-N-CA 123.366 0.666 . . . . 0.0 110.1 178.231 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 17.5 p -147.78 -163.08 1.69 Allowed 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 124.448 1.099 . . . . 0.0 109.989 169.435 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.8 tpp180 -90.83 5.23 49.26 Favored 'General case' 0 CA--C 1.559 1.296 0 C-N-CA 123.562 0.745 . . . . 0.0 111.152 176.248 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 107.1 63.49 0.59 Allowed Glycine 0 C--N 1.35 1.329 0 N-CA-C 111.799 -0.52 . . . . 0.0 111.799 -178.364 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . 0.591 ' HB3' HD11 ' A' ' 6' ' ' LEU . . . -95.33 168.39 10.75 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 123.811 0.844 . . . . 0.0 111.823 -179.363 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.42 HG23 ' HA ' ' A' ' 127' ' ' GLU . 14.9 p -86.5 141.41 14.44 Favored 'Isoleucine or valine' 0 C--O 1.245 0.845 0 N-CA-C 108.369 -0.975 . . . . 0.0 108.369 165.565 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.659 ' HG ' ' HB2' ' A' ' 6' ' ' LEU . 6.4 mp -102.03 174.62 5.85 Favored 'General case' 0 C--O 1.222 -0.35 0 C-N-CA 124.072 0.949 . . . . 0.0 111.291 -173.667 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 25.4 mmt -121.78 165.71 15.43 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 125.36 1.464 . . . . 0.0 108.752 177.194 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 12.1 t-80 -170.03 97.44 0.28 Allowed 'General case' 0 C--O 1.246 0.879 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 166.435 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 49.1 tttm 56.87 37.63 28.92 Favored 'General case' 0 N--CA 1.489 1.483 0 CA-C-O 121.91 0.862 . . . . 0.0 110.889 173.358 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 101.38 -12.09 58.37 Favored Glycine 0 C--N 1.348 1.22 0 CA-C-O 119.135 -0.814 . . . . 0.0 114.349 177.007 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 53.4 mtpt -102.56 135.18 44.65 Favored 'General case' 0 N--CA 1.49 1.569 0 CA-C-N 118.155 0.977 . . . . 0.0 110.712 178.506 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . 0.434 ' HA ' ' O ' ' A' ' 119' ' ' LEU . 0.1 OUTLIER -85.21 122.79 29.9 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 123.196 0.599 . . . . 0.0 110.82 177.667 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.519 HG23 ' HB2' ' A' ' 140' ' ' TYR . 1.8 mp -87.13 100.07 9.38 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.917 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 172.606 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . 0.42 ' HA ' HG23 ' A' ' 118' ' ' VAL . 36.5 tt0 -92.42 104.63 11.61 Favored Pre-proline 0 CA--C 1.545 0.787 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.371 -177.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 12.9 Cg_exo -68.69 98.2 0.58 Allowed 'Trans proline' 0 C--N 1.374 1.905 0 C-N-CA 122.534 2.156 . . . . 0.0 112.195 -175.697 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 6.4 p -69.08 -24.66 64.17 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 123.797 0.839 . . . . 0.0 111.231 176.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.578 ' HB2' ' HA2' ' A' ' 142' ' ' GLY . 59.7 t-105 -107.32 138.43 43.52 Favored 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 108.712 -0.848 . . . . 0.0 108.712 171.334 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -155.35 120.89 4.99 Favored 'General case' 0 C--O 1.238 0.494 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 176.393 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -143.07 114.08 7.7 Favored 'General case' 0 CA--C 1.544 0.728 0 CA-C-O 120.879 0.371 . . . . 0.0 110.98 -178.099 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 14.2 p -77.45 -17.43 14.29 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.309 0 C-N-CA 124.219 1.008 . . . . 0.0 112.423 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 65.4 mttm -71.73 -45.52 61.5 Favored 'General case' 0 N--CA 1.485 1.306 0 C-N-CA 123.177 0.591 . . . . 0.0 110.735 -173.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . 0.599 ' HG2' ' HG2' ' A' ' 230' ' ' GLU . 4.6 mptp? -88.64 -10.06 49.92 Favored 'General case' 0 N--CA 1.477 0.898 0 C-N-CA 124.653 1.181 . . . . 0.0 109.897 174.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 56.1 t0 63.02 46.11 4.92 Favored 'General case' 0 C--N 1.36 1.037 0 O-C-N 124.549 1.156 . . . . 0.0 109.426 -177.124 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 96.2 mt -136.71 127.67 27.61 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.696 0.798 . . . . 0.0 110.392 -179.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 17.8 tt -124.14 136.81 59.18 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 175.773 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 80.5 p -148.58 146.0 28.07 Favored 'General case' 0 N--CA 1.475 0.796 0 CA-C-O 121.843 0.83 . . . . 0.0 113.146 -171.162 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.519 ' HB2' HG23 ' A' ' 126' ' ' ILE . 81.3 t80 -84.6 122.17 28.66 Favored 'General case' 0 N--CA 1.473 0.695 0 CA-C-N 114.446 -1.252 . . . . 0.0 108.396 172.601 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.746 ' HA3' HG22 ' A' ' 106' ' ' THR . . . 123.69 -82.47 0.35 Allowed Glycine 0 C--N 1.34 0.801 0 O-C-N 124.281 0.988 . . . . 0.0 111.637 177.676 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . 0.578 ' HA2' ' HB2' ' A' ' 130' ' ' TRP . . . 147.57 84.09 0.05 OUTLIER Glycine 0 C--O 1.24 0.495 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 172.683 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 146.94 176.34 20.62 Favored Glycine 0 C--O 1.241 0.565 0 N-CA-C 111.233 -0.747 . . . . 0.0 111.233 177.312 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' TRP . . . . . 0.593 ' HH2' HD13 ' A' ' 210' ' ' LEU . 69.2 t-105 -110.16 109.21 19.64 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 166.491 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 28.7 mmmt -108.98 107.43 17.79 Favored 'General case' 0 N--CA 1.471 0.621 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -175.412 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' LEU . . . . . 0.423 HD22 HG11 ' A' ' 207' ' ' VAL . 60.2 mt -162.63 -45.74 0.04 OUTLIER 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 126.909 2.084 . . . . 0.0 106.784 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 63.89 22.88 13.17 Favored 'General case' 0 N--CA 1.482 1.128 0 C-N-CA 125.256 1.422 . . . . 0.0 112.758 176.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . 0.434 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -76.98 165.96 53.76 Favored Glycine 0 C--N 1.352 1.455 0 CA-C-N 116.262 -0.427 . . . . 0.0 113.017 179.543 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 22.2 tt0 -123.69 96.62 5.03 Favored 'General case' 0 C--O 1.239 0.506 0 C-N-CA 123.485 0.714 . . . . 0.0 109.26 -174.401 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' TRP . . . . . 0.527 ' HA ' ' HB ' ' A' ' 208' ' ' VAL . 29.1 t90 -55.63 116.05 2.68 Favored 'General case' 0 N--CA 1.481 1.098 0 O-C-N 123.308 0.38 . . . . 0.0 111.185 171.33 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 65.9 mttm -94.5 100.3 12.31 Favored 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 123.848 0.859 . . . . 0.0 109.419 -178.366 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -68.21 141.02 56.08 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 124.658 1.183 . . . . 0.0 111.918 -175.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 83.8 -23.56 6.63 Favored Glycine 0 C--N 1.351 1.389 0 CA-C-N 116.47 -0.332 . . . . 0.0 113.518 177.314 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -97.02 151.53 19.63 Favored 'General case' 0 C--O 1.24 0.57 0 C-N-CA 124.546 1.138 . . . . 0.0 108.53 -179.578 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . 0.424 ' HA ' ' HA ' ' A' ' 173' ' ' LYS . 1.2 pm0 -63.6 121.96 15.16 Favored 'General case' 0 C--N 1.345 0.406 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 176.051 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 33.9 m -89.93 179.51 0.5 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.537 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 174.807 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.47 133.4 51.21 Favored 'General case' 0 C--O 1.217 -0.641 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -175.87 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.451 ' O ' ' HA ' ' A' ' 169' ' ' ALA . 86.3 t -107.77 119.35 57.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 -176.795 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -93.1 77.43 4.63 Favored 'General case' 0 CA--C 1.54 0.584 0 N-CA-C 106.665 -1.605 . . . . 0.0 106.665 172.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -77.9 111.87 14.2 Favored 'General case' 0 CA--C 1.539 0.534 0 CA-C-N 114.69 -1.141 . . . . 0.0 111.006 -169.347 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . 0.431 HD21 ' HB1' ' A' ' 83' ' ' ALA . 89.0 mt -79.1 102.61 8.52 Favored 'General case' 0 C--O 1.244 0.805 0 C-N-CA 123.993 0.917 . . . . 0.0 110.195 179.541 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . 0.516 ' HB2' ' HB2' ' A' ' 193' ' ' PRO . 39.1 tt0 -74.82 126.66 88.16 Favored Pre-proline 0 CA--C 1.541 0.614 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 173.124 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -64.13 116.03 3.48 Favored 'Trans proline' 0 C--N 1.376 1.988 0 C-N-CA 121.911 1.741 . . . . 0.0 110.375 173.753 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 113.1 -28.01 9.11 Favored Glycine 0 C--N 1.344 1.006 0 CA-C-O 119.583 -0.565 . . . . 0.0 113.816 177.369 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -136.47 -173.48 3.43 Favored 'General case' 0 N--CA 1.49 1.552 0 CA-C-N 117.986 0.893 . . . . 0.0 112.154 -175.08 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -60.0 161.27 12.88 Favored Pre-proline 0 CA--C 1.554 1.116 0 C-N-CA 124.983 1.313 . . . . 0.0 112.319 175.861 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -77.2 157.4 33.65 Favored 'Trans proline' 0 C--N 1.373 1.823 0 C-N-CA 122.016 1.811 . . . . 0.0 111.759 173.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . 0.517 HH11 ' HG3' ' A' ' 193' ' ' PRO . 58.7 mtp180 -124.58 131.97 53.46 Favored 'General case' 0 C--O 1.238 0.489 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.257 173.773 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . 0.559 ' H ' ' HB2' ' A' ' 19' ' ' GLN . . . -80.02 133.83 36.18 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.053 176.633 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 63.0 t -134.21 117.8 26.05 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.131 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 174.436 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 55.1 mt-30 -81.75 126.28 31.63 Favored 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 108.245 -1.021 . . . . 0.0 108.245 174.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 4.9 t -152.72 132.44 13.16 Favored 'General case' 0 CA--C 1.54 0.561 0 O-C-N 123.571 0.544 . . . . 0.0 111.738 -174.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . 0.496 ' HB2' ' HB2' ' A' ' 25' ' ' SER . 64.0 mttp -75.6 138.13 70.57 Favored Pre-proline 0 N--CA 1.475 0.782 0 C-N-CA 123.146 0.578 . . . . 0.0 110.069 171.69 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_endo -61.78 163.27 19.27 Favored 'Trans proline' 0 C--N 1.379 2.134 0 C-N-CA 123.091 2.527 . . . . 0.0 113.728 178.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -144.45 169.89 26.3 Favored Glycine 0 N--CA 1.468 0.785 0 N-CA-C 110.399 -1.08 . . . . 0.0 110.399 178.217 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 6.5 mp -124.34 152.13 43.5 Favored 'General case' 0 N--CA 1.488 1.463 0 CA-C-N 118.681 1.24 . . . . 0.0 111.887 -176.511 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 177' ' ' PHE . . . . . 0.517 ' HE1' HD23 ' A' ' 29' ' ' LEU . 68.4 m-85 -96.53 122.42 39.41 Favored 'General case' 0 C--N 1.344 0.356 0 CA-C-N 114.756 -1.111 . . . . 0.0 109.593 173.831 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 61.0 tttp -85.47 90.07 7.86 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 167.032 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 23.0 m -104.14 158.79 16.2 Favored 'General case' 0 C--O 1.242 0.689 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 -179.352 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -61.6 -34.88 76.4 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 122.356 0.262 . . . . 0.0 110.471 177.506 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -63.79 -33.85 76.59 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 123.572 0.749 . . . . 0.0 111.155 175.442 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 151.25 -169.13 30.88 Favored Glycine 0 C--N 1.342 0.888 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.97 177.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 183' ' ' THR . . . . . 0.453 ' HA ' ' O ' ' A' ' 177' ' ' PHE . 16.9 p -87.25 119.19 27.23 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 122.986 0.514 . . . . 0.0 109.776 176.522 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . 0.461 ' HB ' ' HB2' ' A' ' 177' ' ' PHE . 65.5 mt -103.01 144.51 13.69 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 124.223 1.009 . . . . 0.0 108.504 -176.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -99.23 120.24 6.79 Favored Glycine 0 C--N 1.345 1.038 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 -175.223 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.403 ' HA ' ' HA ' ' A' ' 225' ' ' ALA . . . -146.93 -160.65 1.19 Allowed 'General case' 0 N--CA 1.465 0.294 0 C-N-CA 123.413 0.685 . . . . 0.0 111.102 -163.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 187' ' ' VAL . . . . . 0.416 ' HB ' HD11 ' A' ' 226' ' ' ILE . 3.7 p -132.22 103.86 7.13 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.989 0 C-N-CA 124.029 0.932 . . . . 0.0 108.498 169.552 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 188' ' ' SER . . . . . 0.46 ' HA ' HG13 ' A' ' 223' ' ' VAL . 15.6 t -76.96 100.65 5.68 Favored 'General case' 0 C--O 1.243 0.753 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.501 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 189' ' ' LEU . . . . . 0.4 HD13 ' N ' ' A' ' 190' ' ' ASP . 0.8 OUTLIER -152.44 155.66 37.96 Favored 'General case' 0 C--N 1.358 0.939 0 CA-C-O 121.365 0.603 . . . . 0.0 110.689 -168.531 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 190' ' ' ASP . . . . . 0.645 ' HA ' ' HB1' ' A' ' 221' ' ' ALA . 16.6 t70 -69.08 162.76 26.26 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 124.869 1.267 . . . . 0.0 109.859 176.048 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 191' ' ' PHE . . . . . 0.536 ' HB3' ' H ' ' A' ' 222' ' ' TYR . 9.6 p90 -74.23 123.92 25.43 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-O 121.958 0.885 . . . . 0.0 110.522 -168.409 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 50.8 m -104.62 158.96 30.88 Favored Pre-proline 0 CA--C 1.547 0.854 0 CA-C-N 114.23 -1.35 . . . . 0.0 110.445 -174.457 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . 0.517 ' HG3' HH11 ' A' ' 168' ' ' ARG . 73.7 Cg_endo -72.78 69.69 3.62 Favored 'Trans proline' 0 C--N 1.372 1.8 0 C-N-CA 122.786 2.324 . . . . 0.0 112.2 173.44 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -154.01 146.63 15.02 Favored Glycine 0 C--N 1.347 1.145 0 CA-C-N 116.178 -0.465 . . . . 0.0 112.46 -177.42 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 25.3 p -110.39 156.37 20.87 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 123.684 0.793 . . . . 0.0 109.469 176.32 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.63 107.2 0.77 Allowed 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 123.858 0.863 . . . . 0.0 110.069 -175.557 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 132.6 -9.55 5.26 Favored Glycine 0 C--N 1.342 0.89 0 CA-C-N 114.749 -1.114 . . . . 0.0 112.338 -172.19 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 54.2 m -63.91 120.12 60.92 Favored Pre-proline 0 CA--C 1.55 0.953 0 C-N-CA 123.351 0.66 . . . . 0.0 109.553 173.48 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -60.39 125.29 17.04 Favored 'Trans proline' 0 C--N 1.375 1.949 0 C-N-CA 122.836 2.357 . . . . 0.0 112.292 -173.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 55.5 mt -88.22 107.56 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 173.665 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 201' ' ' ILE . . . . . 0.8 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 25.9 mt -97.06 176.55 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.044 0 C-N-CA 124.524 1.13 . . . . 0.0 108.942 -175.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -102.93 174.22 5.97 Favored 'General case' 0 C--O 1.24 0.604 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 169.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 2.4 mppt? -70.46 -28.74 65.25 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 123.84 0.856 . . . . 0.0 109.051 174.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp -81.96 1.6 34.65 Favored 'General case' 0 N--CA 1.477 0.878 0 C-N-CA 123.958 0.903 . . . . 0.0 111.927 178.836 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 90.96 -4.82 81.84 Favored Glycine 0 C--N 1.351 1.403 0 CA-C-O 119.965 -0.353 . . . . 0.0 113.562 177.249 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 31.3 mmtp -78.25 108.89 11.9 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 122.931 0.492 . . . . 0.0 110.064 179.651 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 207' ' ' VAL . . . . . 0.8 ' HA ' ' HA ' ' A' ' 201' ' ' ILE . 4.8 p -63.66 103.06 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.053 0 CA-C-O 121.437 0.636 . . . . 0.0 110.218 177.076 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 208' ' ' VAL . . . . . 0.527 ' HB ' ' HA ' ' A' ' 150' ' ' TRP . 27.2 m -81.68 -18.37 11.43 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.987 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.287 -169.782 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . . . . . . . . . . . 170.89 -138.84 5.15 Favored Glycine 0 C--N 1.344 0.99 0 CA-C-N 115.446 -0.797 . . . . 0.0 112.351 179.506 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 210' ' ' LEU . . . . . 0.593 HD13 ' HH2' ' A' ' 144' ' ' TRP . 4.9 tt -153.41 154.13 33.85 Favored 'General case' 0 CA--C 1.549 0.904 0 C-N-CA 123.864 0.866 . . . . 0.0 109.825 -168.219 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -67.97 114.42 6.5 Favored 'General case' 0 N--CA 1.481 1.12 0 C-N-CA 123.885 0.874 . . . . 0.0 109.868 -178.78 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -74.65 -136.67 0.44 Allowed Glycine 0 CA--C 1.528 0.895 0 O-C-N 124.349 1.031 . . . . 0.0 114.754 -169.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 213' ' ' ASN . . . . . 0.404 ' H ' ' HB3' ' A' ' 225' ' ' ALA . 49.0 t-20 -123.99 135.15 53.44 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 -175.164 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 214' ' ' GLY . . . . . 0.507 ' HA3' ' HA ' ' A' ' 224' ' ' SER . . . -164.37 -152.42 6.96 Favored Glycine 0 CA--C 1.506 -0.528 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.918 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 215' ' ' VAL . . . . . 0.466 HG11 ' HA ' ' A' ' 40' ' ' SER . 7.4 p -162.76 157.09 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 123.02 0.528 . . . . 0.0 110.445 -171.412 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 216' ' ' VAL . . . . . 0.46 ' HA ' ' HA ' ' A' ' 222' ' ' TYR . 93.0 t -70.93 116.38 12.36 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 C-N-CA 123.891 0.877 . . . . 0.0 109.064 174.553 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 217' ' ' THR . . . . . 0.796 HG22 HD11 ' A' ' 41' ' ' ILE . 72.9 p -130.68 163.48 27.12 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 125.256 1.423 . . . . 0.0 109.525 -173.572 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 10.1 ttp180 54.31 76.57 0.23 Allowed 'General case' 0 CA--C 1.561 1.367 0 C-N-CA 123.133 0.573 . . . . 0.0 111.957 161.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 45.1 m 71.91 -5.69 1.64 Allowed 'General case' 0 N--CA 1.492 1.663 0 C-N-CA 124.901 1.28 . . . . 0.0 114.393 176.21 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . 118.27 43.82 0.54 Allowed Glycine 0 C--N 1.357 1.71 0 CA-C-N 118.583 0.629 . . . . 0.0 112.909 176.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 221' ' ' ALA . . . . . 0.645 ' HB1' ' HA ' ' A' ' 190' ' ' ASP . . . -130.39 120.91 24.99 Favored 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 124.712 1.205 . . . . 0.0 109.578 -178.611 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 222' ' ' TYR . . . . . 0.536 ' H ' ' HB3' ' A' ' 191' ' ' PHE . 11.0 p90 -86.3 127.45 34.78 Favored 'General case' 0 C--N 1.351 0.665 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 -169.643 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . 0.46 HG13 ' HA ' ' A' ' 188' ' ' SER . 96.4 t -113.49 132.95 60.95 Favored 'Isoleucine or valine' 0 C--O 1.241 0.633 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 176.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 224' ' ' SER . . . . . 0.507 ' HA ' ' HA3' ' A' ' 214' ' ' GLY . 35.8 t -136.3 158.74 43.71 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 124.199 0.999 . . . . 0.0 109.959 -168.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . 0.404 ' HB3' ' H ' ' A' ' 213' ' ' ASN . . . -68.73 166.51 17.28 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 123.708 0.803 . . . . 0.0 111.234 175.232 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 226' ' ' ILE . . . . . 0.416 HD11 ' HB ' ' A' ' 187' ' ' VAL . 70.9 mt -108.71 111.56 36.55 Favored 'Isoleucine or valine' 0 C--O 1.243 0.731 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 168.634 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -74.62 131.83 41.25 Favored 'General case' 0 C--N 1.345 0.381 0 N-CA-C 107.516 -1.291 . . . . 0.0 107.516 169.828 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -111.39 171.12 7.67 Favored 'General case' 0 C--O 1.248 1.01 0 C-N-CA 123.626 0.77 . . . . 0.0 109.371 -177.754 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . 0.474 ' HA ' ' CD1' ' A' ' 144' ' ' TRP . 87.1 m -66.94 115.31 6.53 Favored 'General case' 0 CA--C 1.544 0.738 0 O-C-N 123.59 0.556 . . . . 0.0 110.618 178.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 230' ' ' GLU . . . . . 0.599 ' HG2' ' HG2' ' A' ' 135' ' ' LYS . 10.0 tp10 -117.0 62.75 0.73 Allowed 'General case' 0 C--O 1.242 0.68 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 175.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 24.3 pttm -66.97 157.45 33.33 Favored 'General case' 0 N--CA 1.472 0.662 0 CA-C-N 114.985 -1.007 . . . . 0.0 112.911 -165.733 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 19.8 p . . . . . 0 CA--C 1.549 0.926 0 CA-C-N 113.935 -1.484 . . . . 0.0 112.132 -178.074 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.421 ' HA ' HE22 ' A' ' 88' ' ' GLN . . . . . . . . 0 N--CA 1.484 1.25 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -165.2 23.62 0.05 Allowed 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 123.142 0.577 . . . . 0.0 110.365 -175.489 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 8.9 p30 -175.55 64.73 0.02 OUTLIER 'General case' 0 C--N 1.344 0.367 0 C-N-CA 124.734 1.214 . . . . 0.0 108.069 -173.099 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.683 ' HB2' HD13 ' A' ' 119' ' ' LEU . 15.6 mt -79.58 177.52 8.81 Favored 'General case' 0 C--O 1.213 -0.868 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 168.078 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 17.3 tt0 -152.39 142.35 22.15 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-N 119.104 0.866 . . . . 0.0 111.56 171.15 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.448 ' HB3' ' CD2' ' A' ' 84' ' ' TYR . 89.3 mt -87.9 114.37 24.45 Favored 'General case' 0 C--O 1.24 0.56 0 CA-C-N 114.012 -1.449 . . . . 0.0 110.007 175.029 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -106.79 117.75 34.87 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 173.583 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 21.2 ptt180 -58.98 121.77 12.04 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 122.83 0.452 . . . . 0.0 110.08 177.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -113.8 -33.83 5.67 Favored 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 122.609 0.364 . . . . 0.0 110.676 -176.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -169.17 -172.16 1.46 Allowed 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 123.938 0.895 . . . . 0.0 109.9 -179.096 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -102.04 160.29 14.63 Favored 'General case' 0 C--O 1.245 0.83 0 N-CA-C 107.818 -1.178 . . . . 0.0 107.818 169.208 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 99.7 t -72.38 100.09 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 170.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 63.7 tttt -155.54 127.74 7.68 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 115.126 -0.943 . . . . 0.0 108.725 -166.111 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . 0.5 ' HE1' ' HG2' ' A' ' 157' ' ' GLN . 40.6 t90 -69.74 121.64 17.62 Favored 'General case' 0 C--O 1.236 0.375 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 167.802 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.504 ' HG3' ' HG2' ' A' ' 19' ' ' GLN . 9.4 tp10 -92.74 134.35 35.13 Favored 'General case' 0 C--O 1.238 0.486 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 173.11 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -72.25 0.24 10.38 Favored 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 124.171 0.988 . . . . 0.0 113.093 -173.276 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . 0.504 ' HG2' ' HG3' ' A' ' 17' ' ' GLU . 11.6 mm-40 -74.77 47.73 0.34 Allowed 'General case' 0 CA--C 1.557 1.212 0 C-N-CA 124.326 1.05 . . . . 0.0 111.185 175.206 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.431 ' HA ' ' O ' ' A' ' 169' ' ' ALA . . . -73.87 89.29 1.85 Allowed 'General case' 0 C--N 1.352 0.697 0 C-N-CA 123.915 0.886 . . . . 0.0 110.098 -176.644 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -88.19 141.26 28.7 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 114.762 -1.108 . . . . 0.0 109.196 179.638 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 44.4 mm -76.11 102.58 3.11 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.424 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 173.745 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 47.5 m -121.7 -71.85 0.71 Allowed 'General case' 0 CA--C 1.538 0.497 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.502 -167.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.487 ' HA3' HG23 ' A' ' 172' ' ' THR . . . -85.01 133.05 11.49 Favored Glycine 0 C--N 1.353 1.482 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 174.332 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.546 ' HA ' ' HB2' ' A' ' 173' ' ' LYS . 62.2 p -163.62 10.46 0.05 Allowed 'General case' 0 N--CA 1.481 1.085 0 CA-C-N 117.477 0.638 . . . . 0.0 112.106 -178.112 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.422 ' HA ' ' HD3' ' A' ' 27' ' ' PRO . 20.7 p -94.12 145.51 29.91 Favored Pre-proline 0 CA--C 1.55 0.962 0 C-N-CA 123.0 0.52 . . . . 0.0 110.245 179.838 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 26' ' ' SER . 31.5 Cg_endo -89.45 -82.87 0.0 OUTLIER 'Trans proline' 0 C--N 1.379 2.144 0 C-N-CA 123.005 2.47 . . . . 0.0 114.29 -175.461 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.419 ' HA ' ' O ' ' A' ' 176' ' ' LEU . 33.0 mm -101.93 130.68 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 C-N-CA 122.788 0.435 . . . . 0.0 111.173 -169.84 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.702 HD23 HG21 ' A' ' 217' ' ' THR . 0.0 OUTLIER -139.19 161.37 37.58 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 123.613 0.765 . . . . 0.0 110.586 170.96 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 34.2 p -88.59 144.46 26.3 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 123.171 0.588 . . . . 0.0 111.45 -178.318 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.404 HG23 HG22 ' A' ' 179' ' ' THR . 10.4 tt -155.37 152.63 8.72 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.175 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -178.745 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 3.9 m -97.99 109.42 22.18 Favored 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 123.153 0.581 . . . . 0.0 110.794 -173.076 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 18.1 tt -90.6 141.83 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 O-C-N 121.771 -0.581 . . . . 0.0 110.123 178.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 25.1 m -143.79 151.5 40.03 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 123.217 0.607 . . . . 0.0 111.05 -177.061 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 54.61 25.9 6.83 Favored 'General case' 0 N--CA 1.487 1.418 0 C-N-CA 124.338 1.055 . . . . 0.0 112.307 175.114 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.8 t70 73.35 -60.82 0.52 Allowed 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 125.759 1.624 . . . . 0.0 111.378 -173.648 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -89.21 -34.31 8.85 Favored Glycine 0 C--N 1.348 1.234 0 N-CA-C 114.713 0.645 . . . . 0.0 114.713 -173.523 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 24.4 t -87.34 105.11 17.02 Favored 'General case' 0 N--CA 1.484 1.261 0 CA-C-N 117.428 0.614 . . . . 0.0 109.398 -167.629 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . 0.5 ' HE2' ' HB3' ' A' ' 39' ' ' MET . 43.5 ttp -125.41 131.18 52.97 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 122.656 0.382 . . . . 0.0 110.278 -171.412 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 72.4 m -155.76 -178.36 7.24 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 125.179 1.392 . . . . 0.0 109.177 -175.318 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.601 HG12 HG11 ' A' ' 215' ' ' VAL . 44.8 mm -80.62 150.02 4.9 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.821 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 159.512 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 45.4 pttt -67.61 76.24 0.18 Allowed 'General case' 0 CA--C 1.556 1.189 0 CA-C-O 122.172 0.987 . . . . 0.0 109.839 167.128 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 -148.12 -168.03 2.97 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 124.906 1.282 . . . . 0.0 108.813 -178.601 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -134.93 160.26 38.84 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 123.381 0.672 . . . . 0.0 109.439 -179.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.471 0.624 0 C-N-CA 123.788 0.835 . . . . 0.0 109.761 177.288 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 20.9 t70 . . . . . 0 CA--C 1.549 0.907 0 CA-C-O 119.932 -0.08 . . . . 0.0 110.857 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -177.41 -169.01 37.97 Favored Glycine 0 C--N 1.355 1.615 0 N-CA-C 115.198 0.839 . . . . 0.0 115.198 -175.502 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -97.85 122.65 41.21 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 124.479 1.112 . . . . 0.0 110.803 -176.051 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' TYR . . . . . 0.448 ' CD2' ' HB3' ' A' ' 8' ' ' LEU . 3.4 m-85 -117.42 154.8 30.73 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 123.498 0.719 . . . . 0.0 110.613 -175.383 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' ARG . . . . . 0.525 ' HG2' HG21 ' A' ' 195' ' ' THR . 22.1 mtm180 -99.17 127.91 45.22 Favored 'General case' 0 C--O 1.243 0.76 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 166.196 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.446 HG12 HD23 ' A' ' 8' ' ' LEU . 22.4 mt -92.12 129.7 42.35 Favored 'Isoleucine or valine' 0 C--O 1.25 1.13 0 CA-C-O 121.658 0.742 . . . . 0.0 109.346 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -117.37 154.17 31.78 Favored 'General case' 0 C--O 1.216 -0.675 0 CA-C-N 114.302 -1.317 . . . . 0.0 109.666 177.351 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . 0.421 HE22 ' HA ' ' A' ' 3' ' ' ALA . 6.3 tp-100 -85.58 107.17 17.37 Favored 'General case' 0 C--O 1.243 0.719 0 N-CA-C 104.807 -2.294 . . . . 0.0 104.807 163.58 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.4 tttp -88.55 98.17 11.5 Favored 'General case' 0 C--O 1.242 0.679 0 CA-C-N 114.706 -1.134 . . . . 0.0 108.522 -173.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -71.54 131.94 19.83 Favored Glycine 0 N--CA 1.439 -1.141 0 N-CA-C 108.021 -2.032 . . . . 0.0 108.021 161.267 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 33.1 mm -62.57 -12.87 10.03 Favored 'Isoleucine or valine' 0 CA--C 1.566 1.584 0 C-N-CA 123.171 0.588 . . . . 0.0 110.569 -178.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 2.3 pp -111.93 -18.27 12.7 Favored 'General case' 0 CA--C 1.562 1.414 0 C-N-CA 123.974 0.91 . . . . 0.0 112.889 168.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -160.81 127.18 1.72 Allowed Glycine 0 N--CA 1.488 2.132 0 N-CA-C 114.763 0.665 . . . . 0.0 114.763 -172.25 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 9.2 m-85 -84.16 160.37 20.87 Favored 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 123.409 0.684 . . . . 0.0 111.635 -178.682 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 37.9 t -148.42 139.21 22.95 Favored 'General case' 0 C--O 1.207 -1.169 0 C-N-CA 124.616 1.167 . . . . 0.0 108.325 169.696 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . . . . . . . . . 9.5 tt0 -90.68 125.61 35.72 Favored 'General case' 0 N--CA 1.493 1.71 0 CA-C-N 119.461 1.028 . . . . 0.0 109.64 -178.687 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 27.6 pt -124.02 -8.62 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 N-CA-C 112.559 0.578 . . . . 0.0 112.559 -172.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 160.92 -139.39 6.02 Favored Glycine 0 C--N 1.343 0.926 0 C-N-CA 120.903 -0.665 . . . . 0.0 113.05 170.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.476 ' HB2' HG22 ' A' ' 195' ' ' THR . . . -153.19 168.72 25.0 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 123.515 0.726 . . . . 0.0 111.786 -178.159 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -174.51 154.17 18.2 Favored Glycine 0 C--N 1.345 1.071 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.903 177.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 28.1 m -97.85 126.86 50.7 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 CA-C-N 117.607 0.703 . . . . 0.0 110.678 -179.346 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 24.3 t80 -100.76 106.4 17.81 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.489 ' HB3' ' O ' ' A' ' 106' ' ' THR . 14.2 tmtt? -100.87 149.85 23.45 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 -172.144 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -62.31 96.15 0.07 Allowed 'General case' 0 CA--C 1.56 1.348 0 CA-C-O 121.982 0.896 . . . . 0.0 111.713 -178.06 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 104.58 -9.01 48.11 Favored Glycine 0 C--N 1.342 0.882 0 CA-C-N 115.29 -0.868 . . . . 0.0 112.867 177.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . 0.489 ' O ' ' HB3' ' A' ' 103' ' ' LYS . 54.6 m -151.21 124.25 8.7 Favored 'General case' 0 CA--C 1.547 0.854 0 CA-C-N 117.363 0.581 . . . . 0.0 110.314 -175.402 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' PHE . . . . . 0.635 ' HB3' ' HB3' ' A' ' 140' ' ' TYR . 27.4 t80 -96.35 133.66 40.45 Favored 'General case' 0 CA--C 1.545 0.786 0 O-C-N 121.461 -0.774 . . . . 0.0 110.075 176.244 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . 0.449 ' HB3' ' HE3' ' A' ' 144' ' ' TRP . 32.1 m170 -133.34 115.89 15.44 Favored 'General case' 0 N--CA 1.48 1.04 0 C-N-CA 124.113 0.965 . . . . 0.0 110.707 -178.48 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . 0.621 HG23 ' HB ' ' A' ' 138' ' ' ILE . 10.1 t -136.87 -176.39 4.35 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 122.749 0.42 . . . . 0.0 110.736 174.466 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' MET . . . . . 0.627 ' HA ' ' HA ' ' A' ' 137' ' ' LEU . 34.6 mtp -93.78 163.15 13.64 Favored 'General case' 0 C--O 1.24 0.558 0 C-N-CA 123.785 0.834 . . . . 0.0 111.098 169.626 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' TRP . . . . . 0.61 ' HA ' HG13 ' A' ' 138' ' ' ILE . 83.9 t90 -80.23 -38.36 31.19 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 123.523 0.729 . . . . 0.0 111.62 -175.908 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . 0.434 ' CE1' ' SD ' ' A' ' 110' ' ' MET . 1.1 p-80 -64.07 -9.42 16.17 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 125.03 1.332 . . . . 0.0 113.933 -169.162 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 33.9 m -57.36 -36.4 52.62 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.911 0 O-C-N 123.471 0.482 . . . . 0.0 110.278 176.424 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -152.74 -151.6 0.39 Allowed 'General case' 0 CA--C 1.56 1.334 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 175.022 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 55.8 ttt85 -99.4 32.73 2.67 Favored 'General case' 0 CA--C 1.557 1.227 0 C-N-CA 123.64 0.776 . . . . 0.0 110.112 176.251 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.51 ' HA2' HD11 ' A' ' 138' ' ' ILE . . . 85.0 53.29 3.2 Favored Glycine 0 C--N 1.346 1.131 0 N-CA-C 111.848 -0.501 . . . . 0.0 111.848 -176.338 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -94.83 169.43 10.15 Favored 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 123.513 0.725 . . . . 0.0 112.251 -174.034 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.562 HG23 ' HA ' ' A' ' 127' ' ' GLU . 7.1 p -91.69 142.83 12.46 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.073 0 CA-C-N 114.962 -1.017 . . . . 0.0 111.281 -176.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.683 HD13 ' HB2' ' A' ' 6' ' ' LEU . 2.9 mm? -93.48 152.87 18.79 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 124.236 1.015 . . . . 0.0 110.779 -174.517 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' MET . . . . . 0.657 ' HE1' ' HG3' ' A' ' 125' ' ' ARG . 32.5 mmt -110.32 158.2 18.68 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 169.581 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 80.3 t60 -161.95 96.54 1.01 Allowed 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 175.204 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 77.7 tttt 59.23 31.17 20.99 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 123.774 0.83 . . . . 0.0 111.085 176.088 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 101.63 -11.23 57.87 Favored Glycine 0 C--N 1.355 1.587 0 CA-C-N 115.945 -0.571 . . . . 0.0 113.553 -179.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 49.9 tttm -90.2 127.23 36.07 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 123.122 0.569 . . . . 0.0 109.612 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . 0.657 ' HG3' ' HE1' ' A' ' 120' ' ' MET . 28.2 ttm-85 -89.66 101.25 13.94 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 123.444 0.698 . . . . 0.0 109.518 179.0 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 68.7 mt -85.2 99.92 7.81 Favored 'Isoleucine or valine' 0 C--O 1.239 0.542 0 C-N-CA 123.837 0.855 . . . . 0.0 109.949 178.646 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . 0.562 ' HA ' HG23 ' A' ' 118' ' ' VAL . 0.3 OUTLIER -74.1 149.91 87.54 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.177 174.979 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_endo -79.59 152.95 23.18 Favored 'Trans proline' 0 C--N 1.366 1.499 0 C-N-CA 122.115 1.877 . . . . 0.0 111.8 167.587 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 95.3 p -89.36 -26.8 20.87 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 122.874 0.47 . . . . 0.0 110.131 171.744 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 74.7 t-105 -165.88 156.12 12.78 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 123.497 0.719 . . . . 0.0 109.665 179.344 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . 0.428 ' HB1' ' HD1' ' A' ' 111' ' ' TRP . . . -133.95 118.62 18.08 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.574 0.75 . . . . 0.0 109.024 172.664 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 22.5 t0 -90.09 104.41 16.98 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 124.288 1.035 . . . . 0.0 108.269 175.318 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 45.7 t -75.79 -26.79 18.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 122.929 0.492 . . . . 0.0 111.08 -176.428 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 26.6 mtpp -73.14 -51.47 17.79 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.351 0.661 . . . . 0.0 111.358 -175.158 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 42.8 mtpt -85.73 -4.14 59.08 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 115.45 -0.795 . . . . 0.0 111.554 -179.255 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 37.0 t0 65.22 56.77 0.98 Allowed 'General case' 0 CA--C 1.552 1.025 0 O-C-N 124.554 1.159 . . . . 0.0 109.621 175.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.627 ' HA ' ' HA ' ' A' ' 110' ' ' MET . 62.6 mt -143.49 137.58 28.62 Favored 'General case' 0 N--CA 1.478 0.958 0 O-C-N 121.482 -0.762 . . . . 0.0 110.329 -177.701 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.621 ' HB ' HG23 ' A' ' 109' ' ' THR . 84.8 mt -111.99 149.44 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.376 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 169.305 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . 0.421 ' HB2' ' O ' ' A' ' 142' ' ' GLY . 33.5 p -145.44 148.44 33.3 Favored 'General case' 0 C--O 1.241 0.65 0 C-N-CA 123.374 0.67 . . . . 0.0 110.519 -172.545 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.635 ' HB3' ' HB3' ' A' ' 107' ' ' PHE . 37.5 t80 -144.27 120.01 10.51 Favored 'General case' 0 N--CA 1.466 0.333 0 C-N-CA 124.662 1.185 . . . . 0.0 108.705 178.004 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 86.25 3.69 84.51 Favored Glycine 0 C--N 1.345 1.054 0 O-C-N 123.572 0.545 . . . . 0.0 112.725 -178.003 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . 0.421 ' O ' ' HB2' ' A' ' 139' ' ' SER . . . 147.28 148.82 4.83 Favored Glycine 0 C--N 1.344 0.995 0 N-CA-C 110.386 -1.085 . . . . 0.0 110.386 -177.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -67.83 169.71 37.88 Favored Glycine 0 C--N 1.348 1.234 0 C-N-CA 123.126 0.393 . . . . 0.0 112.608 -179.562 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' TRP . . . . . 0.644 ' HZ2' ' HA2' ' A' ' 209' ' ' GLY . 57.1 t-105 -58.43 105.54 0.3 Allowed 'General case' 0 CA--C 1.555 1.135 0 CA-C-O 121.209 0.528 . . . . 0.0 110.977 -177.517 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . 0.643 ' HA ' ' HB ' ' A' ' 229' ' ' THR . 50.1 tttm -163.82 126.97 2.59 Favored 'General case' 0 CA--C 1.54 0.562 0 CA-C-N 115.04 -0.982 . . . . 0.0 109.433 176.513 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' LEU . . . . . 0.444 ' H ' ' HB ' ' A' ' 229' ' ' THR . 79.5 mt -141.8 -2.74 1.17 Allowed 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 125.744 1.618 . . . . 0.0 110.219 179.727 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 29.2 tt0 86.69 18.53 0.09 Allowed 'General case' 0 N--CA 1.5 2.043 0 C-N-CA 125.355 1.462 . . . . 0.0 110.848 171.197 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . 0.577 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -85.15 117.72 4.59 Favored Glycine 0 N--CA 1.434 -1.489 0 CA-C-N 115.376 -0.829 . . . . 0.0 113.466 173.578 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -116.04 95.12 4.95 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 124.06 0.944 . . . . 0.0 110.175 -175.311 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' TRP . . . . . 0.608 ' HZ2' ' HG3' ' A' ' 174' ' ' PRO . 35.8 t90 -82.86 146.97 28.6 Favored 'General case' 0 CA--C 1.553 1.095 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.27 168.313 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.414 ' HB3' ' HG2' ' A' ' 154' ' ' GLU . 22.5 tptp -112.67 128.79 56.49 Favored 'General case' 0 N--CA 1.476 0.841 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 177.095 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -63.13 99.69 0.19 Allowed 'General case' 0 N--CA 1.483 1.221 0 C-N-CA 123.494 0.718 . . . . 0.0 111.059 -179.214 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 143.54 -23.25 2.18 Favored Glycine 0 C--N 1.341 0.851 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.345 -177.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . 0.414 ' HG2' ' HB3' ' A' ' 151' ' ' LYS . 32.7 mm-40 -75.91 133.58 40.48 Favored 'General case' 0 C--O 1.24 0.581 0 C-N-CA 123.324 0.65 . . . . 0.0 111.604 -179.452 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . 0.536 ' HG2' ' HG2' ' A' ' 173' ' ' LYS . 35.8 mt-10 -74.84 101.62 4.44 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 174.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 9.7 p -114.72 145.83 19.99 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 123.257 0.623 . . . . 0.0 109.577 -168.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . 0.5 ' HG2' ' HE1' ' A' ' 16' ' ' TRP . 1.8 mp0 -93.34 141.19 28.72 Favored 'General case' 0 C--O 1.217 -0.641 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 -172.541 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.465 ' O ' ' HA ' ' A' ' 169' ' ' ALA . 46.9 t -101.2 116.11 44.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 177.019 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -72.08 86.37 1.04 Allowed 'General case' 0 CA--C 1.548 0.869 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 176.647 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -88.44 139.13 30.8 Favored 'General case' 0 C--O 1.249 1.044 0 CA-C-N 114.181 -1.372 . . . . 0.0 110.738 -174.453 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 35.2 mt -112.7 84.29 1.96 Allowed 'General case' 0 C--O 1.245 0.854 0 C-N-CA 124.718 1.207 . . . . 0.0 108.936 -178.891 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . 0.675 ' HB2' ' HB2' ' A' ' 165' ' ' LYS . 44.2 mt-10 -75.98 143.48 74.21 Favored Pre-proline 0 CA--C 1.547 0.855 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 176.183 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -70.35 114.12 3.69 Favored 'Trans proline' 0 C--N 1.374 1.897 0 C-N-CA 122.209 1.939 . . . . 0.0 110.591 -177.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 90.85 -11.24 72.54 Favored Glycine 0 C--N 1.34 0.76 0 CA-C-N 115.954 -0.566 . . . . 0.0 113.42 179.022 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . 0.675 ' HB2' ' HB2' ' A' ' 162' ' ' GLU . 47.5 mmtm -104.53 147.83 27.17 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 176.096 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -58.85 149.5 64.42 Favored Pre-proline 0 CA--C 1.554 1.111 0 O-C-N 123.553 0.533 . . . . 0.0 111.832 179.399 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo -56.56 118.09 4.87 Favored 'Trans proline' 0 C--N 1.376 1.994 0 C-N-CA 122.497 2.131 . . . . 0.0 110.348 171.442 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 16.0 ptt180 -135.25 134.09 39.64 Favored 'General case' 0 N--CA 1.47 0.556 0 CA-C-O 120.825 0.345 . . . . 0.0 110.202 -176.606 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . 0.487 ' H ' ' HB3' ' A' ' 17' ' ' GLU . . . -97.75 105.24 17.35 Favored 'General case' 0 C--O 1.225 -0.219 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.557 -177.691 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 27.7 m -97.64 133.63 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.234 0 C-N-CA 123.663 0.785 . . . . 0.0 110.125 -174.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 171' ' ' GLN . . . . . 0.42 ' HA ' ' HA ' ' A' ' 157' ' ' GLN . 37.3 tt0 -77.75 128.41 33.99 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-O 121.656 0.741 . . . . 0.0 110.328 -171.593 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . 0.583 HG21 HG13 ' A' ' 187' ' ' VAL . 68.7 m -128.08 123.3 34.21 Favored 'General case' 0 C--O 1.246 0.908 0 CA-C-N 113.842 -1.526 . . . . 0.0 109.448 -175.205 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . 0.546 ' HB2' ' HA ' ' A' ' 25' ' ' SER . 27.5 mtpp -76.15 141.61 70.95 Favored Pre-proline 0 CA--C 1.544 0.743 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 168.808 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 174' ' ' PRO . . . . . 0.608 ' HG3' ' HZ2' ' A' ' 150' ' ' TRP . 39.4 Cg_exo -55.37 122.95 12.64 Favored 'Trans proline' 0 C--N 1.371 1.74 0 C-N-CA 122.511 2.14 . . . . 0.0 113.66 -171.481 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . 0.484 ' H ' ' C ' ' A' ' 186' ' ' ALA . . . -117.26 127.33 7.34 Favored Glycine 0 N--CA 1.482 1.723 0 CA-C-O 121.606 0.559 . . . . 0.0 113.594 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.459 HD23 ' N ' ' A' ' 176' ' ' LEU . 0.4 OUTLIER -132.01 127.97 37.35 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 121.914 0.864 . . . . 0.0 109.52 -169.031 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 177' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -102.58 138.94 38.83 Favored 'General case' 0 C--O 1.245 0.86 0 CA-C-N 114.069 -1.423 . . . . 0.0 110.494 -169.505 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 58.5 tptt -86.0 124.89 32.95 Favored 'General case' 0 C--O 1.243 0.716 0 C-N-CA 124.585 1.154 . . . . 0.0 109.953 -178.552 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . 0.404 HG22 HG23 ' A' ' 31' ' ' ILE . 68.9 p -120.53 175.86 5.78 Favored 'General case' 0 C--O 1.242 0.697 0 C-N-CA 123.31 0.644 . . . . 0.0 109.612 169.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 -68.07 -21.37 64.98 Favored 'General case' 0 CA--C 1.546 0.806 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.206 172.694 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -78.65 -53.04 7.58 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 123.724 0.81 . . . . 0.0 110.301 176.011 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 177.48 176.97 45.98 Favored Glycine 0 C--N 1.344 0.999 0 CA-C-N 115.623 -0.717 . . . . 0.0 112.331 -178.742 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 15.5 m -93.91 104.32 16.38 Favored 'General case' 0 CA--C 1.542 0.663 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 176.421 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . 0.483 HD13 ' H ' ' A' ' 184' ' ' ILE . 0.2 OUTLIER -123.63 161.09 26.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 C-N-CA 123.455 0.702 . . . . 0.0 109.732 -174.122 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . 113.48 178.41 19.37 Favored Glycine 0 N--CA 1.47 0.912 0 CA-C-O 119.802 -0.443 . . . . 0.0 113.074 176.401 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.484 ' C ' ' H ' ' A' ' 175' ' ' GLY . . . -173.22 38.12 0.01 OUTLIER 'General case' 0 C--N 1.364 1.222 0 C-N-CA 123.75 0.82 . . . . 0.0 110.967 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 187' ' ' VAL . . . . . 0.583 HG13 HG21 ' A' ' 172' ' ' THR . 58.5 t -155.1 117.51 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 C-N-CA 125.146 1.378 . . . . 0.0 107.48 171.539 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 188' ' ' SER . . . . . 0.546 ' HA ' HG12 ' A' ' 223' ' ' VAL . 68.4 m -129.83 86.2 2.38 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-O 121.877 0.846 . . . . 0.0 108.747 170.531 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 32.4 tp -106.38 103.77 13.31 Favored 'General case' 0 CA--C 1.543 0.687 0 CA-C-N 113.907 -1.497 . . . . 0.0 110.231 -173.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 190' ' ' ASP . . . . . 0.711 ' HA ' ' HA ' ' A' ' 221' ' ' ALA . 11.0 p-10 -90.52 102.04 14.78 Favored 'General case' 0 N--CA 1.478 0.934 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 175.348 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 191' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 179.41 -174.88 0.23 Allowed 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 125.981 1.713 . . . . 0.0 108.254 -174.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 9.5 m -51.19 119.89 13.25 Favored Pre-proline 0 CA--C 1.551 0.994 0 O-C-N 123.872 0.733 . . . . 0.0 109.801 172.627 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_exo -48.01 132.61 22.73 Favored 'Trans proline' 0 C--N 1.379 2.138 0 C-N-CA 123.471 2.781 . . . . 0.0 114.226 -171.024 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -67.0 167.18 39.37 Favored Glycine 0 C--N 1.348 1.232 0 CA-C-N 115.633 -0.712 . . . . 0.0 112.085 175.069 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 195' ' ' THR . . . . . 0.525 HG21 ' HG2' ' A' ' 85' ' ' ARG . 1.4 m -89.99 103.77 16.41 Favored 'General case' 0 CA--C 1.54 0.559 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -173.617 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 43.6 t -51.72 85.08 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.09 0 C-N-CA 125.285 1.434 . . . . 0.0 113.389 -170.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 126.03 16.01 2.74 Favored Glycine 0 C--N 1.355 1.586 0 CA-C-N 115.253 -0.885 . . . . 0.0 113.083 179.123 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 84.2 p -82.81 155.86 67.87 Favored Pre-proline 0 N--CA 1.483 1.21 0 CA-C-N 117.477 0.638 . . . . 0.0 110.156 178.082 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -74.15 142.64 31.02 Favored 'Trans proline' 0 C--N 1.386 2.535 0 C-N-CA 122.308 2.006 . . . . 0.0 113.157 -178.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 62.6 mt -108.59 113.57 44.37 Favored 'Isoleucine or valine' 0 C--O 1.255 1.36 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 175.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 201' ' ' ILE . . . . . 0.607 HG12 ' HA ' ' A' ' 208' ' ' VAL . 14.3 mt -117.24 134.95 59.19 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.085 0 CA-C-N 114.822 -1.081 . . . . 0.0 110.799 -167.445 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -68.37 162.82 24.5 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 125.06 1.344 . . . . 0.0 110.704 174.454 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 63.2 tttm -67.45 -15.54 63.73 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 124.6 1.16 . . . . 0.0 112.061 -173.049 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 21.6 ptmt -94.15 4.01 54.48 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 123.232 0.613 . . . . 0.0 112.147 177.387 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 80.41 38.87 16.39 Favored Glycine 0 C--N 1.351 1.393 0 C-N-CA 122.9 0.286 . . . . 0.0 112.856 -178.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 58.0 tttp -128.78 167.1 17.78 Favored 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 124.272 1.029 . . . . 0.0 109.758 -174.341 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 207' ' ' VAL . . . . . 0.577 ' O ' ' HA3' ' A' ' 148' ' ' GLY . 89.5 t 95.64 -74.91 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.146 0 C-N-CA 125.719 1.608 . . . . 0.0 110.157 171.079 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 208' ' ' VAL . . . . . 0.607 ' HA ' HG12 ' A' ' 201' ' ' ILE . 3.2 m 63.1 22.37 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 CA-C-O 122.484 1.135 . . . . 0.0 109.787 166.414 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.644 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . -83.08 128.85 8.72 Favored Glycine 0 C--N 1.347 1.18 0 CA-C-N 113.376 -1.738 . . . . 0.0 109.353 -172.456 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 87.4 mt -65.65 173.28 2.87 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-N 117.908 0.854 . . . . 0.0 111.287 -165.47 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 211' ' ' TYR . . . . . 0.457 ' CZ ' HG11 ' A' ' 158' ' ' VAL . 6.3 m-85 -56.56 157.78 4.97 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.824 163.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 212' ' ' GLY . . . . . 0.612 ' HA3' ' HB3' ' A' ' 225' ' ' ALA . . . -105.87 -141.18 10.38 Favored Glycine 0 C--O 1.24 0.492 0 N-CA-C 111.264 -0.735 . . . . 0.0 111.264 173.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 213' ' ' ASN . . . . . . . . . . . . . 23.5 p-10 -100.13 130.47 46.27 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 -176.327 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . -176.45 -135.96 2.27 Favored Glycine 0 C--N 1.337 0.617 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.962 176.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 215' ' ' VAL . . . . . 0.601 HG11 HG12 ' A' ' 41' ' ' ILE . 7.4 p 176.06 162.85 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 C-N-CA 125.415 1.486 . . . . 0.0 107.936 -171.485 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 216' ' ' VAL . . . . . 0.661 ' HA ' ' HA ' ' A' ' 222' ' ' TYR . 7.8 p -75.07 110.27 9.5 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.498 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 161.167 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 217' ' ' THR . . . . . 0.702 HG21 HD23 ' A' ' 29' ' ' LEU . 53.2 m -87.69 141.82 28.31 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.992 0.917 . . . . 0.0 110.19 -178.448 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 218' ' ' ARG . . . . . 0.46 ' HG3' HG22 ' A' ' 217' ' ' THR . 57.3 mtp180 62.71 8.6 3.09 Favored 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 124.093 0.957 . . . . 0.0 111.574 -175.047 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 68.0 m 62.75 26.31 15.55 Favored 'General case' 0 C--N 1.359 1.006 0 C-N-CA 124.734 1.214 . . . . 0.0 112.077 -176.224 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . -153.88 -19.4 0.05 OUTLIER Glycine 0 C--N 1.349 1.277 0 CA-C-N 116.637 -0.256 . . . . 0.0 113.653 179.29 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 221' ' ' ALA . . . . . 0.711 ' HA ' ' HA ' ' A' ' 190' ' ' ASP . . . -113.87 89.65 3.14 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 123.333 0.653 . . . . 0.0 109.757 -175.576 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 222' ' ' TYR . . . . . 0.661 ' HA ' ' HA ' ' A' ' 216' ' ' VAL . 50.2 t80 -69.15 118.2 11.75 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 123.149 0.58 . . . . 0.0 110.453 -177.45 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . 0.546 HG12 ' HA ' ' A' ' 188' ' ' SER . 21.5 m -123.05 145.43 29.95 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.731 0 C-N-CA 123.507 0.723 . . . . 0.0 110.687 -179.039 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 70.2 m -158.7 159.78 35.67 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 124.915 1.286 . . . . 0.0 108.757 178.483 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . 0.612 ' HB3' ' HA3' ' A' ' 212' ' ' GLY . . . -76.64 -169.06 1.14 Allowed 'General case' 0 N--CA 1.482 1.147 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 167.239 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 226' ' ' ILE . . . . . . . . . . . . . 54.9 mt -127.83 106.34 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.12 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 174.5 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -85.14 92.03 8.28 Favored 'General case' 0 C--O 1.239 0.551 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 177.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 20.1 pt20 -92.31 158.88 15.87 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-N 115.248 -0.887 . . . . 0.0 108.813 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . 0.643 ' HB ' ' HA ' ' A' ' 145' ' ' LYS . 30.5 p -69.12 107.44 3.19 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-O 121.589 0.709 . . . . 0.0 110.738 -161.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -168.75 79.59 0.14 Allowed 'General case' 0 N--CA 1.451 -0.401 0 N-CA-C 106.366 -1.716 . . . . 0.0 106.366 -171.801 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 231' ' ' LYS . . . . . 0.413 ' HD3' ' H ' ' A' ' 144' ' ' TRP . 59.1 tttp -145.85 -78.82 0.18 Allowed 'General case' 0 N--CA 1.48 1.07 0 CA-C-N 115.912 -0.585 . . . . 0.0 112.297 167.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 68.0 p . . . . . 0 N--CA 1.485 1.312 0 CA-C-N 118.884 0.765 . . . . 0.0 112.036 -174.098 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.429 ' HB3' ' NE2' ' A' ' 88' ' ' GLN . . . . . . . . 0 N--CA 1.473 0.724 0 CA-C-O 120.98 0.419 . . . . 0.0 110.674 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.58 41.11 1.06 Allowed 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 124.186 0.994 . . . . 0.0 109.798 -171.415 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . 0.489 ' HA ' ' HG2' ' A' ' 120' ' ' MET . 7.1 m-20 -153.86 52.53 0.7 Allowed 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 -163.168 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.633 ' HB2' ' HG ' ' A' ' 119' ' ' LEU . 7.9 mt -95.18 89.36 5.49 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 177.113 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.707 ' HB3' ' HD2' ' A' ' 89' ' ' LYS . 11.8 pt-20 -78.7 147.26 33.55 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-O 121.446 0.641 . . . . 0.0 111.771 -173.63 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 41.9 mt -98.02 113.71 25.65 Favored 'General case' 0 C--O 1.238 0.489 0 CA-C-N 114.281 -1.327 . . . . 0.0 108.9 179.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -109.47 144.56 37.56 Favored 'General case' 0 N--CA 1.482 1.132 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 171.383 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 18.0 ttm-85 -69.24 129.09 38.85 Favored 'General case' 0 C--O 1.24 0.604 0 CA-C-O 121.169 0.509 . . . . 0.0 111.476 -173.09 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.593 ' HB2' ' HB2' ' A' ' 85' ' ' ARG . . . -103.21 -37.62 7.62 Favored 'General case' 0 C--O 1.239 0.531 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.13 178.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . 0.428 ' HB3' ' HB3' ' A' ' 83' ' ' ALA . . . -165.87 170.3 13.96 Favored 'General case' 0 N--CA 1.474 0.733 0 CA-C-O 121.595 0.712 . . . . 0.0 111.456 -176.523 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -111.55 145.94 38.21 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 171.074 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 59.7 t -74.26 97.75 1.09 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.919 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 -179.29 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 24.1 ttmm -175.13 111.66 0.13 Allowed 'General case' 0 C--O 1.239 0.507 0 C-N-CA 125.615 1.566 . . . . 0.0 107.271 178.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . 0.513 ' HE1' ' HB1' ' A' ' 169' ' ' ALA . 34.7 t90 -93.5 95.01 8.99 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 122.086 0.155 . . . . 0.0 111.07 -178.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -159.68 64.36 0.37 Allowed 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 148.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -89.61 -62.06 1.56 Allowed 'General case' 0 N--CA 1.481 1.111 0 CA-C-O 121.242 0.544 . . . . 0.0 112.192 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . 0.494 ' H ' ' HB3' ' A' ' 169' ' ' ALA . 23.0 mt-30 -150.88 47.74 0.86 Allowed 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 124.203 1.001 . . . . 0.0 109.606 -168.575 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -48.77 95.42 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 113.556 0.947 . . . . 0.0 113.556 -172.368 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -136.48 164.5 28.01 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 125.631 1.572 . . . . 0.0 108.864 -177.532 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.606 HG22 ' HB2' ' A' ' 171' ' ' GLN . 0.2 OUTLIER -122.57 140.3 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.242 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 177.464 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 63.1 m -139.84 -57.82 0.56 Allowed 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -68.93 118.67 9.04 Favored Glycine 0 C--N 1.349 1.28 0 N-CA-C 114.469 0.547 . . . . 0.0 114.469 -168.628 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 68.0 m -164.31 24.32 0.07 Allowed 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 124.864 1.266 . . . . 0.0 109.572 -173.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.629 ' HB2' ' HB2' ' A' ' 188' ' ' SER . 18.4 m -73.88 161.53 78.19 Favored Pre-proline 0 CA--C 1.555 1.163 0 C-N-CA 123.323 0.649 . . . . 0.0 110.701 -177.549 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_exo -71.77 -173.68 1.09 Allowed 'Trans proline' 0 C--N 1.378 2.1 0 C-N-CA 122.471 2.114 . . . . 0.0 112.874 174.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.55 HD12 ' HB2' ' A' ' 176' ' ' LEU . 27.3 mm -76.14 140.91 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.461 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.406 ' HB3' HG21 ' A' ' 217' ' ' THR . 14.0 mt -131.07 132.24 44.76 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 122.796 0.438 . . . . 0.0 111.605 -168.734 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 178' ' ' LYS . 49.3 m -69.97 135.15 49.1 Favored 'General case' 0 C--N 1.35 0.62 0 O-C-N 124.098 0.874 . . . . 0.0 111.096 179.493 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 19.6 tt -142.62 141.26 27.79 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.744 0 C-N-CA 123.829 0.852 . . . . 0.0 109.205 -177.655 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 56.0 p -99.42 109.6 22.16 Favored 'General case' 0 CA--C 1.555 1.154 0 C-N-CA 123.24 0.616 . . . . 0.0 110.168 -176.546 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 1.5 mp -80.75 120.31 32.1 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 C-N-CA 123.687 0.795 . . . . 0.0 109.038 176.33 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 26.0 m -97.71 122.78 41.19 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 124.254 1.022 . . . . 0.0 110.094 -178.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 67.57 12.4 8.86 Favored 'General case' 0 N--CA 1.493 1.677 0 C-N-CA 124.358 1.063 . . . . 0.0 112.383 171.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 61.73 24.86 14.88 Favored 'General case' 0 N--CA 1.491 1.618 0 C-N-CA 124.436 1.094 . . . . 0.0 112.113 -177.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -143.03 -42.97 0.05 OUTLIER Glycine 0 C--N 1.338 0.683 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 -178.712 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 39.4 t -93.66 162.93 13.75 Favored 'General case' 0 C--O 1.241 0.609 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 175.092 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 20.9 ptm -161.73 134.77 6.18 Favored 'General case' 0 C--O 1.241 0.609 0 C-N-CA 122.829 0.452 . . . . 0.0 110.065 -175.694 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 28.5 p -173.26 -179.07 1.86 Allowed 'General case' 0 C--O 1.221 -0.43 0 C-N-CA 123.786 0.835 . . . . 0.0 109.422 179.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.755 HD11 HG23 ' A' ' 217' ' ' THR . 28.3 mm -72.12 151.03 8.46 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.971 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 165.593 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 15.3 ptmt -42.62 140.0 1.41 Allowed 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 124.968 1.307 . . . . 0.0 112.104 171.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 65.07 85.57 0.14 Allowed 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 124.999 1.319 . . . . 0.0 108.952 -160.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -86.18 26.91 0.97 Allowed 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 123.86 0.864 . . . . 0.0 113.125 -169.156 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 . . . . . 0 N--CA 1.48 1.07 0 C-N-CA 123.671 0.788 . . . . 0.0 110.772 172.461 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 . . . . . 0 N--CA 1.476 0.873 0 CA-C-O 121.548 0.689 . . . . 0.0 110.923 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -129.23 137.97 9.94 Favored Glycine 0 C--N 1.338 0.66 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 174.835 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . 0.428 ' HB3' ' HB3' ' A' ' 12' ' ' ALA . . . -89.21 120.64 30.76 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 178.544 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 47.6 m-85 -112.55 171.47 7.5 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-O 121.603 0.716 . . . . 0.0 111.127 -176.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' ARG . . . . . 0.593 ' HB2' ' HB2' ' A' ' 11' ' ' ALA . 44.4 ttm105 -131.77 122.83 26.48 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 -177.104 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.465 ' H ' ' HA ' ' A' ' 99' ' ' ALA . 24.5 mt -83.29 133.18 29.67 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 -175.856 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.597 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 76.8 tttt -137.88 131.18 30.61 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 114.743 -1.117 . . . . 0.0 108.405 -170.205 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . 0.429 ' NE2' ' HB3' ' A' ' 3' ' ' ALA . 0.0 OUTLIER -82.55 130.11 35.05 Favored 'General case' 0 C--O 1.245 0.822 0 N-CA-C 106.753 -1.573 . . . . 0.0 106.753 176.315 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . 0.707 ' HD2' ' HB3' ' A' ' 7' ' ' GLU . 48.3 tttp -123.11 135.72 54.49 Favored 'General case' 0 CA--C 1.549 0.914 0 CA-C-N 114.573 -1.194 . . . . 0.0 112.264 -162.024 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . 0.55 ' O ' ' HG2' ' A' ' 89' ' ' LYS . . . -91.83 162.11 27.43 Favored Glycine 0 C--O 1.207 -1.569 0 N-CA-C 106.464 -2.654 . . . . 0.0 106.464 149.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 31.1 mm -54.99 -18.74 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.195 0 CA-C-N 121.333 2.566 . . . . 0.0 114.47 -167.444 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 66.5 mt -86.1 -38.21 18.02 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.385 -0.822 . . . . 0.0 110.464 167.524 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.444 ' HA2' ' HG3' ' A' ' 89' ' ' LYS . . . 145.29 -167.63 27.36 Favored Glycine 0 N--CA 1.477 1.399 0 CA-C-O 118.348 -1.251 . . . . 0.0 110.381 176.608 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . 0.583 ' H ' ' HE2' ' A' ' 87' ' ' LYS 0.285 3.0 p90 178.68 -79.51 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.728 0 C-N-CA 123.838 0.855 . . . . 0.0 112.276 146.488 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 93.6 p -117.45 135.07 54.16 Favored 'General case' 0 N--CA 1.504 2.246 0 CA-C-N 120.384 1.447 . . . . 0.0 112.444 -161.328 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.597 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 5.1 pp0? -81.58 148.48 29.09 Favored 'General case' 0 N--CA 1.485 1.317 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 177.109 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 26.0 pt -133.18 -28.6 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 C-N-CA 123.354 0.662 . . . . 0.0 112.037 -171.758 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -167.41 -155.38 9.15 Favored Glycine 0 C--N 1.344 1.012 0 CA-C-O 119.803 -0.443 . . . . 0.0 112.237 -176.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.545 ' HA ' ' HA ' ' A' ' 85' ' ' ARG . . . -154.96 171.97 18.85 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 123.544 0.738 . . . . 0.0 110.507 -178.24 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -178.92 151.42 10.3 Favored Glycine 0 C--N 1.347 1.151 0 O-C-N 123.135 0.272 . . . . 0.0 112.594 179.487 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.446 HG12 HD11 ' A' ' 210' ' ' LEU . 14.9 p -89.15 138.17 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 122.93 0.492 . . . . 0.0 109.908 179.671 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -118.28 138.63 52.24 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 170.43 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -135.14 105.9 6.53 Favored 'General case' 0 C--O 1.238 0.472 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 176.395 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 29.3 mt-10 63.39 -87.14 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.167 0 C-N-CA 125.031 1.332 . . . . 0.0 112.251 171.516 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -126.11 11.05 7.33 Favored Glycine 0 C--N 1.349 1.27 0 CA-C-O 120.163 -0.243 . . . . 0.0 113.025 -176.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 15.2 t -132.89 131.36 40.85 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 122.96 0.504 . . . . 0.0 110.094 -177.317 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 30.9 t80 -115.49 131.56 56.89 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 123.258 0.623 . . . . 0.0 109.805 -175.322 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 80.7 m-70 -135.15 123.5 23.22 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 123.058 0.543 . . . . 0.0 110.56 -177.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . 0.682 HG23 HG23 ' A' ' 138' ' ' ILE . 1.9 t -139.35 175.24 9.73 Favored 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 123.245 0.618 . . . . 0.0 111.911 -179.324 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' MET . . . . . . . . . . . . . 8.0 mmt -75.07 150.1 38.97 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 124.36 1.064 . . . . 0.0 109.561 172.212 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' TRP . . . . . 0.413 ' HA ' HG22 ' A' ' 138' ' ' ILE . 76.0 t90 -78.89 -43.98 23.75 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 123.071 0.549 . . . . 0.0 111.854 -169.282 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -65.76 -6.58 12.17 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 114.312 1.227 . . . . 0.0 114.312 -172.273 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 19.7 m -60.35 -40.4 83.85 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 176.455 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 90.0 m -164.5 140.0 5.82 Favored 'General case' 0 CA--C 1.551 1.017 0 C-N-CA 126.287 1.835 . . . . 0.0 107.396 171.299 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 32.8 mtt180 -80.85 33.08 0.32 Allowed 'General case' 0 N--CA 1.485 1.305 0 N-CA-C 114.152 1.167 . . . . 0.0 114.152 -166.45 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 107.27 62.15 0.57 Allowed Glycine 0 C--N 1.346 1.091 0 O-C-N 122.085 -0.384 . . . . 0.0 112.656 178.225 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -122.78 168.23 12.5 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 123.441 0.696 . . . . 0.0 110.064 174.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 87.9 t -75.44 144.43 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.802 0 C-N-CA 123.99 0.916 . . . . 0.0 110.96 -177.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.735 ' HB2' ' HB ' ' A' ' 126' ' ' ILE . 5.2 mp -111.16 161.17 16.23 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 123.077 0.551 . . . . 0.0 111.831 178.853 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' MET . . . . . 0.489 ' HG2' ' HA ' ' A' ' 5' ' ' ASP . 19.6 mmt -110.7 106.99 16.4 Favored 'General case' 0 C--O 1.241 0.619 0 CA-C-O 121.935 0.874 . . . . 0.0 110.1 179.191 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.558 ' HB2' HD11 ' A' ' 126' ' ' ILE . 13.9 t60 -104.13 95.07 5.73 Favored 'General case' 0 CA--C 1.542 0.663 0 N-CA-C 107.929 -1.137 . . . . 0.0 107.929 169.17 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 65.5 tttp 44.43 65.31 1.08 Allowed 'General case' 0 CA--C 1.554 1.115 0 C-N-CA 124.893 1.277 . . . . 0.0 112.76 176.109 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 80.73 -27.29 2.98 Favored Glycine 0 CA--C 1.531 1.076 0 CA-C-N 115.047 -0.979 . . . . 0.0 113.881 -179.576 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 94.7 mttt -85.36 154.34 21.94 Favored 'General case' 0 C--N 1.35 0.598 0 CA-C-N 117.395 0.598 . . . . 0.0 109.476 179.124 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 33.8 ptt85 -92.22 160.34 15.21 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-O 121.008 0.432 . . . . 0.0 110.367 178.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.735 ' HB ' ' HB2' ' A' ' 119' ' ' LEU . 80.8 mt -128.52 111.46 23.75 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 171.709 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -93.81 108.66 36.32 Favored Pre-proline 0 CA--C 1.546 0.818 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 178.7 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -56.7 103.65 0.13 Allowed 'Trans proline' 0 C--N 1.377 2.072 0 C-N-CA 122.884 2.389 . . . . 0.0 112.193 -178.42 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 86.5 p -74.9 -17.23 60.61 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 123.173 0.589 . . . . 0.0 111.277 -177.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 30.4 t-105 -143.26 149.92 38.55 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 -178.663 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -166.59 120.41 1.07 Allowed 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 122.98 0.512 . . . . 0.0 110.72 176.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -120.99 120.83 36.56 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.077 0.951 . . . . 0.0 109.265 171.643 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.493 HG13 ' HG3' ' A' ' 134' ' ' LYS . 4.6 p -69.05 -38.97 79.02 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 CA-C-N 114.657 -1.156 . . . . 0.0 111.844 -178.473 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.493 ' HG3' HG13 ' A' ' 133' ' ' VAL . 97.1 mttt -82.52 -27.95 31.39 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 123.307 0.643 . . . . 0.0 112.218 -173.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . 0.508 ' HB3' HD12 ' A' ' 137' ' ' LEU . 33.5 mmtp -71.83 -27.74 63.1 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 167.661 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . 0.497 ' HB3' HD22 ' A' ' 213' ' ' ASN . 8.9 t70 56.64 58.61 4.03 Favored 'General case' 0 CA--C 1.538 0.494 0 O-C-N 125.27 1.606 . . . . 0.0 109.37 -167.878 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.508 HD12 ' HB3' ' A' ' 135' ' ' LYS . 6.6 mt -144.1 121.98 12.0 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 113.6 -1.637 . . . . 0.0 109.223 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.682 HG23 HG23 ' A' ' 109' ' ' THR . 9.2 tt -121.85 133.32 68.6 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 174.16 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 73.4 m -146.6 165.51 29.29 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-O 122.138 0.97 . . . . 0.0 112.575 -169.798 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 46.4 t80 -133.44 128.69 36.02 Favored 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 125.778 1.631 . . . . 0.0 107.764 175.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 102.29 -4.01 51.3 Favored Glycine 0 C--N 1.345 1.029 0 O-C-N 123.671 0.607 . . . . 0.0 112.324 -175.363 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 147.17 -165.58 28.58 Favored Glycine 0 C--N 1.349 1.272 0 N-CA-C 111.392 -0.683 . . . . 0.0 111.392 179.324 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -77.95 -173.64 41.34 Favored Glycine 0 C--N 1.353 1.501 0 CA-C-O 118.98 -0.9 . . . . 0.0 111.059 172.42 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' TRP . . . . . 0.529 ' HZ2' ' HA2' ' A' ' 209' ' ' GLY . 5.1 t-105 -55.0 108.01 0.36 Allowed 'General case' 0 N--CA 1.477 0.909 0 CA-C-N 118.267 1.033 . . . . 0.0 109.986 176.856 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 30.7 tptt -144.5 133.35 22.49 Favored 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 113.725 -1.579 . . . . 0.0 107.617 -174.463 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' LEU . . . . . . . . . . . . . 32.9 tp -153.37 -86.75 0.06 Allowed 'General case' 0 CA--C 1.534 0.345 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 174.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 161.31 38.23 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.078 0 C-N-CA 125.362 1.465 . . . . 0.0 109.384 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -126.29 119.78 3.52 Favored Glycine 0 C--N 1.336 0.583 0 CA-C-N 115.879 -0.6 . . . . 0.0 113.279 -172.234 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 5.0 mp0 -113.78 100.34 8.38 Favored 'General case' 0 N--CA 1.474 0.751 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 179.457 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' TRP . . . . . 0.483 ' HZ2' ' HG3' ' A' ' 174' ' ' PRO . 28.8 t90 -71.28 130.23 40.88 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 174.752 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 18.2 ttmm -87.29 106.87 18.22 Favored 'General case' 0 C--O 1.242 0.673 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 176.184 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -62.19 104.14 0.45 Allowed 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.122 0.969 . . . . 0.0 111.688 -173.155 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 141.68 -38.15 1.53 Allowed Glycine 0 C--N 1.347 1.176 0 CA-C-N 116.58 -0.282 . . . . 0.0 112.989 178.026 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 -72.51 152.9 41.62 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 123.054 0.542 . . . . 0.0 111.805 -178.338 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -69.73 120.06 14.92 Favored 'General case' 0 C--O 1.244 0.786 0 N-CA-C 108.258 -1.015 . . . . 0.0 108.258 169.042 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.51 HG21 HG21 ' A' ' 208' ' ' VAL . 8.9 p -119.17 151.31 21.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.474 0 N-CA-C 108.974 -0.751 . . . . 0.0 108.974 -173.292 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . 0.44 ' HA ' ' HA ' ' A' ' 171' ' ' GLN . 0.0 OUTLIER -99.77 141.05 33.09 Favored 'General case' 0 N--CA 1.478 0.954 0 CA-C-O 121.081 0.467 . . . . 0.0 110.704 -168.779 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 89.7 t -117.6 131.35 70.59 Favored 'Isoleucine or valine' 0 C--O 1.245 0.825 0 C-N-CA 124.075 0.95 . . . . 0.0 108.444 170.258 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.401 HD12 ' HG2' ' A' ' 199' ' ' PRO . 44.6 mt -73.8 86.99 1.73 Allowed 'General case' 0 CA--C 1.544 0.717 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 171.356 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . 0.586 ' HB3' ' HB2' ' A' ' 168' ' ' ARG . . . -64.13 98.61 0.23 Allowed 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 123.357 0.663 . . . . 0.0 110.82 -176.882 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . 0.645 ' H ' ' HA2' ' A' ' 194' ' ' GLY . 71.6 mt -70.78 88.22 0.72 Allowed 'General case' 0 C--O 1.241 0.631 0 C-N-CA 124.549 1.139 . . . . 0.0 111.229 -173.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -85.34 119.08 71.96 Favored Pre-proline 0 CA--C 1.553 1.09 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.316 174.326 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_exo -59.0 115.78 2.8 Favored 'Trans proline' 0 C--N 1.379 2.167 0 C-N-CA 123.115 2.543 . . . . 0.0 113.322 -176.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 113.79 -15.26 21.7 Favored Glycine 0 N--CA 1.471 0.969 0 CA-C-O 119.348 -0.695 . . . . 0.0 113.663 174.073 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -123.21 -169.62 1.97 Allowed 'General case' 0 C--N 1.355 0.814 0 CA-C-N 117.63 0.715 . . . . 0.0 109.787 -177.249 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 -70.46 162.24 71.62 Favored Pre-proline 0 CA--C 1.563 1.445 0 CA-C-N 114.695 -1.139 . . . . 0.0 109.359 161.482 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_exo -71.17 135.54 27.34 Favored 'Trans proline' 0 C--N 1.365 1.414 0 C-N-CA 121.95 1.767 . . . . 0.0 111.934 172.284 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . 0.586 ' HB2' ' HB3' ' A' ' 160' ' ' ALA . 85.7 mtt180 -70.88 109.26 4.93 Favored 'General case' 0 CA--C 1.546 0.801 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 171.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . 0.513 ' HB1' ' HE1' ' A' ' 16' ' ' TRP . . . -75.78 102.11 5.33 Favored 'General case' 0 N--CA 1.474 0.725 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -179.483 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.443 HG21 ' CE2' ' A' ' 191' ' ' PHE . 40.6 t -120.99 116.3 49.41 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 C-N-CA 122.52 0.328 . . . . 0.0 111.158 -170.02 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 171' ' ' GLN . . . . . 0.606 ' HB2' HG22 ' A' ' 22' ' ' ILE . 26.6 mt-30 -83.91 142.41 30.58 Favored 'General case' 0 C--O 1.243 0.751 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 173.565 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 5.6 t -152.38 136.28 16.34 Favored 'General case' 0 C--O 1.242 0.694 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.652 -168.736 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . 0.501 ' HD3' ' HD2' ' A' ' 174' ' ' PRO . 4.5 tppp? -72.33 126.04 91.17 Favored Pre-proline 0 CA--C 1.543 0.696 0 C-N-CA 123.557 0.743 . . . . 0.0 109.554 175.471 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 174' ' ' PRO . . . . . 0.501 ' HD2' ' HD3' ' A' ' 173' ' ' LYS . 9.2 Cg_endo -48.05 139.14 21.04 Favored 'Trans proline' 0 C--N 1.374 1.912 0 C-N-CA 123.739 2.96 . . . . 0.0 113.475 172.689 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . 0.695 ' H ' ' HA ' ' A' ' 187' ' ' VAL . . . -118.09 -172.77 15.84 Favored Glycine 0 C--O 1.237 0.293 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 175.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.55 ' HB2' HD12 ' A' ' 28' ' ' ILE . 5.5 mp -138.47 152.36 48.24 Favored 'General case' 0 N--CA 1.479 0.983 0 CA-C-N 117.8 0.8 . . . . 0.0 110.11 178.588 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 177' ' ' PHE . . . . . 0.652 ' HB2' ' HB ' ' A' ' 184' ' ' ILE . 35.7 m-85 -92.18 123.58 35.63 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.531 0.732 . . . . 0.0 109.85 176.571 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 178' ' ' LYS . . . . . 0.409 ' O ' ' HA ' ' A' ' 30' ' ' SER . 23.8 ttmm -86.57 94.87 9.56 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 172.383 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 63.0 m -103.1 153.68 20.05 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 123.469 0.708 . . . . 0.0 110.621 -173.536 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 7.0 t30 -80.14 64.93 5.12 Favored 'General case' 0 N--CA 1.48 1.044 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 173.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -175.47 -38.83 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.569 1.548 . . . . 0.0 108.706 -176.495 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 170.49 -144.17 8.23 Favored Glycine 0 C--N 1.341 0.86 0 CA-C-N 114.862 -1.063 . . . . 0.0 111.143 -178.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 10.2 m -127.13 131.87 50.7 Favored 'General case' 0 CA--C 1.548 0.866 0 C-N-CA 123.319 0.648 . . . . 0.0 109.546 179.075 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . 0.652 ' HB ' ' HB2' ' A' ' 177' ' ' PHE . 31.4 mt -107.16 163.28 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 C-N-CA 124.152 0.981 . . . . 0.0 108.561 -179.537 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -99.89 132.34 10.9 Favored Glycine 0 N--CA 1.478 1.488 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.677 ' HA ' ' HA ' ' A' ' 225' ' ' ALA . . . -154.51 -159.02 0.91 Allowed 'General case' 0 N--CA 1.474 0.751 0 CA-C-O 121.083 0.468 . . . . 0.0 112.105 -164.122 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 187' ' ' VAL . . . . . 0.695 ' HA ' ' H ' ' A' ' 175' ' ' GLY . 10.4 p -149.25 135.46 12.18 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 C-N-CA 123.98 0.912 . . . . 0.0 108.731 167.446 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 188' ' ' SER . . . . . 0.629 ' HB2' ' HB2' ' A' ' 26' ' ' SER . 11.9 p -106.38 101.87 11.31 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 123.679 0.792 . . . . 0.0 110.009 -173.322 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 65.5 tp -127.15 109.95 12.39 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 123.969 0.908 . . . . 0.0 110.786 -168.525 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 190' ' ' ASP . . . . . 0.48 ' HA ' ' HA ' ' A' ' 221' ' ' ALA . 13.5 p-10 -96.25 102.74 14.57 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 167.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 191' ' ' PHE . . . . . 0.443 ' CE2' HG21 ' A' ' 170' ' ' VAL . 50.5 t80 179.68 174.96 0.79 Allowed 'General case' 0 CA--C 1.551 0.985 0 CA-C-N 114.985 -1.007 . . . . 0.0 108.541 -168.117 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 33.6 m -86.87 96.17 0.51 Allowed Pre-proline 0 CA--C 1.554 1.114 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 169.548 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . 0.457 ' HG3' ' HB2' ' A' ' 222' ' ' TYR . 10.0 Cg_endo -93.1 -164.76 0.12 Allowed 'Trans proline' 0 C--N 1.373 1.828 0 C-N-CA 123.266 2.644 . . . . 0.0 114.055 -165.587 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 194' ' ' GLY . . . . . 0.645 ' HA2' ' H ' ' A' ' 161' ' ' LEU . . . -82.11 153.73 32.71 Favored Glycine 0 C--N 1.35 1.32 0 CA-C-N 115.053 -0.976 . . . . 0.0 112.793 176.395 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 2.8 m -70.87 155.08 41.24 Favored 'General case' 0 CA--C 1.554 1.128 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 174.201 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 4.1 m -63.67 87.41 0.04 OUTLIER 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 123.493 0.717 . . . . 0.0 112.428 -168.405 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 134.35 17.81 0.96 Allowed Glycine 0 N--CA 1.469 0.883 0 CA-C-N 114.797 -1.092 . . . . 0.0 111.823 -175.43 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 42.6 t -62.09 138.31 95.86 Favored Pre-proline 0 CA--C 1.545 0.762 0 C-N-CA 124.777 1.231 . . . . 0.0 111.388 177.246 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 199' ' ' PRO . . . . . 0.401 ' HG2' HD12 ' A' ' 159' ' ' LEU . 74.1 Cg_endo -71.9 129.79 15.86 Favored 'Trans proline' 0 C--N 1.37 1.71 0 C-N-CA 122.039 1.826 . . . . 0.0 112.259 179.371 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 22.9 mt -100.71 120.5 50.28 Favored 'Isoleucine or valine' 0 C--O 1.238 0.473 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 173.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 201' ' ' ILE . . . . . 0.49 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 56.5 mt -113.55 160.57 12.98 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.942 0 N-CA-C 107.826 -1.176 . . . . 0.0 107.826 178.221 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -99.6 169.27 9.4 Favored 'General case' 0 N--CA 1.478 0.942 0 O-C-N 121.739 -0.601 . . . . 0.0 110.539 176.188 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 7.3 ptpp? -58.66 -26.57 63.93 Favored 'General case' 0 CA--C 1.55 0.957 0 C-N-CA 124.207 1.003 . . . . 0.0 111.497 174.221 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 51.2 tptt -67.0 -20.62 65.91 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 124.064 0.946 . . . . 0.0 111.401 179.863 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 98.82 -14.1 61.88 Favored Glycine 0 C--N 1.345 1.078 0 N-CA-C 111.791 -0.524 . . . . 0.0 111.791 -175.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -85.79 136.89 33.14 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 123.96 0.904 . . . . 0.0 109.705 179.042 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 207' ' ' VAL . . . . . 0.49 ' HA ' ' HA ' ' A' ' 201' ' ' ILE . 13.7 p -67.88 151.95 9.95 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 123.627 0.771 . . . . 0.0 110.101 -179.629 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 208' ' ' VAL . . . . . 0.51 HG21 HG21 ' A' ' 156' ' ' VAL . 28.8 m -127.49 -26.62 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 CA-C-O 118.683 -0.675 . . . . 0.0 112.568 -179.211 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.529 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . 171.72 -147.03 9.82 Favored Glycine 0 C--N 1.36 1.871 0 C-N-CA 119.202 -1.475 . . . . 0.0 116.618 176.128 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 210' ' ' LEU . . . . . 0.446 HD11 HG12 ' A' ' 101' ' ' VAL . 50.6 mt -129.65 143.33 50.77 Favored 'General case' 0 N--CA 1.491 1.623 0 C-N-CA 124.45 1.1 . . . . 0.0 111.804 -175.06 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 47.7 t80 -117.5 105.74 12.41 Favored 'General case' 0 C--O 1.236 0.386 0 C-N-CA 124.951 1.3 . . . . 0.0 108.505 -177.025 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . 172.86 71.49 0.05 OUTLIER Glycine 0 N--CA 1.442 -0.906 0 N-CA-C 111.348 -0.701 . . . . 0.0 111.348 160.286 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 213' ' ' ASN . . . . . 0.672 ' HB2' ' HB3' ' A' ' 225' ' ' ALA . 2.8 m120 -140.17 79.62 1.72 Allowed 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 175.308 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 169.17 -152.63 20.41 Favored Glycine 0 C--O 1.247 0.927 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.756 -176.265 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 215' ' ' VAL . . . . . . . . . . . . . 9.9 p -163.24 171.02 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.832 0 CA-C-N 116.905 0.353 . . . . 0.0 111.831 -166.476 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 216' ' ' VAL . . . . . . . . . . . . . 14.4 p -69.0 128.42 32.44 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.048 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 167.021 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 217' ' ' THR . . . . . 0.755 HG23 HD11 ' A' ' 41' ' ' ILE . 47.7 m -138.12 169.27 18.09 Favored 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 124.98 1.312 . . . . 0.0 108.848 -170.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 218' ' ' ARG . . . . . 0.405 ' HB3' ' HB3' ' A' ' 221' ' ' ALA . 59.9 ttt180 69.22 -83.99 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 123.69 0.796 . . . . 0.0 111.526 168.099 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 23.2 p -163.27 42.36 0.11 Allowed 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 124.216 1.006 . . . . 0.0 109.011 -174.191 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . 101.39 37.89 3.42 Favored Glycine 0 C--N 1.345 1.069 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.149 -178.562 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 221' ' ' ALA . . . . . 0.48 ' HA ' ' HA ' ' A' ' 190' ' ' ASP . . . -118.96 100.61 7.48 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 123.802 0.841 . . . . 0.0 109.234 -172.479 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 222' ' ' TYR . . . . . 0.457 ' HB2' ' HG3' ' A' ' 193' ' ' PRO . 69.7 m-85 -77.4 97.81 5.05 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-O 121.601 0.715 . . . . 0.0 109.212 -177.003 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 45.7 t -97.52 113.71 32.72 Favored 'Isoleucine or valine' 0 C--O 1.235 0.29 0 CA-C-N 114.398 -1.273 . . . . 0.0 107.957 -178.708 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 8.8 t -130.91 154.58 47.95 Favored 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 124.737 1.215 . . . . 0.0 109.367 -173.025 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . 0.677 ' HA ' ' HA ' ' A' ' 186' ' ' ALA . . . -84.03 152.43 24.41 Favored 'General case' 0 C--O 1.247 0.947 0 CA-C-O 120.949 0.404 . . . . 0.0 110.545 178.545 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 226' ' ' ILE . . . . . . . . . . . . . 8.5 pt -114.53 93.14 2.37 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.806 0 CA-C-O 121.914 0.864 . . . . 0.0 109.855 -176.394 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 227' ' ' ALA . . . . . 0.434 ' O ' ' HA3' ' A' ' 209' ' ' GLY . . . -80.69 119.38 23.23 Favored 'General case' 0 N--CA 1.48 1.027 0 CA-C-N 114.939 -1.028 . . . . 0.0 111.108 -172.006 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . 0.477 HE21 ' HB3' ' A' ' 150' ' ' TRP . 4.0 pt20 -93.81 152.9 18.59 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 123.902 0.881 . . . . 0.0 109.188 177.621 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . 0.422 ' HA ' ' NE1' ' A' ' 144' ' ' TRP . 87.4 m -65.06 122.36 16.85 Favored 'General case' 0 N--CA 1.477 0.907 0 CA-C-O 121.005 0.431 . . . . 0.0 111.872 -170.131 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 30.2 mt-10 -84.69 -41.73 15.99 Favored 'General case' 0 CA--C 1.543 0.694 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.313 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 61.99 95.11 0.04 OUTLIER 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 124.9 1.28 . . . . 0.0 110.742 -177.284 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 85.2 p . . . . . 0 N--CA 1.476 0.858 0 CA-C-O 119.124 -0.465 . . . . 0.0 110.97 178.446 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.394 0 N-CA-C 114.214 1.191 . . . . 0.0 114.214 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -128.84 20.39 5.99 Favored 'General case' 0 N--CA 1.476 0.869 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 -177.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -123.94 10.41 8.86 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 126.109 1.764 . . . . 0.0 107.242 -177.18 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.521 ' HB2' HD13 ' A' ' 119' ' ' LEU . 16.9 mt -67.73 166.51 15.12 Favored 'General case' 0 C--O 1.201 -1.461 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 -174.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -154.6 146.7 23.68 Favored 'General case' 0 C--O 1.247 0.968 0 CA-C-N 118.7 0.682 . . . . 0.0 110.144 176.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.58 ' HB2' ' CD2' ' A' ' 121' ' ' HIS . 83.7 mt -87.54 125.45 34.34 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 115.032 -0.985 . . . . 0.0 109.933 172.536 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 22.7 tt0 -104.18 125.27 50.34 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 124.893 1.277 . . . . 0.0 108.275 178.391 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 15.5 ttt180 -60.24 109.35 0.96 Allowed 'General case' 0 N--CA 1.477 0.917 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 -179.849 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.458 ' HB2' ' HG3' ' A' ' 85' ' ' ARG . . . -106.56 -43.88 4.62 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 122.487 0.315 . . . . 0.0 111.267 -170.113 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -174.25 172.91 3.16 Favored 'General case' 0 N--CA 1.477 0.913 0 O-C-N 124.095 0.872 . . . . 0.0 110.409 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -87.12 144.62 26.78 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 162.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 61.9 t -72.06 100.6 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.003 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 176.778 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 26.8 ttpp -172.05 103.49 0.17 Allowed 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 124.483 1.113 . . . . 0.0 108.884 -175.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . 0.532 ' NE1' ' HB1' ' A' ' 169' ' ' ALA . 92.4 t90 -80.59 94.78 6.36 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 123.224 0.61 . . . . 0.0 110.351 -179.244 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -157.81 57.62 0.48 Allowed 'General case' 0 CA--C 1.557 1.217 0 C-N-CA 123.195 0.598 . . . . 0.0 111.587 157.232 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.406 ' H ' ' HB2' ' A' ' 169' ' ' ALA . 4.8 m-20 -92.3 -63.42 1.24 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.445 -0.784 . . . . 0.0 112.689 177.675 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . 0.808 ' H ' ' HB3' ' A' ' 169' ' ' ALA . 48.8 mt-30 -153.09 43.8 0.63 Allowed 'General case' 0 N--CA 1.489 1.477 0 CA-C-N 114.693 -1.14 . . . . 0.0 111.248 -158.199 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -35.05 99.78 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.014 0 C-N-CA 125.537 1.535 . . . . 0.0 114.486 -175.135 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -126.52 118.48 24.99 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 123.748 0.819 . . . . 0.0 110.163 -176.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.543 ' HA ' ' HB2' ' A' ' 171' ' ' GLN . 0.2 OUTLIER -76.16 143.87 12.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 CA-C-O 121.052 0.453 . . . . 0.0 111.872 -174.478 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 77.2 p -154.35 156.71 37.39 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 124.558 1.143 . . . . 0.0 109.654 -178.502 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 160.25 103.82 0.19 Allowed Glycine 0 C--N 1.339 0.747 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -174.293 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.405 ' H ' ' HB3' ' A' ' 189' ' ' LEU . 29.4 t -109.72 -70.27 0.82 Allowed 'General case' 0 N--CA 1.478 0.961 0 CA-C-N 117.566 0.683 . . . . 0.0 111.342 -168.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 26.5 m -123.49 85.68 52.52 Favored Pre-proline 0 CA--C 1.551 1.014 0 C-N-CA 123.3 0.64 . . . . 0.0 109.526 -172.891 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 82.3 Cg_exo -45.41 -49.76 10.01 Favored 'Trans proline' 0 C--N 1.39 2.761 0 C-N-CA 124.293 3.329 . . . . 0.0 114.162 -173.149 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 49.1 mm -104.01 117.04 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 175.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.578 HD11 ' HB2' ' A' ' 218' ' ' ARG . 0.5 OUTLIER -138.26 128.52 25.95 Favored 'General case' 0 N--CA 1.478 0.942 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 -177.232 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 60.1 p -79.24 159.24 27.39 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 122.949 0.5 . . . . 0.0 111.195 179.088 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 16.0 tt -150.68 159.62 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 -177.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 35.3 m -94.88 110.81 22.65 Favored 'General case' 0 C--O 1.241 0.622 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 176.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 45.5 mm -72.12 115.75 12.98 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 173.673 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.491 ' HB2' ' HB3' ' A' ' 38' ' ' SER . 15.5 m -79.65 117.63 20.74 Favored 'General case' 0 C--O 1.241 0.627 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 170.641 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -60.37 -8.49 2.69 Favored 'General case' 0 N--CA 1.491 1.608 0 C-N-CA 124.473 1.109 . . . . 0.0 113.491 -169.206 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -65.79 -13.75 60.05 Favored 'General case' 0 CA--C 1.551 1.0 0 C-N-CA 124.756 1.222 . . . . 0.0 112.24 172.823 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.04 14.39 26.66 Favored Glycine 0 C--N 1.347 1.141 0 N-CA-C 111.693 -0.563 . . . . 0.0 111.693 -171.249 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . 0.491 ' HB3' ' HB2' ' A' ' 34' ' ' SER . 23.1 t -109.03 164.97 11.95 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.496 0.719 . . . . 0.0 110.481 -179.303 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 68.3 mtp -133.29 134.71 44.23 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 123.518 0.727 . . . . 0.0 109.808 -179.015 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 13.3 p -169.44 174.4 6.0 Favored 'General case' 0 C--N 1.353 0.749 0 CA-C-O 121.436 0.636 . . . . 0.0 112.611 -175.185 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.635 HD11 HG23 ' A' ' 217' ' ' THR . 50.7 mm -89.44 152.33 3.35 Favored 'Isoleucine or valine' 0 C--O 1.241 0.635 0 N-CA-C 107.0 -1.482 . . . . 0.0 107.0 160.062 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 47.6 mtmt -72.65 75.74 1.1 Allowed 'General case' 0 CA--C 1.55 0.977 0 CA-C-O 121.665 0.745 . . . . 0.0 110.51 177.195 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 36.0 t30 -173.05 143.42 1.15 Allowed 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 126.079 1.752 . . . . 0.0 107.667 -176.504 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -148.5 150.53 33.56 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 122.537 0.335 . . . . 0.0 111.155 177.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 . . . . . 0 N--CA 1.473 0.682 0 C-N-CA 124.425 1.09 . . . . 0.0 109.866 179.419 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.532 ' HB2' ' HA ' ' A' ' 103' ' ' LYS . 38.5 p-10 . . . . . 0 CA--C 1.537 0.449 0 N-CA-C 112.271 0.471 . . . . 0.0 112.271 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 142.27 -162.82 27.2 Favored Glycine 0 C--N 1.345 1.06 0 CA-C-N 115.296 -0.866 . . . . 0.0 112.256 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . 0.512 ' HB1' HD11 ' A' ' 161' ' ' LEU . . . -85.76 123.26 30.93 Favored 'General case' 0 N--CA 1.477 0.88 0 C-N-CA 123.67 0.788 . . . . 0.0 109.865 177.587 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 15.0 m-85 -129.79 140.43 51.04 Favored 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 123.356 0.663 . . . . 0.0 110.686 -176.145 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' ARG . . . . . 0.527 ' HD3' HE22 ' A' ' 96' ' ' GLN . 80.7 mtt85 -88.09 128.8 35.42 Favored 'General case' 0 N--CA 1.479 0.997 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 173.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.411 ' H ' ' HA ' ' A' ' 99' ' ' ALA . 53.3 mt -91.02 122.03 42.0 Favored 'Isoleucine or valine' 0 C--O 1.247 0.957 0 CA-C-O 121.432 0.634 . . . . 0.0 110.209 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.561 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 34.4 mtmm -114.84 146.96 40.5 Favored 'General case' 0 C--O 1.216 -0.675 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.316 174.657 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 19.7 tm0? -87.05 107.15 18.3 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 105.872 -1.899 . . . . 0.0 105.872 165.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . 0.405 ' HD2' ' HE2' ' A' ' 87' ' ' LYS . 50.0 mtpt -114.38 94.04 4.62 Favored 'General case' 0 C--O 1.241 0.641 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 -176.078 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -70.28 137.9 28.5 Favored Glycine 0 C--O 1.242 0.619 0 N-CA-C 108.221 -1.951 . . . . 0.0 108.221 165.816 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 2.9 mp -75.13 68.9 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.566 1.584 0 N-CA-C 107.103 -1.443 . . . . 0.0 107.103 176.854 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 3.9 pp 170.5 -38.16 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.468 0 C-N-CA 126.435 1.894 . . . . 0.0 109.834 -165.549 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -161.66 134.33 3.48 Favored Glycine 0 C--N 1.353 1.492 0 CA-C-N 115.994 -0.548 . . . . 0.0 112.201 -174.417 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 8.2 m-85 -123.25 131.65 53.75 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.75 0.82 . . . . 0.0 109.756 -167.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 53.6 m -148.65 146.32 28.13 Favored 'General case' 0 N--CA 1.483 1.21 0 C-N-CA 123.956 0.902 . . . . 0.0 109.383 176.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.561 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 61.9 tt0 -92.52 144.08 25.7 Favored 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 123.127 0.571 . . . . 0.0 110.904 178.312 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 25.5 pt -128.34 -26.4 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 C-N-CA 123.138 0.575 . . . . 0.0 112.158 -173.255 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . 0.421 ' HA2' ' HB ' ' A' ' 195' ' ' THR . . . -177.52 -149.54 7.93 Favored Glycine 0 C--N 1.349 1.271 0 C-N-CA 121.144 -0.55 . . . . 0.0 113.263 -177.643 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.411 ' HA ' ' H ' ' A' ' 86' ' ' ILE . . . -157.23 175.47 13.98 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 124.119 0.967 . . . . 0.0 110.969 -176.447 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -178.21 -171.18 41.28 Favored Glycine 0 C--N 1.346 1.117 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.646 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 34.7 t -135.64 127.0 44.92 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.065 0 CA-C-O 121.552 0.691 . . . . 0.0 111.023 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 8.5 t80 -91.03 145.0 25.07 Favored 'General case' 0 CA--C 1.548 0.874 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 170.698 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.532 ' HA ' ' HB2' ' A' ' 81' ' ' ASP . 20.1 tptp -152.65 118.14 5.3 Favored 'General case' 0 N--CA 1.483 1.196 0 CA-C-N 119.168 0.895 . . . . 0.0 111.667 177.303 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 52.3 43.2 30.99 Favored 'General case' 0 N--CA 1.486 1.344 0 C-N-CA 124.629 1.171 . . . . 0.0 113.262 166.286 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 96.31 -33.76 5.42 Favored Glycine 0 C--N 1.348 1.244 0 CA-C-N 115.935 -0.575 . . . . 0.0 112.947 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 60.5 p -88.88 118.93 28.94 Favored 'General case' 0 CA--C 1.542 0.639 0 CA-C-N 117.023 0.412 . . . . 0.0 110.433 -178.213 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' PHE . . . . . 0.429 ' CE2' ' HG ' ' A' ' 119' ' ' LEU . 23.1 t80 -95.23 115.25 27.18 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 176.638 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . 0.618 ' HB2' ' HE3' ' A' ' 144' ' ' TRP . 1.0 OUTLIER -136.2 121.2 18.81 Favored 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 122.698 0.399 . . . . 0.0 110.808 -176.703 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 14.7 t -135.88 -179.71 5.82 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 122.999 0.52 . . . . 0.0 112.035 -169.09 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -72.72 141.52 48.17 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 124.839 1.256 . . . . 0.0 110.023 171.247 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 80.7 t90 -76.03 -53.01 9.0 Favored 'General case' 0 N--CA 1.483 1.202 0 CA-C-O 119.328 -0.367 . . . . 0.0 111.616 -174.482 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . 0.62 ' HE1' ' HA ' ' A' ' 213' ' ' ASN . 3.4 p-80 -65.35 -2.88 3.48 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 114.119 1.155 . . . . 0.0 114.119 -170.437 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.405 HG13 ' HA3' ' A' ' 98' ' ' GLY . 78.1 t -58.07 -39.58 73.22 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.934 0 CA-C-O 121.524 0.678 . . . . 0.0 109.705 167.639 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.618 HG23 ' H ' ' A' ' 116' ' ' GLY . 9.4 t -138.6 -168.48 2.41 Favored 'General case' 0 CA--C 1.555 1.161 0 CA-C-N 114.607 -1.179 . . . . 0.0 109.765 -178.492 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 31.5 ttt180 -93.03 14.94 16.26 Favored 'General case' 0 CA--C 1.561 1.401 0 C-N-CA 124.063 0.945 . . . . 0.0 110.951 177.316 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.618 ' H ' HG23 ' A' ' 114' ' ' THR . . . 80.17 40.7 13.2 Favored Glycine 0 C--N 1.346 1.084 0 N-CA-C 111.816 -0.513 . . . . 0.0 111.816 -175.167 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -120.23 -169.89 1.88 Allowed 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 123.336 0.654 . . . . 0.0 111.543 -173.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 48.9 t -75.36 136.93 23.94 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 N-CA-C 114.184 1.179 . . . . 0.0 114.184 -159.854 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.521 HD13 ' HB2' ' A' ' 6' ' ' LEU . 3.7 mm? -103.13 151.63 22.36 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 124.89 1.276 . . . . 0.0 110.616 174.505 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 38.1 mmt -104.1 151.45 23.26 Favored 'General case' 0 C--O 1.262 1.744 0 C-N-CA 124.57 1.148 . . . . 0.0 108.197 173.284 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.58 ' CD2' ' HB2' ' A' ' 8' ' ' LEU . 0.1 OUTLIER -143.52 92.45 2.36 Favored 'General case' 0 CA--C 1.538 0.495 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 165.072 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 10.1 mtmp? 56.72 28.45 14.24 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 124.591 1.157 . . . . 0.0 112.619 -174.614 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 100.66 -8.91 58.45 Favored Glycine 0 C--N 1.347 1.176 0 CA-C-O 119.683 -0.509 . . . . 0.0 113.229 -176.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 61.2 tttm -72.94 114.55 11.22 Favored 'General case' 0 C--N 1.357 0.901 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 171.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 47.1 ttp180 -82.86 86.13 6.98 Favored 'General case' 0 C--O 1.241 0.605 0 C-N-CA 124.258 1.023 . . . . 0.0 109.271 -174.368 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.461 HG13 ' HB2' ' A' ' 119' ' ' LEU . 23.8 pt -91.71 100.49 11.3 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 CA-C-O 122.334 1.064 . . . . 0.0 109.346 -177.71 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -94.22 126.79 47.14 Favored Pre-proline 0 CA--C 1.546 0.789 0 CA-C-N 113.972 -1.467 . . . . 0.0 110.063 -175.382 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.401 ' HB3' HG23 ' A' ' 138' ' ' ILE . 88.0 Cg_exo -49.53 119.5 4.72 Favored 'Trans proline' 0 C--N 1.373 1.865 0 C-N-CA 123.266 2.644 . . . . 0.0 113.834 175.666 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 59.1 p -82.13 -10.41 59.19 Favored 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 123.799 0.84 . . . . 0.0 110.51 174.425 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.703 ' HB3' ' HB2' ' A' ' 139' ' ' SER . 64.8 t-105 -155.79 152.77 28.86 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 124.912 1.285 . . . . 0.0 109.096 178.176 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -161.86 120.48 2.33 Favored 'General case' 0 C--O 1.241 0.622 0 C-N-CA 124.152 0.981 . . . . 0.0 108.546 169.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -108.84 112.5 24.79 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 123.324 0.65 . . . . 0.0 109.627 176.652 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 11.5 t -75.47 -17.47 15.8 Favored 'Isoleucine or valine' 0 CA--C 1.557 1.228 0 C-N-CA 123.139 0.576 . . . . 0.0 110.159 179.316 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 23.4 ttmm -59.62 -51.5 69.55 Favored 'General case' 0 C--N 1.358 0.974 0 C-N-CA 124.486 1.114 . . . . 0.0 112.359 -174.584 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 79.6 tttt -109.79 4.9 22.2 Favored 'General case' 0 N--CA 1.485 1.291 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 172.606 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 15.6 t70 67.96 71.15 0.33 Allowed 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 124.341 1.056 . . . . 0.0 111.368 170.175 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 47.8 mt -147.43 160.29 42.73 Favored 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 124.317 1.047 . . . . 0.0 110.278 178.043 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.449 HD11 ' HA2' ' A' ' 116' ' ' GLY . 38.0 mt -132.24 150.72 33.83 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 C-N-CA 125.739 1.615 . . . . 0.0 108.214 -176.675 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . 0.703 ' HB2' ' HB3' ' A' ' 130' ' ' TRP . 20.4 m -145.36 143.98 30.44 Favored 'General case' 0 CA--C 1.554 1.123 0 C-N-CA 123.81 0.844 . . . . 0.0 110.887 -179.393 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 19.8 t80 -139.35 128.98 24.52 Favored 'General case' 0 N--CA 1.48 1.029 0 C-N-CA 125.544 1.538 . . . . 0.0 107.942 178.207 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.03 2.51 88.83 Favored Glycine 0 C--N 1.35 1.347 0 O-C-N 123.848 0.717 . . . . 0.0 113.178 179.336 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 165.09 -153.49 23.69 Favored Glycine 0 C--N 1.339 0.725 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -173.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -105.62 173.47 20.24 Favored Glycine 0 C--N 1.343 0.968 0 CA-C-N 117.122 0.461 . . . . 0.0 112.034 174.66 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' TRP . . . . . 0.618 ' HE3' ' HB2' ' A' ' 108' ' ' HIS . 36.2 t-105 -66.6 110.51 3.22 Favored 'General case' 0 C--O 1.245 0.853 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 170.064 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . 0.516 ' HA ' ' HB ' ' A' ' 229' ' ' THR . 0.1 OUTLIER -150.49 146.34 26.55 Favored 'General case' 0 CA--C 1.538 0.499 0 CA-C-O 121.6 0.714 . . . . 0.0 110.475 171.345 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' LEU . . . . . 0.518 HD12 ' HA2' ' A' ' 209' ' ' GLY . 72.7 mt -144.06 2.21 1.15 Allowed 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 125.997 1.719 . . . . 0.0 108.099 170.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 36.6 mt-10 71.07 36.2 1.47 Allowed 'General case' 0 C--N 1.372 1.564 0 C-N-CA 124.157 0.983 . . . . 0.0 111.421 171.045 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . 0.532 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -149.94 156.51 26.78 Favored Glycine 0 C--N 1.347 1.174 0 CA-C-O 121.436 0.465 . . . . 0.0 113.932 -177.613 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -151.12 131.29 13.53 Favored 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 124.022 0.929 . . . . 0.0 109.224 -176.071 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' TRP . . . . . 0.567 ' HE1' ' HB3' ' A' ' 174' ' ' PRO . 50.8 t-105 -91.7 143.78 26.19 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 122.985 0.514 . . . . 0.0 110.027 170.599 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 26.5 tptp -131.14 139.44 49.8 Favored 'General case' 0 CA--C 1.536 0.412 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 169.101 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -44.27 147.11 0.58 Allowed 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 126.165 1.786 . . . . 0.0 113.73 -178.162 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 152.12 -84.7 0.15 Allowed Glycine 0 C--N 1.342 0.867 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.804 179.389 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -88.73 -174.88 4.71 Favored 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 124.446 1.099 . . . . 0.0 110.538 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 11.6 mp0 -63.97 130.95 46.1 Favored 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 169.67 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 13.0 p -90.53 148.0 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 166.444 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 7.9 mm100 -103.72 140.5 37.52 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -170.24 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.568 HG22 HG12 ' A' ' 200' ' ' ILE . 19.1 t -127.63 120.02 53.35 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 176.139 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.601 ' HB3' ' HG2' ' A' ' 199' ' ' PRO . 0.2 OUTLIER -81.39 86.18 6.33 Favored 'General case' 0 CA--C 1.558 1.269 0 N-CA-C 107.481 -1.304 . . . . 0.0 107.481 174.249 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . 0.422 ' HA ' ' OG ' ' A' ' 198' ' ' SER . . . -68.97 104.99 2.24 Favored 'General case' 0 N--CA 1.481 1.121 0 C-N-CA 123.263 0.625 . . . . 0.0 112.089 -172.43 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . 0.512 HD11 ' HB1' ' A' ' 83' ' ' ALA . 74.9 mt -75.42 83.8 2.52 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 174.359 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 15.0 tp10 -70.25 119.75 74.02 Favored Pre-proline 0 CA--C 1.551 1.017 0 CA-C-N 114.886 -1.052 . . . . 0.0 110.176 -176.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . 0.487 ' HG3' HG23 ' A' ' 195' ' ' THR . 63.5 Cg_exo -55.43 114.1 1.72 Allowed 'Trans proline' 0 C--N 1.377 2.045 0 C-N-CA 123.132 2.554 . . . . 0.0 113.378 -178.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 75.99 22.08 74.9 Favored Glycine 0 C--N 1.344 1.019 0 O-C-N 123.724 0.64 . . . . 0.0 113.418 175.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 54.1 tptt -151.69 156.88 41.25 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -174.434 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -58.28 148.21 64.08 Favored Pre-proline 0 CA--C 1.558 1.259 0 C-N-CA 123.034 0.534 . . . . 0.0 112.312 177.594 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -59.62 146.89 94.04 Favored 'Trans proline' 0 C--N 1.379 2.134 0 C-N-CA 123.213 2.609 . . . . 0.0 113.233 179.048 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . 0.413 ' HB2' ' HB3' ' A' ' 160' ' ' ALA . 80.9 mtp180 -123.91 110.54 14.96 Favored 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 123.804 0.842 . . . . 0.0 108.828 -172.465 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . 0.808 ' HB3' ' H ' ' A' ' 19' ' ' GLN . . . -78.84 106.37 10.81 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-O 120.808 0.337 . . . . 0.0 110.701 -178.662 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 21.9 t -105.64 139.19 27.57 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.894 0 C-N-CA 123.176 0.591 . . . . 0.0 109.778 -178.023 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 171' ' ' GLN . . . . . 0.543 ' HB2' ' HA ' ' A' ' 22' ' ' ILE . 11.2 mt-30 -97.09 102.87 14.73 Favored 'General case' 0 C--N 1.348 0.53 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 170.335 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . 0.519 ' HB ' HD11 ' A' ' 189' ' ' LEU . 71.4 p -101.71 124.06 46.73 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -178.816 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 28.1 mtpp -71.03 133.17 86.06 Favored Pre-proline 0 CA--C 1.546 0.806 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 174.049 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 174' ' ' PRO . . . . . 0.567 ' HB3' ' HE1' ' A' ' 150' ' ' TRP . 37.7 Cg_endo -64.1 123.53 12.03 Favored 'Trans proline' 0 C--N 1.377 2.053 0 C-N-CA 122.288 1.992 . . . . 0.0 111.776 -169.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -100.0 -173.94 30.37 Favored Glycine 0 N--CA 1.45 -0.428 0 CA-C-N 114.956 -1.02 . . . . 0.0 112.229 177.064 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 5.6 mp -148.73 145.84 27.82 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.096 0.958 . . . . 0.0 109.172 178.476 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 177' ' ' PHE . . . . . 0.729 ' HB2' ' HB ' ' A' ' 184' ' ' ILE . 59.1 m-85 -92.71 122.67 35.35 Favored 'General case' 0 C--O 1.245 0.866 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 167.705 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 77.8 tttt -95.21 104.8 16.7 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 114.809 -1.087 . . . . 0.0 109.187 177.063 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 36.4 p -132.81 156.98 46.14 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 169.481 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 10.3 t30 -56.61 -38.74 72.47 Favored 'General case' 0 N--CA 1.484 1.232 0 C-N-CA 123.874 0.87 . . . . 0.0 112.892 -169.078 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -94.93 -35.68 11.91 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 123.067 0.547 . . . . 0.0 110.8 178.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -112.94 118.19 4.5 Favored Glycine 0 C--N 1.347 1.153 0 CA-C-N 116.279 -0.419 . . . . 0.0 113.859 -169.319 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 30.2 m -98.57 100.88 12.16 Favored 'General case' 0 CA--C 1.538 0.507 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 163.167 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . 0.729 ' HB ' ' HB2' ' A' ' 177' ' ' PHE . 46.9 mt -104.17 149.73 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 C-N-CA 123.512 0.725 . . . . 0.0 109.07 -169.546 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -99.17 124.6 8.29 Favored Glycine 0 C--N 1.349 1.305 0 N-CA-C 109.808 -1.317 . . . . 0.0 109.808 -179.577 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.657 ' HA ' ' HA ' ' A' ' 225' ' ' ALA . . . -140.27 -174.66 4.0 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 114.125 1.157 . . . . 0.0 114.125 -159.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 187' ' ' VAL . . . . . . . . . . . . . 98.4 t -126.27 99.86 6.14 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.641 0 N-CA-C 105.683 -1.969 . . . . 0.0 105.683 171.183 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 188' ' ' SER . . . . . 0.559 ' HA ' HG13 ' A' ' 223' ' ' VAL . 60.6 p -113.64 79.64 1.27 Allowed 'General case' 0 C--O 1.243 0.731 0 CA-C-O 122.243 1.021 . . . . 0.0 111.044 -171.343 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 189' ' ' LEU . . . . . 0.519 HD11 ' HB ' ' A' ' 172' ' ' THR . 0.0 OUTLIER -151.49 178.9 8.83 Favored 'General case' 0 N--CA 1.477 0.923 0 CA-C-N 114.596 -1.184 . . . . 0.0 111.528 175.723 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -80.03 102.33 9.21 Favored 'General case' 0 CA--C 1.542 0.635 0 N-CA-C 107.307 -1.368 . . . . 0.0 107.307 171.622 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 191' ' ' PHE . . . . . 0.73 ' HB3' ' HB2' ' A' ' 222' ' ' TYR . 69.5 t80 -106.58 164.22 12.24 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 124.32 1.048 . . . . 0.0 109.53 -174.269 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 16.8 m -58.79 155.15 32.7 Favored Pre-proline 0 CA--C 1.561 1.394 0 C-N-CA 124.748 1.219 . . . . 0.0 112.134 178.297 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_exo -64.84 10.91 0.12 Allowed 'Trans proline' 0 C--N 1.381 2.263 0 C-N-CA 123.123 2.548 . . . . 0.0 115.342 171.555 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 194' ' ' GLY . . . . . 0.458 ' HA2' ' HD3' ' A' ' 163' ' ' PRO . . . -50.05 134.13 27.72 Favored Glycine 0 CA--C 1.54 1.643 0 C-N-CA 123.621 0.629 . . . . 0.0 112.995 168.712 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 195' ' ' THR . . . . . 0.487 HG23 ' HG3' ' A' ' 163' ' ' PRO . 6.6 p -75.34 151.39 38.25 Favored 'General case' 0 CA--C 1.552 1.03 0 C-N-CA 124.285 1.034 . . . . 0.0 113.381 -169.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -62.98 128.91 38.03 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 124.333 1.053 . . . . 0.0 111.213 -172.643 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 197' ' ' GLY . . . . . 0.422 ' O ' HD22 ' A' ' 210' ' ' LEU . . . 96.68 8.19 57.35 Favored Glycine 0 C--N 1.34 0.755 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 -167.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 198' ' ' SER . . . . . 0.422 ' OG ' ' HA ' ' A' ' 160' ' ' ALA . 34.0 t -57.15 119.06 28.31 Favored Pre-proline 0 CA--C 1.557 1.243 0 C-N-CA 123.684 0.793 . . . . 0.0 109.839 164.278 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 199' ' ' PRO . . . . . 0.601 ' HG2' ' HB3' ' A' ' 159' ' ' LEU . 19.6 Cg_endo -58.04 131.63 44.61 Favored 'Trans proline' 0 C--N 1.377 2.033 0 C-N-CA 123.171 2.581 . . . . 0.0 113.832 -170.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 200' ' ' ILE . . . . . 0.568 HG12 HG22 ' A' ' 158' ' ' VAL . 18.9 mt -97.98 130.87 46.1 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.754 0 C-N-CA 123.988 0.915 . . . . 0.0 109.062 171.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 201' ' ' ILE . . . . . . . . . . . . . 50.3 mt -123.03 169.55 14.26 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.369 0 C-N-CA 124.706 1.202 . . . . 0.0 108.525 179.045 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -108.55 155.82 20.21 Favored 'General case' 0 N--CA 1.483 1.177 0 C-N-CA 124.346 1.058 . . . . 0.0 108.867 173.258 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 18.7 ptmt -66.4 -19.5 65.82 Favored 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 -170.578 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 45.3 mttp -73.99 -17.4 61.0 Favored 'General case' 0 N--CA 1.488 1.443 0 CA-C-N 117.911 0.323 . . . . 0.0 110.739 176.011 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 115.4 -16.45 17.16 Favored Glycine 0 C--N 1.351 1.362 0 N-CA-C 111.898 -0.481 . . . . 0.0 111.898 -176.066 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 206' ' ' LYS . . . . . 0.423 ' HA ' ' HE3' ' A' ' 206' ' ' LYS . 1.2 tpmt? -73.21 119.2 17.12 Favored 'General case' 0 C--O 1.219 -0.502 0 C-N-CA 123.985 0.914 . . . . 0.0 109.239 -177.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 207' ' ' VAL . . . . . 0.532 ' O ' ' HA3' ' A' ' 148' ' ' GLY . 12.7 p -64.02 150.23 10.13 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.926 0 C-N-CA 122.798 0.439 . . . . 0.0 110.239 176.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 208' ' ' VAL . . . . . 0.502 ' HB ' HG22 ' A' ' 200' ' ' ILE . 93.4 t -106.26 -49.84 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 177.542 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.518 ' HA2' HD12 ' A' ' 146' ' ' LEU . . . 161.33 -117.49 0.77 Allowed Glycine 0 N--CA 1.441 -1.014 0 CA-C-N 114.876 -1.056 . . . . 0.0 112.986 178.709 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 210' ' ' LEU . . . . . 0.58 ' HG ' ' CH2' ' A' ' 144' ' ' TRP . 69.2 mt -124.37 166.43 15.96 Favored 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 123.406 0.683 . . . . 0.0 111.841 -177.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -69.9 112.65 6.46 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-N 114.213 -1.358 . . . . 0.0 107.602 167.608 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -74.5 -145.66 1.07 Allowed Glycine 0 C--N 1.341 0.814 0 N-CA-C 115.984 1.154 . . . . 0.0 115.984 -163.849 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 213' ' ' ASN . . . . . 0.62 ' HA ' ' HE1' ' A' ' 112' ' ' HIS . 14.2 p30 -100.66 123.56 45.04 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 121.295 0.569 . . . . 0.0 110.716 -166.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 177.49 -134.31 2.44 Favored Glycine 0 N--CA 1.442 -0.906 0 CA-C-N 114.736 -1.12 . . . . 0.0 111.293 178.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 215' ' ' VAL . . . . . 0.423 HG22 ' N ' ' A' ' 216' ' ' VAL . 10.0 p -176.55 178.09 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 -165.133 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 216' ' ' VAL . . . . . 0.423 ' N ' HG22 ' A' ' 215' ' ' VAL . 6.7 m -75.35 110.36 10.08 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.024 0 O-C-N 121.159 -0.963 . . . . 0.0 108.922 160.213 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 217' ' ' THR . . . . . 0.635 HG23 HD11 ' A' ' 41' ' ' ILE . 13.4 m -104.14 177.02 4.96 Favored 'General case' 0 CA--C 1.548 0.886 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 175.86 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 218' ' ' ARG . . . . . 0.578 ' HB2' HD11 ' A' ' 29' ' ' LEU . 71.0 ttt-85 63.38 30.98 15.42 Favored 'General case' 0 N--CA 1.491 1.604 0 CA-C-O 121.98 0.895 . . . . 0.0 110.119 176.096 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 19.6 m 68.33 17.32 9.24 Favored 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 125.47 1.508 . . . . 0.0 113.203 177.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . 153.14 -6.87 0.44 Allowed Glycine 0 C--N 1.355 1.618 0 N-CA-C 115.05 0.78 . . . . 0.0 115.05 174.779 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 221' ' ' ALA . . . . . 0.463 ' HB3' ' HB3' ' A' ' 218' ' ' ARG . . . -78.58 125.97 30.1 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 123.205 0.602 . . . . 0.0 110.167 -179.816 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 222' ' ' TYR . . . . . 0.73 ' HB2' ' HB3' ' A' ' 191' ' ' PHE . 11.6 m-85 -65.97 102.03 0.74 Allowed 'General case' 0 N--CA 1.481 1.087 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 178.216 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . 0.559 HG13 ' HA ' ' A' ' 188' ' ' SER . 92.4 t -124.64 108.54 20.46 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.922 0 C-N-CA 124.296 1.038 . . . . 0.0 109.469 -176.726 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 50.6 m -142.1 159.0 43.11 Favored 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 123.871 0.868 . . . . 0.0 109.451 -178.571 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . 0.657 ' HA ' ' HA ' ' A' ' 186' ' ' ALA . . . -65.12 -171.36 0.07 Allowed 'General case' 0 N--CA 1.482 1.155 0 N-CA-C 113.349 0.87 . . . . 0.0 113.349 -174.809 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 226' ' ' ILE . . . . . . . . . . . . . 46.5 mt -118.29 105.84 18.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 172.786 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -80.34 99.72 8.05 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 122.965 0.506 . . . . 0.0 109.857 -178.713 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 18.2 pt20 -94.25 162.14 13.97 Favored 'General case' 0 N--CA 1.484 1.235 0 C-N-CA 123.929 0.892 . . . . 0.0 110.184 -178.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . 0.516 ' HB ' ' HA ' ' A' ' 145' ' ' LYS . 24.6 p -90.06 121.83 32.49 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 122.669 0.388 . . . . 0.0 111.284 -170.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -139.65 -21.0 0.91 Allowed 'General case' 0 N--CA 1.483 1.221 0 C-N-CA 123.464 0.706 . . . . 0.0 112.284 -166.695 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 2.4 mptp? -82.33 -80.42 0.16 Allowed 'General case' 0 N--CA 1.488 1.463 0 CA-C-N 117.921 0.328 . . . . 0.0 110.453 -164.165 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 232' ' ' SER . . . . . 0.41 ' HB2' ' HD2' ' A' ' 145' ' ' LYS . 73.0 m . . . . . 0 C--N 1.36 1.03 0 CA-C-N 118.304 0.502 . . . . 0.0 109.788 171.566 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.95 0 CA-C-O 119.541 -0.266 . . . . 0.0 110.463 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.554 ' O ' HG22 ' A' ' 118' ' ' VAL . . . -162.7 8.06 0.06 Allowed 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 112.175 0.435 . . . . 0.0 112.175 -175.774 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -123.37 83.92 2.2 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 177.223 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.693 ' HA ' ' HA ' ' A' ' 88' ' ' GLN . 4.8 mp -125.07 98.79 5.83 Favored 'General case' 0 N--CA 1.481 1.122 0 CA-C-O 119.333 -0.365 . . . . 0.0 111.559 -173.663 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 30.3 tt0 -81.58 144.84 30.98 Favored 'General case' 0 C--O 1.252 1.207 0 CA-C-O 121.979 0.895 . . . . 0.0 111.197 -175.125 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.634 HD21 HD13 ' A' ' 119' ' ' LEU . 53.9 mt -85.31 115.3 22.98 Favored 'General case' 0 C--O 1.242 0.706 0 CA-C-N 113.556 -1.656 . . . . 0.0 109.752 176.04 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -104.03 125.96 50.78 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 171.319 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 47.0 ptt85 -67.17 129.39 39.76 Favored 'General case' 0 N--CA 1.478 0.958 0 CA-C-N 118.36 0.527 . . . . 0.0 109.76 178.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.41 ' HB3' HD13 ' A' ' 161' ' ' LEU . . . -121.69 -21.35 6.18 Favored 'General case' 0 N--CA 1.479 0.983 0 C-N-CA 122.746 0.418 . . . . 0.0 111.239 -176.366 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . 0.668 ' HB3' ' HB3' ' A' ' 83' ' ' ALA . . . -164.01 161.4 22.63 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 121.639 0.733 . . . . 0.0 111.058 178.592 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -93.71 155.84 17.02 Favored 'General case' 0 C--O 1.245 0.826 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 161.31 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.592 HG23 ' HA2' ' A' ' 82' ' ' GLY . 85.9 t -67.21 103.35 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 175.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 58.8 tttp -168.55 133.32 1.64 Allowed 'General case' 0 C--O 1.239 0.528 0 CA-C-N 115.123 -0.944 . . . . 0.0 108.617 -170.308 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 23.3 t90 -74.61 114.01 12.54 Favored 'General case' 0 CA--C 1.542 0.655 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 167.504 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.565 ' HB3' ' HB2' ' A' ' 169' ' ' ALA . 39.6 tt0 -72.25 145.42 47.94 Favored 'General case' 0 CA--C 1.548 0.888 0 C-N-CA 123.344 0.658 . . . . 0.0 109.825 176.825 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -78.32 -2.73 39.48 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 123.878 0.871 . . . . 0.0 112.716 -172.579 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 31.6 mm-40 -87.08 43.44 1.1 Allowed 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 122.99 0.516 . . . . 0.0 110.152 -175.616 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -60.4 101.27 0.12 Allowed 'General case' 0 C--N 1.354 0.788 0 C-N-CA 124.775 1.23 . . . . 0.0 110.803 -174.603 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -105.37 117.44 34.02 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 124.236 1.014 . . . . 0.0 109.496 -173.662 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.513 HD13 ' HB2' ' A' ' 171' ' ' GLN . 43.4 mm -76.55 127.43 37.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 C-N-CA 123.025 0.53 . . . . 0.0 110.063 -172.82 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.433 ' HG ' ' HE2' ' A' ' 191' ' ' PHE . 29.2 m -148.25 -171.55 3.86 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 124.149 0.98 . . . . 0.0 110.796 -172.604 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 133.4 66.28 0.08 OUTLIER Glycine 0 C--N 1.347 1.185 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.515 ' H ' ' HA ' ' A' ' 189' ' ' LEU . 13.1 m -66.62 -52.6 43.36 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-N 114.648 -0.776 . . . . 0.0 111.845 -167.308 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.446 ' HB2' ' OG ' ' A' ' 188' ' ' SER . 14.8 m -95.26 144.12 27.26 Favored Pre-proline 0 CA--C 1.552 1.048 0 C-N-CA 123.119 0.568 . . . . 0.0 110.525 -172.747 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -84.97 -161.06 0.12 Allowed 'Trans proline' 0 C--N 1.378 2.113 0 C-N-CA 123.0 2.467 . . . . 0.0 112.623 174.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 45.3 mm -63.05 133.72 28.68 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 168.405 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.529 HD13 HG21 ' A' ' 217' ' ' THR . 0.2 OUTLIER -143.75 163.72 32.53 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 123.719 0.808 . . . . 0.0 109.639 -163.428 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.3 t -108.65 145.84 34.34 Favored 'General case' 0 N--CA 1.479 1.013 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 172.699 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.447 HD12 ' CE2' ' A' ' 177' ' ' PHE . 14.9 tt -135.27 154.38 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 C-N-CA 123.4 0.68 . . . . 0.0 109.336 -174.143 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 34.7 p -95.35 103.77 15.65 Favored 'General case' 0 C--O 1.243 0.713 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 171.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.45 ' HA ' ' HA ' ' A' ' 39' ' ' MET . 15.7 tt -91.05 117.53 34.47 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.764 179.432 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.615 ' HB3' ' HB3' ' A' ' 38' ' ' SER . 35.5 t -82.97 118.52 23.55 Favored 'General case' 0 C--O 1.242 0.662 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.003 -178.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -52.84 -28.15 21.55 Favored 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 125.3 1.44 . . . . 0.0 112.474 -177.682 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -48.22 -41.26 26.94 Favored 'General case' 0 CA--C 1.55 0.957 0 C-N-CA 125.265 1.426 . . . . 0.0 111.884 174.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 145.68 9.89 0.28 Allowed Glycine 0 C--N 1.34 0.791 0 CA-C-N 114.929 -1.032 . . . . 0.0 111.942 178.507 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . 0.615 ' HB3' ' HB3' ' A' ' 34' ' ' SER . 32.7 t -109.82 164.2 12.79 Favored 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 123.537 0.735 . . . . 0.0 110.334 -173.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . 0.45 ' HA ' ' HA ' ' A' ' 33' ' ' ILE . 22.3 ptm -153.67 127.64 8.95 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 123.439 0.696 . . . . 0.0 109.133 173.604 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 17.7 p -169.46 169.82 8.68 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 123.091 0.556 . . . . 0.0 110.862 -175.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.0 mp -78.69 124.32 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 N-CA-C 104.815 -2.291 . . . . 0.0 104.815 157.699 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.43 79.02 0.01 OUTLIER 'General case' 0 CA--C 1.558 1.278 0 C-N-CA 124.238 1.015 . . . . 0.0 112.824 -170.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 92.5 m-20 -130.5 173.65 10.65 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 125.017 1.327 . . . . 0.0 109.088 -177.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -72.23 143.08 48.94 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 123.54 0.736 . . . . 0.0 110.755 177.063 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 . . . . . 0 N--CA 1.473 0.678 0 C-N-CA 123.207 0.603 . . . . 0.0 110.594 177.593 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.411 ' HB2' ' HA ' ' A' ' 103' ' ' LYS . 6.3 p-10 . . . . . 0 C--O 1.239 0.524 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.592 ' HA2' HG23 ' A' ' 14' ' ' VAL . . . 163.28 -175.05 39.6 Favored Glycine 0 C--N 1.34 0.79 0 O-C-N 123.167 0.292 . . . . 0.0 112.574 -173.106 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . 0.668 ' HB3' ' HB3' ' A' ' 12' ' ' ALA . . . -93.18 110.17 21.68 Favored 'General case' 0 C--O 1.244 0.789 0 CA-C-O 121.102 0.477 . . . . 0.0 110.503 -177.761 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 18.1 m-85 -107.41 136.92 46.39 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 176.731 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.68 131.79 36.82 Favored 'General case' 0 C--O 1.245 0.837 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 175.183 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.533 HD11 ' HE2' ' A' ' 107' ' ' PHE . 38.0 mt -90.58 111.46 23.54 Favored 'Isoleucine or valine' 0 C--O 1.273 2.3 0 CA-C-O 122.559 1.171 . . . . 0.0 110.482 -176.426 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.417 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 7.1 tmtm? -116.73 130.89 57.0 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-N 112.857 -1.974 . . . . 0.0 107.061 179.075 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . 0.693 ' HA ' ' HA ' ' A' ' 6' ' ' LEU . 21.0 tm0? -79.86 111.08 15.84 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 106.838 -1.541 . . . . 0.0 106.838 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . 0.432 ' HE3' ' HB2' ' A' ' 89' ' ' LYS . 35.0 ttmt -117.1 93.61 4.25 Favored 'General case' 0 C--O 1.238 0.458 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 -178.277 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -104.51 144.61 15.86 Favored Glycine 0 CA--C 1.496 -1.152 0 CA-C-N 114.158 -1.383 . . . . 0.0 110.953 -176.263 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 2.9 mp -65.3 -15.34 18.27 Favored 'Isoleucine or valine' 0 CA--C 1.566 1.589 0 C-N-CA 125.087 1.355 . . . . 0.0 109.675 179.735 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 1.1 pp -118.43 0.31 11.6 Favored 'General case' 0 CA--C 1.557 1.229 0 N-CA-C 113.467 0.914 . . . . 0.0 113.467 175.658 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 175.67 154.45 11.43 Favored Glycine 0 N--CA 1.488 2.128 0 CA-C-N 119.289 0.95 . . . . 0.0 114.185 -175.048 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 75.4 m-85 -130.71 125.39 33.79 Favored 'General case' 0 N--CA 1.487 1.405 0 C-N-CA 123.421 0.688 . . . . 0.0 112.086 -171.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 39.8 m -135.66 157.36 47.06 Favored 'General case' 0 N--CA 1.492 1.675 0 C-N-CA 124.794 1.237 . . . . 0.0 110.734 171.506 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.417 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 11.7 pt20 -100.19 148.89 24.12 Favored 'General case' 0 N--CA 1.496 1.875 0 N-CA-C 107.977 -1.12 . . . . 0.0 107.977 158.366 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.649 HD11 ' HB2' ' A' ' 88' ' ' GLN . 0.0 OUTLIER -132.17 -39.01 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 CA-C-N 119.629 1.104 . . . . 0.0 111.305 179.167 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -175.59 -145.99 5.68 Favored Glycine 0 C--N 1.347 1.143 0 C-N-CA 119.652 -1.261 . . . . 0.0 114.199 -171.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -158.64 175.28 13.85 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 123.488 0.715 . . . . 0.0 111.449 -177.048 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -172.25 176.47 45.25 Favored Glycine 0 C--N 1.344 0.993 0 CA-C-N 115.401 -0.818 . . . . 0.0 111.539 -178.608 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.447 HG11 HD11 ' A' ' 146' ' ' LEU . 47.2 t -123.12 125.93 72.81 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.012 0 C-N-CA 122.866 0.466 . . . . 0.0 111.028 -175.325 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 39.4 t80 -85.34 144.63 27.94 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 167.092 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.603 ' HG3' ' HG3' ' A' ' 104' ' ' GLU . 22.9 tptm -157.0 133.83 10.19 Favored 'General case' 0 C--O 1.239 0.518 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 173.665 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.603 ' HG3' ' HG3' ' A' ' 103' ' ' LYS . 29.5 mt-10 62.6 -91.83 0.03 OUTLIER 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 124.983 1.313 . . . . 0.0 111.569 176.062 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -143.89 31.26 1.88 Allowed Glycine 0 C--N 1.341 0.831 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.4 t -146.28 129.4 16.55 Favored 'General case' 0 C--O 1.241 0.653 0 C-N-CA 123.694 0.798 . . . . 0.0 110.614 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' PHE . . . . . 0.533 ' HE2' HD11 ' A' ' 86' ' ' ILE . 67.2 t80 -94.92 104.01 15.89 Favored 'General case' 0 C--N 1.345 0.386 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 171.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . 0.541 ' CE1' ' HB3' ' A' ' 103' ' ' LYS . 1.5 p-80 -107.8 121.08 44.01 Favored 'General case' 0 C--N 1.325 -0.481 0 C-N-CA 123.247 0.619 . . . . 0.0 109.492 -178.862 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 8.6 t -136.62 179.77 6.17 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 123.839 0.856 . . . . 0.0 111.241 -172.52 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' MET . . . . . 0.449 ' SD ' ' O ' ' A' ' 212' ' ' GLY . 27.7 ttm -74.92 150.42 39.12 Favored 'General case' 0 CA--C 1.547 0.86 0 C-N-CA 125.463 1.505 . . . . 0.0 109.94 173.204 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' TRP . . . . . 0.407 ' HA ' HG22 ' A' ' 138' ' ' ILE . 86.8 t90 -73.61 -56.32 5.16 Favored 'General case' 0 N--CA 1.494 1.747 0 CA-C-N 118.32 0.509 . . . . 0.0 111.967 -168.474 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 1.2 p-80 -68.69 2.96 2.12 Favored 'General case' 0 N--CA 1.485 1.314 0 N-CA-C 114.332 1.234 . . . . 0.0 114.332 -171.358 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.412 HG21 HD12 ' A' ' 86' ' ' ILE . 23.0 m -60.32 -38.64 78.27 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 167.273 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 12.0 t -122.48 174.24 7.17 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 124.663 1.185 . . . . 0.0 108.498 178.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 50.7 ttt-85 -93.14 31.26 1.48 Allowed 'General case' 0 N--CA 1.485 1.275 0 CA-C-O 121.326 0.584 . . . . 0.0 109.588 -179.005 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.418 ' HA2' HD12 ' A' ' 138' ' ' ILE . . . 73.74 35.43 54.91 Favored Glycine 0 C--N 1.348 1.234 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 -167.22 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -122.36 -163.31 1.07 Allowed 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 123.663 0.785 . . . . 0.0 111.782 -168.833 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.698 HG21 ' HG3' ' A' ' 125' ' ' ARG . 2.0 m -89.21 156.56 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.127 0 C-N-CA 123.359 0.664 . . . . 0.0 110.822 -172.413 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.634 HD13 HD21 ' A' ' 8' ' ' LEU . 54.8 mt -110.46 174.78 5.7 Favored 'General case' 0 CA--C 1.551 1.018 0 C-N-CA 124.357 1.063 . . . . 0.0 109.586 170.758 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 23.5 mmt -124.63 137.6 54.36 Favored 'General case' 0 C--O 1.25 1.093 0 C-N-CA 123.534 0.734 . . . . 0.0 110.165 -176.026 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.446 ' HB2' HD11 ' A' ' 126' ' ' ILE . 77.6 t60 -130.88 95.85 3.93 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 168.002 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 62.93 20.44 12.25 Favored 'General case' 0 N--CA 1.495 1.811 0 C-N-CA 124.513 1.125 . . . . 0.0 111.523 -168.461 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 88.52 14.65 61.31 Favored Glycine 0 C--N 1.345 1.054 0 CA-C-O 119.7 -0.5 . . . . 0.0 112.682 -172.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -82.18 129.5 34.85 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 169.072 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . 0.698 ' HG3' HG21 ' A' ' 118' ' ' VAL . 35.8 ttm180 -78.59 98.71 6.25 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 124.794 1.237 . . . . 0.0 111.217 -173.619 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.446 HD11 ' HB2' ' A' ' 121' ' ' HIS . 18.4 mt -89.08 95.48 5.44 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.693 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 175.751 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -91.68 141.57 25.84 Favored Pre-proline 0 N--CA 1.487 1.422 0 C-N-CA 122.732 0.413 . . . . 0.0 110.256 -179.212 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -73.42 153.8 50.36 Favored 'Trans proline' 0 C--N 1.382 2.307 0 C-N-CA 122.924 2.416 . . . . 0.0 114.791 -170.786 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 66.4 p -101.88 -32.45 10.22 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 123.97 0.908 . . . . 0.0 110.209 172.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 72.4 t-105 -130.38 149.71 51.94 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 124.059 0.944 . . . . 0.0 109.355 -177.76 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -156.77 125.69 5.93 Favored 'General case' 0 C--O 1.241 0.654 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 175.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -141.75 110.16 6.0 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 123.108 0.563 . . . . 0.0 109.896 179.717 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 3.5 t -77.09 -17.02 14.56 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.286 0 C-N-CA 123.654 0.782 . . . . 0.0 111.307 -176.552 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 58.3 mttp -65.21 -53.79 39.36 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 123.697 0.799 . . . . 0.0 110.903 -176.53 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 47.6 mmtm -82.93 -17.38 43.81 Favored 'General case' 0 N--CA 1.478 0.934 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.181 172.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 11.5 t70 60.49 66.74 0.9 Allowed 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 125.865 1.666 . . . . 0.0 109.44 -173.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 51.8 mt -143.63 123.94 13.83 Favored 'General case' 0 CA--C 1.547 0.844 0 CA-C-N 113.673 -1.603 . . . . 0.0 108.7 -179.17 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.418 HD12 ' HA2' ' A' ' 116' ' ' GLY . 16.8 tt -118.7 138.79 48.26 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 176.076 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 35.0 t -134.37 151.76 51.4 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 121.785 0.802 . . . . 0.0 111.797 -175.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 18.8 m-85 -124.25 102.77 7.87 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 113.784 -1.553 . . . . 0.0 107.423 -169.754 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 97.09 -1.98 61.22 Favored Glycine 0 C--N 1.346 1.092 0 O-C-N 123.776 0.672 . . . . 0.0 113.366 -177.09 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . -175.69 -150.54 8.06 Favored Glycine 0 C--N 1.347 1.155 0 CA-C-O 119.503 -0.61 . . . . 0.0 111.986 -177.52 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -116.83 -179.43 17.79 Favored Glycine 0 C--N 1.352 1.419 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 171.185 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' TRP . . . . . 0.527 ' HA ' ' HB2' ' A' ' 108' ' ' HIS . 54.1 t-105 -70.61 105.15 3.03 Favored 'General case' 0 N--CA 1.476 0.867 0 CA-C-N 118.655 1.227 . . . . 0.0 108.782 175.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 19.2 ptmt -138.41 121.55 16.86 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 122.944 0.498 . . . . 0.0 110.944 -171.058 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' LEU . . . . . 0.447 HD11 HG11 ' A' ' 101' ' ' VAL . 46.1 mt -153.17 -33.13 0.12 Allowed 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 125.586 1.554 . . . . 0.0 107.928 172.609 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 71.65 101.55 0.07 Allowed 'General case' 0 C--N 1.362 1.12 0 C-N-CA 126.166 1.786 . . . . 0.0 110.545 -179.048 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . 0.455 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -167.75 148.03 12.37 Favored Glycine 0 C--O 1.242 0.655 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 178.218 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -151.66 108.57 3.53 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -177.193 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' TRP . . . . . 0.605 ' HB2' HG21 ' A' ' 208' ' ' VAL . 81.5 t90 -65.9 123.95 21.2 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-O 120.762 0.315 . . . . 0.0 110.692 172.775 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -151.52 90.49 1.57 Allowed 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 160.567 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . 0.5 ' HG3' ' H ' ' A' ' 154' ' ' GLU . 12.0 tp10 -131.81 142.91 49.86 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 115.133 -0.94 . . . . 0.0 109.285 178.793 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -64.19 -30.42 77.75 Favored Glycine 0 C--N 1.349 1.287 0 N-CA-C 111.404 -0.678 . . . . 0.0 111.404 173.158 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . 0.5 ' H ' ' HG3' ' A' ' 152' ' ' GLU . 29.9 mt-10 -81.22 173.34 12.61 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 124.786 1.234 . . . . 0.0 110.003 172.566 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . 0.495 ' HB2' ' HB3' ' A' ' 171' ' ' GLN . 4.4 mp0 -67.31 166.76 13.71 Favored 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 123.738 0.815 . . . . 0.0 112.41 -173.394 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 15.0 p -92.67 141.47 14.58 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.167 172.117 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . 0.41 ' HG3' ' HG2' ' A' ' 171' ' ' GLN . 20.4 mp0 -99.22 131.51 45.2 Favored 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -173.392 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 41.4 t -133.95 102.06 4.2 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 -178.432 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.531 HD23 ' H ' ' A' ' 159' ' ' LEU . 2.3 pt? -76.3 85.5 3.08 Favored 'General case' 0 CA--C 1.545 0.768 0 CA-C-O 122.386 1.089 . . . . 0.0 108.893 176.004 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -64.65 114.53 4.48 Favored 'General case' 0 C--O 1.239 0.549 0 CA-C-N 114.221 -1.354 . . . . 0.0 108.64 178.441 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . 0.41 HD13 ' HB3' ' A' ' 11' ' ' ALA . 84.6 mt -69.0 94.49 0.64 Allowed 'General case' 0 C--O 1.239 0.503 0 O-C-N 123.655 0.597 . . . . 0.0 109.913 -172.312 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -65.28 112.6 8.74 Favored Pre-proline 0 CA--C 1.548 0.889 0 CA-C-N 114.267 -1.333 . . . . 0.0 109.436 -177.479 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -61.31 115.91 3.05 Favored 'Trans proline' 0 C--N 1.375 1.933 0 C-N-CA 122.503 2.135 . . . . 0.0 112.522 -171.405 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 93.12 -6.42 75.96 Favored Glycine 0 C--N 1.348 1.196 0 CA-C-N 114.966 -1.016 . . . . 0.0 113.883 177.542 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 61.3 mttm -128.07 -179.3 4.91 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 123.626 0.77 . . . . 0.0 109.207 -176.691 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -61.38 160.7 22.54 Favored Pre-proline 0 CA--C 1.558 1.26 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 164.302 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . 0.498 ' HG3' ' HB2' ' A' ' 12' ' ' ALA . 30.9 Cg_exo -61.93 -172.53 0.11 Allowed 'Trans proline' 0 C--N 1.375 1.951 0 C-N-CA 122.361 2.041 . . . . 0.0 114.491 -178.309 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 20.0 ttm-85 -138.13 99.46 3.88 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 171.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . 0.565 ' HB2' ' HB3' ' A' ' 17' ' ' GLU . . . -73.39 107.2 5.56 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.341 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 77.2 t -112.11 123.94 68.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 C-N-CA 123.493 0.717 . . . . 0.0 110.069 -176.584 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 171' ' ' GLN . . . . . 0.513 ' HB2' HD13 ' A' ' 22' ' ' ILE . 20.9 mt-30 -93.03 118.29 31.02 Favored 'General case' 0 C--N 1.341 0.217 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 175.362 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . 0.723 HG21 HG23 ' A' ' 187' ' ' VAL . 5.9 t -126.29 142.8 51.39 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 123.206 0.603 . . . . 0.0 109.471 176.511 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -75.89 156.89 84.21 Favored Pre-proline 0 CA--C 1.561 1.368 0 CA-C-N 115.993 -0.548 . . . . 0.0 109.612 178.058 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -69.43 124.55 11.33 Favored 'Trans proline' 0 C--N 1.375 1.939 0 C-N-CA 122.178 1.919 . . . . 0.0 112.708 -177.492 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -158.78 139.38 6.22 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 108.74 -1.744 . . . . 0.0 108.74 175.238 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.749 ' HG ' ' HB3' ' A' ' 186' ' ' ALA 0.264 0.0 OUTLIER -175.8 -169.97 0.37 Allowed 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 123.949 0.899 . . . . 0.0 110.754 178.95 . . . . . . . . 4 4 . 1 . 008 nuclear nobuild core ' A' A ' 177' ' ' PHE . . . . . 0.449 ' HA ' ' O ' ' A' ' 29' ' ' LEU . 79.3 m-85 -91.8 158.3 16.41 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 114.863 -1.062 . . . . 0.0 111.118 -152.28 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -133.36 109.48 9.38 Favored 'General case' 0 C--O 1.239 0.523 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 170.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 1.2 m -140.55 170.18 16.26 Favored 'General case' 0 N--CA 1.479 1.018 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 175.118 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 36.1 t30 -59.85 102.43 0.16 Allowed 'General case' 0 CA--C 1.548 0.892 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 168.324 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . 79.22 1.24 2.34 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 125.415 1.486 . . . . 0.0 111.492 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -123.86 54.2 0.73 Allowed Glycine 0 C--N 1.348 1.225 0 N-CA-C 111.409 -0.676 . . . . 0.0 111.409 178.547 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 84.6 m -110.21 98.16 7.48 Favored 'General case' 0 CA--C 1.536 0.441 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 175.452 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . 0.514 ' O ' ' HB3' ' A' ' 176' ' ' LEU . 3.6 mp -125.13 152.82 31.93 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 178.569 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -127.62 116.98 2.52 Favored Glycine 0 C--N 1.377 2.851 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 172.066 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.749 ' HB3' ' HG ' ' A' ' 176' ' ' LEU . . . -161.87 -149.34 0.16 Allowed 'General case' 0 C--N 1.373 1.598 0 CA-C-N 119.056 1.428 . . . . 0.0 111.9 -159.225 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 187' ' ' VAL . . . . . 0.723 HG23 HG21 ' A' ' 172' ' ' THR . 0.4 OUTLIER -91.57 117.77 35.54 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.971 0 C-N-CA 124.288 1.035 . . . . 0.0 110.028 -176.228 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 188' ' ' SER . . . . . 0.446 ' OG ' ' HB2' ' A' ' 26' ' ' SER . 10.6 t -130.44 90.78 2.98 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 123.406 0.682 . . . . 0.0 109.861 -174.123 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 189' ' ' LEU . . . . . 0.515 ' HA ' ' H ' ' A' ' 25' ' ' SER . 1.7 pp -136.91 -175.0 3.89 Favored 'General case' 0 N--CA 1.489 1.524 0 C-N-CA 123.423 0.689 . . . . 0.0 112.081 -174.292 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -135.19 119.29 17.57 Favored 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 124.238 1.015 . . . . 0.0 108.982 171.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 191' ' ' PHE . . . . . 0.433 ' HE2' ' HG ' ' A' ' 23' ' ' SER . 9.6 m-85 -149.15 -178.89 6.64 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 123.223 0.609 . . . . 0.0 111.916 -178.711 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 42.3 m -60.71 157.09 40.72 Favored Pre-proline 0 CA--C 1.555 1.161 0 C-N-CA 124.787 1.235 . . . . 0.0 111.28 176.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 3.8 Cg_exo -34.58 91.23 0.01 OUTLIER 'Trans proline' 0 C--N 1.393 2.881 0 C-N-CA 125.236 3.957 . . . . 0.0 115.225 -178.018 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -74.08 134.48 18.5 Favored Glycine 0 C--N 1.35 1.325 0 CA-C-N 114.582 -1.19 . . . . 0.0 112.394 -179.669 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 40.7 p -82.72 122.75 28.57 Favored 'General case' 0 C--O 1.244 0.796 0 C-N-CA 123.752 0.821 . . . . 0.0 110.097 178.013 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 18.1 m -62.45 88.08 0.03 OUTLIER 'General case' 0 C--N 1.363 1.17 0 C-N-CA 123.591 0.756 . . . . 0.0 110.847 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 197' ' ' GLY . . . . . 0.468 ' O ' HD22 ' A' ' 210' ' ' LEU . . . 129.12 21.14 1.37 Allowed Glycine 0 CA--C 1.523 0.553 0 CA-C-N 114.897 -1.047 . . . . 0.0 112.574 -179.276 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 198' ' ' SER . . . . . 0.444 ' HA ' ' HD3' ' A' ' 199' ' ' PRO . 32.2 p -70.18 123.64 89.23 Favored Pre-proline 0 N--CA 1.478 0.951 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 172.758 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 199' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' A' ' 198' ' ' SER . 32.1 Cg_exo -58.71 141.88 98.13 Favored 'Trans proline' 0 C--N 1.374 1.918 0 C-N-CA 122.9 2.4 . . . . 0.0 114.368 -168.538 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 200' ' ' ILE . . . . . 0.513 HD13 HG12 ' A' ' 226' ' ' ILE . 47.8 mt -110.8 118.96 58.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.325 0 C-N-CA 124.851 1.26 . . . . 0.0 108.754 175.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 201' ' ' ILE . . . . . 0.592 HG12 HG22 ' A' ' 207' ' ' VAL . 24.0 mt -113.02 143.47 22.64 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.377 0 C-N-CA 124.563 1.145 . . . . 0.0 110.029 -176.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -84.83 153.6 22.84 Favored 'General case' 0 N--CA 1.486 1.357 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 170.21 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 84.0 tttt -48.33 -27.29 2.45 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 124.689 1.196 . . . . 0.0 113.96 -172.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . 0.582 ' H ' ' HD2' ' A' ' 204' ' ' LYS . 9.7 mptt -64.1 -20.09 65.71 Favored 'General case' 0 N--CA 1.484 1.227 0 C-N-CA 124.27 1.028 . . . . 0.0 111.78 -177.448 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 101.6 5.85 50.9 Favored Glycine 0 C--N 1.345 1.033 0 CA-C-N 116.361 -0.382 . . . . 0.0 112.676 -177.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 39.8 tttm -106.61 140.74 39.01 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 123.162 0.585 . . . . 0.0 109.618 -179.762 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 207' ' ' VAL . . . . . 0.592 HG22 HG12 ' A' ' 201' ' ' ILE . 61.9 t -82.63 123.98 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 123.208 0.603 . . . . 0.0 111.41 -168.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 208' ' ' VAL . . . . . 0.605 HG21 ' HB2' ' A' ' 150' ' ' TRP . 45.6 t -69.46 -52.56 31.39 Favored 'Isoleucine or valine' 0 C--O 1.239 0.548 0 O-C-N 124.574 1.171 . . . . 0.0 110.48 173.714 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.519 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . 177.71 -134.24 2.4 Favored Glycine 0 C--N 1.348 1.2 0 CA-C-N 115.157 -0.928 . . . . 0.0 113.694 -175.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 210' ' ' LEU . . . . . 0.468 HD22 ' O ' ' A' ' 197' ' ' GLY . 86.1 mt -131.44 152.64 50.5 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 123.836 0.854 . . . . 0.0 110.926 -176.793 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 51.1 t80 -102.15 104.54 15.15 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 123.861 0.864 . . . . 0.0 108.986 175.696 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 212' ' ' GLY . . . . . 0.449 ' O ' ' SD ' ' A' ' 110' ' ' MET . . . 169.72 74.27 0.04 OUTLIER Glycine 0 C--N 1.337 0.632 0 C-N-CA 120.892 -0.67 . . . . 0.0 113.424 161.514 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 213' ' ' ASN . . . . . 0.705 ' H ' ' HB3' ' A' ' 224' ' ' SER . 71.7 m-20 -146.09 81.96 1.6 Allowed 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 170.368 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 178.03 -121.58 0.78 Allowed Glycine 0 N--CA 1.445 -0.714 0 CA-C-N 114.71 -1.132 . . . . 0.0 111.839 178.303 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 215' ' ' VAL . . . . . . . . . . . . . 10.2 p -172.81 165.61 0.24 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.843 0 C-N-CA 122.883 0.473 . . . . 0.0 109.955 -164.015 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 216' ' ' VAL . . . . . . . . . . . . . 27.7 m -77.45 107.7 9.46 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.137 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 158.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 217' ' ' THR . . . . . 0.529 HG21 HD13 ' A' ' 29' ' ' LEU . 74.6 m -82.41 144.03 30.79 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 123.998 0.919 . . . . 0.0 109.351 -179.751 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 13.6 mmm180 63.81 17.54 10.56 Favored 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 124.03 0.932 . . . . 0.0 110.077 -169.633 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 35.5 m 61.33 31.95 19.23 Favored 'General case' 0 C--N 1.364 1.239 0 C-N-CA 125.536 1.534 . . . . 0.0 112.175 -175.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . -157.93 -52.85 0.01 OUTLIER Glycine 0 C--N 1.352 1.464 0 CA-C-O 120.019 -0.323 . . . . 0.0 113.358 -179.122 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -69.71 114.22 7.71 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 123.185 0.594 . . . . 0.0 111.562 -172.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 222' ' ' TYR . . . . . . . . . . . . . 7.5 m-85 -68.11 98.06 0.75 Allowed 'General case' 0 CA--C 1.551 1.0 0 C-N-CA 123.0 0.52 . . . . 0.0 110.272 179.063 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 94.9 t -127.5 127.17 68.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 C-N-CA 123.798 0.839 . . . . 0.0 110.089 -171.445 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 224' ' ' SER . . . . . 0.705 ' HB3' ' H ' ' A' ' 213' ' ' ASN . 58.5 m -153.75 159.06 41.82 Favored 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 123.237 0.615 . . . . 0.0 111.384 -171.026 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . . . . . . . . . . . -80.03 145.15 32.65 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.352 1.061 . . . . 0.0 110.986 177.451 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 226' ' ' ILE . . . . . 0.637 HG13 ' HB1' ' A' ' 186' ' ' ALA . 85.3 mt -78.85 102.89 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 174.065 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 227' ' ' ALA . . . . . 0.435 ' O ' ' HA3' ' A' ' 209' ' ' GLY . . . -77.76 101.75 6.83 Favored 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 177.757 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 49.0 mt-30 -89.87 169.37 11.3 Favored 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 123.088 0.555 . . . . 0.0 110.098 -171.316 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . 0.43 ' HA ' ' CD1' ' A' ' 144' ' ' TRP . 71.4 p -80.05 123.41 27.82 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 123.079 0.552 . . . . 0.0 111.506 -177.566 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -99.6 -24.18 14.82 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 123.244 0.618 . . . . 0.0 109.504 167.886 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 13.4 ptpt 68.72 157.06 0.14 Allowed 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 127.392 2.277 . . . . 0.0 113.098 174.132 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 22.4 m . . . . . 0 CA--C 1.543 0.678 0 CA-C-N 115.536 -0.756 . . . . 0.0 110.64 166.58 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.432 ' O ' ' HB1' ' A' ' 117' ' ' ALA . . . . . . . . 0 N--CA 1.482 1.165 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -102.81 18.03 22.47 Favored 'General case' 0 N--CA 1.478 0.937 0 O-C-N 121.851 -0.531 . . . . 0.0 109.652 -175.027 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . 0.5 ' HB3' ' O ' ' A' ' 89' ' ' LYS . 6.2 m-20 -126.02 26.88 6.45 Favored 'General case' 0 C--O 1.237 0.444 0 C-N-CA 124.525 1.13 . . . . 0.0 108.976 -169.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.424 ' O ' HD13 ' A' ' 119' ' ' LEU . 83.7 mt -75.8 93.56 3.17 Favored 'General case' 0 C--O 1.215 -0.739 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.085 -173.172 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.446 ' HA ' ' O ' ' A' ' 120' ' ' MET . 23.2 tt0 -83.54 135.19 34.73 Favored 'General case' 0 N--CA 1.475 0.796 0 O-C-N 122.139 -0.351 . . . . 0.0 111.326 -179.651 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.475 HD23 ' H ' ' A' ' 8' ' ' LEU . 2.6 pt? -102.1 138.89 38.46 Favored 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.337 177.096 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 19.1 pt-20 -143.33 144.51 32.12 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.802 0.841 . . . . 0.0 109.096 176.182 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . 0.517 ' NH2' ' HB3' ' A' ' 13' ' ' ASP . 50.7 ttt180 -63.41 120.73 12.21 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 112.286 0.476 . . . . 0.0 112.286 -165.603 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.706 ' HB2' ' HG3' ' A' ' 85' ' ' ARG . . . -84.64 -45.89 12.05 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 124.108 0.963 . . . . 0.0 109.896 173.081 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -170.95 -178.21 2.44 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-N 115.178 -0.919 . . . . 0.0 112.006 -173.733 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . 0.517 ' HB3' ' NH2' ' A' ' 10' ' ' ARG . 10.4 p-10 -103.63 164.77 11.46 Favored 'General case' 0 CA--C 1.54 0.571 0 CA-C-N 114.121 -1.4 . . . . 0.0 108.571 165.373 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 53.0 t -88.11 101.44 11.61 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.856 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 179.03 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 62.7 tttp -172.73 113.74 0.27 Allowed 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 124.42 1.088 . . . . 0.0 108.187 -177.738 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 79.8 t90 -100.95 91.71 4.7 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 122.503 0.321 . . . . 0.0 110.465 -176.714 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -158.27 58.05 0.46 Allowed 'General case' 0 CA--C 1.549 0.931 0 C-N-CA 123.593 0.757 . . . . 0.0 109.746 162.114 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.425 ' HB3' ' H ' ' A' ' 169' ' ' ALA . 8.0 t70 -86.93 -56.04 3.57 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 122.833 0.453 . . . . 0.0 111.17 179.052 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . 0.656 ' H ' ' HB3' ' A' ' 169' ' ' ALA . 0.0 OUTLIER -148.38 4.35 0.69 Allowed 'General case' 0 N--CA 1.484 1.267 0 C-N-CA 123.186 0.595 . . . . 0.0 111.396 -173.615 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . 13.71 81.55 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 126.521 1.928 . . . . 0.0 114.228 -168.422 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.473 ' HB2' ' NE2' ' A' ' 19' ' ' GLN . 34.2 tt0 -101.97 147.44 26.55 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 114.306 -1.316 . . . . 0.0 109.221 -176.503 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 9.4 tp -93.03 149.05 4.34 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.798 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 174.348 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . 0.559 ' HB3' HD23 ' A' ' 189' ' ' LEU . 69.1 m -91.73 -174.67 3.92 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 123.642 0.777 . . . . 0.0 111.455 178.341 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -87.23 -41.88 6.43 Favored Glycine 0 C--N 1.347 1.194 0 CA-C-N 115.436 -0.802 . . . . 0.0 111.28 178.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 35.5 m 63.0 87.47 0.1 Allowed 'General case' 0 C--N 1.358 0.968 0 C-N-CA 124.299 1.039 . . . . 0.0 110.219 177.836 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.553 ' HB2' ' HB3' ' A' ' 188' ' ' SER . 17.2 m -85.49 156.31 59.26 Favored Pre-proline 0 CA--C 1.555 1.147 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.988 -174.672 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -65.63 -168.56 0.13 Allowed 'Trans proline' 0 C--N 1.376 2.018 0 C-N-CA 123.244 2.63 . . . . 0.0 112.448 167.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 35.0 mm -66.14 138.37 23.14 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.267 0 CA-C-O 120.811 0.339 . . . . 0.0 110.662 -174.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.563 HD22 HG22 ' A' ' 217' ' ' THR . 4.3 mt -114.85 161.46 18.21 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 123.282 0.633 . . . . 0.0 110.564 175.167 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 30.4 t -112.24 114.65 27.56 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 178.579 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 12.9 tt -113.62 160.56 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 C-N-CA 124.649 1.18 . . . . 0.0 108.306 -174.793 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 82.2 p -93.89 104.96 17.0 Favored 'General case' 0 C--N 1.363 1.164 0 CA-C-N 119.845 1.202 . . . . 0.0 108.184 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.807 HG21 ' HA ' ' A' ' 179' ' ' THR . 3.5 tp -107.86 154.65 8.91 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 C-N-CA 125.887 1.675 . . . . 0.0 107.549 -176.62 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 9.1 p -157.27 161.91 39.18 Favored 'General case' 0 C--O 1.249 1.061 0 C-N-CA 123.264 0.626 . . . . 0.0 110.547 -171.743 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -58.29 158.02 7.76 Favored 'General case' 0 N--CA 1.481 1.103 0 C-N-CA 124.594 1.158 . . . . 0.0 111.505 -175.548 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 30.7 t70 78.39 14.55 1.38 Allowed 'General case' 0 N--CA 1.491 1.616 0 C-N-CA 124.911 1.284 . . . . 0.0 110.396 178.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 73.98 34.23 56.05 Favored Glycine 0 C--N 1.356 1.644 0 CA-C-N 115.343 -0.844 . . . . 0.0 112.265 -178.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 47.5 t -99.54 143.87 29.29 Favored 'General case' 0 N--CA 1.469 0.522 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -175.718 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 19.3 ptm -163.03 154.24 17.23 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 122.571 0.348 . . . . 0.0 111.053 -177.087 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 35.5 p -176.29 -179.09 1.03 Allowed 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 125.035 1.334 . . . . 0.0 108.96 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.415 HG21 ' O ' ' A' ' 216' ' ' VAL . 10.4 tp -107.17 96.72 4.86 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 172.309 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 7.5 mtpm? 50.77 31.0 5.47 Favored 'General case' 0 CA--C 1.559 1.318 0 C-N-CA 124.247 1.019 . . . . 0.0 113.082 170.729 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 41.8 t-20 79.15 -30.02 0.14 Allowed 'General case' 0 N--CA 1.502 2.132 0 C-N-CA 125.885 1.674 . . . . 0.0 111.959 -174.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -58.54 107.36 0.49 Allowed 'General case' 0 CA--C 1.55 0.949 0 C-N-CA 125.533 1.533 . . . . 0.0 112.86 -171.005 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 . . . . . 0 N--CA 1.474 0.759 0 C-N-CA 123.419 0.687 . . . . 0.0 110.684 172.471 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.609 ' N ' ' HH ' ' A' ' 84' ' ' TYR . 18.9 t70 . . . . . 0 N--CA 1.487 1.413 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.421 ' HA3' ' HA ' ' A' ' 13' ' ' ASP . . . 93.49 -147.54 18.63 Favored Glycine 0 C--N 1.344 0.984 0 C-N-CA 123.076 0.369 . . . . 0.0 113.34 177.199 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -84.44 138.22 32.94 Favored 'General case' 0 N--CA 1.48 1.062 0 C-N-CA 123.493 0.717 . . . . 0.0 110.155 -177.397 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' TYR . . . . . 0.609 ' HH ' ' N ' ' A' ' 81' ' ' ASP . 12.0 m-85 -125.74 140.02 53.04 Favored 'General case' 0 N--CA 1.494 1.761 0 C-N-CA 123.334 0.654 . . . . 0.0 111.324 -179.061 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' ARG . . . . . 0.706 ' HG3' ' HB2' ' A' ' 11' ' ' ALA . 58.2 mtt-85 -85.41 122.21 29.23 Favored 'General case' 0 C--O 1.239 0.521 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 169.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.48 HD11 ' HZ ' ' A' ' 107' ' ' PHE . 62.6 mt -98.3 119.82 46.82 Favored 'Isoleucine or valine' 0 C--O 1.253 1.237 0 CA-C-O 121.589 0.709 . . . . 0.0 109.394 175.299 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.442 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 58.4 pttt -111.12 146.9 36.0 Favored 'General case' 0 C--O 1.239 0.548 0 CA-C-N 114.26 -1.336 . . . . 0.0 108.477 174.001 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . 0.491 ' NE2' ' HB2' ' A' ' 5' ' ' ASP . 0.1 OUTLIER -83.09 107.81 15.92 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 104.294 -2.484 . . . . 0.0 104.294 166.31 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . 0.5 ' O ' ' HB3' ' A' ' 5' ' ' ASP . 28.8 ttpt -117.34 96.92 5.64 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -175.506 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -67.11 154.2 52.86 Favored Glycine 0 C--N 1.339 0.725 0 N-CA-C 107.436 -2.266 . . . . 0.0 107.436 166.097 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 20.1 mm -78.86 63.93 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.39 0 CA-C-N 118.637 1.219 . . . . 0.0 108.926 -173.265 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 22.3 tp 167.81 -32.62 0.0 OUTLIER 'General case' 0 CA--C 1.562 1.431 0 C-N-CA 125.535 1.534 . . . . 0.0 109.854 -166.336 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -145.36 149.14 21.25 Favored Glycine 0 C--N 1.369 2.39 0 N-CA-C 114.265 0.466 . . . . 0.0 114.265 -171.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -124.98 133.36 53.04 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 124.614 1.166 . . . . 0.0 110.33 -169.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 44.7 m -151.45 103.19 2.96 Favored 'General case' 0 N--CA 1.493 1.705 0 CA-C-N 118.602 0.637 . . . . 0.0 112.085 176.724 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.442 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 43.7 mt-30 -53.76 120.39 6.19 Favored 'General case' 0 N--CA 1.495 1.818 0 C-N-CA 123.489 0.716 . . . . 0.0 111.215 173.446 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.5 pp -122.54 -13.07 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 C-N-CA 123.806 0.842 . . . . 0.0 112.061 -176.645 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 174.87 -152.51 13.96 Favored Glycine 0 C--N 1.342 0.903 0 CA-C-O 119.637 -0.535 . . . . 0.0 112.313 174.619 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -156.36 164.3 38.46 Favored 'General case' 0 C--O 1.241 0.652 0 C-N-CA 123.384 0.674 . . . . 0.0 110.973 -176.594 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -158.31 149.94 20.46 Favored Glycine 0 C--N 1.339 0.731 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 177.209 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 37.2 t -96.14 118.91 43.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 C-N-CA 123.328 0.651 . . . . 0.0 110.192 -176.576 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 85.5 t80 -94.93 126.9 40.58 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 171.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.441 ' HA ' ' HD2' ' A' ' 103' ' ' LYS . 42.7 tptt -133.55 114.5 13.64 Favored 'General case' 0 C--O 1.239 0.548 0 C-N-CA 123.28 0.632 . . . . 0.0 109.565 175.054 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 68.52 -78.14 0.05 OUTLIER 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 125.282 1.433 . . . . 0.0 112.415 169.185 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -147.46 32.43 1.36 Allowed Glycine 0 N--CA 1.465 0.569 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 176.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 44.6 m -136.84 124.86 22.82 Favored 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 124.21 1.004 . . . . 0.0 109.563 178.331 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' PHE . . . . . 0.48 ' HZ ' HD11 ' A' ' 86' ' ' ILE . 57.0 t80 -110.13 118.05 35.35 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 172.634 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . 0.527 ' NE2' ' HB3' ' A' ' 137' ' ' LEU . 60.5 t60 -123.69 114.82 20.47 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 122.809 0.443 . . . . 0.0 109.97 -178.654 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 9.0 t -114.14 -165.71 1.03 Allowed 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 124.338 1.055 . . . . 0.0 109.525 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' MET . . . . . 0.589 ' HA ' ' HA ' ' A' ' 137' ' ' LEU . 13.6 mtp -107.43 160.56 15.55 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 124.13 0.972 . . . . 0.0 110.033 177.075 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 11.6 t90 -80.79 -31.47 35.74 Favored 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 122.645 0.378 . . . . 0.0 111.512 -175.561 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 46.1 p-80 -75.02 -18.02 60.41 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.639 -0.663 . . . . 0.0 111.051 174.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 68.7 t -81.98 -44.02 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.523 0.729 . . . . 0.0 109.519 173.675 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 90.1 m -135.16 108.3 7.7 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 107.752 -1.203 . . . . 0.0 107.752 -178.767 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 19.3 ptp180 -85.69 33.33 0.58 Allowed 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 123.298 0.639 . . . . 0.0 112.211 -172.533 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 91.74 27.76 16.06 Favored Glycine 0 N--CA 1.47 0.912 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -170.083 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . 0.432 ' HB1' ' O ' ' A' ' 3' ' ' ALA . . . -94.41 -178.92 4.74 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.065 0.946 . . . . 0.0 110.971 -177.189 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 70.2 t -100.3 133.25 43.99 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 123.404 0.681 . . . . 0.0 110.47 -176.341 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.541 ' HB2' ' HB ' ' A' ' 126' ' ' ILE . 2.4 mm? -92.01 162.31 14.43 Favored 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 124.155 0.982 . . . . 0.0 110.049 172.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' MET . . . . . 0.446 ' O ' ' HA ' ' A' ' 7' ' ' GLU . 23.5 mmt -139.25 136.79 35.33 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 124.066 0.947 . . . . 0.0 110.458 -171.609 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 56.8 t60 -169.38 137.0 1.8 Allowed 'General case' 0 N--CA 1.476 0.825 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 153.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 85.5 mttt 70.45 9.69 7.0 Favored 'General case' 0 N--CA 1.503 2.208 0 C-N-CA 124.238 1.015 . . . . 0.0 111.753 -178.45 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 83.46 -4.95 79.96 Favored Glycine 0 C--N 1.349 1.266 0 CA-C-O 119.953 -0.359 . . . . 0.0 112.519 -167.289 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 31.0 mmmt -72.64 117.61 14.54 Favored 'General case' 0 C--O 1.248 0.998 0 C-N-CA 123.512 0.725 . . . . 0.0 109.123 175.593 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 85.3 mtm180 -87.4 96.05 10.23 Favored 'General case' 0 C--O 1.237 0.418 0 O-C-N 124.665 1.228 . . . . 0.0 108.869 -179.122 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.541 ' HB ' ' HB2' ' A' ' 119' ' ' LEU . 97.2 mt -75.19 114.78 15.65 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.664 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.271 -179.069 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -92.91 146.9 32.92 Favored Pre-proline 0 CA--C 1.548 0.875 0 C-N-CA 124.126 0.97 . . . . 0.0 110.63 -174.554 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_exo -67.9 101.01 0.65 Allowed 'Trans proline' 0 C--N 1.367 1.528 0 C-N-CA 122.088 1.859 . . . . 0.0 110.866 169.336 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 22.7 t -64.33 -31.25 72.38 Favored 'General case' 0 N--CA 1.483 1.216 0 CA-C-O 121.271 0.558 . . . . 0.0 109.877 177.19 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 75.0 t-105 -150.7 156.33 41.11 Favored 'General case' 0 CA--C 1.543 0.695 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 165.306 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -136.76 120.09 16.86 Favored 'General case' 0 N--CA 1.467 0.419 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 176.278 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 27.3 m-20 -95.13 106.78 18.81 Favored 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 124.394 1.078 . . . . 0.0 109.247 175.518 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 60.3 t -75.59 -41.87 41.58 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.659 0 C-N-CA 123.141 0.577 . . . . 0.0 110.351 178.74 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 55.7 tttm -73.76 -34.98 64.95 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.954 -175.242 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 13.6 tppt? -80.88 -18.78 46.12 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 123.096 0.558 . . . . 0.0 110.797 176.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 26.3 t70 62.5 48.32 4.58 Favored 'General case' 0 N--CA 1.481 1.083 0 CA-C-O 122.72 1.248 . . . . 0.0 110.379 -175.4 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.589 ' HA ' ' HA ' ' A' ' 110' ' ' MET . 74.8 mt -149.98 138.6 20.76 Favored 'General case' 0 N--CA 1.476 0.838 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.155 -176.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 5.8 mt -112.22 145.02 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 C-N-CA 123.384 0.674 . . . . 0.0 110.416 175.206 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . 0.415 ' HB3' ' O ' ' A' ' 142' ' ' GLY . 34.6 m -118.64 141.61 48.43 Favored 'General case' 0 CA--C 1.557 1.217 0 C-N-CA 125.015 1.326 . . . . 0.0 110.945 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 19.6 t80 -135.38 142.13 45.64 Favored 'General case' 0 N--CA 1.488 1.472 0 C-N-CA 124.835 1.254 . . . . 0.0 108.515 173.203 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.26 -60.5 4.7 Favored Glycine 0 C--N 1.352 1.42 0 N-CA-C 111.254 -0.738 . . . . 0.0 111.254 -176.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . 0.415 ' O ' ' HB3' ' A' ' 139' ' ' SER . . . -148.28 -171.82 17.57 Favored Glycine 0 C--O 1.242 0.635 0 N-CA-C 109.871 -1.292 . . . . 0.0 109.871 172.394 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -77.46 -177.17 46.06 Favored Glycine 0 C--N 1.337 0.627 0 N-CA-C 112.13 -0.388 . . . . 0.0 112.13 175.333 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' TRP . . . . . 0.501 ' HB2' ' CE1' ' A' ' 108' ' ' HIS . 13.4 t-105 -69.78 111.6 5.65 Favored 'General case' 0 C--O 1.243 0.756 0 O-C-N 122.585 -0.362 . . . . 0.0 110.44 177.19 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . 0.412 ' HB3' ' O ' ' A' ' 232' ' ' SER . 23.0 pttm -135.64 152.34 51.12 Favored 'General case' 0 N--CA 1.466 0.334 0 O-C-N 124.092 0.87 . . . . 0.0 110.308 173.015 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' LEU . . . . . 0.443 ' H ' ' H ' ' A' ' 147' ' ' GLU . 4.1 mt 174.63 -8.89 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.945 0 C-N-CA 127.158 2.183 . . . . 0.0 108.207 178.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.46 ' N ' HG21 ' A' ' 229' ' ' THR . 7.6 mm-40 60.0 70.93 0.6 Allowed 'General case' 0 C--N 1.365 1.269 0 C-N-CA 125.387 1.475 . . . . 0.0 110.66 173.377 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -104.15 159.23 16.48 Favored Glycine 0 N--CA 1.444 -0.789 0 CA-C-N 114.069 -1.423 . . . . 0.0 113.998 -177.204 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -129.35 93.01 3.46 Favored 'General case' 0 C--O 1.243 0.742 0 C-N-CA 123.856 0.862 . . . . 0.0 109.142 178.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' TRP . . . . . . . . . . . . . 25.2 t90 -74.24 120.63 20.07 Favored 'General case' 0 C--O 1.238 0.498 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 173.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 20.4 mttm -85.15 94.68 8.93 Favored 'General case' 0 C--O 1.243 0.722 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 176.695 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -66.39 97.15 0.4 Allowed 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 123.671 0.788 . . . . 0.0 109.053 -176.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 143.27 -49.33 0.72 Allowed Glycine 0 C--N 1.341 0.842 0 CA-C-N 115.371 -0.832 . . . . 0.0 111.365 -178.357 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -85.33 157.94 20.41 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 122.889 0.476 . . . . 0.0 112.042 -175.659 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . 0.467 ' HA ' ' HA ' ' A' ' 173' ' ' LYS . 0.8 OUTLIER -62.5 131.1 48.0 Favored 'General case' 0 C--N 1.351 0.654 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.926 177.918 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.53 HG11 HD13 ' A' ' 226' ' ' ILE . 34.0 m -93.25 159.11 2.83 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.562 179.421 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 25.2 mp0 -113.02 130.36 56.17 Favored 'General case' 0 C--O 1.215 -0.727 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -172.079 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 44.6 t -133.99 137.07 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -174.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.582 HD23 ' H ' ' A' ' 159' ' ' LEU . 2.2 pt? -92.57 96.53 10.26 Favored 'General case' 0 CA--C 1.545 0.777 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 169.269 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -64.91 104.02 0.8 Allowed 'General case' 0 C--O 1.24 0.603 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.243 -178.565 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . 0.613 HD23 ' HB3' ' A' ' 167' ' ' PRO . 78.0 mt -69.01 84.74 0.33 Allowed 'General case' 0 C--O 1.241 0.641 0 C-N-CA 123.704 0.802 . . . . 0.0 108.873 177.109 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 28.3 tt0 -74.9 134.11 75.34 Favored Pre-proline 0 CA--C 1.545 0.767 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.297 -177.085 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_exo -46.25 112.59 0.48 Allowed 'Trans proline' 0 C--N 1.382 2.342 0 C-N-CA 123.53 2.82 . . . . 0.0 113.881 178.198 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 63.79 27.87 71.78 Favored Glycine 0 C--N 1.35 1.356 0 O-C-N 123.903 0.752 . . . . 0.0 113.819 173.703 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 53.0 tptt -146.49 173.21 12.51 Favored 'General case' 0 C--O 1.245 0.837 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 -176.03 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -56.87 151.09 34.6 Favored Pre-proline 0 CA--C 1.558 1.28 0 C-N-CA 123.701 0.8 . . . . 0.0 112.595 177.317 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . 0.613 ' HB3' HD23 ' A' ' 161' ' ' LEU . 6.9 Cg_exo -74.86 92.42 0.97 Allowed 'Trans proline' 0 C--N 1.372 1.789 0 C-N-CA 123.249 2.632 . . . . 0.0 110.188 171.393 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 31.7 ttp-105 -75.68 122.08 23.45 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.065 -170.211 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . 0.656 ' HB3' ' H ' ' A' ' 19' ' ' GLN . . . -68.77 105.36 2.29 Favored 'General case' 0 CA--C 1.538 0.505 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.934 179.606 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 18.8 t -129.24 135.01 62.85 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.095 0 C-N-CA 124.866 1.266 . . . . 0.0 108.257 176.353 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 171' ' ' GLN . . . . . 0.472 ' HG2' ' O ' ' A' ' 21' ' ' GLU . 27.3 pt20 -117.07 126.73 53.3 Favored 'General case' 0 N--CA 1.478 0.933 0 C-N-CA 123.651 0.781 . . . . 0.0 110.318 -176.122 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . 0.527 HG21 HG13 ' A' ' 187' ' ' VAL . 5.4 t -118.0 143.13 46.65 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 124.207 1.003 . . . . 0.0 110.911 -173.006 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . 0.467 ' HA ' ' HA ' ' A' ' 155' ' ' GLU . 37.2 ttmt -85.46 142.07 37.26 Favored Pre-proline 0 N--CA 1.479 0.983 0 CA-C-O 118.549 -0.738 . . . . 0.0 109.334 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 174' ' ' PRO . . . . . 0.577 ' HA ' ' O ' ' A' ' 186' ' ' ALA . 89.6 Cg_exo -47.32 122.69 6.85 Favored 'Trans proline' 0 C--N 1.396 3.04 0 C-N-CA 123.116 2.544 . . . . 0.0 114.562 -175.244 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . 0.526 ' H ' ' C ' ' A' ' 186' ' ' ALA . . . -135.47 139.59 10.91 Favored Glycine 0 CA--C 1.541 1.679 0 CA-C-N 115.159 -0.928 . . . . 0.0 114.543 179.342 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.434 HD23 ' N ' ' A' ' 176' ' ' LEU . 0.3 OUTLIER -132.22 162.5 30.77 Favored 'General case' 0 C--O 1.241 0.619 0 O-C-N 121.551 -0.97 . . . . 0.0 110.18 -171.412 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 177' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -138.51 139.53 38.79 Favored 'General case' 0 C--O 1.242 0.668 0 CA-C-N 114.141 -1.391 . . . . 0.0 109.727 -167.334 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 178' ' ' LYS . . . . . 0.435 ' HE3' ' HB3' ' A' ' 178' ' ' LYS . 1.3 tmmt? -69.07 120.77 15.45 Favored 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 124.481 1.112 . . . . 0.0 111.648 -165.488 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . 0.807 ' HA ' HG21 ' A' ' 33' ' ' ILE . 7.4 m -90.09 165.4 14.02 Favored 'General case' 0 CA--C 1.551 1.01 0 C-N-CA 125.89 1.676 . . . . 0.0 109.787 177.619 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 180' ' ' ASN . . . . . 0.561 ' ND2' HG23 ' A' ' 33' ' ' ILE . 63.4 m-80 -64.53 -35.14 79.99 Favored 'General case' 0 N--CA 1.487 1.384 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 170.82 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . 0.4 ' H ' HG22 ' A' ' 179' ' ' THR . . . -75.62 -48.22 23.14 Favored 'General case' 0 CA--C 1.54 0.566 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.977 175.798 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . 0.682 ' H ' ' HB ' ' A' ' 179' ' ' THR . . . -165.73 -94.43 0.1 OUTLIER Glycine 0 C--N 1.345 1.045 0 CA-C-O 119.756 -0.469 . . . . 0.0 112.638 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 7.5 t -163.46 135.83 5.21 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 124.719 1.208 . . . . 0.0 109.354 178.092 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -132.98 155.73 41.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 122.898 0.479 . . . . 0.0 109.814 177.052 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . 129.83 177.58 14.96 Favored Glycine 0 C--N 1.343 0.935 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 173.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.577 ' O ' ' HA ' ' A' ' 174' ' ' PRO . . . -171.66 38.85 0.02 OUTLIER 'General case' 0 C--O 1.193 -1.901 0 C-N-CA 123.486 0.715 . . . . 0.0 110.329 177.867 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 187' ' ' VAL . . . . . 0.527 HG13 HG21 ' A' ' 172' ' ' THR . 95.1 t -153.15 125.22 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 120.012 -1.68 . . . . 0.0 107.648 167.399 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 188' ' ' SER . . . . . 0.635 ' HA ' HG12 ' A' ' 223' ' ' VAL . 73.6 m -132.54 91.13 2.88 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 168.115 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 189' ' ' LEU . . . . . 0.559 HD23 ' HB3' ' A' ' 23' ' ' SER . 0.5 OUTLIER -126.97 104.36 7.96 Favored 'General case' 0 N--CA 1.48 1.039 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 -176.285 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 190' ' ' ASP . . . . . 0.681 ' HA ' ' HA ' ' A' ' 221' ' ' ALA . 8.0 p-10 -85.72 103.16 14.25 Favored 'General case' 0 C--N 1.356 0.865 0 CA-C-O 121.875 0.845 . . . . 0.0 109.992 -179.243 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 191' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -174.19 172.92 3.19 Favored 'General case' 0 N--CA 1.475 0.776 0 CA-C-N 115.059 -0.973 . . . . 0.0 108.541 -167.393 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 44.5 p -58.3 121.91 55.51 Favored Pre-proline 0 CA--C 1.548 0.883 0 C-N-CA 123.127 0.571 . . . . 0.0 110.614 175.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_endo -61.16 127.66 22.81 Favored 'Trans proline' 0 C--N 1.376 2.021 0 C-N-CA 122.246 1.964 . . . . 0.0 112.661 -178.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -72.41 173.44 46.43 Favored Glycine 0 C--N 1.35 1.326 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 162.099 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 7.4 m -80.66 135.78 36.09 Favored 'General case' 0 CA--C 1.562 1.416 0 CA-C-N 118.626 1.213 . . . . 0.0 111.334 -172.532 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -65.19 88.44 0.08 Allowed 'General case' 0 C--N 1.367 1.339 0 C-N-CA 124.13 0.972 . . . . 0.0 111.304 -171.641 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 197' ' ' GLY . . . . . 0.645 ' HA2' HD21 ' A' ' 210' ' ' LEU . . . 144.59 9.58 0.36 Allowed Glycine 0 C--N 1.335 0.499 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.984 -175.908 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 198' ' ' SER . . . . . 0.431 ' O ' ' HB2' ' A' ' 211' ' ' TYR . 39.3 m -57.36 132.09 81.31 Favored Pre-proline 0 CA--C 1.556 1.208 0 C-N-CA 122.942 0.497 . . . . 0.0 109.838 166.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -69.91 137.44 35.02 Favored 'Trans proline' 0 C--N 1.369 1.621 0 C-N-CA 121.965 1.777 . . . . 0.0 111.108 174.072 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 39.9 mt -91.92 119.6 39.61 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 N-CA-C 107.923 -1.139 . . . . 0.0 107.923 170.732 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 201' ' ' ILE . . . . . 0.642 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 46.7 mt -103.61 168.87 2.19 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.483 0 C-N-CA 125.632 1.573 . . . . 0.0 109.786 179.768 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -104.6 167.19 9.89 Favored 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 124.752 1.221 . . . . 0.0 109.402 178.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 18.5 ptpt -55.11 -29.24 57.24 Favored 'General case' 0 N--CA 1.481 1.106 0 C-N-CA 124.626 1.17 . . . . 0.0 112.444 177.762 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 52.9 mtmt -82.33 10.57 6.75 Favored 'General case' 0 N--CA 1.481 1.11 0 C-N-CA 123.324 0.65 . . . . 0.0 112.277 -179.072 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 70.0 19.73 75.68 Favored Glycine 0 C--N 1.356 1.669 0 N-CA-C 112.115 -0.394 . . . . 0.0 112.115 -177.235 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 62.4 tttp -110.73 121.14 44.59 Favored 'General case' 0 C--O 1.212 -0.892 0 C-N-CA 124.381 1.072 . . . . 0.0 108.662 -176.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 207' ' ' VAL . . . . . 0.642 ' HA ' ' HA ' ' A' ' 201' ' ' ILE . 7.1 p -53.9 139.67 11.87 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.092 0 C-N-CA 123.191 0.596 . . . . 0.0 111.687 178.092 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 3.6 m -98.34 -35.43 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.854 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 170.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.555 ' HA3' ' HA ' ' A' ' 228' ' ' GLN . . . 166.86 -138.18 5.05 Favored Glycine 0 C--N 1.348 1.226 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.268 -178.229 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 210' ' ' LEU . . . . . 0.645 HD21 ' HA2' ' A' ' 197' ' ' GLY . 5.1 tt -122.58 154.01 38.52 Favored 'General case' 0 CA--C 1.545 0.779 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 -172.122 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 211' ' ' TYR . . . . . 0.461 ' N ' HD23 ' A' ' 210' ' ' LEU . 10.2 t80 -62.45 142.19 58.01 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 123.592 0.757 . . . . 0.0 109.956 178.467 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -77.45 -157.83 9.26 Favored Glycine 0 N--CA 1.475 1.298 0 CA-C-N 118.103 0.41 . . . . 0.0 112.622 178.392 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 213' ' ' ASN . . . . . . . . . . . . . 14.7 t-20 -81.92 85.59 6.66 Favored 'General case' 0 N--CA 1.477 0.904 0 N-CA-C 108.442 -0.948 . . . . 0.0 108.442 -176.658 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . -71.66 123.3 9.87 Favored Glycine 0 C--N 1.347 1.174 0 CA-C-N 114.789 -1.096 . . . . 0.0 112.008 177.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 215' ' ' VAL . . . . . . . . . . . . . 21.7 t -134.59 143.56 37.44 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.672 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 173.63 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 216' ' ' VAL . . . . . 0.563 ' HB ' ' HA2' ' A' ' 220' ' ' GLY . 15.4 m -87.98 111.3 22.01 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.891 0 CA-C-O 121.781 0.8 . . . . 0.0 109.536 -178.718 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 217' ' ' THR . . . . . 0.563 HG22 HD22 ' A' ' 29' ' ' LEU . 38.8 m -107.74 162.53 13.9 Favored 'General case' 0 N--CA 1.475 0.825 0 C-N-CA 124.329 1.052 . . . . 0.0 109.659 -170.692 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 20.3 ttm180 71.45 -73.77 0.09 Allowed 'General case' 0 N--CA 1.492 1.646 0 C-N-CA 124.217 1.007 . . . . 0.0 109.592 -177.065 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 41.1 m -140.96 -43.86 0.39 Allowed 'General case' 0 CA--C 1.547 0.838 0 C-N-CA 124.519 1.127 . . . . 0.0 109.19 178.833 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 220' ' ' GLY . . . . . 0.563 ' HA2' ' HB ' ' A' ' 216' ' ' VAL . . . -169.04 27.65 0.13 Allowed Glycine 0 C--N 1.348 1.218 0 CA-C-N 115.49 -0.777 . . . . 0.0 112.181 -175.744 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 221' ' ' ALA . . . . . 0.681 ' HA ' ' HA ' ' A' ' 190' ' ' ASP . . . -80.32 96.11 6.55 Favored 'General case' 0 N--CA 1.465 0.317 0 C-N-CA 123.684 0.794 . . . . 0.0 110.607 179.717 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 222' ' ' TYR . . . . . . . . . . . . . 12.3 t80 -66.61 95.9 0.36 Allowed 'General case' 0 CA--C 1.554 1.123 0 CA-C-N 114.804 -1.089 . . . . 0.0 109.543 -176.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . 0.635 HG12 ' HA ' ' A' ' 188' ' ' SER . 35.3 m -114.59 140.14 37.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 C-N-CA 123.81 0.844 . . . . 0.0 109.774 -177.157 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 33.1 t -152.16 160.68 43.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.623 -169.598 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . . . . . . . . . . . -81.64 -175.02 5.32 Favored 'General case' 0 CA--C 1.546 0.792 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.643 164.43 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 226' ' ' ILE . . . . . 0.53 HD13 HG11 ' A' ' 156' ' ' VAL . 78.2 mt -133.57 116.44 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 176.005 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -95.78 137.2 35.18 Favored 'General case' 0 C--O 1.233 0.196 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 176.015 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . 0.555 ' HA ' ' HA3' ' A' ' 209' ' ' GLY . 29.0 pt20 -120.26 174.3 6.59 Favored 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 175.318 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . 0.464 ' HA ' ' CD1' ' A' ' 144' ' ' TRP . 39.4 p -66.14 107.71 2.02 Favored 'General case' 0 CA--C 1.546 0.825 0 CA-C-O 121.208 0.528 . . . . 0.0 110.802 -176.502 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 230' ' ' GLU . . . . . 0.482 ' HG2' ' O ' ' A' ' 228' ' ' GLN . 26.7 mm-40 -108.06 -30.16 8.58 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 124.425 1.09 . . . . 0.0 112.437 -168.384 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 29.8 mmtp -107.06 -99.78 0.35 Allowed 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 113.477 0.917 . . . . 0.0 113.477 -160.38 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 232' ' ' SER . . . . . 0.412 ' O ' ' HB3' ' A' ' 145' ' ' LYS . 64.3 p . . . . . 0 C--N 1.361 1.093 0 CA-C-O 121.958 0.885 . . . . 0.0 110.672 -165.207 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.529 ' HB3' HD11 ' A' ' 6' ' ' LEU . . . . . . . . 0 N--CA 1.494 1.753 0 N-CA-C 111.317 0.117 . . . . 0.0 111.317 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -150.76 -62.01 0.19 Allowed 'General case' 0 N--CA 1.477 0.875 0 C-N-CA 123.287 0.635 . . . . 0.0 110.054 -173.131 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . 0.732 ' HA ' ' HG3' ' A' ' 120' ' ' MET . 32.6 t70 -144.5 76.92 1.52 Allowed 'General case' 0 CA--C 1.528 0.113 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 -172.386 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.529 HD11 ' HB3' ' A' ' 3' ' ' ALA . 5.8 mp -117.56 124.4 48.57 Favored 'General case' 0 N--CA 1.488 1.471 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.051 -179.283 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.794 ' HB2' ' HD3' ' A' ' 89' ' ' LYS . 14.5 tp10 -80.9 134.54 35.76 Favored 'General case' 0 C--O 1.252 1.229 0 CA-C-N 118.06 0.391 . . . . 0.0 110.449 178.023 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.462 ' HB2' HD11 ' A' ' 119' ' ' LEU . 18.1 tp -87.16 113.34 22.81 Favored 'General case' 0 CA--C 1.542 0.649 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 171.027 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -104.87 143.64 32.87 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 125.826 1.65 . . . . 0.0 108.176 -173.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.8 ptt-85 -76.29 147.16 38.42 Favored 'General case' 0 N--CA 1.481 1.104 0 CA-C-N 118.336 0.516 . . . . 0.0 110.505 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.656 ' HB2' ' HG3' ' A' ' 85' ' ' ARG . . . -125.89 -51.12 1.57 Allowed 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 169.2 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -166.65 175.34 8.0 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.012 0.925 . . . . 0.0 110.279 -177.038 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -98.59 159.44 14.95 Favored 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 108.401 -0.962 . . . . 0.0 108.401 164.11 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 83.4 t -88.39 103.18 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 CA-C-O 121.545 0.688 . . . . 0.0 111.281 -176.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 2.4 ptpp? -155.98 158.67 38.28 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 124.891 1.277 . . . . 0.0 107.97 168.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 10.6 t90 -67.83 105.43 1.96 Allowed 'General case' 0 CA--C 1.549 0.923 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.26 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.57 ' HB3' ' HB2' ' A' ' 169' ' ' ALA . 2.6 tm-20 -70.35 145.03 51.45 Favored 'General case' 0 CA--C 1.554 1.127 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 170.496 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -75.65 -19.45 59.16 Favored 'General case' 0 N--CA 1.481 1.117 0 N-CA-C 113.885 1.069 . . . . 0.0 113.885 -165.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 6.6 tp60 -94.1 53.37 1.74 Allowed 'General case' 0 N--CA 1.476 0.828 0 CA-C-O 121.46 0.648 . . . . 0.0 110.592 -168.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.617 ' HB1' ' HB2' ' A' ' 171' ' ' GLN . . . -56.04 91.24 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 124.558 1.143 . . . . 0.0 111.843 178.34 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -62.74 126.51 27.59 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 124.851 1.261 . . . . 0.0 110.746 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 50.4 mm -77.08 109.16 11.3 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.613 0 C-N-CA 123.073 0.549 . . . . 0.0 109.609 -178.256 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.1 m -135.38 -174.78 3.72 Favored 'General case' 0 CA--C 1.551 1.015 0 C-N-CA 124.038 0.935 . . . . 0.0 110.026 -179.436 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.413 ' H ' ' HB3' ' A' ' 189' ' ' LEU . . . 98.11 73.1 1.1 Allowed Glycine 0 C--N 1.349 1.259 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 -172.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.8 m -124.57 1.93 8.27 Favored 'General case' 0 N--CA 1.478 0.963 0 C-N-CA 122.971 0.508 . . . . 0.0 112.291 -164.636 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 13.7 m -120.45 137.88 26.7 Favored Pre-proline 0 CA--C 1.55 0.957 0 C-N-CA 123.291 0.636 . . . . 0.0 109.675 -176.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -82.43 -155.82 0.06 OUTLIER 'Trans proline' 0 C--N 1.379 2.151 0 C-N-CA 123.204 2.603 . . . . 0.0 112.253 179.506 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 48.6 mm -66.32 121.05 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 123.16 0.584 . . . . 0.0 110.632 -178.749 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.2 mt -105.53 164.87 11.55 Favored 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 124.658 1.183 . . . . 0.0 111.752 -175.139 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 39.4 m -122.46 116.18 23.52 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 123.5 0.72 . . . . 0.0 109.542 176.122 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.509 HD11 HG11 ' A' ' 223' ' ' VAL . 62.5 mt -116.24 145.09 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 C-N-CA 124.292 1.037 . . . . 0.0 108.561 178.391 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 35.9 p -93.56 105.13 17.21 Favored 'General case' 0 CA--C 1.543 0.703 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.125 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 9.2 tp -69.91 141.14 17.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 C-N-CA 124.159 0.983 . . . . 0.0 110.403 175.019 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 34.3 t -135.47 140.17 44.64 Favored 'General case' 0 C--O 1.242 0.701 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 176.788 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 65.14 15.98 10.3 Favored 'General case' 0 CA--C 1.563 1.476 0 C-N-CA 123.893 0.877 . . . . 0.0 111.133 174.756 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 58.12 32.65 22.27 Favored 'General case' 0 N--CA 1.49 1.545 0 C-N-CA 124.744 1.218 . . . . 0.0 111.67 -179.0 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -169.55 -44.41 0.03 OUTLIER Glycine 0 C--N 1.348 1.236 0 CA-C-N 116.32 -0.4 . . . . 0.0 112.669 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 25.6 m -89.15 106.2 18.29 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -176.373 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 27.3 mtm -88.05 162.59 16.71 Favored 'General case' 0 N--CA 1.476 0.873 0 O-C-N 121.909 -0.494 . . . . 0.0 110.856 -176.21 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 39.1 m -147.51 148.56 31.34 Favored 'General case' 0 C--O 1.238 0.492 0 C-N-CA 123.707 0.803 . . . . 0.0 109.379 -178.553 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 9.1 tp -96.12 151.7 3.97 Favored 'Isoleucine or valine' 0 C--O 1.239 0.55 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 169.326 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 50.2 mtmt -81.93 40.92 0.63 Allowed 'General case' 0 CA--C 1.558 1.261 0 C-N-CA 123.532 0.733 . . . . 0.0 111.222 175.31 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 7.8 t30 -167.49 75.34 0.14 Allowed 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 125.047 1.339 . . . . 0.0 107.661 176.518 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -75.29 117.66 17.34 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 177.398 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 . . . . . 0 C--O 1.245 0.827 0 C-N-CA 123.912 0.885 . . . . 0.0 109.398 177.939 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 CA--C 1.549 0.939 0 CA-C-O 121.458 0.647 . . . . 0.0 109.731 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -166.16 166.33 38.7 Favored Glycine 0 C--N 1.34 0.802 0 CA-C-N 115.805 -0.634 . . . . 0.0 113.455 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . 0.68 ' HB1' HD11 ' A' ' 161' ' ' LEU . . . -86.3 118.14 25.55 Favored 'General case' 0 C--O 1.243 0.719 0 CA-C-N 114.117 -1.041 . . . . 0.0 108.701 175.096 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 79.9 m-85 -118.46 142.4 47.6 Favored 'General case' 0 C--O 1.216 -0.676 0 C-N-CA 123.09 0.556 . . . . 0.0 109.622 -179.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' ARG . . . . . 0.656 ' HG3' ' HB2' ' A' ' 11' ' ' ALA . 54.9 mtt-85 -92.29 137.0 32.73 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 174.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.404 ' H ' ' HA ' ' A' ' 99' ' ' ALA . 51.6 mt -102.37 121.3 53.26 Favored 'Isoleucine or valine' 0 C--O 1.26 1.629 0 CA-C-O 121.673 0.749 . . . . 0.0 110.151 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.489 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 22.7 pttm -122.82 144.79 48.96 Favored 'General case' 0 C--N 1.349 0.554 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.823 177.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.18 119.65 24.33 Favored 'General case' 0 C--O 1.249 1.027 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 173.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . 0.794 ' HD3' ' HB2' ' A' ' 7' ' ' GLU . 53.2 pttt -115.31 152.74 32.23 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.686 -172.318 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -100.93 103.2 2.55 Favored Glycine 0 C--N 1.347 1.157 0 N-CA-C 106.135 -2.786 . . . . 0.0 106.135 160.414 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 4.8 tp 19.36 29.66 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.58 2.118 0 C-N-CA 129.298 3.039 . . . . 0.0 116.882 -167.542 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.444 ' N ' ' HD2' ' A' ' 89' ' ' LYS . 0.7 OUTLIER -177.41 -57.27 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.873 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 -169.77 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 177.05 161.89 26.52 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 114.732 0.653 . . . . 0.0 114.732 -177.604 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 53.2 p90 -165.8 -48.0 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 124.308 1.043 . . . . 0.0 112.05 156.17 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 12.6 t -152.72 149.83 28.8 Favored 'General case' 0 N--CA 1.495 1.783 0 CA-C-N 119.63 1.105 . . . . 0.0 112.067 -175.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' GLN . . . . . 0.489 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 0.8 OUTLIER -95.38 142.31 27.91 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 124.417 1.087 . . . . 0.0 110.445 -179.782 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.485 HD11 HD23 ' A' ' 6' ' ' LEU . 1.3 pp -133.49 -7.66 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 N-CA-C 113.575 0.954 . . . . 0.0 113.575 -175.052 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 175.92 -148.92 9.58 Favored Glycine 0 N--CA 1.475 1.242 0 CA-C-N 118.359 0.527 . . . . 0.0 113.017 173.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.404 ' HA ' ' H ' ' A' ' 86' ' ' ILE . . . -156.41 176.06 13.19 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 123.585 0.754 . . . . 0.0 110.985 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -172.87 135.3 3.27 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -177.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.491 HG21 ' HB3' ' A' ' 199' ' ' PRO . 71.3 t -95.65 110.67 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 C-N-CA 123.285 0.634 . . . . 0.0 109.328 -177.447 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 17.7 t80 -77.66 134.51 38.14 Favored 'General case' 0 CA--C 1.536 0.439 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -179.468 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' LYS . . . . . 0.66 ' HD2' HD21 ' A' ' 146' ' ' LEU . 35.5 mmtm -118.64 157.65 27.0 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 124.96 1.304 . . . . 0.0 109.045 -179.583 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -53.76 100.18 0.03 OUTLIER 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 123.86 0.864 . . . . 0.0 112.176 -173.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 83.55 -9.97 60.57 Favored Glycine 0 C--N 1.351 1.386 0 CA-C-N 115.48 -0.782 . . . . 0.0 113.766 178.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 20.3 p -123.81 120.45 32.65 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 124.038 0.935 . . . . 0.0 111.02 -175.121 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' PHE . . . . . 0.702 ' HB3' ' HB3' ' A' ' 140' ' ' TYR . 37.2 t80 -84.42 122.6 29.19 Favored 'General case' 0 N--CA 1.48 1.027 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 176.483 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 5.3 t-80 -132.97 102.3 5.57 Favored 'General case' 0 CA--C 1.554 1.129 0 C-N-CA 123.776 0.83 . . . . 0.0 110.434 -167.111 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' THR . . . . . 0.485 HG23 ' HB ' ' A' ' 138' ' ' ILE . 10.2 t -136.74 177.19 8.05 Favored 'General case' 0 N--CA 1.488 1.457 0 C-N-CA 123.889 0.876 . . . . 0.0 111.135 -178.601 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' MET . . . . . 0.476 ' HA ' ' HA ' ' A' ' 137' ' ' LEU . 44.2 mtp -93.55 157.14 16.34 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 124.296 1.038 . . . . 0.0 109.148 173.536 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 79.7 t90 -80.46 -61.88 1.84 Allowed 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 112.28 0.474 . . . . 0.0 112.28 -166.149 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 2.3 p-80 -73.97 3.93 6.12 Favored 'General case' 0 N--CA 1.5 2.048 0 N-CA-C 114.009 1.114 . . . . 0.0 114.009 -167.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 40.7 t -42.99 -41.6 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.279 0 C-N-CA 123.734 0.814 . . . . 0.0 110.29 161.676 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.526 HG21 HD21 ' A' ' 6' ' ' LEU . 0.2 OUTLIER -153.29 -163.03 1.59 Allowed 'General case' 0 CA--C 1.558 1.286 0 C-N-CA 125.267 1.427 . . . . 0.0 109.207 170.395 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 77.5 mtp180 -66.01 -26.65 67.63 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 113.362 0.875 . . . . 0.0 113.362 -172.747 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 93.78 62.84 1.07 Allowed Glycine 0 CA--C 1.53 0.983 0 O-C-N 123.205 0.316 . . . . 0.0 113.715 178.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -141.98 -85.66 0.17 Allowed 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 112.461 0.541 . . . . 0.0 112.461 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 26.6 t -110.98 109.0 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 123.359 0.663 . . . . 0.0 112.331 -169.028 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.515 HD12 HD12 ' A' ' 126' ' ' ILE . 1.3 tm? -91.33 152.06 20.61 Favored 'General case' 0 C--O 1.212 -0.908 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 169.108 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' MET . . . . . 0.732 ' HG3' ' HA ' ' A' ' 5' ' ' ASP . 45.7 mmm -135.01 138.85 44.36 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 124.06 0.944 . . . . 0.0 108.717 -172.755 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' HIS . . . . . 0.518 ' O ' ' HG2' ' A' ' 122' ' ' LYS . 18.5 t-160 -167.53 141.84 3.68 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -177.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.518 ' HG2' ' O ' ' A' ' 121' ' ' HIS . 32.8 pttt 68.92 3.12 3.84 Favored 'General case' 0 N--CA 1.501 2.086 0 C-N-CA 125.649 1.579 . . . . 0.0 112.766 176.194 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 99.96 -0.76 56.35 Favored Glycine 0 C--N 1.351 1.362 0 C-N-CA 123.144 0.402 . . . . 0.0 113.084 -174.282 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -118.45 152.93 34.97 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 123.813 0.845 . . . . 0.0 110.744 179.482 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' ARG . . . . . 0.444 ' HB3' ' SD ' ' A' ' 120' ' ' MET . 20.8 ptp180 -93.07 164.67 13.18 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.11 -179.276 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.515 HD12 HD12 ' A' ' 119' ' ' LEU . 27.5 mt -142.8 122.97 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 C-N-CA 125.628 1.571 . . . . 0.0 107.086 -172.396 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 44.8 mt-10 -125.73 132.69 24.39 Favored Pre-proline 0 N--CA 1.474 0.758 0 N-CA-C 108.604 -0.888 . . . . 0.0 108.604 175.427 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.48 ' HA ' ' HB2' ' A' ' 140' ' ' TYR . 96.9 Cg_endo -73.78 157.65 47.62 Favored 'Trans proline' 0 C--N 1.373 1.86 0 C-N-CA 122.934 2.423 . . . . 0.0 113.943 -168.806 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' SER . . . . . 0.558 ' H ' ' HA ' ' A' ' 140' ' ' TYR . 28.8 p -76.77 -27.62 55.37 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-N 114.884 -1.053 . . . . 0.0 109.623 172.385 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 67.6 t-105 -152.5 144.94 24.07 Favored 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 123.314 0.645 . . . . 0.0 110.21 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -136.72 121.19 18.22 Favored 'General case' 0 C--O 1.241 0.613 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 171.566 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -114.13 109.09 17.88 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 123.437 0.695 . . . . 0.0 109.467 -173.571 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 17.1 t -77.44 -19.38 14.15 Favored 'Isoleucine or valine' 0 CA--C 1.562 1.407 0 C-N-CA 123.9 0.88 . . . . 0.0 111.304 -175.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 2.8 mptp? -69.46 -51.31 37.27 Favored 'General case' 0 N--CA 1.487 1.419 0 C-N-CA 123.461 0.704 . . . . 0.0 109.557 -177.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 31.9 mmtp -84.13 -20.08 33.1 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-N 115.088 -0.96 . . . . 0.0 110.346 178.681 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 14.2 t70 65.5 63.57 0.62 Allowed 'General case' 0 C--O 1.24 0.595 0 C-N-CA 125.56 1.544 . . . . 0.0 110.607 -175.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' LEU . . . . . 0.495 HD21 HD12 ' A' ' 210' ' ' LEU . 1.5 mp -143.77 172.64 12.56 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.802 174.461 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.485 ' HB ' HG23 ' A' ' 109' ' ' THR . 21.6 mt -141.46 131.33 25.15 Favored 'Isoleucine or valine' 0 C--O 1.245 0.868 0 C-N-CA 125.952 1.701 . . . . 0.0 108.08 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 29.9 p -136.48 123.09 20.98 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 124.13 0.972 . . . . 0.0 110.282 -177.566 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.702 ' HB3' ' HB3' ' A' ' 107' ' ' PHE . 47.8 t80 -109.68 123.97 50.41 Favored 'General case' 0 N--CA 1.464 0.24 0 C-N-CA 124.626 1.17 . . . . 0.0 108.06 172.79 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 113.91 0.4 24.23 Favored Glycine 0 N--CA 1.474 1.19 0 O-C-N 123.885 0.741 . . . . 0.0 111.98 -173.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 147.46 -141.74 9.58 Favored Glycine 0 C--N 1.346 1.125 0 N-CA-C 109.944 -1.262 . . . . 0.0 109.944 177.734 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.809 ' HA3' ' HB2' ' A' ' 232' ' ' SER . . . -97.45 -175.06 34.19 Favored Glycine 0 C--N 1.345 1.058 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 164.285 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' TRP . . . . . 0.609 ' HZ2' ' HA2' ' A' ' 209' ' ' GLY . 7.4 t90 -69.76 104.02 2.32 Favored 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 177.279 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . 0.616 ' HB3' ' HA ' ' A' ' 231' ' ' LYS . 11.7 pttt -164.87 113.85 1.08 Allowed 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 123.7 0.8 . . . . 0.0 109.692 -177.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' LEU . . . . . 0.66 HD21 ' HD2' ' A' ' 103' ' ' LYS . 0.0 OUTLIER 167.62 -33.12 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 C-N-CA 125.178 1.391 . . . . 0.0 110.602 161.409 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.569 ' HG2' ' HE2' ' A' ' 103' ' ' LYS . 31.6 mt-10 -62.3 -81.91 0.02 OUTLIER 'General case' 0 C--N 1.367 1.353 0 O-C-N 123.714 0.634 . . . . 0.0 111.057 -166.139 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . 0.424 ' O ' ' HB ' ' A' ' 229' ' ' THR . . . 177.66 -174.26 46.75 Favored Glycine 0 C--N 1.341 0.813 0 O-C-N 123.464 0.477 . . . . 0.0 111.963 -178.097 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -124.85 107.37 10.83 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 -172.765 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' TRP . . . . . . . . . . . . . 27.5 t90 -54.89 135.57 48.0 Favored 'General case' 0 N--CA 1.477 0.923 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.625 172.161 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 53.6 mmtt -84.48 101.8 12.33 Favored 'General case' 0 C--O 1.239 0.508 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 179.042 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -62.65 107.72 1.01 Allowed 'General case' 0 CA--C 1.546 0.803 0 O-C-N 124.022 0.826 . . . . 0.0 109.765 -172.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 134.16 -31.62 2.77 Favored Glycine 0 C--N 1.34 0.803 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.688 -176.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -82.81 156.34 23.71 Favored 'General case' 0 C--O 1.242 0.708 0 C-N-CA 123.349 0.66 . . . . 0.0 109.48 178.559 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 10.0 pm0 -64.02 142.93 58.23 Favored 'General case' 0 C--O 1.243 0.731 0 O-C-N 124.207 0.942 . . . . 0.0 109.956 174.442 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 15.8 m -92.48 142.34 13.26 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 CA-C-O 121.184 0.516 . . . . 0.0 109.822 174.552 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 157' ' ' GLN . . . . . 0.482 HE22 ' HB2' ' A' ' 171' ' ' GLN . 9.9 tp-100 -101.32 144.96 29.52 Favored 'General case' 0 N--CA 1.454 -0.235 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 173.008 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.594 ' HB ' ' HB ' ' A' ' 170' ' ' VAL . 49.1 t -128.03 146.02 34.28 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 123.445 0.698 . . . . 0.0 110.014 -174.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 159' ' ' LEU . . . . . 0.424 ' HB2' ' HG2' ' A' ' 199' ' ' PRO . 33.7 mt -97.04 85.55 3.76 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 160.82 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -64.16 100.5 0.34 Allowed 'General case' 0 C--O 1.237 0.403 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 -179.233 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 161' ' ' LEU . . . . . 0.68 HD11 ' HB1' ' A' ' 83' ' ' ALA . 70.6 mt -78.03 80.28 4.47 Favored 'General case' 0 C--O 1.242 0.691 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.628 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 162' ' ' GLU . . . . . 0.425 ' HB2' ' HB2' ' A' ' 165' ' ' LYS . 10.1 mm-40 -61.59 125.3 84.26 Favored Pre-proline 0 CA--C 1.555 1.151 0 CA-C-N 113.412 -1.722 . . . . 0.0 110.074 -176.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -58.1 112.8 1.28 Allowed 'Trans proline' 0 C--N 1.382 2.293 0 C-N-CA 122.875 2.383 . . . . 0.0 112.626 -174.006 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 67.06 26.87 73.31 Favored Glycine 0 C--N 1.349 1.305 0 O-C-N 124.139 0.9 . . . . 0.0 113.291 176.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . 0.425 ' HB2' ' HB2' ' A' ' 162' ' ' GLU . 49.8 mtpt -131.54 -172.49 2.87 Favored 'General case' 0 C--O 1.242 0.703 0 C-N-CA 124.282 1.033 . . . . 0.0 109.306 -176.533 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -72.48 141.7 83.23 Favored Pre-proline 0 CA--C 1.555 1.139 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.053 170.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_exo -67.48 122.33 9.54 Favored 'Trans proline' 0 C--N 1.368 1.577 0 C-N-CA 122.522 2.148 . . . . 0.0 111.006 170.384 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 56.6 mtp180 -105.51 167.6 9.65 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 123.912 0.885 . . . . 0.0 110.549 -178.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 169' ' ' ALA . . . . . 0.57 ' HB2' ' HB3' ' A' ' 17' ' ' GLU . . . -102.24 151.21 22.49 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 109.408 -0.589 . . . . 0.0 109.408 170.493 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.594 ' HB ' ' HB ' ' A' ' 158' ' ' VAL . 95.5 t -136.17 117.08 18.51 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.239 0 C-N-CA 123.276 0.63 . . . . 0.0 110.286 175.159 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 171' ' ' GLN . . . . . 0.617 ' HB2' ' HB1' ' A' ' 20' ' ' ALA . 65.0 tt0 -94.81 111.24 23.03 Favored 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 172.441 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 4.5 t -140.52 140.53 35.27 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-O 121.001 0.429 . . . . 0.0 110.742 -174.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 21.5 ptmt -75.61 152.43 85.27 Favored Pre-proline 0 CA--C 1.55 0.953 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.961 177.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -70.3 143.54 48.52 Favored 'Trans proline' 0 C--N 1.374 1.909 0 C-N-CA 122.314 2.009 . . . . 0.0 112.692 171.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -132.84 155.55 21.67 Favored Glycine 0 N--CA 1.467 0.729 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 170.406 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.49 ' HG ' ' HA2' ' A' ' 185' ' ' GLY . 6.5 mp -116.81 157.17 26.02 Favored 'General case' 0 N--CA 1.482 1.143 0 CA-C-N 119.019 1.409 . . . . 0.0 109.231 -174.562 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 177' ' ' PHE . . . . . . . . . . . . . 50.2 p90 -137.02 149.55 47.53 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.802 175.301 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 60.1 tttp -97.78 128.01 44.13 Favored 'General case' 0 C--O 1.239 0.547 0 CA-C-N 115.577 -0.738 . . . . 0.0 109.977 -177.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 75.5 p -123.48 171.82 9.19 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.017 0.927 . . . . 0.0 109.355 168.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -65.94 -27.07 67.9 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 123.564 0.746 . . . . 0.0 110.607 174.334 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -68.65 -40.71 80.08 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 123.757 0.823 . . . . 0.0 110.602 175.455 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 158.22 -175.9 35.31 Favored Glycine 0 C--N 1.35 1.346 0 CA-C-N 115.831 -0.622 . . . . 0.0 112.423 177.634 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 8.5 t -77.98 115.42 17.71 Favored 'General case' 0 CA--C 1.543 0.695 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 172.55 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 52.8 mt -104.5 138.95 26.98 Favored 'Isoleucine or valine' 0 C--O 1.246 0.909 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -177.504 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 185' ' ' GLY . . . . . 0.49 ' HA2' ' HG ' ' A' ' 176' ' ' LEU . . . -100.45 119.43 6.51 Favored Glycine 0 C--N 1.349 1.291 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -175.121 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 186' ' ' ALA . . . . . 0.563 ' HA ' ' H ' ' A' ' 226' ' ' ILE . . . -144.94 -156.85 0.74 Allowed 'General case' 0 C--O 1.235 0.323 0 C-N-CA 123.837 0.855 . . . . 0.0 109.928 -165.694 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 187' ' ' VAL . . . . . 0.544 HG13 ' HB3' ' A' ' 224' ' ' SER . 2.4 p -135.77 123.06 34.98 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 C-N-CA 123.648 0.779 . . . . 0.0 109.285 175.085 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 41.6 m -117.75 115.29 24.72 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 123.779 0.832 . . . . 0.0 109.262 -176.796 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 189' ' ' LEU . . . . . 0.421 HD13 ' HB3' ' A' ' 191' ' ' PHE . 0.5 OUTLIER -149.44 164.0 36.22 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 124.065 0.946 . . . . 0.0 110.962 -175.44 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -101.52 104.1 14.99 Favored 'General case' 0 CA--C 1.541 0.634 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 170.246 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 191' ' ' PHE . . . . . 0.421 ' HB3' HD13 ' A' ' 189' ' ' LEU . 67.9 t80 -154.11 166.58 32.62 Favored 'General case' 0 N--CA 1.484 1.238 0 C-N-CA 123.217 0.607 . . . . 0.0 110.486 -171.79 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 48.8 m -69.53 156.25 92.01 Favored Pre-proline 0 CA--C 1.559 1.295 0 C-N-CA 124.952 1.301 . . . . 0.0 112.631 -178.713 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 193' ' ' PRO . . . . . 0.537 ' HA ' ' CE1' ' A' ' 222' ' ' TYR . 39.7 Cg_endo -64.24 99.18 0.28 Allowed 'Trans proline' 0 C--N 1.387 2.554 0 C-N-CA 123.009 2.473 . . . . 0.0 113.02 176.392 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -70.47 -136.39 0.12 Allowed Glycine 0 C--N 1.361 1.918 0 C-N-CA 123.745 0.688 . . . . 0.0 112.596 177.749 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 25.4 p -124.79 143.94 50.54 Favored 'General case' 0 N--CA 1.489 1.501 0 CA-C-N 118.979 1.39 . . . . 0.0 112.245 169.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 14.1 m -73.88 83.19 1.68 Allowed 'General case' 0 C--N 1.354 0.765 0 C-N-CA 123.645 0.778 . . . . 0.0 110.305 170.729 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 127.98 19.86 1.73 Allowed Glycine 0 C--N 1.339 0.747 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.536 -170.275 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 33.4 t -65.49 140.23 97.53 Favored Pre-proline 0 CA--C 1.554 1.108 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 164.118 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 199' ' ' PRO . . . . . 0.491 ' HB3' HG21 ' A' ' 101' ' ' VAL . 65.7 Cg_endo -81.04 131.85 8.1 Favored 'Trans proline' 0 C--N 1.374 1.881 0 C-N-CA 121.647 1.565 . . . . 0.0 113.374 179.016 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 43.9 mt -87.43 117.91 32.33 Favored 'Isoleucine or valine' 0 C--O 1.248 1.002 0 CA-C-O 121.962 0.887 . . . . 0.0 108.739 163.091 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 201' ' ' ILE . . . . . . . . . . . . . 80.4 mt -102.87 136.49 35.12 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.812 0 CA-C-N 113.248 -1.796 . . . . 0.0 107.54 172.421 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 202' ' ' ASP . . . . . 0.529 ' HB3' ' HB2' ' A' ' 206' ' ' LYS . 19.1 t70 -73.31 148.56 43.41 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 167.415 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 60.6 pttt -60.38 -18.96 53.85 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 -172.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 86.1 tttt -67.52 -21.34 65.49 Favored 'General case' 0 CA--C 1.557 1.247 0 C-N-CA 123.546 0.738 . . . . 0.0 111.766 177.497 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 108.27 3.32 33.37 Favored Glycine 0 N--CA 1.471 0.967 0 C-N-CA 123.3 0.476 . . . . 0.0 111.949 -171.691 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 206' ' ' LYS . . . . . 0.529 ' HB2' ' HB3' ' A' ' 202' ' ' ASP . 46.4 mttm -74.45 136.22 42.3 Favored 'General case' 0 C--O 1.205 -1.244 0 C-N-CA 123.985 0.914 . . . . 0.0 109.428 173.436 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 7.5 p -86.68 135.91 24.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 N-CA-C 106.403 -1.702 . . . . 0.0 106.403 163.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 30.9 m -135.8 -21.08 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 N-CA-C 113.153 0.797 . . . . 0.0 113.153 -168.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 209' ' ' GLY . . . . . 0.609 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . 178.4 -151.37 10.47 Favored Glycine 0 C--N 1.35 1.329 0 C-N-CA 119.751 -1.214 . . . . 0.0 115.815 -176.116 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 210' ' ' LEU . . . . . 0.495 HD12 HD21 ' A' ' 137' ' ' LEU . 33.6 mt -130.82 133.74 46.22 Favored 'General case' 0 C--N 1.365 1.241 0 CA-C-O 121.88 0.848 . . . . 0.0 112.366 -175.751 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 64.0 t80 -94.09 133.96 37.03 Favored 'General case' 0 C--O 1.241 0.655 0 C-N-CA 126.409 1.884 . . . . 0.0 108.223 168.061 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -137.38 -138.05 3.69 Favored Glycine 0 C--O 1.229 -0.189 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 177.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 213' ' ' ASN . . . . . 0.403 ' HB2' ' CZ ' ' A' ' 222' ' ' TYR . 9.2 t30 -156.79 101.09 1.95 Allowed 'General case' 0 C--O 1.237 0.396 0 C-N-CA 125.694 1.598 . . . . 0.0 107.05 170.666 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . -56.22 -56.39 24.5 Favored Glycine 0 C--N 1.342 0.894 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 172.782 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 215' ' ' VAL . . . . . . . . . . . . . 3.4 m -162.2 -172.74 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 C-N-CA 125.241 1.416 . . . . 0.0 108.952 176.057 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 216' ' ' VAL . . . . . 0.462 HG12 ' HA ' ' A' ' 222' ' ' TYR . 3.4 m -117.83 129.89 73.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 168.135 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 217' ' ' THR . . . . . 0.451 HG22 ' H ' ' A' ' 218' ' ' ARG . 4.9 m -126.69 -178.9 4.54 Favored 'General case' 0 CA--C 1.552 1.031 0 N-CA-C 107.829 -1.175 . . . . 0.0 107.829 -178.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 218' ' ' ARG . . . . . 0.451 ' H ' HG22 ' A' ' 217' ' ' THR . 10.9 ttt85 64.19 25.57 13.66 Favored 'General case' 0 N--CA 1.496 1.863 0 CA-C-O 122.393 1.092 . . . . 0.0 110.879 171.367 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 10.2 t 69.9 2.07 3.72 Favored 'General case' 0 N--CA 1.489 1.507 0 C-N-CA 125.412 1.485 . . . . 0.0 112.975 176.501 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . 159.64 45.81 0.02 OUTLIER Glycine 0 C--N 1.349 1.263 0 CA-C-N 117.706 0.23 . . . . 0.0 112.572 -177.447 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -122.69 121.45 36.41 Favored 'General case' 0 C--O 1.238 0.478 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 176.048 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 222' ' ' TYR . . . . . 0.537 ' CE1' ' HA ' ' A' ' 193' ' ' PRO . 56.6 t80 -69.8 101.29 1.68 Allowed 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 125.136 1.374 . . . . 0.0 109.059 179.282 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 223' ' ' VAL . . . . . 0.509 HG11 HD11 ' A' ' 31' ' ' ILE . 8.2 t -96.89 98.56 7.68 Favored 'Isoleucine or valine' 0 C--O 1.249 1.039 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 -176.467 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 224' ' ' SER . . . . . 0.544 ' HB3' HG13 ' A' ' 187' ' ' VAL . 38.0 t -97.3 155.19 16.98 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 125.144 1.378 . . . . 0.0 109.744 179.059 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 225' ' ' ALA . . . . . . . . . . . . . . . -104.83 131.38 52.38 Favored 'General case' 0 C--O 1.241 0.626 0 C-N-CA 123.449 0.7 . . . . 0.0 109.675 176.428 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 226' ' ' ILE . . . . . 0.563 ' H ' ' HA ' ' A' ' 186' ' ' ALA . 78.8 mt -77.98 95.04 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.352 0.68 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 173.196 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 227' ' ' ALA . . . . . 0.419 ' O ' ' HA3' ' A' ' 209' ' ' GLY . . . -85.18 147.18 26.73 Favored 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 172.632 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 3.7 pt20 -147.54 153.56 39.63 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 123.918 0.887 . . . . 0.0 109.446 -169.246 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . 0.424 ' HB ' ' O ' ' A' ' 148' ' ' GLY . 89.4 m -69.0 109.28 3.88 Favored 'General case' 0 CA--C 1.545 0.764 0 CA-C-O 121.161 0.505 . . . . 0.0 109.817 179.242 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 230' ' ' GLU . . . . . 0.411 ' O ' ' HG2' ' A' ' 231' ' ' LYS . 38.3 mt-10 -98.01 -11.83 22.58 Favored 'General case' 0 N--CA 1.481 1.081 0 CA-C-N 114.916 -1.038 . . . . 0.0 111.302 -175.193 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 231' ' ' LYS . . . . . 0.616 ' HA ' ' HB3' ' A' ' 145' ' ' LYS . 11.7 pttm 66.78 128.48 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 127.06 2.144 . . . . 0.0 112.189 -177.51 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 232' ' ' SER . . . . . 0.809 ' HB2' ' HA3' ' A' ' 143' ' ' GLY . 30.1 m . . . . . 0 C--N 1.351 0.659 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 172.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.652 0 CA-C-O 119.869 -0.406 . . . . 0.0 112.614 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.8 m -60.24 -42.05 94.42 Favored 'General case' 0 N--CA 1.48 1.04 0 C-N-CA 123.405 0.682 . . . . 0.0 111.605 -178.462 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 56.93 39.06 29.7 Favored 'General case' 0 N--CA 1.484 1.238 0 O-C-N 124.34 1.025 . . . . 0.0 111.626 175.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -170.95 11.37 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 123.736 0.814 . . . . 0.0 109.669 -170.836 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . 0.414 ' H ' HD12 ' A' ' 6' ' ' LEU . 13.0 m-20 -158.25 82.33 0.84 Allowed 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 -169.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.414 HD12 ' H ' ' A' ' 5' ' ' ASP . 7.4 mp -117.01 109.65 17.27 Favored 'General case' 0 C--O 1.202 -1.432 0 O-C-N 121.474 -0.766 . . . . 0.0 110.284 -175.221 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.618 ' HB2' ' HD3' ' A' ' 89' ' ' LYS . 37.3 tp10 -83.68 145.46 28.76 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.551 -0.718 . . . . 0.0 110.627 -176.304 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.455 ' HB2' ' CD2' ' A' ' 121' ' ' HIS . 81.6 mt -89.32 114.66 26.08 Favored 'General case' 0 CA--C 1.547 0.856 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.508 171.177 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -112.28 107.88 16.89 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 125.108 1.363 . . . . 0.0 108.274 178.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 15.9 ttp180 -67.75 125.05 25.02 Favored 'General case' 0 N--CA 1.481 1.102 0 CA-C-N 118.441 0.564 . . . . 0.0 111.616 -172.088 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.543 ' HB2' ' HG3' ' A' ' 85' ' ' ARG . . . -89.06 -40.54 12.89 Favored 'General case' 0 C--N 1.347 0.473 0 C-N-CA 124.02 0.928 . . . . 0.0 109.986 177.188 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -166.09 -176.25 3.67 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 115.08 -0.964 . . . . 0.0 110.776 -173.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 65.2 m-20 -110.22 146.78 35.01 Favored 'General case' 0 C--O 1.242 0.696 0 C-N-CA 124.085 0.954 . . . . 0.0 108.838 171.401 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.435 HG11 HG12 ' A' ' 208' ' ' VAL . 94.6 t -78.86 101.01 3.97 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 CA-C-O 121.503 0.668 . . . . 0.0 109.469 -177.171 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 33.8 ttpt -167.96 109.74 0.59 Allowed 'General case' 0 C--O 1.247 0.966 0 N-CA-C 105.247 -2.131 . . . . 0.0 105.247 175.767 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . 0.442 ' NE1' ' HB1' ' A' ' 169' ' ' ALA . 68.2 t90 -80.3 90.57 5.56 Favored 'General case' 0 CA--C 1.539 0.553 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 -177.153 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -157.88 60.46 0.47 Allowed 'General case' 0 CA--C 1.543 0.677 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 158.046 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.601 ' HB3' ' HB2' ' A' ' 169' ' ' ALA . 12.6 t70 -90.6 -58.93 2.32 Favored 'General case' 0 CA--C 1.554 1.134 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.775 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . 0.698 ' H ' ' HB3' ' A' ' 169' ' ' ALA . 17.7 mt-30 -150.28 4.27 0.52 Allowed 'General case' 0 N--CA 1.5 2.027 0 N-CA-C 113.953 1.094 . . . . 0.0 113.953 -172.485 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . 11.84 70.91 0.01 OUTLIER 'General case' 0 N--CA 1.506 2.365 0 C-N-CA 126.549 1.94 . . . . 0.0 115.484 -169.053 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -88.22 123.59 33.0 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 123.603 0.761 . . . . 0.0 109.9 -176.253 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 30.8 mm -75.58 134.87 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 C-N-CA 123.045 0.538 . . . . 0.0 110.187 -176.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 78.5 p -174.84 -162.46 0.12 Allowed 'General case' 0 CA--C 1.55 0.949 0 O-C-N 124.581 1.176 . . . . 0.0 109.954 172.696 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.653 ' HA3' ' H ' ' A' ' 173' ' ' LYS . . . 102.77 178.49 26.86 Favored Glycine 0 C--N 1.349 1.259 0 CA-C-O 119.522 -0.599 . . . . 0.0 111.805 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 44.0 t 64.02 98.17 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 124.212 1.005 . . . . 0.0 111.176 176.287 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 28.8 t -140.63 148.83 54.73 Favored Pre-proline 0 N--CA 1.479 0.993 0 CA-C-O 118.406 -0.807 . . . . 0.0 109.345 -176.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_exo -42.63 138.12 3.7 Favored 'Trans proline' 0 C--N 1.391 2.81 0 C-N-CA 123.87 3.046 . . . . 0.0 113.785 177.243 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.678 HD12 ' HB2' ' A' ' 176' ' ' LEU . 31.0 mm -63.52 111.13 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 -175.728 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.689 ' HB3' HG21 ' A' ' 217' ' ' THR . 13.6 mt -94.11 142.33 27.52 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 115.373 -0.83 . . . . 0.0 111.732 -167.69 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 60.4 p -85.52 140.8 30.36 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 123.358 0.663 . . . . 0.0 110.316 177.474 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.739 HG21 ' HD2' ' A' ' 177' ' ' PHE . 14.6 tt -148.39 138.6 16.7 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.794 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 -172.372 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 39.4 p -102.27 117.05 33.93 Favored 'General case' 0 CA--C 1.547 0.855 0 O-C-N 121.881 -0.512 . . . . 0.0 110.997 -170.794 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.602 ' HA ' ' HG3' ' A' ' 39' ' ' MET . 10.6 tp -61.25 145.11 13.09 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.077 0 C-N-CA 124.902 1.281 . . . . 0.0 112.208 -177.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 47.5 m -152.25 130.91 12.31 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 124.103 0.961 . . . . 0.0 110.068 -176.041 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 60.71 19.24 9.32 Favored 'General case' 0 CA--C 1.566 1.586 0 C-N-CA 123.479 0.712 . . . . 0.0 111.437 174.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 24.3 t70 76.05 -55.55 0.6 Allowed 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 125.617 1.567 . . . . 0.0 112.318 -178.359 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -89.0 -20.27 47.23 Favored Glycine 0 N--CA 1.475 1.268 0 N-CA-C 115.002 0.761 . . . . 0.0 115.002 -175.359 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 66.5 m -106.0 165.49 11.17 Favored 'General case' 0 N--CA 1.478 0.941 0 CA-C-N 117.646 0.723 . . . . 0.0 110.252 -177.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . 0.602 ' HG3' ' HA ' ' A' ' 33' ' ' ILE . 3.7 mpp? -138.99 168.31 20.11 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 123.808 0.843 . . . . 0.0 108.861 168.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.841 ' HA ' HG11 ' A' ' 215' ' ' VAL . 64.5 m -150.39 -179.47 7.24 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 124.788 1.235 . . . . 0.0 108.282 167.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 41.7 mm -99.0 96.51 5.08 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 N-CA-C 108.261 -1.015 . . . . 0.0 108.261 167.417 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER 53.16 -79.63 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.154 0 C-N-CA 125.999 1.72 . . . . 0.0 112.164 -176.579 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 4.4 p30 -136.27 87.08 2.27 Favored 'General case' 0 CA--C 1.551 0.985 0 C-N-CA 124.486 1.115 . . . . 0.0 108.94 178.073 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -100.67 148.09 25.26 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.81 -172.215 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -85.27 178.08 7.61 Favored 'General case' 0 N--CA 1.475 0.793 0 C-N-CA 124.17 0.988 . . . . 0.0 110.97 176.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -152.44 146.01 24.96 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 123.347 0.659 . . . . 0.0 110.422 -176.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 -138.91 148.43 43.59 Favored 'General case' 0 C--O 1.244 0.791 0 C-N-CA 123.714 0.806 . . . . 0.0 110.134 -179.336 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 29.5 pt20 -71.21 146.76 48.86 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 123.572 0.749 . . . . 0.0 110.057 171.084 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.498 HG23 ' HB3' ' A' ' 163' ' ' PRO . 56.5 m -77.21 -39.19 49.58 Favored 'General case' 0 CA--C 1.554 1.109 0 C-N-CA 123.372 0.669 . . . . 0.0 110.997 178.409 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.424 ' HA ' ' H ' ' A' ' 96' ' ' GLN . 44.8 tp 68.54 132.61 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 125.814 1.645 . . . . 0.0 112.187 -175.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -143.85 157.37 27.04 Favored Glycine 0 C--N 1.353 1.514 0 N-CA-C 111.419 -0.672 . . . . 0.0 111.419 -178.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -112.84 -33.81 1.97 Allowed Glycine 0 C--N 1.348 1.218 0 CA-C-O 119.823 -0.432 . . . . 0.0 114.051 -168.496 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -62.95 153.82 44.53 Favored Glycine 0 N--CA 1.477 1.401 0 C-N-CA 123.241 0.448 . . . . 0.0 113.523 -176.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.49 ' HA2' ' HZ2' ' A' ' 66' ' ' TRP . . . 92.75 81.6 1.48 Allowed Glycine 0 C--N 1.339 0.729 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 -171.489 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 77.7 p -69.59 154.12 42.47 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 123.325 0.65 . . . . 0.0 112.001 -177.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -80.2 -9.27 86.79 Favored Glycine 0 C--N 1.347 1.187 0 CA-C-N 115.611 -0.722 . . . . 0.0 113.563 178.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -67.22 84.56 0.13 Allowed Glycine 0 C--N 1.349 1.264 0 N-CA-C 112.028 -0.429 . . . . 0.0 112.028 177.001 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 73.5 35.83 55.31 Favored Glycine 0 C--N 1.35 1.34 0 N-CA-C 112.064 -0.414 . . . . 0.0 112.064 -173.09 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -62.04 -26.83 67.9 Favored Glycine 0 C--N 1.356 1.659 0 O-C-N 123.828 0.369 . . . . 0.0 113.538 -175.728 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.594 ' HG3' ' H ' ' A' ' 61' ' ' PHE . 9.6 pt-20 -90.48 -69.53 0.72 Allowed 'General case' 0 CA--C 1.549 0.912 0 CA-C-O 118.908 -0.568 . . . . 0.0 110.695 172.13 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.594 ' H ' ' HG3' ' A' ' 60' ' ' GLU . 74.2 t80 48.3 -86.23 0.01 OUTLIER 'General case' 0 CA--C 1.557 1.25 0 C-N-CA 124.966 1.306 . . . . 0.0 111.716 -176.639 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -177.31 -52.36 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 125.307 1.443 . . . . 0.0 108.273 -178.008 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 174.71 93.73 0.09 OUTLIER Glycine 0 C--N 1.342 0.861 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 178.232 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.566 ' HB ' ' HD2' ' A' ' 122' ' ' LYS . 1.8 t -90.94 -11.15 9.82 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.277 0 C-N-CA 123.59 0.756 . . . . 0.0 110.04 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.455 ' N ' ' HG3' ' A' ' 122' ' ' LYS . 3.9 mm? 69.29 129.96 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 125.813 1.645 . . . . 0.0 114.302 176.135 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . 0.559 ' CD1' ' HG2' ' A' ' 122' ' ' LYS . 68.3 m95 -92.79 79.19 4.74 Favored 'General case' 0 N--CA 1.482 1.164 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 166.732 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 30.5 t70 179.64 69.58 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 106.497 -1.668 . . . . 0.0 106.497 161.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 6.4 m -126.2 100.91 29.14 Favored Pre-proline 0 CA--C 1.553 1.093 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.99 -171.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -70.98 -47.08 0.6 Allowed 'Trans proline' 0 C--N 1.374 1.888 0 C-N-CA 122.333 2.022 . . . . 0.0 111.314 165.192 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 44.0 m -109.38 171.83 4.12 Favored Pre-proline 0 CA--C 1.561 1.376 0 C-N-CA 124.985 1.314 . . . . 0.0 108.789 171.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -52.65 146.27 35.24 Favored 'Trans proline' 0 C--N 1.386 2.511 0 C-N-CA 122.56 2.174 . . . . 0.0 111.788 171.448 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_exo -42.78 104.14 0.05 OUTLIER 'Trans proline' 0 C--N 1.39 2.717 0 C-N-CA 124.164 3.243 . . . . 0.0 114.321 -172.59 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -82.05 39.03 0.79 Allowed 'Trans proline' 0 C--N 1.376 1.982 0 C-N-CA 124.184 3.256 . . . . 0.0 113.444 -173.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 42.9 t 68.24 8.61 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.567 1.599 0 C-N-CA 124.27 1.028 . . . . 0.0 110.974 174.758 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -64.81 -45.75 91.71 Favored Glycine 0 C--N 1.362 1.976 0 CA-C-N 116.345 -0.388 . . . . 0.0 112.777 -175.347 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 38.3 ttmt 71.99 0.96 3.73 Favored 'General case' 0 CA--C 1.562 1.431 0 C-N-CA 125.135 1.374 . . . . 0.0 113.085 168.485 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -142.08 11.58 1.98 Allowed 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.803 -0.56 . . . . 0.0 112.444 -173.459 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -75.41 123.3 25.16 Favored 'General case' 0 CA--C 1.55 0.977 0 CA-C-O 121.313 0.578 . . . . 0.0 109.6 -179.419 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 1.2 pp -128.83 119.09 23.86 Favored 'General case' 0 N--CA 1.473 0.678 0 C-N-CA 124.254 1.022 . . . . 0.0 109.738 -173.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -84.12 61.77 6.69 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 124.325 1.05 . . . . 0.0 108.617 176.671 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 12.4 p-10 -66.8 142.95 57.18 Favored 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 114.03 -1.441 . . . . 0.0 111.298 -169.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 169.0 -154.32 23.83 Favored Glycine 0 C--O 1.258 1.61 0 CA-C-N 115.34 -0.846 . . . . 0.0 111.85 -175.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -81.75 108.74 15.54 Favored 'General case' 0 C--O 1.237 0.445 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 176.364 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . 0.427 ' CD1' ' HB3' ' A' ' 8' ' ' LEU . 47.0 m-85 -102.91 156.56 17.58 Favored 'General case' 0 N--CA 1.469 0.479 0 C-N-CA 123.643 0.777 . . . . 0.0 110.704 -179.3 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . 0.543 ' HG3' ' HB2' ' A' ' 11' ' ' ALA . 60.0 mtt180 -103.06 132.57 49.23 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 106.09 -1.818 . . . . 0.0 106.09 166.36 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.521 ' H ' ' HA ' ' A' ' 99' ' ' ALA . 12.9 mt -91.84 107.83 19.31 Favored 'Isoleucine or valine' 0 C--O 1.256 1.434 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 171.388 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.879 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 19.3 ptmt -99.27 139.2 35.27 Favored 'General case' 0 N--CA 1.441 -0.907 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 169.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -82.85 105.99 14.31 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 105.192 -2.151 . . . . 0.0 105.192 168.271 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . 0.618 ' HD3' ' HB2' ' A' ' 7' ' ' GLU . 60.0 tttt -113.67 98.5 7.08 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-N 114.562 -1.199 . . . . 0.0 108.082 -177.541 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -66.33 154.78 51.68 Favored Glycine 0 C--O 1.246 0.903 0 N-CA-C 108.279 -1.929 . . . . 0.0 108.279 160.557 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 22.8 mm -68.19 -6.24 5.27 Favored 'Isoleucine or valine' 0 CA--C 1.572 1.796 0 CA-C-N 117.728 0.764 . . . . 0.0 110.483 -176.518 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 1.1 pp -134.52 25.44 3.76 Favored 'General case' 0 CA--C 1.564 1.507 0 C-N-CA 124.585 1.154 . . . . 0.0 111.901 172.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -164.98 133.07 2.85 Favored Glycine 0 N--CA 1.486 1.968 0 CA-C-N 117.869 0.304 . . . . 0.0 113.357 -178.416 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 71.6 m-85 -122.69 120.19 32.92 Favored 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 124.082 0.953 . . . . 0.0 110.015 -174.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 37.3 p -152.75 109.24 3.42 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 122.965 0.506 . . . . 0.0 110.75 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.879 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 39.9 tt0 -74.1 140.53 45.34 Favored 'General case' 0 N--CA 1.485 1.3 0 CA-C-N 118.227 0.467 . . . . 0.0 110.705 179.046 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 1.6 pp -134.59 -16.25 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 N-CA-C 112.993 0.738 . . . . 0.0 112.993 -174.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -165.31 -157.75 10.05 Favored Glycine 0 C--N 1.342 0.867 0 C-N-CA 121.498 -0.382 . . . . 0.0 112.529 179.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.521 ' HA ' ' H ' ' A' ' 86' ' ' ILE . . . -146.01 170.81 15.89 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 123.489 0.716 . . . . 0.0 110.367 176.813 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -161.9 156.18 27.65 Favored Glycine 0 C--N 1.335 0.526 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 -179.294 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 24.1 t -118.15 114.0 43.82 Favored 'Isoleucine or valine' 0 C--O 1.241 0.608 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -175.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.466 ' CD2' ' HB2' ' A' ' 107' ' ' PHE . 0.4 OUTLIER -105.2 121.78 44.56 Favored 'General case' 0 N--CA 1.478 0.943 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 174.049 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.698 ' HB2' HD11 ' A' ' 146' ' ' LEU . 4.6 mmmp? -146.6 150.46 35.53 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 174.451 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 66.13 -84.28 0.03 OUTLIER 'General case' 0 CA--C 1.548 0.866 0 O-C-N 124.929 1.393 . . . . 0.0 110.49 173.684 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -154.59 21.27 0.62 Allowed Glycine 0 C--N 1.337 0.61 0 N-CA-C 111.816 -0.514 . . . . 0.0 111.816 178.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 97.1 m -142.65 135.1 27.75 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 123.583 0.753 . . . . 0.0 110.499 -175.753 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' PHE . . . . . 0.676 ' HB3' ' HB3' ' A' ' 140' ' ' TYR . 36.2 t80 -109.31 104.98 14.19 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 124.554 1.142 . . . . 0.0 109.363 175.635 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 42.1 p-80 -100.46 126.69 46.9 Favored 'General case' 0 C--O 1.239 0.521 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 173.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 13.8 t -137.77 -162.0 1.24 Allowed 'General case' 0 CA--C 1.545 0.751 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.319 176.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' MET . . . . . 0.522 ' HA ' ' HA ' ' A' ' 137' ' ' LEU . 1.9 ttm -115.84 150.2 37.37 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.949 1.3 . . . . 0.0 109.817 -173.896 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 21.3 t90 -78.88 -42.76 26.51 Favored 'General case' 0 CA--C 1.553 1.077 0 C-N-CA 122.72 0.408 . . . . 0.0 110.777 -175.766 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 1.8 p-80 -71.47 3.47 3.82 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 113.807 1.04 . . . . 0.0 113.807 -175.393 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 30.7 m -53.95 -40.26 44.21 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.096 0 CA-C-N 118.273 0.488 . . . . 0.0 110.591 175.123 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 11.2 m -148.29 -83.61 0.11 Allowed 'General case' 0 CA--C 1.553 1.088 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 167.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 41.9 ttm180 -135.73 28.22 3.28 Favored 'General case' 0 N--CA 1.489 1.482 0 CA-C-O 121.696 0.76 . . . . 0.0 109.284 179.487 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.632 ' HA2' HD11 ' A' ' 138' ' ' ILE . . . 58.83 36.71 88.41 Favored Glycine 0 C--N 1.348 1.231 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 -166.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -79.02 175.31 10.7 Favored 'General case' 0 C--O 1.246 0.873 0 C-N-CA 124.161 0.985 . . . . 0.0 111.761 -169.428 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.6 m -72.83 142.36 15.21 Favored 'Isoleucine or valine' 0 C--O 1.244 0.782 0 CA-C-O 121.37 0.605 . . . . 0.0 109.784 -176.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.4 HD11 HD13 ' A' ' 86' ' ' ILE . 3.4 mm? -88.12 177.24 6.96 Favored 'General case' 0 CA--C 1.548 0.869 0 CA-C-N 114.676 -1.147 . . . . 0.0 110.099 171.357 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' MET . . . . . 0.467 ' HA ' ' O ' ' A' ' 124' ' ' LYS . 9.1 ptp -159.04 155.76 28.03 Favored 'General case' 0 C--O 1.253 1.274 0 C-N-CA 123.874 0.87 . . . . 0.0 110.399 178.544 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.455 ' CD2' ' HB2' ' A' ' 8' ' ' LEU . 0.1 OUTLIER -153.19 104.13 2.77 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 114.727 -1.124 . . . . 0.0 108.134 -179.238 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.566 ' HD2' ' HB ' ' A' ' 64' ' ' VAL . 70.5 mmtt 61.74 30.08 18.27 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 123.844 0.715 . . . . 0.0 110.024 -175.246 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.442 ' HA3' ' O ' ' A' ' 60' ' ' GLU . . . 83.94 -5.06 81.02 Favored Glycine 0 C--N 1.347 1.142 0 CA-C-O 119.012 -0.882 . . . . 0.0 114.185 -177.45 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . 0.467 ' O ' ' HA ' ' A' ' 120' ' ' MET . 21.6 ttmm -69.21 114.21 7.27 Favored 'General case' 0 C--N 1.357 0.924 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 170.65 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 36.2 ttm-85 -80.21 95.36 6.26 Favored 'General case' 0 CA--C 1.538 0.499 0 O-C-N 123.895 0.747 . . . . 0.0 109.36 -171.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 74.6 mt -80.14 93.74 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 C-N-CA 123.918 0.887 . . . . 0.0 108.701 -177.093 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -94.02 128.95 39.2 Favored Pre-proline 0 CA--C 1.542 0.636 0 CA-C-O 118.768 -0.634 . . . . 0.0 109.556 -177.117 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_exo -51.09 142.78 33.93 Favored 'Trans proline' 0 C--N 1.384 2.42 0 C-N-CA 123.419 2.746 . . . . 0.0 114.516 -176.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 54.7 p -97.8 -10.69 24.36 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 123.558 0.743 . . . . 0.0 110.429 172.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.677 ' HB3' ' HB2' ' A' ' 139' ' ' SER . 35.9 t-105 -155.38 147.18 23.26 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.647 1.179 . . . . 0.0 107.869 176.007 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.401 ' HA ' ' HA ' ' A' ' 138' ' ' ILE . . . -154.79 119.97 4.98 Favored 'General case' 0 C--O 1.237 0.436 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 170.669 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 3.8 p-10 -109.7 112.24 24.19 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 123.859 0.864 . . . . 0.0 108.684 176.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 18.2 t -77.43 -27.4 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 C-N-CA 122.512 0.325 . . . . 0.0 110.739 -176.368 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 52.5 tttp -67.31 -49.39 64.38 Favored 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.022 0.529 . . . . 0.0 111.996 -172.442 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -80.19 -23.0 41.29 Favored 'General case' 0 N--CA 1.485 1.284 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 169.028 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 18.8 t70 74.46 55.37 0.09 Allowed 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 125.367 1.467 . . . . 0.0 110.202 176.631 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.522 ' HA ' ' HA ' ' A' ' 110' ' ' MET . 4.6 mp -133.8 174.89 9.97 Favored 'General case' 0 CA--C 1.541 0.604 0 CA-C-N 115.074 -0.966 . . . . 0.0 111.368 172.616 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.632 HD11 ' HA2' ' A' ' 116' ' ' GLY . 78.9 mt -139.9 150.94 21.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 125.318 1.447 . . . . 0.0 108.327 -176.549 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . 0.677 ' HB2' ' HB3' ' A' ' 130' ' ' TRP . 19.6 m -134.44 141.64 46.86 Favored 'General case' 0 CA--C 1.546 0.794 0 C-N-CA 123.585 0.754 . . . . 0.0 109.563 171.507 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.676 ' HB3' ' HB3' ' A' ' 107' ' ' PHE . 83.4 t80 -128.79 142.16 51.07 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 177.241 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 90.48 -5.86 82.43 Favored Glycine 0 CA--C 1.531 1.044 0 N-CA-C 112.28 -0.328 . . . . 0.0 112.28 -173.701 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . 0.485 ' HA3' ' O ' ' A' ' 233' ' ' ILE . . . 146.87 -139.37 7.92 Favored Glycine 0 C--N 1.342 0.904 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -178.5 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -90.15 165.25 31.47 Favored Glycine 0 C--N 1.344 1.006 0 N-CA-C 110.157 -1.177 . . . . 0.0 110.157 167.16 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' TRP . . . . . 0.549 ' HZ2' ' HA2' ' A' ' 209' ' ' GLY . 7.0 t90 -61.11 105.58 0.5 Allowed 'General case' 0 CA--C 1.548 0.893 0 CA-C-O 121.281 0.562 . . . . 0.0 110.601 174.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . 0.601 ' HG2' ' HA ' ' A' ' 233' ' ' ILE . 0.0 OUTLIER -137.88 156.28 48.07 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 115.352 -0.84 . . . . 0.0 109.386 176.022 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' LEU . . . . . 0.698 HD11 ' HB2' ' A' ' 103' ' ' LYS . 5.7 mt 169.24 -25.46 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.535 0 O-C-N 125.625 1.828 . . . . 0.0 109.015 -174.43 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 67.49 83.78 0.16 Allowed 'General case' 0 C--N 1.362 1.111 0 C-N-CA 125.185 1.394 . . . . 0.0 109.035 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -164.34 86.25 0.1 Allowed Glycine 0 C--N 1.337 0.599 0 CA-C-N 115.045 -0.979 . . . . 0.0 110.849 -170.292 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 28.1 tt0 -103.45 122.61 45.25 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 124.739 1.216 . . . . 0.0 109.327 177.317 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' TRP . . . . . . . . . . . . . 42.3 t90 -68.71 129.28 39.47 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 172.038 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 22.9 pttm -86.38 110.18 19.52 Favored 'General case' 0 CA--C 1.553 1.088 0 CA-C-O 121.408 0.623 . . . . 0.0 109.872 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -66.92 112.37 4.28 Favored 'General case' 0 N--CA 1.483 1.203 0 CA-C-O 121.609 0.718 . . . . 0.0 111.068 -178.036 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 153.81 -41.83 0.64 Allowed Glycine 0 N--CA 1.465 0.628 0 N-CA-C 110.191 -1.163 . . . . 0.0 110.191 -176.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 3.8 mp0 -88.55 -179.29 6.02 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 124.617 1.167 . . . . 0.0 109.907 175.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -73.23 142.34 47.28 Favored 'General case' 0 C--O 1.242 0.669 0 C-N-CA 122.976 0.51 . . . . 0.0 110.05 172.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 5.0 p -91.68 139.2 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 170.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 10.9 mm-40 -112.17 131.75 55.29 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 -176.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 53.7 t -126.21 124.08 65.05 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.642 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -177.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.46 ' HB2' ' HD2' ' A' ' 199' ' ' PRO . 51.1 mt -73.54 78.35 1.46 Allowed 'General case' 0 C--N 1.351 0.642 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 164.225 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -63.53 99.1 0.2 Allowed 'General case' 0 C--N 1.349 0.557 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -179.552 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 68.6 mt -72.16 95.95 1.73 Allowed 'General case' 0 C--O 1.24 0.563 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 179.719 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . 0.402 ' HB2' ' HB2' ' A' ' 165' ' ' LYS . 42.9 mt-10 -62.47 139.09 96.63 Favored Pre-proline 0 CA--C 1.556 1.204 0 CA-C-N 115.249 -0.887 . . . . 0.0 109.775 178.866 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . 0.498 ' HB3' HG23 ' A' ' 49' ' ' THR . 63.1 Cg_exo -54.48 111.55 0.75 Allowed 'Trans proline' 0 C--N 1.38 2.219 0 C-N-CA 123.16 2.573 . . . . 0.0 113.862 -173.485 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 63.49 19.17 62.09 Favored Glycine 0 C--N 1.355 1.622 0 O-C-N 123.572 0.545 . . . . 0.0 113.784 179.067 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . 0.402 ' HB2' ' HB2' ' A' ' 162' ' ' GLU . 56.7 mtpt -129.31 178.55 6.36 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 124.473 1.109 . . . . 0.0 110.348 -173.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -52.81 155.68 3.9 Favored Pre-proline 0 CA--C 1.559 1.291 0 CA-C-N 114.759 -1.109 . . . . 0.0 112.31 169.531 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -69.52 168.74 20.37 Favored 'Trans proline' 0 C--N 1.371 1.711 0 C-N-CA 122.235 1.957 . . . . 0.0 110.932 168.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 16.2 ttm180 -137.09 109.88 7.59 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 172.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . 0.698 ' HB3' ' H ' ' A' ' 19' ' ' GLN . . . -69.4 105.88 2.75 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 172.076 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 24.8 t -113.75 128.23 70.74 Favored 'Isoleucine or valine' 0 C--O 1.24 0.586 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 -178.185 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 14.6 mt-30 -83.73 103.84 13.35 Favored 'General case' 0 C--O 1.237 0.42 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 168.488 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 11.9 p -106.4 124.25 49.3 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 178.397 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . 0.653 ' H ' ' HA3' ' A' ' 24' ' ' GLY . 50.1 mttm -78.78 132.86 63.32 Favored Pre-proline 0 CA--C 1.548 0.884 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 171.244 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -59.37 171.92 2.2 Favored 'Trans proline' 0 C--N 1.377 2.061 0 C-N-CA 123.38 2.72 . . . . 0.0 114.242 -172.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -164.67 -177.12 37.03 Favored Glycine 0 C--N 1.335 0.512 0 CA-C-N 114.786 -1.097 . . . . 0.0 111.011 -179.644 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.678 ' HB2' HD12 ' A' ' 28' ' ' ILE . 69.6 mt -131.82 159.52 38.28 Favored 'General case' 0 N--CA 1.485 1.319 0 CA-C-N 117.414 0.607 . . . . 0.0 110.07 -174.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 177' ' ' PHE . . . . . 0.739 ' HD2' HG21 ' A' ' 31' ' ' ILE . 0.2 OUTLIER -141.18 125.3 17.32 Favored 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 123.101 0.56 . . . . 0.0 110.839 176.047 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 178' ' ' LYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 183' ' ' THR . 10.3 ptpp? -95.02 123.08 38.3 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 123.375 0.67 . . . . 0.0 111.028 -173.189 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 52.3 p -95.4 -173.44 2.91 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 123.771 0.828 . . . . 0.0 109.391 169.739 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 30.3 p-10 -68.9 -22.75 64.15 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 123.003 0.521 . . . . 0.0 110.764 171.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -77.87 -51.28 10.7 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 123.99 0.916 . . . . 0.0 110.322 176.787 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 164.46 -177.63 40.03 Favored Glycine 0 C--N 1.342 0.897 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.587 -179.713 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 183' ' ' THR . . . . . 0.48 ' HA ' ' HA ' ' A' ' 178' ' ' LYS . 13.2 t -80.23 136.71 36.52 Favored 'General case' 0 CA--C 1.544 0.749 0 CA-C-O 121.317 0.58 . . . . 0.0 110.735 -177.798 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . 0.414 ' HB ' ' CE1' ' A' ' 177' ' ' PHE . 14.9 mt -119.01 161.27 18.21 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.866 0 C-N-CA 124.9 1.28 . . . . 0.0 107.546 -177.087 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -100.74 138.78 14.05 Favored Glycine 0 C--N 1.349 1.281 0 N-CA-C 112.319 -0.312 . . . . 0.0 112.319 -176.257 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.497 ' HB2' ' CE1' ' A' ' 177' ' ' PHE . . . -162.63 -169.95 2.25 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-O 122.029 0.919 . . . . 0.0 112.543 -169.616 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 187' ' ' VAL . . . . . . . . . . . . . 2.0 p -105.41 100.98 11.69 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.999 0 CA-C-N 113.76 -1.564 . . . . 0.0 107.317 156.513 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 65.8 p -98.38 111.44 23.78 Favored 'General case' 0 C--O 1.24 0.56 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 172.195 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 46.0 tp -146.22 138.41 25.15 Favored 'General case' 0 N--CA 1.485 1.306 0 CA-C-O 120.881 0.372 . . . . 0.0 111.811 -177.593 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 190' ' ' ASP . . . . . 0.471 ' HA ' ' HA ' ' A' ' 221' ' ' ALA . 32.7 t70 -81.92 103.23 11.42 Favored 'General case' 0 C--N 1.351 0.658 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 170.504 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 191' ' ' PHE . . . . . 0.54 ' HB3' ' HE1' ' A' ' 222' ' ' TYR . 68.2 t80 -177.23 166.71 2.36 Favored 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 124.71 1.204 . . . . 0.0 108.659 -173.655 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 33.7 p -64.94 117.04 35.05 Favored Pre-proline 0 CA--C 1.557 1.22 0 C-N-CA 123.639 0.776 . . . . 0.0 111.234 177.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . 0.579 ' HG2' ' HG3' ' B' ' 254' ' ' ARG . 30.0 Cg_endo -62.45 140.7 83.54 Favored 'Trans proline' 0 C--N 1.378 2.109 0 C-N-CA 123.078 2.519 . . . . 0.0 112.855 176.638 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -84.09 -176.24 51.09 Favored Glycine 0 C--N 1.344 0.977 0 N-CA-C 111.051 -0.819 . . . . 0.0 111.051 168.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 62.5 p -77.39 131.7 38.17 Favored 'General case' 0 CA--C 1.551 0.991 0 CA-C-N 117.149 0.474 . . . . 0.0 110.725 178.072 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -63.57 100.14 0.25 Allowed 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.561 0.744 . . . . 0.0 109.776 -176.833 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 140.05 -1.22 2.19 Favored Glycine 0 C--N 1.341 0.86 0 CA-C-N 114.519 -1.219 . . . . 0.0 112.148 -174.282 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 198' ' ' SER . . . . . 0.455 ' HB2' ' HD2' ' A' ' 211' ' ' TYR . 48.9 m -57.43 138.6 81.18 Favored Pre-proline 0 CA--C 1.558 1.277 0 C-N-CA 123.495 0.718 . . . . 0.0 111.512 173.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . 0.46 ' HD2' ' HB2' ' A' ' 159' ' ' LEU . 17.3 Cg_exo -67.05 132.81 29.04 Favored 'Trans proline' 0 C--N 1.38 2.203 0 C-N-CA 123.268 2.645 . . . . 0.0 113.492 -177.37 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 200' ' ' ILE . . . . . 0.449 HD13 HG23 ' A' ' 226' ' ' ILE . 16.6 mt -98.81 110.12 25.51 Favored 'Isoleucine or valine' 0 C--O 1.241 0.618 0 CA-C-O 121.982 0.896 . . . . 0.0 109.666 172.421 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 201' ' ' ILE . . . . . . . . . . . . . 47.0 mt -108.91 148.75 12.56 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.894 0 CA-C-N 114.644 -1.162 . . . . 0.0 108.082 177.769 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 202' ' ' ASP . . . . . 0.573 ' H ' ' HB ' ' A' ' 207' ' ' VAL . 18.1 t70 -89.51 160.21 16.85 Favored 'General case' 0 N--CA 1.48 1.075 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 172.215 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 83.1 tttt -63.37 -15.48 57.61 Favored 'General case' 0 CA--C 1.555 1.141 0 N-CA-C 113.479 0.918 . . . . 0.0 113.479 -170.487 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 7.9 mtpm? -76.42 -1.02 24.94 Favored 'General case' 0 N--CA 1.485 1.318 0 N-CA-C 112.502 0.556 . . . . 0.0 112.502 176.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 82.7 7.01 87.97 Favored Glycine 0 C--N 1.349 1.283 0 CA-C-O 120.913 0.174 . . . . 0.0 112.695 -178.734 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -117.2 164.09 15.31 Favored 'General case' 0 N--CA 1.475 0.793 0 C-N-CA 124.733 1.213 . . . . 0.0 108.714 174.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.573 ' HB ' ' H ' ' A' ' 202' ' ' ASP . 57.4 t 90.77 160.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.254 0 C-N-CA 125.905 1.682 . . . . 0.0 108.562 -171.662 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 208' ' ' VAL . . . . . 0.585 HG21 ' HB3' ' A' ' 146' ' ' LEU . 1.8 m -174.34 13.8 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 C-N-CA 124.444 1.098 . . . . 0.0 109.666 -144.391 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.549 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . -64.87 -154.78 0.15 Allowed Glycine 0 C--N 1.354 1.549 0 C-N-CA 124.105 0.86 . . . . 0.0 115.013 -177.098 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . 0.474 HD13 HD23 ' A' ' 137' ' ' LEU . 6.0 tt -142.12 133.4 26.34 Favored 'General case' 0 C--O 1.242 0.691 0 O-C-N 122.048 -0.678 . . . . 0.0 110.588 -172.399 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 211' ' ' TYR . . . . . 0.455 ' HD2' ' HB2' ' A' ' 198' ' ' SER . 0.4 OUTLIER -102.49 108.56 19.91 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 124.844 1.258 . . . . 0.0 108.935 175.208 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 212' ' ' GLY . . . . . 0.519 ' O ' ' SD ' ' A' ' 110' ' ' MET . . . 171.22 70.05 0.04 OUTLIER Glycine 0 C--N 1.345 1.081 0 C-N-CA 120.65 -0.786 . . . . 0.0 114.719 156.061 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 213' ' ' ASN . . . . . 0.669 ' HB2' ' HB3' ' A' ' 225' ' ' ALA . 18.5 m120 -131.76 81.85 2.0 Allowed 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 172.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 160.57 -152.38 23.08 Favored Glycine 0 C--O 1.242 0.619 0 CA-C-N 113.965 -1.471 . . . . 0.0 111.341 -178.231 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 215' ' ' VAL . . . . . 0.841 HG11 ' HA ' ' A' ' 40' ' ' SER . 15.8 m -152.57 -173.94 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.213 0 C-N-CA 123.45 0.7 . . . . 0.0 111.235 -167.345 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 216' ' ' VAL . . . . . 0.489 ' HB ' ' HA2' ' A' ' 220' ' ' GLY . 17.0 m -85.15 113.0 22.9 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.771 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 164.706 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 217' ' ' THR . . . . . 0.689 HG21 ' HB3' ' A' ' 29' ' ' LEU . 23.5 m -102.81 158.99 15.88 Favored 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 123.944 0.898 . . . . 0.0 109.644 -174.806 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 2.5 tpm_? 69.89 -74.63 0.08 Allowed 'General case' 0 CA--C 1.552 1.023 0 C-N-CA 124.957 1.303 . . . . 0.0 110.095 -176.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 21.8 t -164.42 26.21 0.07 Allowed 'General case' 0 CA--C 1.551 1.007 0 C-N-CA 123.856 0.862 . . . . 0.0 110.148 175.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 220' ' ' GLY . . . . . 0.489 ' HA2' ' HB ' ' A' ' 216' ' ' VAL . . . 141.98 -6.88 2.35 Favored Glycine 0 N--CA 1.477 1.418 0 CA-C-O 119.884 -0.398 . . . . 0.0 113.72 -179.086 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . 0.471 ' HA ' ' HA ' ' A' ' 190' ' ' ASP . . . -70.76 97.83 1.44 Allowed 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.943 0.897 . . . . 0.0 110.044 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 222' ' ' TYR . . . . . 0.54 ' HE1' ' HB3' ' A' ' 191' ' ' PHE . 15.8 p90 -66.1 124.72 23.37 Favored 'General case' 0 CA--C 1.544 0.715 0 CA-C-O 121.534 0.683 . . . . 0.0 110.88 -171.08 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . 0.637 HG11 ' HB3' ' A' ' 177' ' ' PHE . 62.1 t -123.92 115.66 45.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 173.721 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 67.9 m -142.71 141.85 31.88 Favored 'General case' 0 N--CA 1.48 1.06 0 O-C-N 123.855 0.722 . . . . 0.0 110.312 176.062 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . 0.669 ' HB3' ' HB2' ' A' ' 213' ' ' ASN . . . -75.31 153.29 37.96 Favored 'General case' 0 C--O 1.244 0.782 0 C-N-CA 123.087 0.555 . . . . 0.0 112.238 -174.656 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 226' ' ' ILE . . . . . 0.449 HG23 HD13 ' A' ' 200' ' ' ILE . 88.9 mt -91.4 103.06 14.12 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.623 0 CA-C-N 114.758 -1.11 . . . . 0.0 109.748 -176.594 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -96.07 152.65 18.34 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 122.895 0.478 . . . . 0.0 109.952 178.36 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -148.19 168.55 22.17 Favored 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 124.515 1.126 . . . . 0.0 109.736 -172.118 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . 0.425 HG22 ' NE1' ' A' ' 144' ' ' TRP . 59.0 p -66.88 110.61 3.38 Favored 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 123.006 0.522 . . . . 0.0 110.527 -176.232 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -116.97 -24.37 7.63 Favored 'General case' 0 N--CA 1.482 1.169 0 C-N-CA 123.418 0.687 . . . . 0.0 111.406 -172.34 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 23.3 mmtp -91.88 -141.02 0.19 Allowed 'General case' 0 CA--C 1.566 1.561 0 C-N-CA 122.974 0.51 . . . . 0.0 109.682 -172.409 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 70.0 p -158.13 178.39 10.25 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 124.221 1.009 . . . . 0.0 108.873 -167.555 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 233' ' ' ILE . . . . . 0.601 ' HA ' ' HG2' ' A' ' 145' ' ' LYS . 82.1 mt -53.79 -42.7 53.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 CA-C-N 118.391 0.541 . . . . 0.0 110.467 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 234' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 174.07 -72.52 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 125.363 1.465 . . . . 0.0 107.237 174.187 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -104.38 -38.89 6.65 Favored 'General case' 0 C--O 1.238 0.467 0 C-N-CA 124.852 1.261 . . . . 0.0 108.282 174.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 236' ' ' ASN . . . . . 0.411 ' HB2' ' HB ' ' A' ' 233' ' ' ILE . 17.0 m120 -67.73 152.79 96.01 Favored Pre-proline 0 CA--C 1.548 0.902 0 CA-C-N 114.882 -1.054 . . . . 0.0 109.776 172.625 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -60.38 -177.48 0.16 Allowed 'Trans proline' 0 C--N 1.381 2.263 0 C-N-CA 123.549 2.833 . . . . 0.0 113.5 177.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 238' ' ' GLU . . . . . 0.467 ' HG3' ' H ' ' A' ' 239' ' ' ILE . 4.9 pt-20 -51.31 -49.04 62.1 Favored 'General case' 0 CA--C 1.555 1.151 0 C-N-CA 123.498 0.719 . . . . 0.0 110.703 172.274 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 239' ' ' ILE . . . . . 0.467 ' H ' ' HG3' ' A' ' 238' ' ' GLU . 6.5 tp -153.07 -45.08 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 C-N-CA 124.521 1.128 . . . . 0.0 108.123 176.123 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 . . . . . 0 C--O 1.248 1.019 0 C-N-CA 124.088 0.955 . . . . 0.0 108.616 -179.507 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 251' ' ' BEZ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 253' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 68.51 -76.08 0.06 Allowed 'General case' 0 C--N 1.359 0.994 0 C-N-CA 124.818 1.247 . . . . 0.0 109.872 -169.377 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 254' ' ' ARG . . . . . 0.579 ' HG3' ' HG2' ' A' ' 193' ' ' PRO . 5.4 mmp_? 73.5 -30.27 0.21 Allowed 'General case' 0 N--CA 1.496 1.831 0 C-N-CA 125.749 1.619 . . . . 0.0 112.085 -172.678 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 255' ' ' M9P . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.888 0 N-CA-C 112.794 -0.123 . . . . 0.0 112.794 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 39.0 t -144.0 152.57 41.22 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 123.707 0.803 . . . . 0.0 109.42 179.419 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.43 151.74 37.91 Favored 'General case' 0 N--CA 1.477 0.889 0 C-N-CA 123.538 0.735 . . . . 0.0 109.431 -179.343 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -131.99 2.09 3.97 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 124.05 0.94 . . . . 0.0 109.742 -175.14 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -127.34 80.65 1.97 Allowed 'General case' 0 CA--C 1.533 0.306 0 CA-C-N 114.526 -1.216 . . . . 0.0 108.14 -168.708 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 5.0 mp -127.05 101.97 6.77 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 -178.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.425 ' HA ' ' HB2' ' A' ' 120' ' ' MET . 10.7 mm-40 -78.65 146.59 33.97 Favored 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 123.244 0.618 . . . . 0.0 110.979 -172.403 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.555 HD21 HD13 ' A' ' 119' ' ' LEU . 30.4 mt -90.58 114.39 26.62 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-N 115.042 -0.981 . . . . 0.0 109.14 171.849 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.417 ' HB2' ' HD2' ' A' ' 87' ' ' LYS . 31.4 tt0 -103.52 120.28 40.54 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 124.503 1.121 . . . . 0.0 108.328 -176.455 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 26.3 ptt180 -59.76 132.69 54.74 Favored 'General case' 0 N--CA 1.475 0.817 0 C-N-CA 122.859 0.464 . . . . 0.0 110.893 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.447 ' HB2' ' HG3' ' A' ' 85' ' ' ARG . . . -121.27 -43.18 2.43 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 122.379 0.272 . . . . 0.0 111.362 -177.046 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . 178.37 -158.45 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 124.184 0.994 . . . . 0.0 110.041 -173.703 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -128.01 164.67 21.86 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 123.777 0.831 . . . . 0.0 108.85 168.503 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 53.9 t -75.45 102.36 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 N-CA-C 109.414 -0.588 . . . . 0.0 109.414 177.444 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 4.5 ptpp? -167.89 146.23 4.56 Favored 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 124.633 1.173 . . . . 0.0 108.557 174.294 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 28.8 t90 -78.99 110.7 14.48 Favored 'General case' 0 CA--C 1.547 0.844 0 O-C-N 123.533 0.52 . . . . 0.0 111.402 -172.505 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -73.68 145.43 45.26 Favored 'General case' 0 CA--C 1.544 0.737 0 CA-C-O 121.66 0.743 . . . . 0.0 111.506 172.427 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -68.01 -1.62 6.14 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 125.47 1.508 . . . . 0.0 112.967 -177.072 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 22.8 mm-40 -80.2 50.4 1.24 Allowed 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 123.766 0.826 . . . . 0.0 111.112 -178.306 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.428 ' HA ' ' O ' ' A' ' 169' ' ' ALA . . . -73.32 84.02 1.42 Allowed 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 124.615 1.166 . . . . 0.0 111.464 -174.67 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 38.8 mt-10 -103.57 123.12 46.35 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 124.031 0.932 . . . . 0.0 110.425 -175.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 9.6 tp -76.91 132.68 32.41 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.134 0 C-N-CA 122.47 0.308 . . . . 0.0 110.763 -177.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 95.7 p -148.68 -35.71 0.19 Allowed 'General case' 0 N--CA 1.484 1.275 0 N-CA-C 112.14 0.422 . . . . 0.0 112.14 175.567 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -53.39 98.1 0.03 OUTLIER Glycine 0 C--N 1.353 1.476 0 N-CA-C 113.917 0.327 . . . . 0.0 113.917 178.45 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 40.7 p -103.9 -68.72 0.83 Allowed 'General case' 0 CA--C 1.547 0.865 0 C-N-CA 124.014 0.926 . . . . 0.0 111.468 -172.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 20.0 m -72.98 126.08 90.7 Favored Pre-proline 0 N--CA 1.477 0.88 0 C-N-CA 123.598 0.759 . . . . 0.0 111.381 -171.12 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -70.85 -74.27 0.01 OUTLIER 'Trans proline' 0 C--N 1.366 1.467 0 C-N-CA 122.13 1.887 . . . . 0.0 111.59 167.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 51.0 mm -90.55 121.12 40.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.913 0 C-N-CA 123.26 0.624 . . . . 0.0 111.448 -167.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.409 HD22 HG22 ' A' ' 217' ' ' THR . 17.2 mt -143.37 133.48 24.34 Favored 'General case' 0 N--CA 1.48 1.064 0 C-N-CA 123.737 0.815 . . . . 0.0 110.333 174.068 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 35.0 p -97.07 140.02 32.21 Favored 'General case' 0 N--CA 1.477 0.892 0 C-N-CA 123.851 0.86 . . . . 0.0 110.538 179.189 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 39.5 mt -131.53 160.58 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 124.265 1.026 . . . . 0.0 108.594 -178.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 66.7 p -96.03 114.33 26.03 Favored 'General case' 0 C--N 1.367 1.327 0 CA-C-N 118.889 0.768 . . . . 0.0 109.001 176.102 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 8.8 mm -55.93 125.89 12.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 C-N-CA 123.987 0.915 . . . . 0.0 109.934 175.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 5.8 m -117.42 135.53 53.82 Favored 'General case' 0 C--O 1.252 1.224 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.322 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 30.4 tt0 60.3 28.82 18.46 Favored 'General case' 0 CA--C 1.558 1.263 0 C-N-CA 124.725 1.21 . . . . 0.0 110.791 178.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 3.8 p30 46.5 30.05 1.02 Allowed 'General case' 0 N--CA 1.493 1.708 0 C-N-CA 125.631 1.572 . . . . 0.0 113.109 -174.584 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -145.13 -63.7 0.02 OUTLIER Glycine 0 C--N 1.353 1.515 0 CA-C-N 116.562 -0.29 . . . . 0.0 112.487 -177.67 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 38.8 t -105.85 125.97 51.62 Favored 'General case' 0 N--CA 1.486 1.361 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 -172.242 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 1.8 mpp? -88.8 136.95 32.74 Favored 'General case' 0 CA--C 1.546 0.823 0 O-C-N 121.875 -0.515 . . . . 0.0 111.472 -173.745 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.5 m -125.15 164.12 20.95 Favored 'General case' 0 N--CA 1.482 1.125 0 C-N-CA 124.622 1.169 . . . . 0.0 109.915 176.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.529 ' H ' HG21 ' A' ' 215' ' ' VAL . 7.5 tp -93.07 92.51 3.74 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.845 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 -177.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 42.5 mmtm 57.88 -74.78 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.336 0 C-N-CA 123.382 0.673 . . . . 0.0 109.831 -161.238 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 5.2 p30 -147.32 118.16 7.62 Favored 'General case' 0 CA--C 1.552 1.045 0 C-N-CA 124.608 1.163 . . . . 0.0 110.034 175.181 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -174.13 130.78 0.39 Allowed 'General case' 0 N--CA 1.492 1.629 0 C-N-CA 123.685 0.794 . . . . 0.0 109.176 171.275 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.418 ' HA ' ' NZ ' ' B' ' 253' ' ' LYS . 0.5 OUTLIER -166.52 27.51 0.04 OUTLIER 'General case' 0 CA--C 1.554 1.108 0 C-N-CA 123.42 0.688 . . . . 0.0 110.104 -178.275 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -105.65 125.21 50.72 Favored 'General case' 0 N--CA 1.483 1.18 0 C-N-CA 122.989 0.515 . . . . 0.0 111.246 -176.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -173.59 139.72 0.75 Allowed 'General case' 0 N--CA 1.478 0.952 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 171.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 27.7 tt0 -158.06 79.91 0.84 Allowed 'General case' 0 C--O 1.24 0.555 0 CA-C-O 121.14 0.495 . . . . 0.0 109.673 178.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 93.4 m -81.69 135.09 35.52 Favored 'General case' 0 CA--C 1.537 0.473 0 N-CA-C 108.577 -0.898 . . . . 0.0 108.577 165.685 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 8.1 mp -72.77 90.92 1.44 Allowed 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 123.159 0.583 . . . . 0.0 109.652 -178.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -63.17 150.78 48.81 Favored Glycine 0 C--N 1.35 1.327 0 CA-C-N 114.854 -1.066 . . . . 0.0 112.488 177.075 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 99.11 -31.08 8.66 Favored Glycine 0 C--N 1.34 0.796 0 N-CA-C 111.501 -0.64 . . . . 0.0 111.501 -172.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 128.72 -50.42 0.89 Allowed Glycine 0 C--N 1.349 1.256 0 N-CA-C 110.67 -0.972 . . . . 0.0 110.67 -176.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 145.82 -34.27 1.47 Allowed Glycine 0 C--N 1.349 1.305 0 O-C-N 123.666 0.274 . . . . 0.0 112.459 177.355 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 75.0 p -77.37 -22.74 51.27 Favored 'General case' 0 CA--C 1.555 1.136 0 C-N-CA 123.584 0.754 . . . . 0.0 111.787 -178.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 93.0 -50.79 2.51 Favored Glycine 0 C--N 1.35 1.316 0 C-N-CA 122.864 0.269 . . . . 0.0 112.894 177.506 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.41 ' HA3' ' HB2' ' A' ' 60' ' ' GLU . . . 137.35 146.53 5.12 Favored Glycine 0 C--N 1.347 1.174 0 N-CA-C 111.52 -0.632 . . . . 0.0 111.52 -178.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -74.84 -84.74 0.32 Allowed Glycine 0 C--N 1.35 1.315 0 CA-C-N 117.13 0.465 . . . . 0.0 112.011 -178.681 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -71.09 -15.37 74.35 Favored Glycine 0 C--N 1.347 1.165 0 O-C-N 123.567 0.216 . . . . 0.0 112.682 174.558 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.424 ' O ' HG22 ' A' ' 64' ' ' VAL . 36.6 mt-10 -71.14 -10.3 59.52 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 124.283 1.033 . . . . 0.0 112.349 179.212 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 81.8 t80 -65.98 117.14 7.91 Favored 'General case' 0 N--CA 1.478 0.937 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 173.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . 70.12 -65.43 0.32 Allowed 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 124.971 1.308 . . . . 0.0 110.476 -174.42 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -76.28 75.9 1.53 Allowed Glycine 0 C--N 1.344 1.013 0 N-CA-C 112.042 -0.423 . . . . 0.0 112.042 175.304 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.424 HG22 ' O ' ' A' ' 60' ' ' GLU . 5.0 t -85.18 60.7 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.116 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 178.777 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -45.36 132.32 7.82 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 124.686 1.194 . . . . 0.0 112.573 -169.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . 0.606 ' HE1' ' HB2' ' A' ' 122' ' ' LYS . 62.8 m95 -111.65 179.82 3.91 Favored 'General case' 0 C--O 1.243 0.713 0 C-N-CA 123.611 0.764 . . . . 0.0 111.242 -177.223 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -77.41 85.76 3.81 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 114.984 -1.007 . . . . 0.0 108.773 173.23 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 46.3 t -122.69 96.81 45.06 Favored Pre-proline 0 CA--C 1.551 0.995 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 175.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 11.9 Cg_exo -74.05 -27.6 11.8 Favored 'Trans proline' 0 C--N 1.379 2.17 0 C-N-CA 123.483 2.789 . . . . 0.0 111.853 172.822 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 52.1 p -69.07 162.21 66.95 Favored Pre-proline 0 CA--C 1.551 0.991 0 C-N-CA 123.733 0.813 . . . . 0.0 110.292 175.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 81.3 Cg_exo -47.2 149.07 4.05 Favored 'Trans proline' 0 C--N 1.377 2.027 0 C-N-CA 122.785 2.323 . . . . 0.0 113.492 171.463 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 80.3 Cg_exo -51.02 160.13 2.14 Favored 'Trans proline' 0 C--N 1.384 2.424 0 C-N-CA 123.563 2.842 . . . . 0.0 113.395 176.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_exo -45.7 84.05 0.01 OUTLIER 'Trans proline' 0 C--N 1.389 2.706 0 C-N-CA 124.332 3.354 . . . . 0.0 114.697 -179.121 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 26.8 m -137.64 -36.32 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 C-N-CA 124.441 1.096 . . . . 0.0 109.951 178.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -102.57 -37.97 3.12 Favored Glycine 0 C--N 1.348 1.241 0 CA-C-N 116.034 -0.53 . . . . 0.0 112.524 -178.815 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 55.7 tptt -157.34 -42.49 0.07 Allowed 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 122.891 0.476 . . . . 0.0 111.824 -179.171 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . 74.25 110.83 0.07 Allowed 'General case' 0 N--CA 1.491 1.606 0 C-N-CA 124.827 1.251 . . . . 0.0 109.625 -166.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -83.96 150.97 25.31 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 123.044 0.537 . . . . 0.0 111.024 -176.245 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 2.6 pp -100.29 -177.99 3.68 Favored 'General case' 0 CA--C 1.549 0.913 0 C-N-CA 123.88 0.872 . . . . 0.0 110.074 174.647 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 -112.77 -170.97 1.77 Allowed 'General case' 0 N--CA 1.483 1.208 0 C-N-CA 123.34 0.656 . . . . 0.0 109.586 -176.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.684 ' HB2' ' HD2' ' A' ' 103' ' ' LYS . 8.2 p-10 -135.84 129.28 32.16 Favored 'General case' 0 CA--C 1.54 0.57 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 163.771 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 168.32 178.92 40.4 Favored Glycine 0 C--N 1.339 0.699 0 CA-C-N 115.973 -0.558 . . . . 0.0 112.42 177.268 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . 0.558 ' HB1' HD11 ' A' ' 161' ' ' LEU . . . -88.32 125.07 34.5 Favored 'General case' 0 CA--C 1.549 0.911 0 C-N-CA 123.947 0.899 . . . . 0.0 109.79 176.717 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 -122.12 148.46 44.87 Favored 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 123.596 0.758 . . . . 0.0 109.963 -177.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . 0.781 ' HG2' HG21 ' A' ' 195' ' ' THR . 37.3 mtm-85 -95.99 124.43 39.99 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 166.05 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.486 ' H ' ' HA ' ' A' ' 99' ' ' ALA . 27.8 mt -90.65 131.05 38.83 Favored 'Isoleucine or valine' 0 C--O 1.26 1.656 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.437 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 0.2 OUTLIER -124.67 140.83 52.58 Favored 'General case' 0 N--CA 1.45 -0.459 0 CA-C-N 114.504 -1.226 . . . . 0.0 108.684 -174.224 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -84.76 104.09 14.42 Favored 'General case' 0 C--N 1.344 0.331 0 N-CA-C 104.581 -2.377 . . . . 0.0 104.581 175.549 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 14.4 tmtt? -120.64 98.27 5.95 Favored 'General case' 0 CA--C 1.518 -0.288 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 -170.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -79.91 152.47 35.01 Favored Glycine 0 C--O 1.242 0.644 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 170.359 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 2.3 mp -78.46 70.26 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.13 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 174.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 58.7 tp 167.29 -41.4 0.0 OUTLIER 'General case' 0 CA--C 1.554 1.123 0 C-N-CA 126.388 1.875 . . . . 0.0 109.029 -167.04 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -148.22 161.02 28.53 Favored Glycine 0 C--N 1.365 2.174 0 N-CA-C 114.8 0.68 . . . . 0.0 114.8 -169.56 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 77.4 m-85 -132.12 129.33 39.73 Favored 'General case' 0 N--CA 1.481 1.095 0 C-N-CA 124.049 0.94 . . . . 0.0 110.427 -172.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 24.5 m -145.42 153.75 41.53 Favored 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 124.652 1.181 . . . . 0.0 108.254 175.173 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.437 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 1.5 pp0? -96.15 146.72 24.43 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-N 118.738 0.699 . . . . 0.0 109.242 168.509 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.46 HD11 HG22 ' A' ' 86' ' ' ILE . 1.6 pp -136.71 -10.03 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 177.443 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . 0.552 ' HA3' HG12 ' A' ' 113' ' ' VAL . . . 168.26 -147.06 11.01 Favored Glycine 0 C--N 1.348 1.241 0 C-N-CA 121.003 -0.618 . . . . 0.0 113.19 174.049 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.486 ' HA ' ' H ' ' A' ' 86' ' ' ILE . . . -154.33 153.76 32.2 Favored 'General case' 0 C--O 1.24 0.603 0 C-N-CA 123.663 0.785 . . . . 0.0 111.196 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -155.75 157.18 27.58 Favored Glycine 0 C--N 1.338 0.665 0 CA-C-N 114.937 -1.029 . . . . 0.0 111.209 178.748 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 53.1 t -120.82 120.69 63.16 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.778 0 C-N-CA 123.528 0.731 . . . . 0.0 111.517 -169.376 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.531 ' HB3' ' HA ' ' A' ' 81' ' ' ASP . 10.6 m-85 -74.36 135.81 42.47 Favored 'General case' 0 N--CA 1.482 1.163 0 N-CA-C 107.861 -1.163 . . . . 0.0 107.861 165.037 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.684 ' HD2' ' HB2' ' A' ' 81' ' ' ASP . 29.3 tptt -172.4 149.71 2.23 Favored 'General case' 0 N--CA 1.483 1.177 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 171.322 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 60.21 20.14 9.52 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 124.494 1.118 . . . . 0.0 112.048 -178.771 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 80.09 17.06 75.32 Favored Glycine 0 C--N 1.346 1.115 0 CA-C-N 116.036 -0.529 . . . . 0.0 114.377 -178.011 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 18.8 p -140.07 137.18 34.36 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.604 0.762 . . . . 0.0 109.716 -176.316 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' PHE . . . . . 0.602 ' HB3' ' HB2' ' A' ' 140' ' ' TYR . 42.2 t80 -89.87 103.43 16.09 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 120.937 0.399 . . . . 0.0 111.131 -175.084 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . 0.613 ' HB3' ' HE3' ' A' ' 144' ' ' TRP . 18.6 m170 -100.4 114.25 27.65 Favored 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 124.488 1.115 . . . . 0.0 110.563 -176.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . 0.592 HG23 HG23 ' A' ' 138' ' ' ILE . 3.9 t -135.71 175.44 9.59 Favored 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 118.758 0.708 . . . . 0.0 112.158 -177.86 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' MET . . . . . 0.499 ' SD ' ' HB2' ' A' ' 210' ' ' LEU . 79.2 mmm -87.95 154.47 20.48 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 123.886 0.874 . . . . 0.0 109.014 172.807 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' TRP . . . . . 0.416 ' CE2' HG22 ' A' ' 133' ' ' VAL . 50.2 t90 -71.52 -45.74 61.58 Favored 'General case' 0 N--CA 1.486 1.338 0 CA-C-N 118.159 0.436 . . . . 0.0 111.504 -170.611 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 4.3 p-80 -51.52 -21.09 2.21 Favored 'General case' 0 N--CA 1.488 1.465 0 C-N-CA 124.769 1.228 . . . . 0.0 114.247 -173.146 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.552 HG12 ' HA3' ' A' ' 98' ' ' GLY . 16.6 m -59.85 -44.14 93.53 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 CA-C-O 121.43 0.633 . . . . 0.0 110.265 -178.603 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 9.0 t -113.76 168.51 9.72 Favored 'General case' 0 C--O 1.238 0.488 0 C-N-CA 123.905 0.882 . . . . 0.0 109.212 -179.45 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 92.9 mtt180 -95.95 33.43 1.7 Allowed 'General case' 0 CA--C 1.546 0.811 0 C-N-CA 124.194 0.997 . . . . 0.0 109.132 178.146 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 68.81 38.85 85.82 Favored Glycine 0 C--N 1.362 1.983 0 CA-C-N 115.158 -0.928 . . . . 0.0 111.528 -174.193 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -127.83 -179.96 5.23 Favored 'General case' 0 C--O 1.244 0.763 0 C-N-CA 123.647 0.779 . . . . 0.0 110.955 -171.106 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.2 p -75.4 139.65 18.71 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.211 0 CA-C-N 114.716 -1.129 . . . . 0.0 111.963 -176.329 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.555 HD13 HD21 ' A' ' 8' ' ' LEU . 58.3 mt -97.9 -177.78 3.87 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 124.084 0.953 . . . . 0.0 110.77 177.812 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' MET . . . . . 0.425 ' HB2' ' HA ' ' A' ' 7' ' ' GLU . 23.2 mmt -133.49 147.9 51.67 Favored 'General case' 0 N--CA 1.477 0.92 0 C-N-CA 125.308 1.443 . . . . 0.0 109.762 -176.557 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.777 ' HB2' HD11 ' A' ' 126' ' ' ILE . 34.9 t-80 -151.03 96.63 2.35 Favored 'General case' 0 CA--C 1.54 0.595 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.606 ' HB2' ' HE1' ' A' ' 66' ' ' TRP . 25.5 ttpp 57.69 29.77 17.83 Favored 'General case' 0 N--CA 1.496 1.826 0 C-N-CA 124.186 0.995 . . . . 0.0 111.117 -175.693 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 94.95 -3.53 67.3 Favored Glycine 0 C--N 1.345 1.043 0 CA-C-N 115.768 -0.651 . . . . 0.0 113.47 -179.628 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -94.92 122.45 37.57 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 122.92 0.488 . . . . 0.0 109.92 177.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 91.0 mtm-85 -69.39 146.01 52.41 Favored 'General case' 0 C--O 1.243 0.734 0 C-N-CA 123.774 0.83 . . . . 0.0 111.976 178.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.777 HD11 ' HB2' ' A' ' 121' ' ' HIS . 5.0 mt -127.19 112.41 28.51 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.801 0 C-N-CA 123.791 0.836 . . . . 0.0 109.225 -179.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -83.01 139.36 42.68 Favored Pre-proline 0 CA--C 1.554 1.104 0 C-N-CA 123.838 0.855 . . . . 0.0 110.025 179.007 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -75.61 148.7 33.34 Favored 'Trans proline' 0 C--N 1.379 2.181 0 C-N-CA 122.808 2.339 . . . . 0.0 112.482 179.462 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 32.5 p -109.23 -32.35 7.23 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 124.031 0.932 . . . . 0.0 110.707 177.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 4.5 t-105 -132.87 144.03 49.91 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 107.624 -1.251 . . . . 0.0 107.624 -176.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -160.53 123.53 3.37 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.205 0.602 . . . . 0.0 110.222 178.488 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 41.4 m-20 -123.32 105.23 9.67 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 124.345 1.058 . . . . 0.0 108.552 167.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.416 HG22 ' CE2' ' A' ' 111' ' ' TRP . 16.7 t -68.24 -33.39 60.36 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.884 0 C-N-CA 123.53 0.732 . . . . 0.0 109.313 175.164 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -72.01 -33.13 67.82 Favored 'General case' 0 CA--C 1.547 0.863 0 CA-C-N 114.347 -1.297 . . . . 0.0 111.926 -179.177 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -97.07 -7.47 32.7 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 122.946 0.498 . . . . 0.0 111.792 179.586 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 27.5 t70 60.85 47.52 7.69 Favored 'General case' 0 CA--C 1.548 0.873 0 CA-C-O 122.449 1.118 . . . . 0.0 110.604 -178.027 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 49.7 mt -135.1 147.9 49.66 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 123.833 0.853 . . . . 0.0 109.557 176.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.592 HG23 HG23 ' A' ' 109' ' ' THR . 18.4 tt -153.54 143.66 14.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 N-CA-C 107.313 -1.365 . . . . 0.0 107.313 173.441 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . 0.479 ' HB3' ' HA2' ' A' ' 143' ' ' GLY . 44.1 t -150.68 152.89 34.63 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-O 121.876 0.846 . . . . 0.0 110.97 -175.378 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.602 ' HB2' ' HB3' ' A' ' 107' ' ' PHE . 8.7 m-85 -125.26 108.71 12.0 Favored 'General case' 0 CA--C 1.543 0.708 0 CA-C-N 113.524 -1.671 . . . . 0.0 107.499 -164.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 97.48 -4.33 61.9 Favored Glycine 0 C--N 1.348 1.243 0 CA-C-N 116.149 -0.478 . . . . 0.0 112.821 -173.339 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 171.14 -152.64 18.77 Favored Glycine 0 C--N 1.347 1.163 0 CA-C-O 118.744 -1.031 . . . . 0.0 111.295 -179.625 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.479 ' HA2' ' HB3' ' A' ' 139' ' ' SER . . . -119.6 170.2 13.99 Favored Glycine 0 C--N 1.357 1.743 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 173.338 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' TRP . . . . . 0.613 ' HE3' ' HB3' ' A' ' 108' ' ' HIS . 41.6 t-105 -60.23 108.88 0.86 Allowed 'General case' 0 N--CA 1.483 1.188 0 CA-C-O 121.671 0.748 . . . . 0.0 110.728 176.291 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . 0.676 ' HA ' HG23 ' A' ' 229' ' ' THR . 0.0 OUTLIER -145.54 135.1 23.26 Favored 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 114.903 -1.044 . . . . 0.0 108.824 171.007 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' LEU . . . . . 0.601 HD21 ' HB3' ' A' ' 103' ' ' LYS . 13.6 mt -144.69 10.29 1.38 Allowed 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 123.67 0.788 . . . . 0.0 110.586 168.607 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.442 ' H ' HG21 ' A' ' 229' ' ' THR . 14.3 tt0 75.37 -18.5 0.44 Allowed 'General case' 0 N--CA 1.498 1.942 0 C-N-CA 124.67 1.188 . . . . 0.0 111.431 177.071 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.43 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -77.65 138.47 21.66 Favored Glycine 0 C--N 1.346 1.119 0 C-N-CA 123.4 0.524 . . . . 0.0 113.135 -169.478 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -130.1 142.03 50.64 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 124.306 1.042 . . . . 0.0 108.399 -178.565 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' TRP . . . . . . . . . . . . . 43.2 t90 -73.19 137.34 44.99 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 122.719 0.407 . . . . 0.0 110.759 172.357 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 54.3 tttm -92.85 133.57 35.94 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 123.776 0.83 . . . . 0.0 109.225 174.368 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -66.85 146.42 54.44 Favored 'General case' 0 N--CA 1.479 1.012 0 CA-C-O 121.118 0.485 . . . . 0.0 111.826 178.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 92.56 -12.89 68.72 Favored Glycine 0 C--N 1.348 1.237 0 CA-C-N 115.027 -0.988 . . . . 0.0 112.921 -177.571 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 29.7 mm-40 -94.07 131.83 39.18 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 123.045 0.538 . . . . 0.0 111.696 -173.836 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -76.06 123.78 26.34 Favored 'General case' 0 C--O 1.245 0.863 0 N-CA-C 107.008 -1.478 . . . . 0.0 107.008 162.489 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -91.13 158.76 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 -168.544 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . 0.412 ' OE1' ' HG2' ' A' ' 171' ' ' GLN . 13.9 mm100 -100.58 133.61 44.77 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 123.32 0.648 . . . . 0.0 109.297 179.561 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 46.2 t -107.84 102.35 13.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 107.164 -1.421 . . . . 0.0 107.164 177.516 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.557 HD23 ' HB2' ' A' ' 169' ' ' ALA . 1.8 tm? -74.93 78.42 2.16 Favored 'General case' 0 CA--C 1.546 0.796 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 -175.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -72.05 110.18 6.36 Favored 'General case' 0 C--O 1.242 0.699 0 CA-C-N 114.129 -1.396 . . . . 0.0 111.004 -168.359 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . 0.558 HD11 ' HB1' ' A' ' 83' ' ' ALA . 29.9 mt -81.55 83.89 6.89 Favored 'General case' 0 C--O 1.24 0.599 0 CA-C-N 115.099 -0.955 . . . . 0.0 109.182 177.371 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 29.7 mm-40 -68.74 126.92 93.2 Favored Pre-proline 0 CA--C 1.552 1.031 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 174.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -61.77 115.76 3.01 Favored 'Trans proline' 0 C--N 1.384 2.4 0 C-N-CA 123.231 2.621 . . . . 0.0 112.503 -174.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 81.61 10.99 83.62 Favored Glycine 0 C--N 1.351 1.388 0 CA-C-N 115.485 -0.78 . . . . 0.0 113.467 -179.36 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 49.5 mttp -128.54 172.45 11.16 Favored 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 123.395 0.678 . . . . 0.0 110.9 -178.41 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -74.03 156.59 87.74 Favored Pre-proline 0 CA--C 1.555 1.159 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.989 173.826 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 15.8 Cg_exo -68.79 137.38 38.25 Favored 'Trans proline' 0 C--N 1.375 1.937 0 C-N-CA 122.581 2.187 . . . . 0.0 112.568 178.179 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 69.5 mtp180 -117.06 105.75 12.63 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 176.396 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . 0.557 ' HB2' HD23 ' A' ' 159' ' ' LEU . . . -86.04 103.3 14.6 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-O 121.034 0.445 . . . . 0.0 110.559 -176.797 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 42.8 t -94.63 129.71 44.46 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.718 0 C-N-CA 124.288 1.035 . . . . 0.0 111.269 -164.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . 0.412 ' HG2' ' OE1' ' A' ' 157' ' ' GLN . 20.6 mt-30 -79.3 121.37 25.01 Favored 'General case' 0 C--N 1.354 0.767 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 178.627 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 41.9 p -140.34 124.76 17.84 Favored 'General case' 0 C--O 1.237 0.436 0 C-N-CA 122.92 0.488 . . . . 0.0 109.753 -173.064 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 62.2 tttp -70.17 127.58 92.16 Favored Pre-proline 0 CA--C 1.547 0.862 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 171.487 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_exo -57.91 126.4 21.57 Favored 'Trans proline' 0 C--N 1.379 2.175 0 C-N-CA 122.686 2.257 . . . . 0.0 112.767 -179.574 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . 0.431 ' H ' ' HA ' ' A' ' 187' ' ' VAL . . . -98.34 178.44 31.6 Favored Glycine 0 C--N 1.337 0.638 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.391 176.488 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 5.3 mp -141.3 146.3 36.58 Favored 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 123.501 0.72 . . . . 0.0 109.267 176.351 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 177' ' ' PHE . . . . . 0.7 ' HE1' HG12 ' A' ' 223' ' ' VAL . 22.3 m-85 -93.47 121.63 35.07 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 176.551 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 57.1 tptt -86.29 95.87 9.77 Favored 'General case' 0 CA--C 1.541 0.596 0 O-C-N 123.783 0.677 . . . . 0.0 109.201 177.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . 0.524 HG22 ' H ' ' A' ' 181' ' ' ALA . 23.0 m -110.47 150.6 28.63 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 176.383 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 24.7 p30 -61.75 -24.35 66.76 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 123.578 0.751 . . . . 0.0 111.914 175.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . 0.524 ' H ' HG22 ' A' ' 179' ' ' THR . . . -74.18 -39.91 62.87 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.274 1.03 . . . . 0.0 111.388 174.579 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 169.25 -174.16 43.67 Favored Glycine 0 C--N 1.341 0.841 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.569 -177.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 13.2 t -97.78 134.55 40.78 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 175.2 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . 0.556 ' HB ' ' HB2' ' A' ' 177' ' ' PHE . 23.6 mt -104.65 160.02 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 177.905 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -99.09 124.23 8.16 Favored Glycine 0 C--N 1.349 1.279 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 179.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.428 ' HA ' ' HA ' ' A' ' 225' ' ' ALA . . . -147.98 -165.56 2.3 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-O 121.22 0.533 . . . . 0.0 112.395 -161.753 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 187' ' ' VAL . . . . . 0.431 ' HA ' ' H ' ' A' ' 175' ' ' GLY . 4.7 p -158.39 131.12 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.728 0 C-N-CA 124.615 1.166 . . . . 0.0 108.9 175.671 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 7.1 m -111.42 103.5 11.87 Favored 'General case' 0 N--CA 1.479 1.005 0 C-N-CA 123.118 0.567 . . . . 0.0 110.168 176.557 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 4.3 pp -125.67 141.63 51.92 Favored 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 123.37 0.668 . . . . 0.0 109.224 179.586 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -113.53 104.49 12.31 Favored 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 168.102 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 191' ' ' PHE . . . . . . . . . . . . . 43.4 t80 -163.07 -178.3 5.96 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 124.143 0.977 . . . . 0.0 108.725 -170.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 31.4 m -52.11 122.34 23.21 Favored Pre-proline 0 CA--C 1.549 0.939 0 CA-C-O 118.542 -0.742 . . . . 0.0 109.86 170.406 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . 0.493 ' HB2' ' HG3' ' B' ' 254' ' ' ARG . 29.4 Cg_endo -61.57 91.31 0.11 Allowed 'Trans proline' 0 C--N 1.378 2.129 0 C-N-CA 122.695 2.263 . . . . 0.0 112.155 -173.905 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -60.02 123.28 32.62 Favored Glycine 0 C--N 1.348 1.219 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 172.43 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 195' ' ' THR . . . . . 0.781 HG21 ' HG2' ' A' ' 85' ' ' ARG . 8.8 t -54.22 144.37 20.24 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-O 121.663 0.744 . . . . 0.0 112.035 -173.207 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . 0.468 ' HA ' ' HD2' ' A' ' 211' ' ' TYR . 13.4 m -72.28 95.56 1.72 Allowed 'General case' 0 C--O 1.242 0.688 0 CA-C-N 115.077 -0.965 . . . . 0.0 111.406 -169.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . 0.496 ' H ' ' HB3' ' A' ' 211' ' ' TYR . . . 133.63 4.94 2.99 Favored Glycine 0 C--N 1.34 0.753 0 CA-C-N 115.279 -0.873 . . . . 0.0 111.663 -176.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 72.0 m -56.32 131.81 75.86 Favored Pre-proline 0 C--N 1.361 1.101 0 C-N-CA 123.143 0.577 . . . . 0.0 110.229 171.089 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -64.23 111.67 1.67 Allowed 'Trans proline' 0 C--N 1.372 1.777 0 C-N-CA 122.209 1.939 . . . . 0.0 111.635 -176.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 55.3 mt -77.93 111.69 15.04 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.414 0 N-CA-C 107.964 -1.125 . . . . 0.0 107.964 174.32 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 201' ' ' ILE . . . . . 0.424 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 63.5 mt -112.28 148.51 15.33 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.61 0 C-N-CA 124.741 1.216 . . . . 0.0 108.739 -174.545 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 10.0 t70 -71.55 160.49 32.61 Favored 'General case' 0 N--CA 1.482 1.166 0 C-N-CA 123.802 0.841 . . . . 0.0 108.871 171.823 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 3.7 ttmp? -70.17 -13.18 62.07 Favored 'General case' 0 N--CA 1.483 1.195 0 C-N-CA 123.343 0.657 . . . . 0.0 111.358 -178.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 27.1 mtpp -89.23 15.11 9.46 Favored 'General case' 0 CA--C 1.552 1.052 0 C-N-CA 123.9 0.88 . . . . 0.0 111.788 175.499 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 70.53 22.9 77.94 Favored Glycine 0 C--N 1.356 1.642 0 O-C-N 123.102 0.251 . . . . 0.0 113.316 176.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 206' ' ' LYS . . . . . 0.405 ' HE2' ' HB3' ' A' ' 206' ' ' LYS . 22.1 ttpt -112.62 112.84 24.65 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 124.715 1.206 . . . . 0.0 108.261 -176.585 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.43 ' O ' ' HA3' ' A' ' 148' ' ' GLY . 7.4 p -56.61 141.64 13.19 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 CA-C-N 118.953 0.797 . . . . 0.0 110.714 179.057 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 6.0 m -119.02 -33.9 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 C-N-CA 122.606 0.363 . . . . 0.0 110.363 178.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . . . . . . . . . . . -175.82 -167.13 34.33 Favored Glycine 0 C--N 1.349 1.304 0 O-C-N 123.197 0.311 . . . . 0.0 113.819 -174.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . 0.499 ' HB2' ' SD ' ' A' ' 110' ' ' MET . 87.3 mt -117.29 156.2 28.2 Favored 'General case' 0 C--O 1.255 1.356 0 C-N-CA 124.196 0.998 . . . . 0.0 109.916 175.107 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 211' ' ' TYR . . . . . 0.496 ' HB3' ' H ' ' A' ' 197' ' ' GLY . 37.8 t80 -73.33 116.09 13.47 Favored 'General case' 0 C--N 1.35 0.63 0 CA-C-N 114.644 -1.162 . . . . 0.0 109.251 178.561 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -73.99 -142.74 0.7 Allowed Glycine 0 C--N 1.339 0.731 0 O-C-N 124.051 0.844 . . . . 0.0 114.272 -174.291 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 213' ' ' ASN . . . . . . . . . . . . . 3.9 p30 -127.96 159.23 35.62 Favored 'General case' 0 C--O 1.239 0.503 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 -177.27 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 173.62 -136.03 3.47 Favored Glycine 0 N--CA 1.438 -1.227 0 N-CA-C 109.646 -1.381 . . . . 0.0 109.646 178.351 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 215' ' ' VAL . . . . . 0.568 ' HA ' ' HG2' ' B' ' 253' ' ' LYS . 11.3 p -170.0 170.75 0.16 Allowed 'Isoleucine or valine' 0 C--O 1.242 0.683 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 -172.163 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 216' ' ' VAL . . . . . 0.613 HG21 ' H2 ' ' B' ' 251' ' ' BEZ . 35.7 m -70.28 112.6 5.25 Favored 'Isoleucine or valine' 0 CA--C 1.557 1.221 0 CA-C-O 121.882 0.848 . . . . 0.0 108.908 168.548 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 217' ' ' THR . . . . . 0.409 HG22 HD22 ' A' ' 29' ' ' LEU . 8.3 m -119.69 171.84 8.1 Favored 'General case' 0 C--O 1.254 1.323 0 C-N-CA 124.661 1.184 . . . . 0.0 108.393 -174.747 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 22.2 ttt180 73.46 -74.68 0.08 Allowed 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 124.636 1.174 . . . . 0.0 110.327 -179.205 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 35.8 p -148.06 -0.47 0.6 Allowed 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 123.651 0.78 . . . . 0.0 111.297 -178.298 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 220' ' ' GLY . . . . . 0.429 ' HA2' ' HB ' ' A' ' 216' ' ' VAL . . . 134.27 12.55 1.42 Allowed Glycine 0 C--N 1.351 1.386 0 CA-C-O 120.0 -0.334 . . . . 0.0 113.048 -174.586 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . 0.492 ' O ' HG23 ' A' ' 223' ' ' VAL . . . -78.61 139.99 38.5 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 123.023 0.529 . . . . 0.0 109.597 178.449 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 222' ' ' TYR . . . . . . . . . . . . . 37.8 m-85 -78.81 99.21 6.61 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 123.614 0.766 . . . . 0.0 109.532 -176.093 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . 0.7 HG12 ' HE1' ' A' ' 177' ' ' PHE . 39.1 t -118.91 111.31 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 123.142 0.577 . . . . 0.0 110.148 -169.167 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 16.5 m -137.54 159.57 41.58 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.242 1.017 . . . . 0.0 110.554 -171.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . 0.428 ' HA ' ' HA ' ' A' ' 186' ' ' ALA . . . -70.93 171.92 9.89 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 123.921 0.888 . . . . 0.0 112.309 -179.009 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 226' ' ' ILE . . . . . . . . . . . . . 39.3 mt -127.22 124.47 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.183 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 173.298 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -114.18 109.67 18.77 Favored 'General case' 0 N--CA 1.487 1.402 0 CA-C-N 118.019 0.372 . . . . 0.0 110.525 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 -92.89 168.97 10.81 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 123.673 0.789 . . . . 0.0 111.37 -176.477 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . 0.676 HG23 ' HA ' ' A' ' 145' ' ' LYS . 97.4 m -64.41 108.37 1.61 Allowed 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.602 0.761 . . . . 0.0 111.089 -174.736 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 16.2 mm-40 -156.34 12.98 0.29 Allowed 'General case' 0 N--CA 1.484 1.245 0 C-N-CA 123.645 0.778 . . . . 0.0 112.173 -176.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 231' ' ' LYS . . . . . 0.538 ' HA ' ' HE2' ' A' ' 231' ' ' LYS . 11.1 mmpt? -96.52 -92.33 0.22 Allowed 'General case' 0 N--CA 1.486 1.334 0 CA-C-N 119.103 0.865 . . . . 0.0 111.955 -174.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 66.8 p -89.21 113.08 24.25 Favored 'General case' 0 C--N 1.353 0.754 0 CA-C-N 118.735 0.698 . . . . 0.0 112.255 -169.362 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 233' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -86.78 -13.74 10.54 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.312 0 CA-C-N 114.612 -1.176 . . . . 0.0 109.362 166.508 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 234' ' ' GLU . . . . . 0.57 ' HG2' ' H ' ' A' ' 235' ' ' ASP 0.275 1.4 pm0 40.14 -87.46 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 127.574 2.35 . . . . 0.0 114.811 -178.897 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . 0.57 ' H ' ' HG2' ' A' ' 234' ' ' GLU . 29.8 t70 -141.01 18.49 2.29 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 123.175 0.59 . . . . 0.0 110.043 -172.592 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 236' ' ' ASN . . . . . . . . . . . . . 31.9 t30 -76.62 107.45 4.73 Favored Pre-proline 0 CA--C 1.555 1.146 0 C-N-CA 124.276 1.031 . . . . 0.0 110.429 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_endo -85.08 83.73 1.48 Allowed 'Trans proline' 0 C--N 1.377 2.048 0 C-N-CA 122.604 2.202 . . . . 0.0 111.955 -176.106 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 238' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -104.36 121.52 43.54 Favored 'General case' 0 N--CA 1.477 0.889 0 C-N-CA 123.49 0.716 . . . . 0.0 110.459 -179.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 239' ' ' ILE . . . . . . . . . . . . . 9.7 tt -84.88 -52.56 12.27 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.069 0 C-N-CA 123.154 0.581 . . . . 0.0 110.035 176.834 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.556 1.178 0 C-N-CA 123.54 0.736 . . . . 0.0 110.248 179.579 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 251' ' ' BEZ . . . . . 0.613 ' H2 ' HG21 ' A' ' 216' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 253' ' ' LYS . . . . . 0.568 ' HG2' ' HA ' ' A' ' 215' ' ' VAL . 0.1 OUTLIER -83.31 159.66 21.85 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.744 0.818 . . . . 0.0 110.082 173.763 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 254' ' ' ARG . . . . . 0.493 ' HG3' ' HB2' ' A' ' 193' ' ' PRO . 63.0 mtt-85 -72.95 -68.82 0.45 Allowed 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 176.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 255' ' ' M9P . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.93 0 CA-C-O 119.34 -0.7 . . . . 0.0 111.663 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 52.6 p -170.88 117.39 0.48 Allowed 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 124.351 1.061 . . . . 0.0 108.552 176.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -131.98 -59.83 0.93 Allowed 'General case' 0 N--CA 1.482 1.173 0 C-N-CA 122.877 0.471 . . . . 0.0 111.054 -177.853 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -163.48 20.74 0.08 Allowed 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 123.901 0.88 . . . . 0.0 109.406 -171.778 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 21.1 p-10 -142.84 58.83 1.43 Allowed 'General case' 0 N--CA 1.453 -0.291 0 CA-C-N 114.426 -1.261 . . . . 0.0 108.938 -162.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.466 ' HG ' ' HG2' ' A' ' 88' ' ' GLN . 2.9 mp -134.32 117.73 16.72 Favored 'General case' 0 C--O 1.207 -1.149 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 173.143 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.493 ' HB3' ' HE3' ' A' ' 87' ' ' LYS . 37.4 tt0 -114.48 156.26 24.89 Favored 'General case' 0 N--CA 1.495 1.789 0 CA-C-N 119.745 1.157 . . . . 0.0 112.202 -175.645 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 81.6 mt -95.77 143.07 27.32 Favored 'General case' 0 N--CA 1.481 1.121 0 C-N-CA 124.161 0.984 . . . . 0.0 113.011 178.446 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 -131.34 116.3 17.39 Favored 'General case' 0 N--CA 1.483 1.18 0 C-N-CA 124.283 1.033 . . . . 0.0 108.637 172.349 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.508 ' HA ' ' HA ' ' A' ' 84' ' ' TYR . 36.7 ptt85 -62.33 110.66 1.71 Allowed 'General case' 0 N--CA 1.487 1.407 0 CA-C-N 119.503 1.047 . . . . 0.0 110.17 173.671 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.49 ' HB3' HD13 ' A' ' 161' ' ' LEU . . . -91.5 -28.3 17.69 Favored 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 123.552 0.741 . . . . 0.0 110.457 -177.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -160.22 175.05 13.34 Favored 'General case' 0 C--O 1.239 0.504 0 C-N-CA 123.808 0.843 . . . . 0.0 110.613 -179.366 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -102.66 170.1 8.23 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 124.044 0.938 . . . . 0.0 109.947 175.883 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.645 HG23 ' HA2' ' A' ' 82' ' ' GLY . 82.0 t -72.22 101.54 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.626 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 167.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 31.0 ttmt -169.08 140.79 2.49 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -169.589 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 28.6 t90 -102.45 122.3 44.05 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 122.745 0.418 . . . . 0.0 110.064 179.313 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -81.33 146.18 30.5 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 124.08 0.952 . . . . 0.0 110.889 171.713 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -73.95 0.89 12.09 Favored 'General case' 0 N--CA 1.483 1.182 0 C-N-CA 124.325 1.05 . . . . 0.0 112.607 176.758 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 23.9 mt-30 -75.96 14.95 0.6 Allowed 'General case' 0 CA--C 1.555 1.143 0 C-N-CA 124.325 1.05 . . . . 0.0 112.966 -176.169 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.525 ' HB1' ' HB2' ' A' ' 171' ' ' GLN . . . -52.99 90.64 0.01 OUTLIER 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 124.367 1.067 . . . . 0.0 113.255 -168.594 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -62.56 131.94 50.75 Favored 'General case' 0 C--N 1.353 0.745 0 C-N-CA 124.46 1.104 . . . . 0.0 110.64 -178.876 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 3.0 mp -75.37 111.0 11.11 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.689 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 -173.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 19.1 m -142.13 179.35 6.95 Favored 'General case' 0 C--O 1.246 0.885 0 C-N-CA 124.663 1.185 . . . . 0.0 109.208 -175.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.474 ' HA3' ' H ' ' A' ' 173' ' ' LYS . . . 88.27 84.75 1.23 Allowed Glycine 0 C--N 1.341 0.823 0 N-CA-C 111.306 -0.717 . . . . 0.0 111.306 -176.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 50.4 m -150.3 -28.13 0.23 Allowed 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.14 0.576 . . . . 0.0 111.555 -177.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 9.3 p -66.14 126.55 92.15 Favored Pre-proline 0 CA--C 1.553 1.086 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 177.612 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -75.82 -165.3 0.29 Allowed 'Trans proline' 0 C--N 1.377 2.061 0 C-N-CA 123.214 2.609 . . . . 0.0 113.452 -172.587 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 36.3 mm -63.17 111.82 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.953 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 177.833 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.635 HD21 ' HB2' ' A' ' 218' ' ' ARG . 0.3 OUTLIER -109.59 160.33 16.35 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.218 -172.249 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.427 ' H ' HD23 ' A' ' 29' ' ' LEU . 65.6 m -94.54 149.12 21.56 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 123.119 0.568 . . . . 0.0 110.05 171.608 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 17.6 tt -139.31 160.55 28.58 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.593 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 27.7 m -93.9 105.91 17.91 Favored 'General case' 0 CA--C 1.541 0.623 0 N-CA-C 108.693 -0.855 . . . . 0.0 108.693 178.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 10.8 tp -73.71 148.55 8.49 Favored 'Isoleucine or valine' 0 C--O 1.246 0.903 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 169.803 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.561 ' HB2' ' HB2' ' A' ' 38' ' ' SER . 50.4 m -138.48 138.7 38.34 Favored 'General case' 0 C--O 1.242 0.695 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 178.302 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -60.41 156.47 15.92 Favored 'General case' 0 CA--C 1.55 0.975 0 C-N-CA 123.499 0.72 . . . . 0.0 111.105 -174.61 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.8 t70 77.85 21.35 0.94 Allowed 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 125.317 1.447 . . . . 0.0 110.727 -179.01 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 78.7 38.49 23.87 Favored Glycine 0 C--N 1.35 1.317 0 CA-C-N 115.556 -0.747 . . . . 0.0 113.755 174.021 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.561 ' HB2' ' HB2' ' A' ' 34' ' ' SER . 28.4 m -107.33 150.36 26.78 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 122.937 0.495 . . . . 0.0 109.793 175.589 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 5.4 ptm -160.65 123.8 3.37 Favored 'General case' 0 N--CA 1.481 1.107 0 CA-C-O 120.901 0.382 . . . . 0.0 111.723 -175.041 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.509 ' HA ' HG11 ' A' ' 215' ' ' VAL . 15.7 p -177.42 -176.17 0.6 Allowed 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 124.549 1.139 . . . . 0.0 109.434 -178.525 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 1.4 mp -92.13 131.09 40.16 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 N-CA-C 105.796 -1.928 . . . . 0.0 105.796 156.283 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 49.3 pttt -52.98 89.76 0.01 OUTLIER 'General case' 0 CA--C 1.551 0.986 0 C-N-CA 124.531 1.132 . . . . 0.0 112.048 -177.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 64.0 m-20 -158.13 149.82 21.53 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.462 1.505 . . . . 0.0 108.329 -177.251 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -68.69 108.62 3.46 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 123.328 0.651 . . . . 0.0 110.234 -179.605 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -91.46 121.88 33.56 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 122.978 0.511 . . . . 0.0 109.954 176.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.423 ' HG2' ' NH1' ' B' ' 255' ' ' M9P . 0.4 OUTLIER -170.12 124.09 0.73 Allowed 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 175.683 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.462 ' HB3' ' HA ' ' B' ' 254' ' ' ARG . 8.4 tp10 -159.39 93.95 1.15 Allowed 'General case' 0 C--O 1.24 0.58 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 178.646 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 8.4 pt20 -103.43 99.31 9.14 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 123.947 0.899 . . . . 0.0 109.563 176.644 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.409 ' OG1' ' HD3' ' B' ' 254' ' ' ARG . 28.0 m -71.29 -78.08 0.08 Allowed 'General case' 0 CA--C 1.547 0.827 0 C-N-CA 123.52 0.728 . . . . 0.0 110.662 -175.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 57.8 tp -175.18 127.21 0.27 Allowed 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 123.017 0.527 . . . . 0.0 109.889 -177.498 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -76.04 -155.7 5.9 Favored Glycine 0 C--N 1.346 1.122 0 O-C-N 123.436 0.46 . . . . 0.0 112.273 171.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -143.79 -64.26 0.02 OUTLIER Glycine 0 N--CA 1.467 0.767 0 N-CA-C 111.696 -0.562 . . . . 0.0 111.696 -178.459 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 80.48 -72.16 2.71 Favored Glycine 0 C--N 1.341 0.823 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 -175.076 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 98.45 156.84 29.63 Favored Glycine 0 C--N 1.342 0.906 0 C-N-CA 122.917 0.294 . . . . 0.0 112.644 177.224 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.423 ' HB3' ' HA2' ' A' ' 59' ' ' GLY . 15.2 t 59.83 33.23 21.63 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 124.72 1.208 . . . . 0.0 111.366 177.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 119.71 -37.31 3.16 Favored Glycine 0 C--N 1.343 0.947 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.891 -178.302 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 149.07 -12.72 1.09 Allowed Glycine 0 C--N 1.35 1.309 0 CA-C-O 119.949 -0.362 . . . . 0.0 113.049 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -168.32 35.68 0.2 Allowed Glycine 0 C--N 1.349 1.288 0 N-CA-C 112.074 -0.41 . . . . 0.0 112.074 -179.449 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.423 ' HA2' ' HB3' ' A' ' 55' ' ' SER . . . 83.76 -61.93 4.67 Favored Glycine 0 C--N 1.351 1.363 0 N-CA-C 112.46 -0.256 . . . . 0.0 112.46 -178.494 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -170.26 -62.45 0.02 OUTLIER 'General case' 0 C--O 1.236 0.39 0 N-CA-C 107.073 -1.454 . . . . 0.0 107.073 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -114.41 -61.32 1.76 Allowed 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 114.829 -1.078 . . . . 0.0 108.923 171.378 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -148.73 13.2 0.91 Allowed 'General case' 0 N--CA 1.478 0.939 0 C-N-CA 123.494 0.717 . . . . 0.0 111.006 -178.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -81.45 71.72 2.88 Favored Glycine 0 C--N 1.35 1.334 0 N-CA-C 113.729 0.252 . . . . 0.0 113.729 -173.844 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.414 ' H ' ' HG3' ' A' ' 122' ' ' LYS . 14.2 t -85.71 64.91 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.808 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 175.455 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -37.22 130.31 0.89 Allowed 'General case' 0 N--CA 1.481 1.089 0 C-N-CA 125.836 1.655 . . . . 0.0 112.096 -178.376 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 29.0 m0 -69.63 158.42 35.35 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.037 -173.141 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.603 ' HB2' ' H ' ' A' ' 80' ' ' GLU . 1.0 OUTLIER -82.83 71.33 9.93 Favored 'General case' 0 CA--C 1.54 0.574 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 -168.866 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.409 HG22 ' HB3' ' A' ' 78' ' ' GLU . 16.3 t -106.9 112.52 63.32 Favored Pre-proline 0 CA--C 1.545 0.782 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 -174.493 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -57.27 -32.96 95.16 Favored 'Trans proline' 0 C--N 1.375 1.938 0 C-N-CA 123.516 2.811 . . . . 0.0 114.276 -170.642 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 36.3 p -128.7 147.44 64.36 Favored Pre-proline 0 CA--C 1.55 0.976 0 C-N-CA 123.751 0.821 . . . . 0.0 110.787 -179.352 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_exo -53.87 -44.24 50.93 Favored 'Trans proline' 0 CA--C 1.573 2.467 0 C-N-CA 123.675 2.916 . . . . 0.0 117.035 174.326 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -52.86 -51.61 10.72 Favored 'Trans proline' 0 C--N 1.399 3.214 0 C-N-CA 122.16 1.907 . . . . 0.0 116.544 -176.274 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_endo -82.84 169.77 13.05 Favored 'Trans proline' 0 C--N 1.386 2.534 0 CA-C-N 122.322 1.865 . . . . 0.0 112.827 178.136 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 11.7 p -163.49 -36.52 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 C-N-CA 124.38 1.072 . . . . 0.0 108.386 172.576 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 52.17 -99.55 0.04 OUTLIER Glycine 0 C--N 1.352 1.458 0 O-C-N 124.702 1.251 . . . . 0.0 114.227 172.427 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 40.2 ttmt -159.86 -58.11 0.06 Allowed 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 124.227 1.011 . . . . 0.0 108.897 -174.028 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -112.95 37.31 3.16 Favored 'General case' 0 N--CA 1.472 0.632 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.381 -178.48 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.409 ' HB3' HG22 ' A' ' 68' ' ' VAL . 11.1 mm-40 -71.67 83.39 0.87 Allowed 'General case' 0 N--CA 1.479 0.991 0 CA-C-O 121.547 0.689 . . . . 0.0 110.486 171.195 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 6.4 mp -117.76 131.96 56.52 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 114.877 -1.056 . . . . 0.0 108.255 168.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.603 ' H ' ' HB2' ' A' ' 67' ' ' ASP . 37.8 tt0 -70.27 -11.93 61.24 Favored 'General case' 0 CA--C 1.549 0.926 0 C-N-CA 125.459 1.504 . . . . 0.0 110.5 177.574 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.413 ' HB2' ' O ' ' A' ' 102' ' ' TYR . 0.5 OUTLIER 66.89 -179.53 0.21 Allowed 'General case' 0 C--N 1.352 0.71 0 C-N-CA 126.559 1.944 . . . . 0.0 112.478 170.806 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.645 ' HA2' HG23 ' A' ' 14' ' ' VAL . . . 128.84 -157.9 21.7 Favored Glycine 0 C--O 1.248 1.031 0 CA-C-N 115.364 -0.834 . . . . 0.0 111.384 -177.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . 0.667 ' HB1' HD11 ' A' ' 161' ' ' LEU . . . -90.35 107.06 18.91 Favored 'General case' 0 CA--C 1.54 0.57 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -179.228 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . 0.508 ' HA ' ' HA ' ' A' ' 10' ' ' ARG . 7.4 m-85 -92.51 176.23 6.54 Favored 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 123.18 0.592 . . . . 0.0 109.405 177.455 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . 0.626 ' HA ' ' HA ' ' A' ' 99' ' ' ALA . 53.8 ttp180 -138.36 121.82 17.22 Favored 'General case' 0 C--O 1.239 0.54 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 -174.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 41.7 mt -90.67 116.04 31.16 Favored 'Isoleucine or valine' 0 C--O 1.25 1.116 0 CA-C-O 121.607 0.718 . . . . 0.0 110.134 -172.257 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.609 ' HE3' ' HD2' ' A' ' 89' ' ' LYS . 48.3 pttt -105.35 142.13 35.65 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 168.564 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . 0.612 ' HB2' HD13 ' A' ' 97' ' ' ILE . 18.0 tm0? -84.44 106.48 16.06 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 104.534 -2.395 . . . . 0.0 104.534 165.784 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . 0.609 ' HD2' ' HE3' ' A' ' 87' ' ' LYS . 78.6 tttt -119.41 104.09 10.04 Favored 'General case' 0 C--O 1.241 0.613 0 C-N-CA 123.666 0.786 . . . . 0.0 110.36 -167.203 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -72.32 155.31 51.36 Favored Glycine 0 C--O 1.243 0.701 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 167.474 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 22.2 mm -79.41 62.15 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.563 1.442 0 CA-C-N 118.174 0.987 . . . . 0.0 109.067 -176.102 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 1.6 tm? 170.16 -40.1 0.0 OUTLIER 'General case' 0 CA--C 1.556 1.204 0 C-N-CA 126.347 1.859 . . . . 0.0 107.556 -168.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -137.96 151.66 21.45 Favored Glycine 0 C--N 1.369 2.379 0 N-CA-C 114.926 0.731 . . . . 0.0 114.926 -166.576 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -111.89 142.81 43.81 Favored 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 125.037 1.335 . . . . 0.0 110.738 -179.167 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 49.5 m -150.52 96.67 2.41 Favored 'General case' 0 N--CA 1.477 0.915 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 168.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.555 HE22 ' HB3' ' A' ' 163' ' ' PRO . 35.8 tt0 -62.48 140.25 58.6 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 123.237 0.615 . . . . 0.0 111.243 -178.605 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.612 HD13 ' HB2' ' A' ' 88' ' ' GLN . 8.5 pt -132.76 -24.68 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 N-CA-C 112.604 0.594 . . . . 0.0 112.604 -173.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 178.85 -149.4 8.86 Favored Glycine 0 C--N 1.345 1.074 0 C-N-CA 120.847 -0.692 . . . . 0.0 113.031 179.484 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.626 ' HA ' ' HA ' ' A' ' 85' ' ' ARG . . . -143.59 178.11 8.01 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 124.44 1.096 . . . . 0.0 109.805 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -176.89 140.84 5.13 Favored Glycine 0 C--N 1.34 0.796 0 CA-C-O 119.826 -0.43 . . . . 0.0 112.123 174.042 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.599 ' HB ' ' HG3' ' A' ' 199' ' ' PRO . 3.3 p -89.36 127.14 42.22 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.942 0 CA-C-N 117.422 0.611 . . . . 0.0 111.001 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.443 ' HD2' ' HB2' ' A' ' 107' ' ' PHE . 29.4 t80 -98.05 136.77 37.83 Favored 'General case' 0 N--CA 1.477 0.881 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 169.562 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.435 ' HD2' HG21 ' A' ' 14' ' ' VAL . 35.2 tttp -169.02 154.23 6.01 Favored 'General case' 0 N--CA 1.47 0.57 0 O-C-N 123.69 0.618 . . . . 0.0 110.071 171.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 11.8 tp10 72.86 17.28 4.35 Favored 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 124.684 1.194 . . . . 0.0 110.752 171.301 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 80.51 18.01 72.02 Favored Glycine 0 C--N 1.345 1.033 0 CA-C-N 115.925 -0.58 . . . . 0.0 113.303 -176.159 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . 0.468 HG23 ' HD2' ' A' ' 108' ' ' HIS . 2.7 t -139.54 134.8 32.69 Favored 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 123.013 0.525 . . . . 0.0 110.584 176.662 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' PHE . . . . . 0.556 ' HB3' ' HB2' ' A' ' 140' ' ' TYR . 38.3 t80 -88.55 118.81 28.47 Favored 'General case' 0 C--N 1.349 0.579 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 174.716 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . 0.468 ' HD2' HG23 ' A' ' 106' ' ' THR . 4.1 p80 -133.45 114.1 13.27 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 123.051 0.54 . . . . 0.0 109.969 -175.267 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 11.5 t -136.17 -172.89 3.24 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 124.187 0.995 . . . . 0.0 110.359 -176.081 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' MET . . . . . 0.414 ' SD ' ' HE1' ' A' ' 112' ' ' HIS . 1.0 OUTLIER -67.14 152.57 45.51 Favored 'General case' 0 N--CA 1.479 1.02 0 C-N-CA 124.189 0.996 . . . . 0.0 110.702 171.542 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 84.1 t90 -74.0 -47.65 35.71 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 122.848 0.459 . . . . 0.0 110.654 -178.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . 0.414 ' HE1' ' SD ' ' A' ' 110' ' ' MET . 22.1 p-80 -59.78 -15.46 20.57 Favored 'General case' 0 N--CA 1.489 1.506 0 C-N-CA 124.38 1.072 . . . . 0.0 113.755 -170.035 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.5 ' O ' HD12 ' A' ' 97' ' ' ILE . 23.2 m -57.62 -27.53 29.84 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 C-N-CA 123.185 0.594 . . . . 0.0 111.032 178.695 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 10.8 t -135.5 165.22 26.03 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.163 0.985 . . . . 0.0 109.263 177.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 14.7 tpp180 -92.74 16.03 13.21 Favored 'General case' 0 N--CA 1.484 1.252 0 CA-C-O 121.642 0.734 . . . . 0.0 109.887 176.048 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 98.72 42.23 2.94 Favored Glycine 0 C--N 1.347 1.153 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 -177.169 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -106.79 167.56 9.79 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 123.608 0.763 . . . . 0.0 110.621 -179.646 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.43 HG23 ' HA ' ' A' ' 127' ' ' GLU . 7.3 p -84.93 137.73 20.33 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.006 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.408 178.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 1.8 mm? -84.37 -177.97 6.78 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 124.429 1.092 . . . . 0.0 111.1 -178.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 47.9 mtm -145.23 164.87 30.02 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 124.165 0.986 . . . . 0.0 111.119 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 12.0 t-160 -164.92 111.28 0.97 Allowed 'General case' 0 C--O 1.239 0.536 0 N-CA-C 106.497 -1.668 . . . . 0.0 106.497 171.454 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.414 ' HG3' ' H ' ' A' ' 64' ' ' VAL . 73.1 tttt 70.55 20.34 5.88 Favored 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 124.131 0.972 . . . . 0.0 110.802 -179.739 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 93.13 -19.95 49.06 Favored Glycine 0 C--N 1.344 0.985 0 CA-C-N 114.811 -1.086 . . . . 0.0 113.334 -172.134 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 38.8 ttmt -77.37 119.6 21.21 Favored 'General case' 0 C--N 1.36 1.027 0 CA-C-N 117.509 0.654 . . . . 0.0 109.76 -179.135 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 3.6 mpt_? -59.68 143.8 49.7 Favored 'General case' 0 CA--C 1.551 1.014 0 C-N-CA 124.383 1.073 . . . . 0.0 111.75 177.306 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 57.9 mt -119.1 109.05 25.45 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 176.367 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . 0.43 ' HA ' HG23 ' A' ' 118' ' ' VAL . 10.8 pt-20 -80.01 134.42 56.39 Favored Pre-proline 0 CA--C 1.557 1.241 0 C-N-CA 124.42 1.088 . . . . 0.0 112.997 -167.793 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 127' ' ' GLU . 3.7 Cg_exo -76.3 110.38 3.05 Favored 'Trans proline' 0 C--N 1.383 2.357 0 C-N-CA 123.023 2.482 . . . . 0.0 111.365 176.845 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 34.1 p -85.6 -27.46 25.46 Favored 'General case' 0 N--CA 1.479 1.0 0 C-N-CA 123.315 0.646 . . . . 0.0 111.416 -179.362 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 69.9 t-105 -147.86 153.9 39.72 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 123.706 0.802 . . . . 0.0 109.127 -178.538 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -155.99 118.28 4.08 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 123.196 0.599 . . . . 0.0 110.089 175.443 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 12.8 t0 -117.14 106.95 13.89 Favored 'General case' 0 N--CA 1.475 0.793 0 C-N-CA 124.312 1.045 . . . . 0.0 108.555 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 21.5 t -76.88 -16.42 14.7 Favored 'Isoleucine or valine' 0 CA--C 1.565 1.543 0 C-N-CA 123.263 0.625 . . . . 0.0 111.643 -174.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -79.16 -43.04 24.75 Favored 'General case' 0 N--CA 1.492 1.66 0 C-N-CA 123.203 0.601 . . . . 0.0 111.06 -175.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 11.8 mptt -78.19 -15.55 58.72 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 170.189 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 11.1 t0 58.69 61.86 2.09 Favored 'General case' 0 C--N 1.356 0.888 0 O-C-N 124.834 1.334 . . . . 0.0 108.512 -170.37 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.506 HD11 ' HB1' ' A' ' 227' ' ' ALA . 87.0 mt -139.66 131.97 28.35 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 123.973 0.909 . . . . 0.0 109.607 176.808 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.403 HG22 ' O ' ' A' ' 110' ' ' MET . 20.2 tt -119.7 138.08 51.48 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.18 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 171.451 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 21.0 p -133.3 147.77 51.9 Favored 'General case' 0 CA--C 1.544 0.733 0 CA-C-O 121.827 0.822 . . . . 0.0 112.113 -171.501 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.556 ' HB2' ' HB3' ' A' ' 107' ' ' PHE . 17.5 m-85 -132.25 112.02 11.89 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.333 1.453 . . . . 0.0 108.476 -162.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.62 20.49 63.77 Favored Glycine 0 N--CA 1.474 1.229 0 O-C-N 123.084 0.24 . . . . 0.0 112.625 -176.029 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 157.04 -160.71 30.62 Favored Glycine 0 C--N 1.34 0.8 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 177.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.706 ' HA3' ' HB2' ' A' ' 232' ' ' SER . . . -98.75 -175.81 32.31 Favored Glycine 0 C--N 1.346 1.119 0 CA-C-N 117.348 0.574 . . . . 0.0 111.732 171.575 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' TRP . . . . . 0.581 ' CD1' ' HA ' ' A' ' 229' ' ' THR . 47.6 t-105 -61.78 107.64 0.87 Allowed 'General case' 0 C--N 1.352 0.707 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 167.828 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 38.6 ttpt -150.52 112.16 4.48 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-O 121.197 0.523 . . . . 0.0 110.791 -172.201 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' LEU . . . . . . . . . . . . . 1.6 pp -146.19 -2.37 0.7 Allowed 'General case' 0 N--CA 1.48 1.036 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.728 169.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 79.44 -22.86 0.26 Allowed 'General case' 0 N--CA 1.484 1.232 0 C-N-CA 126.108 1.763 . . . . 0.0 113.338 166.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -70.11 157.51 53.51 Favored Glycine 0 C--N 1.355 1.59 0 CA-C-N 118.055 0.389 . . . . 0.0 112.842 -175.149 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -141.12 154.05 45.7 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 123.097 0.559 . . . . 0.0 110.093 -173.026 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' TRP . . . . . 0.553 ' HB2' HG13 ' A' ' 208' ' ' VAL . 25.7 t90 -68.81 133.78 48.8 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 122.712 0.405 . . . . 0.0 110.107 169.709 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 60.2 tttm -86.33 97.5 10.45 Favored 'General case' 0 CA--C 1.549 0.921 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 171.246 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -59.06 109.91 0.94 Allowed 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 124.548 1.139 . . . . 0.0 112.144 -170.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 123.39 -9.24 8.83 Favored Glycine 0 N--CA 1.475 1.253 0 CA-C-N 115.764 -0.653 . . . . 0.0 112.056 -175.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . 0.477 ' HB3' ' HE3' ' A' ' 203' ' ' LYS . 62.3 mm-40 -101.17 163.25 12.37 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 123.424 0.689 . . . . 0.0 110.256 174.36 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 13.2 mp0 -82.57 146.2 29.3 Favored 'General case' 0 N--CA 1.477 0.919 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 172.071 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 29.6 m -89.8 140.55 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.558 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 25.5 mm-40 -99.66 128.26 45.76 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 178.293 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.506 ' HA ' HG22 ' A' ' 200' ' ' ILE . 58.0 t -98.97 103.18 14.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 N-CA-C 107.678 -1.23 . . . . 0.0 107.678 -176.709 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -80.8 72.57 7.78 Favored 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 106.946 -1.501 . . . . 0.0 106.946 178.084 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -77.13 130.01 36.77 Favored 'General case' 0 C--N 1.343 0.321 0 CA-C-N 113.496 -1.684 . . . . 0.0 110.647 -173.671 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . 0.667 HD11 ' HB1' ' A' ' 83' ' ' ALA . 45.6 mt -95.93 108.91 21.33 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 177.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 57.9 mt-10 -90.26 115.29 63.7 Favored Pre-proline 0 CA--C 1.544 0.728 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 167.499 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . 0.555 ' HB3' HE22 ' A' ' 96' ' ' GLN . 35.5 Cg_exo -61.55 116.05 3.17 Favored 'Trans proline' 0 C--N 1.372 1.811 0 C-N-CA 123.41 2.74 . . . . 0.0 112.259 -176.71 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 109.53 -23.72 21.69 Favored Glycine 0 C--N 1.341 0.851 0 CA-C-N 115.518 -0.765 . . . . 0.0 112.203 -176.035 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 11.8 mmpt? -105.76 173.94 6.1 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 123.902 0.881 . . . . 0.0 111.532 -172.11 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -67.77 161.84 63.13 Favored Pre-proline 0 CA--C 1.558 1.287 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.021 168.573 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_exo -56.83 138.85 87.36 Favored 'Trans proline' 0 C--N 1.378 2.114 0 C-N-CA 122.968 2.445 . . . . 0.0 111.979 172.05 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 17.1 mmt85 -121.28 97.7 5.64 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 123.681 0.792 . . . . 0.0 109.692 -171.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . . . . . . . . . . . -79.24 132.72 36.59 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 175.489 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.494 ' HB ' ' HB ' ' A' ' 158' ' ' VAL . 95.5 t -129.8 122.06 53.84 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.163 0 C-N-CA 123.196 0.599 . . . . 0.0 110.266 -178.478 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . 0.525 ' HB2' ' HB1' ' A' ' 20' ' ' ALA . 11.5 tt0 -80.82 110.58 16.47 Favored 'General case' 0 N--CA 1.48 1.03 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 -179.867 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 6.9 m -126.73 137.22 53.22 Favored 'General case' 0 C--O 1.238 0.499 0 CA-C-O 121.023 0.44 . . . . 0.0 109.954 -179.563 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . 0.474 ' H ' ' HA3' ' A' ' 24' ' ' GLY . 47.3 mttp -83.17 153.62 66.36 Favored Pre-proline 0 C--O 1.246 0.883 0 C-N-CA 124.115 0.966 . . . . 0.0 108.981 177.555 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . 0.489 ' HA ' ' O ' ' A' ' 186' ' ' ALA . 87.3 Cg_exo -49.73 125.99 15.47 Favored 'Trans proline' 0 C--N 1.381 2.252 0 C-N-CA 122.914 2.41 . . . . 0.0 113.36 179.627 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . 0.543 ' H ' ' C ' ' A' ' 186' ' ' ALA . . . -141.11 131.76 5.04 Favored Glycine 0 CA--C 1.541 1.662 0 CA-C-O 122.292 0.94 . . . . 0.0 114.616 178.444 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.579 HD12 ' HB ' ' A' ' 183' ' ' THR . 0.6 OUTLIER -139.31 155.09 47.95 Favored 'General case' 0 C--O 1.242 0.705 0 O-C-N 121.714 -0.874 . . . . 0.0 111.493 -170.292 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 177' ' ' PHE . . . . . 0.429 ' HZ ' ' HB2' ' A' ' 225' ' ' ALA . 3.1 p90 -124.13 139.32 54.04 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 113.696 -1.593 . . . . 0.0 109.781 -175.546 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 3.5 ttpm? -85.01 121.36 27.69 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 124.407 1.083 . . . . 0.0 110.167 -173.376 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 77.8 p -117.78 170.61 8.65 Favored 'General case' 0 C--O 1.243 0.731 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 164.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 10.5 t30 -66.21 -26.66 67.49 Favored 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 123.072 0.549 . . . . 0.0 109.91 173.807 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -68.76 -33.66 74.27 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 123.971 0.908 . . . . 0.0 111.055 173.178 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 150.66 172.43 19.81 Favored Glycine 0 C--N 1.35 1.323 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.341 175.325 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 183' ' ' THR . . . . . 0.579 ' HB ' HD12 ' A' ' 176' ' ' LEU . 44.5 p -75.83 95.8 3.56 Favored 'General case' 0 CA--C 1.545 0.782 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 174.723 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 20.3 pt -107.76 141.11 23.83 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 124.292 1.037 . . . . 0.0 110.378 -170.628 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 185' ' ' GLY . . . . . 0.613 ' HA2' ' HA ' ' A' ' 225' ' ' ALA . . . 115.92 173.61 17.35 Favored Glycine 0 N--CA 1.476 1.351 0 CA-C-O 119.432 -0.649 . . . . 0.0 112.612 -178.593 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.543 ' C ' ' H ' ' A' ' 175' ' ' GLY . . . -175.55 40.58 0.01 OUTLIER 'General case' 0 C--O 1.206 -1.225 0 C-N-CA 123.328 0.651 . . . . 0.0 109.882 178.836 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 187' ' ' VAL . . . . . 0.561 HG13 ' HB3' ' A' ' 224' ' ' SER . 2.4 p -164.39 100.42 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.552 1.036 0 O-C-N 120.412 -1.43 . . . . 0.0 108.893 172.857 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . 0.433 ' O ' ' HA2' ' A' ' 24' ' ' GLY . 80.3 p -118.13 125.67 50.71 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 123.17 0.588 . . . . 0.0 110.266 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 3.6 pp -150.73 -177.81 6.2 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-O 121.095 0.474 . . . . 0.0 110.958 176.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -138.8 103.42 4.82 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 166.749 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 191' ' ' PHE . . . . . . . . . . . . . 29.9 t80 -168.15 -179.61 4.15 Favored 'General case' 0 N--CA 1.486 1.326 0 C-N-CA 122.787 0.435 . . . . 0.0 109.934 -172.256 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 36.6 m -49.05 117.93 7.0 Favored Pre-proline 0 CA--C 1.554 1.125 0 C-N-CA 124.656 1.183 . . . . 0.0 111.585 175.259 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -69.2 99.79 0.71 Allowed 'Trans proline' 0 C--N 1.378 2.09 0 C-N-CA 122.421 2.081 . . . . 0.0 112.111 -179.347 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -60.93 130.94 48.4 Favored Glycine 0 C--N 1.348 1.22 0 N-CA-C 110.589 -1.005 . . . . 0.0 110.589 170.104 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 195' ' ' THR . . . . . 0.451 HG22 ' O ' ' A' ' 161' ' ' LEU . 12.6 t -59.45 140.37 56.25 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 123.202 0.601 . . . . 0.0 112.004 -169.811 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -69.47 104.08 2.21 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 123.961 0.904 . . . . 0.0 110.826 -165.026 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . 0.487 ' HA2' HD11 ' A' ' 210' ' ' LEU . . . 135.66 -7.2 4.22 Favored Glycine 0 C--O 1.24 0.525 0 CA-C-N 115.097 -0.956 . . . . 0.0 111.384 -172.526 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 69.6 m -60.99 124.93 82.28 Favored Pre-proline 0 CA--C 1.548 0.897 0 C-N-CA 123.802 0.841 . . . . 0.0 109.554 169.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . 0.599 ' HG3' ' HB ' ' A' ' 101' ' ' VAL . 2.9 Cg_exo -73.13 153.52 51.78 Favored 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 122.409 2.073 . . . . 0.0 111.553 -177.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 200' ' ' ILE . . . . . 0.506 HG22 ' HA ' ' A' ' 158' ' ' VAL . 9.7 pt -108.54 129.4 63.05 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 169.084 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 201' ' ' ILE . . . . . 0.438 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 66.4 mt -115.29 152.89 16.88 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.912 0 C-N-CA 125.165 1.386 . . . . 0.0 108.187 -178.252 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -84.9 162.03 19.62 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 175.139 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 203' ' ' LYS . . . . . 0.477 ' HE3' ' HB3' ' A' ' 154' ' ' GLU . 18.5 ptpt -61.98 -24.07 66.79 Favored 'General case' 0 N--CA 1.482 1.154 0 C-N-CA 123.316 0.646 . . . . 0.0 111.765 179.283 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 50.5 tttp -69.48 -21.62 63.69 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 124.012 0.925 . . . . 0.0 111.33 179.567 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 109.14 -12.61 34.06 Favored Glycine 0 C--N 1.349 1.269 0 CA-C-N 116.188 -0.46 . . . . 0.0 113.082 179.351 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 44.7 mmtm -88.51 138.98 30.94 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 177.505 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.438 ' HA ' ' HA ' ' A' ' 201' ' ' ILE . 21.4 t -63.36 151.08 8.86 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.936 0 C-N-CA 123.566 0.746 . . . . 0.0 110.867 -176.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 208' ' ' VAL . . . . . 0.553 HG13 ' HB2' ' A' ' 150' ' ' TRP . 54.8 t -100.35 -52.48 8.65 Favored 'Isoleucine or valine' 0 C--O 1.241 0.656 0 C-N-CA 124.415 1.086 . . . . 0.0 109.02 173.083 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . . . . . . . . . . . 171.35 -121.79 0.92 Allowed Glycine 0 C--N 1.345 1.053 0 CA-C-N 114.582 -1.19 . . . . 0.0 111.495 -176.248 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . 0.544 ' HB2' ' CH2' ' A' ' 144' ' ' TRP . 9.0 tt -142.03 139.6 32.38 Favored 'General case' 0 CA--C 1.549 0.926 0 CA-C-N 117.481 0.641 . . . . 0.0 110.426 -175.842 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 79.5 t80 -71.64 109.31 5.48 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 123.922 0.889 . . . . 0.0 108.807 174.126 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -76.79 -138.74 0.92 Allowed Glycine 0 C--N 1.34 0.776 0 O-C-N 123.632 0.583 . . . . 0.0 114.455 -170.115 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 213' ' ' ASN . . . . . . . . . . . . . 81.0 m-20 -74.74 85.47 2.16 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 123.294 0.638 . . . . 0.0 109.93 -176.028 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . -72.32 73.22 0.92 Allowed Glycine 0 C--N 1.355 1.593 0 C-N-CA 123.69 0.662 . . . . 0.0 111.571 175.213 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 215' ' ' VAL . . . . . 0.704 ' HA ' ' HD3' ' B' ' 253' ' ' LYS . 54.7 t -84.37 147.24 5.8 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 C-N-CA 123.282 0.633 . . . . 0.0 111.1 -170.128 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 216' ' ' VAL . . . . . 0.518 ' HB ' ' HA2' ' A' ' 220' ' ' GLY . 14.7 m -68.34 111.95 3.0 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.109 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 165.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 217' ' ' THR . . . . . 0.587 HG23 HD13 ' A' ' 29' ' ' LEU . 13.5 t -125.09 159.89 30.36 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 122.686 0.394 . . . . 0.0 110.977 -179.043 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 218' ' ' ARG . . . . . 0.635 ' HB2' HD21 ' A' ' 29' ' ' LEU . 65.0 ttt180 66.45 -74.25 0.06 Allowed 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 124.924 1.289 . . . . 0.0 109.799 -170.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 16.6 p -131.3 -36.89 1.27 Allowed 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 124.02 0.928 . . . . 0.0 109.903 175.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 220' ' ' GLY . . . . . 0.518 ' HA2' ' HB ' ' A' ' 216' ' ' VAL . . . -176.78 11.83 0.03 OUTLIER Glycine 0 C--N 1.358 1.781 0 CA-C-O 119.341 -0.699 . . . . 0.0 114.64 -178.103 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . 0.47 ' O ' HG22 ' A' ' 217' ' ' THR . . . -70.95 119.23 14.76 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 117.664 0.732 . . . . 0.0 109.939 -175.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 222' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -76.92 95.69 4.17 Favored 'General case' 0 N--CA 1.473 0.71 0 CA-C-O 121.64 0.733 . . . . 0.0 109.975 -177.636 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 96.5 t -116.67 135.88 55.56 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.092 -179.26 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . 0.561 ' HB3' HG13 ' A' ' 187' ' ' VAL . 35.2 t -131.18 155.74 46.53 Favored 'General case' 0 C--O 1.243 0.752 0 C-N-CA 124.324 1.05 . . . . 0.0 111.102 -164.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . 0.613 ' HA ' ' HA2' ' A' ' 185' ' ' GLY . . . -97.49 121.27 39.2 Favored 'General case' 0 N--CA 1.467 0.388 0 C-N-CA 123.76 0.824 . . . . 0.0 109.319 174.818 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 226' ' ' ILE . . . . . 0.439 HG23 HD11 ' A' ' 200' ' ' ILE . 7.1 mt -64.77 114.18 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 CA-C-O 120.857 0.36 . . . . 0.0 110.501 174.451 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 227' ' ' ALA . . . . . 0.506 ' HB1' HD11 ' A' ' 137' ' ' LEU . . . -76.79 113.13 14.12 Favored 'General case' 0 C--O 1.239 0.501 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 168.444 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . 0.433 ' HG3' ' HG3' ' A' ' 230' ' ' GLU . 29.7 pt20 -93.39 156.24 16.9 Favored 'General case' 0 N--CA 1.476 0.831 0 C-N-CA 123.782 0.833 . . . . 0.0 109.474 -174.36 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . 0.581 ' HA ' ' CD1' ' A' ' 144' ' ' TRP . 40.7 m -80.11 107.43 12.89 Favored 'General case' 0 C--N 1.347 0.487 0 CA-C-O 121.605 0.717 . . . . 0.0 111.536 179.389 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 230' ' ' GLU . . . . . 0.433 ' HG3' ' HG3' ' A' ' 228' ' ' GLN . 40.5 mt-10 -125.22 88.42 2.88 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 107.049 -1.463 . . . . 0.0 107.049 171.433 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 231' ' ' LYS . . . . . 0.449 ' HA ' ' O ' ' A' ' 144' ' ' TRP . 54.6 pttt -57.73 107.92 0.51 Allowed 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.329 -178.64 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 232' ' ' SER . . . . . 0.706 ' HB2' ' HA3' ' A' ' 143' ' ' GLY . 13.9 m -80.79 91.91 6.0 Favored 'General case' 0 C--O 1.239 0.527 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 -175.401 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 233' ' ' ILE . . . . . . . . . . . . . 6.6 tt -137.62 99.15 1.61 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.721 0 C-N-CA 124.588 1.155 . . . . 0.0 108.062 -176.66 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 234' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -90.3 35.94 0.87 Allowed 'General case' 0 N--CA 1.478 0.957 0 CA-C-N 114.859 -1.064 . . . . 0.0 111.156 -176.361 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 13.6 p-10 -58.34 -35.04 71.32 Favored 'General case' 0 N--CA 1.479 0.983 0 C-N-CA 124.062 0.945 . . . . 0.0 110.029 175.177 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 236' ' ' ASN . . . . . . . . . . . . . 50.0 m-80 -113.68 106.35 53.97 Favored Pre-proline 0 CA--C 1.537 0.459 0 CA-C-N 114.594 -1.185 . . . . 0.0 107.84 165.335 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -60.7 -49.99 7.53 Favored 'Trans proline' 0 C--N 1.374 1.912 0 C-N-CA 122.125 1.884 . . . . 0.0 110.009 167.362 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 238' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 -136.42 145.49 45.34 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 125.239 1.415 . . . . 0.0 107.769 173.529 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 239' ' ' ILE . . . . . . . . . . . . . 12.9 tt -154.18 70.53 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 CA-C-O 122.886 1.327 . . . . 0.0 108.549 175.722 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 . . . . . 0 C--O 1.247 0.956 0 CA-C-N 114.59 -1.186 . . . . 0.0 108.781 -174.069 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 251' ' ' BEZ . . . . . 0.472 ' H6 ' HG21 ' A' ' 216' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 253' ' ' LYS . . . . . 0.704 ' HD3' ' HA ' ' A' ' 215' ' ' VAL . 54.0 pttt -67.0 146.1 54.71 Favored 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 124.02 0.928 . . . . 0.0 111.625 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 254' ' ' ARG . . . . . 0.462 ' HA ' ' HB3' ' A' ' 47' ' ' GLU . 22.5 mtm-85 -84.87 24.82 1.0 Allowed 'General case' 0 N--CA 1.489 1.48 0 C-N-CA 123.943 0.897 . . . . 0.0 110.925 171.204 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 255' ' ' M9P . . . . . 0.423 ' NH1' ' HG2' ' A' ' 46' ' ' GLU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.678 0 N-CA-C 112.288 -0.325 . . . . 0.0 112.288 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.534 ' HB3' ' HB2' ' A' ' 117' ' ' ALA . 42.9 t -167.73 -62.73 0.03 OUTLIER 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 123.922 0.889 . . . . 0.0 110.061 177.823 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -165.22 -170.96 2.04 Favored 'General case' 0 N--CA 1.482 1.143 0 C-N-CA 124.233 1.013 . . . . 0.0 110.169 -178.068 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -155.9 47.42 0.49 Allowed 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 124.246 1.018 . . . . 0.0 108.356 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 22.3 m-20 -144.33 -18.38 0.55 Allowed 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 113.229 0.826 . . . . 0.0 113.229 -158.478 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.659 ' HB2' ' HG ' ' A' ' 119' ' ' LEU . 1.9 mt -75.88 92.12 3.06 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 118.143 0.429 . . . . 0.0 111.124 -158.436 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -77.2 141.06 40.25 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.969 0.89 . . . . 0.0 111.575 -174.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.475 ' HB3' ' CE2' ' A' ' 84' ' ' TYR . 11.3 mp -83.69 115.38 22.15 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 113.587 -1.642 . . . . 0.0 107.586 175.416 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -111.6 126.37 54.93 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 108.374 -0.972 . . . . 0.0 108.374 179.37 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.617 HH22 ' HB3' ' A' ' 13' ' ' ASP . 60.8 ttt85 -75.03 129.19 37.2 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 120.527 0.203 . . . . 0.0 110.539 -177.469 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.474 ' HB2' ' HG3' ' A' ' 85' ' ' ARG . . . -104.23 -35.07 8.13 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 123.177 0.591 . . . . 0.0 109.96 175.149 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -177.72 -160.95 0.05 Allowed 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 124.421 1.088 . . . . 0.0 110.59 -175.218 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.617 ' HB3' HH22 ' A' ' 10' ' ' ARG . 6.8 p-10 -126.56 170.03 12.46 Favored 'General case' 0 N--CA 1.476 0.87 0 C-N-CA 124.149 0.98 . . . . 0.0 109.847 171.568 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 60.2 t -73.66 104.4 2.5 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.861 -177.414 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 59.2 pttt -164.81 146.29 7.94 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 124.278 1.031 . . . . 0.0 108.804 -178.464 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 24.7 t90 -84.11 113.92 21.4 Favored 'General case' 0 CA--C 1.544 0.713 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 177.395 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 38.2 mm-40 -67.89 147.11 52.94 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 123.557 0.743 . . . . 0.0 111.54 174.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -70.44 -2.46 13.9 Favored 'General case' 0 CA--C 1.556 1.18 0 C-N-CA 125.153 1.381 . . . . 0.0 111.807 175.593 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . 0.559 ' HB2' ' H ' ' A' ' 169' ' ' ALA . 12.9 mm100 -80.14 14.11 2.02 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 124.532 1.133 . . . . 0.0 112.585 -174.355 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -53.89 100.32 0.03 OUTLIER 'General case' 0 C--N 1.364 1.196 0 C-N-CA 124.605 1.162 . . . . 0.0 112.92 -168.743 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.6 mm-40 -82.74 121.88 27.45 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.165 179.294 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 3.6 mp -78.62 103.5 5.66 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.807 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 63.5 m -142.64 -171.59 3.46 Favored 'General case' 0 CA--C 1.542 0.658 0 C-N-CA 125.403 1.481 . . . . 0.0 107.2 174.163 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.427 ' HA3' ' H ' ' A' ' 173' ' ' LYS . . . 133.67 148.66 5.9 Favored Glycine 0 N--CA 1.468 0.828 0 N-CA-C 114.887 0.715 . . . . 0.0 114.887 169.37 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.496 ' HB2' ' HB2' ' A' ' 173' ' ' LYS . 15.4 t 65.57 97.98 0.05 OUTLIER 'General case' 0 CA--C 1.546 0.821 0 C-N-CA 125.07 1.348 . . . . 0.0 111.733 173.317 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 15.6 m -111.29 160.96 27.27 Favored Pre-proline 0 CA--C 1.553 1.069 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 169.291 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -57.28 158.59 18.05 Favored 'Trans proline' 0 C--N 1.384 2.418 0 C-N-CA 122.715 2.277 . . . . 0.0 113.074 -176.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 35.5 mm -57.74 120.87 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 123.63 0.772 . . . . 0.0 110.334 -177.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.517 HD23 ' HE1' ' A' ' 177' ' ' PHE . 38.1 tp -98.85 143.12 29.53 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 115.096 -0.957 . . . . 0.0 110.145 -170.343 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 50.4 m -123.06 116.46 23.54 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 122.872 0.469 . . . . 0.0 109.766 -175.789 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 14.4 pt -138.29 173.48 12.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 C-N-CA 124.149 0.98 . . . . 0.0 110.155 178.475 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 36.4 p -93.85 125.26 38.37 Favored 'General case' 0 C--N 1.353 0.736 0 C-N-CA 122.787 0.435 . . . . 0.0 109.92 -173.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 10.6 tp -65.15 128.55 28.07 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.001 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 170.058 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 24.8 t -108.47 103.61 12.78 Favored 'General case' 0 C--O 1.267 2.005 0 CA-C-O 121.437 0.637 . . . . 0.0 109.567 -176.251 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 68.26 -79.57 0.04 OUTLIER 'General case' 0 C--N 1.357 0.914 0 CA-C-N 113.179 -1.828 . . . . 0.0 111.282 176.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -144.37 -72.84 0.27 Allowed 'General case' 0 N--CA 1.477 0.891 0 C-N-CA 123.873 0.869 . . . . 0.0 109.26 -177.799 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -97.95 4.95 61.32 Favored Glycine 0 C--N 1.347 1.171 0 CA-C-O 118.812 -0.993 . . . . 0.0 114.227 -174.325 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 35.8 t -107.04 164.33 12.24 Favored 'General case' 0 C--N 1.359 1.021 0 CA-C-N 119.026 1.413 . . . . 0.0 107.967 172.405 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . 0.437 ' HE1' ' CE2' ' A' ' 177' ' ' PHE . 39.7 ttp -164.24 126.47 2.36 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 178.85 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.466 ' HA ' HG11 ' A' ' 215' ' ' VAL . 68.3 m -150.95 -178.91 6.87 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 123.53 0.732 . . . . 0.0 110.968 -173.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.796 HD11 HG22 ' A' ' 217' ' ' THR . 2.3 mp -83.95 97.88 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 N-CA-C 105.729 -1.952 . . . . 0.0 105.729 163.255 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 13.2 mptt 57.64 -86.24 0.02 OUTLIER 'General case' 0 CA--C 1.55 0.952 0 C-N-CA 124.139 0.976 . . . . 0.0 108.731 -165.226 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 8.7 t30 -140.54 140.05 35.15 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 123.553 0.741 . . . . 0.0 109.318 172.001 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -154.86 121.64 5.45 Favored 'General case' 0 CA--C 1.537 0.458 0 N-CA-C 106.406 -1.702 . . . . 0.0 106.406 179.204 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.3 tp10 -163.09 136.28 5.7 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 122.836 0.454 . . . . 0.0 110.33 -177.067 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -143.31 135.54 27.05 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 123.336 0.654 . . . . 0.0 110.987 179.563 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 28.7 mm-40 -80.43 93.85 6.08 Favored 'General case' 0 C--O 1.243 0.719 0 C-N-CA 123.628 0.771 . . . . 0.0 109.454 169.193 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 51.8 tt0 -76.26 150.45 36.99 Favored 'General case' 0 N--CA 1.475 0.796 0 N-CA-C 109.114 -0.698 . . . . 0.0 109.114 174.814 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 95.0 m -147.08 124.47 11.62 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 123.142 0.577 . . . . 0.0 109.947 179.553 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.455 HD23 ' HB2' ' A' ' 163' ' ' PRO . 61.0 tp -164.41 -70.12 0.04 OUTLIER 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 175.207 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 70.1 -133.3 24.31 Favored Glycine 0 CA--C 1.531 1.058 0 CA-C-N 115.388 -0.824 . . . . 0.0 112.929 -175.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 155.26 -24.81 0.6 Allowed Glycine 0 C--N 1.348 1.241 0 C-N-CA 122.941 0.305 . . . . 0.0 113.285 177.254 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -77.12 79.15 1.35 Allowed Glycine 0 C--N 1.341 0.831 0 C-N-CA 123.68 0.657 . . . . 0.0 112.755 -179.254 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 62.44 -157.92 36.39 Favored Glycine 0 C--N 1.351 1.406 0 O-C-N 124.103 0.531 . . . . 0.0 112.811 -177.429 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 25.7 t -143.77 39.74 1.38 Allowed 'General case' 0 N--CA 1.476 0.869 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 176.464 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 80.1 -69.22 3.14 Favored Glycine 0 C--N 1.352 1.454 0 CA-C-N 115.405 -0.816 . . . . 0.0 113.522 173.514 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -65.37 98.55 0.33 Allowed Glycine 0 C--N 1.348 1.231 0 O-C-N 124.089 0.523 . . . . 0.0 113.243 -178.82 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.574 ' HA3' ' HB3' ' A' ' 62' ' ' ALA . . . 149.44 -29.2 1.19 Allowed Glycine 0 N--CA 1.466 0.68 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 -173.55 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 68.91 -84.72 0.21 Allowed Glycine 0 C--N 1.355 1.637 0 O-C-N 124.455 0.738 . . . . 0.0 113.776 169.45 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.418 ' HA ' ' HE2' ' A' ' 122' ' ' LYS . 13.7 mt-10 -82.73 -26.46 31.93 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.268 0.627 . . . . 0.0 110.74 -179.655 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -98.75 -65.25 0.97 Allowed 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 123.712 0.805 . . . . 0.0 109.87 -175.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.574 ' HB3' ' HA3' ' A' ' 58' ' ' GLY . . . -97.2 48.03 1.04 Allowed 'General case' 0 N--CA 1.481 1.107 0 CA-C-O 121.559 0.695 . . . . 0.0 110.813 179.679 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -149.8 -105.66 0.34 Allowed Glycine 0 C--N 1.338 0.663 0 N-CA-C 109.239 -1.545 . . . . 0.0 109.239 174.507 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.772 HG23 ' HB2' ' A' ' 122' ' ' LYS . 2.4 m -140.75 -166.41 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 C-N-CA 123.803 0.841 . . . . 0.0 109.201 172.214 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.468 HD22 ' HE3' ' A' ' 122' ' ' LYS . 2.1 tm? -145.53 132.56 20.31 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 107.656 -1.238 . . . . 0.0 107.656 -178.21 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . 0.628 ' HE1' ' HB3' ' A' ' 122' ' ' LYS . 1.1 m0 -89.92 109.3 20.33 Favored 'General case' 0 C--N 1.361 1.072 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 174.563 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -69.48 109.53 4.28 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 171.275 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 18.3 m -125.63 160.75 54.47 Favored Pre-proline 0 N--CA 1.479 1.0 0 C-N-CA 123.277 0.631 . . . . 0.0 110.52 -173.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -64.84 163.59 27.53 Favored 'Trans proline' 0 C--N 1.375 1.933 0 C-N-CA 122.373 2.049 . . . . 0.0 112.61 174.037 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 56.8 p -103.85 160.46 26.02 Favored Pre-proline 0 CA--C 1.557 1.249 0 C-N-CA 123.778 0.831 . . . . 0.0 109.821 178.226 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_endo -43.66 -35.36 6.33 Favored 'Trans proline' 0 CA--C 1.575 2.567 0 C-N-CA 124.722 3.614 . . . . 0.0 117.224 176.506 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_exo -48.35 152.1 4.06 Favored 'Trans proline' 0 C--N 1.402 3.348 0 C-N-CA 122.289 1.993 . . . . 0.0 113.968 165.239 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_exo -59.3 83.15 0.06 OUTLIER 'Trans proline' 0 C--N 1.383 2.385 0 C-N-CA 123.348 2.699 . . . . 0.0 114.009 -177.156 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 5.7 m -141.53 -174.33 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 C-N-CA 125.326 1.45 . . . . 0.0 109.073 174.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 122.32 49.55 0.25 Allowed Glycine 0 C--N 1.349 1.273 0 N-CA-C 111.343 -0.703 . . . . 0.0 111.343 -177.279 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 17.6 pttp -82.39 -62.49 1.6 Allowed 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 123.423 0.689 . . . . 0.0 111.696 -169.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -174.38 19.26 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.244 0 C-N-CA 124.002 0.921 . . . . 0.0 110.25 -173.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -91.66 12.67 20.37 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 124.538 1.135 . . . . 0.0 111.514 -172.635 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.673 HD11 ' HA2' ' A' ' 105' ' ' GLY . 0.3 OUTLIER -73.72 67.94 1.2 Allowed 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 124.362 1.065 . . . . 0.0 112.43 -173.963 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 11.9 tp10 52.96 77.87 0.15 Allowed 'General case' 0 C--O 1.244 0.765 0 C-N-CA 125.35 1.46 . . . . 0.0 112.366 176.43 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.514 ' HB2' ' HA ' ' A' ' 103' ' ' LYS . 8.2 p-10 -119.87 146.76 45.45 Favored 'General case' 0 C--O 1.245 0.861 0 CA-C-N 114.633 -1.167 . . . . 0.0 109.579 -179.268 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 159.52 -163.73 33.66 Favored Glycine 0 C--N 1.343 0.917 0 CA-C-N 116.031 -0.531 . . . . 0.0 113.396 178.536 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . 0.431 ' HB1' HD21 ' A' ' 161' ' ' LEU . . . -89.84 123.99 34.29 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 124.137 0.975 . . . . 0.0 109.232 -177.451 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . 0.475 ' CE2' ' HB3' ' A' ' 8' ' ' LEU . 4.0 m-85 -126.09 151.38 47.29 Favored 'General case' 0 N--CA 1.48 1.034 0 C-N-CA 123.723 0.809 . . . . 0.0 112.09 -166.566 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . 0.476 ' HA ' ' HA ' ' A' ' 99' ' ' ALA . 25.3 mtm180 -113.71 131.02 56.33 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 124.817 1.247 . . . . 0.0 107.897 167.371 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 25.7 mt -94.33 124.55 46.85 Favored 'Isoleucine or valine' 0 C--O 1.249 1.048 0 CA-C-O 121.684 0.754 . . . . 0.0 110.513 -179.401 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.482 ' HD3' ' HB3' ' A' ' 94' ' ' TYR . 1.7 ttmp? -105.72 136.68 44.88 Favored 'General case' 0 C--O 1.213 -0.816 0 C-N-CA 126.114 1.766 . . . . 0.0 108.305 177.599 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 22.9 tm0? -83.07 106.98 15.33 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 104.435 -2.431 . . . . 0.0 104.435 166.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 1.9 tmtp? -118.49 95.21 4.77 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-N 114.975 -1.011 . . . . 0.0 108.298 -166.577 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -82.48 150.52 28.53 Favored Glycine 0 C--O 1.248 1.012 0 N-CA-C 108.911 -1.675 . . . . 0.0 108.911 166.562 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 16.1 mm -80.2 59.63 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.265 0 CA-C-O 121.614 0.721 . . . . 0.0 109.07 -177.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 4.6 pp 168.55 -20.59 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 126.331 1.853 . . . . 0.0 110.433 -173.662 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -157.36 145.51 12.08 Favored Glycine 0 C--N 1.37 2.462 0 CA-C-O 119.841 -0.422 . . . . 0.0 113.239 -174.703 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . 0.482 ' HB3' ' HD3' ' A' ' 87' ' ' LYS . 28.3 m-85 -130.56 147.67 52.27 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-N 117.434 0.617 . . . . 0.0 111.192 -171.177 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 25.1 t -151.18 149.83 29.92 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 123.806 0.843 . . . . 0.0 109.447 175.2 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . . . . . . . . . 22.2 tp60 -94.83 111.22 23.01 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 108.858 -0.794 . . . . 0.0 108.858 177.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.444 HD11 ' HB3' ' A' ' 6' ' ' LEU . 28.6 pt -106.33 -16.86 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 N-CA-C 113.375 0.88 . . . . 0.0 113.375 -173.222 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 170.35 -146.32 9.76 Favored Glycine 0 N--CA 1.472 1.044 0 C-N-CA 120.453 -0.879 . . . . 0.0 113.193 173.604 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.476 ' HA ' ' HA ' ' A' ' 85' ' ' ARG . . . -149.32 176.36 10.62 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 123.684 0.794 . . . . 0.0 110.787 177.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -166.81 -170.52 31.81 Favored Glycine 0 C--N 1.344 1.02 0 N-CA-C 111.368 -0.693 . . . . 0.0 111.368 178.12 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 6.2 p -142.83 117.4 4.34 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.728 0 C-N-CA 124.034 0.934 . . . . 0.0 109.278 178.432 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 3.0 t80 -88.5 136.71 32.86 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 171.313 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.514 ' HA ' ' HB2' ' A' ' 81' ' ' ASP . 17.2 tptp -160.12 153.47 22.14 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 110.41 -0.219 . . . . 0.0 110.41 177.244 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 71.52 -85.47 0.03 OUTLIER 'General case' 0 CA--C 1.55 0.981 0 C-N-CA 124.868 1.267 . . . . 0.0 110.576 169.651 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . 0.673 ' HA2' HD11 ' A' ' 79' ' ' LEU . . . -155.88 24.81 0.56 Allowed Glycine 0 N--CA 1.469 0.889 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 174.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . 0.746 HG22 ' HA3' ' A' ' 141' ' ' GLY . 7.0 p -147.03 151.75 37.45 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.377 1.071 . . . . 0.0 110.011 -167.865 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' PHE . . . . . 0.518 ' HB3' ' HB3' ' A' ' 140' ' ' TYR . 31.4 t80 -104.63 139.16 39.88 Favored 'General case' 0 N--CA 1.484 1.235 0 N-CA-C 108.031 -1.099 . . . . 0.0 108.031 174.02 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . 0.436 ' HB3' ' CZ3' ' A' ' 144' ' ' TRP . 78.0 m-70 -132.35 113.58 13.36 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 123.549 0.74 . . . . 0.0 110.173 -175.555 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 9.0 t -136.47 -177.8 4.88 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 122.761 0.424 . . . . 0.0 110.673 177.495 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' MET . . . . . 0.506 ' SD ' ' HE1' ' A' ' 112' ' ' HIS . 3.3 mtp -89.52 152.42 21.44 Favored 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 123.677 0.791 . . . . 0.0 110.195 178.656 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 53.9 t90 -73.45 -39.13 65.2 Favored 'General case' 0 CA--C 1.542 0.642 0 O-C-N 123.634 0.584 . . . . 0.0 110.365 -175.848 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . 0.506 ' HE1' ' SD ' ' A' ' 110' ' ' MET . 18.6 p-80 -65.87 -8.39 21.76 Favored 'General case' 0 N--CA 1.49 1.555 0 C-N-CA 124.474 1.11 . . . . 0.0 113.087 -172.665 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 95.1 t -58.08 -37.97 64.82 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.977 0 C-N-CA 123.366 0.666 . . . . 0.0 110.1 178.231 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.4 ' HB ' ' OG ' ' A' ' 2' ' ' SER . 17.5 p -147.78 -163.08 1.69 Allowed 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 124.448 1.099 . . . . 0.0 109.989 169.435 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.441 ' HB3' ' HB2' ' A' ' 2' ' ' SER . 17.8 tpp180 -90.83 5.23 49.26 Favored 'General case' 0 CA--C 1.559 1.296 0 C-N-CA 123.562 0.745 . . . . 0.0 111.152 176.248 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 107.1 63.49 0.59 Allowed Glycine 0 C--N 1.35 1.329 0 N-CA-C 111.799 -0.52 . . . . 0.0 111.799 -178.364 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . 0.591 ' HB3' HD11 ' A' ' 6' ' ' LEU . . . -95.33 168.39 10.75 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 123.811 0.844 . . . . 0.0 111.823 -179.363 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.42 HG23 ' HA ' ' A' ' 127' ' ' GLU . 14.9 p -86.5 141.41 14.44 Favored 'Isoleucine or valine' 0 C--O 1.245 0.845 0 N-CA-C 108.369 -0.975 . . . . 0.0 108.369 165.565 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.659 ' HG ' ' HB2' ' A' ' 6' ' ' LEU . 6.4 mp -102.03 174.62 5.85 Favored 'General case' 0 C--O 1.222 -0.35 0 C-N-CA 124.072 0.949 . . . . 0.0 111.291 -173.667 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 25.4 mmt -121.78 165.71 15.43 Favored 'General case' 0 N--CA 1.479 0.976 0 C-N-CA 125.36 1.464 . . . . 0.0 108.752 177.194 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 12.1 t-80 -170.03 97.44 0.28 Allowed 'General case' 0 C--O 1.246 0.879 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 166.435 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.772 ' HB2' HG23 ' A' ' 64' ' ' VAL . 49.1 tttm 56.87 37.63 28.92 Favored 'General case' 0 N--CA 1.489 1.483 0 CA-C-O 121.91 0.862 . . . . 0.0 110.889 173.358 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 101.38 -12.09 58.37 Favored Glycine 0 C--N 1.348 1.22 0 CA-C-O 119.135 -0.814 . . . . 0.0 114.349 177.007 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 53.4 mtpt -102.56 135.18 44.65 Favored 'General case' 0 N--CA 1.49 1.569 0 CA-C-N 118.155 0.977 . . . . 0.0 110.712 178.506 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . 0.434 ' HA ' ' O ' ' A' ' 119' ' ' LEU . 0.1 OUTLIER -85.21 122.79 29.9 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 123.196 0.599 . . . . 0.0 110.82 177.667 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.519 HG23 ' HB2' ' A' ' 140' ' ' TYR . 1.8 mp -87.13 100.07 9.38 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.917 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 172.606 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . 0.42 ' HA ' HG23 ' A' ' 118' ' ' VAL . 36.5 tt0 -92.42 104.63 11.61 Favored Pre-proline 0 CA--C 1.545 0.787 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.371 -177.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 12.9 Cg_exo -68.69 98.2 0.58 Allowed 'Trans proline' 0 C--N 1.374 1.905 0 C-N-CA 122.534 2.156 . . . . 0.0 112.195 -175.697 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 6.4 p -69.08 -24.66 64.17 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 123.797 0.839 . . . . 0.0 111.231 176.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.578 ' HB2' ' HA2' ' A' ' 142' ' ' GLY . 59.7 t-105 -107.32 138.43 43.52 Favored 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 108.712 -0.848 . . . . 0.0 108.712 171.334 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -155.35 120.89 4.99 Favored 'General case' 0 C--O 1.238 0.494 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 176.393 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -143.07 114.08 7.7 Favored 'General case' 0 CA--C 1.544 0.728 0 CA-C-O 120.879 0.371 . . . . 0.0 110.98 -178.099 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 14.2 p -77.45 -17.43 14.29 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.309 0 C-N-CA 124.219 1.008 . . . . 0.0 112.423 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 65.4 mttm -71.73 -45.52 61.5 Favored 'General case' 0 N--CA 1.485 1.306 0 C-N-CA 123.177 0.591 . . . . 0.0 110.735 -173.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . 0.599 ' HG2' ' HG2' ' A' ' 230' ' ' GLU . 4.6 mptp? -88.64 -10.06 49.92 Favored 'General case' 0 N--CA 1.477 0.898 0 C-N-CA 124.653 1.181 . . . . 0.0 109.897 174.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 56.1 t0 63.02 46.11 4.92 Favored 'General case' 0 C--N 1.36 1.037 0 O-C-N 124.549 1.156 . . . . 0.0 109.426 -177.124 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 96.2 mt -136.71 127.67 27.61 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.696 0.798 . . . . 0.0 110.392 -179.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 17.8 tt -124.14 136.81 59.18 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 175.773 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 80.5 p -148.58 146.0 28.07 Favored 'General case' 0 N--CA 1.475 0.796 0 CA-C-O 121.843 0.83 . . . . 0.0 113.146 -171.162 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.519 ' HB2' HG23 ' A' ' 126' ' ' ILE . 81.3 t80 -84.6 122.17 28.66 Favored 'General case' 0 N--CA 1.473 0.695 0 CA-C-N 114.446 -1.252 . . . . 0.0 108.396 172.601 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.746 ' HA3' HG22 ' A' ' 106' ' ' THR . . . 123.69 -82.47 0.35 Allowed Glycine 0 C--N 1.34 0.801 0 O-C-N 124.281 0.988 . . . . 0.0 111.637 177.676 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . 0.578 ' HA2' ' HB2' ' A' ' 130' ' ' TRP . . . 147.57 84.09 0.05 OUTLIER Glycine 0 C--O 1.24 0.495 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 172.683 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . 146.94 176.34 20.62 Favored Glycine 0 C--O 1.241 0.565 0 N-CA-C 111.233 -0.747 . . . . 0.0 111.233 177.312 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' TRP . . . . . 0.593 ' HH2' HD13 ' A' ' 210' ' ' LEU . 69.2 t-105 -110.16 109.21 19.64 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 166.491 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 28.7 mmmt -108.98 107.43 17.79 Favored 'General case' 0 N--CA 1.471 0.621 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -175.412 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' LEU . . . . . 0.423 HD22 HG11 ' A' ' 207' ' ' VAL . 60.2 mt -162.63 -45.74 0.04 OUTLIER 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 126.909 2.084 . . . . 0.0 106.784 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 63.89 22.88 13.17 Favored 'General case' 0 N--CA 1.482 1.128 0 C-N-CA 125.256 1.422 . . . . 0.0 112.758 176.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.434 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -76.98 165.96 53.76 Favored Glycine 0 C--N 1.352 1.455 0 CA-C-N 116.262 -0.427 . . . . 0.0 113.017 179.543 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 22.2 tt0 -123.69 96.62 5.03 Favored 'General case' 0 C--O 1.239 0.506 0 C-N-CA 123.485 0.714 . . . . 0.0 109.26 -174.401 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' TRP . . . . . 0.527 ' HA ' ' HB ' ' A' ' 208' ' ' VAL . 29.1 t90 -55.63 116.05 2.68 Favored 'General case' 0 N--CA 1.481 1.098 0 O-C-N 123.308 0.38 . . . . 0.0 111.185 171.33 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 65.9 mttm -94.5 100.3 12.31 Favored 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 123.848 0.859 . . . . 0.0 109.419 -178.366 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 29.6 tt0 -68.21 141.02 56.08 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 124.658 1.183 . . . . 0.0 111.918 -175.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 83.8 -23.56 6.63 Favored Glycine 0 C--N 1.351 1.389 0 CA-C-N 116.47 -0.332 . . . . 0.0 113.518 177.314 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -97.02 151.53 19.63 Favored 'General case' 0 C--O 1.24 0.57 0 C-N-CA 124.546 1.138 . . . . 0.0 108.53 -179.578 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . 0.424 ' HA ' ' HA ' ' A' ' 173' ' ' LYS . 1.2 pm0 -63.6 121.96 15.16 Favored 'General case' 0 C--N 1.345 0.406 0 N-CA-C 109.862 -0.422 . . . . 0.0 109.862 176.051 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 33.9 m -89.93 179.51 0.5 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.537 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 174.807 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.47 133.4 51.21 Favored 'General case' 0 C--O 1.217 -0.641 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -175.87 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.451 ' O ' ' HA ' ' A' ' 169' ' ' ALA . 86.3 t -107.77 119.35 57.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 -176.795 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -93.1 77.43 4.63 Favored 'General case' 0 CA--C 1.54 0.584 0 N-CA-C 106.665 -1.605 . . . . 0.0 106.665 172.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -77.9 111.87 14.2 Favored 'General case' 0 CA--C 1.539 0.534 0 CA-C-N 114.69 -1.141 . . . . 0.0 111.006 -169.347 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . 0.431 HD21 ' HB1' ' A' ' 83' ' ' ALA . 89.0 mt -79.1 102.61 8.52 Favored 'General case' 0 C--O 1.244 0.805 0 C-N-CA 123.993 0.917 . . . . 0.0 110.195 179.541 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . 0.516 ' HB2' ' HB2' ' A' ' 193' ' ' PRO . 39.1 tt0 -74.82 126.66 88.16 Favored Pre-proline 0 CA--C 1.541 0.614 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 173.124 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . 0.455 ' HB2' HD23 ' A' ' 50' ' ' LEU . 36.5 Cg_endo -64.13 116.03 3.48 Favored 'Trans proline' 0 C--N 1.376 1.988 0 C-N-CA 121.911 1.741 . . . . 0.0 110.375 173.753 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 113.1 -28.01 9.11 Favored Glycine 0 C--N 1.344 1.006 0 CA-C-O 119.583 -0.565 . . . . 0.0 113.816 177.369 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -136.47 -173.48 3.43 Favored 'General case' 0 N--CA 1.49 1.552 0 CA-C-N 117.986 0.893 . . . . 0.0 112.154 -175.08 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -60.0 161.27 12.88 Favored Pre-proline 0 CA--C 1.554 1.116 0 C-N-CA 124.983 1.313 . . . . 0.0 112.319 175.861 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -77.2 157.4 33.65 Favored 'Trans proline' 0 C--N 1.373 1.823 0 C-N-CA 122.016 1.811 . . . . 0.0 111.759 173.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . 0.517 HH11 ' HG3' ' A' ' 193' ' ' PRO . 58.7 mtp180 -124.58 131.97 53.46 Favored 'General case' 0 C--O 1.238 0.489 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.257 173.773 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . 0.559 ' H ' ' HB2' ' A' ' 19' ' ' GLN . . . -80.02 133.83 36.18 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.053 176.633 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 63.0 t -134.21 117.8 26.05 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.131 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 174.436 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 55.1 mt-30 -81.75 126.28 31.63 Favored 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 108.245 -1.021 . . . . 0.0 108.245 174.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 4.9 t -152.72 132.44 13.16 Favored 'General case' 0 CA--C 1.54 0.561 0 O-C-N 123.571 0.544 . . . . 0.0 111.738 -174.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . 0.496 ' HB2' ' HB2' ' A' ' 25' ' ' SER . 64.0 mttp -75.6 138.13 70.57 Favored Pre-proline 0 N--CA 1.475 0.782 0 C-N-CA 123.146 0.578 . . . . 0.0 110.069 171.69 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_endo -61.78 163.27 19.27 Favored 'Trans proline' 0 C--N 1.379 2.134 0 C-N-CA 123.091 2.527 . . . . 0.0 113.728 178.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -144.45 169.89 26.3 Favored Glycine 0 N--CA 1.468 0.785 0 N-CA-C 110.399 -1.08 . . . . 0.0 110.399 178.217 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 6.5 mp -124.34 152.13 43.5 Favored 'General case' 0 N--CA 1.488 1.463 0 CA-C-N 118.681 1.24 . . . . 0.0 111.887 -176.511 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 177' ' ' PHE . . . . . 0.517 ' HE1' HD23 ' A' ' 29' ' ' LEU . 68.4 m-85 -96.53 122.42 39.41 Favored 'General case' 0 C--N 1.344 0.356 0 CA-C-N 114.756 -1.111 . . . . 0.0 109.593 173.831 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 61.0 tttp -85.47 90.07 7.86 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 167.032 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 23.0 m -104.14 158.79 16.2 Favored 'General case' 0 C--O 1.242 0.689 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 -179.352 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -61.6 -34.88 76.4 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 122.356 0.262 . . . . 0.0 110.471 177.506 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -63.79 -33.85 76.59 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 123.572 0.749 . . . . 0.0 111.155 175.442 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 151.25 -169.13 30.88 Favored Glycine 0 C--N 1.342 0.888 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.97 177.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 183' ' ' THR . . . . . 0.453 ' HA ' ' O ' ' A' ' 177' ' ' PHE . 16.9 p -87.25 119.19 27.23 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 122.986 0.514 . . . . 0.0 109.776 176.522 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . 0.461 ' HB ' ' HB2' ' A' ' 177' ' ' PHE . 65.5 mt -103.01 144.51 13.69 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 124.223 1.009 . . . . 0.0 108.504 -176.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -99.23 120.24 6.79 Favored Glycine 0 C--N 1.345 1.038 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 -175.223 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.403 ' HA ' ' HA ' ' A' ' 225' ' ' ALA . . . -146.93 -160.65 1.19 Allowed 'General case' 0 N--CA 1.465 0.294 0 C-N-CA 123.413 0.685 . . . . 0.0 111.102 -163.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 187' ' ' VAL . . . . . 0.416 ' HB ' HD11 ' A' ' 226' ' ' ILE . 3.7 p -132.22 103.86 7.13 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.989 0 C-N-CA 124.029 0.932 . . . . 0.0 108.498 169.552 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . 0.46 ' HA ' HG13 ' A' ' 223' ' ' VAL . 15.6 t -76.96 100.65 5.68 Favored 'General case' 0 C--O 1.243 0.753 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.501 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 189' ' ' LEU . . . . . 0.4 HD13 ' N ' ' A' ' 190' ' ' ASP . 0.8 OUTLIER -152.44 155.66 37.96 Favored 'General case' 0 C--N 1.358 0.939 0 CA-C-O 121.365 0.603 . . . . 0.0 110.689 -168.531 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 190' ' ' ASP . . . . . 0.645 ' HA ' ' HB1' ' A' ' 221' ' ' ALA . 16.6 t70 -69.08 162.76 26.26 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 124.869 1.267 . . . . 0.0 109.859 176.048 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 191' ' ' PHE . . . . . 0.536 ' HB3' ' H ' ' A' ' 222' ' ' TYR . 9.6 p90 -74.23 123.92 25.43 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-O 121.958 0.885 . . . . 0.0 110.522 -168.409 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 50.8 m -104.62 158.96 30.88 Favored Pre-proline 0 CA--C 1.547 0.854 0 CA-C-N 114.23 -1.35 . . . . 0.0 110.445 -174.457 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . 0.517 ' HG3' HH11 ' A' ' 168' ' ' ARG . 73.7 Cg_endo -72.78 69.69 3.62 Favored 'Trans proline' 0 C--N 1.372 1.8 0 C-N-CA 122.786 2.324 . . . . 0.0 112.2 173.44 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -154.01 146.63 15.02 Favored Glycine 0 C--N 1.347 1.145 0 CA-C-N 116.178 -0.465 . . . . 0.0 112.46 -177.42 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 25.3 p -110.39 156.37 20.87 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 123.684 0.793 . . . . 0.0 109.469 176.32 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.63 107.2 0.77 Allowed 'General case' 0 N--CA 1.481 1.099 0 C-N-CA 123.858 0.863 . . . . 0.0 110.069 -175.557 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 132.6 -9.55 5.26 Favored Glycine 0 C--N 1.342 0.89 0 CA-C-N 114.749 -1.114 . . . . 0.0 112.338 -172.19 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 54.2 m -63.91 120.12 60.92 Favored Pre-proline 0 CA--C 1.55 0.953 0 C-N-CA 123.351 0.66 . . . . 0.0 109.553 173.48 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -60.39 125.29 17.04 Favored 'Trans proline' 0 C--N 1.375 1.949 0 C-N-CA 122.836 2.357 . . . . 0.0 112.292 -173.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 55.5 mt -88.22 107.56 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 173.665 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 201' ' ' ILE . . . . . 0.8 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 25.9 mt -97.06 176.55 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.044 0 C-N-CA 124.524 1.13 . . . . 0.0 108.942 -175.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -102.93 174.22 5.97 Favored 'General case' 0 C--O 1.24 0.604 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 169.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 2.4 mppt? -70.46 -28.74 65.25 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 123.84 0.856 . . . . 0.0 109.051 174.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp -81.96 1.6 34.65 Favored 'General case' 0 N--CA 1.477 0.878 0 C-N-CA 123.958 0.903 . . . . 0.0 111.927 178.836 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 90.96 -4.82 81.84 Favored Glycine 0 C--N 1.351 1.403 0 CA-C-O 119.965 -0.353 . . . . 0.0 113.562 177.249 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 31.3 mmtp -78.25 108.89 11.9 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 122.931 0.492 . . . . 0.0 110.064 179.651 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.8 ' HA ' ' HA ' ' A' ' 201' ' ' ILE . 4.8 p -63.66 103.06 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.053 0 CA-C-O 121.437 0.636 . . . . 0.0 110.218 177.076 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 208' ' ' VAL . . . . . 0.527 ' HB ' ' HA ' ' A' ' 150' ' ' TRP . 27.2 m -81.68 -18.37 11.43 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.987 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.287 -169.782 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . . . . . . . . . . . 170.89 -138.84 5.15 Favored Glycine 0 C--N 1.344 0.99 0 CA-C-N 115.446 -0.797 . . . . 0.0 112.351 179.506 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . 0.593 HD13 ' HH2' ' A' ' 144' ' ' TRP . 4.9 tt -153.41 154.13 33.85 Favored 'General case' 0 CA--C 1.549 0.904 0 C-N-CA 123.864 0.866 . . . . 0.0 109.825 -168.219 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -67.97 114.42 6.5 Favored 'General case' 0 N--CA 1.481 1.12 0 C-N-CA 123.885 0.874 . . . . 0.0 109.868 -178.78 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -74.65 -136.67 0.44 Allowed Glycine 0 CA--C 1.528 0.895 0 O-C-N 124.349 1.031 . . . . 0.0 114.754 -169.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 213' ' ' ASN . . . . . 0.404 ' H ' ' HB3' ' A' ' 225' ' ' ALA . 49.0 t-20 -123.99 135.15 53.44 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 -175.164 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 214' ' ' GLY . . . . . 0.507 ' HA3' ' HA ' ' A' ' 224' ' ' SER . . . -164.37 -152.42 6.96 Favored Glycine 0 CA--C 1.506 -0.528 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.918 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 215' ' ' VAL . . . . . 0.466 HG11 ' HA ' ' A' ' 40' ' ' SER . 7.4 p -162.76 157.09 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 123.02 0.528 . . . . 0.0 110.445 -171.412 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 216' ' ' VAL . . . . . 0.46 ' HA ' ' HA ' ' A' ' 222' ' ' TYR . 93.0 t -70.93 116.38 12.36 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 C-N-CA 123.891 0.877 . . . . 0.0 109.064 174.553 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 217' ' ' THR . . . . . 0.796 HG22 HD11 ' A' ' 41' ' ' ILE . 72.9 p -130.68 163.48 27.12 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 125.256 1.423 . . . . 0.0 109.525 -173.572 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 10.1 ttp180 54.31 76.57 0.23 Allowed 'General case' 0 CA--C 1.561 1.367 0 C-N-CA 123.133 0.573 . . . . 0.0 111.957 161.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 45.1 m 71.91 -5.69 1.64 Allowed 'General case' 0 N--CA 1.492 1.663 0 C-N-CA 124.901 1.28 . . . . 0.0 114.393 176.21 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . 118.27 43.82 0.54 Allowed Glycine 0 C--N 1.357 1.71 0 CA-C-N 118.583 0.629 . . . . 0.0 112.909 176.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . 0.645 ' HB1' ' HA ' ' A' ' 190' ' ' ASP . . . -130.39 120.91 24.99 Favored 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 124.712 1.205 . . . . 0.0 109.578 -178.611 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 222' ' ' TYR . . . . . 0.536 ' H ' ' HB3' ' A' ' 191' ' ' PHE . 11.0 p90 -86.3 127.45 34.78 Favored 'General case' 0 C--N 1.351 0.665 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 -169.643 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . 0.46 HG13 ' HA ' ' A' ' 188' ' ' SER . 96.4 t -113.49 132.95 60.95 Favored 'Isoleucine or valine' 0 C--O 1.241 0.633 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 176.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . 0.507 ' HA ' ' HA3' ' A' ' 214' ' ' GLY . 35.8 t -136.3 158.74 43.71 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 124.199 0.999 . . . . 0.0 109.959 -168.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . 0.404 ' HB3' ' H ' ' A' ' 213' ' ' ASN . . . -68.73 166.51 17.28 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 123.708 0.803 . . . . 0.0 111.234 175.232 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 226' ' ' ILE . . . . . 0.416 HD11 ' HB ' ' A' ' 187' ' ' VAL . 70.9 mt -108.71 111.56 36.55 Favored 'Isoleucine or valine' 0 C--O 1.243 0.731 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 168.634 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -74.62 131.83 41.25 Favored 'General case' 0 C--N 1.345 0.381 0 N-CA-C 107.516 -1.291 . . . . 0.0 107.516 169.828 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -111.39 171.12 7.67 Favored 'General case' 0 C--O 1.248 1.01 0 C-N-CA 123.626 0.77 . . . . 0.0 109.371 -177.754 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . 0.474 ' HA ' ' CD1' ' A' ' 144' ' ' TRP . 87.1 m -66.94 115.31 6.53 Favored 'General case' 0 CA--C 1.544 0.738 0 O-C-N 123.59 0.556 . . . . 0.0 110.618 178.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 230' ' ' GLU . . . . . 0.599 ' HG2' ' HG2' ' A' ' 135' ' ' LYS . 10.0 tp10 -117.0 62.75 0.73 Allowed 'General case' 0 C--O 1.242 0.68 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 175.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 24.3 pttm -66.97 157.45 33.33 Favored 'General case' 0 N--CA 1.472 0.662 0 CA-C-N 114.985 -1.007 . . . . 0.0 112.911 -165.733 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 19.8 p -50.51 106.55 0.13 Allowed 'General case' 0 CA--C 1.549 0.926 0 CA-C-N 113.935 -1.484 . . . . 0.0 112.132 -178.074 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 233' ' ' ILE . . . . . 0.448 ' O ' HG12 ' A' ' 233' ' ' ILE . 1.4 tt -90.14 7.37 4.07 Favored 'Isoleucine or valine' 0 CA--C 1.562 1.426 0 C-N-CA 124.309 1.044 . . . . 0.0 110.341 176.158 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 234' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 64.86 31.83 11.28 Favored 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 124.486 1.115 . . . . 0.0 110.815 -174.261 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -62.05 -51.49 67.75 Favored 'General case' 0 N--CA 1.479 0.999 0 C-N-CA 123.86 0.864 . . . . 0.0 108.678 171.016 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 236' ' ' ASN . . . . . . . . . . . . . 4.7 p-10 -74.94 149.02 85.13 Favored Pre-proline 0 C--O 1.244 0.779 0 CA-C-N 114.039 -1.437 . . . . 0.0 109.174 168.014 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 16.3 Cg_endo -57.97 142.48 96.66 Favored 'Trans proline' 0 C--N 1.376 2.018 0 C-N-CA 121.848 1.699 . . . . 0.0 111.311 175.768 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 238' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -65.5 -27.55 68.56 Favored 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 123.505 0.722 . . . . 0.0 110.951 -178.051 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 239' ' ' ILE . . . . . 0.452 ' H ' HD12 ' A' ' 239' ' ' ILE . 3.8 mp -79.41 -6.87 9.96 Favored 'Isoleucine or valine' 0 CA--C 1.568 1.638 0 C-N-CA 124.358 1.063 . . . . 0.0 109.698 -179.241 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 . . . . . 0 C--O 1.254 1.323 0 C-N-CA 125.152 1.381 . . . . 0.0 110.594 177.27 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 251' ' ' BEZ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 253' ' ' LYS . . . . . . . . . . . . . 5.0 tppp? -57.73 91.23 0.01 OUTLIER 'General case' 0 CA--C 1.55 0.979 0 C-N-CA 123.79 0.836 . . . . 0.0 112.124 -176.397 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 254' ' ' ARG . . . . . . . . . . . . . 26.1 mtp180 -79.22 -15.45 58.01 Favored 'General case' 0 N--CA 1.482 1.151 0 CA-C-N 114.363 -1.289 . . . . 0.0 109.964 172.026 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 255' ' ' M9P . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.563 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 41.6 t -166.32 -52.44 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 123.335 0.654 . . . . 0.0 109.663 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.421 ' HA ' HE22 ' A' ' 88' ' ' GLN . . . 67.41 43.18 2.01 Favored 'General case' 0 N--CA 1.484 1.25 0 C-N-CA 123.962 0.905 . . . . 0.0 111.848 173.84 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -165.2 23.62 0.05 Allowed 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 123.142 0.577 . . . . 0.0 110.365 -175.489 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 8.9 p30 -175.55 64.73 0.02 OUTLIER 'General case' 0 C--N 1.344 0.367 0 C-N-CA 124.734 1.214 . . . . 0.0 108.069 -173.099 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.683 ' HB2' HD13 ' A' ' 119' ' ' LEU . 15.6 mt -79.58 177.52 8.81 Favored 'General case' 0 C--O 1.213 -0.868 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 168.078 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 17.3 tt0 -152.39 142.35 22.15 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-N 119.104 0.866 . . . . 0.0 111.56 171.15 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.448 ' HB3' ' CD2' ' A' ' 84' ' ' TYR . 89.3 mt -87.9 114.37 24.45 Favored 'General case' 0 C--O 1.24 0.56 0 CA-C-N 114.012 -1.449 . . . . 0.0 110.007 175.029 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -106.79 117.75 34.87 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 173.583 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 21.2 ptt180 -58.98 121.77 12.04 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 122.83 0.452 . . . . 0.0 110.08 177.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -113.8 -33.83 5.67 Favored 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 122.609 0.364 . . . . 0.0 110.676 -176.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -169.17 -172.16 1.46 Allowed 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 123.938 0.895 . . . . 0.0 109.9 -179.096 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -102.04 160.29 14.63 Favored 'General case' 0 C--O 1.245 0.83 0 N-CA-C 107.818 -1.178 . . . . 0.0 107.818 169.208 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 99.7 t -72.38 100.09 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 170.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 63.7 tttt -155.54 127.74 7.68 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 115.126 -0.943 . . . . 0.0 108.725 -166.111 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . 0.5 ' HE1' ' HG2' ' A' ' 157' ' ' GLN . 40.6 t90 -69.74 121.64 17.62 Favored 'General case' 0 C--O 1.236 0.375 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 167.802 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.504 ' HG3' ' HG2' ' A' ' 19' ' ' GLN . 9.4 tp10 -92.74 134.35 35.13 Favored 'General case' 0 C--O 1.238 0.486 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 173.11 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -72.25 0.24 10.38 Favored 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 124.171 0.988 . . . . 0.0 113.093 -173.276 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . 0.504 ' HG2' ' HG3' ' A' ' 17' ' ' GLU . 11.6 mm-40 -74.77 47.73 0.34 Allowed 'General case' 0 CA--C 1.557 1.212 0 C-N-CA 124.326 1.05 . . . . 0.0 111.185 175.206 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.431 ' HA ' ' O ' ' A' ' 169' ' ' ALA . . . -73.87 89.29 1.85 Allowed 'General case' 0 C--N 1.352 0.697 0 C-N-CA 123.915 0.886 . . . . 0.0 110.098 -176.644 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -88.19 141.26 28.7 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 114.762 -1.108 . . . . 0.0 109.196 179.638 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 44.4 mm -76.11 102.58 3.11 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.424 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 173.745 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 47.5 m -121.7 -71.85 0.71 Allowed 'General case' 0 CA--C 1.538 0.497 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.502 -167.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.487 ' HA3' HG23 ' A' ' 172' ' ' THR . . . -85.01 133.05 11.49 Favored Glycine 0 C--N 1.353 1.482 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 174.332 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.546 ' HA ' ' HB2' ' A' ' 173' ' ' LYS . 62.2 p -163.62 10.46 0.05 Allowed 'General case' 0 N--CA 1.481 1.085 0 CA-C-N 117.477 0.638 . . . . 0.0 112.106 -178.112 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.422 ' HA ' ' HD3' ' A' ' 27' ' ' PRO . 20.7 p -94.12 145.51 29.91 Favored Pre-proline 0 CA--C 1.55 0.962 0 C-N-CA 123.0 0.52 . . . . 0.0 110.245 179.838 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 26' ' ' SER . 31.5 Cg_endo -89.45 -82.87 0.0 OUTLIER 'Trans proline' 0 C--N 1.379 2.144 0 C-N-CA 123.005 2.47 . . . . 0.0 114.29 -175.461 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.419 ' HA ' ' O ' ' A' ' 176' ' ' LEU . 33.0 mm -101.93 130.68 51.29 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 C-N-CA 122.788 0.435 . . . . 0.0 111.173 -169.84 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.702 HD23 HG21 ' A' ' 217' ' ' THR . 0.0 OUTLIER -139.19 161.37 37.58 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 123.613 0.765 . . . . 0.0 110.586 170.96 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 34.2 p -88.59 144.46 26.3 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 123.171 0.588 . . . . 0.0 111.45 -178.318 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.404 HG23 HG22 ' A' ' 179' ' ' THR . 10.4 tt -155.37 152.63 8.72 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.175 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -178.745 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 3.9 m -97.99 109.42 22.18 Favored 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 123.153 0.581 . . . . 0.0 110.794 -173.076 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 18.1 tt -90.6 141.83 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 O-C-N 121.771 -0.581 . . . . 0.0 110.123 178.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 25.1 m -143.79 151.5 40.03 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 123.217 0.607 . . . . 0.0 111.05 -177.061 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 54.61 25.9 6.83 Favored 'General case' 0 N--CA 1.487 1.418 0 C-N-CA 124.338 1.055 . . . . 0.0 112.307 175.114 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 18.8 t70 73.35 -60.82 0.52 Allowed 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 125.759 1.624 . . . . 0.0 111.378 -173.648 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -89.21 -34.31 8.85 Favored Glycine 0 C--N 1.348 1.234 0 N-CA-C 114.713 0.645 . . . . 0.0 114.713 -173.523 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 24.4 t -87.34 105.11 17.02 Favored 'General case' 0 N--CA 1.484 1.261 0 CA-C-N 117.428 0.614 . . . . 0.0 109.398 -167.629 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . 0.5 ' HE2' ' HB3' ' A' ' 39' ' ' MET . 43.5 ttp -125.41 131.18 52.97 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 122.656 0.382 . . . . 0.0 110.278 -171.412 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.555 ' HB3' ' HE2' ' B' ' 253' ' ' LYS . 72.4 m -155.76 -178.36 7.24 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 125.179 1.392 . . . . 0.0 109.177 -175.318 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.601 HG12 HG11 ' A' ' 215' ' ' VAL . 44.8 mm -80.62 150.02 4.9 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.821 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 159.512 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 45.4 pttt -67.61 76.24 0.18 Allowed 'General case' 0 CA--C 1.556 1.189 0 CA-C-O 122.172 0.987 . . . . 0.0 109.839 167.128 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 -148.12 -168.03 2.97 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 124.906 1.282 . . . . 0.0 108.813 -178.601 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -134.93 160.26 38.84 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 123.381 0.672 . . . . 0.0 109.439 -179.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -111.12 133.1 53.74 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 123.788 0.835 . . . . 0.0 109.761 177.288 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -106.41 -41.38 5.31 Favored 'General case' 0 N--CA 1.475 0.783 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 174.452 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 48.3 mm-40 63.39 -168.73 0.2 Allowed 'General case' 0 C--N 1.352 0.708 0 C-N-CA 125.215 1.406 . . . . 0.0 113.523 175.653 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.505 HE21 ' HB3' ' A' ' 96' ' ' GLN . 0.3 OUTLIER -146.94 152.78 39.22 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 124.157 0.983 . . . . 0.0 109.198 -174.086 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 13.1 t -85.11 -11.38 55.3 Favored 'General case' 0 CA--C 1.545 0.755 0 C-N-CA 123.247 0.619 . . . . 0.0 110.334 176.112 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 67.1 mt -56.4 131.11 47.44 Favored 'General case' 0 C--N 1.355 0.818 0 C-N-CA 124.449 1.1 . . . . 0.0 112.1 -176.179 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -153.38 -101.8 0.21 Allowed Glycine 0 C--N 1.335 0.498 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 175.131 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -83.3 76.99 2.17 Favored Glycine 0 C--N 1.343 0.946 0 N-CA-C 111.42 -0.672 . . . . 0.0 111.42 175.386 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -67.15 87.89 0.15 Allowed Glycine 0 C--N 1.348 1.221 0 C-N-CA 123.01 0.338 . . . . 0.0 112.681 -179.207 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 128.83 -144.03 14.98 Favored Glycine 0 C--N 1.342 0.884 0 N-CA-C 111.306 -0.718 . . . . 0.0 111.306 -177.431 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 43.4 m -74.36 84.45 1.94 Allowed 'General case' 0 CA--C 1.552 1.033 0 C-N-CA 123.128 0.571 . . . . 0.0 110.656 -179.184 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -78.9 -32.31 40.76 Favored Glycine 0 C--N 1.348 1.22 0 CA-C-N 115.373 -0.83 . . . . 0.0 112.431 177.468 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -118.23 -149.4 8.74 Favored Glycine 0 C--N 1.346 1.111 0 N-CA-C 111.743 -0.543 . . . . 0.0 111.743 176.566 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -92.96 -70.22 1.14 Allowed Glycine 0 C--N 1.343 0.939 0 N-CA-C 111.692 -0.563 . . . . 0.0 111.692 177.846 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 130.32 -41.39 1.54 Allowed Glycine 0 C--N 1.345 1.064 0 C-N-CA 123.054 0.359 . . . . 0.0 112.652 176.355 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.7 tm-20 -82.78 80.78 8.76 Favored 'General case' 0 CA--C 1.546 0.803 0 C-N-CA 123.231 0.612 . . . . 0.0 109.369 -174.118 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 67.8 t80 49.55 -74.9 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.896 0 C-N-CA 126.831 2.052 . . . . 0.0 114.106 172.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -61.06 -14.13 21.67 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 124.222 1.009 . . . . 0.0 112.873 178.201 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -114.62 47.12 1.07 Allowed Glycine 0 C--N 1.342 0.863 0 CA-C-O 119.671 -0.516 . . . . 0.0 113.005 178.842 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.798 HG23 ' HG3' ' A' ' 122' ' ' LYS . 29.9 m -89.1 0.55 7.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 CA-C-N 118.756 1.278 . . . . 0.0 112.175 178.392 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.429 ' HB3' ' HB2' ' A' ' 122' ' ' LYS . 3.2 tt -166.92 -90.05 0.02 OUTLIER 'General case' 0 C--N 1.361 1.086 0 C-N-CA 123.392 0.677 . . . . 0.0 110.271 162.519 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . 0.64 ' CD1' ' HD3' ' A' ' 122' ' ' LYS . 66.9 p-90 -59.1 122.68 14.37 Favored 'General case' 0 C--N 1.377 1.764 0 N-CA-C 112.458 0.54 . . . . 0.0 112.458 -160.134 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.434 ' O ' ' HD3' ' A' ' 69' ' ' PRO . 5.0 p-10 -79.08 119.3 22.0 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-N 115.075 -0.966 . . . . 0.0 109.009 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.538 ' HB ' ' HZ3' ' A' ' 66' ' ' TRP . 2.0 p -89.95 103.14 5.74 Favored Pre-proline 0 CA--C 1.56 1.344 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.439 170.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.434 ' HD3' ' O ' ' A' ' 67' ' ' ASP . 23.5 Cg_exo -69.14 -22.96 34.19 Favored 'Trans proline' 0 C--N 1.382 2.291 0 C-N-CA 122.814 2.343 . . . . 0.0 112.702 174.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 33.1 m -78.63 178.03 2.48 Favored Pre-proline 0 CA--C 1.562 1.408 0 C-N-CA 123.746 0.819 . . . . 0.0 110.21 175.473 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -54.72 157.26 12.91 Favored 'Trans proline' 0 C--N 1.383 2.363 0 C-N-CA 122.169 1.913 . . . . 0.0 112.1 165.336 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_exo -41.52 140.85 1.57 Allowed 'Trans proline' 0 C--N 1.385 2.457 0 C-N-CA 124.25 3.3 . . . . 0.0 114.155 179.553 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -23.59 80.71 0.0 OUTLIER 'Trans proline' 0 C--N 1.392 2.842 1 C-N-CA 126.454 4.77 . . . . 0.0 116.423 -165.76 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 35.1 m -74.24 -36.98 44.89 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.167 179.584 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -89.75 -84.53 1.33 Allowed Glycine 0 C--N 1.346 1.089 0 N-CA-C 110.496 -1.042 . . . . 0.0 110.496 173.507 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . 0.467 ' HG3' ' H ' ' A' ' 77' ' ' ALA . 18.4 ptpt -162.09 -62.35 0.05 OUTLIER 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 123.359 0.664 . . . . 0.0 110.697 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.467 ' H ' ' HG3' ' A' ' 76' ' ' LYS . . . -163.39 82.91 0.47 Allowed 'General case' 0 C--O 1.237 0.408 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 -173.293 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -71.11 135.48 47.7 Favored 'General case' 0 CA--C 1.546 0.812 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.287 178.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.723 HD22 ' H ' ' A' ' 105' ' ' GLY . 6.3 mp -84.48 117.8 23.89 Favored 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 124.074 0.95 . . . . 0.0 109.321 -171.31 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -71.5 84.94 0.84 Allowed 'General case' 0 N--CA 1.482 1.159 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 -179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -55.42 106.19 0.22 Allowed 'General case' 0 CA--C 1.549 0.907 0 C-N-CA 124.624 1.17 . . . . 0.0 110.857 -178.021 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -177.41 -169.01 37.97 Favored Glycine 0 C--N 1.355 1.615 0 N-CA-C 115.198 0.839 . . . . 0.0 115.198 -175.502 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -97.85 122.65 41.21 Favored 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 124.479 1.112 . . . . 0.0 110.803 -176.051 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . 0.448 ' CD2' ' HB3' ' A' ' 8' ' ' LEU . 3.4 m-85 -117.42 154.8 30.73 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 123.498 0.719 . . . . 0.0 110.613 -175.383 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . 0.525 ' HG2' HG21 ' A' ' 195' ' ' THR . 22.1 mtm180 -99.17 127.91 45.22 Favored 'General case' 0 C--O 1.243 0.76 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 166.196 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.446 HG12 HD23 ' A' ' 8' ' ' LEU . 22.4 mt -92.12 129.7 42.35 Favored 'Isoleucine or valine' 0 C--O 1.25 1.13 0 CA-C-O 121.658 0.742 . . . . 0.0 109.346 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -117.37 154.17 31.78 Favored 'General case' 0 C--O 1.216 -0.675 0 CA-C-N 114.302 -1.317 . . . . 0.0 109.666 177.351 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . 0.421 HE22 ' HA ' ' A' ' 3' ' ' ALA . 6.3 tp-100 -85.58 107.17 17.37 Favored 'General case' 0 C--O 1.243 0.719 0 N-CA-C 104.807 -2.294 . . . . 0.0 104.807 163.58 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.4 tttp -88.55 98.17 11.5 Favored 'General case' 0 C--O 1.242 0.679 0 CA-C-N 114.706 -1.134 . . . . 0.0 108.522 -173.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -71.54 131.94 19.83 Favored Glycine 0 N--CA 1.439 -1.141 0 N-CA-C 108.021 -2.032 . . . . 0.0 108.021 161.267 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 33.1 mm -62.57 -12.87 10.03 Favored 'Isoleucine or valine' 0 CA--C 1.566 1.584 0 C-N-CA 123.171 0.588 . . . . 0.0 110.569 -178.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 2.3 pp -111.93 -18.27 12.7 Favored 'General case' 0 CA--C 1.562 1.414 0 C-N-CA 123.974 0.91 . . . . 0.0 112.889 168.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -160.81 127.18 1.72 Allowed Glycine 0 N--CA 1.488 2.132 0 N-CA-C 114.763 0.665 . . . . 0.0 114.763 -172.25 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 9.2 m-85 -84.16 160.37 20.87 Favored 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 123.409 0.684 . . . . 0.0 111.635 -178.682 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 37.9 t -148.42 139.21 22.95 Favored 'General case' 0 C--O 1.207 -1.169 0 C-N-CA 124.616 1.167 . . . . 0.0 108.325 169.696 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.505 ' HB3' HE21 ' A' ' 48' ' ' GLN . 9.5 tt0 -90.68 125.61 35.72 Favored 'General case' 0 N--CA 1.493 1.71 0 CA-C-N 119.461 1.028 . . . . 0.0 109.64 -178.687 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 27.6 pt -124.02 -8.62 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 N-CA-C 112.559 0.578 . . . . 0.0 112.559 -172.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 160.92 -139.39 6.02 Favored Glycine 0 C--N 1.343 0.926 0 C-N-CA 120.903 -0.665 . . . . 0.0 113.05 170.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.476 ' HB2' HG22 ' A' ' 195' ' ' THR . . . -153.19 168.72 25.0 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 123.515 0.726 . . . . 0.0 111.786 -178.159 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -174.51 154.17 18.2 Favored Glycine 0 C--N 1.345 1.071 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.903 177.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 28.1 m -97.85 126.86 50.7 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 CA-C-N 117.607 0.703 . . . . 0.0 110.678 -179.346 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 24.3 t80 -100.76 106.4 17.81 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.489 ' HB3' ' O ' ' A' ' 106' ' ' THR . 14.2 tmtt? -100.87 149.85 23.45 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 -172.144 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -62.31 96.15 0.07 Allowed 'General case' 0 CA--C 1.56 1.348 0 CA-C-O 121.982 0.896 . . . . 0.0 111.713 -178.06 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . 0.723 ' H ' HD22 ' A' ' 79' ' ' LEU . . . 104.58 -9.01 48.11 Favored Glycine 0 C--N 1.342 0.882 0 CA-C-N 115.29 -0.868 . . . . 0.0 112.867 177.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . 0.489 ' O ' ' HB3' ' A' ' 103' ' ' LYS . 54.6 m -151.21 124.25 8.7 Favored 'General case' 0 CA--C 1.547 0.854 0 CA-C-N 117.363 0.581 . . . . 0.0 110.314 -175.402 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' PHE . . . . . 0.635 ' HB3' ' HB3' ' A' ' 140' ' ' TYR . 27.4 t80 -96.35 133.66 40.45 Favored 'General case' 0 CA--C 1.545 0.786 0 O-C-N 121.461 -0.774 . . . . 0.0 110.075 176.244 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . 0.449 ' HB3' ' HE3' ' A' ' 144' ' ' TRP . 32.1 m170 -133.34 115.89 15.44 Favored 'General case' 0 N--CA 1.48 1.04 0 C-N-CA 124.113 0.965 . . . . 0.0 110.707 -178.48 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . 0.621 HG23 ' HB ' ' A' ' 138' ' ' ILE . 10.1 t -136.87 -176.39 4.35 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 122.749 0.42 . . . . 0.0 110.736 174.466 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' MET . . . . . 0.627 ' HA ' ' HA ' ' A' ' 137' ' ' LEU . 34.6 mtp -93.78 163.15 13.64 Favored 'General case' 0 C--O 1.24 0.558 0 C-N-CA 123.785 0.834 . . . . 0.0 111.098 169.626 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' TRP . . . . . 0.61 ' HA ' HG13 ' A' ' 138' ' ' ILE . 83.9 t90 -80.23 -38.36 31.19 Favored 'General case' 0 N--CA 1.475 0.804 0 C-N-CA 123.523 0.729 . . . . 0.0 111.62 -175.908 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . 0.434 ' CE1' ' SD ' ' A' ' 110' ' ' MET . 1.1 p-80 -64.07 -9.42 16.17 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 125.03 1.332 . . . . 0.0 113.933 -169.162 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 33.9 m -57.36 -36.4 52.62 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.911 0 O-C-N 123.471 0.482 . . . . 0.0 110.278 176.424 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -152.74 -151.6 0.39 Allowed 'General case' 0 CA--C 1.56 1.334 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 175.022 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 55.8 ttt85 -99.4 32.73 2.67 Favored 'General case' 0 CA--C 1.557 1.227 0 C-N-CA 123.64 0.776 . . . . 0.0 110.112 176.251 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.51 ' HA2' HD11 ' A' ' 138' ' ' ILE . . . 85.0 53.29 3.2 Favored Glycine 0 C--N 1.346 1.131 0 N-CA-C 111.848 -0.501 . . . . 0.0 111.848 -176.338 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -94.83 169.43 10.15 Favored 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 123.513 0.725 . . . . 0.0 112.251 -174.034 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.562 HG23 ' HA ' ' A' ' 127' ' ' GLU . 7.1 p -91.69 142.83 12.46 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.073 0 CA-C-N 114.962 -1.017 . . . . 0.0 111.281 -176.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.683 HD13 ' HB2' ' A' ' 6' ' ' LEU . 2.9 mm? -93.48 152.87 18.79 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 124.236 1.015 . . . . 0.0 110.779 -174.517 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' MET . . . . . 0.657 ' HE1' ' HG3' ' A' ' 125' ' ' ARG . 32.5 mmt -110.32 158.2 18.68 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 169.581 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . . . . . . . . . 80.3 t60 -161.95 96.54 1.01 Allowed 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 175.204 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.798 ' HG3' HG23 ' A' ' 64' ' ' VAL . 77.7 tttt 59.23 31.17 20.99 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 123.774 0.83 . . . . 0.0 111.085 176.088 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 101.63 -11.23 57.87 Favored Glycine 0 C--N 1.355 1.587 0 CA-C-N 115.945 -0.571 . . . . 0.0 113.553 -179.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 49.9 tttm -90.2 127.23 36.07 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 123.122 0.569 . . . . 0.0 109.612 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . 0.657 ' HG3' ' HE1' ' A' ' 120' ' ' MET . 28.2 ttm-85 -89.66 101.25 13.94 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 123.444 0.698 . . . . 0.0 109.518 179.0 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 68.7 mt -85.2 99.92 7.81 Favored 'Isoleucine or valine' 0 C--O 1.239 0.542 0 C-N-CA 123.837 0.855 . . . . 0.0 109.949 178.646 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . 0.562 ' HA ' HG23 ' A' ' 118' ' ' VAL . 0.3 OUTLIER -74.1 149.91 87.54 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.177 174.979 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_endo -79.59 152.95 23.18 Favored 'Trans proline' 0 C--N 1.366 1.499 0 C-N-CA 122.115 1.877 . . . . 0.0 111.8 167.587 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 95.3 p -89.36 -26.8 20.87 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 122.874 0.47 . . . . 0.0 110.131 171.744 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 74.7 t-105 -165.88 156.12 12.78 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 123.497 0.719 . . . . 0.0 109.665 179.344 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . 0.428 ' HB1' ' HD1' ' A' ' 111' ' ' TRP . . . -133.95 118.62 18.08 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.574 0.75 . . . . 0.0 109.024 172.664 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 22.5 t0 -90.09 104.41 16.98 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 124.288 1.035 . . . . 0.0 108.269 175.318 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 45.7 t -75.79 -26.79 18.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 122.929 0.492 . . . . 0.0 111.08 -176.428 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 26.6 mtpp -73.14 -51.47 17.79 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 123.351 0.661 . . . . 0.0 111.358 -175.158 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 42.8 mtpt -85.73 -4.14 59.08 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 115.45 -0.795 . . . . 0.0 111.554 -179.255 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 37.0 t0 65.22 56.77 0.98 Allowed 'General case' 0 CA--C 1.552 1.025 0 O-C-N 124.554 1.159 . . . . 0.0 109.621 175.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.627 ' HA ' ' HA ' ' A' ' 110' ' ' MET . 62.6 mt -143.49 137.58 28.62 Favored 'General case' 0 N--CA 1.478 0.958 0 O-C-N 121.482 -0.762 . . . . 0.0 110.329 -177.701 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.621 ' HB ' HG23 ' A' ' 109' ' ' THR . 84.8 mt -111.99 149.44 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.376 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 169.305 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . 0.421 ' HB2' ' O ' ' A' ' 142' ' ' GLY . 33.5 p -145.44 148.44 33.3 Favored 'General case' 0 C--O 1.241 0.65 0 C-N-CA 123.374 0.67 . . . . 0.0 110.519 -172.545 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.635 ' HB3' ' HB3' ' A' ' 107' ' ' PHE . 37.5 t80 -144.27 120.01 10.51 Favored 'General case' 0 N--CA 1.466 0.333 0 C-N-CA 124.662 1.185 . . . . 0.0 108.705 178.004 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 86.25 3.69 84.51 Favored Glycine 0 C--N 1.345 1.054 0 O-C-N 123.572 0.545 . . . . 0.0 112.725 -178.003 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . 0.421 ' O ' ' HB2' ' A' ' 139' ' ' SER . . . 147.28 148.82 4.83 Favored Glycine 0 C--N 1.344 0.995 0 N-CA-C 110.386 -1.085 . . . . 0.0 110.386 -177.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -67.83 169.71 37.88 Favored Glycine 0 C--N 1.348 1.234 0 C-N-CA 123.126 0.393 . . . . 0.0 112.608 -179.562 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' TRP . . . . . 0.644 ' HZ2' ' HA2' ' A' ' 209' ' ' GLY . 57.1 t-105 -58.43 105.54 0.3 Allowed 'General case' 0 CA--C 1.555 1.135 0 CA-C-O 121.209 0.528 . . . . 0.0 110.977 -177.517 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . 0.643 ' HA ' ' HB ' ' A' ' 229' ' ' THR . 50.1 tttm -163.82 126.97 2.59 Favored 'General case' 0 CA--C 1.54 0.562 0 CA-C-N 115.04 -0.982 . . . . 0.0 109.433 176.513 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' LEU . . . . . 0.444 ' H ' ' HB ' ' A' ' 229' ' ' THR . 79.5 mt -141.8 -2.74 1.17 Allowed 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 125.744 1.618 . . . . 0.0 110.219 179.727 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 29.2 tt0 86.69 18.53 0.09 Allowed 'General case' 0 N--CA 1.5 2.043 0 C-N-CA 125.355 1.462 . . . . 0.0 110.848 171.197 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.577 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -85.15 117.72 4.59 Favored Glycine 0 N--CA 1.434 -1.489 0 CA-C-N 115.376 -0.829 . . . . 0.0 113.466 173.578 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -116.04 95.12 4.95 Favored 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 124.06 0.944 . . . . 0.0 110.175 -175.311 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' TRP . . . . . 0.608 ' HZ2' ' HG3' ' A' ' 174' ' ' PRO . 35.8 t90 -82.86 146.97 28.6 Favored 'General case' 0 CA--C 1.553 1.095 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.27 168.313 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.414 ' HB3' ' HG2' ' A' ' 154' ' ' GLU . 22.5 tptp -112.67 128.79 56.49 Favored 'General case' 0 N--CA 1.476 0.841 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 177.095 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 5.1 mp0 -63.13 99.69 0.19 Allowed 'General case' 0 N--CA 1.483 1.221 0 C-N-CA 123.494 0.718 . . . . 0.0 111.059 -179.214 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 143.54 -23.25 2.18 Favored Glycine 0 C--N 1.341 0.851 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.345 -177.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . 0.414 ' HG2' ' HB3' ' A' ' 151' ' ' LYS . 32.7 mm-40 -75.91 133.58 40.48 Favored 'General case' 0 C--O 1.24 0.581 0 C-N-CA 123.324 0.65 . . . . 0.0 111.604 -179.452 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . 0.536 ' HG2' ' HG2' ' A' ' 173' ' ' LYS . 35.8 mt-10 -74.84 101.62 4.44 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 174.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 9.7 p -114.72 145.83 19.99 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 123.257 0.623 . . . . 0.0 109.577 -168.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . 0.5 ' HG2' ' HE1' ' A' ' 16' ' ' TRP . 1.8 mp0 -93.34 141.19 28.72 Favored 'General case' 0 C--O 1.217 -0.641 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 -172.541 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.465 ' O ' ' HA ' ' A' ' 169' ' ' ALA . 46.9 t -101.2 116.11 44.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 177.019 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -72.08 86.37 1.04 Allowed 'General case' 0 CA--C 1.548 0.869 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 176.647 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -88.44 139.13 30.8 Favored 'General case' 0 C--O 1.249 1.044 0 CA-C-N 114.181 -1.372 . . . . 0.0 110.738 -174.453 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . . . . . . . . . 35.2 mt -112.7 84.29 1.96 Allowed 'General case' 0 C--O 1.245 0.854 0 C-N-CA 124.718 1.207 . . . . 0.0 108.936 -178.891 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . 0.675 ' HB2' ' HB2' ' A' ' 165' ' ' LYS . 44.2 mt-10 -75.98 143.48 74.21 Favored Pre-proline 0 CA--C 1.547 0.855 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 176.183 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . 0.506 ' HD3' ' NH2' ' B' ' 254' ' ' ARG . 74.5 Cg_endo -70.35 114.12 3.69 Favored 'Trans proline' 0 C--N 1.374 1.897 0 C-N-CA 122.209 1.939 . . . . 0.0 110.591 -177.785 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 90.85 -11.24 72.54 Favored Glycine 0 C--N 1.34 0.76 0 CA-C-N 115.954 -0.566 . . . . 0.0 113.42 179.022 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . 0.675 ' HB2' ' HB2' ' A' ' 162' ' ' GLU . 47.5 mmtm -104.53 147.83 27.17 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 176.096 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -58.85 149.5 64.42 Favored Pre-proline 0 CA--C 1.554 1.111 0 O-C-N 123.553 0.533 . . . . 0.0 111.832 179.399 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo -56.56 118.09 4.87 Favored 'Trans proline' 0 C--N 1.376 1.994 0 C-N-CA 122.497 2.131 . . . . 0.0 110.348 171.442 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 16.0 ptt180 -135.25 134.09 39.64 Favored 'General case' 0 N--CA 1.47 0.556 0 CA-C-O 120.825 0.345 . . . . 0.0 110.202 -176.606 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . 0.487 ' H ' ' HB3' ' A' ' 17' ' ' GLU . . . -97.75 105.24 17.35 Favored 'General case' 0 C--O 1.225 -0.219 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.557 -177.691 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 27.7 m -97.64 133.63 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.234 0 C-N-CA 123.663 0.785 . . . . 0.0 110.125 -174.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . 0.42 ' HA ' ' HA ' ' A' ' 157' ' ' GLN . 37.3 tt0 -77.75 128.41 33.99 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-O 121.656 0.741 . . . . 0.0 110.328 -171.593 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . 0.583 HG21 HG13 ' A' ' 187' ' ' VAL . 68.7 m -128.08 123.3 34.21 Favored 'General case' 0 C--O 1.246 0.908 0 CA-C-N 113.842 -1.526 . . . . 0.0 109.448 -175.205 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . 0.546 ' HB2' ' HA ' ' A' ' 25' ' ' SER . 27.5 mtpp -76.15 141.61 70.95 Favored Pre-proline 0 CA--C 1.544 0.743 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 168.808 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . 0.608 ' HG3' ' HZ2' ' A' ' 150' ' ' TRP . 39.4 Cg_exo -55.37 122.95 12.64 Favored 'Trans proline' 0 C--N 1.371 1.74 0 C-N-CA 122.511 2.14 . . . . 0.0 113.66 -171.481 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . 0.484 ' H ' ' C ' ' A' ' 186' ' ' ALA . . . -117.26 127.33 7.34 Favored Glycine 0 N--CA 1.482 1.723 0 CA-C-O 121.606 0.559 . . . . 0.0 113.594 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.459 HD23 ' N ' ' A' ' 176' ' ' LEU . 0.4 OUTLIER -132.01 127.97 37.35 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 121.914 0.864 . . . . 0.0 109.52 -169.031 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 177' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -102.58 138.94 38.83 Favored 'General case' 0 C--O 1.245 0.86 0 CA-C-N 114.069 -1.423 . . . . 0.0 110.494 -169.505 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 58.5 tptt -86.0 124.89 32.95 Favored 'General case' 0 C--O 1.243 0.716 0 C-N-CA 124.585 1.154 . . . . 0.0 109.953 -178.552 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . 0.404 HG22 HG23 ' A' ' 31' ' ' ILE . 68.9 p -120.53 175.86 5.78 Favored 'General case' 0 C--O 1.242 0.697 0 C-N-CA 123.31 0.644 . . . . 0.0 109.612 169.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 -68.07 -21.37 64.98 Favored 'General case' 0 CA--C 1.546 0.806 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.206 172.694 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -78.65 -53.04 7.58 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 123.724 0.81 . . . . 0.0 110.301 176.011 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 177.48 176.97 45.98 Favored Glycine 0 C--N 1.344 0.999 0 CA-C-N 115.623 -0.717 . . . . 0.0 112.331 -178.742 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 15.5 m -93.91 104.32 16.38 Favored 'General case' 0 CA--C 1.542 0.663 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 176.421 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . 0.483 HD13 ' H ' ' A' ' 184' ' ' ILE . 0.2 OUTLIER -123.63 161.09 26.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 C-N-CA 123.455 0.702 . . . . 0.0 109.732 -174.122 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . 113.48 178.41 19.37 Favored Glycine 0 N--CA 1.47 0.912 0 CA-C-O 119.802 -0.443 . . . . 0.0 113.074 176.401 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.484 ' C ' ' H ' ' A' ' 175' ' ' GLY . . . -173.22 38.12 0.01 OUTLIER 'General case' 0 C--N 1.364 1.222 0 C-N-CA 123.75 0.82 . . . . 0.0 110.967 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 187' ' ' VAL . . . . . 0.583 HG13 HG21 ' A' ' 172' ' ' THR . 58.5 t -155.1 117.51 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 C-N-CA 125.146 1.378 . . . . 0.0 107.48 171.539 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . 0.546 ' HA ' HG12 ' A' ' 223' ' ' VAL . 68.4 m -129.83 86.2 2.38 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-O 121.877 0.846 . . . . 0.0 108.747 170.531 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 32.4 tp -106.38 103.77 13.31 Favored 'General case' 0 CA--C 1.543 0.687 0 CA-C-N 113.907 -1.497 . . . . 0.0 110.231 -173.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 190' ' ' ASP . . . . . 0.711 ' HA ' ' HA ' ' A' ' 221' ' ' ALA . 11.0 p-10 -90.52 102.04 14.78 Favored 'General case' 0 N--CA 1.478 0.934 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 175.348 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 191' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 179.41 -174.88 0.23 Allowed 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 125.981 1.713 . . . . 0.0 108.254 -174.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 9.5 m -51.19 119.89 13.25 Favored Pre-proline 0 CA--C 1.551 0.994 0 O-C-N 123.872 0.733 . . . . 0.0 109.801 172.627 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_exo -48.01 132.61 22.73 Favored 'Trans proline' 0 C--N 1.379 2.138 0 C-N-CA 123.471 2.781 . . . . 0.0 114.226 -171.024 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -67.0 167.18 39.37 Favored Glycine 0 C--N 1.348 1.232 0 CA-C-N 115.633 -0.712 . . . . 0.0 112.085 175.069 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 195' ' ' THR . . . . . 0.525 HG21 ' HG2' ' A' ' 85' ' ' ARG . 1.4 m -89.99 103.77 16.41 Favored 'General case' 0 CA--C 1.54 0.559 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -173.617 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 43.6 t -51.72 85.08 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.09 0 C-N-CA 125.285 1.434 . . . . 0.0 113.389 -170.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 126.03 16.01 2.74 Favored Glycine 0 C--N 1.355 1.586 0 CA-C-N 115.253 -0.885 . . . . 0.0 113.083 179.123 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 84.2 p -82.81 155.86 67.87 Favored Pre-proline 0 N--CA 1.483 1.21 0 CA-C-N 117.477 0.638 . . . . 0.0 110.156 178.082 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -74.15 142.64 31.02 Favored 'Trans proline' 0 C--N 1.386 2.535 0 C-N-CA 122.308 2.006 . . . . 0.0 113.157 -178.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 62.6 mt -108.59 113.57 44.37 Favored 'Isoleucine or valine' 0 C--O 1.255 1.36 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 175.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 201' ' ' ILE . . . . . 0.607 HG12 ' HA ' ' A' ' 208' ' ' VAL . 14.3 mt -117.24 134.95 59.19 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.085 0 CA-C-N 114.822 -1.081 . . . . 0.0 110.799 -167.445 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -68.37 162.82 24.5 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 125.06 1.344 . . . . 0.0 110.704 174.454 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 63.2 tttm -67.45 -15.54 63.73 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 124.6 1.16 . . . . 0.0 112.061 -173.049 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 21.6 ptmt -94.15 4.01 54.48 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 123.232 0.613 . . . . 0.0 112.147 177.387 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 80.41 38.87 16.39 Favored Glycine 0 C--N 1.351 1.393 0 C-N-CA 122.9 0.286 . . . . 0.0 112.856 -178.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 58.0 tttp -128.78 167.1 17.78 Favored 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 124.272 1.029 . . . . 0.0 109.758 -174.341 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.577 ' O ' ' HA3' ' A' ' 148' ' ' GLY . 89.5 t 95.64 -74.91 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.146 0 C-N-CA 125.719 1.608 . . . . 0.0 110.157 171.079 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 208' ' ' VAL . . . . . 0.607 ' HA ' HG12 ' A' ' 201' ' ' ILE . 3.2 m 63.1 22.37 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 CA-C-O 122.484 1.135 . . . . 0.0 109.787 166.414 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.644 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . -83.08 128.85 8.72 Favored Glycine 0 C--N 1.347 1.18 0 CA-C-N 113.376 -1.738 . . . . 0.0 109.353 -172.456 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . . . . . . . . . 87.4 mt -65.65 173.28 2.87 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-N 117.908 0.854 . . . . 0.0 111.287 -165.47 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 211' ' ' TYR . . . . . 0.457 ' CZ ' HG11 ' A' ' 158' ' ' VAL . 6.3 m-85 -56.56 157.78 4.97 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.824 163.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 212' ' ' GLY . . . . . 0.612 ' HA3' ' HB3' ' A' ' 225' ' ' ALA . . . -105.87 -141.18 10.38 Favored Glycine 0 C--O 1.24 0.492 0 N-CA-C 111.264 -0.735 . . . . 0.0 111.264 173.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 213' ' ' ASN . . . . . . . . . . . . . 23.5 p-10 -100.13 130.47 46.27 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 -176.327 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . -176.45 -135.96 2.27 Favored Glycine 0 C--N 1.337 0.617 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.962 176.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 215' ' ' VAL . . . . . 0.734 HG23 ' HD3' ' B' ' 253' ' ' LYS . 7.4 p 176.06 162.85 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 C-N-CA 125.415 1.486 . . . . 0.0 107.936 -171.485 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 216' ' ' VAL . . . . . 0.661 ' HA ' ' HA ' ' A' ' 222' ' ' TYR . 7.8 p -75.07 110.27 9.5 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.498 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 161.167 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 217' ' ' THR . . . . . 0.702 HG21 HD23 ' A' ' 29' ' ' LEU . 53.2 m -87.69 141.82 28.31 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.992 0.917 . . . . 0.0 110.19 -178.448 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 218' ' ' ARG . . . . . 0.46 ' HG3' HG22 ' A' ' 217' ' ' THR . 57.3 mtp180 62.71 8.6 3.09 Favored 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 124.093 0.957 . . . . 0.0 111.574 -175.047 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 68.0 m 62.75 26.31 15.55 Favored 'General case' 0 C--N 1.359 1.006 0 C-N-CA 124.734 1.214 . . . . 0.0 112.077 -176.224 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . -153.88 -19.4 0.05 OUTLIER Glycine 0 C--N 1.349 1.277 0 CA-C-N 116.637 -0.256 . . . . 0.0 113.653 179.29 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . 0.711 ' HA ' ' HA ' ' A' ' 190' ' ' ASP . . . -113.87 89.65 3.14 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 123.333 0.653 . . . . 0.0 109.757 -175.576 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 222' ' ' TYR . . . . . 0.661 ' HA ' ' HA ' ' A' ' 216' ' ' VAL . 50.2 t80 -69.15 118.2 11.75 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 123.149 0.58 . . . . 0.0 110.453 -177.45 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . 0.546 HG12 ' HA ' ' A' ' 188' ' ' SER . 21.5 m -123.05 145.43 29.95 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.731 0 C-N-CA 123.507 0.723 . . . . 0.0 110.687 -179.039 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 70.2 m -158.7 159.78 35.67 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 124.915 1.286 . . . . 0.0 108.757 178.483 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . 0.612 ' HB3' ' HA3' ' A' ' 212' ' ' GLY . . . -76.64 -169.06 1.14 Allowed 'General case' 0 N--CA 1.482 1.147 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 167.239 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 226' ' ' ILE . . . . . . . . . . . . . 54.9 mt -127.83 106.34 14.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.12 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 174.5 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -85.14 92.03 8.28 Favored 'General case' 0 C--O 1.239 0.551 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 177.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 20.1 pt20 -92.31 158.88 15.87 Favored 'General case' 0 N--CA 1.471 0.6 0 CA-C-N 115.248 -0.887 . . . . 0.0 108.813 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . 0.643 ' HB ' ' HA ' ' A' ' 145' ' ' LYS . 30.5 p -69.12 107.44 3.19 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-O 121.589 0.709 . . . . 0.0 110.738 -161.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -168.75 79.59 0.14 Allowed 'General case' 0 N--CA 1.451 -0.401 0 N-CA-C 106.366 -1.716 . . . . 0.0 106.366 -171.801 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 231' ' ' LYS . . . . . 0.413 ' HD3' ' H ' ' A' ' 144' ' ' TRP . 59.1 tttp -145.85 -78.82 0.18 Allowed 'General case' 0 N--CA 1.48 1.07 0 CA-C-N 115.912 -0.585 . . . . 0.0 112.297 167.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 68.0 p -93.37 -174.73 3.6 Favored 'General case' 0 N--CA 1.485 1.312 0 CA-C-N 118.884 0.765 . . . . 0.0 112.036 -174.098 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 233' ' ' ILE . . . . . . . . . . . . . 31.2 pt -123.15 13.17 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 C-N-CA 123.809 0.844 . . . . 0.0 109.475 167.123 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 234' ' ' GLU . . . . . . . . . . . . . 4.0 mp0 47.62 -86.84 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.36 0 C-N-CA 125.377 1.471 . . . . 0.0 111.139 -170.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 24.8 m-20 -141.48 0.82 1.51 Allowed 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 123.497 0.719 . . . . 0.0 112.06 -179.165 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 236' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -72.25 141.79 83.91 Favored Pre-proline 0 N--CA 1.482 1.152 0 CA-C-N 118.461 0.573 . . . . 0.0 110.003 179.517 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_exo -63.13 125.72 16.4 Favored 'Trans proline' 0 C--N 1.367 1.544 0 C-N-CA 122.41 2.074 . . . . 0.0 110.781 172.26 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 238' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -84.68 -23.87 29.23 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 123.47 0.708 . . . . 0.0 110.16 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 239' ' ' ILE . . . . . . . . . . . . . 3.6 mp 57.77 85.38 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.36 1.045 0 C-N-CA 125.014 1.325 . . . . 0.0 108.577 -170.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.248 1.004 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -173.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 251' ' ' BEZ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 253' ' ' LYS . . . . . 0.734 ' HD3' HG23 ' A' ' 215' ' ' VAL . 28.7 mmtp -138.71 -59.1 0.61 Allowed 'General case' 0 C--O 1.239 0.522 0 C-N-CA 124.703 1.201 . . . . 0.0 109.967 175.275 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 254' ' ' ARG . . . . . 0.506 ' NH2' ' HD3' ' A' ' 163' ' ' PRO . 16.8 mmt85 77.26 -49.8 0.53 Allowed 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 125.725 1.61 . . . . 0.0 109.282 -156.203 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 255' ' ' M9P . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.674 0 N-CA-C 111.795 -0.522 . . . . 0.0 111.795 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 70.4 m -139.55 134.08 31.67 Favored 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 123.836 0.854 . . . . 0.0 109.386 177.004 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.429 ' HB3' ' NE2' ' A' ' 88' ' ' GLN . . . -140.6 172.76 12.26 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 123.27 0.628 . . . . 0.0 110.674 -179.742 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -91.58 41.11 1.06 Allowed 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 124.186 0.994 . . . . 0.0 109.798 -171.415 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . 0.489 ' HA ' ' HG2' ' A' ' 120' ' ' MET . 7.1 m-20 -153.86 52.53 0.7 Allowed 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 -163.168 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.633 ' HB2' ' HG ' ' A' ' 119' ' ' LEU . 7.9 mt -95.18 89.36 5.49 Favored 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 177.113 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.707 ' HB3' ' HD2' ' A' ' 89' ' ' LYS . 11.8 pt-20 -78.7 147.26 33.55 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-O 121.446 0.641 . . . . 0.0 111.771 -173.63 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 41.9 mt -98.02 113.71 25.65 Favored 'General case' 0 C--O 1.238 0.489 0 CA-C-N 114.281 -1.327 . . . . 0.0 108.9 179.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -109.47 144.56 37.56 Favored 'General case' 0 N--CA 1.482 1.132 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 171.383 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 18.0 ttm-85 -69.24 129.09 38.85 Favored 'General case' 0 C--O 1.24 0.604 0 CA-C-O 121.169 0.509 . . . . 0.0 111.476 -173.09 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.593 ' HB2' ' HB2' ' A' ' 85' ' ' ARG . . . -103.21 -37.62 7.62 Favored 'General case' 0 C--O 1.239 0.531 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.13 178.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.428 ' HB3' ' HB3' ' A' ' 83' ' ' ALA . . . -165.87 170.3 13.96 Favored 'General case' 0 N--CA 1.474 0.733 0 CA-C-O 121.595 0.712 . . . . 0.0 111.456 -176.523 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -111.55 145.94 38.21 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 171.074 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 59.7 t -74.26 97.75 1.09 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.919 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 -179.29 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 24.1 ttmm -175.13 111.66 0.13 Allowed 'General case' 0 C--O 1.239 0.507 0 C-N-CA 125.615 1.566 . . . . 0.0 107.271 178.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . 0.513 ' HE1' ' HB1' ' A' ' 169' ' ' ALA . 34.7 t90 -93.5 95.01 8.99 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 122.086 0.155 . . . . 0.0 111.07 -178.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -159.68 64.36 0.37 Allowed 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 148.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -89.61 -62.06 1.56 Allowed 'General case' 0 N--CA 1.481 1.111 0 CA-C-O 121.242 0.544 . . . . 0.0 112.192 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . 0.494 ' H ' ' HB3' ' A' ' 169' ' ' ALA . 23.0 mt-30 -150.88 47.74 0.86 Allowed 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 124.203 1.001 . . . . 0.0 109.606 -168.575 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -48.77 95.42 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 113.556 0.947 . . . . 0.0 113.556 -172.368 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -136.48 164.5 28.01 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 125.631 1.572 . . . . 0.0 108.864 -177.532 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.606 HG22 ' HB2' ' A' ' 171' ' ' GLN . 0.2 OUTLIER -122.57 140.3 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.242 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 177.464 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 63.1 m -139.84 -57.82 0.56 Allowed 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -68.93 118.67 9.04 Favored Glycine 0 C--N 1.349 1.28 0 N-CA-C 114.469 0.547 . . . . 0.0 114.469 -168.628 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 68.0 m -164.31 24.32 0.07 Allowed 'General case' 0 CA--C 1.549 0.942 0 C-N-CA 124.864 1.266 . . . . 0.0 109.572 -173.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.629 ' HB2' ' HB2' ' A' ' 188' ' ' SER . 18.4 m -73.88 161.53 78.19 Favored Pre-proline 0 CA--C 1.555 1.163 0 C-N-CA 123.323 0.649 . . . . 0.0 110.701 -177.549 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_exo -71.77 -173.68 1.09 Allowed 'Trans proline' 0 C--N 1.378 2.1 0 C-N-CA 122.471 2.114 . . . . 0.0 112.874 174.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.55 HD12 ' HB2' ' A' ' 176' ' ' LEU . 27.3 mm -76.14 140.91 16.49 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.461 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.406 ' HB3' HG21 ' A' ' 217' ' ' THR . 14.0 mt -131.07 132.24 44.76 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 122.796 0.438 . . . . 0.0 111.605 -168.734 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 178' ' ' LYS . 49.3 m -69.97 135.15 49.1 Favored 'General case' 0 C--N 1.35 0.62 0 O-C-N 124.098 0.874 . . . . 0.0 111.096 179.493 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 19.6 tt -142.62 141.26 27.79 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.744 0 C-N-CA 123.829 0.852 . . . . 0.0 109.205 -177.655 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 56.0 p -99.42 109.6 22.16 Favored 'General case' 0 CA--C 1.555 1.154 0 C-N-CA 123.24 0.616 . . . . 0.0 110.168 -176.546 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 1.5 mp -80.75 120.31 32.1 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 C-N-CA 123.687 0.795 . . . . 0.0 109.038 176.33 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 26.0 m -97.71 122.78 41.19 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 124.254 1.022 . . . . 0.0 110.094 -178.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 67.57 12.4 8.86 Favored 'General case' 0 N--CA 1.493 1.677 0 C-N-CA 124.358 1.063 . . . . 0.0 112.383 171.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 61.73 24.86 14.88 Favored 'General case' 0 N--CA 1.491 1.618 0 C-N-CA 124.436 1.094 . . . . 0.0 112.113 -177.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -143.03 -42.97 0.05 OUTLIER Glycine 0 C--N 1.338 0.683 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 -178.712 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 39.4 t -93.66 162.93 13.75 Favored 'General case' 0 C--O 1.241 0.609 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 175.092 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 20.9 ptm -161.73 134.77 6.18 Favored 'General case' 0 C--O 1.241 0.609 0 C-N-CA 122.829 0.452 . . . . 0.0 110.065 -175.694 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 28.5 p -173.26 -179.07 1.86 Allowed 'General case' 0 C--O 1.221 -0.43 0 C-N-CA 123.786 0.835 . . . . 0.0 109.422 179.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.755 HD11 HG23 ' A' ' 217' ' ' THR . 28.3 mm -72.12 151.03 8.46 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.971 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 165.593 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 15.3 ptmt -42.62 140.0 1.41 Allowed 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 124.968 1.307 . . . . 0.0 112.104 171.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 65.07 85.57 0.14 Allowed 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 124.999 1.319 . . . . 0.0 108.952 -160.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -86.18 26.91 0.97 Allowed 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 123.86 0.864 . . . . 0.0 113.125 -169.156 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -56.1 134.94 53.06 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 123.671 0.788 . . . . 0.0 110.772 172.461 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -82.61 173.86 11.56 Favored 'General case' 0 N--CA 1.482 1.157 0 C-N-CA 123.931 0.893 . . . . 0.0 112.003 -174.258 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -144.59 142.07 29.89 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 124.158 0.983 . . . . 0.0 109.708 174.735 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 17.7 pt20 -155.09 -179.43 8.06 Favored 'General case' 0 N--CA 1.479 1.02 0 C-N-CA 123.998 0.919 . . . . 0.0 109.341 176.24 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.491 HG22 HE21 ' A' ' 96' ' ' GLN . 15.4 t -165.26 175.07 9.55 Favored 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 122.817 0.447 . . . . 0.0 110.239 -179.49 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 34.4 tp -60.94 133.72 56.38 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.673 0.789 . . . . 0.0 110.449 176.677 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.53 -162.59 35.02 Favored Glycine 0 C--N 1.34 0.788 0 O-C-N 123.508 0.505 . . . . 0.0 112.971 177.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 91.65 36.9 6.29 Favored Glycine 0 C--N 1.337 0.629 0 C-N-CA 123.069 0.366 . . . . 0.0 112.336 -179.117 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -77.96 63.64 3.49 Favored Glycine 0 C--N 1.353 1.479 0 C-N-CA 123.372 0.511 . . . . 0.0 112.291 -178.717 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -167.93 151.5 18.79 Favored Glycine 0 C--O 1.246 0.882 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -178.509 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 32.7 t -68.88 121.1 15.88 Favored 'General case' 0 CA--C 1.544 0.725 0 C-N-CA 123.042 0.537 . . . . 0.0 110.342 -176.628 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 126.09 -27.19 5.14 Favored Glycine 0 C--N 1.343 0.924 0 N-CA-C 111.31 -0.716 . . . . 0.0 111.31 -177.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 126.24 -29.41 4.57 Favored Glycine 0 C--N 1.353 1.481 0 CA-C-O 119.906 -0.385 . . . . 0.0 112.645 178.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 62.4 49.76 71.03 Favored Glycine 0 C--N 1.353 1.502 0 C-N-CA 123.48 0.562 . . . . 0.0 113.692 175.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -120.04 -140.73 6.18 Favored Glycine 0 N--CA 1.472 1.048 0 N-CA-C 112.115 -0.394 . . . . 0.0 112.115 -179.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 19.5 tp10 -108.54 89.67 3.06 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 123.522 0.729 . . . . 0.0 109.324 -179.502 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 5.5 p90 -121.54 80.15 1.64 Allowed 'General case' 0 CA--C 1.543 0.707 0 CA-C-N 114.946 -1.025 . . . . 0.0 109.099 -179.269 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . 61.5 26.42 16.16 Favored 'General case' 0 N--CA 1.481 1.119 0 C-N-CA 124.339 1.055 . . . . 0.0 111.491 -175.161 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.511 ' HA3' ' HG3' ' A' ' 122' ' ' LYS . . . 99.39 179.16 31.22 Favored Glycine 0 C--N 1.353 1.507 0 CA-C-N 115.614 -0.721 . . . . 0.0 113.722 -178.854 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.414 ' HB ' ' H ' ' A' ' 65' ' ' LEU . 4.6 t -92.67 -92.66 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.556 1.176 0 C-N-CA 124.724 1.21 . . . . 0.0 110.194 177.761 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.461 ' N ' ' HD2' ' A' ' 122' ' ' LYS . 24.0 tp -167.98 132.34 1.74 Allowed 'General case' 0 C--N 1.37 1.464 0 C-N-CA 123.928 0.891 . . . . 0.0 109.563 -177.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 18.1 m0 -96.93 175.17 6.43 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 123.91 0.884 . . . . 0.0 111.898 -178.73 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.531 ' HB2' HD23 ' A' ' 79' ' ' LEU . 33.9 t70 -93.45 82.14 4.42 Favored 'General case' 0 N--CA 1.478 0.973 0 CA-C-N 115.229 -0.896 . . . . 0.0 108.934 170.004 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 35.8 m -92.37 147.39 34.37 Favored Pre-proline 0 CA--C 1.549 0.916 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.162 -175.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -60.66 83.85 0.08 OUTLIER 'Trans proline' 0 C--N 1.377 2.051 0 C-N-CA 122.53 2.153 . . . . 0.0 111.206 169.62 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 22.2 t -91.13 123.41 64.52 Favored Pre-proline 0 CA--C 1.541 0.608 0 C-N-CA 123.925 0.89 . . . . 0.0 110.084 -174.108 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -56.92 151.21 50.54 Favored 'Trans proline' 0 C--N 1.374 1.916 0 C-N-CA 122.932 2.421 . . . . 0.0 112.413 177.24 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 88.9 Cg_exo -44.58 -45.85 12.74 Favored 'Trans proline' 0 CA--C 1.572 2.401 0 C-N-CA 123.853 3.035 . . . . 0.0 116.899 -175.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_exo -65.02 -31.34 55.66 Favored 'Trans proline' 0 C--N 1.397 3.131 0 CA-C-N 121.999 1.75 . . . . 0.0 113.367 176.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 23.5 t -86.21 -36.95 11.15 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.918 0 C-N-CA 123.587 0.755 . . . . 0.0 111.084 -173.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -64.13 133.4 39.71 Favored Glycine 0 C--N 1.35 1.357 0 O-C-N 124.015 0.822 . . . . 0.0 114.119 -170.627 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 60.2 mttm -130.64 -82.89 0.54 Allowed 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 122.843 0.457 . . . . 0.0 110.398 -173.392 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -166.31 27.33 0.04 OUTLIER 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 123.9 0.88 . . . . 0.0 109.657 -170.67 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -57.21 -23.54 48.55 Favored 'General case' 0 N--CA 1.491 1.615 0 C-N-CA 125.699 1.6 . . . . 0.0 114.904 -164.164 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.531 HD23 ' HB2' ' A' ' 67' ' ' ASP . 12.2 tp -173.67 -37.41 0.01 OUTLIER 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 105.625 -1.991 . . . . 0.0 105.625 173.627 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -44.43 83.17 0.0 OUTLIER 'General case' 0 CA--C 1.552 1.054 0 CA-C-N 112.579 -2.1 . . . . 0.0 111.901 154.737 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.534 ' H ' ' HA ' ' A' ' 103' ' ' LYS . 4.5 m-20 61.21 71.13 0.57 Allowed 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 124.345 1.058 . . . . 0.0 110.923 179.689 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -129.23 137.97 9.94 Favored Glycine 0 C--N 1.338 0.66 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 174.835 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . 0.428 ' HB3' ' HB3' ' A' ' 12' ' ' ALA . . . -89.21 120.64 30.76 Favored 'General case' 0 C--O 1.235 0.299 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 178.544 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 47.6 m-85 -112.55 171.47 7.5 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-O 121.603 0.716 . . . . 0.0 111.127 -176.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . 0.593 ' HB2' ' HB2' ' A' ' 11' ' ' ALA . 44.4 ttm105 -131.77 122.83 26.48 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 -177.104 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.465 ' H ' ' HA ' ' A' ' 99' ' ' ALA . 24.5 mt -83.29 133.18 29.67 Favored 'Isoleucine or valine' 0 C--O 1.233 0.217 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 -175.856 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.597 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 76.8 tttt -137.88 131.18 30.61 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 114.743 -1.117 . . . . 0.0 108.405 -170.205 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . 0.429 ' NE2' ' HB3' ' A' ' 3' ' ' ALA . 0.0 OUTLIER -82.55 130.11 35.05 Favored 'General case' 0 C--O 1.245 0.822 0 N-CA-C 106.753 -1.573 . . . . 0.0 106.753 176.315 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . 0.707 ' HD2' ' HB3' ' A' ' 7' ' ' GLU . 48.3 tttp -123.11 135.72 54.49 Favored 'General case' 0 CA--C 1.549 0.914 0 CA-C-N 114.573 -1.194 . . . . 0.0 112.264 -162.024 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . 0.55 ' O ' ' HG2' ' A' ' 89' ' ' LYS . . . -91.83 162.11 27.43 Favored Glycine 0 C--O 1.207 -1.569 0 N-CA-C 106.464 -2.654 . . . . 0.0 106.464 149.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 31.1 mm -54.99 -18.74 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.195 0 CA-C-N 121.333 2.566 . . . . 0.0 114.47 -167.444 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 66.5 mt -86.1 -38.21 18.02 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.385 -0.822 . . . . 0.0 110.464 167.524 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.444 ' HA2' ' HG3' ' A' ' 89' ' ' LYS . . . 145.29 -167.63 27.36 Favored Glycine 0 N--CA 1.477 1.399 0 CA-C-O 118.348 -1.251 . . . . 0.0 110.381 176.608 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . 0.583 ' H ' ' HE2' ' A' ' 87' ' ' LYS 0.285 3.0 p90 178.68 -79.51 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.728 0 C-N-CA 123.838 0.855 . . . . 0.0 112.276 146.488 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 93.6 p -117.45 135.07 54.16 Favored 'General case' 0 N--CA 1.504 2.246 0 CA-C-N 120.384 1.447 . . . . 0.0 112.444 -161.328 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.597 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 5.1 pp0? -81.58 148.48 29.09 Favored 'General case' 0 N--CA 1.485 1.317 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 177.109 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 26.0 pt -133.18 -28.6 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 C-N-CA 123.354 0.662 . . . . 0.0 112.037 -171.758 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -167.41 -155.38 9.15 Favored Glycine 0 C--N 1.344 1.012 0 CA-C-O 119.803 -0.443 . . . . 0.0 112.237 -176.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.545 ' HA ' ' HA ' ' A' ' 85' ' ' ARG . . . -154.96 171.97 18.85 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 123.544 0.738 . . . . 0.0 110.507 -178.24 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -178.92 151.42 10.3 Favored Glycine 0 C--N 1.347 1.151 0 O-C-N 123.135 0.272 . . . . 0.0 112.594 179.487 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.446 HG12 HD11 ' A' ' 210' ' ' LEU . 14.9 p -89.15 138.17 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 122.93 0.492 . . . . 0.0 109.908 179.671 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -118.28 138.63 52.24 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 170.43 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.534 ' HA ' ' H ' ' A' ' 81' ' ' ASP . 64.4 tttp -135.14 105.9 6.53 Favored 'General case' 0 C--O 1.238 0.472 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 176.395 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 29.3 mt-10 63.39 -87.14 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.167 0 C-N-CA 125.031 1.332 . . . . 0.0 112.251 171.516 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -126.11 11.05 7.33 Favored Glycine 0 C--N 1.349 1.27 0 CA-C-O 120.163 -0.243 . . . . 0.0 113.025 -176.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 15.2 t -132.89 131.36 40.85 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 122.96 0.504 . . . . 0.0 110.094 -177.317 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 30.9 t80 -115.49 131.56 56.89 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 123.258 0.623 . . . . 0.0 109.805 -175.322 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 80.7 m-70 -135.15 123.5 23.22 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 123.058 0.543 . . . . 0.0 110.56 -177.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . 0.682 HG23 HG23 ' A' ' 138' ' ' ILE . 1.9 t -139.35 175.24 9.73 Favored 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 123.245 0.618 . . . . 0.0 111.911 -179.324 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' MET . . . . . . . . . . . . . 8.0 mmt -75.07 150.1 38.97 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 124.36 1.064 . . . . 0.0 109.561 172.212 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' TRP . . . . . 0.413 ' HA ' HG22 ' A' ' 138' ' ' ILE . 76.0 t90 -78.89 -43.98 23.75 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 123.071 0.549 . . . . 0.0 111.854 -169.282 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -65.76 -6.58 12.17 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 114.312 1.227 . . . . 0.0 114.312 -172.273 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 19.7 m -60.35 -40.4 83.85 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 176.455 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 90.0 m -164.5 140.0 5.82 Favored 'General case' 0 CA--C 1.551 1.017 0 C-N-CA 126.287 1.835 . . . . 0.0 107.396 171.299 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 32.8 mtt180 -80.85 33.08 0.32 Allowed 'General case' 0 N--CA 1.485 1.305 0 N-CA-C 114.152 1.167 . . . . 0.0 114.152 -166.45 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 107.27 62.15 0.57 Allowed Glycine 0 C--N 1.346 1.091 0 O-C-N 122.085 -0.384 . . . . 0.0 112.656 178.225 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -122.78 168.23 12.5 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 123.441 0.696 . . . . 0.0 110.064 174.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 87.9 t -75.44 144.43 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.802 0 C-N-CA 123.99 0.916 . . . . 0.0 110.96 -177.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.735 ' HB2' ' HB ' ' A' ' 126' ' ' ILE . 5.2 mp -111.16 161.17 16.23 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 123.077 0.551 . . . . 0.0 111.831 178.853 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' MET . . . . . 0.489 ' HG2' ' HA ' ' A' ' 5' ' ' ASP . 19.6 mmt -110.7 106.99 16.4 Favored 'General case' 0 C--O 1.241 0.619 0 CA-C-O 121.935 0.874 . . . . 0.0 110.1 179.191 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.558 ' HB2' HD11 ' A' ' 126' ' ' ILE . 13.9 t60 -104.13 95.07 5.73 Favored 'General case' 0 CA--C 1.542 0.663 0 N-CA-C 107.929 -1.137 . . . . 0.0 107.929 169.17 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.511 ' HG3' ' HA3' ' A' ' 63' ' ' GLY . 65.5 tttp 44.43 65.31 1.08 Allowed 'General case' 0 CA--C 1.554 1.115 0 C-N-CA 124.893 1.277 . . . . 0.0 112.76 176.109 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 80.73 -27.29 2.98 Favored Glycine 0 CA--C 1.531 1.076 0 CA-C-N 115.047 -0.979 . . . . 0.0 113.881 -179.576 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 94.7 mttt -85.36 154.34 21.94 Favored 'General case' 0 C--N 1.35 0.598 0 CA-C-N 117.395 0.598 . . . . 0.0 109.476 179.124 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 33.8 ptt85 -92.22 160.34 15.21 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-O 121.008 0.432 . . . . 0.0 110.367 178.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.735 ' HB ' ' HB2' ' A' ' 119' ' ' LEU . 80.8 mt -128.52 111.46 23.75 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 107.388 -1.338 . . . . 0.0 107.388 171.709 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -93.81 108.66 36.32 Favored Pre-proline 0 CA--C 1.546 0.818 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 178.7 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -56.7 103.65 0.13 Allowed 'Trans proline' 0 C--N 1.377 2.072 0 C-N-CA 122.884 2.389 . . . . 0.0 112.193 -178.42 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 86.5 p -74.9 -17.23 60.61 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 123.173 0.589 . . . . 0.0 111.277 -177.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 30.4 t-105 -143.26 149.92 38.55 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 -178.663 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -166.59 120.41 1.07 Allowed 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 122.98 0.512 . . . . 0.0 110.72 176.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -120.99 120.83 36.56 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 124.077 0.951 . . . . 0.0 109.265 171.643 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.493 HG13 ' HG3' ' A' ' 134' ' ' LYS . 4.6 p -69.05 -38.97 79.02 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 CA-C-N 114.657 -1.156 . . . . 0.0 111.844 -178.473 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.493 ' HG3' HG13 ' A' ' 133' ' ' VAL . 97.1 mttt -82.52 -27.95 31.39 Favored 'General case' 0 N--CA 1.478 0.972 0 C-N-CA 123.307 0.643 . . . . 0.0 112.218 -173.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . 0.508 ' HB3' HD12 ' A' ' 137' ' ' LEU . 33.5 mmtp -71.83 -27.74 63.1 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 109.908 -0.404 . . . . 0.0 109.908 167.661 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . 0.497 ' HB3' HD22 ' A' ' 213' ' ' ASN . 8.9 t70 56.64 58.61 4.03 Favored 'General case' 0 CA--C 1.538 0.494 0 O-C-N 125.27 1.606 . . . . 0.0 109.37 -167.878 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.508 HD12 ' HB3' ' A' ' 135' ' ' LYS . 6.6 mt -144.1 121.98 12.0 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 113.6 -1.637 . . . . 0.0 109.223 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.682 HG23 HG23 ' A' ' 109' ' ' THR . 9.2 tt -121.85 133.32 68.6 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 174.16 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 73.4 m -146.6 165.51 29.29 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-O 122.138 0.97 . . . . 0.0 112.575 -169.798 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 46.4 t80 -133.44 128.69 36.02 Favored 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 125.778 1.631 . . . . 0.0 107.764 175.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 102.29 -4.01 51.3 Favored Glycine 0 C--N 1.345 1.029 0 O-C-N 123.671 0.607 . . . . 0.0 112.324 -175.363 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 147.17 -165.58 28.58 Favored Glycine 0 C--N 1.349 1.272 0 N-CA-C 111.392 -0.683 . . . . 0.0 111.392 179.324 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -77.95 -173.64 41.34 Favored Glycine 0 C--N 1.353 1.501 0 CA-C-O 118.98 -0.9 . . . . 0.0 111.059 172.42 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' TRP . . . . . 0.529 ' HZ2' ' HA2' ' A' ' 209' ' ' GLY . 5.1 t-105 -55.0 108.01 0.36 Allowed 'General case' 0 N--CA 1.477 0.909 0 CA-C-N 118.267 1.033 . . . . 0.0 109.986 176.856 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 30.7 tptt -144.5 133.35 22.49 Favored 'General case' 0 CA--C 1.538 0.488 0 CA-C-N 113.725 -1.579 . . . . 0.0 107.617 -174.463 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' LEU . . . . . . . . . . . . . 32.9 tp -153.37 -86.75 0.06 Allowed 'General case' 0 CA--C 1.534 0.345 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 174.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 161.31 38.23 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.078 0 C-N-CA 125.362 1.465 . . . . 0.0 109.384 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -126.29 119.78 3.52 Favored Glycine 0 C--N 1.336 0.583 0 CA-C-N 115.879 -0.6 . . . . 0.0 113.279 -172.234 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 5.0 mp0 -113.78 100.34 8.38 Favored 'General case' 0 N--CA 1.474 0.751 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 179.457 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' TRP . . . . . 0.483 ' HZ2' ' HG3' ' A' ' 174' ' ' PRO . 28.8 t90 -71.28 130.23 40.88 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 174.752 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 18.2 ttmm -87.29 106.87 18.22 Favored 'General case' 0 C--O 1.242 0.673 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 176.184 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -62.19 104.14 0.45 Allowed 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 124.122 0.969 . . . . 0.0 111.688 -173.155 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 141.68 -38.15 1.53 Allowed Glycine 0 C--N 1.347 1.176 0 CA-C-N 116.58 -0.282 . . . . 0.0 112.989 178.026 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 -72.51 152.9 41.62 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 123.054 0.542 . . . . 0.0 111.805 -178.338 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -69.73 120.06 14.92 Favored 'General case' 0 C--O 1.244 0.786 0 N-CA-C 108.258 -1.015 . . . . 0.0 108.258 169.042 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.51 HG21 HG21 ' A' ' 208' ' ' VAL . 8.9 p -119.17 151.31 21.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.474 0 N-CA-C 108.974 -0.751 . . . . 0.0 108.974 -173.292 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . 0.44 ' HA ' ' HA ' ' A' ' 171' ' ' GLN . 0.0 OUTLIER -99.77 141.05 33.09 Favored 'General case' 0 N--CA 1.478 0.954 0 CA-C-O 121.081 0.467 . . . . 0.0 110.704 -168.779 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 89.7 t -117.6 131.35 70.59 Favored 'Isoleucine or valine' 0 C--O 1.245 0.825 0 C-N-CA 124.075 0.95 . . . . 0.0 108.444 170.258 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.401 HD12 ' HG2' ' A' ' 199' ' ' PRO . 44.6 mt -73.8 86.99 1.73 Allowed 'General case' 0 CA--C 1.544 0.717 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 171.356 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . 0.586 ' HB3' ' HB2' ' A' ' 168' ' ' ARG . . . -64.13 98.61 0.23 Allowed 'General case' 0 CA--C 1.545 0.781 0 C-N-CA 123.357 0.663 . . . . 0.0 110.82 -176.882 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . 0.645 ' H ' ' HA2' ' A' ' 194' ' ' GLY . 71.6 mt -70.78 88.22 0.72 Allowed 'General case' 0 C--O 1.241 0.631 0 C-N-CA 124.549 1.139 . . . . 0.0 111.229 -173.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -85.34 119.08 71.96 Favored Pre-proline 0 CA--C 1.553 1.09 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.316 174.326 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_exo -59.0 115.78 2.8 Favored 'Trans proline' 0 C--N 1.379 2.167 0 C-N-CA 123.115 2.543 . . . . 0.0 113.322 -176.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 113.79 -15.26 21.7 Favored Glycine 0 N--CA 1.471 0.969 0 CA-C-O 119.348 -0.695 . . . . 0.0 113.663 174.073 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -123.21 -169.62 1.97 Allowed 'General case' 0 C--N 1.355 0.814 0 CA-C-N 117.63 0.715 . . . . 0.0 109.787 -177.249 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 -70.46 162.24 71.62 Favored Pre-proline 0 CA--C 1.563 1.445 0 CA-C-N 114.695 -1.139 . . . . 0.0 109.359 161.482 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_exo -71.17 135.54 27.34 Favored 'Trans proline' 0 C--N 1.365 1.414 0 C-N-CA 121.95 1.767 . . . . 0.0 111.934 172.284 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . 0.586 ' HB2' ' HB3' ' A' ' 160' ' ' ALA . 85.7 mtt180 -70.88 109.26 4.93 Favored 'General case' 0 CA--C 1.546 0.801 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 171.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . 0.513 ' HB1' ' HE1' ' A' ' 16' ' ' TRP . . . -75.78 102.11 5.33 Favored 'General case' 0 N--CA 1.474 0.725 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -179.483 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.443 HG21 ' CE2' ' A' ' 191' ' ' PHE . 40.6 t -120.99 116.3 49.41 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 C-N-CA 122.52 0.328 . . . . 0.0 111.158 -170.02 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . 0.606 ' HB2' HG22 ' A' ' 22' ' ' ILE . 26.6 mt-30 -83.91 142.41 30.58 Favored 'General case' 0 C--O 1.243 0.751 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 173.565 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 5.6 t -152.38 136.28 16.34 Favored 'General case' 0 C--O 1.242 0.694 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.652 -168.736 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . 0.501 ' HD3' ' HD2' ' A' ' 174' ' ' PRO . 4.5 tppp? -72.33 126.04 91.17 Favored Pre-proline 0 CA--C 1.543 0.696 0 C-N-CA 123.557 0.743 . . . . 0.0 109.554 175.471 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . 0.501 ' HD2' ' HD3' ' A' ' 173' ' ' LYS . 9.2 Cg_endo -48.05 139.14 21.04 Favored 'Trans proline' 0 C--N 1.374 1.912 0 C-N-CA 123.739 2.96 . . . . 0.0 113.475 172.689 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . 0.695 ' H ' ' HA ' ' A' ' 187' ' ' VAL . . . -118.09 -172.77 15.84 Favored Glycine 0 C--O 1.237 0.293 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 175.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.55 ' HB2' HD12 ' A' ' 28' ' ' ILE . 5.5 mp -138.47 152.36 48.24 Favored 'General case' 0 N--CA 1.479 0.983 0 CA-C-N 117.8 0.8 . . . . 0.0 110.11 178.588 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 177' ' ' PHE . . . . . 0.652 ' HB2' ' HB ' ' A' ' 184' ' ' ILE . 35.7 m-85 -92.18 123.58 35.63 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.531 0.732 . . . . 0.0 109.85 176.571 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 178' ' ' LYS . . . . . 0.409 ' O ' ' HA ' ' A' ' 30' ' ' SER . 23.8 ttmm -86.57 94.87 9.56 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 172.383 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 63.0 m -103.1 153.68 20.05 Favored 'General case' 0 CA--C 1.545 0.778 0 C-N-CA 123.469 0.708 . . . . 0.0 110.621 -173.536 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 7.0 t30 -80.14 64.93 5.12 Favored 'General case' 0 N--CA 1.48 1.044 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 173.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -175.47 -38.83 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.749 0 C-N-CA 125.569 1.548 . . . . 0.0 108.706 -176.495 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 170.49 -144.17 8.23 Favored Glycine 0 C--N 1.341 0.86 0 CA-C-N 114.862 -1.063 . . . . 0.0 111.143 -178.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 10.2 m -127.13 131.87 50.7 Favored 'General case' 0 CA--C 1.548 0.866 0 C-N-CA 123.319 0.648 . . . . 0.0 109.546 179.075 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . 0.652 ' HB ' ' HB2' ' A' ' 177' ' ' PHE . 31.4 mt -107.16 163.28 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 C-N-CA 124.152 0.981 . . . . 0.0 108.561 -179.537 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -99.89 132.34 10.9 Favored Glycine 0 N--CA 1.478 1.488 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.677 ' HA ' ' HA ' ' A' ' 225' ' ' ALA . . . -154.51 -159.02 0.91 Allowed 'General case' 0 N--CA 1.474 0.751 0 CA-C-O 121.083 0.468 . . . . 0.0 112.105 -164.122 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 187' ' ' VAL . . . . . 0.695 ' HA ' ' H ' ' A' ' 175' ' ' GLY . 10.4 p -149.25 135.46 12.18 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 C-N-CA 123.98 0.912 . . . . 0.0 108.731 167.446 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . 0.629 ' HB2' ' HB2' ' A' ' 26' ' ' SER . 11.9 p -106.38 101.87 11.31 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 123.679 0.792 . . . . 0.0 110.009 -173.322 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 189' ' ' LEU . . . . . . . . . . . . . 65.5 tp -127.15 109.95 12.39 Favored 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 123.969 0.908 . . . . 0.0 110.786 -168.525 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 190' ' ' ASP . . . . . 0.48 ' HA ' ' HA ' ' A' ' 221' ' ' ALA . 13.5 p-10 -96.25 102.74 14.57 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 167.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 191' ' ' PHE . . . . . 0.443 ' CE2' HG21 ' A' ' 170' ' ' VAL . 50.5 t80 179.68 174.96 0.79 Allowed 'General case' 0 CA--C 1.551 0.985 0 CA-C-N 114.985 -1.007 . . . . 0.0 108.541 -168.117 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 33.6 m -86.87 96.17 0.51 Allowed Pre-proline 0 CA--C 1.554 1.114 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 169.548 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . 0.457 ' HG3' ' HB2' ' A' ' 222' ' ' TYR . 10.0 Cg_endo -93.1 -164.76 0.12 Allowed 'Trans proline' 0 C--N 1.373 1.828 0 C-N-CA 123.266 2.644 . . . . 0.0 114.055 -165.587 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 194' ' ' GLY . . . . . 0.645 ' HA2' ' H ' ' A' ' 161' ' ' LEU . . . -82.11 153.73 32.71 Favored Glycine 0 C--N 1.35 1.32 0 CA-C-N 115.053 -0.976 . . . . 0.0 112.793 176.395 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 2.8 m -70.87 155.08 41.24 Favored 'General case' 0 CA--C 1.554 1.128 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 174.201 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 4.1 m -63.67 87.41 0.04 OUTLIER 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 123.493 0.717 . . . . 0.0 112.428 -168.405 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 134.35 17.81 0.96 Allowed Glycine 0 N--CA 1.469 0.883 0 CA-C-N 114.797 -1.092 . . . . 0.0 111.823 -175.43 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 42.6 t -62.09 138.31 95.86 Favored Pre-proline 0 CA--C 1.545 0.762 0 C-N-CA 124.777 1.231 . . . . 0.0 111.388 177.246 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . 0.401 ' HG2' HD12 ' A' ' 159' ' ' LEU . 74.1 Cg_endo -71.9 129.79 15.86 Favored 'Trans proline' 0 C--N 1.37 1.71 0 C-N-CA 122.039 1.826 . . . . 0.0 112.259 179.371 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 22.9 mt -100.71 120.5 50.28 Favored 'Isoleucine or valine' 0 C--O 1.238 0.473 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 173.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 201' ' ' ILE . . . . . 0.49 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 56.5 mt -113.55 160.57 12.98 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.942 0 N-CA-C 107.826 -1.176 . . . . 0.0 107.826 178.221 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -99.6 169.27 9.4 Favored 'General case' 0 N--CA 1.478 0.942 0 O-C-N 121.739 -0.601 . . . . 0.0 110.539 176.188 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 7.3 ptpp? -58.66 -26.57 63.93 Favored 'General case' 0 CA--C 1.55 0.957 0 C-N-CA 124.207 1.003 . . . . 0.0 111.497 174.221 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 51.2 tptt -67.0 -20.62 65.91 Favored 'General case' 0 CA--C 1.55 0.973 0 C-N-CA 124.064 0.946 . . . . 0.0 111.401 179.863 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 98.82 -14.1 61.88 Favored Glycine 0 C--N 1.345 1.078 0 N-CA-C 111.791 -0.524 . . . . 0.0 111.791 -175.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -85.79 136.89 33.14 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 123.96 0.904 . . . . 0.0 109.705 179.042 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.49 ' HA ' ' HA ' ' A' ' 201' ' ' ILE . 13.7 p -67.88 151.95 9.95 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 C-N-CA 123.627 0.771 . . . . 0.0 110.101 -179.629 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 208' ' ' VAL . . . . . 0.51 HG21 HG21 ' A' ' 156' ' ' VAL . 28.8 m -127.49 -26.62 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 CA-C-O 118.683 -0.675 . . . . 0.0 112.568 -179.211 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.529 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . 171.72 -147.03 9.82 Favored Glycine 0 C--N 1.36 1.871 0 C-N-CA 119.202 -1.475 . . . . 0.0 116.618 176.128 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . 0.446 HD11 HG12 ' A' ' 101' ' ' VAL . 50.6 mt -129.65 143.33 50.77 Favored 'General case' 0 N--CA 1.491 1.623 0 C-N-CA 124.45 1.1 . . . . 0.0 111.804 -175.06 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 47.7 t80 -117.5 105.74 12.41 Favored 'General case' 0 C--O 1.236 0.386 0 C-N-CA 124.951 1.3 . . . . 0.0 108.505 -177.025 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . 172.86 71.49 0.05 OUTLIER Glycine 0 N--CA 1.442 -0.906 0 N-CA-C 111.348 -0.701 . . . . 0.0 111.348 160.286 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 213' ' ' ASN . . . . . 0.672 ' HB2' ' HB3' ' A' ' 225' ' ' ALA . 2.8 m120 -140.17 79.62 1.72 Allowed 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 175.308 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 169.17 -152.63 20.41 Favored Glycine 0 C--O 1.247 0.927 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.756 -176.265 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 215' ' ' VAL . . . . . 0.491 HG21 ' HE2' ' B' ' 253' ' ' LYS . 9.9 p -163.24 171.02 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.832 0 CA-C-N 116.905 0.353 . . . . 0.0 111.831 -166.476 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 216' ' ' VAL . . . . . . . . . . . . . 14.4 p -69.0 128.42 32.44 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.048 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 167.021 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 217' ' ' THR . . . . . 0.755 HG23 HD11 ' A' ' 41' ' ' ILE . 47.7 m -138.12 169.27 18.09 Favored 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 124.98 1.312 . . . . 0.0 108.848 -170.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 218' ' ' ARG . . . . . 0.405 ' HB3' ' HB3' ' A' ' 221' ' ' ALA . 59.9 ttt180 69.22 -83.99 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 123.69 0.796 . . . . 0.0 111.526 168.099 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 23.2 p -163.27 42.36 0.11 Allowed 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 124.216 1.006 . . . . 0.0 109.011 -174.191 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . 101.39 37.89 3.42 Favored Glycine 0 C--N 1.345 1.069 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.149 -178.562 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . 0.48 ' HA ' ' HA ' ' A' ' 190' ' ' ASP . . . -118.96 100.61 7.48 Favored 'General case' 0 N--CA 1.472 0.669 0 C-N-CA 123.802 0.841 . . . . 0.0 109.234 -172.479 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 222' ' ' TYR . . . . . 0.457 ' HB2' ' HG3' ' A' ' 193' ' ' PRO . 69.7 m-85 -77.4 97.81 5.05 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-O 121.601 0.715 . . . . 0.0 109.212 -177.003 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 45.7 t -97.52 113.71 32.72 Favored 'Isoleucine or valine' 0 C--O 1.235 0.29 0 CA-C-N 114.398 -1.273 . . . . 0.0 107.957 -178.708 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 8.8 t -130.91 154.58 47.95 Favored 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 124.737 1.215 . . . . 0.0 109.367 -173.025 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . 0.677 ' HA ' ' HA ' ' A' ' 186' ' ' ALA . . . -84.03 152.43 24.41 Favored 'General case' 0 C--O 1.247 0.947 0 CA-C-O 120.949 0.404 . . . . 0.0 110.545 178.545 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 226' ' ' ILE . . . . . . . . . . . . . 8.5 pt -114.53 93.14 2.37 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.806 0 CA-C-O 121.914 0.864 . . . . 0.0 109.855 -176.394 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 227' ' ' ALA . . . . . 0.434 ' O ' ' HA3' ' A' ' 209' ' ' GLY . . . -80.69 119.38 23.23 Favored 'General case' 0 N--CA 1.48 1.027 0 CA-C-N 114.939 -1.028 . . . . 0.0 111.108 -172.006 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . 0.477 HE21 ' HB3' ' A' ' 150' ' ' TRP . 4.0 pt20 -93.81 152.9 18.59 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 123.902 0.881 . . . . 0.0 109.188 177.621 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . 0.422 ' HA ' ' NE1' ' A' ' 144' ' ' TRP . 87.4 m -65.06 122.36 16.85 Favored 'General case' 0 N--CA 1.477 0.907 0 CA-C-O 121.005 0.431 . . . . 0.0 111.872 -170.131 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 30.2 mt-10 -84.69 -41.73 15.99 Favored 'General case' 0 CA--C 1.543 0.694 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.313 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 231' ' ' LYS . . . . . 0.592 ' HE2' ' HB3' ' A' ' 235' ' ' ASP . 0.0 OUTLIER 61.99 95.11 0.04 OUTLIER 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 124.9 1.28 . . . . 0.0 110.742 -177.284 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 85.2 p -89.07 138.56 31.31 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-O 119.124 -0.465 . . . . 0.0 110.97 178.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 233' ' ' ILE . . . . . . . . . . . . . 7.0 tt 66.87 -32.84 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.512 2.627 0 C-N-CA 127.838 2.455 . . . . 0.0 115.921 167.089 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 234' ' ' GLU . . . . . 0.518 ' HB3' ' HD3' ' A' ' 231' ' ' LYS . 30.4 tt0 -59.57 -26.56 65.49 Favored 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 124.352 1.061 . . . . 0.0 113.001 -169.56 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . 0.592 ' HB3' ' HE2' ' A' ' 231' ' ' LYS . 6.4 p-10 -54.68 -28.85 50.61 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 124.147 0.979 . . . . 0.0 111.654 178.221 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 236' ' ' ASN . . . . . . . . . . . . . 5.4 p30 -114.84 107.33 50.56 Favored Pre-proline 0 CA--C 1.561 1.386 0 C-N-CA 124.192 0.997 . . . . 0.0 108.734 169.274 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_exo -69.81 88.75 0.54 Allowed 'Trans proline' 0 C--N 1.379 2.151 0 C-N-CA 122.706 2.27 . . . . 0.0 111.662 175.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 238' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 -93.92 -59.52 1.96 Allowed 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 123.403 0.681 . . . . 0.0 110.282 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 239' ' ' ILE . . . . . . . . . . . . . 37.2 pt -113.45 -39.08 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 C-N-CA 123.028 0.531 . . . . 0.0 112.187 -172.571 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 23.9 mm-40 . . . . . 0 CA--C 1.558 1.25 0 C-N-CA 124.547 1.139 . . . . 0.0 111.206 -177.048 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 251' ' ' BEZ . . . . . 0.601 ' H6 ' ' HB2' ' B' ' 253' ' ' LYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 253' ' ' LYS . . . . . 0.601 ' HB2' ' H6 ' ' B' ' 251' ' ' BEZ . 1.0 OUTLIER -71.44 78.77 0.77 Allowed 'General case' 0 N--CA 1.476 0.829 0 C-N-CA 124.721 1.208 . . . . 0.0 111.202 -175.551 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 254' ' ' ARG . . . . . 0.46 ' HG2' HH11 ' B' ' 254' ' ' ARG . 7.2 mmt-85 -79.45 164.49 23.92 Favored 'General case' 0 C--O 1.244 0.767 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 172.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 255' ' ' M9P . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.384 0 N-CA-C 111.302 -0.719 . . . . 0.0 111.302 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 27.6 t -141.02 111.41 6.81 Favored 'General case' 0 C--N 1.353 0.72 0 C-N-CA 123.078 0.551 . . . . 0.0 110.386 -174.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 61.29 15.65 6.65 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 124.79 1.236 . . . . 0.0 114.214 171.567 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -128.84 20.39 5.99 Favored 'General case' 0 N--CA 1.476 0.869 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 -177.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -123.94 10.41 8.86 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 126.109 1.764 . . . . 0.0 107.242 -177.18 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.521 ' HB2' HD13 ' A' ' 119' ' ' LEU . 16.9 mt -67.73 166.51 15.12 Favored 'General case' 0 C--O 1.201 -1.461 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 -174.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -154.6 146.7 23.68 Favored 'General case' 0 C--O 1.247 0.968 0 CA-C-N 118.7 0.682 . . . . 0.0 110.144 176.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.58 ' HB2' ' CD2' ' A' ' 121' ' ' HIS . 83.7 mt -87.54 125.45 34.34 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 115.032 -0.985 . . . . 0.0 109.933 172.536 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 22.7 tt0 -104.18 125.27 50.34 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 124.893 1.277 . . . . 0.0 108.275 178.391 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 15.5 ttt180 -60.24 109.35 0.96 Allowed 'General case' 0 N--CA 1.477 0.917 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 -179.849 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.458 ' HB2' ' HG3' ' A' ' 85' ' ' ARG . . . -106.56 -43.88 4.62 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 122.487 0.315 . . . . 0.0 111.267 -170.113 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -174.25 172.91 3.16 Favored 'General case' 0 N--CA 1.477 0.913 0 O-C-N 124.095 0.872 . . . . 0.0 110.409 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -87.12 144.62 26.78 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 162.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 61.9 t -72.06 100.6 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.003 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 176.778 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 26.8 ttpp -172.05 103.49 0.17 Allowed 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 124.483 1.113 . . . . 0.0 108.884 -175.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . 0.532 ' NE1' ' HB1' ' A' ' 169' ' ' ALA . 92.4 t90 -80.59 94.78 6.36 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 123.224 0.61 . . . . 0.0 110.351 -179.244 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -157.81 57.62 0.48 Allowed 'General case' 0 CA--C 1.557 1.217 0 C-N-CA 123.195 0.598 . . . . 0.0 111.587 157.232 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.406 ' H ' ' HB2' ' A' ' 169' ' ' ALA . 4.8 m-20 -92.3 -63.42 1.24 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.445 -0.784 . . . . 0.0 112.689 177.675 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . 0.808 ' H ' ' HB3' ' A' ' 169' ' ' ALA . 48.8 mt-30 -153.09 43.8 0.63 Allowed 'General case' 0 N--CA 1.489 1.477 0 CA-C-N 114.693 -1.14 . . . . 0.0 111.248 -158.199 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -35.05 99.78 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.014 0 C-N-CA 125.537 1.535 . . . . 0.0 114.486 -175.135 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -126.52 118.48 24.99 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 123.748 0.819 . . . . 0.0 110.163 -176.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.543 ' HA ' ' HB2' ' A' ' 171' ' ' GLN . 0.2 OUTLIER -76.16 143.87 12.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 CA-C-O 121.052 0.453 . . . . 0.0 111.872 -174.478 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 77.2 p -154.35 156.71 37.39 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 124.558 1.143 . . . . 0.0 109.654 -178.502 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 160.25 103.82 0.19 Allowed Glycine 0 C--N 1.339 0.747 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -174.293 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.405 ' H ' ' HB3' ' A' ' 189' ' ' LEU . 29.4 t -109.72 -70.27 0.82 Allowed 'General case' 0 N--CA 1.478 0.961 0 CA-C-N 117.566 0.683 . . . . 0.0 111.342 -168.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 26.5 m -123.49 85.68 52.52 Favored Pre-proline 0 CA--C 1.551 1.014 0 C-N-CA 123.3 0.64 . . . . 0.0 109.526 -172.891 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 82.3 Cg_exo -45.41 -49.76 10.01 Favored 'Trans proline' 0 C--N 1.39 2.761 0 C-N-CA 124.293 3.329 . . . . 0.0 114.162 -173.149 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 49.1 mm -104.01 117.04 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 175.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.578 HD11 ' HB2' ' A' ' 218' ' ' ARG . 0.5 OUTLIER -138.26 128.52 25.95 Favored 'General case' 0 N--CA 1.478 0.942 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 -177.232 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 60.1 p -79.24 159.24 27.39 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 122.949 0.5 . . . . 0.0 111.195 179.088 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 16.0 tt -150.68 159.62 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 -177.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 35.3 m -94.88 110.81 22.65 Favored 'General case' 0 C--O 1.241 0.622 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 176.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 45.5 mm -72.12 115.75 12.98 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 173.673 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.491 ' HB2' ' HB3' ' A' ' 38' ' ' SER . 15.5 m -79.65 117.63 20.74 Favored 'General case' 0 C--O 1.241 0.627 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 170.641 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -60.37 -8.49 2.69 Favored 'General case' 0 N--CA 1.491 1.608 0 C-N-CA 124.473 1.109 . . . . 0.0 113.491 -169.206 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -65.79 -13.75 60.05 Favored 'General case' 0 CA--C 1.551 1.0 0 C-N-CA 124.756 1.222 . . . . 0.0 112.24 172.823 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.04 14.39 26.66 Favored Glycine 0 C--N 1.347 1.141 0 N-CA-C 111.693 -0.563 . . . . 0.0 111.693 -171.249 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.491 ' HB3' ' HB2' ' A' ' 34' ' ' SER . 23.1 t -109.03 164.97 11.95 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.496 0.719 . . . . 0.0 110.481 -179.303 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 68.3 mtp -133.29 134.71 44.23 Favored 'General case' 0 N--CA 1.479 1.022 0 C-N-CA 123.518 0.727 . . . . 0.0 109.808 -179.015 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.417 ' HB3' ' HE3' ' B' ' 253' ' ' LYS . 13.3 p -169.44 174.4 6.0 Favored 'General case' 0 C--N 1.353 0.749 0 CA-C-O 121.436 0.636 . . . . 0.0 112.611 -175.185 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.635 HD11 HG23 ' A' ' 217' ' ' THR . 50.7 mm -89.44 152.33 3.35 Favored 'Isoleucine or valine' 0 C--O 1.241 0.635 0 N-CA-C 107.0 -1.482 . . . . 0.0 107.0 160.062 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 47.6 mtmt -72.65 75.74 1.1 Allowed 'General case' 0 CA--C 1.55 0.977 0 CA-C-O 121.665 0.745 . . . . 0.0 110.51 177.195 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 36.0 t30 -173.05 143.42 1.15 Allowed 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 126.079 1.752 . . . . 0.0 107.667 -176.504 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.475 ' HA ' ' HB2' ' B' ' 253' ' ' LYS . 12.5 pt-20 -148.5 150.53 33.56 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 122.537 0.335 . . . . 0.0 111.155 177.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -166.91 172.96 9.8 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 124.425 1.09 . . . . 0.0 109.866 179.419 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -65.44 119.3 10.76 Favored 'General case' 0 CA--C 1.558 1.28 0 N-CA-C 113.578 0.955 . . . . 0.0 113.578 -171.644 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -83.11 76.12 9.87 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 124.482 1.113 . . . . 0.0 109.82 173.022 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 75.5 mt-30 -117.59 104.11 10.71 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.055 -0.975 . . . . 0.0 110.097 -178.318 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.402 HG23 ' HB3' ' A' ' 96' ' ' GLN . 2.2 t -133.38 175.58 9.29 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 125.06 1.344 . . . . 0.0 107.794 171.119 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 53.4 tp -150.77 128.21 11.41 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 176.346 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -90.0 -122.89 2.41 Favored Glycine 0 C--N 1.345 1.079 0 N-CA-C 110.891 -0.884 . . . . 0.0 110.891 173.094 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -100.72 -144.82 16.19 Favored Glycine 0 C--N 1.337 0.629 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 168.352 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.25 42.94 96.02 Favored Glycine 0 C--N 1.348 1.197 0 CA-C-N 116.874 0.337 . . . . 0.0 113.897 173.326 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -170.98 -121.99 0.61 Allowed Glycine 0 C--N 1.339 0.718 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 178.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 11.0 t 67.85 165.04 0.23 Allowed 'General case' 0 N--CA 1.485 1.312 0 C-N-CA 125.337 1.455 . . . . 0.0 112.681 176.549 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -77.34 -17.74 78.95 Favored Glycine 0 C--N 1.348 1.23 0 CA-C-N 115.552 -0.749 . . . . 0.0 113.073 179.272 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -68.39 98.6 0.52 Allowed Glycine 0 C--N 1.346 1.123 0 N-CA-C 112.283 -0.327 . . . . 0.0 112.283 176.608 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -76.61 -137.76 0.81 Allowed Glycine 0 CA--C 1.531 1.073 0 N-CA-C 112.184 -0.366 . . . . 0.0 112.184 175.063 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 71.12 -76.88 0.58 Allowed Glycine 0 C--N 1.346 1.11 0 N-CA-C 111.364 -0.694 . . . . 0.0 111.364 -176.276 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 23.9 mm-40 -81.13 -22.88 38.71 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 123.711 0.804 . . . . 0.0 110.929 172.274 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 48.3 p90 40.86 95.94 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.831 0 C-N-CA 126.672 1.989 . . . . 0.0 114.14 177.445 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . 69.4 8.8 6.98 Favored 'General case' 0 N--CA 1.487 1.414 0 C-N-CA 124.823 1.249 . . . . 0.0 112.854 177.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 87.21 -57.12 4.57 Favored Glycine 0 C--N 1.349 1.299 0 N-CA-C 111.746 -0.542 . . . . 0.0 111.746 -178.308 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 8.8 p 44.37 50.84 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.568 1.639 0 C-N-CA 126.43 1.892 . . . . 0.0 112.945 172.231 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -159.18 97.85 1.4 Allowed 'General case' 0 N--CA 1.485 1.31 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 -178.385 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . 0.533 ' NE1' ' HG3' ' A' ' 122' ' ' LYS . 1.1 p90 -168.99 60.46 0.05 Allowed 'General case' 0 N--CA 1.49 1.572 0 C-N-CA 123.791 0.837 . . . . 0.0 110.674 -179.044 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . 0.492 ' HB3' ' H ' ' A' ' 68' ' ' VAL . 15.1 m-20 177.59 -141.82 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.933 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 -171.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.492 ' H ' ' HB3' ' A' ' 67' ' ' ASP . 6.1 m -52.99 123.25 32.46 Favored Pre-proline 0 CA--C 1.566 1.592 0 CA-C-N 114.898 -1.046 . . . . 0.0 110.831 153.45 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_exo -60.28 -34.41 93.77 Favored 'Trans proline' 0 C--N 1.377 2.071 0 C-N-CA 122.801 2.334 . . . . 0.0 112.384 171.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 53.5 m -86.96 171.44 10.0 Favored Pre-proline 0 CA--C 1.554 1.13 0 C-N-CA 124.077 0.951 . . . . 0.0 110.022 174.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 76.7 Cg_exo -53.4 147.6 36.65 Favored 'Trans proline' 0 C--N 1.384 2.395 0 C-N-CA 122.349 2.033 . . . . 0.0 112.066 166.435 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 97.2 Cg_exo -47.56 111.16 0.38 Allowed 'Trans proline' 0 C--N 1.377 2.071 0 C-N-CA 123.46 2.774 . . . . 0.0 113.399 177.565 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . 0.407 ' HG2' ' H ' ' A' ' 76' ' ' LYS . 70.5 Cg_endo -71.06 -179.93 3.89 Favored 'Trans proline' 0 C--N 1.379 2.147 0 C-N-CA 123.261 2.64 . . . . 0.0 112.845 -178.418 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 41.2 t -64.66 -43.04 96.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 C-N-CA 123.021 0.528 . . . . 0.0 110.067 -179.83 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -66.53 -43.77 91.54 Favored Glycine 0 C--N 1.348 1.248 0 CA-C-N 115.38 -0.827 . . . . 0.0 112.553 176.44 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . 0.407 ' H ' ' HG2' ' A' ' 73' ' ' PRO . 64.1 pttt 47.3 15.97 0.05 Allowed 'General case' 0 N--CA 1.503 2.193 0 C-N-CA 126.632 1.973 . . . . 0.0 115.247 176.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -74.79 -23.67 58.54 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 123.664 0.786 . . . . 0.0 110.571 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -70.61 104.92 2.95 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 123.608 0.763 . . . . 0.0 109.62 173.355 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.424 HD13 ' OH ' ' A' ' 102' ' ' TYR . 88.6 mt -135.08 134.34 40.21 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 124.568 1.147 . . . . 0.0 108.236 178.229 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -95.01 145.24 25.08 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 121.525 0.679 . . . . 0.0 110.572 -177.432 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.532 ' HB2' ' HA ' ' A' ' 103' ' ' LYS . 38.5 p-10 -127.93 169.76 13.6 Favored 'General case' 0 CA--C 1.537 0.449 0 CA-C-N 114.449 -1.25 . . . . 0.0 112.271 -172.473 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 142.27 -162.82 27.2 Favored Glycine 0 C--N 1.345 1.06 0 CA-C-N 115.296 -0.866 . . . . 0.0 112.256 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . 0.512 ' HB1' HD11 ' A' ' 161' ' ' LEU . . . -85.76 123.26 30.93 Favored 'General case' 0 N--CA 1.477 0.88 0 C-N-CA 123.67 0.788 . . . . 0.0 109.865 177.587 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 15.0 m-85 -129.79 140.43 51.04 Favored 'General case' 0 N--CA 1.48 1.061 0 C-N-CA 123.356 0.663 . . . . 0.0 110.686 -176.145 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . 0.527 ' HD3' HE22 ' A' ' 96' ' ' GLN . 80.7 mtt85 -88.09 128.8 35.42 Favored 'General case' 0 N--CA 1.479 0.997 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 173.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.411 ' H ' ' HA ' ' A' ' 99' ' ' ALA . 53.3 mt -91.02 122.03 42.0 Favored 'Isoleucine or valine' 0 C--O 1.247 0.957 0 CA-C-O 121.432 0.634 . . . . 0.0 110.209 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.561 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 34.4 mtmm -114.84 146.96 40.5 Favored 'General case' 0 C--O 1.216 -0.675 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.316 174.657 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 19.7 tm0? -87.05 107.15 18.3 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 105.872 -1.899 . . . . 0.0 105.872 165.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . 0.405 ' HD2' ' HE2' ' A' ' 87' ' ' LYS . 50.0 mtpt -114.38 94.04 4.62 Favored 'General case' 0 C--O 1.241 0.641 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 -176.078 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -70.28 137.9 28.5 Favored Glycine 0 C--O 1.242 0.619 0 N-CA-C 108.221 -1.951 . . . . 0.0 108.221 165.816 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 2.9 mp -75.13 68.9 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.566 1.584 0 N-CA-C 107.103 -1.443 . . . . 0.0 107.103 176.854 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 3.9 pp 170.5 -38.16 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.468 0 C-N-CA 126.435 1.894 . . . . 0.0 109.834 -165.549 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -161.66 134.33 3.48 Favored Glycine 0 C--N 1.353 1.492 0 CA-C-N 115.994 -0.548 . . . . 0.0 112.201 -174.417 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 8.2 m-85 -123.25 131.65 53.75 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.75 0.82 . . . . 0.0 109.756 -167.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 53.6 m -148.65 146.32 28.13 Favored 'General case' 0 N--CA 1.483 1.21 0 C-N-CA 123.956 0.902 . . . . 0.0 109.383 176.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.561 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 61.9 tt0 -92.52 144.08 25.7 Favored 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 123.127 0.571 . . . . 0.0 110.904 178.312 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 25.5 pt -128.34 -26.4 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 C-N-CA 123.138 0.575 . . . . 0.0 112.158 -173.255 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . 0.421 ' HA2' ' HB ' ' A' ' 195' ' ' THR . . . -177.52 -149.54 7.93 Favored Glycine 0 C--N 1.349 1.271 0 C-N-CA 121.144 -0.55 . . . . 0.0 113.263 -177.643 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.411 ' HA ' ' H ' ' A' ' 86' ' ' ILE . . . -157.23 175.47 13.98 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 124.119 0.967 . . . . 0.0 110.969 -176.447 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -178.21 -171.18 41.28 Favored Glycine 0 C--N 1.346 1.117 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.646 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 34.7 t -135.64 127.0 44.92 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.065 0 CA-C-O 121.552 0.691 . . . . 0.0 111.023 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . 0.424 ' OH ' HD13 ' A' ' 79' ' ' LEU . 8.5 t80 -91.03 145.0 25.07 Favored 'General case' 0 CA--C 1.548 0.874 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 170.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.532 ' HA ' ' HB2' ' A' ' 81' ' ' ASP . 20.1 tptp -152.65 118.14 5.3 Favored 'General case' 0 N--CA 1.483 1.196 0 CA-C-N 119.168 0.895 . . . . 0.0 111.667 177.303 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 52.3 43.2 30.99 Favored 'General case' 0 N--CA 1.486 1.344 0 C-N-CA 124.629 1.171 . . . . 0.0 113.262 166.286 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 96.31 -33.76 5.42 Favored Glycine 0 C--N 1.348 1.244 0 CA-C-N 115.935 -0.575 . . . . 0.0 112.947 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 60.5 p -88.88 118.93 28.94 Favored 'General case' 0 CA--C 1.542 0.639 0 CA-C-N 117.023 0.412 . . . . 0.0 110.433 -178.213 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' PHE . . . . . 0.429 ' CE2' ' HG ' ' A' ' 119' ' ' LEU . 23.1 t80 -95.23 115.25 27.18 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 176.638 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . 0.618 ' HB2' ' HE3' ' A' ' 144' ' ' TRP . 1.0 OUTLIER -136.2 121.2 18.81 Favored 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 122.698 0.399 . . . . 0.0 110.808 -176.703 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 14.7 t -135.88 -179.71 5.82 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 122.999 0.52 . . . . 0.0 112.035 -169.09 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -72.72 141.52 48.17 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 124.839 1.256 . . . . 0.0 110.023 171.247 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 80.7 t90 -76.03 -53.01 9.0 Favored 'General case' 0 N--CA 1.483 1.202 0 CA-C-O 119.328 -0.367 . . . . 0.0 111.616 -174.482 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . 0.62 ' HE1' ' HA ' ' A' ' 213' ' ' ASN . 3.4 p-80 -65.35 -2.88 3.48 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 114.119 1.155 . . . . 0.0 114.119 -170.437 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.405 HG13 ' HA3' ' A' ' 98' ' ' GLY . 78.1 t -58.07 -39.58 73.22 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.934 0 CA-C-O 121.524 0.678 . . . . 0.0 109.705 167.639 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.618 HG23 ' H ' ' A' ' 116' ' ' GLY . 9.4 t -138.6 -168.48 2.41 Favored 'General case' 0 CA--C 1.555 1.161 0 CA-C-N 114.607 -1.179 . . . . 0.0 109.765 -178.492 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 31.5 ttt180 -93.03 14.94 16.26 Favored 'General case' 0 CA--C 1.561 1.401 0 C-N-CA 124.063 0.945 . . . . 0.0 110.951 177.316 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.618 ' H ' HG23 ' A' ' 114' ' ' THR . . . 80.17 40.7 13.2 Favored Glycine 0 C--N 1.346 1.084 0 N-CA-C 111.816 -0.513 . . . . 0.0 111.816 -175.167 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -120.23 -169.89 1.88 Allowed 'General case' 0 CA--C 1.554 1.112 0 C-N-CA 123.336 0.654 . . . . 0.0 111.543 -173.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 48.9 t -75.36 136.93 23.94 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 N-CA-C 114.184 1.179 . . . . 0.0 114.184 -159.854 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.521 HD13 ' HB2' ' A' ' 6' ' ' LEU . 3.7 mm? -103.13 151.63 22.36 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 124.89 1.276 . . . . 0.0 110.616 174.505 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 38.1 mmt -104.1 151.45 23.26 Favored 'General case' 0 C--O 1.262 1.744 0 C-N-CA 124.57 1.148 . . . . 0.0 108.197 173.284 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.58 ' CD2' ' HB2' ' A' ' 8' ' ' LEU . 0.1 OUTLIER -143.52 92.45 2.36 Favored 'General case' 0 CA--C 1.538 0.495 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 165.072 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.533 ' HG3' ' NE1' ' A' ' 66' ' ' TRP . 10.1 mtmp? 56.72 28.45 14.24 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 124.591 1.157 . . . . 0.0 112.619 -174.614 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 100.66 -8.91 58.45 Favored Glycine 0 C--N 1.347 1.176 0 CA-C-O 119.683 -0.509 . . . . 0.0 113.229 -176.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 61.2 tttm -72.94 114.55 11.22 Favored 'General case' 0 C--N 1.357 0.901 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 171.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 47.1 ttp180 -82.86 86.13 6.98 Favored 'General case' 0 C--O 1.241 0.605 0 C-N-CA 124.258 1.023 . . . . 0.0 109.271 -174.368 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.461 HG13 ' HB2' ' A' ' 119' ' ' LEU . 23.8 pt -91.71 100.49 11.3 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 CA-C-O 122.334 1.064 . . . . 0.0 109.346 -177.71 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -94.22 126.79 47.14 Favored Pre-proline 0 CA--C 1.546 0.789 0 CA-C-N 113.972 -1.467 . . . . 0.0 110.063 -175.382 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.401 ' HB3' HG23 ' A' ' 138' ' ' ILE . 88.0 Cg_exo -49.53 119.5 4.72 Favored 'Trans proline' 0 C--N 1.373 1.865 0 C-N-CA 123.266 2.644 . . . . 0.0 113.834 175.666 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 59.1 p -82.13 -10.41 59.19 Favored 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 123.799 0.84 . . . . 0.0 110.51 174.425 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.703 ' HB3' ' HB2' ' A' ' 139' ' ' SER . 64.8 t-105 -155.79 152.77 28.86 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 124.912 1.285 . . . . 0.0 109.096 178.176 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -161.86 120.48 2.33 Favored 'General case' 0 C--O 1.241 0.622 0 C-N-CA 124.152 0.981 . . . . 0.0 108.546 169.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -108.84 112.5 24.79 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 123.324 0.65 . . . . 0.0 109.627 176.652 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 11.5 t -75.47 -17.47 15.8 Favored 'Isoleucine or valine' 0 CA--C 1.557 1.228 0 C-N-CA 123.139 0.576 . . . . 0.0 110.159 179.316 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 23.4 ttmm -59.62 -51.5 69.55 Favored 'General case' 0 C--N 1.358 0.974 0 C-N-CA 124.486 1.114 . . . . 0.0 112.359 -174.584 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 79.6 tttt -109.79 4.9 22.2 Favored 'General case' 0 N--CA 1.485 1.291 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 172.606 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 15.6 t70 67.96 71.15 0.33 Allowed 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 124.341 1.056 . . . . 0.0 111.368 170.175 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 47.8 mt -147.43 160.29 42.73 Favored 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 124.317 1.047 . . . . 0.0 110.278 178.043 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.449 HD11 ' HA2' ' A' ' 116' ' ' GLY . 38.0 mt -132.24 150.72 33.83 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 C-N-CA 125.739 1.615 . . . . 0.0 108.214 -176.675 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . 0.703 ' HB2' ' HB3' ' A' ' 130' ' ' TRP . 20.4 m -145.36 143.98 30.44 Favored 'General case' 0 CA--C 1.554 1.123 0 C-N-CA 123.81 0.844 . . . . 0.0 110.887 -179.393 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 19.8 t80 -139.35 128.98 24.52 Favored 'General case' 0 N--CA 1.48 1.029 0 C-N-CA 125.544 1.538 . . . . 0.0 107.942 178.207 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 80.03 2.51 88.83 Favored Glycine 0 C--N 1.35 1.347 0 O-C-N 123.848 0.717 . . . . 0.0 113.178 179.336 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 165.09 -153.49 23.69 Favored Glycine 0 C--N 1.339 0.725 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -173.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -105.62 173.47 20.24 Favored Glycine 0 C--N 1.343 0.968 0 CA-C-N 117.122 0.461 . . . . 0.0 112.034 174.66 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' TRP . . . . . 0.618 ' HE3' ' HB2' ' A' ' 108' ' ' HIS . 36.2 t-105 -66.6 110.51 3.22 Favored 'General case' 0 C--O 1.245 0.853 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 170.064 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . 0.516 ' HA ' ' HB ' ' A' ' 229' ' ' THR . 0.1 OUTLIER -150.49 146.34 26.55 Favored 'General case' 0 CA--C 1.538 0.499 0 CA-C-O 121.6 0.714 . . . . 0.0 110.475 171.345 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' LEU . . . . . 0.518 HD12 ' HA2' ' A' ' 209' ' ' GLY . 72.7 mt -144.06 2.21 1.15 Allowed 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 125.997 1.719 . . . . 0.0 108.099 170.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 36.6 mt-10 71.07 36.2 1.47 Allowed 'General case' 0 C--N 1.372 1.564 0 C-N-CA 124.157 0.983 . . . . 0.0 111.421 171.045 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.532 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -149.94 156.51 26.78 Favored Glycine 0 C--N 1.347 1.174 0 CA-C-O 121.436 0.465 . . . . 0.0 113.932 -177.613 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -151.12 131.29 13.53 Favored 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 124.022 0.929 . . . . 0.0 109.224 -176.071 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' TRP . . . . . 0.567 ' HE1' ' HB3' ' A' ' 174' ' ' PRO . 50.8 t-105 -91.7 143.78 26.19 Favored 'General case' 0 N--CA 1.474 0.758 0 C-N-CA 122.985 0.514 . . . . 0.0 110.027 170.599 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 26.5 tptp -131.14 139.44 49.8 Favored 'General case' 0 CA--C 1.536 0.412 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 169.101 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -44.27 147.11 0.58 Allowed 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 126.165 1.786 . . . . 0.0 113.73 -178.162 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 152.12 -84.7 0.15 Allowed Glycine 0 C--N 1.342 0.867 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.804 179.389 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -88.73 -174.88 4.71 Favored 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 124.446 1.099 . . . . 0.0 110.538 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 11.6 mp0 -63.97 130.95 46.1 Favored 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 169.67 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 13.0 p -90.53 148.0 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 166.444 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 7.9 mm100 -103.72 140.5 37.52 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -170.24 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.568 HG22 HG12 ' A' ' 200' ' ' ILE . 19.1 t -127.63 120.02 53.35 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 176.139 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.601 ' HB3' ' HG2' ' A' ' 199' ' ' PRO . 0.2 OUTLIER -81.39 86.18 6.33 Favored 'General case' 0 CA--C 1.558 1.269 0 N-CA-C 107.481 -1.304 . . . . 0.0 107.481 174.249 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . 0.422 ' HA ' ' OG ' ' A' ' 198' ' ' SER . . . -68.97 104.99 2.24 Favored 'General case' 0 N--CA 1.481 1.121 0 C-N-CA 123.263 0.625 . . . . 0.0 112.089 -172.43 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . 0.512 HD11 ' HB1' ' A' ' 83' ' ' ALA . 74.9 mt -75.42 83.8 2.52 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 174.359 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 15.0 tp10 -70.25 119.75 74.02 Favored Pre-proline 0 CA--C 1.551 1.017 0 CA-C-N 114.886 -1.052 . . . . 0.0 110.176 -176.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . 0.487 ' HG3' HG23 ' A' ' 195' ' ' THR . 63.5 Cg_exo -55.43 114.1 1.72 Allowed 'Trans proline' 0 C--N 1.377 2.045 0 C-N-CA 123.132 2.554 . . . . 0.0 113.378 -178.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 75.99 22.08 74.9 Favored Glycine 0 C--N 1.344 1.019 0 O-C-N 123.724 0.64 . . . . 0.0 113.418 175.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 54.1 tptt -151.69 156.88 41.25 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -174.434 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -58.28 148.21 64.08 Favored Pre-proline 0 CA--C 1.558 1.259 0 C-N-CA 123.034 0.534 . . . . 0.0 112.312 177.594 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -59.62 146.89 94.04 Favored 'Trans proline' 0 C--N 1.379 2.134 0 C-N-CA 123.213 2.609 . . . . 0.0 113.233 179.048 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . 0.413 ' HB2' ' HB3' ' A' ' 160' ' ' ALA . 80.9 mtp180 -123.91 110.54 14.96 Favored 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 123.804 0.842 . . . . 0.0 108.828 -172.465 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . 0.808 ' HB3' ' H ' ' A' ' 19' ' ' GLN . . . -78.84 106.37 10.81 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-O 120.808 0.337 . . . . 0.0 110.701 -178.662 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 21.9 t -105.64 139.19 27.57 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.894 0 C-N-CA 123.176 0.591 . . . . 0.0 109.778 -178.023 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . 0.543 ' HB2' ' HA ' ' A' ' 22' ' ' ILE . 11.2 mt-30 -97.09 102.87 14.73 Favored 'General case' 0 C--N 1.348 0.53 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 170.335 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . 0.519 ' HB ' HD11 ' A' ' 189' ' ' LEU . 71.4 p -101.71 124.06 46.73 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -178.816 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 28.1 mtpp -71.03 133.17 86.06 Favored Pre-proline 0 CA--C 1.546 0.806 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 174.049 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . 0.567 ' HB3' ' HE1' ' A' ' 150' ' ' TRP . 37.7 Cg_endo -64.1 123.53 12.03 Favored 'Trans proline' 0 C--N 1.377 2.053 0 C-N-CA 122.288 1.992 . . . . 0.0 111.776 -169.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -100.0 -173.94 30.37 Favored Glycine 0 N--CA 1.45 -0.428 0 CA-C-N 114.956 -1.02 . . . . 0.0 112.229 177.064 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 5.6 mp -148.73 145.84 27.82 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.096 0.958 . . . . 0.0 109.172 178.476 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 177' ' ' PHE . . . . . 0.729 ' HB2' ' HB ' ' A' ' 184' ' ' ILE . 59.1 m-85 -92.71 122.67 35.35 Favored 'General case' 0 C--O 1.245 0.866 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 167.705 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 77.8 tttt -95.21 104.8 16.7 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 114.809 -1.087 . . . . 0.0 109.187 177.063 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 36.4 p -132.81 156.98 46.14 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 169.481 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 10.3 t30 -56.61 -38.74 72.47 Favored 'General case' 0 N--CA 1.484 1.232 0 C-N-CA 123.874 0.87 . . . . 0.0 112.892 -169.078 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -94.93 -35.68 11.91 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 123.067 0.547 . . . . 0.0 110.8 178.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -112.94 118.19 4.5 Favored Glycine 0 C--N 1.347 1.153 0 CA-C-N 116.279 -0.419 . . . . 0.0 113.859 -169.319 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 30.2 m -98.57 100.88 12.16 Favored 'General case' 0 CA--C 1.538 0.507 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 163.167 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . 0.729 ' HB ' ' HB2' ' A' ' 177' ' ' PHE . 46.9 mt -104.17 149.73 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 C-N-CA 123.512 0.725 . . . . 0.0 109.07 -169.546 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -99.17 124.6 8.29 Favored Glycine 0 C--N 1.349 1.305 0 N-CA-C 109.808 -1.317 . . . . 0.0 109.808 -179.577 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.657 ' HA ' ' HA ' ' A' ' 225' ' ' ALA . . . -140.27 -174.66 4.0 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 114.125 1.157 . . . . 0.0 114.125 -159.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 187' ' ' VAL . . . . . . . . . . . . . 98.4 t -126.27 99.86 6.14 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.641 0 N-CA-C 105.683 -1.969 . . . . 0.0 105.683 171.183 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . 0.559 ' HA ' HG13 ' A' ' 223' ' ' VAL . 60.6 p -113.64 79.64 1.27 Allowed 'General case' 0 C--O 1.243 0.731 0 CA-C-O 122.243 1.021 . . . . 0.0 111.044 -171.343 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 189' ' ' LEU . . . . . 0.519 HD11 ' HB ' ' A' ' 172' ' ' THR . 0.0 OUTLIER -151.49 178.9 8.83 Favored 'General case' 0 N--CA 1.477 0.923 0 CA-C-N 114.596 -1.184 . . . . 0.0 111.528 175.723 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -80.03 102.33 9.21 Favored 'General case' 0 CA--C 1.542 0.635 0 N-CA-C 107.307 -1.368 . . . . 0.0 107.307 171.622 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 191' ' ' PHE . . . . . 0.73 ' HB3' ' HB2' ' A' ' 222' ' ' TYR . 69.5 t80 -106.58 164.22 12.24 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 124.32 1.048 . . . . 0.0 109.53 -174.269 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 16.8 m -58.79 155.15 32.7 Favored Pre-proline 0 CA--C 1.561 1.394 0 C-N-CA 124.748 1.219 . . . . 0.0 112.134 178.297 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_exo -64.84 10.91 0.12 Allowed 'Trans proline' 0 C--N 1.381 2.263 0 C-N-CA 123.123 2.548 . . . . 0.0 115.342 171.555 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 194' ' ' GLY . . . . . 0.458 ' HA2' ' HD3' ' A' ' 163' ' ' PRO . . . -50.05 134.13 27.72 Favored Glycine 0 CA--C 1.54 1.643 0 C-N-CA 123.621 0.629 . . . . 0.0 112.995 168.712 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 195' ' ' THR . . . . . 0.487 HG23 ' HG3' ' A' ' 163' ' ' PRO . 6.6 p -75.34 151.39 38.25 Favored 'General case' 0 CA--C 1.552 1.03 0 C-N-CA 124.285 1.034 . . . . 0.0 113.381 -169.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -62.98 128.91 38.03 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 124.333 1.053 . . . . 0.0 111.213 -172.643 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . 0.422 ' O ' HD22 ' A' ' 210' ' ' LEU . . . 96.68 8.19 57.35 Favored Glycine 0 C--N 1.34 0.755 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 -167.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 198' ' ' SER . . . . . 0.422 ' OG ' ' HA ' ' A' ' 160' ' ' ALA . 34.0 t -57.15 119.06 28.31 Favored Pre-proline 0 CA--C 1.557 1.243 0 C-N-CA 123.684 0.793 . . . . 0.0 109.839 164.278 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . 0.601 ' HG2' ' HB3' ' A' ' 159' ' ' LEU . 19.6 Cg_endo -58.04 131.63 44.61 Favored 'Trans proline' 0 C--N 1.377 2.033 0 C-N-CA 123.171 2.581 . . . . 0.0 113.832 -170.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 200' ' ' ILE . . . . . 0.568 HG12 HG22 ' A' ' 158' ' ' VAL . 18.9 mt -97.98 130.87 46.1 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.754 0 C-N-CA 123.988 0.915 . . . . 0.0 109.062 171.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 201' ' ' ILE . . . . . . . . . . . . . 50.3 mt -123.03 169.55 14.26 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.369 0 C-N-CA 124.706 1.202 . . . . 0.0 108.525 179.045 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -108.55 155.82 20.21 Favored 'General case' 0 N--CA 1.483 1.177 0 C-N-CA 124.346 1.058 . . . . 0.0 108.867 173.258 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 18.7 ptmt -66.4 -19.5 65.82 Favored 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 113.908 1.077 . . . . 0.0 113.908 -170.578 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 45.3 mttp -73.99 -17.4 61.0 Favored 'General case' 0 N--CA 1.488 1.443 0 CA-C-N 117.911 0.323 . . . . 0.0 110.739 176.011 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 115.4 -16.45 17.16 Favored Glycine 0 C--N 1.351 1.362 0 N-CA-C 111.898 -0.481 . . . . 0.0 111.898 -176.066 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 206' ' ' LYS . . . . . 0.423 ' HA ' ' HE3' ' A' ' 206' ' ' LYS . 1.2 tpmt? -73.21 119.2 17.12 Favored 'General case' 0 C--O 1.219 -0.502 0 C-N-CA 123.985 0.914 . . . . 0.0 109.239 -177.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.532 ' O ' ' HA3' ' A' ' 148' ' ' GLY . 12.7 p -64.02 150.23 10.13 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.926 0 C-N-CA 122.798 0.439 . . . . 0.0 110.239 176.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 208' ' ' VAL . . . . . 0.502 ' HB ' HG22 ' A' ' 200' ' ' ILE . 93.4 t -106.26 -49.84 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 177.542 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.518 ' HA2' HD12 ' A' ' 146' ' ' LEU . . . 161.33 -117.49 0.77 Allowed Glycine 0 N--CA 1.441 -1.014 0 CA-C-N 114.876 -1.056 . . . . 0.0 112.986 178.709 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . 0.58 ' HG ' ' CH2' ' A' ' 144' ' ' TRP . 69.2 mt -124.37 166.43 15.96 Favored 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 123.406 0.683 . . . . 0.0 111.841 -177.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -69.9 112.65 6.46 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-N 114.213 -1.358 . . . . 0.0 107.602 167.608 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -74.5 -145.66 1.07 Allowed Glycine 0 C--N 1.341 0.814 0 N-CA-C 115.984 1.154 . . . . 0.0 115.984 -163.849 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 213' ' ' ASN . . . . . 0.62 ' HA ' ' HE1' ' A' ' 112' ' ' HIS . 14.2 p30 -100.66 123.56 45.04 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 121.295 0.569 . . . . 0.0 110.716 -166.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 177.49 -134.31 2.44 Favored Glycine 0 N--CA 1.442 -0.906 0 CA-C-N 114.736 -1.12 . . . . 0.0 111.293 178.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 215' ' ' VAL . . . . . 0.423 HG22 ' N ' ' A' ' 216' ' ' VAL . 10.0 p -176.55 178.09 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.938 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 -165.133 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 216' ' ' VAL . . . . . 0.589 HG13 ' HB2' ' B' ' 254' ' ' ARG . 6.7 m -75.35 110.36 10.08 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.024 0 O-C-N 121.159 -0.963 . . . . 0.0 108.922 160.213 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 217' ' ' THR . . . . . 0.635 HG23 HD11 ' A' ' 41' ' ' ILE . 13.4 m -104.14 177.02 4.96 Favored 'General case' 0 CA--C 1.548 0.886 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 175.86 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 218' ' ' ARG . . . . . 0.578 ' HB2' HD11 ' A' ' 29' ' ' LEU . 71.0 ttt-85 63.38 30.98 15.42 Favored 'General case' 0 N--CA 1.491 1.604 0 CA-C-O 121.98 0.895 . . . . 0.0 110.119 176.096 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 19.6 m 68.33 17.32 9.24 Favored 'General case' 0 CA--C 1.551 1.004 0 C-N-CA 125.47 1.508 . . . . 0.0 113.203 177.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . 153.14 -6.87 0.44 Allowed Glycine 0 C--N 1.355 1.618 0 N-CA-C 115.05 0.78 . . . . 0.0 115.05 174.779 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . 0.463 ' HB3' ' HB3' ' A' ' 218' ' ' ARG . . . -78.58 125.97 30.1 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 123.205 0.602 . . . . 0.0 110.167 -179.816 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 222' ' ' TYR . . . . . 0.73 ' HB2' ' HB3' ' A' ' 191' ' ' PHE . 11.6 m-85 -65.97 102.03 0.74 Allowed 'General case' 0 N--CA 1.481 1.087 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 178.216 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . 0.559 HG13 ' HA ' ' A' ' 188' ' ' SER . 92.4 t -124.64 108.54 20.46 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.922 0 C-N-CA 124.296 1.038 . . . . 0.0 109.469 -176.726 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 50.6 m -142.1 159.0 43.11 Favored 'General case' 0 N--CA 1.481 1.096 0 C-N-CA 123.871 0.868 . . . . 0.0 109.451 -178.571 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . 0.657 ' HA ' ' HA ' ' A' ' 186' ' ' ALA . . . -65.12 -171.36 0.07 Allowed 'General case' 0 N--CA 1.482 1.155 0 N-CA-C 113.349 0.87 . . . . 0.0 113.349 -174.809 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 226' ' ' ILE . . . . . . . . . . . . . 46.5 mt -118.29 105.84 18.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 172.786 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -80.34 99.72 8.05 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 122.965 0.506 . . . . 0.0 109.857 -178.713 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 18.2 pt20 -94.25 162.14 13.97 Favored 'General case' 0 N--CA 1.484 1.235 0 C-N-CA 123.929 0.892 . . . . 0.0 110.184 -178.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . 0.516 ' HB ' ' HA ' ' A' ' 145' ' ' LYS . 24.6 p -90.06 121.83 32.49 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 122.669 0.388 . . . . 0.0 111.284 -170.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -139.65 -21.0 0.91 Allowed 'General case' 0 N--CA 1.483 1.221 0 C-N-CA 123.464 0.706 . . . . 0.0 112.284 -166.695 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 2.4 mptp? -82.33 -80.42 0.16 Allowed 'General case' 0 N--CA 1.488 1.463 0 CA-C-N 117.921 0.328 . . . . 0.0 110.453 -164.165 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 232' ' ' SER . . . . . 0.41 ' HB2' ' HD2' ' A' ' 145' ' ' LYS . 73.0 m -76.46 93.5 3.53 Favored 'General case' 0 C--N 1.36 1.03 0 CA-C-N 118.304 0.502 . . . . 0.0 109.788 171.566 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 233' ' ' ILE . . . . . . . . . . . . . 33.2 pt -69.99 -34.59 60.44 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.671 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.328 177.342 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 234' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 52.46 27.56 5.09 Favored 'General case' 0 N--CA 1.493 1.703 0 C-N-CA 125.068 1.347 . . . . 0.0 111.696 179.408 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -103.81 -11.79 17.33 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 124.718 1.207 . . . . 0.0 111.506 -168.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 236' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 -59.57 134.28 88.95 Favored Pre-proline 0 CA--C 1.55 0.965 0 C-N-CA 122.731 0.413 . . . . 0.0 110.888 -175.283 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -68.64 89.29 0.42 Allowed 'Trans proline' 0 C--N 1.373 1.825 0 C-N-CA 122.252 1.968 . . . . 0.0 110.36 174.374 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 238' ' ' GLU . . . . . . . . . . . . . 16.2 tp10 -66.29 -80.46 0.04 OUTLIER 'General case' 0 CA--C 1.549 0.92 0 CA-C-N 115.123 -0.944 . . . . 0.0 111.148 -170.352 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 239' ' ' ILE . . . . . . . . . . . . . 8.2 tp -95.96 -23.47 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.135 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 174.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 . . . . . 0 C--O 1.25 1.101 0 C-N-CA 124.808 1.243 . . . . 0.0 108.101 -177.604 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 251' ' ' BEZ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 253' ' ' LYS . . . . . 0.475 ' HB2' ' HA ' ' A' ' 44' ' ' GLU . 18.3 tptm -126.41 57.21 1.42 Allowed 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 107.907 -1.146 . . . . 0.0 107.907 165.39 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 254' ' ' ARG . . . . . 0.589 ' HB2' HG13 ' A' ' 216' ' ' VAL . 18.2 mmm180 -68.44 149.33 49.44 Favored 'General case' 0 C--O 1.241 0.633 0 CA-C-N 113.991 -1.459 . . . . 0.0 109.746 173.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 255' ' ' M9P . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.879 0 CA-C-O 120.801 0.112 . . . . 0.0 113.237 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.655 ' HA ' ' HG3' ' A' ' 88' ' ' GLN . 38.2 t -77.53 154.02 32.83 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 123.733 0.813 . . . . 0.0 110.549 177.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -154.03 -74.92 0.12 Allowed 'General case' 0 N--CA 1.478 0.95 0 C-N-CA 122.458 0.303 . . . . 0.0 110.463 173.043 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.554 ' O ' HG22 ' A' ' 118' ' ' VAL . . . -162.7 8.06 0.06 Allowed 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 112.175 0.435 . . . . 0.0 112.175 -175.774 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -123.37 83.92 2.2 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 177.223 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.693 ' HA ' ' HA ' ' A' ' 88' ' ' GLN . 4.8 mp -125.07 98.79 5.83 Favored 'General case' 0 N--CA 1.481 1.122 0 CA-C-O 119.333 -0.365 . . . . 0.0 111.559 -173.663 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 30.3 tt0 -81.58 144.84 30.98 Favored 'General case' 0 C--O 1.252 1.207 0 CA-C-O 121.979 0.895 . . . . 0.0 111.197 -175.125 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.634 HD21 HD13 ' A' ' 119' ' ' LEU . 53.9 mt -85.31 115.3 22.98 Favored 'General case' 0 C--O 1.242 0.706 0 CA-C-N 113.556 -1.656 . . . . 0.0 109.752 176.04 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -104.03 125.96 50.78 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 171.319 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 47.0 ptt85 -67.17 129.39 39.76 Favored 'General case' 0 N--CA 1.478 0.958 0 CA-C-N 118.36 0.527 . . . . 0.0 109.76 178.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.41 ' HB3' HD13 ' A' ' 161' ' ' LEU . . . -121.69 -21.35 6.18 Favored 'General case' 0 N--CA 1.479 0.983 0 C-N-CA 122.746 0.418 . . . . 0.0 111.239 -176.366 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . 0.668 ' HB3' ' HB3' ' A' ' 83' ' ' ALA . . . -164.01 161.4 22.63 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 121.639 0.733 . . . . 0.0 111.058 178.592 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -93.71 155.84 17.02 Favored 'General case' 0 C--O 1.245 0.826 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 161.31 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.592 HG23 ' HA2' ' A' ' 82' ' ' GLY . 85.9 t -67.21 103.35 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 175.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 58.8 tttp -168.55 133.32 1.64 Allowed 'General case' 0 C--O 1.239 0.528 0 CA-C-N 115.123 -0.944 . . . . 0.0 108.617 -170.308 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 23.3 t90 -74.61 114.01 12.54 Favored 'General case' 0 CA--C 1.542 0.655 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 167.504 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.565 ' HB3' ' HB2' ' A' ' 169' ' ' ALA . 39.6 tt0 -72.25 145.42 47.94 Favored 'General case' 0 CA--C 1.548 0.888 0 C-N-CA 123.344 0.658 . . . . 0.0 109.825 176.825 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -78.32 -2.73 39.48 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 123.878 0.871 . . . . 0.0 112.716 -172.579 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 31.6 mm-40 -87.08 43.44 1.1 Allowed 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 122.99 0.516 . . . . 0.0 110.152 -175.616 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -60.4 101.27 0.12 Allowed 'General case' 0 C--N 1.354 0.788 0 C-N-CA 124.775 1.23 . . . . 0.0 110.803 -174.603 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -105.37 117.44 34.02 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 124.236 1.014 . . . . 0.0 109.496 -173.662 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.513 HD13 ' HB2' ' A' ' 171' ' ' GLN . 43.4 mm -76.55 127.43 37.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 C-N-CA 123.025 0.53 . . . . 0.0 110.063 -172.82 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.433 ' HG ' ' HE2' ' A' ' 191' ' ' PHE . 29.2 m -148.25 -171.55 3.86 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 124.149 0.98 . . . . 0.0 110.796 -172.604 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 133.4 66.28 0.08 OUTLIER Glycine 0 C--N 1.347 1.185 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 -179.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.515 ' H ' ' HA ' ' A' ' 189' ' ' LEU . 13.1 m -66.62 -52.6 43.36 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-N 114.648 -0.776 . . . . 0.0 111.845 -167.308 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.446 ' HB2' ' OG ' ' A' ' 188' ' ' SER . 14.8 m -95.26 144.12 27.26 Favored Pre-proline 0 CA--C 1.552 1.048 0 C-N-CA 123.119 0.568 . . . . 0.0 110.525 -172.747 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -84.97 -161.06 0.12 Allowed 'Trans proline' 0 C--N 1.378 2.113 0 C-N-CA 123.0 2.467 . . . . 0.0 112.623 174.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 45.3 mm -63.05 133.72 28.68 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 168.405 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.529 HD13 HG21 ' A' ' 217' ' ' THR . 0.2 OUTLIER -143.75 163.72 32.53 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 123.719 0.808 . . . . 0.0 109.639 -163.428 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 11.3 t -108.65 145.84 34.34 Favored 'General case' 0 N--CA 1.479 1.013 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 172.699 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.447 HD12 ' CE2' ' A' ' 177' ' ' PHE . 14.9 tt -135.27 154.38 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 C-N-CA 123.4 0.68 . . . . 0.0 109.336 -174.143 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 34.7 p -95.35 103.77 15.65 Favored 'General case' 0 C--O 1.243 0.713 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 171.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.45 ' HA ' ' HA ' ' A' ' 39' ' ' MET . 15.7 tt -91.05 117.53 34.47 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.764 179.432 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.615 ' HB3' ' HB3' ' A' ' 38' ' ' SER . 35.5 t -82.97 118.52 23.55 Favored 'General case' 0 C--O 1.242 0.662 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.003 -178.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -52.84 -28.15 21.55 Favored 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 125.3 1.44 . . . . 0.0 112.474 -177.682 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -48.22 -41.26 26.94 Favored 'General case' 0 CA--C 1.55 0.957 0 C-N-CA 125.265 1.426 . . . . 0.0 111.884 174.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 145.68 9.89 0.28 Allowed Glycine 0 C--N 1.34 0.791 0 CA-C-N 114.929 -1.032 . . . . 0.0 111.942 178.507 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.615 ' HB3' ' HB3' ' A' ' 34' ' ' SER . 32.7 t -109.82 164.2 12.79 Favored 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 123.537 0.735 . . . . 0.0 110.334 -173.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . 0.45 ' HA ' ' HA ' ' A' ' 33' ' ' ILE . 22.3 ptm -153.67 127.64 8.95 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 123.439 0.696 . . . . 0.0 109.133 173.604 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 17.7 p -169.46 169.82 8.68 Favored 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 123.091 0.556 . . . . 0.0 110.862 -175.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.0 mp -78.69 124.32 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 N-CA-C 104.815 -2.291 . . . . 0.0 104.815 157.699 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.43 79.02 0.01 OUTLIER 'General case' 0 CA--C 1.558 1.278 0 C-N-CA 124.238 1.015 . . . . 0.0 112.824 -170.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 92.5 m-20 -130.5 173.65 10.65 Favored 'General case' 0 N--CA 1.475 0.818 0 C-N-CA 125.017 1.327 . . . . 0.0 109.088 -177.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -72.23 143.08 48.94 Favored 'General case' 0 CA--C 1.544 0.738 0 C-N-CA 123.54 0.736 . . . . 0.0 110.755 177.063 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -115.41 149.29 38.22 Favored 'General case' 0 N--CA 1.473 0.678 0 C-N-CA 123.207 0.603 . . . . 0.0 110.594 177.593 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -145.19 152.2 39.62 Favored 'General case' 0 C--O 1.242 0.694 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 177.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -101.1 -176.43 3.16 Favored 'General case' 0 N--CA 1.476 0.848 0 C-N-CA 123.209 0.603 . . . . 0.0 110.501 176.605 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.482 ' N ' HE21 ' A' ' 48' ' ' GLN . 0.0 OUTLIER -164.68 175.46 9.73 Favored 'General case' 0 N--CA 1.486 1.346 0 C-N-CA 124.426 1.09 . . . . 0.0 109.874 -176.609 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.583 ' HB ' ' HA ' ' A' ' 95' ' ' SER . 13.4 t -135.0 146.72 49.32 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 123.589 0.756 . . . . 0.0 109.188 171.535 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.438 ' HB3' ' OE1' ' A' ' 96' ' ' GLN . 29.5 tp -167.13 68.8 0.09 Allowed 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 175.828 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -173.87 142.89 6.76 Favored Glycine 0 C--N 1.342 0.888 0 CA-C-N 114.175 -1.375 . . . . 0.0 110.617 -177.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -115.89 -58.22 0.33 Allowed Glycine 0 C--N 1.348 1.205 0 CA-C-N 117.465 0.632 . . . . 0.0 112.472 -175.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 59.56 52.64 51.87 Favored Glycine 0 C--N 1.356 1.682 0 C-N-CA 123.251 0.453 . . . . 0.0 112.192 -179.407 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 100.89 -133.08 11.17 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 110.55 -1.02 . . . . 0.0 110.55 -169.742 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 38.4 t -163.37 -36.7 0.04 OUTLIER 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 123.429 0.692 . . . . 0.0 110.502 179.546 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -72.96 -15.01 78.44 Favored Glycine 0 C--N 1.357 1.726 0 O-C-N 123.579 0.549 . . . . 0.0 114.337 -176.392 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 70.85 -98.51 0.7 Allowed Glycine 0 C--N 1.346 1.136 0 N-CA-C 112.324 -0.311 . . . . 0.0 112.324 -177.566 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -87.38 71.69 2.64 Favored Glycine 0 C--N 1.348 1.215 0 N-CA-C 111.205 -0.758 . . . . 0.0 111.205 177.184 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -67.82 88.98 0.19 Allowed Glycine 0 C--N 1.346 1.095 0 C-N-CA 122.964 0.316 . . . . 0.0 113.133 -178.109 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 7.8 tp10 -74.95 -51.0 14.84 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 123.346 0.659 . . . . 0.0 109.542 176.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 89.2 t80 -76.46 105.18 7.37 Favored 'General case' 0 C--O 1.24 0.595 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 174.491 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . 65.7 114.55 0.03 OUTLIER 'General case' 0 CA--C 1.546 0.816 0 O-C-N 124.384 1.052 . . . . 0.0 110.512 -170.222 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -57.35 150.61 29.54 Favored Glycine 0 CA--C 1.533 1.176 0 CA-C-N 115.769 -0.65 . . . . 0.0 112.968 176.512 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.477 ' HB ' ' HG3' ' A' ' 122' ' ' LYS . 4.6 t -81.93 20.46 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 C-N-CA 124.356 1.062 . . . . 0.0 111.883 -169.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 3.3 tm? 74.33 102.69 0.07 Allowed 'General case' 0 N--CA 1.484 1.274 0 C-N-CA 124.85 1.26 . . . . 0.0 110.043 173.76 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . 0.467 ' CD1' ' HD2' ' A' ' 122' ' ' LYS . 30.2 m-90 -80.13 142.18 35.03 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 123.755 0.822 . . . . 0.0 109.712 178.103 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 27.1 t0 -83.68 75.84 10.03 Favored 'General case' 0 CA--C 1.54 0.56 0 CA-C-O 121.759 0.79 . . . . 0.0 109.077 -178.833 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.411 ' HA ' ' O ' ' A' ' 78' ' ' GLU . 6.4 m -107.15 101.37 37.84 Favored Pre-proline 0 CA--C 1.554 1.098 0 CA-C-N 114.75 -1.114 . . . . 0.0 111.19 -173.562 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.64 ' HG3' ' HB3' ' A' ' 80' ' ' GLU . 73.7 Cg_endo -75.02 -46.38 0.24 Allowed 'Trans proline' 0 C--N 1.377 2.04 0 C-N-CA 122.274 1.982 . . . . 0.0 111.489 174.644 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 9.0 p -92.1 128.8 43.9 Favored Pre-proline 0 CA--C 1.547 0.843 0 C-N-CA 124.197 0.999 . . . . 0.0 110.072 178.678 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -58.39 151.28 62.15 Favored 'Trans proline' 0 C--N 1.374 1.901 0 C-N-CA 123.232 2.621 . . . . 0.0 113.296 168.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 66.8 Cg_exo -50.58 -47.0 26.72 Favored 'Trans proline' 0 C--N 1.384 2.41 0 C-N-CA 123.686 2.924 . . . . 0.0 115.703 176.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_exo -70.72 128.36 15.04 Favored 'Trans proline' 0 C--N 1.389 2.665 0 CA-C-N 121.884 1.709 . . . . 0.0 111.35 175.586 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 39.7 t 54.18 85.77 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.315 0 C-N-CA 125.009 1.324 . . . . 0.0 111.648 -177.543 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 168.64 124.82 0.75 Allowed Glycine 0 C--N 1.34 0.788 0 N-CA-C 111.034 -0.827 . . . . 0.0 111.034 -179.189 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 65.8 mttm -83.26 -27.66 29.71 Favored 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 123.286 0.635 . . . . 0.0 110.887 -176.565 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -89.3 151.81 21.9 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 123.611 0.764 . . . . 0.0 111.069 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.411 ' O ' ' HA ' ' A' ' 68' ' ' VAL . 3.9 tm-20 -126.21 -69.46 0.77 Allowed 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 174.328 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.431 HD12 ' CE1' ' A' ' 121' ' ' HIS . 7.9 tt -84.88 128.17 34.49 Favored 'General case' 0 C--O 1.244 0.764 0 N-CA-C 106.685 -1.598 . . . . 0.0 106.685 170.533 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.64 ' HB3' ' HG3' ' A' ' 69' ' ' PRO . 8.7 pt-20 -68.01 148.0 51.63 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-O 121.178 0.513 . . . . 0.0 111.661 -175.155 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.411 ' HB2' ' HA ' ' A' ' 103' ' ' LYS . 6.3 p-10 -72.27 136.42 46.29 Favored 'General case' 0 C--O 1.239 0.524 0 CA-C-N 115.74 -0.663 . . . . 0.0 109.552 173.13 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.592 ' HA2' HG23 ' A' ' 14' ' ' VAL . . . 163.28 -175.05 39.6 Favored Glycine 0 C--N 1.34 0.79 0 O-C-N 123.167 0.292 . . . . 0.0 112.574 -173.106 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . 0.668 ' HB3' ' HB3' ' A' ' 12' ' ' ALA . . . -93.18 110.17 21.68 Favored 'General case' 0 C--O 1.244 0.789 0 CA-C-O 121.102 0.477 . . . . 0.0 110.503 -177.761 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 18.1 m-85 -107.41 136.92 46.39 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 176.731 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.68 131.79 36.82 Favored 'General case' 0 C--O 1.245 0.837 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 175.183 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.533 HD11 ' HE2' ' A' ' 107' ' ' PHE . 38.0 mt -90.58 111.46 23.54 Favored 'Isoleucine or valine' 0 C--O 1.273 2.3 0 CA-C-O 122.559 1.171 . . . . 0.0 110.482 -176.426 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.473 ' HZ1' ' HB3' ' A' ' 94' ' ' TYR . 7.1 tmtm? -116.73 130.89 57.0 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-N 112.857 -1.974 . . . . 0.0 107.061 179.075 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . 0.693 ' HA ' ' HA ' ' A' ' 6' ' ' LEU . 21.0 tm0? -79.86 111.08 15.84 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 106.838 -1.541 . . . . 0.0 106.838 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . 0.432 ' HE3' ' HB2' ' A' ' 89' ' ' LYS . 35.0 ttmt -117.1 93.61 4.25 Favored 'General case' 0 C--O 1.238 0.458 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 -178.277 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -104.51 144.61 15.86 Favored Glycine 0 CA--C 1.496 -1.152 0 CA-C-N 114.158 -1.383 . . . . 0.0 110.953 -176.263 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 2.9 mp -65.3 -15.34 18.27 Favored 'Isoleucine or valine' 0 CA--C 1.566 1.589 0 C-N-CA 125.087 1.355 . . . . 0.0 109.675 179.735 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 1.1 pp -118.43 0.31 11.6 Favored 'General case' 0 CA--C 1.557 1.229 0 N-CA-C 113.467 0.914 . . . . 0.0 113.467 175.658 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 175.67 154.45 11.43 Favored Glycine 0 N--CA 1.488 2.128 0 CA-C-N 119.289 0.95 . . . . 0.0 114.185 -175.048 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . 0.473 ' HB3' ' HZ1' ' A' ' 87' ' ' LYS . 75.4 m-85 -130.71 125.39 33.79 Favored 'General case' 0 N--CA 1.487 1.405 0 C-N-CA 123.421 0.688 . . . . 0.0 112.086 -171.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.583 ' HA ' ' HB ' ' A' ' 49' ' ' THR . 39.8 m -135.66 157.36 47.06 Favored 'General case' 0 N--CA 1.492 1.675 0 C-N-CA 124.794 1.237 . . . . 0.0 110.734 171.506 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.471 ' H ' ' HA ' ' A' ' 49' ' ' THR . 11.7 pt20 -100.19 148.89 24.12 Favored 'General case' 0 N--CA 1.496 1.875 0 N-CA-C 107.977 -1.12 . . . . 0.0 107.977 158.366 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.649 HD11 ' HB2' ' A' ' 88' ' ' GLN . 0.0 OUTLIER -132.17 -39.01 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 CA-C-N 119.629 1.104 . . . . 0.0 111.305 179.167 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -175.59 -145.99 5.68 Favored Glycine 0 C--N 1.347 1.143 0 C-N-CA 119.652 -1.261 . . . . 0.0 114.199 -171.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -158.64 175.28 13.85 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 123.488 0.715 . . . . 0.0 111.449 -177.048 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -172.25 176.47 45.25 Favored Glycine 0 C--N 1.344 0.993 0 CA-C-N 115.401 -0.818 . . . . 0.0 111.539 -178.608 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.447 HG11 HD11 ' A' ' 146' ' ' LEU . 47.2 t -123.12 125.93 72.81 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.012 0 C-N-CA 122.866 0.466 . . . . 0.0 111.028 -175.325 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 39.4 t80 -85.34 144.63 27.94 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 167.092 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.603 ' HG3' ' HG3' ' A' ' 104' ' ' GLU . 22.9 tptm -157.0 133.83 10.19 Favored 'General case' 0 C--O 1.239 0.518 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 173.665 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.603 ' HG3' ' HG3' ' A' ' 103' ' ' LYS . 29.5 mt-10 62.6 -91.83 0.03 OUTLIER 'General case' 0 N--CA 1.479 1.004 0 C-N-CA 124.983 1.313 . . . . 0.0 111.569 176.062 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -143.89 31.26 1.88 Allowed Glycine 0 C--N 1.341 0.831 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.4 t -146.28 129.4 16.55 Favored 'General case' 0 C--O 1.241 0.653 0 C-N-CA 123.694 0.798 . . . . 0.0 110.614 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' PHE . . . . . 0.533 ' HE2' HD11 ' A' ' 86' ' ' ILE . 67.2 t80 -94.92 104.01 15.89 Favored 'General case' 0 C--N 1.345 0.386 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 171.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . 0.541 ' CE1' ' HB3' ' A' ' 103' ' ' LYS . 1.5 p-80 -107.8 121.08 44.01 Favored 'General case' 0 C--N 1.325 -0.481 0 C-N-CA 123.247 0.619 . . . . 0.0 109.492 -178.862 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 8.6 t -136.62 179.77 6.17 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 123.839 0.856 . . . . 0.0 111.241 -172.52 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' MET . . . . . 0.449 ' SD ' ' O ' ' A' ' 212' ' ' GLY . 27.7 ttm -74.92 150.42 39.12 Favored 'General case' 0 CA--C 1.547 0.86 0 C-N-CA 125.463 1.505 . . . . 0.0 109.94 173.204 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' TRP . . . . . 0.407 ' HA ' HG22 ' A' ' 138' ' ' ILE . 86.8 t90 -73.61 -56.32 5.16 Favored 'General case' 0 N--CA 1.494 1.747 0 CA-C-N 118.32 0.509 . . . . 0.0 111.967 -168.474 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 1.2 p-80 -68.69 2.96 2.12 Favored 'General case' 0 N--CA 1.485 1.314 0 N-CA-C 114.332 1.234 . . . . 0.0 114.332 -171.358 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.412 HG21 HD12 ' A' ' 86' ' ' ILE . 23.0 m -60.32 -38.64 78.27 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 167.273 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 12.0 t -122.48 174.24 7.17 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 124.663 1.185 . . . . 0.0 108.498 178.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 50.7 ttt-85 -93.14 31.26 1.48 Allowed 'General case' 0 N--CA 1.485 1.275 0 CA-C-O 121.326 0.584 . . . . 0.0 109.588 -179.005 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.418 ' HA2' HD12 ' A' ' 138' ' ' ILE . . . 73.74 35.43 54.91 Favored Glycine 0 C--N 1.348 1.234 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 -167.22 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -122.36 -163.31 1.07 Allowed 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 123.663 0.785 . . . . 0.0 111.782 -168.833 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.698 HG21 ' HG3' ' A' ' 125' ' ' ARG . 2.0 m -89.21 156.56 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.127 0 C-N-CA 123.359 0.664 . . . . 0.0 110.822 -172.413 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.634 HD13 HD21 ' A' ' 8' ' ' LEU . 54.8 mt -110.46 174.78 5.7 Favored 'General case' 0 CA--C 1.551 1.018 0 C-N-CA 124.357 1.063 . . . . 0.0 109.586 170.758 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 23.5 mmt -124.63 137.6 54.36 Favored 'General case' 0 C--O 1.25 1.093 0 C-N-CA 123.534 0.734 . . . . 0.0 110.165 -176.026 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.45 ' NE2' ' HD1' ' A' ' 66' ' ' TRP . 77.6 t60 -130.88 95.85 3.93 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 168.002 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.477 ' HG3' ' HB ' ' A' ' 64' ' ' VAL . 0.1 OUTLIER 62.93 20.44 12.25 Favored 'General case' 0 N--CA 1.495 1.811 0 C-N-CA 124.513 1.125 . . . . 0.0 111.523 -168.461 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 88.52 14.65 61.31 Favored Glycine 0 C--N 1.345 1.054 0 CA-C-O 119.7 -0.5 . . . . 0.0 112.682 -172.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -82.18 129.5 34.85 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 169.072 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . 0.698 ' HG3' HG21 ' A' ' 118' ' ' VAL . 35.8 ttm180 -78.59 98.71 6.25 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 124.794 1.237 . . . . 0.0 111.217 -173.619 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.446 HD11 ' HB2' ' A' ' 121' ' ' HIS . 18.4 mt -89.08 95.48 5.44 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.693 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 175.751 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -91.68 141.57 25.84 Favored Pre-proline 0 N--CA 1.487 1.422 0 C-N-CA 122.732 0.413 . . . . 0.0 110.256 -179.212 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -73.42 153.8 50.36 Favored 'Trans proline' 0 C--N 1.382 2.307 0 C-N-CA 122.924 2.416 . . . . 0.0 114.791 -170.786 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 66.4 p -101.88 -32.45 10.22 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 123.97 0.908 . . . . 0.0 110.209 172.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 72.4 t-105 -130.38 149.71 51.94 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 124.059 0.944 . . . . 0.0 109.355 -177.76 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -156.77 125.69 5.93 Favored 'General case' 0 C--O 1.241 0.654 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 175.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -141.75 110.16 6.0 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 123.108 0.563 . . . . 0.0 109.896 179.717 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 3.5 t -77.09 -17.02 14.56 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.286 0 C-N-CA 123.654 0.782 . . . . 0.0 111.307 -176.552 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 58.3 mttp -65.21 -53.79 39.36 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 123.697 0.799 . . . . 0.0 110.903 -176.53 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 47.6 mmtm -82.93 -17.38 43.81 Favored 'General case' 0 N--CA 1.478 0.934 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.181 172.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 11.5 t70 60.49 66.74 0.9 Allowed 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 125.865 1.666 . . . . 0.0 109.44 -173.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . . . . . . . . . 51.8 mt -143.63 123.94 13.83 Favored 'General case' 0 CA--C 1.547 0.844 0 CA-C-N 113.673 -1.603 . . . . 0.0 108.7 -179.17 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.418 HD12 ' HA2' ' A' ' 116' ' ' GLY . 16.8 tt -118.7 138.79 48.26 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 176.076 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 35.0 t -134.37 151.76 51.4 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 121.785 0.802 . . . . 0.0 111.797 -175.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 18.8 m-85 -124.25 102.77 7.87 Favored 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 113.784 -1.553 . . . . 0.0 107.423 -169.754 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 97.09 -1.98 61.22 Favored Glycine 0 C--N 1.346 1.092 0 O-C-N 123.776 0.672 . . . . 0.0 113.366 -177.09 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . -175.69 -150.54 8.06 Favored Glycine 0 C--N 1.347 1.155 0 CA-C-O 119.503 -0.61 . . . . 0.0 111.986 -177.52 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -116.83 -179.43 17.79 Favored Glycine 0 C--N 1.352 1.419 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 171.185 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' TRP . . . . . 0.527 ' HA ' ' HB2' ' A' ' 108' ' ' HIS . 54.1 t-105 -70.61 105.15 3.03 Favored 'General case' 0 N--CA 1.476 0.867 0 CA-C-N 118.655 1.227 . . . . 0.0 108.782 175.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 19.2 ptmt -138.41 121.55 16.86 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 122.944 0.498 . . . . 0.0 110.944 -171.058 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' LEU . . . . . 0.447 HD11 HG11 ' A' ' 101' ' ' VAL . 46.1 mt -153.17 -33.13 0.12 Allowed 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 125.586 1.554 . . . . 0.0 107.928 172.609 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 71.65 101.55 0.07 Allowed 'General case' 0 C--N 1.362 1.12 0 C-N-CA 126.166 1.786 . . . . 0.0 110.545 -179.048 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.455 ' HA3' ' O ' ' A' ' 207' ' ' VAL . . . -167.75 148.03 12.37 Favored Glycine 0 C--O 1.242 0.655 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 178.218 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -151.66 108.57 3.53 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -177.193 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' TRP . . . . . 0.605 ' HB2' HG21 ' A' ' 208' ' ' VAL . 81.5 t90 -65.9 123.95 21.2 Favored 'General case' 0 CA--C 1.537 0.459 0 CA-C-O 120.762 0.315 . . . . 0.0 110.692 172.775 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -151.52 90.49 1.57 Allowed 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 160.567 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . 0.5 ' HG3' ' H ' ' A' ' 154' ' ' GLU . 12.0 tp10 -131.81 142.91 49.86 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 115.133 -0.94 . . . . 0.0 109.285 178.793 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -64.19 -30.42 77.75 Favored Glycine 0 C--N 1.349 1.287 0 N-CA-C 111.404 -0.678 . . . . 0.0 111.404 173.158 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . 0.5 ' H ' ' HG3' ' A' ' 152' ' ' GLU . 29.9 mt-10 -81.22 173.34 12.61 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 124.786 1.234 . . . . 0.0 110.003 172.566 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . 0.495 ' HB2' ' HB3' ' A' ' 171' ' ' GLN . 4.4 mp0 -67.31 166.76 13.71 Favored 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 123.738 0.815 . . . . 0.0 112.41 -173.394 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 15.0 p -92.67 141.47 14.58 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.167 172.117 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . 0.41 ' HG3' ' HG2' ' A' ' 171' ' ' GLN . 20.4 mp0 -99.22 131.51 45.2 Favored 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -173.392 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 41.4 t -133.95 102.06 4.2 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 -178.432 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.531 HD23 ' H ' ' A' ' 159' ' ' LEU . 2.3 pt? -76.3 85.5 3.08 Favored 'General case' 0 CA--C 1.545 0.768 0 CA-C-O 122.386 1.089 . . . . 0.0 108.893 176.004 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -64.65 114.53 4.48 Favored 'General case' 0 C--O 1.239 0.549 0 CA-C-N 114.221 -1.354 . . . . 0.0 108.64 178.441 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . 0.41 HD13 ' HB3' ' A' ' 11' ' ' ALA . 84.6 mt -69.0 94.49 0.64 Allowed 'General case' 0 C--O 1.239 0.503 0 O-C-N 123.655 0.597 . . . . 0.0 109.913 -172.312 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -65.28 112.6 8.74 Favored Pre-proline 0 CA--C 1.548 0.889 0 CA-C-N 114.267 -1.333 . . . . 0.0 109.436 -177.479 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -61.31 115.91 3.05 Favored 'Trans proline' 0 C--N 1.375 1.933 0 C-N-CA 122.503 2.135 . . . . 0.0 112.522 -171.405 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 93.12 -6.42 75.96 Favored Glycine 0 C--N 1.348 1.196 0 CA-C-N 114.966 -1.016 . . . . 0.0 113.883 177.542 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 61.3 mttm -128.07 -179.3 4.91 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 123.626 0.77 . . . . 0.0 109.207 -176.691 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -61.38 160.7 22.54 Favored Pre-proline 0 CA--C 1.558 1.26 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 164.302 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . 0.498 ' HG3' ' HB2' ' A' ' 12' ' ' ALA . 30.9 Cg_exo -61.93 -172.53 0.11 Allowed 'Trans proline' 0 C--N 1.375 1.951 0 C-N-CA 122.361 2.041 . . . . 0.0 114.491 -178.309 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 20.0 ttm-85 -138.13 99.46 3.88 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 171.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . 0.565 ' HB2' ' HB3' ' A' ' 17' ' ' GLU . . . -73.39 107.2 5.56 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.341 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 77.2 t -112.11 123.94 68.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 C-N-CA 123.493 0.717 . . . . 0.0 110.069 -176.584 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . 0.513 ' HB2' HD13 ' A' ' 22' ' ' ILE . 20.9 mt-30 -93.03 118.29 31.02 Favored 'General case' 0 C--N 1.341 0.217 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 175.362 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . 0.723 HG21 HG23 ' A' ' 187' ' ' VAL . 5.9 t -126.29 142.8 51.39 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 123.206 0.603 . . . . 0.0 109.471 176.511 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -75.89 156.89 84.21 Favored Pre-proline 0 CA--C 1.561 1.368 0 CA-C-N 115.993 -0.548 . . . . 0.0 109.612 178.058 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -69.43 124.55 11.33 Favored 'Trans proline' 0 C--N 1.375 1.939 0 C-N-CA 122.178 1.919 . . . . 0.0 112.708 -177.492 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -158.78 139.38 6.22 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 108.74 -1.744 . . . . 0.0 108.74 175.238 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.749 ' HG ' ' HB3' ' A' ' 186' ' ' ALA 0.264 0.0 OUTLIER -175.8 -169.97 0.37 Allowed 'General case' 0 N--CA 1.48 1.046 0 C-N-CA 123.949 0.899 . . . . 0.0 110.754 178.95 . . . . . . . . 4 4 . 1 . 008 nuclear nobuild full ' A' A ' 177' ' ' PHE . . . . . 0.449 ' HA ' ' O ' ' A' ' 29' ' ' LEU . 79.3 m-85 -91.8 158.3 16.41 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 114.863 -1.062 . . . . 0.0 111.118 -152.28 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -133.36 109.48 9.38 Favored 'General case' 0 C--O 1.239 0.523 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 170.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 1.2 m -140.55 170.18 16.26 Favored 'General case' 0 N--CA 1.479 1.018 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 175.118 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 36.1 t30 -59.85 102.43 0.16 Allowed 'General case' 0 CA--C 1.548 0.892 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 168.324 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . 79.22 1.24 2.34 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 125.415 1.486 . . . . 0.0 111.492 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -123.86 54.2 0.73 Allowed Glycine 0 C--N 1.348 1.225 0 N-CA-C 111.409 -0.676 . . . . 0.0 111.409 178.547 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 84.6 m -110.21 98.16 7.48 Favored 'General case' 0 CA--C 1.536 0.441 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 175.452 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . 0.514 ' O ' ' HB3' ' A' ' 176' ' ' LEU . 3.6 mp -125.13 152.82 31.93 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 178.569 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . -127.62 116.98 2.52 Favored Glycine 0 C--N 1.377 2.851 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 172.066 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.749 ' HB3' ' HG ' ' A' ' 176' ' ' LEU . . . -161.87 -149.34 0.16 Allowed 'General case' 0 C--N 1.373 1.598 0 CA-C-N 119.056 1.428 . . . . 0.0 111.9 -159.225 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 187' ' ' VAL . . . . . 0.723 HG23 HG21 ' A' ' 172' ' ' THR . 0.4 OUTLIER -91.57 117.77 35.54 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.971 0 C-N-CA 124.288 1.035 . . . . 0.0 110.028 -176.228 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . 0.446 ' OG ' ' HB2' ' A' ' 26' ' ' SER . 10.6 t -130.44 90.78 2.98 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 123.406 0.682 . . . . 0.0 109.861 -174.123 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 189' ' ' LEU . . . . . 0.515 ' HA ' ' H ' ' A' ' 25' ' ' SER . 1.7 pp -136.91 -175.0 3.89 Favored 'General case' 0 N--CA 1.489 1.524 0 C-N-CA 123.423 0.689 . . . . 0.0 112.081 -174.292 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -135.19 119.29 17.57 Favored 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 124.238 1.015 . . . . 0.0 108.982 171.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 191' ' ' PHE . . . . . 0.433 ' HE2' ' HG ' ' A' ' 23' ' ' SER . 9.6 m-85 -149.15 -178.89 6.64 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 123.223 0.609 . . . . 0.0 111.916 -178.711 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 42.3 m -60.71 157.09 40.72 Favored Pre-proline 0 CA--C 1.555 1.161 0 C-N-CA 124.787 1.235 . . . . 0.0 111.28 176.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . 0.41 ' HB3' HH12 ' B' ' 254' ' ' ARG . 3.8 Cg_exo -34.58 91.23 0.01 OUTLIER 'Trans proline' 0 C--N 1.393 2.881 0 C-N-CA 125.236 3.957 . . . . 0.0 115.225 -178.018 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -74.08 134.48 18.5 Favored Glycine 0 C--N 1.35 1.325 0 CA-C-N 114.582 -1.19 . . . . 0.0 112.394 -179.669 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 40.7 p -82.72 122.75 28.57 Favored 'General case' 0 C--O 1.244 0.796 0 C-N-CA 123.752 0.821 . . . . 0.0 110.097 178.013 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 18.1 m -62.45 88.08 0.03 OUTLIER 'General case' 0 C--N 1.363 1.17 0 C-N-CA 123.591 0.756 . . . . 0.0 110.847 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . 0.468 ' O ' HD22 ' A' ' 210' ' ' LEU . . . 129.12 21.14 1.37 Allowed Glycine 0 CA--C 1.523 0.553 0 CA-C-N 114.897 -1.047 . . . . 0.0 112.574 -179.276 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 198' ' ' SER . . . . . 0.444 ' HA ' ' HD3' ' A' ' 199' ' ' PRO . 32.2 p -70.18 123.64 89.23 Favored Pre-proline 0 N--CA 1.478 0.951 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 172.758 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' A' ' 198' ' ' SER . 32.1 Cg_exo -58.71 141.88 98.13 Favored 'Trans proline' 0 C--N 1.374 1.918 0 C-N-CA 122.9 2.4 . . . . 0.0 114.368 -168.538 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 200' ' ' ILE . . . . . 0.513 HD13 HG12 ' A' ' 226' ' ' ILE . 47.8 mt -110.8 118.96 58.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.325 0 C-N-CA 124.851 1.26 . . . . 0.0 108.754 175.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 201' ' ' ILE . . . . . 0.592 HG12 HG22 ' A' ' 207' ' ' VAL . 24.0 mt -113.02 143.47 22.64 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.377 0 C-N-CA 124.563 1.145 . . . . 0.0 110.029 -176.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 43.5 t0 -84.83 153.6 22.84 Favored 'General case' 0 N--CA 1.486 1.357 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 170.21 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 84.0 tttt -48.33 -27.29 2.45 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 124.689 1.196 . . . . 0.0 113.96 -172.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . 0.582 ' H ' ' HD2' ' A' ' 204' ' ' LYS . 9.7 mptt -64.1 -20.09 65.71 Favored 'General case' 0 N--CA 1.484 1.227 0 C-N-CA 124.27 1.028 . . . . 0.0 111.78 -177.448 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 101.6 5.85 50.9 Favored Glycine 0 C--N 1.345 1.033 0 CA-C-N 116.361 -0.382 . . . . 0.0 112.676 -177.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 39.8 tttm -106.61 140.74 39.01 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 123.162 0.585 . . . . 0.0 109.618 -179.762 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.592 HG22 HG12 ' A' ' 201' ' ' ILE . 61.9 t -82.63 123.98 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 123.208 0.603 . . . . 0.0 111.41 -168.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 208' ' ' VAL . . . . . 0.605 HG21 ' HB2' ' A' ' 150' ' ' TRP . 45.6 t -69.46 -52.56 31.39 Favored 'Isoleucine or valine' 0 C--O 1.239 0.548 0 O-C-N 124.574 1.171 . . . . 0.0 110.48 173.714 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.519 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . 177.71 -134.24 2.4 Favored Glycine 0 C--N 1.348 1.2 0 CA-C-N 115.157 -0.928 . . . . 0.0 113.694 -175.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . 0.468 HD22 ' O ' ' A' ' 197' ' ' GLY . 86.1 mt -131.44 152.64 50.5 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 123.836 0.854 . . . . 0.0 110.926 -176.793 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 51.1 t80 -102.15 104.54 15.15 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 123.861 0.864 . . . . 0.0 108.986 175.696 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 212' ' ' GLY . . . . . 0.449 ' O ' ' SD ' ' A' ' 110' ' ' MET . . . 169.72 74.27 0.04 OUTLIER Glycine 0 C--N 1.337 0.632 0 C-N-CA 120.892 -0.67 . . . . 0.0 113.424 161.514 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 213' ' ' ASN . . . . . 0.705 ' H ' ' HB3' ' A' ' 224' ' ' SER . 71.7 m-20 -146.09 81.96 1.6 Allowed 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 170.368 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . 178.03 -121.58 0.78 Allowed Glycine 0 N--CA 1.445 -0.714 0 CA-C-N 114.71 -1.132 . . . . 0.0 111.839 178.303 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 215' ' ' VAL . . . . . 0.516 HG23 ' HG2' ' B' ' 253' ' ' LYS . 10.2 p -172.81 165.61 0.24 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.843 0 C-N-CA 122.883 0.473 . . . . 0.0 109.955 -164.015 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 216' ' ' VAL . . . . . . . . . . . . . 27.7 m -77.45 107.7 9.46 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.137 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 158.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 217' ' ' THR . . . . . 0.529 HG21 HD13 ' A' ' 29' ' ' LEU . 74.6 m -82.41 144.03 30.79 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 123.998 0.919 . . . . 0.0 109.351 -179.751 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 13.6 mmm180 63.81 17.54 10.56 Favored 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 124.03 0.932 . . . . 0.0 110.077 -169.633 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 35.5 m 61.33 31.95 19.23 Favored 'General case' 0 C--N 1.364 1.239 0 C-N-CA 125.536 1.534 . . . . 0.0 112.175 -175.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 220' ' ' GLY . . . . . . . . . . . . . . . -157.93 -52.85 0.01 OUTLIER Glycine 0 C--N 1.352 1.464 0 CA-C-O 120.019 -0.323 . . . . 0.0 113.358 -179.122 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -69.71 114.22 7.71 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 123.185 0.594 . . . . 0.0 111.562 -172.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 222' ' ' TYR . . . . . . . . . . . . . 7.5 m-85 -68.11 98.06 0.75 Allowed 'General case' 0 CA--C 1.551 1.0 0 C-N-CA 123.0 0.52 . . . . 0.0 110.272 179.063 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . . . . . . . . . 94.9 t -127.5 127.17 68.54 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 C-N-CA 123.798 0.839 . . . . 0.0 110.089 -171.445 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . 0.705 ' HB3' ' H ' ' A' ' 213' ' ' ASN . 58.5 m -153.75 159.06 41.82 Favored 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 123.237 0.615 . . . . 0.0 111.384 -171.026 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . . . . . . . . . . . -80.03 145.15 32.65 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.352 1.061 . . . . 0.0 110.986 177.451 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 226' ' ' ILE . . . . . 0.637 HG13 ' HB1' ' A' ' 186' ' ' ALA . 85.3 mt -78.85 102.89 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 174.065 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 227' ' ' ALA . . . . . 0.435 ' O ' ' HA3' ' A' ' 209' ' ' GLY . . . -77.76 101.75 6.83 Favored 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 177.757 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 49.0 mt-30 -89.87 169.37 11.3 Favored 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 123.088 0.555 . . . . 0.0 110.098 -171.316 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . 0.43 ' HA ' ' CD1' ' A' ' 144' ' ' TRP . 71.4 p -80.05 123.41 27.82 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 123.079 0.552 . . . . 0.0 111.506 -177.566 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 230' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -99.6 -24.18 14.82 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 123.244 0.618 . . . . 0.0 109.504 167.886 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 13.4 ptpt 68.72 157.06 0.14 Allowed 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 127.392 2.277 . . . . 0.0 113.098 174.132 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 232' ' ' SER . . . . . . . . . . . . . 22.4 m -61.02 138.33 58.19 Favored 'General case' 0 CA--C 1.543 0.678 0 CA-C-N 115.536 -0.756 . . . . 0.0 110.64 166.58 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 233' ' ' ILE . . . . . . . . . . . . . 13.4 tt -162.09 -33.29 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 C-N-CA 124.003 0.921 . . . . 0.0 108.996 -178.254 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 234' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 55.54 36.13 26.55 Favored 'General case' 0 C--N 1.364 1.209 0 C-N-CA 124.677 1.191 . . . . 0.0 109.898 175.86 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 10.1 p-10 -60.96 -25.06 66.56 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 125.04 1.336 . . . . 0.0 112.178 -174.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 236' ' ' ASN . . . . . . . . . . . . . 31.9 t30 -54.3 121.29 30.57 Favored Pre-proline 0 CA--C 1.55 0.956 0 C-N-CA 124.742 1.217 . . . . 0.0 110.442 169.247 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -68.8 98.53 0.6 Allowed 'Trans proline' 0 C--N 1.375 1.942 0 C-N-CA 121.93 1.753 . . . . 0.0 111.035 175.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 238' ' ' GLU . . . . . . . . . . . . . 48.0 mt-10 -99.26 32.3 2.78 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 123.982 0.913 . . . . 0.0 110.069 -179.26 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 239' ' ' ILE . . . . . 0.48 HG13 ' HG3' ' A' ' 240' ' ' GLU . 38.2 pt -62.91 -30.5 49.7 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 C-N-CA 123.986 0.915 . . . . 0.0 112.543 -176.249 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . 0.48 ' HG3' HG13 ' A' ' 239' ' ' ILE . 42.2 mt-10 . . . . . 0 CA--C 1.55 0.974 0 C-N-CA 124.323 1.049 . . . . 0.0 108.961 177.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 251' ' ' BEZ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 253' ' ' LYS . . . . . 0.516 ' HG2' HG23 ' A' ' 215' ' ' VAL . 1.5 tmtp? 70.49 -71.03 0.14 Allowed 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 125.385 1.474 . . . . 0.0 110.872 176.326 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 254' ' ' ARG . . . . . 0.412 ' O ' ' HD3' ' B' ' 253' ' ' LYS . 41.5 mtp85 69.85 171.67 0.31 Allowed 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 124.816 1.246 . . . . 0.0 113.254 175.083 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 255' ' ' M9P . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.634 0 N-CA-C 111.466 -0.654 . . . . 0.0 111.466 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.488 ' HA ' HD21 ' A' ' 6' ' ' LEU . 24.0 p -102.12 102.85 13.37 Favored 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 123.063 0.545 . . . . 0.0 109.946 178.537 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.432 ' O ' ' HB1' ' A' ' 117' ' ' ALA . . . -103.99 -158.99 0.69 Allowed 'General case' 0 N--CA 1.482 1.165 0 C-N-CA 123.769 0.828 . . . . 0.0 109.225 176.46 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -102.81 18.03 22.47 Favored 'General case' 0 N--CA 1.478 0.937 0 O-C-N 121.851 -0.531 . . . . 0.0 109.652 -175.027 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . 0.5 ' HB3' ' O ' ' A' ' 89' ' ' LYS . 6.2 m-20 -126.02 26.88 6.45 Favored 'General case' 0 C--O 1.237 0.444 0 C-N-CA 124.525 1.13 . . . . 0.0 108.976 -169.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.488 HD21 ' HA ' ' A' ' 2' ' ' SER . 83.7 mt -75.8 93.56 3.17 Favored 'General case' 0 C--O 1.215 -0.739 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.085 -173.172 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.446 ' HA ' ' O ' ' A' ' 120' ' ' MET . 23.2 tt0 -83.54 135.19 34.73 Favored 'General case' 0 N--CA 1.475 0.796 0 O-C-N 122.139 -0.351 . . . . 0.0 111.326 -179.651 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.475 HD23 ' H ' ' A' ' 8' ' ' LEU . 2.6 pt? -102.1 138.89 38.46 Favored 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.337 177.096 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 19.1 pt-20 -143.33 144.51 32.12 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.802 0.841 . . . . 0.0 109.096 176.182 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.517 ' NH2' ' HB3' ' A' ' 13' ' ' ASP . 50.7 ttt180 -63.41 120.73 12.21 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 112.286 0.476 . . . . 0.0 112.286 -165.603 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.706 ' HB2' ' HG3' ' A' ' 85' ' ' ARG . . . -84.64 -45.89 12.05 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 124.108 0.963 . . . . 0.0 109.896 173.081 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -170.95 -178.21 2.44 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-N 115.178 -0.919 . . . . 0.0 112.006 -173.733 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.517 ' HB3' ' NH2' ' A' ' 10' ' ' ARG . 10.4 p-10 -103.63 164.77 11.46 Favored 'General case' 0 CA--C 1.54 0.571 0 CA-C-N 114.121 -1.4 . . . . 0.0 108.571 165.373 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 53.0 t -88.11 101.44 11.61 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.856 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 179.03 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 62.7 tttp -172.73 113.74 0.27 Allowed 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 124.42 1.088 . . . . 0.0 108.187 -177.738 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 79.8 t90 -100.95 91.71 4.7 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 122.503 0.321 . . . . 0.0 110.465 -176.714 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -158.27 58.05 0.46 Allowed 'General case' 0 CA--C 1.549 0.931 0 C-N-CA 123.593 0.757 . . . . 0.0 109.746 162.114 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.425 ' HB3' ' H ' ' A' ' 169' ' ' ALA . 8.0 t70 -86.93 -56.04 3.57 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 122.833 0.453 . . . . 0.0 111.17 179.052 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . 0.656 ' H ' ' HB3' ' A' ' 169' ' ' ALA . 0.0 OUTLIER -148.38 4.35 0.69 Allowed 'General case' 0 N--CA 1.484 1.267 0 C-N-CA 123.186 0.595 . . . . 0.0 111.396 -173.615 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . 13.71 81.55 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 126.521 1.928 . . . . 0.0 114.228 -168.422 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.473 ' HB2' ' NE2' ' A' ' 19' ' ' GLN . 34.2 tt0 -101.97 147.44 26.55 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 114.306 -1.316 . . . . 0.0 109.221 -176.503 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 9.4 tp -93.03 149.05 4.34 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.798 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 174.348 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.559 ' HB3' HD23 ' A' ' 189' ' ' LEU . 69.1 m -91.73 -174.67 3.92 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 123.642 0.777 . . . . 0.0 111.455 178.341 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -87.23 -41.88 6.43 Favored Glycine 0 C--N 1.347 1.194 0 CA-C-N 115.436 -0.802 . . . . 0.0 111.28 178.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 35.5 m 63.0 87.47 0.1 Allowed 'General case' 0 C--N 1.358 0.968 0 C-N-CA 124.299 1.039 . . . . 0.0 110.219 177.836 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.553 ' HB2' ' HB3' ' A' ' 188' ' ' SER . 17.2 m -85.49 156.31 59.26 Favored Pre-proline 0 CA--C 1.555 1.147 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.988 -174.672 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -65.63 -168.56 0.13 Allowed 'Trans proline' 0 C--N 1.376 2.018 0 C-N-CA 123.244 2.63 . . . . 0.0 112.448 167.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 35.0 mm -66.14 138.37 23.14 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.267 0 CA-C-O 120.811 0.339 . . . . 0.0 110.662 -174.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.563 HD22 HG22 ' A' ' 217' ' ' THR . 4.3 mt -114.85 161.46 18.21 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 123.282 0.633 . . . . 0.0 110.564 175.167 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 30.4 t -112.24 114.65 27.56 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 178.579 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 12.9 tt -113.62 160.56 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 C-N-CA 124.649 1.18 . . . . 0.0 108.306 -174.793 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 82.2 p -93.89 104.96 17.0 Favored 'General case' 0 C--N 1.363 1.164 0 CA-C-N 119.845 1.202 . . . . 0.0 108.184 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.807 HG21 ' HA ' ' A' ' 179' ' ' THR . 3.5 tp -107.86 154.65 8.91 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 C-N-CA 125.887 1.675 . . . . 0.0 107.549 -176.62 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 9.1 p -157.27 161.91 39.18 Favored 'General case' 0 C--O 1.249 1.061 0 C-N-CA 123.264 0.626 . . . . 0.0 110.547 -171.743 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -58.29 158.02 7.76 Favored 'General case' 0 N--CA 1.481 1.103 0 C-N-CA 124.594 1.158 . . . . 0.0 111.505 -175.548 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 30.7 t70 78.39 14.55 1.38 Allowed 'General case' 0 N--CA 1.491 1.616 0 C-N-CA 124.911 1.284 . . . . 0.0 110.396 178.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 73.98 34.23 56.05 Favored Glycine 0 C--N 1.356 1.644 0 CA-C-N 115.343 -0.844 . . . . 0.0 112.265 -178.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 47.5 t -99.54 143.87 29.29 Favored 'General case' 0 N--CA 1.469 0.522 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -175.718 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 19.3 ptm -163.03 154.24 17.23 Favored 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 122.571 0.348 . . . . 0.0 111.053 -177.087 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 35.5 p -176.29 -179.09 1.03 Allowed 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 125.035 1.334 . . . . 0.0 108.96 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.415 HG21 ' O ' ' A' ' 216' ' ' VAL . 10.4 tp -107.17 96.72 4.86 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 172.309 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 7.5 mtpm? 50.77 31.0 5.47 Favored 'General case' 0 CA--C 1.559 1.318 0 C-N-CA 124.247 1.019 . . . . 0.0 113.082 170.729 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 41.8 t-20 79.15 -30.02 0.14 Allowed 'General case' 0 N--CA 1.502 2.132 0 C-N-CA 125.885 1.674 . . . . 0.0 111.959 -174.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -58.54 107.36 0.49 Allowed 'General case' 0 CA--C 1.55 0.949 0 C-N-CA 125.533 1.533 . . . . 0.0 112.86 -171.005 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.715 ' HB2' ' HG2' ' B' ' 253' ' ' LYS . 22.6 pt-20 -162.52 176.0 10.88 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 123.419 0.687 . . . . 0.0 110.684 172.471 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . 0.473 ' H ' ' HB3' ' B' ' 253' ' ' LYS . 12.9 pt-20 -158.76 -172.5 3.85 Favored 'General case' 0 C--O 1.245 0.854 0 C-N-CA 123.714 0.806 . . . . 0.0 110.225 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.412 ' HB3' ' NH2' ' B' ' 255' ' ' M9P . 7.8 pt-20 -146.67 151.33 37.05 Favored 'General case' 0 C--O 1.244 0.787 0 C-N-CA 124.211 1.004 . . . . 0.0 109.164 179.855 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.472 ' OE1' ' HB3' ' A' ' 163' ' ' PRO . 35.8 tt0 -109.13 157.85 18.35 Favored 'General case' 0 N--CA 1.481 1.113 0 C-N-CA 123.096 0.558 . . . . 0.0 111.214 -169.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . 0.51 HG23 ' HG ' ' A' ' 50' ' ' LEU . 12.3 t -80.75 -151.8 0.08 Allowed 'General case' 0 CA--C 1.563 1.46 0 C-N-CA 124.326 1.05 . . . . 0.0 109.725 170.687 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.51 ' HG ' HG23 ' A' ' 49' ' ' THR . 78.1 mt 77.65 -98.85 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 125.143 1.377 . . . . 0.0 111.534 172.669 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 119.28 -145.09 18.0 Favored Glycine 0 C--N 1.342 0.904 0 N-CA-C 111.826 -0.51 . . . . 0.0 111.826 -173.465 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -158.74 -142.54 3.42 Favored Glycine 0 C--N 1.339 0.724 0 N-CA-C 111.058 -0.817 . . . . 0.0 111.058 177.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 153.39 141.24 3.23 Favored Glycine 0 C--N 1.341 0.825 0 N-CA-C 111.543 -0.623 . . . . 0.0 111.543 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -155.87 154.28 25.4 Favored Glycine 0 C--N 1.343 0.944 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 179.083 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.725 ' HB2' ' HA ' ' A' ' 72' ' ' PRO . 68.0 m -121.57 156.96 31.79 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 123.631 0.772 . . . . 0.0 110.956 -179.378 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.41 ' HA3' ' HG2' ' A' ' 80' ' ' GLU . . . -145.28 -136.17 2.95 Favored Glycine 0 C--N 1.346 1.123 0 CA-C-O 119.586 -0.563 . . . . 0.0 111.94 -174.829 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -177.7 45.74 0.1 OUTLIER Glycine 0 C--N 1.347 1.166 0 CA-C-N 117.057 0.429 . . . . 0.0 112.137 178.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -76.55 -55.9 4.44 Favored Glycine 0 C--N 1.348 1.216 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 -178.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 72.62 79.78 0.44 Allowed Glycine 0 C--N 1.344 0.984 0 CA-C-N 114.996 -0.602 . . . . 0.0 113.266 170.084 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -75.46 -12.5 60.25 Favored 'General case' 0 N--CA 1.483 1.22 0 C-N-CA 122.948 0.499 . . . . 0.0 111.094 174.627 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 26.7 m-85 65.2 -177.12 0.18 Allowed 'General case' 0 N--CA 1.49 1.56 0 C-N-CA 125.288 1.435 . . . . 0.0 112.645 172.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . 67.42 -76.67 0.05 Allowed 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 124.984 1.314 . . . . 0.0 112.021 177.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -165.14 -178.27 38.25 Favored Glycine 0 N--CA 1.469 0.889 0 CA-C-O 119.081 -0.844 . . . . 0.0 111.269 179.295 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.432 HG22 ' HD3' ' A' ' 122' ' ' LYS . 9.9 p 47.92 46.35 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.951 0 CA-C-O 123.508 1.623 . . . . 0.0 110.715 178.039 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 3.2 pp -117.53 118.92 33.49 Favored 'General case' 0 C--N 1.339 0.128 0 CA-C-N 113.759 -1.564 . . . . 0.0 109.636 -174.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . 0.531 ' CD1' ' HG2' ' A' ' 122' ' ' LYS . 8.4 m95 -127.24 70.88 1.31 Allowed 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 104.726 -2.324 . . . . 0.0 104.726 168.426 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -170.92 70.24 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 105.521 -2.029 . . . . 0.0 105.521 -179.703 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 3.2 t -115.4 139.15 24.23 Favored Pre-proline 0 CA--C 1.538 0.518 0 CA-C-N 113.953 -1.476 . . . . 0.0 108.346 -168.074 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -60.05 81.21 0.06 OUTLIER 'Trans proline' 0 C--N 1.38 2.187 0 C-N-CA 122.708 2.272 . . . . 0.0 111.673 171.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 35.4 t -128.23 141.2 40.55 Favored Pre-proline 0 C--O 1.241 0.642 0 CA-C-N 113.985 -1.461 . . . . 0.0 108.403 -176.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_endo -44.73 122.95 4.43 Favored 'Trans proline' 0 C--N 1.377 2.078 0 C-N-CA 123.263 2.642 . . . . 0.0 112.545 176.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 0.725 ' HA ' ' HB2' ' A' ' 55' ' ' SER . 76.2 Cg_exo -43.41 -41.23 10.41 Favored 'Trans proline' 0 CA--C 1.568 2.204 0 C-N-CA 124.047 3.165 . . . . 0.0 116.464 177.123 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_exo -51.94 -23.78 17.45 Favored 'Trans proline' 0 C--N 1.395 3.004 0 C-N-CA 122.861 2.374 . . . . 0.0 116.029 173.152 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 81.2 t -61.52 -57.58 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.214 0 C-N-CA 122.985 0.514 . . . . 0.0 109.74 175.705 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 55.67 54.83 32.18 Favored Glycine 0 C--N 1.346 1.128 0 O-C-N 123.83 0.706 . . . . 0.0 114.031 175.088 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 57.6 pttt -86.6 44.41 1.15 Allowed 'General case' 0 N--CA 1.483 1.213 0 C-N-CA 123.253 0.621 . . . . 0.0 111.918 -173.303 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . 59.92 33.0 21.45 Favored 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 124.712 1.205 . . . . 0.0 112.322 174.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 59.3 mt-10 -66.24 134.06 51.9 Favored 'General case' 0 CA--C 1.544 0.74 0 N-CA-C 112.461 0.541 . . . . 0.0 112.461 -174.708 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.417 ' HB2' ' CD2' ' A' ' 121' ' ' HIS . 0.8 OUTLIER -89.5 66.73 7.43 Favored 'General case' 0 CA--C 1.548 0.867 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 170.951 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.41 ' HG2' ' HA3' ' A' ' 56' ' ' GLY . 22.0 tp10 -80.45 -83.07 0.11 Allowed 'General case' 0 CA--C 1.553 1.067 0 CA-C-N 113.445 -1.707 . . . . 0.0 111.022 175.127 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -175.43 162.66 2.89 Favored 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 123.92 0.888 . . . . 0.0 109.909 -168.584 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.421 ' HA3' ' HA ' ' A' ' 13' ' ' ASP . . . 93.49 -147.54 18.63 Favored Glycine 0 C--N 1.344 0.984 0 C-N-CA 123.076 0.369 . . . . 0.0 113.34 177.199 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -84.44 138.22 32.94 Favored 'General case' 0 N--CA 1.48 1.062 0 C-N-CA 123.493 0.717 . . . . 0.0 110.155 -177.397 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 12.0 m-85 -125.74 140.02 53.04 Favored 'General case' 0 N--CA 1.494 1.761 0 C-N-CA 123.334 0.654 . . . . 0.0 111.324 -179.061 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . 0.706 ' HG3' ' HB2' ' A' ' 11' ' ' ALA . 58.2 mtt-85 -85.41 122.21 29.23 Favored 'General case' 0 C--O 1.239 0.521 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 169.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.48 HD11 ' HZ ' ' A' ' 107' ' ' PHE . 62.6 mt -98.3 119.82 46.82 Favored 'Isoleucine or valine' 0 C--O 1.253 1.237 0 CA-C-O 121.589 0.709 . . . . 0.0 109.394 175.299 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.442 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 58.4 pttt -111.12 146.9 36.0 Favored 'General case' 0 C--O 1.239 0.548 0 CA-C-N 114.26 -1.336 . . . . 0.0 108.477 174.001 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . 0.491 ' NE2' ' HB2' ' A' ' 5' ' ' ASP . 0.1 OUTLIER -83.09 107.81 15.92 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 104.294 -2.484 . . . . 0.0 104.294 166.31 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . 0.5 ' O ' ' HB3' ' A' ' 5' ' ' ASP . 28.8 ttpt -117.34 96.92 5.64 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -175.506 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -67.11 154.2 52.86 Favored Glycine 0 C--N 1.339 0.725 0 N-CA-C 107.436 -2.266 . . . . 0.0 107.436 166.097 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 20.1 mm -78.86 63.93 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.39 0 CA-C-N 118.637 1.219 . . . . 0.0 108.926 -173.265 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 22.3 tp 167.81 -32.62 0.0 OUTLIER 'General case' 0 CA--C 1.562 1.431 0 C-N-CA 125.535 1.534 . . . . 0.0 109.854 -166.336 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -145.36 149.14 21.25 Favored Glycine 0 C--N 1.369 2.39 0 N-CA-C 114.265 0.466 . . . . 0.0 114.265 -171.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -124.98 133.36 53.04 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 124.614 1.166 . . . . 0.0 110.33 -169.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 44.7 m -151.45 103.19 2.96 Favored 'General case' 0 N--CA 1.493 1.705 0 CA-C-N 118.602 0.637 . . . . 0.0 112.085 176.724 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.442 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 43.7 mt-30 -53.76 120.39 6.19 Favored 'General case' 0 N--CA 1.495 1.818 0 C-N-CA 123.489 0.716 . . . . 0.0 111.215 173.446 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 2.5 pp -122.54 -13.07 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 C-N-CA 123.806 0.842 . . . . 0.0 112.061 -176.645 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 174.87 -152.51 13.96 Favored Glycine 0 C--N 1.342 0.903 0 CA-C-O 119.637 -0.535 . . . . 0.0 112.313 174.619 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -156.36 164.3 38.46 Favored 'General case' 0 C--O 1.241 0.652 0 C-N-CA 123.384 0.674 . . . . 0.0 110.973 -176.594 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -158.31 149.94 20.46 Favored Glycine 0 C--N 1.339 0.731 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 177.209 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 37.2 t -96.14 118.91 43.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 C-N-CA 123.328 0.651 . . . . 0.0 110.192 -176.576 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 85.5 t80 -94.93 126.9 40.58 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 171.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.441 ' HA ' ' HD2' ' A' ' 103' ' ' LYS . 42.7 tptt -133.55 114.5 13.64 Favored 'General case' 0 C--O 1.239 0.548 0 C-N-CA 123.28 0.632 . . . . 0.0 109.565 175.054 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 68.52 -78.14 0.05 OUTLIER 'General case' 0 N--CA 1.479 0.982 0 C-N-CA 125.282 1.433 . . . . 0.0 112.415 169.185 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . -147.46 32.43 1.36 Allowed Glycine 0 N--CA 1.465 0.569 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 176.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 44.6 m -136.84 124.86 22.82 Favored 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 124.21 1.004 . . . . 0.0 109.563 178.331 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' PHE . . . . . 0.48 ' HZ ' HD11 ' A' ' 86' ' ' ILE . 57.0 t80 -110.13 118.05 35.35 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 172.634 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . 0.527 ' NE2' ' HB3' ' A' ' 137' ' ' LEU . 60.5 t60 -123.69 114.82 20.47 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 122.809 0.443 . . . . 0.0 109.97 -178.654 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . . . . . . . . . 9.0 t -114.14 -165.71 1.03 Allowed 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 124.338 1.055 . . . . 0.0 109.525 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' MET . . . . . 0.589 ' HA ' ' HA ' ' A' ' 137' ' ' LEU . 13.6 mtp -107.43 160.56 15.55 Favored 'General case' 0 N--CA 1.48 1.042 0 C-N-CA 124.13 0.972 . . . . 0.0 110.033 177.075 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 11.6 t90 -80.79 -31.47 35.74 Favored 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 122.645 0.378 . . . . 0.0 111.512 -175.561 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 46.1 p-80 -75.02 -18.02 60.41 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.639 -0.663 . . . . 0.0 111.051 174.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 68.7 t -81.98 -44.02 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.523 0.729 . . . . 0.0 109.519 173.675 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 90.1 m -135.16 108.3 7.7 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 107.752 -1.203 . . . . 0.0 107.752 -178.767 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 19.3 ptp180 -85.69 33.33 0.58 Allowed 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 123.298 0.639 . . . . 0.0 112.211 -172.533 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 91.74 27.76 16.06 Favored Glycine 0 N--CA 1.47 0.912 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -170.083 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . 0.432 ' HB1' ' O ' ' A' ' 3' ' ' ALA . . . -94.41 -178.92 4.74 Favored 'General case' 0 CA--C 1.544 0.713 0 C-N-CA 124.065 0.946 . . . . 0.0 110.971 -177.189 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 70.2 t -100.3 133.25 43.99 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 123.404 0.681 . . . . 0.0 110.47 -176.341 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.541 ' HB2' ' HB ' ' A' ' 126' ' ' ILE . 2.4 mm? -92.01 162.31 14.43 Favored 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 124.155 0.982 . . . . 0.0 110.049 172.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' MET . . . . . 0.446 ' O ' ' HA ' ' A' ' 7' ' ' GLU . 23.5 mmt -139.25 136.79 35.33 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 124.066 0.947 . . . . 0.0 110.458 -171.609 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.417 ' CD2' ' HB2' ' A' ' 79' ' ' LEU . 56.8 t60 -169.38 137.0 1.8 Allowed 'General case' 0 N--CA 1.476 0.825 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 153.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.531 ' HG2' ' CD1' ' A' ' 66' ' ' TRP . 85.5 mttt 70.45 9.69 7.0 Favored 'General case' 0 N--CA 1.503 2.208 0 C-N-CA 124.238 1.015 . . . . 0.0 111.753 -178.45 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 83.46 -4.95 79.96 Favored Glycine 0 C--N 1.349 1.266 0 CA-C-O 119.953 -0.359 . . . . 0.0 112.519 -167.289 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 31.0 mmmt -72.64 117.61 14.54 Favored 'General case' 0 C--O 1.248 0.998 0 C-N-CA 123.512 0.725 . . . . 0.0 109.123 175.593 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . . . . . . . . . 85.3 mtm180 -87.4 96.05 10.23 Favored 'General case' 0 C--O 1.237 0.418 0 O-C-N 124.665 1.228 . . . . 0.0 108.869 -179.122 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.541 ' HB ' ' HB2' ' A' ' 119' ' ' LEU . 97.2 mt -75.19 114.78 15.65 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.664 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.271 -179.069 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -92.91 146.9 32.92 Favored Pre-proline 0 CA--C 1.548 0.875 0 C-N-CA 124.126 0.97 . . . . 0.0 110.63 -174.554 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_exo -67.9 101.01 0.65 Allowed 'Trans proline' 0 C--N 1.367 1.528 0 C-N-CA 122.088 1.859 . . . . 0.0 110.866 169.336 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . . . . . . . . . 22.7 t -64.33 -31.25 72.38 Favored 'General case' 0 N--CA 1.483 1.216 0 CA-C-O 121.271 0.558 . . . . 0.0 109.877 177.19 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 75.0 t-105 -150.7 156.33 41.11 Favored 'General case' 0 CA--C 1.543 0.695 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 165.306 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -136.76 120.09 16.86 Favored 'General case' 0 N--CA 1.467 0.419 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 176.278 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 27.3 m-20 -95.13 106.78 18.81 Favored 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 124.394 1.078 . . . . 0.0 109.247 175.518 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 60.3 t -75.59 -41.87 41.58 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.659 0 C-N-CA 123.141 0.577 . . . . 0.0 110.351 178.74 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 55.7 tttm -73.76 -34.98 64.95 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.954 -175.242 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 13.6 tppt? -80.88 -18.78 46.12 Favored 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 123.096 0.558 . . . . 0.0 110.797 176.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 26.3 t70 62.5 48.32 4.58 Favored 'General case' 0 N--CA 1.481 1.083 0 CA-C-O 122.72 1.248 . . . . 0.0 110.379 -175.4 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.589 ' HA ' ' HA ' ' A' ' 110' ' ' MET . 74.8 mt -149.98 138.6 20.76 Favored 'General case' 0 N--CA 1.476 0.838 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.155 -176.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 5.8 mt -112.22 145.02 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 C-N-CA 123.384 0.674 . . . . 0.0 110.416 175.206 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . 0.415 ' HB3' ' O ' ' A' ' 142' ' ' GLY . 34.6 m -118.64 141.61 48.43 Favored 'General case' 0 CA--C 1.557 1.217 0 C-N-CA 125.015 1.326 . . . . 0.0 110.945 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 19.6 t80 -135.38 142.13 45.64 Favored 'General case' 0 N--CA 1.488 1.472 0 C-N-CA 124.835 1.254 . . . . 0.0 108.515 173.203 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 81.26 -60.5 4.7 Favored Glycine 0 C--N 1.352 1.42 0 N-CA-C 111.254 -0.738 . . . . 0.0 111.254 -176.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . 0.415 ' O ' ' HB3' ' A' ' 139' ' ' SER . . . -148.28 -171.82 17.57 Favored Glycine 0 C--O 1.242 0.635 0 N-CA-C 109.871 -1.292 . . . . 0.0 109.871 172.394 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . . . . . . . . . . . -77.46 -177.17 46.06 Favored Glycine 0 C--N 1.337 0.627 0 N-CA-C 112.13 -0.388 . . . . 0.0 112.13 175.333 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' TRP . . . . . 0.501 ' HB2' ' CE1' ' A' ' 108' ' ' HIS . 13.4 t-105 -69.78 111.6 5.65 Favored 'General case' 0 C--O 1.243 0.756 0 O-C-N 122.585 -0.362 . . . . 0.0 110.44 177.19 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . 0.412 ' HB3' ' O ' ' A' ' 232' ' ' SER . 23.0 pttm -135.64 152.34 51.12 Favored 'General case' 0 N--CA 1.466 0.334 0 O-C-N 124.092 0.87 . . . . 0.0 110.308 173.015 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' LEU . . . . . 0.443 ' H ' ' H ' ' A' ' 147' ' ' GLU . 4.1 mt 174.63 -8.89 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.945 0 C-N-CA 127.158 2.183 . . . . 0.0 108.207 178.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.46 ' N ' HG21 ' A' ' 229' ' ' THR . 7.6 mm-40 60.0 70.93 0.6 Allowed 'General case' 0 C--N 1.365 1.269 0 C-N-CA 125.387 1.475 . . . . 0.0 110.66 173.377 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -104.15 159.23 16.48 Favored Glycine 0 N--CA 1.444 -0.789 0 CA-C-N 114.069 -1.423 . . . . 0.0 113.998 -177.204 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -129.35 93.01 3.46 Favored 'General case' 0 C--O 1.243 0.742 0 C-N-CA 123.856 0.862 . . . . 0.0 109.142 178.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' TRP . . . . . . . . . . . . . 25.2 t90 -74.24 120.63 20.07 Favored 'General case' 0 C--O 1.238 0.498 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 173.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 20.4 mttm -85.15 94.68 8.93 Favored 'General case' 0 C--O 1.243 0.722 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 176.695 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -66.39 97.15 0.4 Allowed 'General case' 0 CA--C 1.545 0.783 0 C-N-CA 123.671 0.788 . . . . 0.0 109.053 -176.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 143.27 -49.33 0.72 Allowed Glycine 0 C--N 1.341 0.842 0 CA-C-N 115.371 -0.832 . . . . 0.0 111.365 -178.357 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -85.33 157.94 20.41 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 122.889 0.476 . . . . 0.0 112.042 -175.659 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . 0.467 ' HA ' ' HA ' ' A' ' 173' ' ' LYS . 0.8 OUTLIER -62.5 131.1 48.0 Favored 'General case' 0 C--N 1.351 0.654 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.926 177.918 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.53 HG11 HD13 ' A' ' 226' ' ' ILE . 34.0 m -93.25 159.11 2.83 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.562 179.421 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . . . . . . . . . 25.2 mp0 -113.02 130.36 56.17 Favored 'General case' 0 C--O 1.215 -0.727 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -172.079 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 44.6 t -133.99 137.07 52.86 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -174.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.582 HD23 ' H ' ' A' ' 159' ' ' LEU . 2.2 pt? -92.57 96.53 10.26 Favored 'General case' 0 CA--C 1.545 0.777 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 169.269 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -64.91 104.02 0.8 Allowed 'General case' 0 C--O 1.24 0.603 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.243 -178.565 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . 0.613 HD23 ' HB3' ' A' ' 167' ' ' PRO . 78.0 mt -69.01 84.74 0.33 Allowed 'General case' 0 C--O 1.241 0.641 0 C-N-CA 123.704 0.802 . . . . 0.0 108.873 177.109 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . . . . . . . . . 28.3 tt0 -74.9 134.11 75.34 Favored Pre-proline 0 CA--C 1.545 0.767 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.297 -177.085 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . 0.472 ' HB3' ' OE1' ' A' ' 48' ' ' GLN . 93.1 Cg_exo -46.25 112.59 0.48 Allowed 'Trans proline' 0 C--N 1.382 2.342 0 C-N-CA 123.53 2.82 . . . . 0.0 113.881 178.198 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 63.79 27.87 71.78 Favored Glycine 0 C--N 1.35 1.356 0 O-C-N 123.903 0.752 . . . . 0.0 113.819 173.703 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 53.0 tptt -146.49 173.21 12.51 Favored 'General case' 0 C--O 1.245 0.837 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 -176.03 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -56.87 151.09 34.6 Favored Pre-proline 0 CA--C 1.558 1.28 0 C-N-CA 123.701 0.8 . . . . 0.0 112.595 177.317 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . 0.613 ' HB3' HD23 ' A' ' 161' ' ' LEU . 6.9 Cg_exo -74.86 92.42 0.97 Allowed 'Trans proline' 0 C--N 1.372 1.789 0 C-N-CA 123.249 2.632 . . . . 0.0 110.188 171.393 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 31.7 ttp-105 -75.68 122.08 23.45 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.065 -170.211 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . 0.656 ' HB3' ' H ' ' A' ' 19' ' ' GLN . . . -68.77 105.36 2.29 Favored 'General case' 0 CA--C 1.538 0.505 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.934 179.606 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 18.8 t -129.24 135.01 62.85 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.095 0 C-N-CA 124.866 1.266 . . . . 0.0 108.257 176.353 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . 0.472 ' HG2' ' O ' ' A' ' 21' ' ' GLU . 27.3 pt20 -117.07 126.73 53.3 Favored 'General case' 0 N--CA 1.478 0.933 0 C-N-CA 123.651 0.781 . . . . 0.0 110.318 -176.122 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . 0.527 HG21 HG13 ' A' ' 187' ' ' VAL . 5.4 t -118.0 143.13 46.65 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 124.207 1.003 . . . . 0.0 110.911 -173.006 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . 0.467 ' HA ' ' HA ' ' A' ' 155' ' ' GLU . 37.2 ttmt -85.46 142.07 37.26 Favored Pre-proline 0 N--CA 1.479 0.983 0 CA-C-O 118.549 -0.738 . . . . 0.0 109.334 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . 0.577 ' HA ' ' O ' ' A' ' 186' ' ' ALA . 89.6 Cg_exo -47.32 122.69 6.85 Favored 'Trans proline' 0 C--N 1.396 3.04 0 C-N-CA 123.116 2.544 . . . . 0.0 114.562 -175.244 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . 0.526 ' H ' ' C ' ' A' ' 186' ' ' ALA . . . -135.47 139.59 10.91 Favored Glycine 0 CA--C 1.541 1.679 0 CA-C-N 115.159 -0.928 . . . . 0.0 114.543 179.342 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.434 HD23 ' N ' ' A' ' 176' ' ' LEU . 0.3 OUTLIER -132.22 162.5 30.77 Favored 'General case' 0 C--O 1.241 0.619 0 O-C-N 121.551 -0.97 . . . . 0.0 110.18 -171.412 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 177' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -138.51 139.53 38.79 Favored 'General case' 0 C--O 1.242 0.668 0 CA-C-N 114.141 -1.391 . . . . 0.0 109.727 -167.334 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 178' ' ' LYS . . . . . 0.435 ' HE3' ' HB3' ' A' ' 178' ' ' LYS . 1.3 tmmt? -69.07 120.77 15.45 Favored 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 124.481 1.112 . . . . 0.0 111.648 -165.488 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . 0.807 ' HA ' HG21 ' A' ' 33' ' ' ILE . 7.4 m -90.09 165.4 14.02 Favored 'General case' 0 CA--C 1.551 1.01 0 C-N-CA 125.89 1.676 . . . . 0.0 109.787 177.619 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 180' ' ' ASN . . . . . 0.561 ' ND2' HG23 ' A' ' 33' ' ' ILE . 63.4 m-80 -64.53 -35.14 79.99 Favored 'General case' 0 N--CA 1.487 1.384 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 170.82 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . 0.4 ' H ' HG22 ' A' ' 179' ' ' THR . . . -75.62 -48.22 23.14 Favored 'General case' 0 CA--C 1.54 0.566 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.977 175.798 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . 0.682 ' H ' ' HB ' ' A' ' 179' ' ' THR . . . -165.73 -94.43 0.1 OUTLIER Glycine 0 C--N 1.345 1.045 0 CA-C-O 119.756 -0.469 . . . . 0.0 112.638 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 7.5 t -163.46 135.83 5.21 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 124.719 1.208 . . . . 0.0 109.354 178.092 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -132.98 155.73 41.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 122.898 0.479 . . . . 0.0 109.814 177.052 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 185' ' ' GLY . . . . . . . . . . . . . . . 129.83 177.58 14.96 Favored Glycine 0 C--N 1.343 0.935 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 173.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.577 ' O ' ' HA ' ' A' ' 174' ' ' PRO . . . -171.66 38.85 0.02 OUTLIER 'General case' 0 C--O 1.193 -1.901 0 C-N-CA 123.486 0.715 . . . . 0.0 110.329 177.867 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 187' ' ' VAL . . . . . 0.527 HG13 HG21 ' A' ' 172' ' ' THR . 95.1 t -153.15 125.22 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 120.012 -1.68 . . . . 0.0 107.648 167.399 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . 0.635 ' HA ' HG12 ' A' ' 223' ' ' VAL . 73.6 m -132.54 91.13 2.88 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 108.639 -0.874 . . . . 0.0 108.639 168.115 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 189' ' ' LEU . . . . . 0.559 HD23 ' HB3' ' A' ' 23' ' ' SER . 0.5 OUTLIER -126.97 104.36 7.96 Favored 'General case' 0 N--CA 1.48 1.039 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 -176.285 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 190' ' ' ASP . . . . . 0.681 ' HA ' ' HA ' ' A' ' 221' ' ' ALA . 8.0 p-10 -85.72 103.16 14.25 Favored 'General case' 0 C--N 1.356 0.865 0 CA-C-O 121.875 0.845 . . . . 0.0 109.992 -179.243 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 191' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -174.19 172.92 3.19 Favored 'General case' 0 N--CA 1.475 0.776 0 CA-C-N 115.059 -0.973 . . . . 0.0 108.541 -167.393 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 44.5 p -58.3 121.91 55.51 Favored Pre-proline 0 CA--C 1.548 0.883 0 C-N-CA 123.127 0.571 . . . . 0.0 110.614 175.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_endo -61.16 127.66 22.81 Favored 'Trans proline' 0 C--N 1.376 2.021 0 C-N-CA 122.246 1.964 . . . . 0.0 112.661 -178.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -72.41 173.44 46.43 Favored Glycine 0 C--N 1.35 1.326 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 162.099 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 7.4 m -80.66 135.78 36.09 Favored 'General case' 0 CA--C 1.562 1.416 0 CA-C-N 118.626 1.213 . . . . 0.0 111.334 -172.532 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -65.19 88.44 0.08 Allowed 'General case' 0 C--N 1.367 1.339 0 C-N-CA 124.13 0.972 . . . . 0.0 111.304 -171.641 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . 0.645 ' HA2' HD21 ' A' ' 210' ' ' LEU . . . 144.59 9.58 0.36 Allowed Glycine 0 C--N 1.335 0.499 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.984 -175.908 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 198' ' ' SER . . . . . 0.431 ' O ' ' HB2' ' A' ' 211' ' ' TYR . 39.3 m -57.36 132.09 81.31 Favored Pre-proline 0 CA--C 1.556 1.208 0 C-N-CA 122.942 0.497 . . . . 0.0 109.838 166.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -69.91 137.44 35.02 Favored 'Trans proline' 0 C--N 1.369 1.621 0 C-N-CA 121.965 1.777 . . . . 0.0 111.108 174.072 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 39.9 mt -91.92 119.6 39.61 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 N-CA-C 107.923 -1.139 . . . . 0.0 107.923 170.732 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 201' ' ' ILE . . . . . 0.642 ' HA ' ' HA ' ' A' ' 207' ' ' VAL . 46.7 mt -103.61 168.87 2.19 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.483 0 C-N-CA 125.632 1.573 . . . . 0.0 109.786 179.768 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 202' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -104.6 167.19 9.89 Favored 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 124.752 1.221 . . . . 0.0 109.402 178.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 18.5 ptpt -55.11 -29.24 57.24 Favored 'General case' 0 N--CA 1.481 1.106 0 C-N-CA 124.626 1.17 . . . . 0.0 112.444 177.762 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 52.9 mtmt -82.33 10.57 6.75 Favored 'General case' 0 N--CA 1.481 1.11 0 C-N-CA 123.324 0.65 . . . . 0.0 112.277 -179.072 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 70.0 19.73 75.68 Favored Glycine 0 C--N 1.356 1.669 0 N-CA-C 112.115 -0.394 . . . . 0.0 112.115 -177.235 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 206' ' ' LYS . . . . . . . . . . . . . 62.4 tttp -110.73 121.14 44.59 Favored 'General case' 0 C--O 1.212 -0.892 0 C-N-CA 124.381 1.072 . . . . 0.0 108.662 -176.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . 0.642 ' HA ' ' HA ' ' A' ' 201' ' ' ILE . 7.1 p -53.9 139.67 11.87 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.092 0 C-N-CA 123.191 0.596 . . . . 0.0 111.687 178.092 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 3.6 m -98.34 -35.43 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.854 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 170.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.555 ' HA3' ' HA ' ' A' ' 228' ' ' GLN . . . 166.86 -138.18 5.05 Favored Glycine 0 C--N 1.348 1.226 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.268 -178.229 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . 0.645 HD21 ' HA2' ' A' ' 197' ' ' GLY . 5.1 tt -122.58 154.01 38.52 Favored 'General case' 0 CA--C 1.545 0.779 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 -172.122 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 211' ' ' TYR . . . . . 0.461 ' N ' HD23 ' A' ' 210' ' ' LEU . 10.2 t80 -62.45 142.19 58.01 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 123.592 0.757 . . . . 0.0 109.956 178.467 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -77.45 -157.83 9.26 Favored Glycine 0 N--CA 1.475 1.298 0 CA-C-N 118.103 0.41 . . . . 0.0 112.622 178.392 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 213' ' ' ASN . . . . . . . . . . . . . 14.7 t-20 -81.92 85.59 6.66 Favored 'General case' 0 N--CA 1.477 0.904 0 N-CA-C 108.442 -0.948 . . . . 0.0 108.442 -176.658 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . -71.66 123.3 9.87 Favored Glycine 0 C--N 1.347 1.174 0 CA-C-N 114.789 -1.096 . . . . 0.0 112.008 177.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 215' ' ' VAL . . . . . 0.706 ' HA ' ' HE3' ' B' ' 253' ' ' LYS . 21.7 t -134.59 143.56 37.44 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.672 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 173.63 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 216' ' ' VAL . . . . . 0.563 ' HB ' ' HA2' ' A' ' 220' ' ' GLY . 15.4 m -87.98 111.3 22.01 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.891 0 CA-C-O 121.781 0.8 . . . . 0.0 109.536 -178.718 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 217' ' ' THR . . . . . 0.563 HG22 HD22 ' A' ' 29' ' ' LEU . 38.8 m -107.74 162.53 13.9 Favored 'General case' 0 N--CA 1.475 0.825 0 C-N-CA 124.329 1.052 . . . . 0.0 109.659 -170.692 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 218' ' ' ARG . . . . . . . . . . . . . 20.3 ttm180 71.45 -73.77 0.09 Allowed 'General case' 0 N--CA 1.492 1.646 0 C-N-CA 124.217 1.007 . . . . 0.0 109.592 -177.065 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 41.1 m -140.96 -43.86 0.39 Allowed 'General case' 0 CA--C 1.547 0.838 0 C-N-CA 124.519 1.127 . . . . 0.0 109.19 178.833 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 220' ' ' GLY . . . . . 0.563 ' HA2' ' HB ' ' A' ' 216' ' ' VAL . . . -169.04 27.65 0.13 Allowed Glycine 0 C--N 1.348 1.218 0 CA-C-N 115.49 -0.777 . . . . 0.0 112.181 -175.744 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . 0.681 ' HA ' ' HA ' ' A' ' 190' ' ' ASP . . . -80.32 96.11 6.55 Favored 'General case' 0 N--CA 1.465 0.317 0 C-N-CA 123.684 0.794 . . . . 0.0 110.607 179.717 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 222' ' ' TYR . . . . . . . . . . . . . 12.3 t80 -66.61 95.9 0.36 Allowed 'General case' 0 CA--C 1.554 1.123 0 CA-C-N 114.804 -1.089 . . . . 0.0 109.543 -176.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . 0.635 HG12 ' HA ' ' A' ' 188' ' ' SER . 35.3 m -114.59 140.14 37.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 C-N-CA 123.81 0.844 . . . . 0.0 109.774 -177.157 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 33.1 t -152.16 160.68 43.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.623 -169.598 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . . . . . . . . . . . -81.64 -175.02 5.32 Favored 'General case' 0 CA--C 1.546 0.792 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.643 164.43 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 226' ' ' ILE . . . . . 0.53 HD13 HG11 ' A' ' 156' ' ' VAL . 78.2 mt -133.57 116.44 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.828 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 176.005 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 227' ' ' ALA . . . . . . . . . . . . . . . -95.78 137.2 35.18 Favored 'General case' 0 C--O 1.233 0.196 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 176.015 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . 0.555 ' HA ' ' HA3' ' A' ' 209' ' ' GLY . 29.0 pt20 -120.26 174.3 6.59 Favored 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 175.318 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . 0.464 ' HA ' ' CD1' ' A' ' 144' ' ' TRP . 39.4 p -66.14 107.71 2.02 Favored 'General case' 0 CA--C 1.546 0.825 0 CA-C-O 121.208 0.528 . . . . 0.0 110.802 -176.502 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 230' ' ' GLU . . . . . 0.482 ' HG2' ' O ' ' A' ' 228' ' ' GLN . 26.7 mm-40 -108.06 -30.16 8.58 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 124.425 1.09 . . . . 0.0 112.437 -168.384 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 231' ' ' LYS . . . . . . . . . . . . . 29.8 mmtp -107.06 -99.78 0.35 Allowed 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 113.477 0.917 . . . . 0.0 113.477 -160.38 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 232' ' ' SER . . . . . 0.412 ' O ' ' HB3' ' A' ' 145' ' ' LYS . 64.3 p -76.45 89.44 3.24 Favored 'General case' 0 C--N 1.361 1.093 0 CA-C-O 121.958 0.885 . . . . 0.0 110.672 -165.207 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 233' ' ' ILE . . . . . . . . . . . . . 12.4 tt -116.76 -23.85 3.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 C-N-CA 125.18 1.392 . . . . 0.0 108.207 178.015 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 234' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER 58.07 58.43 3.56 Favored 'General case' 0 C--O 1.242 0.693 0 C-N-CA 125.417 1.487 . . . . 0.0 110.133 -173.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -90.72 17.84 7.16 Favored 'General case' 0 CA--C 1.551 0.992 0 CA-C-N 113.639 -1.619 . . . . 0.0 109.578 176.407 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 236' ' ' ASN . . . . . . . . . . . . . 30.1 t30 -48.1 118.47 6.49 Favored Pre-proline 0 C--N 1.36 1.03 0 C-N-CA 124.392 1.077 . . . . 0.0 109.494 173.336 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_endo -57.39 82.78 0.04 OUTLIER 'Trans proline' 0 C--N 1.378 2.094 0 C-N-CA 123.455 2.77 . . . . 0.0 113.083 -174.891 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 238' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -110.75 -14.96 13.93 Favored 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 124.182 0.993 . . . . 0.0 111.232 -178.316 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 239' ' ' ILE . . . . . . . . . . . . . 9.0 tt -64.83 -38.45 82.76 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 C-N-CA 123.758 0.823 . . . . 0.0 110.755 176.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 2.8 pp20? . . . . . 0 C--O 1.251 1.144 0 C-N-CA 123.717 0.807 . . . . 0.0 110.027 171.205 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 251' ' ' BEZ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 253' ' ' LYS . . . . . 0.715 ' HG2' ' HB2' ' A' ' 45' ' ' GLU . 21.8 tptm -138.57 131.89 30.23 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.095 -174.202 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 254' ' ' ARG . . . . . 0.44 HH12 ' NE2' ' A' ' 96' ' ' GLN . 28.6 mmm180 -105.68 -9.28 17.4 Favored 'General case' 0 N--CA 1.478 0.947 0 C-N-CA 124.483 1.113 . . . . 0.0 110.356 171.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 255' ' ' M9P . . . . . 0.412 ' NH2' ' HB3' ' A' ' 47' ' ' GLU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.454 ' H2 ' HD12 ' A' ' 138' ' ' ILE . . . . . . . . 0 N--CA 1.481 1.663 0 N-CA-C 111.754 -0.538 . . . . 0.0 111.754 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 41.1 p 172.14 152.92 0.07 Allowed 'General case' 0 CA--C 1.549 0.909 0 C-N-CA 125.267 1.427 . . . . 0.0 108.392 -171.277 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.529 ' HB3' HD11 ' A' ' 6' ' ' LEU . . . -162.57 -61.38 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.753 0 CA-C-N 119.256 0.935 . . . . 0.0 111.317 176.406 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -150.76 -62.01 0.19 Allowed 'General case' 0 N--CA 1.477 0.875 0 C-N-CA 123.287 0.635 . . . . 0.0 110.054 -173.131 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . 0.732 ' HA ' ' HG3' ' A' ' 120' ' ' MET . 32.6 t70 -144.5 76.92 1.52 Allowed 'General case' 0 CA--C 1.528 0.113 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 -172.386 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.529 HD11 ' HB3' ' A' ' 3' ' ' ALA . 5.8 mp -117.56 124.4 48.57 Favored 'General case' 0 N--CA 1.488 1.471 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.051 -179.283 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.794 ' HB2' ' HD3' ' A' ' 89' ' ' LYS . 14.5 tp10 -80.9 134.54 35.76 Favored 'General case' 0 C--O 1.252 1.229 0 CA-C-N 118.06 0.391 . . . . 0.0 110.449 178.023 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.462 ' HB2' HD11 ' A' ' 119' ' ' LEU . 18.1 tp -87.16 113.34 22.81 Favored 'General case' 0 CA--C 1.542 0.649 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 171.027 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -104.87 143.64 32.87 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 125.826 1.65 . . . . 0.0 108.176 -173.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.8 ptt-85 -76.29 147.16 38.42 Favored 'General case' 0 N--CA 1.481 1.104 0 CA-C-N 118.336 0.516 . . . . 0.0 110.505 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.656 ' HB2' ' HG3' ' A' ' 85' ' ' ARG . . . -125.89 -51.12 1.57 Allowed 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 169.2 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ALA . . . . . . . . . . . . . . . -166.65 175.34 8.0 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 124.012 0.925 . . . . 0.0 110.279 -177.038 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -98.59 159.44 14.95 Favored 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 108.401 -0.962 . . . . 0.0 108.401 164.11 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 83.4 t -88.39 103.18 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 CA-C-O 121.545 0.688 . . . . 0.0 111.281 -176.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 2.4 ptpp? -155.98 158.67 38.28 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 124.891 1.277 . . . . 0.0 107.97 168.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 10.6 t90 -67.83 105.43 1.96 Allowed 'General case' 0 CA--C 1.549 0.923 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.26 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.57 ' HB3' ' HB2' ' A' ' 169' ' ' ALA . 2.6 tm-20 -70.35 145.03 51.45 Favored 'General case' 0 CA--C 1.554 1.127 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 170.496 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 35.3 t70 -75.65 -19.45 59.16 Favored 'General case' 0 N--CA 1.481 1.117 0 N-CA-C 113.885 1.069 . . . . 0.0 113.885 -165.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 6.6 tp60 -94.1 53.37 1.74 Allowed 'General case' 0 N--CA 1.476 0.828 0 CA-C-O 121.46 0.648 . . . . 0.0 110.592 -168.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.617 ' HB1' ' HB2' ' A' ' 171' ' ' GLN . . . -56.04 91.24 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 124.558 1.143 . . . . 0.0 111.843 178.34 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -62.74 126.51 27.59 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 124.851 1.261 . . . . 0.0 110.746 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 50.4 mm -77.08 109.16 11.3 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.613 0 C-N-CA 123.073 0.549 . . . . 0.0 109.609 -178.256 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.1 m -135.38 -174.78 3.72 Favored 'General case' 0 CA--C 1.551 1.015 0 C-N-CA 124.038 0.935 . . . . 0.0 110.026 -179.436 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.413 ' H ' ' HB3' ' A' ' 189' ' ' LEU . . . 98.11 73.1 1.1 Allowed Glycine 0 C--N 1.349 1.259 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 -172.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.8 m -124.57 1.93 8.27 Favored 'General case' 0 N--CA 1.478 0.963 0 C-N-CA 122.971 0.508 . . . . 0.0 112.291 -164.636 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 13.7 m -120.45 137.88 26.7 Favored Pre-proline 0 CA--C 1.55 0.957 0 C-N-CA 123.291 0.636 . . . . 0.0 109.675 -176.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -82.43 -155.82 0.06 OUTLIER 'Trans proline' 0 C--N 1.379 2.151 0 C-N-CA 123.204 2.603 . . . . 0.0 112.253 179.506 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 48.6 mm -66.32 121.05 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 123.16 0.584 . . . . 0.0 110.632 -178.749 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 60.2 mt -105.53 164.87 11.55 Favored 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 124.658 1.183 . . . . 0.0 111.752 -175.139 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 39.4 m -122.46 116.18 23.52 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 123.5 0.72 . . . . 0.0 109.542 176.122 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.509 HD11 HG11 ' A' ' 223' ' ' VAL . 62.5 mt -116.24 145.09 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 C-N-CA 124.292 1.037 . . . . 0.0 108.561 178.391 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 35.9 p -93.56 105.13 17.21 Favored 'General case' 0 CA--C 1.543 0.703 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 178.125 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 9.2 tp -69.91 141.14 17.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 C-N-CA 124.159 0.983 . . . . 0.0 110.403 175.019 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 34.3 t -135.47 140.17 44.64 Favored 'General case' 0 C--O 1.242 0.701 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 176.788 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 65.14 15.98 10.3 Favored 'General case' 0 CA--C 1.563 1.476 0 C-N-CA 123.893 0.877 . . . . 0.0 111.133 174.756 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 58.12 32.65 22.27 Favored 'General case' 0 N--CA 1.49 1.545 0 C-N-CA 124.744 1.218 . . . . 0.0 111.67 -179.0 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -169.55 -44.41 0.03 OUTLIER Glycine 0 C--N 1.348 1.236 0 CA-C-N 116.32 -0.4 . . . . 0.0 112.669 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 25.6 m -89.15 106.2 18.29 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -176.373 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 27.3 mtm -88.05 162.59 16.71 Favored 'General case' 0 N--CA 1.476 0.873 0 O-C-N 121.909 -0.494 . . . . 0.0 110.856 -176.21 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 39.1 m -147.51 148.56 31.34 Favored 'General case' 0 C--O 1.238 0.492 0 C-N-CA 123.707 0.803 . . . . 0.0 109.379 -178.553 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 9.1 tp -96.12 151.7 3.97 Favored 'Isoleucine or valine' 0 C--O 1.239 0.55 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 169.326 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . 50.2 mtmt -81.93 40.92 0.63 Allowed 'General case' 0 CA--C 1.558 1.261 0 C-N-CA 123.532 0.733 . . . . 0.0 111.222 175.31 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ASN . . . . . . . . . . . . . 7.8 t30 -167.49 75.34 0.14 Allowed 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 125.047 1.339 . . . . 0.0 107.661 176.518 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -75.29 117.66 17.34 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 177.398 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -168.95 154.97 6.49 Favored 'General case' 0 C--O 1.245 0.827 0 C-N-CA 123.912 0.885 . . . . 0.0 109.398 177.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 26.0 mm-40 65.38 161.57 0.13 Allowed 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 125.577 1.551 . . . . 0.0 113.796 176.185 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -133.19 173.19 11.71 Favored 'General case' 0 CA--C 1.549 0.919 0 CA-C-N 114.824 -1.08 . . . . 0.0 108.851 -177.487 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.443 ' HB2' ' NH1' ' B' ' 254' ' ' ARG . 29.6 pt20 -75.25 -179.09 4.24 Favored 'General case' 0 N--CA 1.477 0.893 0 C-N-CA 124.467 1.107 . . . . 0.0 111.873 175.241 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' THR . . . . . . . . . . . . . 37.9 p -116.32 -164.65 0.98 Allowed 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 124.238 1.015 . . . . 0.0 108.995 -178.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 2.3 pp -67.73 167.97 12.26 Favored 'General case' 0 C--O 1.244 0.764 0 CA-C-O 121.559 0.695 . . . . 0.0 111.803 175.149 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -82.2 -97.49 0.48 Allowed Glycine 0 C--O 1.224 -0.499 0 CA-C-N 114.648 -1.16 . . . . 0.0 112.435 174.571 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -128.97 -35.02 0.49 Allowed Glycine 0 N--CA 1.468 0.768 0 N-CA-C 111.645 -0.582 . . . . 0.0 111.645 -178.246 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 102.79 47.74 1.34 Allowed Glycine 0 C--N 1.354 1.564 0 C-N-CA 123.033 0.349 . . . . 0.0 112.481 176.188 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -70.57 123.88 12.04 Favored Glycine 0 C--N 1.346 1.112 0 C-N-CA 123.465 0.555 . . . . 0.0 111.929 178.256 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 39.1 t -80.19 158.7 26.21 Favored 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 124.343 1.057 . . . . 0.0 110.707 -178.208 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -73.02 90.45 0.59 Allowed Glycine 0 C--N 1.347 1.144 0 CA-C-N 116.309 -0.405 . . . . 0.0 112.543 -178.103 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -65.44 -48.8 65.05 Favored Glycine 0 C--N 1.35 1.315 0 O-C-N 123.881 0.4 . . . . 0.0 112.221 177.368 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 70.53 -114.89 5.65 Favored Glycine 0 C--N 1.354 1.548 0 O-C-N 123.77 0.335 . . . . 0.0 112.497 178.659 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 136.94 -143.28 14.54 Favored Glycine 0 C--N 1.346 1.112 0 N-CA-C 111.396 -0.682 . . . . 0.0 111.396 -179.694 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 -92.07 -5.49 52.74 Favored 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 123.824 0.85 . . . . 0.0 110.835 174.427 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 56.5 t80 75.47 -3.54 2.56 Favored 'General case' 0 N--CA 1.488 1.458 0 C-N-CA 125.48 1.512 . . . . 0.0 112.176 177.319 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -72.45 -38.64 68.23 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 123.391 0.676 . . . . 0.0 110.571 177.504 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 137.61 108.36 0.85 Allowed Glycine 0 C--N 1.344 1.006 0 CA-C-N 115.685 -0.689 . . . . 0.0 112.148 176.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 36.0 t -71.63 -86.29 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.565 1.532 0 C-N-CA 123.548 0.739 . . . . 0.0 109.197 178.264 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.606 HD23 ' HG2' ' A' ' 78' ' ' GLU . 33.6 tp 174.92 146.92 0.07 Allowed 'General case' 0 N--CA 1.483 1.182 0 C-N-CA 126.888 2.075 . . . . 0.0 106.172 171.772 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 6.7 m0 -91.2 62.43 4.76 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 118.526 0.603 . . . . 0.0 111.651 -176.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 8.6 t0 179.15 70.64 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.266 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 173.096 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 14.5 m -129.52 109.41 17.5 Favored Pre-proline 0 CA--C 1.555 1.152 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.443 -169.101 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.552 ' HD3' ' HG3' ' A' ' 80' ' ' GLU . 87.6 Cg_endo -81.9 -33.04 0.66 Allowed 'Trans proline' 0 C--N 1.38 2.222 0 C-N-CA 123.03 2.487 . . . . 0.0 112.247 177.051 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 51.1 m -129.83 152.64 80.2 Favored Pre-proline 0 CA--C 1.544 0.727 0 C-N-CA 125.395 1.478 . . . . 0.0 107.684 173.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 22.7 Cg_endo -59.11 109.54 0.55 Allowed 'Trans proline' 0 C--N 1.376 2.005 0 C-N-CA 122.574 2.183 . . . . 0.0 111.564 175.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -78.25 164.15 27.01 Favored 'Trans proline' 0 C--N 1.38 2.214 0 C-N-CA 122.809 2.339 . . . . 0.0 111.961 -176.083 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -79.99 55.28 5.58 Favored 'Trans proline' 0 CA--C 1.558 1.716 0 C-N-CA 122.768 2.312 . . . . 0.0 111.542 171.461 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 9.3 p 37.86 75.69 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 C-N-CA 126.125 1.77 . . . . 0.0 112.355 -171.494 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -90.23 -131.89 4.8 Favored Glycine 0 C--N 1.342 0.884 0 CA-C-N 115.201 -0.909 . . . . 0.0 111.909 -178.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . . . . . . . . . 25.3 pttm 178.76 -22.84 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 125.112 1.365 . . . . 0.0 110.168 -179.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -94.17 1.33 56.08 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 123.444 0.698 . . . . 0.0 112.607 -176.088 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.606 ' HG2' HD23 ' A' ' 65' ' ' LEU . 8.7 pm0 -82.62 72.78 9.69 Favored 'General case' 0 N--CA 1.479 0.993 0 CA-C-O 122.206 1.003 . . . . 0.0 111.165 -179.292 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.423 HD22 HD21 ' A' ' 65' ' ' LEU . 4.1 mm? -105.45 81.57 1.71 Allowed 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 106.86 -1.533 . . . . 0.0 106.86 168.13 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.552 ' HG3' ' HD3' ' A' ' 69' ' ' PRO . 29.6 mm-40 -71.09 -38.7 72.39 Favored 'General case' 0 C--O 1.243 0.738 0 CA-C-N 114.563 -1.198 . . . . 0.0 111.742 -171.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 70.02 125.58 0.03 OUTLIER 'General case' 0 CA--C 1.549 0.939 0 O-C-N 125.008 1.443 . . . . 0.0 109.731 -161.517 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -166.16 166.33 38.7 Favored Glycine 0 C--N 1.34 0.802 0 CA-C-N 115.805 -0.634 . . . . 0.0 113.455 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . 0.68 ' HB1' HD11 ' A' ' 161' ' ' LEU . . . -86.3 118.14 25.55 Favored 'General case' 0 C--O 1.243 0.719 0 CA-C-N 114.117 -1.041 . . . . 0.0 108.701 175.096 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' TYR . . . . . . . . . . . . . 79.9 m-85 -118.46 142.4 47.6 Favored 'General case' 0 C--O 1.216 -0.676 0 C-N-CA 123.09 0.556 . . . . 0.0 109.622 -179.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . 0.656 ' HG3' ' HB2' ' A' ' 11' ' ' ALA . 54.9 mtt-85 -92.29 137.0 32.73 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 174.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.404 ' H ' ' HA ' ' A' ' 99' ' ' ALA . 51.6 mt -102.37 121.3 53.26 Favored 'Isoleucine or valine' 0 C--O 1.26 1.629 0 CA-C-O 121.673 0.749 . . . . 0.0 110.151 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.489 ' HA ' ' HA ' ' A' ' 96' ' ' GLN . 22.7 pttm -122.82 144.79 48.96 Favored 'General case' 0 C--N 1.349 0.554 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.823 177.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.18 119.65 24.33 Favored 'General case' 0 C--O 1.249 1.027 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 173.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . 0.794 ' HD3' ' HB2' ' A' ' 7' ' ' GLU . 53.2 pttt -115.31 152.74 32.23 Favored 'General case' 0 C--O 1.232 0.156 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.686 -172.318 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -100.93 103.2 2.55 Favored Glycine 0 C--N 1.347 1.157 0 N-CA-C 106.135 -2.786 . . . . 0.0 106.135 160.414 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 4.8 tp 19.36 29.66 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.58 2.118 0 C-N-CA 129.298 3.039 . . . . 0.0 116.882 -167.542 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.444 ' N ' ' HD2' ' A' ' 89' ' ' LYS . 0.7 OUTLIER -177.41 -57.27 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.873 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 -169.77 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 177.05 161.89 26.52 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 114.732 0.653 . . . . 0.0 114.732 -177.604 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 53.2 p90 -165.8 -48.0 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 124.308 1.043 . . . . 0.0 112.05 156.17 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 12.6 t -152.72 149.83 28.8 Favored 'General case' 0 N--CA 1.495 1.783 0 CA-C-N 119.63 1.105 . . . . 0.0 112.067 -175.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' GLN . . . . . 0.489 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 0.8 OUTLIER -95.38 142.31 27.91 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 124.417 1.087 . . . . 0.0 110.445 -179.782 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.485 HD11 HD23 ' A' ' 6' ' ' LEU . 1.3 pp -133.49 -7.66 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 N-CA-C 113.575 0.954 . . . . 0.0 113.575 -175.052 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 175.92 -148.92 9.58 Favored Glycine 0 N--CA 1.475 1.242 0 CA-C-N 118.359 0.527 . . . . 0.0 113.017 173.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.404 ' HA ' ' H ' ' A' ' 86' ' ' ILE . . . -156.41 176.06 13.19 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 123.585 0.754 . . . . 0.0 110.985 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . -172.87 135.3 3.27 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -177.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.491 HG21 ' HB3' ' A' ' 199' ' ' PRO . 71.3 t -95.65 110.67 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 C-N-CA 123.285 0.634 . . . . 0.0 109.328 -177.447 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' TYR . . . . . . . . . . . . . 17.7 t80 -77.66 134.51 38.14 Favored 'General case' 0 CA--C 1.536 0.439 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 -179.468 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' LYS . . . . . 0.66 ' HD2' HD21 ' A' ' 146' ' ' LEU . 35.5 mmtm -118.64 157.65 27.0 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 124.96 1.304 . . . . 0.0 109.045 -179.583 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -53.76 100.18 0.03 OUTLIER 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 123.86 0.864 . . . . 0.0 112.176 -173.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 83.55 -9.97 60.57 Favored Glycine 0 C--N 1.351 1.386 0 CA-C-N 115.48 -0.782 . . . . 0.0 113.766 178.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 20.3 p -123.81 120.45 32.65 Favored 'General case' 0 CA--C 1.55 0.966 0 C-N-CA 124.038 0.935 . . . . 0.0 111.02 -175.121 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' PHE . . . . . 0.702 ' HB3' ' HB3' ' A' ' 140' ' ' TYR . 37.2 t80 -84.42 122.6 29.19 Favored 'General case' 0 N--CA 1.48 1.027 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 176.483 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' HIS . . . . . . . . . . . . . 5.3 t-80 -132.97 102.3 5.57 Favored 'General case' 0 CA--C 1.554 1.129 0 C-N-CA 123.776 0.83 . . . . 0.0 110.434 -167.111 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' THR . . . . . 0.485 HG23 ' HB ' ' A' ' 138' ' ' ILE . 10.2 t -136.74 177.19 8.05 Favored 'General case' 0 N--CA 1.488 1.457 0 C-N-CA 123.889 0.876 . . . . 0.0 111.135 -178.601 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' MET . . . . . 0.476 ' HA ' ' HA ' ' A' ' 137' ' ' LEU . 44.2 mtp -93.55 157.14 16.34 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 124.296 1.038 . . . . 0.0 109.148 173.536 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' TRP . . . . . . . . . . . . . 79.7 t90 -80.46 -61.88 1.84 Allowed 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 112.28 0.474 . . . . 0.0 112.28 -166.149 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 2.3 p-80 -73.97 3.93 6.12 Favored 'General case' 0 N--CA 1.5 2.048 0 N-CA-C 114.009 1.114 . . . . 0.0 114.009 -167.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 40.7 t -42.99 -41.6 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.279 0 C-N-CA 123.734 0.814 . . . . 0.0 110.29 161.676 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.526 HG21 HD21 ' A' ' 6' ' ' LEU . 0.2 OUTLIER -153.29 -163.03 1.59 Allowed 'General case' 0 CA--C 1.558 1.286 0 C-N-CA 125.267 1.427 . . . . 0.0 109.207 170.395 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 77.5 mtp180 -66.01 -26.65 67.63 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 113.362 0.875 . . . . 0.0 113.362 -172.747 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 93.78 62.84 1.07 Allowed Glycine 0 CA--C 1.53 0.983 0 O-C-N 123.205 0.316 . . . . 0.0 113.715 178.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -141.98 -85.66 0.17 Allowed 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 112.461 0.541 . . . . 0.0 112.461 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 26.6 t -110.98 109.0 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 123.359 0.663 . . . . 0.0 112.331 -169.028 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.515 HD12 HD12 ' A' ' 126' ' ' ILE . 1.3 tm? -91.33 152.06 20.61 Favored 'General case' 0 C--O 1.212 -0.908 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 169.108 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' MET . . . . . 0.732 ' HG3' ' HA ' ' A' ' 5' ' ' ASP . 45.7 mmm -135.01 138.85 44.36 Favored 'General case' 0 N--CA 1.479 0.993 0 C-N-CA 124.06 0.944 . . . . 0.0 108.717 -172.755 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' HIS . . . . . 0.518 ' O ' ' HG2' ' A' ' 122' ' ' LYS . 18.5 t-160 -167.53 141.84 3.68 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -177.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.518 ' HG2' ' O ' ' A' ' 121' ' ' HIS . 32.8 pttt 68.92 3.12 3.84 Favored 'General case' 0 N--CA 1.501 2.086 0 C-N-CA 125.649 1.579 . . . . 0.0 112.766 176.194 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 99.96 -0.76 56.35 Favored Glycine 0 C--N 1.351 1.362 0 C-N-CA 123.144 0.402 . . . . 0.0 113.084 -174.282 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -118.45 152.93 34.97 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 123.813 0.845 . . . . 0.0 110.744 179.482 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' ARG . . . . . 0.444 ' HB3' ' SD ' ' A' ' 120' ' ' MET . 20.8 ptp180 -93.07 164.67 13.18 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.11 -179.276 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.515 HD12 HD12 ' A' ' 119' ' ' LEU . 27.5 mt -142.8 122.97 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 C-N-CA 125.628 1.571 . . . . 0.0 107.086 -172.396 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' GLU . . . . . . . . . . . . . 44.8 mt-10 -125.73 132.69 24.39 Favored Pre-proline 0 N--CA 1.474 0.758 0 N-CA-C 108.604 -0.888 . . . . 0.0 108.604 175.427 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.48 ' HA ' ' HB2' ' A' ' 140' ' ' TYR . 96.9 Cg_endo -73.78 157.65 47.62 Favored 'Trans proline' 0 C--N 1.373 1.86 0 C-N-CA 122.934 2.423 . . . . 0.0 113.943 -168.806 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' SER . . . . . 0.558 ' H ' ' HA ' ' A' ' 140' ' ' TYR . 28.8 p -76.77 -27.62 55.37 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-N 114.884 -1.053 . . . . 0.0 109.623 172.385 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . . . . . . . . . 67.6 t-105 -152.5 144.94 24.07 Favored 'General case' 0 CA--C 1.542 0.638 0 C-N-CA 123.314 0.645 . . . . 0.0 110.21 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' ALA . . . . . . . . . . . . . . . -136.72 121.19 18.22 Favored 'General case' 0 C--O 1.241 0.613 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 171.566 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -114.13 109.09 17.88 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 123.437 0.695 . . . . 0.0 109.467 -173.571 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 17.1 t -77.44 -19.38 14.15 Favored 'Isoleucine or valine' 0 CA--C 1.562 1.407 0 C-N-CA 123.9 0.88 . . . . 0.0 111.304 -175.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 2.8 mptp? -69.46 -51.31 37.27 Favored 'General case' 0 N--CA 1.487 1.419 0 C-N-CA 123.461 0.704 . . . . 0.0 109.557 -177.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 31.9 mmtp -84.13 -20.08 33.1 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-N 115.088 -0.96 . . . . 0.0 110.346 178.681 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' ASP . . . . . . . . . . . . . 14.2 t70 65.5 63.57 0.62 Allowed 'General case' 0 C--O 1.24 0.595 0 C-N-CA 125.56 1.544 . . . . 0.0 110.607 -175.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' LEU . . . . . 0.495 HD21 HD12 ' A' ' 210' ' ' LEU . 1.5 mp -143.77 172.64 12.56 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.802 174.461 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.485 ' HB ' HG23 ' A' ' 109' ' ' THR . 21.6 mt -141.46 131.33 25.15 Favored 'Isoleucine or valine' 0 C--O 1.245 0.868 0 C-N-CA 125.952 1.701 . . . . 0.0 108.08 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 29.9 p -136.48 123.09 20.98 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 124.13 0.972 . . . . 0.0 110.282 -177.566 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.702 ' HB3' ' HB3' ' A' ' 107' ' ' PHE . 47.8 t80 -109.68 123.97 50.41 Favored 'General case' 0 N--CA 1.464 0.24 0 C-N-CA 124.626 1.17 . . . . 0.0 108.06 172.79 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 113.91 0.4 24.23 Favored Glycine 0 N--CA 1.474 1.19 0 O-C-N 123.885 0.741 . . . . 0.0 111.98 -173.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 147.46 -141.74 9.58 Favored Glycine 0 C--N 1.346 1.125 0 N-CA-C 109.944 -1.262 . . . . 0.0 109.944 177.734 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.809 ' HA3' ' HB2' ' A' ' 232' ' ' SER . . . -97.45 -175.06 34.19 Favored Glycine 0 C--N 1.345 1.058 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 164.285 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' TRP . . . . . 0.609 ' HZ2' ' HA2' ' A' ' 209' ' ' GLY . 7.4 t90 -69.76 104.02 2.32 Favored 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 177.279 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . 0.616 ' HB3' ' HA ' ' A' ' 231' ' ' LYS . 11.7 pttt -164.87 113.85 1.08 Allowed 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 123.7 0.8 . . . . 0.0 109.692 -177.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' LEU . . . . . 0.66 HD21 ' HD2' ' A' ' 103' ' ' LYS . 0.0 OUTLIER 167.62 -33.12 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 C-N-CA 125.178 1.391 . . . . 0.0 110.602 161.409 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.569 ' HG2' ' HE2' ' A' ' 103' ' ' LYS . 31.6 mt-10 -62.3 -81.91 0.02 OUTLIER 'General case' 0 C--N 1.367 1.353 0 O-C-N 123.714 0.634 . . . . 0.0 111.057 -166.139 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . 0.424 ' O ' ' HB ' ' A' ' 229' ' ' THR . . . 177.66 -174.26 46.75 Favored Glycine 0 C--N 1.341 0.813 0 O-C-N 123.464 0.477 . . . . 0.0 111.963 -178.097 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -124.85 107.37 10.83 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 -172.765 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' TRP . . . . . . . . . . . . . 27.5 t90 -54.89 135.57 48.0 Favored 'General case' 0 N--CA 1.477 0.923 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.625 172.161 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 53.6 mmtt -84.48 101.8 12.33 Favored 'General case' 0 C--O 1.239 0.508 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 179.042 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -62.65 107.72 1.01 Allowed 'General case' 0 CA--C 1.546 0.803 0 O-C-N 124.022 0.826 . . . . 0.0 109.765 -172.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 134.16 -31.62 2.77 Favored Glycine 0 C--N 1.34 0.803 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.688 -176.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -82.81 156.34 23.71 Favored 'General case' 0 C--O 1.242 0.708 0 C-N-CA 123.349 0.66 . . . . 0.0 109.48 178.559 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 10.0 pm0 -64.02 142.93 58.23 Favored 'General case' 0 C--O 1.243 0.731 0 O-C-N 124.207 0.942 . . . . 0.0 109.956 174.442 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 15.8 m -92.48 142.34 13.26 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 CA-C-O 121.184 0.516 . . . . 0.0 109.822 174.552 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' GLN . . . . . 0.482 HE22 ' HB2' ' A' ' 171' ' ' GLN . 9.9 tp-100 -101.32 144.96 29.52 Favored 'General case' 0 N--CA 1.454 -0.235 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 173.008 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.594 ' HB ' ' HB ' ' A' ' 170' ' ' VAL . 49.1 t -128.03 146.02 34.28 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 123.445 0.698 . . . . 0.0 110.014 -174.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' LEU . . . . . 0.424 ' HB2' ' HG2' ' A' ' 199' ' ' PRO . 33.7 mt -97.04 85.55 3.76 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 160.82 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -64.16 100.5 0.34 Allowed 'General case' 0 C--O 1.237 0.403 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 -179.233 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' LEU . . . . . 0.68 HD11 ' HB1' ' A' ' 83' ' ' ALA . 70.6 mt -78.03 80.28 4.47 Favored 'General case' 0 C--O 1.242 0.691 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.628 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' GLU . . . . . 0.425 ' HB2' ' HB2' ' A' ' 165' ' ' LYS . 10.1 mm-40 -61.59 125.3 84.26 Favored Pre-proline 0 CA--C 1.555 1.151 0 CA-C-N 113.412 -1.722 . . . . 0.0 110.074 -176.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . 0.413 ' HB3' ' NH2' ' B' ' 254' ' ' ARG . 18.4 Cg_endo -58.1 112.8 1.28 Allowed 'Trans proline' 0 C--N 1.382 2.293 0 C-N-CA 122.875 2.383 . . . . 0.0 112.626 -174.006 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 67.06 26.87 73.31 Favored Glycine 0 C--N 1.349 1.305 0 O-C-N 124.139 0.9 . . . . 0.0 113.291 176.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . 0.425 ' HB2' ' HB2' ' A' ' 162' ' ' GLU . 49.8 mtpt -131.54 -172.49 2.87 Favored 'General case' 0 C--O 1.242 0.703 0 C-N-CA 124.282 1.033 . . . . 0.0 109.306 -176.533 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 166' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -72.48 141.7 83.23 Favored Pre-proline 0 CA--C 1.555 1.139 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.053 170.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_exo -67.48 122.33 9.54 Favored 'Trans proline' 0 C--N 1.368 1.577 0 C-N-CA 122.522 2.148 . . . . 0.0 111.006 170.384 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 168' ' ' ARG . . . . . . . . . . . . . 56.6 mtp180 -105.51 167.6 9.65 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 123.912 0.885 . . . . 0.0 110.549 -178.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 169' ' ' ALA . . . . . 0.57 ' HB2' ' HB3' ' A' ' 17' ' ' GLU . . . -102.24 151.21 22.49 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 109.408 -0.589 . . . . 0.0 109.408 170.493 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.594 ' HB ' ' HB ' ' A' ' 158' ' ' VAL . 95.5 t -136.17 117.08 18.51 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.239 0 C-N-CA 123.276 0.63 . . . . 0.0 110.286 175.159 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . 0.617 ' HB2' ' HB1' ' A' ' 20' ' ' ALA . 65.0 tt0 -94.81 111.24 23.03 Favored 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 172.441 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 4.5 t -140.52 140.53 35.27 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-O 121.001 0.429 . . . . 0.0 110.742 -174.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 173' ' ' LYS . . . . . . . . . . . . . 21.5 ptmt -75.61 152.43 85.27 Favored Pre-proline 0 CA--C 1.55 0.953 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.961 177.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -70.3 143.54 48.52 Favored 'Trans proline' 0 C--N 1.374 1.909 0 C-N-CA 122.314 2.009 . . . . 0.0 112.692 171.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 175' ' ' GLY . . . . . . . . . . . . . . . -132.84 155.55 21.67 Favored Glycine 0 N--CA 1.467 0.729 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 170.406 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.49 ' HG ' ' HA2' ' A' ' 185' ' ' GLY . 6.5 mp -116.81 157.17 26.02 Favored 'General case' 0 N--CA 1.482 1.143 0 CA-C-N 119.019 1.409 . . . . 0.0 109.231 -174.562 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 177' ' ' PHE . . . . . . . . . . . . . 50.2 p90 -137.02 149.55 47.53 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.802 175.301 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 178' ' ' LYS . . . . . . . . . . . . . 60.1 tttp -97.78 128.01 44.13 Favored 'General case' 0 C--O 1.239 0.547 0 CA-C-N 115.577 -0.738 . . . . 0.0 109.977 -177.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 179' ' ' THR . . . . . . . . . . . . . 75.5 p -123.48 171.82 9.19 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.017 0.927 . . . . 0.0 109.355 168.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 180' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -65.94 -27.07 67.9 Favored 'General case' 0 N--CA 1.483 1.186 0 C-N-CA 123.564 0.746 . . . . 0.0 110.607 174.334 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -68.65 -40.71 80.08 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 123.757 0.823 . . . . 0.0 110.602 175.455 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 158.22 -175.9 35.31 Favored Glycine 0 C--N 1.35 1.346 0 CA-C-N 115.831 -0.622 . . . . 0.0 112.423 177.634 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 183' ' ' THR . . . . . . . . . . . . . 8.5 t -77.98 115.42 17.71 Favored 'General case' 0 CA--C 1.543 0.695 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 172.55 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 52.8 mt -104.5 138.95 26.98 Favored 'Isoleucine or valine' 0 C--O 1.246 0.909 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -177.504 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 185' ' ' GLY . . . . . 0.49 ' HA2' ' HG ' ' A' ' 176' ' ' LEU . . . -100.45 119.43 6.51 Favored Glycine 0 C--N 1.349 1.291 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -175.121 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.563 ' HA ' ' H ' ' A' ' 226' ' ' ILE . . . -144.94 -156.85 0.74 Allowed 'General case' 0 C--O 1.235 0.323 0 C-N-CA 123.837 0.855 . . . . 0.0 109.928 -165.694 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 187' ' ' VAL . . . . . 0.544 HG13 ' HB3' ' A' ' 224' ' ' SER . 2.4 p -135.77 123.06 34.98 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 C-N-CA 123.648 0.779 . . . . 0.0 109.285 175.085 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 41.6 m -117.75 115.29 24.72 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 123.779 0.832 . . . . 0.0 109.262 -176.796 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 189' ' ' LEU . . . . . 0.421 HD13 ' HB3' ' A' ' 191' ' ' PHE . 0.5 OUTLIER -149.44 164.0 36.22 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 124.065 0.946 . . . . 0.0 110.962 -175.44 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 190' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -101.52 104.1 14.99 Favored 'General case' 0 CA--C 1.541 0.634 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 170.246 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 191' ' ' PHE . . . . . 0.421 ' HB3' HD13 ' A' ' 189' ' ' LEU . 67.9 t80 -154.11 166.58 32.62 Favored 'General case' 0 N--CA 1.484 1.238 0 C-N-CA 123.217 0.607 . . . . 0.0 110.486 -171.79 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 192' ' ' SER . . . . . . . . . . . . . 48.8 m -69.53 156.25 92.01 Favored Pre-proline 0 CA--C 1.559 1.295 0 C-N-CA 124.952 1.301 . . . . 0.0 112.631 -178.713 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 193' ' ' PRO . . . . . 0.537 ' HA ' ' CE1' ' A' ' 222' ' ' TYR . 39.7 Cg_endo -64.24 99.18 0.28 Allowed 'Trans proline' 0 C--N 1.387 2.554 0 C-N-CA 123.009 2.473 . . . . 0.0 113.02 176.392 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 194' ' ' GLY . . . . . . . . . . . . . . . -70.47 -136.39 0.12 Allowed Glycine 0 C--N 1.361 1.918 0 C-N-CA 123.745 0.688 . . . . 0.0 112.596 177.749 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 195' ' ' THR . . . . . . . . . . . . . 25.4 p -124.79 143.94 50.54 Favored 'General case' 0 N--CA 1.489 1.501 0 CA-C-N 118.979 1.39 . . . . 0.0 112.245 169.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 196' ' ' SER . . . . . . . . . . . . . 14.1 m -73.88 83.19 1.68 Allowed 'General case' 0 C--N 1.354 0.765 0 C-N-CA 123.645 0.778 . . . . 0.0 110.305 170.729 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 197' ' ' GLY . . . . . . . . . . . . . . . 127.98 19.86 1.73 Allowed Glycine 0 C--N 1.339 0.747 0 CA-C-N 115.758 -0.655 . . . . 0.0 111.536 -170.275 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 198' ' ' SER . . . . . . . . . . . . . 33.4 t -65.49 140.23 97.53 Favored Pre-proline 0 CA--C 1.554 1.108 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 164.118 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 199' ' ' PRO . . . . . 0.491 ' HB3' HG21 ' A' ' 101' ' ' VAL . 65.7 Cg_endo -81.04 131.85 8.1 Favored 'Trans proline' 0 C--N 1.374 1.881 0 C-N-CA 121.647 1.565 . . . . 0.0 113.374 179.016 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 200' ' ' ILE . . . . . . . . . . . . . 43.9 mt -87.43 117.91 32.33 Favored 'Isoleucine or valine' 0 C--O 1.248 1.002 0 CA-C-O 121.962 0.887 . . . . 0.0 108.739 163.091 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 201' ' ' ILE . . . . . . . . . . . . . 80.4 mt -102.87 136.49 35.12 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.812 0 CA-C-N 113.248 -1.796 . . . . 0.0 107.54 172.421 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 202' ' ' ASP . . . . . 0.529 ' HB3' ' HB2' ' A' ' 206' ' ' LYS . 19.1 t70 -73.31 148.56 43.41 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 167.415 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 203' ' ' LYS . . . . . . . . . . . . . 60.6 pttt -60.38 -18.96 53.85 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 -172.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 86.1 tttt -67.52 -21.34 65.49 Favored 'General case' 0 CA--C 1.557 1.247 0 C-N-CA 123.546 0.738 . . . . 0.0 111.766 177.497 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 205' ' ' GLY . . . . . . . . . . . . . . . 108.27 3.32 33.37 Favored Glycine 0 N--CA 1.471 0.967 0 C-N-CA 123.3 0.476 . . . . 0.0 111.949 -171.691 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 206' ' ' LYS . . . . . 0.529 ' HB2' ' HB3' ' A' ' 202' ' ' ASP . 46.4 mttm -74.45 136.22 42.3 Favored 'General case' 0 C--O 1.205 -1.244 0 C-N-CA 123.985 0.914 . . . . 0.0 109.428 173.436 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 207' ' ' VAL . . . . . . . . . . . . . 7.5 p -86.68 135.91 24.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 N-CA-C 106.403 -1.702 . . . . 0.0 106.403 163.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 208' ' ' VAL . . . . . . . . . . . . . 30.9 m -135.8 -21.08 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 N-CA-C 113.153 0.797 . . . . 0.0 113.153 -168.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 209' ' ' GLY . . . . . 0.609 ' HA2' ' HZ2' ' A' ' 144' ' ' TRP . . . 178.4 -151.37 10.47 Favored Glycine 0 C--N 1.35 1.329 0 C-N-CA 119.751 -1.214 . . . . 0.0 115.815 -176.116 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 210' ' ' LEU . . . . . 0.495 HD12 HD21 ' A' ' 137' ' ' LEU . 33.6 mt -130.82 133.74 46.22 Favored 'General case' 0 C--N 1.365 1.241 0 CA-C-O 121.88 0.848 . . . . 0.0 112.366 -175.751 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 211' ' ' TYR . . . . . . . . . . . . . 64.0 t80 -94.09 133.96 37.03 Favored 'General case' 0 C--O 1.241 0.655 0 C-N-CA 126.409 1.884 . . . . 0.0 108.223 168.061 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 212' ' ' GLY . . . . . . . . . . . . . . . -137.38 -138.05 3.69 Favored Glycine 0 C--O 1.229 -0.189 0 N-CA-C 111.442 -0.663 . . . . 0.0 111.442 177.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 213' ' ' ASN . . . . . 0.403 ' HB2' ' CZ ' ' A' ' 222' ' ' TYR . 9.2 t30 -156.79 101.09 1.95 Allowed 'General case' 0 C--O 1.237 0.396 0 C-N-CA 125.694 1.598 . . . . 0.0 107.05 170.666 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 214' ' ' GLY . . . . . . . . . . . . . . . -56.22 -56.39 24.5 Favored Glycine 0 C--N 1.342 0.894 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 172.782 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 215' ' ' VAL . . . . . . . . . . . . . 3.4 m -162.2 -172.74 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 C-N-CA 125.241 1.416 . . . . 0.0 108.952 176.057 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 216' ' ' VAL . . . . . 0.518 HG22 ' HD3' ' B' ' 253' ' ' LYS . 3.4 m -117.83 129.89 73.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 168.135 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 217' ' ' THR . . . . . 0.451 HG22 ' H ' ' A' ' 218' ' ' ARG . 4.9 m -126.69 -178.9 4.54 Favored 'General case' 0 CA--C 1.552 1.031 0 N-CA-C 107.829 -1.175 . . . . 0.0 107.829 -178.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 218' ' ' ARG . . . . . 0.451 ' H ' HG22 ' A' ' 217' ' ' THR . 10.9 ttt85 64.19 25.57 13.66 Favored 'General case' 0 N--CA 1.496 1.863 0 CA-C-O 122.393 1.092 . . . . 0.0 110.879 171.367 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 219' ' ' SER . . . . . . . . . . . . . 10.2 t 69.9 2.07 3.72 Favored 'General case' 0 N--CA 1.489 1.507 0 C-N-CA 125.412 1.485 . . . . 0.0 112.975 176.501 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 220' ' ' GLY . . . . . 0.421 ' HA2' ' H5 ' ' B' ' 251' ' ' BEZ . . . 159.64 45.81 0.02 OUTLIER Glycine 0 C--N 1.349 1.263 0 CA-C-N 117.706 0.23 . . . . 0.0 112.572 -177.447 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 221' ' ' ALA . . . . . . . . . . . . . . . -122.69 121.45 36.41 Favored 'General case' 0 C--O 1.238 0.478 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 176.048 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 222' ' ' TYR . . . . . 0.537 ' CE1' ' HA ' ' A' ' 193' ' ' PRO . 56.6 t80 -69.8 101.29 1.68 Allowed 'General case' 0 CA--C 1.548 0.872 0 C-N-CA 125.136 1.374 . . . . 0.0 109.059 179.282 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 223' ' ' VAL . . . . . 0.509 HG11 HD11 ' A' ' 31' ' ' ILE . 8.2 t -96.89 98.56 7.68 Favored 'Isoleucine or valine' 0 C--O 1.249 1.039 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 -176.467 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . 0.544 ' HB3' HG13 ' A' ' 187' ' ' VAL . 38.0 t -97.3 155.19 16.98 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 125.144 1.378 . . . . 0.0 109.744 179.059 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 225' ' ' ALA . . . . . . . . . . . . . . . -104.83 131.38 52.38 Favored 'General case' 0 C--O 1.241 0.626 0 C-N-CA 123.449 0.7 . . . . 0.0 109.675 176.428 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 226' ' ' ILE . . . . . 0.563 ' H ' ' HA ' ' A' ' 186' ' ' ALA . 78.8 mt -77.98 95.04 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.352 0.68 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 173.196 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 227' ' ' ALA . . . . . 0.419 ' O ' ' HA3' ' A' ' 209' ' ' GLY . . . -85.18 147.18 26.73 Favored 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 172.632 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 228' ' ' GLN . . . . . . . . . . . . . 3.7 pt20 -147.54 153.56 39.63 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 123.918 0.887 . . . . 0.0 109.446 -169.246 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . 0.424 ' HB ' ' O ' ' A' ' 148' ' ' GLY . 89.4 m -69.0 109.28 3.88 Favored 'General case' 0 CA--C 1.545 0.764 0 CA-C-O 121.161 0.505 . . . . 0.0 109.817 179.242 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 230' ' ' GLU . . . . . 0.411 ' O ' ' HG2' ' A' ' 231' ' ' LYS . 38.3 mt-10 -98.01 -11.83 22.58 Favored 'General case' 0 N--CA 1.481 1.081 0 CA-C-N 114.916 -1.038 . . . . 0.0 111.302 -175.193 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 231' ' ' LYS . . . . . 0.616 ' HA ' ' HB3' ' A' ' 145' ' ' LYS . 11.7 pttm 66.78 128.48 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 127.06 2.144 . . . . 0.0 112.189 -177.51 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 232' ' ' SER . . . . . 0.809 ' HB2' ' HA3' ' A' ' 143' ' ' GLY . 30.1 m -144.03 93.38 2.44 Favored 'General case' 0 C--N 1.351 0.659 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 172.814 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 233' ' ' ILE . . . . . . . . . . . . . 6.4 tt -75.08 -24.68 17.9 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.057 0 CA-C-N 114.767 -1.106 . . . . 0.0 110.725 179.616 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 234' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 78.9 -39.87 0.24 Allowed 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 126.431 1.893 . . . . 0.0 111.945 -178.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 235' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -60.12 -56.89 16.05 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 123.642 0.777 . . . . 0.0 110.522 176.196 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 236' ' ' ASN . . . . . . . . . . . . . 38.7 m-20 -107.54 106.38 58.3 Favored Pre-proline 0 N--CA 1.477 0.908 0 C-N-CA 123.428 0.691 . . . . 0.0 110.045 -176.629 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 237' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_exo -73.3 136.27 23.94 Favored 'Trans proline' 0 C--N 1.374 1.908 0 C-N-CA 122.623 2.215 . . . . 0.0 110.577 170.655 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 238' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -84.98 39.3 0.76 Allowed 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 123.778 0.831 . . . . 0.0 112.634 -170.19 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 239' ' ' ILE . . . . . . . . . . . . . 49.8 mm 73.92 -51.93 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 C-N-CA 126.05 1.74 . . . . 0.0 110.946 -177.537 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 240' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 . . . . . 0 CA--C 1.556 1.191 0 C-N-CA 123.818 0.847 . . . . 0.0 109.726 174.907 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 251' ' ' BEZ . . . . . 0.421 ' H5 ' ' HA2' ' A' ' 220' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 252' ' ' NLE . . . . . 0.506 ' HN2' ' HD2' ' B' ' 252' ' ' NLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 253' ' ' LYS . . . . . 0.518 ' HD3' HG22 ' A' ' 216' ' ' VAL . 24.8 pttm -144.95 177.04 9.04 Favored 'General case' 0 N--CA 1.478 0.943 0 C-N-CA 123.125 0.57 . . . . 0.0 111.544 -172.705 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 254' ' ' ARG . . . . . 0.443 ' NH1' ' HB2' ' A' ' 48' ' ' GLN . 38.3 mmt180 -115.78 -169.46 1.59 Allowed 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 124.544 1.137 . . . . 0.0 109.003 172.292 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 255' ' ' M9P . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 stop_ save_